PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	Forsen, T; Eriksson, JG; Tuomilehto, J; Osmond, C; Barker, DJP				Forsen, T; Eriksson, JG; Tuomilehto, J; Osmond, C; Barker, DJP			Growth in utero and during childhood among women who develop coronary heart disease: longitudinal study	BRITISH MEDICAL JOURNAL			English	Article							FETAL GROWTH; CARDIOVASCULAR-DISEASE; ADULT LIFE; IN-UTERO; MEN; COHORT; DEATH; SIZE; VALIDITY; FINLAND	Objective To examine whether women who develop coronary heart disease have different patterns of fetal and childhood growth from men in the same cohort who develop the disease. Design Follow up study of women whose body size at birth was recorded and who had an average of 10 measurements of height and weight during childhood. Setting Helsinki, Finland. Subjects 3447 women who were born in Helsinki University Central Hospital during 1924-33 and who went to school in Helsinki. Main outcome measures Hazard ratios for hospital admission for or death from coronary heart disease. Results Coronary heart disease among women was associated with low birth weight (P = 0.08 after adjustment for gestation, P = 0.007 after adjustment for placental weight) and was more strongly associated with short body length at birth (P = 0.001 and P < 0.0001, respectively). The hazard ratio for women developing coronary heart disease increased by 10.2% (95% confidence interval 4.3 to 15.7) for each rm decrease in length at birth. The effect of short length at birth was greatest in women whose height "caught up" after birth so that as girls they were tall. Such girls tended to have tall mothers. In contrast, men in the same cohort who developed the disease were thin at birth rather than short, showed "catch up" growth in weight rather than height, and their mothers tended to be overweight rather than tall. Conclusion Coronary heart disease among both women and men reflects poor prenatal nutrition and consequent small body size at birth combined with improved postnatal nutrition and "catch up" growth in childhood. The disease is associated with reductions in those aspects of body proportions at birth that distinguish die two sexes-short body length in women and thinness in men.	Univ Southampton, Southampton Gen Hosp, MRC, Environm Epidemiol Unit, Southampton SO16 6YD, Hants, England; Natl Publ Hlth Inst, Dept Epidemiol & Hlth Promot, Diabet & Genet Epidemiol Unit, Helsinki, Finland	University of Southampton; Finland National Institute for Health & Welfare	Barker, DJP (corresponding author), Univ Southampton, Southampton Gen Hosp, MRC, Environm Epidemiol Unit, Southampton SO16 6YD, Hants, England.			Osmond, Clive/0000-0002-9054-4655				Barker D J, 1992, Paediatr Perinat Epidemiol, V6, P35, DOI 10.1111/j.1365-3016.1992.tb00741.x; Barker D.J.P., 1998, MOTHERS BABIES HLTH; BARKER DJP, 1995, BRIT MED J, V311, P171, DOI 10.1136/bmj.311.6998.171; BARKER DJP, 1993, BRIT MED J, V307, P1524, DOI 10.1136/bmj.307.6918.1524; Eriksson JG, 1999, BMJ-BRIT MED J, V318, P427, DOI 10.1136/bmj.318.7181.427; Forsen T, 1997, BRIT MED J, V315, P837, DOI 10.1136/bmj.315.7112.837; GARN SM, 1974, AM J PHYS ANTHROPOL, V41, P353, DOI 10.1002/ajpa.1330410302; HARDING J, 1992, EARLY HUM DEV, V29, P193, DOI 10.1016/0378-3782(92)90149-B; HARDING JE, 1995, REPROD FERT DEVELOP, V7, P539, DOI 10.1071/RD9950539; Leon DA, 1998, BMJ-BRIT MED J, V317, P241, DOI 10.1136/bmj.317.7153.241; Lithell HO, 1996, BMJ-BRIT MED J, V312, P406; Mahonen M, 1997, EUR J EPIDEMIOL, V13, P403, DOI 10.1023/A:1007306110822; Martyn CN, 1996, LANCET, V348, P1264, DOI 10.1016/S0140-6736(96)04257-2; MARTYN CN, 1995, BRIT J HAEMATOL, V89, P142, DOI 10.1111/j.1365-2141.1995.tb08920.x; MARTYN CN, 1995, BRIT HEART J, V73, P116; OSMOND C, 1993, BRIT MED J, V307, P1519, DOI 10.1136/bmj.307.6918.1519; OUNSTED M, 1986, ANN HUM BIOL, V13, P143, DOI 10.1080/03014468600008281; PEDERSEN JF, 1980, BRIT MED J, V281, P1253, DOI 10.1136/bmj.281.6250.1253; PITTS GC, 1986, GROWTH, V50, P419; Rapola JM, 1997, EUR J EPIDEMIOL, V13, P133, DOI 10.1023/A:1007380408729; RichEdwards JW, 1997, BRIT MED J, V315, P396, DOI 10.1136/bmj.315.7105.396; ROYSTON P, 1991, STAT MED, V10, P675, DOI 10.1002/sim.4780100502; Stein CE, 1996, LANCET, V348, P1269, DOI 10.1016/S0140-6736(96)04547-3; TANNER JM, 1989, FOETUS MAN; WIDDOWSON EM, 1963, PROC R SOC SER B-BIO, V158, P329, DOI 10.1098/rspb.1963.0051	25	333	334	0	9	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	NOV 27	1999	319	7222					1403	1407		10.1136/bmj.319.7222.1403	http://dx.doi.org/10.1136/bmj.319.7222.1403			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	261EE	10574856	Bronze, Green Published			2022-12-01	WOS:000083995200027
J	Murphy, PC; Duckett, SG; Sillito, AM				Murphy, PC; Duckett, SG; Sillito, AM			Feedback connections to the lateral geniculate nucleus and cortical response properties	SCIENCE			English	Article							CAT VISUAL-CORTEX; CORTICOFUGAL FEEDBACK; NEURONS; PATHWAY; CELLS; AREA-17; HYPOTHESIS; MORPHOLOGY	The cerebral cortex receives sensory input from the periphery by means of thalamic relay nuclei, but the flow of information goes both ways. Each cortical area sends a reciprocal projection back to the thalamus. In the visual system, the synaptic relations that govern the influence of thalamic afferents on orientation selectivity in the cortex have been studied extensively. It now appears that the connectivity of the corticofugal feedback pathway is also fundamentally linked to the orientation preference of the cortical cells involved.	Univ London St Georges Hosp, Sch Med, Dept Physiol, London SW17 0RE, England; UCL, Inst Ophthalmol, Dept Visual Sci, London EC1V 9EL, England	St Georges University London; University of London; University College London	Murphy, PC (corresponding author), Univ London St Georges Hosp, Sch Med, Dept Physiol, London SW17 0RE, England.	p.murphy@sghms.ac.uk						AHMED B, 1994, J COMP NEUROL, V341, P39, DOI 10.1002/cne.903410105; ALBUS K, 1975, EXP BRAIN RES, V24, P181, DOI 10.1007/BF00234062; ANDOLINA IM, UNPUB; Cudeiro J, 1996, J PHYSIOL-LONDON, V490, P481, DOI 10.1113/jphysiol.1996.sp021159; Das A, 1999, NATURE, V399, P655, DOI 10.1038/21371; DAVIES OL, 1984, STAT METHODS RES PRO, P208; Erisir A, 1997, P NATL ACAD SCI USA, V94, P1517, DOI 10.1073/pnas.94.4.1517; GRIEVE KL, 1995, J NEUROSCI, V15, P4868; HARVEY AR, 1980, J PHYSIOL-LONDON, V302, P507; HENRY GH, 1994, PROG NEUROBIOL, V43, P381, DOI 10.1016/0301-0082(94)90061-2; HUBEL DH, 1962, J PHYSIOL-LONDON, V160, P106, DOI 10.1113/jphysiol.1962.sp006837; KATZ LC, 1987, J NEUROSCI, V7, P1223; KOCH C, 1987, NEUROSCIENCE, V23, P399, DOI 10.1016/0306-4522(87)90064-9; Maldonado PE, 1996, VISUAL NEUROSCI, V13, P509, DOI 10.1017/S095252380000818X; MCCORMICK DA, 1992, P NATL ACAD SCI USA, V89, P2774, DOI 10.1073/pnas.89.7.2774; MONTERO VM, 1991, EXP BRAIN RES, V86, P257; MURPHY PC, 1987, NATURE, V329, P727, DOI 10.1038/329727a0; Murphy PC, 1996, J NEUROSCI, V16, P1180; Murphy PC, 1996, J PHYSIOL-LONDON, V494P, pP17; Pinault D, 1996, J NEUROSCI METH, V65, P113, DOI 10.1016/0165-0270(95)00144-1; SANDERUD A, 1971, Scandinavian Journal of Thoracic and Cardiovascular Surgery, V5, P143, DOI 10.3109/14017437109135546; SILLITO AM, 1993, EXP BRAIN RES, V93, P6; SILLITO AM, 1995, NATURE, V378, P492, DOI 10.1038/378492a0; SILLITO AM, 1994, NATURE, V369, P479, DOI 10.1038/369479a0; SINGER W, 1995, ANNU REV NEUROSCI, V18, P555, DOI 10.1146/annurev.neuro.18.1.555; Usrey WM, 1999, ANNU REV PHYSIOL, V61, P435, DOI 10.1146/annurev.physiol.61.1.435; VARELA FJ, 1987, EXP BRAIN RES, V66, P10; WILSON JR, 1984, PROC R SOC SER B-BIO, V221, P411, DOI 10.1098/rspb.1984.0042	28	114	116	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 19	1999	286	5444					1552	1554		10.1126/science.286.5444.1552	http://dx.doi.org/10.1126/science.286.5444.1552			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	257DZ	10567260				2022-12-01	WOS:000083768300056
J	Arango, NA; Lovell-Badge, R; Behringer, RR				Arango, NA; Lovell-Badge, R; Behringer, RR			Targeted mutagenesis of the endogenous mouse Mis gene promoter: In vivo definition of genetic pathways of vertebrate sexual development	CELL			English	Article							MULLERIAN-INHIBITING SUBSTANCE; STEROIDOGENIC FACTOR-I; SRY-RELATED GENE; NUCLEAR RECEPTOR SF-1; CAMPOMELIC DYSPLASIA; GONADAL DEVELOPMENT; HORMONE-RECEPTOR; TRANSGENIC MICE; SOX9 EXPRESSION; DIFFERENTIATION	Mutations were introduced into conserved steroidogenic factor 1 (SF1)- and SOX9-binding sites within the endogenous mouse Mullerian inhibiting substance (Mis) promoter. Male mice homozygous for the mutant SF1-binding site correctly initiated Mis transcription in fetal testes, although at significantly reduced levels. Surprisingly, sufficient MIS was produced to eliminate the Mullerian ducts. In contrast, males homozygous for the mutant SOX9-binding site did not initiate Mis transcription, resulting in pseudohermaphrodites. These studies suggest an essential role for SOX9 in the initiation of Mis transcription, whereas SF1 appears to act as a quantitative regulator of Mis transcript levels, perhaps for influencing non-Mullerian duct tissues. Comparative studies of Mis expression in vertebrates indicate that the Mis promoter receives transcriptional inputs that vary between species but result in the same functional readout.	Univ Texas, MD Anderson Canc Ctr, Dept Mol Genet, Houston, TX 77030 USA; Natl Inst Med Res, Div Dev Genet, London NW7 1AA, England	University of Texas System; UTMD Anderson Cancer Center; MRC National Institute for Medical Research	Behringer, RR (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Mol Genet, Houston, TX 77030 USA.	rrb@notes.mdacc.tmc.edu		Lovell-Badge, Robin/0000-0001-9364-4179	MRC [MC_U117562207] Funding Source: UKRI; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [R37HD030284, R01HD030284] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [T32CA009299] Funding Source: NIH RePORTER; Medical Research Council [MC_U117562207] Funding Source: Medline; NCI NIH HHS [CA09299] Funding Source: Medline; NICHD NIH HHS [HD30284] Funding Source: Medline	MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ARCECI RJ, 1993, MOL CELL BIOL, V13, P2235, DOI 10.1128/MCB.13.4.2235; BAARENDS WM, 1994, DEVELOPMENT, V120, P189; Baroiller JF, 1999, CELL MOL LIFE SCI, V55, P910, DOI 10.1007/s000180050344; BEHRINGER RR, 1990, NATURE, V345, P167, DOI 10.1038/345167a0; BEHRINGER RR, 1994, CELL, V79, P415, DOI 10.1016/0092-8674(94)90251-8; CALL KM, 1990, CELL, V60, P509, DOI 10.1016/0092-8674(90)90601-A; CARREEUSEBE D, 1996, J BIOL CHEM, V271, P4798; CATE RL, 1986, CELL, V45, P685, DOI 10.1016/0092-8674(86)90783-X; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; daSilva SM, 1996, NAT GENET, V14, P62, DOI 10.1038/ng0996-62; De Santa Barbara P, 1998, MOL CELL BIOL, V18, P6653, DOI 10.1128/MCB.18.11.6653; DICLEMENTE N, 1994, MOL ENDOCRINOL, V8, P1006, DOI 10.1210/me.8.8.1006; DRESSER DW, 1995, HUM MOL GENET, V4, P1613, DOI 10.1093/hmg/4.9.1613; ELBRECHT A, 1992, SCIENCE, V255, P467, DOI 10.1126/science.1734525; FOSTER JW, 1994, NATURE, V372, P525, DOI 10.1038/372525a0; Giuili G, 1997, DEVELOPMENT, V124, P1799; GOODFELLOW PN, 1993, ANNU REV GENET, V27, P71, DOI 10.1146/annurev.ge.27.120193.000443; GUBBAY J, 1990, NATURE, V346, P245, DOI 10.1038/346245a0; HACKER A, 1995, DEVELOPMENT, V121, P1603; HAQQ C, 1992, GENOMICS, V12, P665, DOI 10.1016/0888-7543(92)90291-Y; HAQQ CM, 1994, SCIENCE, V266, P1494, DOI 10.1126/science.7985018; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; HONDA S, 1993, J BIOL CHEM, V268, P7494; IKEDA Y, 1994, MOL ENDOCRINOL, V8, P654, DOI 10.1210/me.8.5.654; IMBEAUD S, 1995, NAT GENET, V11, P382, DOI 10.1038/ng1295-382; Josso N, 1997, CLIN ENDOCRINOL, V47, P137, DOI 10.1046/j.1365-2265.1997.2411044.x; JOSSO N, 1993, RECENT PROG HORM RES, V48, P1; JOST A, 1953, RECENT PROG HORM RES, V8, P379; Kent J, 1996, DEVELOPMENT, V122, P2813; Ketola I, 1999, ENDOCRINOLOGY, V140, P1470, DOI 10.1210/en.140.3.1470; Koopman P, 1993, ESSENTIAL DEV BIOL P, P233; KREIDBERG JA, 1993, CELL, V74, P679, DOI 10.1016/0092-8674(93)90515-R; LALA DS, 1992, MOL ENDOCRINOL, V6, P1249, DOI 10.1210/me.6.8.1249; Lee MM, 1999, ENDOCRINOLOGY, V140, P2819, DOI 10.1210/en.140.6.2819; LUO XR, 1994, CELL, V77, P481, DOI 10.1016/0092-8674(94)90211-9; LYET L, 1995, BIOL REPROD, V52, P444, DOI 10.1095/biolreprod52.2.444; MANSOUR S, 1995, J MED GENET, V32, P415, DOI 10.1136/jmg.32.6.415; MANSOUR SL, 1988, NATURE, V336, P348, DOI 10.1038/336348a0; MATZUK MM, 1995, MOL ENDOCRINOL, V9, P1337, DOI 10.1210/me.9.10.1337; MCMAHON AP, 1990, CELL, V62, P1073, DOI 10.1016/0092-8674(90)90385-R; Meier C, 1998, CAN J ZOOL, V76, P1188, DOI 10.1139/cjz-76-6-1188; Mishina Y, 1996, GENE DEV, V10, P2577, DOI 10.1101/gad.10.20.2577; MOROHASHI K, 1992, J BIOL CHEM, V267, P17913; MUNSTERBERG A, 1991, DEVELOPMENT, V113, P613; MUSCATELLI F, 1994, NATURE, V372, P672, DOI 10.1038/372672a0; Nachtigal MW, 1998, CELL, V93, P445, DOI 10.1016/S0092-8674(00)81172-1; Neeper M, 1996, GENE, V176, P203, DOI 10.1016/0378-1119(96)00248-X; Oreal E, 1998, DEV DYNAM, V212, P522, DOI 10.1002/(SICI)1097-0177(199808)212:4<522::AID-AJA5>3.0.CO;2-J; Parker KL, 1997, ENDOCR REV, V18, P361, DOI 10.1210/er.18.3.361; Pham CTN, 1996, P NATL ACAD SCI USA, V93, P13090, DOI 10.1073/pnas.93.23.13090; PICARD JY, 1986, P NATL ACAD SCI USA, V83, P5464, DOI 10.1073/pnas.83.15.5464; Pieau Claude, 1994, P433; Racine C, 1998, P NATL ACAD SCI USA, V95, P594, DOI 10.1073/pnas.95.2.594; RAMIREZSOLIS R, 1992, ANAL BIOCHEM, V201, P331, DOI 10.1016/0003-2697(92)90347-A; SHEN WH, 1994, CELL, V77, P651, DOI 10.1016/0092-8674(94)90050-7; Smith CA, 1999, GEN COMP ENDOCR, V113, P187, DOI 10.1006/gcen.1998.7214; Swain A, 1999, GENE DEV, V13, P755, DOI 10.1101/gad.13.7.755; Swain A, 1996, NAT GENET, V12, P404, DOI 10.1038/ng0496-404; Tremblay JJ, 1999, MOL ENDOCRINOL, V13, P1388, DOI 10.1210/me.13.8.1388; Viger RS, 1998, DEVELOPMENT, V125, P2665; WAGNER T, 1994, CELL, V79, P1111, DOI 10.1016/0092-8674(94)90041-8; Western PS, 1999, DEV DYNAM, V214, P171, DOI 10.1002/(SICI)1097-0177(199903)214:3<171::AID-AJA1>3.3.CO;2-J; WIBBELS T, 1992, J EXP ZOOL, V262, P454, DOI 10.1002/jez.1402620413; Wibbels T, 1998, J EXP ZOOL, V281, P409, DOI 10.1002/(SICI)1097-010X(19980801)281:5<409::AID-JEZ6>3.0.CO;2-S; WILSON TE, 1993, MOL CELL BIOL, V13, P5794, DOI 10.1128/MCB.13.9.5794; WRIGHT E, 1995, NAT GENET, V9, P15, DOI 10.1038/ng0195-15	66	356	364	3	10	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	NOV 12	1999	99	4					409	419		10.1016/S0092-8674(00)81527-5	http://dx.doi.org/10.1016/S0092-8674(00)81527-5			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	256CX	10571183	Bronze			2022-12-01	WOS:000083709300008
J	Gross, SD; Schwab, MS; Lewellyn, AL; Maller, JL				Gross, SD; Schwab, MS; Lewellyn, AL; Maller, JL			Induction of metaphase arrest in cleaving Xenopus embryos in by the protein kinase p90(Rsk)	SCIENCE			English	Article							OOCYTE MATURATION; MAP KINASE; MOS; PHOSPHORYLATION; DOMAINS; ACTIVATION; PP90(RSK); CELLS	Before fertilization, vertebrate eggs are arrested in metaphase of meiosis II by cytostatic factor (CSF), an activity that requires activation of the mitogen-activated protein kinase (MAPK) pathway. To investigate whether CSF arrest is mediated by the protein kinase p90(Rsk), which is phosphorylated and activated by MAPK, a constitutively activated (CA) form of Rsk was expressed in Xenopus embryos. Expression of CA Rsk resulted in cleavage arrest, and cytological analysis showed that arrested blastomeres were in M phase with prominent spindles characteristic of meiotic metaphase. Thus, Rsk appears to be the mediator of MAPK-dependent CSF arrest in vertebrate unfertilized eggs.	Univ Colorado, Sch Med, Howard Hughes Med Inst, Denver, CO 80262 USA; Univ Colorado, Sch Med, Dept Pharmacol, Denver, CO 80262 USA	Howard Hughes Medical Institute; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	Maller, JL (corresponding author), Univ Colorado, Sch Med, Howard Hughes Med Inst, Denver, CO 80262 USA.			Gross, Stefan/0000-0002-5645-7304	NIDDK NIH HHS [DK28353] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK028353] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Alessi DR, 1998, CURR BIOL, V8, P69, DOI 10.1016/S0960-9822(98)70037-5; Bhatt RR, 1999, SCIENCE, V286, P1362, DOI 10.1126/science.286.5443.1362; BJORBAEK C, 1995, J BIOL CHEM, V270, P18848, DOI 10.1074/jbc.270.32.18848; Dalby KN, 1998, J BIOL CHEM, V273, P1496, DOI 10.1074/jbc.273.3.1496; ERIKSON E, 1989, J BIOL CHEM, V264, P13711; Fisher TL, 1996, MOL CELL BIOL, V16, P1212; FUKASAWA K, 1995, P NATL ACAD SCI USA, V92, P3430, DOI 10.1073/pnas.92.8.3430; GARD DL, 1992, DEV BIOL, V151, P516, DOI 10.1016/0012-1606(92)90190-R; HACCARD O, 1993, SCIENCE, V262, P1262, DOI 10.1126/science.8235656; JONES SW, 1988, P NATL ACAD SCI USA, V85, P3377, DOI 10.1073/pnas.85.10.3377; MANSOUR SJ, 1994, SCIENCE, V265, P966, DOI 10.1126/science.8052857; MASUI Y, 1971, J EXP ZOOL, V177, P129, DOI 10.1002/jez.1401770202; Matten WT, 1996, DEV BIOL, V179, P485, DOI 10.1006/dbio.1996.0277; MOLLER DE, 1994, AM J PHYSIOL, V266, P351; Pullen N, 1998, SCIENCE, V279, P707, DOI 10.1126/science.279.5351.707; Qian YW, 1998, MOL CELL BIOL, V18, P4262, DOI 10.1128/MCB.18.7.4262; Roy LM, 1996, ONCOGENE, V12, P2203; SAGATA N, 1989, NATURE, V342, P512, DOI 10.1038/342512a0; STURGILL TW, 1988, NATURE, V334, P715, DOI 10.1038/334715a0; ZHAO Y, 1995, MOL CELL BIOL, V15, P4353	20	133	141	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 12	1999	286	5443					1365	1367		10.1126/science.286.5443.1365	http://dx.doi.org/10.1126/science.286.5443.1365			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	255NF	10558992				2022-12-01	WOS:000083675500044
J	Jonas, EA; Buchanan, J; Kaczmarek, LK				Jonas, EA; Buchanan, J; Kaczmarek, LK			Prolonged activation of mitochondrial conductances during synaptic transmission	SCIENCE			English	Article							SQUID GIANT SYNAPSE; PERMEABILITY TRANSITION PORE; DIVALENT-CATIONS; OUTER-MEMBRANE; POSTTETANIC POTENTIATION; TRANSMITTER RELEASE; CHANNEL ACTIVITY; CA2+ TRANSIENTS; CALCIUM; MODULATION	Although ion channels have been detected in mitochondria, scientists have not been able to record ion transport in mitochondria of intact cells. A Variation of the patch clamp technique was used to record ion channel activity from intracellular organelles in the presynaptic terminal of the squid. Electron microscopy indicated that mitochondria are numerous in this terminal and are the only organelles compatible with the tips of the pipettes. Before synaptic stimulation, channel activity was infrequent and its conductance was small, although Large conductances (similar to 0.5 to 2.5 nanosiemens) could be detected occasionally. During a train of action potentials, the conductance of the mitochondrial membrane increased up to 60-fold, The conductance increased after a delay of several hundred milliseconds and continued to increase after stimulation had stopped. Recovery occurred over tens of seconds.	Yale Univ, Sch Med, Dept Pharmacol, New Haven, CT 06520 USA; Stanford Univ, Med Ctr, Dept Mol & Cellular Physiol, Stanford, CA 94305 USA	Yale University; Stanford University	Kaczmarek, LK (corresponding author), Yale Univ, Sch Med, Dept Pharmacol, New Haven, CT 06520 USA.	leonard.kaczmarek@yale.edu						ADAMS V, 1989, BIOCHIM BIOPHYS ACTA, V981, P213, DOI 10.1016/0005-2736(89)90031-X; ANTONENKO YN, 1994, BBA-BIOMEMBRANES, V1194, P247, DOI 10.1016/0005-2736(94)90306-9; AUGUSTINE GJ, 1984, J PHYSIOL-LONDON, V346, P257, DOI 10.1113/jphysiol.1984.sp015020; Babcock DF, 1998, CURR OPIN NEUROBIOL, V8, P398, DOI 10.1016/S0959-4388(98)80067-6; Babcock DF, 1997, J CELL BIOL, V136, P833, DOI 10.1083/jcb.136.4.833; BERNARDI P, 1992, J BIOL CHEM, V267, P2934; BRDICZKA D, 1994, J BIOL CHEM, V269, P27640; Budd SL, 1996, J NEUROCHEM, V66, P403, DOI 10.1046/j.1471-4159.1996.66010403.x; CHARLTON MP, 1978, J GEN PHYSIOL, V72, P471, DOI 10.1085/jgp.72.4.471; Colombini M, 1996, Ion Channels, V4, P169; DENTON RM, 1990, ANNU REV PHYSIOL, V52, P451, DOI 10.1146/annurev.ph.52.030190.002315; Dresbach T, 1998, J NEUROSCI, V18, P2923; FRIEL DD, 1994, J NEUROSCI, V14, P4007; GUNTER TE, 1990, AM J PHYSIOL, V258, pC755, DOI 10.1152/ajpcell.1990.258.5.C755; Herrington J, 1996, NEURON, V16, P219, DOI 10.1016/S0896-6273(00)80038-0; Hill K, 1998, NATURE, V395, P516, DOI 10.1038/26780; Hodge T, 1997, J MEMBRANE BIOL, V157, P271, DOI 10.1007/s002329900235; Ichas F, 1997, CELL, V89, P1145, DOI 10.1016/S0092-8674(00)80301-3; Jonas EA, 1997, NEURON, V19, P7, DOI 10.1016/S0896-6273(00)80343-8; JOUAVILLE LS, 1995, NATURE, V377, P438, DOI 10.1038/377438a0; Juin P, 1997, J BIOL CHEM, V272, P6044, DOI 10.1074/jbc.272.9.6044; KINNALLY KW, 1991, BIOCHEM BIOPH RES CO, V176, P1183, DOI 10.1016/0006-291X(91)90410-9; KINNALLY KW, 1994, MOL BIOL MITOCHONDRI, P169; Kunkele KP, 1998, CELL, V93, P1009, DOI 10.1016/S0092-8674(00)81206-4; LEHNINGE.AL, 1970, BIOCHEM J, V119, P128; LLINAS R, 1981, BIOPHYS J, V33, P289, DOI 10.1016/S0006-3495(81)84898-9; LOEW LM, 1994, P NATL ACAD SCI USA, V91, P12579, DOI 10.1073/pnas.91.26.12579; MITCHELL P, 1961, NATURE, V191, P144, DOI 10.1038/191144a0; MIYATA H, 1991, AM J PHYSIOL, V261, pH1123, DOI 10.1152/ajpheart.1991.261.4.H1123; Peng YY, 1998, J NEUROPHYSIOL, V80, P186, DOI 10.1152/jn.1998.80.1.186; PETRONILLI V, 1989, FEBS LETT, V259, P137, DOI 10.1016/0014-5793(89)81513-3; Pivovarova NB, 1998, J GEN PHYSIOL, V112, p39A; PRALONG WF, 1994, J BIOL CHEM, V269, P27310; Rizzuto R, 1998, SCIENCE, V280, P1763, DOI 10.1126/science.280.5370.1763; RIZZUTO R, 1993, SCIENCE, V262, P744, DOI 10.1126/science.8235595; RIZZUTO R, 1992, NATURE, V358, P325, DOI 10.1038/358325a0; Rostovtseva T, 1996, J BIOL CHEM, V271, P28006, DOI 10.1074/jbc.271.45.28006; Schatz G, 1998, NATURE, V395, P439, DOI 10.1038/26620; Scorrano L, 1997, J BIOL CHEM, V272, P12295, DOI 10.1074/jbc.272.19.12295; SORGATO MC, 1987, NATURE, V330, P498, DOI 10.1038/330498a0; SORGATO MC, 1993, CRIT REV BIOCHEM MOL, V28, P127; SPARAGNA GC, 1995, J BIOL CHEM, V270, P27510, DOI 10.1074/jbc.270.46.27510; SWANDULLA D, 1991, NEURON, V7, P915, DOI 10.1016/0896-6273(91)90337-Y; SZABO I, 1992, J BIOL CHEM, V267, P2940; Tang YG, 1997, NEURON, V18, P483, DOI 10.1016/S0896-6273(00)81248-9	45	76	77	0	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 12	1999	286	5443					1347	1350		10.1126/science.286.5443.1347	http://dx.doi.org/10.1126/science.286.5443.1347			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	255NF	10558987				2022-12-01	WOS:000083675500039
J	Puigserver, P; Adelmant, C; Wu, ZD; Fan, M; Xu, JM; O'Malley, B; Spiegelman, BM				Puigserver, P; Adelmant, C; Wu, ZD; Fan, M; Xu, JM; O'Malley, B; Spiegelman, BM			Activation of PPAR gamma coactivator-1 through transcription factor docking	SCIENCE			English	Article							STEROID-RECEPTOR COACTIVATOR-1; HISTONE ACETYLTRANSFERASE; ONCOPROTEIN; BINDING; SRC-1; E1A	Transcriptional coactivators have been viewed as constitutively active components, using transcription factors mainly to Localize their functions. Here, it is shown that PPAR gamma coactivator-1 (PGC-1) promotes transcription through the assembly of a complex that includes the histone acetyltransferases steroid receptor coactivator-1 (SRC-1) and CREB binding protein (CBP)/p300. PGC-1 has a Low inherent transcriptional activity when it is not bound to a transcription factor. The docking of PGC-1 to peroxisome proliferator-activated receptor gamma (PPAR gamma) stimulates an apparent conformational change in PGC-1 that permits binding of SRC-1 and CBP/p300, resulting in a Large increase in transcriptional activity. Thus, transcription factor docking switches on the activity of a coactivator protein.	Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02115 USA; Baylor Coll Med, Dept Cell Biol, Houston, TX 77040 USA	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Harvard Medical School; Baylor College of Medicine	Spiegelman, BM (corresponding author), Harvard Univ, Sch Med, Dana Farber Canc Inst, 44 Binney St, Boston, MA 02115 USA.	bruce_spiegelman@dfci.harvard.edu			NIDDK NIH HHS [DK54477] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK054477, R56DK054477] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ARANY Z, 1995, NATURE, V374, P81, DOI 10.1038/374081a0; BROWNELL JE, 1995, P NATL ACAD SCI USA, V92, P6364, DOI 10.1073/pnas.92.14.6364; Chakravarti D, 1999, CELL, V96, P393, DOI 10.1016/S0092-8674(00)80552-8; Chawla S, 1998, SCIENCE, V281, P1505, DOI 10.1126/science.281.5382.1505; Fondell JD, 1999, P NATL ACAD SCI USA, V96, P1959, DOI 10.1073/pnas.96.5.1959; Gelman L, 1999, J BIOL CHEM, V274, P7681, DOI 10.1074/jbc.274.12.7681; Hamamori Y, 1999, CELL, V96, P405, DOI 10.1016/S0092-8674(00)80553-X; Hardingham GE, 1999, NEURON, V22, P789, DOI 10.1016/S0896-6273(00)80737-0; Hu SC, 1999, NEURON, V22, P799, DOI 10.1016/S0896-6273(00)80738-2; Ito M, 1999, MOL CELL, V3, P361, DOI 10.1016/S1097-2765(00)80463-3; Kurokawa R, 1998, SCIENCE, V279, P700, DOI 10.1126/science.279.5351.700; Naar AM, 1999, NATURE, V398, P828, DOI 10.1038/19789; Nolte RT, 1998, NATURE, V395, P137, DOI 10.1038/25931; Puigserver P, 1998, CELL, V92, P829, DOI 10.1016/S0092-8674(00)81410-5; Rachez C, 1999, NATURE, V398, P824, DOI 10.1038/19783; Spencer TE, 1997, NATURE, V389, P194, DOI 10.1038/38304; Xu JM, 1998, SCIENCE, V279, P1922, DOI 10.1126/science.279.5358.1922; Xu L, 1999, CURR OPIN GENET DEV, V9, P140, DOI 10.1016/S0959-437X(99)80021-5; Yang XJ, 1996, NATURE, V382, P319, DOI 10.1038/382319a0; Yao TP, 1996, P NATL ACAD SCI USA, V93, P10626, DOI 10.1073/pnas.93.20.10626; ZU Z, 1999, CELL, V98, P115	21	465	489	0	20	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 12	1999	286	5443					1368	1371		10.1126/science.286.5443.1368	http://dx.doi.org/10.1126/science.286.5443.1368			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	255NF	10558993				2022-12-01	WOS:000083675500045
J	Buschbeck, E; Ehmer, B; Hoy, R				Buschbeck, E; Ehmer, B; Hoy, R			Chunk versus point sampling: Visual imaging in a small insect	SCIENCE			English	Article							SPIDER CUPIENNIUS-SALEI; ONE BRAIN; EYES; SYSTEMS	The eyes of strepsipteran insects are very unusual among living insects. In their anatomical organization they may form a modern counterpart to the structural plan proposed for the eyes of some trilobites. Externally they differ from the usual "insect plan" by presenting far fewer but much larger lenses. Beneath each lens is its own independent retina. Anatomical and optical measurements indicate that each of these units is image-forming, so that the visual field is subdivided into and represented by "chunks," unlike the conventional insect compound eye that decomposes the visual image in a pointwise manner. This results in profound changes In the neural centers for vision and implies major evolutionary changes.	Cornell Univ, Ithaca, NY 14853 USA	Cornell University	Ehmer, B (corresponding author), Cornell Univ, Mudd Hall, Ithaca, NY 14853 USA.							BRUNO MS, 1977, J COMP PHYSIOL, V120, P123, DOI 10.1007/BF00619310; DUELLI P, 1994, CELL TISSUE RES, V187, P417; FORDYCE D, 1993, PALEOBIOLOGY, V19, P288, DOI 10.1017/S0094837300000282; GILBERT C, 1994, ANNU REV ENTOMOL, V39, P23; HORRIDGE GA, 1977, ENDEAVOUR, V1, P7, DOI 10.1016/0160-9327(77)90004-7; Kinzelbach R., 1971, Handb Zool Berl, V4, P1; Land M.F., 1981, HDB SENSORY PHYSL, P471, DOI DOI 10.1007/978-3-642-66907-14; LAND MF, 1969, J EXP BIOL, V51, P443; MACCARTHY H R, 1991, Journal of the Entomological Society of British Columbia, V88, P27; MEIXNER J, 1936, HDB ZOOLOGIE, P1349; Nilsson D.-E., 1989, P30; Paulus H.F., 1979, P299; ROSCH P, 1913, Z NATURWISS, V50, P97; Sanchez D., 1915, TRAB LAB INVEST BIOL, V13, P1, DOI DOI 10.5962/BHL.TITLE.37839; SNYDER AW, 1977, J COMP PHYSIOL, V116, P161, DOI 10.1007/BF00605401; STRAUSFELD NJ, 1993, J COMP NEUROL, V328, P63, DOI 10.1002/cne.903280105; STRAUSFELD NJ, 1993, J COMP NEUROL, V328, P43, DOI 10.1002/cne.903280104; Strohm Karl, 1910, Zoologischer Anzeiger Leipzig, V36; TOH Y, 1994, CELL TISSUE RES, V278, P125, DOI 10.1007/BF00305784; WACHMANN E, 1972, Z ZELLFORSCH MIK ANA, V123, P411, DOI 10.1007/BF00335640; WARRANT EJ, 1993, PROG NEUROBIOL, V40, P413, DOI 10.1016/0301-0082(93)90017-M; WILSON M, 1978, J COMP PHYSIOL, V124, P297, DOI 10.1007/BF00661380	22	54	56	2	15	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 5	1999	286	5442					1178	1180		10.1126/science.286.5442.1178	http://dx.doi.org/10.1126/science.286.5442.1178			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	253AJ	10550059				2022-12-01	WOS:000083534200049
J	Gibson, JR; Beierlein, M; Connors, BW				Gibson, JR; Beierlein, M; Connors, BW			Two networks of electrically coupled inhibitory neurons in neocortex	NATURE			English	Article							INTRINSIC FIRING PATTERNS; RAT FRONTAL-CORTEX; BARREL CORTEX; IN-VITRO; SOMATOSENSORY CORTEX; CIRCUIT FORMATION; GAP-JUNCTIONS; SYNCHRONIZATION; INTERNEURONS; EXCITATION	Inhibitory interneurons are critical to sensory transformations, plasticity and synchronous activity in the neocortex(1,2). There are many types of inhibitory neurons, but their synaptic organization is poorly understood. Here we describe two functionally distinct inhibitory networks comprising either fast-spiking (FS) or low-threshold spiking (LTS) neurons. Paired-cell recordings showed that inhibitory neurons of the same type were strongly interconnected by electrical synapses, but electrical synapses between different inhibitory cell types were rare. The electrical synapses;were strong enough to synchronize spikes in coupled interneurons. Inhibitory chemical synapses were also common between FS cells, and between FS and LTS cells, but LTS cells rarely inhibited one another. Thalamocortical synapses, which convey sensory information to the cortex, specifically and strongly excited only the FS cell network. The electrical and chemical synaptic connections of different types of inhibitory neurons are specific, and may allow each inhibitory network to function independently.	Brown Univ, Dept Neurosci, Div Biol & Med, Providence, RI 02912 USA	Brown University	Connors, BW (corresponding author), Brown Univ, Dept Neurosci, Div Biol & Med, Providence, RI 02912 USA.		Connors, Barry/AAX-1975-2020	Beierlein, Michael/0000-0003-2210-3118; Connors, Barry/0000-0002-3739-3157				AGMON A, 1992, J NEUROSCI, V12, P319; AGMON A, 1991, NEUROSCIENCE, V41, P365, DOI 10.1016/0306-4522(91)90333-J; Benardo LS, 1997, J NEUROPHYSIOL, V77, P3134, DOI 10.1152/jn.1997.77.6.3134; Bennett M., 1977, HDB PHYSL          1, P357; BozhilovaPastirova A, 1995, NEUROSCI LETT, V201, P265, DOI 10.1016/0304-3940(95)12193-5; Buhl EH, 1998, J PHYSIOL-LONDON, V513, P117, DOI 10.1111/j.1469-7793.1998.117by.x; CHRISTIE MJ, 1989, J NEUROSCI, V9, P3584; CONNORS BW, 1990, TRENDS NEUROSCI, V13, P99, DOI 10.1016/0166-2236(90)90185-D; CONNORS BW, 1983, J NEUROSCI, V3, P773; DERMIETZEL R, 1993, TRENDS NEUROSCI, V16, P186, DOI 10.1016/0166-2236(93)90151-B; Gil Z, 1999, NEURON, V23, P385, DOI 10.1016/S0896-6273(00)80788-6; JEFFERYS JGR, 1995, PHYSIOL REV, V75, P689, DOI 10.1152/physrev.1995.75.4.689; Jefferys JGR, 1996, TRENDS NEUROSCI, V19, P202, DOI 10.1016/S0166-2236(96)10023-0; JOHNSTON MF, 1980, NATURE, V286, P498, DOI 10.1038/286498a0; JONES EG, 1993, CEREB CORTEX, V3, P361, DOI 10.1093/cercor/3.5.361-a; Kawaguchi Y, 1998, J NEUROSCI, V18, P6963; Kawaguchi Y, 1997, CEREB CORTEX, V7, P476, DOI 10.1093/cercor/7.6.476; Mann-Metzer P, 1999, J NEUROSCI, V19, P3298; MICHELSON HB, 1994, J PHYSIOL-LONDON, V477, P35, DOI 10.1113/jphysiol.1994.sp020169; Nadarajah B, 1997, J NEUROSCI, V17, P3096; PEINADO A, 1993, NEURON, V10, P103, DOI 10.1016/0896-6273(93)90246-N; Reyes A, 1998, NAT NEUROSCI, V1, P279, DOI 10.1038/1092; SIMONS DJ, 1984, J COMP NEUROL, V230, P119, DOI 10.1002/cne.902300111; SLOPER JJ, 1978, PROC R SOC SER B-BIO, V203, P39, DOI 10.1098/rspb.1978.0089; Somogyi P, 1998, BRAIN RES REV, V26, P113, DOI 10.1016/S0165-0173(97)00061-1; Staiger JF, 1996, EUR J NEUROSCI, V8, P2273, DOI 10.1111/j.1460-9568.1996.tb01191.x; Swadlow HA, 1998, J NEUROPHYSIOL, V79, P567, DOI 10.1152/jn.1998.79.2.567; Thomson AM, 1997, CEREB CORTEX, V7, P510, DOI 10.1093/cercor/7.6.510; Veenstra RD, 1996, J BIOENERG BIOMEMBR, V28, P327, DOI 10.1007/BF02110109; Xiang ZX, 1998, SCIENCE, V281, P985, DOI 10.1126/science.281.5379.985	30	1087	1105	0	48	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	NOV 4	1999	402	6757					75	79		10.1038/47035	http://dx.doi.org/10.1038/47035			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	254XC	10573419				2022-12-01	WOS:000083638600045
J	Lee, MJ; Thangada, S; Claffey, KP; Ancellin, N; Liu, CH; Kluk, M; Volpi, M; Sha'afi, RI; Hla, T				Lee, MJ; Thangada, S; Claffey, KP; Ancellin, N; Liu, CH; Kluk, M; Volpi, M; Sha'afi, RI; Hla, T			Vascular endothelial cell adherens junction assembly and morphogenesis induced by sphingosine-1-phosphate	CELL			English	Article							PROTEIN-COUPLED RECEPTOR; DEPENDENT NEURITE RETRACTION; CAPILLARY-TUBE FORMATION; FIBROBLAST GROWTH-FACTOR; LYSOPHOSPHATIDIC ACID; ANGIOGENESIS INVITRO; SIGNAL-TRANSDUCTION; ACTIN CYTOSKELETON; MOLECULAR-CLONING; RHO	Vascular endothelial cells undergo morphogenesis into capillary networks in response to angiogenic factors. We show here that sphingosine-1-phosphate (SPP), a platelet-derived bioactive lipid, activates the EDG-1 and -3 subtypes of G protein-coupled receptors on endothelial cells to regulate angiogenesis. SPP induces the G(i)/mitogen-activated protein kinase/cell survival pathway and the smalt GTPase Rho- and Rac-coupled adherens junction assembly. Both EDG-1- and EDG-3-regulated signaling pathways are required for endothelial cell morphogenesis into capillary-like networks. Indeed, SPP synergized with polypeptide angiogenic growth factors in the formation of mature neovessels in vivo. These data define SPP as a novel regulator of angiogenesis.	Univ Connecticut, Ctr Hlth, Dept Physiol, Ctr Vasc Biol, Farmington, CT 06030 USA	University of Connecticut	Hla, T (corresponding author), Univ Connecticut, Ctr Hlth, Dept Physiol, Ctr Vasc Biol, Farmington, CT 06030 USA.		Hla, Timothy/G-5873-2012	Hla, Timothy/0000-0001-8355-4065	NCI NIH HHS [CA64436] Funding Source: Medline; NHLBI NIH HHS [HL54710] Funding Source: Medline; NIDDK NIH HHS [DK45659] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA064436, R29CA064436] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL054710] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK045659] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Ackermann EJ, 1999, J BIOL CHEM, V274, P11245, DOI 10.1074/jbc.274.16.11245; An SZ, 1998, J BIOL CHEM, V273, P7906, DOI 10.1074/jbc.273.14.7906; ANDELLIN N, 1999, J BIOL CHEM, V274, P18997; Bach TL, 1998, EXP CELL RES, V238, P324, DOI 10.1006/excr.1997.3844; Bader BL, 1998, CELL, V95, P507, DOI 10.1016/S0092-8674(00)81618-9; Bishop-Bailey D, 1999, J BIOL CHEM, V274, P17042, DOI 10.1074/jbc.274.24.17042; Braga VMM, 1997, J CELL BIOL, V137, P1421, DOI 10.1083/jcb.137.6.1421; Carmeliet P, 1999, CELL, V98, P147, DOI 10.1016/S0092-8674(00)81010-7; Cuvillier O, 1996, NATURE, V381, P800, DOI 10.1038/381800a0; Eliceiri BP, 1999, J CLIN INVEST, V103, P1227, DOI 10.1172/JCI6869; Esser S, 1998, J CELL SCI, V111, P1853; Exton JH, 1997, EUR J BIOCHEM, V243, P10, DOI 10.1111/j.1432-1033.1997.t01-1-00010.x; FOLKMAN J, 1980, NATURE, V288, P551, DOI 10.1038/288551a0; FOLKMAN J, 1995, NAT MED, V1, P27, DOI 10.1038/nm0195-27; FRIEDLANDER M, 1995, SCIENCE, V270, P1500, DOI 10.1126/science.270.5241.1500; FRIESEL RE, 1995, FASEB J, V9, P919, DOI 10.1096/fasebj.9.10.7542215; GAMBLE JR, 1993, J CELL BIOL, V121, P931, DOI 10.1083/jcb.121.4.931; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; Hecht JH, 1996, J CELL BIOL, V135, P1071, DOI 10.1083/jcb.135.4.1071; HINCK L, 1994, J CELL BIOL, V125, P1327, DOI 10.1083/jcb.125.6.1327; HLA T, 1990, J BIOL CHEM, V265, P9308; Hla T, 1999, BIOCHEM PHARMACOL, V58, P201; Ilan N, 1998, J CELL SCI, V111, P3621; IruelaArispe ML, 1997, THROMB HAEMOSTASIS, V78, P672; Katoh H, 1998, J BIOL CHEM, V273, P28700, DOI 10.1074/jbc.273.44.28700; Lee MJ, 1998, SCIENCE, V279, P1552, DOI 10.1126/science.279.5356.1552; Lee MJ, 1996, J BIOL CHEM, V271, P11272, DOI 10.1074/jbc.271.19.11272; LEUNG DW, 1989, SCIENCE, V246, P1306, DOI 10.1126/science.2479986; Liu CH, 1999, MOL BIOL CELL, V10, P1179, DOI 10.1091/mbc.10.4.1179; Liu CH, 1997, GENOMICS, V43, P15, DOI 10.1006/geno.1997.4759; MacrezLepretre N, 1997, J BIOL CHEM, V272, P10095; MICHIELS F, 1995, NATURE, V375, P338, DOI 10.1038/375338a0; Mitchell R, 1998, NATURE, V392, P411, DOI 10.1038/32937; MONTESANO R, 1985, CELL, V42, P469, DOI 10.1016/0092-8674(85)90104-7; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; OKAZAKI H, 1993, BIOCHEM BIOPH RES CO, V190, P1104, DOI 10.1006/bbrc.1993.1163; OReilly MS, 1997, CELL, V88, P277, DOI 10.1016/S0092-8674(00)81848-6; PASSANITI A, 1992, LAB INVEST, V67, P519; Postma FR, 1996, EMBO J, V15, P2388, DOI 10.1002/j.1460-2075.1996.tb00595.x; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; Satake S, 1998, BIOCHEM BIOPH RES CO, V244, P642, DOI 10.1006/bbrc.1998.8313; Spiegel S, 1996, FASEB J, V10, P1388, DOI 10.1096/fasebj.10.12.8903509; Takaishi K, 1997, J CELL BIOL, V139, P1047, DOI 10.1083/jcb.139.4.1047; VOLPI M, 1988, J CELL BIOL, V107, P2533, DOI 10.1083/jcb.107.6.2533; Windh RT, 1999, J BIOL CHEM, V274, P27351, DOI 10.1074/jbc.274.39.27351; Wojciak-Stothard B, 1998, J CELL PHYSIOL, V176, P150, DOI 10.1002/(SICI)1097-4652(199807)176:1<150::AID-JCP17>3.0.CO;2-B; Yamaguchi F, 1996, BIOCHEM BIOPH RES CO, V227, P608, DOI 10.1006/bbrc.1996.1553; Yap AS, 1997, ANNU REV CELL DEV BI, V13, P119, DOI 10.1146/annurev.cellbio.13.1.119; Yatomi Y, 1997, J BIOCHEM, V121, P969	49	826	853	0	24	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	OCT 29	1999	99	3					301	312		10.1016/S0092-8674(00)81661-X	http://dx.doi.org/10.1016/S0092-8674(00)81661-X			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	251HX	10555146	Bronze			2022-12-01	WOS:000083440600008
J	Okano, M; Bell, DW; Haber, DA; Li, E				Okano, M; Bell, DW; Haber, DA; Li, E			DNA methyltransferases Dnmt3a and Dnmt3b are essential for de novo methylation and mammalian development	CELL			English	Article							EMBRYONIC STEM-CELLS; ICF SYNDROME; MOUSE CELLS; GERM-LINE; CYTOSINE-5 METHYLTRANSFERASES; DENOVO METHYLATION; RETROVIRAL GENOMES; DE-NOVO; GENE; EXPRESSION	The establishment of DNA methylation patterns requires de novo methylation that occurs predominantly during early development and gametogenesis in mice. Here we demonstrate that two recently identified DNA methyltransferases, Dnmt3a and Dnmt3b, are essential for de novo methylation and for mouse development. inactivation of both genes by gene targeting blocks de novo methylation in ES cells and early embryos, but it has no effect on maintenance of imprinted methylation patterns. Dnmt3a and Dnmt3b also exhibit nonoverlapping functions in development, with Dnmt3b specifically required for methylation of centromeric minor satellite repeats. Mutations of human DNMT3B are found in ICF syndrome, a developmental defect characterized by hypomethylation of pericentromeric repeats. Our results indicate that both Dnmt3a and Dnmt3b function as de novo methyltransferases that play important roles in normal development and disease.	Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept Med,Cardiovasc Res Ctr, Charlestown, MA 02129 USA; Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept Med,Canc Ctr, Charlestown, MA 02129 USA	Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital	Li, E (corresponding author), Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept Med,Cardiovasc Res Ctr, Charlestown, MA 02129 USA.	en@cvrc.mgh.harvard.edu			NATIONAL CANCER INSTITUTE [R01CA082389] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM052106] Funding Source: NIH RePORTER; NCI NIH HHS [CA82389] Funding Source: Medline; NIGMS NIH HHS [GM52106] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BESTOR T, 1988, J MOL BIOL, V203, P971, DOI 10.1016/0022-2836(88)90122-2; BESTOR TH, 1992, EMBO J, V11, P2611, DOI 10.1002/j.1460-2075.1992.tb05326.x; BROCKDORFF N, 1997, GENOMIC IMPRINTING, P191; CARPENTER NJ, 1988, J PEDIATR-US, V112, P757, DOI 10.1016/S0022-3476(88)80698-X; CHAILLET JR, 1991, CELL, V66, P77, DOI 10.1016/0092-8674(91)90140-T; CHAPMAN V, 1984, NATURE, V307, P284, DOI 10.1038/307284a0; Colot V, 1999, BIOESSAYS, V21, P402, DOI 10.1002/(SICI)1521-1878(199905)21:5<402::AID-BIES7>3.0.CO;2-B; EHRLICH M, 1999, DNA ALTERATIONS CANC; FEIL R, 1994, DEVELOPMENT, V120, P2933; Hasties ND, 1989, GENETIC VARIANTS STR, P559; Hogan B., 2014, MANIPULATING MOUSE E; HOLLIDAY R, 1975, SCIENCE, V187, P226, DOI 10.1126/science.1111098; HOWLETT SK, 1991, DEVELOPMENT, V113, P119; JAHNER D, 1982, NATURE, V298, P623, DOI 10.1038/298623a0; Jahner D., 1984, DNA METHYLATION BIOC, P189; JEANPIERRE M, 1993, HUM MOL GENET, V2, P731, DOI 10.1093/hmg/2.6.731; Ji WZ, 1997, MUTAT RES-FUND MOL M, V379, P33, DOI 10.1016/S0027-5107(97)00088-2; Jones PA, 1999, NAT GENET, V21, P163, DOI 10.1038/5947; KAFRI T, 1992, GENE DEV, V6, P705, DOI 10.1101/gad.6.5.705; KUMAR S, 1994, NUCLEIC ACIDS RES, V22, P1, DOI 10.1093/nar/22.1.1; Lei H, 1996, DEVELOPMENT, V122, P3195; LEONHARDT H, 1992, CELL, V71, P865, DOI 10.1016/0092-8674(92)90561-P; LI E, 1992, CELL, V69, P915, DOI 10.1016/0092-8674(92)90611-F; Li E., 1997, V18, P1; Liu WG, 1998, NUCLEIC ACIDS RES, V26, P1396, DOI 10.1093/nar/26.6.1396; MONK M, 1987, DEVELOPMENT, V99, P371; MOUNTFORD P, 1994, P NATL ACAD SCI USA, V91, P4303, DOI 10.1073/pnas.91.10.4303; Ng HH, 1999, CURR OPIN GENET DEV, V9, P158, DOI 10.1016/S0959-437X(99)80024-0; Okano M, 1998, NAT GENET, V19, P219, DOI 10.1038/890; Okano M, 1998, NUCLEIC ACIDS RES, V26, P2536, DOI 10.1093/nar/26.11.2536; PALMITER RD, 1982, CELL, V29, P701, DOI 10.1016/0092-8674(82)90186-6; Razin A., 1993, Experientia Supplementum (Basel), V64, P343; RIGGS AD, 1975, CYTOGENET CELL GENET, V14, P9, DOI 10.1159/000130315; Robertson KD, 1999, NUCLEIC ACIDS RES, V27, P2291, DOI 10.1093/nar/27.11.2291; SANFORD JP, 1987, GENE DEV, V1, P1039, DOI 10.1101/gad.1.10.1039; SMEETS DFCM, 1994, HUM GENET, V94, P240; STEIN R, 1982, P NATL ACAD SCI-BIOL, V79, P61, DOI 10.1073/pnas.79.1.61; STEWART CL, 1982, P NATL ACAD SCI-BIOL, V79, P4098, DOI 10.1073/pnas.79.13.4098; STOGER R, 1993, CELL, V73, P61, DOI 10.1016/0092-8674(93)90160-R; Surani MA, 1998, CELL, V93, P309, DOI 10.1016/S0092-8674(00)81156-3; TREMBLAY KD, 1995, NAT GENET, V9, P407, DOI 10.1038/ng0495-407; Tucker KL, 1996, GENE DEV, V10, P1008, DOI 10.1101/gad.10.8.1008; Walsh CP, 1998, NAT GENET, V20, P116, DOI 10.1038/2413; WIGLER M, 1981, CELL, V24, P33, DOI 10.1016/0092-8674(81)90498-0; Wijmenga C, 1998, AM J HUM GENET, V63, P803, DOI 10.1086/302021; Xie SP, 1999, GENE, V236, P87, DOI 10.1016/S0378-1119(99)00252-8; Yoder JA, 1997, J MOL BIOL, V270, P385, DOI 10.1006/jmbi.1997.1125	47	4191	4393	16	376	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	OCT 29	1999	99	3					247	257		10.1016/S0092-8674(00)81656-6	http://dx.doi.org/10.1016/S0092-8674(00)81656-6			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	251HX	10555141	Bronze			2022-12-01	WOS:000083440600003
J	Shatursky, O; Heuck, AP; Shepard, LA; Rossjohn, J; Parker, MW; Johnson, AE; Tweten, RK				Shatursky, O; Heuck, AP; Shepard, LA; Rossjohn, J; Parker, MW; Johnson, AE; Tweten, RK			The mechanism of membrane insertion for a cholesterol-dependent cytolysin: A novel paradigm for pore-forming toxins	CELL			English	Article							PERFRINGOLYSIN-O; PROTECTIVE ANTIGEN; THETA-TOXIN; BINDING; IDENTIFICATION; HEMOLYSIN; BILAYERS; DOMAIN	Perfringolysin O (PFO), a water-soluble monomeric cytolysin secreted by pathogenic Clostridium perfringens, oligomerizes and forms large pores upon encountering cholesterol-containing membranes. Whereas all pore-forming bacterial toxins examined previously have been shown to penetrate the membrane using a single amphipathic beta hairpin per polypeptide, cysteine-scanning mutagenesis and multiple independent fluorescence techniques here reveal that each PFO monomer contains a second domain involved in pore formation, and that each of the two amphipathic a hairpins completely spans the membrane. In the soluble monomer, these transmembrane segments are folded into six alpha helices. The insertion of two transmembrane hairpins per toxin monomer and the major change in secondary structure are striking and define a novel paradigm far the mechanism of membrane insertion by a cytolytic toxin.	Texas A&M Univ, Dept Med Biochem & Genet, College Stn, TX 77843 USA; Univ Oklahoma, Hlth Sci Ctr, Dept Microbiol & Immunol, Oklahoma City, OK 73190 USA; Texas A&M Univ, Dept Chem, College Stn, TX 77843 USA; Texas A&M Univ, Dept Biochem & Biophys, College Stn, TX 77843 USA; St Vincents Inst Med Res, Ian Potter Fdn, Prot Crystallog Lab, Fitzroy, Vic 3065, Australia	Texas A&M University System; Texas A&M University College Station; University of Oklahoma System; University of Oklahoma Health Sciences Center; Texas A&M University System; Texas A&M University College Station; Texas A&M University System; Texas A&M University College Station; St. Vincent's Institute of Medical Research	Johnson, AE (corresponding author), Texas A&M Univ, Dept Med Biochem & Genet, College Stn, TX 77843 USA.		Parker, Michael W/F-9069-2013; Johnson, Arthur E/G-3457-2012; Rossjohn, Jamie/F-9032-2013	Parker, Michael W/0000-0002-3101-1138; Rossjohn, Jamie/0000-0002-2020-7522	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI037657, R37AI037657] Funding Source: NIH RePORTER; NIAID NIH HHS [R01 AI037657, AI37657] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Benson EL, 1998, BIOCHEMISTRY-US, V37, P3941, DOI 10.1021/bi972657b; CHATTOPADHYAY A, 1987, BIOCHEMISTRY-US, V26, P39, DOI 10.1021/bi00375a006; CROWLEY KS, 1993, CELL, V73, P1101, DOI 10.1016/0092-8674(93)90640-C; CROWLEY KS, 1994, CELL, V78, P461, DOI 10.1016/0092-8674(94)90424-3; Gilbert RJC, 1999, CELL, V97, P647, DOI 10.1016/S0092-8674(00)80775-8; MENESTRINA G, 1990, TOXICON, V28, P477, DOI 10.1016/0041-0101(90)90292-F; NAKAMURA M, 1995, BIOCHEMISTRY-US, V34, P6513, DOI 10.1021/bi00019a032; Oh KJ, 1996, SCIENCE, V273, P810, DOI 10.1126/science.273.5276.810; OLOFSSON A, 1993, FEBS LETT, V319, P125, DOI 10.1016/0014-5793(93)80050-5; Olson R, 1999, NAT STRUCT BIOL, V6, P134; Petosa C, 1997, NATURE, V385, P833, DOI 10.1038/385833a0; Rossjohn J, 1997, CELL, V89, P685, DOI 10.1016/S0092-8674(00)80251-2; Shepard LA, 1998, BIOCHEMISTRY-US, V37, P14563, DOI 10.1021/bi981452f; SHIN YK, 1993, SCIENCE, V259, P960, DOI 10.1126/science.8382373; Song LZ, 1996, SCIENCE, V274, P1859, DOI 10.1126/science.274.5294.1859; TWETEN RK, 1995, VIRULENCE MECHANISMS OF BACTERIAL PATHOGENS, 2ND EDITION, P207	16	288	292	0	18	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	OCT 29	1999	99	3					293	299		10.1016/S0092-8674(00)81660-8	http://dx.doi.org/10.1016/S0092-8674(00)81660-8			7	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	251HX	10555145	Bronze			2022-12-01	WOS:000083440600007
J	Turner, S				Turner, S			Place of pharmacotherapy in post-traumatic stress disorder	LANCET			English	Editorial Material									Camden & Islington Community Trust, Traumat Stress Clin, London W1P 1LB, England; UCL, London W1P 1LB, England	University of London; University College London; University of London; University College London	Turner, S (corresponding author), Camden & Islington Community Trust, Traumat Stress Clin, London W1P 1LB, England.							American Psychiatric Association (Washington), 2000, DSM 4 T DIAGN STAT M; Connor KM, 1999, BRIT J PSYCHIAT, V175, P17, DOI 10.1192/bjp.175.1.17; Foa EB, 1999, J CLIN PSYCHIAT S16, V60; KESSLER RC, 1995, ARCH GEN PSYCHIAT, V52, P1048, DOI 10.1001/archpsyc.1995.03950240066012; Shapiro F., 2001, EYE MOVEMENT DESENSI, V22; Van Etten ML, 1998, CLIN PSYCHOL PSYCHOT, V5, P126, DOI 10.1002/(SICI)1099-0879(199809)5:3<126::AID-CPP153>3.3.CO;2-8; Yehuda R, 1998, REV PSYCHIAT SER, V17, P97	7	5	5	0	3	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	OCT 23	1999	354	9188					1404	1405		10.1016/S0140-6736(99)00245-7	http://dx.doi.org/10.1016/S0140-6736(99)00245-7			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	248LY	10543663				2022-12-01	WOS:000083277400006
J	Lukas, C; Sorensen, CS; Kramer, E; Santoni-Rugiu, E; Lindeneg, C; Peters, JM; Bartek, J; Lukas, J				Lukas, C; Sorensen, CS; Kramer, E; Santoni-Rugiu, E; Lindeneg, C; Peters, JM; Bartek, J; Lukas, J			Accumulation of cyclin B1 requires E2F and cyclin-A-dependent rearrangement of the anaphase-promoting complex	NATURE			English	Article							S-PHASE PROGRESSION; CELL-CYCLE; RETINOBLASTOMA-PROTEIN; MITOTIC CYCLINS; PROTEOLYSIS; MITOSIS; ACTIVATION; FAMILY; UBIQUITIN; YEAST	In mammalian somatic-cell cycles, progression through the G1-phase restriction point and initiation of DNA replication are controlled by the ability of the retinoblastoma tumour-suppressor protein (pRb) family to regulate the E2F/DP transcription factors(1,2). Continuing transcription of E2F target genes beyond the G1/S transition is required for coordinating S-phase progression with cell division(3-5), a process driven by cyclin-B-dependent kinase(6,7) and anaphase-promoting complex (APC)-mediated proteolysis(8). How E2F-dependent events at G1/S transition are orchestrated with cyclin B and APC activity remains unknown. Here, using an in vivo assay to measure protein stability in real time during the cell cycle, we show that repression of E2F activity or inhibition of cyclin-A-dependent kinase in S phase triggers the destruction of cyclin B1 through the re-assembly of APC, the ubiquitin ligase that is essential for mitotic cyclin proteolysis(9), with its activatory subunit Cdh1 (refs 10-13). Phosphorylation-deficient mutant Cdh1 or immunodepletion of cyclin A resulted in assembly of active Cdh1-APC even in S-phase cells. These results implicate an E2F-dependent, cyclin A/Cdk2-mediated phosphorylation of Cdh1 in the timely accumulation of cyclin B1 and the coordination of cell-cycle progression during the post-restriction point period.	Danish Canc Soc, Inst Canc Biol, DK-2100 Copenhagen O, Denmark; Res Inst Mol Pathol, A-1030 Vienna, Austria	Danish Cancer Society; Vienna Biocenter (VBC); Research Institute of Molecular Pathology (IMP)	Bartek, J (corresponding author), Danish Canc Soc, Inst Canc Biol, Strandblvd 49, DK-2100 Copenhagen O, Denmark.		Santoni-Rugiu, Eric/AAH-3368-2020; Kramer, Edgar/A-9288-2012; Santoni-Rugiu, Eric/H-4913-2019; Bartek, Jiri/G-5870-2014	Santoni-Rugiu, Eric/0000-0002-2283-3535; Kramer, Edgar/0000-0002-4882-4143; Lukas, Claudia/0000-0001-7169-6883; Sorensen, Claus/0000-0001-6022-9710				AMON A, 1994, CELL, V77, P1037, DOI 10.1016/0092-8674(94)90443-X; Brandeis M, 1996, EMBO J, V15, P5280, DOI 10.1002/j.1460-2075.1996.tb00913.x; Chew YP, 1998, ONCOGENE, V17, P2177, DOI 10.1038/sj.onc.1202443; Dyson N, 1998, GENE DEV, V12, P2245, DOI 10.1101/gad.12.15.2245; Fang GW, 1998, MOL CELL, V2, P163, DOI 10.1016/S1097-2765(00)80126-4; GLOTZER M, 1991, NATURE, V349, P132, DOI 10.1038/349132a0; IOWNSLEY FM, 1998, TRENDS CELL BIOL, V8, P238; Irniger S, 1997, J CELL SCI, V110, P1523; Jaspersen SL, 1999, CURR BIOL, V9, P227, DOI 10.1016/S0960-9822(99)80111-0; JOHNSON DG, 1994, P NATL ACAD SCI USA, V91, P12823, DOI 10.1073/pnas.91.26.12823; KING RW, 1995, CELL, V81, P279, DOI 10.1016/0092-8674(95)90338-0; King RW, 1996, SCIENCE, V274, P1652, DOI 10.1126/science.274.5293.1652; KNOBLICH JA, 1994, CELL, V77, P107, DOI 10.1016/0092-8674(94)90239-9; Knudsen ES, 1998, GENE DEV, V12, P2278, DOI 10.1101/gad.12.15.2278; Kramer ER, 1998, CURR BIOL, V8, P1207, DOI 10.1016/S0960-9822(07)00510-6; LUKAS J, 1995, ONCOGENE, V10, P2125; LUKAS J, 1995, NATURE, V375, P503, DOI 10.1038/375503a0; Lukas J, 1997, GENE DEV, V11, P1479, DOI 10.1101/gad.11.11.1479; Lukas J, 1999, ONCOGENE, V18, P3930, DOI 10.1038/sj.onc.1202777; Nguyen H, 1999, MOL CELL BIOL, V19, P1190; NURSE P, 1990, NATURE, V344, P503, DOI 10.1038/344503a0; PINES J, 1991, J CELL BIOL, V115, P1, DOI 10.1083/jcb.115.1.1; Schwab M, 1997, CELL, V90, P683, DOI 10.1016/S0092-8674(00)80529-2; Sigrist SJ, 1997, CELL, V90, P671, DOI 10.1016/S0092-8674(00)80528-0; SOLOMON MJ, 1990, CELL, V63, P1013, DOI 10.1016/0092-8674(90)90504-8; SUDAKIN V, 1995, MOL BIOL CELL, V6, P185, DOI 10.1091/mbc.6.2.185; Visintin R, 1997, SCIENCE, V278, P460, DOI 10.1126/science.278.5337.460; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; Wu CL, 1996, MOL CELL BIOL, V16, P3698; Zachariae W, 1998, SCIENCE, V282, P1721, DOI 10.1126/science.282.5394.1721	30	250	255	0	8	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	OCT 21	1999	401	6755					815	818		10.1038/44611	http://dx.doi.org/10.1038/44611			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	250BG	10548110				2022-12-01	WOS:000083368700059
J	Gould, E; Reeves, AJ; Graziano, MSA; Gross, CG				Gould, E; Reeves, AJ; Graziano, MSA; Gross, CG			Neurogenesis in the neocortex of adult primates	SCIENCE			English	Article							HUMAN CEREBRAL-CORTEX; DENTATE GYRUS; PREFRONTAL CORTEX; HIPPOCAMPAL-NEURONS; RHESUS-MONKEY; CELL-CYCLE; YOUNG NEURONS; BRAIN; RAT; REPLACEMENT	In primates, prefrontal, inferior temporal, and posterior parietal cortex are important for cognitive function. It is shown that in adult macaques, new neurons are added to these three neocortical association areas, but not to a primary sensory area (striate cortex). The new neurons appeared to originate in the subventricular zone and to migrate through the white matter to the neocortex, where they extended axons, These new neurons, which are continually added in adulthood, may play a role in the functions of association neocortex.	Princeton Univ, Dept Psychol, Princeton, NJ 08544 USA	Princeton University	Gould, E (corresponding author), Princeton Univ, Dept Psychol, Princeton, NJ 08544 USA.				NEI NIH HHS [EY11347-29] Funding Source: Medline; NIMH NIH HHS [MH52423-05] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY011347] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [R29MH052423] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		ALTMAN J, 1963, ANAT REC, V145, P573, DOI 10.1002/ar.1091450409; ALTMAN J, 1969, J COMP NEUROL, V137, P433, DOI 10.1002/cne.901370404; ALTMAN J, 1965, J COMP NEUROL, V124, P319, DOI 10.1002/cne.901240303; ALTMAN J, 1967, NEUROSCIENCES STUDY, P723; ALVAREZBUYLLA A, 1988, NATURE, V335, P353, DOI 10.1038/335353a0; ALVAREZBUYLLA A, 1995, STEM CELLS, V13, P263, DOI 10.1002/stem.5530130307; ALVAREZBUYLLA A, 1992, J NEUROBIOL, V23, P396, DOI 10.1002/neu.480230406; ANDERSEN RA, 1985, J COMP NEUROL, V232, P443, DOI 10.1002/cne.902320403; Andersen RA, 1987, HDB PHYSL 1, VV, P483; BARBAS H, 1989, J COMP NEUROL, V286, P353, DOI 10.1002/cne.902860306; BARBAS H, 1988, J COMP NEUROL, V276, P313, DOI 10.1002/cne.902760302; Barnea A, 1996, P NATL ACAD SCI USA, V93, P714, DOI 10.1073/pnas.93.2.714; BARNEA A, 1994, P NATL ACAD SCI USA, V91, P11217, DOI 10.1073/pnas.91.23.11217; BAYER SA, 1990, EXP NEUROL, V107, P48, DOI 10.1016/0014-4886(90)90062-W; BOURGEOIS JP, 1994, CEREB CORTEX, V4, P78, DOI 10.1093/cercor/4.1.78; Cajal SRY., 1995, HISTOLOGY NERVOUS SY, V1; CAMERON HA, 1994, NEUROSCIENCE, V61, P203, DOI 10.1016/0306-4522(94)90224-0; CAMERON HA, 1993, NEUROSCIENCE, V56, P337, DOI 10.1016/0306-4522(93)90335-D; COLOMBEL M, 1992, CANCER RES, V52, P4313; Doetsch F, 1997, J NEUROSCI, V17, P5046; Eriksson PS, 1998, NAT MED, V4, P1313, DOI 10.1038/3305; Feinendegen LE, 1967, TRITIUM LABELED MOL; GOLDMAN SA, 1983, P NATL ACAD SCI-BIOL, V80, P2390, DOI 10.1073/pnas.80.8.2390; Goldman-Rakic P. S., 1987, HDB PHYSL, V5, P373, DOI DOI 10.1002/CPHY.CP010509; Gould E, 1999, NAT NEUROSCI, V2, P260, DOI 10.1038/6365; Gould E, 1999, TRENDS COGN SCI, V3, P186, DOI 10.1016/S1364-6613(99)01310-8; GOULD E, 1992, J NEUROSCI, V12, P3642; Gould E, 1997, J NEUROSCI, V17, P2492; Gould E, 1998, P NATL ACAD SCI USA, V95, P3168, DOI 10.1073/pnas.95.6.3168; Gould E, 1999, P NATL ACAD SCI USA, V96, P5263, DOI 10.1073/pnas.96.9.5263; GOULD E, UNPUB; Gross C. G., 1973, HDB SENSORY PHYSIOLO, P451; Honig LS, 1996, CEREB CORTEX, V6, P794, DOI 10.1093/cercor/6.6.794; KAPLAN MS, 1981, J COMP NEUROL, V195, P323, DOI 10.1002/cne.901950211; KAPLAN MS, 1977, SCIENCE, V197, P1092, DOI 10.1126/science.887941; Kempermann G, 1997, NATURE, V386, P493, DOI 10.1038/386493a0; Kolb B, 1998, BEHAV BRAIN RES, V91, P127, DOI 10.1016/S0166-4328(97)00112-5; LOPEZGARCIA C, 1988, BRAIN RES, V471, P167; Magiakou MA, 1996, CLIN ENDOCRINOL, V44, P419, DOI 10.1046/j.1365-2265.1996.683505.x; Martin RF, 1996, NEUROIMAGE, V4, P119, DOI 10.1006/nimg.1996.0036; Melchitzky DS, 1998, J COMP NEUROL, V390, P211, DOI 10.1002/(SICI)1096-9861(19980112)390:2<211::AID-CNE4>3.0.CO;2-4; Miller EK, 1996, J NEUROSCI, V16, P5154; MINTURN JE, 1995, J COMP NEUROL, V355, P369, DOI 10.1002/cne.903550304; Nauta WJ, 1970, NEUROSCIENCES, P7; NOTTEBOHM F, 1985, ANN NY ACAD SCI, V457, P143, DOI 10.1111/j.1749-6632.1985.tb20803.x; NOTTEBOHM F, 1989, NEURAL CONTROL REPRO, P583; NOWAKOWSKI RS, 1989, J NEUROCYTOL, V18, P311, DOI 10.1007/BF01190834; PATON JA, 1984, SCIENCE, V225, P1046, DOI 10.1126/science.6474166; Pincus D W, 1997, Clin Neurosurg, V44, P17; RAKIC P, 1985, ANN NY ACAD SCI, V457, P193, DOI 10.1111/j.1749-6632.1985.tb20806.x; Rakic P, 1998, NAT NEUROSCI, V1, P645, DOI 10.1038/3643; RAKIC P, 1985, SCIENCE, V227, P1054, DOI 10.1126/science.3975601; RAKIC P, 1978, POSTGRAD MED J, V54, P25; Rosselli-Austin L, 1979, J Dev Physiol, V1, P295; ROUSSELOT P, 1995, J COMP NEUROL, V351, P51, DOI 10.1002/cne.903510106; SCHWARTZ ML, 1984, J COMP NEUROL, V226, P403, DOI 10.1002/cne.902260309; Shankle WR, 1998, J THEOR BIOL, V191, P115, DOI 10.1006/jtbi.1997.0570; Sugita N, 1918, J COMP NEUROL, V29, P61, DOI 10.1002/cne.900290202; Thomaidou D, 1997, J NEUROSCI, V17, P1075, DOI 10.1523/jneurosci.17-03-01075.1997; WEST MJ, 1991, ANAT RECORD, V231, P482, DOI 10.1002/ar.1092310411	60	933	1011	2	37	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	OCT 15	1999	286	5439					548	552		10.1126/science.286.5439.548	http://dx.doi.org/10.1126/science.286.5439.548			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	245RD	10521353				2022-12-01	WOS:000083121200065
J	Luecke, H; Schobert, B; Richter, HT; Cartailler, JP; Lanyi, JK				Luecke, H; Schobert, B; Richter, HT; Cartailler, JP; Lanyi, JK			Structural changes in bacteriorhodopsin during ion transport at 2 Angstrom resolution	SCIENCE			English	Article							ORIENTED PURPLE MEMBRANES; LIPIDIC CUBIC PHASES; RETINAL SCHIFF-BASE; LOCAL-ACCESS MODEL; X-RAY-DIFFRACTION; REPROTONATION SWITCH; PROTON-TRANSFER; N-INTERMEDIATE; CHROMOPHORE ISOMERIZATION; DIFFERENCE SPECTROSCOPY	Crystal structures of the Asp(96) to Asn mutant of the light-driven proton pump bacteriorhodopsin and its M photointermediate produced by illumination at ambient temperature have been determined to 1.8 and 2.0 angstroms resolution, respectively. The trapped photoproduct corresponds to the Late M state in the transport cycle-that is, after proton transfer to Asp(85) and release of a proton to the extracellular membrane surface, but before reprotonation of the deprotonated retinal Schiff base. Its density map describes displacements of side chains near the retinal induced by its photoisomerization to 13-cis, 15-anti and an extensive rearrangement of the three-dimensional network of hydrogen-bonded residues and bound water that accounts for the changed pK(a) values (where K-a is the acid constant) of the Schiff base and Asp(85). The structural changes detected suggest the means for conserving energy at the active site and for ensuring the directionality of proton translocation.	Univ Calif Irvine, Dept Mol Biol & Biochem, Irvine, CA 92697 USA; Univ Calif Irvine, Dept Physiol & Biophys, Irvine, CA 92697 USA; Univ Calif Irvine, UCI Program Macromol Struct, Irvine, CA 92697 USA	University of California System; University of California Irvine; University of California System; University of California Irvine; University of California System; University of California Irvine	Luecke, H (corresponding author), Univ Calif Irvine, Dept Mol Biol & Biochem, Irvine, CA 92697 USA.		Cartailler, Jean-Philippe/D-2543-2010; Lanyi, Janos/C-3808-2011; Luecke, Hartmut/F-4712-2012	Cartailler, Jean-Philippe/0000-0002-0312-2391; Luecke, Hartmut/0000-0002-4938-0775	NIGMS NIH HHS [R01-GM59970, R01-GM29498, R01-GM56445] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM056445, R01GM029498, R01GM059970] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Balashov SP, 1996, BIOPHYS J, V70, P473, DOI 10.1016/S0006-3495(96)79591-7; Belrhali H, 1999, STRUCTURE, V7, P909, DOI 10.1016/S0969-2126(99)80118-X; Borucki B, 1998, J PHYS CHEM B, V102, P3821, DOI 10.1021/jp980433c; BRAIMAN MS, 1991, P NATL ACAD SCI USA, V88, P2388, DOI 10.1073/pnas.88.6.2388; Braiman MS, 1996, BIOPHYS J, V70, P939, DOI 10.1016/S0006-3495(96)79637-6; Brown LS, 1996, P NATL ACAD SCI USA, V93, P1731, DOI 10.1073/pnas.93.4.1731; Brown LS, 1998, BIOPHYS J, V75, P1455, DOI 10.1016/S0006-3495(98)74064-0; Brown LS, 1998, BIOCHEMISTRY-US, V37, P3982, DOI 10.1021/bi9728396; Brown LS, 1995, BIOPHYS J, V69, P2103, DOI 10.1016/S0006-3495(95)80081-0; CAO Y, 1991, BIOCHEMISTRY-US, V30, P10972, DOI 10.1021/bi00109a023; Dickopf S, 1997, BIOPHYS J, V73, P3171, DOI 10.1016/S0006-3495(97)78343-7; Dioumaev AK, 1998, BIOCHEMISTRY-US, V37, P9889, DOI 10.1021/bi980934o; EARNEST TN, 1986, BIOCHEMISTRY-US, V25, P7793, DOI 10.1021/bi00372a002; Essen LO, 1998, P NATL ACAD SCI USA, V95, P11673, DOI 10.1073/pnas.95.20.11673; GERWERT K, 1986, EMBO J, V5, P805, DOI 10.1002/j.1460-2075.1986.tb04285.x; Haupts U, 1999, ANNU REV BIOPH BIOM, V28, P367, DOI 10.1146/annurev.biophys.28.1.367; HESSLING B, 1993, BIOPHYS J, V65, P1929, DOI 10.1016/S0006-3495(93)81264-5; HOLZ M, 1989, P NATL ACAD SCI USA, V86, P2167, DOI 10.1073/pnas.86.7.2167; Kamikubo H, 1996, P NATL ACAD SCI USA, V93, P1386, DOI 10.1073/pnas.93.4.1386; Kandori H, 1997, BIOCHEMISTRY-US, V36, P5134, DOI 10.1021/bi9629788; KATAOKA M, 1994, J MOL BIOL, V243, P621, DOI 10.1016/0022-2836(94)90037-X; Kimura Y, 1997, NATURE, V389, P206, DOI 10.1038/38323; Lanyi JK, 1995, ISR J CHEM, V35, P365; Lanyi JK, 1998, J STRUCT BIOL, V124, P164, DOI 10.1006/jsbi.1998.4044; Luecke H, 1998, SCIENCE, V280, P1934, DOI 10.1126/science.280.5371.1934; Luecke H, 1999, J MOL BIOL, V291, P899, DOI 10.1006/jmbi.1999.3027; Moltke S, 1998, BIOCHEMISTRY-US, V37, P11821, DOI 10.1021/bi980676v; Nagel G, 1998, BIOPHYS J, V74, P403, DOI 10.1016/S0006-3495(98)77797-5; OESTERHELT D, 1986, EUR BIOPHYS J BIOPHY, V14, P123, DOI 10.1007/BF00263069; Otwinowski Z., 1993, DATA COLLECTION PROC, P56; PebayPeyroula E, 1997, SCIENCE, V277, P1676, DOI 10.1126/science.277.5332.1676; Rammelsberg R, 1998, BIOCHEMISTRY-US, V37, P5001, DOI 10.1021/bi971701k; Richter HT, 1996, BIOCHEMISTRY-US, V35, P4054, DOI 10.1021/bi952883q; Rodig C, 1999, FEBS LETT, V445, P14, DOI 10.1016/S0014-5793(99)00088-5; Rummel G, 1998, J STRUCT BIOL, V121, P82, DOI 10.1006/jsbi.1997.3952; SASAKI J, 1992, J BIOL CHEM, V267, P20782; Sass HJ, 1997, EMBO J, V16, P1484, DOI 10.1093/emboj/16.7.1484; SCHARNAGL C, 1995, J PHYS CHEM-US, V99, P7787, DOI 10.1021/j100019a068; SCHULTEN K, 1978, NATURE, V272, P85, DOI 10.1038/272085a0; Sheldrick GM, 1997, METHOD ENZYMOL, V277, P319, DOI 10.1016/S0076-6879(97)77018-6; SUBRAMANIAM S, 1991, P NATL ACAD SCI USA, V88, P6873, DOI 10.1073/pnas.88.15.6873; Subramaniam S, 1999, J MOL BIOL, V287, P145, DOI 10.1006/jmbi.1999.2589; SUBRAMANIAM S, 1993, EMBO J, V12, P1; Thorgeirsson TE, 1997, J MOL BIOL, V273, P951, DOI 10.1006/jmbi.1997.1362; TITTOR J, 1989, EMBO J, V8, P3477, DOI 10.1002/j.1460-2075.1989.tb08512.x; VARO G, 1991, BIOPHYS J, V59, P313, DOI 10.1016/S0006-3495(91)82225-1; VARO G, 1991, BIOCHEMISTRY-US, V30, P5016, DOI 10.1021/bi00234a025; Vonck J, 1996, BIOCHEMISTRY-US, V35, P5870, DOI 10.1021/bi952663c; WELDLICH O, 1996, BIOCHEMISTRY-US, V35, P10807; ZIMANYI L, 1992, BIOCHEMISTRY-US, V31, P8535, DOI 10.1021/bi00151a022	50	491	540	1	53	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	OCT 8	1999	286	5438					255	260		10.1126/science.286.5438.255	http://dx.doi.org/10.1126/science.286.5438.255			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	243YE	10514362				2022-12-01	WOS:000083024400034
J	Hertel, P; Fagerquist, MV; Svensson, TH				Hertel, P; Fagerquist, MV; Svensson, TH			Enhanced cortical dopamine output and antipsychotic-like effects of raclopride by alpha(2) adrenoceptor blockade	SCIENCE			English	Article							INCREASES EXTRACELLULAR DOPAMINE; MEDIAL PREFRONTAL CORTEX; D-1 RECEPTOR AGONIST; IN-VIVO; ALPHA(2)-ADRENOCEPTOR ANTAGONISM; NUCLEUS-ACCUMBENS; FRONTAL-CORTEX; HIGH-AFFINITY; RAT-BRAIN; SCHIZOPHRENIA	Clozapine exerts superior clinical efficacy and markedly enhances cortical dopamine output compared with classical antipsychotic drugs, Here the alpha(2) adrenoceptor antagonist idazoxan was administered to rats alone or in combination with the D-2/3 dopamine receptor antagonist raclopride. Dopamine efflux in the medial prefrontal cortex and conditioned avoidance responding were analyzed. Idazoxan selectively potentiated the cortical output of dopamine and augmented the suppression of conditioned avoidance responding induced by raclopride. These results challenge basic assumptions underlying the dopamine hypothesis of schizophrenia and provide insight into clozapine's mode of action.	Karolinska Inst, Dept Physiol & Pharmacol, Sect Neuropsychopharmacol, S-17177 Stockholm, Sweden	Karolinska Institutet	Svensson, TH (corresponding author), Karolinska Inst, Dept Physiol & Pharmacol, Sect Neuropsychopharmacol, S-17177 Stockholm, Sweden.							Abi-Dargham A, 1997, J NEUROPSYCH CLIN N, V9, P1; AHLENIUS S, 1986, PHARMACOL BIOCHEM BE, V24, P1409, DOI 10.1016/0091-3057(86)90203-0; ARNSTEN AFT, 1994, PSYCHOPHARMACOLOGY, V116, P143, DOI 10.1007/BF02245056; ARNT J, 1982, ACTA PHARMACOL TOX, V51, P321; Ashby CR, 1996, SYNAPSE, V24, P349, DOI 10.1002/(SICI)1098-2396(199612)24:4<349::AID-SYN5>3.0.CO;2-D; BALDESSARINI RJ, 1991, NEW ENGL J MED, V324, P746; BROWNING JL, 1998, SOC NEUR ABSTR, V28, P1741; BROZOSKI TJ, 1979, SCIENCE, V205, P929, DOI 10.1126/science.112679; CARBONI E, 1990, J NEUROCHEM, V55, P1067, DOI 10.1111/j.1471-4159.1990.tb04599.x; CARLSSON A, 1988, NEUROPSYCHOPHARMACOL, V1, P179, DOI 10.1016/0893-133X(88)90012-7; Coull JT, 1996, PSYCHOPHARMACOLOGY, V123, P239, DOI 10.1007/BF02246578; DOLAN RJ, 1995, NATURE, V378, P180, DOI 10.1038/378180a0; DOXEY JC, 1983, BRIT J PHARMACOL, V78, P489, DOI 10.1111/j.1476-5381.1983.tb08809.x; ELLENBROEK BA, 1993, PHARMACOL THERAPEUT, V57, P1, DOI 10.1016/0163-7258(93)90036-D; FARDE L, 1992, ARCH GEN PSYCHIAT, V49, P538; GARRATT JC, 1991, EUR J PHARMACOL, V193, P87, DOI 10.1016/0014-2999(91)90204-4; Green MF, 1996, AM J PSYCHIAT, V153, P321; GRESCH PJ, 1995, J NEUROCHEM, V65, P111; Harvey PD, 1998, AM J PSYCHIAT, V155, P1080, DOI 10.1176/ajp.155.8.1080; HERNANDEZ L, 1995, PHARMACOL BIOCHEM BE, V52, P581, DOI 10.1016/0091-3057(95)00144-L; Hertel P, 1997, NEUROPSYCHOPHARMACOL, V17, P44; Hertel P, 1996, PSYCHOPHARMACOLOGY, V124, P74, DOI 10.1007/BF02245607; JANSSEN PAJ, 1965, J PHARMACOL EXP THER, V244, P684; Jentsch JD, 1997, SCIENCE, V277, P953, DOI 10.1126/science.277.5328.953; KANE J, 1988, ARCH GEN PSYCHIAT, V45, P789; KOHLER C, 1985, BIOCHEM PHARMACOL, V34, P2251, DOI 10.1016/0006-2952(85)90778-6; KURIBARA H, 1981, PHARMACOL BIOCHEM BE, V14, P181; Kuroki T, 1999, J PHARMACOL EXP THER, V288, P774; LEYSEN JE, 1993, PSYCHOPHARMACOLOGY, V112, pS40, DOI 10.1007/BF02245006; Litman RE, 1996, BRIT J PSYCHIAT, V168, P571, DOI 10.1192/bjp.168.5.571; MOGHADDAM B, 1990, J NEUROCHEM, V54, P1755, DOI 10.1111/j.1471-4159.1990.tb01230.x; NOMIKOS GG, 1994, PSYCHOPHARMACOLOGY, V115, P147, DOI 10.1007/BF02244765; NUTT DJ, 1994, J PSYCHOPHARMACOL, V8, P193, DOI 10.1177/026988119400800401; POZZI L, 1994, J NEUROCHEM, V63, P195; Prinssen EPM, 1996, PSYCHOPHARMACOLOGY, V128, P191, DOI 10.1007/s002130050124; Salmi P, 1996, EUR J PHARMACOL, V307, P27, DOI 10.1016/0014-2999(96)00181-1; SANBERG PR, 1988, BEHAV NEUROSCI, V102, P748, DOI 10.1037/0735-7044.102.5.748; SAWAGUCHI T, 1994, J NEUROPHYSIOL, V71, P515, DOI 10.1152/jn.1994.71.2.515; SCHNEIDER JS, 1994, BRAIN RES, V663, P140, DOI 10.1016/0006-8993(94)90471-5; SVARTENGREN J, 1994, EUR J PHARMACOL, V254, P73, DOI 10.1016/0014-2999(94)90372-7; Tanda G, 1996, PSYCHOPHARMACOLOGY, V123, P127, DOI 10.1007/BF02246169; VANTOL HHM, 1991, NATURE, V350, P610, DOI 10.1038/350610a0; Volonte M, 1997, J NEUROCHEM, V69, P182; WADENBERG ML, 1990, BIOL PSYCHIAT, V28, P297, DOI 10.1016/0006-3223(90)90657-N; WADENBERG ML, 1991, J NEURAL TRANSM-GEN, V83, P43, DOI 10.1007/BF01244451; Wadenberg ML, 1996, EUR NEUROPSYCHOPHARM, V6, P305, DOI 10.1016/S0924-977X(96)00035-1; WEINBERGER DR, 1994, J NEUROPSYCH CLIN N, V6, P419; Yamamoto BK, 1998, J NEUROCHEM, V71, P274; Youngren KD, 1999, NEUROPSYCHOPHARMACOL, V20, P403, DOI 10.1016/S0893-133X(98)00082-7	49	165	166	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	OCT 1	1999	286	5437					105	107		10.1126/science.286.5437.105	http://dx.doi.org/10.1126/science.286.5437.105			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	241WT	10506554				2022-12-01	WOS:000082907400044
J	Chen, XZ; Vassilev, PM; Basora, N; Peng, JB; Nomura, H; Segal, Y; Brown, EM; Reeders, ST; Hediger, MA; Zhou, J				Chen, XZ; Vassilev, PM; Basora, N; Peng, JB; Nomura, H; Segal, Y; Brown, EM; Reeders, ST; Hediger, MA; Zhou, J			Polycystin-L is a calcium-regulated cation channel permeable to calcium ions	NATURE			English	Article							XENOPUS-LAEVIS OOCYTES; KIDNEY-DISEASE; GENE; PROTEINS; CHLORIDE; CELLS; PKD1; INHIBIT; ENCODES; ENTRY	Polycystic kidney diseases are genetic disorders in which the renal parenchyma is progressively replaced by fluid-filled cysts(1). Two members of the polycystin family (polycystin-1 and -2) are mutated in autosomal dominant polycystic kidney disease (ADPKD)(2-5), and polycystin-L is deleted in mice with renal and retinal defects(6), Polycystins are membrane proteins that share significant sequence homology(6,7), especially polycystin-2 and -L (50% identity and 71% similarity). The functions of the polycystins remain unknown. Here we show that polycystin-L is a calcium-modulated nonselective cation channel that is permeable to sodium, potassium and calcium ions. Patch-clamp experiments revealed single-channel activity with a unitary conductance of 137 pS. Channel activity was substantially increased when either the extracellular or intracellular calcium-ion concentration was raised, indicating that polycystin-L may act as a transducer of calcium-mediated signalling in vivo. Its large single-channel conductance and regulation by calcium ions distinguish it from other structurally related cation channels.	Brigham & Womens Hosp, Dept Med, Div Renal, Boston, MA 02115 USA; Brigham & Womens Hosp, Dept Med, Div Endocrine Hypertens, Boston, MA 02115 USA; Brigham & Womens Hosp, Dept Med, Membrane Biol Program, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School	Zhou, J (corresponding author), Brigham & Womens Hosp, Dept Med, Div Renal, Boston, MA 02115 USA.			Hediger, Matthias/0000-0003-1946-027X				Birnbaumer L, 1996, P NATL ACAD SCI USA, V93, P15195, DOI 10.1073/pnas.93.26.15195; BOTON R, 1989, J PHYSIOL-LONDON, V408, P511, DOI 10.1113/jphysiol.1989.sp017473; Caterina MJ, 1997, NATURE, V389, P816, DOI 10.1038/39807; Chen XZ, 1998, J BIOL CHEM, V273, P20972, DOI 10.1074/jbc.273.33.20972; Chen XZ, 1999, J BIOL CHEM, V274, P2773, DOI 10.1074/jbc.274.5.2773; GABOW PA, 1993, NEW ENGL J MED, V329, P332, DOI 10.1056/NEJM199307293290508; Gillo B, 1996, P NATL ACAD SCI USA, V93, P14146, DOI 10.1073/pnas.93.24.14146; GLUCKSMANNKUIS MA, 1995, CELL, V81, P289; GOGELEIN H, 1990, FEBS LETT, V268, P79, DOI 10.1016/0014-5793(90)80977-Q; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; HILLE B, 1992, IONIC CHANNELS EXCIT, P105; HUGHES J, 1995, NAT GENET, V10, P151, DOI 10.1038/ng0695-151; Jorgensen AJ, 1997, PFLUG ARCH EUR J PHY, V434, P261; Kiselyov K, 1998, NATURE, V396, P478, DOI 10.1038/24890; Kunze DL, 1997, AM J PHYSIOL-CELL PH, V272, pC27, DOI 10.1152/ajpcell.1997.272.1.C27; LANE JW, 1993, BRIT J PHARMACOL, V108, P116, DOI 10.1111/j.1476-5381.1993.tb13449.x; Mochizuki T, 1996, SCIENCE, V272, P1339, DOI 10.1126/science.272.5266.1339; Nomura H, 1998, J BIOL CHEM, V273, P25967, DOI 10.1074/jbc.273.40.25967; Perez-Reyes E, 1998, NATURE, V391, P896, DOI 10.1038/36110; Qian F, 1997, NAT GENET, V16, P179, DOI 10.1038/ng0697-179; Saadi I, 1998, KIDNEY INT, V54, P48, DOI 10.1046/j.1523-1755.1998.00956.x; Sullivan LP, 1998, J AM SOC NEPHROL, V9, P903; Tsiokas L, 1997, P NATL ACAD SCI USA, V94, P6965, DOI 10.1073/pnas.94.13.6965; TZOUNOPOULOS T, 1995, BIOPHYS J, V69, P904, DOI 10.1016/S0006-3495(95)79964-7; WARD CJ, 1994, CELL, V77, P881; Wu GQ, 1998, GENOMICS, V54, P564, DOI 10.1006/geno.1998.5618; Xia XM, 1998, NATURE, V395, P503, DOI 10.1038/26758; YANG XC, 1989, SCIENCE, V243, P1068, DOI 10.1126/science.2466333; Zitt C, 1997, J CELL BIOL, V138, P1333, DOI 10.1083/jcb.138.6.1333; Zuhlke RD, 1998, P NATL ACAD SCI USA, V95, P3287, DOI 10.1073/pnas.95.6.3287	30	190	202	0	7	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	SEP 23	1999	401	6751					383	386		10.1038/43910	http://dx.doi.org/10.1038/43910			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	240JJ	10517637				2022-12-01	WOS:000082822600053
J	Muhlbauer, RC; Li, F				Muhlbauer, RC; Li, F			Nutrition - Effect of vegetables on bone metabolism	NATURE			English	Article							OVARIECTOMIZED RATS; DIURNAL RHYTHM; RESORPTION		Univ Bern, Dept Clin Res, Bone Biol Grp, CH-3010 Bern, Switzerland	University of Bern	Muhlbauer, RC (corresponding author), Univ Bern, Dept Clin Res, Bone Biol Grp, Murtenstr 35, CH-3010 Bern, Switzerland.							Anderson JJB, 1997, NUTR RES, V17, P1617, DOI 10.1016/S0271-5317(97)00156-5; Antic VN, 1996, CALCIFIED TISSUE INT, V58, P443, DOI 10.1007/s002239900073; Cecchini MG, 1997, CALCIFIED TISSUE INT, V61, pS9, DOI 10.1007/s002239900377; Kanis JA, 1999, BONE, V24, P279, DOI 10.1016/S8756-3282(99)00010-1; Li F, 1999, J BONE MINER RES, V14, P1457, DOI 10.1359/jbmr.1999.14.8.1457; MUHLBAUER RC, 1990, AM J PHYSIOL, V259, pR679, DOI 10.1152/ajpregu.1990.259.4.R679; MUHLBAUER RC, 1995, J CLIN INVEST, V95, P1933, DOI 10.1172/JCI117875; SILVERMAN SL, 1998, BONE, V23, P1108; White P, 1998, OSTEOPOROSIS CLIN CO; WRONSKI TJ, 1986, BONE, V7, P119, DOI 10.1016/8756-3282(86)90683-6	10	93	96	0	9	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	SEP 23	1999	401	6751					343	344		10.1038/43824	http://dx.doi.org/10.1038/43824			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	240JJ	10517630				2022-12-01	WOS:000082822600040
J	Bernard, A; Hermans, C; Broeckaert, F; De Poorter, G; De Cock, A; Houins, G				Bernard, A; Hermans, C; Broeckaert, F; De Poorter, G; De Cock, A; Houins, G			Food contamination by PCBs and dioxins	NATURE			English	Article							POLYCHLORINATED-BIPHENYLS		Catholic Univ Louvain, Toxicol Unit, B-1200 Brussels, Belgium; Belgian Fed Minist Agr, B-1000 Brussels, Belgium	Universite Catholique Louvain	Bernard, A (corresponding author), Catholic Univ Louvain, Toxicol Unit, 30-54 Clos Chapelle Champs, B-1200 Brussels, Belgium.		BERNARD, Alfred M/A-6511-2010	BERNARD, Alfred M/0000-0003-3171-3743				ASPLUND L, 1994, ARCH ENVIRON HEALTH, V49, P477, DOI 10.1080/00039896.1994.9955004; GILBERTSON M, 1991, J TOXICOL ENV HEALTH, V33, P455, DOI 10.1080/15287399109531538; HARRIS JR, 1972, J AM VET MED ASSOC, V161, P1584; KOHANAWA M, 1969, NATL I ANIM HEALTH Q, V9, P220; MASUDA Y, 1994, DIOXINS HLTH, V1, P633; Papke O, 1998, ENVIRON HEALTH PERSP, V106, P723, DOI 10.2307/3433826	6	132	140	1	32	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	SEP 16	1999	401	6750					231	232		10.1038/45717	http://dx.doi.org/10.1038/45717			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	237VZ	10499576				2022-12-01	WOS:000082678400038
J	Smith, O				Smith, O			Nota bene: Neuroscience - For time is the longest distance between two places	SCIENCE			English	Editorial Material																		Bontempi B, 1999, NATURE, V400, P671, DOI 10.1038/23270; Teng E, 1999, NATURE, V400, P675, DOI 10.1038/23276	2	0	0	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	SEP 3	1999	285	5433					1504	1504		10.1126/science.285.5433.1504	http://dx.doi.org/10.1126/science.285.5433.1504			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	232FD	10498536				2022-12-01	WOS:000082359500039
J	Thomson, M				Thomson, M			Helicobacter pylori - the story so far	BRITISH MEDICAL JOURNAL			English	Editorial Material							CAMPYLOBACTER-PYLORI; INFECTION; DISEASE		Univ London, Royal Free Hosp NHS Trust, Dept Paediat Gastroenterol & Nutr, London, England	University of London; University College London	Thomson, M (corresponding author), Univ London, Royal Free Hosp NHS Trust, Dept Paediat Gastroenterol & Nutr, London, England.							COGHLAN JG, 1987, LANCET, V2, P109; FORMAN D, 1993, GUT, V34, P1672, DOI 10.1136/gut.34.12.1672; FORMAN D, 1991, BRIT MED J, V302, P1302, DOI 10.1136/bmj.302.6788.1302; MACARTHUR C, 1995, JAMA-J AM MED ASSOC, V273, P729, DOI 10.1001/jama.273.9.729; Malfertheiner P, 1997, EUR J GASTROEN HEPAT, V9, P1; MARSHALL BJ, 1988, LANCET, V2, P1437; MARSHALL BJ, 1985, MED J AUSTRALIA, V142, P436, DOI 10.5694/j.1326-5377.1985.tb113443.x; MITCHELL HM, 1992, J INFECT DIS, V166, P149, DOI 10.1093/infdis/166.1.149; OCONNOR HJ, 1987, LANCET, V2, P633; Talley NJ, 1999, BMJ-BRIT MED J, V318, P833, DOI 10.1136/bmj.318.7187.833; TATSUTA M, 1990, GUT, V31, P973, DOI 10.1136/gut.31.9.973; YAMADA T, 1994, JAMA-J AM MED ASSOC, V272, P65, DOI 10.1001/jama.272.1.65	12	4	4	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	AUG 28	1999	319	7209					541	541						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	232CB	10523085				2022-12-01	WOS:000082347200018
J	Wilmot, CM; Hajdu, J; McPherson, MJ; Knowles, PF; Phillips, SEV				Wilmot, CM; Hajdu, J; McPherson, MJ; Knowles, PF; Phillips, SEV			Visualization of dioxygen bound to copper during enzyme catalysis	SCIENCE			English	Article							SERUM AMINE OXIDASE; CRYSTAL-STRUCTURE; BENZYLAMINE OXIDASE; ESCHERICHIA-COLI; HALF-REACTION; PIG PLASMA; MECHANISM; TOPAQUINONE; RESOLUTION; CRYSTALLOGRAPHY	X-ray crystal structures of three species related to the oxidative half of the reaction of the copper-containing quinoprotein amine oxidase from Escherichia coli have been determined. Crystals were freeze-trapped either anaerobically or aerobically after exposure to substrate, and structures were determined to resolutions between 2.1 and 2.4 angstroms. The oxidation state of the quinone cofactor was investigated by single-crystal spectrophotometry. The structures reveal the site of bound dioxygen and the proton transfer pathways involved in oxygen reduction. The quinone cofactor is regenerated from the iminoquinone intermediate by hydrolysis involving Asp(383), the catalytic base in the reductive half-reaction. Product aldehyde inhibits the hydrolysis, making release of product the rate-determining step of the reaction in the crystal.	Univ Leeds, Sch Biochem & Mol Biol, Astbury Ctr Struct Mol Biol, Leeds LS2 9JT, W Yorkshire, England; Uppsala Univ, Dept Biochem, S-75123 Uppsala, Sweden	University of Leeds; Uppsala University	Wilmot, CM (corresponding author), Univ Leeds, Sch Biochem & Mol Biol, Astbury Ctr Struct Mol Biol, Leeds LS2 9JT, W Yorkshire, England.			McPherson, Michael/0000-0002-0719-6427				BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; CHRISTOPHER JA, 1997, SPOCK; DOOLEY DM, 1991, NATURE, V349, P262, DOI 10.1038/349262a0; ENGH RA, 1991, ACTA CRYSTALLOGR A, V47, P392, DOI 10.1107/S0108767391001071; FARNUM M, 1986, BIOCHEMISTRY-US, V25, P1898, DOI 10.1021/bi00356a010; FERRIN TE, 1988, J MOL GRAPHICS, V6, P13, DOI 10.1016/0263-7855(88)80054-7; HARTMANN C, 1991, BIOCHEMISTRY-US, V30, P4605, DOI 10.1021/bi00232a035; HARTMANN C, 1993, BIOCHEMISTRY-US, V32, P2234, DOI 10.1021/bi00060a015; JANES SM, 1992, BIOCHEMISTRY-US, V31, P12147, DOI 10.1021/bi00163a025; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kleywegt GJ, 1998, ACTA CRYSTALLOGR D, V54, P1119, DOI 10.1107/S0907444998007100; KLINMAN JP, 1994, ANNU REV BIOCHEM, V63, P299, DOI 10.1146/annurev.bi.63.070194.001503; Klinman JP, 1996, CHEM REV, V96, P2541, DOI 10.1021/cr950047g; KNOWLES P, UNPUB, P66115; Kumar V, 1996, STRUCTURE, V4, P943, DOI 10.1016/S0969-2126(96)00101-3; Leslie A. G. W., 1992, JOINT CCP4 ESF EACBM, V26; Li RB, 1998, STRUCTURE, V6, P293, DOI 10.1016/S0969-2126(98)00033-1; MURE M, 1993, J AM CHEM SOC, V115, P7117, DOI 10.1021/ja00069a008; MURE M, 1995, J AM CHEM SOC, V117, P8707, DOI 10.1021/ja00139a003; Murray JM, 1999, BIOCHEMISTRY-US, V38, P8217, DOI 10.1021/bi9900469; NYLEN U, 1974, ACTA CHEM SCAND B, VB 28, P1153, DOI 10.3891/acta.chem.scand.28b-1153; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; PARSONS MR, 1995, STRUCTURE, V3, P1171, DOI 10.1016/S0969-2126(01)00253-2; PREUT H, 1987, ACTA CRYSTALLOGR C, V43, P374, DOI 10.1107/S0108270187095726; RINALDI A, 1984, BIOCHEM BIOPH RES CO, V120, P242, DOI 10.1016/0006-291X(84)91440-2; Su QJ, 1998, BIOCHEMISTRY-US, V37, P12513, DOI 10.1021/bi981103l; TANIZAWA K, 1995, J BIOCHEM, V118, P671, DOI 10.1093/oxfordjournals.jbchem.a124962; TAYLOR CE, 1972, BIOCHEM J, V130, P713, DOI 10.1042/bj1300713; TSOUCARIS G, 1961, ACTA CRYSTALLOGR, V14, P909, DOI 10.1107/S0365110X61002679; Wilce MCJ, 1997, BIOCHEMISTRY-US, V36, P16116, DOI 10.1021/bi971797i; Williams PA, 1997, NATURE, V389, P406, DOI 10.1038/38775; Wilmot CM, 1997, BIOCHEMISTRY-US, V36, P1608, DOI 10.1021/bi962205j; YADAV KDS, 1981, EUR J BIOCHEM, V114, P139	34	136	137	0	27	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 26	1999	286	5445					1724	1728		10.1126/science.286.5445.1724	http://dx.doi.org/10.1126/science.286.5445.1724			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	259UK	10576737				2022-12-01	WOS:000083912200035
J	Nichols, ML; Allen, BJ; Rogers, SD; Ghilardi, JR; Honore, P; Luger, NM; Finke, MP; Li, J; Lappi, DA; Simone, DA; Mantyh, PW				Nichols, ML; Allen, BJ; Rogers, SD; Ghilardi, JR; Honore, P; Luger, NM; Finke, MP; Li, J; Lappi, DA; Simone, DA; Mantyh, PW			Transmission of chronic nociception by spinal neurons expressing the substance P receptor	SCIENCE			English	Article							NEUROKININ-1 RECEPTORS; TRACT NEURONS; DORSAL HORN; RAT; PAIN; CORD; INFLAMMATION; HYPERALGESIA; MODEL	Substance P receptor (SPR)-expressing spinal neurons were ablated with the selective cytotoxin substance P-saporin. Loss of these neurons resulted in a reduction of thermal hyperalgesia and mechanical allodynia associated with persistent neuropathic and inflammatory pain states. This Loss appeared to be permanent. Responses to mildly painful stimuli and morphine analgesia were unaffected by this treatment. These results identify a target for treating persistent pain and suggest that the small population of SPR-expressing neurons in the dorsal horn of the spinal cord plays a pivotal role in the generation and maintenance of chronic neuropathic and inflammatory pain.	Univ Minnesota, Dept Prevent Sci, Minneapolis, MN 55455 USA; Univ Minnesota, Dept Psychiat, Minneapolis, MN 55455 USA; Univ Minnesota, Dept Neurosci, Minneapolis, MN 55455 USA; Univ Minnesota, Ctr Canc, Minneapolis, MN 55455 USA; Vet Affairs Med Ctr, Mol Neurobiol Lab 151, Minneapolis, MN 55417 USA; Adv Targeting Syst, San Diego, CA 92121 USA	University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities; US Department of Veterans Affairs; Veterans Health Administration (VHA); Minneapolis VA Health Care System	Mantyh, PW (corresponding author), Univ Minnesota, Dept Prevent Sci, Minneapolis, MN 55455 USA.			Lappi, Douglas/0000-0003-4239-7387	NIDCR NIH HHS [DEO 7288] Funding Source: Medline; PHS HHS [23970, 31223] Funding Source: Medline	NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		ARNER S, 1988, PAIN, V33, P11, DOI 10.1016/0304-3959(88)90198-4; Bozic CR, 1996, SCIENCE, V273, P1722, DOI 10.1126/science.273.5282.1722; BROWN JL, 1995, J COMP NEUROL, V356, P327, DOI 10.1002/cne.903560302; CALVINO B, 1990, PHYSIOL BEHAV, V47, P907, DOI 10.1016/0031-9384(90)90018-Y; Cao YQ, 1998, NATURE, V392, P390, DOI 10.1038/32897; COGGESHALL RE, 1992, TRENDS NEUROSCI, V15, P9, DOI 10.1016/0166-2236(92)90339-A; De Felipe C, 1998, NATURE, V392, P394, DOI 10.1038/32904; DING YQ, 1995, BRAIN RES, V674, P336, DOI 10.1016/0006-8993(95)00022-I; Doyle CA, 1999, NEUROSCIENCE, V89, P17, DOI 10.1016/S0306-4522(98)00276-0; DUBNER R, 1989, J NEUROPHYSIOL, V62, P450, DOI 10.1152/jn.1989.62.2.450; DUBUISSON D, 1977, PAIN, V4, P161, DOI 10.1016/0304-3959(77)90130-0; Fields HL, 1998, NEUROBIOL DIS, V5, P209, DOI 10.1006/nbdi.1998.0204; KIM SH, 1992, PAIN, V50, P355, DOI 10.1016/0304-3959(92)90041-9; KOCHER L, 1987, PAIN, V29, P363, DOI 10.1016/0304-3959(87)90051-0; Koltzenburg M, 1998, CURR OPIN NEUROL, V11, P515, DOI 10.1097/00019052-199810000-00014; Kramer MS, 1998, SCIENCE, V281, P1640, DOI 10.1126/science.281.5383.1640; LITTLEWOOD NK, 1995, NEUROSCIENCE, V66, P597, DOI 10.1016/0306-4522(95)00039-L; Mantyh PW, 1997, SCIENCE, V278, P275, DOI 10.1126/science.278.5336.275; Marshall GE, 1996, NEUROSCIENCE, V72, P255, DOI 10.1016/0306-4522(95)00558-7; MAYER DJ, 1975, PAIN, V1, P51, DOI 10.1016/0304-3959(75)90004-4; MILLAN MJ, 1988, PAIN, V35, P299, DOI 10.1016/0304-3959(88)90140-6; MULLEN RJ, 1992, DEVELOPMENT, V116, P201; PORRO CA, 1991, EXP BRAIN RES, V83, P549; SIMONE DA, 1991, J NEUROPHYSIOL, V66, P228, DOI 10.1152/jn.1991.66.1.228; Suhonen JO, 1996, NATURE, V383, P624, DOI 10.1038/383624a0	25	346	360	0	26	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 19	1999	286	5444					1558	1561		10.1126/science.286.5444.1558	http://dx.doi.org/10.1126/science.286.5444.1558			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	257DZ	10567262				2022-12-01	WOS:000083768300058
J	Vanzetta, I; Grinvald, A				Vanzetta, I; Grinvald, A			Increased cortical oxidative metabolism due to sensory stimulation: Implications for functional brain imaging	SCIENCE			English	Article							HUMAN VISUAL-CORTEX; POSITRON-EMISSION TOMOGRAPHY; CEREBRAL BLOOD OXYGENATION; RETINOTOPIC ORGANIZATION; GLUCOSE CONSUMPTION; FLUORESCENCE DECAY; INTRINSIC SIGNALS; NEURONAL-ACTIVITY; OCULAR-DOMINANCE; NEURAL ACTIVITY	Modern functional brain mapping relies on interactions of neuronal electrical activity with the cortical microcirculation. The existence of a highly localized, stimulus-evoked initial deoxygenation has remained a controversy. Here, the activity-dependent oxygen tension changes in the microcirculation were measured directly, using oxygen-dependent phosphorescence quenching of an exogenous indicator. The first event after sensory stimulation was an increase in oxygen consumption, followed by an increase in blood flow. Because oxygen consumption and neuronal activity are colocalized but the delayed blood flow is not, functional magnetic resonance imaging focused on this initial phase will yield much higher spatial resolution, ultimately enabling the noninvasive visualization of fundamental processing modules in the human brain.	Weizmann Inst Sci, Ctr Res Higher Brain Funct, Dept Neurobiol, IL-76100 Rehovot, Israel	Weizmann Institute of Science	Vanzetta, I (corresponding author), Weizmann Inst Sci, Ctr Res Higher Brain Funct, Dept Neurobiol, IL-76100 Rehovot, Israel.							BARTFELD E, 1992, P NATL ACAD SCI USA, V89, P11905, DOI 10.1073/pnas.89.24.11905; BELLIVEAU JW, 1991, SCIENCE, V254, P716, DOI 10.1126/science.1948051; BLOMQVIST G, 1994, ACTA PHYSIOL SCAND, V151, P29, DOI 10.1111/j.1748-1716.1994.tb09718.x; BONHOEFFER T, 1991, NATURE, V353, P429, DOI 10.1038/353429a0; Buxton RB, 1998, MAGNET RESON MED, V39, P855, DOI 10.1002/mrm.1910390602; Buxton RB, 1997, J CEREBR BLOOD F MET, V17, P64, DOI 10.1097/00004647-199701000-00009; CHANCE B, 1962, NATURE, V195, P956, DOI 10.1038/195956a0; DeYoe EA, 1996, P NATL ACAD SCI USA, V93, P2382, DOI 10.1073/pnas.93.6.2382; Engel SA, 1997, CEREB CORTEX, V7, P181, DOI 10.1093/cercor/7.2.181; FILHO IPT, 1993, AM J PHYSIOL, V265, pH1434; FOX PT, 1986, NATURE, V323, P806, DOI 10.1038/323806a0; FOX PT, 1985, ANN NEUROL, V17, P303, DOI 10.1002/ana.410170315; FOX PT, 1988, SCIENCE, V241, P462, DOI 10.1126/science.3260686; FOX PT, 1987, J NEUROSCI, V7, P913; Frahm J, 1997, ADV EXP MED BIOL, V413, P195; Fransson P, 1998, MAGNET RESON MED, V39, P912, DOI 10.1002/mrm.1910390608; FROSTIG RD, 1990, P NATL ACAD SCI USA, V87, P6082, DOI 10.1073/pnas.87.16.6082; Fujita H, 1999, J CEREBR BLOOD F MET, V19, P266, DOI 10.1097/00004647-199903000-00004; GRINVALD A, 1974, ANAL BIOCHEM, V59, P583, DOI 10.1016/0003-2697(74)90312-1; GRINVALD A, 1986, NATURE, V324, P361, DOI 10.1038/324361a0; GRINVALD A, 1972, P NATL ACAD SCI USA, V69, P2273, DOI 10.1073/pnas.69.8.2273; Hu XP, 1997, MAGNET RESON MED, V37, P877, DOI 10.1002/mrm.1910370612; Hubener M, 1997, J NEUROSCI, V17, P9270; Hyder F, 1996, P NATL ACAD SCI USA, V93, P7612, DOI 10.1073/pnas.93.15.7612; IADECOLA C, 1993, TRENDS NEUROSCI, V16, P206, DOI 10.1016/0166-2236(93)90156-G; KATO M, 1974, EXP NEUROL, V42, P65, DOI 10.1016/0014-4886(74)90006-5; Kerger H, 1997, ANESTHESIOLOGY, V86, P372, DOI 10.1097/00000542-199702000-00012; KERGER H, 1995, AM J PHYSIOL-HEART C, V268, pH802, DOI 10.1152/ajpheart.1995.268.2.H802; KETY SS, 1955, AM SOC PHYS ABSTR, V85; KIM DS, 1999, NEUR ABSTR, V25, P783; Kleinfeld D, 1998, P NATL ACAD SCI USA, V95, P15741, DOI 10.1073/pnas.95.26.15741; Kleinschmidt A, 1996, J CEREBR BLOOD F MET, V16, P817, DOI 10.1097/00004647-199609000-00006; Kruger G, 1996, MAGNET RESON MED, V35, P797, DOI 10.1002/mrm.1910350602; KWONG KK, 1992, P NATL ACAD SCI USA, V89, P5675, DOI 10.1073/pnas.89.12.5675; LASSEN NA, 1961, EXPERIENTIA, V17, P42, DOI 10.1007/BF02157946; LINDAUER U, 1999, NEUR ABSTR, V25, P1639; LIPTON P, 1973, BIOCHEM J, V136, P999, DOI 10.1042/bj1360999; Lo LW, 1996, ANAL BIOCHEM, V236, P153, DOI 10.1006/abio.1996.0144; Lo LW, 1997, ADV EXP MED BIOL, V428, P651; Logothetis NK, 1999, NAT NEUROSCI, V2, P555, DOI 10.1038/9210; LOTHMAN E, 1975, BRAIN RES, V88, P15, DOI 10.1016/0006-8993(75)90943-9; LOU HC, 1987, ANN NEUROL, V22, P289, DOI 10.1002/ana.410220302; Malonek D, 1996, SCIENCE, V272, P551, DOI 10.1126/science.272.5261.551; Malonek D, 1997, P NATL ACAD SCI USA, V94, P14826, DOI 10.1073/pnas.94.26.14826; Marota JJA, 1999, MAGNET RESON MED, V41, P247, DOI 10.1002/(SICI)1522-2594(199902)41:2<247::AID-MRM6>3.0.CO;2-U; Mayhew J, 1999, NEUROIMAGE, V10, P304, DOI 10.1006/nimg.1999.0460; Mayhew J, 1998, NEUROIMAGE, V7, P49, DOI 10.1006/nimg.1997.0311; Menon RS, 1997, J NEUROPHYSIOL, V77, P2780, DOI 10.1152/jn.1997.77.5.2780; Menon RS, 1999, MAGNET RESON MED, V41, P230, DOI 10.1002/(SICI)1522-2594(199902)41:2<230::AID-MRM3>3.0.CO;2-O; Nemoto M, 1999, J CEREBR BLOOD F MET, V19, P246, DOI 10.1097/00004647-199903000-00002; OGAWA S, 1992, P NATL ACAD SCI USA, V89, P5951, DOI 10.1073/pnas.89.13.5951; PAWLOWSKI M, 1999, ADV EXP MED BIOL, V316, P179; RATZLAFF EH, 1991, J NEUROSCI METH, V36, P127, DOI 10.1016/0165-0270(91)90038-2; Roy C S, 1890, J Physiol, V11, P85; RUMSEY WL, 1988, SCIENCE, V241, P1649, DOI 10.1126/science.3420417; SERENO MI, 1995, SCIENCE, V268, P889, DOI 10.1126/science.7754376; Shmuel A, 1996, J NEUROSCI, V16, P6945; SHTOYERMAN E, UNPUB; SILVER IA, 1978, CEREBRAL VASCULAR SM, V56, P49; SOKOLOFF L, 1977, J NEUROCHEM, V29, P13, DOI 10.1111/j.1471-4159.1977.tb03919.x; TOOTELL RBH, 1995, J NEUROSCI, V15, P3215; TSO DY, 1990, SCIENCE, V240, P333; TURNER R, 1993, MAGNET RESON MED, V29, P277, DOI 10.1002/mrm.1910290221; Vafaee MS, 1999, J CEREBR BLOOD F MET, V19, P272, DOI 10.1097/00004647-199903000-00005; VANZETTA L, UNPUB; VINOGRADOV SA, 1994, ADV EXP MED BIOL, V361, P67; Wang G, 1996, SCIENCE, V272, P1665, DOI 10.1126/science.272.5268.1665; Weliky M, 1996, NATURE, V379, P725, DOI 10.1038/379725a0; Wilson D F, 1987, Adv Exp Med Biol, V215, P71; WILSON DF, 1988, J BIOL CHEM, V263, P2712; WILSON DF, 1993, ADV EXP MED BIOL, V333, P225; Yacoub E, 1999, MAGN RESON MED, V41, P436, DOI 10.1002/(SICI)1522-2594(199903)41:3<436::AID-MRM2>3.0.CO;2-#	72	235	240	2	12	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 19	1999	286	5444					1555	1558		10.1126/science.286.5444.1555	http://dx.doi.org/10.1126/science.286.5444.1555			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	257DZ	10567261				2022-12-01	WOS:000083768300057
J	Cortez, D; Wang, Y; Qin, J; Elledge, SJ				Cortez, D; Wang, Y; Qin, J; Elledge, SJ			Requirement of ATM-dependent phosphorylation of BRCA1 in the DNA damage response to double-strand breaks	SCIENCE			English	Article							SUSCEPTIBILITY GENE BRCA2; ATAXIA-TELANGIECTASIA; CELL-CYCLE; IONIZING-RADIATION; NUCLEAR PHOSPHOPROTEIN; GEL-ELECTROPHORESIS; TARGETED DISRUPTION; GAMMA-IRRADIATION; MEIOTIC CELLS; C-ABL	The Brca1 (breast cancer gene 1) tumor suppressor protein is phosphorylated in response to DNA damage, Results from this study indicate that the checkpoint protein kinase ATM (mutated in ataxia telangiectasia) was required for phosphorylation of Brca1 in response to ionizing radiation. ATM resides in a complex with Brca1 and phosphorylated Brca1 in vivo and in vitro in a region that contains clusters of serine-glutamine residues. Phosphorylation of this domain appears to be functionally important because a mutated Brca1 protein lacking two phosphorylation sires failed to rescue the radiation hypersensitivity of a Brca1-deficient cell line. Thus, phosphorylation of Brca1 by the checkpoint kinase ATM may be critical for proper responses to DNA double-strand breaks and may provide a molecular explanation far the role of ATM in breast cancer.	Baylor Coll Med, Verna & Mars McLean Dept Biochem & Mol Biol, Houston, TX 77030 USA; Baylor Coll Med, Howard Hughes Med Inst, Houston, TX 77030 USA; Baylor Coll Med, Dept Cell Biol, Houston, TX 77030 USA; Baylor Coll Med, Dept Mol & Human Genet, Houston, TX 77030 USA	Baylor College of Medicine; Baylor College of Medicine; Howard Hughes Medical Institute; Baylor College of Medicine; Baylor College of Medicine	Elledge, SJ (corresponding author), Baylor Coll Med, Verna & Mars McLean Dept Biochem & Mol Biol, Houston, TX 77030 USA.				NIGMS NIH HHS [GM44664] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM044664, R01GM044664] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abbott DW, 1999, J BIOL CHEM, V274, P18808, DOI 10.1074/jbc.274.26.18808; Athma P, 1996, CANCER GENET CYTOGEN, V92, P130, DOI 10.1016/S0165-4608(96)00328-7; Barlow C, 1999, NAT GENET, V21, P359, DOI 10.1038/7684; Baskaran R, 1997, NATURE, V387, P516, DOI 10.1038/387516a0; BIEMANN K, 1988, BIOMED ENVIRON MASS, V16, P99, DOI 10.1002/bms.1200160119; Blasina A, 1999, CURR BIOL, V9, P1, DOI 10.1016/S0960-9822(99)80041-4; BLOCHER D, 1991, INT J RADIAT BIOL, V60, P791, DOI 10.1080/09553009114552601; Brown AL, 1999, P NATL ACAD SCI USA, V96, P3745, DOI 10.1073/pnas.96.7.3745; Canman CE, 1998, SCIENCE, V281, P1677, DOI 10.1126/science.281.5383.1677; Chaturvedi P, 1999, ONCOGENE, V18, P4047, DOI 10.1038/sj.onc.1202925; Chen JJ, 1998, MOL CELL, V2, P317, DOI 10.1016/S1097-2765(00)80276-2; Chen YM, 1996, CANCER RES, V56, P3168; Connor F, 1997, NAT GENET, V17, P423, DOI 10.1038/ng1297-423; CORTEZ D, UNPUB; Elledge SJ, 1996, SCIENCE, V274, P1664, DOI 10.1126/science.274.5293.1664; Elson A, 1996, P NATL ACAD SCI USA, V93, P13084, DOI 10.1073/pnas.93.23.13084; Foray N, 1997, INT J RADIAT BIOL, V72, P271, DOI 10.1080/095530097143266; Goggins M, 1996, CANCER RES, V56, P5360; Humphrey JS, 1997, P NATL ACAD SCI USA, V94, P5820, DOI 10.1073/pnas.94.11.5820; Janin N, 1999, BRIT J CANCER, V80, P1042, DOI 10.1038/sj.bjc.6690460; Johnson RT, 1999, BIOCHEM BIOPH RES CO, V261, P317, DOI 10.1006/bbrc.1999.1024; Kinzler KW, 1997, NATURE, V386, P761, DOI 10.1038/386761a0; Liu QH, 1998, CURR BIOL, V8, P1300, DOI 10.1016/S0960-9822(07)00560-X; Ludwig T, 1997, GENE DEV, V11, P1226, DOI 10.1101/gad.11.10.1226; Marmorstein LY, 1998, P NATL ACAD SCI USA, V95, P13869, DOI 10.1073/pnas.95.23.13869; Matsuoka S, 1998, SCIENCE, V282, P1893, DOI 10.1126/science.282.5395.1893; MAYNAHAN ME, IN PRESS MOL CELL; Mizuta R, 1997, P NATL ACAD SCI USA, V94, P6927, DOI 10.1073/pnas.94.13.6927; Monteiro ANA, 1996, P NATL ACAD SCI USA, V93, P13595, DOI 10.1073/pnas.93.24.13595; PANDITA TK, 1992, RADIAT RES, V131, P214, DOI 10.2307/3578443; Patel KJ, 1998, MOL CELL, V1, P347, DOI 10.1016/S1097-2765(00)80035-0; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; Rotman G, 1998, HUM MOL GENET, V7, P1555, DOI 10.1093/hmg/7.10.1555; Ruffner H, 1999, MOL CELL BIOL, V19, P4843; Ruffner H, 1997, P NATL ACAD SCI USA, V94, P7138, DOI 10.1073/pnas.94.14.7138; SAVITSKY K, 1995, SCIENCE, V268, P1749, DOI 10.1126/science.7792600; Scully R, 1997, CELL, V88, P265, DOI 10.1016/S0092-8674(00)81847-4; Scully R, 1997, CELL, V90, P425, DOI 10.1016/S0092-8674(00)80503-6; Shafman T, 1997, NATURE, V387, P520, DOI 10.1038/387520a0; Sharan SK, 1997, NATURE, V386, P804, DOI 10.1038/386804a0; Shen SX, 1998, ONCOGENE, V17, P3115, DOI 10.1038/sj.onc.1202243; Siliciano JD, 1997, GENE DEV, V11, P3471, DOI 10.1101/gad.11.24.3471; Somasundaram K, 1997, NATURE, V389, P187, DOI 10.1038/38291; Suzuki A, 1997, GENE DEV, V11, P1242, DOI 10.1101/gad.11.10.1242; Tomlinson GE, 1998, CANCER RES, V58, P3237; Vaughn JP, 1996, CANCER RES, V56, P4590; Wong AKC, 1997, J BIOL CHEM, V272, P31941, DOI 10.1074/jbc.272.51.31941; WOOSTER R, 1995, NATURE, V378, P789, DOI 10.1038/378789a0; Xu XL, 1999, MOL CELL, V3, P389, DOI 10.1016/S1097-2765(00)80466-9; Xu Y, 1996, GENE DEV, V10, P2411, DOI 10.1101/gad.10.19.2411; Zhang XL, 1998, ANAL CHEM, V70, P2050, DOI 10.1021/ac971207m; Ziv Y, 1997, ONCOGENE, V15, P159, DOI 10.1038/sj.onc.1201319	52	815	841	0	51	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 5	1999	286	5442					1162	1166		10.1126/science.286.5442.1162	http://dx.doi.org/10.1126/science.286.5442.1162			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	253AJ	10550055				2022-12-01	WOS:000083534200045
J	Annibale, B; Marignani, M; Monarca, B; Antonelli, G; Marcheggiano, A; Martino, G; Mandelli, F; Caprilli, R; Delle Fave, G				Annibale, B; Marignani, M; Monarca, B; Antonelli, G; Marcheggiano, A; Martino, G; Mandelli, F; Caprilli, R; Delle Fave, G			Reversal of iron deficiency anemia after Helicobacter pylori eradication in patients with asymptomatic gastritis	ANNALS OF INTERNAL MEDICINE			English	Article							SYDNEY SYSTEM; INFECTION; CLASSIFICATION; FERRITIN	Background: Iron deficiency anemia is the most common form of anemia worldwide. Recent studies have suggested an association between Helicobacter pylori infection and iron deficiency. Objective: To investigate the effects of eradicating H. pylori with combination antibiotic therapy on iron deficiency anemia in patients with H. pylori-associated gastritis. Design: Case series. Setting: University hospital. Patients: 30 patients with a long history of iron deficiency anemia in whom H. pylori-associated gastritis was the only pathologic gastrointestinal finding detected. Intervention: Eradication therapy with two antibiotics and discontinuation of iron replacement therapy. Measurements: Complete blood count ferritin levels, and gastroscopy with biopsy to evaluate H. pylori status. Results: At 6 months, 75% of patients had recovered from anemia (P < 0.001), ferritin values increased from 5.7 +/- 0.7 mu g/L to 24.5 +/- 5.2 mu g/L (95% CI, 8.85 to 29.97). After 12 months, 91.7% of patients had recovered from anemia. Conclusions: Cure of H, pylori infection is associated with reversal of iron dependence and recovery from iron deficiency anemia.	Univ Roma La Sapienza, Rome, Italy	Sapienza University Rome	Annibale, B (corresponding author), Univ Rome, Policlin Umberto I, Dept Clin Med 2, I-00161 Rome, Italy.		Annibale, Bruno/A-5372-2008	Annibale, Bruno/0000-0001-9120-5957; Marignani, Massimo/0000-0002-8912-9972				BAIRD IM, 1959, Q J MED, V28, P21; BANERJEE S, 1994, GUT, V35, P317, DOI 10.1136/gut.35.3.317; BAYERDORFFER E, 1992, GASTROENTEROLOGY, V102, P1575, DOI 10.1016/0016-5085(92)91716-H; Carnicer J, 1997, J PEDIATR GASTR NUTR, V25, P441, DOI 10.1097/00005176-199710000-00017; Dixon MF, 1996, AM J SURG PATHOL, V20, P1161, DOI 10.1097/00000478-199610000-00001; DOIG P, 1993, J BACTERIOL, V175, P557, DOI 10.1128/JB.175.2.557-560.1993; DOOLEY CP, 1989, NEW ENGL J MED, V321, P1562, DOI 10.1056/NEJM198912073212302; DUFOUR C, 1993, J PEDIATR GASTR NUTR, V17, P225, DOI 10.1097/00005176-199308000-00018; HALLEBERG L, 1993, DAVIDSON PASSMORE HU, P174; HUSSON MO, 1993, INFECT IMMUN, V61, P2694, DOI 10.1128/IAI.61.6.2694-2697.1993; LAINE L, 1998, SLEISENGER FORDTRANS, P198; Marignani M, 1996, CURR THER RES CLIN E, V57, P544, DOI 10.1016/S0011-393X(96)80064-6; Marignani M, 1999, AM J GASTROENTEROL, V94, P766; Marignani M, 1997, SCAND J GASTROENTERO, V32, P617, DOI 10.3109/00365529709025109; Meining A, 1997, VIRCHOWS ARCH, V431, P11, DOI 10.1007/s004280050063; Milman N, 1998, GASTROENTEROLOGY, V115, P268, DOI 10.1016/S0016-5085(98)70192-1; Peach HG, 1998, MED J AUSTRALIA, V169, P188, DOI 10.5694/j.1326-5377.1998.tb140218.x; ROCKEY DC, 1993, NEW ENGL J MED, V329, P1691, DOI 10.1056/NEJM199312023292303; ZAITOUN AM, 1994, J CLIN PATHOL, V47, P810, DOI 10.1136/jcp.47.9.810; Zhang ZW, 1998, GUT, V43, P322, DOI 10.1136/gut.43.3.322	20	172	178	0	9	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	NOV 2	1999	131	9					668	672		10.7326/0003-4819-131-9-199911020-00006	http://dx.doi.org/10.7326/0003-4819-131-9-199911020-00006			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	251LB	10577329				2022-12-01	WOS:000083446200005
J	Gabolde, M; Guilloud-Bataille, M; Feingold, J; Besmond, C				Gabolde, M; Guilloud-Bataille, M; Feingold, J; Besmond, C			Association of variant alleles of mannose binding lectin with severity of pulmonary disease in cystic fibrosis: cohort study	BRITISH MEDICAL JOURNAL			English	Article									Hop Robert Debre, INSERM, U458, F-75019 Paris, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Robert-Debre - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite	Besmond, C (corresponding author), Hop Robert Debre, INSERM, U458, F-75019 Paris, France.		BESMOND, Claude/L-8451-2018	BESMOND, Claude/0000-0001-9073-8225				Gabolde M, 1999, HUM MUTAT, V14, P80, DOI 10.1002/(SICI)1098-1004(1999)14:1<80::AID-HUMU10>3.0.CO;2-J; GARRED P, 1995, LANCET, V346, P941, DOI 10.1016/S0140-6736(95)91559-1; Hull J, 1998, THORAX, V53, P1018, DOI 10.1136/thx.53.12.1018; SUMIYA M, 1991, LANCET, V337, P1569, DOI 10.1016/0140-6736(91)93263-9; SUMMERFIELD JA, 1995, LANCET, V345, P886, DOI 10.1016/S0140-6736(95)90009-8	5	79	79	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	OCT 30	1999	319	7218					1166	1167		10.1136/bmj.319.7218.1166	http://dx.doi.org/10.1136/bmj.319.7218.1166			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	253BF	10541506	Green Published, Bronze			2022-12-01	WOS:000083536200022
J	Weissmann, C; Aguzzi, A				Weissmann, C; Aguzzi, A			Perspectives: Neurobiology - PrP's double causes trouble	SCIENCE			English	Editorial Material							SCRAPIE; PROTEIN; LESIONS; GENE		St Marys Hosp, Imperial Coll Sch Med, MRC, Prion Unit Neurogenet, London W2 1PG, England; Univ Spital Zurich, Inst Neuropathol, CH-8091 Zurich, Switzerland	Imperial College London; University of Zurich; University Zurich Hospital	Weissmann, C (corresponding author), St Marys Hosp, Imperial Coll Sch Med, MRC, Prion Unit Neurogenet, Praed St, London W2 1PG, England.		Aguzzi, Adriano/A-3351-2008	Aguzzi, Adriano/0000-0002-0344-6708				BUELER H, 1993, CELL, V73, P1339, DOI 10.1016/0092-8674(93)90360-3; BUELER H, 1992, NATURE, V356, P577, DOI 10.1038/356577a0; COZZIO A, UNPUB; FLECHSIG E, UNPUB; MANSON JC, 1994, NEURODEGENERATION, V3, P331; Moore RC, 1999, J MOL BIOL, V292, P797, DOI 10.1006/jmbi.1999.3108; Nishida N, 1999, LAB INVEST, V79, P689; Prusiner SB, 1998, P NATL ACAD SCI USA, V95, P13363, DOI 10.1073/pnas.95.23.13363; Riek R, 1997, FEBS LETT, V413, P282, DOI 10.1016/S0014-5793(97)00920-4; Sakaguchi S, 1996, NATURE, V380, P528, DOI 10.1038/380528a0; Shmerling D, 1998, CELL, V93, P203, DOI 10.1016/S0092-8674(00)81572-X; Weissmann C, 1996, CURR BIOL, V6, P1359, DOI 10.1016/S0960-9822(96)00729-4; WESTAWAY D, COMMUNICATION	13	80	83	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	OCT 29	1999	286	5441					914	915		10.1126/science.286.5441.914	http://dx.doi.org/10.1126/science.286.5441.914			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	250BE	10577243				2022-12-01	WOS:000083368500033
J	Yan, J; Magnasco, MO; Marko, JF				Yan, J; Magnasco, MO; Marko, JF			A kinetic proofreading mechanism for disentanglement of DNA by topoisomerases	NATURE			English	Article							STEADY-STATE ANALYSIS; ESCHERICHIA-COLI; ATP HYDROLYSIS; DOUBLE HELIX; TRANSPORT; TOPOLOGY	Cells must remove all entanglements between their replicated chromosomal DNAs to segregate them during cell division. Entanglement removal is done by ATP-driven enzymes that pass DNA strands through one another, called type II topoisomerases. In vitro, some type II topoisomerases can reduce entanglements much more than expected, given the assumption that they pass DNA segments through one another in a random way(1). These type II topoisomerases (of less than 10 nm in diameter) thus use ATP hydrolysis to sense and remove entanglements spread along flexible DNA strands of up to 3,000 nm long. Here we propose a mechanism for this, based on the higher rate of collisions along entangled DNA strands, relative to collision rates on disentangled DNA strands. We show theoretically that if a type II topoisomerase requires an initial 'activating' collision before a second strand-passing collision, the probability of entanglement may be reduced to experimentally observed levels. This proposed two-collision reaction is similar to 'kinetic proofreading' models of molecular recognition(2,3).	Univ Illinois, Dept Phys, Chicago, IL 60607 USA; Rockefeller Univ, Ctr Studies Phys & Biol, New York, NY 10021 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; Rockefeller University	Marko, JF (corresponding author), Univ Illinois, Dept Phys, 845 W Taylor St, Chicago, IL 60607 USA.		Yan, Jie/G-2725-2012; Marko, John F./AAY-7111-2021	Yan, Jie/0000-0002-8555-7291; Marko, John F./0000-0003-4151-9530				DEGUCHI T, 1994, J KNOT THEOR RAMIF, V3, P321; FRANKKAMENETSKII MD, 1975, NATURE, V258, P398, DOI 10.1038/258398a0; Harkins TT, 1998, BIOCHEMISTRY-US, V37, P7299, DOI 10.1021/bi9729108; Harkins TT, 1998, BIOCHEMISTRY-US, V37, P7292, DOI 10.1021/bi9729099; HOPFIELD JJ, 1974, P NATL ACAD SCI USA, V71, P4135, DOI 10.1073/pnas.71.10.4135; KLENIN KV, 1988, J BIOMOL STRUCT DYN, V5, P1173, DOI 10.1080/07391102.1988.10506462; NINIO J, 1975, BIOCHIMIE, V57, P587, DOI 10.1016/S0300-9084(75)80139-8; ROCA J, 1993, J BIOL CHEM, V268, P14250; ROCA J, 1994, CELL, V77, P609, DOI 10.1016/0092-8674(94)90222-4; ROCA J, 1992, CELL, V71, P833, DOI 10.1016/0092-8674(92)90558-T; RYBENKOV VV, 1993, P NATL ACAD SCI USA, V90, P5307, DOI 10.1073/pnas.90.11.5307; Rybenkov VV, 1997, SCIENCE, V277, P690, DOI 10.1126/science.277.5326.690; SHAW SY, 1993, SCIENCE, V260, P533, DOI 10.1126/science.8475384; SINDEN RR, 1981, P NATL ACAD SCI-BIOL, V78, P224, DOI 10.1073/pnas.78.1.224; Vologodskii A, 1998, P 2 ANN INT C COMP M, P266; WORCEL A, 1972, J MOL BIOL, V71, P127, DOI 10.1016/0022-2836(72)90342-7	16	97	97	0	11	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	OCT 28	1999	401	6756					932	935		10.1038/44872	http://dx.doi.org/10.1038/44872			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	251UL	10553912				2022-12-01	WOS:000083464700064
J	Knight, BP; Pelosi, F; Michaud, GF; Strickberger, SA; Morady, F				Knight, BP; Pelosi, F; Michaud, GF; Strickberger, SA; Morady, F			Clinical consequences of electrocardiographic artifact mimicking ventricular tachycardia	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							HIGH-RISK		Univ Michigan, Med Ctr, Dept Internal Med, Div Cardiol, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan	Knight, BP (corresponding author), Univ Michigan Hlth Syst, 1500 E Med Ctr Dr,B1F245, Ann Arbor, MI 48109 USA.							Dyke DBS, 1997, J CARDIOVASC ELECTR, V8, P1327, DOI 10.1111/j.1540-8167.1997.tb01025.x; FALK RH, 1987, AM J CARDIOL, V59, P924, DOI 10.1016/0002-9149(87)91124-6; Gregoratos G, 1998, J AM COLL CARDIOL, V31, P1175; KANTOR HI, 1966, AM J OBSTET GYNECOL, V94, P287, DOI 10.1016/0002-9378(66)90484-4; KLEINMAN B, 1990, J CLIN MONITOR, V6, P258; KRASNOW AZ, 1976, AM HEART J, V91, P349, DOI 10.1016/S0002-8703(76)80220-7; LAMPERT BA, 1988, ANESTH ANALG, V67, P1096, DOI 10.1213/00000539-198867110-00014; LIN SL, 1991, JPN HEART J, V32, P847; MOSS AJ, 1991, CIRCULATION, V84, P1524, DOI 10.1161/01.CIR.84.4.1524; Moss AJ, 1996, NEW ENGL J MED, V335, P1933, DOI 10.1056/NEJM199612263352601; MURDOCK DK, 1986, HEART LUNG, V15, P150; PAULSEN AW, 1988, ANESTHESIOLOGY, V69, P803, DOI 10.1097/00000542-198811000-00043; SCHILLER EC, 1988, ANESTHESIOLOGY, V68, P477, DOI 10.1097/00000542-198803000-00043	13	143	147	0	4	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 21	1999	341	17					1270	1274		10.1056/NEJM199910213411704	http://dx.doi.org/10.1056/NEJM199910213411704			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	247NF	10528037				2022-12-01	WOS:000083226300004
J	Friedberg, M; Saffran, B; Stinson, TJ; Nelson, W; Bennett, CL				Friedberg, M; Saffran, B; Stinson, TJ; Nelson, W; Bennett, CL			Evaluation of conflict of interest in economic analyses of new drugs used in oncology	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							COLONY-STIMULATING FACTOR; BONE-MARROW TRANSPLANTATION; COST-EFFECTIVENESS ANALYSIS; ADVANCED OVARIAN-CANCER; CELL LUNG-CANCER; PLACEBO-CONTROLLED TRIAL; BLOOD PROGENITOR CELLS; NON-HODGKINS-LYMPHOMA; FIRST-LINE THERAPY; FACTOR GM-CSF	Context Recent studies have found that when investigators have financial relationships with pharmaceutical or product manufacturers, they are less likely to criticize the safety or efficacy of these agents. The effects of health economics research on pharmaceutical company revenue make drug investigations potentially vulnerable to this bias. Objective To determine whether there is an association between pharmaceutical industry sponsorship and economic assessment of oncology drugs. Design MEDLINE and HealthSTAR databases (1988-1998) were searched for original English-language research articles of cost or cost-effectiveness analyses of 6 oncology drugs in 3 new drug categories (hematopoietic colony-stimulating factors, serotonin antagonist antiemetics, and taxanes), yielding 44 eligible articles. Two investigators independently abstracted each article based on specific criteria. Main Outcome Measure Relationships between funding source and (1) qualitative cost assessment (favorable, neutral, or unfavorable) and (2) qualitative conclusions that overstated quantitative results. Results Pharmaceutical company-sponsored studies were less likely than nonprofit-sponsored studies to report unfavorable qualitative conclusions (1/20 [5%] vs 9/24 [38%]; P = .04), whereas overstatements of quantitative results were not significantly different in pharmaceutical company-sponsored (6/20 [30%]) vs nonprofit-sponsored (3/24 [13%]) studies (P = .26). Conclusions Although we did riot identify bias in individual studies, these findings indicate that pharmaceutical company sponsorship of economic analyses is associated with reduced likelihood of reporting unfavorable results.	Lakeside Vet Adm Med Ctr, Chicago, IL 60611 USA; Northwestern Univ, Inst Hlth Serv Res & Policy Studies, Evanston, IL USA; Northwestern Univ, Div Hematol Oncol, Evanston, IL USA; Swarthmore Coll, Dept Econ, Swarthmore, PA USA	Northwestern University; Northwestern University; Swarthmore College	Bennett, CL (corresponding author), Lakeside Vet Adm Med Ctr, 400 E Ontario Ave, Chicago, IL 60611 USA.	cbenne@nwu.edu	Friedberg, Mark William/Y-2607-2019; Bennett, Charles L/C-2050-2008	Friedberg, Mark William/0000-0002-7907-8358; 				Azimi NA, 1998, J GEN INTERN MED, V13, P664, DOI 10.1046/j.1525-1497.1998.00201.x; BALLATORI E, 1994, PHARMACOECONOMICS, V5, P227, DOI 10.2165/00019053-199405030-00006; Barnes DE, 1998, JAMA-J AM MED ASSOC, V279, P1566, DOI 10.1001/jama.279.19.1566; BENNETT CL, 1995, STEM CELLS, V13, P414, DOI 10.1002/stem.5530130412; Bennett CL, 1997, CANCER INVEST, V15, P227, DOI 10.3109/07357909709039720; BENNETT CL, 1995, J CLIN ONCOL, V13, P2457, DOI 10.1200/JCO.1995.13.9.2457; Bernini JC, 1996, J PEDIATR-US, V129, P551, DOI 10.1016/S0022-3476(96)70120-8; BLEIBERG H, 1994, SUPPORT CARE CANCER, V2, P145, DOI 10.1007/BF00417472; BRICE P, 1995, PHARMACOECONOMICS, V7, P238, DOI 10.2165/00019053-199507030-00007; BUXTON MJ, 1992, BRIT J CANCER, V66, pS64; Callaham ML, 1998, JAMA-J AM MED ASSOC, V280, P254, DOI 10.1001/jama.280.3.254; CHAO NJ, 1993, BLOOD, V81, P2031; Chouaid C, 1998, J CLIN ONCOL, V16, P2700, DOI 10.1200/JCO.1998.16.8.2700; Cieslak GD, 1996, ANESTHESIOLOGY, V85, P1076, DOI 10.1097/00000542-199611000-00016; CLARK RE, 1994, LEUKEMIA LYMPHOMA, V16, P141, DOI 10.3109/10428199409114151; Covens A, 1996, CANCER, V77, P2086, DOI 10.1002/(SICI)1097-0142(19960515)77:10<2086::AID-CNCR18>3.0.CO;2-R; CUNNINGHAM D, 1993, EUR J CANCER, V29A, P303, DOI 10.1016/0959-8049(93)90372-M; DAVIDSON RA, 1986, J GEN INTERN MED, V1, P155, DOI 10.1007/BF02602327; Dranitsaris G, 1997, PHARMACOECONOMICS, V11, P566, DOI 10.2165/00019053-199711060-00005; DRANITSARIS G, 1995, LEUKEMIA LYMPHOMA, V17, P139, DOI 10.3109/10428199509051714; DRUMMOND M, 1994, PHARMACOECONOMICS, V6, P42, DOI 10.2165/00019053-199400061-00012; Duncan N, 1997, PHARMACOECONOMICS, V11, P169, DOI 10.2165/00019053-199711020-00006; DUNLOP DJ, 1994, BRIT J CANCER, V70, P943, DOI 10.1038/bjc.1994.425; Edwards G, 1998, BRIT MED J, V317, P336; Eichenwald Kurt, 1999, N Y Times Web, pA16; Eichenwald Kurt, 1999, N Y Times Web, P34; Elit LM, 1997, J CLIN ONCOL, V15, P632, DOI 10.1200/JCO.1997.15.2.632; ELKS ML, 1995, J LAB CLIN MED, V126, P19; FAUCHER C, 1994, BONE MARROW TRANSPL, V14, P895; GLASPY JA, 1993, EUR J CANCER, V29A, pS23, DOI 10.1016/0959-8049(93)90613-K; GULATI S, 1993, STEM CELLS, V11, P20, DOI 10.1002/stem.5530110105; GULATI S, 1993, ANTI-CANCER DRUG, V4, P13, DOI 10.1097/00001813-199305001-00003; GULATI SC, 1992, ANN INTERN MED, V116, P177, DOI 10.7326/0003-4819-116-3-177; GULATI SC, 1995, J CLIN ONCOL, V13, P2152, DOI 10.1200/JCO.1995.13.9.2152; HILLMAN AL, 1995, ANN INTERN MED, V123, P61; Jefferson T, 1998, JAMA-J AM MED ASSOC, V280, P275, DOI 10.1001/jama.280.3.275; Johnson N E, 1993, Pharmacoeconomics, V3, P471, DOI 10.2165/00019053-199303060-00007; Krimsky S, 1998, JAMA-J AM MED ASSOC, V280, P225, DOI 10.1001/jama.280.3.225; LUCE BR, 1994, PHARMACOECONOMICS, V6, P42, DOI 10.2165/00019053-199406010-00005; Lyman G H, 1995, Oncology (Williston Park), V9, P85; LYMAN GH, 1995, JNCI-J NATL CANCER I, V85, P488; Mapelli V, 1994, Pharmacoeconomics, V6 Suppl 2, P27; McGuire W, 1997, J CLIN ONCOL, V15, P640, DOI 10.1200/JCO.1997.15.2.640; McQuaker IG, 1997, J CLIN ONCOL, V15, P451, DOI 10.1200/JCO.1997.15.2.451; Messori A, 1996, CANCER, V78, P2366, DOI 10.1002/(SICI)1097-0142(19961201)78:11<2366::AID-CNCR15>3.3.CO;2-R; Messori A, 1996, J CLIN PHARM THER, V21, P57, DOI 10.1111/j.1365-2710.1996.tb00001.x; Mitchell PLR, 1997, J CLIN ONCOL, V15, P1163, DOI 10.1200/JCO.1997.15.3.1163; NICHOLS CR, 1994, J CLIN ONCOL, V12, P1245, DOI 10.1200/JCO.1994.12.6.1245; Ortega A, 1997, GYNECOL ONCOL, V66, P454, DOI 10.1006/gyno.1997.4786; PEROUTKA JA, 1995, FORMULARY, V30, P394; Pui CH, 1997, NEW ENGL J MED, V336, P1781, DOI 10.1056/NEJM199706193362503; RIIKONEN P, 1995, STEM CELLS, V13, P289, DOI 10.1002/stem.5530130310; ROCHON PA, 1994, ARCH INTERN MED, V154, P157, DOI 10.1001/archinte.154.2.157; Rundall P, 1998, BRIT MED J, V317, P338; Smith R, 1998, BMJ-BRIT MED J, V317, P291, DOI 10.1136/bmj.317.7154.291; SMITH TJ, 1993, JNCI-J NATL CANCER I, V85, P1460, DOI 10.1093/jnci/85.18.1460; Sorell T, 1998, BRIT MED J, V317, P334; Souetre E, 1996, EUR J CANCER, V32A, P1162, DOI 10.1016/0959-8049(95)00655-9; Splinter WM, 1997, CAN J ANAESTH, V44, P825, DOI 10.1007/BF03013158; Stelfox HT, 1998, NEW ENGL J MED, V338, P101, DOI 10.1056/NEJM199801083380206; Tang J, 1996, ANESTH ANALG, V83, P304, DOI 10.1097/00000539-199608000-00018; TANNEBERGER S, 1992, J CHEMOTHERAPY, V4, P326; Teoh G. K. H., 1994, Annals Academy of Medicine Singapore, V23, P823; UYLDEGROOT CA, 1994, EUR J CANCER, V30A, P1631; Vellenga E, 1996, J CLIN ONCOL, V14, P619, DOI 10.1200/JCO.1996.14.2.619; WATCHA MF, 1994, J CLIN ANESTH, V6, P370, DOI 10.1016/S0952-8180(05)80006-6; ZAGONEL V, 1994, ANN ONCOL, V5, pS127, DOI 10.1093/annonc/5.suppl_2.S127; ZBROZEK AS, 1994, AM J HOSP PHARM, V51, P1555, DOI 10.1093/ajhp/51.12.1555	68	311	320	0	11	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 20	1999	282	15					1453	1457		10.1001/jama.282.15.1453	http://dx.doi.org/10.1001/jama.282.15.1453			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	245LT	10535436	Bronze			2022-12-01	WOS:000083111000031
J	Takei, Y; Ikeda, S; Hashikura, Y; Ikegami, T; Kawasaki, S				Takei, Y; Ikeda, S; Hashikura, Y; Ikegami, T; Kawasaki, S			Partial-liver transplantation to treat familial amyloid polyneuropathy: Follow-up of 11 patients	ANNALS OF INTERNAL MEDICINE			English	Article							TRANSTHYRETIN AMYLOIDOSIS; CLINICAL IMPROVEMENT; SWEDISH PATIENTS; NERVE	Background: Recently, liver transplantation has been used to treat patients with familial amyloid polyneuropathy (FAP). Objective: To describe the clinical course of patients with FAP who received partial-liver transplantation from living donors. Design: Case series. Setting: University hospital in Matsumoto, Japan. Patients: 11 patients with FAP who underwent partial-liver transplantation. The transthyretin gene abnormality in all 11 patients was the substitution of methionine for valine at position 30. Intervention: Partial liver transplantation from living donors. Measurements: Preoperative and follow-up (3 to 64 months) clinical data, including routine laboratory data, nerve conduction velocity tests, and sural nerve histology. Results: All 7 patients who had severe gastrointestinal autonomic disorders or polyneuropathy localized to the lower limbs for less than 4 years showed improvement. Three of 4 patients with polyneuropathy involving both the upper and lower limbs had adverse outcomes, including two deaths. The preoperative duration of their illness was more than 6 years. These 3 patients also had marked decreases in creatinine clearance and nerve conduction velocities and severe loss of myelinated fibers in sural nerves. Conclusion: Preoperative clinical severity and duration of illness are associated with outcomes after liver transplantation for FAP.	Shinshu Univ, Sch Med, Dept Med Neurol, Matsumoto, Nagano 3908621, Japan; Shinshu Univ, Sch Med, Dept Surg, Matsumoto, Nagano 3908621, Japan	Shinshu University; Shinshu University	Ikeda, S (corresponding author), Shinshu Univ, Sch Med, Dept Med Neurol, Matsumoto, Nagano 3908621, Japan.	ikedasi@hsp.md.shinshu-u.ac.jp						Benson MD, 1996, AMYLOID, V3, P44, DOI 10.3109/13506129609014354; Bergethon PR, 1996, NEUROLOGY, V47, P944, DOI 10.1212/WNL.47.4.944; ERICZON BG, 1999, FAMILIAL AMYLOID POL; Glenner G.G, 1980, AMYLOID AMYLOIDOSIS, P88; HANYU N, 1989, ANN NEUROL, V25, P340, DOI 10.1002/ana.410250405; HOLMGREN G, 1993, LANCET, V341, P1113, DOI 10.1016/0140-6736(93)93127-M; HOLMGREN G, 1991, CLIN GENET, V40, P242; Ikeda S, 1997, AMYLOID, V4, P18, DOI 10.3109/13506129708995264; IKEDA S, 1992, EUR NEUROL, V32, P308, DOI 10.1159/000116850; IKEDA SI, 1987, BRAIN, V110, P315, DOI 10.1093/brain/110.2.315; Kawasaki S, 1998, ANN SURG, V227, P269, DOI 10.1097/00000658-199802000-00017; KYLE RA, 1993, PERIPHERAL NEUROPATH, P1294; MAKUUCHI M, 1993, SURGERY, V113, P395; PARRILLA P, 1995, BRIT J SURG, V82, P825, DOI 10.1002/bjs.1800820634; SKINNER M, 1994, ANN INTERN MED, V120, P133, DOI 10.7326/0003-4819-120-2-199401150-00006; SOPRANO DR, 1985, J BIOL CHEM, V260, P1793; STEEN L, 1994, AMYLOID, V1, P138, DOI 10.3109/13506129409148636; SUHR OB, 1995, TRANSPLANTATION, V60, P933, DOI 10.1097/00007890-199511150-00009; THOMAS PK, 1974, BRAIN, V97, P395, DOI 10.1093/brain/97.1.395	19	44	45	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	OCT 19	1999	131	8					592	595		10.7326/0003-4819-131-8-199910190-00008	http://dx.doi.org/10.7326/0003-4819-131-8-199910190-00008			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	246ZR	10523220				2022-12-01	WOS:000083196600006
J	Eshed, Y; Baum, SF; Bowman, JL				Eshed, Y; Baum, SF; Bowman, JL			Distinct mechanisms promote polarity establishment in carpels of Arabidopsis	CELL			English	Article							HISTONE DEACETYLASE; OVULE DEVELOPMENT; GENE; THALIANA; PROTEINS; FAMILY; AINTEGUMENTA; PLANTS; MEMBER	Lateral organs of plants display asymmetry with abaxial identity being specified by members of the Arabidopsis YABBY gene family. Mutations in CRABS CLAW, the founding family member, display ectopic formation of adaxial carpel tissues only when the functions of other genes, such as GYMNOS or KANADI, are also compromised. Mutations in these genes alone do not result in loss of polar differentiation, and therefore, they act redundantly with CRABS CLAW to establish polarity. As GYMNOS encodes a uniformly expressed homolog of the chromatin-remodeling protein, Mi2, we argue that the unique genetic interactions do not reflect a molecular redundancy. Rather, CRABS CLAW regulates transcription spatially, whereas GYMNOS regulates downstream targets temporally to ensure proper differentiation of the carpels.	Univ Calif Davis, Plant Biol Sect, Davis, CA 95616 USA	University of California System; University of California Davis	Bowman, JL (corresponding author), Univ Calif Davis, Plant Biol Sect, Davis, CA 95616 USA.	jlbowman@ucdavis.edu	Bowman, John P./ABF-5108-2020	Bowman, John P./0000-0002-4528-9333; Bowman, John/0000-0001-7347-3691; Eshed, Yuval/0000-0001-8290-0018				Alvarez J, 1999, DEVELOPMENT, V126, P2377; Baker SC, 1997, GENETICS, V145, P1109; Baum SF, 1996, PROTOPLASMA, V192, P178, DOI 10.1007/BF01273890; BECHTOLD N, 1993, CR ACAD SCI III-VIE, V316, P1194; BENFEY PN, 1990, SCIENCE, V250, P959, DOI 10.1126/science.250.4983.959; Bowman JL, 1999, CURR TOP DEV BIOL, V45, P155, DOI 10.1016/S0070-2153(08)60316-6; Bowman JL, 1999, DEVELOPMENT, V126, P2387; EISEN JA, 1995, NUCLEIC ACIDS RES, V23, P2715, DOI 10.1093/nar/23.14.2715; Elliott RC, 1996, PLANT CELL, V8, P155, DOI 10.1105/tpc.8.2.155; ESTRUCH JJ, 1991, SCIENCE, V254, P1364, DOI 10.1126/science.254.5036.1364; Grossniklaus U, 1998, SCIENCE, V280, P446, DOI 10.1126/science.280.5362.446; HAKE S, 1995, PHILOS T R SOC B, V350, P45, DOI 10.1098/rstb.1995.0136; Kehle J, 1998, SCIENCE, V282, P1897, DOI 10.1126/science.282.5395.1897; KIEBER JJ, 1993, CELL, V72, P427, DOI 10.1016/0092-8674(93)90119-B; Klucher KM, 1996, PLANT CELL, V8, P137, DOI 10.1105/tpc.8.2.137; Long JA, 1996, NATURE, V379, P66, DOI 10.1038/379066a0; McConnell JR, 1998, DEVELOPMENT, V125, P2935; Ogas J, 1997, SCIENCE, V277, P91, DOI 10.1126/science.277.5322.91; Ori N, 1999, PLANT CELL, V11, P1073, DOI 10.1105/tpc.11.6.1073; Pearse A.G.E., 1985, ANAL TECHNOLOGY, V2, P748; Riou-Khamlichi C, 1999, SCIENCE, V283, P1541, DOI 10.1126/science.283.5407.1541; Sawa S, 1999, GENE DEV, V13, P1079, DOI 10.1101/gad.13.9.1079; Sessions A, 1999, GENE DEV, V13, P1051, DOI 10.1101/gad.13.9.1051; SESSIONS RA, 1995, DEVELOPMENT, V121, P1519; Siegfried KR, 1999, DEVELOPMENT, V126, P4117; SMYTH DR, 1990, PLANT CELL, V2, P755, DOI 10.1105/tpc.2.8.755; SUSSEX I. M., 1955, PHYTOMORPHOLOGY [DELHI], V5, P286; THOMAS JH, 1993, TRENDS GENET, V9, P395, DOI 10.1016/0168-9525(93)90140-D; Wade PA, 1998, CURR BIOL, V8, P843, DOI 10.1016/S0960-9822(98)70328-8; Woodage T, 1997, P NATL ACAD SCI USA, V94, P11472, DOI 10.1073/pnas.94.21.11472; Zhang Y, 1998, CELL, V95, P279, DOI 10.1016/S0092-8674(00)81758-4	31	286	301	2	30	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	OCT 15	1999	99	2					199	209		10.1016/S0092-8674(00)81651-7	http://dx.doi.org/10.1016/S0092-8674(00)81651-7			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	246JB	10535738	Bronze			2022-12-01	WOS:000083159700010
J	Peters, R; Sikorski, R				Peters, R; Sikorski, R			Immunotherapy - PEG antibodies	SCIENCE			English	Article									Mednavcom, Byfield, MA 01922 USA		Peters, R (corresponding author), Mednavcom, Byfield, MA 01922 USA.							Chapman AP, 1999, NAT BIOTECHNOL, V17, P780, DOI 10.1038/11717	1	6	6	0	8	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	OCT 15	1999	286	5439					434	434		10.1126/science.286.5439.434	http://dx.doi.org/10.1126/science.286.5439.434			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	245RD	10577206				2022-12-01	WOS:000083121200037
J	Henney, JE				Henney, JE			Warning on dietary supplements	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	News Item											Henney, JE (corresponding author), HF-1,Room 14-71,5600 Fishers Ln, Rockville, MD 20857 USA.								0	3	3	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 6	1999	282	13					1218	1218		10.1001/jama.282.13.1218	http://dx.doi.org/10.1001/jama.282.13.1218			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	241UM	10517411				2022-12-01	WOS:000082901100006
J	van Weel, C; van Grunsven, P				van Weel, C; van Grunsven, P			Resistance to prescribing and to antibiotics	LANCET			English	Editorial Material							DOXYCYCLINE; TRIAL		Univ Nijmegen, Dept Gen Practice & Social Med, NL-6500 HB Nijmegen, Netherlands	Radboud University Nijmegen	van Weel, C (corresponding author), Univ Nijmegen, Dept Gen Practice & Social Med, NL-6500 HB Nijmegen, Netherlands.		van Weel, Chris/D-4375-2009	van Weel, Chris/0000-0003-3653-4701				Froom J, 1997, BRIT MED J, V315, P98, DOI 10.1136/bmj.315.7100.98; Graham A, 1999, BRIT MED J, V319, P173, DOI 10.1136/bmj.319.7203.173; HAYNES RB, COMPLIANCE HLTH CARE; Lambert HP, 1999, LANCET, V354, P943, DOI 10.1016/S0140-6736(99)01139-3; Spach DH, 1998, ANN ALLERG ASTHMA IM, V81, P293, DOI 10.1016/S1081-1206(10)63121-3; Stalman W, 1997, BRIT J GEN PRACT, V47, P794; VERHEIJ TJM, 1994, BRIT J GEN PRACT, V44, P400; ZWART S, 1999, THESIS U UTRECHT UTR; 1990, LANCET, V335, P262	9	5	5	0	2	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	SEP 25	1999	354	9184					1052	1052		10.1016/S0140-6736(99)90107-1	http://dx.doi.org/10.1016/S0140-6736(99)90107-1			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	239PA	10509494				2022-12-01	WOS:000082777500008
J	Javaheri, S				Javaheri, S			A mechanism of central sleep apnea in patients with heart failure	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CHEYNE-STOKES RESPIRATION; VENTILATORY RESPONSE; HYPOPNEA SYNDROME; HYPERCAPNIA; RESPONSIVENESS; PATHOGENESIS; THEOPHYLLINE; INSTABILITY; HYPOCAPNIA; DISEASE	Background Breathing is controlled by a negative-feedback system in which an increase in the partial pressure of arterial carbon dioxide stimulates breathing and a decrease inhibits it. Although enhanced sensitivity to carbon dioxide helps maintain the partial pressure of arterial carbon dioxide within a narrow range during waking hours, in some persons a large hyperventilatory response during sleep may lower the value below the apneic threshold, thereby resulting in central apnea. I tested the hypothesis that enhanced sensitivity to carbon dioxide contributes to the development of central sleep apnea in some patients with heart failure. Methods This prospective study included 20 men who had treated, stable heart failure with left ventricular systolic dysfunction. Ten had central sleep apnea, and 10 did not. The patients underwent polysomnography and studies of their ventilatory response to carbon dioxide. Results Patients who met the criteria for central sleep apnea had significantly more episodes of central apnea per hour than those without central sleep apnea (mean [+/-SD], 35+/-24 vs. 0.5+/-1.0 episodes per hour). Those with sleep apnea also had a significantly larger ventilatory response to carbon dioxide than those without central sleep apnea (5.1+/-3.1 vs. 2.1=/-1.0 liters per minute per millimeter of mercury, P=0.007), and there was a significant positive correlation between ventilatory response and the number of episodes of apnea and hypopnea per hour during sleep (r=0.6, P=0.01). Conclusions Enhanced sensitivity to carbon dioxide may predispose some patients with heart failure to the development of central sleep apnea. (N Engl J Med 1999;341:949-54.) (C) 1999, Massachusetts Medical Society.	Vet Affairs Med Ctr, Pulm Serv, Cincinnati, OH 45267 USA; Univ Cincinnati, Coll Med, Dept Med, Cincinnati, OH USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); Case Western Reserve University; Louis Stokes Cleveland Veterans Affairs Medical Center; Cincinnati VA Medical Center; University System of Ohio; University of Cincinnati	Javaheri, S (corresponding author), VA Med Ctr, Pulm Sect 111F, 3200 Vine St, Cincinnati, OH 45220 USA.	javaheri.shahrokh@cincinnati.va.gov						Andreas S, 1998, RESP MED, V92, P426, DOI 10.1016/S0954-6111(98)90286-4; [Anonymous], 1992, SLEEP, V15, P174; Bradley T D, 1996, J Card Fail, V2, P223, DOI 10.1016/S1071-9164(96)80045-5; CARSKADON MA, 1994, PRINCIPLES PRACTICE, P16; CHAPMAN KR, 1988, J APPL PHYSIOL, V64, P1000, DOI 10.1152/jappl.1988.64.3.1000; CHERNIACK NS, 1990, PROG CLIN BIOL RES, V345, P167; CHERNIACK NS, 1973, NEW ENGL J MED, V288, P952, DOI 10.1056/NEJM197305032881810; CHERNIACK NS, 1981, NEW ENGL J MED, V305, P325; Dempsey JA, 1996, SLEEP, V19, P236; DOWDELL WT, 1990, AM REV RESPIR DIS, V141, P871, DOI 10.1164/ajrccm/141.4_Pt_1.871; ESPINOZA H, 1991, AM REV RESPIR DIS, V144, P1121, DOI 10.1164/ajrccm/144.5.1121; GUYTON AC, 1956, AM J PHYSIOL, V187, P395, DOI 10.1152/ajplegacy.1956.187.2.395; Hall MJ, 1996, AM J RESP CRIT CARE, V154, P376, DOI 10.1164/ajrccm.154.2.8756809; HANLY P, 1993, CHEST, V104, P1079, DOI 10.1378/chest.104.4.1079; Javaheri S, 1998, ANN INTERN MED, V128, P204, DOI 10.7326/0003-4819-128-3-199802010-00006; JAVAHERI S, 1995, ANN INTERN MED, V123, P77; JAVAHERI S, 1987, AM REV RESPIR DIS, V135, P597; JAVAHERI S, 1990, THORAX, V45, P743, DOI 10.1136/thx.45.10.743; Javaheri S, 1996, NEW ENGL J MED, V335, P562, DOI 10.1056/NEJM199608223350805; JAVAHERI S, 1992, AM REV RESPIR DIS, V145, P837, DOI 10.1164/ajrccm/145.4_Pt_1.837; Javaheri S, 1998, CIRCULATION, V97, P2154, DOI 10.1161/01.CIR.97.21.2154; Javaheri S, 1996, SLEEP, V19, pS229; JAVAHERI S, 1995, ANN INTERN MED, V122, P487, DOI 10.7326/0003-4819-122-7-199504010-00002; JAVAHERI S, 1994, SLEEP, V17, P416, DOI 10.1093/sleep/17.5.416; JAVAHERI S, 1990, RESP PHYSIOL, V81, P359, DOI 10.1016/0034-5687(90)90116-G; KAWAKAMI Y, 1984, AM REV RESPIR DIS, V129, P703, DOI 10.1164/arrd.1984.129.5.703; KELLER CA, 1984, AM REV RESPIR DIS, V130, P606; KELSEN SG, 1984, CHRONIC OBSTRUCTIVE, P65; KHOO MCK, 1982, J APPL PHYSIOL, V53, P644, DOI 10.1152/jappl.1982.53.3.644; KHOO MCK, 1991, LUNG SCI FDN, V2, P1419; MOORE GC, 1976, NEW ENGL J MED, V295, P861, DOI 10.1056/NEJM197610142951604; MOUNTAIN R, 1978, NEW ENGL J MED, V298, P521, DOI 10.1056/NEJM197803092981001; NAUGHTON M, 1993, AM REV RESPIR DIS, V148, P330, DOI 10.1164/ajrccm/148.2.330; READ DJC, 1967, AUSTRALAS ANN MED, V16, P20; SAUNDERS NA, 1976, AM REV RESPIR DIS, V113, P497; SKATRUD JB, 1983, J APPL PHYSIOL, V55, P813, DOI 10.1152/jappl.1983.55.3.813; SMITH CA, 1995, J APPL PHYSIOL, V79, P689, DOI 10.1152/jappl.1995.79.3.689; Weil J, 1984, PULMONARY HYPERTENSI, P321; WHITE DP, 1983, AM REV RESPIR DIS, V128, P984; WHITE DP, 1994, PRINCIPLES PRACTICE, P630; Wilcox I, 1998, EUR RESPIR J, V11, P7, DOI 10.1183/09031936.98.11010007; XIE AL, 1995, AM J RESP CRIT CARE, V152, P1950, DOI 10.1164/ajrccm.152.6.8520761; YAMASHIRO Y, 1993, SLEEP, V16, P513, DOI 10.1093/sleep/16.6.513	43	330	365	0	7	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	SEP 23	1999	341	13					949	954		10.1056/NEJM199909233411304	http://dx.doi.org/10.1056/NEJM199909233411304			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	237LP	10498490				2022-12-01	WOS:000082658100004
J	Liebelt, EL; DeAngelis, CD				Liebelt, EL; DeAngelis, CD			Evolving trends and treatment advances in pediatric poisoning	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							CONTROL-CENTERS; EFFICACY; CHARCOAL; IPECAC; SAFETY; HOME		Johns Hopkins Sch Med, Dept Pediat, Baltimore, MD 21287 USA	Johns Hopkins University; Johns Hopkins Medicine	Liebelt, EL (corresponding author), Johns Hopkins Sch Med, Dept Pediat, 600 N Wolfe St,CMSC 144, Baltimore, MD 21287 USA.							*AM AC CLIN TOX EU, 1997, CLIN TOXICOL, V35, P711; *AM AC CLIN TOX EU, 1997, CLIN TOXICOL, V35, P699; American Academy of Clinical Toxicology European Association of Poison Centres and Clinical Toxicologists, 1997, CLIN TOXICOL, V35, P721; BOND GR, 1995, ANN EMERG MED, V25, P338, DOI 10.1016/S0196-0644(95)70291-1; BOND GR, 1993, ANN EMERG MED, V22, P1403, DOI 10.1016/S0196-0644(05)81986-9; BOYLE PJ, 1993, J CLIN ENDOCR METAB, V76, P752, DOI 10.1210/jc.76.3.752; Brent J, 1999, NEW ENGL J MED, V340, P832, DOI 10.1056/NEJM199903183401102; KORNBERG AE, 1991, ANN EMERG MED, V20, P648, DOI 10.1016/S0196-0644(05)82385-6; LAMMINPAA A, 1993, HUM EXP TOXICOL, V12, P29, DOI 10.1177/096032719301200106; LITOVITZ T, 1992, PEDIATRICS, V89, P999; LOVEJOY FH, 1994, PEDIATRICS, V94, P220; Miller TR, 1997, ANN EMERG MED, V29, P239, DOI 10.1016/S0196-0644(97)70275-0; POND SM, 1995, MED J AUSTRALIA, V163, P345, DOI 10.5694/j.1326-5377.1995.tb124625.x; Rodgers GB, 1996, JAMA-J AM MED ASSOC, V275, P1661, DOI 10.1001/jama.275.21.1661; SCALZO AJ, 1990, AM J DIS CHILD, V144, P867, DOI 10.1001/archpedi.1990.02150320031020; Shannon M, 1997, J PEDIATR-US, V131, P582, DOI 10.1016/S0022-3476(97)70066-0; Shanon M, 1998, PEDIATR EMERG CARE, V14, P293, DOI 10.1097/00006565-199808000-00015; TENENBEIN M, 1987, J PEDIATR-US, V111, P142, DOI 10.1016/S0022-3476(87)80365-7; WOOLF AD, 1992, NEW ENGL J MED, V326, P1739, DOI 10.1056/NEJM199206253262604	19	40	44	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 22	1999	282	12					1113	1115		10.1001/jama.282.12.1113	http://dx.doi.org/10.1001/jama.282.12.1113			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	236JJ	10501099				2022-12-01	WOS:000082596200002
J	Hendrich, B; Hardeland, U; Ng, HH; Jiricny, J; Bird, A				Hendrich, B; Hardeland, U; Ng, HH; Jiricny, J; Bird, A			The thymine glycosylase MBD4 can bind to the product of deamination at methylated CpG sites	NATURE			English	Article							CYTOSINE RESIDUES; DNA GLYCOSYLASES; ESCHERICHIA-COLI; ENDONUCLEASE; DINUCLEOTIDE; MUTATION; MISPAIRS; CLONING; URACIL; CANCER	In addition to its well-documented effects on gene silencing, cytosine methylation is a prominent cause of mutations. In humans, the mutation rate from 5-methylcytosine (m(5)C) to thymine (T) is 10-50-fold higher(1-4) than other transitions and the methylated sequence CpG is consequently under-represented(5). Over one-third of germline point mutations associated with human genetic disease(6) and many somatic mutations leading to cancer(7,8) involve loss of CpG. The primary cause of mutability appears to be hydrolytic deamination. Cytosine deamination produces mismatched uracil (U), which can be removed by uracil glycosylase(9,10), whereas m(5)C deamination generates a GT mispair that cannot be processed by this enzyme. Correction of m(5)CpG.TpG mismatches may instead be initiated by the thymine DNA glycosylase, TDG(11,12). Here we show that MBD4, an unrelated mammalian protein that contains a methyl-CpG binding domain(13,14), can also efficiently remove thymine or uracil from a mismatches CpG site in vitro. Furthermore, the methyl-CpG binding domain of MBD4 binds preferentially to m(5)CpG.TpG mismatches-the primary product of deamination at methyl-CpG. The combined specificities of binding and catalysis indicate that this enzyme may function to minimize mutation at methyl-CpG.	Univ Edinburgh, Inst Cell & Mol Biol, Edinburgh EH9 3JR, Midlothian, Scotland; Inst Med Radiobiol, CH-8008 Zurich, Switzerland	University of Edinburgh	Bird, A (corresponding author), Univ Edinburgh, Inst Cell & Mol Biol, Kings Bldg, Edinburgh EH9 3JR, Midlothian, Scotland.	A.Bird@ed.ac.uk	Hendrich, Brian/AAG-5898-2020; Ng, Huck Hui/A-1135-2009	Hendrich, Brian/0000-0002-0231-3073; Bird, Adrian/0000-0002-8600-0372	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ASAHARA H, 1989, BIOCHEMISTRY-US, V28, P444; Bellacosa A, 1999, P NATL ACAD SCI USA, V96, P3969, DOI 10.1073/pnas.96.7.3969; BIRD AP, 1980, NUCLEIC ACIDS RES, V8, P1499, DOI 10.1093/nar/8.7.1499; BRITTEN RJ, 1988, P NATL ACAD SCI USA, V85, P4770, DOI 10.1073/pnas.85.13.4770; BULMER M, 1986, MOL BIOL EVOL, V3, P322; COOPER DN, 1988, HUM GENET, V78, P151, DOI 10.1007/BF00278187; DUNCAN BK, 1980, NATURE, V287, P560, DOI 10.1038/287560a0; Gallinari P, 1996, NATURE, V383, P735, DOI 10.1038/383735a0; Hendrich B, 1998, MOL CELL BIOL, V18, P6538, DOI 10.1128/MCB.18.11.6538; HOLLSTEIN M, 1994, NUCLEIC ACIDS RES, V22, P3551; Horst JP, 1996, EMBO J, V15, P5459, DOI 10.1002/j.1460-2075.1996.tb00929.x; Jiricny J, 1998, EMBO J, V17, P6427, DOI 10.1093/emboj/17.22.6427; JONES PA, 1992, BIOESSAYS, V14, P33, DOI 10.1002/bies.950140107; LINDAHL T, 1974, P NATL ACAD SCI USA, V71, P3649, DOI 10.1073/pnas.71.9.3649; Lindahl T, 1997, CURR OPIN GENET DEV, V7, P158, DOI 10.1016/S0959-437X(97)80124-4; MANIATIS T, 1982, MOL CLONING LABORATO, P196; MICHAELS ML, 1990, NUCLEIC ACIDS RES, V18, P3841, DOI 10.1093/nar/18.13.3841; Modrich P, 1996, ANNU REV BIOCHEM, V65, P101, DOI 10.1146/annurev.bi.65.070196.000533; NAN XS, 1993, NUCLEIC ACIDS RES, V21, P4886, DOI 10.1093/nar/21.21.4886; Nan XS, 1997, CELL, V88, P471, DOI 10.1016/S0092-8674(00)81887-5; Neddermann P, 1996, J BIOL CHEM, V271, P12767, DOI 10.1074/jbc.271.22.12767; ROBSON CN, 1991, NUCLEIC ACIDS RES, V19, P5519, DOI 10.1093/nar/19.20.5519; Scharer OD, 1998, J BIOL CHEM, V273, P8592, DOI 10.1074/jbc.273.15.8592; Shiota S, 1997, P NATL ACAD SCI USA, V94, P593, DOI 10.1073/pnas.94.2.593; SibghatUllah, 1996, BIOCHEMISTRY-US, V35, P12926, DOI 10.1021/bi961022u; SVED J, 1990, P NATL ACAD SCI USA, V87, P4692, DOI 10.1073/pnas.87.12.4692; WIEBAUER K, 1989, NATURE, V339, P234, DOI 10.1038/339234a0	27	496	510	1	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	SEP 16	1999	401	6750					301	304		10.1038/45843	http://dx.doi.org/10.1038/45843			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	237VZ	10499592				2022-12-01	WOS:000082678400060
J	Rossi, JJ				Rossi, JJ			Molecular biology - Ribozymes in the nucleolus	SCIENCE			English	Editorial Material							VIRAL-RNA; LOCALIZATION		City Hope Natl Med Ctr, Beckman Res Inst, Dept Mol Biol, Duarte, CA 91010 USA	City of Hope; Beckman Research Institute of City of Hope	Rossi, JJ (corresponding author), City Hope Natl Med Ctr, Beckman Res Inst, Dept Mol Biol, Duarte, CA 91010 USA.	jrossi@coh.org						Bertrand E, 1998, GENE DEV, V12, P2463, DOI 10.1101/gad.12.16.2463; BOND VC, 1993, MOL CELL BIOL, V13, P3221, DOI 10.1128/MCB.13.6.3221; Buonomo SBC, 1999, RNA, V5, P993, DOI 10.1017/S1355838299990064; CULLEN BR, 1988, J VIROL, V62, P2498, DOI 10.1128/JVI.62.7.2498-2501.1988; Lafontaine DLJ, 1998, TRENDS BIOCHEM SCI, V23, P383, DOI 10.1016/S0968-0004(98)01260-2; Lee NS, 1999, RNA, V5, P1200, DOI 10.1017/S1355838299990246; Pederson T, 1998, NUCLEIC ACIDS RES, V26, P3871, DOI 10.1093/nar/26.17.3871; Pyper JM, 1998, J VIROL, V72, P7697, DOI 10.1128/JVI.72.9.7697-7702.1998; Samarsky DA, 1999, P NATL ACAD SCI USA, V96, P6609, DOI 10.1073/pnas.96.12.6609; Samarsky DA, 1998, EMBO J, V17, P3747, DOI 10.1093/emboj/17.13.3747; SIOMI H, 1988, CELL, V55, P197, DOI 10.1016/0092-8674(88)90043-8; Stauber RH, 1998, VIROLOGY, V252, P126, DOI 10.1006/viro.1998.9400; SULLENGER BA, 1993, SCIENCE, V262, P1566, DOI 10.1126/science.8248806; Weinstein LB, 1999, CURR OPIN CELL BIOL, V11, P378, DOI 10.1016/S0955-0674(99)80053-2	14	14	18	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 10	1999	285	5434					1685	1685		10.1126/science.285.5434.1685	http://dx.doi.org/10.1126/science.285.5434.1685			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	234EY	10523186				2022-12-01	WOS:000082472600022
J	Usui, T; Shima, Y; Shimada, Y; Hirano, S; Burgess, RW; Schwarz, TL; Takeichi, M; Uemura, T				Usui, T; Shima, Y; Shimada, Y; Hirano, S; Burgess, RW; Schwarz, TL; Takeichi, M; Uemura, T			Flamingo, a seven-pass transmembrane cadherin, regulates planar cell polarity under the control of frizzled	CELL			English	Article							TISSUE POLARITY; DROSOPHILA-MELANOGASTER; MOLECULAR ANALYSIS; GENE-EXPRESSION; MORPHOGENESIS; PROTEIN; RECEPTOR; ADHESION; DOMAINS; ROLES	We identified a seven-pass transmembrane receptor of the cadherin superfamily, designated Flamingo (Fmi), localized at cell-cell boundaries in the Drosophila wing. In the absence of Fmi, planar polarity was distorted. Before morphological polarization of wing cells along the proximal-distal (P-D) axis, Fmi was redistributed predominantly to proximal and distal cell edges. This biased localization of Fmi appears to be driven by an imbalance of the activity of Frizzled (Fz) across the proximal/distal cell boundary. These results, together with phenotypes caused by ectopic expression of fz and fmi, suggest that cells acquire the P-D polarity by way of the Fz-dependent boundary localization of Fmi.	Kyoto Univ, Grad Sch Biostudies, Dept Cell & Dev Biol, Kyoto 6068502, Japan; Kyoto Univ, Fac Sci, Dept Biophys, Kyoto 6068502, Japan; Japan Sci & Technol Corp, PRESTO, Osaka 5650082, Japan; Stanford Univ, Dept Mol Cellular Physiol, Sch Med, Stanford, CA 94305 USA	Kyoto University; Kyoto University; Japan Science & Technology Agency (JST); Stanford University	Uemura, T (corresponding author), Kyoto Univ, Grad Sch Biostudies, Dept Cell & Dev Biol, Kyoto 6068502, Japan.		Takeichi, Masatoshi/G-5903-2012	Takeichi, Masatoshi/0000-0002-9931-3378; Usui, Tadao/0000-0002-0507-1495; UEMURA, Tadashi/0000-0001-7204-3606; Burgess, Robert/0000-0002-9229-3407				ADLER PN, 1994, MECH DEVELOP, V46, P101, DOI 10.1016/0925-4773(94)90079-5; ADLER PN, 1992, BIOESSAYS, V14, P735, DOI 10.1002/bies.950141103; Adler PN, 1997, CURR BIOL, V7, P940, DOI 10.1016/S0960-9822(06)00413-1; Axelrod JD, 1998, GENE DEV, V12, P2610, DOI 10.1101/gad.12.16.2610; Bhanot P, 1996, NATURE, V382, P225, DOI 10.1038/382225a0; Bockaert J, 1999, EMBO J, V18, P1723, DOI 10.1093/emboj/18.7.1723; Bolt MW, 1997, ANAL BIOCHEM, V247, P185, DOI 10.1006/abio.1997.2061; Boutros M, 1998, CELL, V94, P109, DOI 10.1016/S0092-8674(00)81226-X; BRAND AH, 1993, DEVELOPMENT, V118, P401; Cooper MTD, 1999, NATURE, V397, P526, DOI 10.1038/17395; Costa M, 1998, J CELL BIOL, V141, P297, DOI 10.1083/jcb.141.1.297; Eaton S, 1996, J CELL BIOL, V135, P1277, DOI 10.1083/jcb.135.5.1277; Eaton S, 1997, CURR OPIN CELL BIOL, V9, P860, DOI 10.1016/S0955-0674(97)80089-0; Fanto M, 1999, NATURE, V397, P523, DOI 10.1038/17389; Gho M, 1998, NATURE, V393, P178, DOI 10.1038/30265; GUBB D, 1982, J EMBRYOL EXP MORPH, V68, P37; Gubb D, 1998, INT J DEV BIOL, V42, P369; Hadjantonakis AK, 1998, MECH DEVELOP, V78, P91, DOI 10.1016/S0925-4773(98)00153-1; HINZ U, 1994, CELL, V76, P77, DOI 10.1016/0092-8674(94)90174-0; Hirokawa T, 1998, BIOINFORMATICS, V14, P378, DOI 10.1093/bioinformatics/14.4.378; Hough CD, 1997, GENE DEV, V11, P3242, DOI 10.1101/gad.11.23.3242; ISHIHARA T, 1991, EMBO J, V10, P1635, DOI 10.1002/j.1460-2075.1991.tb07686.x; Iwai Y, 1997, NEURON, V19, P77, DOI 10.1016/S0896-6273(00)80349-9; Jan YN, 1998, NATURE, V392, P775, DOI 10.1038/33854; Jones KH, 1996, GENETICS, V142, P205; Krasnow RE, 1995, DEVELOPMENT, V121, P4095; Lennon G, 1996, GENOMICS, V33, P151, DOI 10.1006/geno.1996.0177; Lu BW, 1998, CELL, V95, P225, DOI 10.1016/S0092-8674(00)81753-5; LUO LQ, 1994, GENE DEV, V8, P1787, DOI 10.1101/gad.8.15.1787; Miller JR, 1997, DEV BIOL, V192, P323, DOI 10.1006/dbio.1997.8740; MITCHELL HK, 1983, DEV BIOL, V95, P387, DOI 10.1016/0012-1606(83)90040-4; Nagase T, 1996, DNA Res, V3, P321, DOI 10.1093/dnares/3.5.321; Nagase T., 1996, DNA RES, V3; Nakayama M, 1998, GENOMICS, V51, P27, DOI 10.1006/geno.1998.5341; ODA H, 1994, DEV BIOL, V165, P716, DOI 10.1006/dbio.1994.1287; PARK WJ, 1994, MECH DEVELOP, V45, P127, DOI 10.1016/0925-4773(94)90026-4; PARK WJ, 1994, DEV GENET, V15, P383, DOI 10.1002/dvg.1020150410; PERRIMON N, 1987, DEV BIOL, V119, P587, DOI 10.1016/0012-1606(87)90061-3; Rodriguez I, 1997, NATURE, V389, P614, DOI 10.1038/39343; Shulman JM, 1998, TRENDS GENET, V14, P452, DOI 10.1016/S0168-9525(98)01584-4; TAKEICHI M, 1995, CURR OPIN CELL BIOL, V7, P619, DOI 10.1016/0955-0674(95)80102-2; Taylor J, 1998, GENETICS, V150, P199; Turner CM, 1998, MECH DEVELOP, V70, P181, DOI 10.1016/S0925-4773(97)00194-9; Uemura T, 1996, GENE DEV, V10, P659, DOI 10.1101/gad.10.6.659; Uemura T, 1998, CELL, V93, P1095, DOI 10.1016/S0092-8674(00)81452-X; VINSON CR, 1989, NATURE, V338, P263, DOI 10.1038/338263a0; VINSON CR, 1987, NATURE, V329, P549, DOI 10.1038/329549a0; Wolff T, 1998, DEVELOPMENT, V125, P1149; WONG LL, 1993, J CELL BIOL, V123, P209, DOI 10.1083/jcb.123.1.209; XU T, 1993, DEVELOPMENT, V117, P1223; ZernickaGoetz M, 1996, DEVELOPMENT, V122, P3719	51	558	566	0	20	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	SEP 3	1999	98	5					585	595		10.1016/S0092-8674(00)80046-X	http://dx.doi.org/10.1016/S0092-8674(00)80046-X			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	233NT	10490098	Bronze			2022-12-01	WOS:000082433500006
J	Bruner, JP; Tulipan, N; Paschall, RL; Boehm, FH; Walsh, WF; Silva, SR; Hernanz-Schulman, M; Lowe, LH; Reed, GW				Bruner, JP; Tulipan, N; Paschall, RL; Boehm, FH; Walsh, WF; Silva, SR; Hernanz-Schulman, M; Lowe, LH; Reed, GW			Fetal surgery for myelomeningocele and the incidence of shunt-dependent hydrocephalus	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							GESTATIONAL-AGE; IN-UTERO; INFANTS; INJURY; REPAIR; MODEL	Context Intrauterine closure of exposed spinal cord tissue prevents secondary neurologic injury in animals with a surgically created spinal defect; however, whether in utero repair of myelomeningocele improves neurologic outcome in infants with spina bifida is not known. Objective To determine whether intrauterine repair of myelomeningocele improves patient outcomes compared with standard care. Design Single-institution, nonrandomized observational study conducted between January 1990 and February 1999. Setting Tertiary care medical center. Participants A sample of 29 study patients with isolated fetal myelomeningocele referred for intrauterine repair that was performed between 24 and 30 gestational weeks and 23 controls matched to cases for diagnosis, level of lesion, practice parameters, and calendar time. All infants were followed up for a minimum of 6 months after delivery. Main Outcome Measures Requirement for ventriculoperitoneal shunt placement, obstetrical complications, gestational age at delivery, and birth weight for study vs control subjects. Results The requirement for ventriculoperitoneal shunt placement for decompression of hydrocephalus was significantly decreased among study infants (59% vs 91%, P =.01). The median age at shunt placement was also older among study infants (50 vs 5 days; P =.006). This may be explained by the reduced incidence of hindbrain herniation among study infants (38% vs 95%; P<.001), Following hysterotomy, study patients had an increased risk of oligohydramnios (48% vs 4%; P =.001) and admission to the hospital for preterm uterine contractions (50% vs 9%; P =.002). The estimated gestational age at delivery was earlier for study patients (33.2 vs 37.0 weeks; P<.001), and the birth weight of study neonates was less (2171 vs 3075 g; P<.001). Conclusions Our study suggests that intrauterine repair of myelomeningocele decreases the incidence of hindbrain herniation and shunt-dependent hydrocephalus in infants with spina bifida, but increases the incidence of premature delivery.	Vanderbilt Univ, Med Ctr, Dept Obstet & Gynecol, Nashville, TN 37232 USA; Vanderbilt Univ, Med Ctr, Dept Pediat Neurosurg, Nashville, TN 37232 USA; Vanderbilt Univ, Med Ctr, Dept Obstet Anesthesia, Nashville, TN 37232 USA; Vanderbilt Univ, Med Ctr, Dept Neonatol, Nashville, TN 37232 USA; Vanderbilt Univ, Med Ctr, Dept Radiol, Nashville, TN 37232 USA; New England Res Inst, Watertown, MA 02172 USA	Vanderbilt University; Vanderbilt University; Vanderbilt University; Vanderbilt University; Vanderbilt University; HealthCore, Inc	Bruner, JP (corresponding author), Vanderbilt Univ, Med Ctr, Dept Obstet & Gynecol, B-1100 Med Ctr N, Nashville, TN 37232 USA.							BABCOOK CJ, 1994, RADIOLOGY, V190, P703, DOI 10.1148/radiology.190.3.8115615; BABSON SG, 1976, J PEDIATR-US, V89, P814, DOI 10.1016/S0022-3476(76)80815-3; BEALER JF, 1995, J PEDIATR SURG, V30, P1150, DOI 10.1016/0022-3468(95)90009-8; BRUNER JP, IN PRESS AM J OBSTET; CANTOR AB, 1992, STAT MED, V11, P931, DOI 10.1002/sim.4780110710; FLETCHER JC, 1991, UNBORN PATIENT, P12; HEFFEZ DS, 1990, NEUROSURGERY, V26, P987, DOI 10.1227/00006123-199006000-00011; HEFFEZ DS, 1993, NEUROSURGERY, V32, P1005, DOI 10.1227/00006123-199306000-00021; Lary J M, 1996, MMWR CDC Surveill Summ, V45, P15; MEULI M, 1995, J PEDIATR SURG, V30, P1028, DOI 10.1016/0022-3468(95)90335-6; MICHEJDA M, 1984, Z KINDERCHIR, V39, P259; Ranzini AC, 1999, OBSTET GYNECOL, V93, P826, DOI 10.1016/S0029-7844(98)00423-2; Rekate H L, 1985, Clin Neurosurg, V32, P593; RUTHERFORD SE, 1987, J REPROD MED, V32, P587; SCHLIEVERT P, 1977, SEMIN PERINATOL, V1, P59; SCHROEDER SA, 1992, CHEST, V101, P1065, DOI 10.1378/chest.101.4.1065; SPOSTO R, 1992, BIOMETRICS, V48, P87, DOI 10.2307/2532741; STEINBOK P, 1992, CHILD NERV SYST, V8, P92, DOI 10.1007/BF00298448; Storrs BB, 1988, CONCEPTS PEDIAT NEUR, V8, P51; Tulipan N, 1998, PEDIATR NEUROSURG, V29, P274, DOI 10.1159/000028735; Tulipan N, 1998, PEDIATR NEUROSURG, V28, P177, DOI 10.1159/000028645; WERNER EE, 1966, CHILD DEV, V37, P39, DOI 10.1111/j.1467-8624.1966.tb05367.x	22	296	300	0	12	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 17	1999	282	19					1819	1825		10.1001/jama.282.19.1819	http://dx.doi.org/10.1001/jama.282.19.1819			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	254MD	10573272	Bronze			2022-12-01	WOS:000083615700024
J	Ades, AE; Sculpher, MJ; Gibb, DM; Gupta, R; Ratcliffe, J				Ades, AE; Sculpher, MJ; Gibb, DM; Gupta, R; Ratcliffe, J			Cost effectiveness analysis of antenatal HIV screening in United Kingdom	BRITISH MEDICAL JOURNAL			English	Article							TO-CHILD TRANSMISSION; ZIDOVUDINE; STRATEGIES; INFECTION; IMPACT; AIDS	Objective To assess the cost effectiveness of universal antenatal HIV screening compared with selective screening in the United Kingdom. Design Incremental cost effectiveness analysis relating additional costs of screening to life years gained. Maternal and paediatric costs and life years were combined. Setting United Kingdom. Main outcome measures Number of districts for which universal screening would be cost effective compared with selective screening under various conditions. Results On base case assumptions, a new diagnosis of a pregnant woman with HIV results in a gain of 6.392 life years and additional expenditure of pound 14 833. If decision makers are prepared to pay up to pound 10 000 for an additional life year, this would imply a net benefit of pound 49 090 (range pound 12 300-pound 59 000), which would be available to detect each additional infected woman in an antenatal screening programme. In London, universal antenatal screening would be cost effective compared with a selective screening under any reasonable assumptions about screening costs. Outside London, universal screening with uptake above 90% would be cost effective with a pound 0.60 HIV antibody test cost and up to 3.5 minutes for pretest discussion. Cost effectiveness of universal testing is lower if selective testing can achieve high uptake among those at higher risk. A universal strategy with only 50% uptake may not be less cost effective in low prevalence districts and may cost more and be less effective than a well run selective strategy. Conclusions Universal screening with pretest discussion should be adopted throughout the United Kingdom as part of routine antenatal care as long as test costs can be kept low and uptake high.	Inst Child Hlth, Dept Epidemiol & Publ Hlth, London WC1N 1EH, England; York Univ, Ctr Hlth Econ, York YO10 5DD, N Yorkshire, England; Brunel Univ, Hlth Econ Res Grp, Uxbridge UB8 3PH, Middx, England	University of London; University College London; University of York - UK; Brunel University	Ades, AE (corresponding author), Inst Child Hlth, Dept Epidemiol & Publ Hlth, 30 Guilford St, London WC1N 1EH, England.		Ratcliffe, Julie/G-3169-2017	Ratcliffe, Julie/0000-0001-7365-1988; Gibb, Diana/0000-0002-9738-5490; Sculpher, Mark/0000-0003-3746-9913				Ades AE, 1999, AIDS, V13, P271, DOI 10.1097/00002030-199902040-00016; ADES AE, 25 BRUN U HLTH EC RE; Andiman W, 1999, NEW ENGL J MED, V340, P977, DOI 10.1056/NEJM199904013401301; CONNOR EM, 1994, NEW ENGL J MED, V331, P1173, DOI 10.1056/NEJM199411033311801; *DEP HLTH, 1994, REG COST EFF STUD 19; *DEP HLTH, 1999, 1999183 DEP HLTH; *DEP HLTH, 1994, PLCO945 DEP HLTH; *DEP HLTH, 1995, POL APPR HLTH; Ecker JL, 1996, AM J OBSTET GYNECOL, V174, P716, DOI 10.1016/S0002-9378(96)70455-6; GIBB D, 1998, GUIDELINES MANAGEMEN; Gibb DM, 1999, AIDS, V13, P1569, DOI 10.1097/00002030-199908200-00018; Gibb DM, 1997, AIDS, V11, pF53, DOI 10.1097/00002030-199707000-00001; Gorsky RD, 1996, PUBLIC HEALTH REP, V111, P335; LEWIS R, 1995, AM J OBSTET GYNECOL, V173, P1329, DOI 10.1016/0002-9378(95)91381-5; Mauskopf JA, 1996, JAMA-J AM MED ASSOC, V276, P132, DOI 10.1001/jama.276.2.132; Parry J V, 1993, Clin Diagn Virol, V1, P167, DOI 10.1016/0928-0197(93)90011-S; Postma MJ, 1999, BMJ-BRIT MED J, V318, P1656, DOI 10.1136/bmj.318.7199.1656; Raleigh VS, 1997, J EPIDEMIOL COMMUN H, V51, P649, DOI 10.1136/jech.51.6.649; Ratcliffe J, 1998, AIDS, V12, P1381, DOI 10.1097/00002030-199811000-00021; Sculpher MJ, 1998, AIDS, V12, P1371, DOI 10.1097/00002030-199811000-00020; SIMPSON WM, 1999, HLTH TECHNOLOGY ASSE, P3; Sperling RS, 1998, AIDS, V12, P1805, DOI 10.1097/00002030-199814000-00012; Stinnett AA, 1998, MED DECIS MAKING, V18, pS68, DOI 10.1177/0272989X98018002S09; STOTO MA, 1998, REDUCING ODDS PREVEN, P397; Stringer JSA, 1999, JAMA-J AM MED ASSOC, V281, P1946, DOI 10.1001/jama.281.20.1946; Tookey PA, 1998, J MED SCREEN, V5, P133, DOI 10.1136/jms.5.3.133	26	33	34	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	NOV 6	1999	319	7219					1230	1234		10.1136/bmj.319.7219.1230	http://dx.doi.org/10.1136/bmj.319.7219.1230			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	254RH	10550083	Green Published, Bronze			2022-12-01	WOS:000083625600022
J	Jehle, PM; Micheler, C; Jehle, DR; Breitig, D; Boehm, BB				Jehle, PM; Micheler, C; Jehle, DR; Breitig, D; Boehm, BB			Inadequate suspension of neutral protamine Hagendorn (NPH) insulin in pens	LANCET			English	Article							QUALITY-OF-LIFE; DIABETES-MELLITUS; INJECTOR; KINETICS; THERAPY	Background Neutral protamine Hagedorn (NPH) insulin is one of the most commonly used insulins in insulin pens. NPH in pen cartridges is in a two-phase solution with either a solvent or a short-acting insulin, and needs adequate mixing for complete resuspension. We assessed whether NPH insulin is accurately resuspended by patients and the association of suspension errors with diabetes control. Methods 109 patients (39 with type 1 diabetes) who had received conventional diabetic education had the NPH content of their cartridges measured by an optical system; a control cartridge was designated as 100%. A questionnaire was used to assess clinical details and insulin suspension habits. After the information about residual insulin error was known, all 109 patients were instructed to resuspend their insulin by rolling and tipping the pen 20 times. 52 patients were randomly selected to have cartridges reanalysed 3 months or 6 months later and to complete another questionnaire. Findings Only 10 (9%) of 109 patients tipped and rolled their pen more than ten times. NPH insulin content ranged from 5% to 214% and varied by more than 20% in 71 (65%) of 109 cartridges. There was no relation between inadequate suspension and the frequency of hypoglycaemic episodes (r=0.2, p=0.08). For all patients, there was a correlation between the absolute error of NPH suspension and cycles of rolling and tipping the pen (r=-0.23, p<0.05). After education on resuspending the pen's contents, data were available from 44 of 52 patients; suspension errors decreased in 35 (80%), were unchanged in three (7%), and increased in six (13%). The 35 patients with improved NPH insulin suspension had fewer mean hypoglycaemic episodes per month compared with the previous period (0.4 [SD 0.1] vs 1.0 [0.3], p<0.05). Mean HbA(1c) values in patients with improved suspension quality did not differ from baseline (8.4% [0.3] vs 8.9% [0.4], p=0.07). Mixing of NPH insulin by a mechanical device showed that at least 20 cycles were necessary before complete resuspension was obtained. Interpretation Inadequate NPH insulin suspension is common. We recommended that patients tip pens that contain NPH insulin at least 20 times, since inadequate mixing may impair diabetes control.	Univ Hosp Ulm, Div Nephrol, Ulm, Germany; Univ Hosp Ulm, Div Endocrinol, Ulm, Germany; Univ Ulm, Isotope Div, Ulm, Germany	Ulm University; Ulm University; Ulm University	Jehle, PM (corresponding author), Univ Ulm, Dept Internal Med 2, Div Nephrol, Robert Koch Str 8, D-89081 Ulm, Germany.		Boehm, Bernhard Otto/F-8750-2015					*AM DIAB ASS, 1998, DIABETES CARE S1, V21, pS72; Andersson PO, 1997, DIABETES RES CLIN PR, V36, P169, DOI 10.1016/S0168-8227(97)00048-X; BAK JF, 1987, DIABETES RES CLIN EX, V6, P155; BERGER M, 1982, DIABETES CARE, V5, P77, DOI 10.2337/diacare.5.2.77; BROGDEN RN, 1987, DRUGS, V34, P650; BUYSSCHAERT M, 1988, DIABETES METAB, V14, P75; BUYSSCHAERT M, 1989, LANCET, V1, P965; Chantelau E, 1997, PATIENT EDUC COUNS, V30, P167, DOI 10.1016/S0738-3991(96)00964-0; CHASE HP, 1991, J ADOLESCENT HEALTH, V12, P373, DOI 10.1016/0197-0070(91)90050-V; DINNEEN SF, 1991, IRISH J MED SCI, V160, P286, DOI 10.1007/BF02948414; FISKEN RA, 1989, DIABETES RES CLIN EX, V11, P195; GINSBERG BH, 1994, HORM METAB RES, V26, P584, DOI 10.1055/s-2007-1001764; HARDY KJ, 1991, DIABETIC MED, V8, P69, DOI 10.1111/j.1464-5491.1991.tb01518.x; JORGENSEN JOL, 1988, DIABETIC MED, V5, P574, DOI 10.1111/j.1464-5491.1988.tb01054.x; MURRAY DP, 1988, DIABETIC MED, V5, P750, DOI 10.1111/j.1464-5491.1988.tb01102.x; REICHARD P, 1993, NEW ENGL J MED, V329, P304, DOI 10.1056/NEJM199307293290502; SHAMOON H, 1993, NEW ENGL J MED, V329, P977, DOI 10.1056/nejm199309303291401; SKYLER JS, 1988, MED CLIN N AM, V72, P1337, DOI 10.1016/S0025-7125(16)30710-6; STEINEMANN MA, 1990, THER UMSCH, V47, P22; Turner RC, 1998, LANCET, V352, P837, DOI 10.1016/s0140-6736(98)07019-6; 1989, LANCET, V1, P307	21	119	128	1	2	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	NOV 6	1999	354	9190					1604	1607		10.1016/S0140-6736(98)12459-5	http://dx.doi.org/10.1016/S0140-6736(98)12459-5			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	253HM	10560676				2022-12-01	WOS:000083551000013
J	Huang, JF; Yang, Y; Sepulveda, H; Shi, WX; Hwang, I; Peterson, PA; Jackson, MR; Sprent, J; Cai, ZL				Huang, JF; Yang, Y; Sepulveda, H; Shi, WX; Hwang, I; Peterson, PA; Jackson, MR; Sprent, J; Cai, ZL			TCR-mediated internalization of peptide-MHC complexes acquired by T cells	SCIENCE			English	Article							CLASS-II MOLECULES; TRANSGENIC MICE; LYMPHOCYTES-T; RECEPTOR; ANTIGEN; ACTIVATION; VIRUS; PROTEIN; REQUIREMENTS; RECOGNITION	Peptide-major histocompatibility complex protein complexes (pMHCs) on antigen-presenting cells (APCs) are central to T cell activation. Within minutes of peptide-specific T cells interacting with APCs, pMHCs on APCs formed clusters at the site of T cell contact. Thereafter, these clusters were acquired by T cells and internalized through T cell receptor-mediated endocytosis. During this process, T cells became sensitive to peptide-specific Lysis by neighboring T cells (fratricide). This form of immunoregulation could explain the "exhaustion" of T cell responses that is induced by high viral Loads and may serve to downregulate immune responses.	RW Johnson Pharmaceut Res Inst, San Diego, CA 92121 USA; Scripps Res Inst, Res Inst, Dept Immunol, IMM4, La Jolla, CA 92037 USA	Johnson & Johnson; Johnson & Johnson USA; Scripps Research Institute	Cai, ZL (corresponding author), RW Johnson Pharmaceut Res Inst, 3210 Merryfield Row, San Diego, CA 92121 USA.			Hwang, Inkyu/0000-0001-8997-6090				BORROW P, 1991, J EXP MED, V174, P203, DOI 10.1084/jem.174.1.203; Buchmeier M J, 1980, Adv Immunol, V30, P275, DOI 10.1016/S0065-2776(08)60197-2; Cai ZL, 1997, J EXP MED, V185, P641, DOI 10.1084/jem.185.4.641; Cai ZL, 1996, P NATL ACAD SCI USA, V93, P14736, DOI 10.1073/pnas.93.25.14736; Davis MM, 1998, ANNU REV IMMUNOL, V16, P523, DOI 10.1146/annurev.immunol.16.1.523; Dustin ML, 1998, CELL, V94, P667, DOI 10.1016/S0092-8674(00)81608-6; Gallimore A, 1998, J EXP MED, V187, P1383, DOI 10.1084/jem.187.9.1383; GERMAIN RN, 1994, CELL, V76, P287, DOI 10.1016/0092-8674(94)90336-0; Grakoui A, 1999, SCIENCE, V285, P221, DOI 10.1126/science.285.5425.221; HWANG I, UNPUB; LIE WR, 1991, J EXP MED, V173, P449, DOI 10.1084/jem.173.2.449; LORBER MI, 1982, J IMMUNOL, V128, P2798; Monks CRF, 1998, NATURE, V395, P82, DOI 10.1038/25764; Monks CRF, 1997, NATURE, V385, P83, DOI 10.1038/385083a0; MOSKOPHIDIS D, 1993, NATURE, V362, P758, DOI 10.1038/362758a0; NEPOM JT, 1981, J IMMUNOL, V127, P888; Penninger JM, 1999, CELL, V96, P9, DOI 10.1016/S0092-8674(00)80954-X; PIRCHER H, 1989, NATURE, V342, P559, DOI 10.1038/342559a0; Preckel T, 1997, J EXP MED, V185, P1803, DOI 10.1084/jem.185.10.1803; PULLEN JK, 1991, J IMMUNOL, V146, P2145; SAIZAWA MK, 1992, J CELL BIOCHEM, V16, P54; SHA WC, 1988, NATURE, V335, P271, DOI 10.1038/335271a0; Shen ZH, 1997, J IMMUNOL, V158, P2723; TOWNSEND A, 1990, CELL, V62, P285, DOI 10.1016/0092-8674(90)90366-M; UDAKA K, 1992, CELL, V69, P989, DOI 10.1016/0092-8674(92)90617-L; Valitutti S, 1997, J EXP MED, V185, P1859, DOI 10.1084/jem.185.10.1859; VALITUTTI S, 1995, NATURE, V375, P148, DOI 10.1038/375148a0; VANDENEYNDE B, 1991, J EXP MED, V173, P1373, DOI 10.1084/jem.173.6.1373; Viola A, 1999, SCIENCE, V283, P680, DOI 10.1126/science.283.5402.680; Wubbolts R, 1996, J CELL BIOL, V135, P611, DOI 10.1083/jcb.135.3.611; Wulfing C, 1998, SCIENCE, V282, P2266, DOI 10.1126/science.282.5397.2266	31	367	379	1	20	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	OCT 29	1999	286	5441					952	954		10.1126/science.286.5441.952	http://dx.doi.org/10.1126/science.286.5441.952			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	250BE	10542149				2022-12-01	WOS:000083368500044
J	Mokdad, AH; Serdula, MK; Dietz, WH; Bowman, BA; Marks, JS; Koplan, JP				Mokdad, AH; Serdula, MK; Dietz, WH; Bowman, BA; Marks, JS; Koplan, JP			The spread of the obesity epidemic in the United States, 1991-1998	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							MULTISTATE TELEPHONE SURVEY; WEIGHT; ADULTS; OVERWEIGHT; TRENDS; HEIGHT	Context The increasing prevalence of obesity is a major public health concern, since obesity is associated with several chronic diseases. Objective To monitor trends in state-specific data and to examine changes in the prevalence of obesity among adults. Design Cross-sectional random-digit telephone survey (Behavioral Risk Factor Surveillance System) of noninstitutionalized adults aged 18 years or older conducted by the Centers for Disease Control and Prevention and state health departments from 1991 to 1998. Setting States that participated in the Behavioral Risk Factor Surveillance System. Main Outcome Measures Body mass index calculated from self-reported weight and height. Results The prevalence of obesity (defined as a body mass index greater than or equal to 30 kg/m(2)) increased from 12.0% in 1991 to 17.9% in 1998. A steady increase was observed in all states; in both sexes; across age groups, races, educational levels; and occurred regardless of smoking status. The greatest magnitude of increase was found in the following groups: 18- to 29-year-olds (7.1% to 12.1%), those with some college education (10.6% to 17.8%), and those of Hispanic ethnicity (11.6% to 20.8%), The magnitude of the increased prevalence varied by region (ranging from 31.9% for mid Atlantic to 67.2% for South Atlantic, the area with the greatest increases) and by state (ranging from 11.3% for Delaware to 101.8% for Georgia, the state with the greatest increases). Conclusions Obesity continues to increase rapidly in the United States. To alter this trend, strategies and programs for weight maintenance as well as weight reduction must become a higher public health priority.	Ctr Dis Control & Prevent, Div Nutr & Phys Act, Atlanta, GA 30341 USA; Ctr Dis Control & Prevent, Off Director, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30341 USA	Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA	Mokdad, AH (corresponding author), Ctr Dis Control & Prevent, Div Nutr & Phys Act, 4770 Buford Hwy NE,Mailstop K26, Atlanta, GA 30341 USA.	ahm1@cdc.gov						ADAY LA, 1989, DESIGNING CONDUCTING, P79; [Anonymous], 1985, ANN INTERN MED, V103, P1073, DOI 10.7326/0003-4819-103-6-1073; BRAY GA, 1992, OBESITY, P301; CAPERSEN CJ, DEP HLTH HUMAN SERVI; CASPERSEN CJ, 1987, P 21 NAT M PUBL HLTH; Flegal KM, 1998, INT J OBESITY, V22, P39, DOI 10.1038/sj.ijo.0800541; Galuska DA, 1996, AM J PUBLIC HEALTH, V86, P1729, DOI 10.2105/AJPH.86.12.1729; NELSON DE, 1998, P SECT SURV METH AM; PALTA M, 1982, AM J EPIDEMIOL, V115, P223, DOI 10.1093/oxfordjournals.aje.a113294; PISUNYER FX, 1991, AM J CLIN NUTR, V53, pS1595; REMINGTON PL, 1988, PUBLIC HEALTH REP, V103, P366; ROWLAND ML, 1990, AM J CLIN NUTR, V52, P1125, DOI 10.1093/ajcn/52.6.1125; *SAS I INC, 1998, SAS SYST COMP PROGR; SERDULA MK, 1994, AM J PUBLIC HEALTH, V84, P1821, DOI 10.2105/AJPH.84.11.1821; SHAH BV, 1997, SUDAN USERS MANUAL R; WAKSBERG J, 1978, J AM STAT ASSOC, V73, P40, DOI 10.2307/2286513; WILLIAMSON DF, 1992, AM J PUBLIC HEALTH, V82, P1251, DOI 10.2105/AJPH.82.9.1251; Wolf A M, 1996, Am J Clin Nutr, V63, p466S, DOI 10.1093/ajcn/63.3.466; World Health Organization Expert Committee on Physical Status, 1995, TECHNICAL REPORT SER, V854	19	1653	1699	2	55	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 27	1999	282	16					1519	1522		10.1001/jama.282.16.1519	http://dx.doi.org/10.1001/jama.282.16.1519			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	248MB	10546690	Bronze			2022-12-01	WOS:000083277800018
J	Yanovski, JA; Yanovski, SZ				Yanovski, JA; Yanovski, SZ			Recent advances in basic obesity research	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							BODY-MASS INDEX; LEPTIN RECEPTOR; FRAMESHIFT MUTATION; REARED APART; EARLY-ONSET; GENE; WEIGHT; MICE; PROTEIN; INTERVENTION		NICHHD, Unit Growth & Obes, Dev Endocrinol Branch, NIH, Bethesda, MD 20892 USA; NICHHD, Div Digest Dis & Nutr, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)	Yanovski, JA (corresponding author), NICHHD, Unit Growth & Obes, Dev Endocrinol Branch, NIH, Bldg 10,Room 10N262,10 Ctr Dr,MSC 1862, Bethesda, MD 20892 USA.	jy15i@nih.gov		Yanovski, Jack/0000-0001-8542-1637	CENTER FOR INFORMATION TECHNOLOGY [ZIACT000268, Z01CT000268] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [ZIAHD000641] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [Z01HD000641] Funding Source: NIH RePORTER	CENTER FOR INFORMATION TECHNOLOGY(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Center for Information Technology (CIT)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Ahima RS, 1996, NATURE, V382, P250, DOI 10.1038/382250a0; Allison DB, 1996, INT J OBESITY, V20, P501; [Anonymous], 1996, NUTRITION, V12, P397; Argyropoulos G, 1998, J CLIN INVEST, V102, P1345, DOI 10.1172/JCI4115; Barlow SE, 1998, PEDIATRICS, V102, DOI 10.1542/peds.102.3.e29; BULTMAN SJ, 1992, CELL, V71, P1195, DOI 10.1016/S0092-8674(05)80067-4; CAMPFIELD LA, 1995, SCIENCE, V269, P546, DOI 10.1126/science.7624778; Chehab FF, 1997, SCIENCE, V275, P88, DOI 10.1126/science.275.5296.88; Chua SC, 1996, SCIENCE, V271, P994, DOI 10.1126/science.271.5251.994; Clement K, 1998, NATURE, V392, P398, DOI 10.1038/32911; COLEMAN DL, 1978, DIABETOLOGIA, V14, P141, DOI 10.1007/BF00429772; Considine RV, 1996, NEW ENGL J MED, V334, P292, DOI 10.1056/NEJM199602013340503; CONSIDINE RV, 1999, CURR OPIN ENDOCRINOL, V6, P163; Flegal KM, 1998, INT J OBESITY, V22, P39, DOI 10.1038/sj.ijo.0800541; GREENBERG AS, 1998, DIABETES S, V47, pLB16; HALAAS JL, 1995, SCIENCE, V269, P543, DOI 10.1126/science.7624777; Hill JO, 1997, PHYSICAL ACTIVITY AND CARDIOVASCULAR HEALTH, P88; Huszar D, 1997, CELL, V88, P131, DOI 10.1016/S0092-8674(00)81865-6; Karlsson J, 1998, INT J OBESITY, V22, P113, DOI 10.1038/sj.ijo.0800553; Klem ML, 1997, AM J CLIN NUTR, V66, P239, DOI 10.1093/ajcn/66.2.239; Krude H, 1998, NAT GENET, V19, P155, DOI 10.1038/509; KUCZMARSKI RJ, 1994, JAMA-J AM MED ASSOC, V272, P205, DOI 10.1001/jama.272.3.205; Levine James A., 1999, Science (Washington D C), V283, P212, DOI 10.1126/science.283.5399.212; LU DS, 1994, NATURE, V371, P799, DOI 10.1038/371799a0; Montague CT, 1997, NATURE, V387, P903, DOI 10.1038/43185; PELLEYMOUNTER MA, 1995, SCIENCE, V269, P540, DOI 10.1126/science.7624776; Perusse L, 1999, OBES RES, V7, P111, DOI 10.1002/j.1550-8528.1999.tb00398.x; Pi-Sunyer FX, 1998, OBES RES, V6, p51S; Ristow M, 1998, NEW ENGL J MED, V339, P953, DOI 10.1056/NEJM199810013391403; ROLLS BJ, 1995, AM J CLIN NUTR, V62, P1086; Sjostrom CD, 1997, OBES RES, V5, P519; STUNKARD AJ, 1990, NEW ENGL J MED, V322, P1483, DOI 10.1056/NEJM199005243222102; Tartaglia LA, 1995, CELL, V83, P1263, DOI 10.1016/0092-8674(95)90151-5; Vaisse C, 1998, NAT GENET, V20, P113, DOI 10.1038/2407; World Health Organization, 1997, PROGR NUTR FAM REPR; Yeo GSH, 1998, NAT GENET, V20, P111, DOI 10.1038/2404; ZHANG YY, 1994, NATURE, V372, P425, DOI 10.1038/372425a0	37	63	66	0	4	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 27	1999	282	16					1504	1506		10.1001/jama.282.16.1504	http://dx.doi.org/10.1001/jama.282.16.1504			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	248MB	10546681				2022-12-01	WOS:000083277800001
J	Hartman, JJ; Vale, RD				Hartman, JJ; Vale, RD			Microtubule disassembly by ATP-dependent oligomerization of the AAA enzyme katanin	SCIENCE			English	Article							SENSITIVE FUSION PROTEIN; CRYSTAL-STRUCTURE; DOMAIN; NSF; CENTROSOME; DYNAMICS; COMPLEX; SPINDLE	Katanin, a member of the AAA adenosine triphosphatase (ATPase) superfamily, uses nucleotide hydrolysis energy to sever and disassemble microtubules. Many AAA enzymes disassemble stable protein-protein complexes, but their mechanisms are not well understood. A fluorescence resonance energy transfer assay demonstrated that the p60 subunit of katanin oligomerized in an adenosine triphosphate (ATP)- and microtubule-dependent manner. Oligomerization increased the affinity of katanin for microtubules and stimulated its ATPase activity. After hydrolysis of ATP, microtubule-bound katanin oligomers disassembled microtubules and then dissociated into free katanin monomers. Coupling a nucleotide-dependent oligomerization cycle to the disassembly of a target protein complex may be a general feature of ATP-hydrolyzing AAA domains.	Univ Calif San Francisco, Howard Hughes Med Inst, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Mol & Cellular Pharmacol, San Francisco, CA 94143 USA	Howard Hughes Medical Institute; University of California System; University of California San Francisco; University of California System; University of California San Francisco	Vale, RD (corresponding author), Univ Calif San Francisco, Howard Hughes Med Inst, San Francisco, CA 94143 USA.	vale@phy.ucsf.edu						Ahmad FJ, 1999, J CELL BIOL, V145, P305, DOI 10.1083/jcb.145.2.305; Babst M, 1998, EMBO J, V17, P2982, DOI 10.1093/emboj/17.11.2982; CONFALONIERI F, 1995, BIOESSAYS, V17, P639, DOI 10.1002/bies.950170710; Desai A, 1997, ANNU REV CELL DEV BI, V13, P83, DOI 10.1146/annurev.cellbio.13.1.83; Desai A, 1999, CELL, V96, P69, DOI 10.1016/S0092-8674(00)80960-5; Fleming KG, 1998, J BIOL CHEM, V273, P15675, DOI 10.1074/jbc.273.25.15675; GILBERT SP, 1993, BIOCHEMISTRY-US, V32, P4677, DOI 10.1021/bi00068a028; Hanson PI, 1997, CELL, V90, P523, DOI 10.1016/S0092-8674(00)80512-7; Hartman JJ, 1998, CELL, V93, P277, DOI 10.1016/S0092-8674(00)81578-0; Keating TJ, 1997, P NATL ACAD SCI USA, V94, P5078, DOI 10.1073/pnas.94.10.5078; Lenzen CU, 1998, CELL, V94, P525, DOI 10.1016/S0092-8674(00)81593-7; Leonhard K, 1999, NATURE, V398, P348, DOI 10.1038/18704; MCNALLY FJ, 1993, CELL, V75, P419, DOI 10.1016/0092-8674(93)90377-3; MCNALLY FJ, UNPUB; MITCHISON T, 1984, NATURE, V312, P237, DOI 10.1038/312237a0; MITCHISON TJ, 1989, J CELL BIOL, V109, P637, DOI 10.1083/jcb.109.2.637; Miyawaki A, 1997, NATURE, V388, P882, DOI 10.1038/42264; MORGAN A, 1995, TRENDS CELL BIOL, V5, P335, DOI 10.1016/S0962-8924(00)89059-5; NAGIEC EE, 1995, J BIOL CHEM, V270, P29182, DOI 10.1074/jbc.270.49.29182; Patel S, 1998, TRENDS CELL BIOL, V8, P65, DOI 10.1016/S0962-8924(97)01212-9; Shtilerman M, 1999, SCIENCE, V284, P822, DOI 10.1126/science.284.5415.822; Sigler PB, 1998, ANNU REV BIOCHEM, V67, P581, DOI 10.1146/annurev.biochem.67.1.581; Sweitzer SM, 1998, CELL, V93, P1021, DOI 10.1016/S0092-8674(00)81207-6; TSIEN R, COMMUNICATION; WHITEHEART SW, 1994, J CELL BIOL, V126, P945, DOI 10.1083/jcb.126.4.945; Xu ZH, 1997, NATURE, V388, P741, DOI 10.1038/41944; Yu RC, 1998, NAT STRUCT BIOL, V5, P803, DOI 10.1038/1843; Zhai Y, 1996, J CELL BIOL, V135, P201, DOI 10.1083/jcb.135.1.201	28	175	181	0	7	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 22	1999	286	5440					782	785		10.1126/science.286.5440.782	http://dx.doi.org/10.1126/science.286.5440.782			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	248XZ	10531065				2022-12-01	WOS:000083303200057
J	Mao, ZX; Bonni, A; Xia, F; Nadal-Vicens, M; Greenberg, ME				Mao, ZX; Bonni, A; Xia, F; Nadal-Vicens, M; Greenberg, ME			Neuronal activity-dependent cell survival mediated by transcription factor MEF2	SCIENCE			English	Article							CENTRAL-NERVOUS-SYSTEM; GENE-EXPRESSION; CREB PHOSPHORYLATION; ACTIVATION; NUCLEUS; CALCIUM; DEATH; DROSOPHILA; MYOGENESIS; APOPTOSIS	During mammalian development, electrical activity promotes the calcium-dependent survival of neurons that have made appropriate synaptic connections. However, the mechanisms by which calcium mediates neuronal survival during development are not well characterized. A transcription-dependent mechanism was identified by which calcium influx into neurons promoted cell survival. The transcription factor MEF2 was selectively expressed in newly generated postmitotic neurons and was required for the survival of these neurons. Calcium influx into cerebellar granule neurons Led to activation of p38 mitogen-activated protein kinase-dependent phosphorylation and activation of MEF2. Once activated, MEF2 regulated neuronal survival by stimulating MEF2-dependent gene transcription. These findings demonstrate that MEF2 is a calcium-regulated transcription factor and define a function for MEF2 during nervous system development that is distinct from previously Well-characterized functions of MEF2 during muscle differentiation.	Childrens Hosp, Dept Neurol, Div Neurosci, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Neurobiol, Boston, MA 02115 USA; Massachusetts Gen Hosp, Dept Radiat Oncol, Charlestown, MA 02129 USA	Harvard University; Boston Children's Hospital; Harvard University; Harvard Medical School; Harvard University; Massachusetts General Hospital	Greenberg, ME (corresponding author), Childrens Hosp, Dept Neurol, Div Neurosci, Boston, MA 02115 USA.		Xia, Fen/G-3708-2013		EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [P30HD018655] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS028829, R37NS028829, T32NS007112] Funding Source: NIH RePORTER; NICHD NIH HHS [P30-HD18655] Funding Source: Medline; NINDS NIH HHS [5T32NS07112, NS28829] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BAYER SA, 1990, EXP NEUROL, V107, P48, DOI 10.1016/0014-4886(90)90062-W; Bito H, 1996, CELL, V87, P1203, DOI 10.1016/S0092-8674(00)81816-4; Bito H, 1997, CURR OPIN NEUROBIOL, V7, P419, DOI 10.1016/S0959-4388(97)80072-4; CHAMBERS AE, 1992, EMBO J, V11, P4981, DOI 10.1002/j.1460-2075.1992.tb05605.x; CHAMBERS AE, 1994, GENE DEV, V8, P1324, DOI 10.1101/gad.8.11.1324; Deisseroth K, 1996, NEURON, V16, P89, DOI 10.1016/S0896-6273(00)80026-4; Dudek H, 1997, SCIENCE, V275, P661, DOI 10.1126/science.275.5300.661; EDMONDSON DG, 1994, DEVELOPMENT, V120, P1251; FRANKLIN JL, 1994, ANN NY ACAD SCI, V747, P195; FRANKLIN JL, 1992, TRENDS NEUROSCI, V15, P501, DOI 10.1016/0166-2236(92)90103-F; GEISERT EE, 1989, NEUROSCI LETT, V102, P137, DOI 10.1016/0304-3940(89)90068-2; Han J, 1997, NATURE, V386, P296, DOI 10.1038/386296a0; HAN TH, 1995, MOL CELL BIOL, V15, P2907; IKESHIMA H, 1995, NEUROSCI LETT, V200, P117, DOI 10.1016/0304-3940(95)12092-I; KAUSHAL S, 1994, SCIENCE, V266, P1236, DOI 10.1126/science.7973707; LEIFER D, 1993, P NATL ACAD SCI USA, V90, P1546, DOI 10.1073/pnas.90.4.1546; LILLY B, 1995, SCIENCE, V267, P688, DOI 10.1126/science.7839146; Lin MH, 1997, DEV BIOL, V182, P240, DOI 10.1006/dbio.1996.8484; Lin Q, 1997, SCIENCE, V276, P1404, DOI 10.1126/science.276.5317.1404; Lin X, 1996, MOL BRAIN RES, V42, P307, DOI 10.1016/S0169-328X(96)00135-0; LYONS GE, 1995, J NEUROSCI, V15, P5727, DOI 10.1523/jneurosci.15-08-05727.1995; MAO Z, UNPUB; Miller TM, 1997, J BIOL CHEM, V272, P9847; Molkentin JD, 1996, MOL CELL BIOL, V16, P2627; Molkentin JD, 1995, CELL, V83, P1125, DOI 10.1016/0092-8674(95)90139-6; MONTMINY MR, 1986, J NEUROSCI, V6, P1171; RANGANAYAKULU G, 1995, DEV BIOL, V171, P169, DOI 10.1006/dbio.1995.1269; Santella L, 1997, FASEB J, V11, P1091, DOI 10.1096/fasebj.11.13.9367344; Saudou F, 1998, CELL, V95, P55, DOI 10.1016/S0092-8674(00)81782-1; SHENG M, 1991, SCIENCE, V252, P1427, DOI 10.1126/science.1646483; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; YU YT, 1992, GENE DEV, V6, P1783, DOI 10.1101/gad.6.9.1783	32	431	448	0	13	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	OCT 22	1999	286	5440					785	790		10.1126/science.286.5440.785	http://dx.doi.org/10.1126/science.286.5440.785			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	248XZ	10531066				2022-12-01	WOS:000083303200058
J	Bodenheimer, T				Bodenheimer, T			Long-term care for frail elderly people - The On Lok model	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							PROGRAM											Aaron HJ, 1995, HEALTH AFFAIR, V14, P8, DOI 10.1377/hlthaff.14.4.8; Binstock RH, 1997, HEALTH SERV RES, V32, P715; CHATTERJI P, 1998, IMPACT PACE PARTICIP; Eng C, 1997, J AM GERIATR SOC, V45, P223, DOI 10.1111/j.1532-5415.1997.tb04513.x; Eng C., 1996, CURR CONCEPTS GERIAT, V2, P4; Fisher Ian, 1998, N Y Times Web, P30; GRUENBERG L, 1993, ANAL EXPECTED MED CO; HARRINGTON C, 1991, JAMA-J AM MED ASSOC, V266, P3023, DOI 10.1001/jama.266.21.3023; IRVIN CV, 1999, NEW ENGL J MED, V340, P1283; Kassirer JP, 1998, NEW ENGL J MED, V339, P1925, DOI 10.1056/NEJM199812243392609; KUNZ E, 1996, AM J MANAGE CARE, V2, P301; Levit KR, 1998, HEALTH AFFAIR, V17, P35, DOI 10.1377/hlthaff.17.1.35; MCLEOD D, 1998, AARP B           APR; NEWCOMER R, 1996, ANNU REV GERONTOL, V16, P1; RIMER S, 1998, NY TIMES        0315, P1; Vladeck B.C., 1980, UNLOVING CARE NURSIN; White A.J., 1998, EFFECT PACE COSTS ME; [No title captured]; [No title captured]	19	78	82	2	8	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 21	1999	341	17					1324	1328		10.1056/NEJM199910213411722	http://dx.doi.org/10.1056/NEJM199910213411722			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	247NF	10528046				2022-12-01	WOS:000083226300034
J	Elliott, AM; Smith, BH; Penny, KI; Smith, WC; Chambers, WA				Elliott, AM; Smith, BH; Penny, KI; Smith, WC; Chambers, WA			The epidemiology of chronic pain in the community	LANCET			English	Article							GENERAL-POPULATION; PERSISTENT PAIN; PREVALENCE; HEALTH; CARE	Background Chronic pain is recognised as an important problem in the community but our understanding of the epidemiology of chronic pain remains limited. We undertook a study designed to quantify and describe the prevalence and distribution of chronic pain in the community. Methods A random sample of 5036 patients, aged 25 and over, was drawn from 29 general practices in the Grampian region of the UK and surveyed by a postal self-completion questionnaire. The questionnaire included case-screening questions, a question on the cause of the pain, the chronic pain grade questionnaire, the level of expressed needs questionnaire, and sociodemographic questions. Findings 3605 questionnaires were returned completed. 1817 (50.4%) of patients self reported chronic pain, equivalent to 46.5% of the general population. 576 reported back pain and 570 reported arthritis; these were the most common complaints and accounted for a third of all complaints. Backward stepwise logistic-regression modelling identified age, sex, housing tenure, and employment status as significant predictors of the presence of chronic pain in the community. 703 (48.7%) individuals with chronic pain had the least severe grade of pain, and 228 (15.8%) the most severe grade. Of those who reported chronic pain, 312 (17.2%) reported no expressed need, and 509 (28.0%) reported the highest expressed need. Interpretation Chronic pain is a major problem in the community and certain groups within the population are more likely to have chronic pain. A detailed understanding of the epidemiology of chronic pain is essential for efficient management of chronic pain in primary care.	Univ Aberdeen, Sch Med, Dept Gen Practice, Aberdeen AB9 2ZD, Scotland; Univ Aberdeen, Sch Med, Dept Publ Hlth, Aberdeen AB9 2ZD, Scotland; Aberdeen Royal Infirm, Dept Anaesthet, Aberdeen, Scotland; Univ Edinburgh, Sch Med, Med Stat Unit, Edinburgh, Midlothian, Scotland	University of Aberdeen; University of Aberdeen; University of Aberdeen; University of Edinburgh	Elliott, AM (corresponding author), Univ Aberdeen, Foresterhill Hlth Ctr, Dept Gen Practice & Primary Care, Aberdeen AB25 2AY, Scotland.		G, G/A-3459-2012; Smith, Blair H/G-2834-2012	Smith, Blair H/0000-0002-5362-9430				Becker N, 1997, PAIN, V73, P393, DOI 10.1016/S0304-3959(97)00126-7; Blaxter M., 1990, HLTH LIFESTYLES; BOWSHER D, 1991, Pain Clinic, V4, P223; BRATTBERG G, 1989, PAIN, V37, P215, DOI 10.1016/0304-3959(89)90133-4; CROFT P, 1993, J RHEUMATOL, V20, P710; Croft PR, 1998, BRIT MED J, V316, P1356, DOI 10.1136/bmj.316.7141.1356; Crombie IK, 1998, PAIN, V74, P1; CROOK J, 1989, PAIN, V36, P49, DOI 10.1016/0304-3959(89)90111-5; CROOK J, 1984, PAIN, V18, P299, DOI 10.1016/0304-3959(84)90824-8; Davies Huw T. O., 1992, Pain Clinic, V5, P129; DIAMOND A, 1991, ANAESTHESIA, V46, P83, DOI 10.1111/j.1365-2044.1991.tb09343.x; Gureje O, 1998, JAMA-J AM MED ASSOC, V280, P147, DOI 10.1001/jama.280.2.147; International Association for the Study of Pain: Subcommittee on Taxonomy, 1986, PAIN S, V3, pS1, DOI DOI 10.1016/0304-3959(86)90106-5; Latham J, 1994, Disabil Rehabil, V16, P39; Locker David, 1983, DISABILITY DISADVANT; MAGNI G, 1993, PAIN, V53, P163, DOI 10.1016/0304-3959(93)90076-2; Purves AM, 1998, PAIN CLINIC, V10, P139; Rothman KJ., 2008, MODERN EPIDEMIOLOGY, V3; Smith BH, 1997, PAIN, V71, P141, DOI 10.1016/S0304-3959(97)03347-2; Smith BH, 1996, J ROY SOC MED, V89, P181, DOI 10.1177/014107689608900402; TURK DC, 1988, J CONSULT CLIN PSYCH, V56, P233, DOI 10.1037/0022-006X.56.2.233; Verhaak PFM, 1998, PAIN, V77, P231, DOI 10.1016/S0304-3959(98)00117-1; Von Korff M, 1990, PAIN, V279, P91, DOI DOI 10.1016/0304-3959(90)91125-3; VONKORFF M, 1991, PSYCHOSOM MED, V53, P61, DOI 10.1097/00006842-199101000-00006; VONKORFF M, 1992, PAIN, V50, P133, DOI 10.1016/0304-3959(92)90154-4	25	813	851	0	49	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	OCT 9	1999	354	9186					1248	1252		10.1016/S0140-6736(99)03057-3	http://dx.doi.org/10.1016/S0140-6736(99)03057-3			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	243RE	10520633				2022-12-01	WOS:000083010400010
J	Henney, JE				Henney, JE			New drug for sleeplessness	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	News Item											Henney, JE (corresponding author), HF-1,Room 14-71,5600 Fishers Ln, Rockville, MD 20857 USA.								0	3	3	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 6	1999	282	13					1218	1218		10.1001/jama.282.13.1218	http://dx.doi.org/10.1001/jama.282.13.1218			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	241UM	10517411				2022-12-01	WOS:000082901100007
J	Bisang, C; Long, PF; Cortes, J; Westcott, J; Crosby, J; Matharu, AL; Cox, RJ; Simpson, TJ; Staunton, J; Leadlay, PF				Bisang, C; Long, PF; Cortes, J; Westcott, J; Crosby, J; Matharu, AL; Cox, RJ; Simpson, TJ; Staunton, J; Leadlay, PF			A chain initiation factor common to both modular and aromatic polyketide synthases	NATURE			English	Article							ACYL CARRIER PROTEINS; ENGINEERED BIOSYNTHESIS; IN-VITRO; STREPTOMYCES-GLAUCESCENS; RATIONAL DESIGN; PURIFICATION; SPECIFICITY; EXPRESSION; RECONSTITUTION; COMPONENTS	Antibiotic-producing polyketide synthases (PKSs) are enzymes responsible for the biosynthesis in Streptomyces and related filamentous bacteria of a remarkably broad range of bioactive metabolites, including antitumour aromatic compounds such as mithramycin(1) and macrolide antibiotics such as erythromycin(2). The molecular basis for the selection of the starter unit on aromatic PKSs is unknown(3). Here we show that a component of aromatic PKS, previously named 'chain-length factor'(4), is a factor required for polyketide chain initiation and that this factor has decarboxylase activity towards malonyl-ACP (acyl carrier protein). We have re-examined the mechanism of initiation on modular PKSs and have identified as a specific initiation factor a domain of previously unknown function named KSQ, which operates like chain-length factor. Both KSQ and chain-length factor are similar to the ketosynthase domains that catalyse polyketide chain extension in modular multifunctional PKSs and in aromatic PKSs, respectively, except that the ketosynthase domain active-site cysteine residue is replaced by a highly conserved glutamine in KSQ and in chain-length factor. The glutamine residue is important both for decarboxylase activity and for polyketide synthesis.	Dept Biochem, Cambridge CB2 1GA, England; Univ Cambridge, Chem Lab, Cambridge CB2 1EW, England	University of Cambridge	Leadlay, PF (corresponding author), Univ Wisconsin, Sch Pharm, 425 N Charter St, Madison, WI 53706 USA.		Cox, Russell John/F-9190-2015; Simpson, Thomas J/P-5058-2015	Cox, Russell John/0000-0002-1844-0157; Cortes, Jesus/0000-0002-2475-6983; Leadlay, Peter/0000-0002-3247-509X				Bao WL, 1998, BIOCHEMISTRY-US, V37, P8132, DOI 10.1021/bi980466i; Carreras CW, 1998, BIOCHEMISTRY-US, V37, P2084, DOI 10.1021/bi972919+; CROSBY J, 1995, BBA-PROTEIN STRUCT M, V1251, P32, DOI 10.1016/0167-4838(95)00053-W; Hitchman TS, 1998, CHEM BIOL, V5, P35, DOI 10.1016/S1074-5521(98)90085-0; Hopwood DA, 1997, CHEM REV, V97, P2465, DOI 10.1021/cr960034i; Joshi AK, 1997, BIOCHEMISTRY-US, V36, P2316, DOI 10.1021/bi9626968; Kao CM, 1996, BIOCHEMISTRY-US, V35, P12363, DOI 10.1021/bi9616312; KIM ES, 1995, J BACTERIOL, V177, P1202, DOI 10.1128/jb.177.5.1202-1207.1995; Kramer PJ, 1997, J AM CHEM SOC, V119, P635, DOI 10.1021/ja962888q; KRESZE GB, 1977, EUR J BIOCHEM, V79, P191, DOI 10.1111/j.1432-1033.1977.tb11797.x; Lombo F, 1997, J BACTERIOL, V179, P3354, DOI 10.1128/jb.179.10.3354-3357.1997; Marsden AFA, 1998, SCIENCE, V279, P199, DOI 10.1126/science.279.5348.199; Matharu AL, 1998, CHEM BIOL, V5, P699, DOI 10.1016/S1074-5521(98)90663-9; MCDANIEL R, 1994, P NATL ACAD SCI USA, V91, P11542, DOI 10.1073/pnas.91.24.11542; MCDANIEL R, 1993, SCIENCE, V262, P1546, DOI 10.1126/science.8248802; MCDANIEL R, 1995, NATURE, V375, P549, DOI 10.1038/375549a0; MEURER G, 1995, J BACTERIOL, V177, P477, DOI 10.1128/jb.177.2.477-481.1995; Pieper R, 1997, BIOCHEMISTRY-US, V36, P1846, DOI 10.1021/bi962324z; PIEPER R, 1995, J AM CHEM SOC, V117, P11373, DOI 10.1021/ja00150a049; Rowe CJ, 1998, GENE, V216, P215, DOI 10.1016/S0378-1119(98)00327-8; SHEN B, 1995, J AM CHEM SOC, V117, P6811, DOI 10.1021/ja00131a002; Siggaard-Andersen Mads, 1993, Protein Sequences and Data Analysis, V5, P325; Staunton J, 1998, TOP CURR CHEM, V195, P49; Weissman KJ, 1998, BIOCHEMISTRY-US, V37, P11012, DOI 10.1021/bi9806246; WIESMANN KEH, 1995, CHEM BIOL, V2, P583, DOI 10.1016/1074-5521(95)90122-1; Yu TW, 1998, J AM CHEM SOC, V120, P7749, DOI 10.1021/ja9803658; Zawada RJX, 1997, J BIOL CHEM, V272, P16184, DOI 10.1074/jbc.272.26.16184	27	225	264	2	36	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	SEP 30	1999	401	6752					502	505		10.1038/46829	http://dx.doi.org/10.1038/46829			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	243DF	10519556				2022-12-01	WOS:000082981200062
J	Di Cristofano, A; Kotsi, P; Peng, YF; Cordon-Cardo, C; Elkon, KB; Pandolfi, PP				Di Cristofano, A; Kotsi, P; Peng, YF; Cordon-Cardo, C; Elkon, KB; Pandolfi, PP			Impaired Fas response and autoimmunity in Pten(+/-) mice	SCIENCE			English	Article							TUMOR-SUPPRESSOR GENE; PROSTATE-CANCER; COWDEN-DISEASE; CELL-DEATH; PTEN GENE; PTEN/MMAC1; MUTATIONS; APOPTOSIS; BREAST; FREQUENT	Inactivating mutations in the PTEN tumor suppressor gene, encoding a phosphatase, occur in three related human autosomal dominant disorders characterized by tumor Susceptibility. Here it is shown that Pten heterozygous (Pten(+/-)) mutants develop a lethal polyclonal autoimmune disorder with features reminiscent of those observed in Fas-deficient mutants. Fas-mediated apoptosis was impaired in Pten(+/-) mice, and T Lymphocytes from these mice show reduced activation-induced cell death and increased proliferation upon activation. Phosphatidylinositol (PI) 3-kinase inhibitors restored Fas responsiveness in Pten(+/-) cells. These results indicate that Pten is an essential mediator of the Fas response and a repressor of autoimmunity and thus implicate the PI 3-kinase/Akt pathway in Fas-mediated apoptosis.	Mem Sloan Kettering Canc Ctr, Sloan Kettering Inst, Dept Human Genet, Program Mol Biol, New York, NY 10021 USA; Mem Sloan Kettering Canc Ctr, Sloan Kettering Inst, Dept Pathol, New York, NY 10021 USA; Cornell Univ, Coll Med, Hosp Special Surg, New York, NY 10021 USA	Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; Cornell University	Pandolfi, PP (corresponding author), Mem Sloan Kettering Canc Ctr, Sloan Kettering Inst, Dept Human Genet, Program Mol Biol, 1275 York Ave, New York, NY 10021 USA.		kotsi, paraskevi/GRR-7445-2022; di cristofano, antonio/AAJ-3796-2020; Di Cristofano, Antonio/B-4148-2016	di cristofano, antonio/0000-0003-2537-3228; kotsi, paraskevi/0000-0003-3696-6731	NATIONAL CANCER INSTITUTE [P30CA008748, R01CA082328] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR045482] Funding Source: NIH RePORTER; NCI NIH HHS [CA-08748, CA-82328] Funding Source: Medline; NIAMS NIH HHS [AR45482] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Cairns P, 1997, CANCER RES, V57, P4997; Dahia PLM, 1999, HUM MOL GENET, V8, P185, DOI 10.1093/hmg/8.2.185; Di Cristofano A, 1998, NAT GENET, V19, P348, DOI 10.1038/1235; Elkon KB, 1996, CURR OPIN IMMUNOL, V8, P852, DOI 10.1016/S0952-7915(96)80015-X; LAZEBNIK YA, 1994, NATURE, V371, P346, DOI 10.1038/371346a0; Lenardo M J, 1997, Semin Immunol, V9, P1, DOI 10.1006/smim.1996.0050; Levine JS, 1999, SEMIN NEPHROL, V19, P34; Li J, 1997, SCIENCE, V275, P1943, DOI 10.1126/science.275.5308.1943; Li J, 1998, CANCER RES, V58, P5667; Liaw D, 1997, NAT GENET, V16, P64, DOI 10.1038/ng0597-64; Lim MS, 1998, AM J PATHOL, V153, P1541, DOI 10.1016/S0002-9440(10)65742-2; Maehama T, 1998, J BIOL CHEM, V273, P13375, DOI 10.1074/jbc.273.22.13375; Marsh DJ, 1998, J MED GENET, V35, P881, DOI 10.1136/jmg.35.11.881; Marsh DJ, 1998, HUM MOL GENET, V7, P507, DOI 10.1093/hmg/7.3.507; Mevorach D, 1998, J EXP MED, V188, P387, DOI 10.1084/jem.188.2.387; Myers MP, 1998, P NATL ACAD SCI USA, V95, P13513, DOI 10.1073/pnas.95.23.13513; Penninger JM, 1998, ADV IMMUNOL, V68, P51, DOI 10.1016/S0065-2776(08)60558-1; Podsypanina K, 1999, P NATL ACAD SCI USA, V96, P1563, DOI 10.1073/pnas.96.4.1563; Rasheed BKA, 1997, CANCER RES, V57, P4187; Reininger L, 1996, J EXP MED, V184, P853, DOI 10.1084/jem.184.3.853; Rhei E, 1997, CANCER RES, V57, P3657; SADLACK B, 1993, CELL, V75, P253, DOI 10.1016/0092-8674(93)80067-O; Stambolic V, 1998, CELL, V95, P29, DOI 10.1016/S0092-8674(00)81780-8; Steck PA, 1997, NAT GENET, V15, P356, DOI 10.1038/ng0497-356; SUDA T, 1994, J EXP MED, V179, P873, DOI 10.1084/jem.179.3.873; Suzuki A, 1998, CURR BIOL, V8, P1169, DOI 10.1016/S0960-9822(07)00488-5; TAKAHASHI T, 1994, CELL, V76, P969, DOI 10.1016/0092-8674(94)90375-1; Tashiro H, 1997, CANCER RES, V57, P3935; vanParijs L, 1996, CURR OPIN IMMUNOL, V8, P355, DOI 10.1016/S0952-7915(96)80125-7; WATANABEFUKUNAGA R, 1992, NATURE, V356, P314, DOI 10.1038/356314a0; Weintraub JP, 1997, J IMMUNOL, V159, P4117; Widmann C, 1998, J BIOL CHEM, V273, P7141, DOI 10.1074/jbc.273.12.7141; WILLERFORD DM, 1995, IMMUNITY, V3, P521, DOI 10.1016/1074-7613(95)90180-9	33	438	451	1	7	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	SEP 24	1999	285	5436					2122	2125		10.1126/science.285.5436.2122	http://dx.doi.org/10.1126/science.285.5436.2122			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	238VF	10497129				2022-12-01	WOS:000082734300041
J	Barr, MM; Sternberg, PW				Barr, MM; Sternberg, PW			A polycystic kidney-disease gene homologue required for male mating behaviour in C-elegans	NATURE			English	Article							NEMATODE CAENORHABDITIS-ELEGANS; PROTEIN; INSIGHTS; NEURON; PKD1	The stereotyped mating behaviour of the Caenorhabditis elegans male is made up of several substeps: response, backing, turning, vulva location, spicule insertion and sperm transfer. The complexity of this behaviour is reflected in the sexually dimorphic anatomy and nervous system(1). Behavioural functions have been assigned to most of the male-specific sensory neurons by means of cell ablations; for example, the hook sensory neurons HOA and HOB are specifically required for vulva location(2). We have investigated how sensory perception of the hermaphrodite by the C. elegans male controls mating behaviours. Here we identify a gene, lov-1 (for location of vulva), that is required for two male sensory behaviours: response and vulva location. lov-1 encodes a putative membrane protein with a mucin-like, serine-threonine-rich amino terminus' followed by two blocks of homology to human polycystins, products of the autosomal dominant polycystic kidney-disease loci PKD1 and PKD2 (ref 4). LOV-1 is the closest C. elegans homologue of PKD1. lov-1 is expressed in adult males in sensory neurons of the rays, hook and head, which mediate response, vulva location, and potentially chemotaxis to hermaphrodites, respectively(2,5). PKD-2, the C. elegans homologue of PKD2, is localized to the same neurons as LOV-1, suggesting that they function in the same pathway.	CALTECH, Howard Hughes Med Inst, Pasadena, CA 91125 USA; CALTECH, Div Biol, Pasadena, CA 91125 USA	California Institute of Technology; Howard Hughes Medical Institute; California Institute of Technology	Sternberg, PW (corresponding author), CALTECH, Howard Hughes Med Inst, Pasadena, CA 91125 USA.			Sternberg, Paul/0000-0002-7699-0173				Arnould T, 1998, J BIOL CHEM, V273, P6013, DOI 10.1074/jbc.273.11.6013; BRENNER S, 1974, GENETICS, V77, P71; CARRAWAY KL, 1995, TRENDS GLYCOSCI GLYC, V7, P31, DOI 10.4052/tigg.7.31; CHALFIE M, 1994, SCIENCE, V263, P802, DOI 10.1126/science.8303295; Collet J, 1998, GENETICS, V148, P187; DRISCOLL M, 1997, NEMATODE C ELEGANS, V2, P645; Hodgkin J, 1997, GENETICS, V146, P149; HODGKIN J, 1983, GENETICS, V103, P43; Hodgkin J., 1988, NEMATODE CAENORHABDI, P243; HUDSPETH AJ, 1989, NATURE, V341, P397, DOI 10.1038/341397a0; KAPLAN JM, 1993, P NATL ACAD SCI USA, V90, P2227, DOI 10.1073/pnas.90.6.2227; Kim E, 1999, J BIOL CHEM, V274, P4947, DOI 10.1074/jbc.274.8.4947; LIU KS, 1995, NEURON, V14, P79, DOI 10.1016/0896-6273(95)90242-2; Mochizuki T, 1996, SCIENCE, V272, P1339, DOI 10.1126/science.272.5266.1339; Montell C, 1998, CURR OPIN NEUROBIOL, V8, P389, DOI 10.1016/S0959-4388(98)80066-4; MONTELL C, 1989, NEURON, V2, P1313, DOI 10.1016/0896-6273(89)90069-X; Nomura H, 1998, J BIOL CHEM, V273, P25967, DOI 10.1074/jbc.273.40.25967; Parnell SC, 1998, BIOCHEM BIOPH RES CO, V251, P625, DOI 10.1006/bbrc.1998.9514; PERKINS LA, 1986, DEV BIOL, V117, P456, DOI 10.1016/0012-1606(86)90314-3; Qian F, 1997, NAT GENET, V16, P179, DOI 10.1038/ng0697-179; SANFORD R, 1997, HUM MOL GENET, V9, P1483; SCHNABEL H, 1990, SCIENCE, V250, P686, DOI 10.1126/science.250.4981.686; Sullivan LP, 1998, PHYSIOL REV, V78, P1165, DOI 10.1152/physrev.1998.78.4.1165; SULSTON JE, 1980, DEV BIOL, V78, P542, DOI 10.1016/0012-1606(80)90352-8; Torres VE, 1998, CURR OPIN NEPHROL HY, V7, P159, DOI 10.1097/00041552-199803000-00004; Tsiokas L, 1999, P NATL ACAD SCI USA, V96, P3934, DOI 10.1073/pnas.96.7.3934; Tsiokas L, 1997, P NATL ACAD SCI USA, V94, P6965, DOI 10.1073/pnas.94.13.6965; WARD S, 1975, J COMP NEUROL, V160, P313, DOI 10.1002/cne.901600305; WHITE JG, 1986, PHILOS T R SOC B, V314, P1, DOI 10.1098/rstb.1986.0056; Wu GQ, 1998, GENOMICS, V54, P564, DOI 10.1006/geno.1998.5618	30	386	434	1	23	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	SEP 23	1999	401	6751					386	389		10.1038/43916	http://dx.doi.org/10.1038/43916			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	240JJ	10517638				2022-12-01	WOS:000082822600054
J	Fatkin, D; MacRae, C; Sasaki, T; Wolff, MR; Porcu, M; Frenneaux, M; Atherton, J; Vidaillet, HJ; Spudich, S; De Girolami, U; Seidman, JG; Seidman, CE; Muntoni, F; Muehle, G; Johnson, W; McDonough, B				Fatkin, D; MacRae, C; Sasaki, T; Wolff, MR; Porcu, M; Frenneaux, M; Atherton, J; Vidaillet, HJ; Spudich, S; De Girolami, U; Seidman, JG; Seidman, CE; Muntoni, F; Muehle, G; Johnson, W; McDonough, B			Missense mutations in the rod domain of the lamin A/C gene as causes of dilated cardiomyopathy and conduction-system disease.	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							DREIFUSS MUSCULAR-DYSTROPHY; HEART-FAILURE; ORGANIZATION; LOCUS; DEFICIENCY; FREQUENCY; LINKAGE; CDNA	Background: Inherited mutations cause approximately 35 percent of cases of dilated cardiomyopathy; however, few genes associated with this disease have been identified. Previously, we located a gene defect that was responsible for autosomal dominant dilated cardiomyopathy and conduction-system disease on chromosome 1p1-q21, where nuclear-envelope proteins lamin A and lamin C are encoded by the LMNA (lamin A/C) gene. Mutations in the head or tail domain of this gene cause Emery-Dreifuss muscular dystrophy, a childhood-onset disease characterized by joint contractures and in some cases by abnormalities of cardiac conduction during adulthood. Methods: We evaluated 11 families with autosomal dominant dilated cardiomyopathy and conduction-system disease. Sequences of the lamin A/C exons were determined in probands from each family, and variants were confirmed by restriction-enzyme digestion. The genotypes of the family members were ascertained. Results: Five novel missense mutations were identified: four in the (alpha)-helical rod domain of the lamin A/C gene, and one in the lamin C tail domain. Each mutation caused heritable, progressive conduction-system disease (sinus bradycardia, atrioventricular conduction block, or atrial arrhythmias) and dilated cardiomyopathy. Heart failure and sudden death occurred frequently within these families. No family members with mutations had either joint contractures or skeletal myopathy. Serum creatine kinase levels were normal in family members with mutations of the lamin rod but mildly elevated in some family members with a defect in the tail domain of lamin C. Conclusions: Genetic defects in distinct domains of the nuclear-envelope proteins lamin A and lamin C selectively cause dilated cardiomyopathy with conduction-system disease or autosomal dominant Emery-Dreifuss muscular dystrophy. Missense mutations in the rod domain of the lamin A/C gene provide a genetic cause for dilated cardiomyopathy and indicate that this intermediate filament protein has an important role in cardiac conduction and contractility. (N Engl J Med 1999;341:1715-24.) (C)1999, Massachusetts Medical Society.	Harvard Univ, Sch Med, Dept Genet, Boston, MA 02115 USA; Brigham & Womens Hosp, Div Cardiovasc, Boston, MA 02115 USA; Brigham & Womens Hosp, Howard Hughes Med Inst, Boston, MA 02115 USA; Brigham & Womens Hosp, Div Neuropathol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Genet, Boston, MA USA; Harvard Univ, Sch Med, Howard Hughes Med Inst, Boston, MA 02115 USA; Univ Wisconsin, Div Cardiovasc, Madison, WI USA; Hosp G Brotzu, Div Cardiovasc, Cagliari, Italy; Cardiff Univ, Wales Heart Res Inst, Dept Cardiol, Cardiff CF4 4XN, S Glam, Wales; Royal Brisbane Hosp, Dept Cardiol, Brisbane, Qld 4029, Australia; Marshfield Clin Fdn Med Res & Educ, Div Cardiovasc, Marshfield, WI USA; Hammersmith Hosp, London, England	Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital; Howard Hughes Medical Institute; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Howard Hughes Medical Institute; University of Wisconsin System; University of Wisconsin Madison; Cardiff University; Royal Brisbane & Women's Hospital; Marshfield Clinic; Imperial College London	Seidman, CE (corresponding author), Harvard Univ, Sch Med, Dept Genet, Alpert Rm 533,200 Longwood Ave, Boston, MA 02115 USA.	cseidman@rascal.med.harvard.edu	Atherton, John J/B-9994-2011	Atherton, John J/0000-0003-2271-578X				Barresi R, 1997, ACTA NEUROPATHOL, V94, P28, DOI 10.1007/s004010050668; BHARATI S, 1992, PACE, V15, P1720, DOI 10.1111/j.1540-8159.1992.tb02960.x; BIONE S, 1994, NAT GENET, V8, P323, DOI 10.1038/ng1294-323; Bonne G, 1999, NAT GENET, V21, P285, DOI 10.1038/6799; Bowles KR, 1996, J CLIN INVEST, V98, P1355, DOI 10.1172/JCI118922; Broers JLV, 1997, HISTOCHEM CELL BIOL, V107, P505, DOI 10.1007/s004180050138; Cohn JN, 1997, CIRCULATION, V95, P766; DEC GW, 1994, NEW ENGL J MED, V331, P1564, DOI 10.1056/NEJM199412083312307; DURAND JB, 1995, CIRCULATION, V92, P3387, DOI 10.1161/01.CIR.92.12.3387; EMERY AEH, 1987, CLIN GENET, V32, P360; FISHER DZ, 1986, P NATL ACAD SCI USA, V83, P6450, DOI 10.1073/pnas.83.17.6450; Fuchs E, 1998, SCIENCE, V279, P514, DOI 10.1126/science.279.5350.514; GERACE L, 1980, CELL, V19, P277, DOI 10.1016/0092-8674(80)90409-2; GERACE L, 1986, TRENDS BIOCHEM SCI, V11, P443, DOI 10.1016/0968-0004(86)90243-4; Grunig E, 1998, J AM COLL CARDIOL, V31, P186, DOI 10.1016/S0735-1097(97)00434-8; Herrmann H, 1998, CURR OPIN STRUC BIOL, V8, P177, DOI 10.1016/S0959-440X(98)80035-3; HOFFMAN EP, 1987, CELL, V51, P919, DOI 10.1016/0092-8674(87)90579-4; HOFFMAN EP, 1988, NEW ENGL J MED, V318, P1363, DOI 10.1056/NEJM198805263182104; Jung M, 1998, CIRCULATION, V98, P246; KASPER EK, 1994, J AM COLL CARDIOL, V23, P586, DOI 10.1016/0735-1097(94)90740-4; KASS S, 1994, NAT GENET, V7, P546, DOI 10.1038/ng0894-546; KEELING PJ, 1995, BRIT HEART J, V73, P417; KOENIG M, 1987, CELL, V50, P509, DOI 10.1016/0092-8674(87)90504-6; KRAJINOVIC M, 1995, AM J HUM GENET, V57, P846; Ku NO, 1996, CANCER METAST REV, V15, P429, DOI 10.1007/BF00054011; Manilal S, 1999, HUM MOL GENET, V8, P353, DOI 10.1093/hmg/8.2.353; MAWATARI S, 1973, ARCH NEUROL-CHICAGO, V28, P55, DOI 10.1001/archneur.1973.00490190073010; MICHELS VV, 1992, NEW ENGL J MED, V326, P77, DOI 10.1056/NEJM199201093260201; MUNTONI F, 1993, NEW ENGL J MED, V329, P921, DOI 10.1056/NEJM199309233291304; Nagano A, 1996, NAT GENET, V12, P254, DOI 10.1038/ng0396-254; Olson TM, 1996, J CLIN INVEST, V97, P528, DOI 10.1172/JCI118445; Olson TM, 1998, SCIENCE, V280, P750, DOI 10.1126/science.280.5364.750; Siu BL, 1999, CIRCULATION, V99, P1022, DOI 10.1161/01.CIR.99.8.1022; Spann TP, 1997, J CELL BIOL, V136, P1201, DOI 10.1083/jcb.136.6.1201; Stuurman N, 1998, J STRUCT BIOL, V122, P42, DOI 10.1006/jsbi.1998.3987; TOWBIN JA, 1993, CIRCULATION, V87, P1854, DOI 10.1161/01.CIR.87.6.1854; VOIT T, 1988, NEUROPEDIATRICS, V19, P62, DOI 10.1055/s-2008-1052404; WATERS DD, 1975, NEW ENGL J MED, V293, P1017, DOI 10.1056/NEJM197511132932004; Wydner KL, 1996, GENOMICS, V32, P474, DOI 10.1006/geno.1996.0146; Yates JRW, 1999, NEUROMUSCULAR DISORD, V9, P199, DOI 10.1016/S0960-8966(98)00095-9	40	951	984	1	37	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	DEC 2	1999	341	23					1715	1724		10.1056/NEJM199912023412302	http://dx.doi.org/10.1056/NEJM199912023412302			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	260NB	10580070				2022-12-01	WOS:000083955800002
J	Guardiola, J; Xiol, X; Sallie, R; Nolla, JM; Roig-Escofet, D; Jaurrieta, E; Casais, L				Guardiola, J; Xiol, X; Sallie, R; Nolla, JM; Roig-Escofet, D; Jaurrieta, E; Casais, L			Influence of the vitamin D receptor gene polymorphism on bone loss in men after liver transplantation	ANNALS OF INTERNAL MEDICINE			English	Article							MINERAL DENSITY; RHEUMATOID-ARTHRITIS; WOMEN; ALLELES; CALCIUM; GENOTYPE; DISEASE; RATES; LOCUS	Background: Bone loss is a frequent complication after liver transplantation. Objective: To investigate whether vitamin D receptor gene polymorphism influences bone loss in men after liver transplantation. Design: Prospective cohort study. Setting: University hospital. Patients: 55 male candidates for liver transplantation. Measurements: Lumbar spine bone mineral density was measured before and 3, 6, 12, and 24 months after liver transplantation. Vitamin D receptor genotype was determined by restriction endonuclease Bsml. Results: Vitamin D receptor genotypes were significantly associated with post-transplantation changes in bone mineral density (P = 0.028). Within 3 months after transplantation, patients with the genotypes Bb or BE showed a vertebral bone loss substantially greater than that in patients with the bb genotype (between-group difference in the percentage change with respect to baseline bone mineral density, 3.7% [95% CI, 0.6% to 6.9%]). In 3 to 24 months after transplantation, bone mineral density increased steadily in the three allelic groups. Conclusions: Vitamin D receptor gene polymorphism influences bone loss after liver transplantation. Patients with the bb genotype are, to some extent, protected against post-transplantation bone loss.	Ciudad Sanitaria & Univ Bellvitge, Hosp Princeps Espanya, Dept Gastroenterol, Barcelona 08907, Spain; Ciudad Sanitaria & Univ Bellvitge, Hosp Princeps Espanya, Dept Rheumatol, Barcelona 08907, Spain; Ciudad Sanitaria & Univ Bellvitge, Hosp Princeps Espanya, Dept Gen Surg, Barcelona 08907, Spain; NIDDKD, Liver Unit, NIH, Bethesda, MD 20892 USA	Institut d'Investigacio Biomedica de Bellvitge (IDIBELL); Bellvitge University Hospital; Institut d'Investigacio Biomedica de Bellvitge (IDIBELL); Bellvitge University Hospital; Institut d'Investigacio Biomedica de Bellvitge (IDIBELL); Bellvitge University Hospital; National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)	Guardiola, J (corresponding author), Hosp Comarcal LAlt Penedes, Gastroenterol Unit, Espriall S-N, Barcelona 08720, Spain.			Guardiola, Jordi/0000-0002-0464-241X; Xiol, Xavier/0000-0002-4461-4704				AN SF, 1991, J CLIN PATHOL, V44, P924, DOI 10.1136/jcp.44.11.924; Buckley LM, 1996, ANN INTERN MED, V125, P961, DOI 10.7326/0003-4819-125-12-199612150-00004; DAWSONHUGHES B, 1995, J CLIN ENDOCR METAB, V80, P3657, DOI 10.1210/jc.80.12.3657; DIAMOND TH, 1989, GASTROENTEROLOGY, V96, P213, DOI 10.1016/0016-5085(89)90783-X; EASTELL R, 1991, HEPATOLOGY, V14, P296, DOI 10.1002/hep.1840140215; FERRARI S, 1995, LANCET, V345, P423, DOI 10.1016/S0140-6736(95)90404-2; FLEET JC, 1995, J BONE MINER RES, V10, P985; GARNERO P, 1995, J BONE MINER RES, V10, P1283; Gough A, 1998, J RHEUMATOL, V25, P864; HAY JE, 1993, GASTROENTEROL CLIN N, V22, P337; HUSTMYER FG, 1994, J CLIN INVEST, V94, P2130, DOI 10.1172/JCI117568; Jorgensen HL, 1996, BRIT MED J, V313, P586, DOI 10.1136/bmj.313.7057.586; KRALL EA, 1995, J BONE MINER RES, V10, P978; MCDONALD JA, 1991, HEPATOLOGY, V14, P613, DOI 10.1002/hep.1840140407; MEYS E, 1994, AM J MED, V97, P445, DOI 10.1016/0002-9343(94)90324-7; MORRISON NA, 1994, NATURE, V367, P284, DOI 10.1038/367284a0; RIGGS BL, 1995, J BONE MINER RES, V10, P991; Sainz J, 1997, NEW ENGL J MED, V337, P77, DOI 10.1056/NEJM199707103370202; SPECTOR TD, 1995, BRIT MED J, V310, P1357, DOI 10.1136/bmj.310.6991.1357; WILLETT WC, 1985, AM J EPIDEMIOL, V122, P51, DOI 10.1093/oxfordjournals.aje.a114086	20	17	17	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	NOV 16	1999	131	10					752	755		10.7326/0003-4819-131-10-199911160-00006	http://dx.doi.org/10.7326/0003-4819-131-10-199911160-00006			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	255QC	10577298				2022-12-01	WOS:000083680100005
J	Duong, T; Ades, AE; Gibb, DM; Tookey, PA; Masters, J				Duong, T; Ades, AE; Gibb, DM; Tookey, PA; Masters, J			Vertical transmission rates for HIV in the British Isles: estimates based on surveillance data	BRITISH MEDICAL JOURNAL			English	Article							ZIDOVUDINE PROPHYLAXIS; CESAREAN-SECTION	Objective To estimate and interpret time trends in vertical transmission rates for HIV using data from national obstetric and paediatric surveillance registers. Design Prospective study of HIV infected women reported through obstetric surveillance. HIV infection status of the child and onset of AIDS were reported through paediatric surveillance. Rates of Vertical transmission and progression to AIDS rate were estimated by methods that take account of incomplete follow up of children with indeterminate infection status and delay in AIDS reporting. Setting British Isles. Subjects Pregnant women infected with HIV whose infection was diagnosed before delivery, and their babies. Main outcome measures Mother to child transmission of infection and progression to AIDS in children. Results By January 1999, 800 children born to diagnosed HN infected women who had not breast fed had been reported. Vertical transmission rates rose to 19.6% (95% confidence interval 8.0% to 32.5%) in 1993 before falling to 2.2% (0% to 7.8%) in 1998, Between 1995 and 1998 use of antiretroviral treatment increased significantly each year, reaching 97% of live births in 1998. The rate of elective caesarean section remained constant, at around 40%, up to 1997 but increased to 62% in 1998, Caesarean section and antiretroviral treatment together were estimated to reduce risk of transmission from 31.6% (13.6% to 52.2%) to 4.2% (0.8% to 8.5%). The proportion of infected children developing AIDS in the first 6 months fell from 17.7% (6.8% to 30.8%) before 1994 to 7.2% (0% to 15.7%) after, coinciding with increased use of prophylaxis against Pneumocystis carinii pneumonia. Conclusions In the British Isles both HIV related morbidity and vertical transmission are being reduced through increased use of interventions.	Inst Child Hlth, Dept Epidemiol & Publ Hlth, London WC1N 1EH, England; Med Res Ctr, Clin Trials Unit, Mortimer Market Ctr, London WC1E 6AU, England	University of London; University College London; Medical Research Council Clinical Trials Unit	Ades, AE (corresponding author), Inst Child Hlth, Dept Epidemiol & Publ Hlth, 30 Guilford St, London WC1N 1EH, England.		Tookey, Pat A/G-2732-2010	Tookey, Pat A/0000-0001-6258-0387; Gibb, Diana/0000-0002-9738-5490				Andiman W, 1999, NEW ENGL J MED, V340, P977, DOI 10.1056/NEJM199904013401301; CIRIA LM, 1998, 12 WORLD AIDS C GEN; CONNOR EM, 1994, NEW ENGL J MED, V331, P1173, DOI 10.1056/NEJM199411033311801; Dempster A. P., 1977, JRSSSB, V39, P1; Dunn DT, 1996, J AM STAT ASSOC, V91, P935, DOI 10.2307/2291712; Efron B., 1986, STAT SCI, V1, P54, DOI DOI 10.1214/SS/1177013815; *EUR MOD DEL COLL, 1999, MANDET, V353, P1035; FISCUS S, 1998, 12 WORLD AIDS C GEN; GALVAAO NO, 1998, 12 WORLD AIDS C GEN; GIBB DM, 1993, GUIDELINES MANAGEMEN, P1; Kind C, 1998, AIDS, V12, P205, DOI 10.1097/00002030-199802000-00011; LINDEGREN ML, 1999, 6 C RETR OPP INF CHI; Lorenzi P, 1998, AIDS, V12, pF241, DOI 10.1097/00002030-199818000-00002; Maguire A, 1997, AIDS, V11, P1851, DOI 10.1097/00002030-199715000-00010; Mandelbrot L, 1998, JAMA-J AM MED ASSOC, V280, P55, DOI 10.1001/jama.280.1.55; Newell ML, 1996, AIDS, V10, P1675; Nicoll A, 1998, BRIT MED J, V316, P253, DOI 10.1136/bmj.316.7127.253; Parazzini F, 1999, LANCET, V353, P1035, DOI 10.1016/S0140-6736(98)08084-2; RAKUSAN TA, 1998, 12 WORLD AIDS C GEN; ROSENBERG PS, 1990, J ACQ IMMUN DEF SYND, V3, P49; *US PUBL HLTH SERV, 1995, MMWR-MORBID MORTAL W, V44, P1	21	58	60	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	NOV 6	1999	319	7219					1227	1229		10.1136/bmj.319.7219.1227	http://dx.doi.org/10.1136/bmj.319.7219.1227			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	254RH	10550082	Green Published, Bronze			2022-12-01	WOS:000083625600021
J	Hu, X; Lazar, MA				Hu, X; Lazar, MA			The CoRNR motif controls the recruitment of corepressors by nuclear hormone receptors	NATURE			English	Article							RETINOID-X-RECEPTOR; PROMYELOCYTIC LEUKEMIA; HISTONE DEACETYLASE; LIGAND-BINDING; CO-REPRESSOR; ACTIVATION; DOMAINS; SPECIFICITY; COMPLEX; BETA	N-CoR1 and SMRT2 are transcriptional corepressors that associate with nuclear hormone receptors (NRs) in the absence of ligand. This interaction is the molecular target of differentiation therapy for acute promyelocytic leukaemia, wherein retinoic acid dissociates corepressor from leukaemogenic receptor fusion pioteins(3,4). Binding of ligand to NRs induces a conformation that attracts coactivator proteins containing an Leu-x-x-Leu-Leu motif (the 'NR box')(5,6). Here we show that N-CoR and SMRT contain sequences that are similar to the NR pox and are repeated in each of two NR interaction domains(7-10). We show that this CoRNR ('corner') box is required for NR interaction, and that CoRNR box peptides specifically block corepressor interaction in vitro and repression in vivo. Sequences flanking the CoRNR box determine NR specificity. Thus, the key feature of hormone action, differential recognition of unliganded and liganded NRs by coactivators and corepressors, is due to very subtle differences between CoRNR and NR boxes. The molecular mechanisms of repression and activation by NRs are thus linked in an unexpected manner.	Univ Penn, Sch Med, Dept Med, Div Endocrinol Diabet & Metab, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Dept Genet, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Penn Diabet Ctr, Philadelphia, PA 19104 USA	University of Pennsylvania; University of Pennsylvania; University of Pennsylvania	Lazar, MA (corresponding author), Univ Penn, Sch Med, Dept Med, Div Endocrinol Diabet & Metab, Philadelphia, PA 19104 USA.		Lazar, Mitchell A/AAF-3738-2019					CHEN JD, 1995, NATURE, V377, P454, DOI 10.1038/377454a0; Cohen RN, 1998, MOL ENDOCRINOL, V12, P1567, DOI 10.1210/me.12.10.1567; Collingwood TN, 1997, J BIOL CHEM, V272, P13060, DOI 10.1074/jbc.272.20.13060; Darimont BD, 1998, GENE DEV, V12, P3343, DOI 10.1101/gad.12.21.3343; Dressel U, 1999, MOL CELL BIOL, V19, P3383; Feng WJ, 1998, SCIENCE, V280, P1747, DOI 10.1126/science.280.5370.1747; Forman BM, 1998, NATURE, V395, P612, DOI 10.1038/26996; Grignani F, 1998, NATURE, V391, P815, DOI 10.1038/35901; Heery DM, 1997, NATURE, V387, P733, DOI 10.1038/42750; HORLEIN AJ, 1995, NATURE, V377, P397, DOI 10.1038/377397a0; LeDouarin B, 1996, EMBO J, V15, P6701, DOI 10.1002/j.1460-2075.1996.tb01060.x; Lin RJ, 1998, NATURE, V391, P811, DOI 10.1038/35895; Mak HY, 1999, MOL CELL BIOL, V19, P3895; McInerney EM, 1998, GENE DEV, V12, P3357, DOI 10.1101/gad.12.21.3357; Moras D, 1998, CURR OPIN CELL BIOL, V10, P384, DOI 10.1016/S0955-0674(98)80015-X; Nolte RT, 1998, NATURE, V395, P137, DOI 10.1038/25931; Onate SA, 1998, J BIOL CHEM, V273, P12101, DOI 10.1074/jbc.273.20.12101; Schulman IG, 1996, MOL CELL BIOL, V16, P3807; Seol W, 1996, MOL ENDOCRINOL, V10, P1646, DOI 10.1210/me.10.12.1646; Shiau AK, 1998, CELL, V95, P927, DOI 10.1016/S0092-8674(00)81717-1; Voegel JJ, 1996, EMBO J, V15, P3667, DOI 10.1002/j.1460-2075.1996.tb00736.x; WAGNER RL, 1995, NATURE, V378, P690, DOI 10.1038/378690a0; Wong CW, 1998, MOL CELL BIOL, V18, P5724, DOI 10.1128/MCB.18.10.5724; Yoh SM, 1997, MOL ENDOCRINOL, V11, P470, DOI 10.1210/me.11.4.470; Zamir I, 1997, P NATL ACAD SCI USA, V94, P14400, DOI 10.1073/pnas.94.26.14400; Zamir I, 1997, GENE DEV, V11, P835, DOI 10.1101/gad.11.7.835; Zamir I, 1996, MOL CELL BIOL, V16, P5458; Zhang JS, 1999, MOL CELL BIOL, V19, P6448; Zhang JS, 1997, MOL CELL BIOL, V17, P6887, DOI 10.1128/MCB.17.12.6887	29	500	509	0	12	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	NOV 4	1999	402	6757					93	96		10.1038/47069	http://dx.doi.org/10.1038/47069			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	254XC	10573424				2022-12-01	WOS:000083638600050
J	Kafitz, KW; Rose, CR; Thoenen, H; Konnerth, A				Kafitz, KW; Rose, CR; Thoenen, H; Konnerth, A			Neurotrophin-evoked rapid excitation through TrkB receptors	NATURE			English	Article							CENTRAL-NERVOUS-SYSTEM; CULTURED HIPPOCAMPAL-NEURONS; SYNAPTIC TRANSMISSION; BRAIN; BDNF; RAT; LOCALIZATION; PLASTICITY; RELEASE; POTENTIATION	Neurotrophins are a family of structurally related proteins that regulate the survival, differentiation and maintenance of function of different populations of peripheral and central neurons(1-3). They are also essential for modulating activity-dependent neuronal plasticity(4-7). Here we show that neurotrophins elicit action potentials in central neurons. Even at low concentrations, brain-derived neurotrophic factor (BDNF) excited neurons in the hippocampus, cortex and cerebellum. We found that BDNF and neurotrophin-4/5 depolarized neurons just as rapidly as the neurotransmitter glutamate, even at a more than thousand-fold lower concentration. Neurotrophin-3 produced much smaller responses, and nerve growth factor was ineffective. The neurotrophin-induced depolarization resulted from the activation of a sodium ion conductance which was reversibly blocked by K-252a, a protein kinase blocker which prefers tyrosine kinase Trk receptors(8). Our results demonstrate a very rapid excitatory action of neurotrophins, placing them among the most potent endogenous neuro-excitants in the mammalian central nervous system described so far.	Tech Univ Munich, Inst Physiol, D-80802 Munich, Germany; Univ Saarlandes, Inst Physiol 1, D-66421 Homburg, Germany; Max Planck Inst Neurobiol, D-82152 Martinsried, Germany	Technical University of Munich; Saarland University; Max Planck Society	Konnerth, A (corresponding author), Tech Univ Munich, Inst Physiol, Biedersteinerstr 29, D-80802 Munich, Germany.							BARBACID M, 1995, CURR OPIN CELL BIOL, V7, P148, DOI 10.1016/0955-0674(95)80022-0; BERNAL I, 1993, STRUCT CHEM, V4, P131, DOI 10.1007/BF00677373; Berninger B, 1996, CURR OPIN NEUROBIOL, V6, P324, DOI 10.1016/S0959-4388(96)80115-2; Blochl A, 1996, MOL CELL NEUROSCI, V7, P173, DOI 10.1006/mcne.1996.0014; Bonhoeffer T, 1996, CURR OPIN NEUROBIOL, V6, P119, DOI 10.1016/S0959-4388(96)80017-1; BOTHWELL M, 1995, ANNU REV NEUROSCI, V18, P223, DOI 10.1146/annurev.neuro.18.1.223; Canossa M, 1997, P NATL ACAD SCI USA, V94, P13279, DOI 10.1073/pnas.94.24.13279; Cellerino A, 1996, PROG NEUROBIOL, V50, P333; Cellerino A, 1996, PROG NEUROBIOL, V49, P53, DOI 10.1016/0301-0082(96)00008-1; EDWARDS FA, 1989, PFLUG ARCH EUR J PHY, V414, P600, DOI 10.1007/BF00580998; Figurov A, 1996, NATURE, V381, P706, DOI 10.1038/381706a0; Goodman LJ, 1996, MOL CELL NEUROSCI, V7, P222, DOI 10.1006/mcne.1996.0017; Ibanez CF, 1998, TRENDS NEUROSCI, V21, P438, DOI 10.1016/S0166-2236(98)01266-1; IP NY, 1993, J NEUROSCI, V13, P3394; KAHLE P, 1994, J NEUROSCI RES, V38, P599, DOI 10.1002/jnr.490380512; KANG HJ, 1995, SCIENCE, V267, P1658, DOI 10.1126/science.7886457; KNUSEL B, 1992, J NEUROCHEM, V59, P1987; Korte M, 1996, P NATL ACAD SCI USA, V93, P12547, DOI 10.1073/pnas.93.22.12547; LESSMANN V, 1994, NEUROREPORT, V6, P21; Levine ES, 1998, P NATL ACAD SCI USA, V95, P10235, DOI 10.1073/pnas.95.17.10235; Lewin GR, 1996, ANNU REV NEUROSCI, V19, P289, DOI 10.1146/annurev.ne.19.030196.001445; LOHOF AM, 1993, NATURE, V363, P350, DOI 10.1038/363350a0; MERLIO JP, 1992, NEUROSCIENCE, V51, P513, DOI 10.1016/0306-4522(92)90292-A; Patterson SL, 1996, NEURON, V16, P1137, DOI 10.1016/S0896-6273(00)80140-3; RINGSTEDT T, 1993, DEV BRAIN RES, V72, P119, DOI 10.1016/0165-3806(93)90165-7; Rose CR, 1997, J PHYSIOL-LONDON, V499, P573, DOI 10.1113/jphysiol.1997.sp021951; Schuman EM, 1999, CURR OPIN NEUROBIOL, V9, P105, DOI 10.1016/S0959-4388(99)80013-0; Suen PC, 1997, P NATL ACAD SCI USA, V94, P8191, DOI 10.1073/pnas.94.15.8191; THOENEN H, 1995, SCIENCE, V270, P593, DOI 10.1126/science.270.5236.593; Yan Q, 1997, J COMP NEUROL, V382, P546; Yan Q, 1997, J COMP NEUROL, V378, P135; Zhou XF, 1996, NEUROSCIENCE, V74, P945, DOI 10.1016/S0306-4522(96)00237-0	32	455	464	0	10	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	OCT 28	1999	401	6756					918	921		10.1038/44847	http://dx.doi.org/10.1038/44847			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	251UL	10553907				2022-12-01	WOS:000083464700059
J	Pagel, M				Pagel, M			Inferring the historical patterns of biological evolution	NATURE			English	Review							PHYLOGENETICALLY INDEPENDENT CONTRASTS; CORRELATED EVOLUTION; MOLECULAR EVIDENCE; METAZOAN PHYLA; PHYLOGENIES; CHARACTERS; SEQUENCES; RECONSTRUCTION; RATES; BIRDS	Phylogenetic trees describe the pattern of descent amongst a group of species. With the rapid accumulation of DNA sequence data, more and more phylogenies are being constructed based upon sequence comparisons. The combination of these phylogenies with powerful new statistical approaches for the analysis of biological evolution is challenging widely held beliefs about the history and evolution of life on Earth.	Univ Reading, Sch Anim & Microbial Sci, Reading RG6 6AJ, Berks, England	University of Reading	Pagel, M (corresponding author), Univ Reading, Sch Anim & Microbial Sci, Reading RG6 6AJ, Berks, England.		Rohlf, F J/A-8710-2008					Arnason U, 1998, J MOL EVOL, V47, P718, DOI 10.1007/PL00006431; Ayala FJ, 1998, P NATL ACAD SCI USA, V95, P606, DOI 10.1073/pnas.95.2.606; BOWLER PJ, 1991, C DARWIN MAN HIS INF; BOWRING SA, 1993, SCIENCE, V261, P1293, DOI 10.1126/science.11539488; Bromham L, 1998, P NATL ACAD SCI USA, V95, P12386, DOI 10.1073/pnas.95.21.12386; Brown JR, 1997, MICROBIOL MOL BIOL R, V61, P456, DOI 10.1128/.61.4.456-502.1997; Bull JJ, 1997, GENETICS, V147, P1497; COLLINS TM, 1994, SYST BIOL, V43, P482, DOI 10.2307/2413547; Cooper A, 1997, SCIENCE, V275, P1109, DOI 10.1126/science.275.5303.1109; Crandall KA, 1999, MOL BIOL EVOL, V16, P372, DOI 10.1093/oxfordjournals.molbev.a026118; Darwin Charles, 1888, ORIGIN SPECIES MEANS, VSixth; Durham W. H., 1991, COEVOLUTION GENES CU; Edwards A.W.F., 1972, LIKELIHOOD; FELSENSTEIN J, 1985, AM NAT, V125, P1, DOI 10.1086/284325; FITCH WM, 1991, P NATL ACAD SCI USA, V88, P4270, DOI 10.1073/pnas.88.10.4270; Foote M, 1999, NATURE, V398, P415, DOI 10.1038/18872; Fortey R., 1997, LIFE UNAUTHORISED BI; Galtier N, 1999, SCIENCE, V283, P220, DOI 10.1126/science.283.5399.220; GARLAND T, 1992, SYST BIOL, V41, P18, DOI 10.2307/2992503; Golding GB, 1998, MOL BIOL EVOL, V15, P355, DOI 10.1093/oxfordjournals.molbev.a025932; GOULD SJ, 1993, NATURE, V366, P223, DOI 10.1038/366223a0; Harvey P.H., 1991, COMP METHOD EVOLUTIO; Harvey PH, 1998, P ROY SOC B-BIOL SCI, V265, P1691, DOI 10.1098/rspb.1998.0490; Healy SD, 1996, BRAIN BEHAV EVOLUT, V47, P195, DOI 10.1159/000113239; Hecht M.K., 1986, Oxford Surveys in Evolutionary Biology, V3, P1; Hedges SB, 1996, NATURE, V381, P226, DOI 10.1038/381226a0; HILLIS DM, 1992, SCIENCE, V255, P589, DOI 10.1126/science.1736360; Hillis DM, 1996, MOL SYSTEMATICS; Holden C, 1997, HUM BIOL, V69, P605; Ivics Z, 1997, CELL, V91, P501, DOI 10.1016/S0092-8674(00)80436-5; Jerison HJ., 1973, EVOLUTION BRAIN INTE, DOI 10.4324/9781315787107-3; JERMANN TM, 1995, NATURE, V374, P57, DOI 10.1038/374057a0; Johnston J., 1963, ECONOMETRIC METHODS; Kerr RA, 1999, SCIENCE, V284, P412; Koshi JM, 1996, J MOL EVOL, V42, P313, DOI 10.1007/BF02198858; Krings M, 1997, CELL, V90, P19, DOI 10.1016/S0092-8674(00)80310-4; Larget B, 1999, MOL BIOL EVOL, V16, P750, DOI 10.1093/oxfordjournals.molbev.a026160; Li W.H., 1997, MOL EVOLUTION; MADDISON DR, 1994, ANNU REV ENTOMOL, V39, P267, DOI 10.1146/annurev.en.39.010194.001411; MADDISON WP, 1990, EVOLUTION, V44, P539, DOI 10.2307/2409434; MARTIN RD, 1981, NATURE, V293, P57, DOI 10.1038/293057a0; MARTINS EP, 1991, EVOLUTION, V45, P534, DOI 10.1111/j.1558-5646.1991.tb04328.x; Martins EP, 1997, AM NAT, V149, P646, DOI 10.1086/286013; Mojzsis SJ, 1996, NATURE, V384, P55, DOI 10.1038/384055a0; Mooers AO, 1999, SYST BIOL, V48, P623, DOI 10.1080/106351599260193; Mooers AO, 1999, AM NAT, V154, P249, DOI 10.1086/303226; Omland KE, 1997, EVOLUTION, V51, P1381, DOI 10.2307/2411190; OMLAND KE, 1994, SYST BIOL, V43, P369, DOI 10.2307/2413674; Pace NR, 1997, SCIENCE, V276, P734, DOI 10.1126/science.276.5313.734; Pagel M, 1999, SYST BIOL, V48, P612, DOI 10.1080/106351599260184; PAGEL M, 1994, P ROY SOC B-BIOL SCI, V255, P37, DOI 10.1098/rspb.1994.0006; Pagel M, 1997, ZOOL SCR, V26, P331, DOI 10.1111/j.1463-6409.1997.tb00423.x; PAGEL M, 1993, J THEOR BIOL, V164, P191, DOI 10.1006/jtbi.1993.1148; PAGEL MD, 1989, SCIENCE, V244, P1589, DOI 10.1126/science.2740904; PAGEL MD, 1992, J THEOR BIOL, V156, P431, DOI 10.1016/S0022-5193(05)80637-X; Price T, 1997, PHILOS T ROY SOC B, V352, P519, DOI 10.1098/rstb.1997.0036; PURVIS A, 1994, J THEOR BIOL, V167, P293, DOI 10.1006/jtbi.1994.1071; PURVIS A, 1995, PHILOS T ROY SOC B, V348, P405, DOI 10.1098/rstb.1995.0078; Rambaut A, 1998, MOL BIOL EVOL, V15, P442, DOI 10.1093/oxfordjournals.molbev.a025940; RAUP DM, 1991, MASS EXTINCTIONS BAD; Ricklefs RE, 1996, OIKOS, V77, P167, DOI 10.2307/3545598; RIDLEY M, 1981, EXPLANATION ORGANIC; Rolland C, 1998, AM NAT, V151, P514, DOI 10.1086/286137; Roux KH, 1998, P NATL ACAD SCI USA, V95, P11804, DOI 10.1073/pnas.95.20.11804; Schluter D, 1997, EVOLUTION, V51, P1699, DOI 10.1111/j.1558-5646.1997.tb05095.x; SCHLUTER D, 1995, NATURE, V377, P108, DOI 10.1038/377108a0; Strauss E, 1999, SCIENCE, V283, P1435, DOI 10.1126/science.283.5407.1435; Tuffley C, 1997, B MATH BIOL, V59, P581, DOI 10.1007/BF02459467; URSING BM, 1998, P R SOC LOND B, V265, P2252; Valentine JW, 1996, DEV BIOL, V173, P373, DOI 10.1006/dbio.1996.0033; Vila C, 1997, SCIENCE, V276, P1687, DOI 10.1126/science.276.5319.1687; Williams G. C., 1992, NATURAL SELECTION; Wilson IJ, 1998, GENETICS, V150, P499; WOESE CR, 1987, MICROBIOL REV, V51, P221, DOI 10.1128/MMBR.51.2.221-271.1987; Wray GA, 1996, SCIENCE, V274, P568, DOI 10.1126/science.274.5287.568; YANG ZH, 1995, GENETICS, V141, P1641; Yeager M, 1999, IMMUNOL REV, V167, P45, DOI 10.1111/j.1600-065X.1999.tb01381.x	77	3188	3223	25	588	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	OCT 28	1999	401	6756					877	884		10.1038/44766	http://dx.doi.org/10.1038/44766			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	251UL	10553904				2022-12-01	WOS:000083464700048
J	Cremona, O; Di Paolo, G; Wenk, MR; Luthi, A; Kim, WT; Takei, K; Daniell, L; Nemoto, Y; Shears, SB; Flavell, RA; McCormick, DA; De Camilli, P				Cremona, O; Di Paolo, G; Wenk, MR; Luthi, A; Kim, WT; Takei, K; Daniell, L; Nemoto, Y; Shears, SB; Flavell, RA; McCormick, DA; De Camilli, P			Essential role of phosphoinositide metabolism in synaptic vesicle recycling	CELL			English	Article							NERVE-TERMINALS; INOSITOL PHOSPHOLIPIDS; NONUNIFORM PROBABILITY; MEDIATED ENDOCYTOSIS; TRANSFER PROTEIN; YEAST GOLGI; BINDING; MEMBRANE; DYNAMIN; SYNAPTOJANIN	Growing evidence suggests that phosphoinositides play an important role in membrane traffic. A polyphosphoinositide phosphatase, synaptojanin 1, was identified as a major presynaptic protein associated with endocytic coated intermediates. We report here that synaptojanin 1-deficient mice exhibit neurological defects and die shortly after birth. In neurons of mutant animals, PI(4,5)beta(2) levels are increased, and clathrin-coated vesicles accumulate in the cytomatrix-rich area that surrounds the synaptic vesicle cluster in nerve endings. In cell-free assays, reduced phosphoinositide phosphatase activity correlated with increased association of clathrin coats with liposomes. Intracellular recording in hippocampal slices revealed enhanced synaptic depression during prolonged high-frequency stimulation followed by delayed recovery. These results provide genetic evidence far a crucial role of phosphoinositide metabolism in synaptic vesicle recycling.	Yale Univ, Sch Med, Howard Hughes Med Inst, New Haven, CT 06510 USA; Yale Univ, Sch Med, Dept Cell Biol, New Haven, CT 06510 USA; Yale Univ, Sch Med, Neurobiol Sect, New Haven, CT 06510 USA; Yale Univ, Sch Med, Immunobiol Sect, New Haven, CT 06510 USA; Univ Piemonte Orientale A Avogadro, Dipartimento Sci Med, I-28100 Novara, Italy; NIEHS, Lab Signal Transduct, NIH, Res Triangle Pk, NC 27709 USA	Howard Hughes Medical Institute; Yale University; Yale University; Yale University; Yale University; University of Eastern Piedmont Amedeo Avogadro; National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS)	De Camilli, P (corresponding author), Yale Univ, Sch Med, Howard Hughes Med Inst, 333 Cedar St, New Haven, CT 06510 USA.		McCormick, David A/J-2649-2015; Shears, Stephen B/C-6335-2019; Wenk, Markus Rene/D-1441-2014; Luthi, Anita/ABE-1411-2021; Kobelt, Liza/F-5926-2011; Cremona, Ottavio/AAB-8793-2019	McCormick, David A/0000-0002-9803-8335; Shears, Stephen B/0000-0001-7309-8916; Cremona, Ottavio/0000-0001-9462-1040; Luthi, Anita/0000-0002-4954-4143; Takei, Kohji/0000-0002-6555-9425	NINDS NIH HHS [NS46128, NS36251, NS26143] Funding Source: Medline; Telethon [D.111, D.061] Funding Source: Medline; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [Z01ES080046] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R37NS026143, R29NS026143, R37NS036251, R01NS026143, R01NS036251] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); Telethon(Fondazione Telethon); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Achiriloaie M, 1999, MOL CELL BIOL, V19, P1410; Arneson LS, 1999, J BIOL CHEM, V274, P17794, DOI 10.1074/jbc.274.25.17794; Auger K. R., 1990, METHODS INOSITIDE RE, P159; BANKAITIS VA, 1990, NATURE, V347, P561, DOI 10.1038/347561a0; Banker G, 1991, CULTURING NERVE CELL; CLEVES AE, 1989, J CELL BIOL, V109, P2939, DOI 10.1083/jcb.109.6.2939; Cremona O, 1997, CURR OPIN NEUROBIOL, V7, P323, DOI 10.1016/S0959-4388(97)80059-1; David C, 1996, P NATL ACAD SCI USA, V93, P331, DOI 10.1073/pnas.93.1.331; DeCamilli P, 1996, SCIENCE, V271, P1533, DOI 10.1126/science.271.5255.1533; deHeuvel E, 1997, J BIOL CHEM, V272, P8710, DOI 10.1074/jbc.272.13.8710; EBERHARD DA, 1990, BIOCHEM J, V268, P15, DOI 10.1042/bj2680015; Gaidarov I, 1999, J CELL BIOL, V146, P755, DOI 10.1083/jcb.146.4.755; Guo SL, 1999, J BIOL CHEM, V274, P12990, DOI 10.1074/jbc.274.19.12990; GUSTAFSSON J, 1998, NEUROSCI SOC ABSTR, V327, P19; Haffner C, 1997, FEBS LETT, V419, P175, DOI 10.1016/S0014-5793(97)01451-8; Hao WH, 1997, J BIOL CHEM, V272, P6393, DOI 10.1074/jbc.272.10.6393; HARRIS KM, 1995, NEUROPHARMACOLOGY, V34, P1387, DOI 10.1016/0028-3908(95)00142-S; Haucke V, 1999, SCIENCE, V285, P1268, DOI 10.1126/science.285.5431.1268; HAWTHORNE JN, 1979, J NEUROCHEM, V32, P5, DOI 10.1111/j.1471-4159.1979.tb04503.x; HAY JC, 1995, NATURE, V374, P173, DOI 10.1038/374173a0; HEUSER JE, 1973, J CELL BIOL, V57, P315, DOI 10.1083/jcb.57.2.315; HOKIN MR, 1953, J BIOL CHEM, V203, P967; Irvine R, 1998, CURR BIOL, V8, pR557, DOI 10.1016/S0960-9822(07)00360-0; Janmey PA, 1998, PHYSIOL REV, V78, P763, DOI 10.1152/physrev.1998.78.3.763; Jost M, 1998, CURR BIOL, V8, P1399, DOI 10.1016/S0960-9822(98)00022-0; Kavran JM, 1998, J BIOL CHEM, V273, P30497, DOI 10.1074/jbc.273.46.30497; Kirk CJ., 1990, PEPTIDE HORMONE ACTI, P151; Lamaze C, 1996, NATURE, V382, P177, DOI 10.1038/382177a0; Lee A, 1999, CURR BIOL, V9, P261, DOI 10.1016/S0960-9822(99)80115-8; Martin TFJ, 1998, ANNU REV CELL DEV BI, V14, P231, DOI 10.1146/annurev.cellbio.14.1.231; MCPHERSON PS, 1994, J BIOL CHEM, V269, P30132; McPherson PS, 1996, NATURE, V379, P353, DOI 10.1038/379353a0; Mikoshiba K, 1999, CHEM PHYS LIPIDS, V98, P59, DOI 10.1016/S0009-3084(99)00018-3; MUNN AL, 1995, MOL BIOL CELL, V6, P1721, DOI 10.1091/mbc.6.12.1721; Odorizzi G, 1998, CELL, V95, P847, DOI 10.1016/S0092-8674(00)81707-9; OHASHI M, 1995, NATURE, V377, P544, DOI 10.1038/377544a0; OSTERMANN J, 1993, CELL, V75, P1015, DOI 10.1016/0092-8674(93)90545-2; Qualmann B, 1999, MOL BIOL CELL, V10, P501, DOI 10.1091/mbc.10.2.501; Ramjaun AR, 1996, J BIOL CHEM, V271, P24856, DOI 10.1074/jbc.271.40.24856; Ringstad N, 1997, P NATL ACAD SCI USA, V94, P8569, DOI 10.1073/pnas.94.16.8569; Roos J, 1998, J BIOL CHEM, V273, P19108, DOI 10.1074/jbc.273.30.19108; ROSENMUND C, 1993, SCIENCE, V262, P754, DOI 10.1126/science.7901909; Ryan TA, 1996, J CELL BIOL, V134, P1219, DOI 10.1083/jcb.134.5.1219; Sakisaka T, 1997, MOL CELL BIOL, V17, P3841, DOI 10.1128/MCB.17.7.3841; Schmid SL, 1997, ANNU REV BIOCHEM, V66, P511, DOI 10.1146/annurev.biochem.66.1.511; SCHU PV, 1993, SCIENCE, V260, P88, DOI 10.1126/science.8385367; Singer-Kruger B, 1998, J CELL SCI, V111, P3347; Slepnev VI, 1998, SCIENCE, V281, P821, DOI 10.1126/science.281.5378.821; Springer S, 1999, CELL, V97, P145, DOI 10.1016/S0092-8674(00)80722-9; Takei K, 1998, CELL, V94, P131, DOI 10.1016/S0092-8674(00)81228-3; Vallis Y, 1999, CURR BIOL, V9, P257, DOI 10.1016/S0960-9822(99)80114-6; VERHAGE M, 1997, NEUR SOC ABSTR, V23, P1168; Wiedemann C, 1998, J NEUROSCI, V18, P5594; Witke W, 1998, EMBO J, V17, P967, DOI 10.1093/emboj/17.4.967; Woscholski R, 1997, J BIOL CHEM, V272, P9625; Wurmser AE, 1999, J BIOL CHEM, V274, P9129, DOI 10.1074/jbc.274.14.9129; Yang D, 1997, P NATL ACAD SCI USA, V94, P3004, DOI 10.1073/pnas.94.7.3004; ZHANG JZ, 1994, CELL, V78, P751, DOI 10.1016/S0092-8674(94)90442-1; Zheng J, 1996, J MOL BIOL, V255, P14, DOI 10.1006/jmbi.1996.0002	59	608	625	4	31	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	OCT 15	1999	99	2					179	188		10.1016/S0092-8674(00)81649-9	http://dx.doi.org/10.1016/S0092-8674(00)81649-9			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	246JB	10535736	Bronze			2022-12-01	WOS:000083159700008
J	Folsch, H; Ohno, H; Bonifacino, JS; Mellman, I				Folsch, H; Ohno, H; Bonifacino, JS; Mellman, I			A novel clathrin adaptor complex mediates basolateral targeting in polarized epithelial cells	CELL			English	Article							POLYMERIC IMMUNOGLOBULIN RECEPTOR; DARBY CANINE KIDNEY; MDCK CELLS; SORTING SIGNALS; CYTOPLASMIC DOMAIN; MEMBRANE-PROTEINS; PLASMA-MEMBRANE; STRUCTURAL REQUIREMENTS; GOLGI-COMPLEX; FC-RECEPTORS	Although polarized epithelial cells are well known to maintain distinct apical and basolateral plasma membrane domains, the mechanisms responsible for targeting membrane proteins to the apical or basolateral surfaces have remained elusive. We have identified a novel form of the AP-1 clathrin adaptor complex that contains as one of its subunits mu 1B, an epithelial cell-specific homolog of the ubiquitously expressed mu 1A. LLC-PK1 kidney epithelial cells do not express mu 1B and missort many basolateral proteins to the apical surface. Stable expression of mu 1B selectively restored basolateral targeting, improved the overall organization of LLC-PK1 monolayers, and had no effect on apical targeting. We conclude that basolateral sorting is mediated by an epithelial cell-specific version of the AP-1 complex containing mu 1B.	Yale Univ, Sch Med, Dept Cell Biol, New Haven, CT 06520 USA; Yale Univ, Sch Med, Ludwig Inst Canc Res, New Haven, CT 06520 USA; NICHHD, Cell Biol & Metab Branch, NIH, Bethesda, MD 20892 USA; Kanazawa Univ, Canc Res Inst, Div Mol Membrane Biol, Kanazawa, Ishikawa 9200934, Japan	Yale University; Ludwig Institute for Cancer Research; Yale University; National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); Kanazawa University	Mellman, I (corresponding author), Yale Univ, Sch Med, Dept Cell Biol, 333 Cedar St, New Haven, CT 06520 USA.		Mellman, Ira/ABG-5896-2020; Ohno, Hiroshi/L-7899-2014	Ohno, Hiroshi/0000-0001-8776-9661; Folsch, Heike/0000-0003-0897-0311; Bonifacino, Juan S./0000-0002-5673-6370	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM029765] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-29765] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AROETI B, 1994, EMBO J, V13, P2297, DOI 10.1002/j.1460-2075.1994.tb06513.x; Bonifacino JS, 1999, J CELL BIOL, V145, P923, DOI 10.1083/jcb.145.5.923; CASANOVA JE, 1991, CELL, V66, P65, DOI 10.1016/0092-8674(91)90139-P; Cohen AR, 1998, J CELL BIOL, V142, P129, DOI 10.1083/jcb.142.1.129; Dell'Angelica EC, 1999, MOL CELL, V3, P11, DOI 10.1016/S1097-2765(00)80170-7; Dell'Angelica EC, 1999, J BIOL CHEM, V274, P7278, DOI 10.1074/jbc.274.11.7278; DellAngelica EC, 1997, EMBO J, V16, P917, DOI 10.1093/emboj/16.5.917; Drubin DG, 1996, CELL, V84, P335, DOI 10.1016/S0092-8674(00)81278-7; Futter CE, 1998, J CELL BIOL, V141, P611, DOI 10.1083/jcb.141.3.611; GRIFFITHS G, 1985, J CELL BIOL, V101, P949, DOI 10.1083/jcb.101.3.949; He TC, 1998, P NATL ACAD SCI USA, V95, P2509, DOI 10.1073/pnas.95.5.2509; Hirst J, 1999, MOL BIOL CELL, V10, P2787, DOI 10.1091/mbc.10.8.2787; Hirst J, 1998, BBA-MOL CELL RES, V1404, P173, DOI 10.1016/S0167-4889(98)00056-1; HUBBARD AL, 1989, ANNU REV PHYSIOL, V51, P755, DOI 10.1146/annurev.ph.51.030189.003543; HUNZIKER W, 1991, CELL, V66, P907, DOI 10.1016/0092-8674(91)90437-4; HUNZIKER W, 1994, EMBO J, V13, P2963, DOI 10.1002/j.1460-2075.1994.tb06594.x; Jareb M, 1998, NEURON, V20, P855, DOI 10.1016/S0896-6273(00)80468-7; Keller P, 1997, J CELL SCI, V110, P3001; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEBIVIC A, 1991, J CELL BIOL, V115, P607, DOI 10.1083/jcb.115.3.607; Marks MS, 1997, TRENDS CELL BIOL, V7, P124, DOI 10.1016/S0962-8924(96)10057-X; MATTER K, 1994, CURR OPIN CELL BIOL, V6, P545, DOI 10.1016/0955-0674(94)90075-2; MATTER K, 1993, CELL, V74, P1053, DOI 10.1016/0092-8674(93)90727-8; MATTER K, 1994, J CELL BIOL, V126, P991, DOI 10.1083/jcb.126.4.991; MATTER K, 1992, CELL, V71, P741, DOI 10.1016/0092-8674(92)90551-M; MAYS RW, 1995, J CELL BIOL, V130, P1105, DOI 10.1083/jcb.130.5.1105; Mellman I, 1996, ANNU REV CELL DEV BI, V12, P575, DOI 10.1146/annurev.cellbio.12.1.575; Musch A, 1996, J CELL BIOL, V133, P543, DOI 10.1083/jcb.133.3.543; NABI IR, 1991, J CELL BIOL, V115, P1573, DOI 10.1083/jcb.115.6.1573; Odorizzi G, 1997, J CELL BIOL, V137, P1255, DOI 10.1083/jcb.137.6.1255; Ohno H, 1999, FEBS LETT, V449, P215, DOI 10.1016/S0014-5793(99)00432-9; Ohno H, 1996, J BIOL CHEM, V271, P29009, DOI 10.1074/jbc.271.46.29009; OHNO H, 1995, SCIENCE, V269, P1872, DOI 10.1126/science.7569928; Owen DJ, 1998, SCIENCE, V282, P1327, DOI 10.1126/science.282.5392.1327; Rapoport I, 1998, EMBO J, V17, P2148, DOI 10.1093/emboj/17.8.2148; RODRIGUEZBOULAN E, 1992, ANNU REV CELL BIOL, V8, P395, DOI 10.1146/annurev.cb.08.110192.002143; Roush DL, 1998, J BIOL CHEM, V273, P26862, DOI 10.1074/jbc.273.41.26862; Simons K, 1997, NATURE, V387, P569, DOI 10.1038/42408; Simpson F, 1996, J CELL BIOL, V133, P749, DOI 10.1083/jcb.133.4.749; WEISZ OA, 1992, J BIOL CHEM, V267, P22282; Wilton JC, 1996, BIOESSAYS, V18, P229, DOI 10.1002/bies.950180310; Winckler B, 1999, NEURON, V23, P637, DOI 10.1016/S0896-6273(01)80021-0; Yeaman C, 1997, J CELL BIOL, V139, P929, DOI 10.1083/jcb.139.4.929; Yeaman C, 1999, PHYSIOL REV, V79, P73, DOI 10.1152/physrev.1999.79.1.73; YOKODE M, 1992, J CELL BIOL, V117, P39, DOI 10.1083/jcb.117.1.39; Yoshimori T, 1996, J CELL BIOL, V133, P247, DOI 10.1083/jcb.133.2.247	46	419	421	0	4	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	OCT 15	1999	99	2					189	198		10.1016/S0092-8674(00)81650-5	http://dx.doi.org/10.1016/S0092-8674(00)81650-5			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	246JB	10535737	Bronze			2022-12-01	WOS:000083159700009
J	Ketting, RF; Haverkamp, THA; van Luenen, HGAM; Plasterk, RHA				Ketting, RF; Haverkamp, THA; van Luenen, HGAM; Plasterk, RHA			mut-7 of C-elegans, required for transposon silencing and RNA interference, is a homolog of Werner syndrome helicase and RNaseD	CELL			English	Article							NEMATODE CAENORHABDITIS-ELEGANS; DE-NOVO METHYLATION; M HYBRID DYSGENESIS; DNA-BINDING DOMAIN; TC3 TRANSPOSASE; MUTATOR ACTIVITY; MOLECULAR-BASIS; IN-VITRO; EXCISION; ELEMENTS	While all known natural isolates of C. elegans contain multiple copies of the Tc1 transposon, which are active in the soma, Tc1 transposition is fully silenced in the germline of many strains. We mutagenized one such silenced strain and isolated mutants in which Tct had been activated in the germline ("mutators"). Interestingly, many other transposons of unrelated sequence had also become active. Most of these mutants are resistant to RNA interference (RNAi). We found one of the mutated genes, mut-7, to encode a protein with homology to RNaseD. This provides support for the notion that RNAi works by dsRNA-directed, enzymatic RNA degradation. We propose a model in which MUT-7, guided by transposon-derived dsRNA, represses transposition by degrading transposon-specific messengers, thus preventing transposase production and transposition.	Netherlands Canc Inst, Div Mol Biol, Ctr Biomed Genet, NL-1066 CX Amsterdam, Netherlands	Netherlands Cancer Institute	Plasterk, RHA (corresponding author), Netherlands Canc Inst, Div Mol Biol, Ctr Biomed Genet, Plesmanlaan 121, NL-1066 CX Amsterdam, Netherlands.	rplas@nki.nl	Haverkamp, Thomas/B-3479-2008; Haverkamp, Thomas H.A./H-2783-2019	Haverkamp, Thomas H.A./0000-0002-3070-9745; Ketting, Rene/0000-0001-6161-5621; van Luenen, Henri/0000-0002-5584-7968				Alvarado AS, 1999, P NATL ACAD SCI USA, V96, P5049, DOI 10.1073/pnas.96.9.5049; BABITY JM, 1990, MOL GEN GENET, V222, P65, DOI 10.1007/BF00283024; BINGHAM PM, 1982, CELL, V29, P995, DOI 10.1016/0092-8674(82)90463-9; Brigneti G, 1998, EMBO J, V17, P6739, DOI 10.1093/emboj/17.22.6739; BRYAN GJ, 1988, SCIENCE, V240, P215, DOI 10.1126/science.2832948; C elegans Sequencing Consortium, 1998, SCIENCE, V282, P2012, DOI 10.1126/science.282.5396.2012; Cogoni C, 1999, NATURE, V399, P166, DOI 10.1038/20215; COLLINS J, 1989, GENETICS, V121, P47; COLLINS J, 1987, NATURE, V328, P726, DOI 10.1038/328726a0; COLLINS JJ, 1994, GENETICS, V137, P771; COLLOMS SD, 1994, NUCLEIC ACIDS RES, V22, P5548, DOI 10.1093/nar/22.25.5548; DEUTSCHER MP, 1993, J BACTERIOL, V175, P4577, DOI 10.1128/JB.175.15.4577-4583.1993; EIDE D, 1985, P NATL ACAD SCI USA, V82, P1756, DOI 10.1073/pnas.82.6.1756; EMMONS SW, 1984, CELL, V36, P599, DOI 10.1016/0092-8674(84)90339-8; EMMONS SW, 1983, CELL, V32, P55, DOI 10.1016/0092-8674(83)90496-8; Fire A, 1998, NATURE, V391, P806, DOI 10.1038/35888; Grant SR, 1999, CELL, V96, P303, DOI 10.1016/S0092-8674(00)80541-3; Jensen S, 1999, NAT GENET, V21, P209, DOI 10.1038/5997; Jones AL, 1998, EMBO J, V17, P6385, DOI 10.1093/emboj/17.21.6385; Jorgensen RA, 1998, SCIENCE, V279, P1486, DOI 10.1126/science.279.5356.1486; Kasschau KD, 1998, CELL, V95, P461, DOI 10.1016/S0092-8674(00)81614-1; Kelly WG, 1997, GENETICS, V146, P227; Kennerdell JR, 1998, CELL, V95, P1017, DOI 10.1016/S0092-8674(00)81725-0; Mian IS, 1997, NUCLEIC ACIDS RES, V25, P3187, DOI 10.1093/nar/25.16.3187; MOERMAN DG, 1984, GENETICS, V108, P859; Montgomery MK, 1998, P NATL ACAD SCI USA, V95, P15502, DOI 10.1073/pnas.95.26.15502; MORI I, 1990, MOL GEN GENET, V220, P251, DOI 10.1007/BF00260490; MORI I, 1988, GENETICS, V120, P397; Ngo H, 1998, P NATL ACAD SCI USA, V95, P14687, DOI 10.1073/pnas.95.25.14687; PalBhadra M, 1997, CELL, V90, P479, DOI 10.1016/S0092-8674(00)80508-5; PEREIRA A, 1986, EMBO J, V5, P835, DOI 10.1002/j.1460-2075.1986.tb04292.x; PLASTERK RHA, 1991, EMBO J, V10, P1919, DOI 10.1002/j.1460-2075.1991.tb07718.x; RUBIN GM, 1982, CELL, V29, P987, DOI 10.1016/0092-8674(82)90462-7; Sharp PA, 1999, GENE DEV, V13, P139, DOI 10.1101/gad.13.2.139; Smyth DR, 1997, CURR BIOL, V7, pR793, DOI 10.1016/S0960-9822(06)00407-6; Suzuki N, 1999, NUCLEIC ACIDS RES, V27, P2361, DOI 10.1093/nar/27.11.2361; Tabara H, 1999, CELL, V99, P123, DOI 10.1016/S0092-8674(00)81644-X; VANLUENEN HGAM, 1994, CELL, V79, P293, DOI 10.1016/0092-8674(94)90198-8; VANLUENEN HGAM, 1993, EMBO J, V12, P2513, DOI 10.1002/j.1460-2075.1993.tb05906.x; vanPouderoyen G, 1997, EMBO J, V16, P6044, DOI 10.1093/emboj/16.19.6044; VOS JC, 1993, GENE DEV, V7, P1244, DOI 10.1101/gad.7.7a.1244; Vos JC, 1996, GENE DEV, V10, P755, DOI 10.1101/gad.10.6.755; VOS JC, 1994, EMBO J, V13, P6125, DOI 10.1002/j.1460-2075.1994.tb06959.x; WASSENEGGER M, 1994, CELL, V76, P567, DOI 10.1016/0092-8674(94)90119-8; Waterhouse PM, 1998, P NATL ACAD SCI USA, V95, P13959, DOI 10.1073/pnas.95.23.13959	45	573	647	2	23	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	OCT 15	1999	99	2					133	141		10.1016/S0092-8674(00)81645-1	http://dx.doi.org/10.1016/S0092-8674(00)81645-1			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	246JB	10535732	Bronze			2022-12-01	WOS:000083159700004
J	Graef, IA; Mermelstein, PG; Stankunas, K; Neilson, JR; Deisseroth, K; Tsien, RW; Crabtree, GR				Graef, IA; Mermelstein, PG; Stankunas, K; Neilson, JR; Deisseroth, K; Tsien, RW; Crabtree, GR			L-type calcium channels and GSK-3 regulate the activity of NF-ATc4 in hippocampal neurons	NATURE			English	Article							LONG-TERM DEPRESSION; GLYCOGEN-SYNTHASE KINASE-3; LYMPHOCYTE-T ACTIVATION; CREB PHOSPHORYLATION; GENE-EXPRESSION; CYCLOSPORINE-A; NF-ATC; CALCINEURIN; INDUCTION; TRANSCRIPTION	The molecular basis of learning and memory has been the object of several recent advances, which have focused attention on calcium-regulated pathways controlling transcription. One of the molecules implicated by pharmacological, biochemical and genetic approaches is the calcium/calmodulin-regulated phosphatase, calcineurin(1-5). In lymphocytes, calcineurin responds to specific calcium signals and regulates expression of several immediate early genes by controlling the nuclear import of the NF-ATc family of transcription factors(6-9). Here we show that NF-ATc4/NF-AT3 (ref. 10) in hippocampal neurons can rapidly translocate from cytoplasm to nucleus and activate NF-AT-dependent transcription in response to electrical activity or potassium depolarization. The calcineurin-mediated translocation is critically dependent on calcium entry through L-type voltage-gated calcium channels. GSK-3 can phosphorylate NF-ATc4, promoting its export from the nucleus and antagonizing NF-ATc4-dependent transcription. Furthermore, we show that induction of the inositol 1,4,5-trisphosphate receptor type 1 is controlled by the calcium/calcineurin/NF-ATc pathway. This provides a new perspective on the function of calcineurin in the central nervous system and indicates that NF-AT-mediated gene expression may be involved in the induction of hippocampal synaptic plasticity and memory formation.	Stanford Univ, Howard Hughes Med Inst, Sch Med, Dept Pathol, Stanford, CA 94305 USA; Stanford Univ, Howard Hughes Med Inst, Sch Med, Dept Dev Biol, Stanford, CA 94305 USA; Stanford Univ, Beckman Ctr Mol & Genet Med, Sch Med, Dept Cellular & Mol Physiol, Stanford, CA 94305 USA	Howard Hughes Medical Institute; Stanford University; Howard Hughes Medical Institute; Stanford University; Stanford University	Crabtree, GR (corresponding author), Stanford Univ, Howard Hughes Med Inst, Sch Med, Dept Pathol, 300 Pasteur Dr, Stanford, CA 94305 USA.							Beals CR, 1997, SCIENCE, V275, P1930, DOI 10.1126/science.275.5308.1930; Beals CR, 1997, GENE DEV, V11, P824, DOI 10.1101/gad.11.7.824; Bito H, 1996, CELL, V87, P1203, DOI 10.1016/S0092-8674(00)81816-4; Bito H, 1997, CURR OPIN NEUROBIOL, V7, P419, DOI 10.1016/S0959-4388(97)80072-4; Chow CW, 1997, SCIENCE, V278, P1638, DOI 10.1126/science.278.5343.1638; CLIPSTONE NA, 1992, NATURE, V357, P695, DOI 10.1038/357695a0; CRABTREE GR, 1989, SCIENCE, V243, P355, DOI 10.1126/science.2783497; Crabtree GR, 1999, CELL, V96, P611, DOI 10.1016/S0092-8674(00)80571-1; Deisseroth K, 1998, NATURE, V392, P198, DOI 10.1038/32448; FLANAGAN WM, 1991, NATURE, V352, P803, DOI 10.1038/352803a0; FLEXNER LB, 1967, SCIENCE, V155, P1377, DOI 10.1126/science.155.3768.1377; Genazzani AA, 1999, P NATL ACAD SCI USA, V96, P5797, DOI 10.1073/pnas.96.10.5797; GHOSH A, 1995, SCIENCE, V268, P239, DOI 10.1126/science.7716515; HE X, 1995, NATURE, V374, P617, DOI 10.1038/374617a0; HOEY T, 1995, IMMUNITY, V2, P461, DOI 10.1016/1074-7613(95)90027-6; Inoue T, 1998, J NEUROSCI, V18, P5366, DOI 10.1523/JNEUROSCI.18-14-05366.1998; JAIN JN, 1993, NATURE, V365, P352, DOI 10.1038/365352a0; KASONO K, 1995, NEUROREPORT, V6, P569, DOI 10.1097/00001756-199502000-00040; KLEE CB, 1979, P NATL ACAD SCI USA, V76, P6270, DOI 10.1073/pnas.76.12.6270; LIU J, 1991, CELL, V66, P807, DOI 10.1016/0092-8674(91)90124-H; Lu YF, 1996, NEUROSCI LETT, V205, P103, DOI 10.1016/0304-3940(96)12384-3; Mansuy IM, 1998, CELL, V92, P39, DOI 10.1016/S0092-8674(00)80897-1; MULKEY RM, 1994, NATURE, V369, P486, DOI 10.1038/369486a0; NGUYEN PV, 1994, SCIENCE, V265, P1104, DOI 10.1126/science.8066450; Reyes M, 1996, J NEUROSCI, V16, P5951; SHAW JP, 1988, SCIENCE, V241, P202, DOI 10.1126/science.3260404; Timmerman LA, 1996, NATURE, V383, P837, DOI 10.1038/383837a0; Winder DG, 1998, CELL, V92, P25, DOI 10.1016/S0092-8674(00)80896-X; Zhou P, 1998, CELL, V92, P687, DOI 10.1016/S0092-8674(00)81136-8; Zhu JY, 1998, CELL, V93, P851, DOI 10.1016/S0092-8674(00)81445-2	30	404	417	0	16	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	OCT 14	1999	401	6754					703	708		10.1038/44378	http://dx.doi.org/10.1038/44378			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	247EJ	10537109				2022-12-01	WOS:000083207400058
J	Lee, JT; Lu, NF				Lee, JT; Lu, NF			Targeted mutagenesis of Tsix leads to nonrandom X inactivation	CELL			English	Article							CHROMOSOME INACTIVATION; XIST GENE; MOUSE EMBRYOS; INSITU HYBRIDIZATION; LINKED GENES; RNA; DIFFERENTIATION; STABILIZATION; EXPRESSION; INTERPHASE	During X inactivation, mammalian female cells make the selection of one active and one inactive X chromosome. X chromosome choice occurs randomly and results in Xist upregulation on the inactive X. We have hypothesized that the antisense gene, Tsix, controls Xist expression. Here, we create a targeted deletion of Tsix in female and male mouse cells. Despite a deficiency of Tsix RNA, X chromosome counting remains intact: female cells still inactivate one X, while male cells block X inactivation. However, heterozygous female cells show skewed Xist expression and primary nonrandom inactivation of the mutant X. The ability of the mutant X to block Xist accumulation is compromised. We conclude that Tsix regulates Xist in cis and determines X chromosome choice without affecting silencing. Therefore, counting, choice, and silencing are genetically separable. Contrasting effects in XX and XY cells argue that negative and positive factors are involved in choosing active and inactive Xs.	Massachusetts Gen Hosp, Dept Biol Mol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Genet, Boston, MA 02114 USA	Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School	Lee, JT (corresponding author), Massachusetts Gen Hosp, Dept Biol Mol, Boston, MA 02115 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM058839] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM58839A01] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Avner P, 1998, GENET RES, V72, P217, DOI 10.1017/S0016672398003516; Brockdorff N, 1998, CURR OPIN GENET DEV, V8, P328, DOI 10.1016/S0959-437X(98)80090-7; BROCKDORFF N, 1992, CELL, V71, P515, DOI 10.1016/0092-8674(92)90519-I; BROWN CJ, 1992, CELL, V71, P527, DOI 10.1016/0092-8674(92)90520-M; Carrel L, 1996, HUM MOL GENET, V5, P1361, DOI 10.1093/hmg/5.9.1361; CATTANACH BM, 1981, GENET RES, V38, P57, DOI 10.1017/S0016672300020401; Cattanach BM, 1994, MOUSE GENOME, V92, P114; Clemson CM, 1996, J CELL BIOL, V132, P259, DOI 10.1083/jcb.132.3.259; Clerc P, 1998, NAT GENET, V19, P249, DOI 10.1038/924; COOPER DW, 1971, NATURE-NEW BIOL, V230, P155, DOI 10.1038/newbio230155a0; COURTIER B, 1995, P NATL ACAD SCI USA, V92, P3531, DOI 10.1073/pnas.92.8.3531; DREWS U, 1974, CELL, V1, P3, DOI 10.1016/0092-8674(74)90148-2; EICHER EM, 1970, ADV GENET, V15, P175, DOI 10.1016/S0065-2660(08)60074-7; EPSTEIN CJ, 1978, NATURE, V274, P500, DOI 10.1038/274500a0; GARTLER SM, 1983, ANNU REV GENET, V17, P155, DOI 10.1146/annurev.ge.17.120183.001103; Gorman JR, 1996, IMMUNITY, V5, P241, DOI 10.1016/S1074-7613(00)80319-2; HENDRICH BD, 1993, HUM MOL GENET, V2, P663, DOI 10.1093/hmg/2.6.663; Herzing LBK, 1997, NATURE, V386, P272, DOI 10.1038/386272a0; KRATZER PG, 1978, NATURE, V274, P503, DOI 10.1038/274503a0; LAWRENCE JB, 1989, CELL, V57, P493, DOI 10.1016/0092-8674(89)90924-0; Lee JT, 1999, P NATL ACAD SCI USA, V96, P3836, DOI 10.1073/pnas.96.7.3836; Lee JT, 1999, NAT GENET, V21, P400, DOI 10.1038/7734; Lee JT, 1997, NATURE, V386, P275, DOI 10.1038/386275a0; Lee JT, 1996, CELL, V86, P83, DOI 10.1016/S0092-8674(00)80079-3; LI E, 1992, CELL, V69, P915, DOI 10.1016/0092-8674(92)90611-F; Lyon MF, 1996, NATURE, V379, P116, DOI 10.1038/379116a0; LYON MF, 1971, NATURE-NEW BIOL, V232, P229, DOI 10.1038/newbio232229a0; LYON MF, 1972, BIOL REV, V47, P1; LYON MF, 1961, NATURE, V190, P372, DOI 10.1038/190372a0; Marahrens Y, 1998, CELL, V92, P657, DOI 10.1016/S0092-8674(00)81133-2; MARTIN GR, 1975, P NATL ACAD SCI USA, V72, P1441, DOI 10.1073/pnas.72.4.1441; MCMAHON A, 1983, J EMBRYOL EXP MORPH, V74, P207; MONK M, 1979, NATURE, V281, P311, DOI 10.1038/281311a0; OHNO S, 1969, ANNU REV GENET, V3, P495, DOI 10.1146/annurev.ge.03.120169.002431; Panning B, 1996, GENE DEV, V10, P1991, DOI 10.1101/gad.10.16.1991; Panning B, 1997, CELL, V90, P907, DOI 10.1016/S0092-8674(00)80355-4; Papaioannou V., 1993, Gene targeting: a practical approach., P107; Penny GD, 1996, NATURE, V379, P131, DOI 10.1038/379131a0; Plenge RM, 1997, NAT GENET, V17, P353, DOI 10.1038/ng1197-353; RASTAN S, 1985, J EMBRYOL EXP MORPH, V90, P379; RASTAN S, 1990, GENET RES, V56, P99, DOI 10.1017/S0016672300035163; Sheardown SA, 1997, CELL, V91, P99, DOI 10.1016/S0092-8674(01)80012-X; SIMMLER MC, 1993, MAMM GENOME, V4, P523, DOI 10.1007/BF00364788; TAKAGI N, 1975, NATURE, V256, P640, DOI 10.1038/256640a0; Torres RM, 1997, LAB PROTOCOLS CONDIT; TRASK BJ, 1991, TRENDS GENET, V7, P149, DOI 10.1016/0168-9525(91)90378-4; Wurst W., 1993, Gene targeting: a practical approach., P33	47	398	417	0	8	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	OCT 1	1999	99	1					47	57		10.1016/S0092-8674(00)80061-6	http://dx.doi.org/10.1016/S0092-8674(00)80061-6			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	243DK	10520993	Bronze			2022-12-01	WOS:000082981600007
J	Pal-Bhadra, M; Bhadra, U; Birchler, JA				Pal-Bhadra, M; Bhadra, U; Birchler, JA			Cosuppression of nonhomologous transgenes in Drosophila involves mutually related endogenous sequences	CELL			English	Article							POLYCOMB RESPONSE ELEMENT; ADH PROMOTER SWITCH; GENE-EXPRESSION; ALCOHOL-DEHYDROGENASE; DNA-METHYLATION; VIRUS-RESISTANCE; BITHORAX COMPLEX; MELANOGASTER; PLANTS; WHITE	Cosuppression refers to the phenomenon in which silencing among dispersed homologous genes occurs. Here we demonstrate that two nonhomologous reciprocal fusion genes, white-Alcohol dehydrogenase (w-Adh) and Adh-w, exhibit cosuppression using the endogenous Adh sequence as an intermediary. Deletion of the endogenous Adh gene eliminates the interaction, while reintroduction of an 8.6 kb Adh fragment restores the silencing. Using truncated Adh constructs, a nontranscribed segment in the Adh regulatory region was found to be one of the sequences required for homology recognition. The silencing interaction is initiated during early development. The silenced transgenes are associated with the Polycomb group complex of chromatin proteins.	Univ Missouri, Div Biol Sci, Columbia, MO 65211 USA	University of Missouri System; University of Missouri Columbia	Birchler, JA (corresponding author), Univ Missouri, Div Biol Sci, Columbia, MO 65211 USA.	birchlerj@missouri.edu						Bahramian MB, 1999, MOL CELL BIOL, V19, P274; Baulcombe DC, 1996, CURR OPIN BIOTECH, V7, P173, DOI 10.1016/S0958-1669(96)80009-7; BENYAJATI C, 1982, NUCLEIC ACIDS RES, V10, P7261, DOI 10.1093/nar/10.22.7261; BIRCHLER JA, 1990, GENETICS, V124, P677; Brown JL, 1998, MOL CELL, V1, P1057, DOI 10.1016/S1097-2765(00)80106-9; Chaboissier MC, 1998, P NATL ACAD SCI USA, V95, P11781, DOI 10.1073/pnas.95.20.11781; CHAN CS, 1994, EMBO J, V13, P2553, DOI 10.1002/j.1460-2075.1994.tb06545.x; Cogoni C, 1997, P NATL ACAD SCI USA, V94, P10233, DOI 10.1073/pnas.94.19.10233; Cogoni C, 1996, EMBO J, V15, P3153, DOI 10.1002/j.1460-2075.1996.tb00678.x; Colot V, 1996, CELL, V86, P855, DOI 10.1016/S0092-8674(00)80161-0; CORBIN V, 1989, GENE DEV, V3, P2191, DOI 10.1101/gad.3.12b.2191; CORBIN V, 1989, NATURE, V337, P279, DOI 10.1038/337279a0; Csink AK, 1996, NATURE, V381, P529, DOI 10.1038/381529a0; English JJ, 1997, PLANT J, V12, P597, DOI 10.1046/j.1365-313X.1997.00597.x; FAUVARQUE MO, 1993, GENE DEV, V7, P1508, DOI 10.1101/gad.7.8.1508; Fire A, 1998, NATURE, V391, P806, DOI 10.1038/35888; FLAVELL RB, 1994, P NATL ACAD SCI USA, V91, P3490, DOI 10.1073/pnas.91.9.3490; FRANKE A, 1992, EMBO J, V11, P2941, DOI 10.1002/j.1460-2075.1992.tb05364.x; Gubb D, 1997, GENETICS, V146, P919; Hagstrom K, 1997, GENETICS, V146, P1365; HIEBERT JC, 1994, GENETICS, V136, P913; HIRAOKA Y, 1993, J CELL BIOL, V120, P591, DOI 10.1083/jcb.120.3.591; Jensen S, 1999, NAT GENET, V21, P209, DOI 10.1038/5997; JORGENSEN RA, 1995, SCIENCE, V268, P686, DOI 10.1126/science.268.5211.686; Jorgensen RA, 1998, SCIENCE, V279, P1486, DOI 10.1126/science.279.5356.1486; KASSIS JA, 1991, GENETICS, V128, P751; Kennerdell JR, 1998, CELL, V95, P1017, DOI 10.1016/S0092-8674(00)81725-0; LAURIEAHLBERG CC, 1987, GENETICS, V115, P129; Mallin DR, 1998, GENETICS, V148, P331; MATZKE MA, 1989, EMBO J, V8, P643, DOI 10.1002/j.1460-2075.1989.tb03421.x; MATZKE MA, 1995, PLANT PHYSIOL, V107, P679, DOI 10.1104/pp.107.3.679; McCall K, 1996, EMBO J, V15, P569, DOI 10.1002/j.1460-2075.1996.tb00389.x; Meller VH, 1997, CELL, V88, P445, DOI 10.1016/S0092-8674(00)81885-1; Metzlaff M, 1997, CELL, V88, P845, DOI 10.1016/S0092-8674(00)81930-3; MEYER P, 1993, PLANT J, V4, P89, DOI 10.1046/j.1365-313X.1993.04010089.x; Mihaly J, 1998, MOL CELL, V1, P1065, DOI 10.1016/S1097-2765(00)80107-0; Montgomery MK, 1998, P NATL ACAD SCI USA, V95, P15502, DOI 10.1073/pnas.95.26.15502; NAPOLI C, 1990, PLANT CELL, V2, P279, DOI 10.1105/tpc.2.4.279; PalBhadra M, 1997, CELL, V90, P479, DOI 10.1016/S0092-8674(00)80508-5; PARO R, 1990, TRENDS GENET, V6, P416, DOI 10.1016/0168-9525(90)90303-N; Paro R., 1996, EPIGENETIC MECH GENE, P507; RABINOW L, 1991, GENETICS, V129, P463; RASTELLI L, 1993, EMBO J, V12, P1513, DOI 10.1002/j.1460-2075.1993.tb05795.x; ROBERTSON HM, 1988, GENETICS, V118, P461; Ruiz F, 1998, MOL BIOL CELL, V9, P931, DOI 10.1091/mbc.9.4.931; SCHMIDT ER, 1988, CHROMOSOMA, V96, P353, DOI 10.1007/BF00330701; Selker EU, 1999, CELL, V97, P157, DOI 10.1016/S0092-8674(00)80725-4; Sigrist CJA, 1997, GENETICS, V147, P209; Sijen T, 1996, PLANT CELL, V8, P2277, DOI 10.1105/tpc.8.12.2277; TAUTZ D, 1989, CHROMOSOMA, V98, P81, DOI 10.1007/BF00291041; VANDERKROL AR, 1990, PLANT CELL, V2, P291, DOI 10.1105/tpc.2.4.291; Vaucheret H, 1998, PLANT J, V16, P651, DOI 10.1046/j.1365-313x.1998.00337.x; Voinnet O, 1998, CELL, V95, P177, DOI 10.1016/S0092-8674(00)81749-3; Waterhouse PM, 1998, P NATL ACAD SCI USA, V95, P13959, DOI 10.1073/pnas.95.23.13959; ZACHAR Z, 1982, CELL, V30, P529, DOI 10.1016/0092-8674(82)90250-1	55	67	75	0	1	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	OCT 1	1999	99	1					35	46		10.1016/S0092-8674(00)80060-4	http://dx.doi.org/10.1016/S0092-8674(00)80060-4			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	243DK	10520992	Bronze			2022-12-01	WOS:000082981600006
J	Emanuel, EJ; Fairclough, DL; Slutsman, J; Alpert, H; Baldwin, D; Emanuel, LL				Emanuel, EJ; Fairclough, DL; Slutsman, J; Alpert, H; Baldwin, D; Emanuel, LL			Assistance from family members, friends, paid care givers, and volunteers in the care of terminally ill patients	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							HOSPITALIZED ADULTS; ALZHEIMERS-DISEASE; MENTAL-HEALTH; BURDEN; CANCER; NEEDS	Background In addition to medical care, dying patients often need many types of assistance, including help with transportation, nursing care, homemaking services, and personal care. We interviewed terminally ill adults and their care givers in six randomly selected areas of the United States (five metropolitan areas and one rural county) to determine how their needs for assistance were met and the frequency with which they received such assistance from family members and paid and volunteer care givers. Methods The patients, whose physicians estimated them to have less than six months to live and who had clinically significant illness other than human immunodeficiency virus infection or the acquired immunodeficiency syndrome, were referred to the study by their physicians. Of the 1131 eligible patients, 988 (87.4 percent) consented to a detailed in-person interview conducted in English, as did 893 of the 915 eligible primary care givers (97.6 percent). Results Of the 988 terminally ill patients, 59.4 percent: were over the age of 65 years, and 51.5 percent were women; The most frequent terminal illness was cancer (in 51.8 percent of the patients), followed by heart disease (18.0 percent) and chronic obstructive pulmonary disease (10.9 percent). Four percent of the patients were in an institution, such as a nursing home, residential hospice, or hospital; the rest were living in a private residence. A need for assistance was reported by 86.8 percent of the patients; they required help with transportation (reported by 62.0 percent), homemaking services (55.2 percent), nursing care (28.7 percent), and personal care (26.0 percent). Of the care givers, 72.1 percent were women. Primary care givers were family members in 96.0 percent of cases; only 4.0 percent were unrelated. Most patients relied completely on family members and friends for assistance. A total of 15.5 percent of patients relied only on paid assistance for more than half of the types of care that they needed. Volunteers (that is, unpaid helpers who were not family members or friends) provided less than 3 percent of all care. Conclusions In our survey of terminally ill patients, family members, usually women, provided the majority of assistance with nonmedical care. Although many people received assistance from paid care givers, very few had assistance from volunteers; (N Engl J Med 1999;341:956-63.) (C) 1999, Massachusetts Medical Society.	NIH, Dept Clin Bioeth, Warren G Magnuson Clin Ctr, Bethesda, MD 20892 USA; Amer Med Ctr, Canc Res Ctr, Ctr Res Methodol & Biometr, Denver, CO USA; Johns Hopkins Univ, Sch Hyg & Publ Hlth, Dept Hlth Policy & Management, Baltimore, MD USA; Vital Sci & Hlth, Newtonville, MA USA; Amer Med Assoc, Inst Eth, Chicago, IL 60610 USA	National Institutes of Health (NIH) - USA; Johns Hopkins University; American Medical Association	Emanuel, EJ (corresponding author), NIH, Dept Clin Bioeth, Warren G Magnuson Clin Ctr, Bethesda, MD 20892 USA.							BERWICK DM, 1991, MED CARE, V29, P169, DOI 10.1097/00005650-199102000-00008; COVINSKY KE, 1994, JAMA-J AM MED ASSOC, V272, P1839, DOI 10.1001/jama.272.23.1839; Emanuel EJ, 1998, LANCET, V351, P21, DOI 10.1016/S0140-6736(98)90329-4; Field MJ., 1997, APPROACHING DEATH IM, P50; Ganzini L, 1998, NEW ENGL J MED, V339, P967, DOI 10.1056/NEJM199810013391406; GEORGE LK, 1986, GERONTOLOGIST, V26, P253, DOI 10.1093/geront/26.3.253; GREER DS, 1986, J CHRON DIS, V39, P9, DOI 10.1016/0021-9681(86)90103-7; HEINRICH RL, 1984, J CLIN PSYCHOL, V40, P972, DOI 10.1002/1097-4679(198407)40:4<972::AID-JCLP2270400417>3.0.CO;2-W; HOUTS PS, 1988, CANCER, V62, P627, DOI 10.1002/1097-0142(19880801)62:3<627::AID-CNCR2820620331>3.0.CO;2-1; JOHNSON CL, 1983, GERONTOLOGIST, V23, P612, DOI 10.1093/geront/23.6.612; KISSANE DW, 1994, PSYCHO-ONCOLOGY, V3, P47, DOI DOI 10.1002/P0N.2960030109; Kleinbaum D.G., 1988, STUDENTS PARTIAL SOL; KNAUS WA, 1995, JAMA-J AM MED ASSOC, V274, P1591, DOI 10.1001/jama.1995.03530200027032; KNAUS WA, 1995, ANN INTERN MED, V122, P191, DOI 10.7326/0003-4819-122-3-199502010-00007; KNAUS WA, 1991, CHEST, V100, P1619, DOI 10.1378/chest.100.6.1619; MAX W, 1995, J AGING HEALTH, V7, P179, DOI 10.1177/089826439500700202; Meyer H, 1997, HOSP HEALTH NETWORK, V71, P26; MOR V, 1987, Journal of Psychosocial Oncology, V5, P1, DOI 10.1300/J077v05n01_01; PRUCHNO RA, 1989, J AM GERIATR SOC, V37, P697, DOI 10.1111/j.1532-5415.1989.tb02230.x; RICE DP, 1993, HEALTH AFFAIR, V12, P164, DOI 10.1377/hlthaff.12.2.164; SHERBOURNE CD, 1991, SOC SCI MED, V32, P705, DOI 10.1016/0277-9536(91)90150-B; SIEGEL K, 1991, CANCER, V68, P1131, DOI 10.1002/1097-0142(19910901)68:5<1131::AID-CNCR2820680541>3.0.CO;2-N; TAYLOR RJ, 1991, J GERONTOL, V46, pS210, DOI 10.1093/geronj/46.4.S210; The SUPPORT Principal Investigators, 1995, J AMER MED ASSOC, V274, P1591; US Bureau of the Census, 1998, STAT ABSTR US 1998; WACHTER RM, 1989, ANN INTERN MED, V111, P525, DOI 10.7326/0003-4819-111-6-525; Ware J.E., 1993, SCORING SF 36 SF 36, DOI DOI 10.6-10.7; Zubrod CG, 1960, J CHRON DIS, V11, P7; 1998, WASHINGTON POST 0304, pA13; [No title captured]	30	240	246	1	18	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	SEP 23	1999	341	13					956	963		10.1056/NEJM199909233411306	http://dx.doi.org/10.1056/NEJM199909233411306			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	237LP	10498492				2022-12-01	WOS:000082658100006
J	Ho, MT; Chen, ER; Hsu, KH; Twu, SJ; Chen, KT; Tsai, SF; Wang, JR; Shih, SR				Ho, MT; Chen, ER; Hsu, KH; Twu, SJ; Chen, KT; Tsai, SF; Wang, JR; Shih, SR		Taiwan Enterovirus Epidemic Working Grp	An epidemic of enterovirus 71 infection in Taiwan	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							NEUROGENIC PULMONARY-EDEMA; CENTRAL NERVOUS-SYSTEM; MOUTH-DISEASE; ENCEPHALOMYELITIS; HAND; FOOT	Background Enteroviruses can cause outbreaks of hand-foot-and-mouth disease (characterized by vesicular lesions on the hands, feet, and oral mucosa) or herpangina, usually without life-threatening manifestations. In 1998 an epidemic of enterovirus 71 infection caused hand-foot-and-mouth disease and herpangina in thousands of people in Taiwan, some of whom died. Methods We assessed the epidemiologic aspects of this outbreak. Cases of hand-foot-and-mouth disease or herpangina in ambulatory patients were reported to the Taiwan Department of Health by a mean of 818 sentinel physicians. Severe cases in hospitalized patients were reported by 40 medical centers and regional hospitals. Viruses were isolated by 10 hospital laboratories and the department of health. Results The sentinel physicians reported 129,106 cases of hand-foot-and-mouth disease or herpangina in two waves of the epidemic, which probably represents less than 10 percent of the estimated total number of cases. There were 405 patients with severe disease, most of whom were five years old or younger; severe disease was seen in all regions of the island. Complications included encephalitis, aseptic meningitis, pulmonary edema or hemorrhage, acute flaccid paralysis, and myocarditis. Seventy-eight patients died, 71 of whom (91 percent) were five years of age or younger. Of the patients who died, 65 (83 percent) had pulmonary edema or pulmonary hemorrhage. Among patients from whom a virus was isolated, enterovirus 71 was present in 48.7 percent of outpatients with uncomplicated hand-foot-and-mouth disease or herpangina, 75 percent of hospitalized patients who survived, and 92 percent of patients who died. Conclusions Although several enteroviruses were circulating in Taiwan during the 1998 epidemic, enterovirus 71 infection was associated with most of the serious clinical manifestations and with nearly all the deaths. Most of those who died were young, and the majority died of pulmonary edema and pulmonary hemorrhage. (N Engl J Med 1999;341:929-35.) (C) 1999. Massachusetts Medical Society.	Natl Hlth Res Inst, Div Clin Res, Taipei 115, Taiwan; Natl Dept Hlth, Taipei, Taiwan; Natl Cheng Kung Univ, Med Ctr, Virus Lab, Tainan 70101, Taiwan; Chang Gung Med Ctr, Virus Lab, Lin Ko, Taiwan	National Health Research Institutes - Taiwan; National Cheng Kung University; Chang Gung Memorial Hospital	Ho, MT (corresponding author), Natl Hlth Res Inst, Div Clin Res, 128 Yen Chiu Yuan Rd,Sect 2, Taipei 115, Taiwan.		Shih, Shin-Ru/M-9711-2016; Wang, Jen-Ren/F-5254-2011	Chen, Kow-Tong/0000-0001-9129-7054; Shih, Shin-Ru/0000-0003-4874-401X; Wang, Jen-Ren/0000-0002-4127-4046				ALEXANDER JP, 1994, J INFECT DIS, V169, P905, DOI 10.1093/infdis/169.4.905; [Anonymous], 1998, MMWR MORB MORTAL WKL, V47, P629; BAKER AB, 1957, NEUROLOGY, V7, P743, DOI 10.1212/WNL.7.11.743; Chang LY, 1998, LANCET, V352, P367, DOI 10.1016/S0140-6736(98)24031-1; *DEP ENV, 1995, POL GUID COAST, P65; Gubler DJ, 1998, CLIN MICROBIOL REV, V11, P480, DOI 10.1128/CMR.11.3.480; ISHIMARU Y, 1980, ARCH DIS CHILD, V55, P583, DOI 10.1136/adc.55.8.583; Landry ML, 1995, PEDIATR INFECT DIS J, V14, P1095, DOI 10.1097/00006454-199512000-00013; Lum LCS, 1998, LANCET, V352, P1391, DOI 10.1016/S0140-6736(05)60789-1; Lum LCS, 1998, J PEDIATR-US, V133, P795, DOI 10.1016/S0022-3476(98)70155-6; MELNICK JL, 1984, REV INFECT DIS, V6, pS387; MODLIN JF, 1995, PRINCIPLES PRACTICE, P1621; NAGY G, 1982, ARCH VIROL, V71, P217, DOI 10.1007/BF01314873; SCHMIDT NJ, 1974, J INFECT DIS, V129, P304, DOI 10.1093/infdis/129.3.304; SHINDAROV LM, 1979, J HYG EPID MICROB IM, V23, P284; Wu TN, 1999, EMERG INFECT DIS, V5, P458, DOI 10.3201/eid0503.990321; 1998, MMWR MORB MORTAL WKL, V47, P718	17	938	1103	1	122	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	SEP 23	1999	341	13					929	935		10.1056/NEJM199909233411301	http://dx.doi.org/10.1056/NEJM199909233411301			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	237LP	10498487				2022-12-01	WOS:000082658100001
J	Fairley, CK; Sinclair, MI; Rizak, S				Fairley, CK; Sinclair, MI; Rizak, S			Monitoring not the answer to cryptosporidium in water	LANCET			English	Editorial Material									Monash Univ, Alfred Hosp, Monash Med Sch, Cooperat Res Ctr Water Qual & Treatment, Prahran, Vic 3181, Australia	Florey Institute of Neuroscience & Mental Health; Monash University	Fairley, CK (corresponding author), Monash Univ, Alfred Hosp, Monash Med Sch, Cooperat Res Ctr Water Qual & Treatment, Prahran, Vic 3181, Australia.			Sinclair, Martha/0000-0002-5900-487X; Christopher, Fairley/0000-0001-9081-1664				*AUSTR DRINK WAT G, 1996, AGR RES MAN COUNC AU; BOUCHIER I, 1998, CRYPTOSPOIRIDIUM WAT; CHAPPELL CH, 1998, CRYPTOSPORIDIUM WATE, P11; *DEP ENV TRANSP RE, 1998, PUBL HLTH DRINK WAT; EPA, 1998, FED REGISTER, V2040, P69389; *FED PROV SUBC DRI, 1997, PROT DRINK WAT DOC P; MARK DB, 1995, NEW ENGL J MED, V332, P1418, DOI 10.1056/NEJM199505253322106; MCCLELLAN P, 1998, SYDNEY WATER INQUIRY; ODONOGHUE PJ, 1995, INT J PARASITOL, V25, P139, DOI 10.1016/0020-7519(94)E0059-V; *PUBL HLTH LAB SER, 1999, FACTS FIG CRYPT; Sinclair MI, 1998, MED J AUSTRALIA, V169, P296, DOI 10.5694/j.1326-5377.1998.tb140278.x; VANINEVELD BM, 1993, EUR J CANCER, V29A, P1663, DOI 10.1016/0959-8049(93)90100-T; VESEY G, 1997, INT S WAT CRYPT MARC; Wheeler JG, 1999, BMJ-BRIT MED J, V318, P1046, DOI 10.1136/bmj.318.7190.1046; 1999, WATER SUPPLY WATER Q	15	8	8	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	SEP 18	1999	354	9183					967	969		10.1016/S0140-6736(99)90065-X	http://dx.doi.org/10.1016/S0140-6736(99)90065-X			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	236JG	10501354				2022-12-01	WOS:000082596000005
J	Poglitsch, CL; Meredith, GD; Gnatt, AL; Jensen, GJ; Chang, WH; Fu, JH; Kornberg, RD				Poglitsch, CL; Meredith, GD; Gnatt, AL; Jensen, GJ; Chang, WH; Fu, JH; Kornberg, RD			Electron crystal structure of an RNA polymerase II transcription elongation complex	CELL			English	Article							3-DIMENSIONAL STRUCTURE; 2-DIMENSIONAL CRYSTALS; ESCHERICHIA-COLI; DNA; CRYSTALLOGRAPHY; MICROSCOPY; CRYSTALLIZATION; BINDING; SITE; CONFORMATIONS	The structure of an actively transcribing complex, containing yeast RNA polymerase II with associated template DNA and product RNA, was determined by electron crystallography. Nucleic acid, in all likelihood the "transcription bubble" at the active center of the enzyme, occupies a previously noted 25 Angstrom channel in the protein structure. Details are indicative of a roughly 90 degrees bend of the DNA between upstream and downstream regions. The DNA apparently lies entirely on one face of the polymerase, rather than passing through a hole to the opposite side, as previously suggested.	Stanford Univ, Sch Med, Dept Biol Struct, Stanford, CA 94305 USA	Stanford University	Kornberg, RD (corresponding author), Stanford Univ, Sch Med, Dept Biol Struct, Stanford, CA 94305 USA.		Chang, Wei-Hau/F-1965-2015	Chang, Wei-Hau/0000-0002-2612-850X	NIAID NIH HHS [AI21144] Funding Source: Medline; NIGMS NIH HHS [GM07365, 2T32GM082494] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI021144] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AMOS LA, 1983, PROG BIOPHYS MOL BIO, V39, P183, DOI 10.1016/0079-6107(83)90017-2; Asturias FJ, 1998, ULTRAMICROSCOPY, V70, P133, DOI 10.1016/S0304-3991(97)00108-3; Asturias FJ, 1997, J MOL BIOL, V272, P536, DOI 10.1006/jmbi.1997.1273; ASTURIAS FJ, 1995, J STRUCT BIOL, V114, P60, DOI 10.1006/jsbi.1995.1005; Asturias FJ, 1999, J BIOL CHEM, V274, P6813, DOI 10.1074/jbc.274.11.6813; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Carson M, 1997, METHOD ENZYMOL, V277, P493, DOI 10.1016/S0076-6879(97)77027-7; Crowther RA, 1996, J STRUCT BIOL, V116, P9, DOI 10.1006/jsbi.1996.0003; DARST SA, 1989, NATURE, V340, P730, DOI 10.1038/340730a0; DARST SA, 1991, CELL, V66, P121, DOI 10.1016/0092-8674(91)90144-N; DARST SA, 1991, J MOL BIOL, V221, P347, DOI 10.1016/0022-2836(91)90823-O; DARST SA, 1991, BIOPHYS J, V59, P387, DOI 10.1016/S0006-3495(91)82232-9; EDWARDS AM, 1991, J BIOL CHEM, V266, P71; Fu JH, 1998, J MOL BIOL, V280, P317, DOI 10.1006/jmbi.1998.1557; Fu JH, 1999, CELL, V98, P799, DOI 10.1016/S0092-8674(00)81514-7; Gnatt A, 1997, J BIOL CHEM, V272, P30799, DOI 10.1074/jbc.272.49.30799; Gu WG, 1996, P NATL ACAD SCI USA, V93, P6935, DOI 10.1073/pnas.93.14.6935; HENDERSON R, 1986, ULTRAMICROSCOPY, V19, P147, DOI 10.1016/0304-3991(86)90203-2; Hessler D, 1992, Neuroimage, V1, P55, DOI 10.1016/1053-8119(92)90007-A; Jensen GJ, 1998, EMBO J, V17, P2353, DOI 10.1017/S1431927600024983; JOHNSON TL, 1994, CELL, V77, P217, DOI 10.1016/0092-8674(94)90314-X; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KADESCH TR, 1982, J BIOL CHEM, V257, P5286; Leuther KK, 1996, CELL, V85, P773, DOI 10.1016/S0092-8674(00)81242-8; Markovtsov V, 1996, P NATL ACAD SCI USA, V93, P3221, DOI 10.1073/pnas.93.8.3221; McRee DE, 1999, J STRUCT BIOL, V125, P156, DOI 10.1006/jsbi.1999.4094; Meredith GD, 1996, J MOL BIOL, V258, P413, DOI 10.1006/jmbi.1996.0258; Mustaev A, 1997, P NATL ACAD SCI USA, V94, P6641, DOI 10.1073/pnas.94.13.6641; Nudler E, 1998, SCIENCE, V281, P424, DOI 10.1126/science.281.5375.424; Nudler E, 1999, J MOL BIOL, V288, P1, DOI 10.1006/jmbi.1999.2641; Nudler E, 1996, SCIENCE, V273, P211, DOI 10.1126/science.273.5272.211; POLYAKOV A, 1995, CELL, V83, P365, DOI 10.1016/0092-8674(95)90114-0; REES WA, 1993, SCIENCE, V260, P1646, DOI 10.1126/science.8503010; RICE GA, 1991, P NATL ACAD SCI USA, V88, P4245, DOI 10.1073/pnas.88.10.4245; RICE GA, 1993, NUCLEIC ACIDS RES, V21, P113, DOI 10.1093/nar/21.1.113; Rippe K, 1997, J MOL BIOL, V270, P125, DOI 10.1006/jmbi.1997.1079; SCHULTZ P, 1993, EMBO J, V12, P2601, DOI 10.1002/j.1460-2075.1993.tb05920.x; Selby CP, 1997, NUCLEIC ACIDS RES, V25, P787, DOI 10.1093/nar/25.4.787; Sidorenkov I, 1998, MOL CELL, V2, P55, DOI 10.1016/S1097-2765(00)80113-6; TREICH I, 1992, NUCLEIC ACIDS RES, V20, P4721, DOI 10.1093/nar/20.18.4721; Uptain SM, 1997, ANNU REV BIOCHEM, V66, P117, DOI 10.1146/annurev.biochem.66.1.117; YOUNG RA, 1991, ANNU REV BIOCHEM, V60, P689, DOI 10.1146/annurev.bi.60.070191.003353	42	56	56	0	3	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	SEP 17	1999	98	6					791	798		10.1016/S0092-8674(00)81513-5	http://dx.doi.org/10.1016/S0092-8674(00)81513-5			8	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	237WH	10499796	Bronze			2022-12-01	WOS:000082679200006
J	Zengler, K; Richnow, HH; Rossello-Mora, R; Michaelis, W; Widdel, F				Zengler, K; Richnow, HH; Rossello-Mora, R; Michaelis, W; Widdel, F			Methane formation from long-chain alkanes by anaerobic microorganisms	NATURE			English	Article							MICROBIAL PROCESSES; HYDROCARBONS; DEGRADATION; ENRICHMENT; SEDIMENTS	Biological formation of methane is the terminal process of biomass degradation in aquatic habitats where oxygen, nitrate, ferric iron and sulphate have been depleted as electron accepters. The pathway leading from dead biomass to methane through the metabolism of anaerobic bacteria and archaea is well understood for easily degradable biomolecules such as carbohydrates, proteins and lipids(1,2). However, little is known about the organic compounds that lead to methane in old anoxic sediments where easily degradable biomolecules are no longer available. One class of naturally formed long-lived compounds in such sediments is the saturated hydrocarbons (alkanes)(3-5). Alkanes are usually considered to be inert in the absence of oxygen, nitrate or sulphate(6), and the analysis of alkane patterns is often used for biogeochemical characterization of sediments(7,8), However, alkanes might be consumed in anoxic sediments below the zone of sulphate reduction(9,10), but the underlying process has not been elucidated. Here we used enrichment cultures to show that the biological conversion of long-chain alkanes to the simplest hydrocarbon, methane, is possible under strictly anoxic conditions.	Max Planck Inst Marine Microbiol, D-28359 Bremen, Germany; Univ Hamburg, Inst Biogeochem & Marine Chem, D-20146 Hamburg, Germany	Max Planck Society; University of Hamburg	Widdel, F (corresponding author), Max Planck Inst Marine Microbiol, Celsiusstr 1, D-28359 Bremen, Germany.	fwiddel@mpi-bremen.de	Rossello-Mora, Ramon/L-4650-2014; Richnow, Hans/AAD-9016-2022; Richnow, Hans H./H-8523-2017	Rossello-Mora, Ramon/0000-0001-8253-3107; Richnow, Hans/0000-0002-6144-4129; Richnow, Hans H./0000-0002-6144-4129; Zengler, Karsten/0000-0002-8062-3296				Albert DB, 1997, MAR CHEM, V56, P27, DOI 10.1016/S0304-4203(96)00083-7; BEIER JA, 1991, NATURE, V351, P642, DOI 10.1038/351642a0; Birch L., 1988, BIOTECHNOLOGY B, V6b, P71; BLUMER M, 1971, MAR BIOL, V8, P183, DOI 10.1007/BF00355214; Castellano J.A., 1992, HDB DISPLAY TECHNOLO; Dojka MA, 1998, APPL ENVIRON MICROB, V64, P3869; EGLINTON G, 1968, ADV ORG GEOCHEM, V31, P1; GIGER W, 1980, GEOCHIM COSMOCHIM AC, V44, P119, DOI 10.1016/0016-7037(80)90182-9; HARDER J, IN PRESS GEOMICROBIO; HAYES JM, 1990, ORG GEOCHEM, V16, P1115, DOI 10.1016/0146-6380(90)90147-R; Heider J, 1998, FEMS MICROBIOL REV, V22, P459, DOI 10.1111/j.1574-6976.1998.tb00381.x; LIDE DR, 1998, HDB CHEM PHYSICS; LOVLEY DR, 1995, REV GEOPHYS, V33, P365, DOI 10.1029/95RG01305; Ludwig W, 1998, ELECTROPHORESIS, V19, P554, DOI 10.1002/elps.1150190416; Martini AM, 1996, NATURE, V383, P155, DOI 10.1038/383155a0; MULLER FM, 1957, ANTON LEEUW INT J G, V23, P269; PARKES RJ, 1994, NATURE, V371, P410, DOI 10.1038/371410a0; Rowe D, 1999, NATURE, V398, P61, DOI 10.1038/18007; Rozanova EP, 1997, MICROBIOLOGY+, V66, P718; Schink B, 1997, MICROBIOL MOL BIOL R, V61, P262, DOI 10.1128/.61.2.262-280.1997; SCHINK B, 1985, FEMS MICROBIOL ECOL, V31, P69, DOI 10.1111/j.1574-6968.1985.tb01133.x; SCOTT AR, 1994, AAPG BULL, V78, P1186; Seiler W., 1980, ATMOS TECHNOL, V12, P40; SIMONEIT BRT, 1986, MAR GEOL, V70, P9, DOI 10.1016/0025-3227(86)90087-3; Tissot B.P., 1984, PETROLEUM FORMATION, DOI DOI 10.1007/978-3-642-96446-6; WERSIN P, 1991, CHEM GEOL, V90, P233, DOI 10.1016/0009-2541(91)90102-W; Widdel F., 1992, PROKARYOTES, P3352, DOI [10.1007/978-1-4757-2191-1_2, 10.1007/978-1-4757-2191-1_21]	28	454	490	2	121	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	SEP 16	1999	401	6750					266	269		10.1038/45777	http://dx.doi.org/10.1038/45777			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	237VZ	10499582				2022-12-01	WOS:000082678400050
J	Rommel, C; Clarke, BA; Zimmermann, S; Nunez, L; Rossman, R; Reid, K; Moelling, K; Yancopoulos, GD; Glass, DJ				Rommel, C; Clarke, BA; Zimmermann, S; Nunez, L; Rossman, R; Reid, K; Moelling, K; Yancopoulos, GD; Glass, DJ			Differentiation stage-specific inhibition of the Raf-MEK-ERK pathway by Akt	SCIENCE			English	Article							PROTEIN-KINASE CASCADE; PHOSPHATIDYLINOSITOL 3-KINASE; EXPRESSION; ACTIVATION; RECEPTOR; MYOGENESIS; TARGET; CELLS	Extracellular signals often result in simultaneous activation of both the Raf-MEK-ERK and PI3K-Akt pathways (where ERK is extracellular-regulated kinase, MEK is mitogen-activated protein kinase or ERK kinase, and PI3K is phosphatidylinositol 3-kinase). However, these two signaling pathways were shown to exert opposing effects on muscle cell hypertrophy. Furthermore, the PI3K-Akt pathway was shown to inhibit the Raf-MEK-ERK pathway: this cross-regulation depended on the differentiation state of the cell: Akt activation inhibited the Raf-MEK-ERK pathway in differentiated myotubes, but not in their myoblast precursors. The stage-specific inhibitory action of Akt correlated with its stage-specific ability to form a complex with Raf, suggesting the existence of differentially expressed mediators of an inhibitory Akt-Raf complex.	Regeneron Pharmaceut Inc, Tarrytown, NY 10591 USA; Univ Zurich, Inst Med Virol, CH-8028 Zurich, Switzerland	Regeneron; University of Zurich	Glass, DJ (corresponding author), Regeneron Pharmaceut Inc, 777 Old Saw Mill River Rd, Tarrytown, NY 10591 USA.		Glass, David/AAI-3910-2021					Andres V, 1996, J CELL BIOL, V132, P657, DOI 10.1083/jcb.132.4.657; Avruch J, 1998, MOL CELL BIOCHEM, V182, P31, DOI 10.1023/A:1006823109415; BELLACOSA A, 1991, SCIENCE, V254, P274, DOI 10.1126/science.1833819; Bennett AM, 1997, SCIENCE, V278, P1288, DOI 10.1126/science.278.5341.1288; BRUDER JT, 1992, GENE DEV, V6, P545, DOI 10.1101/gad.6.4.545; COLEMAN ME, 1995, J BIOL CHEM, V270, P12109, DOI 10.1074/jbc.270.20.12109; Coolican SA, 1997, J BIOL CHEM, V272, P6653, DOI 10.1074/jbc.272.10.6653; Cossu G, 1996, TRENDS GENET, V12, P218, DOI 10.1016/0168-9525(96)10025-1; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; Eves EM, 1998, MOL CELL BIOL, V18, P2143, DOI 10.1128/MCB.18.4.2143; Florini JR, 1996, ENDOCR REV, V17, P481, DOI 10.1210/er.17.5.481; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; GLASS DJ, 1991, CELL, V66, P405, DOI 10.1016/0092-8674(91)90629-D; Glass DJ, 1996, CELL, V85, P513, DOI 10.1016/S0092-8674(00)81252-0; HEIDECKER G, 1990, MOL CELL BIOL, V10, P2503, DOI 10.1128/MCB.10.6.2503; Hunter T, 1997, CELL, V88, P333, DOI 10.1016/S0092-8674(00)81872-3; JAYNES JB, 1988, MOL CELL BIOL, V8, P62, DOI 10.1128/MCB.8.1.62; Jiang BH, 1998, P NATL ACAD SCI USA, V95, P14179, DOI 10.1073/pnas.95.24.14179; Katz ME, 1997, CURR OPIN GENET DEV, V7, P75, DOI 10.1016/S0959-437X(97)80112-8; Khwaja A, 1998, J BIOL CHEM, V273, P18793, DOI 10.1074/jbc.273.30.18793; King AJ, 1998, NATURE, V396, P180, DOI 10.1038/24184; Klippel A, 1996, MOL CELL BIOL, V16, P4117; Kohn AD, 1996, J BIOL CHEM, V271, P31372, DOI 10.1074/jbc.271.49.31372; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; Mason CS, 1999, EMBO J, V18, P2137, DOI 10.1093/emboj/18.8.2137; Morrison DK, 1997, CURR OPIN CELL BIOL, V9, P174, DOI 10.1016/S0955-0674(97)80060-9; RodriguezViciana P, 1997, CELL, V89, P457, DOI 10.1016/S0092-8674(00)80226-3; Rommel C, 1997, MECH DEVELOP, V64, P95, DOI 10.1016/S0925-4773(97)00052-X; Rommel C, 1998, CURR OPIN GENET DEV, V8, P412, DOI 10.1016/S0959-437X(98)80111-1; SAMUELS ML, 1993, MOL CELL BIOL, V13, P6241, DOI 10.1128/MCB.13.10.6241; Zimmermann S, 1999, SCIENCE, V286, P1741, DOI 10.1126/science.286.5445.1741	31	652	677	1	27	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 26	1999	286	5445					1738	1741		10.1126/science.286.5445.1738	http://dx.doi.org/10.1126/science.286.5445.1738			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	259UK	10576741				2022-12-01	WOS:000083912200039
J	Ramratnam, B; Bonhoeffer, S; Binley, J; Hurley, A; Zhang, LQ; Mittler, JE; Markowitz, M; Moore, JP; Perelson, AS; Ho, DD				Ramratnam, B; Bonhoeffer, S; Binley, J; Hurley, A; Zhang, LQ; Mittler, JE; Markowitz, M; Moore, JP; Perelson, AS; Ho, DD			Rapid production and clearance of HIV-1 and hepatitis C virus assessed by large volume plasma apheresis	LANCET			English	Article							DYNAMICS IN-VIVO; ACQUIRED IMMUNODEFICIENCY SYNDROME; INTERFERON-ALPHA; MONKEY MODEL; TURNOVER; INFECTION; THERAPY; TYPE-1; SYSTEM	Background In chronic HIV-1 infection, dynamic equilibrium exists between viral production and clearance. The half-life of free virions can be estimated by inhibiting virion production with antiretroviral agents and modelling the resulting decline in plasma HIV-1 RNA. To define HIV-1 and hepatitis C virus (HCV) dynamics, we used plasma apheresis to increase virion clearance temporarily while leaving Virion production unaffected. Methods Plasma virus loads were measured frequently before, during, and after apheresis in four HIV-1-infected patients, two of whom were also co-infected with HCV. Rates of virion clearance were derived by non-linear least-square fitting of plasma virus load to a model of Viral dynamics. Findings Virion clearance rate constants were 0.0063/min (9.1/day) to 0.025/min (36.0/day; half-life 28-110 min) for HIV-1 and 0.0038/min (5.5/day) to 0.0069/min (9.9/day; half-life 100-182 min) for HCV. These values provided estimates of daily particle production of 9.3 log(10)-10.2 log(10) particles for HIV-1 and 11.6 log(10)-13.0 log(10) particles for HCV. Interpretation Our findings confirm that HIV-1 and HCV are produced and cleared extremely rapidly. New estimates for HIV-1 clearance are up to ten times higher than previous ones, whereas HCV clearance is similar to previous estimates.	Rockefeller Univ, Aaron Diamond AIDS Res Ctr, New York, NY 10016 USA; ETH Zentrum NW, Zurich, Switzerland; Friedrich Miescher Inst, CH-4002 Basel, Switzerland; Los Alamos Natl Lab, Los Alamos, NM USA	Rockefeller University; Swiss Federal Institutes of Technology Domain; ETH Zurich; Friedrich Miescher Institute for Biomedical Research; United States Department of Energy (DOE); Los Alamos National Laboratory	Ho, DD (corresponding author), Rockefeller Univ, Aaron Diamond AIDS Res Ctr, 455 1st Ave, New York, NY 10016 USA.	dho@ADARC.org	Bonhoeffer, Sebastian/A-2735-2008; Perelson, Alan S/Z-1959-2019	Bonhoeffer, Sebastian/0000-0001-8052-3925; Perelson, Alan S/0000-0002-2455-0002	NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000102] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U01AI041534, R01AI040387] Funding Source: NIH RePORTER; NCRR NIH HHS [MO1-RR00102] Funding Source: Medline; NIAID NIH HHS [AI41534, AI40387] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Bagnarelli P, 1997, J INFECT DIS, V176, P801, DOI 10.1086/517306; BALDWIN GC, 1990, P NATL ACAD SCI USA, V87, P3933, DOI 10.1073/pnas.87.10.3933; BENDER BS, 1988, REV INFECT DIS, V10, P1142; BENDER BS, 1987, J CLIN INVEST, V79, P715, DOI 10.1172/JCI112876; Binley JM, 1997, J VIROL, V71, P2799, DOI 10.1128/JVI.71.4.2799-2809.1997; Efron B., 1986, STAT SCI, V1, P54, DOI DOI 10.1214/SS/1177013815; Harrigan PR, 1999, AIDS, V13, pF59, DOI 10.1097/00002030-199905280-00001; HO DD, 1995, NATURE, V373, P123, DOI 10.1038/373123a0; Mittler JE, 1999, AIDS, V13, P1415, DOI 10.1097/00002030-199907300-00023; Neumann AU, 1999, AIDS, V13, P677, DOI 10.1097/00002030-199904160-00008; Neumann AU, 1998, SCIENCE, V282, P103, DOI 10.1126/science.282.5386.103; Ortiz GM, 1999, J CLIN INVEST, V104, pR13, DOI 10.1172/JCI7371; Perelson AS, 1996, SCIENCE, V271, P1582, DOI 10.1126/science.271.5255.1582; Perelson AS, 1997, NATURE, V387, P188, DOI 10.1038/387188a0; Taylor RP, 1997, J IMMUNOL, V158, P842; Taylor RP, 1997, CLIN IMMUNOL IMMUNOP, V82, P49, DOI 10.1006/clin.1996.4286; WEI XP, 1995, NATURE, V373, P117, DOI 10.1038/373117a0; Zeuzem S, 1998, HEPATOLOGY, V28, P245, DOI 10.1002/hep.510280132; Zeuzem S, 1996, HEPATOLOGY, V23, P366; Zhang LQ, 1999, J VIROL, V73, P855, DOI 10.1128/JVI.73.1.855-860.1999	20	375	377	0	6	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	NOV 20	1999	354	9192					1782	1785		10.1016/S0140-6736(99)02035-8	http://dx.doi.org/10.1016/S0140-6736(99)02035-8			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	258RM	10577640				2022-12-01	WOS:000083853000013
J	Liu, JE; Roman, MJ; Pini, R; Schwartz, JE; Pickering, TG; Devereux, RB				Liu, JE; Roman, MJ; Pini, R; Schwartz, JE; Pickering, TG; Devereux, RB			Cardiac and arterial target organ damage in adults with elevated ambulatory and normal office blood pressure	ANNALS OF INTERNAL MEDICINE			English	Article						hypertension; blood pressure monitoring, ambulatory; hypertrophy, left ventricular; coronary arteriosclerosis; blood pressure	LEFT-VENTRICULAR MASS; WHITE COAT HYPERTENSION; CORONARY HEART-DISEASE; CAROTID ATHEROSCLEROSIS; HYPERTROPHY; VARIABILITY; MORBIDITY; MORTALITY; THICKNESS; CHILDREN	Background: Ambulatory blood pressure may be higher or lower than clinic blood pressure. Attention has focused on "white coat hypertension" (normal ambulatory blood pressure elevated in the clinic). The converse phenomenon of high ambulatory blood pressure but normal office blood pressure-"white coat normotension"-has not been studied. Objective: To assess whether white coat normotension (awake ambulatory blood pressure > 134/90 mm Hg and clinic blood pressure < 140/90 mm Hg) is associated with target organ damage. Design: Cross-sectional observational study. Setting: University hospital hypertension center and participant work sites. Patients: 295 clinically normotensive adults and 64 patients with sustained hypertension (elevated clinic and ambulatory blood pressure). Measurements: Target organ abnormalities were measured by echocardiography and arterial ultrasonography in 61 patients with white coat normotension, 234 with sustained normotension (normal clinic and ambulatory blood pressure), and 64 with sustained hypertension. Results: Patients with white coat normotension were older; had higher body mass indices, serum creatinine concentrations, and glucose levels; and a higher prevalence of current smokers. Left ventricular mass index and relative wall thickness were higher by 13 g/m(2) (Cl, 8 to18 g/m(2)) and by 0.03 (Cl, 0.01 to 0.04), respectively, in patients with white coat normotension compared with those who had sustained normotension. Patients with white coat normotension and those with sustained hypertension did not differ significantly for left ventricular mass index (4 g/m(2) [Cl, -3 to 10 g/m(2)) or relative wall thickness (0.01 [Cl, -0.01 to 0.03]). The prevalence of discrete atherosclerotic plaques was similar in patients with white coat normotension (17 of 61, or 28% [Cl, 17% to 39%]) and those with sustained hypertension (17 of 64, or 27% [Cl, 16% to 38%]), but the difference lost significance after adjustment for age. Conclusions: White coat normotension is associated with left ventricular mass and carotid wall thickness similar to those in sustained hypertension. The association of white coat normotension with prognostically important target organ damage may partly explain the ability of high normal left ventricular mass and high normal clinic blood pressure to predict subsequent hypertension and cardiovascular events in patients with clinical normotension.	Cornell Univ, New York Presbyterian Hosp, Weill Med Coll, Div Cardiol, New York, NY 10021 USA; Univ Florence, Div Gerontol & Geriatr, I-50141 Florence, Italy	Cornell University; NewYork-Presbyterian Hospital; University of Florence	Devereux, RB (corresponding author), Cornell Univ, New York Presbyterian Hosp, Weill Med Coll, Div Cardiol, Box 222,525 E 68th St, New York, NY 10021 USA.	rbdevere@mail.med.cornell.edu		Pini, Riccardo/0000-0002-7940-7908; Schwartz, Joseph/0000-0002-8944-3566	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL018323, P01HL047540] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 47540, HL 30606, HL 18323, P01 HL047540] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALDERMAN MH, 1980, CARDIOLOGY REV REPOR, V1, P509; CAVALLINI MC, 1995, HYPERTENSION, V26, P413, DOI 10.1161/01.HYP.26.3.413; DESIMONE G, 1995, J AM COLL CARDIOL, V25, P1056, DOI 10.1016/0735-1097(94)00540-7; DESIMONE G, 1992, J AM COLL CARDIOL, V20, P1251, DOI 10.1016/0735-1097(92)90385-Z; Devereux RB, 1997, CIRCULATION, V96, P1416, DOI 10.1161/01.CIR.96.5.1416; DEVEREUX RB, 1977, CIRCULATION, V55, P613, DOI 10.1161/01.CIR.55.4.613; DEVEREUX RB, 1983, CIRCULATION, V68, P470, DOI 10.1161/01.CIR.68.3.470; Devereux RB, 1996, AM J CARDIOL, V78, P61, DOI 10.1016/S0002-9149(96)00228-7; Devereux RB, 1991, BLOOD PRESSURE MEASU, P261; FAGARD R, 1995, AM J HYPERTENS, V8, P533, DOI 10.1016/0895-7061(95)00043-O; GANAU A, 1990, CIRCULATION, V81, P25, DOI 10.1161/01.CIR.81.1.25; GIFFORD RW, 1993, ARCH INTERN MED, V153, P154; GOSSE P, 1986, J HYPERTENS, V4, pS297; Hansson L, 1998, LANCET, V351, P1755, DOI 10.1016/S0140-6736(98)04311-6; Jones EC, 1997, J AM COLL CARDIOL, V29, P1303, DOI 10.1016/S0735-1097(97)82755-6; JULIUS S, 1990, HYPERTENSION, V16, P617, DOI 10.1161/01.HYP.16.6.617; KANNEL WB, 1974, PROG CARDIOVASC DIS, V17, P5, DOI 10.1016/0033-0620(74)90034-6; KOREN MJ, 1991, ANN INTERN MED, V114, P345, DOI 10.7326/0003-4819-114-5-345; LARKIN KT, 1998, BLOOD PRESS MONIT, V3, P247; LEVY D, 1990, NEW ENGL J MED, V322, P1561, DOI 10.1056/NEJM199005313222203; MACMAHON S, 1990, LANCET, V335, P765, DOI 10.1016/0140-6736(90)90878-9; MANN SJ, 1991, JAMA-J AM MED ASSOC, V265, P2226, DOI 10.1001/jama.265.17.2226; NEATON JD, 1993, JAMA-J AM MED ASSOC, V270, P713, DOI 10.1001/jama.270.6.713; O'Leary DH, 1999, NEW ENGL J MED, V340, P14, DOI 10.1056/NEJM199901073400103; PALATINI P, 1985, J HYPERTENS, V3, pS425; Palmieri V, 1998, CIRCULATION, V98, P29; PERLOFF D, 1989, J HYPERTENS, V7, pS3; PICKERING TG, 1988, JAMA-J AM MED ASSOC, V259, P225, DOI 10.1001/jama.259.2.225; PIGNOLI P, 1986, CIRCULATION, V74, P1399, DOI 10.1161/01.CIR.74.6.1399; PRISANT LM, 1990, AM J HYPERTENS, V3, P81, DOI 10.1093/ajh/3.2.81; RAVOGLI A, 1990, HYPERTENSION, V16, P491, DOI 10.1161/01.HYP.16.5.491; ROMAN MJ, 1995, J AM COLL CARDIOL, V25, P83, DOI 10.1016/0735-1097(94)00316-I; ROSENMAN RH, 1976, CIRCULATION, V54, P51, DOI 10.1161/01.CIR.54.1.51; ROWLANDS DB, 1982, LANCET, V1, P467; SAHN DJ, 1978, CIRCULATION, V58, P1072, DOI 10.1161/01.CIR.58.6.1072; SALONEN R, 1988, ARTERIOSCLEROSIS, V8, P788, DOI 10.1161/01.ATV.8.6.788; Schiller N B, 1989, J Am Soc Echocardiogr, V2, P358; SCHNALL PL, 1992, HYPERTENSION, V19, P488, DOI 10.1161/01.HYP.19.5.488; Stearne MR, 1998, BMJ-BRIT MED J, V317, P703; VERDECCHIA P, 1992, HYPERTENSION, V20, P555, DOI 10.1161/01.HYP.20.4.555; VERDECCHIA P, 1995, J HYPERTENS, V13, P1209, DOI 10.1097/00004872-199510000-00016; VERDECCHIA P, 1994, HYPERTENSION, V24, P793, DOI 10.1161/01.HYP.24.6.793	42	284	301	0	8	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	OCT 19	1999	131	8					564	+		10.7326/0003-4819-131-8-199910190-00003	http://dx.doi.org/10.7326/0003-4819-131-8-199910190-00003			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	246ZR	10523216	Green Published			2022-12-01	WOS:000083196600002
J	Duke, T				Duke, T			Decline in child health in rural Papua New guinea	LANCET			English	Editorial Material									Goroka Base Hosp, Dept Paediat, Goroka, Eastern Highlan, Papua N Guinea		Duke, T (corresponding author), Goroka Base Hosp, Dept Paediat, POB 392, Goroka, Eastern Highlan, Papua N Guinea.	duke@global.net.pg						Alto William A., 1996, Papua New Guinea Medical Journal, V39, P315; Decosas J, 1999, LANCET, V353, P143, DOI 10.1016/S0140-6736(98)11454-X; *DEP HLTH, 1996, PNG NAT HLTH PLAN, P40; *DEP HLTH PAP NEW, 1997, DHS SURV; PATAKISCHWEIZER KJ, 1983, PAPUA NEW GUINEA MED, V26, P178; REILLY Q, 1990, ACHIEVING HLTH ALL Y, P213; Shann F, 1979, P N G Med J, V22, P170; Summerfield D, 1998, LANCET, V351, P1955, DOI 10.1016/S0140-6736(98)06056-5; *UNICEF, 1999, STAT WORLDS CHILDR 1, P91; World Bank, 2013, WOR DEV REP, P1, DOI 10.1596/978-0-8213-9575-2	10	22	23	0	1	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	OCT 9	1999	354	9186					1291	1294		10.1016/S0140-6736(99)00335-9	http://dx.doi.org/10.1016/S0140-6736(99)00335-9			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	243RE	10520651				2022-12-01	WOS:000083010400046
J	Molster, FJ; Yamamura, I; Waters, LBFM; Tielens, AGGM; de Graauw, T; de Jong, T; de Koter, A; Malfait, K; van den Ancker, ME; van Winckel, H; Voors, RHM; Waelkens, C				Molster, FJ; Yamamura, I; Waters, LBFM; Tielens, AGGM; de Graauw, T; de Jong, T; de Koter, A; Malfait, K; van den Ancker, ME; van Winckel, H; Voors, RHM; Waelkens, C			Low-temperature crystallization of silicate dust in circumstellar disks	NATURE			English	Article							SPECTRUM; GRAINS; COMETS; STARS	Silicate dust in the interstellar medium is observed to be amorphous(1), yet silicate dust in comets(2,3) and interplanetary dust particles(4) is sometimes partially crystalline. The dust in young stars(5,6) also appears to be partially crystalline. These clouds to a planetary system, it must undergo some processing, Here we report observations of highly crystalline silicate dust in the disks surrounding binary red-giant stars. The dust was created in amorphous form in the outer atmospheres of the red giants, and therefore must be processed in the disks to become crystalline. The temperatures in these disks are too low for the grains to anneal; therefore, some low-temperature process must be responsible. As the physical properties of the disks around young stars and red giants are similar, our results suggest that low-temperature crystallization of silicate grains also can occur in protoplanetary systems.	Univ Amsterdam, Astron Inst Anton Pannekoek, NL-1098 SJ Amsterdam, Netherlands; Katholieke Univ Leuven, Inst Sterrenkunde, B-3001 Heverlee, Belgium; SRON, Lab Space Res Groningen, NL-9700 AV Groningen, Netherlands; SRON, Space Res Lab, NL-3584 CA Utrecht, Netherlands; Univ Utrecht, Astron Inst, NL-3508 TA Utrecht, Netherlands	University of Amsterdam; KU Leuven; Utrecht University	Molster, FJ (corresponding author), Univ Amsterdam, Astron Inst Anton Pannekoek, Kruislaan 403, NL-1098 SJ Amsterdam, Netherlands.		Van Winckel, Hans/I-7863-2013	Van Winckel, Hans/0000-0001-5158-9327; van den Ancker, Mario/0000-0001-6992-3100				Bradley J. P., 1999, Solid interstellar matter: the ISO revolution, P297; BRADLEY JP, 1994, SCIENCE, V265, P925, DOI 10.1126/science.265.5174.925; Crovisier J, 1997, SCIENCE, V275, P1904, DOI 10.1126/science.275.5308.1904; deGraauw T, 1996, ASTRON ASTROPHYS, V315, pL49; Dorschner J, 1995, ASTRON ASTROPHYS REV, V6, P271, DOI 10.1007/BF00873686; Elliman R. G., 1986, MATER RES SOC S P, V51, P319; Gail HP, 1998, ASTRON ASTROPHYS, V332, P1099; GALVIN GJ, 1982, PHYS REV LETT, V48, P33, DOI 10.1103/PhysRevLett.48.33; Grun J, 1997, PHYS REV LETT, V78, P1584, DOI 10.1103/PhysRevLett.78.1584; Hallenbeck S, 1998, ASTROPHYS SPACE SCI, V255, P427; HANNER MS, 1994, ASTROPHYS J, V425, P274, DOI 10.1086/173984; JONES TW, 1976, ASTROPHYS J, V209, P509, DOI 10.1086/154746; JURA M, 1995, ASTROPHYS J, V453, P721, DOI 10.1086/176433; Kessler MF, 1996, ASTRON ASTROPHYS, V315, pL27; Malfait K, 1998, ASTRON ASTROPHYS, V332, pL25; MOLSTER PJ, IN PRESS ASTRON ASTR; Shu FH, 1996, SCIENCE, V271, P1545, DOI 10.1126/science.271.5255.1545; Shu FH, 1997, SCIENCE, V277, P1475, DOI 10.1126/science.277.5331.1475; THIEL K, 1991, NUCL TRACKS RAD MEAS, V19, P709; TIELENS AGGM, 1994, ASTROPHYS J, V431, P321, DOI 10.1086/174488; Van Winckel H, 1998, ASTRON ASTROPHYS, V336, pL17; VANDENANCKER ME, IN PRESS ASTRON ASTR; Waelkens C, 1998, ASTROPHYS SPACE SCI, V255, P25; WATERS LBF, 1999, IAU S, V191, P209; Waters LBFM, 1996, ASTRON ASTROPHYS, V315, pL361; WILLIAMS JS, 1985, PHYS REV LETT, V55, P1482, DOI 10.1103/PhysRevLett.55.1482; WOOD JA, 1985, PROTOSTARS PLANETS, V2, P687; YAMAMURA I, 1997, ESA, P313	28	162	164	1	5	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	OCT 7	1999	401	6753					563	565		10.1038/44085	http://dx.doi.org/10.1038/44085			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	244MG	10524623				2022-12-01	WOS:000083054900042
J	Joshipura, KJ; Ascherio, A; Manson, JE; Stampfer, MJ; Rimm, EB; Speizer, FE; Hennekens, CH; Spiegelman, D; Willett, WC				Joshipura, KJ; Ascherio, A; Manson, JE; Stampfer, MJ; Rimm, EB; Speizer, FE; Hennekens, CH; Spiegelman, D; Willett, WC			Fruit and vegetable intake in relation to risk of ischemic stroke	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CORONARY HEART-DISEASE; FOOD FREQUENCY QUESTIONNAIRE; CARDIOVASCULAR-DISEASE; PLASMA HOMOCYSTEINE; MEN; REPRODUCIBILITY; CONSUMPTION; POTASSIUM; MORTALITY; VALIDITY	Context Few studies have evaluated the relationship between fruit and vegetable intake and cardiovascular disease. Objective To examine the associations between fruit and vegetable intake and ischemic stroke. Design, Setting, and Subjects Prospective cohort studies, including 75 596 women aged 34 to 59 years in the Nurses' Health Study with 14 years of follow-up (1980-1994), and 38 683 men aged 40 to 75 years in the Health Professionals' Follow-up Study with 8 years of follow-up (1986-1994). All individuals were free of cardiovascular disease, cancer, and diabetes at baseline. Main Outcome Measure Incidence of ischemic stroke by quintile of fruit and vegetable intake. Results A total of 366 women and 204 men had an ischemic stroke. After controlling for standard cardiovascular risk factors, persons in the highest quintile of fruit and vegetable intake (median of 5.1 servings per day among men and 5.8 servings per day among women) had a relative risk (RR) of 0.69 (95% confidence interval [CI], 0.52-0.92) compared with those in the lowest quintile. An increment of 1 serving per day of fruits or vegetables was associated with a 6% tower risk of ischemic stroke (RR, 0.94; 95% CI, 0.90-0.99; P = .01, test for trend). Cruciferous vegetables (RR, 0.68 for an increment of 1 serving per day; 95% CI, 0.49-0.94), green leafy vegetables (RR, 0.79; 95% CI, 0.62-0.99), citrus fruit including juice (RR, 0.81; 95% CI, 0.68-0.96), and citrus fruit juice (RR, 0.75; 95% CI, 0.61-0.93) contributed most to the apparent protective effect of total fruits and vegetables. Legumes or potatoes were not associated with lower ischemic stroke risk. The multivariate pooled RR for total stroke was 0.96 (95% CI, 0.93-1.00) for each increment of 2 servings per day. Conclusions These data support a protective relationship between consumption of fruit and vegetables-particularly cruciferous and green leafy vegetables and citrus fruit and juice-and ischemic stroke risk.	Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA; Harvard Univ, Sch Publ Hlth, Dept Nutr, Boston, MA 02115 USA; Harvard Univ, Sch Publ Hlth, Dept Biostat, Boston, MA 02115 USA; Harvard Univ, Sch Publ Hlth, Dept Environm Hlth, Boston, MA 02115 USA; Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Med,Channing Lab, Boston, MA 02115 USA; Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Med,Div Prevent Med, Boston, MA 02115 USA	Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Brigham & Women's Hospital; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard Medical School	Joshipura, KJ (corresponding author), Harvard Univ, Sch Dent Med, Dept Oral Hlth Policy & Epidemiol, 188 Longwood Ave, Boston, MA 02115 USA.		Joshipura, Kaumudi J/AAA-3852-2020	Joshipura, Kaumudi/0000-0003-1964-7579	NATIONAL CANCER INSTITUTE [R01CA040356, R37CA040356] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL035464, R01HL034595] Funding Source: NIH RePORTER; NCI NIH HHS [CA40356] Funding Source: Medline; NHLBI NIH HHS [HL34595, HL35464] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Ascherio A, 1998, CIRCULATION, V98, P1198, DOI 10.1161/01.CIR.98.12.1198; Committee on Diet and Health, 1989, DIET HLTH IMPL RED C; CUPPLES LA, 1988, STAT MED, V7, P205, DOI 10.1002/sim.4780070122; DAGOSTINO RB, 1990, STAT MED, V9, P1501, DOI 10.1002/sim.4780091214; DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2; FESKANICH D, 1993, J AM DIET ASSOC, V93, P790, DOI 10.1016/0002-8223(93)91754-E; GAZIANO JM, 1995, ANN EPIDEMIOL, V5, P225; GILLMAN MW, 1995, JAMA-J AM MED ASSOC, V273, P1113, DOI 10.1001/jama.273.14.1113; Hirayama T, 1986, Prog Clin Biol Res, V206, P299; Hu FB, 1997, NEW ENGL J MED, V337, P1491, DOI 10.1056/NEJM199711203372102; Keli SO, 1996, ARCH INTERN MED, V156, P637, DOI 10.1001/archinte.156.6.637; KHAW KT, 1987, NEW ENGL J MED, V316, P235, DOI 10.1056/NEJM198701293160502; Knekt P, 1996, BRIT MED J, V312, P478, DOI 10.1136/bmj.312.7029.478; KNEKT P, 1994, AM J EPIDEMIOL, V139, P180; LEE CN, 1988, NEW ENGL J MED, V318, P995; Ness AR, 1997, INT J EPIDEMIOL, V26, P1, DOI 10.1093/ije/26.1.1; RIMM EB, 1992, AM J EPIDEMIOL, V135, P1114, DOI 10.1093/oxfordjournals.aje.a116211; Rimm EB, 1996, JAMA-J AM MED ASSOC, V275, P447, DOI 10.1001/jama.275.6.447; RIMM EB, 1993, NEW ENGL J MED, V328, P1450, DOI 10.1056/NEJM199305203282004; SALVINI S, 1989, INT J EPIDEMIOL, V18, P858, DOI 10.1093/ije/18.4.858; SELHUB J, 1995, NEW ENGL J MED, V332, P286, DOI 10.1056/NEJM199502023320502; STEINMETZ KA, 1993, CANCER RES, V53, P536; Walker A, 1981, STROKE S1, V12, P113; Ward M, 1997, QJM-MON J ASSOC PHYS, V90, P519, DOI 10.1093/qjmed/90.8.519; *WHO STUD GROUP, 1990, WHO TECHNICAL REPORT, V797; WILLETT W, 1986, AM J EPIDEMIOL, V124, P17, DOI 10.1093/oxfordjournals.aje.a114366; Willett W., 1990, NUTR EPIDEMIOLOGY	27	732	760	2	40	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 6	1999	282	13					1233	1239		10.1001/jama.282.13.1233	http://dx.doi.org/10.1001/jama.282.13.1233			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	241UM	10517425	Bronze			2022-12-01	WOS:000082901100030
J	Wigmore, SJ; Seeney, FM; Pleass, HCC; Praseedom, RK; Forsythe, JLR				Wigmore, SJ; Seeney, FM; Pleass, HCC; Praseedom, RK; Forsythe, JLR		Kidney Advisory Grp	Kidney damage during organ retrieval: data from UK National Transplant Database	LANCET			English	Article								Background Kidney damage at organ retrieval is believed to be an increasing problem that is under reported. We aimed to identify the true rate of such damage and assess the effects on transplant survival. Methods Data from the UK National Transplant Database were analysed on all cadaveric kidneys donated over a 5-year period in the UK. Records indicated whether kidneys had been retrieved by a liver or renal surgical team and whether damage was noted at the time of retrieval or at the transplant procedure. Multivariate Cox's regression models were fitted to 1-year and 3-year transplant-survival data in those kidneys that were transplanted between 1992 and 1994. Findings Of 9014 kidneys retrieved, 96 could not be transplanted because of damage sustained at retrieval. Damage was reported in 1726 (19%) kidneys although by both donor and recipient centres iri only 270 (3%). 1070 (62%) of the damaged organs were from donors aged 40 years or older. Reported kidney damage was more likely for retrievals of kidney only by a renal team (503 [26%]) than for multiorgan retrieval (454 [21%]), the proportion was lower when a liver team retrieved both liver and kidneys (415 [17%]). 794 (14%) kidneys retrieved and retained locally were reported as damaged, compared with 932 (29%) kidneys which had been exported. Donors' age had a significant effect on both 1-year and 3-year transplant survival (p<0.01 for both) but kidney damage did not (1 year p=0.40; 3 year p=0.81). Interpretation Despite the high rate of damage to kidneys at retrieval, most of the organs can be transplanted with no adverse effect on transplant survival. Kidney damage is least likely to occur with kidneys from young donors, and when liver teams or centres undertaking more than 50 retrievals per year do the retrieval.	Univ Edinburgh, Royal Infirm Edinburgh, Dept Surg, Scottish Liver Transplant Unit, Edinburgh EH3 9YW, Midlothian, Scotland; United Kingdom Transplant Support Serv Author, Stoke Gifford, England	Royal Infirmary of Edinburgh; University of Edinburgh	Forsythe, JLR (corresponding author), Univ Edinburgh, Royal Infirm Edinburgh, Dept Surg, Scottish Liver Transplant Unit, Edinburgh EH3 9YW, Midlothian, Scotland.		Wigmore, Stephen/AAF-3562-2019	Wigmore, Stephen/0000-0002-3614-8002				Cecka J M, 1988, Clin Transpl, P399; GENTLEMAN D, 1990, BMJ-BRIT MED J, V301, P1203, DOI 10.1136/bmj.301.6762.1203; Grossman MD, 1996, TRANSPLANTATION, V62, P1828, DOI 10.1097/00007890-199612270-00026; Lee CM, 1996, TRANSPLANTATION, V62, P1832, DOI 10.1097/00007890-199612270-00027; Nicholls J, 1996, TRANSPLANT P, V28, P142; NYGAARD CE, 1990, J TRAUMA, V30, P728, DOI 10.1097/00005373-199006000-00013; 1995, UNOS UPDATE, V11, P30	7	39	39	0	4	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	OCT 2	1999	354	9185					1143	1146		10.1016/S0140-6736(98)09409-4	http://dx.doi.org/10.1016/S0140-6736(98)09409-4			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	242QX	10513706				2022-12-01	WOS:000082954100008
J	Altmann, P; Cunningham, J; Dhanesha, U; Ballard, M; Thompson, J; Marsh, F				Altmann, P; Cunningham, J; Dhanesha, U; Ballard, M; Thompson, J; Marsh, F			Disturbance of cerebral function in people exposed to drinking water contaminated with aluminium sulphate: retrospective study of the Camelford water incident	BMJ-BRITISH MEDICAL JOURNAL			English	Article							ALZHEIMERS-DISEASE; GASTROINTESTINAL ABSORPTION; DIALYSIS ENCEPHALOPATHY; ENVIRONMENTAL ALUMINUM; HEMODIALYSIS-PATIENTS; CEREBROSPINAL-FLUID; PRESENILE-DEMENTIA; NORTH CORNWALL; METABOLISM; POLLUTION	Objective To establish whether people exposed to drinking water contaminated with 20 tonnes of aluminium sulphate in the Camelford area of Cornwall in the south west of England in July 1988 had suffered organic brain damage as opposed to psychological trauma only. Design Retrospective study of affected people. Participants 55 affected people and 15 siblings nearest in age to one of the group but who had not been exposed to the contaminated water were studied. Main outcome measures Various clinical and psychological tests to determine medical condition and anxiety levels in affected people. Assessment of premorbid IQ (pFSIQ) with the national adult reading test, a computerised battery of psychomotor testing, and measurement of the difference in latencies between the flash and pattern visual evoked potentials in all participants. Results The mean (SE) pFSIQ was above average at 114.4 (1.1). The most sensitive of the psychomotor tests for organic brain disease was the symbol digit coding (SDC) test (normal score 100, abnormal <85). Participants performed less well on this test (54.5 (6.0)) than expected from their pFSIQ (P < 0.0001) and a little less poorly on the averaged less discriminating tests within the battery (86.1 (2.5), P < 0.0001). In a comparison with the 15 sibling pairs (affected people's age 41.0 (3.3) years v sibling age of 42.7 (3.1) years (P = 0.36) the exposed people had similar pFSIQ (114.7 (2.1)) to their siblings (116.3 (2.1), (P = 0.59) but performed badly on the symbol digit coding test (51.8 (16.6)) v (87.5 (4.9) for siblings, P = 0.03), The flash-pattern differences in exposed people were greater than in 42 unrelated control subjects of similar age (27.33 (1.64) ms v 18.57 (1.47) ms, P = 0.0002). The 15 unexposed siblings had significantly better flash-pattern differences than their affected siblings (13.4 (2.4) ms v 29.6 (2.9) ms, P = 0.0002). No effect of anxiety could be shown on these measurements from the analysis of the anxiety scores of exposed people. Conclusion People who were exposed to the contaminated water at Camelford suffered considerable damage to cerebral function, which was not related to anxiety. Follow up studies would be required to determine the longer term prognosis for affected individuals.	Oxford Radcliffe Hosp, Oxford Kidney Unit, Oxford OX3 7LJ, England; Royal London Hosp, London E1 1BB, England; Coventry & Warwickshire Hosp, Paybody Eye Unit, Coventry CV1 4FH, W Midlands, England; Priory Hosp, London SW15 5JJ, England; UCL, Sch Med, London W1N 8AA, England	University of Oxford; Barts Health NHS Trust; Royal London Hospital; University of London; University College London; UCL Medical School	Altmann, P (corresponding author), Oxford Radcliffe Hosp, Oxford Kidney Unit, Oxford OX3 7LJ, England.	paul.altmann@orh.anglox.nhs.uk						ACKER W, 1982, B MAUDSLEY AUTOMATED; Acker W., 1982, BEXLEY MAUDSLEY AUTO; ALFREY AC, 1976, NEW ENGL J MED, V294, P184, DOI 10.1056/NEJM197601222940402; ALLEN WM, 1989, VET REC, V124, P479, DOI 10.1136/vr.124.18.479; ALTMANN P, 1989, LANCET, V2, P7, DOI 10.1016/S0140-6736(89)90254-7; ALTMANN P, 1987, KIDNEY INT, V32, P710, DOI 10.1038/ki.1987.264; ALTMANN P, 1987, NEW ENGL J MED, V317, P80, DOI 10.1056/NEJM198707093170204; ALTMANN P, 1991, THESIS U LONDON LOND; BARLOW PJ, 1986, J ROY SOC MED, V79, P581, DOI 10.1177/014107688607901007; BASUN H, 1991, J NEURAL TRANSM-PARK, V3, P231; BIRCHALL JD, 1988, LANCET, V2, P1008, DOI 10.1016/S0140-6736(88)90754-4; BLAND JM, 1986, LANCET, V1, P307, DOI 10.1016/s0140-6736(86)90837-8; BRUN A, 1981, ACTA PATH MICRO IM A, V89, P193; Cacabelos R, 1996, ACTA NEUROL SCAND, V93, P72; CLAYTON B, 1991, WATER POLLUTION LOWE; Clayton B., 1989, WATER POLLUTION LOWE; COGGON D, 1991, BRIT MED J, V303, P1280, DOI 10.1136/bmj.303.6813.1280; CRAPPER DR, 1973, SCIENCE, V180, P511, DOI 10.1126/science.180.4085.511; DAVID AS, 1995, J PSYCHOSOM RES, V39, P1, DOI 10.1016/0022-3999(94)00085-J; DELABAR JM, 1987, SCIENCE, V235, P1390, DOI 10.1126/science.2950593; DEROGATIS LR, 1977, S CHECKL 90 R ADM SC; DHAESE PC, 1985, CLIN CHEM, V31, P24; DOLL R, 1993, AGE AGEING, V22, P138, DOI 10.1093/ageing/22.2.138; ELLIOTT HL, 1978, BRIT MED J, V1, P1101, DOI 10.1136/bmj.1.6120.1101; Exley C, 1996, J TOXICOL ENV HEALTH, V48, P569, DOI 10.1080/009841096161078; FARRAR G, 1990, LANCET, V335, P747, DOI 10.1016/0140-6736(90)90868-6; Flaten TP, 1996, J TOXICOL ENV HEALTH, V48, P527, DOI 10.1080/009841096161050; GURLING HMD, 1980, 3 INT C TWIN STUD JE; GURLING HMD, 1980, 3 INT C TWIN STUD; HANTSON P, 1994, LANCET, V344, P1647, DOI 10.1016/S0140-6736(94)90446-4; Haycock KH, 1992, STATVIEW; JACQMIN H, 1994, AM J EPIDEMIOL, V139, P48, DOI 10.1093/oxfordjournals.aje.a116934; KAEHNY WD, 1977, NEW ENGL J MED, V296, P1389, DOI 10.1056/NEJM197706162962407; KAPAKI EN, 1993, BIOL PSYCHIAT, V33, P679, DOI 10.1016/0006-3223(93)90114-S; KELLETT JM, 1986, LANCET, V1, P682; Lezak M., 1976, NEUROPSYCHOLOGICAL A; MARTYN CN, 1989, LANCET, V1, P59; MAYEUX R, 1995, AM J PUBLIC HEALTH, V85, P1280, DOI 10.2105/AJPH.85.9.1280; MAYONWHITE RT, 1993, BRIT MED J, V307, P398, DOI 10.1136/bmj.307.6901.398; MCMILLAN TM, 1993, HUM EXP TOXICOL, V12, P37, DOI 10.1177/096032719301200108; MCMILLAN TM, 1993, J CHILD PSYCHOL PSYC, V34, P1449, DOI 10.1111/j.1469-7610.1993.tb02102.x; MEHTA RP, 1979, CAN MED ASSOC J, V120, P1112; MICHEL P, 1990, NEUROBIOL AGING, V11, P264; Mjoberg B, 1997, ACTA ORTHOP SCAND, V68, P511, DOI 10.3109/17453679708999016; Moore PB, 1997, BIOL PSYCHIAT, V41, P488, DOI 10.1016/S0006-3223(96)00045-5; Nelson HE., 1982, NATL ADULT READING T; OWEN PJ, 1995, J PUBLIC HEALTH MED, V17, P200, DOI 10.1093/oxfordjournals.pubmed.a043093; PERL DP, 1980, SCIENCE, V208, P297, DOI 10.1126/science.7367858; PLATTS MM, 1981, CLIN NEPHROL, V15, P223; PLATTS MM, 1977, BRIT MED J, V2, P657, DOI 10.1136/bmj.2.6088.657; POWELL JJ, 1995, ANALYST, V120, P793, DOI 10.1039/an9952000793; Priest ND, 1996, BIOMETALS, V9, P221, DOI 10.1007/BF00817919; PRIEST ND, 1995, HUM EXP TOXICOL, V14, P287, DOI 10.1177/096032719501400309; PRIEST ND, 1993, P NUTR SOC, V52, P231, DOI 10.1079/PNS19930055; RIFAT SL, 1990, LANCET, V336, P1162, DOI 10.1016/0140-6736(90)92775-D; SHARP CA, 1993, EUR J CLIN INVEST, V23, P554, DOI 10.1111/j.1365-2362.1993.tb00965.x; Spofforth J, 1921, LANCET, V1, P1301; TALBOT RJ, 1995, HUM EXP TOXICOL, V14, P595, DOI 10.1177/096032719501400707; TAYLOR GA, 1992, AGE AGEING, V21, P81, DOI 10.1093/ageing/21.2.81; TERRY RD, 1965, NEUROPATHOL EXP NEUR, V23, P200; VONDOLLKEN, 1897, ARCH EXP PATHOL PH, V40, P98; WHALLEY LJ, 1985, LANCET, V1, P578; WHITE DM, 1992, ARCH INTERN MED, V152, P1443, DOI 10.1001/archinte.152.7.1443; WHITE DM, 1992, ARCH INTERN MED, V153, P2796; WRIGHT CE, 1984, ELECTROEN CLIN NEURO, V57, P405, DOI 10.1016/0013-4694(84)90069-5; ZAPATERO MD, 1995, BIOL TRACE ELEM RES, V47, P235, DOI 10.1007/BF02790122	66	82	88	0	16	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	SEP 25	1999	319	7213					807	+		10.1136/bmj.319.7213.807	http://dx.doi.org/10.1136/bmj.319.7213.807			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	241CR	10496822	Green Submitted, Bronze, Green Published			2022-12-01	WOS:000082865200020
J	Spruck, CH; Won, KA; Reed, SI				Spruck, CH; Won, KA; Reed, SI			Deregulated cyclin E induces chromosome instability	NATURE			English	Article							BREAST-CANCER; CELL-CYCLE; DNA-REPLICATION; S-PHASE; EXPRESSION; KINASE; PROLIFERATION; CARCINOMAS; ACTIVATION; INDUCTION	Cyclin E, a regulatory subunit of cyclin-dependent kinase 2 (Cdk2), is an important regulator of entry into S phase in the mammalian cell cycle. In normal dividing cells, cyclin E accumulates at the G(1)/S-phase boundary and is degraded as cells progress through S phase(1,2). However, in many human tumours cyclin E is overexpressed(3) and the levels of protein and kinase activity are often deregulated relative to the cell cycle(4-7). It is not understood how alterations in expression of cyclin E contribute to tumorigenesis. Here we show that constitutive cyclin-E overexpression in both immortalized rat embryo fibroblasts and human breast epithelial cells results in chromosome instability (CIN). In contrast, analogous expression of cyclin D1 or A does not increase the frequency of GIN. Cyclin-E-expressing cells that exhibit CIN have normal centrosome numbers. However, constitutive overexpression of cyclin E impairs S-phase progression, indicating that aberrant regulation of this process may be responsible for the CIN observed. These results indicate that downregulation of cyclin-E/Cdk2 kinase activity following the G(1)/S-phase transition may be necessary for the maintenance of karyotypic stability.	Scripps Res Inst, Dept Mol Biol, La Jolla, CA 92037 USA	Scripps Research Institute	Reed, SI (corresponding author), Scripps Res Inst, Dept Mol Biol, MB-7,10666 N Torrey Pines Rd, La Jolla, CA 92037 USA.							Bito T, 1997, J CUTAN PATHOL, V24, P305, DOI 10.1111/j.1600-0560.1997.tb00796.x; Bortner DM, 1997, MOL CELL BIOL, V17, P453, DOI 10.1128/MCB.17.1.453; Dou QP, 1996, NAT MED, V2, P254, DOI 10.1038/nm0396-254a; DULIC V, 1992, SCIENCE, V257, P1958, DOI 10.1126/science.1329201; DUTTA A, 1995, P NATL ACAD SCI USA, V92, P5386, DOI 10.1073/pnas.92.12.5386; ELBLE R, 1992, MOL BIOL CELL, V3, P971, DOI 10.1091/mbc.3.9.971; Erlanson M, 1998, BLOOD, V92, P770; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; Haas K, 1997, ONCOGENE, V15, P2615, DOI 10.1038/sj.onc.1201434; Hinchcliffe EH, 1999, SCIENCE, V283, P851, DOI 10.1126/science.283.5403.851; Hua XH, 1997, J CELL BIOL, V137, P183, DOI 10.1083/jcb.137.1.183; Keyomarsi K, 1997, Prog Cell Cycle Res, V3, P171; KEYOMARSI K, 1995, ONCOGENE, V11, P941; KOFF A, 1992, SCIENCE, V257, P1689, DOI 10.1126/science.1388288; Lacey KR, 1999, P NATL ACAD SCI USA, V96, P2817, DOI 10.1073/pnas.96.6.2817; Lengauer C, 1998, NATURE, V396, P643, DOI 10.1038/25292; Mumberg D, 1996, ONCOGENE, V13, P2493; Nielsen NH, 1998, ANAL CELL PATHOL, V17, P177, DOI 10.1155/1998/659712; Pihan GA, 1998, CANCER RES, V58, P3974; Porter PL, 1997, NAT MED, V3, P222, DOI 10.1038/nm0297-222; RESNITZKY D, 1995, MOL CELL BIOL, V15, P4347; RESNITZKY D, 1994, MOL CELL BIOL, V14, P1669, DOI 10.1128/MCB.14.3.1669; Sakaguchi T, 1998, CANCER-AM CANCER SOC, V82, P1238, DOI 10.1002/(SICI)1097-0142(19980401)82:7<1238::AID-CNCR5>3.0.CO;2-B; Simpson G.G., 1960, QUANTITATIVE ZOOLOGY; Walter J, 1998, MOL CELL, V1, P519, DOI 10.1016/S1097-2765(00)80052-0; Winey M, 1996, CURR BIOL, V6, P962, DOI 10.1016/S0960-9822(02)00639-5; Won KA, 1996, EMBO J, V15, P4182, DOI 10.1002/j.1460-2075.1996.tb00793.x; Xu XL, 1999, MOL CELL, V3, P389, DOI 10.1016/S1097-2765(00)80466-9	28	587	606	0	7	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	SEP 16	1999	401	6750					297	300		10.1038/45836	http://dx.doi.org/10.1038/45836			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	237VZ	10499591				2022-12-01	WOS:000082678400059
J	Lyons, RA; Sibert, J; McCabe, M				Lyons, RA; Sibert, J; McCabe, M			Sharing data to prevent injuries	BRITISH MEDICAL JOURNAL			English	Article									Iechyd Morgannwg Hlth, Swansea SA1 1LT, W Glam, Wales; Univ Wales Coll Med, Dept Child Hlth, Cardiff CF64 2XX, S Glam, Wales; Morriston Hosp, Swansea NHS Trust, Swansea SA6 6NL, W Glam, Wales	Cardiff University; Morriston Hospital	Lyons, RA (corresponding author), Iechyd Morgannwg Hlth, Swansea SA1 1LT, W Glam, Wales.		Lyons, Ronan/G-7741-2012	Lyons, Ronan/0000-0001-5225-000X				*DEP HLTH, 1998, OUR HLTH NAT CONTR H; Department of Health, 1992, HLTH NAT STRAT HLTH; Lyons R A, 1995, Inj Prev, V1, P173, DOI 10.1136/ip.1.3.173; *WELSH HLTH PLANN, 1992, PROT INV HLTH GAIN I; *WELSH HLTH PLANN, 1989, STRAT INT DIR NHS WA; Welsh Office, 1995, 1992 WELSH SOC SURV	6	6	6	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	AUG 7	1999	319	7206					372	373		10.1136/bmj.319.7206.372	http://dx.doi.org/10.1136/bmj.319.7206.372			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	226CA	10490321				2022-12-01	WOS:000082001700027
J	Wallin, KL; Wiklund, F; Angstrom, T; Bergman, F; Stendahl, U; Wadell, G; Hallmans, G; Dillner, J				Wallin, KL; Wiklund, F; Angstrom, T; Bergman, F; Stendahl, U; Wadell, G; Hallmans, G; Dillner, J			Type-specific persistence of human papillomavirus DNA before the development of invasive cervical cancer	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							POLYMERASE CHAIN-REACTION; SMEARS; WOMEN; INFECTION; PRIMERS; RISK	Background: Infection with the human papillomavirus (HPV) has been established as a cause of cervical cancer, but the association between a positive test for HPV DNA and the risk of the subsequent development of invasive cervical cancer is unknown. Methods: In a study of women who participated in a population-based screening program for cancer of the cervix in Sweden from 1969 to 1995, we compared the proportion of normal cervical smears (Pap smears) that were positive for HPV DNA among 118 women in whom invasive cervical cancer developed an average of 5.6 years later (range, 0.5 month to 26.2 years) with the proportion of HPV DNA-positive smears from 118 women who remained healthy during a similar length of follow-up (controls). The control women were matched for age to the women with cancer, and they had had two normal Pap smears obtained at time points that were similar to the times of the base-line smear and the diagnosis of cancer confirmed by biopsy in the women with cancer. Results: At base line, 35 of the women with cancer (30 percent) and 3 of the control women (3 percent) were positive for HPV DNA (odds ratio, 16.4; 95 percent confidence interval, 4.4 to 75.1). At the time of diagnosis, 80 of the 104 women with cancer for whom tissue samples were available (77 percent) and 4 of the 104 matched control women (4 percent) were positive for HPV DNA. The HPV DNA type was the same in the base-line smear and the biopsy specimen in all of the women with cancer in whom HPV DNA was detected at base line. None of the control women had the same type of HPV in both smears. Conclusions: A single positive finding of HPV DNA in a Pap smear confers an increased risk of future invasive cervical cancer that is positive for the same type of virus. (N Engl J Med 1999;341:1633-8.) (C) 1999, Massachusetts Medical Society.	Karolinska Inst, Ctr Microbiol & Tumor Biol, Lab Tumor Virus Epidemiol, S-17177 Stockholm, Sweden; Univ Hosp No Sweden, Ctr Oncol, Umea, Sweden; Univ Hosp No Sweden, Cytol Lab, Umea, Sweden; Univ Hosp No Sweden, Dept Pathol, Umea, Sweden; Univ Hosp No Sweden, Dept Oncol, Sect Gynecol, Umea, Sweden; Univ Hosp No Sweden, Dept Virol, Umea, Sweden; Univ Hosp No Sweden, Dept Publ Hlth & Clin Med, Med Bank, Umea, Sweden; Univ Tampere, Sch Publ Hlth, FIN-33101 Tampere, Finland	Karolinska Institutet; Umea University; Umea University; Umea University; Umea University; Umea University; Umea University; Tampere University	Wallin, KL (corresponding author), Karolinska Inst, Ctr Microbiol & Tumor Biol, Lab Tumor Virus Epidemiol, POB 280, S-17177 Stockholm, Sweden.							Chua KL, 1996, CANCER, V77, P121, DOI 10.1002/(SICI)1097-0142(19960101)77:1<121::AID-CNCR20>3.0.CO;2-6; CHUA KL, 1995, ANAL QUANT CYTOL, V17, P221; Chua KL, 1996, INT J CANCER, V68, P54, DOI 10.1002/(SICI)1097-0215(19960927)68:1<54::AID-IJC11>3.0.CO;2-6; EVANDER M, 1992, J CLIN MICROBIOL, V30, P987, DOI 10.1128/JCM.30.4.987-992.1992; EVANDER M, 1991, ARCH VIROL, V116, P221, DOI 10.1007/BF01319244; Ho GYF, 1998, NEW ENGL J MED, V338, P423, DOI 10.1056/NEJM199802123380703; HUSMAN AMDR, 1995, J GEN VIROL, V76, P1057; Jenkins D, 1996, INT J CANCER, V65, P768; MANOS MM, 1989, CANCER CEL, V7, P209; Meijer C J, 1992, IARC Sci Publ, P271; RHOADS DD, 1986, MOL CELL BIOL, V6, P2774, DOI 10.1128/MCB.6.8.2774; Rozendaal L, 1996, INT J CANCER, V68, P766, DOI 10.1002/(SICI)1097-0215(19961211)68:6<766::AID-IJC13>3.0.CO;2-Z; TANAKA H, 1993, CYTOPATHOLOGY, V4, P273, DOI 10.1111/j.1365-2303.1993.tb00102.x; vanBallegooijen M, 1997, BRIT J CANCER, V76, P651, DOI 10.1038/bjc.1997.440; WALBOOMERS JMM, 1995, J CLIN PATHOL, V48, P728, DOI 10.1136/jcp.48.8.728; ZURHAUSEN H, 1994, ANNU REV MICROBIOL, V48, P427, DOI 10.1146/annurev.micro.48.1.427	16	391	408	0	12	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	NOV 25	1999	341	22					1633	1638		10.1056/NEJM199911253412201	http://dx.doi.org/10.1056/NEJM199911253412201			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	258PL	10572150	Bronze			2022-12-01	WOS:000083847500001
J	Himsworth, RL; Goldacre, MJ				Himsworth, RL; Goldacre, MJ			Does time spent in hospital in the final 15 years of life increase with age at death? A population based study	BRITISH MEDICAL JOURNAL			English	Article							CARE		Univ Cambridge, Inst Publ Hlth, Cambridge CB2 2SR, England; Univ Oxford, Inst Hlth Sci, Unit Hlth Care Epidemiol, Oxford OX3 7LF, England	University of Cambridge; University of Oxford	Himsworth, RL (corresponding author), Univ Cambridge, Inst Publ Hlth, Cambridge CB2 2SR, England.							GOLDACRE MJ, 1988, BRIT MED J, V296, P583, DOI 10.1136/bmj.296.6621.583; HENDERSON J, 1990, BRIT MED J, V301, P17, DOI 10.1136/bmj.301.6742.17; vanWeel C, 1997, LANCET, V350, P1159, DOI 10.1016/S0140-6736(97)08312-8; Victor C R, 1994, Qual Health Care, V3, P210, DOI 10.1136/qshc.3.4.210	4	25	25	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	NOV 20	1999	319	7221					1338	1339		10.1136/bmj.319.7221.1338	http://dx.doi.org/10.1136/bmj.319.7221.1338			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	260CF	10567138	Green Published, Bronze			2022-12-01	WOS:000083930200025
J	White, O; Eisen, JA; Heidelberg, JF; Hickey, EK; Peterson, JD; Dodson, RJ; Haft, DH; Gwinn, ML; Nelson, WC; Richardson, DL; Moffat, KS; Qin, HY; Jiang, LX; Pamphile, W; Crosby, M; Shen, M; Vamathevan, JJ; Lam, P; McDonald, L; Utterback, T; Zalewski, C; Makarova, KS; Aravind, L; Daly, MJ; Minton, KW; Fleischmann, RD; Ketchum, KA; Nelson, KE; Salzberg, S; Smith, HO; Venter, JC; Fraser, CM				White, O; Eisen, JA; Heidelberg, JF; Hickey, EK; Peterson, JD; Dodson, RJ; Haft, DH; Gwinn, ML; Nelson, WC; Richardson, DL; Moffat, KS; Qin, HY; Jiang, LX; Pamphile, W; Crosby, M; Shen, M; Vamathevan, JJ; Lam, P; McDonald, L; Utterback, T; Zalewski, C; Makarova, KS; Aravind, L; Daly, MJ; Minton, KW; Fleischmann, RD; Ketchum, KA; Nelson, KE; Salzberg, S; Smith, HO; Venter, JC; Fraser, CM			Genome sequence of the radioresistant bacterium Deinococcus radiodurans R1	SCIENCE			English	Article							MICROCOCCUS-RADIODURANS; ESCHERICHIA-COLI; RADIATION-RESISTANT; IONIZING-RADIATION; GENUS DEINOCOCCUS; DNA-REPAIR; PROTEIN; IDENTIFICATION; MUTATION; THERMUS	The complete genome sequence of the radiation-resistant bacterium Deinococcus radiodurans R1 is composed of two chromosomes (2,648,638 and 412,348 base pairs), a megaplasmid (172,466 base pairs), and a small plasmid (45,704 base pairs), yielding a total genome of 3,284,156 base pairs. Multiple components distributed on the chromosomes and megaplasmid that contribute to the ability of D. radiodurans to survive under conditions of starvation, oxidative stress, and high amounts of DNA damage were identified. Deinococcus radiodurans represents an organism in which all systems for DNA repair, DNA damage export, desiccation and starvation recovery, and genetic redundancy are present in one cell.	Inst Genome Res, Rockville, MD 20850 USA; Natl Lib Med, Natl Ctr Biotechnol Informat, Bethesda, MD 20894 USA; Uniformed Serv Univ Hlth Sci, Dept Pathol, Bethesda, MD 20814 USA	J. Craig Venter Institute; National Institutes of Health (NIH) - USA; NIH National Library of Medicine (NLM); Uniformed Services University of the Health Sciences - USA	Fraser, CM (corresponding author), Inst Genome Res, 9712 Med Ctr Dr, Rockville, MD 20850 USA.		Salzberg, Steven L/F-6162-2011; Salzberg, Steven/Q-6514-2019; Eisen, Jonathan A./H-2706-2019; Nelson, William C/E-9263-2016	Salzberg, Steven L/0000-0002-8859-7432; Salzberg, Steven/0000-0002-8859-7432; Eisen, Jonathan A./0000-0002-0159-2197; Nelson, William C/0000-0002-1873-3929; Aravind, L/0000-0003-0771-253X; Fraser, Claire/0000-0003-1462-2428; Heidelberg, John/0000-0003-0673-3224; Vamathevan, Jessica/0000-0003-2016-9754	NATIONAL CANCER INSTITUTE [R01CA077712] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA077712] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Agostini HJ, 1996, J BACTERIOL, V178, P6759, DOI 10.1128/jb.178.23.6759-6765.1996; Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; ANDERSON AW, 1956, FOOD TECHNOL-CHICAGO, V10, P575; Battista JR, 1997, ANNU REV MICROBIOL, V51, P203, DOI 10.1146/annurev.micro.51.1.203; Bauche C, 1999, J BACTERIOL, V181, P262, DOI 10.1128/JB.181.1.262-269.1999; Bessman MJ, 1996, J BIOL CHEM, V271, P25059, DOI 10.1074/jbc.271.41.25059; BOLING ME, 1966, BIOCHIM BIOPHYS ACTA, V123, P26, DOI 10.1016/0005-2787(66)90155-9; COUNSELL TJ, 1986, INT J SYST BACTERIOL, V36, P202, DOI 10.1099/00207713-36-2-202; DALY MJ, 1994, J BACTERIOL, V176, P3508, DOI 10.1128/JB.176.12.3508-3517.1994; Eisen JA, 1995, J MOL EVOL, V41, P1105; EISEN JA, 1999, THESIS STANFORD U ST; Ferreira AC, 1997, INT J SYST BACTERIOL, V47, P939, DOI 10.1099/00207713-47-4-939; Furuya K, 1998, FEMS MICROBIOL LETT, V168, P243, DOI 10.1111/j.1574-6968.1998.tb13280.x; GUTMAN PD, 1993, J BACTERIOL, V175, P3581, DOI 10.1128/jb.175.11.3581-3590.1993; HENSEL R, 1986, INT J SYST BACTERIOL, V36, P444, DOI 10.1099/00207713-36-3-444; Kitayama S, 1997, MUTAT RES-DNA REPAIR, V385, P151, DOI 10.1016/S0921-8777(97)00048-7; Koonin EV, 1997, MOL MICROBIOL, V25, P619, DOI 10.1046/j.1365-2958.1997.4821861.x; Lawrence JG, 1997, J MOL EVOL, V44, P383, DOI 10.1007/PL00006158; Lin CS, 1998, BIOCHEM MOL BIOL INT, V45, P651; Markillie LM, 1999, J BACTERIOL, V181, P666, DOI 10.1128/JB.181.2.666-669.1999; MASTERS CI, 1991, J GEN MICROBIOL, V137, P1459, DOI 10.1099/00221287-137-7-1459; Mattimore V, 1996, J BACTERIOL, V178, P633, DOI 10.1128/jb.178.3.633-637.1996; MINTON KW, 1994, MOL MICROBIOL, V13, P9, DOI 10.1111/j.1365-2958.1994.tb00397.x; MITCHEL REJ, 1980, BIOCHIM BIOPHYS ACTA, V621, P138, DOI 10.1016/0005-2795(80)90069-0; MOSELEY BEB, 1983, J GEN MICROBIOL, V129, P2437; MUN C, 1994, RADIAT RES, V138, P282, DOI 10.2307/3578599; Nelson KE, 1999, NATURE, V399, P323, DOI 10.1038/20601; RILEY M, 1993, MICROBIOL REV, V57, P862, DOI 10.1128/MMBR.57.4.862-952.1993; Salzberg SL, 1998, NUCLEIC ACIDS RES, V26, P544, DOI 10.1093/nar/26.2.544; Salzberg SL, 1998, GENE, V217, P57, DOI 10.1016/S0378-1119(98)00374-6; Sandigursky M, 1999, CURR BIOL, V9, P531, DOI 10.1016/S0960-9822(99)80237-1; SETLOW JK, 1964, BIOCHIM BIOPHYS ACTA, V87, P664, DOI 10.1016/0926-6550(64)90284-1; SHARPLES GJ, 1995, MOL MICROBIOL, V17, P1215, DOI 10.1111/j.1365-2958.1995.mmi_17061215_1.x; SWEET DM, 1976, MUTAT RES, V34, P175, DOI 10.1016/0027-5107(76)90122-6; Tanaka A, 1996, RADIAT ENVIRON BIOPH, V35, P95, DOI 10.1007/s004110050015; TEMPEST PR, 1980, MOL GEN GENET, V179, P191, DOI 10.1007/BF00268463; TIRGARI S, 1980, J GEN MICROBIOL, V119, P287; UDUPA KS, 1994, J BACTERIOL, V176, P7439, DOI 10.1128/JB.176.24.7439-7446.1994; WEISBURG WG, 1989, SYST APPL MICROBIOL, V11, P128, DOI 10.1016/S0723-2020(89)80051-7; Wolf YI, 1999, GENOME RES, V9, P17; Wootton JC, 1996, METHOD ENZYMOL, V266, P554	41	757	1348	4	135	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 19	1999	286	5444					1571	1577		10.1126/science.286.5444.1571	http://dx.doi.org/10.1126/science.286.5444.1571			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	257DZ	10567266	Green Accepted			2022-12-01	WOS:000083768300062
J	Pianko, S; McHutchinson, J				Pianko, S; McHutchinson, J			Chronic hepatitis B: new therapies on the horizon?	LANCET			English	Editorial Material							LAMIVUDINE		Scripps Clin & Res Fdn, Div Gastroenterol & Hepatol, La Jolla, CA 92037 USA	Scripps Research Institute	Pianko, S (corresponding author), Scripps Clin & Res Fdn, Div Gastroenterol & Hepatol, 10666 N Torrey Pines Rd, La Jolla, CA 92037 USA.							Boni C, 1998, J CLIN INVEST, V102, P968, DOI 10.1172/JCI3731; CHISARI FV, 1995, ANNU REV IMMUNOL, V13, P29, DOI 10.1146/annurev.immunol.13.1.29; Couillin I, 1999, J INFECT DIS, V180, P15, DOI 10.1086/314828; Heathcote J, 1999, HEPATOLOGY, V30, P531, DOI 10.1002/hep.510300208; Kane MA, 1996, LANCET, V348, P696, DOI 10.1016/S0140-6736(05)65598-5; Lai CL, 1998, NEW ENGL J MED, V339, P61, DOI 10.1056/NEJM199807093390201; Liaw YF, 1999, HEPATOLOGY, V30, P567, DOI 10.1002/hep.510300221; Livingston BD, 1997, J IMMUNOL, V159, P1383; Niederau C, 1996, NEW ENGL J MED, V334, P1422, DOI 10.1056/NEJM199605303342202; Schiff E, 1998, HEPATOLOGY, V28, p388A; WONG DKH, 1993, ANN INTERN MED, V119, P312, DOI 10.7326/0003-4819-119-4-199308150-00011	11	10	12	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	NOV 13	1999	354	9191					1662	1663		10.1016/S0140-6736(99)00305-0	http://dx.doi.org/10.1016/S0140-6736(99)00305-0			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	255CW	10568564				2022-12-01	WOS:000083652800005
J	Dobson, A				Dobson, A			Is raised serum uric acid a cause of cardiovascular disease or death?	LANCET			English	Editorial Material							HEART-DISEASE; MORTALITY; RISK		Univ Newcastle, Dept Stat, Newcastle, NSW 2308, Australia	University of Newcastle	Dobson, A (corresponding author), Univ Newcastle, Dept Stat, Newcastle, NSW 2308, Australia.							Culleton BF, 1999, ANN INTERN MED, V131, P7, DOI 10.7326/0003-4819-131-1-199907060-00003; FREEDMAN DS, 1995, AM J EPIDEMIOL, V141, P637, DOI 10.1093/oxfordjournals.aje.a117479; HILL AB, 1965, P ROY SOC MED, V58, P295, DOI 10.1177/003591576505800503; LEVINE W, 1989, J CLIN EPIDEMIOL, V42, P257, DOI 10.1016/0895-4356(89)90061-9; LEVYA F, 1997, EUR HEART J, V18, P858; Neter J., 1990, APPL LINEAR STAT MOD; Newland H, 1975, Med Hypotheses, V1, P152, DOI 10.1016/0306-9877(75)90011-0; ROSE BD, 1994, CLIN PHYSL ACID BASE; TAUBES G, 1995, SCIENCE, V269, P164, DOI 10.1126/science.7618077; Wannamethee SG, 1997, HEART, V78, P147, DOI 10.1136/hrt.78.2.147; Ward HJ, 1998, LANCET, V352, P670, DOI 10.1016/S0140-6736(05)60816-1	11	35	36	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	NOV 6	1999	354	9190					1578	1578		10.1016/S0140-6736(99)00260-3	http://dx.doi.org/10.1016/S0140-6736(99)00260-3			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	253HM	10560670				2022-12-01	WOS:000083551000007
J	O'Connor, V; El Far, O; Bofill-Cardona, E; Nanoff, C; Freissmuth, M; Karschin, A; Airas, JM; Betz, H; Boehm, S				O'Connor, V; El Far, O; Bofill-Cardona, E; Nanoff, C; Freissmuth, M; Karschin, A; Airas, JM; Betz, H; Boehm, S			Calmodulin dependence of presynaptic metabotropic glutamate receptor signaling	SCIENCE			English	Article							HIPPOCAMPAL SYNAPSES; CALCIUM; PROTEIN; CHANNELS; INHIBITION; COMPLEX	Glutamatergic neurotransmission is controlled by presynaptic metabotropic glutamate receptors (mGluRs). A subdomain in the intracellular carboxyl-terminal tail of group III mGluRs binds calmodulin and heterotrimeric guanosine triphosphate-binding protein (G protein) beta gamma subunits in a mutually exclusive manner. Mutations interfering with calmodulin binding and calmodulin antagonists inhibit G protein-mediated modulation of ionic currents by mGluR 7. Calmodulin antagonists also prevent inhibition of excitatory neurotransmission via presynaptic mGluRs. These results reveal a novel mechanism of presynaptic modulation in which Ca2+-calmodulin is required to release G protein beta gamma subunits from the C-tail of group III mGluRs in order to mediate glutamatergic autoinhibition.	Max Planck Inst Brain Res, Dept Neurochem, D-60528 Frankfurt, Germany; Univ Vienna, Inst Pharmacol, A-1090 Vienna, Austria; Max Planck Inst Biophys Chem, D-37070 Gottingen, Germany	Max Planck Society; University of Vienna; Max Planck Society	Betz, H (corresponding author), Max Planck Inst Brain Res, Dept Neurochem, Deutschordenstr 46, D-60528 Frankfurt, Germany.		Far, Oussama El/D-4225-2017; EL FAR, Oussama/P-9915-2019	Far, Oussama El/0000-0002-7473-8345; EL FAR, Oussama/0000-0002-7473-8345; Freissmuth, Michael/0000-0001-9398-1765; Boehm, Stefan/0000-0002-0205-2459; nanoff, christian/0000-0002-8857-2470				BEKKERS JM, 1991, P NATL ACAD SCI USA, V88, P7834, DOI 10.1073/pnas.88.17.7834; Boehm S, 1997, J NEUROSCI, V17, P4066; Bradley SR, 1996, J NEUROSCI, V16, P2044; Bushell TJ, 1996, BRIT J PHARMACOL, V117, P1457, DOI 10.1111/j.1476-5381.1996.tb15306.x; CHAPMAN PF, 1995, NEURON, V14, P591, DOI 10.1016/0896-6273(95)90315-1; Conn PJ, 1997, ANNU REV PHARMACOL, V37, P205, DOI 10.1146/annurev.pharmtox.37.1.205; ELFAR O, UNPUB; Flor PJ, 1997, NEUROPHARMACOLOGY, V36, P153, DOI 10.1016/S0028-3908(96)00176-1; GIETZEN K, 1982, BIOCHEM J, V207, P541, DOI 10.1042/bj2070541; HINRICHSEN RD, 1993, BIOCHIM BIOPHYS ACTA, V1155, P277, DOI 10.1016/0304-419X(93)90010-A; Ikeda SR, 1996, NATURE, V380, P255, DOI 10.1038/380255a0; JAMES P, 1995, TRENDS BIOCHEM SCI, V20, P38, DOI 10.1016/S0968-0004(00)88949-5; JOCKERS R, 1994, J BIOL CHEM, V269, P32077; Lee A, 1999, NATURE, V399, P155, DOI 10.1038/20194; LEUNG PC, 1984, J BIOL CHEM, V259, P2742; MINKAMI R, 1997, J BIOL CHEM, V272, P20291; MUMBY SM, 1994, METHOD ENZYMOL, V237, P254; NANOFF C, 1995, MOL PHARMACOL, V48, P806; OCONNOR V, UNPUB; OKAMOTO N, 1994, J BIOL CHEM, V269, P1231; PELLEGRINI LL, 1995, EMBO J, V14, P4705, DOI 10.1002/j.1460-2075.1995.tb00152.x; PIN JP, 1995, CURR OPIN NEUROBIOL, V5, P342, DOI 10.1016/0959-4388(95)80047-6; Saugstad JA, 1997, MOL PHARMACOL, V51, P119, DOI 10.1124/mol.51.1.119; Scanziani M, 1997, NATURE, V385, P630, DOI 10.1038/385630a0; SCHOLZ KP, 1992, NEURON, V8, P1139, DOI 10.1016/0896-6273(92)90134-Y; Shigemoto R, 1996, NATURE, V381, P523, DOI 10.1038/381523a0; Thomas NK, 1996, NEUROPHARMACOLOGY, V35, P637; THOMPSON SM, 1993, TRENDS NEUROSCI, V16, P222, DOI 10.1016/0166-2236(93)90160-N; Wischmeyer E, 1997, MOL CELL NEUROSCI, V9, P194, DOI 10.1006/mcne.1997.0614; Xia XM, 1998, NATURE, V395, P503, DOI 10.1038/26758	30	134	136	0	7	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 5	1999	286	5442					1180	1184		10.1126/science.286.5442.1180	http://dx.doi.org/10.1126/science.286.5442.1180			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	253AJ	10550060	Green Submitted			2022-12-01	WOS:000083534200050
J	Cortez-Pinto, H; Chatham, J; Chacko, VP; Arnold, C; Rashid, A; Diehl, AM				Cortez-Pinto, H; Chatham, J; Chacko, VP; Arnold, C; Rashid, A; Diehl, AM			Alterations in liver ATP homeostasis in human nonalcoholic steatohepatitis - A pilot study	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							MAGNETIC-RESONANCE SPECTROSCOPY; DISEASE; PREVALENCE; METABOLISM; OBESITY; STEATOSIS	Context The mechanisms that drive progression from fatty liver to steatohepatitis and cirrhosis are unknown. In animal models, obese mice with fatty livers are vulnerable to liver adenosine triphosphate (ATP) depletion and necrosis, suggesting that altered hepatic energy homeostasis may be involved. Objective To determine ii patients with fatty liver disease exhibit impaired recovery from hepatic ATP depletion. Design Laboratory analysis of liver ATP stores monitored by nuclear magnetic resonance spectroscopy before and after transient hepatic ATP depletion was induced by fructose injection. The study was conducted between July 15 and August 30, 1998. Setting University hospital. Patients Eight consecutive adults with biopsy-proven nonalcoholic steatohepatitis and 7 healthy age- and sex-matched controls. Main Outcome Measure Level of ATP 1 hour after fructose infusion in patients vs controls. Results In patients, serum aminotransferase levels were increased (P = .02 vs controls); albumin and bilirubin values were normal and clinical evidence of portal hypertension was absent in both groups. However, 2 patients had moderate fibrosis and 1 had cirrhosis on liver biopsy. Mean serum glucose, cholesterol, and triglyceride levels were similar between groups but patients weighed significantly more than controls (P = .02). Liver ATP levels were similar in the 2 groups before fructose infusion and decreased similarly in both after fructose infusion (P = .01 vs initial ATP levels). However, controls replenished their hepatic ATP stores during the 1-hour follow-up period (P<.02 vs minimum ATP) but patients did not. Hence, patients' hepatic ATP levels were lower than those of controls at the end of the study (P = .04), Body mass index (BMI) correlated inversely with ATP recovery, even in controls (R = -0.768; P = .07), Although BMI was greater in patients than controls (P = .02) and correlated strongly with fatty liver and serum aminotransferase elevations, neither of the latter 2 parameters nor the histologic severity of fibrosis strongly predicted hepatic ATP recovery. Conclusions These data suggest that recovery from hepatic ATP depletion becomes progressively less efficient as body mass increases in healthy controls and is severely impaired in patients with obesity-related nonalcoholic steatohepatitis.	Johns Hopkins Univ, Sch Med, Dept Med, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Radiol, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Pathol, Baltimore, MD 21205 USA	Johns Hopkins University; Johns Hopkins University; Johns Hopkins University	Diehl, AM (corresponding author), Johns Hopkins Univ, Sch Med, Dept Med, 912 Ross Bldg,720 Rutland St, Baltimore, MD 21205 USA.	amdiehl@welchlink.welch.jhu.edu	Cortez-Pinto, Helena/A-3586-2012	Chatham, John/0000-0001-7180-9948				BACON BR, 1994, GASTROENTEROLOGY, V107, P1103, DOI 10.1016/0016-5085(94)90235-6; BELLENTANI S, 1994, HEPATOLOGY, V20, P1442, DOI 10.1002/hep.1840200611; Boesch C, 1997, MAGN RESON IMAGING, V15, P1067, DOI 10.1016/S0730-725X(97)00163-X; Boss O, 1998, EUR J ENDOCRINOL, V139, P1, DOI 10.1530/eje.0.1390001; Caldwell SH, 1999, HEPATOLOGY, V29, P664, DOI 10.1002/hep.510290347; Campfield LA, 1996, HORM METAB RES, V28, P619, DOI 10.1055/s-2007-979867; Chavin KD, 1999, J BIOL CHEM, V274, P5692, DOI 10.1074/jbc.274.9.5692; Czaja AJ, 1998, J HEPATOL, V29, P198, DOI 10.1016/S0168-8278(98)80004-4; ELHASSAN AY, 1992, BRIT J RADIOL, V65, P774, DOI 10.1259/0007-1285-65-777-774; Fleury C, 1997, NAT GENET, V15, P269, DOI 10.1038/ng0397-269; FRAHM J, 1989, MAGNET RESON MED, V9, P79, DOI 10.1002/mrm.1910090110; HODGSON M, 1991, BRIT J IND MED, V48, P690; ITURRIAGA H, 1988, AM J CLIN NUTR, V47, P235, DOI 10.1093/ajcn/47.2.235; LEE RG, 1989, HUM PATHOL, V20, P594, DOI 10.1016/0046-8177(89)90249-9; LEE RG, 1995, HEPATOLOGY, V21, P1742, DOI 10.1002/hep.1840210636; Lonardo A, 1997, ITAL J GASTROENTEROL, V29, P351; LUDWIG J, 1980, MAYO CLIN PROC, V55, P347; Naveau S, 1997, HEPATOLOGY, V25, P108, DOI 10.1002/hep.510250120; NOMURA H, 1988, JPN J MED, V27, P142, DOI 10.2169/internalmedicine1962.27.142; OBERHAENSLI RD, 1986, BRIT J RADIOL, V59, P695, DOI 10.1259/0007-1285-59-703-695; OKOLO P, 1998, SLEISENGER FORDTRANS, P1215; PELLEYMOUNTER MA, 1995, SCIENCE, V269, P540, DOI 10.1126/science.7624776; POWELL EE, 1990, HEPATOLOGY, V11, P74, DOI 10.1002/hep.1840110114; Sheth SG, 1997, ANN INTERN MED, V126, P137, DOI 10.7326/0003-4819-126-2-199701150-00008; TERRIER F, 1989, RADIOLOGY, V171, P557, DOI 10.1148/radiology.171.2.2704824; THALER H, 1975, CLIN GASTROENTEROL, V4, P273; WEISS RG, 1990, NEW ENGL J MED, V323, P1593, DOI 10.1056/NEJM199012063232304; Yang SQ, 1997, P NATL ACAD SCI USA, V94, P2557, DOI 10.1073/pnas.94.6.2557	28	361	373	0	10	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 3	1999	282	17					1659	1664		10.1001/jama.282.17.1659	http://dx.doi.org/10.1001/jama.282.17.1659			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	250BD	10553793	Bronze			2022-12-01	WOS:000083368400032
J	Watts, C; Kumaranayake, L				Watts, C; Kumaranayake, L			Thinking big: scaling-up HIV-1 interventions in sub-Saharan Africa	LANCET			English	Editorial Material									Univ London London Sch Hyg & Trop Med, Hlth Policy Unit, London WC1E 7HT, England	University of London; London School of Hygiene & Tropical Medicine	Watts, C (corresponding author), Univ London London Sch Hyg & Trop Med, Hlth Policy Unit, Keppel St, London WC1E 7HT, England.							KUMARANAYAKE L, 1998, COSTING GUIDELINES H; Osborne C M, 1997, AIDS, V11 Suppl B, pS135; *UNICEF, 1999, PROGR NAT; *WHO, 1999, WHO REP 1999; *WORLD BANK, 1997, CONFR AIDS PUBL PRIO	5	13	14	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	OCT 30	1999	354	9189					1492	1492		10.1016/S0140-6736(99)00365-7	http://dx.doi.org/10.1016/S0140-6736(99)00365-7			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	250WB	10551493				2022-12-01	WOS:000083411300007
J	Kobayashi, M; Furuya, H; Holland, PWH				Kobayashi, M; Furuya, H; Holland, PWH			Evolution - Dicyemids are higher animals	NATURE			English	Article							HOX		Univ Reading, Sch Anim & Microbial Sci, Reading RG6 6AJ, Berks, England; Kyoto Univ, Grad Sch Sci, Dept Zool, Kyoto 606, Japan; Osaka Univ, Dept Biol, Grad Sch Sci, Toyonaka, Osaka 560, Japan	University of Reading; Kyoto University; Osaka University	Kobayashi, M (corresponding author), Univ Reading, Sch Anim & Microbial Sci, Reading RG6 6AJ, Berks, England.			Holland, Peter/0000-0003-1533-9376				Aguinaldo AMA, 1997, NATURE, V387, P489, DOI 10.1038/387489a0; Bayascas JR, 1998, DEV GENES EVOL, V208, P467, DOI 10.1007/s004270050204; Brooke NM, 1998, NATURE, V392, P920, DOI 10.1038/31933; CAVALIERSMITH T, 1993, MICROBIOL REV, V57, P953, DOI 10.1128/MMBR.57.4.953-994.1993; de Rosa R, 1999, NATURE, V399, P772, DOI 10.1038/21631; KATAYAMA T, 1995, BIOL BULL-US, V189, P81, DOI 10.2307/1542458; Martinez DE, 1998, NATURE, V393, P748, DOI 10.1038/31616; STUNKARD HW, 1954, Q REV BIOL, V29, P230, DOI 10.1086/400243; van Beneden E., 1876, B ACAD R BELG, V41, P1160	9	66	67	0	11	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	OCT 21	1999	401	6755					762	762		10.1038/44513	http://dx.doi.org/10.1038/44513			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	250BG	10548100	Bronze			2022-12-01	WOS:000083368700041
J	Golubitsky, M; Stewart, I; Buono, PL; Collins, JJ				Golubitsky, M; Stewart, I; Buono, PL; Collins, JJ			Symmetry in locomotor central pattern generators and animal gaits	NATURE			English	Article							COUPLED OSCILLATORS; QUADRUPEDAL GAITS; TRANSITIONS; CHAINS	Animal locomotion is controlled, in part, by a central pattern generator (CPG), which is an intraspinal network of neurons capable of generating a rhythmic output(1-4). The spatio-temporal symmetries of the quadrupedal gaits walk, trot and pace(5-8) lead to plausible assumptions about the symmetries of locomotor CPGs(9-11). These assumptions imply that the CPG of a quadruped should consist of eight nominally identical subcircuits, arranged in an essentially unique matter. Here we apply analogous arguments to myriapod CPGs. Analyses based on symmetry applied to these networks lead to testable predictions, including a distinction between primary and secondary gaits, the existence of a new primary gait called 'jump', and the occurrence of half-integer wave numbers in myriapod gaits. For bipeds, our analysis also predicts two gaits with the out-of-phase symmetry of the walk and two gaits with the in-phase symmetry of the hop. We present data that support each of these predictions. This work suggests that symmetry can be used to infer a plausible dass of CPG network architectures from observed patterns of animal gaits.	Univ Houston, Dept Math, Houston, TX 77204 USA; Univ Warwick, Inst Math, Coventry CV4 7AL, W Midlands, England; Boston Univ, Dept Biomed Engn, Ctr Biodynam, Boston, MA 02215 USA	University of Houston System; University of Houston; University of Warwick; Boston University	Golubitsky, M (corresponding author), Univ Houston, Dept Math, Houston, TX 77204 USA.			Buono, Pietro-Luciano/0000-0003-1460-4465				Alexander R. M., 1977, MECH ENERGETICS ANIM, P168; ALEXANDER RM, 1983, J ZOOL, V201, P135, DOI 10.1111/j.1469-7998.1983.tb04266.x; BUONO PL, UNPUB J MATH BIOL; BUONO PL, 1998, THESIS U HOUSTON; COLLINS FS, 1993, HUM GENOME NEWS, V5, P3; COLLINS JJ, 1992, J MATH BIOL, V30, P827; COLLINS JJ, 1993, BIOL CYBERN, V68, P287, DOI 10.1007/BF00201854; COLLINS JJ, 1994, BIOL CYBERN, V71, P95, DOI 10.1007/BF00197312; DELCOMYN F, 1980, SCIENCE, V210, P492, DOI 10.1126/science.7423199; DEUEL NR, 1987, J BIOMECH, V20, P645, DOI 10.1016/0021-9290(87)90285-5; FULL RJ, 1991, J EXP BIOL, V158, P369; Gambaryan P.P., 1974, MAMMALS RUN ANATOMIC; Golubitsky M, 1998, PHYSICA D, V115, P56, DOI 10.1016/S0167-2789(97)00222-4; GOLUBITSKY M, 1988, SINGULARITIES GROUPS, V2, P275; HILDEBRA.M, 1965, SCIENCE, V150, P701, DOI 10.1126/science.150.3697.701; HILDEBRAND M, 1989, BIOSCIENCE, V39, P766, DOI 10.2307/1311182; Hildebrand M., 1976, NEURAL CONTROL LOCOM, P203, DOI DOI 10.1007/978-1-4757-0964-3_9; KOPELL N, 1990, SIAM J APPL MATH, V50, P1014, DOI 10.1137/0150062; KOPELL N, 1986, COMMUN PUR APPL MATH, V39, P623, DOI 10.1002/cpa.3160390504; Kopell N., 1988, MATH BIOSCI, V89, P14; LEACH DH, 1979, J EQUINE MED SURG, V3, P436; Mann R, 1982, DISORDERS OF THE FOO, P37; MANN RA, 1986, AM J SPORT MED, V14, P501, DOI 10.1177/036354658601400614; MANTON S. M., 1965, J LINN SOC LONDON ZOOL, V45, P251; SCHONER G, 1990, J THEOR BIOL, V142, P359, DOI 10.1016/S0022-5193(05)80558-2; SELVERSTON AI, 1980, BEHAV BRAIN SCI, V3, P535, DOI 10.1017/S0140525X00006580; SHIK ML, 1976, PHYSIOL REV, V56, P465, DOI 10.1152/physrev.1976.56.3.465	27	280	285	0	56	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	OCT 14	1999	401	6754					693	695		10.1038/44416	http://dx.doi.org/10.1038/44416			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	247EJ	10537106				2022-12-01	WOS:000083207400055
J	Serdula, MK; Mokdad, AH; Williamson, DF; Galuska, DA; Mendlein, JM; Heath, GW				Serdula, MK; Mokdad, AH; Williamson, DF; Galuska, DA; Mendlein, JM; Heath, GW			Prevalence of attempting weight loss and strategies for controlling weight	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							FAT-CONTENT; ADULTS; OVERWEIGHT; EXERCISE; WOMEN	Context Overweight and obesity are increasing in the United States. Changes in diet and physical activity are important for weight control. Objectives To examine the prevalence of attempting to lose or to maintain weight and to describe weight control strategies among US adults. Design The Behavioral Risk Factor Surveillance System, a random-digit telephone survey conducted in 1996 by state health departments. Setting The 49 states (and the District of Columbia) that participated in the survey. Participants Adults aged 18 years and older (N = 107 804). Main Outcome Measures Reported current weights and goal weights, prevalence of weight loss or maintenance attempts, and strategies used to control weight (eating fewer calories, eating less fat, or using physical activity) by population subgroup. Results The prevalence of attempting to lose and maintain weight was 28.8% and 35.1% among men and 43.6% and 34.4% among women, respectively. Among those attempting to lose weight, a common strategy was to consume less fat but not fewer calories (34.9% of men and 40.0% of women); only 21.5% of men and 19.4% of women reported using the recommended combination of eating fewer calories and engaging in at least 150 minutes of leisure-time physical activity per week. Among men trying to lose weight, the median weight was 90.4 kg with a goal weight of 81.4 kg. Among women, the median weight was 70.3 kg with a goal weight of 59.0 kg. Conclusions Weight loss and weight maintenance are common concerns for US men and women. Most persons trying to lose weight are not using the recommended combination of reducing calorie intake and engaging in leisure-time physical activity 150 minutes or more per week.	Ctr Dis Control & Prevent, Div Nutr & Phys Act, Chron Dis Nutr Branch, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30341 USA; Ctr Dis Control & Prevent, Div Diabet Translat, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30341 USA; Ctr Dis Control & Prevent, Div Adult & Community Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30341 USA	Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA	Serdula, MK (corresponding author), Ctr Dis Control & Prevent, Div Nutr & Phys Act, Chron Dis Nutr Branch, Natl Ctr Chron Dis Prevent & Hlth Promot, 4770 Buford Hwy NE,Mailstop K26, Atlanta, GA 30341 USA.		Heath, Gregory Wayne/AAE-2464-2020	Heath, Gregory Wayne/0000-0003-2864-5225				ALLRED JB, 1995, J AM DIET ASSOC, V95, P417, DOI 10.1016/S0002-8223(95)00111-5; Bouchard C, 1993, Obes Res, V1, P133; BROWNELL KD, 1995, INT J OBESITY, V19, pS122; CAPUTO FA, 1993, INT J OBESITY, V17, P237; *CDCP, 1997, MMWR-MORBID MORTAL W, V46, P199; CLELAND R, 1998, COMMERCIAL WEIGHT LO; HORM J, 1993, ANN INTERN MED, V119, P672, DOI 10.7326/0003-4819-119-7_Part_2-199310011-00009; JAKICIC JM, 1995, INT J OBESITY, V19, P893; JEFFERY RW, 1995, OBES RES, V3, pS283, DOI 10.1002/j.1550-8528.1995.tb00475.x; KING AC, 1991, SPORTS MED, V11, P331, DOI 10.2165/00007256-199111050-00004; KUCZMARSKI RJ, 1994, JAMA-J AM MED ASSOC, V272, P205, DOI 10.1001/jama.272.3.205; LEVY AS, 1993, ANN INTERN MED, V119, P661, DOI 10.7326/0003-4819-119-7_Part_2-199310011-00007; National Institutes of Health, 1998, CLIN GUID ID EV TREA; NELSON DE, 1998, P SECT SURV METH AM; Pronk N P, 1994, Obes Res, V2, P587; ROWLAND ML, 1990, AM J CLIN NUTR, V52, P1125, DOI 10.1093/ajcn/52.6.1125; SCHULMAN J, 1999, 16 ANN BRFSS C MAY 1; SERDULA MK, 1994, AM J PUBLIC HEALTH, V84, P1821, DOI 10.2105/AJPH.84.11.1821; SHAH BV, 1997, SUDAAN USERS MANUAL; SHIDE DJ, 1995, J AM DIET ASSOC, V95, P993, DOI 10.1016/S0002-8223(95)00273-1; US Department of Health and Human Services, 1996, PHYS ACT HLTH REP SU; [No title captured]	22	351	354	0	24	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 13	1999	282	14					1353	1358		10.1001/jama.282.14.1353	http://dx.doi.org/10.1001/jama.282.14.1353			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	243MB	10527182	Bronze			2022-12-01	WOS:000083000800030
J	Wilson, CL; Ouellette, AJ; Satchell, DP; Ayabe, T; Lopez-Boado, YS; Stratman, JL; Hultgren, SJ; Matrisian, LM; Parks, WC				Wilson, CL; Ouellette, AJ; Satchell, DP; Ayabe, T; Lopez-Boado, YS; Stratman, JL; Hultgren, SJ; Matrisian, LM; Parks, WC			Regulation of intestinal alpha-defensin activation by the metalloproteinase matrilysin in innate host defense	SCIENCE			English	Article							PANETH CELL DEFENSINS; ANTIMICROBIAL PEPTIDES; EPITHELIAL-CELLS; GENE-EXPRESSION; MOUSE; CRYPTDIN; PURIFICATION; VERTEBRATES; DEGRADATION; COMPONENTS	Precursors of alpha-defensin peptides require activation for bactericidal activity. In mouse small intestine, matrilysin colocalized with alpha-defensins (cryptdins) in Paneth cell granules, and in vitro it cleaved the pro segment from cryptdin precursors. Matrilysin-deficient (MAT(-/-)) mice Lacked mature cryptdins and accumulated precursor molecules. Intestinal peptide preparations from MAT(-/-) mice had decreased antimicrobial activity. Orally administered bacteria survived in greater numbers and were more virulent in MAT(-/-) mice than in MAT(+/+) mice Thus, matrilysin functions in intestinal mucosal defense by regulating the activity of defensins, which may be a common role for this metalloproteinase in its numerous epithelial sites of expression.	Washington Univ, Sch Med, Dept Pediat, Div Allergy & Pulm Med, St Louis, MO 63110 USA; Univ Calif Irvine, Coll Med, Dept Pathol, Irvine, CA 92697 USA; Univ Calif Irvine, Coll Med, Dept Microbiol & Mol Genet, Irvine, CA 92697 USA; Washington Univ, Sch Med, Dept Mol Microbiol & Microbial Pathogenesis, St Louis, MO 63110 USA; Vanderbilt Univ, Sch Med, Dept Cell Biol, Nashville, TN 37232 USA	Washington University (WUSTL); University of California System; University of California Irvine; University of California System; University of California Irvine; Washington University (WUSTL); Vanderbilt University	Wilson, CL (corresponding author), Washington Univ, Sch Med, Dept Pediat, Div Allergy & Pulm Med, St Louis, MO 63110 USA.		Parks, William C./AAH-6786-2021; Ayabe, Tokiyoshi/F-5264-2011	Ayabe, Tokiyoshi/0000-0002-8631-5593				AYABE T, UNPUB; BEVINS CL, 1994, CIBA F SYMP, V186, P250; CANOGAUCI DF, 1993, EXP CELL RES, V208, P344, DOI 10.1006/excr.1993.1255; Darmoul D, 1996, AM J PHYSIOL-GASTR L, V271, pG68, DOI 10.1152/ajpgi.1996.271.1.G68; EISENHAUER PB, 1992, INFECT IMMUN, V60, P3556, DOI 10.1128/IAI.60.9.3556-3565.1992; Gad S.C., 1989, PRINCIPLES METHODS T, P463; GANZ T, 1995, PHARMACOL THERAPEUT, V66, P191, DOI 10.1016/0163-7258(94)00076-F; GANZ T, 1990, EUR J HAEMATOL, V44, P1; Ganz T, 1998, CURR OPIN IMMUNOL, V10, P41, DOI 10.1016/S0952-7915(98)80029-0; Ganz T, 1997, SEMIN HEMATOL, V34, P343; GEARING AJH, 1994, NATURE, V370, P555, DOI 10.1038/370555a0; Grandjean V, 1997, BIOL REPROD, V57, P1115, DOI 10.1095/biolreprod57.5.1115; HULTGREN SJ, 1993, CELL, V73, P887, DOI 10.1016/0092-8674(93)90269-V; LOPEZBOADO YS, UNPUB; MARCOTTE PA, 1992, J BIOL CHEM, V267, P13803; MARTIN E, 1995, J LEUKOCYTE BIOL, V58, P128, DOI 10.1002/jlb.58.2.128; MIYAZAKI K, 1990, CANCER RES, V50, P7758; MURPHY G, 1991, BIOCHEM J, V277, P277, DOI 10.1042/bj2770277; OUELLETTE AJ, 1992, FEBS LETT, V304, P146, DOI 10.1016/0014-5793(92)80606-H; OUELLETTE AJ, 1994, INFECT IMMUN, V62, P5040, DOI 10.1128/IAI.62.11.5040-5047.1994; Ouellette AJ, 1996, FASEB J, V10, P1280, DOI 10.1096/fasebj.10.11.8836041; OUELLETTE AJ, 1989, J CELL BIOL, V108, P1687, DOI 10.1083/jcb.108.5.1687; Ouellette AJ, 1997, GASTROENTEROLOGY, V113, P1779, DOI 10.1053/gast.1997.v113.pm9352884; Quayle AJ, 1998, AM J PATHOL, V152, P1247; SATOH Y, 1995, GASTROENTEROLOGY, V108, P1345, DOI 10.1016/0016-5085(95)90681-9; SATOH Y, 1988, CELL TISSUE RES, V253, P397; SATOH Y, 1986, DIGESTION, V34, P115, DOI 10.1159/000199319; SATOH Y, 1988, CELL TISSUE RES, V251, P87, DOI 10.1007/BF00215451; Selsted M E, 1993, Genet Eng (N Y), V15, P131; SELSTED ME, 1986, ANAL BIOCHEM, V155, P270, DOI 10.1016/0003-2697(86)90436-7; SELSTED ME, 1992, J CELL BIOL, V118, P929, DOI 10.1083/jcb.118.4.929; SELSTED ME, 1989, J BIOL CHEM, V264, P4003; Shattuck-Brandt RL, 1999, MOL CARCINOGEN, V24, P177, DOI 10.1002/(SICI)1098-2744(199903)24:3<177::AID-MC4>3.0.CO;2-6; SIRI A, 1995, J BIOL CHEM, V270, P8650, DOI 10.1074/jbc.270.15.8650; SMITH MM, 1995, J BIOL CHEM, V270, P6440, DOI 10.1074/jbc.270.12.6440; Svinarich DM, 1997, AM J OBSTET GYNECOL, V176, P470, DOI 10.1016/S0002-9378(97)70517-9; Valore EV, 1996, J CLIN INVEST, V97, P1624, DOI 10.1172/JCI118588; WELKOS S, 1994, METHOD ENZYMOL, V235, P29; WILSON CL, 1995, MOL BIOL CELL, V6, P851, DOI 10.1091/mbc.6.7.851; Wilson CL, 1997, P NATL ACAD SCI USA, V94, P1402, DOI 10.1073/pnas.94.4.1402	40	870	902	1	24	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	OCT 1	1999	286	5437					113	117		10.1126/science.286.5437.113	http://dx.doi.org/10.1126/science.286.5437.113			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	241WT	10506557				2022-12-01	WOS:000082907400047
J	Cheng, CHC; Chen, LB				Cheng, CHC; Chen, LB			Evolution of an antifreeze glycoprotein	NATURE			English	Article									Univ Illinois, Dept Ecol Ethol & Evolut, Urbana, IL 61801 USA	University of Illinois System; University of Illinois Urbana-Champaign	Cheng, CHC (corresponding author), Univ Illinois, Dept Ecol Ethol & Evolut, Urbana, IL 61801 USA.			, liangbiao/0000-0002-0717-8536				Chen LB, 1997, P NATL ACAD SCI USA, V94, P3811, DOI 10.1073/pnas.94.8.3811; Chen LB, 1997, P NATL ACAD SCI USA, V94, P3817, DOI 10.1073/pnas.94.8.3817; Cheng Chi-Hing C., 1998, P311; CLARKE A, 1996, TRENDS ECOL EVOL, V11, P187; DEVRIES AL, 1982, COMP BIOCHEM PHYS A, V73, P627, DOI 10.1016/0300-9629(82)90270-5; Eastman JT., 1993, ANTARCTIC FISH BIOL; HSIAO KC, 1990, P NATL ACAD SCI USA, V87, P9265, DOI 10.1073/pnas.87.23.9265; LEVINSON G, 1987, MOL BIOL EVOL, V4, P203; LEWIN B, 1994, GENES, V5	9	110	122	1	56	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	SEP 30	1999	401	6752					443	444		10.1038/46721	http://dx.doi.org/10.1038/46721			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	243DF	10519545				2022-12-01	WOS:000082981200042
J	Truman, JW; Riddiford, LM				Truman, JW; Riddiford, LM			The origins of insect metamorphosis	NATURE			English	Article							COCKROACH NAUPHOETA-CINEREA; JUVENILE HORMONE-III; MANDUCA-SEXTA; EMBRYONIC-DEVELOPMENT; LOCUSTA-MIGRATORIA; ECDYSTEROID TITER; TOBACCO HORNWORM; PIONEER NEURONS; NERVOUS-SYSTEM; EMBRYOGENESIS	Insect metamorphosis is a fascinating and highly successful biological adaptation, but there is much uncertainty as to how it evolved. Ancestral insect species did not undergo metamorphosis and there are stilt some existing species that lack metamorphosis or undergo only partial metamorphosis. Based on endocrine studies and morphological comparisons of the development of insect species with and without metamorphosis, a novel hypothesis for the evolution of metamorphosis is proposed. changes in the endocrinology of development are central to this hypothesis The three stages of the ancestral insect species-pronymph, nymph and adult-are proposed to be equivalent to the larva, pupa and adult stages of insects with complete metamorphosis. This proposal has general implications far insect developmental biology.	Univ Washington, Dept Zool, Seattle, WA 98195 USA	University of Washington; University of Washington Seattle	Truman, JW (corresponding author), Univ Washington, Dept Zool, Box 351800, Seattle, WA 98195 USA.	jwt@u.washington.edu						Asahina S., 1954, MORPHOLOGICAL STUDY; AZAM KM, 1969, ANN ENTOMOL SOC AM, V62, P549, DOI 10.1093/aesa/62.3.549; BAKER FC, 1987, INSECT BIOCHEM, V17, P989, DOI 10.1016/0020-1790(87)90108-9; BATE CM, 1976, NATURE, V260, P54, DOI 10.1038/260054a0; Bergot B. J., 1981, JUVENILE HORMONE BIO, P33; Berlese A., 1913, Redia Firenze, V9; BERNAYS EA, 1971, Z MORPHOL TIERE, V70, P183; BOLLENBACHER WE, 1981, GEN COMP ENDOCR, V44, P302, DOI 10.1016/0016-6480(81)90005-8; BROADIE KS, 1991, ROUX ARCH DEV BIOL, V199, P327, DOI 10.1007/BF01705925; BRUNING E, 1985, INT J INVER REP DEV, V8, P269; BRYANT PJ, 1970, DEV BIOL, V22, P389, DOI 10.1016/0012-1606(70)90160-0; Campos-Ortega JA., 1997, EMBRYONIC DEV DROSOP; CARPENTER FM, 1992, ARTHROPODA R, V3, P1; CARROLL SB, 1995, NATURE, V376, P479, DOI 10.1038/376479a0; Champlin DT, 1998, DEVELOPMENT, V125, P2009; CORBET PHILIP S., 1955, ENT GAZ, V6, P189; Couso JP, 1998, INT J DEV BIOL, V42, P345; Dewitz, 1878, Z WISS ZOOL, V30, P78; DORN A, 1981, TISSUE CELL, V13, P461, DOI 10.1016/0040-8166(81)90019-7; DORN A, 1983, ENTOMOL GEN, V8, P193; Durston AJ, 1998, CURR TOP DEV BIOL, V40, P111, DOI 10.1016/S0070-2153(08)60366-X; EDWARDS JS, 1979, ROUX ARCH DEV BIOL, V186, P151, DOI 10.1007/BF00848176; FAIN MJ, 1975, BIOL BULL-US, V149, P506, DOI 10.2307/1540383; Grueber WB, 1999, J COMP NEUROL, V404, P127, DOI 10.1002/(SICI)1096-9861(19990201)404:1<127::AID-CNE10>3.0.CO;2-M; Heeley W, 1941, P ZOOL SOC LOND B-SY, V111, P79; Heming BS, 1996, CAN J ZOOL, V74, P1008, DOI 10.1139/z96-114; HINTON H. E., 1955, TRANS ROY ENT SOC LONDON, V106, P455; Hinton H. E., 1948, Transactions of the Royal Entomological Society of London, V99, P395; Hinton HE, 1981, BIOL INSECT EGGS, V1; IMBODEN H, 1978, GEN COMP ENDOCR, V36, P628, DOI 10.1016/0016-6480(78)90104-1; KARAWAIEW W, 1898, Z WISS ZOOL, V64, P385; KREMEN C, J INSECT PHYSL, V44, P287; KRISHNAN KN, 1975, INDIAN J TECHNOL, V13, P1; KUKALOVAPECK J, 1978, J MORPHOL, V156, P53, DOI 10.1002/jmor.1051560104; KURUSHIMA M, 1975, J INSECT PHYSIOL, V21, P1705, DOI 10.1016/0022-1910(75)90183-3; KUTSCH W, 1987, DEV BIOL, V123, P517, DOI 10.1016/0012-1606(87)90410-6; LAGUEUX M, 1979, J INSECT PHYSIOL, V25, P709, DOI 10.1016/0022-1910(79)90123-9; LAWRENCE JF, 1982, ANNU REV ECOL SYST, V13, P261, DOI 10.1146/annurev.es.13.110182.001401; Lindsay E., 1940, Proceedings of the Royal Society of Victoria N S, V52, P35; MEIER T, 1991, DEVELOPMENT, V112, P241; MERCER WF, 1900, NEW YORK ENTOMOL SOC, V8, P1; MEYER DR, 1980, J EXP ZOOL, V213, P185, DOI 10.1002/jez.1402130205; MICCIARELLI AS, 1977, ACTA EMBRYOL EXP, P295; Monsma SA, 1996, J COMP NEUROL, V367, P10, DOI 10.1002/(SICI)1096-9861(19960325)367:1<10::AID-CNE2>3.0.CO;2-M; Needham JG, 1935, BIOL MAYFLIES; NEUMANN D, 1991, J INSECT PHYSIOL, V37, P101, DOI 10.1016/0022-1910(91)90095-H; NIJHOUT H.F., 1994, INSECT HORMONES; NOVAK VJA, 1969, J EMBRYOL EXP MORPH, V21, P1; NOVAK VJA, 1975, INSECT HORMONES; Oberlander H., 1985, COMPREHENSIVE INSECT, V1st, P151; Powell P. B., 1904, J NY ENTOMOL SOC, V12, P237; Powell PB., 1905, J N Y ENTOMOL SOC, V13, P5; Poyarkoff E., 1914, Archives de Zoologie Paris, V54; PRATT HS, 1897, PSYCHE, V8, P15; QUENNEDEY A, 1990, TISSUE CELL, V22, P721, DOI 10.1016/0040-8166(90)90067-J; REDDY G, 1980, EXPERIENTIA, V36, P461, DOI 10.1007/BF01975148; RIDDIFOR.LM, 1967, P NATL ACAD SCI USA, V57, P595, DOI 10.1073/pnas.57.3.595; Riddiford L.M., 1972, P95; RIDDIFORD LM, 1994, ADV INSECT PHYSIOL, V24, P213, DOI 10.1016/S0065-2806(08)60084-3; RIDDIFORD LM, 1978, INSECT BIOCHEM, P307; ROHDENDORF EB, 1973, J INSECT PHYSIOL, V19, P37, DOI 10.1016/0022-1910(73)90220-5; SBRENNA G, 1991, MORPHOGENETIC HORMON, V3, P44; SBRENNAMICCIARE.A, 1972, J INSECT PHYSIOL, V18, P1027; SEHNAL F, 1985, COMPREHENSIVE INSECT, V2, P1; Sehnal Frantisek, 1996, P3, DOI 10.1016/B978-012283245-1/50003-8; SMITH RF, 1975, J INSECT PHYSIOL, V21, P723, DOI 10.1016/0022-1910(75)90004-9; SVACHA P, 1992, DEV BIOL, V154, P101, DOI 10.1016/0012-1606(92)90052-I; TEMIN G, 1986, INT J INVER REP DEV, V9, P105, DOI 10.1080/01688170.1986.10510184; Tiegs O. W., 1922, Transactions and Proceedings Royal Society South Australia, V46, P319; TOWER WL, 1903, ZOOL JB, V17, P515; van der Hammen L., 1989, INTRO COMP ARACHNOLO; VAUGHT GL, 1974, ANN ENTOMOL SOC AM, V67, P167, DOI 10.1093/aesa/67.2.167; WATSON JAL, 1967, BIOL BULL, V132, P277, DOI 10.2307/1539895; WEISMANN A, 1864, Z WISS ZOOL, V14, P101; Whiting MF, 1997, SYST BIOL, V46, P1, DOI 10.1093/sysbio/46.1.1; WIESMAN A, 1966, Z WISS ZOOL, V16, P1; Williams C.M., 1980, P369; ZACHARUK RY, 1991, ANNU REV ENTOMOL, V36, P331, DOI 10.1146/annurev.en.36.010191.001555	78	352	367	5	159	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	SEP 30	1999	401	6752					447	452		10.1038/46737	http://dx.doi.org/10.1038/46737			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	243DF	10519548				2022-12-01	WOS:000082981200047
J	Dunn, DE; Tanawattanacharoen, P; Boccuni, P; Nagakura, S; Green, SW; Kirby, MR; Kumar, MSA; Rosenfeld, S; Young, NS				Dunn, DE; Tanawattanacharoen, P; Boccuni, P; Nagakura, S; Green, SW; Kirby, MR; Kumar, MSA; Rosenfeld, S; Young, NS			Paroxysmal nocturnal hemoglobinuria cells in patients with bone marrow failure syndromes	ANNALS OF INTERNAL MEDICINE			English	Article							ACQUIRED APLASTIC-ANEMIA; MYELODYSPLASTIC SYNDROMES; FLOW-CYTOMETRY; MONOCLONAL-ANTIBODIES; ANCHORED PROTEINS; PATHOGENETIC LINK; PNH PHENOTYPE; DEFICIENCY; DIAGNOSIS; DISEASE	Background: Paroxysmal nocturnal hemoglobinuria (PNH) is an acquired hematopoietic stem-cell disorder in which the affected cells are deficient in glycosylphosphatidylinositol (GPI)-anchored proteins. Paroxysmal nocturnal hemoglobinuria is frequently associated with aplastic anemia, although the basis of this relation is unknown. Objective: To assess the PNH status of patients with diverse marrow failure syndromes. Design: Correlation of cytofluorometric data with clinical features. Setting: Hematology Branch, National Heart, Lung, and Blood Institute, Bethesda, Maryland. Patients: 115 patients with aplastic anemia, 39 patients with myelodysplasia, 28 patients who had recently undergone bone marrow transplantation, 18 patients with cancer that was treated with chemotherapy, 13 patients with large granular lymphocytosis, 20 controls who had received renal allografts, and 21 healthy participants. Intervention: Patients with aplastic anemia, myelodysplasia, or renal allografts received antithymocyte globulin. Measurements: Flow cytometry was used to assess expression of GPI-anchored proteins on granulocytes. Results: Evidence of PNH was found in 25 of 115 (22%) patients with aplastic anemia. No patient with normal CPI-anchored protein expression at presentation developed PNH after therapy (n = 16). Nine of 39 (23%) patients with myelodysplasia had CPI-anchored protein-deficient cells. Abnormal cells were not detected in patients with constitutional or other forms of bone marrow failure or in renal allograft recipients who had received antithymocyte globulin. Aplastic anemia is known to respond to immunosuppressive therapy; in myelodysplasia, the presence of a PNH population was strongly correlated with hematologic improvement after administration of antithymocyte globulin (P = 0.0015). Conclusions: Flow cytometric analysis is superior to the Ham test and permits concomitant diagnosis of PNH in about 20% of patients with myelodysplasia (a rate similar to that seen in patients with aplastic anemia). The presence of GPI-anchored protein-deficient cells in myelodysplasia predicts responsiveness to immunosuppressive therapy. Early emergence of GPI-anchored protein-deficient hematopoiesis in a patient with marrow failure may point to an underlying immune pathogenesis.	NHLBI, Bethesda, MD 20892 USA; MCP Hahnemann Univ Hosp, Philadelphia, PA USA	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); Drexel University	Dunn, DE (corresponding author), 309 E Osceola St,Suite 208, Stuart, FL 34994 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [Z01HL002315, ZIAHL002315] Funding Source: NIH RePORTER	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Alfinito F, 1996, LEUKEMIA, V10, P1326; Araten DJ, 1999, P NATL ACAD SCI USA, V96, P5209, DOI 10.1073/pnas.96.9.5209; Aul C, 1998, LEUKEMIA RES, V22, P93, DOI 10.1016/S0145-2126(97)00089-1; CONRAD ME, 1979, AM J HEMATOL, V7, P61, DOI 10.1002/ajh.2830070108; Doney K, 1997, ANN INTERN MED, V126, P107, DOI 10.7326/0003-4819-126-2-199701150-00003; Dunn DE, 1996, P NATL ACAD SCI USA, V93, P7938, DOI 10.1073/pnas.93.15.7938; Dunn DE, 1997, BLOOD, V90, P1811; GRAHAM DL, 1992, AM J MED, V93, P671, DOI 10.1016/0002-9343(92)90201-L; GRISCELLIBENNACEUR A, 1995, BLOOD, V85, P1354, DOI 10.1182/blood.V85.5.1354.bloodjournal8551354; Hall SE, 1996, BLOOD, V87, P5332, DOI 10.1182/blood.V87.12.5332.bloodjournal87125332; HERTENSTEIN B, 1995, BLOOD, V86, P1487, DOI 10.1182/blood.V86.4.1487.bloodjournal8641487; IWAMOTO N, 1995, BLOOD, V85, P2228, DOI 10.1182/blood.V85.8.2228.bloodjournal8582228; Iwanaga M, 1998, BRIT J HAEMATOL, V102, P465, DOI 10.1046/j.1365-2141.1998.00794.x; Jonasova A, 1998, BRIT J HAEMATOL, V100, P304, DOI 10.1046/j.1365-2141.1998.00551.x; Kawagoe K, 1996, BLOOD, V87, P3600, DOI 10.1182/blood.V87.9.3600.bloodjournal8793600; Kinoshita T, 1996, ANNU REV MED, V47, P1; LEWIS SM, 1967, BRIT J HAEMATOL, V13, P236, DOI 10.1111/j.1365-2141.1967.tb08736.x; LOUGHRAN TP, 1993, BLOOD, V82, P1; Luzzatto L, 1996, Curr Opin Hematol, V3, P101; Molldrem JJ, 1997, BRIT J HAEMATOL, V99, P699, DOI 10.1046/j.1365-2141.1997.4423249.x; Nagakura S, 1997, INT J HEMATOL, V65, P187; NAKAKUMA H, 1995, BLOOD, V85, P1371, DOI 10.1182/blood.V85.5.1371.bloodjournal8551371; NISSEN C, 1986, BRIT J HAEMATOL, V64, P355, DOI 10.1111/j.1365-2141.1986.tb04129.x; Parker MW, 1996, MOL MICROBIOL, V19, P205, DOI 10.1046/j.1365-2958.1996.355887.x; Raza A, 1996, LEUKEMIA, V10, P1648; ROSSE WF, 1995, BLOOD, V86, P3277, DOI 10.1182/blood.V86.9.3277.bloodjournal8693277; Rosse WF, 1997, MEDICINE, V76, P63, DOI 10.1097/00005792-199703000-00001; Rosti V, 1997, J CLIN INVEST, V100, P1028, DOI 10.1172/JCI119613; ROTOLI B, 1989, SEMIN HEMATOL, V26, P201; Rotoli B, 1989, Baillieres Clin Haematol, V2, P113, DOI 10.1016/S0950-3536(89)80010-1; SCHREZENMEIER H, 1995, EXP HEMATOL, V23, P81; SCHUBERT J, 1991, BRIT J HAEMATOL, V79, P487, DOI 10.1111/j.1365-2141.1991.tb08060.x; SHICHISHIMA T, 1993, BRIT J HAEMATOL, V85, P378, DOI 10.1111/j.1365-2141.1993.tb03182.x; SOCIE G, 1993, NEW ENGL J MED, V329, P1152, DOI 10.1056/NEJM199310143291603; TERSTAPPEN LWMM, 1992, J LEUKOCYTE BIOL, V52, P652, DOI 10.1002/jlb.52.6.652; VANDERSCHOOT CE, 1990, BLOOD, V76, P1853; VANKAMP H, 1994, BRIT J HAEMATOL, V87, P399, DOI 10.1111/j.1365-2141.1994.tb04929.x; WARE RE, 1991, NEW ENGL J MED, V325, P991, DOI 10.1056/NEJM199110033251403; Young NS, 1997, NEW ENGL J MED, V336, P1365, DOI 10.1056/NEJM199705083361906; Young NS, 1999, JAMA-J AM MED ASSOC, V282, P271, DOI 10.1001/jama.282.3.271; YOUNG NS, 1992, BLOOD, V79, P1385, DOI 10.1182/blood.V79.6.1385.bloodjournal7961385	41	210	219	1	5	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	SEP 21	1999	131	6					401	408		10.7326/0003-4819-131-6-199909210-00002	http://dx.doi.org/10.7326/0003-4819-131-6-199909210-00002			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	237DY	10498555				2022-12-01	WOS:000082641100001
J	Treasure, T				Treasure, T			Rethink on biological aortic valves for the elderly	LANCET			English	Editorial Material							HEART-VALVE		Univ London St Georges Hosp, Cardiothorac Unit, London SW17 0QT, England	St Georges University London	Treasure, T (corresponding author), Univ London St Georges Hosp, Cardiothorac Unit, London SW17 0QT, England.							BLOOMFIELD P, 1991, NEW ENGL J MED, V324, P573, DOI 10.1056/NEJM199102283240901; Bouma BJ, 1999, HEART, V82, P143, DOI 10.1136/hrt.82.2.143; Gilbert T, 1999, HEART, V82, P138, DOI 10.1136/hrt.82.2.138; HAMMERMEISTER KE, 1993, NEW ENGL J MED, V328, P1289, DOI 10.1056/NEJM199305063281801; HUYSMANS HA, 1999, STENTLESS BIOPROSTHE; Peterseim DS, 1999, J THORAC CARDIOV SUR, V117, P890, DOI 10.1016/S0022-5223(99)70368-5; Senthilnathan V, 1999, CARDIOVASC SURG, V7, P393, DOI 10.1016/S0967-2109(99)00026-5; TREASURE T, 1990, LANCET, V336, P1115, DOI 10.1016/0140-6736(90)92583-4; TREASURE T, 1995, CURR OPIN CARDIOL, V10, P144, DOI 10.1097/00001573-199503000-00008; *UK HEART VALV REG, 1999, UK HEART VALV REG RE	10	5	5	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	SEP 18	1999	354	9183					964	965		10.1016/S0140-6736(99)00198-1	http://dx.doi.org/10.1016/S0140-6736(99)00198-1			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	236JG	10501351				2022-12-01	WOS:000082596000002
J	Huang, ZJ; Kirkwood, A; Pizzorusso, T; Porciatti, V; Morales, B; Bear, MF; Maffei, L; Tonegawa, S				Huang, ZJ; Kirkwood, A; Pizzorusso, T; Porciatti, V; Morales, B; Bear, MF; Maffei, L; Tonegawa, S			BDNF regulates the maturation of inhibition and the critical period of plasticity in mouse visual cortex	CELL			English	Article							LONG-TERM POTENTIATION; GAMMA-AMINOBUTYRIC-ACID; NERVE GROWTH-FACTOR; DEVELOPING NEUROMUSCULAR SYNAPSES; EXPERIENCE-DEPENDENT PLASTICITY; NEUROTROPHIC FACTOR; MONOCULAR DEPRIVATION; SYNAPTIC PLASTICITY; MESSENGER-RNA; RAT-BRAIN	Maturation of the visual cortex is influenced by visual experience during an early postnatal period. The factors that regulate such a critical period remain unclear. We examined the maturation and plasticity of the visual cortex in transgenic mice in which the postnatal rise of brain-derived neurotrophic factor (BDNF) was accelerated. In these mice, the maturation of GABAergic innervation and inhibition was accelerated. Furthermore, the age-dependent decline of cortical longterm potentiation induced by white matter stimulation, a form of synaptic plasticity sensitive to cortical inhibition, occurred earlier. Finally, transgenic mice showed a precocious development of visual acuity and an earlier termination of the critical period for ocular dominance plasticity. We propose that BDNF promotes the maturation of cortical inhibition during early postnatal life, thereby regulating the critical period for visual cortical plasticity.	MIT, Howard Hughes Med Inst, Cambridge, MA 02139 USA; MIT, Ctr Learning & Memory, Dept Biol, Cambridge, MA 02139 USA; MIT, Dept Brain & Cognit Sci, Cambridge, MA 02139 USA; Johns Hopkins Univ, Zanvyl Krieger Mind Brain Inst, Baltimore, MD 21218 USA; CNR, Ist Neurofisiol, I-56127 Pisa, Italy; Scuola Normale Super Pisa, I-56127 Pisa, Italy; Brown Univ, Dept Neurosci, Providence, RI 02912 USA	Howard Hughes Medical Institute; Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT); Johns Hopkins University; Consiglio Nazionale delle Ricerche (CNR); Scuola Normale Superiore di Pisa; Brown University	Tonegawa, S (corresponding author), MIT, Howard Hughes Med Inst, Cambridge, MA 02139 USA.	tonegawa@mit.edu	Pizzorusso, Tommaso/D-1399-2013	Pizzorusso, Tommaso/0000-0001-5614-0668; Porciatti, Vittorio/0000-0002-1592-3532; Huang, Z. Josh/0000-0003-0592-028X; Bear, Mark/0000-0002-9903-2541	NATIONAL EYE INSTITUTE [R01EY012124] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS032925] Funding Source: NIH RePORTER; NEI NIH HHS [R01EY12124-01] Funding Source: Medline; NINDS NIH HHS [NS32925] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Akaneya Y, 1997, J NEUROSCI, V17, P6707; ARTOLA A, 1987, NATURE, V330, P649, DOI 10.1038/330649a0; BEAR MF, 1987, SCIENCE, V237, P42, DOI 10.1126/science.3037696; BENEVENTO LA, 1992, BRAIN RES, V572, P198, DOI 10.1016/0006-8993(92)90470-T; BENEVENTO LA, 1995, BRAIN RES, V689, P172, DOI 10.1016/0006-8993(95)00553-3; BIENENSTOCK EL, 1982, J NEUROSCI, V2, P32, DOI 10.1523/jneurosci.02-01-00032.1982; BIRCH D, 1979, VISION RES, V19, P933, DOI 10.1016/0042-6989(79)90029-4; BLOCHL A, 1995, EUR J NEUROSCI, V7, P1220, DOI 10.1111/j.1460-9568.1995.tb01112.x; BLUE ME, 1983, J NEUROCYTOL, V12, P697, DOI 10.1007/BF01181531; Bonhoeffer T, 1996, CURR OPIN NEUROBIOL, V6, P119, DOI 10.1016/S0959-4388(96)80017-1; BOOTHE RG, 1985, ANNU REV NEUROSCI, V8, P495, DOI 10.1146/annurev.ne.08.030185.002431; BOZZI Y, 1995, NEUROSCIENCE, V69, P1133, DOI 10.1016/0306-4522(95)00321-9; BURGIN KE, 1990, J NEUROSCI, V10, P1788; CABELLI RJ, 1995, SCIENCE, V267, P1662, DOI 10.1126/science.7886458; Cabelli RJ, 1997, NEURON, V19, P63, DOI 10.1016/S0896-6273(00)80348-7; CAMPBELL FW, 1965, J PHYSIOL-LONDON, V181, P576, DOI 10.1113/jphysiol.1965.sp007784; CARMIGNOTO G, 1993, J PHYSIOL-LONDON, V464, P343, DOI 10.1113/jphysiol.1993.sp019638; CARMIGNOTO G, 1992, SCIENCE, V258, P1007, DOI 10.1126/science.1279803; CASTREN E, 1992, P NATL ACAD SCI USA, V89, P9444, DOI 10.1073/pnas.89.20.9444; Cellerino A, 1996, EUR J NEUROSCI, V8, P1190, DOI 10.1111/j.1460-9568.1996.tb01287.x; COHENCORY S, 1995, NATURE, V378, P192, DOI 10.1038/378192a0; COHENCORY S, 1991, J NEUROSCI, V11, P462; COLLAZO D, 1992, NEURON, V9, P643, DOI 10.1016/0896-6273(92)90028-C; CYNADER M, 1980, J NEUROPHYSIOL, V43, P1026, DOI 10.1152/jn.1980.43.4.1026; DELRIO JA, 1994, DEV BRAIN RES, V81, P247, DOI 10.1016/0165-3806(94)90311-5; DELRIO JA, 1992, J COMP NEUROL, V326, P501, DOI 10.1002/cne.903260403; DIAMOND J, 1992, J NEUROSCI, V12, P1454; DRAGER UC, 1975, J COMP NEUROL, V160, P269, DOI 10.1002/cne.901600302; DRAGER UC, 1980, J COMP NEUROL, V191, P383, DOI 10.1002/cne.901910306; Dupuy ST, 1996, J NEUROSCI, V16, P6919; ERNFORS P, 1994, NATURE, V368, P147, DOI 10.1038/368147a0; ESCLAPEZ M, 1994, J NEUROSCI, V14, P1834, DOI 10.1523/JNEUROSCI.14-03-01834.1994; FAGIOLINI M, 1994, VISION RES, V34, P709, DOI 10.1016/0042-6989(94)90210-0; Figurov A, 1996, NATURE, V381, P706, DOI 10.1038/381706a0; FREEMAN DN, 1975, NATURE, V254, P614, DOI 10.1038/254614a0; Galuske RAW, 1996, EUR J NEUROSCI, V8, P1554, DOI 10.1111/j.1460-9568.1996.tb01618.x; GHOSH A, 1995, NEURON, V15, P89, DOI 10.1016/0896-6273(95)90067-5; Gianfranceschi L, 1999, VISION RES, V39, P569, DOI 10.1016/S0042-6989(98)00169-2; Gonchar Y, 1997, CEREB CORTEX, V7, P347, DOI 10.1093/cercor/7.4.347; GOODMAN CS, 1993, CELL, V72, P77, DOI 10.1016/S0092-8674(05)80030-3; Gorba T, 1999, EUR J NEUROSCI, V11, P1179, DOI 10.1046/j.1460-9568.1999.00551.x; Gordon JA, 1996, J NEUROSCI, V16, P3274; HATA Y, 1994, SCIENCE, V265, P1732, DOI 10.1126/science.8085163; Hensch TK, 1998, SCIENCE, V282, P1504, DOI 10.1126/science.282.5393.1504; HICKS TP, 1983, BRAIN RES, V274, P160, DOI 10.1016/0006-8993(83)90533-4; Huber KM, 1998, NEUROPHARMACOLOGY, V37, P571, DOI 10.1016/S0028-3908(98)00050-1; IP NY, 1993, J NEUROSCI, V13, P3394; ISACKSON PJ, 1991, NEURON, V6, P937, DOI 10.1016/0896-6273(91)90234-Q; JONES KR, 1994, CELL, V76, P989, DOI 10.1016/0092-8674(94)90377-8; KANG HJ, 1995, SCIENCE, V267, P1658, DOI 10.1126/science.7886457; KATO N, 1991, DEV BRAIN RES, V60, P43, DOI 10.1016/0165-3806(91)90153-A; Katz LC, 1996, SCIENCE, V274, P1133, DOI 10.1126/science.274.5290.1133; Kirkwood A, 1997, P NATL ACAD SCI USA, V94, P3380, DOI 10.1073/pnas.94.7.3380; KIRKWOOD A, 1994, J NEUROSCI, V14, P1634, DOI 10.1523/JNEUROSCI.14-03-01634.1994; KIRKWOOD A, 1995, NATURE, V375, P328, DOI 10.1038/375328a0; KOMATSU Y, 1983, DEV BRAIN RES, V8, P136, DOI 10.1016/0165-3806(83)90165-7; Liu XB, 1996, P NATL ACAD SCI USA, V93, P7332, DOI 10.1073/pnas.93.14.7332; LO DC, 1995, NEURON, V15, P979, DOI 10.1016/0896-6273(95)90085-3; LOHOF AM, 1993, NATURE, V363, P350, DOI 10.1038/363350a0; LUHMANN HJ, 1991, J NEUROPHYSIOL, V65, P247, DOI 10.1152/jn.1991.65.2.247; MAFFEI L, 1992, J NEUROSCI, V12, P4651; MARTIN DL, 1993, J NEUROCHEM, V60, P395, DOI 10.1111/j.1471-4159.1993.tb03165.x; Marty S, 1997, TRENDS NEUROSCI, V20, P198, DOI 10.1016/S0166-2236(96)01026-0; Marty S, 1996, J NEUROSCI, V16, P675; MAYFORD M, 1995, CELL, V81, P891, DOI 10.1016/0092-8674(95)90009-8; MCALLISTER AK, 1995, NEURON, V15, P791, DOI 10.1016/0896-6273(95)90171-X; Micheva KD, 1997, CAN J PHYSIOL PHARM, V75, P470, DOI 10.1139/cjpp-75-5-470; MOWER GD, 1991, DEV BRAIN RES, V58, P151, DOI 10.1016/0165-3806(91)90001-Y; NAWA H, 1994, J NEUROSCI, V14, P3751; PATTERSON SL, 1992, NEURON, V9, P1081, DOI 10.1016/0896-6273(92)90067-N; PERKINS AT, 1988, BRAIN RES, V439, P222; PORCIATTI V, 1999, IN PRESS VISION RES; REETZ A, 1991, EMBO J, V10, P1275, DOI 10.1002/j.1460-2075.1991.tb08069.x; REITER HO, 1988, P NATL ACAD SCI USA, V85, P3623, DOI 10.1073/pnas.85.10.3623; RIDDLE DR, 1995, NATURE, V378, P189, DOI 10.1038/378189a0; Rutherford LC, 1998, NEURON, V21, P521, DOI 10.1016/S0896-6273(00)80563-2; Rutherford LC, 1997, J NEUROSCI, V17, P4527; Sambrook J., 1989, MOL CLONING LAB MANU, V3; SHENG M, 1994, NATURE, V368, P144, DOI 10.1038/368144a0; SHI YG, 1994, J CELL BIOL, V124, P927, DOI 10.1083/jcb.124.6.927; SILLITO AM, 1979, J PHYSIOL-LONDON, V289, P33, DOI 10.1113/jphysiol.1979.sp012723; THOENEN H, 1995, SCIENCE, V270, P593, DOI 10.1126/science.270.5236.593; WANG T, 1995, J NEUROSCI, V15, P4796; WIDMER HR, 1994, DEV BRAIN RES, V80, P279, DOI 10.1016/0165-3806(94)90114-7; WOLFF JR, 1984, NEUROSCI LETT, V47, P207, DOI 10.1016/0304-3940(84)90515-9; Yan Q, 1997, NEUROSCIENCE, V78, P431, DOI 10.1016/S0306-4522(96)00613-6	86	893	901	2	56	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	SEP 17	1999	98	6					739	755		10.1016/S0092-8674(00)81509-3	http://dx.doi.org/10.1016/S0092-8674(00)81509-3			17	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	237WH	10499792	Bronze			2022-12-01	WOS:000082679200002
J	Schutzer, SE; Coyle, PK; Reid, P; Holland, B				Schutzer, SE; Coyle, PK; Reid, P; Holland, B			Borrelia burgdorferi-specific immune complexes in acute Lyme disease	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							SURFACE PROTEIN-A; CEREBROSPINAL-FLUID; OSPA; DIAGNOSIS; ANTIBODY; VACCINE	Context Diagnosis of infection with Borrelia burgdorferi, the cause of Lyme disease (LD), has been impeded by the lack of effective assays to detect active infection. Objective To determine whether B burgdorferi-specific immune complexes are detectable during active infection in LD. Design, Setting, and Patients Cross-sectional analysis of serum samples from 168 patients fulfilling Centers for Disease Control and Prevention surveillance criteria for LD and 145 healthy and other disease controls conducted over 8 years. Tests were performed blinded. Main Outcome Measure Detection of B burgdorferi immune complexes by enzyme-linked immunosorbent assay and Western blot. Results The B burgdorferi immune complexes were found in 25 of 26 patients with early seronegative erythema migrans (EM) LD; 105 of 107 patients with seropositive EM LD; 6 of 10 patients who were seronegative with culture-positive EM; 0 of 12 patients who were treated and recovered from LD; and 13 of 13 patients with neurologic LD without EM. Among 147 controls, B burgdorferi immune complex was found in 0 of 50 healthy individuals; 0 of 40 patients with persistent fatigue; 0 of 7 individuals with frequent tick exposure; and 2 of 50 patients with other diseases. Conclusion These data suggest that B burgdorferi immune complex formation is a common process in active LD. Analysis of the B burgdorferi immune complexes by a simple technique has the potential to support or exclude a diagnosis of early as well as active LD infection.	Univ Med & Dent New Jersey, New Jersey Med Sch, Dept Med, Div Allergy & Immunol, Newark, NJ 07103 USA; Univ Med & Dent New Jersey, New Jersey Med Sch, Dept Prevent Med, Newark, NJ 07103 USA; SUNY Stony Brook, Dept Neurol, Stony Brook, NY 11794 USA	Rutgers State University New Brunswick; Rutgers State University Medical Center; Rutgers State University New Brunswick; Rutgers State University Medical Center; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook	Schutzer, SE (corresponding author), Univ Med & Dent New Jersey, New Jersey Med Sch, Dept Med, Div Allergy & Immunol, 1855 S Orange Ave, Newark, NJ 07103 USA.				NIAID NIH HHS [AI31561] Funding Source: Medline; NIAMS NIH HHS [AR41518] Funding Source: Medline; NINDS NIH HHS [NS34092] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI031561] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR041518] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P01NS034092] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BAKKEN LL, 1992, JAMA-J AM MED ASSOC, V268, P891, DOI 10.1001/jama.268.7.891; BENACH JL, 1983, NEW ENGL J MED, V308, P740, DOI 10.1056/NEJM198303313081302; *CDCP, 1997, MMWR-MORBID MORTAL W, V46, P531; Center for Disease Control and Prevention, 1995, MMWR-MORBID MORTAL W, V44, P590; Centers for Disease Control and Prevention, 1997, MMWR-MORBID MORTAL W, V46, P1; COYLE PK, 1990, ANN NEUROL, V28, P739, DOI 10.1002/ana.410280603; DATTWYLER RJ, 1988, NEW ENGL J MED, V319, P1441, DOI 10.1056/NEJM198812013192203; DIGEON M, 1977, J IMMUNOL METHODS, V16, P165, DOI 10.1016/0022-1759(77)90051-5; DOBSON SRM, 1988, J INFECT DIS, V158, P940, DOI 10.1093/infdis/158.5.940; Dunn J J, 1990, Protein Expr Purif, V1, P159, DOI 10.1016/1046-5928(90)90011-M; Fikrig E, 1997, IMMUNITY, V6, P531, DOI 10.1016/S1074-7613(00)80341-6; FIKRIG E, 1992, J INFECT DIS, V165, P1127, DOI 10.1093/infdis/165.6.1127; INMAN RD, 1982, J CLIN INVEST, V70, P271, DOI 10.1172/JCI110614; JONES VE, 1981, J IMMUNOL METHODS, V44, P249, DOI 10.1016/0022-1759(81)90045-4; RAHN DW, 1991, ANN INTERN MED, V114, P472, DOI 10.7326/0003-4819-114-6-472; RYS PN, 1993, J CLIN MICROBIOL, V31, P2356, DOI 10.1128/JCM.31.9.2356-2360.1993; Schutzer SE, 1997, J CLIN INVEST, V100, P763, DOI 10.1172/JCI119589; SCHUTZER SE, 1990, LANCET, V335, P312, DOI 10.1016/0140-6736(90)90606-6; SCHUTZER SE, 1994, J CLIN INVEST, V94, P454, DOI 10.1172/JCI117346; Schutzer SE, 1997, NEW ENGL J MED, V337, P794, DOI 10.1056/NEJM199709113371118; Sigal LH, 1998, NEW ENGL J MED, V339, P216, DOI 10.1056/NEJM199807233390402; STEERE AC, 1989, NEW ENGL J MED, V321, P586, DOI 10.1056/NEJM198908313210906; Steere AC, 1998, NEW ENGL J MED, V339, P209, DOI 10.1056/NEJM199807233390401; THEOFILOPOULOS AN, 1980, AM J PATHOL, V100, P529	24	41	42	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 24	1999	282	20					1942	1946		10.1001/jama.282.20.1942	http://dx.doi.org/10.1001/jama.282.20.1942			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	257BZ	10580460				2022-12-01	WOS:000083763400029
J	Barasch, J; Yang, J; Ware, CB; Taga, T; Yoshida, K; Erdjument-Bromage, H; Tempst, P; Parravicini, E; Malach, S; Aranoff, T; Oliver, JA				Barasch, J; Yang, J; Ware, CB; Taga, T; Yoshida, K; Erdjument-Bromage, H; Tempst, P; Parravicini, E; Malach, S; Aranoff, T; Oliver, JA			Mesenchymal to epithelial conversion in rat metanephros is induced by LIF	CELL			English	Article							LEUKEMIA INHIBITORY FACTOR; ADHESION MOLECULE UVOMORULIN; IL-6 SIGNAL TRANSDUCER; GROWTH-FACTOR; EMBRYONIC KIDNEY; MOUSE KIDNEY; TARGETED DISRUPTION; TYROSINE KINASE; NERVOUS-SYSTEM; ORGAN-CULTURE	Inductive signals cause conversion of mesenchyme into epithelia during the formation of many organs. Yet a century of study has not revealed the inducing molecules. Using a standard model of induction, we found that ureteric bud cells secrete factors that convert kidney mesenchyme to epithelia that, remarkably, then form nephrons. Purification and sequencing of one such factor identified it as leukemia inhibitory factor (LIF). LIF acted on epithelial precursors that we identified by the expression of Pax2 and Wnt4. Other IL-6 type cytokines acted like LIF, and deletion of their shared receptor reduced nephron development. In situ, the ureteric bud expressed LIF, and metanephric mesenchyme expressed its receptors. The data suggest that IL-6 cytokines are candidate regulators of mesenchymal to epithelial conversion during kidney development.	Columbia Univ Coll Phys & Surg, Dept Med, New York, NY 10032 USA; Columbia Univ Coll Phys & Surg, Dept Pediat, New York, NY 10032 USA; Univ Washington, Sch Med, Dept Comparat Med, Seattle, WA 98195 USA; Tokyo Med & Dent Univ, Dept Mol Cell Biol, Chiyoda Ku, Tokyo 1010062, Japan; Osaka Univ, Dept Mol Immunol, Suita, Osaka 5650871, Japan; Mem Sloan Kettering Canc Ctr, Program Mol Biol, New York, NY 10021 USA	Columbia University; Columbia University; University of Washington; University of Washington Seattle; Tokyo Medical & Dental University (TMDU); Osaka University; Memorial Sloan Kettering Cancer Center	Barasch, J (corresponding author), Columbia Univ Coll Phys & Surg, Dept Med, 630 W 168th St, New York, NY 10032 USA.			Malach, Stephen/0000-0002-2771-4957; Erdjument-Bromage, Hediye/0000-0003-0224-3594				ABRAHAMSON DR, 1991, SEMIN NEPHROL, V11, P375; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; ARMSTRONG JF, 1992, MECH DEVELOP, V40, P85; AVNER ED, 1985, IN VITRO CELL DEV B, V21, P297; Barasch J, 1997, AM J PHYSIOL-RENAL, V273, pF757, DOI 10.1152/ajprenal.1997.273.5.F757; Barasch J, 1996, AM J PHYSIOL-RENAL, V271, pF50, DOI 10.1152/ajprenal.1996.271.1.F50; Barasch J, 1999, J CLIN INVEST, V103, P1299, DOI 10.1172/JCI4586; BARD JBL, 1991, DEVELOPMENT, V113, P193; Boccaccio C, 1998, NATURE, V391, P285, DOI 10.1038/34657; Bonni A, 1997, SCIENCE, V278, P477, DOI 10.1126/science.278.5337.477; Boyden EA, 1927, P SOC EXP BIOL MED, V24, P572; Cho EA, 1998, DEVELOPMENT, V125, P803; Dudley AT, 1999, GENE DEV, V13, P1601, DOI 10.1101/gad.13.12.1601; EKBLOM P, 1981, J CELL BIOL, V89, P276, DOI 10.1083/jcb.89.2.276; EKBLOM P, 1989, FASEB J, V3, P2141, DOI 10.1096/fasebj.3.10.2666230; EKBLOM P, 1981, J CELL BIOL, V91, P1, DOI 10.1083/jcb.91.1.1; EKBLOM P, 1983, P NATL ACAD SCI-BIOL, V80, P2651, DOI 10.1073/pnas.80.9.2651; ELICONE C, 1994, J CHROMATOGR A, V676, P121, DOI 10.1016/0021-9673(94)00089-1; Erdjument-Bromage H, 1998, J CHROMATOGR A, V826, P167, DOI 10.1016/S0021-9673(98)00705-5; GEARING DP, 1992, SCIENCE, V255, P1434, DOI 10.1126/science.1542794; GEARING DP, 1991, EMBO J, V10, P2839, DOI 10.1002/j.1460-2075.1991.tb07833.x; Gilbert T, 1996, KIDNEY INT, V50, P783, DOI 10.1038/ki.1996.377; GROBSTEIN C, 1955, J EXP ZOOL, V130, P319, DOI 10.1002/jez.1401300207; Gruenwald P, 1943, ANAT REC, V86, P321, DOI 10.1002/ar.1090860303; Hara T, 1998, DEV BIOL, V201, P144, DOI 10.1006/dbio.1998.8990; HERZLINGER D, 1992, DEVELOPMENT, V114, P565; HERZLINGER D, 1994, DEV BIOL, V166, P815, DOI 10.1006/dbio.1994.1360; HOLTHOFER H, 1984, LAB INVEST, V50, P552; IP NY, 1992, CELL, V69, P1121, DOI 10.1016/0092-8674(92)90634-O; Karavanova ID, 1996, DEVELOPMENT, V122, P4159; Kispert A, 1998, DEVELOPMENT, V125, P4225; Kispert A, 1996, DEVELOPMENT, V122, P3627; KLEIN G, 1988, DEVELOPMENT, V102, P749; KOSEKI C, 1992, J CELL BIOL, V119, P1327, DOI 10.1083/jcb.119.5.1327; Laitinen L, 1987, J HISTOCHEM CYTOCHEM, V35, P55, DOI 10.1177/35.1.3794309; LEHTONEN E, 1985, DEV BIOL, V108, P481, DOI 10.1016/0012-1606(85)90051-X; LEVINE E, 1994, DEVELOPMENT, V120, P901; LIEM KF, 1995, CELL, V82, P969, DOI 10.1016/0092-8674(95)90276-7; Lindahl P, 1998, DEVELOPMENT, V125, P3313; Lui M, 1996, ANAL BIOCHEM, V241, P156, DOI 10.1006/abio.1996.0393; MAYER M, 1994, DEVELOPMENT, V120, P143; MCNEILL H, 1990, CELL, V62, P309, DOI 10.1016/0092-8674(90)90368-O; METCALF D, 1988, LEUKEMIA, V2, P216; MURPHY M, 1993, DEVELOPMENT, V117, P1173; MURPHY M, 1991, P NATL ACAD SCI USA, V88, P3498, DOI 10.1073/pnas.88.8.3498; MURPHY M, 1994, DEVELOPMENT, V120, P3519; Nakashima K, 1999, SCIENCE, V284, P479, DOI 10.1126/science.284.5413.479; NORDLING S, 1971, J EMBRYOL EXP MORPH, V26, P231; PARTANEN AM, 1987, DEV BIOL, V120, P186, DOI 10.1016/0012-1606(87)90117-5; PRITCHARDJONES K, 1990, NATURE, V346, P194, DOI 10.1038/346194a0; REUTER R, 1993, DEVELOPMENT, V119, P1135; ROTHENPIELER UW, 1993, DEVELOPMENT, V119, P711; Sakurai H, 1997, P NATL ACAD SCI USA, V94, P6279, DOI 10.1073/pnas.94.12.6279; SARIOLA H, 1989, DEV BIOL, V132, P271, DOI 10.1016/0012-1606(89)90224-8; Saxen L., 1987, ORGANOGENESIS KIDNEY; SCHINDLER C, 1995, ANNU REV BIOCHEM, V64, P621, DOI 10.1146/annurev.bi.64.070195.003201; SCHUCHARDT A, 1994, NATURE, V367, P380, DOI 10.1038/367380a0; Seifert RA, 1998, KIDNEY INT, V54, P731, DOI 10.1046/j.1523-1755.1998.00046.x; Sheng ZL, 1996, DEVELOPMENT, V122, P419; Sierra-Honigmann MR, 1998, SCIENCE, V281, P1683, DOI 10.1126/science.281.5383.1683; SONNENBERG E, 1993, J CELL BIOL, V123, P223, DOI 10.1083/jcb.123.1.223; STARK K, 1994, NATURE, V372, P679, DOI 10.1038/372679a0; TAGA T, 1989, CELL, V58, P573, DOI 10.1016/0092-8674(89)90438-8; Takeda K, 1997, P NATL ACAD SCI USA, V94, P3801, DOI 10.1073/pnas.94.8.3801; Tempst Paul, 1994, Methods (Orlando), V6, P248, DOI 10.1006/meth.1994.1027; TEPASS U, 1994, DEVELOPMENT, V120, P579; VAINIO S, 1992, DEV BIOL, V152, P221, DOI 10.1016/0012-1606(92)90130-9; VESTWEBER D, 1985, DEV BIOL, V112, P213, DOI 10.1016/0012-1606(85)90135-6; WELLER A, 1991, DEV BIOL, V144, P248, DOI 10.1016/0012-1606(91)90419-4; WOOLF AS, 1995, J CELL BIOL, V128, P171, DOI 10.1083/jcb.128.1.171; Yoshida K, 1996, P NATL ACAD SCI USA, V93, P407, DOI 10.1073/pnas.93.1.407	71	211	221	0	3	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	NOV 12	1999	99	4					377	386		10.1016/S0092-8674(00)81524-X	http://dx.doi.org/10.1016/S0092-8674(00)81524-X			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	256CX	10571180	Bronze			2022-12-01	WOS:000083709300005
J	Huang, L; Kinnucan, E; Wang, GL; Beaudenon, S; Howley, PM; Huibregtse, JM; Pavletich, NP				Huang, L; Kinnucan, E; Wang, GL; Beaudenon, S; Howley, PM; Huibregtse, JM; Pavletich, NP			Structure of an E6AP-UbcH7 complex: Insights into ubiquitination by the E2-E3 enzyme cascade	SCIENCE			English	Article							ANGELMAN-SYNDROME; PROTEIN; E6-AP; P53; EXPRESSION; CLONING; UBE3A; UBCH7	The E6AP ubiquitin-protein Ligase (E3) mediates the human papillomavirus-induced degradation of the p53 tumor suppressor in cervical cancer and is mutated in Angelman syndrome, a neurological disorder. The crystal structure of the catalytic hect domain of E6AP reveals a bilobal structure with a broad catalytic cleft at the junction of the two Lobes. The cleft consists of conserved residues whose mutation interferes with ubiquitin-thioester bond formation and is the site of Angelman syndrome mutations. The crystal structure of the E6AP hect domain bound to the UbcH7 ubiquitin-conjugating enzyme (E2) reveals the determinants of E2-E3 specificity and provides insights into the transfer of ubiquitin from the E2 to the E3.	Mem Sloan Kettering Canc Ctr, Cellular Biochem & Biophys Program, New York, NY 10021 USA; Mem Sloan Kettering Canc Ctr, Howard Hughes Med Inst, New York, NY 10021 USA; Rutgers State Univ, Dept Mol Biol & Biochem, Piscataway, NJ 08855 USA; Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA	Memorial Sloan Kettering Cancer Center; Howard Hughes Medical Institute; Memorial Sloan Kettering Cancer Center; Rutgers State University New Brunswick; Harvard University; Harvard Medical School	Pavletich, NP (corresponding author), Mem Sloan Kettering Canc Ctr, Cellular Biochem & Biophys Program, 1275 York Ave, New York, NY 10021 USA.			Howley, Peter/0000-0002-8668-9579				Albrecht U, 1997, NAT GENET, V17, P75, DOI 10.1038/ng0997-75; Beal R, 1996, P NATL ACAD SCI USA, V93, P861, DOI 10.1073/pnas.93.2.861; Hochstrasser M, 1996, ANNU REV GENET, V30, P405, DOI 10.1146/annurev.genet.30.1.405; HUIBREGTSE JM, 1993, MOL CELL BIOL, V13, P4918, DOI 10.1128/MCB.13.8.4918; HUIBREGTSE JM, 1993, MOL CELL BIOL, V13, P775, DOI 10.1128/MCB.13.2.775; JENTSCH S, 1992, ANNU REV GENET, V26, P179, DOI 10.1146/annurev.ge.26.120192.001143; Kishino T, 1997, NAT GENET, V15, P70, DOI 10.1038/ng0197-70; Kuhne C, 1998, J BIOL CHEM, V273, P34302, DOI 10.1074/jbc.273.51.34302; Laney JD, 1999, CELL, V97, P427, DOI 10.1016/S0092-8674(00)80752-7; Malzac P, 1998, AM J HUM GENET, V62, P1353, DOI 10.1086/301877; MAYER RJ, 1998, UBIQUITIN BIOL CELL, P429; Nuber U, 1996, J BIOL CHEM, V271, P2795, DOI 10.1074/jbc.271.5.2795; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; SCHEFFNER M, 1995, NATURE, V373, P81, DOI 10.1038/373081a0; SCHEFFNER M, 1994, P NATL ACAD SCI USA, V91, P8797, DOI 10.1073/pnas.91.19.8797; Schwarz SE, 1998, J BIOL CHEM, V273, P12148, DOI 10.1074/jbc.273.20.12148; Talis AL, 1998, J BIOL CHEM, V273, P6439, DOI 10.1074/jbc.273.11.6439	17	421	451	1	43	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 12	1999	286	5443					1321	1326		10.1126/science.286.5443.1321	http://dx.doi.org/10.1126/science.286.5443.1321			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	255NF	10558980				2022-12-01	WOS:000083675500032
J	Sobel, N; Khan, RM; Saltman, A; Sullivan, EV; Gabrieli, JDE				Sobel, N; Khan, RM; Saltman, A; Sullivan, EV; Gabrieli, JDE			Olfaction - The world smells different to each nostril	NATURE			English	Article							NASAL CYCLE; ODORANTS; NOSE; FLOW		Stanford Univ, Neurosci Program, Stanford, CA 94305 USA; Stanford Univ, Dept Psychol, Stanford, CA 94305 USA; Stanford Univ, Dept Psychiat & Behav Sci, Stanford, CA 94305 USA; Minist Environm Protect, IL-72100 Ramle, Israel	Stanford University; Stanford University; Stanford University	Sobel, N (corresponding author), Stanford Univ, Neurosci Program, Stanford, CA 94305 USA.		Sullivan, Edith V/ABD-5684-2021; Gabrieli, John/AAJ-2869-2020	Sullivan, Edith V/0000-0001-6739-3716; Sobel, Noam/0000-0002-3232-9391				BOJSENMOLLER F, 1971, J ANAT, V110, P25; ECCLES R, 1989, ACTA OTO-LARYNGOL, V108, P268, DOI 10.3109/00016488909125527; Frye RE, 1995, NEUROL DIS, P471; GILBERT AN, 1987, ACTA OTO-LARYNGOL, V104, P180, DOI 10.3109/00016488709109065; HASEGAWA M, 1977, MAYO CLIN PROC, V52, P28; Kayser R., 1895, ARCH LARYNGOL RHINOL, V8, P101; Mirza N, 1997, LARYNGOSCOPE, V107, P62, DOI 10.1097/00005537-199701000-00014; MOZELL MM, 1973, SCIENCE, V181, P1247, DOI 10.1126/science.181.4106.1247; MOZELL MM, 1991, CHEM SENSES, V16, P631, DOI 10.1093/chemse/16.6.631; PRINCIPATO JJ, 1970, ARCHIV OTOLARYNGOL, V91, P71	10	98	100	0	14	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	NOV 4	1999	402	6757					35	35		10.1038/46944	http://dx.doi.org/10.1038/46944			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	254XC	10573415				2022-12-01	WOS:000083638600032
J	Henney, JE				Henney, JE			First antibacterial for VREF	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	News Item											Henney, JE (corresponding author), HF-1,Room 14-71,5600 Fishers Ln, Rockville, MD 20857 USA.								0	5	5	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 3	1999	282	17					1613	1613		10.1001/jama.282.17.1613	http://dx.doi.org/10.1001/jama.282.17.1613			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	250BD	10553774				2022-12-01	WOS:000083368400007
J	Motchoulski, A; Liscum, E				Motchoulski, A; Liscum, E			Arabidopsis NPH3: A NPH1 photoreceptor-interacting protein essential for phototropism	SCIENCE			English	Article							COILED COILS; LINKAGE MAP; PHOSPHORYLATION; FLAVOPROTEIN; ELONGATION; MUTATIONS; RESPONSES; DOMAIN; KINASE	Phototropism of Arabidopsis thaliana seedlings in response to a blue Light source is initiated by nonphototropic hypocotyl 1 (NPH1), a Light-activated serine-threonine protein kinase. Mutations in three Loci [NPH2, root phototropism 2 (RPT2), and NPH3] disrupt early signaling occurring downstream of the NPH1 photoreceptor, The NPH3 gene, now cloned, encodes a NPH1-interacting protein. NPH3 is a member of a large protein family, apparently specific to higher plants, and may function as an adapter or scaffold protein to bring together the enzymatic components of a NPH1-activated phosphorelay.	Univ Missouri, Div Biol Sci, Columbia, MO 65211 USA	University of Missouri System; University of Missouri Columbia	Liscum, E (corresponding author), Univ Missouri, Div Biol Sci, Columbia, MO 65211 USA.	liscumm@missouri.edu		Liscum, Emmanuel/0000-0002-8672-9315				ALBAGLI O, 1995, CELL GROWTH DIFFER, V6, P1193; Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Aravind L, 1999, J MOL BIOL, V285, P1353, DOI 10.1006/jmbi.1998.2394; BELL CJ, 1994, GENOMICS, V19, P137, DOI 10.1006/geno.1994.1023; Briggs WR, 1999, ANNU REV CELL DEV BI, V15, P33, DOI 10.1146/annurev.cellbio.15.1.33; CHOI S, 1995, WEEDS WORLD, V2, P17; Christie JM, 1999, P NATL ACAD SCI USA, V96, P8779, DOI 10.1073/pnas.96.15.8779; Christie JM, 1998, SCIENCE, V282, P1698, DOI 10.1126/science.282.5394.1698; COHEN C, 1990, PROTEINS, V7, P1, DOI 10.1002/prot.340070102; Fankhauser C, 1999, CURR BIOL, V9, pR123, DOI 10.1016/S0960-9822(99)80078-5; Fankhauser C, 1999, SCIENCE, V284, P1539, DOI 10.1126/science.284.5419.1539; Faux MC, 1996, CELL, V85, P9, DOI 10.1016/S0092-8674(00)81075-2; Fields Stanley, 1993, Methods (Orlando), V5, P116, DOI 10.1006/meth.1993.1016; Huala E, 1997, SCIENCE, V278, P2120, DOI 10.1126/science.278.5346.2120; KIEBER JJ, 1993, CELL, V72, P427, DOI 10.1016/0092-8674(93)90119-B; KUO MS, 1986, CARBOHYD RES, V156, P173, DOI 10.1016/S0008-6215(00)90109-5; Lasceve G, 1999, PLANT PHYSIOL, V120, P605, DOI 10.1104/pp.120.2.605; LISCUM E, 1991, PLANT CELL, V3, P685, DOI 10.1105/tpc.3.7.685; LISCUM E, 1995, PLANT CELL, V7, P473, DOI 10.1105/tpc.7.4.473; LUPAS A, 1991, SCIENCE, V252, P1162, DOI 10.1126/science.252.5009.1162; Lupas A, 1996, TRENDS BIOCHEM SCI, V21, P375, DOI 10.1016/S0968-0004(96)10052-9; MOTCHOULSKI A, UNPUB; NAGAO M, 1992, J BIOL CHEM, V267, P17925; Nakamura Y, 1997, DNA Res, V4, P401, DOI 10.1093/dnares/4.6.401; NAM HG, 1989, PLANT CELL, V1, P699, DOI 10.1105/tpc.1.7.699; Ni M, 1998, CELL, V95, P657, DOI 10.1016/S0092-8674(00)81636-0; Okada K., 1994, ARABIDOPSIS, P665; PATSCHINSKY T, 1982, P NATL ACAD SCI-BIOL, V79, P973, DOI 10.1073/pnas.79.4.973; Quail PH, 1997, PLANT CELL ENVIRON, V20, P657, DOI 10.1046/j.1365-3040.1997.d01-108.x; REED JW, 1993, PLANT CELL, V5, P147, DOI 10.1105/tpc.5.2.147; Sambrook J., 1989, MOL CLONING LAB MANU, V3; Schultz J, 1998, P NATL ACAD SCI USA, V95, P5857, DOI 10.1073/pnas.95.11.5857; SHORT TW, 1993, PLANT PHYSIOL, V101, P647, DOI 10.1104/pp.101.2.647; Stowe-Evans EL, 1998, PLANT PHYSIOL, V118, P1265, DOI 10.1104/pp.118.4.1265	34	235	265	3	26	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 29	1999	286	5441					961	964		10.1126/science.286.5441.961	http://dx.doi.org/10.1126/science.286.5441.961			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	250BE	10542152				2022-12-01	WOS:000083368500047
J	Sun, CH; Cai, ML; Gunasekera, AH; Meadows, RP; Wang, H; Chen, J; Zhang, HC; Wu, W; Xu, N; Ng, SC; Fesik, SW				Sun, CH; Cai, ML; Gunasekera, AH; Meadows, RP; Wang, H; Chen, J; Zhang, HC; Wu, W; Xu, N; Ng, SC; Fesik, SW			NMR structure and mutagenesis of the inhibitor-of-apoptosis protein XIAP	NATURE			English	Article							NUCLEAR-MAGNETIC-RESONANCE; BACULOVIRUS INHIBITOR; CELL-DEATH; MACROMOLECULES; GENE; IAP; COUPLINGS; CASPASES; FAMILY; SURVIVIN	The inhibitor-of-apoptosis (IAP) family of proteins, originally identified in baculoviruses(1), regulate programmed cell death in a variety of organisms(2-6), IAPs inhibit specific enzymes (caspases) in the death cascade(7-11) and contain one to three modules of a common 70-amino-acid motif called the BIR domain(12). Here we describe the nuclear magnetic resonance structure of a region encompassing the second BIR domain (BIR2) of a human IAP family member, XIAP (also called hILP or MIHA). The structure of the BIR domain consists of a three-stranded antiparallel beta-sheet and four alpha-helices and resembles a classical zinc finger(13). Unexpectedly, conserved amino acids within the linker region between the BIR1 and BIR2 domains were found to be critical for inhibiting caspase-3. The absence or presence of these residues may explain the differences in caspase inhibition observed for different truncated and full-length IAPs(10,11). Our data further indicate that these residues may bind to the active site and that the BIR domain may interact with an adjacent site on the enzyme.	Abbott Labs, Div Pharmaceut Discovery, Abbott Pk, IL 60064 USA	Abbott Laboratories	Fesik, SW (corresponding author), Abbott Labs, Div Pharmaceut Discovery, Abbott Pk, IL 60064 USA.							Ambrosini G, 1997, NAT MED, V3, P917, DOI 10.1038/nm0897-917; BRUNGER AT, 1992, XPLOR 3 1 ANUAL; CARSON M, 1987, J MOL GRAPHICS, V5, P103, DOI 10.1016/0263-7855(87)80010-3; Clore GM, 1998, J AM CHEM SOC, V120, P10571, DOI 10.1021/ja982592f; CLORE GM, 1994, METHOD ENZYMOL, V239, P349; Cornilescu G, 1999, J BIOMOL NMR, V13, P289, DOI 10.1023/A:1008392405740; CROOK NE, 1993, J VIROL, V67, P2168, DOI 10.1128/JVI.67.4.2168-2174.1993; Deveraux QL, 1997, NATURE, V388, P300, DOI 10.1038/40901; Duckett CS, 1996, EMBO J, V15, P2685, DOI 10.1002/j.1460-2075.1996.tb00629.x; Hansen MR, 1998, NAT STRUCT BIOL, V5, P1065, DOI 10.1038/4176; Hawkins CJ, 1996, P NATL ACAD SCI USA, V93, P13786, DOI 10.1073/pnas.93.24.13786; Hay BA, 1995, CELL, V83, P1253, DOI 10.1016/0092-8674(95)90150-7; Hinds MG, 1999, NAT STRUCT BIOL, V6, P648; Hu JS, 1997, J AM CHEM SOC, V119, P1803, DOI 10.1021/ja963625z; NERI D, 1989, BIOCHEMISTRY-US, V28, P7510, DOI 10.1021/bi00445a003; NILGES M, 1988, PROTEIN ENG, V2, P27, DOI 10.1093/protein/2.1.27; Pervushin K, 1997, P NATL ACAD SCI USA, V94, P12366, DOI 10.1073/pnas.94.23.12366; Rance M, 1999, J MAGN RESON, V136, P92, DOI 10.1006/jmre.1998.1626; RORUNDA I, 1996, NAT STRUCT BIOL, V3, P619; Roy N, 1997, EMBO J, V16, P6914, DOI 10.1093/emboj/16.23.6914; ROY N, 1995, CELL, V80, P167, DOI 10.1016/0092-8674(95)90461-1; SCHWABE JWR, 1994, NAT STRUCT BIOL, V1, P345, DOI 10.1038/nsb0694-345; Stein EG, 1997, J MAGN RESON, V124, P154, DOI 10.1006/jmre.1996.1027; Takahashi R, 1998, J BIOL CHEM, V273, P7787, DOI 10.1074/jbc.273.14.7787; Tamm I, 1998, CANCER RES, V58, P5315; Thornberry NA, 1997, J BIOL CHEM, V272, P17907, DOI 10.1074/jbc.272.29.17907; Tjandra N, 1997, NAT STRUCT BIOL, V4, P732, DOI 10.1038/nsb0997-732; Uren AG, 1998, TRENDS BIOCHEM SCI, V23, P159, DOI 10.1016/S0968-0004(98)01198-0; Uren AG, 1996, P NATL ACAD SCI USA, V93, P4974, DOI 10.1073/pnas.93.10.4974; VUISTER GW, 1993, J AM CHEM SOC, V115, P7772, DOI 10.1021/ja00070a024	30	288	322	0	19	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	OCT 21	1999	401	6755					818	822		10.1038/44617	http://dx.doi.org/10.1038/44617			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	250BG	10548111				2022-12-01	WOS:000083368700060
J	Netzer, NC; Stoohs, RA; Netzer, CM; Clark, K; Strohl, KP				Netzer, NC; Stoohs, RA; Netzer, CM; Clark, K; Strohl, KP			Using the Berlin Questionnaire to identify patients at risk for the sleep apnea syndrome	ANNALS OF INTERNAL MEDICINE			English	Article						sleep apnea syndromes; questionnaires; hypertension; obesity; snoring	PREVALENCE; POPULATION; ADULTS; PREDICTION; COMMUNITY; ACCIDENTS; HEALTH; SAMPLE; MEN	Background: Although sleep apnea is common, it often goes undiagnosed in primary care encounters. Objective: To test the Berlin Questionnaire as a means of identifying patients with sleep apnea. Design: Survey followed by portable, unattended sleep studies in a subset of patients. Setting: Five primary care sites in Cleveland, Ohio. Patients: 744 adults (of 1008 surveyed [74%]), of whom 100 underwent sleep studies. Measurements: Survey items addressed the presence and frequency of snoring behavior, waketime sleepiness or fatigue, and history of obesity or hypertension. Patients with persistent and frequent symptoms in any two of these three domains were considered to be at high risk for sleep apnea. Portable sleep monitoring was conducted to measure the number of respiratory events per hour in bed (respiratory disturbance index [RDI]). Results: Questions about symptoms demonstrated internal consistency (Cronbach correlations, 0.86 to 0.92). Of the 744 respondents, 279 (37.5%) were in a high-risk group that was defined a priori. For the 100 patients who underwent sleep studies, risk grouping was useful in prediction of the RDI. For example, being in the high-risk group predicted an RDI greater than 5 with a sensitivity of 0.86, a specificity of 0.77, a positive predictive value of 0.89, and a likelihood ratio of 3.79. Conclusion: The Berlin Questionnaire provides a means of identifying patients who are likely to have sleep apnea.	Case Western Reserve Univ, Ctr Sleep Educ & Res, Cleveland, OH 44106 USA; Case Western Reserve Univ, Sleep Disorders Res Ctr, Cleveland, OH 44106 USA	Case Western Reserve University; Case Western Reserve University	Strohl, KP (corresponding author), Case Western Reserve Univ, Ctr Sleep Educ & Res, 10701 E Blvd, Cleveland, OH 44106 USA.			Netzer, Nikolaus/0000-0001-7534-3575	NHLBI NIH HHS [HL-03650, HL-42215] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL042215, K07HL003650] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Ball EM, 1997, ARCH INTERN MED, V157, P419, DOI 10.1001/archinte.157.4.419; Bradley TD, 1998, AM J RESP CRIT CARE, V157, P335; Briones B, 1996, SLEEP, V19, P583, DOI 10.1093/sleep/19.7.583; CIRIGNOTTA F, 1989, ACTA NEUROL SCAND, V79, P366, DOI 10.1111/j.1600-0404.1989.tb03802.x; Flemons WW, 1996, SLEEP, V19, pS243; Flemons WW, 1999, SLEEP, V22, P667, DOI 10.1093/sleep/22.5.667; FLEMONS WW, 1994, AM J RESP CRIT CARE, V150, P1279, DOI 10.1164/ajrccm.150.5.7952553; Haponik EF, 1996, J GEN INTERN MED, V11, P759, DOI 10.1007/BF02598994; KAPUNIAI LE, 1988, SLEEP, V11, P430, DOI 10.1093/sleep/11.5.430; KUCZMARSKI RJ, 1994, JAMA-J AM MED ASSOC, V272, P205, DOI 10.1001/jama.272.3.205; KUMP K, 1994, AM J RESP CRIT CARE, V150, P735, DOI 10.1164/ajrccm.150.3.8087345; LOGUE E, 1995, J FAM PRACTICE, V41, P357; Lyznicki JM, 1998, JAMA-J AM MED ASSOC, V279, P1908, DOI 10.1001/jama.279.23.1908; MAISLIN G, 1995, SLEEP, V18, P158, DOI 10.1093/sleep/18.3.158; Marin JM, 1997, INT J EPIDEMIOL, V26, P381, DOI 10.1093/ije/26.2.381; Ohayon MM, 1997, BRIT MED J, V314, P860; OLSON LG, 1995, AM J RESP CRIT CARE, V152, P711, DOI 10.1164/ajrccm.152.2.7633731; Redline S, 1998, CLIN CHEST MED, V19, P1, DOI 10.1016/S0272-5231(05)70428-7; SACKETT DL, 1992, JAMA-J AM MED ASSOC, V267, P2638, DOI 10.1001/jama.267.19.2638; Stoohs R A, 1997, Sleep Breath, V2, P11; Wu H, 1996, NEUROLOGY, V46, P1254, DOI 10.1212/WNL.46.5.1254; Young T, 1997, SLEEP, V20, P608, DOI 10.1093/sleep/20.8.608; YOUNG T, 1993, NEW ENGL J MED, V328, P1230, DOI 10.1056/NEJM199304293281704; Young T, 1997, SLEEP, V20, P705, DOI 10.1093/sleep/20.9.705	24	1824	1895	0	56	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	OCT 5	1999	131	7					485	+		10.7326/0003-4819-131-7-199910050-00002	http://dx.doi.org/10.7326/0003-4819-131-7-199910050-00002			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	243VU	10507956				2022-12-01	WOS:000083018800001
J	Carlson, RW; Johnson, RE; Anderson, MS				Carlson, RW; Johnson, RE; Anderson, MS			Sulfuric acid on Europa and the radiolytic sulfur cycle	SCIENCE			English	Article							MAGNETOSPHERIC ION-BOMBARDMENT; ICY GALILEAN SATELLITES; IRRADIATION EXPERIMENTS; REFLECTANCE SPECTRA; SURFACE-COMPOSITION; SPECTROSCOPY; OXYGEN; SYSTEM	A comparison of laboratory spectra with Galileo data indicates that hydrated sulfuric acid is present and is a major component of Europa's surface. In addition, this moon's visually dark surface material, which spatially correlates with the sulfuric acid concentration, is identified as radiolytically altered sulfur polymers. Radiolysis of the surface: by magnetospheric plasma bombardment continuously cycles sulfur between three forms: sulfuric acid, sulfur dioxide, and sulfur polymers, with sulfuric acid being about 50 times as abundant as the other forms. Enhanced sulfuric acid concentrations are found in Europa's geologically young terrains, suggesting that low-temperature, liquid sulfuric acid may influence geological processes.	CALTECH, Jet Prop Lab, Pasadena, CA 91109 USA; Univ Virginia, Sch Engn & Appl Sci, Charlottesville, VA 22903 USA	California Institute of Technology; National Aeronautics & Space Administration (NASA); NASA Jet Propulsion Laboratory (JPL); University of Virginia	Carlson, RW (corresponding author), CALTECH, Jet Prop Lab, 4800 Oak Grove Dr, Pasadena, CA 91109 USA.	rcarlson@lively.jpl.nasa.gov						Anderson JD, 1998, SCIENCE, V281, P2019, DOI 10.1126/science.281.5385.2019; CALVIN WM, 1995, J GEOPHYS RES-PLANET, V100, P19041, DOI 10.1029/94JE03349; Carlson RW, 1999, SCIENCE, V283, P2062, DOI 10.1126/science.283.5410.2062; CARLSON RW, 1998, HIGHLIGHTS ASTRONO B, V11, P1078; Carr MH, 1998, NATURE, V391, P363, DOI 10.1038/34857; CLARK RN, 1990, J GEOPHYS RES-SOLID, V95, P12653, DOI 10.1029/JB095iB08p12653; COOPER JR, UNPUB; DONALDSON GW, 1968, J PHYS CHEM-US, V72, P3552, DOI 10.1021/j100856a033; Greeley R, 1998, ICARUS, V135, P4, DOI 10.1006/icar.1998.5969; HOCHANADEL CJ, 1955, J AM CHEM SOC, V77, P3215, DOI 10.1021/ja01617a017; HOGENBOOM DL, 1995, ICARUS, V115, P258, DOI 10.1006/icar.1995.1096; Ip WH, 1996, ICARUS, V120, P317, DOI 10.1006/icar.1996.0052; Jayne JT, 1997, J PHYS CHEM A, V101, P10000, DOI 10.1021/jp972549z; JOHNSON ER, 1952, J AM CHEM SOC, V74, P4147, DOI 10.1021/ja01136a056; Johnson RE, 1997, J GEOPHYS RES-PLANET, V102, P10985, DOI 10.1029/97JE00068; Johnson RE, 1998, GEOPHYS RES LETT, V25, P3257, DOI 10.1029/98GL02565; JOHNSON RE, 1988, ICARUS, V75, P423, DOI 10.1016/0019-1035(88)90155-8; JOHNSON TV, 1983, J GEOPHYS RES, V88, P5789, DOI 10.1029/JB088iB07p05789; Khurana KK, 1998, NATURE, V395, P777, DOI 10.1038/27394; LANE AL, 1981, NATURE, V292, P38, DOI 10.1038/292038a0; LEBOFSKY LA, 1976, ICARUS, V28, P379, DOI 10.1016/0019-1035(76)90151-2; Martin ST, 1997, J PHYS CHEM B, V101, P5307, DOI 10.1021/jp970607a; McCord TB, 1998, SCIENCE, V280, P1242, DOI 10.1126/science.280.5367.1242; McCord TB, 1999, J GEOPHYS RES-PLANET, V104, P11827, DOI 10.1029/1999JE900005; Moore M., COMMUNICATION; MOORE MH, 1984, ICARUS, V59, P114, DOI 10.1016/0019-1035(84)90059-9; MOOTZ D, 1987, Z NATURFORSCH B, V42, P1231, DOI 10.1515/znb-1987-1004; NANOBASHVILI EM, 1957, P 1 ALL UN C RAD CHE, P69; NANOBASHVILI EM, 1964, P 2 ALL UN C RAD CHE, P159; NASH DB, 1977, ICARUS, V31, P40, DOI 10.1016/0019-1035(77)90070-7; NELSON ML, 1986, ICARUS, V65, P129, DOI 10.1016/0019-1035(86)90068-0; NOLL KS, 1995, J GEOPHYS RES-PLANET, V100, P19057, DOI 10.1029/94JE03294; OSHAUGHNESSY DJ, 1988, NATURE, V333, P240, DOI 10.1038/333240a0; Pappalardo RT, 1998, NATURE, V391, P365, DOI 10.1038/34862; POSPIESZALSKA MK, 1989, ICARUS, V78, P1, DOI 10.1016/0019-1035(89)90065-1; SACK NJ, 1992, ICARUS, V100, P534, DOI 10.1016/0019-1035(92)90116-O; SASAKI T, 1978, J CHEM PHYS, V68, P2718, DOI 10.1063/1.436109; SPENCER JR, 1995, J GEOPHYS RES-PLANET, V100, P19049, DOI 10.1029/95JE01503; STRAZZULLA G, 1993, ADV SPACE RES, V13, P189; THOMPSON BA, 1963, J GEOPHYS RES, V68, P6431, DOI 10.1029/JZ068i024p06431; YAROSLAVTSEV AB, 1983, ZH NEORG KHIM+, V28, P2746; ZELEZNIK FJ, 1991, J PHYS CHEM REF DATA, V20, P1157, DOI 10.1063/1.555899	42	258	260	3	33	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 1	1999	286	5437					97	99		10.1126/science.286.5437.97	http://dx.doi.org/10.1126/science.286.5437.97			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	241WT	10506568				2022-12-01	WOS:000082907400041
J	Perrotta, AT; Shih, IH; Been, MD				Perrotta, AT; Shih, IH; Been, MD			Imidazole rescue of a cytosine mutation in a self-cleaving ribozyme	SCIENCE			English	Article							HEPATITIS-DELTA-VIRUS; RNA; CLEAVAGE; CATALYSIS; SEQUENCES; MUTANT; BASES; CORE	Ribozymes use a number of the same catalytic strategies as protein enzymes. However, general base catalysis by a ribozyme has not been demonstrated. In the hepatitis delta virus antigenomic ribozyme, imidazole buffer rescued activity of a mutant with a cytosine-76 (C76) to uracil substitution. In addition, a C76 to adenine substitution reduced the apparent pK(a) (where K-a is the acid constant) of the self-cleavage reaction by an amount consistent with differences in the pK(a) values of these two side chains. These results suggest that, in the wild-type ribozyme, C76 acts as a general base. This finding has implications for potential catalytic functions of conserved cytosines and adenines in other ribozymes and in ribonuclear proteins with enzymatic activity.	Duke Univ, Med Ctr, Dept Biochem, Durham, NC 27710 USA	Duke University	Been, MD (corresponding author), Duke Univ, Med Ctr, Dept Biochem, Box 3711, Durham, NC 27710 USA.				NIGMS NIH HHS [GM47322] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANSLYN E, 1989, J AM CHEM SOC, V111, P4473, DOI 10.1021/ja00194a050; Bravo C, 1996, NUCLEIC ACIDS RES, V24, P1351, DOI 10.1093/nar/24.7.1351; Cech TR, 1999, RNA WORLD, P321; CONNELL GJ, 1994, SCIENCE, V264, P1137, DOI 10.1126/science.7513905; Ferre-D'Amare AR, 1998, NATURE, V395, P567, DOI 10.1038/26912; Huang SQ, 1997, BIOCHEMISTRY-US, V36, P14609, DOI 10.1021/bi9722554; JACK A, 1977, J MOL BIOL, V111, P315, DOI 10.1016/S0022-2836(77)80054-5; KUMAR PKR, 1992, NUCLEIC ACIDS RES, V20, P3919, DOI 10.1093/nar/20.15.3919; KUO MYP, 1988, J VIROL, V62, P4439, DOI 10.1128/JVI.62.12.4439-4444.1988; LEGAULT P, 1994, J AM CHEM SOC, V116, P8390, DOI 10.1021/ja00097a066; Michalowski D, 1996, BIOCHEMISTRY-US, V35, P10727, DOI 10.1021/bi9530393; Narlikar GJ, 1997, ANNU REV BIOCHEM, V66, P19, DOI 10.1146/annurev.biochem.66.1.19; Newmyer SL, 1996, J BIOL CHEM, V271, P14891, DOI 10.1074/jbc.271.25.14891; Peracchi A, 1996, P NATL ACAD SCI USA, V93, P11522, DOI 10.1073/pnas.93.21.11522; Peracchi A, 1998, RNA, V4, P1332, DOI 10.1017/S1355838298980979; Perrin D. D., 2012, BUFFERS PH METAL ION; PERROTTA AT, 1992, BIOCHEMISTRY-US, V31, P16, DOI 10.1021/bi00116a004; PERROTTA AT, 1991, NATURE, V350, P434, DOI 10.1038/350434a0; Perrotta AT, 1998, J MOL BIOL, V279, P361, DOI 10.1006/jmbi.1998.1798; Perrotta AT, 1996, NUCLEIC ACIDS RES, V24, P1314, DOI 10.1093/nar/24.7.1314; Rosenstein SP, 1996, BIOCHEMISTRY-US, V35, P11403, DOI 10.1021/bi9609984; Roth A, 1998, P NATL ACAD SCI USA, V95, P6027, DOI 10.1073/pnas.95.11.6027; Saenger W., 1984, SPRINGER ADV TEXTS C; TANNER NK, 1994, CURR BIOL, V4, P488, DOI 10.1016/S0960-9822(00)00109-3; Wadkins TS, 1999, RNA, V5, P720, DOI 10.1017/S1355838299990209; WADKINS TS, UNPUB; WALSH CT, 1979, ENZYMATIC REACTION M; WU HN, 1989, P NATL ACAD SCI USA, V86, P1831, DOI 10.1073/pnas.86.6.1831	28	249	256	1	10	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	OCT 1	1999	286	5437					123	126		10.1126/science.286.5437.123	http://dx.doi.org/10.1126/science.286.5437.123			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	241WT	10506560				2022-12-01	WOS:000082907400050
J	De Maria, R; Zeuner, A; Eramo, A; Domenichelli, C; Bonci, D; Grignani, F; Srinivasula, SM; Alnemri, ES; Testa, U; Peschle, C				De Maria, R; Zeuner, A; Eramo, A; Domenichelli, C; Bonci, D; Grignani, F; Srinivasula, SM; Alnemri, ES; Testa, U; Peschle, C			Negative regulation of erythropoiesis by caspase-mediated cleavage of GATA-1	NATURE			English	Article							TRANSCRIPTION FACTOR GATA-1; TNF RECEPTORS; APOPTOSIS; ANEMIA; GENE; DIFFERENTIATION; HEMATOPOIESIS; EXPRESSION; PROTEASE; DISEASE	The production of red blood cells follows the sequential formation of proerythroblasts and basophilic, polychromatophilic and orthochromatic erythroblasts, and is promoted by the hormone erythropoietin (Epo) in response to tissue hypoxia(1). However, little is known about the negative regulation of this process(2). Death receptors are a family of surface molecules that trigger caspase activation and apoptosis in a variety of cell types(3-5). Here we show that immature erythroid cells express several death receptors whose ligands are produced by mature erythroblasts. Exposure of erythroid progenitors to mature erythroblasts or death-receptor ligands resulted in caspase-mediated degradation of the transcription factor GATA-1, which is associated with impaired erythroblast development. Expression of a caspase-resistant GATA-1 mutant, but not of the wild-type gene, completely restored erythroid expansion and differentiation following the triggering of death receptors, indicating that there is regulatory feedback between mature and immature erythroblasts through caspase-mediated cleavage of GATA-1. Similarly, erythropoiesis blockade following Epo deprivation was largely prevented by the expression of caspase-inhibitory proteins or caspase-resistant GATA-1 in erythroid progenitors. Caspase-mediated cleavage of GATA-1 may therefore represent an important negative control mechanism in erythropoiesis.	Thomas Jefferson Univ, Kimmel Canc Ctr, Philadelphia, PA 19107 USA; Univ Catania, Ist Patol Gen, I-95124 Catania, Italy; Ist Super Sanita, Dept Haematol & Oncol, I-00161 Rome, Italy; Univ Perugia, Ist Med Interna & Sci Oncol, I-06122 Perugia, Italy	Jefferson University; University of Catania; Istituto Superiore di Sanita (ISS); University of Perugia	De Maria, R (corresponding author), Thomas Jefferson Univ, Kimmel Canc Ctr, Philadelphia, PA 19107 USA.	rdemaria@lac.jci.tju.edu	Zeuner, Ann/K-8607-2016; Eramo, Adriana/K-6694-2016; Alnemri, Emad S/B-4526-2010; Grignani, Francesco/AAC-2565-2022; Testa, Ugo/J-6472-2016; De Maria, Ruggero/S-6385-2019; Bonci, Desiree/K-6488-2016; Zeuner, Ann/A-8529-2010	Eramo, Adriana/0000-0002-0814-6683; Testa, Ugo/0000-0001-7900-8942; De Maria, Ruggero/0000-0003-2255-0583; Bonci, Desiree/0000-0002-2472-5140; Zeuner, Ann/0000-0002-8295-3715				Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305; Cohen GM, 1997, BIOCHEM J, V326, P1, DOI 10.1042/bj3260001; Davis D, 1997, BRIT J RHEUMATOL, V36, P950; De Maria R, 1999, BLOOD, V93, P796, DOI 10.1182/blood.V93.3.796.403k23_796_803; Green DR, 1998, CELL, V94, P695, DOI 10.1016/S0092-8674(00)81728-6; Grignani F, 1998, CANCER RES, V58, P14; Gupta P, 1999, LEUKEMIA, V13, P44, DOI 10.1038/sj.leu.2401233; Hasegawa D, 1998, BLOOD, V91, P2793, DOI 10.1182/blood.V91.8.2793.2793_2793_2799; Irmler M, 1997, NATURE, V388, P190, DOI 10.1038/40657; Krammer P H, 1999, Adv Immunol, V71, P163; KRANTZ SB, 1991, BLOOD, V77, P419; LABBAYE C, 1995, J CLIN INVEST, V95, P2346, DOI 10.1172/JCI117927; Nagata S, 1997, CELL, V88, P355, DOI 10.1016/S0092-8674(00)81874-7; PEVNY L, 1991, NATURE, V349, P257, DOI 10.1038/349257a0; RUSTEN LS, 1995, BLOOD, V85, P989, DOI 10.1182/blood.V85.4.989.bloodjournal854989; SHIVDASANI RA, 1995, CELL, V81, P695, DOI 10.1016/0092-8674(95)90531-6; Srinivasula SM, 1996, P NATL ACAD SCI USA, V93, P14486, DOI 10.1073/pnas.93.25.14486; Srinivasula SM, 1997, J BIOL CHEM, V272, P18542, DOI 10.1074/jbc.272.30.18542; Testa U, 1996, BLOOD, V88, P3391, DOI 10.1182/blood.V88.9.3391.bloodjournal8893391; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; TSAI FY, 1994, NATURE, V371, P221, DOI 10.1038/371221a0; Varfolomeev EE, 1998, IMMUNITY, V9, P267, DOI 10.1016/S1074-7613(00)80609-3; Vincenz C, 1997, J BIOL CHEM, V272, P6578, DOI 10.1074/jbc.272.10.6578; Vyas P, 1999, BLOOD, V93, P2867; WEISS MJ, 1995, EXP HEMATOL, V23, P99; WEISS MJ, 1995, P NATL ACAD SCI USA, V92, P9623, DOI 10.1073/pnas.92.21.9623; Young NS, 1997, NEW ENGL J MED, V336, P1365, DOI 10.1056/NEJM199705083361906; Zhou Q, 1997, J BIOL CHEM, V272, P7797, DOI 10.1074/jbc.272.12.7797	28	322	330	1	18	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	SEP 30	1999	401	6752					489	493		10.1038/46809	http://dx.doi.org/10.1038/46809			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	243DF	10519553				2022-12-01	WOS:000082981200059
J	Kotagal, UR; Atherton, HD; Eshett, R; Schoettker, PJ; Perlstein, PH				Kotagal, UR; Atherton, HD; Eshett, R; Schoettker, PJ; Perlstein, PH			Safety of early discharge for Medicaid newborns	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HOSPITAL READMISSION; STAY	Context Neonates are being discharged from the hospital more rapidly, but the risks associated with this practice, especially for low-income populations, are unclear. Objective To determine the impact of decreasing postnatal length of stay on rehospitalization rates in the immediate postdischarge period for Medicaid neonates. Design and Setting Retrospective, population-based cohort study using Ohio Medicaid claims data linked to vital statistics files from July 1, 1991, to June 15, 1995. Participants A total of 102 678 full-term neonates born to mothers receiving Medicaid for at least 30 days after birth. Main Outcome Measures Rehospitalization rates within 7 and 14 days of discharge, postdischarge health care use, and regional variations in length of stay and rehospitalization. Results The proportion of neonates who were discharged following a short stay (less than 1 day after vaginal delivery, less than 2 days after cesarean birth) increased 185%, from 21 % to 59.8% (P<.001) and the mean (SD) length of stay decreased 27%, from 2.2 (1.0) to 1.6 (0.9) days (P<.001), over the course of the study, The proportion of neonates who received a primary care visit within 14 days of birth increased 117% (P = .001). Rehospitalization rates within 7 and 14 days of discharge decreased by 23 %, from 1.3 % to 1.0% (P = .01), and by 19%, from 2.1% to 1.7% (P = .03), respectively. Short stay across the 6 regions of the state varied significantly over time (P<.001), Factors significantly associated with increased likelihood of rehospitalization within both 7 and 14 days of discharge were white race, shorter gestation, primiparity, earlier year of birth, lower 5-minute Apgar score, vaginal delivery, married mother, and region of the state. Conclusion Our data suggest that reductions in length of stay for full-term Medicaid newborns in Ohio have not resulted in an increase in rehospitalization rates in the immediate postnatal period.	Childrens Hosp, Med Ctr, Dept Pediat, Div Hlth Policy & Clin Effectiveness, Cincinnati, OH 45229 USA; Childrens Hosp, Med Ctr, Div Neonatol, Div Hlth Policy & Clin Effectiveness, Cincinnati, OH 45229 USA; Univ Cincinnati, Inst Hlth Policy & Hlth Serv Res, Cincinnati, OH USA; Ohio Dept Human Serv, Bur Medicaid Policy, Columbus, OH USA	Cincinnati Children's Hospital Medical Center; Cincinnati Children's Hospital Medical Center; University System of Ohio; University of Cincinnati	Kotagal, UR (corresponding author), Childrens Hosp, Med Ctr, Dept Pediat, Div Hlth Policy & Clin Effectiveness, 3333 Burnet Ave, Cincinnati, OH 45229 USA.							ADEBONOJO FO, 1973, CLIN PEDIATR, V12, P644, DOI 10.1177/000992287301201107; Bragg EJ, 1997, OBSTET GYNECOL, V89, P930, DOI 10.1016/S0029-7844(97)85764-X; BRAVEMAN P, 1995, PEDIATRICS, V96, P716; BRITTON JR, 1994, PEDIATRICS, V94, P291; CATZ C, 1995, PEDIATRICS, V96, P743; CONRAD PD, 1989, AM J DIS CHILD, V143, P98, DOI 10.1001/archpedi.1989.02150130108026; COOPER WO, 1995, PEDIATRICS, V96, P957; COTTRELL DG, 1983, J AM OSTEOPATH ASSOC, V83, P216; Czarnecki M T, 1996, J Nurs Care Qual, V10, P1; Edmonson MB, 1997, JAMA-J AM MED ASSOC, V278, P299, DOI 10.1001/jama.278.4.299; Fox M H, 1995, Am J Med Qual, V10, P206, DOI 10.1177/0885713X9501000407; KELLERMANN AL, 1994, NEW ENGL J MED, V330, P1426; Kotagal UR, 1996, J PEDIATR GASTR NUTR, V22, P402, DOI 10.1097/00005176-199605000-00012; KRAMER MS, 1991, PEDIATRICS, V87, P399; LEE KS, 1995, J PEDIATR-US, V127, P758, DOI 10.1016/S0022-3476(95)70170-2; Liu LL, 1997, JAMA-J AM MED ASSOC, V278, P293, DOI 10.1001/jama.278.4.293; Maisels MJ, 1998, PEDIATRICS, V101, P995, DOI 10.1542/peds.101.6.995; *NAT CTR HLTH STAT, 1995, HLTH PEOPL 2000 REV; Norr K F, 1989, J Obstet Gynecol Neonatal Nurs, V18, P133, DOI 10.1111/j.1552-6909.1989.tb00476.x; *OH DEP HLTH, 1977, STAT PER GUID; PIPER JM, 1993, AM J EPIDEMIOL, V137, P758, DOI 10.1093/oxfordjournals.aje.a116736; PITTARD WB, 1988, J PEDIATR-US, V112, P257, DOI 10.1016/S0022-3476(88)80066-0; Pruett S H, 1996, Am J Med Qual, V11, pS39; RASK KJ, 1994, JAMA-J AM MED ASSOC, V271, P1931, DOI 10.1001/jama.271.24.1931; RYAN AS, 1991, PEDIATRICS, V88, P719; Smith R D, 1988, Pediatr Emerg Care, V4, P107, DOI 10.1097/00006565-198806000-00005; SPONG FW, 1997, INPATIENT CARE MOTHE	27	59	59	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 22	1999	282	12					1150	1156		10.1001/jama.282.12.1150	http://dx.doi.org/10.1001/jama.282.12.1150			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	236JJ	10501118				2022-12-01	WOS:000082596200030
J	Jeon, M; Gardner, HF; Miller, EA; Deshler, J; Rougvie, AE				Jeon, M; Gardner, HF; Miller, EA; Deshler, J; Rougvie, AE			Similarity of the C-elegans developmental timing protein LIN-42 to circadian rhythm proteins	SCIENCE			English	Article							MINDED GENE ENCODES; CAENORHABDITIS-ELEGANS; SECONDARY STRUCTURE; NUCLEAR-PROTEIN; TIMELESS; PERIOD; CLOCK; TRANSCRIPTION; LOOP; EXPRESSION	The Caenorhabditis elegans heterochronic genes control the relative timing and sequence of many events during postembryonic development, including the terminal differentiation of the Lateral hypodermis, which occurs during the final (fourth) molt. Inactivation of the heterochronic gene lin-42 causes hypodermal terminal differentiation to occur precociously, during the third molt. LIN-42 most closely resembles the Period family of proteins from Drosophila and other organisms, proteins that function in another type of biological timing mechanism: the timing of circadian rhythms. Per mRNA Levels oscillate with an approximately 24-hour periodicity. lin-42 mRNA Levels also oscillate, but with a faster rhythm; the oscillation occurs relative to the approximately 6-hour molting cycles of postembryonic development.	Univ Minnesota, Dept Genet Cell Biol & Dev, St Paul, MN 55108 USA; Univ Minnesota, Dept Biochem Mol Biol & Biophys, St Paul, MN 55108 USA	University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities	Rougvie, AE (corresponding author), Univ Minnesota, Dept Genet Cell Biol & Dev, St Paul, MN 55108 USA.				NICHD NIH HHS [HD007480] Funding Source: Medline; NIGMS NIH HHS [GM50227] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM050227] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abrahante JE, 1998, GENETICS, V149, P1335; AMBROS V, 1989, CELL, V57, P49, DOI 10.1016/0092-8674(89)90171-2; AMBROS V, 1997, C ELEGANS, V2, P501; Bettinger JC, 1996, DEVELOPMENT, V122, P2517; CREWS ST, 1988, CELL, V52, P143, DOI 10.1016/0092-8674(88)90538-7; Darlington TK, 1998, SCIENCE, V280, P1599, DOI 10.1126/science.280.5369.1599; Dunlap JC, 1999, CELL, V96, P271, DOI 10.1016/S0092-8674(00)80566-8; EBENS AJ, 1993, CELL, V74, P15, DOI 10.1016/0092-8674(93)90291-W; EVANS MMS, 1994, DEVELOPMENT, V120, P1971; FIRE A, COMMUNICATION; GEKAKIS N, 1995, SCIENCE, V270, P811, DOI 10.1126/science.270.5237.811; HARDIN PE, 1990, NATURE, V343, P536, DOI 10.1038/343536a0; IWASAKI K, 1995, P NATL ACAD SCI USA, V92, P10317, DOI 10.1073/pnas.92.22.10317; JEON M, UNPUB; Johnstone IL, 1996, EMBO J, V15, P3633, DOI 10.1002/j.1460-2075.1996.tb00732.x; King DP, 1997, CELL, V89, P641, DOI 10.1016/S0092-8674(00)80245-7; Larminie CGC, 1996, DNA CELL BIOL, V15, P75, DOI 10.1089/dna.1996.15.75; LEE RC, 1993, CELL, V75, P843, DOI 10.1016/0092-8674(93)90529-Y; LINDEBRO MC, 1995, EMBO J, V14, P3528, DOI 10.1002/j.1460-2075.1995.tb07359.x; LIU Z, 1990, THESIS HARVARD U; MELLO CC, 1991, EMBO J, V10, P3959, DOI 10.1002/j.1460-2075.1991.tb04966.x; Moss EG, 1997, CELL, V88, P637, DOI 10.1016/S0092-8674(00)81906-6; NAMBU JR, 1991, CELL, V67, P1157, DOI 10.1016/0092-8674(91)90292-7; POETHIG RS, 1988, GENETICS, V119, P959; ROST B, 1994, PROTEINS, V19, P55, DOI 10.1002/prot.340190108; ROST B, 1993, J MOL BIOL, V232, P584, DOI 10.1006/jmbi.1993.1413; RUVKUN G, 1989, NATURE, V338, P313, DOI 10.1038/338313a0; Saez L, 1996, NEURON, V17, P911, DOI 10.1016/S0896-6273(00)80222-6; Sangoram AM, 1998, NEURON, V21, P1101, DOI 10.1016/S0896-6273(00)80627-3; SEHGAL A, 1995, SCIENCE, V270, P808, DOI 10.1126/science.270.5237.808; Telfer A, 1998, DEVELOPMENT, V125, P1889; VOSSHALL LB, 1994, SCIENCE, V263, P1606, DOI 10.1126/science.8128247; Zylka MJ, 1998, NEURON, V21, P1115, DOI 10.1016/S0896-6273(00)80628-5	33	137	144	0	12	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 5	1999	286	5442					1141	1146		10.1126/science.286.5442.1141	http://dx.doi.org/10.1126/science.286.5442.1141			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	253AJ	10550049				2022-12-01	WOS:000083534200039
J	Nordmann, A; Frach, B; Walker, T; Martina, B; Battegay, E				Nordmann, A; Frach, B; Walker, T; Martina, B; Battegay, E			Reliability of patients measuring blood pressure at home: prospective observational study	BMJ-BRITISH MEDICAL JOURNAL			English	Article									Univ Basel Hosp, Dept Internal Med, Med Outpatient Div, CH-4031 Basel, Switzerland	University of Basel	Battegay, E (corresponding author), Univ Basel Hosp, Dept Internal Med, Med Outpatient Div, CH-4031 Basel, Switzerland.	battegay@ubaclu.unibas.ch						[Anonymous], 1997, ARCH INTERN MED, V157, P2413, DOI DOI 10.1001/ARCHINTE.157.21.2413; AUDET AM, 1993, ANN INTERN MED, V118, P889, DOI 10.7326/0003-4819-118-11-199306010-00010; CAMPBELL NRC, 1995, CAN J CARDIOL SH, P18; JULIUS S, 1990, HYPERTENSION, V16, P617, DOI 10.1161/01.HYP.16.6.617; Ohkubo T, 1998, J HYPERTENS, V16, P971, DOI 10.1097/00004872-199816070-00010	5	53	55	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	OCT 30	1999	319	7218					1172	1172		10.1136/bmj.319.7218.1172	http://dx.doi.org/10.1136/bmj.319.7218.1172			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	253BF	10541509	Bronze, Green Published			2022-12-01	WOS:000083536200024
J	Draper, ES; Manktelow, B; Field, DJ; James, D				Draper, ES; Manktelow, B; Field, DJ; James, D			Prediction of survival for preterm births by weight and gestational age: restrospective population based study	BRITISH MEDICAL JOURNAL			English	Article							NEONATAL-MORTALITY; INFANTS; ORIGIN	Objective To produce current data on survival of preterm infants. Design Retrospective population based study. Setting Trent health region. Subjects All European and Asian live births, stillbirths, and late fetal losses from 22 to 32 weeks' gestation, excluding those with major congenital malformations, in women resident in the Trent health region between 1 January 1994 and 31 December 1997. Main outcome measures Birth weight and gestational age specific survival for both European and Asian infants (a) known to be alive at the onset of labour and (b) admitted for neonatal care. Results 738 deaths occurred in 3760 infants born between 22 and 32 weeks' gestation during the study period, giving an overall survival rate of 80.4%. The survival rate for the 3489 (92.8%) infants admitted for neonatal care was 86.6%. For European infants known to be alive at the onset of labour, significant variations in gestation specific survival by birth weight emerged from 24 weeks' gestation: survival ranged from 9% (95% confidence interval 7% to 13%) for infants of birth weight 250-499 g to 21% (16% to 28%) for those of 1000-1249 g. At 27 weeks' gestation, survival ranged from 55% (49% to 61%) for infants of birth weight 500-749 g (below the 10th centile) to 80% (76%, to 85%) for those of 1250-1499 g. Infants who were large for dates (greater than or equal to 27 weeks' gestation) had a slightly reduced, but not significant, predicted survival. Similar survival rates were observed for Asian infants. The odds ratio for the survival of infants from a multiple birth compared with singleton infants was 1.4 (1.1 to 1.8). Survival graphs for infants admitted for neonatal care are presented by sex. Conclusion Easy to use birth weight and gestational age specific predicted survival graphs for preterm infants facilitate decision making for clinicians and parents. It is important that these graphs are representative, are produced for a geographically defined population, and are not biased towards the outcomes of particular centres. Such graphs, produced in two stages, allow for the changing pattern of survival of infants from the start of the intrapartum period to immediately after admission for neonatal care.	Univ Leicester, Sch Med, Dept Epidemiol & Publ Hlth, Leicester LE1 6TP, Leics, England; Leicester Royal Infirm, Dept Child Hlth, Leicester LE2 7LX, Leics, England; Univ Nottingham, Queens Med Ctr, Dept Obstet & Gynaecol, Nottingham NG7 2UH, England	University of Leicester; University of Leicester; University of Nottingham	Draper, ES (corresponding author), Univ Leicester, Sch Med, Dept Epidemiol & Publ Hlth, Leicester LE1 6TP, Leics, England.		Draper, Elizabeth/S-6874-2019; Draper, Elizabeth S/I-6304-2018; Manktelow, Bradley N/G-2794-2011	Draper, Elizabeth/0000-0001-9340-8176; Draper, Elizabeth S/0000-0001-9340-8176; Manktelow, Bradley N/0000-0002-3264-0323				BURTON P, 1995, J EPIDEMIOL PUBLIC H, V48, P617; Cartlidge PHT, 1997, ACTA PAEDIATR, V86, P105, DOI 10.1111/j.1651-2227.1997.tb08842.x; CLARKE M, 1996, CONFIDENTIAL ENQUIRY; Cooper TR, 1998, PEDIATRICS, V101, P975, DOI 10.1542/peds.101.6.975; COPPER RL, 1993, AM J OBSTET GYNECOL, V168, P78, DOI 10.1016/S0002-9378(12)90889-3; FIELD D, 1987, PEDIAT PULMONOL, V8, P231; FIELD DJ, 1989, BRIT MED J, V299, P1305, DOI 10.1136/bmj.299.6711.1305; FIELD DJ, 1985, BMJ-BRIT MED J, V290, P1539, DOI 10.1136/bmj.290.6481.1539; FuentesAfflick E, 1997, AM J EPIDEMIOL, V145, P148, DOI 10.1093/oxfordjournals.aje.a009085; GREENBERG DN, 1993, PEDIATRICS, V91, P572; HOSMER DW, 1980, COMMUN STAT A-THEOR, V9, P1043, DOI 10.1080/03610928008827941; Rennie JM, 1996, ARCH DIS CHILD-FETAL, V74, pF214, DOI 10.1136/fn.74.3.F214; Tin W, 1997, BMJ-BRIT MED J, V314, P107, DOI 10.1136/bmj.314.7074.107; VERLOOVEVANHORICK SP, 1986, LANCET, V1, P55; WOLF EJ, 1992, OBSTET GYNECOL, V80, P436; YUKSEL B, 1995, THORAX, V50, P773, DOI 10.1136/thx.50.7.773	16	157	167	0	6	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	OCT 23	1999	319	7217					1093	1097		10.1136/bmj.319.7217.1093	http://dx.doi.org/10.1136/bmj.319.7217.1093			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	250ZE	10531097	Green Published, Bronze			2022-12-01	WOS:000083419500020
J	Glossop, NRJ; Lyons, LC; Hardin, PE				Glossop, NRJ; Lyons, LC; Hardin, PE			Interlocked feedback loops within the Drosophila circadian oscillator	SCIENCE			English	Article							PERIOD PROTEIN; CLOCK GENE; BEHAVIORAL RHYTHMS; DOUBLE-TIME; TRANSCRIPTION; EXPRESSION; PHOSPHORYLATION; HOMOLOG; SYSTEM; BRAIN	Drosophila Clock (dClk) is rhythmically expressed, with peaks in mRNA and protein (dCLK) abundance early in the morning. dClk mRNA cycling is shown here to be regulated by PERIOD-TIMELESS (PER-TIM)-mediated release of dCLK- and CYCLE (CYC)-dependent repression. Lack of both PER-TIM derepression and dCLK-CYC repression results in high levels of dClk mRNA, which implies that a separate dClk activator is present. These results demonstrate that the Drosophila circadian feedback loop is composed of two interlocked negative feedback Loops: a per-tim loop, which is activated by dCLK-CYC and repressed by PER-TIM, and a dClk Loop, which is repressed by dCLK-CYC and derepressed by PER-TIM.	Univ Houston, Dept Biol & Biochem, Houston, TX 77204 USA; Univ Houston, Biol Clocks Program, Houston, TX 77204 USA	University of Houston System; University of Houston; University of Houston System; University of Houston	Hardin, PE (corresponding author), Univ Houston, Dept Biol & Biochem, Houston, TX 77204 USA.			Hardin, Paul/0000-0002-3370-9011	NINDS NIH HHS [NS-31214] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R29NS031214, R01NS031214] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Allada R, 1998, CELL, V93, P791, DOI 10.1016/S0092-8674(00)81440-3; Bae K, 1998, MOL CELL BIOL, V18, P6142, DOI 10.1128/MCB.18.10.6142; CURTIN KD, 1995, NEURON, V14, P365, DOI 10.1016/0896-6273(95)90292-9; Darlington TK, 1998, SCIENCE, V280, P1599, DOI 10.1126/science.280.5369.1599; Dunlap JC, 1999, CELL, V96, P271, DOI 10.1016/S0092-8674(00)80566-8; EDERY I, 1994, P NATL ACAD SCI USA, V91, P2260, DOI 10.1073/pnas.91.6.2260; Emery P, 1998, CELL, V95, P669, DOI 10.1016/S0092-8674(00)81637-2; EWER J, 1992, J NEUROSCI, V12, P3321; FRISCH B, 1994, NEURON, V12, P555, DOI 10.1016/0896-6273(94)90212-7; Gekakis N, 1998, SCIENCE, V280, P1564, DOI 10.1126/science.280.5369.1564; Hao HP, 1997, MOL CELL BIOL, V17, P3687, DOI 10.1128/MCB.17.7.3687; HARDIN PE, 1990, NATURE, V343, P536, DOI 10.1038/343536a0; Helfrich-Forster C, 1998, J COMP PHYSIOL A, V182, P435, DOI 10.1007/s003590050192; Jin XW, 1999, CELL, V96, P57, DOI 10.1016/S0092-8674(00)80959-9; Kloss B, 1998, CELL, V94, P97, DOI 10.1016/S0092-8674(00)81225-8; Lee C, 1999, MOL CELL BIOL, V19, P5316; Lee CG, 1998, NEURON, V21, P857, DOI 10.1016/S0896-6273(00)80601-7; MEESE DA, 1994, 941 CRREL REPORT; Plautz JD, 1997, SCIENCE, V278, P1632, DOI 10.1126/science.278.5343.1632; Price JL, 1998, CELL, V94, P83, DOI 10.1016/S0092-8674(00)81224-6; Rutila JE, 1998, CELL, V93, P805, DOI 10.1016/S0092-8674(00)81441-5; SEHGAL A, 1995, SCIENCE, V270, P808, DOI 10.1126/science.270.5237.808; SEHGAL A, 1994, SCIENCE, V263, P1603, DOI 10.1126/science.8128246; SO VW, 1997, EMBO J, V16, P7146; ZERR DM, 1990, J NEUROSCI, V10, P2749	25	302	311	1	19	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	OCT 22	1999	286	5440					766	768		10.1126/science.286.5440.766	http://dx.doi.org/10.1126/science.286.5440.766			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	248XZ	10531060				2022-12-01	WOS:000083303200052
J	McAlister, FA; Laupacis, A; Wells, GA; Sackett, DL				McAlister, FA; Laupacis, A; Wells, GA; Sackett, DL		Evidence-Based Med Working Grp	Users' Guides to the Medical Literature - XIX. Applying clinical trial results - B. Guidelines for determining whether a drug is exerting (more than) a class effect	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							AVERAGE CHOLESTEROL LEVELS; CORONARY HEART-DISEASE; MYOCARDIAL-INFARCTION; SECONDARY PREVENTION; RANDOMIZED TRIALS; DOUBLE-BLIND; RISK; PRAVASTATIN; HYPERCHOLESTEROLEMIA; TECHNOLOGY		John Radcliffe Hosp, Natl Hlth Serv Res & Dev Ctr Evidence Based Med, Oxford OX3 9DU, England; Ottawa Hosp, Div Gen Internal Med, Ottawa, ON, Canada; Loeb Hlth Res Inst, Clin Epidemiol Unit, Ottawa, ON, Canada	University of Oxford; University of Ottawa; Ottawa Hospital Research Institute; University of Ottawa; Ottawa Hospital Research Institute	McAlister, FA (corresponding author), McMaster Univ, Hlth Sci Ctr, 1200 Main St W,Room 2C12, Hamilton, ON L8N 3Z5, Canada.		Wells, George A/M-4549-2017; McAlister, Finlay/C-4151-2013	Wells, George A/0000-0002-2289-9139; McAlister, Finlay/0000-0001-7435-3341				ALTMAN R, 1994, BMJ-BRIT MED J, V308, P81, DOI 10.1136/bmj.308.6921.81; ANDERSON KM, 1991, CIRCULATION, V83, P356, DOI 10.1161/01.CIR.83.1.356; [Anonymous], 1990, LANCET, V336, P65; [Anonymous], 1994, BMJ-BRIT MED J, V308, P81, DOI DOI 10.1136/BMJ.308.6921.81; Avorn J, 1998, JAMA-J AM MED ASSOC, V279, P1458, DOI 10.1001/jama.279.18.1458; BOISSEL JP, 1990, AM J CARDIOL, V66, P251, DOI 10.1016/0002-9149(90)90831-K; Bucher HC, 1997, J CLIN EPIDEMIOL, V50, P683, DOI 10.1016/S0895-4356(97)00049-8; Bucher HC, 1999, JAMA-J AM MED ASSOC, V282, P771, DOI 10.1001/jama.282.8.771; COLLINS R, 1990, LANCET, V335, P827, DOI 10.1016/0140-6736(90)90944-Z; COOK RJ, 1995, PLANT PHYSIOL, V108, P4; Dans AL, 1998, JAMA-J AM MED ASSOC, V279, P545, DOI 10.1001/jama.279.7.545; DONNER A, 1984, STAT MED, V3, P199, DOI 10.1002/sim.4780030302; Downs JR, 1998, JAMA-J AM MED ASSOC, V279, P1615, DOI 10.1001/jama.279.20.1615; Drummond MF, 1997, JAMA-J AM MED ASSOC, V277, P1552, DOI 10.1001/jama.277.19.1552; Fager G, 1997, ARTERIOSCL THROM VAS, V17, P3527, DOI 10.1161/01.ATV.17.12.3527; Furberg CD, 1996, AM J HYPERTENS, V9, P122, DOI 10.1016/0895-7061(96)00014-3; GARG R, 1995, JAMA-J AM MED ASSOC, V273, P1450, DOI 10.1001/jama.273.18.1450; GOLDBLOOM R, 1988, CAN MED ASSOC J, V138, P618; Gotto AM, 1997, CIRCULATION, V96, P4424; Grover SA, 1998, ARCH INTERN MED, V158, P655, DOI 10.1001/archinte.158.6.655; Grover SA, 1998, ARCH INTERN MED, V158, P1228; GUYATT GH, 1995, JAMA-J AM MED ASSOC, V274, P1800, DOI 10.1001/jama.274.22.1800; HUNT D, 1992, LANCET, V339, P753; Jones P, 1998, AM J CARDIOL, V81, P582, DOI 10.1016/S0002-9149(97)00965-X; Korttila K, 1997, ACTA ANAESTH SCAND, V41, P914, DOI 10.1111/j.1399-6576.1997.tb04809.x; Lacour A, 1998, CAN J CARDIOL, V14, P355; LAUPACIS A, 1992, CAN MED ASSOC J, V146, P473; LAW MR, 1994, BMJ-BRIT MED J, V308, P367, DOI 10.1136/bmj.308.6925.367; Marshall WJS, 1998, CAN MED ASSOC J, V158, P489; McAlister FA, 1997, DRUGS, V54, P235, DOI 10.2165/00003495-199754020-00003; McDonald CJ, 1996, ANN INTERN MED, V124, P56, DOI 10.7326/0003-4819-124-1_Part_1-199601010-00009; Naguib M, 1996, CAN J ANAESTH, V43, P226, DOI 10.1007/BF03011739; NAYLOR CD, 1993, CAN MED ASSOC J, V148, P921; OXMAN AD, 1992, ANN INTERN MED, V116, P78, DOI 10.7326/0003-4819-116-1-78; Packard CJ, 1998, CIRCULATION, V97, P1440; PEDERSEN TR, 1995, LANCET, V345, P1274; PEDERSEN TR, 1994, LANCET, V344, P1383; Psaty BM, 1996, AM J HYPERTENS, V9, P178, DOI 10.1016/0895-7061(96)00015-5; Rosenson RS, 1998, JAMA-J AM MED ASSOC, V279, P1643, DOI 10.1001/jama.279.20.1643; ROTHWELL PM, 1995, LANCET, V345, P1616, DOI 10.1016/S0140-6736(95)90120-5; SACKETT DL, 1980, MONITORING DRUG SAFE, P427; SACKS FM, 1995, AM J CARDIOL, V76, pC78, DOI 10.1016/S0002-9149(99)80475-5; Sacks FM, 1998, CIRCULATION, V97, P1446; Sacks FM, 1996, NEW ENGL J MED, V335, P1001, DOI 10.1056/NEJM199610033351401; SHEPHERD J, 1995, NEW ENGL J MED, V333, P1301, DOI 10.1056/NEJM199511163332001; Skolnick AA, 1998, JAMA-J AM MED ASSOC, V280, P683, DOI 10.1001/jama.280.8.683; SMITH GD, 1993, BMJ-BRIT MED J, V306, P1367, DOI 10.1136/bmj.306.6889.1367; SMITH GD, 1993, BRIT MED J, V306, P1648; Tonkin A, 1998, NEW ENGL J MED, V339, P1349; Tu JV, 1998, CAN J CARDIOL, V14, P349; Waldo AL, 1996, LANCET, V348, P7, DOI 10.1016/S0140-6736(96)02149-6; YUSUF S, 1985, PROG CARDIOVASC DIS, V27, P335, DOI 10.1016/S0033-0620(85)80003-7; YUSUF S, 1991, JAMA-J AM MED ASSOC, V266, P93, DOI 10.1001/jama.266.1.93	53	131	133	0	3	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 13	1999	282	14					1371	1377		10.1001/jama.282.14.1371	http://dx.doi.org/10.1001/jama.282.14.1371			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	243MB	10527185				2022-12-01	WOS:000083000800033
J	Cassell, EJ				Cassell, EJ			Diagnosing suffering: A perspective	ANNALS OF INTERNAL MEDICINE			English	Article									Cornell Univ, Weill Med Coll, New York, NY USA	Cornell University	Cassell, EJ (corresponding author), 28 Old Fulton St, Brooklyn, NY 11201 USA.		COZZA, DEBORA/AAH-2572-2021; De Carlo, Esterina/Q-1309-2016	COZZA, DEBORA/0000-0002-1730-089X; De Carlo, Esterina/0000-0001-7883-1283				CASSEL EJ, 1982, NEW ENGL J MED, V306, P639, DOI 10.1056/NEJM198203183061104; CASSELL EJ, 1991, NATURE SUFFERING GOA, P30; CASSELL EJ, 1997, DOCTORING NATURE PRI, P121; DAVIDOFF F, 1996, WHO HAS SEEN BLOOD S, P141; Emanuel EJ, 1998, LANCET, V351, P21, DOI 10.1016/S0140-6736(98)90329-4; Field MJ, 1997, APPROACHING DEATH IM; FOLEY KM, 1995, PAIN FORUM, V4, P163; HUNTER KM, 1991, DOCTORS STORIES NARR, P121; LAUER Q, 1978, TRIUMPH SUBJECTIVITY, P70; LOCKE J, 1995, ESSAY HUMAN UNDERSTA, P433; Lynn J, 1997, J AM GERIATR SOC, V45, P526; PLATT FW, 1994, J GEN INTERN MED, V9, P222, DOI 10.1007/BF02600129; Schulman KA, 1999, NEW ENGL J MED, V340, P618, DOI 10.1056/NEJM199902253400806; Singer PA, 1999, JAMA-J AM MED ASSOC, V281, P163, DOI 10.1001/jama.281.2.163	14	184	186	0	14	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	OCT 5	1999	131	7					531	534		10.7326/0003-4819-131-7-199910050-00009	http://dx.doi.org/10.7326/0003-4819-131-7-199910050-00009			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	243VU	10507963				2022-12-01	WOS:000083018800007
J	Benedetti, LR; Nguyen, JH; Caldwell, WA; Liu, HJ; Kruger, M; Jeanloz, R				Benedetti, LR; Nguyen, JH; Caldwell, WA; Liu, HJ; Kruger, M; Jeanloz, R			Dissociation of CH4 at high pressures and temperatures: Diamond formation in giant planet interiors?	SCIENCE			English	Article							CHEMICAL-VAPOR-DEPOSITION; X-RAY-DIFFRACTION; METHANE; URANUS; HYDROCARBONS; NEPTUNE; FILMS; MBAR; GPA	Experiments using Laser-heated diamond anvil cells show that methane (CH4) breaks down to form diamond at pressures between 10 and 50 gigapascals and temperatures of about 2000 to 3000 kelvin. Infrared absorption and Raman spectroscopy, along with x-ray diffraction, indicate the presence of polymeric hydrocarbons in addition to the diamond, which is in agreement with theoretical predictions, Dissociation of CH4 at high pressures and temperatures can influence the energy budgets of planets containing substantial amounts of CH4, water, and ammonia, such as Uranus and Neptune.	Univ Calif Berkeley, Dept Phys, Berkeley, CA 94720 USA; Univ Calif Berkeley, Dept Geol & Geophys, Berkeley, CA 94720 USA; Univ Calif Berkeley, Dept Astron, Berkeley, CA 94720 USA; Univ Calif Berkeley, Miller Inst Basic Res Sci, Berkeley, CA 94720 USA; Univ Calif Lawrence Livermore Natl Lab, Phys Directorate, Div H, Livermore, CA 94551 USA; Univ Missouri, Dept Phys, Kansas City, MO 64110 USA	University of California System; University of California Berkeley; University of California System; University of California Berkeley; University of California System; University of California Berkeley; University of California System; University of California Berkeley; United States Department of Energy (DOE); Lawrence Livermore National Laboratory; University of California System; University of Missouri System; University of Missouri Kansas City	Benedetti, LR (corresponding author), Univ Calif Berkeley, Dept Phys, Berkeley, CA 94720 USA.							Ancilotto F, 1997, SCIENCE, V275, P1288, DOI 10.1126/science.275.5304.1288; ANGUS JC, 1993, PHILOS T ROY SOC A, V342, P195, DOI 10.1098/rsta.1993.0014; ATOU T, 1995, J SOLID STATE CHEM, V118, P299, DOI 10.1006/jssc.1995.1348; BADDING JV, 1991, SCIENCE, V253, P412; BENEDETTI LR, UNPUB; Bini R, 1997, PHYS REV B, V55, P14800, DOI 10.1103/PhysRevB.55.14800; BLOCK S, 1970, SCIENCE, V169, P586, DOI 10.1126/science.169.3945.586; Bloss FD., 1961, INTRO METHODS OPTICA, V116, P485, DOI 10.1524/zkri.1961.116.3-6.485; BUTLER RN, UNPUB; HUBBARD WB, 1991, SCIENCE, V253, P648, DOI 10.1126/science.253.5020.648; Jeanloz R, 1996, PHILOS T R SOC A, V354, P1279, DOI 10.1098/rsta.1996.0049; Kavner A, 1998, J APPL PHYS, V83, P7553, DOI 10.1063/1.367520; KLAGES CP, 1993, APPL PHYS A-MATER, V56, P513, DOI 10.1007/BF00331401; Liebert J, 1999, NATURE, V400, P316, DOI 10.1038/22430; Loubeyre P, 1996, NATURE, V383, P702, DOI 10.1038/383702a0; MAO HK, 1979, REV SCI INSTRUM, V50, P1002, DOI 10.1063/1.1135966; MAO HK, 1978, J APPL PHYS, V49, P3276, DOI 10.1063/1.325277; Michler J, 1998, J APPL PHYS, V83, P187, DOI 10.1063/1.366672; NELLIS WJ, 1981, J CHEM PHYS, V75, P3055, DOI 10.1063/1.442401; NGUYEN JH, 1993, REV SCI INSTRUM, V64, P3456, DOI 10.1063/1.1144267; Oppenheimer BR, 1998, ASTROPHYS J, V502, P932, DOI 10.1086/305928; RADOUSKY HB, 1990, J CHEM PHYS, V93, P8235, DOI 10.1063/1.459302; REE FH, 1979, J CHEM PHYS, V70, P974, DOI 10.1063/1.437487; ROSS M, 1981, NATURE, V292, P435, DOI 10.1038/292435a0; WENTORF RH, 1965, J PHYS CHEM-US, V69, P3063, DOI 10.1021/j100893a041; WU YH, 1995, J RAMAN SPECTROSC, V26, P963, DOI 10.1002/jrs.1250261007; Yoshimoto M, 1999, NATURE, V399, P340, DOI 10.1038/20653	27	143	147	2	62	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	OCT 1	1999	286	5437					100	102		10.1126/science.286.5437.100	http://dx.doi.org/10.1126/science.286.5437.100			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	241WT	10506552				2022-12-01	WOS:000082907400042
J	Shellens, T				Shellens, T			The legal position	BRITISH MEDICAL JOURNAL			English	Article									Bevam Ashford Solicitors, Cardiff CF240BA, S Glam, Wales		Shellens, T (corresponding author), Bevam Ashford Solicitors, Waterloo House,Fitzalan Court, Cardiff CF240BA, S Glam, Wales.							Caldicott Committee Department of Health, 1997, REP REV PAT ID INF; *DEP HLTH WELSH OF, 1996, GUID PROT US PAT INF	2	0	0	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	AUG 7	1999	319	7206					374	374						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	226CA	10490323				2022-12-01	WOS:000082001700031
J	Stone, SL; Arnoldo, M; Goring, DR				Stone, SL; Arnoldo, M; Goring, DR			A breakdown of Brassica self-incompatibility in ARC1 antisense transgenic plants	SCIENCE			English	Article							LOCUS RECEPTOR KINASE; PROTEIN PHOSPHATASE; STIGMA PAPILLAE; GENE; OLERACEA; PHENOTYPE; DOMAIN; SLG	Self-incompatibility, the rejection of self pollen, is the most widespread mechanism by which flowering plants prevent inbreeding. In Brassica, the S receptor kinase (SRK) has been implicated in the self-incompatibility response, but the molecular mechanisms involving SRK are unknown. One putative downstream effector for SRK is ARC1, a protein that binds to the SRK kinase domain. Here it is shown that suppression of ARC1 messenger RNA levels in the self-incompatible Brassica napus W1 line is correlated with a partial breakdown of self-incompatibility, resulting in seed production. This provides strong evidence that ARC1 is a positive effector of the Brassica self-incompatibility response.	York Univ, Dept Biol, Toronto, ON M3J 1P3, Canada; Canola Res Stn, Pioneer Hi Bred Prod, Georgetown, ON L7G 4S7, Canada	York University - Canada	Goring, DR (corresponding author), York Univ, Dept Biol, 4700 Keele St, Toronto, ON M3J 1P3, Canada.			Goring, Daphne/0000-0001-5295-4744; Stone, Sophia/0000-0003-2140-6037				Becraft PW, 1998, TRENDS PLANT SCI, V3, P384, DOI 10.1016/S1360-1385(98)01301-6; Bower MS, 1996, PLANT CELL, V8, P1641, DOI 10.1105/tpc.8.9.1641; Braun DM, 1996, TRENDS BIOCHEM SCI, V21, P70, DOI 10.1016/S0968-0004(96)80185-X; Cabrillac D, 1999, PLANT CELL, V11, P971, DOI 10.1105/tpc.11.5.971; DELORME V, 1995, PLANT J, V7, P429, DOI 10.1046/j.1365-313X.1995.7030429.x; DENATTANCOURT D, 1997, SEX PLANT REPROD, V10, P185; DICKINSON H, 1995, SEX PLANT REPROD, V8, P1, DOI 10.1007/BF00228756; Franklin TM, 1996, SEX PLANT REPROD, V9, P203, DOI 10.1007/BF02173099; GAUDE T, 1995, PLANT MOL BIOL, V27, P1003, DOI 10.1007/BF00037027; GORING DR, 1992, MOL GEN GENET, V234, P185, DOI 10.1007/BF00283838; GORING DR, 1992, PLANT CELL, V4, P1273, DOI 10.1105/tpc.4.10.1273; GORING DR, 1996, SIGNAL TRANSDUCTION; Gu TS, 1998, P NATL ACAD SCI USA, V95, P382, DOI 10.1073/pnas.95.1.382; Hatzfeld M, 1999, INT REV CYTOL, V186, P179; Hiscock SJ, 1996, TRENDS CELL BIOL, V6, P421, DOI 10.1016/S0962-8924(96)10037-4; KANDASAMY MK, 1989, DEV BIOL, V134, P462, DOI 10.1016/0012-1606(89)90119-X; MATTON DP, 1994, P NATL ACAD SCI USA, V91, P1992, DOI 10.1073/pnas.91.6.1992; NASRALLAH JB, 1994, SCIENCE, V266, P1506; NASRALLAH JB, 1985, NATURE, V318, P236; STEIN JC, 1991, P NATL ACAD SCI USA, V88, P8816, DOI 10.1073/pnas.88.19.8816; Stephenson AG, 1997, PLANT J, V12, P1351, DOI 10.1046/j.1365-313x.1997.12061351.x; Stone JM, 1998, PLANT PHYSIOL, V117, P1217, DOI 10.1104/pp.117.4.1217; Sulaman W, 1997, PLANTA, V203, P327, DOI 10.1007/s004250050198; Williams RW, 1997, P NATL ACAD SCI USA, V94, P10467, DOI 10.1073/pnas.94.19.10467	24	180	223	0	26	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 26	1999	286	5445					1729	1731		10.1126/science.286.5445.1729	http://dx.doi.org/10.1126/science.286.5445.1729			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	259UK	10576738				2022-12-01	WOS:000083912200036
J	Blass, JP				Blass, JP			Immunologic treatment of Alzheimer's disease	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Cornell Univ, Burke Med Res Inst, White Plains, NY 10605 USA	Cornell University	Blass, JP (corresponding author), Cornell Univ, Burke Med Res Inst, White Plains, NY 10605 USA.							BLASS JP, 1995, CLIN DIAGNOSIS MANAG, P17; Davis DG, 1999, J NEUROPATH EXP NEUR, V58, P376, DOI 10.1097/00005072-199904000-00008; Guo Q, 1999, J NEUROCHEM, V72, P1019, DOI 10.1046/j.1471-4159.1999.0721019.x; Schenk D, 1999, NATURE, V400, P173, DOI 10.1038/22124; Seabrook GR, 1999, NEUROPHARMACOLOGY, V38, P349, DOI 10.1016/S0028-3908(98)00204-4	5	11	27	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	NOV 25	1999	341	22					1694	1695		10.1056/NEJM199911253412213	http://dx.doi.org/10.1056/NEJM199911253412213			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	258PL	10572162				2022-12-01	WOS:000083847500013
J	Klebanoff, MA; Levine, RJ; DerSimonian, R; Clemens, JD; Wilkins, DG				Klebanoff, MA; Levine, RJ; DerSimonian, R; Clemens, JD; Wilkins, DG			Maternal serum paraxanthine, a caffeine metabolite, and the risk of spontaneous abortion	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							PREGNANCY; CONSUMPTION; BEVERAGES; COFFEE	Background: Whether the consumption of caffeine during pregnancy increases the risk of spontaneous abortion is controversial. Prior studies have determined caffeine consumption by questionnaire. We used a biologic marker, serum paraxanthine, a metabolite of caffeine, to measure the dose of caffeine. Methods: In a nested case-control study, we measured serum paraxanthine in 591 women who had spontaneous abortions at less than 140 days' gestation and in 2558 matched women from the same clinic who gave birth to live infants at 28 weeks' gestation or later and who had serum drawn on the same day of gestation as the women who had abortions. The women were enrolled in the Collaborative Perinatal Project during the period from 1959 to 1966, and serum paraxanthine was measured over 30 years later. Results: A total of 487 women who had spontaneous abortions (82 percent) and 2087 controls (82 percent) had quantifiable serum paraxanthine concentrations. However, the mean serum paraxanthine concentration was higher in the women who had spontaneous abortions than in the controls (752 vs. 583 ng per milliliter, P<0.001). The odds ratio for spontaneous abortion was not significantly elevated in the women who had serum paraxanthine concentrations of 1845 ng per milliliter or lower, corresponding to the 95th percentile of the matched women. However, the adjusted odds ratio for spontaneous abortion among women with serum paraxanthine concentrations higher than 1845 ng per milliliter, as compared with women who had concentrations below 50 ng per milliliter, was 1.9 (95 percent confidence interval, 1.2 to 2.8). Conclusions: Only extremely high serum paraxanthine concentrations are associated with spontaneous abortion. This suggests that moderate consumption of caffeine is unlikely to increase the risk of spontaneous abortion. (N Engl J Med 1999;341:1639-44.) (C) 1999, Massachusetts Medical Society.	NICHHD, Div Epidemiol Stat & Prevent Res, NIH, Bethesda, MD 20892 USA; Univ Utah, Ctr Human Toxicol, Salt Lake City, UT USA	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); Utah System of Higher Education; University of Utah	Klebanoff, MA (corresponding author), NICHHD, Div Epidemiol Stat & Prevent Res, NIH, 6100 Bldg,Rm 7B03,MSC 7510, Bethesda, MD 20892 USA.				NICHD NIH HHS [N01-HD-7-3262] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [Z01HD000373, N01HD073262] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ALDRIDGE A, 1981, SEMIN PERINATOL, V5, P310; ARMSTRONG BG, 1992, AM J PUBLIC HEALTH, V82, P85, DOI 10.2105/AJPH.82.1.85; BERGSJO P, 1989, ACTA OBSTET GYN SCAN, V68, P19, DOI 10.3109/00016348909087683; Dlugosz L, 1996, EPIDEMIOLOGY, V7, P250, DOI 10.1097/00001648-199605000-00006; ESKENAZI B, 1993, JAMA-J AM MED ASSOC, V270, P2973, DOI 10.1001/jama.270.24.2973; Fenster L, 1991, Epidemiology, V2, P168, DOI 10.1097/00001648-199105000-00002; Fenster L, 1997, EPIDEMIOLOGY, V8, P515, DOI 10.1097/00001648-199709000-00008; GILBERT RM, 1984, METHYLXANTHINE BEVER, P185; INFANTERIVARD C, 1993, JAMA-J AM MED ASSOC, V270, P2940, DOI 10.1001/jama.270.24.2940; Klebanoff MA, 1998, ANN EPIDEMIOL, V8, P107, DOI 10.1016/S1047-2797(97)00125-7; KLINE J, 1991, EPIDEMIOLOGY, V2, P409, DOI 10.1097/00001648-199111000-00004; KLINE J, 1989, CONCEPTION BIRTH EPI, P81; LELO A, 1986, CLIN PHARMACOL THER, V39, P54, DOI 10.1038/clpt.1986.10; MILLS JL, 1993, JAMA-J AM MED ASSOC, V269, P593, DOI 10.1001/jama.269.5.593; Niswander K.R., 1972, WOMEN THEIR PREGNANC; *SAS I INC, 1992, P229 SAS I INC, P433; SRISUPHAN W, 1986, AM J OBSTET GYNECOL, V154, P14, DOI 10.1016/0002-9378(86)90385-6; STEIN H, 1991, ANN ONCOL, V2, P163, DOI 10.1093/annonc/2.suppl_2.163; van den Berg B J, 1988, Paediatr Perinat Epidemiol, V2, P265; Yesair D W, 1984, Prog Clin Biol Res, V158, P215	20	90	92	0	8	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	NOV 25	1999	341	22					1639	1644		10.1056/NEJM199911253412202	http://dx.doi.org/10.1056/NEJM199911253412202			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	258PL	10572151				2022-12-01	WOS:000083847500002
J	Chang, LY; Lin, TY; Hsu, KH; Huang, YC; Lin, KL; Hsueh, C; Shih, SR; Ning, HC; Hwang, MS; Wang, HS; Lee, CY				Chang, LY; Lin, TY; Hsu, KH; Huang, YC; Lin, KL; Hsueh, C; Shih, SR; Ning, HC; Hwang, MS; Wang, HS; Lee, CY			Clinical features and risk factors of pulmonary oedema after enterovirus-71-related hand, foot, and mouth disease	LANCET			English	Article							CENTRAL NERVOUS-SYSTEM; ENCEPHALOMYELITIS; INFECTIONS; EPIDEMIC; EDEMA	Background In Taiwan, from April to July, 1998, an epidemic of hand, foot, and mouth disease associated with enterovirus 71 (EV71) occurred with fatal complications. We did a clinical study of EV71-related diseases in Taiwan. Methods We studied 154 children with virus-culture-confirmed EV71 infection. Children were divided into three groups: 11 patients with pulmonary oedema; 38 patients with central nervous system (CNS) involvement and no pulmonary oedema; and 105 children without complications. We compared the clinical features, laboratory findings, risk factors, and outcome among these three groups. Findings Nine children with pulmonary oedema had hand, foot, and mouth disease, one had herpangina, and one had febrile illness with eight children with limb weakness and one with limb hypesthesia. All children had had sudden onset of tachycardia, tachypnoea, and cyanosis 1-3 days after onset of the disease. Nine of 11 children died within 12 h of intubation; one child was braindead within 15 h and died 17 days after intubation; one child was in deep coma and died 3 months later. In children with CNS complication and no pulmonary oedema, one child died of pneumonia after 4 months of ventilator support and four children had sequelae. All 105 children without complications recovered. There was a significant association between CNS involvement and pulmonary oedema (odds ratio 12 4 [95% CI 2.6-60.1], p = 0.001). Risk factors for pulmonary oedema after CNS involvement were hyperglycaemia, leucocytosis, and limb weakness. Hyperglycaemia was tbe most significant prognostic factor for pulmonary oedema (odds ratio 21.5 [3-159], p = 0.003). Interpretation EV71 can cause hand. foot, and mouth disease, CNS involvement with severe sequelae, and fatal pulmonary oedema. Hyperglycaemia is the most important prognostic factor.	Chang Gung Childrens Hosp, Dept Pediat, Div Pediat Infect Dis, Tao Yuan, Taiwan; Chang Gung Childrens Hosp, Dept Pediat, Div Pediat Neurol, Tao Yuan, Taiwan; Chang Gung Childrens Hosp, Dept Pediat, Div Pediat Cardiol, Tao Yuan, Taiwan; Chang Gung Childrens Hosp, Dept Pathol, Tao Yuan, Taiwan; Chang Gung Univ, Coll Med, Tao Yuan, Taiwan; Chang Gung Univ, Sch Med Technol, Tao Yuan, Taiwan; Chang Gung Mem Hosp, Clin Virol Lab, Tao Yuan, Taiwan; Chang Gung Univ, Dept Hlth Care Management, Tao Yuan, Taiwan; Chang Gung Univ, Lab Epidemiol, Tao Yuan, Taiwan	Chang Gung Memorial Hospital; Chang Gung Memorial Hospital; Chang Gung Memorial Hospital; Chang Gung Memorial Hospital; Chang Gung University; Chang Gung University; Chang Gung Memorial Hospital; Chang Gung University; Chang Gung University	Lin, TY (corresponding author), Chang Gung Childrens Hosp, Dept Pediat, Div Pediat Infect Dis, 5 Fu Hsing St, Tao Yuan, Taiwan.	pidlin@adm.cgmh.com.tw	Shih, Shin-Ru/M-9711-2016	Hsu, Kuang-Hung/0000-0003-2642-7689; CHANG, LUAN-YIN/0000-0003-2632-1956; LEE, CHIN-YUN/0000-0002-3938-377X; Shih, Shin-Ru/0000-0003-4874-401X; Hsueh, Chuen/0000-0001-7860-5964				ALEXANDER JP, 1994, J INFECT DIS, V169, P905, DOI 10.1093/infdis/169.4.905; BAKER AB, 1957, NEUROLOGY, V7, P743, DOI 10.1212/WNL.7.11.743; BLOMBERG J, 1974, LANCET, V2, P112; Centers for Disease Control and Prevention (CDC), 1998, MMWR Morb Mortal Wkly Rep, V47, P629; Chang LY, 1998, LANCET, V352, P367, DOI 10.1016/S0140-6736(98)24031-1; CHEN HI, 1980, CIRC RES, V47, P366, DOI 10.1161/01.RES.47.3.366; CHUMAKOV M, 1979, ARCH VIROL, V60, P329, DOI 10.1007/BF01317504; GILBERT GL, 1988, PEDIATR INFECT DIS J, V7, P484, DOI 10.1097/00006454-198807000-00007; GRANDIEN M, 1989, DIAGNOSTIC PROCEDURE, P513; HAYWARD JC, 1989, PEDIATR INFECT DIS J, V8, P611, DOI 10.1097/00006454-198909000-00009; ISHIMARU Y, 1980, ARCH DIS CHILD, V55, P583, DOI 10.1136/adc.55.8.583; KENNETT ML, 1974, B WORLD HEALTH ORGAN, V51, P609; Lum LCS, 1998, LANCET, V352, P1391, DOI 10.1016/S0140-6736(05)60789-1; Lum LCS, 1998, J PEDIATR-US, V133, P795, DOI 10.1016/S0022-3476(98)70155-6; MATSUNAGA H, 1989, ENDOCRINOLOGY, V124, P1259, DOI 10.1210/endo-124-3-1259; MELNICK JL, 1984, REV INFECT DIS, V6, pS387; NAGAI K, 1983, AM J PHYSIOL, V245, pE14, DOI 10.1152/ajpendo.1983.245.1.E14; NAGY G, 1982, ARCH VIROL, V71, P217, DOI 10.1007/BF01314873; RICHARDSON HB, 1965, J PEDIATR-US, V67, P6, DOI 10.1016/S0022-3476(65)80297-9; SCHMIDT NJ, 1974, J INFECT DIS, V129, P304, DOI 10.1093/infdis/129.3.304; SHINDAROV LM, 1979, J HYG EPID MICROB IM, V23, P284; SIMMONS RL, 1969, ANN SURG, V170, P39, DOI 10.1097/00000658-196907000-00005; Wu TN, 1999, EMERG INFECT DIS, V5, P458, DOI 10.3201/eid0503.990321	23	321	394	1	28	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	NOV 13	1999	354	9191					1682	1686		10.1016/S0140-6736(99)04434-7	http://dx.doi.org/10.1016/S0140-6736(99)04434-7			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	255CW	10568570				2022-12-01	WOS:000083652800011
J	Moins-Teisserenc, HT; Gadola, SD; Cella, M; Dunbar, PR; Exley, A; Blake, N; Baykal, C; Lambert, J; Bigliardi, P; Willemsen, M; Jones, M; Buechner, S; Colonna, M; Gross, WL; Cerundolo, V				Moins-Teisserenc, HT; Gadola, SD; Cella, M; Dunbar, PR; Exley, A; Blake, N; Baykal, C; Lambert, J; Bigliardi, P; Willemsen, M; Jones, M; Buechner, S; Colonna, M; Gross, WL; Cerundolo, V			Association of a syndrome resembling Wegener's granulomatosis with low surface expression of HLA class-I molecules	LANCET			English	Article							NATURAL-KILLER-CELLS; RECEPTORS; PHENOTYPE	Background Granulomatous syndromes, such as Wegener's granulomatosis, are defined according to complex criteria, but the underlying cause is rarely identified. We present evidence for a new aetiology for chronic granulomatous lesions associated with a recessive genetic defect, which is linked to the human leucocyte antigen (HLA) locus. Methods Five adults with necrotising granulomatous lesions in the upper respiratory tract and skin, associated with recurrent bacterial respiratory infections and skin vasculitis, were identified. A diagnosis of Wegener's granulomatosis was considered in all of them, but abandoned because of an incompatible disease course and resistance to immunosuppressive treatments. Peripheral-blood samples were taken and analysed by immunohistochemistry and fluorescent-activated-cell-sorter analysis. Since all five patients were homozygous for the HLA locus, we looked for genetic defects located within the HLA-locus with PCR and restriction fragment length polymorphism. Findings A severe decrease in cell-surface expression of HLA class-I molecule was seen in all patients. Defective expression of the transporter associated with antigen presentation (TAP) genes was responsible for the HLA class-I down-regulation, and in two patients we identified a mutation in the TAP2 gene responsible for the defective expression of the TAP complex. We showed the presence of autoreactive natural killer (NK) cells and gamma delta T lymphocytes in the peripheral blood cells of two patients. Correction of the genetic defect in vitro restored normal expression of HLA class-I molecules and prevented self-reactivity in the patients' cells. Histology of granulomatous lesions showed the presence of a large proportion of activated NK cells. Interpretation Our findings define the cause and pathogenesis of a new syndrome that affects patients with a defective surface expression of HLA class-I molecules. The syndrome resembles Wegener's granulomatosis both clinically and histologically. Patients have chronic necrotising granulomatous lesions in the upper respiratory tract and skin, recurrent infections of the respiratory tract, and skin vasculitis. A predominant NK population within the granulomatous lesions suggests that the pathophysiology of the skin lesions may relate to the inability of HLA class-I molecules to turn off NK cell responses. Accurate genetic analysis of a defined syndrome can provide a better understanding of the cause and pathogenesis of a disease.	Inst Mol Med, Nuffield Dept Med, Oxford OX3 9DS, England; Univ Lubeck, Rheumaklin Bad Bramstedt, D-2400 Lubeck, Germany; Basel Inst Immunol, Basel, Switzerland; CRC, Inst Canc Studies, Birmingham, W Midlands, England; Istanbul Fac Med, Dept Dermatol, Istanbul, Turkey; Univ Basel, Dept Dermatol, CH-4003 Basel, Switzerland; Univ Birmingham, Dept Immunol, Birmingham B15 2TT, W Midlands, England; Div Cellular Sci, Oxford, England; Univ Ziekenhuis Antwerpen, Dept Dermatol, Edegem, Belgium; Dept Dermatol, Brussels, Belgium; Hop St Louis, INSERM, U0396, F-75010 Paris, France	University of Oxford; University of Lubeck; University of Birmingham; Istanbul University; University of Basel; University of Birmingham; University of Antwerp; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite	Cerundolo, V (corresponding author), Inst Mol Med, Nuffield Dept Med, Oxford OX3 9DS, England.	vcerundo@worf.molbiol.ox.ac.uk	Dunbar, Rod/C-2570-2012; Moins-Teisserenc, helene/AAL-1566-2021; Jones, Margaret/B-4083-2009; Cella, Marina/ABA-8564-2020; Cella, Marina/G-8850-2011	Dunbar, Rod/0000-0001-9626-2600; Moins-Teisserenc, helene/0000-0003-1602-7534; Colonna, Marco/0000-0001-5222-4987; Cella, Marina/0000-0003-1230-1313; Exley, Andrew/0000-0002-2628-6129; Cerundolo, Vincenzo/0000-0003-0040-3793				CELLA M, 1994, J EXP MED, V180, P1235, DOI 10.1084/jem.180.4.1235; Colonna M, 1997, IMMUNOL REV, V155, P127, DOI 10.1111/j.1600-065X.1997.tb00945.x; de la Salle H, 1999, J CLIN INVEST, V103, pR9, DOI 10.1172/JCI5687; DELASALLE H, 1994, SCIENCE, V265, P237, DOI 10.1126/science.7517574; FAUCI AS, 1983, ANN INTERN MED, V98, P76, DOI 10.7326/0003-4819-98-1-76; Furukawa H, 1999, J CLIN INVEST, V103, P755, DOI 10.1172/JCI5335; Furukawa H, 1999, HUM IMMUNOL, V60, P32, DOI 10.1016/S0198-8859(98)00097-4; GROSS WL, 1998, OXFORD TXB RHEUMATOL, V2, P1331; JENNETTE JC, 1994, ARTHRITIS RHEUM-US, V37, P187, DOI 10.1002/art.1780370206; Lanier LL, 1996, IMMUNOL TODAY, V17, P86, DOI 10.1016/0167-5699(96)80585-8; LEAVITT RY, 1990, ARTHRITIS RHEUM, V33, P1101, DOI 10.1002/art.1780330807; Orange JS, 1996, J IMMUNOL, V156, P4746; Plebani A, 1996, J AM ACAD DERMATOL, V35, P814, DOI 10.1016/S0190-9622(96)90091-2; RUSS G, 1995, J BIOL CHEM, V270, P21312, DOI 10.1074/jbc.270.36.21312; SPIES T, 1992, NATURE, V355, P644, DOI 10.1038/355644a0; TAKASHIMA T, 1993, J IMMUNOL, V150, P3002; Teisserenc H, 1997, IMMUNOL LETT, V57, P183, DOI 10.1016/S0165-2478(97)00072-2; WATANABE S, 1987, J AM ACAD DERMATOL, V17, P1006, DOI 10.1016/S0190-9622(87)70290-4; WILLEMSEN M, 1995, J AM ACAD DERMATOL, V33, P887, DOI 10.1016/0190-9622(95)90429-8; Zimmer J, 1998, J EXP MED, V187, P117, DOI 10.1084/jem.187.1.117; Zimmer J, 1999, EUR J IMMUNOL, V29, P1286, DOI 10.1002/(SICI)1521-4141(199904)29:04<1286::AID-IMMU1286>3.0.CO;2-L	21	100	100	0	11	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	NOV 6	1999	354	9190					1598	1603		10.1016/S0140-6736(99)04206-3	http://dx.doi.org/10.1016/S0140-6736(99)04206-3			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	253HM	10560675				2022-12-01	WOS:000083551000012
J	Rayson, D				Rayson, D			Lisa's stories	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material													Rayson, Daniel/W-2800-2019	Rayson, Daniel/0000-0002-2438-3128					0	2	2	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 3	1999	282	17					1605	1606		10.1001/jama.282.17.1605	http://dx.doi.org/10.1001/jama.282.17.1605			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	250BD	10553770				2022-12-01	WOS:000083368400001
J	Griffin, EA; Staknis, D; Weitz, CJ				Griffin, EA; Staknis, D; Weitz, CJ			Light-independent role of CRY1 and CRY2 in the mammalian circadian clock	SCIENCE			English	Article							DROSOPHILA PERIOD GENE; TRANSCRIPTION; PHOTORECEPTOR; CRYPTOCHROME; EXPRESSION; TIMELESS; ORTHOLOG; HOMOLOGS; PROTEIN; MPER1	Cryptochrome (CRY), a photoreceptor for the circadian clock in Drosophila, binds to the clock component TIM in a light-dependent fashion and blocks its function. In mammals, genetic evidence suggests a role for CRYs within the clock, distinct from hypothetical photoreceptor functions. Mammalian CRY1 and CRY2 are here shown to act as light-independent inhibitors of CLOCK-BMAL1, the activator driving Per1 transcription. CRY1 or CRY2 (or both) showed Light-independent interactions with CLOCK and BMAL1, as well as with PER1, PER2, and TIM. Thus, mammalian CRYs act as light-independent components of the circadian clock and probably regulate Per1 transcriptional cycling by contacting both the activator and its feedback inhibitors.	Harvard Univ, Sch Med, Dept Neurobiol, Boston, MA 02115 USA	Harvard University; Harvard Medical School	Weitz, CJ (corresponding author), Harvard Univ, Sch Med, Dept Neurobiol, Boston, MA 02115 USA.	cweitz@hms.harvard.edu		Griffin, Edmund/0000-0001-7291-6091	NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH059943] Funding Source: NIH RePORTER; NIMH NIH HHS [MH-59943] Funding Source: Medline	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		Albrecht U, 1997, CELL, V91, P1055, DOI 10.1016/S0092-8674(00)80495-X; Balsalobre A, 1998, CELL, V93, P929, DOI 10.1016/S0092-8674(00)81199-X; Cashmore AR, 1999, SCIENCE, V284, P760, DOI 10.1126/science.284.5415.760; Ceriani MF, 1999, SCIENCE, V285, P553, DOI 10.1126/science.285.5427.553; Darlington TK, 1998, SCIENCE, V280, P1599, DOI 10.1126/science.280.5369.1599; Dunlap JC, 1999, CELL, V96, P271, DOI 10.1016/S0092-8674(00)80566-8; Gekakis N, 1998, SCIENCE, V280, P1564, DOI 10.1126/science.280.5369.1564; GEKAKIS N, 1995, SCIENCE, V270, P811, DOI 10.1126/science.270.5237.811; GRIFFIN EA, UNPUB; Hogenesch JB, 1998, P NATL ACAD SCI USA, V95, P5474, DOI 10.1073/pnas.95.10.5474; Hsu DS, 1996, BIOCHEMISTRY-US, V35, P13871, DOI 10.1021/bi962209o; Kume K, 1999, CELL, V98, P193, DOI 10.1016/S0092-8674(00)81014-4; Lucas RJ, 1999, CURR BIOL, V9, pR214, DOI 10.1016/S0960-9822(99)80132-8; Lucas RJ, 1999, J BIOL RHYTHM, V14, P4, DOI 10.1177/074873099129000380; PITTENDRIGH CS, 1993, ANNU REV PHYSIOL, V55, P16; Sangoram AM, 1998, NEURON, V21, P1101, DOI 10.1016/S0896-6273(00)80627-3; Shearman LP, 1997, NEURON, V19, P1261, DOI 10.1016/S0896-6273(00)80417-1; Somers DE, 1998, SCIENCE, V282, P1488, DOI 10.1126/science.282.5393.1488; Stanewsky R, 1998, CELL, V95, P681, DOI 10.1016/S0092-8674(00)81638-4; Sun ZS, 1997, CELL, V90, P1003, DOI 10.1016/S0092-8674(00)80366-9; Tei H, 1997, NATURE, V389, P512, DOI 10.1038/39086; Thresher RJ, 1998, SCIENCE, V282, P1490, DOI 10.1126/science.282.5393.1490; van der Horst GTJ, 1999, NATURE, V398, P627, DOI 10.1038/19323; VITATERNA MH, 1994, SCIENCE, V264, P719, DOI 10.1126/science.8171325; VITATERNA MH, IN PRESS P NATL ACAD; Zheng BH, 1999, NATURE, V400, P169, DOI 10.1038/22118; Zylka MJ, 1998, NEURON, V20, P1103, DOI 10.1016/S0896-6273(00)80492-4	27	492	505	1	43	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 22	1999	286	5440					768	771		10.1126/science.286.5440.768	http://dx.doi.org/10.1126/science.286.5440.768			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	248XZ	10531061				2022-12-01	WOS:000083303200053
J	Tang, YQ; Yuan, J; Osapay, G; Osapay, K; Tran, D; Miller, CJ; Ouellette, AJ; Selsted, ME				Tang, YQ; Yuan, J; Osapay, G; Osapay, K; Tran, D; Miller, CJ; Ouellette, AJ; Selsted, ME			A cyclic antimicrobial peptide produced in primate leukocytes by the ligation of two truncated alpha-defensins	SCIENCE			English	Article							INHIBITORY MACROCYCLIC PEPTIDES; HUMAN BETA-DEFENSIN-1; ANTIBIOTIC AS-48; AIRWAY EPITHELIA; CYSTIC-FIBROSIS; BETA-DEFENSINS; HOST-DEFENSE; CIRCULIN-A; PURIFICATION; LUNG	Analysis of rhesus macaque leukocytes disclosed the presence of an 18-residue macrocyclic, tridisulfide antibiotic peptide in granules of neutrophils and monocytes. The peptide, termed rhesus theta defensin-1 (RTD-1), is microbicidal for bacteria and fungi at Low micromolar concentrations. Antibacterial activity of the cyclic peptide was threefold greater than that of an open-chain analog, and the cyclic conformation was required for antimicrobial activity in the presence of 150 millimolar sodium chloride. Biosynthesis of RTD-1 involves the head-to-tail ligation of two alpha-defensin-related nonapeptides, requiring the formation of two new peptide bonds. Thus, host defense cells possess mechanisms for synthesis and granular packaging of macrocyclic antibiotic peptides that are components of the phagocyte antimicrobial armamentarium.	Univ Calif Irvine, Coll Med, Dept Pathol, Irvine, CA 92697 USA; Univ Calif Davis, Sch Vet Med, Calif Reg Primate Res Ctr, Davis, CA 95616 USA; Univ Calif Davis, Sch Vet Med, Ctr Comparat Med, Davis, CA 95616 USA	University of California System; University of California Irvine; University of California System; University of California Davis; University of California System; University of California Davis	Selsted, ME (corresponding author), Univ Calif Irvine, Coll Med, Dept Pathol, Irvine, CA 92697 USA.		Abrams, William R/A-5782-2008		NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI022931, R37AI022931] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK033506, R01DK044632, R55DK044632] Funding Source: NIH RePORTER; NIAID NIH HHS [AI22931] Funding Source: Medline; NIDDK NIH HHS [DK33506, DK44632] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Bals R, 1998, INFECT IMMUN, V66, P1225, DOI 10.1128/IAI.66.3.1225-1232.1998; Blond A, 1999, EUR J BIOCHEM, V259, P747, DOI 10.1046/j.1432-1327.1999.00085.x; Boman HG, 1998, IMMUNOLOGIST, V6, P234; Broekaert WF, 1997, CRIT REV PLANT SCI, V16, P297, DOI 10.1080/713608148; Derua R, 1996, BIOCHEM BIOPH RES CO, V228, P632, DOI 10.1006/bbrc.1996.1708; Diamond G, 1998, CLIN IMMUNOL IMMUNOP, V88, P221, DOI 10.1006/clin.1998.4587; Fahrner RL, 1996, CHEM BIOL, V3, P543, DOI 10.1016/S1074-5521(96)90145-3; Frohman MA, 1990, PCR PROTOCOLS GUIDE, P28; GALVEZ A, 1989, ANTIMICROB AGENTS CH, V33, P437, DOI 10.1128/AAC.33.4.437; Ganz T, 1997, Curr Opin Hematol, V4, P53; Goldman MJ, 1997, CELL, V88, P553, DOI 10.1016/S0092-8674(00)81895-4; GUSTAFSON KR, 1994, J AM CHEM SOC, V116, P9337, DOI 10.1021/ja00099a064; HENSCHEN A, 1986, ADV METHODS PROTEIN, P244; Hoffmann JA, 1999, SCIENCE, V284, P1313, DOI 10.1126/science.284.5418.1313; KOKRYAKOV VN, 1993, FEBS LETT, V327, P231, DOI 10.1016/0014-5793(93)80175-T; LEHRER RI, 1991, J IMMUNOL METHODS, V137, P167, DOI 10.1016/0022-1759(91)90021-7; LEHRER RI, 1989, J CLIN INVEST, V84, P553, DOI 10.1172/JCI114198; MARTINEZBUENO M, 1994, J BACTERIOL, V176, P6334, DOI 10.1128/jb.176.20.6334-6339.1994; Ouellette AJ, 1996, FASEB J, V10, P1280, DOI 10.1096/fasebj.10.11.8836041; Selsted M E, 1993, Genet Eng (N Y), V15, P131; SELSTED ME, 1995, TRENDS CELL BIOL, V5, P114, DOI 10.1016/S0962-8924(00)88961-8; SELSTED ME, 1984, INFECT IMMUN, V45, P150, DOI 10.1128/IAI.45.1.150-154.1984; Singh PK, 1998, P NATL ACAD SCI USA, V95, P14961, DOI 10.1073/pnas.95.25.14961; Smith JJ, 1996, CELL, V85, P229, DOI 10.1016/S0092-8674(00)81099-5; Stolzenberg ED, 1997, P NATL ACAD SCI USA, V94, P8686, DOI 10.1073/pnas.94.16.8686; Tam JP, 1999, P NATL ACAD SCI USA, V96, P8913, DOI 10.1073/pnas.96.16.8913; TANG YQ, 1993, J BIOL CHEM, V268, P6649; TANG YQ, IN PRESS INFECT IMMU; Valore EV, 1998, J CLIN INVEST, V101, P1633, DOI 10.1172/JCI1861; WHITE SH, 1995, CURR OPIN STRUC BIOL, V5, P521, DOI 10.1016/0959-440X(95)80038-7; YOUNT NY, 1995, J IMMUNOL, V155, P4476; ZANETTI M, 1995, FEBS LETT, V374, P1, DOI 10.1016/0014-5793(95)01050-O; ZHAO CQ, 1995, FEBS LETT, V368, P197, DOI 10.1016/0014-5793(95)00633-K	34	592	658	2	92	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	OCT 15	1999	286	5439					498	502		10.1126/science.286.5439.498	http://dx.doi.org/10.1126/science.286.5439.498			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	245RD	10521339	Green Submitted			2022-12-01	WOS:000083121200051
J	Bull, C				Bull, C		British Paediat Cardiac Assoc	Current and potential impact of fetal diagnosis on prevalence and spectrum of serious congenital heart disease at term in the UK	LANCET			English	Article							PRENATAL-DIAGNOSIS; ECHOCARDIOGRAPHY; FETUS	Background Assessment of the effect of fetal diagnosis on the prevalence of congenital heart disease at term requires national ascertainment because referral patterns are not rigorously structured. Methods Between 1993 and 1995, all 17 paediatric cardiac centres in the UK submitted to a database lists of all fetuses diagnosed, and all infants needing surgery or interventional catheterisation or dying in the first year of life because of structural heart disease: details included the postal area of residence. Findings There were 4799 affected pregnancies, 4165 babies born alive, 1124 fetal diagnoses, and 567 terminations of pregnancy because the fetus had structural heart disease. Thus, a fetal diagnosis was made in 23.4% of affected pregnancies (11.7% of all affected livebirths) with geographical variability in diagnostic rates. babies born alive. Interpretation Fetal cardiac screening has an effect on the prevalence and types of congenital heart disease seen at term because many affected pregnancies are terminated. If detection rates of affected fetuses rose nationally to those seen in the 15 postal areas where detection rates were significantly higher than the national average in 1993-95, we would expect about 218 fewer affected individuals to be born annually.	Great Ormond St Hosp Children NHS Trust, Cardiothorac Unit, London WC1N 3JH, England	University of London; University College London; Great Ormond Street Hospital for Children NHS Foundation Trust	Bull, C (corresponding author), Great Ormond St Hosp Children NHS Trust, Cardiothorac Unit, Great Ormond St, London WC1N 3JH, England.							ABUHARB M, 1995, BRIT HEART J, V74, P192; ABUHARB M, 1994, ARCH DIS CHILD, V71, P3, DOI 10.1136/adc.71.1.3; ALLAN LD, 1980, BRIT HEART J, V44, P444; BONNETT D, 1988, FETAL DIAGN THER S1, V13, P148; Breslow NE, 1987, STAT METHODS CANC RE, VII; *CENTR STAT OFF, 1996, SOC TRENDS, V26, P62; CHANG AC, 1991, J THORAC CARDIOV SUR, V102, P841, DOI 10.1016/S0022-5223(19)33933-9; Copel JA, 1997, ULTRASOUND OBST GYN, V10, P237, DOI 10.1046/j.1469-0705.1997.10040237.x; CULLEN S, 1992, ARCH DIS CHILD-FETAL, V67, P775, DOI 10.1136/adc.67.7_Spec_No.775; EWIGMAN BG, 1993, NEW ENGL J MED, V329, P821, DOI 10.1056/NEJM199309163291201; GEMBRUCH U, 1993, ULTRASOUND OBST GYN, V3, P310, DOI 10.1046/j.1469-0705.1993.03050310.x; HOFFMAN JIE, 1995, PEDIATR CARDIOL, V16, P103, DOI 10.1007/BF00801907; Hyett J, 1999, BRIT MED J, V318, P81, DOI 10.1136/bmj.318.7176.81; LANGE LW, 1980, CIRCULATION, V62, P799, DOI 10.1161/01.CIR.62.4.799; LUCK CA, 1992, BRIT MED J, V304, P1474, DOI 10.1136/bmj.304.6840.1474; Marteau TM, 1995, PRENATAL DIAG, V15, P1215, DOI 10.1002/pd.1970151304; *OFF NAT STAT, 1995, AB STAT, V22, P13; *OFF NAT STAT, 1997, REG TRENDS, V32, P37; SADIQ M, 1995, BRIT HEART J, V73, P173; SHARLAND GK, 1992, BRIT J OBSTET GYNAEC, V99, P220, DOI 10.1111/j.1471-0528.1992.tb14503.x; Stumpflen I, 1996, LANCET, V348, P854, DOI 10.1016/S0140-6736(96)04069-X; THORNTON JG, 1995, BMJ-BRIT MED J, V311, P1127, DOI 10.1136/bmj.311.7013.1127; WYLLIE J, 1994, BRIT HEART J, V71, P20	23	255	261	0	3	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	OCT 9	1999	354	9186					1242	1247		10.1016/S0140-6736(99)01167-8	http://dx.doi.org/10.1016/S0140-6736(99)01167-8			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	243RE	10520632				2022-12-01	WOS:000083010400009
J	Henney, JE				Henney, JE			Quick test for pneumonia	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	News Item											Henney, JE (corresponding author), HF-1,Room 14-71,5600 Fishers Ln, Rockville, MD 20857 USA.								0	3	3	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 6	1999	282	13					1218	1218		10.1001/jama.282.13.1218	http://dx.doi.org/10.1001/jama.282.13.1218			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	241UM	10517411				2022-12-01	WOS:000082901100008
J	McNamara, JM; Gasson, CE; Houston, AI				McNamara, JM; Gasson, CE; Houston, AI			Incorporating rules for responding into evolutionary games	NATURE			English	Article							VIGILANCE; PREDATION; RISK	Evolutionary game theory(1,2) is concerned with the evolutionarily stable outcomes of the process of natural selection. The theory is especially relevant when the fitness of an organism depends on the behaviour of other members of its population. Here we focus on the interaction between two organisms that have a conflict of interest. The standard approach to such two-player games is to assume that each player chooses a single action and that the evolutionarily stable action of each player is the best given the action of its opponent. We argue that, instead, most two-player games should be modelled as involving a series of interactions in which opponents negotiate the final outcome, Thus we should be concerned with evolutionarily stable negotiation rules rather than evolutionarily stable actions. The evolutionarily stable negotiation rule of each player is the best rule given the rule of its opponent. As we show, the action chosen as a result of the negotiation is not the best action given the action of the opponent. This conclusion necessitates a fundamental change in the way that evolutionary games are modelled.	Univ Bristol, Sch Math, Bristol BS8 1TW, Avon, England; Univ Bristol, Sch Biol Sci, Bristol BS8 1UG, Avon, England	University of Bristol; University of Bristol	McNamara, JM (corresponding author), Univ Bristol, Sch Math, Univ Walk, Bristol BS8 1TW, Avon, England.	john.mcnamara@bristol.ac.uk						Clutton-Brock T., 1991, P234; Dugatkin LA., 1997, COOPERATION ANIMALS; GODFRAY HCJ, 1991, NATURE, V352, P328, DOI 10.1038/352328a0; GRAFEN A, 1990, J THEOR BIOL, V144, P517, DOI 10.1016/S0022-5193(05)80088-8; HATCHWELL BJ, 1990, BEHAV ECOL SOCIOBIOL, V27, P199; Houston A.I., 1985, P471; JOHNSTONE RA, 1994, P ROY SOC B-BIOL SCI, V256, P169, DOI 10.1098/rspb.1994.0066; LIMA SL, 1987, J THEOR BIOL, V124, P303, DOI 10.1016/S0022-5193(87)80118-2; MARKMAN S, 1995, ANIM BEHAV, V50, P655, DOI 10.1016/0003-3472(95)80127-8; Maynard Smith J., 1982, pi; MCNAMARA JM, 1992, ANIM BEHAV, V43, P641, DOI 10.1016/0003-3472(92)90086-O; Mock D.W., 1997, EVOLUTION SIBLING RI; PARKER GA, 1990, NATURE, V348, P27, DOI 10.1038/348027a0; Parker GA, 1997, P ROY SOC B-BIOL SCI, V264, P1239, DOI 10.1098/rspb.1997.0171; PULLIAM HR, 1982, J THEOR BIOL, V95, P89, DOI 10.1016/0022-5193(82)90289-2; SMITH JM, 1991, ANIM BEHAV, V42, P1034, DOI 10.1016/S0003-3472(05)80161-7; Wright J, 1990, BEHAV ECOL, V1, P116, DOI 10.1093/beheco/1.2.116	17	300	302	0	95	NATURE RESEARCH	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	SEP 23	1999	401	6751					368	371		10.1038/43869	http://dx.doi.org/10.1038/43869			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	240JJ	10517633	Bronze			2022-12-01	WOS:000082822600049
J	Zhen, M; Jin, YS				Zhen, M; Jin, YS			The liprin protein SYD-2 regulates the differentiation of presynaptic termini in C-elegans	NATURE			English	Article							NEMATODE CAENORHABDITIS-ELEGANS; SYNAPTIC VESICLES; TYROSINE-PHOSPHATASE; NERVE-TERMINALS; ACTIVE ZONE; SYNAPTOTAGMIN; ORGANIZATION; MUTANTS; SYSTEM	At synaptic junctions, specialized subcellular structures occur in both pre- and postsynaptic cells. Most presynaptic termini contain electron-dense membrane structures(1), often referred to as active zones, which function in vesicle docking and release(2). The components of those active zones and how they are formed are largely unknown. We report here that a mutation in the Caenorhabditis elegans syd-2 (for synapse-defective) gene causes a diffused localization of several presynaptic proteins and of a synaptic-vesicle membrane associated green fluorescent protein (GFP) marker(3,4). Ultrastructural analysis revealed that the active zones of syd-2 mutants were significantly lengthened, whereas the total number of vesicles per synapse and the number of vesicles at the prominent active zones were comparable to those in wild-type animals. Synaptic transmission is partially impaired in syn-2 mutants. syd-2 encodes a member of the liprin (for LAR-interacting protein) family of proteins which interact with LAR-type (for leukocyte common antigen related) receptor proteins with tyrosine phosphatase activity (RPTPs)(5,6). SYD-2 protein is localized at presynaptic termini independently of the presence of vesicles, and functions cell autonomously. We propose that SYD-2 regulates the differentiation of presynaptic termini in particular the formation of the active zone, by acting as an intracellular anchor for RPTP signalling at synaptic junctions.	Univ Calif Santa Cruz, Dept Biol, Sinsheimer Labs, Santa Cruz, CA 95064 USA	University of California System; University of California Santa Cruz	Jin, YS (corresponding author), Univ Calif Santa Cruz, Dept Biol, Sinsheimer Labs, Santa Cruz, CA 95064 USA.		Zhen, Mei/A-4967-2012	Zhen, Mei/0000-0003-0086-9622; Jin, Yishi/0000-0002-9371-9860	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS035546] Funding Source: NIH RePORTER; NINDS NIH HHS [NS35546] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BETZ WJ, 1994, J CELL BIOL, V124, P843, DOI 10.1083/jcb.124.5.843; BRENNER S, 1974, GENETICS, V77, P71; BURNS ME, 1995, CELL, V83, P187, DOI 10.1016/0092-8674(95)90160-4; Desai CJ, 1996, CELL, V84, P599, DOI 10.1016/S0092-8674(00)81035-1; Dieck ST, 1998, J CELL BIOL, V142, P499, DOI 10.1083/jcb.142.2.499; FINNEY M, 1990, CELL, V63, P895, DOI 10.1016/0092-8674(90)90493-X; HALL DH, 1991, CELL, V65, P837, DOI 10.1016/0092-8674(91)90391-B; Hallam SJ, 1998, NATURE, V395, P78, DOI 10.1038/25757; HEDGECOCK EM, 1990, NEURON, V4, P61, DOI 10.1016/0896-6273(90)90444-K; Jin YS, 1999, J NEUROSCI, V19, P539; JORGENSEN EM, 1995, NATURE, V378, P196, DOI 10.1038/378196a0; KRASZEWSKI K, 1995, J NEUROSCI, V15, P4328; LANDIS DMD, 1988, NEURON, V1, P201, DOI 10.1016/0896-6273(88)90140-7; MELLO CC, 1991, EMBO J, V10, P3959, DOI 10.1002/j.1460-2075.1991.tb04966.x; Nonet ML, 1997, J NEUROSCI, V17, P8061; Nonet ML, 1999, J NEUROSCI METH, V89, P33, DOI 10.1016/S0165-0270(99)00031-X; Rand James B., 1997, Cold Spring Harbor Monograph Series, V33, P611; ROSAHL TW, 1995, NATURE, V375, P488, DOI 10.1038/375488a0; Serra-Pages C, 1998, J BIOL CHEM, V273, P15611, DOI 10.1074/jbc.273.25.15611; SERRAPAGES C, 1995, EMBO J, V14, P2827, DOI 10.1002/j.1460-2075.1995.tb07282.x; Sone M, 1997, SCIENCE, V275, P543, DOI 10.1126/science.275.5299.543; Stapleton D, 1999, NAT STRUCT BIOL, V6, P44; SUDHOF TC, 1995, NATURE, V375, P645, DOI 10.1038/375645a0; Thomas U, 1997, NEURON, V19, P787, DOI 10.1016/S0896-6273(00)80961-7; TRENT C, 1983, GENETICS, V104, P619; WANG YQ, 1993, J MATER RES, V8, P388, DOI 10.1557/JMR.1993.0388; WHITE JG, 1986, PHILOS T R SOC B, V314, P1, DOI 10.1098/rstb.1986.0056; Yochem J, 1998, GENETICS, V149, P1323	28	277	295	0	11	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	SEP 23	1999	401	6751					371	375		10.1038/43886	http://dx.doi.org/10.1038/43886			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	240JJ	10517634	Bronze			2022-12-01	WOS:000082822600050
J	Zhang, GY; Campbell, EA; Minakhin, L; Richter, C; Severinov, K; Darst, SA				Zhang, GY; Campbell, EA; Minakhin, L; Richter, C; Severinov, K; Darst, SA			Crystal structure of Thermus aquaticus core RNA polymerase at 3.3 angstrom resolution	CELL			English	Article							TRANSCRIPTION ELONGATION COMPLEX; COLI RPOB GENE; ESCHERICHIA-COLI; ACTIVE-CENTER; BETA-SUBUNIT; 3-DIMENSIONAL STRUCTURE; ALPHA-SUBUNIT; BINDING; DETERMINANTS; ORGANIZATION	The X-ray crystal structure of Thermus aquaticus core RNA polymerase reveals a "crab claw"-shaped molecule with a 27 Angstrom wide internal channel. Located on the back wall of the channel is a Mg2+ ion required for catalytic activity, which is chelated by an absolutely conserved motif from all bacterial and eukaryotic cellular RNA polymerases. The structure places key functional sites, defined by mutational and cross-linking analysis, on the inner walls of the channel in close proximity to the active center Mg2+. Further out from the catalytic center, structural features are found that may be involved in maintaining the melted transcription bubble, clamping onto the RNA product and/or DNA template to assure processivity, and delivering nucleotide substrates to the active center.	Rockefeller Univ, New York, NY 10021 USA; Rutgers State Univ, Waksman Inst, Piscataway, NJ 08854 USA; Rutgers State Univ, Dept Genet, Piscataway, NJ 08854 USA	Rockefeller University; Rutgers State University New Brunswick; Rutgers State University New Brunswick	Darst, SA (corresponding author), Rockefeller Univ, 1230 York Ave, New York, NY 10021 USA.		Severinov, Konstantin/C-8545-2016	Campbell, Elizabeth/0000-0002-1332-128X	NIGMS NIH HHS [GM19441-01] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Adams PD, 1997, P NATL ACAD SCI USA, V94, P5018, DOI 10.1073/pnas.94.10.5018; ARCHAMBAULT J, 1993, MICROBIOL REV, V57, P703, DOI 10.1128/MMBR.57.3.703-724.1993; BORUKHOV S, 1991, J BIOL CHEM, V266, P23921; CHAMBERLIN M, 1962, P NATL ACAD SCI USA, V48, P81, DOI 10.1073/pnas.48.1.81; Cheetham GMT, 1999, NATURE, V399, P80, DOI 10.1038/19999; CONAWAY JW, 1990, SCIENCE, V248, P1550, DOI 10.1126/science.2193400; DARST SA, 1989, NATURE, V340, P730, DOI 10.1038/340730a0; DARST SA, 1991, CELL, V66, P121, DOI 10.1016/0092-8674(91)90144-N; Darst SA, 1998, COLD SPRING HARB SYM, V63, P269, DOI 10.1101/sqb.1998.63.269; Darst SA, 1998, J STRUCT BIOL, V124, P115, DOI 10.1006/jsbi.1998.4057; de La Fortelle E., 1997, CRYSTALLOGRAPHIC COM, P1; DEGRYSE E, 1978, ARCH MICROBIOL, V117, P189, DOI 10.1007/BF00402307; Doublie S, 1997, METHOD ENZYMOL, V276, P523, DOI 10.1016/S0076-6879(97)76075-0; ERIE DA, 1992, ANNU REV BIOPH BIOM, V21, P379, DOI 10.1146/annurev.bb.21.060192.002115; Furey W, 1997, METHOD ENZYMOL, V277, P590, DOI 10.1016/S0076-6879(97)77033-2; GENTRY DR, 1993, BIOCHEMISTRY-US, V32, P11224, DOI 10.1021/bi00092a036; Gnatt A, 1997, J BIOL CHEM, V272, P30799, DOI 10.1074/jbc.272.49.30799; Gross CA, 1996, PHILOS T R SOC B, V351, P475, DOI 10.1098/rstb.1996.0045; HELMANN JD, 1988, ANNU REV BIOCHEM, V57, P839, DOI 10.1146/annurev.bi.57.070188.004203; Heyduk T, 1996, P NATL ACAD SCI USA, V93, P10162, DOI 10.1073/pnas.93.19.10162; HUANG RC, 1960, BIOCHEM BIOPH RES CO, V3, P689, DOI 10.1016/0006-291X(60)90088-7; HURWITZ J, 1960, BIOCHEM BIOPH RES CO, V3, P15, DOI 10.1016/0006-291X(60)90094-2; JIN DJ, 1988, J MOL BIOL, V202, P45, DOI 10.1016/0022-2836(88)90517-7; JOKERST RS, 1989, MOL GEN GENET, V215, P266, DOI 10.1007/BF00339727; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Komissarova N, 1998, P NATL ACAD SCI USA, V95, P14699, DOI 10.1073/pnas.95.25.14699; LEE B, 1971, J MOL BIOL, V55, P379, DOI 10.1016/0022-2836(71)90324-X; MARKOV D, 1999, IN PRESS GENES DEV; Markovtsov V, 1996, P NATL ACAD SCI USA, V93, P3221, DOI 10.1073/pnas.93.8.3221; MECSAS J, 1991, J MOL BIOL, V220, P585, DOI 10.1016/0022-2836(91)90102-C; METZGER W, 1989, EMBO J, V8, P2745, DOI 10.1002/j.1460-2075.1989.tb08416.x; Mukherjee K, 1997, EUR J BIOCHEM, V247, P884, DOI 10.1111/j.1432-1033.1997.00884.x; MUSTAEV A, 1991, J BIOL CHEM, V266, P23927; Mustaev A, 1997, P NATL ACAD SCI USA, V94, P6641, DOI 10.1073/pnas.94.13.6641; MUSTAEV A, 1994, P NATL ACAD SCI USA, V91, P12036, DOI 10.1073/pnas.91.25.12036; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Nudler E, 1998, SCIENCE, V281, P424, DOI 10.1126/science.281.5375.424; Nudler E, 1999, J MOL BIOL, V288, P1, DOI 10.1006/jmbi.1999.2641; Nudler E, 1997, CELL, V89, P33, DOI 10.1016/S0092-8674(00)80180-4; Nudler E, 1996, SCIENCE, V273, P211, DOI 10.1126/science.273.5272.211; Otwinowski Z., 1991, ISOMORPHOUS REPLACEM; POLYAKOV A, 1995, CELL, V83, P365, DOI 10.1016/0092-8674(95)90114-0; REES WA, 1993, SCIENCE, V260, P1646, DOI 10.1126/science.8503010; ROST B, 1993, J MOL BIOL, V232, P584, DOI 10.1006/jmbi.1993.1413; SCHICKOR P, 1990, EMBO J, V9, P2215, DOI 10.1002/j.1460-2075.1990.tb07391.x; SCHULTZ P, 1993, EMBO J, V12, P2601, DOI 10.1002/j.1460-2075.1993.tb05920.x; Sentenac A., 1992, YEAST RNA POLYM SUBU, P27; SEVERINOV K, 1993, J BIOL CHEM, V268, P14820; SEVERINOV K, 1995, J BIOL CHEM, V270, P29428, DOI 10.1074/jbc.270.49.29428; SEVERINOV K, 1994, MOL GEN GENET, V244, P120, DOI 10.1007/BF00283512; Severinov K, 1997, J BIOL CHEM, V272, P24137, DOI 10.1074/jbc.272.39.24137; SEVERINOV K, 1992, J BIOL CHEM, V267, P12813; STEVENS A, 1960, BIOCHEM BIOPH RES CO, V3, P92, DOI 10.1016/0006-291X(60)90110-8; SWEETSER D, 1987, P NATL ACAD SCI USA, V84, P1192, DOI 10.1073/pnas.84.5.1192; TERWILLIGER TC, 1987, ACTA CRYSTALLOGR A, V43, P34; VONHIPPEL PH, 1984, ANNU REV BIOCHEM, V53, P389, DOI 10.1146/annurev.bi.53.070184.002133; Wang Y, 1997, J MOL BIOL, V270, P648, DOI 10.1006/jmbi.1997.1139; WEISS SB, 1959, J AM CHEM SOC, V81, P4118, DOI 10.1021/ja01524a087; Zakharova N, 1999, J BACTERIOL, V181, P3857, DOI 10.1128/JB.181.12.3857-3859.1999; Zaychikov E, 1996, SCIENCE, V273, P107, DOI 10.1126/science.273.5271.107; Zhang GY, 1998, SCIENCE, V281, P262, DOI 10.1126/science.281.5374.262	61	635	665	0	38	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	SEP 17	1999	98	6					811	824		10.1016/S0092-8674(00)81515-9	http://dx.doi.org/10.1016/S0092-8674(00)81515-9			14	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	237WH	10499798	Bronze			2022-12-01	WOS:000082679200008
J	Yokouchi, Y; Vogan, KJ; Pearse, RV; Tabin, CJ				Yokouchi, Y; Vogan, KJ; Pearse, RV; Tabin, CJ			Antagonistic signaling by Caronte, a novel Cerberus-related gene, establishes left-right asymmetric gene expression	CELL			English	Article							SONIC-HEDGEHOG; NEURALIZING ACTIVITY; CHICK EMBRYOGENESIS; SECRETED FACTOR; PATHWAY; LIMB; CONSERVATION; INDUCTION; ENDODERM; HOMOLOG	Left-right asymmetry is initiated during chick embryogenesis in small domains near Hensen's node. Subsequently, broad asymmetric gene expression domains are established in the lateral plate mesoderm, ultimately determining the directionality of morphogenetic events. The transfer of asymmetric information from the node to the lateral plate is mediated by Caronte (Car), a navel member of the Cerberus/Dan gene family, which induces targets by antagonizing symmetrically expressed BMP signals. In addition, BMP antagonism by Car induces asymmetric expression of Lefty in the midline, preventing spread of left-sided signals to the contralateral side.	Harvard Univ, Sch Med, Dept Genet, Boston, MA 02115 USA; Nagoya Univ, Sch Sci, Dept Mol Biol, Chikusa Ku, Nagoya, Aichi 46401, Japan	Harvard University; Harvard Medical School; Nagoya University	Tabin, CJ (corresponding author), Harvard Univ, Sch Med, Dept Genet, Boston, MA 02115 USA.			Vogan, Kyle/0000-0001-9565-9665; Pearse, Richard/0000-0003-3972-1457				Belo JA, 1997, MECH DEVELOP, V68, P45, DOI 10.1016/S0925-4773(97)00125-1; Biben C, 1998, DEV BIOL, V194, P135, DOI 10.1006/dbio.1997.8812; Boettger T, 1999, CURR BIOL, V9, P277, DOI 10.1016/S0960-9822(99)80119-5; Bouwmeester T, 1996, NATURE, V382, P595, DOI 10.1038/382595a0; Capdevila J, 1998, DEV BIOL, V197, P205, DOI 10.1006/dbio.1997.8824; Duprez D, 1996, MECH DEVELOP, V57, P145, DOI 10.1016/0925-4773(96)00540-0; Ericson J, 1996, CELL, V87, P661, DOI 10.1016/S0092-8674(00)81386-0; Goodrich LV, 1996, GENE DEV, V10, P301, DOI 10.1101/gad.10.3.301; Hammerschmidt M, 1997, TRENDS GENET, V13, P14, DOI 10.1016/S0168-9525(96)10051-2; Harvey RP, 1998, CELL, V94, P273, DOI 10.1016/S0092-8674(00)81468-3; Hsu DR, 1998, MOL CELL, V1, P673, DOI 10.1016/S1097-2765(00)80067-2; HUGHES SH, 1987, J VIROL, V61, P3004, DOI 10.1128/JVI.61.10.3004-3012.1987; Isaac A, 1997, SCIENCE, V275, P1301, DOI 10.1126/science.275.5304.1301; Levin M, 1996, NATURE, V384, P321, DOI 10.1038/384321a0; Levin M, 1997, DEV BIOL, V189, P57, DOI 10.1006/dbio.1997.8662; LEVIN M, 1995, CELL, V82, P803, DOI 10.1016/0092-8674(95)90477-8; LEVIN M, 1996, MOL BASIS LEFT RIGHT; Logan M, 1998, CELL, V94, P307, DOI 10.1016/S0092-8674(00)81474-9; LOHR JL, 1997, DEVELOPMENT, V124, P1467; Marigo V, 1996, DEVELOPMENT, V122, P1225; Meno C, 1997, GENES CELLS, V2, P513, DOI 10.1046/j.1365-2443.1997.1400338.x; Meno C, 1998, CELL, V94, P287, DOI 10.1016/S0092-8674(00)81472-5; NEW DAT, 1955, J EMBRYOL EXP MORPH, V3, P326; Pagan-Westphal SM, 1998, CELL, V93, P25, DOI 10.1016/S0092-8674(00)81143-5; Pearce JJH, 1999, DEV BIOL, V209, P98, DOI 10.1006/dbio.1999.9240; Perrimon N, 1999, CELL, V97, P13, DOI 10.1016/S0092-8674(00)80710-2; Piccolo S, 1999, NATURE, V397, P707, DOI 10.1038/17820; RAMSDELL AF, 1999, IN PRESS DEVELOPMENT; RIDDLE RD, 1993, CELL, V75, P1401, DOI 10.1016/0092-8674(93)90626-2; RODRIGUEZESTEBA.C, 1999, IN PRESS NATURE; Tabin CJ, 1997, TRENDS CELL BIOL, V7, P442, DOI 10.1016/S0962-8924(97)01159-8; Thomas P, 1997, COLD SPRING HARB SYM, V62, P115; THOMSEN HS, 1997, TRENDS GENET, V13, P209; Vogan KJ, 1999, NATURE, V397, P295, DOI 10.1038/16796; Yoshioka H, 1998, CELL, V94, P299, DOI 10.1016/S0092-8674(00)81473-7; ZHU L, 1999, IN PRESS CURR BIOL	36	143	150	0	2	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	SEP 3	1999	98	5					573	583		10.1016/S0092-8674(00)80045-8	http://dx.doi.org/10.1016/S0092-8674(00)80045-8			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	233NT	10490097	Bronze			2022-12-01	WOS:000082433500005
J	Donelly, PD				Donelly, PD			Potential problems for tenants	BRITISH MEDICAL JOURNAL			English	Article									Iechyd Morgannwg Hlth, Swansea SA1 1LT, W Glam, Wales		Donelly, PD (corresponding author), Iechyd Morgannwg Hlth, Swansea SA1 1LT, W Glam, Wales.								0	0	0	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	AUG 7	1999	319	7206					373	373						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	226CA	10490322				2022-12-01	WOS:000082001700029
J	Sambongi, Y; Iko, Y; Tanabe, M; Omote, H; Iwamoto-Kihara, A; Ueda, I; Yanagida, T; Wada, Y; Futai, M				Sambongi, Y; Iko, Y; Tanabe, M; Omote, H; Iwamoto-Kihara, A; Ueda, I; Yanagida, T; Wada, Y; Futai, M			Mechanical rotation of the c subunit oligomer in ATP synthase (F0F1): Direct observation	SCIENCE			English	Article							ESCHERICHIA-COLI F1-ATPASE; CARBOXYL-TERMINAL REGION; GAMMA-SUBUNIT; H+-ATPASE; ENERGY TRANSDUCTION; BETA-SUBUNIT; F-TYPE; CATALYSIS; F-1-ATPASE; MUTATIONS	F0F1, found in mitochondria or bacterial membranes, synthesizes adenosine 5'-triphosphate (ATP) coupling with an electrochemical proton gradient and also reversibly hydrolyzes ATP to form the gradient. An actin filament connected to a c subunit oligomer of F-0 was able to rotate by using the energy of ATP hydrolysis. The rotary torque produced by the c subunit oligomer reached about 40 piconewton-nanometers, which is similar to that generated by the gamma subunit in the F-1 motor. These results suggest that the gamma and c subunits rotate together during ATP hydrolysis and synthesis. Thus, coupled rotation may be essential for energy coupling between proton transport through F-0 and ATP hydrolysis or synthesis in F-1.	Osaka Univ, Japan Sci & Technol Corp, CREST, Inst Sci & Ind Res,Div Biol Sci, Osaka 5670047, Japan; Univ Tokyo, Grad Sch Arts & Sci, Dept Biol, Tokyo 1538902, Japan; Osaka Univ, Sch Med, Dept Physiol, Suita, Osaka 5650871, Japan	Japan Science & Technology Agency (JST); Osaka University; University of Tokyo; Osaka University	Futai, M (corresponding author), Osaka Univ, Japan Sci & Technol Corp, CREST, Inst Sci & Ind Res,Div Biol Sci, Osaka 5670047, Japan.	m-futai@sanken.osaka-u.ac.jp	OMOTE, Hiroshi/B-1635-2011; Yanagida, Toshio/D-1919-2009					ABRAHAMS JP, 1994, NATURE, V370, P621, DOI 10.1038/370621a0; AGGELER R, 1995, J BIOL CHEM, V270, P9185, DOI 10.1074/jbc.270.16.9185; AlShawi MK, 1997, J BIOL CHEM, V272, P2300; Boyer PD, 1997, ANNU REV BIOCHEM, V66, P717, DOI 10.1146/annurev.biochem.66.1.717; Dimroth P, 1999, P NATL ACAD SCI USA, V96, P4924, DOI 10.1073/pnas.96.9.4924; Dmitriev OY, 1999, P NATL ACAD SCI USA, V96, P7785, DOI 10.1073/pnas.96.14.7785; DUNCAN TM, 1995, P NATL ACAD SCI USA, V92, P10964, DOI 10.1073/pnas.92.24.10964; Elston T, 1998, NATURE, V391, P510, DOI 10.1038/35185; Fillingame RH, 1996, CURR OPIN STRUC BIOL, V6, P491, DOI 10.1016/S0959-440X(96)80114-X; FILLINGAME RH, 1991, J BIOL CHEM, V266, P20934; FUTAI M, 1989, ANNU REV BIOCHEM, V58, P111; FUTAI M, 1996, HDB BIOL PHYS, V2, P47; HUNT AJ, 1994, BIOPHYS J, V67, P766, DOI 10.1016/S0006-3495(94)80537-5; IWAMOTO A, 1990, J BIOL CHEM, V265, P5043; JEANTEURDEBEUKELAER C, 1995, J BIOL CHEM, V270, P22850; Jones PC, 1998, J BIOL CHEM, V273, P29701, DOI 10.1074/jbc.273.45.29701; Jones PC, 1998, J BIOL CHEM, V273, P17178, DOI 10.1074/jbc.273.27.17178; Junge W, 1997, TRENDS BIOCHEM SCI, V22, P420, DOI 10.1016/S0968-0004(97)01129-8; Kato-Yamada Y, 1998, J BIOL CHEM, V273, P19375, DOI 10.1074/jbc.273.31.19375; Mehta AD, 1999, SCIENCE, V283, P1689, DOI 10.1126/science.283.5408.1689; MORIYAMA Y, 1991, J BIOL CHEM, V266, P22141; NAKAMOTO RK, 1993, J BIOL CHEM, V268, P867; NAKAMOTO RK, 1995, J BIOL CHEM, V270, P14042, DOI 10.1074/jbc.270.23.14042; Noji H, 1997, NATURE, V386, P299, DOI 10.1038/386299a0; Omote H, 1999, P NATL ACAD SCI USA, V96, P7780, DOI 10.1073/pnas.96.14.7780; PENEFSKY HS, 1991, ADV ENZYMOL RELAT AR, V64, P173; PERLIN DS, 1985, BIOCHIM BIOPHYS ACTA, V807, P238, DOI 10.1016/0005-2728(85)90254-3; SHIN K, 1992, J BIOL CHEM, V267, P20835; SVOBODA K, 1993, NATURE, V365, P721, DOI 10.1038/365721a0; VIK SB, 1994, J BIOL CHEM, V269, P30364; Wang HY, 1998, NATURE, V396, P279, DOI 10.1038/24409; Weber J, 1997, BBA-BIOENERGETICS, V1319, P19, DOI 10.1016/S0005-2728(96)00121-1; Yasuda R, 1998, CELL, V93, P1117, DOI 10.1016/S0092-8674(00)81456-7	33	393	400	3	47	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 26	1999	286	5445					1722	1724		10.1126/science.286.5445.1722	http://dx.doi.org/10.1126/science.286.5445.1722			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	259UK	10576736				2022-12-01	WOS:000083912200034
J	Schrag, A; Ben-Shlomo, Y; Quinn, NP				Schrag, A; Ben-Shlomo, Y; Quinn, NP			Prevalence of progressive supranuclear palsy and multiple system atrophy: a cross-sectional study	LANCET			English	Article							RICHARDSON-OLSZEWSKI-SYNDROME; TO-DOOR SURVEY; PARKINSONS-DISEASE; NATURAL-HISTORY; EPIDEMIOLOGY; POPULATION; DIAGNOSIS; COUNTY	Background The prevalence of progressive supranuclear palsy (PSP) and multiple system atrophy (MSA) in the general population is unknown. Clinicopathological studies of patients diagnosed as having Parkinson's disease suggest that the two disorders may be underdiagnosed. We investigated the population prevalence of these disorders. Methods We screened computerised records of 15 general practices in London, UK, for patients with specific diagnostic labels suggestive of Parkinson's disease or parkinsonism and all patients who had ever received antiparkinsonian medication. We assessed eligible patients by review of records, interview, physical examination, and video recordings of neurological signs for independent diagnostic confirmation. We diagnosed parkinsonian disorders according to published criteria and further reviewed patients with atypical features after 1 year. Findings The participation rate was 84%. The age-adjusted prevalence for PSP was 6.4 per 100 000 (five probable and one possible case [95% CI 2.3-10.6]) and for MSA 4.4 per 100 000 (two probable and two possible cases [1.2-7.6]). An additional four atypical patients were identified at 1 year but did not fulfil criteria for PSP or MSA. Interpretation Our results suggest that the true prevalence of PSP and MSA has been underestimated, since many patients in the community remain undiagnosed or misdiagnosed.	Inst Neurol, Dept Clin Neurol, London WC1N 3BG, England; Univ Bristol, Dept Social Med, Bristol, Avon, England	University of London; University College London; University of Bristol	Quinn, NP (corresponding author), Inst Neurol, Dept Clin Neurol, Queen Sq, London WC1N 3BG, England.		Schrag, Anette E/B-4181-2011; Schrag, Anette/AAA-9344-2020; Ben-Shlomo, Yoav/ABD-2004-2021	Schrag, Anette E/0000-0002-9872-6680; Schrag, Anette/0000-0002-9872-6680; Ben-Shlomo, Yoav/0000-0001-6648-3007				Bower JH, 1997, NEUROLOGY, V49, P1284, DOI 10.1212/WNL.49.5.1284; Chio A, 1998, MOVEMENT DISORD, V13, P400, DOI 10.1002/mds.870130305; Cockerell OC, 1996, NEUROEPIDEMIOLOGY, V15, P73, DOI 10.1159/000109892; COCKERELL OC, 1993, J NEUROL NEUROSUR PS, V56, P735, DOI 10.1136/jnnp.56.7.735; deRijk MC, 1995, NEUROLOGY, V45, P2143, DOI 10.1212/WNL.45.12.2143; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; GOLBE LI, 1988, NEUROLOGY, V38, P1031, DOI 10.1212/WNL.38.7.1031; HUGHES AJ, 1992, NEUROLOGY, V42, P142; Litvan I, 1996, J NEUROL NEUROSUR PS, V60, P615, DOI 10.1136/jnnp.60.6.615; Litvan I, 1996, NEUROLOGY, V47, P1, DOI 10.1212/WNL.47.1.1; Maraganore DM, 1998, NEUROLOGY, V50, pA98; MASTAGLIA F L, 1973, Proceedings of the Australian Association of Neurologists, V10, P35; MORGANTE L, 1992, NEUROLOGY, V42, P1901; *OFF NAT STAT, 1997, EUR DAT SHOP; QUINN N, 1989, J NEUROL NEUROSUR PS, P78; RADHAKRISHNAN K, 1988, NEUROEPIDEMIOLOGY, V7, P159, DOI 10.1159/000110150; RAJPUT AH, 1984, ANN NEUROL, V16, P278, DOI 10.1002/ana.410160303; RAJPUT AH, 1991, CAN J NEUROL SCI, V18, P275, DOI 10.1017/S0317167100031814; RYBICKI BA, 1995, NEUROEPIDEMIOLOGY, V14, P72, DOI 10.1159/000109781; Smith P., 1987, CANC INCIDENCE 5 CON, V88, P790; STEELE JC, 1964, ARCH NEUROL-CHICAGO, V10, P333, DOI 10.1001/archneur.1964.00460160003001; TANDBERG E, 1995, MOVEMENT DISORD, V10, P541, DOI 10.1002/mds.870100503; TISON F, 1994, ACTA NEUROL SCAND, V90, P111; TRENKWALDER C, 1995, ARCH NEUROL-CHICAGO, V52, P1017, DOI 10.1001/archneur.1995.00540340109020; WENNING GK, 1995, J NEUROL NEUROSUR PS, V58, P160, DOI 10.1136/jnnp.58.2.160; WENNING GK, 1994, BRAIN, V117, P835, DOI 10.1093/brain/117.4.835; Wermuth L, 1997, NEUROLOGY, V49, P426, DOI 10.1212/WNL.49.2.426	27	386	403	0	5	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	NOV 20	1999	354	9192					1771	1775		10.1016/S0140-6736(99)04137-9	http://dx.doi.org/10.1016/S0140-6736(99)04137-9			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	258RM	10577638				2022-12-01	WOS:000083853000011
J	Francis, D; Diorio, J; Liu, D; Meaney, MJ				Francis, D; Diorio, J; Liu, D; Meaney, MJ			Nongenomic transmission across generations of maternal behavior and stress responses in the rat	SCIENCE			English	Article							CORTICOTROPIN-RELEASING FACTOR; INTERGENERATIONAL TRANSMISSION; CARE	In the rat, variations in maternal care appear to influence the development of behavioral and endocrine responses to stress in the offspring. The results of cross-fostering studies reported here provide evidence for (i) a causal relationship between maternal behavior and stress reactivity in the offspring and (ii) the transmission of such individual differences in maternal behavior from one generation of females to the next. Moreover, an environmental manipulation imposed during early development that alters maternal behavior can then affect the pattern of transmission in subsequent generations. Taken together, these findings indicate that variations in maternal care can serve as the basis for a nongenomic behavioral transmission of individual differences in stress reactivity across generations.	McGill Univ, Dept Psychiat, Douglas Hosp Res Ctr, Dev Neuroendocrinol Lab, Verdun, PQ H4H 1R3, Canada; McGill Univ, Dept Neurol & Neurosurg, Douglas Hosp Res Ctr, Dev Neuroendocrinol Lab, Verdun, PQ H4H 1R3, Canada	McGill University; McGill University	Meaney, MJ (corresponding author), McGill Univ, Dept Psychiat, Douglas Hosp Res Ctr, Dev Neuroendocrinol Lab, Verdun, PQ H4H 1R3, Canada.	mdmm@musica.mcgill.ca	Meaney, Michael/N-5931-2019					ALBERTS JR, 1989, HDB BEHAV NEUROBIOLO, V9; [Anonymous], 1994, SEMIN NEUROSCI; BARNETT SA, 1967, NATURE, V213, P150, DOI 10.1038/213150a0; BHATNAGAR S, 1995, J NEUROENDOCRINOL, V7, P97, DOI 10.1111/j.1365-2826.1995.tb00672.x; BOWLBY J, 1951, MATERNAL CARE MENT H; BUREAU MH, 1993, J NEUROCHEM, V61, P1479, DOI 10.1111/j.1471-4159.1993.tb13643.x; Caldji C, 1998, P NATL ACAD SCI USA, V95, P5335, DOI 10.1073/pnas.95.9.5335; DALLMAN MF, 1992, J NEUROENDOCRINOL, V4, P517, DOI 10.1111/j.1365-2826.1992.tb00200.x; DENENBERG VH, 1967, NATURE, V216, P549, DOI 10.1038/216549a0; DUNN AJ, 1990, BRAIN RES REV, V15, P71, DOI 10.1016/0165-0173(90)90012-D; EISENBERG L, 1990, MAMMALIAN PARENTING; Fairbanks LA., 1996, ADV STUDY BEHAV VOL, V25, P579, DOI [10.1016/S0065-3454(08)60343-5, DOI 10.1016/S0065-3454(08)60343-5]; Field T, 1998, PREV MED, V27, P200, DOI 10.1006/pmed.1998.0293; FLEMING AS, 1988, PSYCHONEUROENDOCRINO, V13, P189, DOI 10.1016/0306-4530(88)90014-5; FRANCIS D, UNPUB; Gray J.A., 1987, PSYCHOL FEAR STRESS, V2nd, P422; GROSSMAN KE, 1993, ATTACHMENT LIFE CYCL; HARLOW HF, 1958, AM PSYCHOL, V13, P673, DOI 10.1037/h0047884; HENNESSY MB, 1982, PHYSIOL PSYCHOL, V10, P153; Herman JP, 1997, TRENDS NEUROSCI, V20, P78, DOI 10.1016/S0166-2236(96)10069-2; HESS JL, 1969, PHYSIOL BEHAV, V4, P109, DOI 10.1016/0031-9384(69)90023-7; LEE MHS, 1974, ANIM BEHAV, V22, P679, DOI 10.1016/S0003-3472(74)80016-3; LEVINE S, 1967, PHYSIOL BEHAV, V2, P55, DOI 10.1016/0031-9384(67)90011-X; LEVINE S, 1962, SCIENCE, V135, P795, DOI 10.1126/science.135.3506.795-a; Levine S., 1975, SOC STRESS DIS; LEVINE S, 1970, POSTNATAL DEV PHENOT; LIGHTMAN SL, 1994, CIBA F SYMP, V172, P173; Liu D, 1997, SCIENCE, V277, P1659, DOI 10.1126/science.277.5332.1659; MACCARI S, 1995, J NEUROSCI, V15, P110; MALIZIA AL, 1995, GABAA RECEPTORS ANXI; McCarty Richard, 1996, Physiology and Behavior, V59, P71, DOI 10.1016/0031-9384(95)02034-9; MEANEY MJ, 1988, SCIENCE, V239, P766, DOI 10.1126/science.3340858; MEANEY MJ, 1989, NEUROENDOCRINOLOGY, V50, P597, DOI 10.1159/000125287; Miller L, 1997, J AM ACAD CHILD PSY, V36, P1134, DOI 10.1097/00004583-199708000-00022; MYERS MM, 1989, DEV PSYCHOBIOL, V22, P55, DOI 10.1002/dev.420220105; Noone R. J., 1995, FAMILY SYSTEMS, V2, P116; OWENS MJ, 1991, PHARMACOL REV, V43, P425; Paxinos G., 2007, RAT BRAIN STEREOTAXI, V6th; Plomin R., 1997, BEHAV GENET; PLOTSKY PM, 1991, J NEUROENDOCRINOL, V3, P1, DOI 10.1111/j.1365-2826.1991.tb00231.x; ROSENBLATT JS, 1994, ACTA PAEDIATR, V83, P3, DOI 10.1111/j.1651-2227.1994.tb13259.x; RoyByrne P, 1996, AM J PSYCHIAT, V153, P1444; Rutter ML, 1997, AM PSYCHOL, V52, P390; SCHULKIN J, 1994, NEUROSCI BIOBEHAV R, V18, P385, DOI 10.1016/0149-7634(94)90051-5; Smotherman W.P., 1980, MATERNAL INFLUENCES; Stern JM, 1997, DEV PSYCHOBIOL, V31, P19, DOI 10.1002/(SICI)1098-2302(199707)31:1<19::AID-DEV3>3.0.CO;2-X; Suomi SJ, 1997, BRIT MED BULL, V53, P170; Vallee M, 1997, J NEUROSCI, V17, P2626; VAN IJZENDOORN MH, 1992, DEV REV, V12, P76, DOI 10.1016/0273-2297(92)90004-L; ZARROW MX, 1973, P SOC EXP BIOL MED, V356, P141; ZARROW WD, 1973, PHYSIOL BEHAV, V356, P141	51	1321	1348	4	204	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 5	1999	286	5442					1155	1158		10.1126/science.286.5442.1155	http://dx.doi.org/10.1126/science.286.5442.1155			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	253AJ	10550053				2022-12-01	WOS:000083534200043
J	Henney, JE				Henney, JE			Continuing shortage of IGIV	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	News Item											Henney, JE (corresponding author), HF-1,Room 14-71,5600 Fishers Ln, Rockville, MD 20857 USA.							1999, MMWR, V48, P159	1	5	5	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 3	1999	282	17					1613	1613		10.1001/jama.282.17.1613	http://dx.doi.org/10.1001/jama.282.17.1613			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	250BD	10553774				2022-12-01	WOS:000083368400006
J	Lawrence, CM; Ray, S; Babyonyshev, M; Galluser, R; Borhani, DW; Harrison, SC				Lawrence, CM; Ray, S; Babyonyshev, M; Galluser, R; Borhani, DW; Harrison, SC			Crystal structure of the ectodomain of human transferrin receptor	SCIENCE			English	Article							INTERMOLECULAR DISULFIDE BONDS; INDUCED CONFORMATIONAL CHANGE; LINKED GLYCOSYLATION SITE; X-RAY-DIFFRACTION; GLUTAMATE CARBOXYPEPTIDASE; SERUM TRANSFERRIN; LIGAND-BINDING; EXPRESSION; HEMOCHROMATOSIS; ASSOCIATION	The transferrin receptor (TfR) undergoes multiple rounds of clathrin-mediated endocytosis and reemergence at the cell surface, importing iron-loaded transferrin (Tf) and recycling apotransferrin after discharge of iron in the endosome. The crystal structure of the dimeric ectodomain of the human TfR, determined here to 3.2 angstroms resolution, reveals a three-domain subunit. One domain closely resembles carboxy- and aminopeptidases, and features of membrane glutamate carboxypeptidase can be deduced from the TfR structure. A model is proposed for Tf binding to the receptor.	Howard Hughes Med Inst, Boston, MA 02115 USA; Childrens Hosp, Mol Med Lab, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, Boston, MA 02115 USA	Howard Hughes Medical Institute; Harvard University; Boston Children's Hospital; Harvard University; Harvard Medical School	Harrison, SC (corresponding author), Howard Hughes Med Inst, 320 Longwood Ave, Boston, MA 02115 USA.		Lawrence, C. Martin/AAH-3420-2020; Borhani, David/O-2692-2019	Lawrence, C. Martin/0000-0002-5398-466X; Borhani, David/0000-0002-8486-8792				ALVAREZ E, 1989, EMBO J, V8, P2231, DOI 10.1002/j.1460-2075.1989.tb08347.x; ANDERSON BF, 1990, NATURE, V344, P784, DOI 10.1038/344784a0; ANDERSON BF, 1989, J MOL BIOL, V209, P711, DOI 10.1016/0022-2836(89)90602-5; ANDERSSON S, 1989, J BIOL CHEM, V264, P8222; [Anonymous], 1994, ACTA CRYSTALLOGR D, V50, P760; BAILEY S, 1988, BIOCHEMISTRY-US, V27, P5804, DOI 10.1021/bi00415a061; BALI PK, 1991, BIOCHEMISTRY-US, V30, P324, DOI 10.1021/bi00216a003; BORHANI DW, 1991, J MOL BIOL, V218, P685, DOI 10.1016/0022-2836(91)90255-5; BRUNGER A, 1992, XPLOR VERSION 3 0 SY; Buchegger F, 1996, EUR J BIOCHEM, V235, P9, DOI 10.1111/j.1432-1033.1996.0009u.x; Bzdega T, 1997, J NEUROCHEM, V69, P2270; CARSON M, 1986, J MOL GRAPHICS, V4, P121, DOI 10.1016/0263-7855(86)80010-8; Carter RE, 1996, P NATL ACAD SCI USA, V93, P749, DOI 10.1073/pnas.93.2.749; Chevrier B, 1996, EUR J BIOCHEM, V237, P393, DOI 10.1111/j.1432-1033.1996.0393k.x; Feder JN, 1998, P NATL ACAD SCI USA, V95, P1472, DOI 10.1073/pnas.95.4.1472; Fuchs H, 1998, STRUCTURE, V6, P1235, DOI 10.1016/S0969-2126(98)00124-5; HEMMAPLARDH D, 1976, BIOCHIM BIOPHYS ACTA, V426, P3852; Jeffrey PD, 1998, BIOCHEMISTRY-US, V37, P13978, DOI 10.1021/bi9812064; JING S, 1987, EMBO J, V6, P327, DOI 10.1002/j.1460-2075.1987.tb04758.x; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KORNFELD S, 1968, BIOCHEMISTRY-US, V7, P945, DOI 10.1021/bi00843a010; Lebron JA, 1998, CELL, V93, P111, DOI 10.1016/S0092-8674(00)81151-4; Luthi-Carter R, 1998, P NATL ACAD SCI USA, V95, P3215, DOI 10.1073/pnas.95.6.3215; MASON AB, 1993, BIOCHEMISTRY-US, V32, P5472, DOI 10.1021/bi00071a025; Mason AB, 1997, BIOCHEM J, V326, P77, DOI 10.1042/bj3260077; MCCLELLAND A, 1984, CELL, V39, P267, DOI 10.1016/0092-8674(84)90004-7; NICHOLLS A, 1991, PROTEIN-STRUCT FUNCT, V11, P282; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Parkkila S, 1997, P NATL ACAD SCI USA, V94, P13198, DOI 10.1073/pnas.94.24.13198; Rawlings ND, 1997, BBA-PROTEIN STRUCT M, V1339, P247, DOI 10.1016/S0167-4838(97)00008-3; Richardson DR, 1997, BBA-REV BIOMEMBRANES, V1331, P1, DOI 10.1016/S0304-4157(96)00014-7; ROBBINS AH, 1989, PROTEINS, V5, P289, DOI 10.1002/prot.340050406; Roy CN, 1999, J BIOL CHEM, V274, P9022, DOI 10.1074/jbc.274.13.9022; RUTLEDGE EA, 1994, BLOOD, V83, P580; SCHNEIDER C, 1984, NATURE, V311, P675, DOI 10.1038/311675b0; SIPE DM, 1991, J BIOL CHEM, V266, P8002; TURKEWITZ AP, 1988, J BIOL CHEM, V263, P8318; TURKEWITZ AP, 1988, J BIOL CHEM, V263, P16309; WILLIAMS AM, 1993, J BIOL CHEM, V268, P12780; ZAK O, 1994, J BIOL CHEM, V269, P7110	40	240	255	0	23	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	OCT 22	1999	286	5440					779	782		10.1126/science.286.5440.779	http://dx.doi.org/10.1126/science.286.5440.779			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	248XZ	10531064				2022-12-01	WOS:000083303200056
J	Prut, Y; Fetz, EE				Prut, Y; Fetz, EE			Primate spinal interneurons show pre-movement instructed delay activity	NATURE			English	Article							PREMOTOR CORTEX; MOTOR CORTEX; CORTICOSPINAL PROJECTIONS; INTENDED DIRECTION; WRIST MOVEMENTS; REACHING TASK; FRONTAL-LOBE; MONKEY; AREAS; FOREPERIOD	Preparatory changes in neural activity before the execution of a movement have been documented in tasks that involve an instructed delay period (an interval between a transient instruction cue and a subsequently triggered movement). Such preparatory activity occurs in many motor centres in the brain, including the primary motor cortex(1-6), premotor cortex(7-9), supplementary motor area(6,10,11) and basal ganglia(6,12,13). Activity during the instructed delay period reflects movement planning, as it correlates with parameters of the cue and the subsequent movement (such as direction and extent(5,6,9)), although it occurs well before muscle activity. How such delay-period activity shapes the ensuring motor action remains unknown. Here we show that spinal interneurons also exhibit early pre-movement delay activity that often differs from their responses during the subsequent muscle activity. This delay activity resembles the set-related activity found in various supraspinal areas, indicating that movement preparation may occur simultaneously over widely distributed regions, including spinal levels. Our results also suggest that two processes occur in the spinal circuitry during this delay period: the motor network is primed with rate changes in the same direction as subsequent movement-related activity; and a superimposed global inhibition suppresses the expression of this activity in muscles.	Univ Washington, Dept Physiol & Biophys, Seattle, WA 98195 USA; Univ Washington, Reg Primate Res Ctr, Seattle, WA 98195 USA	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle	Prut, Y (corresponding author), Univ Washington, Dept Physiol & Biophys, Box 357330, Seattle, WA 98195 USA.							ALEXANDER GE, 1990, J NEUROPHYSIOL, V64, P133, DOI 10.1152/jn.1990.64.1.133; ALEXANDER GE, 1987, EXP BRAIN RES, V67, P623; Baumgartner C, 1996, NEUROLOGY, V46, P753, DOI 10.1212/WNL.46.3.753; BONNET M, 1991, ELECTROEN CLIN NEURO, V81, P135, DOI 10.1016/0168-5597(91)90007-K; BRUNIA CHM, 1982, PSYCHOPHYSIOLOGY, V19, P63, DOI 10.1111/j.1469-8986.1982.tb02600.x; BURKE D, 1980, J PHYSIOL-LONDON, V306, P337, DOI 10.1113/jphysiol.1980.sp013400; DUM RP, 1991, J NEUROSCI, V11, P667; GEORGOPOULOS AP, 1989, EXP BRAIN RES, V75, P183; GERILOVSKY L, 1983, ELECTROEN CLIN NEURO, V56, P487, DOI 10.1016/0013-4694(83)90233-X; HE SQ, 1993, J NEUROSCI, V13, P952; JAEGER D, 1993, EXP BRAIN RES, V95, P51; KOMIYAMA T, 1990, EXP BRAIN RES, V79, P357, DOI 10.1007/BF00608245; KUBOTA K, 1979, BRAIN RES, V168, P435, DOI 10.1016/0006-8993(79)90189-6; KURATA K, 1993, J NEUROPHYSIOL, V69, P187, DOI 10.1152/jn.1993.69.1.187; KURATA K, 1988, EXP BRAIN RES, V69, P327; KUYPERS HGJ, 1970, BRAIN RES, V24, P29, DOI 10.1016/0006-8993(70)90272-6; MOLL L, 1977, SCIENCE, V198, P317, DOI 10.1126/science.410103; MURRAY EA, 1981, J COMP NEUROL, V195, P339, DOI 10.1002/cne.901950212; Perlmutter SI, 1998, J NEUROPHYSIOL, V80, P2475, DOI 10.1152/jn.1998.80.5.2475; REQUIN J, 1977, ATTENTION PERFORM, V6, P139; RIEHLE A, 1995, BEHAV BRAIN RES, V70, P1, DOI 10.1016/0166-4328(94)00180-N; Sawaguchi T, 1996, J NEUROPHYSIOL, V75, P2150, DOI 10.1152/jn.1996.75.5.2150; TANJI J, 1976, J NEUROPHYSIOL, V39, P1062, DOI 10.1152/jn.1976.39.5.1062; TANJI J, 1980, J NEUROPHYSIOL, V43, P60, DOI 10.1152/jn.1980.43.1.60; TANJI J, 1985, J NEUROPHYSIOL, V53, P129, DOI 10.1152/jn.1985.53.1.129; THACH WT, 1978, J NEUROPHYSIOL, V41, P654, DOI 10.1152/jn.1978.41.3.654; TOYOSHIMA K, 1982, J HIRNFORSCH, V23, P257; WEINRICH M, 1982, J NEUROSCI, V2, P1329; WISE SP, 1986, PROG BRAIN RES, V64, P117	29	169	171	0	11	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	OCT 7	1999	401	6753					590	594		10.1038/44145	http://dx.doi.org/10.1038/44145			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	244MG	10524626				2022-12-01	WOS:000083054900051
J	Schneider, JS; Levin, S				Schneider, JS; Levin, S			Uneasy partners: The lesbian and gay health care community and the AMA	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article									NYU, Sch Med, New York, NY 10012 USA; Access Consulting Int Inc, Washington, DC USA	New York University	Schneider, JS (corresponding author), NYU, Sch Med, New York, NY 10012 USA.							*ACCR COUNC GRAD M, 1999, I REV REQ; *AM AC FAM PHYS, 1999, COMP AAFP POS SEL HL; *AM MED ASS, 1982, P AM MED ASS HOUS DE, V2, P579; *AM MED ASS, 1992, P AM MED ASS HOUS DE, V1, P151; *AM MED ASS, 1999, CULT COMP COMP; *AM MED ASS, 1989, DEL HDB; *AM MED ASS, 1999, POL COMP; *AM MED ASS, 1990, P AM MED ASS HOUS DE, V1, P276; *AM MED ASS, 1998, POLICY COMPENDIUM; *AM MED ASS, 1998, POL COMP; BEACH RK, 1993, PEDIATRICS, V92, P631; Davis RM, 1996, JAMA-J AM MED ASSOC, V275, P1354, DOI 10.1001/jama.1996.03530410068036; JONES RJ, 1982, JAMA-J AM MED ASSOC, V248, P736; Kitchens LW, 1998, ANN INTERN MED, V128, P576, DOI 10.7326/0003-4819-128-7-199804010-00012; Liaison Committee on Medical Education, 1998, FUNCT STRUCT MED SCH; MCCORMICK B, 1998, AM MED NEWS     1019, P24; Wallick M M, 1997, N C Med J, V58, P123; WALLICK MM, 1995, ACAD MED, V70, P2, DOI 10.1097/00001888-199501000-00003	18	6	6	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 6	1999	282	13					1287	1288		10.1001/jama.282.13.1287	http://dx.doi.org/10.1001/jama.282.13.1287			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	241UM	10517435	hybrid			2022-12-01	WOS:000082901100040
J	Holmbeck, K; Bianco, P; Caterina, J; Yamada, S; Kromer, M; Kuznetsov, SA; Mankani, M; Robey, PG; Poole, AR; Pidoux, I; Ward, JM; Birkedal-Hansen, H				Holmbeck, K; Bianco, P; Caterina, J; Yamada, S; Kromer, M; Kuznetsov, SA; Mankani, M; Robey, PG; Poole, AR; Pidoux, I; Ward, JM; Birkedal-Hansen, H			MT1-MMP-deficient mice develop dwarfism, osteopenia, arthritis, and connective tissue disease due to inadequate collagen turnover	CELL			English	Article							TYPE-1 MATRIX METALLOPROTEINASE; PRO-GELATINASE-A; EXTRACELLULAR-MATRIX; OSTEOBLAST DIFFERENTIATION; HYPERTROPHIC CHONDROCYTES; INTERSTITIAL COLLAGENASE; RHEUMATOID-ARTHRITIS; MOUSE EMBRYOGENESIS; BONE-RESORPTION; IN-VIVO	MT1-MMP is a membrane-bound matrix metalloproteinase (MT-MMP) capable of mediating pericellular proteolysis of extracellular matrix components. MT1-MMP is therefore thought to be an important molecular tool for cellular remodeling of the surrounding matrix. To establish the biological role of this membrane proteinase we generated MT1-MMP-deficient mice by gene targeting. MT1-MMP deficiency causes craniofacial dysmorphism, arthritis, osteopenia, dwarfism, and fibrosis of soft tissues due to ablation of a collagenolytic activity that is essential for modeling of skeletal and extraskeletal connective tissues. Our findings demonstrate the pivotal function of MT1-MMP in connective tissue metabolism, and illustrate that modeling of the soft connective tissue matrix by resident cells is essential for the development and maintenance of the hard tissues of the skeleton.	Natl Inst Dent & Craniofacial Res, MMP Unit, Bethesda, MD 20892 USA; Univ Roma La Sapienza, I-00161 Rome, Italy; Univ Aquila, I-67100 Laquila, Italy; McGill Univ, Shriners Hosp Children, Canadian Unit, Joint Dis Lab, Montreal, PQ H3G 1A6, Canada; NCI, Vet & Tumor Pathol Sect, Anim Sci Branch, Div Basic Sci, Frederick, MD 21702 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR); Sapienza University Rome; University of L'Aquila; McGill University; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Birkedal-Hansen, H (corresponding author), Natl Inst Dent & Craniofacial Res, MMP Unit, Bethesda, MD 20892 USA.	hbhansen@dir.nidcr.nih.gov	Robey, Pamela Gehron/H-1429-2011	Robey, Pamela Gehron/0000-0002-5316-5576; Holmbeck, Kenn/0000-0002-4472-3257	NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [ZIADE000676, ZIADE000380] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [Z01DE000676, Z01DE000380] Funding Source: NIH RePORTER; Telethon [E.1029] Funding Source: Medline	NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); Telethon(Fondazione Telethon)		Apte SS, 1997, J BIOL CHEM, V272, P25511, DOI 10.1074/jbc.272.41.25511; BIANCO P, 1984, BASIC APPL HISTOCHEM, V28, P265; BIRKEDALHANSEN H, 1993, CRIT REV ORAL BIOL M, V4, P197, DOI 10.1177/10454411930040020401; BIRKEDALHANSEN H, 1995, CURR OPIN CELL BIOL, V7, P728, DOI 10.1016/0955-0674(95)80116-2; Chen HX, 1998, DEV GENET, V22, P314, DOI 10.1002/(SICI)1520-6408(1998)22:4<314::AID-DVG2>3.0.CO;2-9; Chin JR, 1997, DEVELOPMENT, V124, P1519; COLE AA, 1985, AM J ANAT, V174, P119, DOI 10.1002/aja.1001740203; Cowell S, 1998, BIOCHEM J, V331, P453, DOI 10.1042/bj3310453; Ducy P, 1997, CELL, V89, P747, DOI 10.1016/S0092-8674(00)80257-3; GACK S, 1995, CELL GROWTH DIFFER, V6, P759; GALIS ZS, 1995, P NATL ACAD SCI USA, V92, P402, DOI 10.1073/pnas.92.2.402; GAMERO P, 1998, J BIOL CHEM, V273, P32347; Gravallese EM, 1998, AM J PATHOL, V152, P943; Havemose-Poulsen A, 1998, J PERIODONTAL RES, V33, P280, DOI 10.1111/j.1600-0765.1998.tb02201.x; Hiraoka N, 1998, CELL, V95, P365, DOI 10.1016/S0092-8674(00)81768-7; Itoh T, 1997, J BIOL CHEM, V272, P22389, DOI 10.1074/jbc.272.36.22389; Johnson LL, 1998, CURR OPIN CHEM BIOL, V2, P466, DOI 10.1016/S1367-5931(98)80122-1; Kaufmann MH, 1998, ATLAS MOUSE DEV; KIDWELL JF, 1961, J HERED, V52, P145, DOI 10.1093/oxfordjournals.jhered.a107050; Kinoh H, 1996, J CELL SCI, V109, P953; Krebsbach PH, 1997, TRANSPLANTATION, V63, P1059, DOI 10.1097/00007890-199704270-00003; Kuettner K.E., 1983, SEFER RABIAH, V1, P281; Kuznetsov S, 1996, CALCIFIED TISSUE INT, V59, P265, DOI 10.1007/s002239900121; Lark MW, 1997, J CLIN INVEST, V100, P93, DOI 10.1172/JCI119526; LIOTTA LA, 1991, CELL, V64, P327, DOI 10.1016/0092-8674(91)90642-C; LUFTI AM, 1970, J ANAT, V106, P135; MAGIN TM, 1992, NUCLEIC ACIDS RES, V20, P3795, DOI 10.1093/nar/20.14.3795; Masson R, 1998, J CELL BIOL, V140, P1535, DOI 10.1083/jcb.140.6.1535; MATTOT V, 1995, J CELL SCI, V108, P529; MELCHER AH, 1981, J ULTRA MOL STRUCT R, V77, P1, DOI 10.1016/S0022-5320(81)80064-0; Mignatti P, 1996, ENZYME PROTEIN, V49, P117, DOI 10.1159/000468621; Mudgett JS, 1998, ARTHRITIS RHEUM-US, V41, P110, DOI 10.1002/1529-0131(199801)41:1<110::AID-ART14>3.0.CO;2-G; Nagase H, 1998, Cell Res, V8, P179; Ohuchi E, 1997, J BIOL CHEM, V272, P2446, DOI 10.1074/jbc.272.4.2446; Okada A, 1997, J CELL BIOL, V137, P67, DOI 10.1083/jcb.137.1.67; Otto F, 1997, CELL, V89, P765, DOI 10.1016/S0092-8674(00)80259-7; Pei DQ, 1999, J BIOL CHEM, V274, P8925, DOI 10.1074/jbc.274.13.8925; Puente XS, 1996, CANCER RES, V56, P944; Saftig P, 1998, P NATL ACAD SCI USA, V95, P13453, DOI 10.1073/pnas.95.23.13453; SATO H, 1994, NATURE, V370, P61, DOI 10.1038/370061a0; Sato H, 1996, FEBS LETT, V393, P101, DOI 10.1016/0014-5793(96)00861-7; Shipley JM, 1996, P NATL ACAD SCI USA, V93, P3942, DOI 10.1073/pnas.93.9.3942; StahleBackdahl M, 1997, LAB INVEST, V76, P717; STETLERSTEVENSON WG, 1993, ANNU REV CELL BIOL, V9, P541, DOI 10.1146/annurev.cellbio.9.1.541; STRONGIN AY, 1995, J BIOL CHEM, V270, P5331, DOI 10.1074/jbc.270.10.5331; Suzuki Y, 1998, J RHEUMATOL, V25, P1154; TAKINO T, 1995, J BIOL CHEM, V270, P23013, DOI 10.1074/jbc.270.39.23013; VANDERLUGT N, 1991, GENE, V105, P263, DOI 10.1016/0378-1119(91)90161-4; Vu TH, 1998, CELL, V93, P411, DOI 10.1016/S0092-8674(00)81169-1; Werb Z, 1997, CELL, V91, P439, DOI 10.1016/S0092-8674(00)80429-8; Werb Z, 1996, KIDNEY INT, V49, pS68; WILL H, 1995, EUR J BIOCHEM, V231, P602, DOI 10.1111/j.1432-1033.1995.0602d.x; Wilson CL, 1997, P NATL ACAD SCI USA, V94, P1402, DOI 10.1073/pnas.94.4.1402	53	1038	1071	1	44	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	OCT 1	1999	99	1					81	92		10.1016/S0092-8674(00)80064-1	http://dx.doi.org/10.1016/S0092-8674(00)80064-1			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	243DK	10520996	Bronze			2022-12-01	WOS:000082981600010
J	Dawes, PT				Dawes, PT			MRI abnormalities in rheumatoid arthritis	LANCET			English	Editorial Material									N Staffordshire Hosp NHS Trust, Staffordshire Rheumatol Ctr, Stoke On Trent ST6 7AG, Staffs, England	University Hospital of North Staffordshire NHS Trust	Dawes, PT (corresponding author), N Staffordshire Hosp NHS Trust, Staffordshire Rheumatol Ctr, Stoke On Trent ST6 7AG, Staffs, England.							DAWES P T, 1988, British Journal of Rheumatology, V27, P21; Gaffney K, 1998, ANN RHEUM DIS, V57, P152, DOI 10.1136/ard.57.3.152; HASSELL AB, 1993, Q J MED, V86, P601; Klarlund M, 1999, RHEUMATOLOGY, V38, P66, DOI 10.1093/rheumatology/38.1.66; Mc Gonagle D, 1999, RHEUMATOLOGY, V38, P329, DOI 10.1093/rheumatology/38.4.329; McQueen FM, 1999, ANN RHEUM DIS, V58, P156, DOI 10.1136/ard.58.3.156; Molenaar ETH, 1999, J RHEUMATOL, V26, P749; Mulherin D, 1996, BRIT J RHEUMATOL, V35, P1263; WOLFE F, 1993, J RHEUMATOL, V20, P2005	9	3	3	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	SEP 25	1999	354	9184					1051	1052		10.1016/S0140-6736(99)90121-6	http://dx.doi.org/10.1016/S0140-6736(99)90121-6			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	239PA	10509493				2022-12-01	WOS:000082777500007
J	Romelsjo, A; Leifman, A				Romelsjo, A; Leifman, A			Association between alcohol consumption and mortality, myocardial infarction, and stroke in 25 year follow up of 49 618 young Swedish men	BRITISH MEDICAL JOURNAL			English	Article									Karolinska Inst, Novum, Dept Publ Hlth Sci, S-14157 Huddinge, Sweden; Karolinska Inst, Novum, Ctr Alcohol & Drug Prevent, S-14157 Huddinge, Sweden	Karolinska Institutet; Karolinska Institutet	Romelsjo, A (corresponding author), Karolinska Inst, Novum, Dept Publ Hlth Sci, S-14157 Huddinge, Sweden.							ANDREASSON S, 1988, BRIT MED J, V296, P1021, DOI 10.1136/bmj.296.6628.1021; Beaglehole R, 1992, Drug Alcohol Rev, V11, P275, DOI 10.1080/09595239200185811; Edwards G., 1994, ALCOHOL POLICY PUBLI; REHM J, 1998, ALCOHOLISM CLIN EX S, V22, P15; ROTHMAN K, 1998, MODERN EPIDEMIOLOGY, P430	5	47	47	1	6	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	SEP 25	1999	319	7213					821	822		10.1136/bmj.319.7213.821	http://dx.doi.org/10.1136/bmj.319.7213.821			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	241CR	10496826	Bronze, Green Published			2022-12-01	WOS:000082865200024
J	Kakei, S; Hoffman, DS; Strick, PL				Kakei, S; Hoffman, DS; Strick, PL			Muscle and movement representations in the primary motor cortex	SCIENCE			English	Article							STEP-TRACKING MOVEMENTS; FREE ARM MOVEMENTS; 3-DIMENSIONAL SPACE; CORTICOMOTONEURONAL CELLS; NEURAL REPRESENTATIONS; VISUAL TARGETS; REACHING TASK; DIRECTION; FORCE; DISCHARGE	What aspects of movement are represented in the primary motor cortex (M1): relatively low-level parameters like muscle force, or more abstract parameters like handpath? To examine this issue, the activity of neurons in M1 was recorded in a monkey trained to perform a task that dissociates three major variables of wrist movement: muscle activity, direction of movement at the wrist joint, and direction of movement in space. A substantial group of neurons in M1 (28 out of 88) displayed changes in activity that were muscle-like. Unexpectedly an even larger group of neurons in M1 (44 out of 88) displayed changes in activity that were related to the direction of wrist movement in space independent of the pattern of muscle activity that generated the movement. Thus, both "muscles" and "movements" appear to be strongly represented in M1.	Vet Affairs Med Ctr, Res Serv 151S, Syracuse, NY 13210 USA; SUNY Hlth Sci Ctr, Dept Neurosurg, Syracuse, NY 13210 USA; SUNY Hlth Sci Ctr, Dept Neurosci & Physiol, Syracuse, NY 13210 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); State University of New York (SUNY) System; State University of New York (SUNY) Upstate Medical Center; State University of New York (SUNY) System; State University of New York (SUNY) Upstate Medical Center	Strick, PL (corresponding author), Vet Affairs Med Ctr, Res Serv 151S, 800 Irving Ave, Syracuse, NY 13210 USA.			Kakei, Shinji/0000-0001-5111-5789				ALEXANDER GE, 1990, J NEUROPHYSIOL, V64, P133, DOI 10.1152/jn.1990.64.1.133; ALEXANDER GE, 1990, J NEUROPHYSIOL, V64, P164, DOI 10.1152/jn.1990.64.1.164; BUYS EJ, 1986, J PHYSIOL-LONDON, V381, P529, DOI 10.1113/jphysiol.1986.sp016342; CAMINITI R, 1990, J NEUROSCI, V10, P2039; CHENEY PD, 1980, J NEUROPHYSIOL, V44, P773, DOI 10.1152/jn.1980.44.4.773; Crammond DJ, 1996, EXP BRAIN RES, V108, P45; Evarts E. V., 1967, NEUROPHYSIOLOGICAL B, P215; EVARTS EV, 1968, J NEUROPHYSIOL, V31, P14, DOI 10.1152/jn.1968.31.1.14; EVARTS EV, 1983, J NEUROPHYSIOL, V49, P1199, DOI 10.1152/jn.1983.49.5.1199; FETZ EE, 1980, J NEUROPHYSIOL, V44, P751, DOI 10.1152/jn.1980.44.4.751; GEORGOPOULOS AP, 1992, SCIENCE, V256, P1692, DOI 10.1126/science.256.5064.1692; GEORGOPOULOS AP, 1988, J NEUROSCI, V8, P2928; GEORGOPOULOS AP, 1982, J NEUROSCI, V2, P1527; GEORGOPOULOS AP, 1983, EXP BRAIN RES S, V7; HOFFMAN DS, 1986, J NEUROSCI, V6, P3309; HOFFMAN DS, 1995, J NEUROPHYSIOL, V73, P891, DOI 10.1152/jn.1995.73.2.891; Hoffman DS, 1999, J NEUROPHYSIOL, V81, P319, DOI 10.1152/jn.1999.81.1.319; HOLLERBACH JM, 1982, TRENDS NEUROSCI, V5, P189, DOI 10.1016/0166-2236(82)90111-4; Kakei S., 1998, Society for Neuroscience Abstracts, V24, P2108; Kakei S., 1997, Society for Neuroscience Abstracts, V23, P2096; KALASKA JF, 1989, J NEUROSCI, V9, P2080; SCHWARTZ AB, 1988, J NEUROSCI, V8, P2913; SCHWARTZ AB, 1993, J NEUROPHYSIOL, V70, P28, DOI 10.1152/jn.1993.70.1.28; Scott SH, 1997, J NEUROPHYSIOL, V77, P826, DOI 10.1152/jn.1997.77.2.826; Sergio LE, 1998, J NEUROPHYSIOL, V80, P1577, DOI 10.1152/jn.1998.80.3.1577; Shen LM, 1997, J NEUROPHYSIOL, V77, P1171, DOI 10.1152/jn.1997.77.3.1171; SMITH AM, 1975, EXP BRAIN RES, V23, P315; SOECHTING JF, 1992, ANNU REV NEUROSCI, V15, P167, DOI 10.1146/annurev.ne.15.030192.001123; THACH WT, 1978, J NEUROPHYSIOL, V41, P654, DOI 10.1152/jn.1978.41.3.654	29	514	519	1	36	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	SEP 24	1999	285	5436					2136	2139		10.1126/science.285.5436.2136	http://dx.doi.org/10.1126/science.285.5436.2136			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	238VF	10497133	Green Submitted			2022-12-01	WOS:000082734300045
J	Gallardo, MH; Bickham, JW; Honeycutt, RL; Ojeda, RA; Kohler, N				Gallardo, MH; Bickham, JW; Honeycutt, RL; Ojeda, RA; Kohler, N			Discovery of tetraploidy in a mammal	NATURE			English	Article									Univ Austral Chile, Inst Ecol & Evoluc, Valdivia, Chile; Texas A&M Univ, Dept Wildlife & Fisheries Sci, College Stn, TX 77843 USA; Inst Argentino Invest Zonas Aridas, Cricyt, RA-5500 Mendoza, Argentina	Universidad Austral de Chile; Texas A&M University System; Texas A&M University College Station; Consejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET)	Gallardo, MH (corresponding author), Univ Austral Chile, Inst Ecol & Evoluc, Casilla 567, Valdivia, Chile.			Ojeda, Ricardo/0000-0001-5246-0496				CONTRERAS LC, 1990, EXPERIENTIA, V46, P506, DOI 10.1007/BF01954248; Ferrari MR, 1998, ANDROLOGIA, V30, P85; Gallardo MH, 1997, CHROMOSOM T, V12, P347; Muller HJ, 1925, AM NAT, V59, P346, DOI 10.1086/280047; NIEBUHR E, 1974, HUMANGENETIK, V21, P103, DOI 10.1007/BF00281030; OHNO S., 1963, CYTO GENETICS [BASEL], V2, P42, DOI 10.1159/000129764; Ojeda RA, 1999, J ARID ENVIRON, V41, P443, DOI 10.1006/jare.1999.0496; ORR HA, 1990, AM NAT, V136, P759, DOI 10.1086/285130; PARKHURST SM, 1994, SCIENCE, V264, P924, DOI 10.1126/science.8178152; Vinogradov AE, 1998, CYTOMETRY, V31, P100, DOI 10.1002/(SICI)1097-0320(19980201)31:2<100::AID-CYTO5>3.0.CO;2-Q	10	127	134	0	11	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	SEP 23	1999	401	6751					341	341		10.1038/43815	http://dx.doi.org/10.1038/43815			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	240JJ	10517628	Bronze			2022-12-01	WOS:000082822600037
J	Rao, JK; Mihaliak, K; Kroenke, K; Bradley, J; Tierney, WM; Weinberger, M				Rao, JK; Mihaliak, K; Kroenke, K; Bradley, J; Tierney, WM; Weinberger, M			Use of complementary therapies for arthritis among patients of rheumatologists	ANNALS OF INTERNAL MEDICINE			English	Article							ALTERNATIVE MEDICINE USE; UNCONVENTIONAL MEDICINE; RHEUMATOID-ARTHRITIS; UNITED-STATES; HEALTH-CARE; PREVALENCE; REMEDIES; OSTEOARTHRITIS; COMMUNITY; PRACTITIONERS	Background: Use of complementary and alternative medicine (CAM) is common among persons with chronic conditions. Objective: To identify correlates of and describe patients' perspective on use of CAM for rheumatologic conditions. Design: Telephone survey. Setting: Three university practices and three private rheumatology practices. Patients: 232 of 428 eligible consecutive patients (54%) with scheduled appointments. Measurements: Patients answered questions on CAM use, functional status, pain, provider satisfaction, and health services utilization. Chart reviews provided demographic information and rheumatologic diagnoses. Bivariate analyses identified correlates of four CAM outcomes (history, magnitude, and frequency of CAM use and communication about CAM use with a physician), and multiple logistic regression identified independent correlates of regular CAM use. Results: Approximately two thirds of the respondents (n = 146) had used CAM. Of these 146 respondents, 82 (56%) currently used CAM and 132 (90%) regularly used CAM or had done so in the past. Fifty-five respondents (24%) had used three or more types of CAM. In multivariate analyses, persons who used CAM regularly were more likely to have osteoarthritis (odds ratio, 5.6 [95% CI, 1.9 to 16.8]), severe pain (odds ratio, 2.5 [CI, 1.4 to 4.8]), and a college degree (odds ratio, 2.6 [CI, 1.3 to 5.4]) than patients who had never used CAM. Nearly half of the respondents discussed CAM use with their physicians. The most common reasons for not disclosing CAM use were that the physician had not asked about it and that the patient forgot to tell the physician; fear of disapproval was rarely cited. Discussions about CAM use between patient and physician occurred more frequently among patients with fibromyalgia and persons who regularly used CAM or used several types of CAM. Conclusions: Patients with rheumatologic conditions frequently use CAM. Severe pain and osteoarthritis predict regular use of CAM but do not predict a greater likelihood of discussing CAM use with physicians. Routine inquiry by physicians will probably detect CAM use.	Indiana Univ, Richard L Roudebush Vet Affairs Med Ctr, Sch Med, Indianapolis, IN 46202 USA; Regenstrief Inst Hlth Care, Indianapolis, IN 46202 USA	Indiana University System; Indiana University-Purdue University Indianapolis; US Department of Veterans Affairs; Veterans Health Administration (VHA); Richard L. Roudebush VA Medical Center; Indiana University System; Indiana University-Purdue University Indianapolis; Regenstrief Institute Inc	Rao, JK (corresponding author), Vet Affairs Med Ctr, Hlth Serv Res & Dev 152, MHS, 508 Fulton St, Durham, NC 27705 USA.		anand, amit/A-7222-2009	Kroenke, Kurt/0000-0002-0114-4669				Angell M, 1998, NEW ENGL J MED, V339, P839, DOI 10.1056/NEJM199809173391210; Arcury TA, 1996, ARTHRIT CARE RES, V9, P384, DOI 10.1002/1529-0131(199610)9:5<384::AID-ANR1790090507>3.0.CO;2-Y; Astin JA, 1998, JAMA-J AM MED ASSOC, V279, P1548, DOI 10.1001/jama.279.19.1548; BOISSET M, 1994, J RHEUMATOL, V21, P148; CAMPION EW, 1993, NEW ENGL J MED, V328, P282, DOI 10.1056/NEJM199301283280413; CASSILETH BR, 1984, ANN INTERN MED, V101, P105, DOI 10.7326/0003-4819-101-1-105; Coppes MJ, 1998, NEW ENGL J MED, V339, P846, DOI 10.1056/NEJM199809173391213; CORNELISSEN PGJ, 1988, ANN RHEUM DIS, V47, P150, DOI 10.1136/ard.47.2.150; Cronan T A, 1993, Arthritis Care Res, V6, P149, DOI 10.1002/art.1790060307; CRONAN TA, 1989, ARTHRITIS RHEUM, V32, P1604, DOI 10.1002/anr.1780321217; Dalen JE, 1998, ARCH INTERN MED, V158, P2179, DOI 10.1001/archinte.158.20.2179; Davidoff F, 1998, ANN INTERN MED, V129, P1068, DOI 10.7326/0003-4819-129-12-199812150-00014; DEVELLIS RF, 1993, J RHEUMATOL, V20, P866; DOWNIE WW, 1978, ANN RHEUM DIS, V37, P378, DOI 10.1136/ard.37.4.378; Eisenberg DM, 1997, ANN INTERN MED, V127, P61, DOI 10.7326/0003-4819-127-1-199707010-00010; EISENBERG DM, 1993, NEW ENGL J MED, V328, P246, DOI 10.1056/NEJM199301283280406; Eisenberg DM, 1998, JAMA-J AM MED ASSOC, V280, P1569, DOI 10.1001/jama.280.18.1569; Elder NC, 1997, ARCH FAM MED, V6, P181, DOI 10.1001/archfami.6.2.181; Fairfield KM, 1998, ARCH INTERN MED, V158, P2257, DOI 10.1001/archinte.158.20.2257; Fontanarosa PB, 1997, JAMA-J AM MED ASSOC, V278, P2111, DOI 10.1001/jama.1997.03550230087045; GRAY D, 1985, SOC SCI MED, V21, P507, DOI 10.1016/0277-9536(85)90034-6; GRAY D, 1983, MED ANTHROPOL, V7, P29; HIGHAM C, 1983, PRACTITIONER, V227, P1201; HOCHBERG MC, 1995, ARTHRITIS RHEUM, V38, P1541, DOI 10.1002/art.1780381104; HOCHBERG MC, 1995, ARTHRITIS RHEUM, V38, P1535, DOI 10.1002/art.1780381103; Kaptchuk TJ, 1998, ANN INTERN MED, V129, P1061, DOI 10.7326/0003-4819-129-12-199812150-00011; KAZIS LE, 1990, J CLIN EPIDEMIOL, V43, P1243, DOI 10.1016/0895-4356(90)90025-K; KESTIN M, 1985, MED J AUSTRALIA, V143, P516, DOI 10.5694/j.1326-5377.1985.tb119916.x; KOVAR PA, 1992, ANN INTERN MED, V116, P529, DOI 10.7326/0003-4819-116-7-529; KRONENFELD JJ, 1982, SOC SCI MED, V16, P1119, DOI 10.1016/0277-9536(82)90114-9; Lawrence RC, 1998, ARTHRITIS RHEUM-US, V41, P778, DOI 10.1002/1529-0131(199805)41:5<778::AID-ART4>3.0.CO;2-V; MacLennan AH, 1996, LANCET, V347, P569, DOI 10.1016/S0140-6736(96)91271-4; MILLER IW, 1979, PSYCHOL BULL, V86, P93, DOI 10.1037/0033-2909.86.1.93; Nicassio PM, 1997, J RHEUMATOL, V24, P2008; PINCUS T, 1983, ARTHRITIS RHEUM-US, V26, P1346, DOI 10.1002/art.1780261107; PioroBoisset M, 1996, ARTHRIT CARE RES, V9, P13, DOI 10.1002/art.1790090105; Rao JK, 1998, ARTHRIT CARE RES, V11, P253, DOI 10.1002/art.1790110406; Slifman NR, 1998, NEW ENGL J MED, V339, P806, DOI 10.1056/NEJM199809173391204; STRUTHERS GR, 1983, RHEUMATOL INT, V3, P151, DOI 10.1007/BF00541593; THOMAS KJ, 1991, BRIT MED J, V302, P207, DOI 10.1136/bmj.302.6770.207; VECCHIO PC, 1994, J RHEUMATOL, V21, P145; VISSER GJ, 1992, BRIT J RHEUMATOL, V31, P485; WASNER CK, 1991, RHEUM DIS CLIN N AM, V17, P197; Weisbord SD, 1997, NEW ENGL J MED, V337, P825, DOI 10.1056/NEJM199709183371205; WIENER CL, 1975, SOC SCI MED, V9, P97, DOI 10.1016/0037-7856(75)90101-8; Wolfe F, 1997, ARTHRITIS RHEUM, V40, P1124	46	283	287	0	6	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	SEP 21	1999	131	6					409	416		10.7326/0003-4819-131-6-199909210-00003	http://dx.doi.org/10.7326/0003-4819-131-6-199909210-00003			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	237DY	10498556				2022-12-01	WOS:000082641100002
J	Makridakis, NM; Ross, RK; Pike, MC; Crocitto, LE; Kolonel, LN; Pearce, CL; Henderson, BE; Reichardt, JKV				Makridakis, NM; Ross, RK; Pike, MC; Crocitto, LE; Kolonel, LN; Pearce, CL; Henderson, BE; Reichardt, JKV			Association of mis-sense substitution in SRD5A2 gene with prostate cancer in African-American and Hispanic men in Los Angeles, USA	LANCET			English	Article							STEROID 5-ALPHA-REDUCTASE; SUSCEPTIBILITY LOCUS; RISK; POLYMORPHISM; CHROMOSOME	Background Prostate cancer is a very common disease in more-developed countries, but its cause is largely unknown. It is an androgen-dependent cancer, and androgens have been proposed as having a substantial role in predisposition to the disease. Thus, variations in androgen metabolism genes may affect risk of this disease, Methods We screened 216 African-American and 172 Hispanic men with prostate cancer, and 261 African-American and 200 Hispanic healthy men (controls), from a large prospective cohort study (the Hawaii-Los Angeles Multiethnic Cohort Study) for a mis-sense substitution in the human prostatic (or type II) steroid 5 alpha-reductase (SRD5A2) gene, the product of which controls metabolic activation of testosterone to dihydrotestosterone. This mis-sense substitution results in an alanine residue at codon 49 being replaced with threonine (A49T). We also reconstructed this mutation in the SRD5A2 cDNA, and overexpressed the enzyme in mammalian tissue culture cells, Findings The A49T aminoacid substitution in the SRD5A2 gene increased the risk of clinically significant disease 7.2-fold in African-American men (95% CI=2.17-27.91; p=0.001) and 3.6-fold in Hispanic men (1.09-12.27; p=0.04). The mutant enzyme had a higher in-vitro V-max than the normal enzyme (9.9 vs 1.9 nmol min(-1) mg(-1)). Interpretation The A49T variant of the SRD5A2 gene may be a significant contributor to the incidence of prostate cancer in African-American and Hispanic men in Los Angeles. We estimate that the population attributable risk due to this aminoacid substitution for clinically significant disease is about 8% in both populations. Increased conversion of testosterone to dihydrotestosterone catalysed by this variant steroid 5 alpha-reductase enzyme may be the cause of the increased risk.	Univ So Calif, Sch Med, Inst Med Genet, Los Angeles, CA 90033 USA; Univ So Calif, Sch Med, Dept Biochem, Los Angeles, CA 90033 USA; Univ So Calif, Sch Med, Dept Prevent Med, Los Angeles, CA 90033 USA; Univ So Calif, Sch Med, Kenneth Norris Jr Comprehens Canc Ctr, Los Angeles, CA 90033 USA; Univ So Calif, Sch Med, Dept Urol, Los Angeles, CA 90033 USA; Univ Hawaii, Canc Res Ctr, Honolulu, HI 96813 USA	University of Southern California; University of Southern California; University of Southern California; University of Southern California; University of Southern California; Cancer Research Center of Hawaii; University of Hawaii System	Reichardt, JKV (corresponding author), Univ So Calif, Sch Med, Inst Med Genet, 2250 Alcazar St,IGM 240, Los Angeles, CA 90033 USA.	reichard@hsc.usc.edu		Reichardt, Juergen/0000-0001-6458-2773	NCI NIH HHS [CA68581, CA63464, CA54281] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA054281, U01CA063464, R37CA054281, R01CA068581, R01CA063464] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANDRIOLE GL, 1991, ANNU REV MED, V42, P9, DOI 10.1146/annurev.me.42.020191.000301; Ausubel F.M., 1995, CURRENT PROTOCOLS MO; Berthon P, 1998, AM J HUM GENET, V62, P1416, DOI 10.1086/301879; Black RJ, 1997, EUR J CANCER, V33, P1075, DOI 10.1016/S0959-8049(96)00492-3; CARTER BS, 1992, P NATL ACAD SCI USA, V89, P3367, DOI 10.1073/pnas.89.8.3367; DAVIS DL, 1993, HUM MOL GENET, V2, P820, DOI 10.1093/hmg/2.6.820; HENDERSON BE, 1982, CANCER RES, V42, P3232; Huggins C, 1941, CANCER RES, V1, P293; Kantoff PW, 1997, CANCER EPIDEM BIOMAR, V6, P189; KOLONEL LN, IN PRESS AM J EPIDEM; Landis SH, 1998, CA-CANCER J CLIN, V48, P6, DOI 10.3322/canjclin.48.1.6; Makridakis N, 1997, CANCER RES, V57, P1020; McIndoe RA, 1997, AM J HUM GENET, V61, P347, DOI 10.1086/514853; MIETTINE.OS, 1974, AM J EPIDEMIOL, V99, P325, DOI 10.1093/oxfordjournals.aje.a121617; MONTIE JE, 1992, SEMIN UROL, V11, P10; MONTIE JE, 1996, COMPREHENSIVE TXB GE, P712; REICHARDT JKV, 1995, CANCER RES, V55, P3973; ROSS RK, 1992, LANCET, V339, P887, DOI 10.1016/0140-6736(92)90927-U; Ross RK, 1998, CANCER RES, V58, P4497; Smith JR, 1996, SCIENCE, V274, P1371, DOI 10.1126/science.274.5291.1371; Stoner E, 1996, PROSTATE, P82; THIGPEN AE, 1992, J CLIN INVEST, V90, P799, DOI 10.1172/JCI115954; WIGLEY WC, 1994, BIOCHEMISTRY-US, V33, P1265, DOI 10.1021/bi00171a029; Xu JF, 1998, NAT GENET, V20, P175, DOI 10.1038/2477	24	224	235	0	4	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	SEP 18	1999	354	9183					975	978		10.1016/S0140-6736(98)11282-5	http://dx.doi.org/10.1016/S0140-6736(98)11282-5			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	236JG	10501358				2022-12-01	WOS:000082596000009
J	Fu, YX; Galan, JE				Fu, YX; Galan, JE			A Salmonella protein antagonizes Rac-1 and Cdc42 to mediate host-cell recovery after bacterial invasion	NATURE			English	Article							RHO-GTPASES; PSEUDOMONAS-AERUGINOSA; NUCLEAR RESPONSES; EXOENZYME-S; TYPHIMURIUM; IDENTIFICATION; DISRUPTION; YERSINIA; GENE	An essential feature of the bacterial pathogen Salmonella spp. is its ability to enter cells that are normally non-phagocytic, such as those of the intestinal epithelium(1). The bacterium achieves entry by delivering effector proteins into the host-cell cytosol by means of a specialized protein-secretion system (termed type III), which causes reorganization of the cell's actin cytoskeleton and ruffling of its membrane(2-4). One of the bacterial effecters that stimulates these cellular responses is SopE, which acts as a guanyl-nucleotide-exchange factor on Rho GTPase proteins such as Cdc42 and Rac (ref. 5). As the actin-cytoskeleton reorganization induced by Salmonella is reversible and short-lived, infected cells regain their normal architecture after bacterial internalization(6,7). We show here that the S. Typhimurium effector protein SptP, which is delivered to the host-cell cytosol by the type-III secretion system, is directly responsible for the reversal of the actin cytoskeletal changes induced by the bacterium. SptP exerts this function by acting as a GTPase-activating protein (GAP) for Rac-1 and Cdc42.	Yale Univ, Sch Med, Boyer Ctr Mol Med, Sect Microbial Pathogenesis, New Haven, CT 06536 USA	Yale University	Galan, JE (corresponding author), Yale Univ, Sch Med, Boyer Ctr Mol Med, Sect Microbial Pathogenesis, 333 Cedar St, New Haven, CT 06536 USA.	jorge.galan@yale.edu						Chen LM, 1999, J EXP MED, V189, P1479, DOI 10.1084/jem.189.9.1479; Chen LM, 1996, SCIENCE, V274, P2115, DOI 10.1126/science.274.5295.2115; Cornelis GR, 1997, MOL MICROBIOL, V23, P861, DOI 10.1046/j.1365-2958.1997.2731623.x; FORSBERG A, 1990, J BACTERIOL, V172, P1547, DOI 10.1128/jb.172.3.1547-1555.1990; FrithzLindsten E, 1997, MOL MICROBIOL, V25, P1125, DOI 10.1046/j.1365-2958.1997.5411905.x; Fu YX, 1998, MOL MICROBIOL, V27, P359, DOI 10.1046/j.1365-2958.1998.00684.x; Galan JE, 1999, CURR OPIN MICROBIOL, V2, P46, DOI 10.1016/S1369-5274(99)80008-3; GINOCCHIO C, 1992, P NATL ACAD SCI USA, V89, P5976, DOI 10.1073/pnas.89.13.5976; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; Hardt WD, 1998, CELL, V93, P815, DOI 10.1016/S0092-8674(00)81442-7; Hobbie S, 1997, J IMMUNOL, V159, P5550; Kaniga K, 1996, MOL MICROBIOL, V21, P633, DOI 10.1111/j.1365-2958.1996.tb02571.x; KULICH SM, 1994, J BIOL CHEM, V269, P10431; MICHIELS T, 1990, INFECT IMMUN, V58, P2840, DOI 10.1128/IAI.58.9.2840-2849.1990; ROSQVIST R, 1991, INFECT IMMUN, V59, P4562, DOI 10.1128/IAI.59.12.4562-4569.1991; Scheffzek K, 1998, TRENDS BIOCHEM SCI, V23, P257, DOI 10.1016/S0968-0004(98)01224-9; SELF AJ, 1995, METHOD ENZYMOL, V256, P67; TAKEUCHI A, 1967, AM J PATHOL, V50, P109; Vallis AJ, 1999, INFECT IMMUN, V67, P2040; VanAelst L, 1997, GENE DEV, V11, P2295, DOI 10.1101/gad.11.18.2295; Zhou D, 1999, SCIENCE, V283, P2092, DOI 10.1126/science.283.5410.2092	21	430	444	3	18	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	SEP 16	1999	401	6750					293	297		10.1038/45829	http://dx.doi.org/10.1038/45829			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	237VZ	10499590				2022-12-01	WOS:000082678400058
J	Bouillet, P; Metcalf, D; Huang, DCS; Tarlinton, DM; Kay, TWH; Kontgen, F; Adams, JM; Strasser, A				Bouillet, P; Metcalf, D; Huang, DCS; Tarlinton, DM; Kay, TWH; Kontgen, F; Adams, JM; Strasser, A			Proapoptotic Bcl-2 relative bim required for certain apoptotic responses, leukocyte homeostasis, and to preclude autoimmunity	SCIENCE			English	Article							CELL-DEATH; PROTEIN; FAMILY; MICE; ACTIVATION; THYMOCYTES; CASPASE-9; SURVIVAL; PATHWAYS; DELETION	Apoptosis can be triggered by members of the Bcl-2 protein family, such as Bim, that share only the BH3 domain with this family. Gene targeting in mice revealed important physiological lores for sim. Lymphoid and myeloid cells accumulated, T cell development was perturbed, and most older mice accumulated plasma cells and succumbed to autoimmune kidney disease. Lymphocytes were refractory to apoptotic stimuli such as cytokine deprivation, calcium ion flux, and microtubule perturbation but not to others. Thus, Bim is required for hematopoietic homeostasis and as a barrier to autoimmunity. Moreover, particular death stimuli appear to activate apoptosis through distinct BH3-only proteins.	Walter & Eliza Hall Inst Med Res, Melbourne, Vic 3050, Australia	Walter & Eliza Hall Institute	Adams, JM (corresponding author), Walter & Eliza Hall Inst Med Res, Melbourne, Vic 3050, Australia.		Adams, Jerry M/E-1199-2013; Bouillet, Philippe/E-1241-2013; Huang, David C. S./C-7586-2013; Strasser, Andreas/C-7581-2013	Bouillet, Philippe/0000-0002-9012-6058; Huang, David C. S./0000-0002-3101-4873; Strasser, Andreas/0000-0002-5020-4891; Adams, Jerry/0000-0002-4360-8628; Tarlinton, David/0000-0001-9928-686X	NATIONAL CANCER INSTITUTE [R01CA080188, R01CA043540] Funding Source: NIH RePORTER; NCI NIH HHS [CA43540, CA80188] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adams JM, 1998, SCIENCE, V281, P1322, DOI 10.1126/science.281.5381.1322; Conradt B, 1998, CELL, V93, P519, DOI 10.1016/S0092-8674(00)81182-4; Downward J, 1999, NAT CELL BIOL, V1, pE33, DOI 10.1038/10026; Gross A, 1999, GENE DEV, V13, P1899, DOI 10.1101/gad.13.15.1899; GUILLEMOT F, 1994, NATURE, V371, P333, DOI 10.1038/371333a0; Hakem R, 1998, CELL, V94, P339, DOI 10.1016/S0092-8674(00)81477-4; JACKS T, 1994, CURR BIOL, V4, P1, DOI 10.1016/S0960-9822(00)00002-6; Knudson CM, 1997, NAT GENET, V16, P358, DOI 10.1038/ng0897-358; Kuida K, 1998, CELL, V94, P325, DOI 10.1016/S0092-8674(00)81476-2; Kuida K, 1996, NATURE, V384, P368, DOI 10.1038/384368a0; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; Newton K, 1998, EMBO J, V17, P706, DOI 10.1093/emboj/17.3.706; O'Connor L, 1998, EMBO J, V17, P384, DOI 10.1093/emboj/17.2.384; O'Reilly LA, 1998, BIOTECHNIQUES, V25, P824, DOI 10.2144/98255st03; Puthalakath H, 1999, MOL CELL, V3, P287, DOI 10.1016/S1097-2765(00)80456-6; Reed JC, 1997, NATURE, V387, P773, DOI 10.1038/42867; Salvesen GS, 1997, CELL, V91, P443, DOI 10.1016/S0092-8674(00)80430-4; Schwenk F, 1995, NUCLEIC ACIDS RES, V23, P5080, DOI 10.1093/nar/23.24.5080; SENTMAN CL, 1991, CELL, V67, P879, DOI 10.1016/0092-8674(91)90361-2; STRASSER A, 1991, P NATL ACAD SCI USA, V88, P8661, DOI 10.1073/pnas.88.19.8661; STRASSER A, 1991, CELL, V67, P889, DOI 10.1016/0092-8674(91)90362-3; Strasser A, 1995, EMBO J, V14, P6136, DOI 10.1002/j.1460-2075.1995.tb00304.x; STRASSER A, 1997, BIOCHIM BIOPHYS ACTA, V1333, pR151; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; Vaux DL, 1999, CELL, V96, P245, DOI 10.1016/S0092-8674(00)80564-4; Woo M, 1998, GENE DEV, V12, P806, DOI 10.1101/gad.12.6.806; Yin XM, 1999, NATURE, V400, P886, DOI 10.1038/23730; Zha JP, 1996, CELL, V87, P619, DOI 10.1016/S0092-8674(00)81382-3	30	1230	1274	0	87	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 26	1999	286	5445					1735	1738		10.1126/science.286.5445.1735	http://dx.doi.org/10.1126/science.286.5445.1735			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	259UK	10576740				2022-12-01	WOS:000083912200038
J	Zimmermann, S; Moelling, K				Zimmermann, S; Moelling, K			Phosphorylation and regulation of Raf by Akt (protein kinase B)	SCIENCE			English	Article							TRANSLOCATION; ACTIVATION; C-RAF-1	Activation of the protein kinase Raf can lead to opposing cellular responses such as proliferation, growth arrest, apoptosis, br differentiation. Akt (protein kinase B), a member of a different signaling pathway that also regulates these responses, interacted with Raf and phosphorylated this protein at a highly conserved serine residue in its regulatory domain in vivo. This phosphorylation of Raf by Akt inhibited activation of the Raf-MEK-ERK signaling pathway and shifted the cellular response in a human breast cancer cell line from cell cycle arrest to proliferation. These observations provide a molecular basis for cross talk between two signaling pathways at the level of Raf and Akt.	Univ Zurich, Inst Med Virol, CH-8028 Zurich, Switzerland	University of Zurich	Moelling, K (corresponding author), Univ Zurich, Inst Med Virol, Gloriastr 30-32, CH-8028 Zurich, Switzerland.							ALBAS J, 1998, ONCOGENE, V16, P131; Alessi DR, 1996, FEBS LETT, V399, P333, DOI 10.1016/S0014-5793(96)01370-1; Andjelkovic M, 1997, J BIOL CHEM, V272, P31515, DOI 10.1074/jbc.272.50.31515; BEIMLING P, 1994, BIOCHEM BIOPH RES CO, V204, P841, DOI 10.1006/bbrc.1994.2536; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; Dufourny B, 1997, J BIOL CHEM, V272, P31163, DOI 10.1074/jbc.272.49.31163; GOSH S, 1996, J BIOL CHEM, V271, P8472; Hu E., 1996, SCIENCE, V274, P100; Jiang BH, 1999, P NATL ACAD SCI USA, V96, P2077, DOI 10.1073/pnas.96.5.2077; Khwaja A, 1999, NATURE, V401, P33, DOI 10.1038/43354; Kohn AD, 1996, J BIOL CHEM, V271, P31372, DOI 10.1074/jbc.271.49.31372; KOLCH W, 1993, NATURE, V364, P249, DOI 10.1038/364249a0; Kops GJPL, 1999, NATURE, V398, P630, DOI 10.1038/19328; MARAIS R, 1995, EMBO J, V14, P3136, DOI 10.1002/j.1460-2075.1995.tb07316.x; Meier R, 1999, J RECEPT SIGNAL TR R, V19, P121, DOI 10.3109/10799899909036639; MICHAUD NR, 1995, MOL CELL BIOL, V15, P3390; MOELLING K, 1984, NATURE, V312, P558, DOI 10.1038/312558a0; Morrison DK, 1997, CURR OPIN CELL BIOL, V9, P174, DOI 10.1016/S0955-0674(97)80060-9; RodriguezViciana P, 1997, CELL, V89, P457, DOI 10.1016/S0092-8674(00)80226-3; Rommel C, 1996, ONCOGENE, V12, P609; Rommel C, 1999, SCIENCE, V286, P1738, DOI 10.1126/science.286.5445.1738; Zimmermann S, 1997, ONCOGENE, V15, P1503, DOI 10.1038/sj.onc.1201322; ZIMMERMANN S, UNPUB	24	883	914	0	31	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 26	1999	286	5445					1741	1744		10.1126/science.286.5445.1741	http://dx.doi.org/10.1126/science.286.5445.1741			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	259UK	10576742				2022-12-01	WOS:000083912200040
J	Bewley, MC; Springer, K; Zhang, YB; Freimuth, P; Flanagan, JM				Bewley, MC; Springer, K; Zhang, YB; Freimuth, P; Flanagan, JM			Structural analysis of the mechanism of adenovirus binding to its human cellular receptor, CAR	SCIENCE			English	Article							GP120 ENVELOPE GLYCOPROTEIN; TYPE-5 FIBER PROTEIN; CRYSTAL-STRUCTURE; DOMAIN; HIV; RESOLUTION; CD4	Binding of virus particles to specific host cell surface receptors is known to be an obligatory step in infection even though the molecular basis for these interactions is not well characterized. The crystal structure of the adenovirus fiber knob domain in complex with domain I of its human cellular receptor, coxsackie and adenovirus receptor (CAR), is presented here. Surface-exposed Loops on knob contact one face of CAR, forming a high-affinity complex. Topology mismatches between interacting surfaces create interfacial solvent-filled cavities and channels that may be targets for antiviral drug therapy. The structure identifies key determinants of binding specificity, which may suggest ways to modify the tropism of adenovirus-based gene therapy vectors.	Brookhaven Natl Lab, Dept Biol, Upton, NY 11973 USA	United States Department of Energy (DOE); Brookhaven National Laboratory	Flanagan, JM (corresponding author), Brookhaven Natl Lab, Dept Biol, Upton, NY 11973 USA.			bewley, maria/0000-0001-7097-0123	NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR012408] Funding Source: NIH RePORTER; NCRR NIH HHS [1P41 RR12408-01A1] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		Bella J, 1998, P NATL ACAD SCI USA, V95, P4140, DOI 10.1073/pnas.95.8.4140; Bergelson JM, 1997, SCIENCE, V275, P1320, DOI 10.1126/science.275.5304.1320; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; *CCP4, 1991, 4 DARS LAB SRC UK CO; FENDER P, 1995, VIROLOGY, V214, P110, DOI 10.1006/viro.1995.9949; Freimuth P, 1999, J VIROL, V73, P1392, DOI 10.1128/JVI.73.2.1392-1398.1999; HENRY LJ, 1994, J VIROL, V68, P5239, DOI 10.1128/JVI.68.8.5239-5246.1994; Holm L, 1996, SCIENCE, V273, P595, DOI 10.1126/science.273.5275.595; Ikemizu S, 1999, P NATL ACAD SCI USA, V96, P4289, DOI 10.1073/pnas.96.8.4289; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Kwong PD, 1998, NATURE, V393, P648, DOI 10.1038/31405; LEE B, 1971, J MOL BIOL, V55, P379, DOI 10.1016/0022-2836(71)90324-X; MUCKELBAUER JK, 1995, STRUCTURE, V3, P653, DOI 10.1016/S0969-2126(01)00201-5; Nabel GJ, 1999, P NATL ACAD SCI USA, V96, P324, DOI 10.1073/pnas.96.2.324; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Roelvink PW, 1998, J VIROL, V72, P7909, DOI 10.1128/JVI.72.10.7909-7915.1998; ROSSMANN MG, 1989, J BIOL CHEM, V264, P14587; RYU SE, 1994, STRUCTURE, V2, P59, DOI 10.1016/S0969-2126(00)00008-3; Shapiro L, 1996, NEURON, V17, P435, DOI 10.1016/S0896-6273(00)80176-2; Wyatt R, 1998, NATURE, V393, P705, DOI 10.1038/31514; XIA D, 1994, STRUCTURE, V2, P1259, DOI 10.1016/S0969-2126(94)00126-X; YEH HY, 1994, VIRUS RES, V33, P179	23	349	360	2	21	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 19	1999	286	5444					1579	1583		10.1126/science.286.5444.1579	http://dx.doi.org/10.1126/science.286.5444.1579			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	257DZ	10567268	Green Submitted			2022-12-01	WOS:000083768300064
J	Bhatt, RR; Ferrell, JE				Bhatt, RR; Ferrell, JE			The protein kinase p90 Rsk as an essential mediator of cytostatic factor activity	SCIENCE			English	Article							XENOPUS EGG EXTRACTS; SPINDLE ASSEMBLY CHECKPOINT; MAP KINASE; CELL-CYCLE; MOS; TRANSITION; MATURATION; METAPHASE; PREVENTS; OOCYTES	Persistent activation of p42 mitogen-activated protein kinase (p42 MAPK) during mitosis induces a "cytostatic factor" arrest, the arrest responsible for preventing the parthenogenetic activation of unfertilized eggs. The protein kinase p90 Rsk is a substrate of p42 MAPK; thus, the role of p90 Rsk in p42 MAPK-induced mitotic arrest was examined. Xenopus laevis egg extracts immunodepleted of Rsk lost their capacity to undergo mitotic arrest in response to activation of the Mos-MEK-1-p42 MAPK cascade of protein kinases. Replenishing Rsk-depleted extracts with catalytically competent Rsk protein restored the ability of the extracts to undergo mitotic arrest. Rsk appears to be essential for cytostatic factor arrest.	Stanford Univ, Sch Med, Dept Mol Pharmacol, Stanford, CA 94305 USA	Stanford University	Ferrell, JE (corresponding author), Stanford Univ, Sch Med, Dept Mol Pharmacol, Stanford, CA 94305 USA.				NIGMS NIH HHS [GM46383, GM16415] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [F31GM016415] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abrieu A, 1997, EMBO J, V16, P6407, DOI 10.1093/emboj/16.21.6407; Abrieu A, 1996, J CELL SCI, V109, P239; Bhatt R., UNPUB; BLENIS J, 1993, P NATL ACAD SCI USA, V90, P5889, DOI 10.1073/pnas.90.13.5889; Chau ASS, 1998, BIOL CELL, V90, P565, DOI 10.1016/S0248-4900(99)80014-8; COLLEDGE WH, 1994, NATURE, V370, P65, DOI 10.1038/370065a0; Cross DAE, 1998, EXP CELL RES, V241, P12, DOI 10.1006/excr.1998.4023; ERIKSON E, 1985, P NATL ACAD SCI USA, V82, P742, DOI 10.1073/pnas.82.3.742; Gross SD, 1999, SCIENCE, V286, P1365, DOI 10.1126/science.286.5443.1365; Guadagno TM, 1998, SCIENCE, V282, P1312, DOI 10.1126/science.282.5392.1312; HACCARD O, 1993, SCIENCE, V262, P1262, DOI 10.1126/science.8235656; KOSAKO H, 1994, J BIOL CHEM, V269, P28354; MALLER JL, 1995, TRENDS BIOCHEM SCI, V20, P524, DOI 10.1016/S0968-0004(00)89122-7; MASUI Y, 1971, J EXP ZOOL, V177, P129, DOI 10.1002/jez.1401770202; MINSHULL J, 1994, CELL, V79, P475, DOI 10.1016/0092-8674(94)90256-9; MURRAY AW, 1991, METHOD CELL BIOL, V36, P581; RIVERA VM, 1993, MOL CELL BIOL, V13, P6260, DOI 10.1128/MCB.13.10.6260; SAGATA N, 1989, NATURE, V342, P512, DOI 10.1038/342512a0; Sagata N, 1997, BIOESSAYS, V19, P13, DOI 10.1002/bies.950190105; Trivier E, 1996, NATURE, V384, P567, DOI 10.1038/384567a0; YEW N, 1992, NATURE, V355, P649, DOI 10.1038/355649a0; Zecevic M, 1998, J CELL BIOL, V142, P1547, DOI 10.1083/jcb.142.6.1547	22	143	151	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 12	1999	286	5443					1362	1365		10.1126/science.286.5443.1362	http://dx.doi.org/10.1126/science.286.5443.1362			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	255NF	10558991				2022-12-01	WOS:000083675500043
J	Venn, A; Watson, L; Bruinsma, F; Giles, G; Healy, D				Venn, A; Watson, L; Bruinsma, F; Giles, G; Healy, D			Risk of cancer after use of fertility drugs with in-vitro fertilisation	LANCET			English	Article							EPITHELIAL OVARIAN-CANCER; INFERTILE WOMEN; BREAST-CANCER; COHORT; FERTILIZATION	Background We investigated the incidence of invasive cancer of the breast, ovary, and uterus in a cohort of patients who had undergone in-vitro-fertilisation (IVF) treatment and examined whether cause of infertility or exposure to fertility drugs to induce superovulation was associated with an increased cancer risk. Method Ten Australian IVF clinics provided data for women who had been referred far IVF before Jan 1, 1994. The frequencies of invasive breast, ovarian, and uterine cancer were assessed by record linkage to population-based cancer registries and the national death index. The observed number of cancers was compared with the expected number calculated by application of age-standardised general-population cancer rates to the cohort. Standardised incidence ratios (SIRs) were derived from the ratio of observed to expected cases. Findings The cohort consisted of 29 700 women: 20 656 were exposed to fertility drugs and 9044 were not, 143 breast cancers, 13 ovarian cancers, and 12 cancers of the uterus occurred among these women. For breast and ovarian cancer the incidence was no greater than expected (SIR 0.91 [95% CI 0.74-1.13] for breast cancer and 0.88 [0.42-1.84] for ovarian cancer in the exposed group and 0.95 [0.73-1.23] for breast cancer and 1.16 [0.52-2.59] for ovarian cancer in the unexposed group). The incidence of uterine cancer was no higher than expected in the exposed group (1.09 [0.45-2.61]) but was significantly higher in the unexposed group (2.47 [1.18-5.18]). Women with unexplained infertility had significantly more cancers of the ovary and uterus than expected (2.64 [1.10-6.35] and 4.59 [1.91-11.0], whole cohort). Analysis of cancer incidence within 12 months of exposure to fertility drugs with IVF showed that incidence was significantly higher than expected for breast and uterine cancer (1.96 [1.22-3.15] and 4.96 [1.24-19.8]). Interpretation Women who have been exposed to fertility drugs with IVF seem to have a transient increase in the risk of having breast or uterine cancer diagnosed in the first year after treatment, though the incidence overall is no greater than expected. Unexplained infertility was associated with an increased risk of a diagnosis of ovarian or uterine cancer.	La Trobe Univ, Ctr Study Mothers & Childrens Hlth, Carlton, Vic 3053, Australia; Anticanc Council Victoria, Canc Epidemiol Ctr, Carlton, Vic, Australia; Monash Univ, Monash Med Ctr, Dept Obstet & Gynaecol, Clayton, Vic 3168, Australia; Monash IVF, Richmond, Vic, Australia	La Trobe University; Monash University	Venn, A (corresponding author), La Trobe Univ, Ctr Study Mothers & Childrens Hlth, 251 Faraday St, Carlton, Vic 3053, Australia.		Venn, Alison J/J-2803-2013	Giles, Graham/0000-0003-4946-9099				Calle EE, 1996, LANCET, V347, P1713, DOI 10.1016/S0140-6736(96)90806-5; DEMOUZON J, 1997, J ASSIST REPROD GEN, V14, pS251; FRANCESCHI S, 1994, HUM REPROD, V9, P1673, DOI 10.1093/oxfordjournals.humrep.a138771; HARLOW BL, 1986, J NATL CANCER I, V76, P399; Kroman N, 1997, BRIT MED J, V315, P851, DOI 10.1136/bmj.315.7112.851; KVALE G, 1988, CANCER RES, V48, P6217; LAMBE M, 1994, NEW ENGL J MED, V331, P5, DOI 10.1056/NEJM199407073310102; LAVECCHIA C, 1995, LANCET, V346, P1628; MACLACHLAN V, 1989, NEW ENGL J MED, V320, P1233, DOI 10.1056/NEJM198905113201902; Modan B, 1998, AM J EPIDEMIOL, V147, P1038; Mosgaard BJ, 1997, FERTIL STERIL, V67, P1005, DOI 10.1016/S0015-0282(97)81431-8; Potashnik G, 1999, FERTIL STERIL, V71, P853, DOI 10.1016/S0015-0282(99)00085-0; Ricci E, 1999, HUM REPROD, V14, P1653, DOI 10.1093/humrep/14.6.1653; ROSSING MA, 1995, LANCET, V346, P1627; Rossing MA, 1996, GYNECOL ONCOL, V60, P3, DOI 10.1006/gyno.1996.0002; ROSSING MA, 1994, NEW ENGL J MED, V331, P771, DOI 10.1056/NEJM199409223311204; Shushan A, 1996, FERTIL STERIL, V65, P13, DOI 10.1016/S0015-0282(16)58020-0; Sundstrom I, 1997, ACTA OBSTET GYN SCAN, V76, P238, DOI 10.1111/j.1600-0412.1997.tb07852.x; VENN A, 1995, LANCET, V346, P995, DOI 10.1016/S0140-6736(95)91687-3; VENN R, 1995, LANCET, V346, P1627; WHITTEMORE AS, 1992, AM J EPIDEMIOL, V136, P1184, DOI 10.1093/oxfordjournals.aje.a116427	21	268	282	0	18	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	NOV 6	1999	354	9190					1586	1590		10.1016/S0140-6736(99)05203-4	http://dx.doi.org/10.1016/S0140-6736(99)05203-4			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	253HM	10560672				2022-12-01	WOS:000083551000009
J	Marshall, J; Oberwinkler, J				Marshall, J; Oberwinkler, J			The colourful world of the mantis shrimp	NATURE			English	Article							STOMATOPOD CRUSTACEANS; COMPOUND EYES; OIL DROPLETS; PHOTORECEPTORS; COLOR; RETINA; VISION		Univ Queensland, VTHRC, Brisbane, Qld 4071, Australia; Univ Groningen, Dept Neurobiophys, NL-9747 AG Groningen, Netherlands	University of Queensland; University of Groningen	Marshall, J (corresponding author), Univ Queensland, VTHRC, Brisbane, Qld 4071, Australia.			Oberwinkler, Johannes/0000-0002-8541-3626; Marshall, Justin/0000-0001-9006-6713				Arikawa K, 1999, VISION RES, V39, P1, DOI 10.1016/S0042-6989(98)00070-4; CALDWELL RL, 1976, SCI AM, V234, P80, DOI 10.1038/scientificamerican0176-80; CRONIN TW, 1989, J COMP PHYSIOL A, V166, P261; CRONIN TW, 1994, VISION RES, V34, P2639, DOI 10.1016/0042-6989(94)90221-6; CRONIN TW, 1989, NATURE, V339, P137, DOI 10.1038/339137a0; HARDIE RC, 1986, TRENDS NEUROSCI, V9, P419, DOI 10.1016/0166-2236(86)90136-0; Hart NS, 1998, J EXP BIOL, V201, P1433; Marshall NJ, 1996, J COMP PHYSIOL A, V179, P473; MARSHALL NJ, 1991, PHILOS T ROY SOC B, V334, P33, DOI 10.1098/rstb.1991.0096; MARSHALL NJ, 1988, NATURE, V333, P557, DOI 10.1038/333557a0; NEUMEYER C, 1991, EVOLUTION EYE VISUAL, V2, P284; Osorio D, 1997, VISION RES, V37, P3299, DOI 10.1016/S0042-6989(97)00136-3; SELIGER HH, 1994, J COMP PHYSIOL A, V175, P475; SMITH RC, 1981, APPL OPTICS, V20, P177, DOI 10.1364/AO.20.000177; TOVEE MJ, 1995, TRENDS ECOL EVOL, V10, P455, DOI 10.1016/S0169-5347(00)89179-X; Vorobyev M, 1998, J COMP PHYSIOL A, V183, P621, DOI 10.1007/s003590050286	16	87	90	9	104	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	OCT 28	1999	401	6756					873	874		10.1038/44751	http://dx.doi.org/10.1038/44751			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	251UL	10553902				2022-12-01	WOS:000083464700043
J	Jarecki, J; Johnson, E; Krasnow, MA				Jarecki, J; Johnson, E; Krasnow, MA			Oxygen regulation of airway branching in Drosophila is mediated by branchless FGF	CELL			English	Article							TRACHEAL CELL-MIGRATION; RECEPTOR HOMOLOG; BETA-GALACTOSIDASE; FUSION PROTEIN; EXPRESSION; BREATHLESS; GROWTH; SYSTEM; MORPHOGENESIS; ANGIOGENESIS	The Drosophila tracheal (respiratory) system is a tubular epithelial network that delivers oxygen to internal tissues. Sprouting of the major tracheal branches is stereotyped and controlled by hard-wired developmental cues. Here we show that ramification of the fine terminal branches is variable and regulated by oxygen, and that this process is controlled by a local signal or signals produced by oxygen-starved cells. We provide evidence that the critical signal is Branchless (Bnl) FGF, the same growth factor that patterns the major branches during embryogenesis. During larval life, oxygen deprivation stimulates expression of Bnl, and the secreted growth factor functions as a chemoattractant that guides new terminal branches to the expressing cells. Thus, a single growth factor is reiteratively used to pattern each level of airway branching, and the change in branch patterning results from a switch from developmental to physiological control of its expression.	Stanford Univ, Sch Med, Dept Biochem, Howard Hughes Med Inst, Stanford, CA 94305 USA	Howard Hughes Medical Institute; Stanford University	Krasnow, MA (corresponding author), Stanford Univ, Sch Med, Dept Biochem, Howard Hughes Med Inst, Stanford, CA 94305 USA.	krasnow@cmgm.stanford.edu						AFFOLTER M, 1994, DEVELOPMENT, V120, P743; BRAND AH, 1994, METHOD CELL BIOL, V44, P635, DOI 10.1016/S0091-679X(08)60936-X; BRAND AH, 1993, DEVELOPMENT, V118, P401; CALLAHAN CA, 1994, P NATL ACAD SCI USA, V91, P5972, DOI 10.1073/pnas.91.13.5972; Cormack BP, 1996, GENE, V173, P33, DOI 10.1016/0378-1119(95)00685-0; CUNNINGHAM EL, 1974, J APPL PHYSIOL, V37, P362, DOI 10.1152/jappl.1974.37.3.362; Gale NW, 1999, GENE DEV, V13, P1055, DOI 10.1101/gad.13.9.1055; GOODMAN CS, 1993, CELL, V72, P77, DOI 10.1016/S0092-8674(05)80030-3; Guillemin K, 1996, DEVELOPMENT, V122, P1353; KLAMBT C, 1992, GENE DEV, V6, P1668, DOI 10.1101/gad.6.9.1668; Kopczynski CC, 1996, SCIENCE, V271, P1867, DOI 10.1126/science.271.5257.1867; Lee T, 1996, GENE DEV, V10, P2912, DOI 10.1101/gad.10.22.2912; LIN DM, 1994, NEURON, V13, P507, DOI 10.1016/0896-6273(94)90022-1; Lindsley D.L., 1992, GENOME DROSOPHILA ME; LOCKE M, 1958, Q J MICROSC SCI, V99, P373; Manning G., 1993, DEV DROSOPHILA MELAN, V1, P609; MEINHARDT H, 1976, DIFFERENTIATION, V6, P117, DOI 10.1111/j.1432-0436.1976.tb01478.x; Metzger RJ, 1999, SCIENCE, V284, P1635, DOI 10.1126/science.284.5420.1635; Nagao M, 1996, FEBS LETT, V387, P161, DOI 10.1016/0014-5793(96)00484-X; ONEILL JW, 1994, BIOTECHNIQUES, V17, P870; PATEL NH, 1994, METHOD CELL BIOL, V44, P445, DOI 10.1016/S0091-679X(08)60927-9; PERRIMON N, 1991, DEV GENET, V12, P238, DOI 10.1002/dvg.1020120309; Pignoni F, 1997, DEVELOPMENT, V124, P271; Pihan J.C., 1972, Bulletin de la Societe Zoologique de France, V97, P351; PIHAN JC, 1971, J EMBRYOL EXP MORPH, V26, P497; REICHMANFRIED M, 1995, MECH DEVELOP, V52, P265, DOI 10.1016/0925-4773(95)00407-R; REICHMANFRIED M, 1994, GENE DEV, V8, P428, DOI 10.1101/gad.8.4.428; Risau W, 1997, NATURE, V386, P671, DOI 10.1038/386671a0; Ruhle H, 1932, Z WISS ZOOL ABT A, V141, P159; Samakovlis C, 1996, DEVELOPMENT, V122, P1395; Semenza GL, 1998, CURR OPIN GENET DEV, V8, P588, DOI 10.1016/S0959-437X(98)80016-6; Shiga Y, 1996, DEV GROWTH DIFFER, V38, P99; Shilo BZ, 1997, COLD SPRING HARB SYM, V62, P241; SHWEIKI D, 1992, NATURE, V359, P843, DOI 10.1038/359843a0; SMITH DE, 1987, J CELL BIOL, V105, P771, DOI 10.1083/jcb.105.2.771; Smith EL, 1996, BONE, V18, pS45, DOI 10.1016/8756-3282(95)00379-7; Sutherland D, 1996, CELL, V87, P1091, DOI 10.1016/S0092-8674(00)81803-6; Vincent S, 1997, DEVELOPMENT, V124, P2741; WALGENBACH KJ, 1995, NAT MED, V1, P453, DOI 10.1038/nm0595-453; WIGGLESWORTH VB, 1954, Q J MICROSC SCI, V95, P115; XU T, 1993, DEVELOPMENT, V117, P1223; [No title captured]	42	189	190	0	7	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	OCT 15	1999	99	2					211	220		10.1016/S0092-8674(00)81652-9	http://dx.doi.org/10.1016/S0092-8674(00)81652-9			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	246JB	10535739	Bronze			2022-12-01	WOS:000083159700011
J	Aritomi, M; Kunishima, N; Okamoto, T; Kuroki, R; Ota, Y; Morikawa, K				Aritomi, M; Kunishima, N; Okamoto, T; Kuroki, R; Ota, Y; Morikawa, K			Atomic structure of the GCSF-receptor complex showing a new cytokine-receptor recognition scheme	NATURE			English	Article							COLONY-STIMULATING FACTOR; EXTRACELLULAR DOMAIN; CRYSTAL-STRUCTURE; GROWTH-HORMONE; LIGAND-BINDING; GRANULOCYTE; CSF; IDENTIFICATION; DIMERIZATION; REGION	Granulocyte colony-stimulating factor (GCSF) is the principal growth factor regulating the maturation, proliferation and differentiation of the precursor cells of neutrophilic granulocytes' and is used to treat neutropenia(2), GCSF is a member of the long-chain subtype of the class 1 cytokine superfamily, which includes growth hormone, erythropoietin, interleukin 6 and oncostatin M (ref. 3), Here we have determined the crystal structure of GCSF complexed to the BN-BC domains, the principal ligand-binding region of the GCSF receptor (GCSFR). The two receptor domains form a complex in a 2:2 ratio with the ligand, with a noncrystallographic pseudo-twofold axis through primarily the interdomain region and secondarily the BC domain. This structural view of a gp130-type receptor-ligand complex presents a new molecular basis for cytokine-receptor recognition.	Kirin Brewery Co Ltd, Cent Labs Key Technol, Kanazawa Ku, Yokohama, Kanagawa 2360004, Japan; Biomol Engn Res Inst, Suita, Osaka 5650874, Japan	Kirin Brewery Company Limited	Morikawa, K (corresponding author), Biomol Engn Res Inst, 6-2-3 Furuedai, Suita, Osaka 5650874, Japan.	morikawa@beri.co.jp	Kunishima, Naoki/N-7464-2015	Kunishima, Naoki/0000-0001-9826-9902; Aritomi, Masaharu/0000-0003-3002-8779				BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BRADEN BC, 1995, FASEB J, V9, P9, DOI 10.1096/fasebj.9.1.7821765; Bravo J, 1998, EMBO J, V17, P1665, DOI 10.1093/emboj/17.6.1665; Brunger A. T., 1992, XPLOR VERSION 3 1 SY; CLACKSON T, 1995, SCIENCE, V267, P383, DOI 10.1126/science.7529940; Covell DG, 1997, J MOL BIOL, V269, P281, DOI 10.1006/jmbi.1997.1028; DEVOS AM, 1992, SCIENCE, V255, P306, DOI 10.1126/science.1549776; FUKUNAGA R, 1991, EMBO J, V10, P2855, DOI 10.1002/j.1460-2075.1991.tb07835.x; Hage T, 1999, CELL, V97, P271, DOI 10.1016/S0092-8674(00)80736-9; HENDSCH ZS, 1994, PROTEIN SCI, V3, P211; HILL CP, 1993, P NATL ACAD SCI USA, V90, P5167, DOI 10.1073/pnas.90.11.5167; Hiraoka O, 1995, BIOSCI BIOTECH BIOCH, V59, P2351, DOI 10.1271/bbb.59.2351; HIRAOKA O, 1994, FEBS LETT, V356, P255, DOI 10.1016/0014-5793(94)01278-4; HIRAOKA O, 1995, J BIOL CHEM, V270, P25928, DOI 10.1074/jbc.270.43.25928; Horan T, 1996, BIOCHEMISTRY-US, V35, P4886, DOI 10.1021/bi9525841; Horan TP, 1998, PROTEIN EXPRES PURIF, V14, P45, DOI 10.1006/prep.1998.0942; KUGA T, 1994, Patent No. 8317; Layton JE, 1997, J BIOL CHEM, V272, P29735, DOI 10.1074/jbc.272.47.29735; Livnah O, 1998, NAT STRUCT BIOL, V5, P993, DOI 10.1038/2965; Livnah O, 1999, SCIENCE, V283, P987, DOI 10.1126/science.283.5404.987; METCALF D, 1989, NATURE, V339, P27, DOI 10.1038/339027a0; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; ReidhaarOlson JF, 1996, BIOCHEMISTRY-US, V35, P9034, DOI 10.1021/bi952705x; Remy I, 1999, SCIENCE, V283, P990, DOI 10.1126/science.283.5404.990; Syed RS, 1998, NATURE, V395, P511, DOI 10.1038/26773; Wells JA, 1996, ANNU REV BIOCHEM, V65, P609, DOI 10.1146/annurev.bi.65.070196.003141; Wells JA, 1996, P NATL ACAD SCI USA, V93, P1, DOI 10.1073/pnas.93.1.1; Welte K, 1996, BLOOD, V88, P1907, DOI 10.1182/blood.V88.6.1907.bloodjournal8861907; Yamasaki K, 1997, NAT STRUCT BIOL, V4, P498, DOI 10.1038/nsb0697-498; Yamasaki M, 1998, BIOSCI BIOTECH BIOCH, V62, P1528, DOI 10.1271/bbb.62.1528	30	118	130	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	OCT 14	1999	401	6754					713	718		10.1038/44394	http://dx.doi.org/10.1038/44394			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	247EJ	10537111				2022-12-01	WOS:000083207400060
J	Chan, TA; Hermeking, H; Lengauer, C; Kinzler, KW; Vogelstein, B				Chan, TA; Hermeking, H; Lengauer, C; Kinzler, KW; Vogelstein, B			14-3-3 sigma is required to prevent mitotic catastrophe after DNA damage	NATURE			English	Article							NUCLEAR EXPORT; G(2) CHECKPOINT; CYCLIN B1; ARREST; P21; LOCALIZATION; KINASE; PHASE; CELLS; CRM1	14-3-3 sigma is a member of a family of proteins that regulate cellular activity by binding and sequestering phosphorylated proteins. It has been suggested that 14-3-3 sigma promotes pre-mitotic cell-cycle arrest following DNA damage, and that its expression can be controlled by the p53 tumour suppressor gene(1). Here we describe an improved approach to the generation of human somatic-cell knockouts, which we have used to generate human colorectal cancer cells in which both 14-3-3 sigma alleles are inactivated. After DNA damage, these cells initially arrested in the G2 phase of the cell cycle, but, unlike Cells containing 14-3-3 sigma, the 14-3-3 sigma(-/-) cells were unable to maintain cell-cycle arrest. The 14-3-3 sigma(-/-) cells died ('mitotic catastrophe') as they entered mitosis. This process was associated with a failure of the 14-3-3 sigma-deficient cells to sequester the proteins (cyclin B1 and cdc2) that initiate mitosis and prevent them from entering the nucleus. These results may indicate a mechanism for maintaining the G2 checkpoint and preventing mitotic death.	Johns Hopkins Univ, Sch Med, Johns Hopkins Oncol Ctr, Program Human Genet, Baltimore, MD 21231 USA; Johns Hopkins Univ, Sch Med, Howard Hughes Med Inst, Baltimore, MD 21231 USA	Johns Hopkins University; Johns Hopkins Medicine; Howard Hughes Medical Institute; Johns Hopkins University	Vogelstein, B (corresponding author), Johns Hopkins Univ, Sch Med, Johns Hopkins Oncol Ctr, Program Human Genet, 424 N Bond St, Baltimore, MD 21231 USA.		Chan, Timothy A/ABD-5850-2021					Bunz F, 1998, SCIENCE, V282, P1497, DOI 10.1126/science.282.5393.1497; Busler DE, 1996, BIOTECHNIQUES, V21, P1002; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Fornerod M, 1997, CELL, V90, P1051, DOI 10.1016/S0092-8674(00)80371-2; Fukuda M, 1997, NATURE, V390, P308, DOI 10.1038/36894; Gardner R, 1999, EMBO J, V18, P3173, DOI 10.1093/emboj/18.11.3173; Hagting A, 1998, EMBO J, V17, P4127, DOI 10.1093/emboj/17.14.4127; HEALD R, 1993, CELL, V74, P463, DOI 10.1016/0092-8674(93)80048-J; Hermeking H, 1997, MOL CELL, V1, P3, DOI 10.1016/S1097-2765(00)80002-7; Honda R, 1997, BIOCHEM BIOPH RES CO, V230, P262, DOI 10.1006/bbrc.1996.5933; Jin P, 1998, J CELL BIOL, V141, P875, DOI 10.1083/jcb.141.4.875; Lopez-Girona A, 1999, NATURE, V397, P172, DOI 10.1038/16488; NURSE P, 1990, NATURE, V344, P503, DOI 10.1038/344503a0; Nurse P, 1997, CELL, V91, P865, DOI 10.1016/S0092-8674(00)80476-6; Peng CY, 1997, SCIENCE, V277, P1501, DOI 10.1126/science.277.5331.1501; Pines J, 1999, NATURE, V397, P104, DOI 10.1038/16344; REYNISDOTTIR I, 1995, GENE DEV, V9, P1831, DOI 10.1101/gad.9.15.1831; Toyoshima F, 1998, EMBO J, V17, P2728, DOI 10.1093/emboj/17.10.2728; WALDMAN T, 1995, CANCER RES, V55, P5187; Waldman T, 1996, NATURE, V381, P713, DOI 10.1038/381713a0	20	781	814	1	33	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	OCT 7	1999	401	6753					616	620		10.1038/44188	http://dx.doi.org/10.1038/44188			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	244MG	10524633				2022-12-01	WOS:000083054900058
J	Cortes, D; Visfeldt, J; Moller, H; Thorup, J				Cortes, D; Visfeldt, J; Moller, H; Thorup, J			Testicular neoplasia in cryptorchid boys at primary surgery: case series	BRITISH MEDICAL JOURNAL			English	Article							TESTIS; CANCER; COHORT; RISK		Rigshosp, Dept Paediat Surg, DK-2100 Copenhagen O, Denmark; Rigshosp, Dept Pathol, DK-2100 Copenhagen, Denmark; Danish Natl Res Fdn, Ctr Res Hlth & Social Stat, DK-2100 Copenhagen O, Denmark	Rigshospitalet; Rigshospitalet; University of Copenhagen; Danmarks Grundforskningsfond	Thorup, J (corresponding author), Rigshosp, Dept Paediat Surg, 4072, DK-2100 Copenhagen O, Denmark.			Cortes, Dina/0000-0002-6852-6530; Thorup, Jorgen/0000-0003-3550-1107; Moller, Henrik/0000-0001-8200-5929				CORTES D, 1994, J UROLOGY, V151, P722, DOI 10.1016/S0022-5347(17)35071-1; CORTES D, 1998, SCAND J UROL NE S196, V32, P54; Moller H, 1998, BMJ-BRIT MED J, V317, P729, DOI 10.1136/bmj.317.7160.729; MULLER J, 1985, J PEDIATR-US, V106, P431, DOI 10.1016/S0022-3476(85)80670-3; Swerdlow AJ, 1997, BRIT MED J, V314, P1507, DOI 10.1136/bmj.314.7093.1507	5	15	16	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	OCT 2	1999	319	7214					888	889		10.1136/bmj.319.7214.888	http://dx.doi.org/10.1136/bmj.319.7214.888			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	243AU	10506044	Green Published, Bronze			2022-12-01	WOS:000082975600024
J	Brewer, LR; Corzett, M; Balhorn, R				Brewer, LR; Corzett, M; Balhorn, R			Protamine-induced condensation and decondensation of the same DNA molecule	SCIENCE			English	Article							BACTERIOPHAGE HEADS; BINDING; MICROSCOPY; COMPLEXES; COLLAPSE; PACKING; PROTEIN; POLYMER; SPERM	The DNA sperm and certain viruses is condensed by arginine-rich proteins into toroidal subunits, a form of packaging that inactivates their entire genome. Individual DNA molecules were manipulated with an optical trap to examine the kinetics of torus formation induced by the binding of protamine and a subset of its DNA binding domain, Arg(6). Condensation and decondensation experiments with lambda-phage DNA show that toroid formation and stability are influenced by the number of arginine-rich anchoring domains in protamine. The results explain why protamines contain so much arginine and suggest that these proteins must be actively removed from sperm chromatin after fertilization.	Univ Calif Lawrence Livermore Natl Lab, Elect Engn Technol Div, Livermore, CA 94550 USA; Univ Calif Lawrence Livermore Natl Lab, Biol & Biotechnol Res Program, Livermore, CA 94550 USA	United States Department of Energy (DOE); Lawrence Livermore National Laboratory; University of California System; United States Department of Energy (DOE); Lawrence Livermore National Laboratory; University of California System	Brewer, LR (corresponding author), Univ Calif Lawrence Livermore Natl Lab, Elect Engn Technol Div, Livermore, CA 94550 USA.		Brewer, Laurence/G-4056-2012					ARSCOTT PG, 1990, BIOPOLYMERS, V30, P619, DOI 10.1002/bip.360300514; Balhorn R., 1989, P366; Balhorn R, 1999, MALE GAMETE: FROM BASIC SCIENCE TO CLINICAL APPLICATIONS, P55; Baumann CG, 1997, P NATL ACAD SCI USA, V94, P6185, DOI 10.1073/pnas.94.12.6185; Bench GS, 1996, CYTOMETRY, V23, P263, DOI 10.1002/(SICI)1097-0320(19960401)23:4<263::AID-CYTO1>3.3.CO;2-9; Bloomfield VA, 1997, BIOPOLYMERS, V44, P269, DOI 10.1002/(SICI)1097-0282(1997)44:3<269::AID-BIP6>3.0.CO;2-T; BUSTAMANTE C, 1991, ANNU REV BIOPHYS BIO, V20, P415, DOI 10.1146/annurev.biophys.20.1.415; CAO TM, 1982, BIOCH BIOPHYS RES CO, V108; HUD NV, 1995, BIOPHYS J, V69, P1355, DOI 10.1016/S0006-3495(95)80002-0; HUD NV, 1993, BIOCHEM BIOPH RES CO, V193, P1347, DOI 10.1006/bbrc.1993.1773; HUD NV, 1994, BIOCHEMISTRY-US, V33, P7528, DOI 10.1021/bi00190a005; KLIMENKO SM, 1967, J MOL BIOL, V23, P523, DOI 10.1016/S0022-2836(67)80122-0; MAEDA S, 1991, VIROLOGY, V180, P807, DOI 10.1016/0042-6822(91)90096-T; NAKANO M, 1989, J BIOCHEM-TOKYO, V105, P133, DOI 10.1093/oxfordjournals.jbchem.a122607; OSTROVSKY B, 1995, BIOPHYS J, V68, P1694, DOI 10.1016/S0006-3495(95)80347-4; PERKINS TT, 1995, SCIENCE, V268, P83, DOI 10.1126/science.7701345; PORSCHKE D, 1991, J MOL BIOL, V222, P423, DOI 10.1016/0022-2836(91)90220-Z; POST CB, 1982, BIOPOLYMERS, V21, P2139, DOI 10.1002/bip.360211105; RICHARDS KE, 1973, J MOL BIOL, V78, P255, DOI 10.1016/0022-2836(73)90114-9; RuizLara SA, 1996, EUR J BIOCHEM, V240, P186, DOI 10.1111/j.1432-1033.1996.0186h.x; Ueda M, 1996, PHYS REV LETT, V77, P2133, DOI 10.1103/PhysRevLett.77.2133; WATANABE F, 1983, J MOL BIOL, V163, P485, DOI 10.1016/0022-2836(83)90070-0; WIDOM J, 1980, J MOL BIOL, V144, P431, DOI 10.1016/0022-2836(80)90330-7	23	198	203	4	37	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	OCT 1	1999	286	5437					120	123		10.1126/science.286.5437.120	http://dx.doi.org/10.1126/science.286.5437.120			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	241WT	10506559	Green Submitted			2022-12-01	WOS:000082907400049
J	Eckert, DM; Malashkevich, VN; Hong, LH; Carr, PA; Kim, PS				Eckert, DM; Malashkevich, VN; Hong, LH; Carr, PA; Kim, PS			Inhibiting HIV-1 entry: Discovery of D-peptide inhibitors that target the gp41 coiled-coil pocket	CELL			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; TRANSMEMBRANE GLYCOPROTEIN; LEUCINE-ZIPPER; ENVELOPE GLYCOPROTEIN; MUTATIONAL ANALYSIS; ATOMIC-STRUCTURE; PROTEIN; FUSION; SUBDOMAIN; DOMAIN	The HIV-1 gp41 protein promotes viral entry by mediating the fusion of viral and cellular membranes. A prominent pocket on the surface of a central trimeric coiled coil within gp41 was previously identified as a potential target for drugs that inhibit HIV-1 entry. We designed a peptide, IQN17, which properly presents this pocket. Utilizing IQN17 and mirror-image phage display, we identified cyclic, D-peptide inhibitors of HIV-1 infection that share a sequence motif. A1.5 Angstrom cocrystal structure of IQN17 in complex with a D-peptide, and NMR studies, show that conserved residues of these inhibitors make intimate contact with the gp41 pocket. Our studies validate the pocket per se as a target for drug development. IQN17 and these D-peptide inhibitors ave likely to be useful for development and identification of a new class of orally bioavailable anti-HIV drugs.	MIT, Howard Hughes Med Inst, Whitehead Inst Biomed Res, Dept Biol,Cambridge Ctr 9, Cambridge, MA 02142 USA	Howard Hughes Medical Institute; Massachusetts Institute of Technology (MIT); Whitehead Institute	Kim, PS (corresponding author), MIT, Howard Hughes Med Inst, Whitehead Inst Biomed Res, Dept Biol,Cambridge Ctr 9, Cambridge, MA 02142 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P01GM056552] Funding Source: NIH RePORTER; NIGMS NIH HHS [P01 GM56552] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		[Anonymous], 1994, ACTA CRYSTALLOGR D, V50, P760; Berger EA, 1999, ANNU REV IMMUNOL, V17, P657, DOI 10.1146/annurev.immunol.17.1.657; BLACKLOW SC, 1995, BIOCHEMISTRY-US, V34, P14955, DOI 10.1021/bi00046a001; Bovey F. A., 1988, NUCL MAGNETIC RESONA; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; CAO J, 1993, J VIROL, V67, P2747, DOI 10.1128/JVI.67.5.2747-2755.1993; CAVANAGH J, 1993, J MAGN RESON SER A, V105, P328; Cavanagh J., 1996, PROTEIN NMR SPECTROS; Chan DC, 1997, CELL, V89, P263, DOI 10.1016/S0092-8674(00)80205-6; Chan DC, 1998, P NATL ACAD SCI USA, V95, P15613, DOI 10.1073/pnas.95.26.15613; Chan DC, 1998, CELL, V93, P681, DOI 10.1016/S0092-8674(00)81430-0; CHEN BK, 1994, J VIROL, V68, P654, DOI 10.1128/JVI.68.2.654-660.1994; CHEN CH, 1995, J VIROL, V69, P3771, DOI 10.1128/JVI.69.6.3771-3777.1995; CHEN SSL, 1993, J VIROL, V67, P3615, DOI 10.1128/JVI.67.6.3615-3619.1993; CRICK FHC, 1953, ACTA CRYSTALLOGR, V6, P689, DOI 10.1107/S0365110X53001964; DUBAY JW, 1992, J VIROL, V66, P4748, DOI 10.1128/JVI.66.8.4748-4756.1992; Eckert DM, 1998, J MOL BIOL, V284, P859, DOI 10.1006/jmbi.1998.2214; EDELHOCH H, 1967, BIOCHEMISTRY-US, V6, P1948, DOI 10.1021/bi00859a010; FIELDS C G, 1991, Peptide Research, V4, P95; Furuta RA, 1998, NAT STRUCT BIOL, V5, P276, DOI 10.1038/nsb0498-276; HARBURY PB, 1995, P NATL ACAD SCI USA, V92, P8408, DOI 10.1073/pnas.92.18.8408; HENDRICKSON WA, 1991, SCIENCE, V254, P51, DOI 10.1126/science.1925561; HERSKOWITZ I, 1987, NATURE, V329, P219, DOI 10.1038/329219a0; Hooft RWW, 1996, NATURE, V381, P272, DOI 10.1038/381272a0; JIANG SB, 1993, NATURE, V365, P113, DOI 10.1038/365113a0; Jones PLS, 1998, J BIOL CHEM, V273, P404, DOI 10.1074/jbc.273.1.404; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kilby JM, 1998, NAT MED, V4, P1302, DOI 10.1038/3293; KIMPTON J, 1992, J VIROL, V66, P2232, DOI 10.1128/JVI.66.4.2232-2239.1992; KING DS, 1990, INT J PEPT PROT RES, V36, P255; KOZARSKY K, 1989, J ACQ IMMUN DEF SYND, V2, P163; Kwong PD, 1998, NATURE, V393, P648, DOI 10.1038/31405; LaCasse RA, 1999, SCIENCE, V283, P357, DOI 10.1126/science.283.5400.357; Lu M, 1997, J BIOMOL STRUCT DYN, V15, P465, DOI 10.1080/07391102.1997.10508958; LU M, 1995, NAT STRUCT BIOL, V2, P1075, DOI 10.1038/nsb1295-1075; MALIM MH, 1989, NATURE, V338, P254, DOI 10.1038/338254a0; Munoz-Barroso I, 1998, J CELL BIOL, V140, P315, DOI 10.1083/jcb.140.2.315; OSAPAY K, 1991, J AM CHEM SOC, V113, P9436, DOI 10.1021/ja00025a002; OTWINOWSKI Z, 1993, DATA COLLECTION PROC, P55; Rimsky LT, 1998, J VIROL, V72, P986, DOI 10.1128/JVI.72.2.986-993.1998; Schumacher TNM, 1996, SCIENCE, V271, P1854, DOI 10.1126/science.271.5257.1854; Shuker SB, 1996, SCIENCE, V274, P1531, DOI 10.1126/science.274.5292.1531; Singh M, 1999, J MOL BIOL, V290, P1031, DOI 10.1006/jmbi.1999.2796; Tan KM, 1997, P NATL ACAD SCI USA, V94, P12303, DOI 10.1073/pnas.94.23.12303; Weissenhorn W, 1997, NATURE, V387, P426, DOI 10.1038/387426a0; Weng YK, 1998, J VIROL, V72, P9676, DOI 10.1128/JVI.72.12.9676-9682.1998; WILD C, 1994, P NATL ACAD SCI USA, V91, P12676, DOI 10.1073/pnas.91.26.12676; WILD C, 1995, AIDS RES HUM RETROV, V11, P323, DOI 10.1089/aid.1995.11.323; Wrighton NC, 1996, SCIENCE, V273, P458, DOI 10.1126/science.273.5274.458; ZAPP ML, 1989, NATURE, V342, P714, DOI 10.1038/342714a0	50	401	445	3	81	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	OCT 1	1999	99	1					103	115		10.1016/S0092-8674(00)80066-5	http://dx.doi.org/10.1016/S0092-8674(00)80066-5			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	243DK	10520998	Bronze			2022-12-01	WOS:000082981600012
J	Shukla, D; Liu, J; Blaiklock, P; Shworak, NW; Bai, XM; Esko, JD; Cohen, GH; Eisenberg, RJ; Rosenberg, RD; Spear, PG				Shukla, D; Liu, J; Blaiklock, P; Shworak, NW; Bai, XM; Esko, JD; Cohen, GH; Eisenberg, RJ; Rosenberg, RD; Spear, PG			A novel role for 3-O-sulfated heparan sulfate in herpes simplex virus 1 entry	CELL			English	Article							D-GLUCOSAMINYL 3-O-SULFOTRANSFERASE; RECEPTOR-RELATED PROTEIN-1; GLYCOPROTEIN-D; POLIOVIRUS RECEPTOR; PSEUDORABIES VIRUS; MOLECULAR-CLONING; CELLS; BINDING; TYPE-1; INFECTION	Herpes simplex virus type 1 (HSV-1) binds to cells through interactions of viral glycoproteins gB and gC with heparan sulfate chains on cell surface proteoglycans. This binding is not sufficient for viral entry, which requires fusion between the viral envelope and cell membrane. Here, we show that heparan sulfate modified by a subset of the multiple D-glucosaminyl 3-O-sulfotransferase isoforms provides sites for the binding of a third viral glycoprotein, go, and for initiation of HSV-1 entry. We conclude that susceptibility of cells to HSV-1 entry depends on (1) presence of heparan sulfate chains to which virus can bind and (2) 3-O-sulfation of specific glucosamine residues in heparan sulfate to generate gD-binding sites or the expression of other previously identified gD-binding receptors.	Northwestern Univ, Sch Med, Dept Microbiol Immunol, Chicago, IL 60611 USA; MIT, Dept Biol, Cambridge, MA 02139 USA; Beth Israel Deaconess Med Ctr, Angiogenesis Res Ctr, Boston, MA 02215 USA; Harvard Univ, Sch Med, Beth Israel Hosp, Dept Med, Boston, MA 02215 USA; Univ Calif San Diego, Dept Cellular & Mol Med, Glycobiol Res & Training Ctr, La Jolla, CA 92093 USA; Univ Penn, Sch Dent Med, Philadelphia, PA 19104 USA; Univ Penn, Ctr Oral Hlth Res, Philadelphia, PA 19104 USA; Univ Penn, Sch Vet Med, Philadelphia, PA 19104 USA	Northwestern University; Massachusetts Institute of Technology (MIT); Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; University of California System; University of California San Diego; University of Pennsylvania; University of Pennsylvania; University of Pennsylvania	Spear, PG (corresponding author), Northwestern Univ, Sch Med, Dept Microbiol Immunol, Chicago, IL 60611 USA.	rdrrosen@mit.edu; p-spear@nwu.edu	Shworak, Nicholas/AAJ-6770-2020	Shworak, Nicholas/0000-0001-7783-4634; Shukla, Deepak/0000-0002-3039-6953	NHLBI NIH HHS [R01 HL 59479] Funding Source: Medline; NIAID NIH HHS [R01 AI 36293, U01 AI 31494] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL059479] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI036293, U01AI031494] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Aikawa J, 1999, J BIOL CHEM, V274, P2690, DOI 10.1074/jbc.274.5.2690; Bai XM, 1996, J BIOL CHEM, V271, P17711, DOI 10.1074/jbc.271.30.17711; BAME KJ, 1989, J BIOL CHEM, V264, P8059; Brynes AP, 1998, J VIROL, V72, P7349, DOI 10.1128/JVI.72.9.7349-7356.1998; Chung CS, 1998, J VIROL, V72, P1577, DOI 10.1128/JVI.72.2.1577-1585.1998; COHEN GH, 1988, J VIROL, V62, P1932, DOI 10.1128/JVI.62.6.1932-1940.1988; COMPTON T, 1993, VIROLOGY, V193, P834, DOI 10.1006/viro.1993.1192; COREY L, 1986, NEW ENGL J MED, V314, P686, DOI 10.1056/NEJM198603133141105; DEAN HJ, 1994, VIROLOGY, V199, P67, DOI 10.1006/viro.1994.1098; EBERLE F, 1995, GENE, V159, P267, DOI 10.1016/0378-1119(95)00180-E; ESKO JD, 1985, P NATL ACAD SCI USA, V82, P3197, DOI 10.1073/pnas.82.10.3197; Feyzi E, 1997, J BIOL CHEM, V272, P24850, DOI 10.1074/jbc.272.40.24850; Geraghty RJ, 1998, SCIENCE, V280, P1618, DOI 10.1126/science.280.5369.1618; HEROLD BC, 1994, J GEN VIROL, V75, P1211, DOI 10.1099/0022-1317-75-6-1211; Herold BC, 1996, J VIROL, V70, P3461, DOI 10.1128/JVI.70.6.3461-3469.1996; HEROLD BC, 1991, J VIROL, V65, P1090, DOI 10.1128/JVI.65.3.1090-1098.1991; ISOLA VJ, 1989, J VIROL, V63, P2325, DOI 10.1128/JVI.63.5.2325-2334.1989; Jackson T, 1996, J VIROL, V70, P5282, DOI 10.1128/JVI.70.8.5282-5287.1996; Kakuta Y, 1999, J BIOL CHEM, V274, P10673, DOI 10.1074/jbc.274.16.10673; Krummenacher C, 1998, J VIROL, V72, P7064, DOI 10.1128/JVI.72.9.7064-7074.1998; KRUMMENACHER C, 1999, IN PRESS J VIROL; LAFFERTY WE, 1987, NEW ENGL J MED, V316, P1444, DOI 10.1056/NEJM198706043162304; LEE MK, 1991, P NATL ACAD SCI USA, V88, P2768, DOI 10.1073/pnas.88.7.2768; LIDHOLT K, 1992, P NATL ACAD SCI USA, V89, P2267, DOI 10.1073/pnas.89.6.2267; Lindahl U, 1998, J BIOL CHEM, V273, P24979, DOI 10.1074/jbc.273.39.24979; Liu J, 1996, J BIOL CHEM, V271, P27072, DOI 10.1074/jbc.271.43.27072; LIU J, 1999, IN PRESS J BIOL CHEM; Liu JA, 1999, J BIOL CHEM, V274, P5185, DOI 10.1074/jbc.274.8.5185; LOPEZ M, 1995, GENE, V155, P261, DOI 10.1016/0378-1119(94)00842-G; Marsolais F, 1995, J BIOL CHEM, V270, P30458, DOI 10.1074/jbc.270.51.30458; Mauri DN, 1998, IMMUNITY, V8, P21, DOI 10.1016/S1074-7613(00)80455-0; MENDELSOHN CL, 1989, CELL, V56, P855, DOI 10.1016/0092-8674(89)90690-9; Montgomery RI, 1996, CELL, V87, P427, DOI 10.1016/S0092-8674(00)81363-X; Nicola AV, 1996, J VIROL, V70, P3815, DOI 10.1128/JVI.70.6.3815-3822.1996; Rosenberg RD, 1997, J CLIN INVEST, V100, pS67; Schmidt J, 1997, J VIROL, V71, P17, DOI 10.1128/JVI.71.1.17-24.1997; Schroder C, 1997, J VIROL, V71, P25; SHIEH MT, 1992, J CELL BIOL, V116, P1273, DOI 10.1083/jcb.116.5.1273; Shworak NW, 1997, J BIOL CHEM, V272, P28008, DOI 10.1074/jbc.272.44.28008; Shworak NW, 1999, J BIOL CHEM, V274, P5170, DOI 10.1074/jbc.274.8.5170; SPEAR PG, 1993, SEMIN VIROL, V4, P167, DOI 10.1006/smvy.1993.1012; Sueyoshi T, 1998, FEBS LETT, V433, P211, DOI 10.1016/S0014-5793(98)00913-2; Summerford C, 1999, NAT MED, V5, P78, DOI 10.1038/4768; Summerford C, 1998, J VIROL, V72, P1438, DOI 10.1128/JVI.72.2.1438-1445.1998; Takahashi K, 1999, J CELL BIOL, V145, P539, DOI 10.1083/jcb.145.3.539; Warner MS, 1998, VIROLOGY, V246, P179, DOI 10.1006/viro.1998.9218; Whitbeck JC, 1997, J VIROL, V71, P6083, DOI 10.1128/JVI.71.8.6083-6093.1997; Willis SH, 1998, J VIROL, V72, P5937, DOI 10.1128/JVI.72.7.5937-5947.1998	48	806	834	0	47	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	OCT 1	1999	99	1					13	22		10.1016/S0092-8674(00)80058-6	http://dx.doi.org/10.1016/S0092-8674(00)80058-6			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	243DK	10520990	Bronze			2022-12-01	WOS:000082981600004
J	Little, SJ; Daar, ES; D'Aquila, RT; Keiser, PH; Connick, E; Whitcomb, JM; Hellmann, NS; Petropoulos, CJ; Sutton, L; Pitt, JA; Rosenberg, ES; Koup, RA; Walker, BD; Richman, DD				Little, SJ; Daar, ES; D'Aquila, RT; Keiser, PH; Connick, E; Whitcomb, JM; Hellmann, NS; Petropoulos, CJ; Sutton, L; Pitt, JA; Rosenberg, ES; Koup, RA; Walker, BD; Richman, DD			Reduced antiretroviral drug susceptibility among patients with primary HIV infection	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; ZIDOVUDINE RESISTANCE; REVERSE-TRANSCRIPTASE; NUCLEOSIDE ANALOGS; THERAPY; LAMIVUDINE; TRANSMISSION; NEVIRAPINE; INDINAVIR; VIREMIA	Context The transmission of drug-resistant hu man immunodeficiency virus (HIV) has been documented, but the prevalence of such transmission is unknown. Objective To assess the spectrum and frequency of antiretroviral susceptibility among subjects with primary HIV infection. Design, Setting, and Patients Retrospective analysis of 141 subjects identified from clinical research centers in 5 major metropolitan areas, enrolled from 1989 to 1998, with HIV seroconversion within the preceding 12 months and no more than 7 days' prior antiretroviral (ARV) therapy. Main Outcome Measures Phenotypic and genotypic ARV susceptibility of HIV from plasma samples. Results The transmission of drug-resistant HIV as assessed by a greater than 10-fold reduction in ARV susceptibility to 1 or more drugs was observed in 3 (2%) of 141 subjects, including to a nonnucleoside reverse transcriptase inhibitor in 1 patient and to a nucleoside reverse transcriptase inhibitor and a protease inhibitor in 2 patients. Population-based sequence analysis of these 3 samples identified multidrug-resistance mutations in reverse transcriptase (M184V, T215Y, K219K/R) and protease (L10I/V, K20R, M36I, M46I, G48V, L63P, A71T, V77I, V82T, I84V, L90M) in the 2 latter patient samples, along with numerous polymorphisms. A reduction in susceptibility of greater than 2.5- to 10-fold to 1 or more drugs was observed in viral isolates from 36 patients (26%). Sequence analysis of these 36 samples identified well-characterized drug resistance mutation in reverse transcriptase and protease in only 1 of these patients. Conclusions Reductions in drug susceptibility of more than 10-fold were rare among this cohort of recently HIV-infected subjects and were distributed among each of the 3 major classes of ARV drugs tested. Reductions in susceptibility of more than 2.5- to 10-fold to certain ARV drugs of unknown clinical significance were highly prevalent among newly infected patients. Resistance testing may be warranted to monitor the frequency of drug resistance over time and to assess the potential for geographic variability.	Univ Calif San Diego, Treatment Ctr, Dept Med, San Diego, CA 92103 USA; Univ Calif San Diego, Dept Pathol, San Diego, CA 92103 USA; Dept Vet Affairs Med Ctr, San Diego, CA USA; Cedars Sinai Burns & Allen Res Inst, Dept Med, Los Angeles, CA USA; Univ Calif Los Angeles, Los Angeles, CA USA; Univ Texas, SW Med Ctr, Dept Med, Dallas, TX USA; Massachusetts Gen Hosp, Dept Med, Boston, MA 02114 USA; Univ Colorado, Hlth Sci Ctr, Dept Med, Denver, CO 80262 USA; Dept Vet Affairs Med Ctr, Denver, CO USA; ViroLog Inc, San Francisco, CA USA; Glaxo Wellcome Inc, Res Triangle Pk, NC 27709 USA; Merck & Co Inc, Blue Bell, PA USA; Bristol Myers Squibb Co, Glaxo Wellcome, Princeton, NJ USA; Agouron Inst, La Jolla, CA 92037 USA; Roxane, Columbus, OH USA	University of California System; University of California San Diego; University of California System; University of California San Diego; Cedars Sinai Medical Center; University of California System; University of California Los Angeles; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Harvard University; Massachusetts General Hospital; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; GlaxoSmithKline; Merck & Company; Bristol-Myers Squibb; GlaxoSmithKline	Little, SJ (corresponding author), Univ Calif San Diego, Treatment Ctr, Dept Med, 2760 5th Ave,Suite 300, San Diego, CA 92103 USA.	slittle@ucsd.edu	Little, Susan/AAA-6116-2019		NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P30AI036214, U01AI027670, K08AI001541] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		[Anonymous], 1998, MMWR Recomm Rep, V47, P1; Carpenter CCJ, 1998, JAMA-J AM MED ASSOC, V280, P78, DOI 10.1001/jama.280.1.78; CLARK SJ, 1991, NEW ENGL J MED, V324, P954, DOI 10.1056/NEJM199104043241404; Conway B, 1999, CLIN INFECT DIS, V28, P910, DOI 10.1086/515225; DAAR E, 1999, 6 C RETR OPP INF JAN; DAAR ES, 1991, NEW ENGL J MED, V324, P961, DOI 10.1056/NEJM199104043241405; DAQUILA RT, 1995, ANN INTERN MED, V122, P401, DOI 10.7326/0003-4819-122-6-199503150-00001; Deeks SG, 1999, J INFECT DIS, V179, P1375, DOI 10.1086/314775; ERICE A, 1993, NEW ENGL J MED, V328, P1163, DOI 10.1056/NEJM199304223281605; Gomez-Cano M, 1998, AIDS, V12, P1015, DOI 10.1097/00002030-199809000-00007; Goudsmit J, 1996, J VIROL, V70, P5662, DOI 10.1128/JVI.70.8.5662-5664.1996; Gulick RM, 1997, NEW ENGL J MED, V337, P734, DOI 10.1056/NEJM199709113371102; Hammer SM, 1997, NEW ENGL J MED, V337, P725, DOI 10.1056/NEJM199709113371101; Harrigan PR, 1998, J VIROL, V72, P3773, DOI 10.1128/JVI.72.5.3773-3778.1998; HARRIGAN R, 1998, 38 INT C ANT AG CHEM; HECHT F, 1998, 12 INT C AIDS JUN 28; Hecht FM, 1998, NEW ENGL J MED, V339, P307, DOI 10.1056/NEJM199807303390504; HELLMAN N, 1999, 3 INT WORKSH DRUG RE; Hirsch MS, 1998, JAMA-J AM MED ASSOC, V279, P1984, DOI 10.1001/jama.279.24.1984; HUANG W, 1999, 3 INT WORKSH DRUG RE; Imrie A, 1997, J INFECT DIS, V175, P1502, DOI 10.1086/516487; Imrie A, 1996, J INFECT DIS, V174, P195, DOI 10.1093/infdis/174.1.195; Kozal MJ, 1996, NAT MED, V2, P753, DOI 10.1038/nm0796-753; Ledergerber B, 1999, LANCET, V353, P863, DOI 10.1016/S0140-6736(99)01122-8; Martinez-Picado J, 1999, J VIROL, V73, P3744, DOI 10.1128/JVI.73.5.3744-3752.1999; MILLER MD, 1999, 3 INT WORKSH DRUG RE; Miller V, 1998, J INFECT DIS, V177, P1521, DOI 10.1086/515304; Parkin NT, 1999, J INFECT DIS, V180, P865, DOI 10.1086/314928; PARKIN NT, 1999, 3 INT WORKSH DRUG RE; Piketty C, 1999, AIDS, V13, pF71, DOI 10.1097/00002030-199907300-00001; Rey D, 1998, J ACQ IMMUN DEF SYND, V17, P203, DOI 10.1097/00042560-199803010-00003; RICHMAN DD, 1994, J VIROL, V68, P1660, DOI 10.1128/JVI.68.3.1660-1666.1994; Rosenberg ES, 1997, SCIENCE, V278, P1447, DOI 10.1126/science.278.5342.1447; Schacker T, 1996, ANN INTERN MED, V125, P257, DOI 10.7326/0003-4819-125-4-199608150-00001; SCHUURMAN R, 1995, J INFECT DIS, V171, P1411, DOI 10.1093/infdis/171.6.1411; SKOWRON G, 1999, 3 INT WORKSH DRUG RE; Vanhems P, 1997, CLIN INFECT DIS, V24, P965, DOI 10.1093/clinids/24.5.965; Weverling GJ, 1998, AIDS, V12, pF117, DOI 10.1097/00002030-199811000-00003; YERLY S, 1998, 12 INT C AIDS JUN 26	39	266	275	0	3	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 22	1999	282	12					1142	1149		10.1001/jama.282.12.1142	http://dx.doi.org/10.1001/jama.282.12.1142			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	236JJ	10501117	Bronze			2022-12-01	WOS:000082596200029
J	Cao, TT; Deacon, HW; Reczek, D; Bretscher, A; von Zastrow, M				Cao, TT; Deacon, HW; Reczek, D; Bretscher, A; von Zastrow, M			A kinase-regulated PDZ-domain interaction controls endocytic sorting of the beta 2-adrenergic receptor	NATURE			English	Article							BETA(2)-ADRENERGIC RECEPTOR; NA+/H+-EXCHANGER; PHOSPHORYLATION SITES; PROTEIN; MEMBRANE; DESENSITIZATION; BINDING; RESENSITIZATION; INTERNALIZATION; IDENTIFICATION	A fundamental question in cell biology is how membrane proteins are sorted in the endocytic pathway, The sorting of internalized beta 2-adrenergic receptors between recycling endosomes and lysosomes is responsible for opposite effects on signal transduction and is regulated by physiological stimuli(1,2). Here we describe a mechanism that controls this sorting operation, which is mediated by a family of conserved protein-interaction modules called PDZ domains(3). The phosphoprotein EBP50 (for ezrin-radixin-moesin(ERM)-binding phosphoprotein-50)(4) binds to the cytoplasmic tail of the beta 2-adrenergic receptor through a PDZ domain and to the cortical actin cytoskeleton through an ERM-binding domain. Disrupting the interaction of EBP50 with either domain or depolymerization of the actin cytoskeleton itself causes missorting of endocytosed beta 2-adrenergic receptors but does not affect the recycling of transferrin receptors. A serine residue at position 411 in the tail of the beta 2-adrenergic receptor is a substrate for phosphorylation by GRK-5 (for G-protein-coupled-receptor kinase-5) (ref. 5) and is required for interaction with EBP50 and for proper recycling of the receptor. Our results identify a new role for PDZ-domain-mediated protein interactions and for the actin cytoskeleton in endocytic sorting, and suggest a mechanism by which GRK-mediated phosphorylation could regulate membrane trafficking of G-protein-coupled receptors after endocytosis.	Univ Calif San Francisco, Program Cell Biol Cellular & Mol Pharmacol & Psyc, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Biochem & Biophys, San Francisco, CA 94143 USA; Cornell Univ, Biochem Mol & Cell Biol Sect, Ithaca, NY 14853 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; Cornell University	von Zastrow, M (corresponding author), Univ Calif San Francisco, Program Cell Biol Cellular & Mol Pharmacol & Psyc, San Francisco, CA 94143 USA.							Cao TT, 1998, J BIOL CHEM, V273, P24592, DOI 10.1074/jbc.273.38.24592; Craven SE, 1998, CELL, V93, P495, DOI 10.1016/S0092-8674(00)81179-4; Doyle DA, 1996, CELL, V85, P1067, DOI 10.1016/S0092-8674(00)81307-0; Durrbach A, 1996, J CELL SCI, V109, P457; Ferguson SSG, 1998, LIFE SCI, V62, P1561, DOI 10.1016/S0024-3205(98)00107-6; Fredericks ZL, 1996, J BIOL CHEM, V271, P13796, DOI 10.1074/jbc.271.23.13796; Goodman OB, 1996, NATURE, V383, P447, DOI 10.1038/383447a0; Hall RA, 1998, NATURE, V392, P626, DOI 10.1038/33458; Hall RA, 1998, P NATL ACAD SCI USA, V95, P8496, DOI 10.1073/pnas.95.15.8496; HINCK L, 1994, J CELL BIOL, V125, P1327, DOI 10.1083/jcb.125.6.1327; KLAUSNER RD, 1983, P NATL ACAD SCI-BIOL, V80, P2263, DOI 10.1073/pnas.80.8.2263; Klein U, 1997, J BIOL CHEM, V272, P19099, DOI 10.1074/jbc.272.31.19099; Lamaze C, 1997, J BIOL CHEM, V272, P20332, DOI 10.1074/jbc.272.33.20332; Lefkowitz R J, 1998, Adv Pharmacol, V42, P416; MAYOR S, 1993, J CELL BIOL, V121, P1257, DOI 10.1083/jcb.121.6.1257; Menard L, 1997, MOL PHARMACOL, V51, P800, DOI 10.1124/mol.51.5.800; OHGURO H, 1995, J BIOL CHEM, V270, P14259, DOI 10.1074/jbc.270.24.14259; Pitcher JA, 1998, ANNU REV BIOCHEM, V67, P653, DOI 10.1146/annurev.biochem.67.1.653; Reczek D, 1997, J CELL BIOL, V139, P169, DOI 10.1083/jcb.139.1.169; Reczek D, 1998, J BIOL CHEM, V273, P18452, DOI 10.1074/jbc.273.29.18452; Seibold A, 1998, J BIOL CHEM, V273, P7637, DOI 10.1074/jbc.273.13.7637; Songyang Z, 1997, SCIENCE, V275, P73, DOI 10.1126/science.275.5296.73; VONZASTROW M, 1994, J BIOL CHEM, V269, P18448; VONZASTROW M, 1992, J BIOL CHEM, V267, P3530; WEINMAN EJ, 1995, J CLIN INVEST, V95, P2143, DOI 10.1172/JCI117903; Yun CHC, 1997, P NATL ACAD SCI USA, V94, P3010, DOI 10.1073/pnas.94.7.3010	26	551	558	0	20	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	SEP 16	1999	401	6750					286	290		10.1038/45816	http://dx.doi.org/10.1038/45816			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	237VZ	10499588				2022-12-01	WOS:000082678400056
J	Kolb, HJ; Socie, G; Duell, T; Van Lint, MT; Tichelli, A; Apperley, JF; Nekolla, E; Ljungman, P; Jacobsen, N; van Weel, M; Wick, R; Weiss, M; Prentice, HG				Kolb, HJ; Socie, G; Duell, T; Van Lint, MT; Tichelli, A; Apperley, JF; Nekolla, E; Ljungman, P; Jacobsen, N; van Weel, M; Wick, R; Weiss, M; Prentice, HG		Late Effects Working Party Europea; European Late Effect Project Grp	Malignant neoplasms in long-term survivors of bone marrow transplantation	ANNALS OF INTERNAL MEDICINE			English	Article						neoplasms; bone marrow transplantation; immunosuppression; cyclosporine; age factors; graft vs host disease	TOTAL-BODY IRRADIATION; SEVERE APLASTIC-ANEMIA; SECONDARY MALIGNANCIES; LEUKEMIA; CANCERS; TUMORS; RISK	Background: Patients who receive bone marrow transplants have increased risk for new malignant conditions because of several risk factors, including conditioning with radiation and chemotherapy, immune stimulation, and malignant primary disease. The occurrence of and risk factors for malignant neoplasm in long-term survivors must be assessed. Objective: To determine the risk and define potential risk factors for new malignant conditions in long-term survivors after marrow transplantation. Design: Retrospective multicenter study. Setting: Study of the Late Effects Working Party with 45 transplantation centers cooperating in the European Cooperative Group for Blood and Marrow Transplantation. Patients: 1036 consecutive patients who underwent transplantation for leukemia, lymphoma, inborn diseases of the hematopoietic and immune systems, or severe aplastic anemia. Transplantation was done before December 1985, and patients had survived more than 5 years. Measurements: Reports on malignant neoplasms were evaluated, and the incidence was compared to that in the general population. Patient age and sex, primary disease and status at transplantation, histocompatibility of the donor, conditioning regimen, type of prophylaxis of graft-versus-host disease, development of acute and chronic graft-versus-host disease, and treatment of chronic graft-versus-host disease were evaluated as variables. Results: Median follow-up since transplantation was 10.7 years (range, 5 to 22.1 years). Malignant neoplasms were seen in 53 patients; the actuarial incidence (+/- SE) was 3.5% +/- 0.6% at 10 years and 12.8% +/- 2.6% at 15 years. The rate of new malignant disease was 3.8-fold higher than that in an age-matched control population (P < 0.001). The most frequent malignant diseases were neoplasms of the skin (14 patients), oral cavity (7 patients), uterus (including cervix) (5 patients), thyroid gland (5 patients), breast (4 patients), and glial tissue (3 patients). Median age of patients and their donors was 21 years. Malignant neoplasms were more frequent in older patients and in patients with chronic graft-versus-host disease. Older patient age and treatment of chronic graft-versus-host disease with cyclosporine were significant risk factors for new malignant neoplasms after bone marrow transplantation. Conclusions: The spectrum of neoplasms and immunosuppressive treatment with cyclosporine for chronic graft-versus-host disease as dominant risk factors indicate that immunosuppression is the major cause of malignant neoplasms in patients receiving marrow transplants.	Univ Munich, Dept Med 3, Hematopoiet Cell Transplantat Unit, Munich, Germany; GSF Munich, Natl Res Ctr Environm & Hlth, Inst Radiobiol, D-81377 Munich, Germany; GSF Munich, Natl Res Ctr Environm & Hlth, Hematopoiet Cell Transplantat Med Clin 3, D-81377 Munich, Germany	University of Munich; Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health; University of Munich; Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health; University of Munich	Kolb, HJ (corresponding author), Univ Munich, Hematopoiet Cell Transplantat Med Clin 3, Marchioninistr 15, D-81377 Munich, Germany.		Ljungman, Per/M-4946-2019					Bhatia S, 1996, BLOOD, V87, P3633, DOI 10.1182/blood.V87.9.3633.bloodjournal8793633; BORTIN MM, 1992, JAMA-J AM MED ASSOC, V268, P607; BORTIN MM, 1992, ANN INTERN MED, V116, P505, DOI 10.7326/0003-4819-116-6-505; Curtis RE, 1997, NEW ENGL J MED, V336, P897, DOI 10.1056/NEJM199703273361301; DEEG HJ, 1980, BLOOD, V55, P233; Deeg HJ, 1996, BLOOD, V87, P386, DOI 10.1182/blood.V87.1.386.bloodjournal871386; DEEG HJ, 1983, INT J RADIAT ONCOL, V9, P1505, DOI 10.1016/0360-3016(83)90325-5; GRATWOHL A, 1994, BONE MARROW TRANSPL, V13, P5; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; KOHN HI, 1984, NEW ENGL J MED, V310, P504, DOI 10.1056/NEJM198402233100807; Kolb H J, 1990, Radiother Oncol, V18 Suppl 1, P51, DOI 10.1016/0167-8140(90)90178-Y; LISHNER M, 1990, CANCER-AM CANCER SOC, V65, P473, DOI 10.1002/1097-0142(19900201)65:3<473::AID-CNCR2820650316>3.0.CO;2-V; LONDON NJ, 1995, LANCET, V346, P403, DOI 10.1016/S0140-6736(95)92780-8; LOWSKY R, 1994, J CLIN ONCOL, V12, P2187, DOI 10.1200/JCO.1994.12.10.2187; MUIR C, 1987, 5 CONTINENTS; NEGLIA JP, 1991, NEW ENGL J MED, V325, P1330, DOI 10.1056/NEJM199111073251902; PENN I, 1987, TRANSPLANTATION, V43, P32, DOI 10.1097/00007890-198701000-00008; PIERGA JY, 1994, RADIOTHER ONCOL, V30, P55, DOI 10.1016/0167-8140(94)90009-4; SEROTA FT, 1983, INT J RADIAT ONCOL, V9, P1941, DOI 10.1016/0360-3016(83)90366-8; SOCIE G, 1993, NEW ENGL J MED, V329, P1152, DOI 10.1056/NEJM199310143291603; SOCIE G, 1991, BLOOD, V78, P277; THOMAS ED, 1975, NEW ENGL J MED, V292, P832, DOI 10.1056/NEJM197504172921605; TUCKER MA, 1988, NEW ENGL J MED, V318, P76, DOI 10.1056/NEJM198801143180203; WITHERSPOON RP, 1989, NEW ENGL J MED, V321, P784, DOI 10.1056/NEJM198909213211203; WITHERSPOON RP, 1994, TRANSPLANTATION, V57, P1413, DOI 10.1097/00007890-199405270-00001	25	188	189	0	5	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	NOV 16	1999	131	10					738	+		10.7326/0003-4819-131-10-199911160-00004	http://dx.doi.org/10.7326/0003-4819-131-10-199911160-00004			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	255QC	10577296				2022-12-01	WOS:000083680100003
J	Siders, CW; Cavalleri, A; Sokolowski-Tinten, K; Toth, C; Guo, T; Kammler, M; von Hoegen, MH; Wilson, KR; von der Linde, D; Barty, CPJ				Siders, CW; Cavalleri, A; Sokolowski-Tinten, K; Toth, C; Guo, T; Kammler, M; von Hoegen, MH; Wilson, KR; von der Linde, D; Barty, CPJ			Detection of nonthermal melting by ultrafast X-ray diffraction	SCIENCE			English	Article							LATTICE INSTABILITY; LASER; SI; GE; TRANSITIONS; DYNAMICS; DISORDER; DIAMOND; SILICON; PULSES	Using ultrafast, time-resolved, 1.54 angstrom x-ray diffraction, thermal and ultrafast nonthermal melting of germanium, involving passage through nonequilibrium extreme states of matter, was observed. Such ultrafast, optical-pump, x-ray diffraction probe measurements provide a way to study many other transient processes in physics, chemistry, and biology, including direct observation of the atomic motion by which many solid-state processes and chemical and biochemical reactions take place.	Univ Calif San Diego, Dept Chem & Biochem, La Jolla, CA 92093 USA; Univ Calif San Diego, Inst Nonlinear Sci, La Jolla, CA 92093 USA; Univ Calif San Diego, Dept Appl Mech Engn Sci, La Jolla, CA 92093 USA; Univ Essen Gesamthsch, Inst Laser & Plasmaphys, D-45117 Essen, Germany; Leibniz Univ Hannover, Inst Halbleitertech, D-30167 Hannover, Germany; Leibniz Univ Hannover, Inst Festkorperphys, D-30167 Hannover, Germany	University of California System; University of California San Diego; University of California System; University of California San Diego; University of California System; University of California San Diego; University of Duisburg Essen; Leibniz University Hannover; Leibniz University Hannover	Siders, CW (corresponding author), Univ Calif San Diego, Dept Chem & Biochem, La Jolla, CA 92093 USA.	csiders@ucsd.edu	Sokolowski-Tinten, Klaus/A-5415-2015; Siders, Craig/AFU-8557-2022; Toth, Csaba/AAD-3106-2019; von Hoegen, Michael Horn/E-4969-2012	von Hoegen, Michael Horn/0000-0003-0324-3457; Guo, Ting/0000-0002-6700-0967; Toth, Csaba/0000-0002-4599-4550				Barty CPJ, 1996, OPT LETT, V21, P668, DOI 10.1364/OL.21.000668; BLOEMBERGEN N, 1992, NATURE, V356, P110, DOI 10.1038/356110a0; CAVALLERI A, 1999, QUANT EL LAS SCI C Q; Chin AH, 1998, SPRINGER SERIES CHEM, V63, P401; DOWNER MC, 1986, PHYS REV LETT, V56, P761, DOI 10.1103/PhysRevLett.56.761; FABRICIUS N, 1986, SOLID STATE COMMUN, V58, P239, DOI 10.1016/0038-1098(86)90209-7; GALLI G, 1990, SCIENCE, V250, P1547, DOI 10.1126/science.250.4987.1547; HORNVONHOEGEN M, 1994, APPL PHYS A-MATER, V59, P503, DOI 10.1007/BF00348268; HORNVONHOEGEN M, 1994, PHYS REV B, V50, P10811, DOI 10.1103/PhysRevB.50.10811; Huang L, 1998, PHYS REV LETT, V80, P185, DOI 10.1103/PhysRevLett.80.185; LARSON BC, 1982, PHYS REV LETT, V48, P337, DOI 10.1103/PhysRevLett.48.337; Larsson J, 1998, APPL PHYS A-MATER, V66, P587, DOI 10.1007/s003390050719; LINDENBERG AM, 1999, QELS 99 SESS QTHJ4 B; LIU JM, 1982, OPT LETT, V7, P196, DOI 10.1364/OL.7.000196; MUMANE MM, 1991, SCIENCE, V25, P531; REITZE DH, 1992, PHYS REV B, V45, P2677, DOI 10.1103/PhysRevB.45.2677; Rischel C, 1997, NATURE, V390, P490, DOI 10.1038/37317; Rose-Petruck C, 1999, NATURE, V398, P310, DOI 10.1038/18631; ROUSSE A, 1999, C LAS EL CLEO 99 SES; SAETA P, 1991, PHYS REV LETT, V67, P1023, DOI 10.1103/PhysRevLett.67.1023; Schoenlein RW, 1996, SCIENCE, V274, P236, DOI 10.1126/science.274.5285.236; SHANK CV, 1983, PHYS REV LETT, V50, P454, DOI 10.1103/PhysRevLett.50.454; Sokolowski-Tinten K, 1998, PHYS REV LETT, V81, P224, DOI 10.1103/PhysRevLett.81.224; Sokolowski-Tinten K, 1998, PHYS REV B, V58, P11805, DOI 10.1103/PhysRevB.58.R11805; SOKOLOWSKITINTEN K, 1995, PHYS REV B, V51, P14186, DOI 10.1103/PhysRevB.51.14186; Spaepen F., 1982, Laser annealing of semiconductors, P15; STAMPFLI P, 1990, PHYS REV B, V42, P7163, DOI 10.1103/PhysRevB.42.7163; STAMPFLI P, 1992, PHYS REV B, V46, P10686, DOI 10.1103/PhysRevB.46.10686; STAMPFLI P, 1994, PHYS REV B, V49, P7299, DOI 10.1103/PhysRevB.49.7299; TOM HWK, 1988, PHYS REV LETT, V60, P1438, DOI 10.1103/PhysRevLett.60.1438; VANVECHTEN JA, 1979, PHYS LETT A, V74, P422, DOI 10.1016/0375-9601(79)90242-1; VONDERLINDE D, 1990, RESONANCES; Wood R F, 1984, PULSED LASER PROCESS, V23	33	458	465	2	89	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 12	1999	286	5443					1340	1342		10.1126/science.286.5443.1340	http://dx.doi.org/10.1126/science.286.5443.1340			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	255NF	10558985				2022-12-01	WOS:000083675500037
J	Berry, RJ; Li, Z; Erickson, JD; Li, S; Moore, CA; Wang, H; Mulinare, J; Zhao, P; Wong, LYC; Gindler, J; Hong, SX; Correa, A				Berry, RJ; Li, Z; Erickson, JD; Li, S; Moore, CA; Wang, H; Mulinare, J; Zhao, P; Wong, LYC; Gindler, J; Hong, SX; Correa, A		China-US Collaborative Project Neu	Prevention of neural-tube defects with folic acid in China	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							PERICONCEPTIONAL VITAMIN SUPPLEMENTATION; DIETARY-FOLATE; PREVALENCE; RISK	Background Periconceptional use of multivitamins containing folic acid can reduce a woman's risk of having a baby with a neural-tube defect. Methods As part of a public health campaign conducted from 1993 to 1995 in an area of China with high rates of neural-tube defects (the northern region) and one with low rates (the southern region), we evaluated the outcomes of pregnancy in women who were asked to take a pill containing 400 mu g of folic acid alone daily from the time of their premarital examination until the end of their first trimester of pregnancy. Results Among the fetuses or infants of 130,142 women who took folic acid at any time before or during pregnancy and 117,689 women who had not taken folic acid, we identified 102 and 173, respectively, with neural-tube defects. Among the fetuses or infants of women who registered before their last menstrual period and who did not take any folic acid, the rates of neural-tube defects were 4.8 per 1000 pregnancies of at least 20 weeks' gestation in the northern region and 1.0 per 1000 in the southern region. Among the fetuses or infants of the women with periconceptional use of folic acid, the rates were 1.0 per 1000 in the northern region and 0.6 per 1000 in the southern region. The greatest reduction in risk occurred among the fetuses or infants of a subgroup of women in the northern region with periconceptional use who took folic acid pills more than 80 percent of the time. In the southern region the reduction in risk among the fetuses or infants of women with periconceptional use of folic acid was also significant (reduction in risk, 41 percent; 95 percent confidence interval, 3 to 64 percent). Conclusions Periconceptional intake of 400 mg of folic acid daily can reduce the risk of neural-tube defects in areas with high rates of these defects and in areas with low rates. (N Engl J Med 1999;341:1485-90.) (C) 1999, Massachusetts Medical Society.	Ctr Dis Control & Prevent, Birth Defects & Genet Dis Branch, Natl Ctr Environm Hlth, Atlanta, GA 30341 USA; Beijing Med Univ, Natl Ctr Maternal & Infant Hlth, Beijing 100083, Peoples R China; Beijing Med Univ, Dept Hlth Care Epidemiol, Beijing 100083, Peoples R China	Centers for Disease Control & Prevention - USA; Peking University; Peking University	Berry, RJ (corresponding author), Ctr Dis Control & Prevent, Birth Defects & Genet Dis Branch, Natl Ctr Environm Hlth, 4770 Buford Hwy,MS F-45, Atlanta, GA 30341 USA.			Berry, Robert/0000-0002-7162-5046				[Anonymous], 1991, MMWR MORB MORTAL WKL, V40, P513; [Anonymous], 1992, MMWR MORB MORTAL WKL, V41, P1; BOWER C, 1989, MED J AUSTRALIA, V150, P613, DOI 10.5694/j.1326-5377.1989.tb136723.x; Cornel MC, 1997, TERATOLOGY, V55, P134; CZEIZEL AE, 1992, NEW ENGL J MED, V327, P1832, DOI 10.1056/NEJM199212243272602; KIRKE PN, 1992, ARCH DIS CHILD, V67, P1442, DOI 10.1136/adc.67.12.1442; MILUNSKY A, 1989, JAMA-J AM MED ASSOC, V262, P2847, DOI 10.1001/jama.262.20.2847; Moore CA, 1997, AM J MED GENET, V73, P113; MULINARE J, 1988, JAMA-J AM MED ASSOC, V260, P3141, DOI 10.1001/jama.260.21.3141; MURRAY CJL, 1996, GLOBAL BURDEN DIS IN, V10; Olney R, 1998, MENT RETARD DEV D R, V4, P241, DOI 10.1002/(SICI)1098-2779(1998)4:4<241::AID-MRDD2>3.0.CO;2-Y; SAS, 1997, SAS STAT SOFTW CHANG; SHAW GM, 1995, EPIDEMIOLOGY, V6, P219, DOI 10.1097/00001648-199505000-00005; SMITHELLS RW, 1980, LANCET, V1, P339; SMITHELLS RW, 1983, LANCET, V1, P1027; WALD N, 1991, LANCET, V338, P131; WERLER MM, 1993, JAMA-J AM MED ASSOC, V269, P1257, DOI 10.1001/jama.269.10.1257; XIAO KZ, 1990, INT J EPIDEMIOL, V19, P978	18	1033	1098	2	85	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	NOV 11	1999	341	20					1485	1490		10.1056/NEJM199911113412001	http://dx.doi.org/10.1056/NEJM199911113412001			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	254RK	10559448				2022-12-01	WOS:000083625800001
J	Bergh, T; Ericson, A; Hillensjo, T; Nygren, KG; Wennerholm, UB				Bergh, T; Ericson, A; Hillensjo, T; Nygren, KG; Wennerholm, UB			Deliveries and children born after in-vitro fertilisation in Sweden 1982-95: a retrospective cohort study	LANCET			English	Article							CONGENITAL-MALFORMATIONS; INVITRO FERTILIZATION; CRYOPRESERVED EMBRYOS; SINGLETON PREGNANCIES; ASSISTED CONCEPTION; BIRTHS; REGISTRY; TWINS; HEALTH	Background In-vitro fertilisation is an effective treatment for infertility, but there is concern about the health of children. We investigated, in a retrospective registry study, malformations, cancers, and deaths In the complete Swedish in-vitro-fertilisation birth cohort compared with the general population. Methods We collected data from all in-vitro-fertilisation clinics in Sweden and compared the obstetric outcomes of babies (n=5856) born between 1982 and 1995 with all babies born in the general population (n=1 505 724) during the same period, according to data from the Swedish Medical Birth Registry and the Registry of Congenital Malformations. We investigated the incidence of childhood cancer through the Swedish Cancer Registry. Data were stratified for maternal age, parity, previous subfertility, year of birth, and multiple of pregnancies. Findings Multiple births occurred in 27% of pregnancies compared with 1% in the control group. In the in-vitro-fertilisation group, more babies were born preterm (<37 weeks) than controls (30.3 vs 6.3%) and more had low birthweights (<2500 g, 27.4 vs 4.6%). The perinatal mortality was 1.9% in the in-vitro fertilisation group and 11% in the controls. For in-vitro-fertilisation singletons, the risk ratios, adjusted for year of birth, for very preterm birth (<32 weeks) and very low birthweight (<1500 g) were 3.54 (95% CI 2.90-4.32) and 4.39 (3.62-5.32), respectively. Malformations occurred in 5.4% of all babies in the in-vitro fertilisation group (1.39 [1.25-1.54]), and the rates of neural-tube defects and oesophageal atresia were higher than those in the controls. There was no increase in childhood cancer in the in-vitro-fertilisation group. Interpretation A high frequency of multiple births and maternal characteristics were the main factors that led to adverse outcomes, and not the in-vitro-fertilisation technique itself. The clinical practice of in-vitro-fertilisation needs to be changed to lower the rate of multiple pregnancy.	Sophiahemmet, S-11486 Stockholm, Sweden; Carl von Linneklin, Uppsala, Sweden; Socialstyrelsen, Epidemiol Ctr, Gothenburg, Sweden; Fertil Ctr, Gothenburg, Sweden; Sahlgrens Univ Hosp, Gothenburg, Sweden	National Board of Health & Welfare; Sahlgrenska University Hospital	Nygren, KG (corresponding author), Sophiahemmet, POB 5605, S-11486 Stockholm, Sweden.							BERAL V, 1990, BMJ-BRIT MED J, V300, P1229; Bonduelle M, 1996, HUM REPROD, V11, P131, DOI 10.1093/humrep/11.suppl_4.131; BONDUELLE M, 1998, PROSPECTIVE FOLLOW U; Bustillo M, 1999, FERTIL STERIL, V71, P798; CNATTINGIUS S, 1990, SCAND J SOC MED, V18, P143, DOI 10.1177/140349489001800209; DEMOUZON J, 1997, J ASSIST REPROD GE S, V14, P251; DEROM R, 1995, MULTIPLE PREGNANCY; Dhont M, 1997, J ASSIST REPROD GEN, V14, P575, DOI 10.1023/A:1022576500894; DOYLE P, 1992, HUM REPROD, V7, P425, DOI 10.1093/oxfordjournals.humrep.a137663; DOYLE PE, 1991, J EPIDEMIOL COMMUN H, V45, P43, DOI 10.1136/jech.45.1.43; FRIEDLER S, 1992, HUM REPROD, V7, P1159, DOI 10.1093/oxfordjournals.humrep.a137813; GHAZI HA, 1991, FERTIL STERIL, V55, P726; GISSLER M, 1995, HUM REPROD, V10, P1856, DOI 10.1093/oxfordjournals.humrep.a136191; KALLEN B, 1986, ACTA GENET MED GEMEL, V35, P167; LANCASTER PAL, 1987, LANCET, V2, P1392; LANCASTER PAL, 1985, BRIT MED J, V291, P1160; LOGEROTLEBRUN H, 1995, FERTIL STERIL, V64, P746; PETTERSON B, 1993, BRIT MED J, V307, P1239, DOI 10.1136/bmj.307.6914.1239; Reubinoff BE, 1997, FERTIL STERIL, V67, P1077, DOI 10.1016/S0015-0282(97)81442-2; ROBERT E, 1993, REPROD TOXICOL, V7, P405, DOI 10.1016/0890-6238(93)90085-L; STEPTOE PC, 1978, LANCET, V2, P366; Sutcliffe AG, 1995, HUM REPROD, V10, P3332, DOI 10.1093/oxfordjournals.humrep.a135915; TANBO T, 1995, OBSTET GYNECOL, V86, P188, DOI 10.1016/0029-7844(95)00159-O; VELD PI, 1995, LANCET, V346, P773, DOI 10.1016/S0140-6736(95)91531-1; von During V, 1995, Tidsskr Nor Laegeforen, V115, P2054; WANG JX, 1994, HUM REPROD, V9, P141, DOI 10.1093/oxfordjournals.humrep.a138304; Weinberg W, 1901, ARCH GESAMTE PHYSIOL, V88, P346, DOI 10.1007/BF01657695; Wennerholm UB, 1998, LANCET, V351, P1085, DOI 10.1016/S0140-6736(97)08247-0; WHITE L, 1990, LANCET, V336, P1577, DOI 10.1016/0140-6736(90)93350-X	29	504	518	4	32	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	NOV 6	1999	354	9190					1579	1585		10.1016/S0140-6736(99)04345-7	http://dx.doi.org/10.1016/S0140-6736(99)04345-7			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	253HM	10560671				2022-12-01	WOS:000083551000008
J	Martzen, MR; McCraith, SM; Spinelli, SL; Torres, FM; Fields, S; Grayhack, EJ; Phizicky, EM				Martzen, MR; McCraith, SM; Spinelli, SL; Torres, FM; Fields, S; Grayhack, EJ; Phizicky, EM			A biochemical genomics approach for identifying genes by the activity of their products	SCIENCE			English	Article							TRANSFER-RNA LIGASE; SACCHAROMYCES-CEREVISIAE; SPLICE JUNCTION; YEAST; 2'-PHOSPHATE; PURIFICATION; EXPRESSION; PHOSPHATE; CLONING	For the identification of yeast genes specifying biochemical activities, a genomic strategy that is rapid, sensitive, and widely applicable was developed with an array of 6144 individual yeast strains, each containing a different yeast open reading frame (ORF) fused to glutathione S-transferase (GSI). For the identification of ORF-associated activities, strains were grown in defined pools, and GST-ORFs were purified. Then, pools were assayed for activities, and active pools were deconvoluted to identify the source strains. Three previously unknown ORF-associated activities were identified with this strategy: a cyclic phosphodiesterase that acts on adenosine diphosphate-ribose 1 "-2 " cyclic phosphate (Appr>p), an Appr-1 "-p-processing activity, and a cytochrome c methyltransferase.	Univ Rochester, Sch Med, Dept Biochem & Biophys, Rochester, NY 14642 USA; Univ Washington, Dept Genet, Seattle, WA 98195 USA; Univ Washington, Dept Med, Seattle, WA 98195 USA; Univ Washington, Howard Hughes Med Inst, Seattle, WA 98195 USA	University of Rochester; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; Howard Hughes Medical Institute; University of Washington; University of Washington Seattle	Phizicky, EM (corresponding author), Univ Rochester, Sch Med, Dept Biochem & Biophys, Rochester, NY 14642 USA.	eric_phizicky@urmc.rochester.edu	Torres, Filipa/G-9742-2016; Grayhack, Elizabeth J/G-4386-2012; McCraith, Stephen/AAX-9625-2020	Grayhack, Elizabeth J/0000-0003-2400-5490; 	NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR011823] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM052347] Funding Source: NIH RePORTER; NCRR NIH HHS [P41 RR11823] Funding Source: Medline; NIGMS NIH HHS [GM52347] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Culver GM, 1997, J BIOL CHEM, V272, P13203, DOI 10.1074/jbc.272.20.13203; CULVER GM, 1994, J BIOL CHEM, V269, P24928; CULVER GM, 1993, SCIENCE, V261, P206, DOI 10.1126/science.8392224; DELANGE RJ, 1970, J BIOL CHEM, V245, P3325; GREER CL, 1983, CELL, V32, P537, DOI 10.1016/0092-8674(83)90473-7; LIAO HH, 1979, J BACTERIOL, V138, P853, DOI 10.1128/JB.138.3.853-860.1979; MACREADIE IG, 1991, GENE, V104, P107, DOI 10.1016/0378-1119(91)90474-P; MCCRAITH SM, 1991, J BIOL CHEM, V266, P11986; MCCRAITH SM, 1990, MOL CELL BIOL, V10, P1049, DOI 10.1128/MCB.10.3.1049; MORINO H, 1987, J NEUROCHEM, V48, P1201, DOI 10.1111/j.1471-4159.1987.tb05647.x; Nelson JR, 1996, SCIENCE, V272, P1646, DOI 10.1126/science.272.5268.1646; PEEBLES CL, 1983, CELL, V32, P525, DOI 10.1016/0092-8674(83)90472-5; PHIZICKY EM, 1992, J BIOL CHEM, V267, P4577; PHIZICKY EM, 1986, J BIOL CHEM, V261, P2978; SHERMAN F, 1991, METHOD ENZYMOL, V194, P3; SIMONSEN H, 1994, TRENDS PHARMACOL SCI, V15, P437, DOI 10.1016/0165-6147(94)90052-3; Spinelli SL, 1999, J BIOL CHEM, V274, P2637, DOI 10.1074/jbc.274.5.2637; Spinelli SL, 1997, RNA, V3, P1388	18	331	347	1	21	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 5	1999	286	5442					1153	1155		10.1126/science.286.5442.1153	http://dx.doi.org/10.1126/science.286.5442.1153			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	253AJ	10550052				2022-12-01	WOS:000083534200042
J	Dornadula, G; Zhang, H; VanUitert, B; Stern, J; Livornese, L; Ingerman, MJ; Witek, J; Kedanis, RJ; Natkin, J; DeSimone, J; Pomerantz, RJ				Dornadula, G; Zhang, H; VanUitert, B; Stern, J; Livornese, L; Ingerman, MJ; Witek, J; Kedanis, RJ; Natkin, J; DeSimone, J; Pomerantz, RJ			Residual HIV-1 RNA in blood plasma of patients taking suppressive highly active antiretroviral therapy	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; REVERSE TRANSCRIPTION; PROLONGED SUPPRESSION; COMBINATION THERAPY; VIRAL LOAD; INFECTION; TYPE-1; ZIDOVUDINE; RESERVOIR; INDINAVIR	Context Despite suppressive treatment with highly active antiretroviral therapy (HAART), replication-competent virus can still be isolated from peripheral blood mononuclear cells and genital cells of many individuals receiving suppressive HAART. Objective To determine whether free virion RNA can be detected in the blood plasma and/or genital tract fluids from patients receiving suppressive HAART. Design Prospective cohort study conducted from November 1998 to May 1999. Setting Academic medical center. Patients Human immunodeficiency virus 1-infected individuals (20 men and 2 women) shown in our laboratories to have fewer than 50 copies/mL of HIV-1 RNA in peripheral blood plasma while taking suppressive HAART. Main Outcome Measures Free virion RNA levels in peripheral blood plasma and genital fluids, quantified using an ultrasensitive reverse transcriptase polymerase chain reaction able to quantify cell-free virion RNA to a lower limit of 5 copies/mL and qualitatively detect viral RNA below this level. Results In all 22 patients, residual viral RNA could be detected in the peripheral blood plasma (mean level, 17 copies/mL). The presence of viral RNA suggests that ongoing viral replication is occurring, albeit at low levels, in each patient evaluated, Viral RNA levels were lower in most patients' genital fluids compared with blood plasma and in 12 patients were undetectable. Conclusions These data suggest that low-level replication of HIV-1 in patients taking suppressive HAART may be demonstrated not only in peripheral blood mononuclear cells but also in peripheral plasma as cell-free virion RNA. Complete ablation of viral replication may require intensification of antiretroviral therapies beyond standard suppressive HAART.	Thomas Jefferson Univ, Jefferson Med Coll, Dept Med,Div Infect Dis, Ctr Human Virol,Dorrance H Hamilton Labs, Philadelphia, PA 19107 USA; Penn Hosp, Philadelphia, PA 19107 USA; Med Coll Penn & Hahnemann Univ, Partnership Comprehens Care, Philadelphia, PA USA	Jefferson University; University of Pennsylvania; Pennsylvania Medicine; Drexel University	Pomerantz, RJ (corresponding author), Thomas Jefferson Univ, Jefferson Med Coll, Dept Med,Div Infect Dis, Ctr Human Virol,Dorrance H Hamilton Labs, Philadelphia, PA 19107 USA.	roger.j.pomerantz@mail.tju.edu			NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI038666] Funding Source: NIH RePORTER; NIAID NIH HHS [AI38666] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Cavert W, 1997, SCIENCE, V276, P960, DOI 10.1126/science.276.5314.960; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Chun TW, 1997, P NATL ACAD SCI USA, V94, P13193, DOI 10.1073/pnas.94.24.13193; Chun TW, 1999, NAT MED, V5, P651, DOI 10.1038/9498; Enting RH, 1998, AIDS, V12, P1941, DOI 10.1097/00002030-199815000-00005; Finzi D, 1999, NAT MED, V5, P512, DOI 10.1038/8394; Finzi D, 1997, SCIENCE, V278, P1295, DOI 10.1126/science.278.5341.1295; Furtado MR, 1999, NEW ENGL J MED, V340, P1614, DOI 10.1056/NEJM199905273402102; Garcia F, 1999, AIDS, V13, pF79, DOI 10.1097/00002030-199907300-00002; Grossman Z, 1999, NAT MED, V5, P1099, DOI 10.1038/13410; Gulick RM, 1997, NEW ENGL J MED, V337, P734, DOI 10.1056/NEJM199709113371102; Hammer SM, 1997, NEW ENGL J MED, V337, P725, DOI 10.1056/NEJM199709113371101; Harrigan PR, 1999, AIDS, V13, pF59, DOI 10.1097/00002030-199905280-00001; HO DD, 1995, NATURE, V373, P123, DOI 10.1038/373123a0; HO DD, 1987, NEW ENGL J MED, V317, P278; Hockett RD, 1999, J EXP MED, V189, P1545, DOI 10.1084/jem.189.10.1545; Lafeuillade A, 1998, J INFECT DIS, V177, P235, DOI 10.1086/517362; Lewin SR, 1999, J VIROL, V73, P6099, DOI 10.1128/JVI.73.7.6099-6103.1999; Lisziewicz J, 1999, NEW ENGL J MED, V340, P1683, DOI 10.1056/NEJM199905273402114; Markowitz M, 1999, J INFECT DIS, V179, P527, DOI 10.1086/314628; Martinez MA, 1999, VIROLOGY, V256, P180, DOI 10.1006/viro.1999.9601; Montaner JSG, 1998, AIDS, V12, P1398, DOI 10.1097/00002030-199811000-00028; Montaner JSG, 1998, JAMA-J AM MED ASSOC, V279, P930, DOI 10.1001/jama.279.12.930; Natarajan V, 1999, LANCET, V353, P119, DOI 10.1016/S0140-6736(05)76156-0; Palella FJ, 1998, NEW ENGL J MED, V338, P853, DOI 10.1056/NEJM199803263381301; Perelson AS, 1997, NATURE, V387, P188, DOI 10.1038/387188a0; Pomerantz RJ, 1999, NEW ENGL J MED, V340, P1672, DOI 10.1056/NEJM199905273402110; POMERANTZ RJ, 1988, ANN INTERN MED, V108, P321, DOI 10.7326/0003-4819-108-3-321; POMERANTZ RJ, 1999, HIV ADV RES THER, V9, P17; Raboud JM, 1998, AIDS, V12, P1619, DOI 10.1097/00002030-199813000-00008; WEI XP, 1995, NATURE, V373, P117, DOI 10.1038/373117a0; Wong JK, 1997, SCIENCE, V278, P1291, DOI 10.1126/science.278.5341.1291; Zhang H, 1996, J VIROL, V70, P628, DOI 10.1128/JVI.70.1.628-634.1996; Zhang H, 1996, J VIROL, V70, P2809, DOI 10.1128/JVI.70.5.2809-2824.1996; ZHANG H, 1993, AIDS RES HUM RETROV, V9, P1287, DOI 10.1089/aid.1993.9.1287; Zhang H, 1998, NEW ENGL J MED, V339, P1803, DOI 10.1056/NEJM199812173392502; Zhang LQ, 1999, NEW ENGL J MED, V340, P1605, DOI 10.1056/NEJM199905273402101; ZHANG ZQ, 1999, 6 C RETR OPP INF FEB; Zhu TF, 1996, J VIROL, V70, P3098, DOI 10.1128/JVI.70.5.3098-3107.1996	39	362	368	0	5	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 3	1999	282	17					1627	1632		10.1001/jama.282.17.1627	http://dx.doi.org/10.1001/jama.282.17.1627			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	250BD	10553788	Bronze			2022-12-01	WOS:000083368400027
J	Hotz, P; Buchet, JP; Bernard, A; Lison, D; Lauwerys, R				Hotz, P; Buchet, JP; Bernard, A; Lison, D; Lauwerys, R			Renal effects of low-level environmental cadmium exposure: 5-year follow-up of a subcohort from the Cadmibel study	LANCET			English	Article							BLOOD-PRESSURE; TUBULAR DYSFUNCTION; GENERAL-POPULATION; POLLUTED AREA; BODY BURDEN; MORTALITY; INHABITANTS; RESIDENTS; REDUCTION; DISEASES	Background The clinical relevance of renal effects of cadmium in people exposed in the environment remains uncertain. This study examined the evolution of renal effects observed in a population exposed to cadmium in the environment. Methods 208 men and 385 women surveyed in 1985-89 (Cadmium in Belgium study [Cadmibel]; baseline) were reexamined on average 5 years later (Public health and environmental exposure to cadmium study [PheeCad]; follow-up). Urinary and blood cadmium and markers of renal tubular dysfunction and glomerular effects were measured. The association between cadmium body burden and renal factors was examined by multivariate logistic and linear regression. Findings In men, mean urinary cadmium excretion and blood cadmium concentration measured at follow-up were 7.5 nmol/24 h (SD 1.9) and 6.1 nmol/L (2.2), reductions of 16% and 35% from baseline, respectively. In women, the corresponding values were 7.6 nmol/24 h (1.9) and 7.8 nmol/L (2.1), reductions of 14% and 28% from baseline. No indication of progressive renal damage was found and the overall results suggest that the effects of low environmental exposure to cadmium on the kidney are weak, stable, or reversible. Interpretation Subclinical renal effects that have been reported in Belgium in patients with increased cadmium body burden are not associated with progressive renal dysfunction and most likely represent non-adverse manifestations.	Univ Catholique Louvain, Ind Toxicol & Occupat Med Unit, B-1200 Brussels, Belgium; Univ Zurich, ISPMZ, Abt Arbeits & Umweltmed, CH-8006 Zurich, Switzerland	Universite Catholique Louvain; University of Zurich	Lison, D (corresponding author), Univ Catholique Louvain, Ind Toxicol & Occupat Med Unit, Clos Chapelle aux Champs 30-54, B-1200 Brussels, Belgium.		Lison, Dominique/A-8985-2010; BERNARD, Alfred M/A-6511-2010	BERNARD, Alfred M/0000-0003-3171-3743; Lison, Dominique/0000-0001-6557-2518				Agency for Toxic Substance and Disease Registry, 1997, TOX PROF CADM; Buchet JP, 1996, OCCUP ENVIRON MED, V53, P320, DOI 10.1136/oem.53.5.320; BUCHET JP, 1990, LANCET, V336, P699, DOI 10.1016/0140-6736(90)92201-R; Cirillo M, 1998, ARCH INTERN MED, V158, P1933, DOI 10.1001/archinte.158.17.1933; GANONG WF, 1997, REV MED PHYSL, P264; Goetz FC, 1997, AM J EPIDEMIOL, V145, P91; HERBER RFM, 1994, PURE APPL CHEM, V66, P915, DOI 10.1351/pac199466040915; INSKIP H, 1982, LANCET, V1, P896; IWATA K, 1991, TOHOKU J EXP MED, V164, P93, DOI 10.1620/tjem.164.93; IWATA K, 1993, ARCH ENVIRON HEALTH, V48, P157, DOI 10.1080/00039896.1993.9940814; JAESCHKE R, 1994, JAMA-J AM MED ASSOC, V271, P703, DOI 10.1001/jama.271.9.703; KIDO T, 1990, ARCH ENVIRON HEALTH, V45, P35, DOI 10.1080/00039896.1990.9935922; KIDO T, 1988, ARCH ENVIRON HEALTH, V43, P213, DOI 10.1080/00039896.1988.9934935; LAUWERYS R, 1981, LANCET, V1, P383; LAUWERYS R, 1990, ENVIRON HEALTH PERSP, V87, P283, DOI 10.2307/3431036; Massey LK, 1996, J BONE MINER RES, V11, P731; NAKAGAWA H, 1993, ARCH ENVIRON HEALTH, V48, P428, DOI 10.1080/00039896.1993.10545965; NISHIJO M, 1994, ENVIRON RES, V64, P112, DOI 10.1006/enrs.1994.1010; NISHIJO M, 1995, OCCUP ENVIRON MED, V52, P181, DOI 10.1136/oem.52.3.181; NOGAWA K, 1984, ENVIRON HEALTH PERSP, V54, P163, DOI 10.2307/3429803; Roels HA, 1997, AM J IND MED, V31, P645, DOI 10.1002/(SICI)1097-0274(199705)31:5<645::AID-AJIM21>3.3.CO;2-M; ROELS HA, 1991, BRIT J IND MED, V48, P365; SARTOR FA, 1992, ARCH ENVIRON HEALTH, V47, P347, DOI 10.1080/00039896.1992.9938373; Shigematsu I., 1982, KANKYO HOKEN REPORT, V48, P118; Shigematsu I., 1980, KANKYO HOKEN REPOR 2, V46, P1; STAESSEN J, 1991, AM J EPIDEMIOL, V134, P257, DOI 10.1093/oxfordjournals.aje.a116079; STAESSEN J, 1988, J HYPERTENS, V6, P965, DOI 10.1097/00004872-198812000-00003; Staessen JA, 1999, LANCET, V353, P1140, DOI 10.1016/S0140-6736(98)09356-8; STAESSEN JA, 1994, LANCET, V343, P1523, DOI 10.1016/S0140-6736(94)92936-X; Tsuchiya K, 1992, IARC Sci Publ, P35	30	108	110	0	14	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	OCT 30	1999	354	9189					1508	1513		10.1016/S0140-6736(99)91145-5	http://dx.doi.org/10.1016/S0140-6736(99)91145-5			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	250WB	10551497				2022-12-01	WOS:000083411300011
J	Alter, DA; Naylor, CD; Austin, P; Tu, JV				Alter, DA; Naylor, CD; Austin, P; Tu, JV			Effects of socioeconomic status on access to invasive cardiac procedures and on mortality after acute myocardial infarction	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CORONARY HEART-DISEASE; UNITED-STATES; SOCIAL-CLASS; CATHETERIZATION FACILITIES; CARDIOVASCULAR-DISEASE; RISK-FACTORS; HEALTH; CANADA; IMPACT; CARE	Background Universal health care systems seek to ensure access to care on the basis of need rather than income and to improve the health status of all citizens. We examined the performance of the Canadian health system with respect to these goals in the province of Ontario by assessing the effects of neighborhood income on access to invasive cardiac procedures and on mortality one year after acute myocardial infarction. Methods We linked claims for payment for physicians' services, hospital-discharge abstracts, and vital-status data for all patients with acute myocardial infarction who were admitted to hospitals in Ontario between April 1994 and March 1997. Patients' income levels were imputed from the median incomes of their residential neighborhoods as determined in Canada's 1996 census. We determined rates of use and waiting times for coronary angiography and revascularization procedures after the index admission for acute myocardial infarction and determined death rates at one year. In multivariate analyses, we controlled for the patient's age, sex, and severity of disease; the specialty of the attending physician; the volume of cases, teaching status, and on-site facilities for cardiac procedures at the admitting hospital; and the geographic proximity of the admitting hospital to tertiary care centers. Results The study cohort consisted of 51,591 patients. With respect to coronary angiography, increases in neighborhood income from the lowest to the highest quintile were associated with a 23 percent increase in rates of use and a 45 percent decrease in waiting times. There was a strong inverse relation between income and mortality at one year (P<0.001). Each $10,000 increase in the neighborhood median income was associated with a 10 percent reduction in the risk of death within one year (adjusted hazard ratio, 0.90; 95 percent confidence interval, 0.86 to 0.94). Conclusions In the province of Ontario, despite Canada's universal health care system, socioeconomic status had pronounced effects on access to specialized cardiac services as well as on mortality one year after acute myocardial infarction. (N Engl J Med 1999;341:1359-67.) (C) 1999, Massachusetts Medical Society.	Sunnybrook & Womens Coll, Hlth Sci Ctr, Inst Clin Evaluat Sci, Toronto, ON M4N 3M5, Canada; Sunnybrook & Womens Coll, Hlth Sci Ctr, Clin Epidemiol & Hlth Care Res Program, Toronto, ON M4N 3M5, Canada; Sunnybrook & Womens Coll, Hlth Sci Ctr, Div Cardiol, Toronto, ON M4N 3M5, Canada; Sunnybrook & Womens Coll, Hlth Sci Ctr, Div Gen Internal Med, Toronto, ON M4N 3M5, Canada; Univ Toronto, Toronto, ON, Canada; Univ Toronto, Dept Publ Hlth Sci, Toronto, ON, Canada; Univ Toronto, Deans Off, Toronto, ON, Canada	University of Manitoba; Children's Hospital Research Institute of Manitoba; University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center; University of Manitoba; Children's Hospital Research Institute of Manitoba; University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center; University of Manitoba; Children's Hospital Research Institute of Manitoba; University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center; University of Manitoba; Children's Hospital Research Institute of Manitoba; University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center; University of Toronto; University of Toronto; University of Toronto	Tu, JV (corresponding author), Sunnybrook & Womens Coll, Hlth Sci Ctr, Inst Clin Evaluat Sci, G-106,2075 Bayview Ave, Toronto, ON M4N 3M5, Canada.			Tu, Jack/0000-0003-0111-722X; Austin, Peter/0000-0003-3337-233X				ADLER NE, 1993, JAMA-J AM MED ASSOC, V269, P3140, DOI 10.1001/jama.269.24.3140; ANDERSON GM, 1993, JAMA-J AM MED ASSOC, V269, P1661; [Anonymous], 1994, Circulation, V89, P1545; [Anonymous], CARDIOVASCULAR HLTH; BADGLEY RF, 1992, CANADIAN HLTH CARE S, P193; Beaudet M P, 1996, Health Rep, V7, P11; BLUSTEIN J, 1993, JAMA-J AM MED ASSOC, V270, P344, DOI 10.1001/jama.270.3.344; Boden WE, 1998, NEW ENGL J MED, V338, P1785, DOI 10.1056/NEJM199806183382501; Boden WE, 1998, NEW ENGL J MED, V339, P1091; Cairney J, 1996, CAN J PUBLIC HEALTH, V87, P199; CarrHill R, 1995, J EPIDEMIOL COMMUN H, V49, pS28, DOI 10.1136/jech.49.Suppl_2.S28; *COMM PROF HOSP AC, 1992, ICD9CM COMM PROF HOS; COS JL, 1994, J GEN INTERN MED, V9, P674, DOI 10.1007/BF02599007; Efron B., 1993, MONOGRAPHS STAT APPL, DOI 10.1007/978-1-4899-4541-9; ENTERLINE PE, 1973, NEW ENGL J MED, V289, P1174, DOI 10.1056/NEJM197311292892206; Evans R. G., 1994, WHY ARE SOME PEOPLE, P3; Every NR, 1997, CIRCULATION, V96, P1770, DOI 10.1161/01.CIR.96.6.1770; GUADAGNOLI E, 1995, NEW ENGL J MED, V333, P573, DOI 10.1056/NEJM199508313330908; JAMES SA, 1987, CIRCULATION, V76, P60; KAPLAN GA, 1993, CIRCULATION, V88, P1973, DOI 10.1161/01.CIR.88.4.1973; KATZ SJ, 1994, JAMA-J AM MED ASSOC, V272, P530, DOI 10.1001/jama.272.7.530; Katz SJ, 1996, CAN J PUBLIC HEALTH, V87, P253; KRIEGER N, 1992, AM J PUBLIC HEALTH, V82, P703, DOI 10.2105/AJPH.82.5.703; Krumholz HM, 1998, CIRCULATION, V98, P2010, DOI 10.1161/01.CIR.98.19.2010; MARK DB, 1994, NEW ENGL J MED, V331, P1130, DOI 10.1056/NEJM199410273311706; MARKOWE HLJ, 1985, BMJ-BRIT MED J, V291, P1312, DOI 10.1136/bmj.291.6505.1312; MARMOT MG, 1983, J PSYCHOSOM RES, V27, P377, DOI 10.1016/0022-3999(83)90069-7; MARMOT MG, 1987, ANNU REV PUBL HEALTH, V8, P111, DOI 10.1146/annurev.pu.08.050187.000551; MARMOT MG, 1978, J EPIDEMIOL COMMUN H, V32, P244, DOI 10.1136/jech.32.4.244; McIsaac W, 1997, J Health Serv Res Policy, V2, P94; Naylor C D, 1992, Health Econ, V1, P19, DOI 10.1002/hec.4730010106; Roos NP, 1997, MILBANK Q, V75, P89, DOI 10.1111/1468-0009.00045; RUBERMAN W, 1984, NEW ENGL J MED, V311, P552, DOI 10.1056/NEJM198408303110902; Smith GD, 1998, J EPIDEMIOL COMMUN H, V52, P399, DOI 10.1136/jech.52.6.399; STERN MP, 1984, AM J EPIDEMIOL, V120, P834, DOI 10.1093/oxfordjournals.aje.a113956; Thiemann DR, 1999, NEW ENGL J MED, V340, P1640, DOI 10.1056/NEJM199905273402106; TOFLER GH, 1993, AM J CARDIOL, V71, P1031, DOI 10.1016/0002-9149(93)90568-W; Tu JV, 1997, NEW ENGL J MED, V337, P139; Tu JV., 1999, CARDIOVASCULAR HLTH, P83; WEINBLATT E, 1978, NEW ENGL J MED, V299, P60, DOI 10.1056/NEJM197807132990202	40	500	506	0	22	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	OCT 28	1999	341	18					1359	1367		10.1056/NEJM199910283411806	http://dx.doi.org/10.1056/NEJM199910283411806			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	249XE	10536129				2022-12-01	WOS:000083357800006
J	van Raaij, MJ; Mitraki, A; Lavigne, G; Cusack, S				van Raaij, MJ; Mitraki, A; Lavigne, G; Cusack, S			A triple beta-spiral in the adenovirus fibre shaft reveals a new structural motif for a fibrous protein	NATURE			English	Article							CRYSTAL-STRUCTURE; TYPE-2 FIBER; RECEPTOR; CRYSTALLOGRAPHY; ATTACHMENT; DOMAIN; LONG	Human adenoviruses(1) are responsible for respiratory, gastroenteric and ocular infections(2) and can serve as gene therapy vectors(3). They form icosahedral particles with 240 copies of the trimeric hexon protein arranged on the planes and a penton complex at each of the twelve vertices. The penton consists of a pentameric base, implicated in virus internalization(4), and a protruding trimeric fibre, responsible for receptor attachment(5). The fibres are homo-trimeric proteins containing an aminoterminal penton base attachment domain, a long, thin central shaft and a carboxy-terminal cell attachment or head domain. The shaft domain contains a repeating sequence motif with an invariant glycine or proline and a conserved pattern of hydrophobic residues(6). Here we describe the crystal structure at 2.4 Angstrom resolution of a recombinant protein containing the four distal repeats of the adenovirus type 2 fibre shaft plus the receptor-binding head domain. The structure reveals a novel triple beta-spiral fibrous fold for the shaft. Implications for folding of fibrous proteins (mis-folding of shaft peptides leads to amyloid-like fibrils) and for the design of a new class of artificial, silk-like fibrous materials are discussed.	Inst Max Von Laue Paul Langevin, European Mol Biol Lab, Grenoble Outstn, F-38042 Grenoble 9, France; CEA, CNRS, Inst Biol Struct, F-38027 Grenoble 1, France	European Molecular Biology Laboratory (EMBL); Institut Laue-Langevin (ILL); UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); CEA; Centre National de la Recherche Scientifique (CNRS)	Cusack, S (corresponding author), Inst Max Von Laue Paul Langevin, European Mol Biol Lab, Grenoble Outstn, BP 156, F-38042 Grenoble 9, France.	cusack@embl-grenoble.fr	van Raaij, Mark J/B-3678-2009; MITRAKI, Anna/A-6034-2014	van Raaij, Mark J/0000-0002-4781-1375; Cusack, Stephen/0000-0002-9324-0796				BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Beck K, 1998, J STRUCT BIOL, V122, P17, DOI 10.1006/jsbi.1998.3965; Bergelson JM, 1997, SCIENCE, V275, P1320, DOI 10.1126/science.275.5304.1320; Betts S, 1999, STRUCT FOLD DES, V7, pR131, DOI 10.1016/S0969-2126(99)80078-1; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Cerritelli ME, 1996, J MOL BIOL, V260, P767, DOI 10.1006/jmbi.1996.0436; Chroboczek J, 1995, Curr Top Microbiol Immunol, V199 ( Pt 1), P163; DEVAUX C, 1987, VIROLOGY, V161, P121, DOI 10.1016/0042-6822(87)90177-2; DEVAUX C, 1990, J MOL BIOL, V215, P567, DOI 10.1016/S0022-2836(05)80169-X; GREEN NM, 1983, EMBO J, V2, P1357, DOI 10.1002/j.1460-2075.1983.tb01592.x; HESS M, 1995, J MOL BIOL, V252, P379, DOI 10.1006/jmbi.1995.0504; Hong JS, 1996, J VIROL, V70, P7071, DOI 10.1128/JVI.70.10.7071-7078.1996; HORWITZ MS, 1996, FIELDS VIROLOGY, P2149; LOUIS N, 1994, THESIS U J FOURIER G; MARSH RE, 1955, ACTA CRYSTALLOGR, V8, P710, DOI 10.1107/S0365110X5500217X; Mitraki A, 1999, EUR J BIOCHEM, V264, P599, DOI 10.1046/j.1432-1327.1999.00683.x; OBRIEN JP, 1993, ACS SYM SER, V544, P104; PHILIPSON L, 1968, J VIROL, V2, P1064, DOI 10.1128/JVI.2.10.1064-1075.1968; Robbins PD, 1998, TRENDS BIOTECHNOL, V16, P35, DOI 10.1016/S0167-7799(97)01137-2; Roelvink PW, 1998, J VIROL, V72, P7909, DOI 10.1128/JVI.72.10.7909-7915.1998; RUIGROK RWH, 1990, J MOL BIOL, V215, P589, DOI 10.1016/S0022-2836(05)80170-6; RUIGROK RWH, 1994, J GEN VIROL, V75, P2069, DOI 10.1099/0022-1317-75-8-2069; SCHENK TS, 1996, FIELDS VIROLOGY, P2111; STEINBACHER S, 1994, SCIENCE, V265, P383, DOI 10.1126/science.8023158; STOUTEN PFW, 1992, J MOL BIOL, V226, P1073, DOI 10.1016/0022-2836(92)91053-R; Tao YZ, 1997, STRUCTURE, V5, P789, DOI 10.1016/S0969-2126(97)00233-5; van Raaij MJ, 1999, VIROLOGY, V262, P333, DOI 10.1006/viro.1999.9849; WICKHAM TJ, 1993, CELL, V73, P309, DOI 10.1016/0092-8674(93)90231-E; XIA D, 1994, STRUCTURE, V2, P1259, DOI 10.1016/S0969-2126(94)00126-X; YODER MD, 1993, SCIENCE, V260, P1503, DOI 10.1126/science.8502994	30	264	275	1	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	OCT 28	1999	401	6756					935	938		10.1038/44880	http://dx.doi.org/10.1038/44880			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	251UL	10553913				2022-12-01	WOS:000083464700065
J	Wei, M; Kampert, JB; Barlow, CE; Nichaman, MZ; Gibbons, LW; Paffenbarger, RS; Blair, SN				Wei, M; Kampert, JB; Barlow, CE; Nichaman, MZ; Gibbons, LW; Paffenbarger, RS; Blair, SN			Relationship between low cardiorespiratory fitness and mortality in normal-weight, overweight, and obese men	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							BODY-MASS INDEX; PHYSICAL-ACTIVITY; ATTRIBUTABLE RISK; ALL-CAUSE; HEALTH; TRIAL; WOMEN	Context Recent guidelines for treatment of overweight and obesity include recommendations for risk stratification by disease conditions and cardiovascular disease (CVD) risk factors, but the role of physical inactivity is not prominent in these recommendations. Objective To quantify the influence of low cardiorespiratory fitness, an objective marker of physical inactivity, on CVD and all-cause mortality in normal-weight, overweight, and obese men and compare low fitness with other mortality predictors. Design Prospective observational data from the Aerobics Center Longitudinal Study. Setting Preventive medicine clinic in Dallas, Tex. Participants A total of 25 714 adult men (average age, 43.8 years [SD, 10.1 years]) who received a medical examination during 1970 to 1993, with mortality follow-up to December 31, 1994, Main Outcome Measures Cardiovascular disease and all-cause mortality based on mortality predictors (baseline CVD, type 2 diabetes mellitus, high serum cholesterol level, hypertension, current cigarette smoking, and low cardiorespiratory fitness) stratified by body mass index. Results During the study period, there were 1025 deaths (439 due to CVD) during 258 781 man-years of follow up. Overweight and obese men with baseline CVD or CVD risk factors were at higher risk for all-cause and CVD mortality compared with normal-weight men without these predictors. Using normal-weight men without CVD as the referent, the strongest predictor of CVD death in obese men was baseline CVD (age- and examination year-adjusted relative risk [RR], 14.0; 95% confidence interval [CI], 9.4-20.8); RRs for obese men with diabetes mellitus, high cholesterol, hypertension, smoking, and low fitness were similar and ranged from 4.4 (95% CI, 2.7-7.1) for smoking to 5.0 (95% CI, 3.6-7.0) for low fitness. Relative risks for all-cause mortality in obese men ranged from 2.3 (95% CI, 1.7-2.9) for men with hypertension to 4.7 (95% CI, 3.6-6.1) for those with CVD at baseline. Relative risk for all-cause mortality in obese men with low fitness was 3.1 (95% CI, 2.5-3.8) and in obese men with diabetes mellitus 3.1 (95 % CI, 2.3-4.2) and as slightly higher than the RRs for obese men who smoked or had high cholesterol levels. Low fitness was an independent predictor of mortality in all body mass index groups after adjustment for other mortality predictors. Approximately 50% (n = 1674) of obese men had low fitness, which led to a population-attributable risk of 39% for CVD mortality and 44% for all-cause mortality. Baseline CVD had population attributable risks of 51% and 27% for CVD and all-cause mortality, respectively. Conclusions In this analysis, low cardiorespiratory fitness was a strong and independent predictor of CVD and all-cause mortality and of comparable importance with that of diabetes mellitus and other CVD risk factors.	Cooper Inst Aerob Res, Dallas, TX 75230 USA; Cooper Clin, Dallas, TX USA; Westat Corp, Rockville, MD USA; Stanford Univ, Sch Med, Stanford, CA USA	Cooper Institute; Cooper Institute; Westat; Stanford University	Blair, SN (corresponding author), Cooper Inst Aerob Res, 12330 Preston Rd, Dallas, TX 75230 USA.	sblair@cooperinst.org	wright, beth/V-7496-2019		NATIONAL INSTITUTE ON AGING [R01AG006945, R37AG006945] Funding Source: NIH RePORTER; NIA NIH HHS [AG06945] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		[Anonymous], 1996, JAMA, V276, P241; BALKE B, 1959, U S Armed Forces Med J, V10, P675; BLAIR SN, 1995, JAMA-J AM MED ASSOC, V273, P1093, DOI 10.1001/jama.273.14.1093; Bouchard C., 1994, PHYS ACTIVITY FITNES, P106; Bouchard C., 1986, SPORT HUMAN GENETICS, P59; BRUZZI P, 1985, AM J EPIDEMIOL, V122, P904, DOI 10.1093/oxfordjournals.aje.a114174; Calfas KJ, 1996, PREV MED, V25, P225, DOI 10.1006/pmed.1996.0050; Calfas KJ, 1997, PREV MED, V26, P297, DOI 10.1006/pmed.1997.0141; COX DR, 1972, J R STAT SOC B, V34, P187; Dorn JM, 1997, AM J EPIDEMIOL, V146, P919, DOI 10.1093/oxfordjournals.aje.a009218; Dunn AL, 1998, MED SCI SPORT EXER, V30, P1076, DOI 10.1097/00005768-199807000-00009; Dunn AL, 1997, PREV MED, V26, P883, DOI 10.1006/pmed.1997.0218; Dunn AL, 1999, JAMA-J AM MED ASSOC, V281, P327, DOI 10.1001/jama.281.4.327; Flegal KM, 1998, INT J OBESITY, V22, P39, DOI 10.1038/sj.ijo.0800541; FROHLICH ED, 1988, CIRCULATION, V77, pA502; Gavin JR, 1997, DIABETES CARE, V20, P1183; GRUNDY SM, 1993, JAMA-J AM MED ASSOC, V269, P3015, DOI 10.1001/jama.269.23.3015; Kampert JB, 1996, ANN EPIDEMIOL, V6, P452, DOI 10.1016/S1047-2797(96)00059-2; KOHL HW, 1992, DIABETES CARE, V15, P184, DOI 10.2337/diacare.15.2.184; *NIH, 1997, NIH PUBL; *NIH NAT HEART LUN, 1998, CLIN GUID ID EV TREA, P1; PATE RR, 1995, JAMA-J AM MED ASSOC, V273, P402, DOI 10.1001/jama.273.5.402; POLLOCK ML, 1976, AM HEART J, V92, P39, DOI 10.1016/S0002-8703(76)80401-2; Pollock ML, 1998, MED SCI SPORT EXER, V30, P975, DOI 10.1097/00005768-199806000-00032; Rothman KJ., 2008, MODERN EPIDEMIOLOGY; STAMPFER MJ, 1984, AM J EPIDEMIOL, V119, P837, DOI 10.1093/oxfordjournals.aje.a113804; Stevens J, 1998, NEW ENGL J MED, V338, P1, DOI 10.1056/NEJM199801013380101; US Department of Health and Human Services, 1996, PHYS ACT HLTH REP SU; WALTER SD, 1983, AM J EPIDEMIOL, V117, P598, DOI 10.1093/oxfordjournals.aje.a113582; WHO, 1998, OB PREV MAN GLOB EP	30	744	765	1	54	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 27	1999	282	16					1547	1553		10.1001/jama.282.16.1547	http://dx.doi.org/10.1001/jama.282.16.1547			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	248MB	10546694	Bronze			2022-12-01	WOS:000083277800022
J	Zakany, J; Duboule, D				Zakany, J; Duboule, D			Hox genes and the making of sphincters	NATURE			English	Article							COMPLEX; EXPRESSION; MICE		Univ Geneva, Dept Zool & Anim Biol, CH-1211 Geneva 4, Switzerland	University of Geneva	Zakany, J (corresponding author), Univ Geneva, Dept Zool & Anim Biol, Quai Ernest Ansermet 30, CH-1211 Geneva 4, Switzerland.			duboule, denis/0000-0001-9961-2960				BIENZ M, 1994, TRENDS GENET, V10, P22, DOI 10.1016/0168-9525(94)90015-9; CONDIE BG, 1993, DEVELOPMENT, V119, P579; DOLLE P, 1989, EMBO J, V8, P1507, DOI 10.1002/j.1460-2075.1989.tb03535.x; DOLLE P, 1989, NATURE, V342, P767, DOI 10.1038/342767a0; GERARD M, 1993, EMBO J, V12, P3539, DOI 10.1002/j.1460-2075.1993.tb06028.x; IZPISUABELMONTE JC, 1990, DEVELOPMENT, V110, P733; Kondo T, 1996, DEVELOPMENT, V122, P2651; KRUMLAUF R, 1994, CELL, V78, P191, DOI 10.1016/0092-8674(94)90290-9; Rijli FM, 1997, CURR OPIN GENET DEV, V7, P481, DOI 10.1016/S0959-437X(97)80074-3; ROBERTS DJ, 1995, DEVELOPMENT, V121, P3163; Sekimoto T, 1998, GENES CELLS, V3, P51, DOI 10.1046/j.1365-2443.1998.00167.x; vanderHoeven F, 1996, CELL, V85, P1025, DOI 10.1016/S0092-8674(00)81303-3; Zakany J, 1996, NATURE, V384, P69, DOI 10.1038/384069a0	13	65	65	0	2	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	OCT 21	1999	401	6755					761	762		10.1038/44511	http://dx.doi.org/10.1038/44511			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	250BG	10548099				2022-12-01	WOS:000083368700040
J	Protheroe, D; Turvey, K; Horgan, K; Benson, E; Bowers, D; House, A				Protheroe, D; Turvey, K; Horgan, K; Benson, E; Bowers, D; House, A			Stressful life events and difficulties and onset of breast cancer: case-control study	BRITISH MEDICAL JOURNAL			English	Article								Objective To determine the relation between stressful life events and difficulties and the onset of breast cancer. Design Case-control study. Setting 3 NHS breast clinics serving west Leeds. Participants 399 consecutive women, aged 40-79, attending the breast clinics who were Leeds residents. Main outcome measures Odds ratios of the risk of developing breast cancer after experiencing one or more severe life events, severe difficulties, severe 2 year non-personal health difficulties, or severe 2 year personal health difficulties in the 5 years before clinical presentation. Results 332 (83%) women participated. Women diagnosed with breast cancer were no more likely to have experienced one or more severe life events (adjusted odds ratio 0.91, 95% confidence interval 0.47 to 1.81; P = 0.79); one or more severe difficulties (0.86, 0.41 to 1.81; P = 0.69); a 2 year severe non-personal health difficulty (0.53, 0.12 to 2.31; P = 0.4); or a 2 year severe personal health difficulty (2.73, 0.68 to 10.93; P = 0.16) than women diagnosed with a benign breast lump. Conclusion These findings do not support the hypothesis that severe life events or difficulties are associated with onset of breast cancer.	Leeds Gen Infirm, Dept Liaison Psychiat, Leeds LS1 3EX, W Yorkshire, England; Univ Leeds, Nuffield Inst Hlth, Sub Unit Med Stat, Leeds LS2 9PL, W Yorkshire, England	Leeds General Infirmary; University of Leeds; University of Leeds	Protheroe, D (corresponding author), No Hosp, Epping, Vic 3076, Australia.		horgan, kieran/I-3892-2016	House, Allan/0000-0001-8721-8026				BAGHURST KI, 1992, J EPIDEMIOL COMMUN H, V46, P120, DOI 10.1136/jech.46.2.120; BARRACLOUGH J, 1992, BRIT MED J, V304, P1078, DOI 10.1136/bmj.304.6834.1078; BECK AT, 1961, ARCH GEN PSYCHIAT, V4, P561, DOI 10.1001/archpsyc.1961.01710120031004; Brown G., 1978, SOCIAL ORIGINS DEPRE; Cassileth BR, 1996, CANCER-AM CANCER SOC, V77, P1015, DOI 10.1002/(SICI)1097-0142(19960315)77:6<1015::AID-CNCR1>3.0.CO;2-G; CHEN CC, 1995, BRIT MED J, V311, P1527, DOI 10.1136/bmj.311.7019.1527; COUNSELL CE, 1994, BMJ-BRIT MED J, V309, P1677, DOI 10.1136/bmj.309.6970.1677; GEYER S, 1991, J PSYCHOSOM RES, V35, P355, DOI 10.1016/0022-3999(91)90090-B; Hosmer DW, 2000, APPL LOGISTIC REGRES, V2nd; LESHAN L, 1959, J NATL CANCER I, V22, P1; McGee R, 1996, PSYCHOL MED, V26, P441, DOI 10.1017/S0033291700035522; MECHANIC D, 1972, NEW ENGL J MED, V286, P1132, DOI 10.1056/NEJM197205252862105; Petticrew M, 1999, BRIT J HEALTH PSYCH, V4, P1, DOI 10.1348/135910799168434; RAMIREZ AJ, 1989, BRIT MED J, V298, P291, DOI 10.1136/bmj.298.6669.291; Reed MJ, 1996, BRIT MED J, V312, P845	15	83	85	0	9	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	OCT 16	1999	319	7216					1027	1030		10.1136/bmj.319.7216.1027	http://dx.doi.org/10.1136/bmj.319.7216.1027			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	247FH	10521192	Bronze, Green Published			2022-12-01	WOS:000083210100022
J	Pouliot, JJ; Yao, KC; Robertson, CA; Nash, HA				Pouliot, JJ; Yao, KC; Robertson, CA; Nash, HA			Yeast gene for a Tyr-DNA phosphodiesterase that repairs topoisomerase I complexes	SCIENCE			English	Article							SACCHAROMYCES-CEREVISIAE; CELL-DEATH; DRUGS; DISRUPTION; DELETION; PROTEIN; ENZYME	Covalent intermediates between topoisomerase I and DNA can become dead-end complexes that read to cell death. Here, the isolation of the gene for an enzyme that can hydrolyze the bond between this protein and DNA is described. Enzyme-defective mutants of yeast are hypersensitive to treatments that increase the amount of covalent complexes, indicative of enzyme involvement in repair. The gene is conserved in eukaryotes and identifies a family of enzymes that has not been previously recognized. The presence of this gene in humans may have implications for the effectiveness of topoisomerase I poisons, such as the camptothecins, in chemotherapy.	NIMH, Mol Biol Lab, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Mental Health (NIMH)	Nash, HA (corresponding author), NIMH, Mol Biol Lab, Bldg 36,Room 1B08, Bethesda, MD 20892 USA.	nash@codon.nih.gov						BAUDIN A, 1993, NUCLEIC ACIDS RES, V21, P3329, DOI 10.1093/nar/21.14.3329; Brachmann CB, 1998, YEAST, V14, P115; CHEN AY, 1994, ANNU REV PHARMACOL, V34, P191, DOI 10.1146/annurev.pa.34.040194.001203; FELDMANN H, 1994, EMBO J, V13, P5795, DOI 10.1002/j.1460-2075.1994.tb06923.x; Friedberg EC, 1995, DNA REPAIR MUTAGENES; GRAHAM TR, 1993, EMBO J, V12, P869, DOI 10.1002/j.1460-2075.1993.tb05727.x; HERSKOWITZ I, 1991, METHOD ENZYMOL, V194, P132; Kanaar R, 1998, TRENDS CELL BIOL, V8, P483, DOI 10.1016/S0962-8924(98)01383-X; Larsen AK, 1998, BBA-GENE STRUCT EXPR, V1400, P257, DOI 10.1016/S0167-4781(98)00140-7; Megonigal MD, 1997, J BIOL CHEM, V272, P12801, DOI 10.1074/jbc.272.19.12801; NITISS J, 1988, P NATL ACAD SCI USA, V85, P7501, DOI 10.1073/pnas.85.20.7501; Pommier Y, 1998, BBA-GENE STRUCT EXPR, V1400, P83, DOI 10.1016/S0167-4781(98)00129-8; Pouliot J. J., UNPUB; ROSE MD, 1987, GENE, V60, P237, DOI 10.1016/0378-1119(87)90232-0; ROTHSTEIN R, 1991, METHOD ENZYMOL, V194, P281; SHERMAN F, 1993, EMBO J, V12, P3; TRECO DA, 1991, CURRENT PROTOCOLS MO, V2; Vialard JE, 1998, EMBO J, V17, P5679, DOI 10.1093/emboj/17.19.5679; Wang JC, 1996, ANNU REV BIOCHEM, V65, P635, DOI 10.1146/annurev.bi.65.070196.003223; Yang SW, 1996, P NATL ACAD SCI USA, V93, P11534, DOI 10.1073/pnas.93.21.11534	20	303	312	0	21	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 15	1999	286	5439					552	555		10.1126/science.286.5439.552	http://dx.doi.org/10.1126/science.286.5439.552			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	245RD	10521354	Green Submitted			2022-12-01	WOS:000083121200066
J	Jiang, GL; den Hertog, J; Su, J; Noel, J; Sap, J; Hunter, T				Jiang, GL; den Hertog, J; Su, J; Noel, J; Sap, J; Hunter, T			Dimerization inhibits the activity of receptor-like protein-tyrosine phosphatase-alpha	NATURE			English	Article							DISULFIDE BOND; KINASE; DOMAIN; FORM; PHOSPHORYLATION; PP60(C-SRC); ACTIVATION	Protein-tyrosine phosphatases (PTPs) are vital for regulating tryosine phosphorylation in many processes, including growth and differentiation(1,2). The regulation of receptor-like PTP (RPTP) activity remains poorly understood, but based on the crystal structure of RPTP alpha domain 1 we have proposed that dimerization can negatively regulate activity, through the interaction of an inhibitory 'wedge' on one monomer with the catalytic cleft of domain 1 in the other monomer(3,4). Here we show that dimerization inhibits the activity of a full-length RPTP in vivo. We generated stable disulphide-bonded full-length RPTP alpha homodimers by expressing mutants with single cysteines at different positions in the ectodomain juxtamembrane region. Expression of wild-type RPTP alpha and Phe135Cys and Thr141Cys mutants in RPTP alpha-null mouse embryo cells increased dephosphorylation and activity of Tyr529 in the protein tyrosine kinase c-Src; in contrast, expression of a Pro137Cys mutant did not. Mutation of Pro 210/211 to leucine in the inhibitory wedge of the Pro137Cys mutant restored its ability to activate c-Src, indicating that dimerization may inhibit full-length RPTP alpha activity in a manner stereochemically consistent with RPTP alpha crystal structures(3). Our results suggest that RPTP alpha activity can in principle be negatively regulated by dimerization in vivo.	Salk Inst Biol Studies, Mol Biol & Virol Lab, La Jolla, CA 92037 USA; Salk Inst Biol Studies, Struct Biol Lab, La Jolla, CA 92037 USA; Netherlands Inst Dev Biol, Hubrecht Lab, NL-3584 CT Utrecht, Netherlands; NYU, Med Ctr, Dept Pharmacol, New York, NY 10016 USA	Salk Institute; Salk Institute; Royal Netherlands Academy of Arts & Sciences; Hubrecht Institute (KNAW); New York University	Jiang, GL (corresponding author), Salk Inst Biol Studies, Mol Biol & Virol Lab, 10010 N Torrey Pines Rd, La Jolla, CA 92037 USA.		Noel, Joseph P/A-9459-2009					Bilwes AM, 1996, NATURE, V382, P555, DOI 10.1038/382555a0; Burke CL, 1998, MOL CELL BIOL, V18, P5371, DOI 10.1128/MCB.18.9.5371; CAO HN, 1992, J BIOL CHEM, V267, P20489; DENHERTOG J, 1993, EMBO J, V12, P3789, DOI 10.1002/j.1460-2075.1993.tb06057.x; DENHERTOG J, 1995, CELL GROWTH DIFFER, V6, P303; denHertog J, 1996, EMBO J, V15, P3016, DOI 10.1002/j.1460-2075.1996.tb00665.x; DESAI DM, 1993, CELL, V73, P541, DOI 10.1016/0092-8674(93)90141-C; Felberg J, 1998, J BIOL CHEM, V273, P17839, DOI 10.1074/jbc.273.28.17839; Harder KW, 1998, J BIOL CHEM, V273, P31890, DOI 10.1074/jbc.273.48.31890; Hoffmann KMV, 1997, J BIOL CHEM, V272, P27505, DOI 10.1074/jbc.272.44.27505; HUNTER T, 1995, CELL, V80, P225, DOI 10.1016/0092-8674(95)90405-0; Kawakatsu H, 1996, J BIOL CHEM, V271, P5680, DOI 10.1074/jbc.271.10.5680; LEVYTOLEDANO R, 1993, ENDOCRINOLOGY, V133, P1803, DOI 10.1210/en.133.4.1803; LIPSICH LA, 1983, J VIROL, V48, P352, DOI 10.1128/JVI.48.2.352-360.1983; Majeti R, 1998, SCIENCE, V279, P88, DOI 10.1126/science.279.5347.88; Nam HJ, 1999, CELL, V97, P449, DOI 10.1016/S0092-8674(00)80755-2; Naviaux RK, 1996, J VIROL, V70, P5701, DOI 10.1128/JVI.70.8.5701-5705.1996; Ponniah S, 1999, CURR BIOL, V9, P535, DOI 10.1016/S0960-9822(99)80238-3; SAP J, 1990, P NATL ACAD SCI USA, V87, P6112, DOI 10.1073/pnas.87.16.6112; SOROKIN A, 1994, J BIOL CHEM, V269, P9752; Su J, 1999, CURR BIOL, V9, P505, DOI 10.1016/S0960-9822(99)80234-6; TAKEDA A, 1992, J BIOL CHEM, V267, P16651; Tonks NK, 1996, CELL, V87, P365, DOI 10.1016/S0092-8674(00)81357-4; TRACY S, 1995, J BIOL CHEM, V270, P10587, DOI 10.1074/jbc.270.18.10587; Wallace MJ, 1998, MOL CELL BIOL, V18, P2608, DOI 10.1128/MCB.18.5.2608; Weiss A, 1998, CELL, V94, P277, DOI 10.1016/S0092-8674(00)81469-5; Wu L, 1997, J BIOL CHEM, V272, P6994, DOI 10.1074/jbc.272.11.6994; ZHENG XM, 1992, NATURE, V359, P336, DOI 10.1038/359336a0	28	152	158	1	10	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	OCT 7	1999	401	6753					606	610		10.1038/44170	http://dx.doi.org/10.1038/44170			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	244MG	10524630				2022-12-01	WOS:000083054900055
J	Remafedi, G				Remafedi, G			Sexual orientation and youth suicide	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Review							BISEXUAL YOUTH; RISK-FACTORS; GAY; ADOLESCENTS; BEHAVIOR; HOMOSEXUALITY; SAMPLE; MALES		Univ Minnesota, Sch Med, Minneapolis, MN 55455 USA	University of Minnesota System; University of Minnesota Twin Cities	Remafedi, G (corresponding author), Univ Minnesota, Sch Med, Minneapolis, MN 55455 USA.				PHS HHS [5-T71-MC-00006-22] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Bagley C, 1997, Crisis, V18, P24, DOI 10.1027/0227-5910.18.1.24; DAUGELLI AR, 1993, AM J COMMUN PSYCHOL, V21, P421, DOI 10.1007/BF00942151; DuRant RH, 1998, J PEDIATR-US, V133, P113, DOI 10.1016/S0022-3476(98)70189-1; Faulkner AH, 1998, AM J PUBLIC HEALTH, V88, P262, DOI 10.2105/AJPH.88.2.262; Garofalo R, 1999, ARCH PEDIAT ADOL MED, V153, P487; Garofalo R, 1998, PEDIATRICS, V101, P895, DOI 10.1542/peds.101.5.895; GIBSON P, 1989, US DEP HLTH HUM SERV, V3; HAMMELMAN TL, 1993, J GAY LESBIAN PSYCHO, V2, P77, DOI DOI 10.1300/J236V02N01_; HARRY J, 1983, J HEALTH SOC BEHAV, V24, P350, DOI 10.2307/2136401; Hershberger SL, 1997, J ADOLESCENT RES, V12, P477, DOI 10.1177/0743554897124004; HUNTER J, 1990, J INTERPERS VIOLENCE, V5, P295, DOI DOI 10.1177/088626090005003004; MUEHRER P, 1995, SUICIDE LIFE-THREAT, V25, P72, DOI 10.1111/j.1943-278X.1995.tb00492.x; Nicholas J., 1998, YOUTH STUDIES AUSTR, V17, P28; PROCTOR CD, 1994, SOC WORK, V39, P504, DOI 10.1093/sw/39.5.504; REMAFEDI G, 1991, PEDIATRICS, V87, P869; REMAFEDI G, 1987, PEDIATRICS, V79, P331; Remafedi G, 1998, AM J PUBLIC HEALTH, V88, P57, DOI 10.2105/AJPH.88.1.57; RICH CL, 1986, SUICIDE LIFE-THREAT, V16, P448; ROESLER T, 1972, J AMER MED ASSOC, V219, P1018, DOI 10.1001/jama.219.8.1018; ROTHERAMBORUS MJ, 1994, J ADOLESCENT RES, V9, P498, DOI 10.1177/074355489494007; SCHNEIDER SG, 1989, SUICIDE LIFE-THREAT, V19, P381; SHAFFER D, 1995, SUICIDE LIFE-THREAT, V25, P64, DOI 10.1111/j.1943-278X.1995.tb00491.x	22	54	55	0	2	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 6	1999	282	13					1291	1292		10.1001/jama.282.13.1291	http://dx.doi.org/10.1001/jama.282.13.1291			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	241UM	10517437	hybrid			2022-12-01	WOS:000082901100043
J	Smith, DE; Sjogren, WL; Tyler, GL; Balmino, G; Lemoine, FG; Konopliv, AS				Smith, DE; Sjogren, WL; Tyler, GL; Balmino, G; Lemoine, FG; Konopliv, AS			The gravity field of Mars: Results from Mars global surveyor	SCIENCE			English	Article							ORBITER LASER ALTIMETER; IMPACT BASINS; GIANT IMPACT; TOPOGRAPHY; DICHOTOMY; MISSION; MODEL; MOON	Observations of the gravity field of Mars reveal a planet that has responded differently in its northern and southern hemispheres to major impacts and volcanic processes. The rough, elevated southern hemisphere has a relatively featureless gravitational signature indicating a state of near-isostatic compensation, whereas the smooth, Low northern plains display a wider range of gravitational anomalies that indicates a thinner but stronger surface Layer than in the south. The northern hemisphere shows evidence for buried impact basins, although none large enough to explain the hemispheric elevation difference. The gravitational potential signature of Tharsis is approximately axisymmetric and contains the Tharsis Montes but not the Olympus Mons or Alba Patera volcanoes. The gravity signature of Valles Marineris extends into Chryse and provides an estimate of material removed by early fluvial activity.	NASA, Terr Phys Lab, Goddard Space Flight Ctr, Greenbelt, MD 20771 USA; CALTECH, Jet Prop Lab, Pasadena, CA 91109 USA; Stanford Univ, Ctr Radio Astron, Stanford, CA 94305 USA; Grp Rech Geodesie Spatiales, Toulouse, France	National Aeronautics & Space Administration (NASA); NASA Goddard Space Flight Center; California Institute of Technology; National Aeronautics & Space Administration (NASA); NASA Jet Propulsion Laboratory (JPL); Stanford University	Smith, DE (corresponding author), NASA, Terr Phys Lab, Goddard Space Flight Ctr, Greenbelt, MD 20771 USA.		Lemoine, Frank/D-1215-2013	Lemoine, Frank G./0000-0002-3051-1456				Acuna MH, 1999, SCIENCE, V284, P790, DOI 10.1126/science.284.5415.790; Albee AL, 1998, SCIENCE, V279, P1671, DOI 10.1126/science.279.5357.1671; Anderson S, 1998, J GEOPHYS RES-PLANET, V103, P11113, DOI 10.1029/98JE00740; BALMINO G, 1982, J GEOPHYS RES, V87, P9735, DOI 10.1029/JB087iB12p09735; BRATT SR, 1985, J GEOPHYS RES-SOLID, V90, P2415, DOI 10.1029/JB090iB14p12415; Carr M., 1981, SURFACE MARS; COMER RP, 1985, REV GEOPHYS, V23, P61, DOI 10.1029/RG023i001p00061; Connerney JEP, 1999, SCIENCE, V284, P794, DOI 10.1126/science.284.5415.794; Folkner WM, 1997, SCIENCE, V278, P1749, DOI 10.1126/science.278.5344.1749; FREY H, 1988, GEOPHYS RES LETT, V15, P229, DOI 10.1029/GL015i003p00229; Heiskanen W.A., 1967, PHYS GEODESY; Johnson C., UNPUB; Kaula W. M., 1966, THEORY SATELLITE GEO; Konopliv AS, 1998, SCIENCE, V281, P1476, DOI 10.1126/science.281.5382.1476; KONOPLIV AS, 1995, JPL PUBL, V955; Lemoine F., 1998, DEV JOINT NASA GSFC; MCGILL GE, 1989, J GEOPHYS RES-SOLID, V94, P2753, DOI 10.1029/JB094iB03p02753; Melosh H.J., 1989, IMPACT CRATERING GEO; Neumann GA, 1996, J GEOPHYS RES-PLANET, V101, P16841, DOI 10.1029/96JE01246; NEUMANN GA, 1997, LUNAR PLANET SCI C, V28, P1713; SCHULTZ RA, 1990, J GEOPHYS RES-SOLID, V95, P14175, DOI 10.1029/JB095iB09p14175; SENGOR AMC, 1978, GEOPHYS RES LETT, V5, P419, DOI 10.1029/GL005i006p00419; SJOGREN WL, 1999, EOS, V80, P204; Smith DE, 1999, SCIENCE, V284, P1495, DOI 10.1126/science.284.5419.1495; Smith DE, 1998, SCIENCE, V279, P1686, DOI 10.1126/science.279.5357.1686; SMITH DE, 1993, J GEOPHYS RES-PLANET, V98, P20871, DOI 10.1029/93JE01839; SMITH DE, 1999, EOS, V80, P204; SOLOMON SC, 1998, LUNAR PLANET SCI, V29, P1389; Turcotte D., 2014, GEODYNAMICS, P1, DOI [10.1017/CBO9780511843877, DOI 10.1017/CBO9780511843877]; TURCOTTE DL, 1981, J GEOPHYS RES, V86, P3951, DOI 10.1029/JB086iB05p03951; TYLER GL, 1992, J GEOPHYS RES-PLANET, V97, P7759, DOI 10.1029/92JE00513; WILHELMS DE, 1984, NATURE, V309, P138, DOI 10.1038/309138a0; Zuber MT, 1997, J GEOPHYS RES-PLANET, V102, P28673, DOI 10.1029/97JE02527; ZUBER MT, 1994, SCIENCE, V266, P1839, DOI 10.1126/science.266.5192.1839; Zuber MT, 1998, SCIENCE, V282, P2053, DOI 10.1126/science.282.5396.2053; Zuber MT, 1998, GEOPHYS RES LETT, V25, P4393, DOI 10.1029/1998GL900129; [No title captured]	37	112	116	1	14	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	OCT 1	1999	286	5437					94	97		10.1126/science.286.5437.94	http://dx.doi.org/10.1126/science.286.5437.94			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	241WT	10506567				2022-12-01	WOS:000082907400040
J	Minning, DM; Gow, AJ; Bonaventura, J; Braun, R; Dewhirst, M; Goldberg, DE; Stamler, JS				Minning, DM; Gow, AJ; Bonaventura, J; Braun, R; Dewhirst, M; Goldberg, DE; Stamler, JS			Ascaris haemoglobin is a nitric oxide-activated 'deoxygenase'	NATURE			English	Article							S-NITROSOHEMOGLOBIN; OXYGEN AVIDITY; HEMOGLOBIN; SUUM; FLAVOHEMOGLOBIN; SUPEROXIDE; BIOSYNTHESIS; EXPRESSION; GLOBIN; GENE	The parasitic nematode Ascaris lumbricoides infects one billion people worldwide. Its perienteric fluid contains an octameric haemoglobin(1-3) that binds oxygen nearly 25,000 times more tightly than does human haemoglobin(4,5). Despite numerous investigations, the biological function of this molecule has remained elusive. The distal haem pocket contains a metal, oxygen and thiol(6), all of which are known to be reactive with nitric oxide. Here we show that Ascaris haemoglobin enzymatically consumes oxygen in a reaction driven by nitric oxide, thus keeping the perienteric fluid hypoxic. The mechanism of this reaction involves unprecedented chemistry of a haem group, a thiol and nitric oxide. We propose that Ascaris haemoglobin functions as a 'deoxygenase', using nitric oxide to detoxify oxygen. The structural and functional adaptations of Ascaris haemoglobin suggest that the molecular evolution of haemoglobin can be rationalized by its nitric oxide related functions.	Duke Univ, Med Ctr, Dept Med, Durham, NC 27710 USA; Duke Univ, Med Ctr, Howard Hughes Med Inst, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Cell Biol, Durham, NC 27710 USA; Washington Univ, Sch Med, Howard Hughes Med Inst, Dep Mol Microbiol & Med, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Med, St Louis, MO 63110 USA; Duke Marine Biomed Ctr, Nicholas Sch Environm, Pivers Isl, NC 28516 USA	Duke University; Duke University; Howard Hughes Medical Institute; Duke University; Howard Hughes Medical Institute; Washington University (WUSTL); Washington University (WUSTL); Duke University	Stamler, JS (corresponding author), Duke Univ, Med Ctr, Dept Med, Durham, NC 27710 USA.		Gow, Andrew/N-8566-2013; Gow, Andrew/AAR-2309-2020; Dewhirst, Mark/Q-1302-2019	Gow, Andrew/0000-0003-0876-5158; Gow, Andrew/0000-0003-0876-5158; Dewhirst, Mark/0000-0003-3459-6546; Stamler, Jonathan/0000-0002-6866-1572	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [T32AI007172] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Balagopalakrishna C, 1996, BIOCHEMISTRY-US, V35, P6393, DOI 10.1021/bi952875+; Balagopalakrishna C, 1998, BIOCHEMISTRY-US, V37, P13194, DOI 10.1021/bi980941c; BASCAL ZA, 1995, J NEUROPHYSIOL, V74, P1880; BLAXTER ML, 1993, PARASITOL TODAY, V9, P353, DOI 10.1016/0169-4758(93)90082-Q; BOWMAN JW, 1995, J NEUROPHYSIOL, V74, P1880, DOI 10.1152/jn.1995.74.5.1880; Crawford MJ, 1998, J BIOL CHEM, V273, P12543, DOI 10.1074/jbc.273.20.12543; DARAWSHE S, 1987, BIOCHEM J, V242, P689, DOI 10.1042/bj2420689; DAVENPORT HE, 1949, PROC R SOC SER B-BIO, V136, P255, DOI 10.1098/rspb.1949.0024; DEBAERE I, 1992, P NATL ACAD SCI USA, V89, P4638, DOI 10.1073/pnas.89.10.4638; DEBAERE I, 1994, P NATL ACAD SCI USA, V91, P1594, DOI 10.1073/pnas.91.4.1594; Gardner PR, 1998, P NATL ACAD SCI USA, V95, P10378, DOI 10.1073/pnas.95.18.10378; Gow AJ, 1999, P NATL ACAD SCI USA, V96, P9027, DOI 10.1073/pnas.96.16.9027; Gow AJ, 1998, NATURE, V391, P169, DOI 10.1038/34402; GREEN LC, 1982, ANAL BIOCHEM, V126, P131, DOI 10.1016/0003-2697(82)90118-X; Hardison R, 1998, J EXP BIOL, V201, P1099; Hausladen A, 1998, P NATL ACAD SCI USA, V95, P14100, DOI 10.1073/pnas.95.24.14100; Jia L, 1996, NATURE, V380, P221, DOI 10.1038/380221a0; KLOEK AP, 1994, J BIOL CHEM, V269, P2377; KLOEK AP, 1993, J BIOL CHEM, V268, P17669; Landino LM, 1996, P NATL ACAD SCI USA, V93, P15069, DOI 10.1073/pnas.93.26.15069; Maccarrone M, 1997, FEBS LETT, V410, P470, DOI 10.1016/S0014-5793(97)00643-1; Nagashima S, 1998, NAT STRUCT BIOL, V5, P347, DOI 10.1038/nsb0598-347; OKAZAKI T, 1965, BIOCHIM BIOPHYS ACTA, V111, P503, DOI 10.1016/0304-4165(65)90060-7; Peterson ES, 1997, BIOCHEMISTRY-US, V36, P13110, DOI 10.1021/bi971156n; SHARMA VS, 1987, BIOCHEMISTRY-US, V26, P3837, DOI 10.1021/bi00387a015; SHERMAN DR, 1992, SCIENCE, V258, P1930, DOI 10.1126/science.1470914; SHERMAN DR, 1992, P NATL ACAD SCI USA, V89, P11696, DOI 10.1073/pnas.89.24.11696; Stamler JS, 1997, SCIENCE, V276, P2034, DOI 10.1126/science.276.5321.2034; YANG J, 1995, P NATL ACAD SCI USA, V92, P4224, DOI 10.1073/pnas.92.10.4224; Young WK, 1996, BRIT J CANCER, V74, pS256	30	182	192	0	15	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	SEP 30	1999	401	6752					497	502		10.1038/46822	http://dx.doi.org/10.1038/46822			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	243DF	10519555				2022-12-01	WOS:000082981200061
J	Macarthur, C; Saunders, N; Feldman, W; Ipp, M; Winders-Lee, P; Roberts, S; Best, L; Sherman, P; Pencharz, P; van Zanten, SV				Macarthur, C; Saunders, N; Feldman, W; Ipp, M; Winders-Lee, P; Roberts, S; Best, L; Sherman, P; Pencharz, P; van Zanten, SV			Helicobacter pylori and childhood recurrent abdominal pain: community based case-control study	BRITISH MEDICAL JOURNAL			English	Article							YOUNG MEN; MORTALITY; ALCOHOL		Univ Calgary, Hlth Sci Ctr, Dept Community Hlth Sci, Calgary, AB T2N 4N1, Canada; Hosp Sick Children, Dept Paediat, Toronto, ON M5G 1X8, Canada; Victoria Gen Hosp, Dept Microbiol, Halifax, NS B3H 2Y9, Canada	University of Calgary; University of Manitoba; Children's Hospital Research Institute of Manitoba; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); Dalhousie University; University of Victoria	Macarthur, C (corresponding author), Univ Calgary, Hlth Sci Ctr, Dept Community Hlth Sci, Calgary, AB T2N 4N1, Canada.			Sherman, Philip/0000-0002-4733-6690				*ADD RES FDN ONT C, 1994, CAN MED ASS J S, V151; ANDERSON P, 1995, ALCOHOL PUBLIC POLIC, P82; ANDREASSON S, 1988, BRIT MED J, V296, P1021, DOI 10.1136/bmj.296.6628.1021; ANDREASSON S, 1991, BRIT J ADDICT, V86, P877; Edwards G., 1994, ALCOHOL POLICY PUBLI; KAPLAN GA, 1993, SOCIOECONOMIC FACTOR; *NAT BOARD HLTH WE, 1996, DODS 1994; *NAT BOARD HLTH WE, 1996, PAT 1987 1994 KVAL I; Rothman KJ., 2008, MODERN EPIDEMIOLOGY, V3	9	40	43	1	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	SEP 25	1999	319	7213					822	+		10.1136/bmj.319.7213.822	http://dx.doi.org/10.1136/bmj.319.7213.822			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	241CR	10496827	Bronze, Green Published			2022-12-01	WOS:000082865200025
J	Johnson, RD; Liu, N; Jasin, M				Johnson, RD; Liu, N; Jasin, M			Mammalian XRCC2 promotes the repair of DNA double-strand breaks by homologous recombination	NATURE			English	Article							EMBRYONIC STEM-CELLS; IONIZING-RADIATION; RAD57 PROTEINS; GENE; RESISTANCE; ENDONUCLEASE; DISRUPTION; EXPRESSION; MEMBER; FAMILY	The repair of DNA double-strand breaks is essential for cells to maintain their genomic integrity. Two major mechanisms are responsible for repairing these breaks in mammalian cells, nonhomologous end-joining (NHEJ) and homologous recombination (HR)(1,2): the importance of the former in mammalian cells is well established(3), whereas the role of the latter is just emerging, Homologous recombination is presumably promoted by an evolutionarily conserved group of genes termed the Rad52 epistasis (4-11). An essential component of the HR pathway is the group strand-exchange protein, known as RecA in bacteria(8) or Rad51 in yeast(6). Several mammalian genes have been implicated in repair by homologous recombination on the basis of their sequence homology to yeast Rad51 (ref. 11): one of these is human XRCC2 (refs 12, 13). Here we show that XRCC2 is essential for the efficient repair of DNA double-strand breaks by homologous recombination between sister chromatids, We find that hamster cells deficient in XRCC2 show more than a 100-fold decrease in HR induced by double-strand breaks compared with the parental cell line. This defect is corrected to almost wild-type levels by transient transfection with a plasmid expressing XRCC2. The repair defect in XRCC2 mutant cells appears to be restricted to recombinational repair because NHEJ is normal. We conclude that XRCC2 is involved in the repair of DNA double-strand breaks by homologous recombination.	Mem Sloan Kettering Canc Ctr, Cell Biol Program, New York, NY 10021 USA; Cornell Univ, Grad Sch Med Sci, New York, NY 10021 USA; Lawrence Livermore Natl Lab, Biol & Biotechnol Res Program, Livermore, CA 94551 USA	Memorial Sloan Kettering Cancer Center; Cornell University; United States Department of Energy (DOE); Lawrence Livermore National Laboratory	Jasin, M (corresponding author), Mem Sloan Kettering Canc Ctr, Cell Biol Program, 1275 York Ave, New York, NY 10021 USA.	m-jasin@ski.mskcc.org						Baumann P, 1996, CELL, V87, P757, DOI 10.1016/S0092-8674(00)81394-X; Bezzubova O, 1997, CELL, V89, P185, DOI 10.1016/S0092-8674(00)80198-1; Cartwright R, 1998, NUCLEIC ACIDS RES, V26, P3084, DOI 10.1093/nar/26.13.3084; CHEONG N, 1994, MUTAT RES, V314, P77, DOI 10.1016/0921-8777(94)90063-9; Donoho G, 1998, MOL CELL BIOL, V18, P4070, DOI 10.1128/MCB.18.7.4070; Dosanjh MK, 1998, NUCLEIC ACIDS RES, V26, P1179, DOI 10.1093/nar/26.5.1179; Essers J, 1997, CELL, V89, P195, DOI 10.1016/S0092-8674(00)80199-3; HAYS SL, 1995, P NATL ACAD SCI USA, V92, P6925, DOI 10.1073/pnas.92.15.6925; JASIN M, DNA DAMAGE REPAIR, V3; Jeggo PA, 1998, ADV GENET, V38, P185, DOI 10.1016/S0065-2660(08)60144-3; JOHNSON RD, 1995, MOL CELL BIOL, V15, P4843; JONES NJ, 1987, MUTAT RES, V183, P279, DOI 10.1016/0167-8817(87)90011-3; Kinzler KW, 1997, NATURE, V386, P761, DOI 10.1038/386761a0; Liang F, 1998, P NATL ACAD SCI USA, V95, P5172, DOI 10.1073/pnas.95.9.5172; Liang F, 1996, P NATL ACAD SCI USA, V93, P8929, DOI 10.1073/pnas.93.17.8929; Lim DS, 1996, MOL CELL BIOL, V16, P7133; LIU BL, 1983, PUBL PURPLE MOUNTAIN, V2, P1; Nickoloff JA, 1998, CONT CANC RES, P335; Rijkers T, 1998, MOL CELL BIOL, V18, P6423, DOI 10.1128/MCB.18.11.6423; ROUET P, 1994, MOL CELL BIOL, V14, P8096, DOI 10.1128/MCB.14.12.8096; ROUET P, 1994, P NATL ACAD SCI USA, V91, P6064, DOI 10.1073/pnas.91.13.6064; Smih F, 1995, NUCLEIC ACIDS RES, V23, P5012, DOI 10.1093/nar/23.24.5012; Smith GR, 1998, CONT CANC RES, P135; Sonoda E, 1998, EMBO J, V17, P598, DOI 10.1093/emboj/17.2.598; Sung P, 1997, GENE DEV, V11, P1111, DOI 10.1101/gad.11.9.1111; Thacker J, 1999, TRENDS GENET, V15, P166, DOI 10.1016/S0168-9525(99)01733-3; Tsuzuki T, 1996, P NATL ACAD SCI USA, V93, P6236, DOI 10.1073/pnas.93.13.6236; Vogelstein B., 1998, GENETIC BASIS HUMAN; Yamaguchi-Iwai Y, 1998, MOL CELL BIOL, V18, P6430, DOI 10.1128/MCB.18.11.6430	29	277	295	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	SEP 23	1999	401	6751					397	399		10.1038/43935	http://dx.doi.org/10.1038/43935			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	240JJ	10517641	Bronze			2022-12-01	WOS:000082822600057
J	Floyd, K; Reid, RA; Wilkinson, D; Gilks, CF				Floyd, K; Reid, RA; Wilkinson, D; Gilks, CF			Admission trends in a rural south African hospital during the early years of the HIV epidemic	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							RESOURCE UTILIZATION; DRUG-USERS; TUBERCULOSIS; INFECTION; RISK; IMPACT; DISTRICT; NAIROBI; COHORT; WOMEN	Context Few studies have attempted to quantify the effect of the epidemic of human immunodeficiency virus (HIV)/acquired immunodeficiency syndrome (AIDS) on demand for health care in developing countries. More data are required to improve understanding of its impact and to guide development of appropriate response strategies. Objective To assess the HIV/AIDS epidemic's impact on demand for inpatient hospital care in a rural area of South Africa. Design Retrospective analysis of data from general hospital and individual ward admission registers, a tuberculosis program database, and patient case notes. Setting and Patients Patients admitted between 1991 and 1998 to a 450-bed hospital that serves Hlabisa District, South Africa (population approximate to 200 000), where HIV seroprevalence among antenatal clinic attendees increased from 4% in 1992 to 29% in 1998, Main Outcome Measures Number of admissions to 9 hospital wards, number of clinical AIDS and general medical admissions (both excluding tuberculosis), and number of tuberculosis admissions to adult medical wards during the study period. Results Total hospital admissions increased by 81%, from 6562 in 1991 to 11 872 in 1998, Adult tuberculosis ward admissions increased by 360%, from 303 to 1393, In 1998, tuberculosis patients accounted for 47% and 30% of adult male and female medical ward admissions, respectively, and for 11% of total hospital admissions. Nontuberculosis clinical AIDS cases increased 43-fold, accounting for 4% of adult medical admissions in 1997 vs 0.2% in 1991. Tuberculosis and nontuberculosis clinical AIDS cases were the only types of admission to show a clear and consistent upward trend over the period studied. Patterns in other types of admissions varied more and changes were smaller. Conclusions The HIV/AIDS epidemic has had an important impact on demand for adult tuberculosis and general medical care in a rural South African district hospital. If this impact is shown to extend to other rural South African areas, response strategies are urgently needed.	Univ Liverpool, Liverpool Sch Trop Med, Div Trop Med, Liverpool L3 5QA, Merseyside, England; Hlabisa Hosp, Hlabisa, South Africa; MRC, Ctr Epidemiol Res S Africa, Mtubatuba, South Africa	Liverpool School of Tropical Medicine; University of Liverpool	Floyd, K (corresponding author), Univ Liverpool, Liverpool Sch Trop Med, Div Trop Med, Liverpool L3 5QA, Merseyside, England.	kfloyd@liverpool.ac.uk	Wilkinson, David/A-6207-2008; Gilks, Charles/B-4184-2012	Wilkinson, David/0000-0002-7265-9846; Gilks, Charles/0000-0002-8953-3123				ALLEN S, 1992, AM REV RESPIR DIS, V146, P1439, DOI 10.1164/ajrccm/146.6.1439; [Anonymous], 1997, HUM DEV REP 1997; ARTHUR G, 1998, 12 WORLD AIDS C JUN; BRAUN MM, 1991, AM REV RESPIR DIS, V143, P501, DOI 10.1164/ajrccm/143.3.501; BUVE AMA, 1992, 8 INT C AIDS JUL 19, V2; Coleman RL, 1997, J ACQ IMMUN DEF SYND, V16, P50, DOI 10.1097/00042560-199709010-00008; DUNN DT, 1992, LANCET, V87, P456; FOSTER SD, 1993, COST BURDEN AIDS ZAM; GILKS CF, 1992, Q J MED, V82, P25; Harries A, 1996, TB HIV CLIN MANUAL; Harries AD, 1997, ANN TROP MED PARASIT, V91, P771, DOI 10.1080/00034989760527; HASSIG SE, 1990, AIDS, V4, P883, DOI 10.1097/00002030-199009000-00009; HAWKEN M, 1993, LANCET, V342, P332, DOI 10.1016/0140-6736(93)91474-Z; KARSTAEDT AS, 1996, S AFR MED J, V86, P1490; KING R, 1994, T ROY SOC TROP MED H, V88, P295, DOI 10.1016/0035-9203(94)90083-3; MORENO S, 1993, ANN INTERN MED, V119, P194, DOI 10.7326/0003-4819-119-3-199308010-00003; NUNN P, 1993, TUBERCLE LUNG DIS, V74, P273, DOI 10.1016/0962-8479(93)90054-2; OKELLO DO, 1994, E AFR MED J, V71, P816; *REP S AFR DEP HLT, 1996, EPIDEMIOLOGICAL COMM, V23, P4; SELWYN PA, 1989, NEW ENGL J MED, V320, P545, DOI 10.1056/NEJM198903023200901; SELWYN PA, 1992, JAMA-J AM MED ASSOC, V268, P504, DOI 10.1001/jama.268.4.504; SMITH PG, 1994, TUBERCULOSIS PATHOGE, pCH4; *STAT CORP, 1999, STAT STAT SOFTW COMP; TEMBO G, 1994, AIDS, V8, P1169, DOI 10.1097/00002030-199408000-00021; *UNAIDS, UNAIDS9810; WILKINSON D, 1994, LANCET, V343, P647, DOI 10.1016/S0140-6736(94)92640-9; Wilkinson D, 1997, T ROY SOC TROP MED H, V91, P420, DOI 10.1016/S0035-9203(97)90263-7; Wilkinson D, 1997, AIDS, V11, P377, DOI 10.1097/00002030-199703110-00016; Wilkinson D, 1997, S AFR MED J, V87, P447; YEUNG S, IN PRESS J TROP PAED	30	45	45	0	4	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 15	1999	282	11					1087	1091		10.1001/jama.282.11.1087	http://dx.doi.org/10.1001/jama.282.11.1087			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	234YQ	10493210				2022-12-01	WOS:000082512300036
J	[Anonymous]				[Anonymous]			Perinatal HIV prevention	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	News Item																			0	1	1	0	1	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 18	1999	282	7					625	625		10.1001/jama.282.7.625	http://dx.doi.org/10.1001/jama.282.7.625			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	226QY	10532854				2022-12-01	WOS:000082033700005
J	Ernst, RK; Yi, EC; Guo, L; Lim, KB; Burns, JL; Hackett, M; Miller, SI				Ernst, RK; Yi, EC; Guo, L; Lim, KB; Burns, JL; Hackett, M; Miller, SI			Specific lipopolysaccharide found in cystic fibrosis airway Pseudomonas aeruginosa	SCIENCE			English	Article							LIPID-A; SALMONELLA-TYPHIMURIUM; ESCHERICHIA-COLI; REGULATED GENES; PHOP-PHOQ; RESISTANCE; QUADRUPOLE; VIRULENCE; PEPTIDES; MUTANT	Cystic fibrosis (CF) patients develop chronic airway infections with Pseudomonas aeruginosa (PA), Pseudomonas aeruginosa synthesized lipopolysaccharide (LPS) with a variety of penta- and hexa-acylated lipid A structures under different environmental conditions. CF patient PA synthesized LPS with specific Lipid A structures indicating unique recognition of the CF airway environment. CF-specific Lipid A forms containing palmitate and aminoarabinose were associated with resistance to cationic antimicrobial peptides and increased inflammatory responses, indicating that they are likely to be involved in airway disease.	Univ Washington, Dept Med, Seattle, WA 98195 USA; Univ Washington, Dept Microbiol, Seattle, WA 98195 USA; Univ Washington, Dept Med Chem, Seattle, WA 98195 USA; Univ Washington, Dept Pediat, Seattle, WA 98195 USA	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle	Miller, SI (corresponding author), Univ Washington, Dept Med, Seattle, WA 98195 USA.	millersi@u.washingtan.edu		Ernst, Robert/0000-0001-5016-8694	NHLBI NIH HHS [R55 HL 48888] Funding Source: Medline; PHS HHS [R21 R13400] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R55HL048888] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		*AM SOC MASS SPECT, 1998, P 46 ASMS C MASS SPE; [Anonymous], 1997, NIH Consens Statement, V15, P1; Basu SS, 1999, J BIOL CHEM, V274, P11150, DOI 10.1074/jbc.274.16.11150; BELL A, 1989, J BACTERIOL, V171, P3211, DOI 10.1128/jb.171.6.3211-3217.1989; BHAT R, 1990, J BACTERIOL, V172, P6631, DOI 10.1128/jb.172.12.6631-6636.1990; BIER ME, 1997, ELECTROSPRAY IONIZAT, P235; CAROFF M, 1988, CARBOHYD RES, V175, P273, DOI 10.1016/0008-6215(88)84149-1; DARVEAU RP, 1995, INFECT IMMUN, V63, P1311, DOI 10.1128/IAI.63.4.1311-1317.1995; DARVEAU RP, 1992, J CLIN INVEST, V90, P447, DOI 10.1172/JCI115880; DARVEAU RP, 1983, J BACTERIOL, V155, P831, DOI 10.1128/JB.155.2.831-838.1983; ERNST RK, UNPUB; GOLDMAN RC, 1988, J BIOL CHEM, V263, P5217; Govan JRW, 1996, MICROBIOL REV, V60, P539, DOI 10.1128/MMBR.60.3.539-574.1996; Gunn JS, 1996, J BACTERIOL, V178, P6369, DOI 10.1128/jb.178.21.6369-6373.1996; Gunn JS, 1996, J BACTERIOL, V178, P6857, DOI 10.1128/jb.178.23.6857-6864.1996; Gunn JS, 1998, MOL MICROBIOL, V27, P1171, DOI 10.1046/j.1365-2958.1998.00757.x; Guo L, 1998, CELL, V95, P189, DOI 10.1016/S0092-8674(00)81750-X; Guo L, 1997, SCIENCE, V276, P250, DOI 10.1126/science.276.5310.250; Hancock R E, 1995, Adv Microb Physiol, V37, P135, DOI 10.1016/S0065-2911(08)60145-9; Jonscher KR, 1997, ANAL BIOCHEM, V244, P1, DOI 10.1006/abio.1996.9877; KARUNARATNE DN, 1992, ARCH BIOCHEM BIOPHYS, V299, P368, DOI 10.1016/0003-9861(92)90289-9; KULSHIN VA, 1991, EUR J BIOCHEM, V198, P697, DOI 10.1111/j.1432-1033.1991.tb16069.x; MILLER SI, 1989, P NATL ACAD SCI USA, V86, P5054, DOI 10.1073/pnas.86.13.5054; NUMMILA K, 1995, MOL MICROBIOL, V16, P271, DOI 10.1111/j.1365-2958.1995.tb02299.x; RAETZ CRH, 1996, ESCHERICHIA COLI SAL, P1035; Somerville JE, 1996, J CLIN INVEST, V97, P359, DOI 10.1172/JCI118423; Soncini FC, 1996, J BACTERIOL, V178, P5092, DOI 10.1128/jb.178.17.5092-5099.1996; Steinberg DA, 1997, ANTIMICROB AGENTS CH, V41, P1738, DOI 10.1128/AAC.41.8.1738; Vescovi EG, 1996, CELL, V84, P165, DOI 10.1016/S0092-8674(00)81003-X; Wang HL, 1998, ANAL CHEM, V70, P205, DOI 10.1021/ac971036l; Wong P.S., 1997, CURRENT SEPARATIONS, V16, P85; Xu NX, 1997, J AM SOC MASS SPECTR, V8, P116, DOI 10.1016/S1044-0305(96)00233-4; Yi E., UNPUB; YOST RA, 1990, METHOD ENZYMOL, V193, P154, DOI 10.1016/0076-6879(90)93415-H	34	386	398	2	47	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 19	1999	286	5444					1561	1565		10.1126/science.286.5444.1561	http://dx.doi.org/10.1126/science.286.5444.1561			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	257DZ	10567263				2022-12-01	WOS:000083768300059
J	Osmond, DH; Bindman, AB; Vranizan, K; Lehman, JS; Hecht, FM; Keane, D; Reingold, A				Osmond, DH; Bindman, AB; Vranizan, K; Lehman, JS; Hecht, FM; Keane, D; Reingold, A		Multistate Evaluation Surveillance	Name-based surveillance and public health interventions for persons with HIV infection	ANNALS OF INTERNAL MEDICINE			English	Article							PARTNER NOTIFICATION; EPIDEMIC	Name-based surveillance of HIV infection is the law in 31 U.S. states but remains controversial, This policy can be advocated solely to support surveillance of the epidemic, but a frequent argument is that it also provides a public health benefit by allowing follow-up of HIV-infected persons. These persons can then receive timely medical care and can be assisted with notifying sex and needle-sharing partners. Few comparative data are available to evaluate the outcomes of these interventions, In five states with name-based surveillance of HIV infection, the Multistate Evaluation of Surveillance for HIV Study Group surveyed a cross-sectional probability sample of persons with AIDS who tested positive for HIV before the date of their AIDS diagnosis, Health department follow-up of a reported HIV infection was not associated with more timely receipt of medical care after a positive HIV test result. Only 8.6% of persons who delayed medical care after their first positive HIV test result gave concern about being reported by name as a reason; no person gave it as the main reason. Persons who were tested anonymously and those who were tested confidentially did not differ in the mean number of sex and needle-sharing partners notified: Those tested anonymously reported personally notifying 3.85 sex and needle-sharing partners, and those tested confidentially reported notifying-personally and through the health department-3.80 partners. Many researchers and policymakers believe that name-based surveillance of HIV infection will have positive or negative effects on partner notification and access to health care, These results suggest that the potential for such effects has been exaggerated.	Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94143 USA	University of California System; University of California San Francisco	Osmond, DH (corresponding author), Univ Calif San Francisco, Dept Epidemiol & Biostat, Box 0866, San Francisco, CA 94143 USA.	dosmond@psg.ucsf.edu		Hecht, Frederick/0000-0002-5782-1171				ANDRUS JK, 1990, ANN INTERN MED, V112, P539, DOI 10.7326/0003-4819-112-7-539; Bindman AB, 1998, JAMA-J AM MED ASSOC, V280, P1416, DOI 10.1001/jama.280.16.1416; Colfax GN, 1998, AM J PUBLIC HEALTH, V88, P876, DOI 10.2105/AJPH.88.6.876; *COUNC STAT TERR E, 1997, POSITION STATEMENT N; Cowan FM, 1996, GENITOURIN MED, V72, P247; FIUMARAN, 1957, NEW ENGL J MED, V256, P982; FRANCIS DP, 1993, J ACQ IMMUN DEF SYND, V6, P285; GERTIG DM, 1991, AIDS, V5, P1157, DOI 10.1097/00002030-199110000-00001; Gostin LO, 1997, NEW ENGL J MED, V337, P1162, DOI 10.1056/NEJM199710163371611; HIRANO D, 1994, AM J PUBLIC HEALTH, V84, P2008, DOI 10.2105/AJPH.84.12.2008; HOFFMAN RE, 1995, J ACQ IMMUN DEF SYND, V8, P406; LANDIS SE, 1992, NEW ENGL J MED, V326, P101, DOI 10.1056/NEJM199201093260205; OXMAN AD, 1994, CAN J PUBLIC HEALTH, V85, pS41; PAVIA AT, 1993, AM J PUBLIC HEALTH, V83, P1418, DOI 10.2105/AJPH.83.10.1418; POTTERAT JJ, 1977, AM J PUBLIC HEALTH, V67, P174, DOI 10.2105/AJPH.67.2.174; Steinbrook LD, 1997, NEW ENGL J MED, V337, P779, DOI 10.1056/NEJM199709113371109; WYKOFF RF, 1988, JAMA-J AM MED ASSOC, V259, P3563, DOI 10.1001/jama.259.24.3563; 1998, MMWR MORB MORTAL WKL, V47, P1086; 1992, MMWR MORB MORTAL WKL, V41, P247; 1998, MMWR MORB MORTAL WKL, V47, P309; 1998, MMWR MORB MORTAL WKL, V46, P1254	21	37	38	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	NOV 16	1999	131	10					775	779		10.7326/0003-4819-131-10-199911160-00010	http://dx.doi.org/10.7326/0003-4819-131-10-199911160-00010			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	255QC	10577302				2022-12-01	WOS:000083680100009
J	Taylor, KA; Schmitz, H; Reedy, MC; Goldman, YE; Franzini-Armstrong, C; Sasaki, H; Tregear, RT; Poole, K; Lucaveche, C; Edwards, RJ; Chen, LF; Winkler, H; Reedy, MK				Taylor, KA; Schmitz, H; Reedy, MC; Goldman, YE; Franzini-Armstrong, C; Sasaki, H; Tregear, RT; Poole, K; Lucaveche, C; Edwards, RJ; Chen, LF; Winkler, H; Reedy, MK			Tomographic 3D reconstruction of quick-frozen, Ca2+-activated contracting insect flight muscle	CELL			English	Article							RABBIT SKELETAL-MUSCLE; MYOSIN HEADS; CROSS-BRIDGES; LIGHT-CHAIN; 3-DIMENSIONAL STRUCTURE; ELECTRON-MICROSCOPY; FORCE GENERATION; FISH MUSCLE; ADP RELEASE; ACTIN	Motor actions of myosin were directly visualized by electron tomography of insect flight muscle quick-frozen during contraction. In 3D images, active crossbridges are usually single myosin heads, bound preferentially to actin target zones sited midway between troponins. Active attached bridges (similar to 30% of all heads) depart markedly in axial and azimuthal angles from Rayment's rigor acto-S1 model, one-third requiring motor domain (MD) tilting on actin, and two-thirds keeping rigor contact with actin while the light chain domain (LCD) tilts axially from similar to 105 degrees to similar to 70 degrees. The results suggest the MD tilts and slews on actin from weak to strong binding, followed by swinging of the LCD through an similar to 35 degrees axial angle, giving an similar to 13 nm interaction distance and an similar to 4-6 nm working stroke.	Florida State Univ, Inst Mol Biophys, Tallahassee, FL 32306 USA; Univ Penn, Penn Muscle Inst, Philadelphia, PA 19104 USA; MRC, Mol Biol Lab, Cambridge CB2 2QH, England; Duke Univ, Med Ctr, Dept Cell Biol, Durham, NC 27710 USA; Max Planck Inst Med Forsch, Biophys Abt, D-69120 Heidelberg, Germany	State University System of Florida; Florida State University; University of Pennsylvania; MRC Laboratory Molecular Biology; Duke University; Max Planck Society	Taylor, KA (corresponding author), Florida State Univ, Inst Mol Biophys, Tallahassee, FL 32306 USA.			Edwards, Robert/0000-0003-4446-1194; Sasaki, Hiroyuki/0000-0002-5358-5853	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR014317] Funding Source: NIH RePORTER; NIAMS NIH HHS [R01 AR014317] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Adhikari B, 1997, P NATL ACAD SCI USA, V94, P9643, DOI 10.1073/pnas.94.18.9643; Bershitsky SY, 1997, NATURE, V388, P186, DOI 10.1038/40651; Brenner B., 1990, MUSCLE MECH BIOLOGIC, P77; Conibear PB, 1998, BIOPHYS J, V75, P926, DOI 10.1016/S0006-3495(98)77581-2; Cooke R, 1997, PHYSIOL REV, V77, P671, DOI 10.1152/physrev.1997.77.3.671; Corrie JET, 1999, NATURE, V400, P425, DOI 10.1038/22704; DANTZIG JA, 1992, J PHYSIOL-LONDON, V451, P247, DOI 10.1113/jphysiol.1992.sp019163; Dobbie I, 1998, NATURE, V396, P383, DOI 10.1038/24647; Dominguez R, 1998, CELL, V94, P559, DOI 10.1016/S0092-8674(00)81598-6; FLICKER PF, 1982, J MOL BIOL, V162, P495, DOI 10.1016/0022-2836(82)90540-X; Frank J, 1992, ELECT TOMOGRAPHY; Goldman YE, 1998, CELL, V93, P1, DOI 10.1016/S0092-8674(00)81137-X; Gulick AM, 1997, BIOESSAYS, V19, P561, DOI 10.1002/bies.950190707; GUTH K, 1986, PFLUG ARCH EUR J PHY, V407, P552, DOI 10.1007/BF00657515; HARFORD JJ, 1992, BIOPHYS J, V63, P387, DOI 10.1016/S0006-3495(92)81613-2; HEINRICH B, 1996, HTERMAL WARRIORS STR, P127; HIROSE K, 1993, J MUSCLE RES CELL M, V14, P432, DOI 10.1007/BF00121295; HIROSE K, 1994, J CELL BIOL, V127, P763, DOI 10.1083/jcb.127.3.763; HOLMES KC, 1990, NATURE, V347, P44, DOI 10.1038/347044a0; Holmes KC, 1996, CURR OPIN STRUC BIOL, V6, P781, DOI 10.1016/S0959-440X(96)80008-X; Hopkins SC, 1998, BIOPHYS J, V74, P3093, DOI 10.1016/S0006-3495(98)78016-6; Houdusse A, 1999, CELL, V97, P459, DOI 10.1016/S0092-8674(00)80756-4; IRVING M, 1995, NATURE, V375, P688, DOI 10.1038/375688a0; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; JONTES JD, 1995, NATURE, V378, P751, DOI 10.1038/378751a0; Lenart TD, 1996, BIOPHYS J, V71, P2289, DOI 10.1016/S0006-3495(96)79464-X; LOMBARDI V, 1995, NATURE, V374, P553, DOI 10.1038/374553a0; MOLLOY JE, 1995, NATURE, V378, P209, DOI 10.1038/378209a0; MORRIS EP, 1991, J STRUCT BIOL, V107, P237, DOI 10.1016/1047-8477(91)90049-3; OSTAP EM, 1995, BIOPHYS J, V69, P177, DOI 10.1016/S0006-3495(95)79888-5; RAYMENT I, 1993, SCIENCE, V261, P58, DOI 10.1126/science.8316858; RAYMENT I, 1993, SCIENCE, V261, P50, DOI 10.1126/science.8316857; REEDY MC, 1994, J MOL BIOL, V239, P52, DOI 10.1006/jmbi.1994.1350; REEDY MC, 1988, J MOL BIOL, V204, P357, DOI 10.1016/0022-2836(88)90582-7; REEDY MK, 1985, J MOL BIOL, V185, P145, DOI 10.1016/0022-2836(85)90188-3; REEDY MK, 1968, J MOL BIOL, V31, P155, DOI 10.1016/0022-2836(68)90437-3; REEDY MK, 1993, ADV EXP MED BIOL, V332, P33; Schmitz H, 1996, J MOL BIOL, V264, P279, DOI 10.1006/jmbi.1996.0641; Schmitz H, 1997, J CELL BIOL, V139, P695, DOI 10.1083/jcb.139.3.695; Taylor KA, 1997, J STRUCT BIOL, V120, P372, DOI 10.1006/jsbi.1997.3932; Tregear RT, 1998, BIOPHYS J, V74, P1439, DOI 10.1016/S0006-3495(98)77856-7; Tsaturyan AK, 1999, BIOPHYS J, V77, P354, DOI 10.1016/S0006-3495(99)76895-5; VARRIANOMARSTON E, 1984, J MUSCLE RES CELL M, V5, P363, DOI 10.1007/BF00818256; Walker M, 1999, P NATL ACAD SCI USA, V96, P465, DOI 10.1073/pnas.96.2.465; Wendt T, 1997, J STRUCT BIOL, V118, P1, DOI 10.1006/jsbi.1996.3834; WHITTAKER M, 1995, NATURE, V378, P748, DOI 10.1038/378748a0; Winkler H, 1996, J MOL BIOL, V264, P302, DOI 10.1006/jmbi.1996.0642; Winkler H, 1996, ULTRAMICROSCOPY, V63, P125, DOI 10.1016/0304-3991(96)00024-1; Wong WNW, 1999, BIOCHEMISTRY-US, V38, P1365, DOI 10.1021/bi982467g	49	134	137	0	6	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	NOV 12	1999	99	4					421	431		10.1016/S0092-8674(00)81528-7	http://dx.doi.org/10.1016/S0092-8674(00)81528-7			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	256CX	10571184	Bronze			2022-12-01	WOS:000083709300009
J	Aurora, P; Whitehead, B; Wade, A; Bowyer, J; Whitmore, P; Rees, PG; Tsang, VT; Elliott, MJ; de Leval, M				Aurora, P; Whitehead, B; Wade, A; Bowyer, J; Whitmore, P; Rees, PG; Tsang, VT; Elliott, MJ; de Leval, M			Lung transplantation and life extension in children with cystic fibrosis	LANCET			English	Article							HEART; SURVIVAL	Background Lung transplantation has been available as therapy for end-stage lung disease since the early 1980s, but survival after transplantation remains poor, with continued controversy as to the survival benefit from the procedure. We examined the effect of lung or heart-lung transplantation on the survival of a cohort of children with cystic fibrosis and severe lung disease. Methods Between May, 1988, and May, 1998, 124 children with cystic fibrosis were accepted for lung transplantation. 47 received transplants, 68 died while they awaited organs, and nine remained on the active waiting list. We constructed a proportional-hazards model that used variables of prognostic significance in this population. By including transplant status as a time-dependent covariate, we were able to calculate a hazard ratio for transplantation. Date of entry into the study was the dale when children were added to the list for transplantation, and measurements were taken at this time. Children were accepted for transplantation if they had a life expectancy of 2 years or less, a poor quality of life, and no contraindications to transplantation. Findings After 1 year, 35 (74%) children were still alive; after 5 years 12 (33%) children were alive. The univariate hazard ratio for transplantation was 0.41 (95% CI 0.23-0.74; p=0.003). Transplantation remained significantly associated with survival after correction for differences in age, sex, height-corrected forced expiratory volume in 1 s, minimum oxygen saturation during a 12 min walk, haemoglobin concentration, albumin concentration, and age-corrected resting heart rate (hazard ratio 0.31 [0.13-0.72]; p=0.007). Interpretation If centres follow our criteria for accepting patients for transplantation, and achieve similar survival after transplantation, they could expect a survival benefit for their patients in line with our results.	Great Ormond St Hosp Children NHS Trust, Cardioresp & Crit Care Directorate, London WC1N 3JH, England; Greenwich Hosp, Inst Child Hlth, London, England; Greenwich Hosp, Dept Paediat, London, England	University of London; University College London; Great Ormond Street Hospital for Children NHS Foundation Trust; University of London; University College London	Aurora, P (corresponding author), Great Ormond St Hosp Children, Resp Unit, Cardiac Wing, Level 6, London WC1N 3JH, England.		Elliott, Martin J/E-9229-2010	Elliott, Martin J/0000-0002-3913-9099				Cox DR., 1984, ANAL SURVIVAL DATA; Geertsma A, 1998, J HEART LUNG TRANSPL, V17, P511; Hosenpud JD, 1998, LANCET, V351, P24, DOI 10.1016/S0140-6736(97)06405-2; Hosenpud JD, 1997, J HEART LUNG TRANSPL, V16, P691; Kalbfleish JD, 1980, STAT ANAL FAILURE TI; KEREM E, 1992, NEW ENGL J MED, V326, P1187, DOI 10.1056/NEJM199204303261804; Mankad Pankaj S., 1997, P167; Milla CE, 1998, CHEST, V113, P1230, DOI 10.1378/chest.113.5.1230; ROSENTHAL M, 1993, THORAX, V48, P794, DOI 10.1136/thx.48.8.794; SHARPLES L, 1993, J HEART LUNG TRANSPL, V12, P669; TURNBULL BW, 1974, J AM STAT ASSOC, V69, P74, DOI 10.2307/2285502; WHITEHEAD BF, 1995, EUR J CARDIO-THORAC, V9, P1, DOI 10.1016/S1010-7940(05)80040-5	12	74	75	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	NOV 6	1999	354	9190					1591	1593		10.1016/S0140-6736(99)03031-7	http://dx.doi.org/10.1016/S0140-6736(99)03031-7			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	253HM	10560673				2022-12-01	WOS:000083551000010
J	Tan, Y; Li, WH				Tan, Y; Li, WH			Vision - Trichromatic vision in prosimians	NATURE			English	Article							COLOR-VISION; BUSH-BABY; PIGMENTS; PHOTOPIGMENTS; MONKEY; GENE; RED		Univ Chicago, Dept Ecol & Evolut, Chicago, IL 60637 USA	University of Chicago	Tan, Y (corresponding author), Univ Chicago, Dept Ecol & Evolut, 1101 E 57th St, Chicago, IL 60637 USA.			Li, Wen-Hsiung/0000-0003-1086-1456				ASENJO AB, 1994, NEURON, V12, P1131, DOI 10.1016/0896-6273(94)90320-4; Casagrande Vivien A., 1994, Cerebral Cortex, V10, P201; Deegan JF, 1996, AM J PRIMATOL, V40, P55, DOI 10.1002/(SICI)1098-2345(1996)40:1<55::AID-AJP4>3.0.CO;2-#; HUNT DM, 1993, VISION RES, V33, P147, DOI 10.1016/0042-6989(93)90153-N; JACOBS GH, 1993, AM J PRIMATOL, V30, P243, DOI 10.1002/ajp.1350300307; Jacobs GH, 1996, NATURE, V382, P156, DOI 10.1038/382156a0; JACOBS GH, 1993, BIOL REV, V68, P413, DOI 10.1111/j.1469-185X.1993.tb00738.x; MERBS SL, 1993, PHOTOCHEM PHOTOBIOL, V58, P706, DOI 10.1111/j.1751-1097.1993.tb04956.x; NEITZ M, 1991, SCIENCE, V252, P971, DOI 10.1126/science.1903559; Shyue SK, 1998, J MOL EVOL, V46, P697, DOI 10.1007/PL00006350; TRAVIS DS, 1988, VISION RES, V28, P481, DOI 10.1016/0042-6989(88)90170-8; Yamada ES, 1998, VISION RES, V38, P3345, DOI 10.1016/S0042-6989(97)00412-4; Zhou YH, 1997, J MOL EVOL, V45, P610, DOI 10.1007/PL00006265	13	130	130	0	37	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	NOV 4	1999	402	6757					36	36		10.1038/46947	http://dx.doi.org/10.1038/46947			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	254XC	10573416	Bronze			2022-12-01	WOS:000083638600033
J	Askling, J; Sorensen, P; Ekbom, A; Frisch, M; Melbye, M; Glimelius, B; Hjalgrim, H				Askling, J; Sorensen, P; Ekbom, A; Frisch, M; Melbye, M; Glimelius, B; Hjalgrim, H			Is history of squamous-cell skin cancer a marker of poor prognosis in patients with cancer?	ANNALS OF INTERNAL MEDICINE			English	Article						carcinoma, squamous cell; lymphoma, non-Hodgkin; colonic neoplasms; prostatic neoplasms; lung neoplasms; breast neoplasms	CYTOKINE DYSREGULATION; CARCINOMA; RISK; LYMPHOMA	Background: Nonmelanoma skin cancer is associated with increased occurrence of subsequent cancer and death from cancer, but it is not known whether a history of skin cancer is associated with poor prognosis after a second diagnosis of cancer. Objective: To determine whether history of squamous-cell skin cancer is a marker of poor prognosis in patients with cancer. Design: Population-based cohort study. Setting: Sweden, 1958 to 1996. Patients: All patients in the Swedish Cancer Registry with or without a first diagnosis of squamous-cell skin cancer and a subsequent or first diagnosis of non-Hodgkin lymphoma (including chronic lymphocytic leukemia) or cancer of the colon, breast, prostate, or lung. Measurements: Relative risk (RR) for death determined by using Cox proportional hazards regression analysis. Results: Patients with a history of squamous-cell skin cancer had a significantly greater risk for death than those with no such history after receiving a diagnosis of non-Hodgkin lymphoma (RR, 1.33). colon cancer (RR, 1.24), breast cancer (RR, 1.19), or prostate cancer (RR, 1.17). Patients with lung cancer and a history of squamous-cell skin cancer who survived for 1 year after diagnosis of lung cancer also had an increased risk for death (RR, 1.29). Conclusion: Patients with a registered history of squamous-cell skin cancer have a poor prognosis after diagnosis of subsequent cancer and warrant careful medical attention.	Karolinska Inst, Dept Med Epidemiol, S-17177 Stockholm, Sweden; State Serum Inst, Dept Epidemiol Res, DK-2300 Copenhagen S, Denmark; Harvard Sch Publ Hlth, Boston, MA USA; NCI, Viral Epidemiol Branch, Rockville, MD 20852 USA; Univ Uppsala Hosp, Uppsala, Sweden	Karolinska Institutet; Statens Serum Institut; Harvard University; Harvard T.H. Chan School of Public Health; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Uppsala University; Uppsala University Hospital	Askling, J (corresponding author), Karolinska Inst, Dept Med Epidemiol, Box 281, S-17177 Stockholm, Sweden.	Johan.Askling@mep.ki.se	Frisch, Morten/E-9206-2016; Hjalgrim, Henrik/AAG-4973-2021	Frisch, Morten/0000-0002-3864-8860; melbye, mads/0000-0001-8264-6785; Sorensen, Per Soelberg/0000-0002-2818-3780				Adami HO, 1996, INT J CANCER, V67, P764, DOI 10.1002/(SICI)1097-0215(19960917)67:6<764::AID-IJC3>3.0.CO;2-P; ADAMI J, 1995, BRIT MED J, V310, P1491, DOI 10.1136/bmj.310.6993.1491; [Anonymous], 1996, ACTA ONCOL, V35, P47; Au WW, 1996, ENVIRON HEALTH PERSP, V104, P579, DOI 10.2307/3432826; BIRKELAND SA, 1995, INT J CANCER, V60, P183, DOI 10.1002/ijc.2910600209; BRASH DE, 1991, P NATL ACAD SCI USA, V88, P10124, DOI 10.1073/pnas.88.22.10124; Clayton D., 1993, STAT METHODS EPIDEMI; Clerici M, 1998, J NATL CANCER I, V90, P261, DOI 10.1093/jnci/90.4.261; Dreyer L, 1997, APMIS, V105, P9; Frisch M, 1996, ANN INTERN MED, V125, P815, DOI 10.7326/0003-4819-125-10-199611150-00005; FRISCH M, 1995, AM J EPIDEMIOL, V141, P916, DOI 10.1093/oxfordjournals.aje.a117358; HARRIS NL, 1994, BLOOD, V84, P1361; HJALGRIM H, IN PRESS INT J CANC; Kahn HS, 1998, JAMA-J AM MED ASSOC, V280, P910, DOI 10.1001/jama.280.10.910; KINLEN LJ, 1992, IARC SCI PUBL, V116, P237; Levi F, 1998, AM J EPIDEMIOL, V147, P722; Levi F, 1996, BRIT J CANCER, V74, P1847, DOI 10.1038/bjc.1996.642; Levi F, 1997, AM J EPIDEMIOL, V146, P734; Lucey DR, 1996, CLIN MICROBIOL REV, V9, P532, DOI 10.1128/CMR.9.4.532; Lunde A S, 1980, Vital Health Stat 2, P1; MATTSSON B, 1984, ACTA RADIOL ONCOL, V23, P305, DOI 10.3109/02841868409136026; STENBECK M, 1995, ACTA ONCOL, V34, P881, DOI 10.3109/02841869509127200; Teppo L, 1999, ACTA ONCOL, V38, P283; TEPPO L, 1985, J NATL CANCER I, V75, P207; Wassberg C, 1999, INT J CANCER, V80, P511, DOI 10.1002/(SICI)1097-0215(19990209)80:4<511::AID-IJC5>3.3.CO;2-G; WEI QY, 1994, CANCER RES, V54, P437	26	21	21	0	3	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	NOV 2	1999	131	9					655	+		10.7326/0003-4819-131-9-199911020-00004	http://dx.doi.org/10.7326/0003-4819-131-9-199911020-00004			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	251LB	10577327				2022-12-01	WOS:000083446200003
J	Walker, AJ; Cross, SS; Harrison, RF				Walker, AJ; Cross, SS; Harrison, RF			Visualisation of biomedical datasets by use of growing cell structure networks: a novel diagnostic classification technique	LANCET			English	Article								Background Medical research produces large multivariable datasets that are difficult to visualise and interpret intuitively. We describe a novel growing cell structure (GCS) technique that compresses multidimensional datasets into two dimensional maps with colour overlays that can be visually interpreted. Methods The two-dimensional map is self-discovered from the training set by distribution of cases to different nodes according to similarity between the cases at each node. Nodes are added to the map until there is no further significant reduction in error. The Parzen window method is used to estimate the probability distribution of the training cases, and this probability is converted to posterior class probabilities by use of Bayes' theorem. Classification performance can be assessed by means of receiver operating characteristic (ROC) curves. Colour maps of the Values of each input variable at each node are constructed, which illustrate the relation between each input variable and the overall distribution of cases in the network map. Findings From a dataset of 11 input variables from 692 fine-needle aspirate samples from breast lesions, a 32-node network produced an area under the ROC curve of 0.96, which was not significantly different from that for logistic regression (0.98, z=1.09, p>0.05). Colour maps of the input variables showed that some variables had discrete distributions over exclusively benign or malignant areas of the network, and were thus discriminant, whereas others, such as foamy macrophages, covered both benign and malignant regions. Interpretation This technique produces dimensional compression that allows multidimensional data to be displayed as two-dimensional colour images. This envisioning of information allows the highly developed visuospatial abilities of human observers to perceive subtle inter-relations in the dataset.	Univ Sheffield, Sch Med, Dept Pathol, Sheffield S10 2RX, S Yorkshire, England; Univ Sheffield, Sch Med, Dept Automat Control & Syst Engn, Sheffield, S Yorkshire, England; Princeton Univ, Dept Mech & Aerosp Engn, Princeton, NJ 08544 USA	University of Sheffield; University of Sheffield; Princeton University	Cross, SS (corresponding author), Univ Sheffield, Sch Med, Dept Pathol, Sheffield S10 2RX, S Yorkshire, England.	s.s.cross@sheffield.ac.uk	Harrison, Robert/B-9034-2008	Harrison, Robert/0000-0002-9323-8637; Cross, Simon/0000-0003-2044-1754				CROSS SS, 1995, LANCET, V346, P1075, DOI 10.1016/S0140-6736(95)91746-2; Fisher B, 1999, LANCET, V353, P1993, DOI 10.1016/S0140-6736(99)05036-9; FRITZKE B, 1994, NEURAL NETWORKS, V7, P1441, DOI 10.1016/0893-6080(94)90091-4; HANLEY JA, 1982, RADIOLOGY, V143, P29, DOI 10.1148/radiology.143.1.7063747; Hjalmarson A, 1999, LANCET, V353, P2001; KOHONEN T, 1982, BIOL CYBERN, V43, P59, DOI 10.1007/BF00337288; PARZEN E, 1962, ANN MATH STAT, V33, P1065, DOI 10.1214/aoms/1177704472; POWSNER SM, 1994, LANCET, V344, P386, DOI 10.1016/S0140-6736(94)91406-0; WELLS CA, 1994, CYTOPATHOLOGY, V5, P316, DOI 10.1111/j.1365-2303.1994.tb00437.x; [No title captured]; [No title captured]; [No title captured]	12	31	32	0	4	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	OCT 30	1999	354	9189					1518	1521		10.1016/S0140-6736(99)02186-8	http://dx.doi.org/10.1016/S0140-6736(99)02186-8			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	250WB	10551499				2022-12-01	WOS:000083411300013
J	Arstila, TP; Casrouge, A; Baron, V; Even, J; Kanellopoulos, J; Kourilsky, P				Arstila, TP; Casrouge, A; Baron, V; Even, J; Kanellopoulos, J; Kourilsky, P			A direct estimate of the human alpha beta T cell receptor diversity	SCIENCE			English	Article							ANTIGEN RECEPTOR; REPERTOIRE; SELECTION; LYMPHOCYTES; RECOGNITION; CHAINS	Generation and maintenance of an effective repertoire of T cell antigen receptors are essential to the immune system, yet the number of distinct T cell receptors (TCRs) expressed by the estimated 10(12) T cells in the human body is not known. In this study, TCR gene amplification and sequencing showed that there are about 10(6) different beta chains in the blood, each pairing, on the average, with at Least 25 different alpha chains. In the memory subset, the diversity decreased to 1 x 10(5) to 2 x 10(5) different beta chains, each pairing with only a single alpha chain. Thus, the naive repertoire is highly diverse, whereas the memory compartment, here one-third of the T cell population, contributes Less than 1 percent of the total diversity.	Inst Pasteur, INSERM, U277, Unite Biol Mol Gene, F-75724 Paris 15, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris	Arstila, TP (corresponding author), Univ Helsinki, Haartman Inst, Dept Virol, Haartmaninkatu 3, FIN-00014 Helsinki, Finland.	petteri.arstila@helsinki.fi	Yang, Chen/G-1379-2010					ALT FW, 1992, IMMUNOL TODAY, V13, P306, DOI 10.1016/0167-5699(92)90043-7; Altman JD, 1996, SCIENCE, V274, P94, DOI 10.1126/science.274.5284.94; Arden Bernhard, 1995, Immunogenetics, V42, P501; ARGAET VP, 1994, J EXP MED, V180, P2335, DOI 10.1084/jem.180.6.2335; BENIT C, 1995, J IMMUNOL, V154, P5103; Berzins SP, 1998, J EXP MED, V187, P1839, DOI 10.1084/jem.187.11.1839; BORGULYA P, 1992, CELL, V69, P529, DOI 10.1016/0092-8674(92)90453-J; CASROUGE A, 1998, J EXP MED, V187, P1871; Davis MM, 1998, ANNU REV IMMUNOL, V16, P523, DOI 10.1146/annurev.immunol.16.1.523; DAVIS MM, 1988, NATURE, V334, P395, DOI 10.1038/334395a0; Douek DC, 1998, NATURE, V396, P690, DOI 10.1038/25374; DUDLEY EC, 1994, IMMUNITY, V1, P83, DOI 10.1016/1074-7613(94)90102-3; FERRADINI L, UNPUB; HALL MA, 1995, HUM IMMUNOL, V43, P207, DOI 10.1016/0198-8859(95)00013-T; McMahan CJ, 1998, IMMUNITY, V9, P637, DOI 10.1016/S1074-7613(00)80661-5; Nanki T, 1998, J IMMUNOL, V161, P228; NOSSAL GJV, 1994, CELL, V76, P229, DOI 10.1016/0092-8674(94)90331-X; PADOVAN E, 1993, SCIENCE, V262, P422, DOI 10.1126/science.8211163; PANNETIER C, 1993, P NATL ACAD SCI USA, V90, P4319, DOI 10.1073/pnas.90.9.4319; PANNETIER C, 1995, IMMUNOL TODAY, V16, P176, DOI 10.1016/0167-5699(95)80117-0; Rodewald HR, 1998, ADV IMMUNOL, V69, P1, DOI 10.1016/S0065-2776(08)60606-9; ROSENBERG WMC, 1992, EUR J IMMUNOL, V22, P541, DOI 10.1002/eji.1830220237; Rowen L, 1996, SCIENCE, V272, P1755, DOI 10.1126/science.272.5269.1755; Tanchot C, 1997, SCIENCE, V276, P2057, DOI 10.1126/science.276.5321.2057; Trigueros C, 1998, J EXP MED, V188, P1401, DOI 10.1084/jem.188.8.1401; Wagner UG, 1998, P NATL ACAD SCI USA, V95, P14447, DOI 10.1073/pnas.95.24.14447	26	645	703	1	22	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 29	1999	286	5441					958	961		10.1126/science.286.5441.958	http://dx.doi.org/10.1126/science.286.5441.958			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	250BE	10542151				2022-12-01	WOS:000083368500046
J	Lewis, DL; Garrison, AW; Wommack, KE; Whittemore, A; Steudler, P; Melillo, J				Lewis, DL; Garrison, AW; Wommack, KE; Whittemore, A; Steudler, P; Melillo, J			Influence of environmental changes on degradation of chiral pollutants in soils	NATURE			English	Article							ENANTIOSELECTIVE DEGRADATION; HERBICIDE	Numerous anthropogenic chemicals of environmental concern-including some phenoxy acid herbicides, organophosphorus insecticides, polychlorinated biphenyls, phthalates, freon substitutes and some DDT derivatives-are chiral. Their potential biological effects, such as toxicity, mutagenicity, carcinogenicity, and endocrine disrupter activity, are generally enantiomer-selective, and different enantiomers are preferentially degraded (transformed) by micro-organisms in various environments(1-8). Here we use field and laboratory experiments to demonstrate that environmental changes in soils can alter these preferences, and to suggest that the preferences shift owing to different groups of related microbial genotypes being activated by different environmental changes. In Brazilian soils, almost all pasture samples preferentially transformed the non-herbicidal enantiomer of dichlorprop ((RS)-2-(2,4-dichlorophenoxy)propionic acid), while most forest samples either transformed the herbicidal enantiomer more readily or as rapidly as the non-herbicidal enantiomer. Organic nutrient enrichments shifted enantioselectivity for methyl dichlorprop ((RS)-methyl 2-(2,4-dichlorophenoxy)propionic acid) strongly towards preferentially removing the non-herbicidal enantiomer in soils from Brazil and North America, potentially increasing phytotoxicity of its residues relative to that of the racemate. Assessments of the risks chemical pollutants pose to public health and the environment need to take into account the chiral selectivity of microbial transformation processes and their alteration by environmental changes, especially for pesticides as up to 25 per cent are chiral(9).	US EPA, Ecosyst Res Div, Natl Exposure Res Lab, Athens, GA 30605 USA; Univ Georgia, Dept Marine Sci, Athens, GA 30602 USA; Marine Biol Lab, Ctr Ecosyst, Woods Hole, MA 02542 USA	United States Environmental Protection Agency; University System of Georgia; University of Georgia; Marine Biological Laboratory - Woods Hole	Lewis, DL (corresponding author), US EPA, Ecosyst Res Div, Natl Exposure Res Lab, Athens, GA 30605 USA.			Lewis, David/0000-0003-0777-2460				Aigner EJ, 1998, ENVIRON SCI TECHNOL, V32, P1162, DOI 10.1021/es970750h; AKKERMANS ADL, 1995, MOL MICROBIAL ECOLOG, P1; BUSER HP, 1997, CHIRAL SEPARATIONS, pCH5; FALCONER RL, 1995, ENVIRON SCI TECHNOL, V29, P1297, DOI 10.1021/es00005a023; Fulthorpe RR, 1998, APPL ENVIRON MICROB, V64, P1620; Garrison AW, 1996, ENVIRON SCI TECHNOL, V30, P2449, DOI 10.1021/es950552v; HOLLIBAUGH JT, 1979, ESTUAR COAST MAR SCI, V9, P215, DOI 10.1016/0302-3524(79)90116-6; JANTUNEN LM, 1996, GEOPHYS RES, V108, P28837; Kohler HPE, 1997, CHIMIA, V51, P947; Lewis DL, 1996, NATURE, V381, P731, DOI 10.1038/381731a0; Lukewille A, 1997, GLOB CHANGE BIOL, V3, P13, DOI 10.1046/j.1365-2486.1997.00088.x; MOYER CL, 1994, APPL ENVIRON MICROB, V60, P871, DOI 10.1128/AEM.60.3.871-879.1994; MULLER MD, 1995, ENVIRON SCI TECHNOL, V29, P2031, DOI 10.1021/es00008a023; PETERJOHN WT, 1994, ECOL APPL, V4, P617, DOI 10.2307/1941962; TETT VA, 1994, FEMS MICROBIOL ECOL, V14, P191, DOI 10.1111/j.1574-6941.1994.tb00105.x; Wiberg K, 1998, ANAL CHEM, V70, P3845, DOI 10.1021/ac980064g; Williams A, 1996, PESTIC SCI, V46, P3, DOI 10.1002/(SICI)1096-9063(199601)46:1&lt;3::AID-PS337&gt;3.0.CO;2-J; Zipper C, 1998, ENVIRON SCI TECHNOL, V32, P2070, DOI 10.1021/es970880q; 1998, CHEM ENG NEWS, V76, P83	19	330	360	9	217	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	OCT 28	1999	401	6756					898	901		10.1038/44801	http://dx.doi.org/10.1038/44801			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	251UL	10553905				2022-12-01	WOS:000083464700053
J	Simon, I; Tenzen, T; Reubinoff, BE; Hillman, D; McCarrey, JR; Cedar, H				Simon, I; Tenzen, T; Reubinoff, BE; Hillman, D; McCarrey, JR; Cedar, H			Asynchronous replication of imprinted genes is established in the gametes and maintained during development	NATURE			English	Article							ALLELE-SPECIFIC REPLICATION; MOUSE; REGION; EXPRESSION; MECHANISMS; CELLS; H19; HYBRIDIZATION; METHYLATION; TRANSITION	Genomic imprinting is characterized by allele-specific expression of multiple genes within large chromosomal domains' that undergo DNA replication asynchronously during S phase(2,3). Here we show, using both fluorescence in situ hybridization analysis and S-phase fractionation techniques, that differential replication timing is associated with imprinted genes in a variety of fell types, and is already present in the pre-implantation embryo soon after fertilization. This pattern is erased before meiosis in the germ line, and parent-specific replication timing is then reset in late gametogenesis in both the male and female. Thus, asynchronous replication timing is established in the gametes and maintained throughout development, indicating that it may function as a primary epigenetic marker for distinguishing between the parental alleles.	Hebrew Univ Jerusalem, Dept Cellular Biochem, IL-91120 Jerusalem, Israel; Natl Inst Genet, Dept Evolut Genet, Mishima, Shizuoka 4118540, Japan; Hadassah Ein Kerem Univ Hosp, Dept Obstet & Gynecol, IL-91120 Jerusalem, Israel; SW Fdn Biomed Res, Dept Genet, San Antonio, TX 78228 USA	Hebrew University of Jerusalem; Research Organization of Information & Systems (ROIS); National Institute of Genetics (NIG) - Japan; Hebrew University of Jerusalem; Hadassah University Medical Center; Texas Biomedical Research Institute	Cedar, H (corresponding author), Hebrew Univ Jerusalem, Dept Cellular Biochem, IL-91120 Jerusalem, Israel.			Reubinoff, Benjamin/0000-0003-0353-1299; Simon, Itamar/0000-0002-8517-1903				BELLVE AR, 1977, J CELL BIOL, V74, P68, DOI 10.1083/jcb.74.1.68; Birger Y, 1999, NATURE, V397, P84, DOI 10.1038/16291; Bix M, 1998, SCIENCE, V281, P1352, DOI 10.1126/science.281.5381.1352; Caspary T, 1998, MOL CELL BIOL, V18, P3466, DOI 10.1128/MCB.18.6.3466; CHESS A, 1994, CELL, V78, P823, DOI 10.1016/S0092-8674(94)90562-2; Davis TL, 1999, GENOMICS, V58, P18, DOI 10.1006/geno.1999.5813; DUNNETT CW, 1955, J AM STAT ASSOC, V50, P1096, DOI 10.2307/2281208; Gabriel JM, 1998, P NATL ACAD SCI USA, V95, P14857, DOI 10.1073/pnas.95.25.14857; Greally JM, 1998, HUM MOL GENET, V7, P91, DOI 10.1093/hmg/7.1.91; GUNARATNE PH, 1995, GENE DEV, V9, P808, DOI 10.1101/gad.9.7.808; HANSEN RS, 1993, CELL, V73, P1403, DOI 10.1016/0092-8674(93)90365-W; HARPER JC, 1994, HUM REPROD, V9, P721, DOI 10.1093/oxfordjournals.humrep.a138577; Hogan B., 2014, MANIPULATING MOUSE E; KAWAME H, 1995, HUM MOL GENET, V4, P2287, DOI 10.1093/hmg/4.12.2287; KITSBERG D, 1993, NATURE, V364, P459, DOI 10.1038/364459a0; KNOLL JHM, 1994, NAT GENET, V6, P41, DOI 10.1038/ng0194-41; LASALLE JM, 1995, NAT GENET, V9, P386, DOI 10.1038/ng0495-386; LEIGHTON PA, 1995, NATURE, V375, P34, DOI 10.1038/375034a0; McCarrey J, 1993, CELL MOL BIOL TESTIS, P58; MCCARREY JR, 1987, J EXP ZOOL, V242, P107, DOI 10.1002/jez.1402420116; RAZIN A, 1994, CELL, V77, P473, DOI 10.1016/0092-8674(94)90208-9; Riviere I, 1998, IMMUNITY, V9, P217, DOI 10.1016/S1074-7613(00)80604-4; SELIG S, 1992, EMBO J, V11, P1217, DOI 10.1002/j.1460-2075.1992.tb05162.x; Shemer R, 1996, P NATL ACAD SCI USA, V93, P6371, DOI 10.1073/pnas.93.13.6371; Shemer R., 1996, Epigenetic mechanisms of gene regulation., P215; SUTCLIFFE JS, 1994, NAT GENET, V8, P52, DOI 10.1038/ng0994-52; SZABO PE, 1995, GENE DEV, V9, P1857, DOI 10.1101/gad.9.15.1857; Tenzen T, 1997, MOL CELL BIOL, V17, P4043, DOI 10.1128/MCB.17.7.4043; Windham CQ, 1997, DEV GENET, V20, P29, DOI 10.1002/(SICI)1520-6408(1997)20:1<29::AID-DVG4>3.0.CO;2-B; Wines ME, 1998, GENOMICS, V51, P223, DOI 10.1006/geno.1998.5347	30	131	132	0	2	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	OCT 28	1999	401	6756					929	932		10.1038/44866	http://dx.doi.org/10.1038/44866			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	251UL	10553911				2022-12-01	WOS:000083464700063
J	Allison, DB; Fontaine, KR; Manson, JE; Stevens, J; VanItallie, TB				Allison, DB; Fontaine, KR; Manson, JE; Stevens, J; VanItallie, TB			Annual deaths attributable to obesity in the United States	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							BODY-MASS INDEX; MORTALITY; WEIGHT; OVERWEIGHT; PREVALENCE; DISEASE; WOMEN	Context Obesity is a major health problem in the United States, but the number of obesity-attributable deaths has not been rigorously estimated. Objective To estimate the number of deaths, annually, attributable to obesity among US adults. Design Data from 5 prospective cohort studies (the Alameda Community Health Study, the Framingham Heart Study, the Tecumseh Community Hearth Study, the American Cancer Society Cancer Prevention Study I, and the National Health and Nutrition Examination Survey I Epidemiologic Follow-up Study) and 1 published study (the Nurses' Health Study) in conjunction with 1991 national statistic; on body mass index distributions, population size, and overall deaths. Subjects Adults, 18 years or older in 1991, classified by body mass index (kg/m(2)) as overweight (25-30), obese (30-35), and severely obese (>35), Main Outcome Measure Relative hazard ratio (HR) of death for obese or overweight persons. Results The estimated number of annual deaths attributable to obesity varied with the cohort used to calculate the HRs, but findings were consistent overall. More than 80% of the estimated obesity-attributable deaths occurred among individuals with a body mass index of more than 30 kg/m(2). When HRs were estimated for all eligible subjects from ail 6 studies, the mean estimate of deaths attributable to obesity in the United States was 280 184 (range, 236 111-341 153),Hazard ratios also were calculated from data for nonsmokers or never-smokers only. When these HRs were applied to the entire population (assuming the HR applied to all individuals), the mean estimate for obesity-attributable death was 324 940 (range, 262 541-383 410). Conclusions The estimated number of annual deaths attributable to obesity among US adults is approximately 280 000 based on HRs from all subjects and 325 000 based on HRs from only nonsmokers and never-smokers.	Columbia Univ, Coll Phys & Surg, St Lukes Roosevelt Hosp Ctr, Obes Res Ctr, New York, NY 10025 USA; Johns Hopkins Univ, Sch Med, Johns Hopkins Bayview Med Ctr, Dept Med, Baltimore, MD USA; Harvard Univ, Sch Med, Boston, MA USA; Brigham & Womens Hosp, Boston, MA USA; Harvard Univ, Sch Publ Hlth, Boston, MA 02115 USA; Univ N Carolina, Dept Nutr, Chapel Hill, NC USA; Univ N Carolina, Dept Epidemiol, Chapel Hill, NC USA	Columbia University; Mount Sinai St. Luke's; Mount Sinai West; Johns Hopkins University; Johns Hopkins Medicine; Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard T.H. Chan School of Public Health; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill	Allison, DB (corresponding author), Columbia Univ, Coll Phys & Surg, St Lukes Roosevelt Hosp Ctr, Obes Res Ctr, 1090 Amsterdam Ave,14th Floor, New York, NY 10025 USA.	dba8@columbia.edu	Kohn, Geoffrey P/A-9056-2009	Allison, David/0000-0003-3566-9399	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK026687, R01DK051716] Funding Source: NIH RePORTER; NIDDK NIH HHS [P30DK26687, R01DK51716] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Allison D B, 1995, Endocr Pract, V1, P353; Allison DB, 1999, ANN EPIDEMIOL, V9, P132, DOI 10.1016/S1047-2797(98)00039-8; Allison DB, 1997, AM J EPIDEMIOL, V146, P672; Allison DB, 1999, AM J PUBLIC HEALTH, V89, P1194, DOI 10.2105/AJPH.89.8.1194; Allison DB, 1999, OBES RES, V7, P342, DOI 10.1002/j.1550-8528.1999.tb00417.x; Amler RW, 1987, AM J PREV MED, V3, P181; BERKHAM LF, 1983, HLTH WAYS LIVING ALA; Cox C S, 1997, Vital Health Stat 1, P1; Cox DR., 1984, ANAL SURVIVAL DATA; D'AGOSTINO R. B., 1988, NIH PUBLICATION, V88-2970; DAGOSTINO RB, 1989, P AM STAT ASS SESQ 1, P707; DAWBER TR, 1951, AM J PUBLIC HEALTH, V41, P279; Dawber TR., 1980, FRAMINGHAM STUDY EPI, DOI DOI 10.4159/HARVARD.9780674492097; Durazo-Arvizu RA, 1998, AM J EPIDEMIOL, V147, P739, DOI 10.1093/oxfordjournals.aje.a009518; EPSTEIN FH, 1970, ARCH ENVIRON HEALTH, V21, P402, DOI 10.1080/00039896.1970.10667258; Flegal KM, 1998, INT J OBESITY, V22, P39, DOI 10.1038/sj.ijo.0800541; Fontaine K.R., 1998, DIS MANAGEMENT HLTH, V3, P61; FORSTER J, 1995, PATIENT CARE, V29, P152; HAHN RA, 1990, JAMA-J AM MED ASSOC, V264, P2654, DOI 10.1001/jama.264.20.2654; Hill JO, 1998, PEDIATRICS, V101, P570, DOI 10.1542/peds.101.3.570; HOCHSTIM JR, 1970, COMMUNITY EPIDEMIOLO; ILIENFELD AM, 1980, FDN EPIDEMIOLOGY; *KNOLL PHARM CO, 1999, MER PAT SUPP PACK; KOLATA G, 1998, NY TIMES        0101, P2; Kuczmarski RJ, 1997, OBES RES, V5, P542, DOI 10.1002/j.1550-8528.1997.tb00575.x; LEW EA, 1979, J CHRON DIS, V32, P563, DOI 10.1016/0021-9681(79)90119-X; MANSON JE, 1987, JAMA-J AM MED ASSOC, V257, P353, DOI 10.1001/jama.257.3.353; Manson JE, 1996, NEW ENGL J MED, V335, P659, DOI 10.1056/NEJM199608293350910; MANSON JE, 1995, NEW ENGL J MED, V333, P677, DOI 10.1056/NEJM199509143331101; MCGINNIS JM, 1993, JAMA-J AM MED ASSOC, V270, P2207, DOI 10.1001/jama.270.18.2207; MEISOL P, 1998, BALTIMORE SUN   0723, P3; *MORT STAT BRANCH, 1993, MMWR-MORBID MORTAL W, V42, P897; *MORT STAT BRANCH, 1993, MMWR-MORBID MORTAL W, V42, P891; NAPIER JA, 1962, AM J PUBLIC HEALTH N, V52, P208, DOI 10.2105/AJPH.52.2.208; NAPIER JA, 1970, COMMUNITY EPIDEMIOLO; *NHANES, 1997, BOOK CD ROM; PETITTI D, 1994, META ANAL DECISION A; Pi-Sunyer FX, 1998, OBES RES, V6, p51S; SEIDELL JC, 1998, HDB OBESITY, P79; STAMPFER MJ, 1985, NEW ENGL J MED, V313, P1044, DOI 10.1056/NEJM198510243131703; Stevens J, 1998, NEW ENGL J MED, V338, P1, DOI 10.1056/NEJM199801013380101; Stevens J, 1999, AM J EPIDEMIOL, V150, P399, DOI 10.1093/oxfordjournals.aje.a010019; Troiano RP, 1996, INT J OBESITY, V20, P63; *US CENS BUR, 1998, 1990 US CENS DAT; WHO, 1998, OB PREV MAN GLOB EP; Wilding J, 1998, NATURE, V391, P759, DOI 10.1038/35793; WILL GF, 1997, NEWSWEEK        0707, P82	47	1272	1312	2	51	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 27	1999	282	16					1530	1538		10.1001/jama.282.16.1530	http://dx.doi.org/10.1001/jama.282.16.1530			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	248MB	10546692	Bronze			2022-12-01	WOS:000083277800020
J	Galuska, DA; Will, JC; Serdula, MK; Ford, ES				Galuska, DA; Will, JC; Serdula, MK; Ford, ES			Are health care professionals advising obese patients to lose weight?	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							UNITED-STATES; PHYSICIAN ADVICE; PRACTITIONERS; PROMOTION; ATTITUDES; BEHAVIOR	Context Implementation of the National Institutes of Health's 1998 guidelines, which recommended that health care professionals advise obese patients to lose weight, required baseline data for evaluation. Objectives To describe the proportion and characteristics of obese persons advised to lose weight by their health care professional during the previous 12 months and to determine whether the advice was associated with reported attempts to lose weight. Design The Behavioral Risk Factor Surveillance System, a random-digit telephone survey conducted in 1996 by state health departments. Setting Population-based sample from 50 states and the District of Columbia. Participants A total of 22 835 adults, 18 years and older, classified as obese (body mass index greater than or equal to 30 kg/m(2)), who had visited their physician for a routine checkup during the previous 12 months. Main Outcome Measures Reported advice from a health care professional to lose weight, and reported attempts to lose weight. Results Forty-two percent of participants reported that their hearth care professional advised them to lose weight. Using multivariate logistic regression analysis, we found that the persons who were more likely to receive advice were female, middle aged, had higher levels of education, lived in the northeast, reported poorer perceived health, were more obese, and had diabetes mellitus. Persons who reported receiving advice to lose weight were significantly more likely to report trying to lose weight than those who did not (OR, 2.79; 95% CI, 2.53-3.08). Conclusions Less than half of obese adults report being advised to lose weight by health care professionals. Barriers to counseling need to be identified and addressed.	Ctr Dis Control & Prevent, Natl Ctr Chron Dis Prevent & Hlth Promot, Div Nutr & Phys Activ, Atlanta, GA 30341 USA	Centers for Disease Control & Prevention - USA	Galuska, DA (corresponding author), Ctr Dis Control & Prevent, Natl Ctr Chron Dis Prevent & Hlth Promot, Div Nutr & Phys Activ, 4770 Bufford Hwy,MS K26, Atlanta, GA 30341 USA.							CAMPBELL MK, 1994, AM J PUBLIC HEALTH, V84, P783, DOI 10.2105/AJPH.84.5.783; Flegal KM, 1998, INT J OBESITY, V22, P39, DOI 10.1038/sj.ijo.0800541; Fontaine KR, 1998, ARCH FAM MED, V7, P381, DOI 10.1001/archfami.7.4.381; Ford ES, 1998, J CLIN EPIDEMIOL, V51, P55, DOI 10.1016/S0895-4356(97)00225-4; FRIEDMAN C, 1994, AM J PREV MED, V10, P367, DOI 10.1016/S0749-3797(18)30567-1; HORM J, 1993, ANN INTERN MED, V119, P672, DOI 10.7326/0003-4819-119-7_Part_2-199310011-00009; JANES GR, 1995, US DEP HLTH HUMAN SE; KOTTKE TE, 1984, PREV MED, V13, P215; Kristeller JL, 1997, PREV MED, V26, P542, DOI 10.1006/pmed.1997.0171; KUSHNER RF, 1995, PREV MED, V24, P546, DOI 10.1006/pmed.1995.1087; LEWIS BS, 1993, PREV MED, V22, P110, DOI 10.1006/pmed.1993.1008; LOGSDON DN, 1989, AM J PREV MED, V5, P249, DOI 10.1016/S0749-3797(18)31065-1; National Institutes of Health, 1998, CLIN GUID ID EV TREA; NELSON DE, 1998, P SECT SURV METH AM; ORLEANS CT, 1985, PREV MED, V14, P636, DOI 10.1016/0091-7435(85)90083-0; PISUNYER FX, 1993, ANN INTERN MED, V119, P655, DOI 10.7326/0003-4819-119-7_Part_2-199310011-00006; PRICE JH, 1987, AM J PREV MED, V3, P339; ROWLAND ML, 1990, AM J CLIN NUTR, V52, P1125, DOI 10.1093/ajcn/52.6.1125; SERDULA MK, 1993, ANN INTERN MED, V119, P667, DOI 10.7326/0003-4819-119-7_Part_2-199310011-00008; SHAH BV, 1997, SUDAAN USERS MANUAL; SWIWBURN BA, 1998, AM J PUBLIC HEALTH, V88, P288; WECHSLER H, 1983, NEW ENGL J MED, V308, P97, DOI 10.1056/NEJM198301133080211; WOODWELL DA, 1997, ADV DATA VITAL HLTH, V295; Yeager KK, 1996, AM J PREV MED, V12, P238, DOI 10.1016/S0749-3797(18)30318-0	24	478	486	0	12	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 27	1999	282	16					1576	1578		10.1001/jama.282.16.1576	http://dx.doi.org/10.1001/jama.282.16.1576			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	248MB	10546698	Bronze			2022-12-01	WOS:000083277800026
J	Bi, GQ; Poo, MM				Bi, GQ; Poo, MM			Distributed synaptic modification in neural networks induced by patterned stimulation	NATURE			English	Article							LONG-TERM POTENTIATION; PLASTICITY; DEPRESSION; HIPPOCAMPUS; NEURONS; COMPUTATION; INFORMATION; SIGNAL; TIME	Activity-dependent changes in synaptic efficacy or connectivity are critical for the development(1), signal processing(2) and learning and memory functions(3-6) of the nervous system. Repetitive correlated spiking of pre- and postsynaptic neurons can induce a persistent increase or decrease in synaptic strength, depending on the timing of the pre- and postsynaptic excitation(7-13). Previous studies on such synaptic modifications have focused on synapses made by the stimulated neuron. Here we examine, in networks of cultured hippocampal neurons, whether and how localized stimulation can modify synapses that are remote from the stimulated neuron. We found that repetitive paired-pulse stimulation of a single neuron for brief periods induces persistent strengthening or weakening of specific polysynaptic pathways in a manner that depends on the interpulse interval. These changes can be accounted for by correlated pre- and postsynaptic excitation at distant synaptic sites, resulting from different transmission delays along separate pathways. Thus, through such a 'delay-line' mechanism, temporal information coded in the timing of individual spikes(14-17) can be converted into and stored as spatially distributed patterns of persistent synaptic modifications in a neural network.	Univ Calif San Diego, Dept Biol, La Jolla, CA 92093 USA	University of California System; University of California San Diego	Bi, GQ (corresponding author), Univ Calif San Diego, Dept Biol, La Jolla, CA 92093 USA.		Bi, Guo-Qiang/E-5075-2013	Bi, Guo-Qiang/0000-0001-8735-3818				Abbott LF, 1997, SCIENCE, V275, P220, DOI 10.1126/science.275.5297.221; Abeles M., 1991, CORTICONICS; Bell CC, 1997, NATURE, V387, P278, DOI 10.1038/387278a0; Bi GQ, 1998, J NEUROSCI, V18, P10464, DOI 10.1523/jneurosci.18-24-10464.1998; BLISS TVP, 1993, NATURE, V361, P31, DOI 10.1038/361031a0; Buonomano DV, 1997, P NATL ACAD SCI USA, V94, P10403, DOI 10.1073/pnas.94.19.10403; BUZSAKI G, 1988, BRAIN RES, V455, P192, DOI 10.1016/0006-8993(88)90133-3; CARR CE, 1990, J NEUROSCI, V10, P3227; Churchland P. S., 1992, COMPUTATIONAL BRAIN, DOI 10.7551/mitpress/2010.001.0001; Debanne D, 1998, J PHYSIOL-LONDON, V507, P237, DOI 10.1111/j.1469-7793.1998.237bu.x; Fitzsimonds RM, 1997, NATURE, V388, P439, DOI 10.1038/41267; Gerstner W, 1996, NATURE, V383, P76, DOI 10.1038/383076a0; Goda Y, 1996, CURR BIOL, V6, P375, DOI 10.1016/S0960-9822(02)00499-2; HOPFIELD JJ, 1995, NATURE, V376, P33, DOI 10.1038/376033a0; Katz LC, 1996, SCIENCE, V274, P1133, DOI 10.1126/science.274.5290.1133; Kristan WB, 1998, NAT NEUROSCI, V1, P643, DOI 10.1038/3640; LEVY WB, 1983, NEUROSCIENCE, V8, P791, DOI 10.1016/0306-4522(83)90010-6; LINDEN DJ, 1995, ANNU REV NEUROSCI, V18, P319, DOI 10.1146/annurev.neuro.18.1.319; Magee JC, 1997, SCIENCE, V275, P209, DOI 10.1126/science.275.5297.209; MALENKA RC, 1993, TRENDS NEUROSCI, V16, P521, DOI 10.1016/0166-2236(93)90197-T; Markram H, 1997, SCIENCE, V275, P213, DOI 10.1126/science.275.5297.213; MILES R, 1987, NATURE, V329, P724, DOI 10.1038/329724a0; Moore JW, 1998, TIMING OF BEHAVIOR, P3; RAE J, 1991, J NEUROSCI METH, V37, P15, DOI 10.1016/0165-0270(91)90017-T; SINGER W, 1995, ANNU REV NEUROSCI, V18, P555, DOI 10.1146/annurev.neuro.18.1.555; Squire L.R., 1987, MEMORY BRAIN; Strong SP, 1998, PHYS REV LETT, V80, P197, DOI 10.1103/PhysRevLett.80.197; TANK DW, 1987, P NATL ACAD SCI USA, V84, P1896, DOI 10.1073/pnas.84.7.1896; TURRIGIANO G, 1994, SCIENCE, V264, P974, DOI 10.1126/science.8178157; Zhang LI, 1998, NATURE, V395, P37, DOI 10.1038/25665	30	181	188	1	33	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	OCT 21	1999	401	6755					792	796		10.1038/44573	http://dx.doi.org/10.1038/44573			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	250BG	10548104				2022-12-01	WOS:000083368700053
J	Steiner, MJ				Steiner, MJ			Contraceptive effectiveness - What should the counseling message be?	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material									Family Hlth Int, Res Triangle Pk, NC 27709 USA		Steiner, MJ (corresponding author), Family Hlth Int, POB 13950, Res Triangle Pk, NC 27709 USA.	msteiner@fhi.org						Fu HS, 1999, FAM PLANN PERSPECT, V31, P56, DOI 10.2307/2991640; GODWIN K, 1999, BR J FAM PLANN, V93, P896; Raymond E, 1999, OBSTET GYNECOL, V93, P896, DOI 10.1016/S0029-7844(99)00002-2; Steiner M, 1996, OBSTET GYNECOL, V88, pS24, DOI 10.1016/0029-7844(96)00251-7; Trussell J, 1999, FAM PLANN PERSPECT, V31, P64, DOI 10.2307/2991641; TRUSSELL J, 1998, CONTRACEPTIVE TECHNO, P211	6	16	16	0	1	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 20	1999	282	15					1405	1407		10.1001/jama.282.15.1405	http://dx.doi.org/10.1001/jama.282.15.1405			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	245LT	10535416				2022-12-01	WOS:000083111000001
J	Jones, TF; Craig, AS; Valway, SE; Woodley, CL; Schaffner, W				Jones, TF; Craig, AS; Valway, SE; Woodley, CL; Schaffner, W			Transmission of tuberculosis in a jail	ANNALS OF INTERNAL MEDICINE			English	Article; Proceedings Paper	36th Annual Meeting of the Infectious-Diseases-Society-of-America	NOV 11-15, 1998	DENVER, CO	Infect Dis Soc Amer		disease outbreaks; tuberculosis; prisoners; infection control; tuberculin test	CORRECTIONAL HEALTH-CARE; YORK-STATE PRISON; RESISTANT TUBERCULOSIS; INFECTION; POLYMORPHISM; ASSOCIATION; POPULATION; ADMISSION; OUTBREAK; FACILITY	Background: Outbreaks of tuberculosis are uncommonly recognized in jails. In 1996, an increase in active tuberculosis cases was noted among inmates of a large urban jail. Objectives: To determine the source and extent of a tuberculosis outbreak in an urban jail and to recommend control measures. Design: Retrospective cohort study. Setting: Urban jail. Patients: Inmates and guards with tuberculosis. Intervention: Outbreak evaluation and control. Measurements: Medical records of inmates and guards with tuberculosis were reviewed, and inmates were interviewed. DNA fingerprinting was performed on Mycobacterium tuberculosis isolates. Results: From 1 January 1995 through 31 December 1997, active tuberculosis was diagnosed in 38 inmates and 5 guards from the jail. Nineteen (79%) of the 24 culture-positive inmates had isolates with DNA fingerprints matching those of other inmates. Isolates from both culture-positive guards matched the predominant inmate strain; only 6 (14%) of 43 isolates from infected persons in the community had this pattern. The median length of incarceration of all inmates in the jail was 1 day; the median length of continuous incarceration before diagnosis of tuberculosis in inmates was 138 days. Inmates with tuberculosis had been incarcerated a median of 15 times. Forty-three percent of persons in this city with tuberculosis diagnosed from January 1995 through July 1997 had been incarcerated in the jail at some time before diagnosis. Conclusions: Traditional and molecular epidemiologic investigations suggest that tuberculosis was transmitted among inmates and guards in an urban jail. Aggressive measures to screen for active tuberculosis upon incarceration are important for preventing spread of disease in jails and to the surrounding community.	Tennessee Dept Hlth, CEDS, Nashville, TN 37247 USA; Ctr Dis Control & Prevent, Div Bacterial & Mycot Dis, Natl Ctr Infect Dis, Atlanta, GA 30333 USA; Ctr Dis Control & Prevent, Div TB Eliminat, Natl Ctr HIV STD TB Prevent, Atlanta, GA 30333 USA; Vanderbilt Univ, Sch Med, Dept Med, Nashville, TN 37232 USA; Vanderbilt Univ, Sch Med, Dept Prevent Med, Nashville, TN 37232 USA	Tennessee Department Health; Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA; Vanderbilt University; Vanderbilt University	Jones, TF (corresponding author), Tennessee Dept Hlth, CEDS, Cordell Hull Bldg,4th Floor,425 5th Ave N, Nashville, TN 37247 USA.	bhudson@mail.acponline.org						ABELES H, 1970, AM REV RESPIR DIS, V101, P706; BELLIN EY, 1993, JAMA-J AM MED ASSOC, V269, P2228, DOI 10.1001/jama.269.17.2228; BergmireSweat D, 1996, EPIDEMIOL INFECT, V117, P485, DOI 10.1017/S095026880005915X; Braden CR, 1997, J INFECT DIS, V175, P1446, DOI 10.1086/516478; BRAUN MM, 1989, JAMA-J AM MED ASSOC, V261, P393, DOI 10.1001/jama.261.3.393; *BUR JUST STAT, 1995, BJS B; *BUR JUST STAT, 1998, PROF JAIL INM; *CAS DEF INF COND, 1997, MMWR-MORBID MORTAL W, V46, P1; CAVE MD, 1991, MOL CELL PROBE, V5, P73, DOI 10.1016/0890-8508(91)90040-Q; Conklin TJ, 1998, AM J PUBLIC HEALTH, V88, P1249; *CONTR TB CORR FAC, 1995, ATL CDCP; DEAN AD, 1994, ATLANTA CDCP; Fountain F F Jr, 1997, Tenn Med, V90, P138; GLASER JB, 1993, ANN INTERN MED, V118, P139, DOI 10.7326/0003-4819-118-2-199301150-00010; HAMMETT T, 1994, TUBERCULOSIS CORRECT; HUTTON MD, 1993, PUBLIC HEALTH REP, V108, P305; KING L, 1977, JAMA-J AM MED ASSOC, V237, P791, DOI 10.1001/jama.237.8.791; Koo DT, 1997, AM J PUBLIC HEALTH, V87, P279, DOI 10.2105/AJPH.87.2.279; Layton MC, 1997, AM J PUBLIC HEALTH, V87, P1335, DOI 10.2105/AJPH.87.8.1335; MacIntyre CR, 1997, CLIN INFECT DIS, V24, P1060, DOI 10.1086/513632; PELLETIER AR, 1993, ARCH INTERN MED, V153, P2692, DOI 10.1001/archinte.153.23.2692; Prevention CfDCa, 1996, MMWR-MORBID MORTAL W, V45, P1; Puisis M, 1996, PUBLIC HEALTH REP, V111, P330; SKOLNICK AA, 1992, JAMA-J AM MED ASSOC, V268, P3175, DOI 10.1001/jama.268.22.3175; SNIDER DE, 1989, JAMA-J AM MED ASSOC, V261, P436, DOI 10.1001/jama.261.3.436; Sreevatsan S, 1997, P NATL ACAD SCI USA, V94, P9869, DOI 10.1073/pnas.94.18.9869; STEAD WW, 1978, JAMA-J AM MED ASSOC, V240, P2544, DOI 10.1001/jama.240.23.2544; *TUB TRANSM STAT C, 1992, MMWR-MORBID MORTAL W, V41, P927; VALWAY SE, 1994, J INFECT DIS, V170, P151, DOI 10.1093/infdis/170.1.151; VALWAY SE, 1994, AM J EPIDEMIOL, V140, P113, DOI 10.1093/oxfordjournals.aje.a117222; WILCOCK K, 1996, TUBERCULOSIS CORRECT	31	71	74	1	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	OCT 19	1999	131	8					557	+		10.7326/0003-4819-131-8-199910190-00002	http://dx.doi.org/10.7326/0003-4819-131-8-199910190-00002			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI); Conference Proceedings Citation Index - Science (CPCI-S)	General & Internal Medicine	246ZR	10523215				2022-12-01	WOS:000083196600001
J	Bos, JD				Bos, JD			Reappraisal of dermatoses of pregnancy	LANCET			English	Editorial Material							ATOPIC-DERMATITIS; CRITERIA; SKIN		Univ Amsterdam, Acad Med Ctr, Dept Dermatol AO235, NL-1100 DE Amsterdam, Netherlands	University of Amsterdam; Academic Medical Center Amsterdam	Bos, JD (corresponding author), Univ Amsterdam, Acad Med Ctr, Dept Dermatol AO235, NL-1100 DE Amsterdam, Netherlands.							Aractingi S, 1998, LANCET, V352, P1898, DOI 10.1016/S0140-6736(98)05121-6; Bos JD, 1998, EXP DERMATOL, V7, P132, DOI 10.1111/j.1600-0625.1998.tb00313.x; HOLMES RC, 1983, J AM ACAD DERMATOL, V8, P405, DOI 10.1016/S0190-9622(83)70046-0; Jones SAV, 1999, BRIT J DERMATOL, V141, P71; PROVOST TT, 1973, J CLIN INVEST, V52, P1779, DOI 10.1172/JCI107359; WILLIAMS HC, 1994, BRIT J DERMATOL, V131, P383, DOI 10.1111/j.1365-2133.1994.tb08530.x; WINSTON G, 1982, J AM ACAD DERMATOL, V6, P977	7	6	6	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	OCT 2	1999	354	9185					1140	1140		10.1016/S0140-6736(99)00244-5	http://dx.doi.org/10.1016/S0140-6736(99)00244-5			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	242QX	10513703				2022-12-01	WOS:000082954100005
J	Takahashi, T; Fournier, A; Nakamura, F; Wang, LH; Murakami, Y; Kalb, RG; Fujisawa, H; Strittmatter, SM				Takahashi, T; Fournier, A; Nakamura, F; Wang, LH; Murakami, Y; Kalb, RG; Fujisawa, H; Strittmatter, SM			Plexin-neuropilin-1 complexes form functional semaphorin-3A receptors	CELL			English	Article							GROWTH CONE COLLAPSE; PERIPHERAL-NERVE PROJECTION; NEUROPILIN; FAMILY; PROTEIN; TRANSMEMBRANE; MOLECULES; GUIDANCE; SIGNALS; SYSTEM	Class 1 and 3 semaphorins repulse axons but bind to different cell surface proteins. We find that the two known semaphorin-binding proteins, plexin 1 (Plex 1) and neuropilin-1 (NP-1), form a stable complex. Plex 1 alone does not bind semaphorin-3A (Sema3A), but the NP-1/Plex 1 complex has a higher affinity for Sema3A than does NP-1 alone. While Sema3A binding to NP-1 does not alter nonneuronal cell morphology, Sema3A interaction with NP-1/Plex 1 complexes induces adherent cells to round up. Expression of a dominant-negative Plex 1 in sensory neurons blocks Sema3A-induced growth cone collapse. Sema3A treatment leads to the redistribution of growth cone NP-1 and plexin into clusters. Thus, physiologic Sema3A receptors consist of NP-1/plexin complexes.	Yale Univ, Sch Med, Dept Neurol, New Haven, CT 06510 USA; Yale Univ, Sch Med, Neurobiol Sect, New Haven, CT 06510 USA; Yale Univ, Sch Med, Dept Mol Cellular & Dev Biol, New Haven, CT 06510 USA; Yale Univ, Sch Med, Dept Pharmacol, New Haven, CT 06510 USA; Nagoya Univ, Grad Sch Sci, Grp Dev Neurobiol, Div Biol Sci, Nagoya, Aichi 4648602, Japan	Yale University; Yale University; Yale University; Yale University; Nagoya University	Strittmatter, SM (corresponding author), Yale Univ, Sch Med, Dept Neurol, New Haven, CT 06510 USA.		Strittmatter, Stephen/F-5739-2011	Strittmatter, Stephen/0000-0001-8188-3092				Behar O, 1996, NATURE, V383, P525, DOI 10.1038/383525a0; Chen H, 1998, NEURON, V21, P1283, DOI 10.1016/S0896-6273(00)80648-0; Chen H, 1997, NEURON, V19, P547, DOI 10.1016/S0896-6273(00)80371-2; Comeau MR, 1998, IMMUNITY, V8, P473, DOI 10.1016/S1074-7613(00)80552-X; Eickholt BJ, 1999, DEVELOPMENT, V126, P2181; Feiner L, 1997, NEURON, V19, P539, DOI 10.1016/S0896-6273(00)80370-0; Giger RJ, 1998, NEURON, V21, P1079, DOI 10.1016/S0896-6273(00)80625-X; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.biochem.56.1.615; Goodman CS, 1999, CELL, V97, P551, DOI 10.1016/S0092-8674(00)80766-7; GOSHIMA Y, 1995, NATURE, V376, P509, DOI 10.1038/376509a0; He ZG, 1997, CELL, V90, P739, DOI 10.1016/S0092-8674(00)80534-6; Jin Z, 1997, J NEUROSCI, V17, P6256; Kameyama T, 1996, BIOCHEM BIOPH RES CO, V226, P396, DOI 10.1006/bbrc.1996.1367; Kawakami A, 1996, J NEUROBIOL, V29, P1, DOI 10.1002/(SICI)1097-4695(199601)29:1<1::AID-NEU1>3.0.CO;2-F; Kitsukawa T, 1997, NEURON, V19, P995, DOI 10.1016/S0896-6273(00)80392-X; Kolodkin AL, 1997, CELL, V90, P753, DOI 10.1016/S0092-8674(00)80535-8; KOLODKIN AL, 1993, CELL, V75, P1389, DOI 10.1016/0092-8674(93)90625-Z; Kuhn TB, 1999, J NEUROSCI, V19, P1965; LUO YL, 1993, CELL, V75, P217, DOI 10.1016/0092-8674(93)80064-L; Maestrini E, 1996, P NATL ACAD SCI USA, V93, P674, DOI 10.1073/pnas.93.2.674; Nakamura F, 1998, NEURON, V21, P1093, DOI 10.1016/S0896-6273(00)80626-1; Soker S, 1998, CELL, V92, P735, DOI 10.1016/S0092-8674(00)81402-6; Song HJ, 1998, SCIENCE, V281, P1515, DOI 10.1126/science.281.5382.1515; Takahashi T, 1997, J NEUROSCI, V17, P9183; Takahashi T, 1998, NAT NEUROSCI, V1, P487, DOI 10.1038/2203; Tamagnone L, 1999, CELL, V99, P71, DOI 10.1016/S0092-8674(00)80063-X; Taniguchi M, 1997, NEURON, V19, P519, DOI 10.1016/S0896-6273(00)80368-2; TessierLavigne M, 1996, SCIENCE, V274, P1123, DOI 10.1126/science.274.5290.1123; Wang LH, 1996, J NEUROSCI, V16, P6197; Wang LH, 1997, J NEUROCHEM, V69, P2261; Winberg ML, 1998, CELL, V95, P903, DOI 10.1016/S0092-8674(00)81715-8	31	667	694	0	23	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	OCT 1	1999	99	1					59	69		10.1016/S0092-8674(00)80062-8	http://dx.doi.org/10.1016/S0092-8674(00)80062-8			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	243DK	10520994	Bronze			2022-12-01	WOS:000082981600008
J	Tamagnone, L; Artigiani, S; Chen, H; He, ZG; Ming, GL; Song, HJ; Chedotal, A; Winberg, ML; Goodman, CS; Poo, MM; Tessier-Lavigne, M; Comoglio, PM				Tamagnone, L; Artigiani, S; Chen, H; He, ZG; Ming, GL; Song, HJ; Chedotal, A; Winberg, ML; Goodman, CS; Poo, MM; Tessier-Lavigne, M; Comoglio, PM			Plexins are a large family of receptors for transmembrane, secreted, and GPI-anchored semaphorins in vertebrates	CELL			English	Article							HEPATOCYTE GROWTH-FACTOR; CELL-SURFACE MOLECULE; MET RECEPTOR; SIGNAL TRANSDUCTION; IDENTIFICATION; NEUROPILIN; NEURONS; GUIDANCE; COLLAPSE; PROTEINS	In Drosophila, plexin A is a functional receptor for semaphorin-1a. Here we show that the human plexin gene family comprises at least nine members in four subfamilies. Plexin-B1 is a receptor for the transmembrane semaphorin Sema4D (CD100), and plexin-C1 is a receptor for the GPI-anchored semaphorin Sema7A (Sema-K1). Secreted (class 3) semaphorins do not bind directly to plexins, but rather plexins associate with neuropilins, coreceptors for these semaphorins. Plexins are widely expressed: in neurons, the expression of a truncated plexin-A1 protein blocks axon repulsion by Sema3A. The cytoplasmic domain of plexins associates with a tyrosine kinase activity. Plexins may also act as ligands mediating repulsion in epithelial cells in vitro. We conclude that plexins are receptors for multiple (and perhaps all) classes of semaphorins, either alone or in combination with neuropilins, and trigger a novel signal transduction pathway controlling cell repulsion.	Univ Turin, Inst Canc Res & Treatment, I-10060 Candiolo, Italy; Univ Calif San Francisco, Howard Hughes Med Inst, Dept Anat, San Francisco, CA 94143 USA; Univ Calif San Francisco, Howard Hughes Med Inst, Dept Biochem & Biophys, San Francisco, CA 94143 USA; Univ Calif Berkeley, Howard Hughes Med Inst, Dept Mol & Cell Biol, Berkeley, CA 94720 USA; Univ Calif San Diego, Dept Biol, La Jolla, CA 92093 USA; Hop La Pitie Salpetriere, INSERM U106, F-75013 Paris, France	IRCCS Fondazione del Piemonte per l'Oncologia; University of Turin; Howard Hughes Medical Institute; University of California System; University of California San Francisco; Howard Hughes Medical Institute; University of California System; University of California San Francisco; Howard Hughes Medical Institute; University of California System; University of California Berkeley; University of California System; University of California San Diego; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite	Tamagnone, L (corresponding author), Univ Turin, Inst Canc Res & Treatment, I-10060 Candiolo, Italy.		Ming, Guo-li/J-7880-2013; Chedotal, Alain/F-2750-2017; Tamagnone, Luca/J-8948-2018	Chedotal, Alain/0000-0001-7577-3794; Tamagnone, Luca/0000-0002-2884-7946; Comoglio, Paolo/0000-0002-7056-5328; Ming, Guo-li/0000-0002-2517-6075	NINDS NIH HHS [NS 22764] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS022764] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Behar O, 1996, NATURE, V383, P525, DOI 10.1038/383525a0; BLADT F, 1995, NATURE, V376, P768, DOI 10.1038/376768a0; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; Chen H, 1998, NEURON, V21, P1283, DOI 10.1016/S0896-6273(00)80648-0; Chen H, 1997, NEURON, V19, P547, DOI 10.1016/S0896-6273(00)80371-2; Christensen CRL, 1998, CANCER RES, V58, P1238; Comeau MR, 1998, IMMUNITY, V8, P473, DOI 10.1016/S1074-7613(00)80552-X; Ebens A, 1996, NEURON, V17, P1157, DOI 10.1016/S0896-6273(00)80247-0; Feiner L, 1997, NEURON, V19, P539, DOI 10.1016/S0896-6273(00)80370-0; FLANAGAN JG, 1990, CELL, V63, P185, DOI 10.1016/0092-8674(90)90299-T; Giger RJ, 1998, NEURON, V21, P1079, DOI 10.1016/S0896-6273(00)80625-X; GIORDANO S, 1989, NATURE, V339, P155, DOI 10.1038/339155a0; Glass DJ, 1996, CELL, V85, P513, DOI 10.1016/S0092-8674(00)81252-0; Goodman CS, 1999, CELL, V97, P551, DOI 10.1016/S0092-8674(00)80766-7; Hall KT, 1996, P NATL ACAD SCI USA, V93, P11780, DOI 10.1073/pnas.93.21.11780; He ZG, 1997, CELL, V90, P739, DOI 10.1016/S0092-8674(00)80534-6; Holland SJ, 1996, NATURE, V383, P722, DOI 10.1038/383722a0; Hong KS, 1999, CELL, V97, P927, DOI 10.1016/S0092-8674(00)80804-1; Kameyama T, 1996, BIOCHEM BIOPH RES CO, V226, P396, DOI 10.1006/bbrc.1996.1367; Kameyama T, 1996, BIOCHEM BIOPH RES CO, V226, P524, DOI 10.1006/bbrc.1996.1388; Kolodkin AL, 1997, CELL, V90, P753, DOI 10.1016/S0092-8674(00)80535-8; KOLODKIN AL, 1993, CELL, V75, P1389, DOI 10.1016/0092-8674(93)90625-Z; LUO YL, 1993, CELL, V75, P217, DOI 10.1016/0092-8674(93)80064-L; Maestrini E, 1996, P NATL ACAD SCI USA, V93, P674, DOI 10.1073/pnas.93.2.674; Maina F, 1997, GENE DEV, V11, P3341, DOI 10.1101/gad.11.24.3341; Maina F, 1998, NEURON, V20, P835, DOI 10.1016/S0896-6273(00)80466-3; Maina F, 1996, CELL, V87, P531, DOI 10.1016/S0092-8674(00)81372-0; Miao HQ, 1999, J CELL BIOL, V146, P233, DOI 10.1083/jcb.146.1.233; Nakamura F, 1998, NEURON, V21, P1093, DOI 10.1016/S0896-6273(00)80626-1; OHTA K, 1995, NEURON, V14, P1189, DOI 10.1016/0896-6273(95)90266-X; Sandoval Ignacio V., 1994, Trends in Cell Biology, V4, P292, DOI 10.1016/0962-8924(94)90220-8; SHINOURA N, 1995, CANCER LETT, V89, P215, DOI 10.1016/0304-3835(95)03690-X; Song HJ, 1998, SCIENCE, V281, P1515, DOI 10.1126/science.281.5382.1515; STAHL N, 1993, CELL, V74, P587, DOI 10.1016/0092-8674(93)90506-L; Steiner DF, 1998, CURR OPIN CHEM BIOL, V2, P31, DOI 10.1016/S1367-5931(98)80033-1; Takahashi T, 1999, CELL, V99, P59, DOI 10.1016/S0092-8674(00)80062-8; Tamagnone Luca, 1997, Cytokine and Growth Factor Reviews, V8, P129, DOI 10.1016/S1359-6101(97)00007-5; TessierLavigne M, 1996, SCIENCE, V274, P1123, DOI 10.1126/science.274.5290.1123; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; Winberg ML, 1998, CELL, V95, P903, DOI 10.1016/S0092-8674(00)81715-8	40	897	963	0	44	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	OCT 1	1999	99	1					71	80		10.1016/S0092-8674(00)80063-X	http://dx.doi.org/10.1016/S0092-8674(00)80063-X			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	243DK	10520995	Bronze			2022-12-01	WOS:000082981600009
J	Lebioda, L; LaCount, MW; Zhang, EL; Chen, YP; Han, KP; Whitton, MM; Lincoln, DE; Woodin, SA				Lebioda, L; LaCount, MW; Zhang, EL; Chen, YP; Han, KP; Whitton, MM; Lincoln, DE; Woodin, SA			Protein structure - An enzymatic globin from a marine worm	NATURE			English	Article							PEROXIDASE		Univ S Carolina, Dept Chem, Columbia, SC 29208 USA; Univ S Carolina, Dept Biochem & Biol Sci, Columbia, SC 29208 USA; Parke Davis Pharmaceut Res, Ann Arbor, MI 48105 USA	University of South Carolina; University of South Carolina System; University of South Carolina Columbia; University of South Carolina; University of South Carolina System; University of South Carolina Columbia; Pfizer	Lebioda, L (corresponding author), Univ S Carolina, Dept Chem, Columbia, SC 29208 USA.	lebioda@psc.sc.edu	Woodin, Sarah A/K-8481-2014	Woodin, Sarah A/0000-0001-5615-2212				ATOR MA, 1987, J BIOL CHEM, V262, P1542; Chen YP, 1996, J BIOL CHEM, V271, P4609; DAWSON JH, 1988, SCIENCE, V240, P433, DOI 10.1126/science.3358128; Matsui T, 1999, J BIOL CHEM, V274, P2838, DOI 10.1074/jbc.274.5.2838; POULOS TL, 1988, ADV INORG BIOCHEM, V7, P1; WOODIN SA, 1993, J CHEM ECOL, V19, P517, DOI 10.1007/BF00994322	6	74	74	1	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	SEP 30	1999	401	6752					445	445		10.1038/46728	http://dx.doi.org/10.1038/46728			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	243DF	10519547				2022-12-01	WOS:000082981200044
J	Freeman, TB; Vawter, DE; Leaverton, PE; Godbold, JH; Hauser, RA; Goetz, CG; Olanow, CW				Freeman, TB; Vawter, DE; Leaverton, PE; Godbold, JH; Hauser, RA; Goetz, CG; Olanow, CW			Use of placebo surgery in controlled trials of a cellular-based therapy for Parkinson's disease	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							FETAL NIGRAL TRANSPLANTATION; LONG-TERM SURVIVAL; DOUBLE-BLIND; DOPAMINERGIC GRAFTS; CLINICAL RESEARCH; GENE-THERAPY; PATIENT; IMPLANTS; LEVODOPA; PET		Univ S Florida, Tampa, FL 33606 USA; Minnesota Ctr Hlth Care Eth, Minneapolis, MN 55454 USA; CUNY Mt Sinai Sch Med, New York, NY 10029 USA; Rush Presbyterian St Lukes Med Ctr, Chicago, IL 60612 USA	State University System of Florida; University of South Florida; City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; Rush University	Freeman, TB (corresponding author), Univ S Florida, Tampa, FL 33606 USA.		Hauser, Robert/I-5372-2012		NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS033772] Funding Source: NIH RePORTER; NINDS NIH HHS [R01 NS32842, R01 NS33772] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		[Anonymous], 1998, FED REGISTER, V63, P26744; Apfel SC, 1998, NEUROLOGY, V51, P695, DOI 10.1212/WNL.51.3.695; BAUM M, 1999, LANCET S1, V353, pS16, DOI DOI 10.1016/S0140-6736(99)90220-9]; BEECHER HK, 1961, JAMA-J AM MED ASSOC, V176, P1102, DOI 10.1001/jama.1961.63040260007008; BONCHEK LI, 1979, NEW ENGL J MED, V301, P44, DOI 10.1056/NEJM197907053010110; BREM H, 1995, LANCET, V345, P1008, DOI 10.1016/S0140-6736(95)90755-6; CLARK PI, 1994, ANNU REV PUBL HEALTH, V15, P19; COBB LA, 1959, NEW ENGL J MED, V260, P1115, DOI 10.1056/NEJM195905282602204; Defer GL, 1996, BRAIN, V119, P41, DOI 10.1093/brain/119.1.41; Delbanco TL, 1996, JAMA-J AM MED ASSOC, V275, P716; DIMOND EG, 1958, CIRCULATION, V18, P712; FREEDMAN B, 1987, NEW ENGL J MED, V317, P141, DOI 10.1056/NEJM198707163170304; Freedman B, 1996, J LAW MED ETHICS, V24, P252, DOI 10.1111/j.1748-720X.1996.tb01860.x; FREEMAN TB, 1995, ANN NEUROL, V38, P379, DOI 10.1002/ana.410380307; Freeman TB, 1997, EXP NEUROL, V144, P47, DOI 10.1006/exnr.1996.6387; GUTTMAN M, 1989, CAN J NEUROL SCI, V16, P305, DOI 10.1017/S0317167100029139; HARBAUGH RE, 1989, J NEUROSURG, V71, P481, DOI 10.3171/jns.1989.71.4.0481; Hauser RA, 1999, ARCH NEUROL-CHICAGO, V56, P179, DOI 10.1001/archneur.56.2.179; HAUSER RA, 1992, SCI BASIS TREATMENT, P275; JOHANNES L, 1998, WALL STREET J   1211, pA8; Johannes Laura, 1998, Wall St J (East Ed), pA1; KORDOWER JH, 1995, NEW ENGL J MED, V332, P1118, DOI 10.1056/NEJM199504273321702; Kordower JH, 1996, J COMP NEUROL, V370, P203; Kordower JH, 1998, MOVEMENT DISORD, V13, P383, DOI 10.1002/mds.870130303; LAW PK, 1991, ACTA CARDIOMIOLOGICA, V3, P281; LEAPE LL, 1991, JRA02 RAND, pR5; LEVINE RJ, 1986, ETHICS REGULATION CL; Levit K R, 1985, Health Care Financ Rev, V7, P1; LINDVALL O, 1994, ANN NEUROL, V35, P172, DOI 10.1002/ana.410350208; Lotz B, 1996, NEUROLOGY, V46, P1244; LOVE JW, 1975, JAMA-J AM MED ASSOC, V232, P37, DOI 10.1001/jama.232.1.37; McCarthy M, 1996, LANCET, V348, P323, DOI 10.1016/S0140-6736(05)64475-3; Moseley JB, 1996, AM J SPORT MED, V24, P28, DOI 10.1177/036354659602400106; Nutt JG, 1996, ANN NEUROL, V39, P561, DOI 10.1002/ana.410390504; Olanow CW, 1996, TRENDS NEUROSCI, V19, P102, DOI 10.1016/S0166-2236(96)80038-5; OLANOW CW, 1994, MOVEMENT DISORD, V9, P40, DOI 10.1002/mds.870090107; OLANOW CW, 1990, ARCH NEUROL-CHICAGO, V47, P1286, DOI 10.1001/archneur.1990.00530120030006; OLANOW CW, 1995, ANN NEUROL, V38, P771, DOI 10.1002/ana.410380512; Pocock SJ., 1983, CLIN TRIALS PRACTICA; Prentice Ernest D, 1989, IRB, V11, P6, DOI 10.2307/3563825; Reeves B, 1999, LANCET S1, V353, pS13; ROTHMAN KJ, 1994, NEW ENGL J MED, V331, P394, DOI 10.1056/NEJM199408113310611; SAWLE GV, 1992, ANN NEUROL, V31, P166, DOI 10.1002/ana.410310207; SCHULZ KF, 1995, JAMA-J AM MED ASSOC, V274, P1456; SHOULSON I, 1993, NEW ENGL J MED, V328, P176, DOI 10.1056/NEJM199301213280305; SPODICK DH, 1971, AM HEART J, V81, P149, DOI 10.1016/0002-8703(71)90125-6; STANLEY B, 1988, PSYCHOPHARMACOL BULL, V24, P18; TAYLOR JR, 1995, CELL TRANSPLANT, V4, P13, DOI 10.1016/0963-6897(94)00035-I; THOMSEN J, 1981, ARCH OTOLARYNGOL, V107, P271; TURNER JA, 1994, JAMA-J AM MED ASSOC, V271, P1609, DOI 10.1001/jama.271.20.1609; Wagner M, 1996, LANCET, V348, P1394, DOI 10.1016/S0140-6736(05)67494-6; Wenning GK, 1997, ANN NEUROL, V42, P95, DOI 10.1002/ana.410420115	52	174	178	0	8	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	SEP 23	1999	341	13					988	992		10.1056/NEJM199909233411311	http://dx.doi.org/10.1056/NEJM199909233411311			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	237LP	10498497				2022-12-01	WOS:000082658100011
J	Joubin, K; Stern, CD				Joubin, K; Stern, CD			Molecular interactions continuously define the organizer during the cell movements of gastrulation	CELL			English	Article							BONE MORPHOGENETIC PROTEIN-4; PRIMITIVE STREAK FORMATION; EARLY XENOPUS DEVELOPMENT; EARLY CHICK-EMBRYO; NEURAL INDUCTION; SPEMANNS ORGANIZER; MESODERM INDUCTION; MARGINAL ZONE; AVIAN EMBRYOS; HENSENS NODE	The organizer is a unique region in the gastrulating embryo that induces and patterns the body axis. It arises before gastrulation under the influence of the Nieuwkoop center. We show that during gastrulation, cell movements bring cells into and out of the chick organizer, Hensen's node. During these movements, cells acquire and lose organizer properties according to their position. A "node inducing center," which emits Vg1 and Wnt8C, is located in the middle of the primitive streak. Its activity is inhibited by ADMP produced by the node and by BMPs at the periphery. These interactions define the organizer as a position in the embryo, whose cellular makeup is constantly changing, and explain the phenomenon of organizer regeneration.	Columbia Univ, Dept Genet & Dev, New York, NY 10032 USA; Columbia Univ, Ctr Neurobiol & Behav, New York, NY 10032 USA	Columbia University; Columbia University	Stern, CD (corresponding author), Columbia Univ, Dept Genet & Dev, New York, NY 10032 USA.	cds20@columbia.edu	Stern, Claudio/AAZ-7381-2021; Stern, Claudio D/C-6265-2008	Stern, Claudio/0000-0002-9907-889X; Stern, Claudio D/0000-0002-9907-889X	NIGMS NIH HHS [GM53456] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM053456] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABERCROMBIE M, 1954, J EMBRYOL EXP MORPH, V2, P55; ALTABA AR, 1995, DEV BIOL, V170, P299; Bachvarova RF, 1998, DEVELOPMENT, V125, P3521; BASLER K, 1993, CELL, V73, P687, DOI 10.1016/0092-8674(93)90249-P; BEDDINGTON RSP, 1994, DEVELOPMENT, V120, P613; Biehs B, 1996, GENE DEV, V10, P2922, DOI 10.1101/gad.10.22.2922; Brannon M, 1996, DEV BIOL, V180, P344, DOI 10.1006/dbio.1996.0306; BUTROS J, 1967, J EMBRYOL EXP MORPH, V17, P119; Connolly DJ, 1997, INT J DEV BIOL, V41, P389; CONNOLLY DJ, 1995, DEV GENET, V17, P65, DOI 10.1002/dvg.1020170108; COOKE J, 1973, J EMBRYOL EXP MORPH, V30, P283; COOKE J, 1975, J EMBRYOL EXP MORPH, V33, P147; Crease DJ, 1998, P NATL ACAD SCI USA, V95, P4398, DOI 10.1073/pnas.95.8.4398; Cui YZ, 1996, DEV BIOL, V180, P22, DOI 10.1006/dbio.1996.0281; DALE L, 1992, DEVELOPMENT, V115, P573; DU SJ, 1995, MOL CELL BIOL, V15, P2625; GALLERA J, 1974, EXPERIENTIA, V30, P183, DOI 10.1007/BF01927723; Gerhart J.C., 1980, Biological Regulation and Development, V2, P133; GRABOWSKI CT, 1956, J EXP ZOOL, V133, P301, DOI 10.1002/jez.1401330207; HAMBURGER V, 1951, J MORPHOL, V88, P49, DOI 10.1002/jmor.1050880104; HARA K, 1978, ORG MILESTONE HALF C, P221; Harland R, 1997, ANNU REV CELL DEV BI, V13, P611, DOI 10.1146/annurev.cellbio.13.1.611; HATADA Y, 1994, DEVELOPMENT, V120, P2879; Hoang BH, 1998, DEV DYNAM, V212, P364, DOI 10.1002/(SICI)1097-0177(199807)212:3<364::AID-AJA4>3.0.CO;2-F; Hoppler S, 1998, MECH DEVELOP, V71, P119, DOI 10.1016/S0925-4773(98)00004-5; Hsu DR, 1998, MOL CELL, V1, P673, DOI 10.1016/S1097-2765(00)80067-2; HUME CR, 1993, DEVELOPMENT, V119, P1147; IZPISUABELMONTE JC, 1993, CELL, V74, P645, DOI 10.1016/0092-8674(93)90512-O; Jones CM, 1996, DEVELOPMENT, V122, P1545; JONES CM, 1992, DEVELOPMENT, V115, P639; KAO KR, 1989, DEV BIOL, V132, P81, DOI 10.1016/0012-1606(89)90207-8; Kessler DS, 1997, P NATL ACAD SCI USA, V94, P13017, DOI 10.1073/pnas.94.24.13017; Kodjabachian L, 1998, CURR BIOL, V8, pR918, DOI 10.1016/S0960-9822(98)00009-8; Kretzschmar M, 1998, CURR OPIN GENET DEV, V8, P103, DOI 10.1016/S0959-437X(98)80069-5; LAMB TM, 1993, SCIENCE, V262, P713, DOI 10.1126/science.8235591; Leyns L, 1997, CELL, V88, P747, DOI 10.1016/S0092-8674(00)81921-2; LIEM KF, 1995, CELL, V82, P969, DOI 10.1016/0092-8674(95)90276-7; Lin KM, 1997, P NATL ACAD SCI USA, V94, P11196, DOI 10.1073/pnas.94.21.11196; Moos M, 1995, DEVELOPMENT, V121, P4293; NEW DAT, 1955, J EMBRYOL EXP MORPH, V3, P320; Nicholas JS, 1942, J EXP ZOOL, V90, P127, DOI 10.1002/jez.1400900108; Nicolas JF, 1996, DEVELOPMENT, V122, P2933; NICOLET G, 1970, Journal of Embryology and Experimental Morphology, V23, P79; Nicolet G., 1971, Adv Morphogen, V9, P231; NIEUWKOOP P D, 1969, Wilhelm Roux' Archiv fuer Entwicklungsmechanik der Organismen, V162, P341, DOI 10.1007/BF00578701; OLSON DJ, 1991, SCIENCE, V252, P1173, DOI 10.1126/science.252.5009.1173; Pannett CA, 1924, LANCET, V1, P381; Piccolo S, 1996, CELL, V86, P589, DOI 10.1016/S0092-8674(00)80132-4; Psychoyos D, 1996, DEVELOPMENT, V122, P1523; Psychoyos D, 1996, DEVELOPMENT, V122, P3263; ROSENQUIST GLENN C., 1966, CARNEGIE INST WASH PUBL, V38, P71; SASAI Y, 1994, CELL, V79, P779, DOI 10.1016/0092-8674(94)90068-X; Schultheiss TM, 1997, GENE DEV, V11, P451, DOI 10.1101/gad.11.4.451; Seleiro EAP, 1996, CURR BIOL, V6, P1476, DOI 10.1016/S0960-9822(96)00752-X; SELLECK MAJ, 1992, NATO ADV SCI I A-LIF, V231, P23; SELLECK MAJ, 1991, DEVELOPMENT, V112, P615; Shah SB, 1997, DEVELOPMENT, V124, P5127; Shih J, 1996, DEVELOPMENT, V122, P1313; Shimizu H, 1997, CELL GROWTH DIFFER, V8, P1349; Smith JL, 1998, CURR TOP DEV BIOL, V40, P79, DOI 10.1016/S0070-2153(08)60365-8; SMITH WC, 1992, CELL, V70, P829, DOI 10.1016/0092-8674(92)90316-5; SOKOL S, 1991, CELL, V67, P741, DOI 10.1016/0092-8674(91)90069-B; SOKOL SY, 1992, DEV BIOL, V154, P348, DOI 10.1016/0012-1606(92)90073-P; STEIN S, 1995, MECH DEVELOP, V49, P37, DOI 10.1016/0925-4773(94)00300-C; STEINBEISSER H, 1995, EMBO J, V14, P5230, DOI 10.1002/j.1460-2075.1995.tb00208.x; STERN CD, 1995, DEV BIOL, V172, P192, DOI 10.1006/dbio.1995.0015; STERN CD, 1981, ANAT EMBRYOL, V163, P245, DOI 10.1007/BF00315703; STOREY KG, 1995, DEVELOPMENT, V121, P417; Streit A, 1997, DEVELOPMENT, V124, P1191; Streit A, 1998, DEVELOPMENT, V125, P507; Streit A, 1999, MECH DEVELOP, V82, P51, DOI 10.1016/S0925-4773(99)00013-1; Tam PPL, 1997, MECH DEVELOP, V68, P3, DOI 10.1016/S0925-4773(97)00123-8; Tonegawa A, 1997, DEVELOPMENT, V124, P1975; Torres MA, 1996, J CELL BIOL, V133, P1123, DOI 10.1083/jcb.133.5.1123; Wang SW, 1997, CELL, V88, P757, DOI 10.1016/S0092-8674(00)81922-4; Wang SW, 1997, BIOCHEM BIOPH RES CO, V236, P502, DOI 10.1006/bbrc.1997.6995; Watabe T, 1995, GENE DEV, V9, P3038, DOI 10.1101/gad.9.24.3038; Watanabe Y, 1996, MECH DEVELOP, V57, P69, DOI 10.1016/0925-4773(96)00534-5; Whitman M, 1998, GENE DEV, V12, P2445, DOI 10.1101/gad.12.16.2445; WU M, 1991, METHOD CELL BIOL, V36, P3; YUAN SP, 1995, DEV GENET, V17, P38, DOI 10.1002/dvg.1020170106; Yuan SP, 1999, DEVELOPMENT, V126, P2461; Yuan SP, 1998, DEVELOPMENT, V125, P201; Yuan SP, 1995, DEV BIOL, V172, P567, DOI 10.1006/dbio.1995.8064; ZOM AM, 1999, DEV BIOL, V209, P282	85	119	122	0	3	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	SEP 3	1999	98	5					559	571		10.1016/S0092-8674(00)80044-6	http://dx.doi.org/10.1016/S0092-8674(00)80044-6			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	233NT	10490096	Bronze			2022-12-01	WOS:000082433500004
J	Oldstone, MBA; Lewicki, H; Thomas, D; Tishon, A; Dales, S; Patterson, J; Manchester, M; Homann, D; Naniche, D; Holz, A				Oldstone, MBA; Lewicki, H; Thomas, D; Tishon, A; Dales, S; Patterson, J; Manchester, M; Homann, D; Naniche, D; Holz, A			Measles virus infection in a transgenic model: Virus-induced immunosuppression and central nervous system disease	CELL			English	Article							DEPENDENT DIABETES-MELLITUS; SINDBIS VIRUS; MOUSE MODEL; T-CELLS; PROTEIN; MICE; CD46; EXPRESSION; RECEPTOR; STRAIN	Measles virus (MV) infects 40 million persons and kills one million per year primarily by suppressing the immune system and afflicting the central nervous system (CNS). The lack of a suitable small animal model has impeded progress of understanding how MV causes disease and the development of novel therapies and improved vaccines. We tested a transgenic mouse line in which expression of the MV receptor CD46 closely mimicked the location and amount of CD46 found in humans. Virus replicated in and was recovered from these animals' immune systems and was associated with suppression of humoral and cellular immune responses. infectious virus was recovered from the CNS, replicated primarily in neurons, and spread to distal sites presumably by fast axonal transport. Thus, a small animal model is available for analysis of MV pathogenesis.	Scripps Res Inst, Res Inst, Dept Neuropharmacol, Div Virol, La Jolla, CA 92037 USA; Rockefeller Univ, Dept Cell Biol, New York, NY 10024 USA	Scripps Research Institute; Rockefeller University	Oldstone, MBA (corresponding author), Scripps Res Inst, Res Inst, Dept Neuropharmacol, Div Virol, 10550 N Torrey Pines Rd, La Jolla, CA 92037 USA.	mbaobo@scripps.edu	Naniche, Denise S/S-1814-2018	Naniche, Denise S/0000-0002-4495-6325; Holz, Andreas/0000-0002-8886-0915; Homann, Dirk/0000-0002-7622-5754	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI036222] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [T32MH019185] Funding Source: NIH RePORTER; NIAID NIH HHS [AI36222] Funding Source: Medline; NIA NIH HHS [AG00080] Funding Source: Medline; NIMH NIH HHS [MH19185] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305; Baskar JF, 1996, J VIROL, V70, P3207, DOI 10.1128/JVI.70.5.3207-3214.1996; Blixenkrone-Moller M, 1998, VIROLOGY, V249, P238, DOI 10.1006/viro.1998.9301; DORIG RE, 1993, CELL, V75, P295, DOI 10.1016/0092-8674(93)80071-L; EASTMAN CL, 1994, EXP NEUROL, V125, P119, DOI 10.1006/exnr.1994.1015; Evans CF, 1996, J EXP MED, V184, P2371, DOI 10.1084/jem.184.6.2371; FugierVivier I, 1997, J EXP MED, V186, P813, DOI 10.1084/jem.186.6.813; GAMES D, 1995, NATURE, V373, P523, DOI 10.1038/373523a0; Griffin D., 1996, FIELDS VIROLOGY, V3rd ed., P1267; Griffin DE, 1999, TRENDS MICROBIOL, V7, P155, DOI 10.1016/S0966-842X(99)01470-5; Grosjean I, 1997, J EXP MED, V186, P801, DOI 10.1084/jem.186.6.801; Holz A, 1996, J NEUROSCI, V16, P467; Homann D, 1998, J VIROL, V72, P9208, DOI 10.1128/JVI.72.11.9208-9216.1998; Horvat B, 1996, J VIROL, V70, P6673, DOI 10.1128/JVI.70.10.6673-6681.1996; Horwitz MS, 1999, LAB INVEST, V79, P235; JOHNSON RT, 1972, J INFECT DIS, V125, P257, DOI 10.1093/infdis/125.3.257; Lawrence DMP, 1999, J VIROL, V73, P1795, DOI 10.1128/JVI.73.3.1795-1801.1999; LIEBERT UG, 1995, CURR TOP MICROBIOL, V191, P149; LIPKIN WI, 1989, CURR TOP MICROBIOL, V143, P33; LISZEWSKI MK, 1991, ANNU REV IMMUNOL, V9, P431, DOI 10.1146/annurev.iy.09.040191.002243; LOMELI H, 1994, SCIENCE, V266, P1709, DOI 10.1126/science.7992055; LONG EO, 1989, IMMUNOL TODAY, V10, P45, DOI 10.1016/0167-5699(89)90303-4; MANCHESTER M, 1994, P NATL ACAD SCI USA, V91, P2161, DOI 10.1073/pnas.91.6.2161; Markowitz LE, 1994, VACCINES, P229; MCCHESNEY MB, 1989, ADV IMMUNOL, V45, P335, DOI 10.1016/S0065-2776(08)60696-3; MOSIER DE, 1974, J IMMUNOL, V112, P305; Mrkic B, 1998, J VIROL, V72, P7420, DOI 10.1128/JVI.72.9.7420-7427.1998; NANICHE D, 1993, J VIROL, V67, P6025, DOI 10.1128/JVI.67.10.6025-6032.1993; OLDSTONE MB, 1973, J IMMUNOL, V110, P1268; Oldstone MBA, 1997, VIROLOGY, V234, P179, DOI 10.1006/viro.1997.8674; OLDSTONE MBA, 1986, NATURE, V321, P239, DOI 10.1038/321239a0; OLDSTONE MBA, 1991, CELL, V65, P319, DOI 10.1016/0092-8674(91)90165-U; OLDSTONE MBA, 1998, VIRUSES PLAGUES HIST, P73; PATTERSON JB, 1995, VIROLOGY, V210, P508, DOI 10.1006/viro.1995.1370; RADECKE F, 1995, EMBO J, V14, P5773, DOI 10.1002/j.1460-2075.1995.tb00266.x; Rall GF, 1997, P NATL ACAD SCI USA, V94, P4659, DOI 10.1073/pnas.94.9.4659; RIMA BK, 1995, CURR TOP MICROBIOL, V191, P65; ROCKENSTEIN EM, 1995, J BIOL CHEM, V270, P28257; Rollins BJ, 1997, BLOOD, V90, P909, DOI 10.1182/blood.V90.3.909.909_909_928; ROZENBLATT S, 1979, J VIROL, V32, P329, DOI 10.1128/JVI.32.1.329-333.1979; RUSSELL SM, 1992, EUR J IMMUNOL, V22, P1513, DOI 10.1002/eji.1830220625; Schnorr JJ, 1997, P NATL ACAD SCI USA, V94, P5326, DOI 10.1073/pnas.94.10.5326; Tanaka N, 1998, GENES CELLS, V3, P29, DOI 10.1046/j.1365-2443.1998.00164.x; TERMEULEN V, 1983, COMPR VIROL, V18, P105; Thorley BR, 1997, EUR J IMMUNOL, V27, P726, DOI 10.1002/eji.1830270322; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; TISHON A, 1988, J IMMUNOL, V140, P1280; Trgovcich J, 1997, VIROLOGY, V227, P234, DOI 10.1006/viro.1996.8289; VONHERRATH MG, 1994, IMMUNITY, V1, P231, DOI 10.1016/1074-7613(94)90101-5; Yannoutsos N, 1996, GENES CELLS, V1, P409, DOI 10.1046/j.1365-2443.1996.d01-244.x; Zingoni A, 1998, J IMMUNOL, V161, P547	51	125	127	0	1	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	SEP 3	1999	98	5					629	640		10.1016/S0092-8674(00)80050-1	http://dx.doi.org/10.1016/S0092-8674(00)80050-1			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	233NT	10490102	Bronze			2022-12-01	WOS:000082433500010
J	Birketvedt, GS; Florholmen, J; Sundsfjord, J; Osterud, B; Dinges, D; Bilker, W; Stunkard, A				Birketvedt, GS; Florholmen, J; Sundsfjord, J; Osterud, B; Dinges, D; Bilker, W; Stunkard, A			Behavioral and neuroendocrine characteristics of the night-eating syndrome	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							OBESITY SURGERY PATIENTS; GENERAL-POPULATION; MELATONIN LEVELS; NOCTURNAL RISE; BINGE; DISORDERS; LEPTIN; SLEEP; PROTEIN; DEPRESSION	Context Investigators first described the night-eating syndrome (NES), which consists of morning anorexia, evening hyperphagia, and insomnia, in 1955, but, to our knowledge, this syndrome has never been subjected to careful clinical study. Objective To characterize NES on the basis of behavioral characteristics and neuroendocrine data. Design and Setting A behavioral observational study was conducted between January 1996 and June 1997 in a weight and eating disorders program at the University of Pennsylvania. A neuroendocrine study was conducted from May through August 1997 at the Clinical Research Center of the University Hospital, Tromso, Norway, Subjects The behavioral study included 10 obese subjects who met criteria for NES and 10 matched control subjects. The neuroendocrine study included 12 night eaters and 21 control subjects. Behavioral study subjects were observed for 1 week on an outpatient basis, and neuroendocrine study subjects were observed during a 24-hour period in the hospital. Main Outcome Measures The behavioral study measured timing of energy intake, mood level, and sleep disturbances. The neuroendocrine study measured circadian levels of plasma melatonin, leptin, and cortisol, Results In the behavioral study, compared with control subjects, night eaters had more eating episodes in the 24 hours (mean [SD], 9.3 [0.6] vs 4.2 [0.2]; P<.001) and consumed significantly more of their daily energy intake at night than did control subjects (56% vs 15%; P<.001), They averaged 3.6 (0.9) awakenings per night compared with 0.3 (0.3) by controls (P<.001). In night eaters, 52% of these awakenings were associated with food intake, with a mean intake per ingestion of 1134 (1197) kJ, None of the controls ate during their awakenings. In the neuroendocrine study, compared with control subjects, night eaters had attenuation of the nocturnal rise in plasma melatonin and leptin levels (P<.001 for both) and higher circadian levels of plasma cortisol (P = .001). Conclusion A coherent pattern of behavioral and neuroendocrine characteristics was found in subjects with NES.	Univ Penn, Sch Med, Dept Psychiat, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Dept Biostat & Epidemiol, Philadelphia, PA 19104 USA; Univ Tromso, Inst Clin Med, Lab Gastroenterol, Tromso, Norway; Univ Tromso, Inst Med Biochem, Tromso, Norway; Univ Tromso Hosp, Dept Clin Chem, N-9012 Tromso, Norway	University of Pennsylvania; University of Pennsylvania; UiT The Arctic University of Tromso; UiT The Arctic University of Tromso; UiT The Arctic University of Tromso; University Hospital of North Norway	Birketvedt, GS (corresponding author), Univ Penn, Sch Med, Dept Psychiat, 3600 Market St,Suite 736, Philadelphia, PA 19104 USA.	gsb42nor@aol.com	Bilker, Warren/AAS-3515-2021; Dinges, David/P-7183-2019					American Sleep Disorders Association. Diagnostic Classification Steering Committee, 1990, INT CLASS SLEEP DIS, pxii, 396; BERRY EM, 1991, NEUROLOGY, V41, P1295, DOI 10.1212/WNL.41.8.1295; Considine RV, 1996, NEW ENGL J MED, V334, P292, DOI 10.1056/NEJM199602013340503; Diggle P., 2002, ANAL LONGITUDINAL DA; Fairburn CG, 1993, BINGE EATING NATURE; GREENO CG, 1995, INT J EAT DISORDER, V18, P343, DOI 10.1002/1098-108X(199512)18:4&lt;343::AID-EAT2260180407&gt;3.0.CO;2-P; GRILO CM, 1994, J CONSULT CLIN PSYCH, V62, P611, DOI 10.1037/0022-006X.62.3.611; HAIMOV I, 1994, BRIT MED J, V309, P167, DOI 10.1136/bmj.309.6948.167; HAIMOV I, 1995, SLEEP, V18, P598, DOI 10.1093/sleep/18.7.598; Hajak G, 1995, J PINEAL RES, V19, P116, DOI 10.1111/j.1600-079X.1995.tb00179.x; HANSEN T, 1987, ACTA PSYCHIAT SCAND, V75, P428, DOI 10.1111/j.1600-0447.1987.tb02811.x; Heiman ML, 1997, ENDOCRINOLOGY, V138, P3859, DOI 10.1210/en.138.9.3859; HEINRICHS SC, 1995, STRESS BASIC MECHANI, P93; Kellner M, 1997, NEUROENDOCRINOLOGY, V65, P284, DOI 10.1159/000127186; KENNEDY SH, 1989, ARCH GEN PSYCHIAT, V46, P73; Manni R, 1997, SLEEP, V20, P734, DOI 10.1093/sleep/20.9.734; Matkovic V, 1997, J CLIN ENDOCR METAB, V82, P1368, DOI 10.1210/jc.82.5.1368; RAND CSW, 1993, INT J OBESITY, V17, P657; Rand CSW, 1997, INT J EAT DISORDER, V22, P65, DOI 10.1002/(SICI)1098-108X(199707)22:1&lt;65::AID-EAT8&gt;3.0.CO;2-0; ROSEN JC, 1986, INT J EAT DISORDER, V5, P255, DOI 10.1002/1098-108X(198602)5:2<255::AID-EAT2260050206>3.0.CO;2-D; ROSSITER EM, 1990, INT J EAT DISORDER, V9, P513, DOI 10.1002/1098-108X(199009)9:5&lt;513::AID-EAT2260090506&gt;3.0.CO;2-T; SADEH A, 1989, J AMBULATORY MONITOR, V25, P305; SCHENCK CH, 1993, SLEEP, V16, P457; SCHENCK CH, 1994, INT J EAT DISORDER, V15, P343, DOI 10.1002/eat.2260150405; Sinha MK, 1996, J CLIN INVEST, V97, P1344, DOI 10.1172/JCI118551; SPAGGIARI MC, 1994, SLEEP, V17, P339, DOI 10.1093/sleep/17.4.339; Stratakis CA, 1995, ANN NY ACAD SCI, V771, P1, DOI 10.1111/j.1749-6632.1995.tb44666.x; Stunkard A, 1996, INT J OBESITY, V20, P1; STUNKARD AJ, 1955, AM J MED, V19, P78, DOI 10.1016/0002-9343(55)90276-X; STUNKARD AJ, 1959, PSYCHIAT QUART, V33, P284, DOI 10.1007/BF01575455; Turnbull AV, 1997, P SOC EXP BIOL MED, V215, P1; VONEN B, 1992, SCAND J CLIN LAB INV, V52, P107, DOI 10.3109/00365519209088773; WINKELMAN JW, 1993, SLEEP RES, V22, P291; WISBERG J, 1990, J SLEEP RES, V19, P384; YOKOGOSHI H, 1986, METABOLISM, V35, P837, DOI 10.1016/0026-0495(86)90225-8; ZEGER SL, 1986, BIOMETRICS, V42, P121, DOI 10.2307/2531248; Zhdanova IV, 1996, SLEEP, V19, P423, DOI 10.1093/sleep/19.5.423	37	270	278	0	20	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 18	1999	282	7					657	663		10.1001/jama.282.7.657	http://dx.doi.org/10.1001/jama.282.7.657			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	226QY	10517719	Bronze			2022-12-01	WOS:000082033700025
J	Hargreave, TB				Hargreave, TB			Understanding the Y chromosome	LANCET			English	Editorial Material							GENE; SPERMATOGENESIS; MICRODELETIONS; INTERVAL-6; DELETIONS; LOCUS; MEN		Western Gen Hosp, Dept Urol, Edinburgh EH4 2XU, Midlothian, Scotland	University of Edinburgh	Hargreave, TB (corresponding author), Western Gen Hosp, Dept Urol, Edinburgh EH4 2XU, Midlothian, Scotland.							BERTA P, 1990, NATURE, V348, P448, DOI 10.1038/348448A0; Brown GM, 1998, HUM MOL GENET, V7, P97, DOI 10.1093/hmg/7.1.97; Cooke HJ, 1998, FERTIL STERIL, V69, P989, DOI 10.1016/S0015-0282(98)00071-5; KOBAYASHI K, 1994, HUM MOL GENET, V3, P1965, DOI 10.1093/hmg/3.11.1965; Kuroki Y, 1999, J HUM GENET, V44, P289, DOI 10.1007/s100380050162; MA K, 1993, CELL, V75, P1287, DOI 10.1016/0092-8674(93)90616-X; MA K, 1992, HUM MOL GENET, V1, P29, DOI 10.1093/hmg/1.1.29; Pryor JL, 1997, NEW ENGL J MED, V336, P534, DOI 10.1056/NEJM199702203360802; REIJO R, 1995, NAT GENET, V10, P383, DOI 10.1038/ng0895-383; Short RV, 1997, ACTA PAEDIATR, V86, P3; Silber SJ, 1998, HUM REPROD, V13, P3332, DOI 10.1093/humrep/13.12.3332; Stuppia L, 1997, J MED GENET, V34, P881, DOI 10.1136/jmg.34.11.881	12	6	6	0	1	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	NOV 20	1999	354	9192					1746	1747		10.1016/S0140-6736(99)00311-6	http://dx.doi.org/10.1016/S0140-6736(99)00311-6			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	258RM	10577631				2022-12-01	WOS:000083853000004
J	Cunha, A; Azevedo, RBR; Emmons, SW; Leroi, AM				Cunha, A; Azevedo, RBR; Emmons, SW; Leroi, AM			Developmental biology - Variable cell number in nematodes	NATURE			English	Article							CAENORHABDITIS-ELEGANS; LINEAGES		Univ London Imperial Coll Sci Technol & Med, Dept Biol, Ascot SL5 7PY, Berks, England; Yeshiva Univ Albert Einstein Coll Med, Dept Mol Genet, Bronx, NY 10461 USA	Imperial College London; Yeshiva University; Albert Einstein College of Medicine	Cunha, A (corresponding author), Univ London Imperial Coll Sci Technol & Med, Dept Biol, Silwood Pk, Ascot SL5 7PY, Berks, England.		Azevedo, Ricardo/AAV-3963-2021	Azevedo, Ricardo/0000-0001-5402-7071				Ambros V., 1987, Development as an Evolutionary Process. MBL Lectures in Biology, vol.8, P139; AZEVEDO RBR, IN PRESS NEMATOLOGY; Blaxter ML, 1998, NATURE, V392, P71, DOI 10.1038/32160; FITCH DHA, 1995, MOL BIOL EVOL, V12, P346; KIMBLE J, 1979, DEV BIOL, V70, P396, DOI 10.1016/0012-1606(79)90035-6; PURVIS A, 1995, COMPUT APPL BIOSCI, V11, P247; Rusin L. Y., 1998, Doklady, Biological Sciences, V361, P331; SOMMER RJ, 1994, DEVELOPMENT, V120, P85; STERNBERG PW, 1982, DEV BIOL, V93, P181, DOI 10.1016/0012-1606(82)90251-2; SULSTON JE, 1977, DEV BIOL, V56, P110, DOI 10.1016/0012-1606(77)90158-0; SULSTON JE, 1983, DEV BIOL, V100, P64, DOI 10.1016/0012-1606(83)90201-4; van Cleave HJ, 1932, Q REV BIOL, V7, P59, DOI 10.1086/394396; Voronov DA, 1998, DEVELOPMENT, V125, P143	13	32	33	0	8	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	NOV 18	1999	402	6759					253	253		10.1038/46211	http://dx.doi.org/10.1038/46211			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	257ZP	10580494	Bronze			2022-12-01	WOS:000083813700037
J	Peterschmitt, MJ; Simmons, JR; Levy, HL				Peterschmitt, MJ; Simmons, JR; Levy, HL			Reduction of false negative results in screening of newborns for homocystinuria.	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							DEFICIENCY; SPECIMEN	Background: Mental retardation and other medical problems (including ectopia lentis, osteoporosis, and thromboembolism) in patients who have homocystinuria as a result of a deficiency of cystathionine beta-synthase can be prevented by the screening of newborns with measurement of blood methionine, followed by the early treatment of affected infants. Many infants with this disorder, however, are not identified by screening and have irreversible brain damage. Methods: We reviewed the results of neonatal screening for homocystinuria over a period of 32 years in New England. Additional specimens were requested for repeated analysis when blood methionine measurements were at or above the established cutoff level. Homocystinuria due to cystathionine beta-synthase deficiency was confirmed by quantitative amino acid analyses. Results: For the first 23.5 years of the review period, the blood methionine cutoff value was 2 mg per deciliter (134 micromol per liter). Among the 2.2 million infants screened during that period, 8 with homocystinuria were identified (1:275,000). In 1990, the cutoff value was reduced to 1 mg per deciliter (67 mu mol per liter). Among the 1.1 million infants screened in the subsequent 8.5 years, 7 with the disorder were identified (1:157,000). During the latter period, the specimens were collected from six of the seven infants when they were two days of age or less; five of the six had blood methionine concentrations below 2 mg per deciliter. Use of the reduced cutoff level increased the false positive rate from 0.006 percent to 0.03 percent. Conclusions: A cutoff level for blood methionine of 1 mg per deciliter in neonatal screening tests for homocystinuria should identify affected infants who have only slightly elevated concentrations of methionine and reduce the frequency of false negative results. (N Engl J Med 1999;341:1572-6.) (C) 1999, Massachusetts Medical Society.	Childrens Hosp, Div Genet, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Pediat, Boston, MA 02115 USA; State Lab Inst, New England Newborn Screening Program, Boston, MA USA	Harvard University; Boston Children's Hospital; Harvard University; Harvard Medical School	Levy, HL (corresponding author), Childrens Hosp, Div Genet, 300 Longwood Ave,IC-106, Boston, MA 02115 USA.	levy_h@al.tch.harvard.edu						BRATTSTROM LE, 1988, SCAND J CLIN LAB INV, V48, P215, DOI 10.3109/00365518809167487; CUNNINGHAM CG, 1995, EARLY HOSP DISCHARGE, P31; DOHERTY LB, 1991, PEDIATRICS, V87, P240; EFRON ML, 1964, NEW ENGL J MED, V270, P1378, DOI 10.1056/NEJM196406252702602; Gaustadnes M, 1999, NEW ENGL J MED, V340, P1513, DOI 10.1056/NEJM199905133401915; GUTHRIE R, 1968, Birth Defects Original Article Series, V4, P92; *IL DEP PUBL HLTH, 1996, NEWB SCREEN OV NEWB; Krans JP, 1998, EUR J PEDIATR, V157, pS50, DOI 10.1007/PL00014304; Levy H.L., 1971, INHERITED DISORDERS, P235; LEVY HL, 1970, LANCET, V2, P522; MORRISON AS, 1992, MONOGRAPHS EPIDEMIOL, V19; Mudd S.H., 1995, METABOLIC MOL BASES, V1, P1279; Naughten ER, 1998, EUR J PEDIATR, V157, pS84, DOI 10.1007/PL00014310; Pang S, 1993, SCREENING, V2, P105, DOI 10.1016/0925-6164(93)90024-D; VERKERK PH, 1993, AM J PUBLIC HEALTH, V83, P868, DOI 10.2105/AJPH.83.6.868; WAGSTAFF J, 1991, J PEDIATR-US, V118, P569, DOI 10.1016/S0022-3476(05)83383-9; WALRAVEN C, 1995, SCREENING, V4, P1, DOI 10.1016/0925-6164(95)00110-8; Walter JH, 1998, EUR J PEDIATR, V157, pS71, DOI 10.1007/PL00014308; Watanabe Toshiyuki, 1997, Journal of Medical Investigation, V44, P95; WHITEMAN PD, 1979, ARCH DIS CHILD, V54, P593, DOI 10.1136/adc.54.8.593; Wilcken DEL, 1997, J INHERIT METAB DIS, V20, P295, DOI 10.1023/A:1005373209964; Yap S, 1998, J INHERIT METAB DIS, V21, P738, DOI 10.1023/A:1005445132327	22	37	43	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	NOV 18	1999	341	21					1572	1576		10.1056/NEJM199911183412103	http://dx.doi.org/10.1056/NEJM199911183412103			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	256GF	10564686				2022-12-01	WOS:000083717000003
J	Marszalek, PE; Lu, H; Li, HB; Carrion-Vazquez, M; Oberhauser, AF; Schulten, K; Fernandez, JM				Marszalek, PE; Lu, H; Li, HB; Carrion-Vazquez, M; Oberhauser, AF; Schulten, K; Fernandez, JM			Mechanical unfolding intermediates in titin modules	NATURE			English	Article							IMMUNOGLOBULIN-LIKE MODULES; MOLECULAR-DYNAMICS; CARDIAC MYOCYTES; PROTEIN TITIN; ELASTICITY; DOMAINS; FORCE; EXTENSIBILITY; REGION	The modular protein titin, which is responsible for the passive elasticity of muscle, is subjected to stretching forces. Previous work on the experimental elongation of single titin molecules has suggested that force causes consecutive unfolding of each domain in an all-or-none fashion(1-6). To avoid problems associated with the heterogeneity of the modular, naturally occurring titin, we engineered single proteins to have multiple copies of single immunoglobulin domains of human cardiac titin(7). Here we report the elongation of these molecules using the atomic force microscope. We find an abrupt extension of each domain by similar to 7 Angstrom before the first unfolding event. This fast initial extension before a full unfolding event produces a reversible 'unfolding intermediate'. Steered molecular dynamics(8,9) simulations show that the rupture of a pair of hydrogen bonds near the amino terminus of the protein domain causes an extension of about 6 Angstrom, which is in good agreement with our observations. Disruption of these hydrogen bonds by site-directed mutagenesis eliminates the unfolding intermediate. The unfolding intermediate extends titin domains by similar to 15% of their slack length, and is, therefore a likely to be an important previously unrecognized component of titin elasticity.	Mayo Clin & Mayo Fdn, Dept Physiol & Biophys, Rochester, MN 55905 USA; Univ Illinois, Beckman Inst Adv Sci & Technol, Urbana, IL 61801 USA	Mayo Clinic; University of Illinois System; University of Illinois Urbana-Champaign	Fernandez, JM (corresponding author), Mayo Clin & Mayo Fdn, Dept Physiol & Biophys, Rochester, MN 55905 USA.	fernandez-julio@mayo.edu	Lu, Hui/K-3264-2019; Schulten, Klaus/D-5561-2009; Li, Hongbin/G-2949-2012; Carrion-Vazquez, Mariano/Y-3741-2018	Li, Hongbin/0000-0001-7813-1332; Carrion-Vazquez, Mariano/0000-0001-7319-406X; Lu, Hui/0000-0001-8347-0830				BrUnger A. T., 1992, X PLOR VERSION 3 1 S; Carrion-Vazquez M, 1999, P NATL ACAD SCI USA, V96, P3694, DOI 10.1073/pnas.96.7.3694; Erickson HP, 1997, SCIENCE, V276, P1090, DOI 10.1126/science.276.5315.1090; Evans E, 1999, BIOPHYS J, V76, P2439, DOI 10.1016/S0006-3495(99)77399-6; FLORIN EL, 1995, BIOSENS BIOELECTRON, V10, P895, DOI 10.1016/0956-5663(95)99227-C; Gautel M, 1996, FEBS LETT, V385, P11, DOI 10.1016/0014-5793(96)00338-9; Granzier H, 1997, BIOPHYS J, V73, P2043, DOI 10.1016/S0006-3495(97)78234-1; Granzier H, 1996, BIOPHYS J, V70, P430, DOI 10.1016/S0006-3495(96)79586-3; HERMANS J, 1984, BIOPOLYMERS, V23, P1513, DOI 10.1002/bip.360230807; Humphrey W, 1996, J MOL GRAPH MODEL, V14, P33, DOI 10.1016/0263-7855(96)00018-5; Improta S, 1998, J MOL BIOL, V284, P761, DOI 10.1006/jmbi.1998.2028; Izrailev S, 1997, BIOPHYS J, V72, P1568, DOI 10.1016/S0006-3495(97)78804-0; Kellermayer MSZ, 1997, SCIENCE, V276, P1112, DOI 10.1126/science.276.5315.1112; Kellermayer MSZ, 1998, J STRUCT BIOL, V122, P197, DOI 10.1006/jsbi.1998.3988; LABEIT S, 1995, SCIENCE, V270, P293, DOI 10.1126/science.270.5234.293; Labeit S, 1997, CIRC RES, V80, P290, DOI 10.1161/01.RES.80.2.290; Linke WA, 1998, J CELL SCI, V111, P1567; Lu H, 1998, BIOPHYS J, V75, P662, DOI 10.1016/S0006-3495(98)77556-3; Lu H, 1999, PROTEINS, V35, P453, DOI 10.1002/(SICI)1097-0134(19990601)35:4<453::AID-PROT9>3.3.CO;2-D; Marszalek PE, 1998, NATURE, V396, P661, DOI 10.1038/25322; Nelson MT, 1996, INT J SUPERCOMPUT AP, V10, P251, DOI 10.1177/109434209601000401; Oberhauser AF, 1998, NATURE, V393, P181, DOI 10.1038/30270; Politou AS, 1996, J MOL BIOL, V255, P604, DOI 10.1006/jmbi.1996.0050; Politou AS, 1995, BIOPHYS J, V69, P2601, DOI 10.1016/S0006-3495(95)80131-1; Rief M, 1997, SCIENCE, V276, P1109, DOI 10.1126/science.276.5315.1109; Rief M, 1998, PHYS REV LETT, V81, P4764, DOI 10.1103/PhysRevLett.81.4764; Rief M, 1999, J MOL BIOL, V286, P553, DOI 10.1006/jmbi.1998.2466; SOTERIOU A, 1993, P ROY SOC B-BIOL SCI, V254, P83, DOI 10.1098/rspb.1993.0130; Trombitas K, 1998, J CELL BIOL, V140, P853, DOI 10.1083/jcb.140.4.853; Tskhovrebova L, 1997, NATURE, V387, P308, DOI 10.1038/387308a0	30	666	681	2	126	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	NOV 4	1999	402	6757					100	103		10.1038/47083	http://dx.doi.org/10.1038/47083			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	254XC	10573426				2022-12-01	WOS:000083638600052
J	Rees, J				Rees, J			Understanding barrier function of the skin	LANCET			English	Editorial Material									Univ Newcastle Upon Tyne, Sch Med, Dept Dermatol, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England	Newcastle University - UK	Rees, J (corresponding author), Univ Newcastle Upon Tyne, Sch Med, Dept Dermatol, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England.							BODDE H, 1996, J INVEST DERMATOL, V5, P1155; Hashimoto T, 1999, J DERMATOL SCI, V20, P81, DOI 10.1016/S0923-1811(99)00014-6; HILLIS WD, 1993, CURR BIOL, V3, P79; Schaefer H., 1996, SKIN BARRIER; Segre JA, 1999, NAT GENET, V22, P356, DOI 10.1038/11926; Shuster S., 1978, DERMATOLOGY INTERNAL, P116; WERNER Y, 1985, ACTA DERM-VENEREOL, V65, P102; Williams M L, 1998, J Investig Dermatol Symp Proc, V3, P75	8	9	9	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	OCT 30	1999	354	9189					1491	1492		10.1016/S0140-6736(99)00281-0	http://dx.doi.org/10.1016/S0140-6736(99)00281-0			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	250WB	10551492				2022-12-01	WOS:000083411300006
J	Armstrong, K; Schwartz, JS; Asch, DA				Armstrong, K; Schwartz, JS; Asch, DA			Direct sale of sildenafil (Viagra) to consumers over the Internet	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							MEDICAL INFORMATION; QUALITY		Univ Penn, Sch Med, Philadelphia, PA 19104 USA; Philadelphia Vet Affairs Med Ctr, Philadelphia, PA 19104 USA	University of Pennsylvania; University of Pennsylvania; Pennsylvania Medicine; US Department of Veterans Affairs; Veterans Health Administration (VHA); Philadelphia Veterans Affairs Medical Center	Armstrong, K (corresponding author), Univ Penn, Sch Med, Philadelphia, PA 19104 USA.			Asch, David/0000-0002-7970-286X	NCI NIH HHS [CA73619] Funding Source: Medline	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Berger A, 1998, BMJ, V317, P824; CAPPASSO T, 1999, STATE J REGISTE 0506, P9; Cheitlin MD, 1999, CIRCULATION, V99, P168, DOI 10.1161/01.CIR.99.1.168; Dorozynski A, 1996, BRIT MED J, V313, P1033; DOULIN T, 1999, COLUMBUS DISPA 0513, pA1; Dyer C, 1996, BRIT MED J, V313, P645; Eysenbach G, 1998, BRIT MED J, V317, P1496, DOI 10.1136/bmj.317.7171.1496; Goldstein I, 1998, NEW ENGL J MED, V338, P1397, DOI 10.1056/NEJM199805143382001; Greenaway NJ, 1999, LANCET, V353, P330, DOI 10.1016/S0140-6736(05)74889-3; HADDON J, 1999, MORNING EDITION 0511; KASSIRER JP, 1995, NEW ENGL J MED, V332, P52, DOI 10.1056/NEJM199501053320110; LEE TH, 1999, HARVARD HEART LETT, V9, P7; Marwick C, 1999, JAMA-J AM MED ASSOC, V281, P975, DOI 10.1001/jama.281.11.975; McDonald CJ, 1998, JAMA-J AM MED ASSOC, V280, P1325, DOI 10.1001/jama.280.15.1325; OSTROM CM, 1999, SEATTLE TIMES   0512, pA1; PERRIN J, 1998, PHARM J, V260, P707; Seaboldt JA, 1997, AM J HEALTH-SYST PH, V54, P1732, DOI 10.1093/ajhp/54.15.1732; Silberg WM, 1997, JAMA-J AM MED ASSOC, V277, P1244, DOI 10.1001/jama.277.15.1244; Skolnick AA, 1997, JAMA-J AM MED ASSOC, V278, P1723; SLIVKA J, 1999, SEATTLE POST IN 0507, pC1; TAYLOR C, 1999, TIME            0524, P73; Wang T, 1997, Methods Mol Biol, V72, P1	22	69	71	0	3	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	OCT 28	1999	341	18					1389	1392		10.1056/NEJM199910283411810	http://dx.doi.org/10.1056/NEJM199910283411810			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	249XE	10536133				2022-12-01	WOS:000083357800010
J	Beck, S; Geraghty, D; Inoko, H; Rowen, L; Aguado, B; Bahram, S; Campbell, RD; Forbes, SA; Guillaudeux, T; Hood, L; Horton, R; Janer, M; Jasoni, C; Madan, A; Milne, S; Neville, M; Oka, A; Qin, S; Ribas-Despuig, G; Rogers, J; Shiina, T; Spies, T; Tamiya, G; Tashiro, H; Trowsdale, J; Vu, Q; Williams, L; Yamazaki, M				Beck, S; Geraghty, D; Inoko, H; Rowen, L; Aguado, B; Bahram, S; Campbell, RD; Forbes, SA; Guillaudeux, T; Hood, L; Horton, R; Janer, M; Jasoni, C; Madan, A; Milne, S; Neville, M; Oka, A; Qin, S; Ribas-Despuig, G; Rogers, J; Shiina, T; Spies, T; Tamiya, G; Tashiro, H; Trowsdale, J; Vu, Q; Williams, L; Yamazaki, M		MHC Sequencing Consortium	Complete sequence and gene map of a human major histocompatibility complex	NATURE			English	Article							HUMAN MHC; DNA-REPLICATION; CLASS-II; REGION; LOCUS; END	Here we report the first complete sequence and gene map of a human major histocompatibility complex (MHC), a region on chromosome 6 which is essential to the immune system (reviewed in ref. 1). When it was discovered over 50 years ago the region was thought to specify histocompatibility genes, but their nature has been resolved only in the last two decades. Although many of the 224 identified gene loci (128 predicted to be expressed) are still of unknown function, we estimate that about 40% of the expressed genes have immune system function. Over 50% of the MHC has been sequenced twice, in different haplotypes, giving insight into the extraordinary polymorphism and evolution of this region. Several genes, particularly of the MHC class II and III regions, can be traced by sequence similarity and synteny to over 700 million years ago, dearly predating the emergence of the adaptive immune system some 400 million years ago. The sequence is expected to be invaluable for the identification of many common disease loci. In the past, the search for these loci has been hampered by the complexity of high gene density and linkage disequilibrium.	Fred Hutchinson Canc Res Ctr, Seattle, WA 98104 USA; Sanger Ctr, Hinxton CB10 1SA, England; Tokai Univ, Sch Med, Dept Mol Life Sci, Isehara, Kanagawa 25911, Japan; Univ Washington, Seattle, WA 98195 USA; HGMP Resource Ctr, Hinxton CB10 1SB, England; Univ Cambridge, Dept Pathol, Div Immunol, Cambridge CB2 1QP, England; Ctr Rech Immunol & Hematol, Strasbourg, France; Fujiya Co Ltd, Biosci Res Lab, Kanagawa 257, Japan	Fred Hutchinson Cancer Center; Wellcome Trust Sanger Institute; Tokai University; University of Washington; University of Washington Seattle; University of Cambridge	Geraghty, D (corresponding author), Fred Hutchinson Canc Res Ctr, 1124 Columbia St, Seattle, WA 98104 USA.		Bahram, Seiamak/GZA-7150-2022; Ribas-Despuig, Gloria/M-6190-2017; Aguado, Begoña/R-4496-2019; Ribas, Gloria/K-3379-2013	Bahram, Seiamak/0000-0002-6928-9952; Ribas, Gloria/0000-0001-6883-4130; Aguado, Begona/0000-0003-4043-6944; Tamiya, Gen/0000-0002-0597-415X; Shiina, Takashi/0000-0002-2067-6708; Bowcock, Anne/0000-0001-8691-9090	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BODMER WF, 1972, NATURE, V237, P139, DOI 10.1038/237139a0; Dawkins R, 1999, IMMUNOL REV, V167, P275, DOI 10.1111/j.1600-065X.1999.tb01399.x; Delgado S, 1998, EMBO J, V17, P2426, DOI 10.1093/emboj/17.8.2426; FUKAGAWA T, 1995, GENOMICS, V25, P184, DOI 10.1016/0888-7543(95)80124-5; Gruen JR, 1997, BLOOD, V90, P4252; Guillaudeux T, 1998, P NATL ACAD SCI USA, V95, P9494, DOI 10.1073/pnas.95.16.9494; HAINO M, 1994, J BIOL CHEM, V269, P2619; HAMILIN JL, 1995, CURR OPIN GENE DEV, V5, P153; Horton R, 1998, J MOL BIOL, V282, P71, DOI 10.1006/jmbi.1998.2018; Kasahara M, 1999, IMMUNOL REV, V167, P17, DOI 10.1111/j.1600-065X.1999.tb01379.x; Klein J., 1986, NATURAL HIST MAJOR H; LIMM TM, 1993, HUM IMMUNOL, V38, P57, DOI 10.1016/0198-8859(93)90520-B; Ruddy DA, 1997, GENOME RES, V7, P441, DOI 10.1101/gr.7.5.441; Satta Y, 1999, IMMUNOL REV, V167, P367, DOI 10.1111/j.1600-065X.1999.tb01405.x; Stephens R, 1999, J MOL BIOL, V291, P789, DOI 10.1006/jmbi.1999.3004; SUGAYA K, 1994, GENOMICS, V23, P408, DOI 10.1006/geno.1994.1517; Tenzen T, 1997, MOL CELL BIOL, V17, P4043, DOI 10.1128/MCB.17.7.4043; Tiwari J.L., 1985, HLA DIS ASS; Trachtulec Z, 1997, GENOMICS, V44, P1, DOI 10.1006/geno.1997.4839; TROWSDALE J, 1997, IMMUNOL TODAY S, V18	20	821	848	0	54	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	OCT 28	1999	401	6756					921	923		10.1038/44853	http://dx.doi.org/10.1038/44853			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	251UL	10553908				2022-12-01	WOS:000083464700060
J	Bisharat, N; Agmon, V; Finkelstein, R; Raz, R; Ben-Dror, G; Lerner, L; Soboh, S; Colodner, R; Cameron, DN; Wykstra, DL; Swerdlow, DL; Farmer, JJ				Bisharat, N; Agmon, V; Finkelstein, R; Raz, R; Ben-Dror, G; Lerner, L; Soboh, S; Colodner, R; Cameron, DN; Wykstra, DL; Swerdlow, DL; Farmer, JJ		Israel Vibrio Study Grp	Clinical, epidemiological, and microbiological features of Vibrio vulnificus biogroup 3 causing outbreaks of wound infection and bacteraemia in Israel	LANCET			English	Article							GULF-COAST; BENECKEA VULNIFICUS; FISH; MANIFESTATIONS; ENVIRONMENT; FLORIDA	Background Vibrio vulnificus is a gram-negative bacterium that causes septicaemia and wound infection. Cases occur sporadically, and no previous outbreaks due to a common source or a clonal strain have been reported. In the summer and autumn of 1996 and 1997, an outbreak of invasive V vulnificus infection occurred in Israel in people who had recently handled fresh, whole fish purchased from artificial fish-ponds. Methods We reviewed clinical and epidemiological information, and undertook an environmental investigation to assess disease characteristics, modes of transmission, phenotypic characteristics of the bacterium, and fish-marketing policy. The clonal nature of 19 isolates was studied by biotyping, pulsed-field gel electrophoresis, and restriction-fragment length polymorphism (RFLP) analysis of a PCR fragment. Findings During 1996-97, 62 cases of wound infection and bacteraemia occurred. 57 patients developed cellulitis, four had necrotising fasciitis, and one developed osteomyelitis. In all cases, the fish were cultivated in inland fish-ponds. In the summer of 1996, fish-pond managers initiated a new marketing policy, in which fish were sold alive instead of being packed in ice. Phenotypically, the isolates had five atypical biochemical test results. The isolates were non-typeable by pulsed-field gel electrophoresis, and all had the same PCR-RFLP pattern which had not been seen previously. Interpretation The cause of the outbreak was a new strain of V vulnificus, classified as biogroup 3. A new fish-marketing policy that began in 1996 may have exposed susceptible people to the organism.	HaEmek Med Ctr, Infect Dis Unit, IL-18101 Afula, Israel; HaEmek Med Ctr, Microbiol Lab, IL-18101 Afula, Israel; Govt Cent Labs, Jerusalem, Israel; Rambam Med Ctr, Infect Dis Unit, Haifa, Israel; Poriah Med Ctr, Dept Med, Tiberias, Israel; Ctr Dis Control & Prevent, Foodborne & Diarrheal Dis Lab Sect, Div Bacterial & Mycot Dis, Natl Ctr Infect Dis, Atlanta, GA USA; Ctr Dis Control & Prevent, Foodborne & Diarrheal Dis Branch, Div Bacterial & Mycot Dis, Natl Ctr Infect Dis, Atlanta, GA USA	Emek Medical Center; Emek Medical Center; Rambam Health Care Campus; Technion Israel Institute of Technology; Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA	Bisharat, N (corresponding author), HaEmek Med Ctr, Infect Dis Unit, IL-18101 Afula, Israel.			Colodner, Raul/0000-0001-9752-1053				[Anonymous], MANUAL CLIN MICROBIO; Bisharat N, 1996, LANCET, V348, P1585, DOI 10.1016/S0140-6736(05)66199-5; BLAKE PA, 1979, NEW ENGL J MED, V300, P1, DOI 10.1056/NEJM197901043000101; BLAKE PA, 1980, ANNU REV MICROBIOL, V34, P341, DOI 10.1146/annurev.mi.34.100180.002013; Brenner D J, 1978, Prog Clin Pathol, V7, P71; BURRAS N, 1985, APPL ENVIRON MICROB, V50, P989; CAMERON D, 1997, 97 C AM SOC MICR; CAMERON D, 1998, INT C EM INF DIS; Centers for Disease Control and Prevention (CDC), 1993, MMWR MORB MORTAL WKL, V42, P405; CHUANG YC, 1992, CLIN INFECT DIS, V15, P271, DOI 10.1093/clinids/15.2.271; Dalsgaard A, 1996, EUR J CLIN MICROBIOL, V15, P227, DOI 10.1007/BF01591359; DEPAOLA A, 1994, APPL ENVIRON MICROB, V60, P984, DOI 10.1128/AEM.60.3.984-988.1994; ELLIOT EL, 1992, FOOD DRUG ADM BACTER, P111; FANG FC, 1992, CLIN INFECT DIS, V15, P1071, DOI 10.1093/clind/15.6.1071; Farmer J. J., 1992, The Prokaryotes. A handbook on the biology of bacteria: ecophysiology, isolation, identification, applications. Volume III.., P2952; FARMER JJ, 1979, LANCET, V2, P903; FARMER JJ, 1985, MANUAL CLIN MICROBIO, P282; Hlady WG, 1996, J INFECT DIS, V173, P1176, DOI 10.1093/infdis/173.5.1176; HOLLIS DG, 1976, J CLIN MICROBIOL, V3, P425; HOWARD RJ, 1985, SURGERY, V98, P126; KELLY MT, 1982, APPL ENVIRON MICROB, V44, P820, DOI 10.1128/AEM.44.4.820-824.1982; KLONTZ KC, 1988, ANN INTERN MED, V109, P318, DOI 10.7326/0003-4819-109-4-318; LEVINE WC, 1993, J INFECT DIS, V167, P479, DOI 10.1093/infdis/167.2.479; MORRIS JG, 1987, APPL ENVIRON MICROB, V53, P193, DOI 10.1128/AEM.53.1.193-195.1987; Oliver J., 1989, FOODBORNE BACTERIAL, P569; OLIVER JD, 1983, APPL ENVIRON MICROB, V45, P985, DOI 10.1128/AEM.45.3.985-998.1983; OVERMAN T, 1986, J CLIN MICROBIOL, V24, P715; SERA H, 1972, B JPN SOC SCI FISH, V38, P853; TACKET CO, 1984, J INFECT DIS, V149, P558, DOI 10.1093/infdis/149.4.558; Tamplin M., 1995, P 1994 VIBR VULN WOR, P75; TISON DL, 1982, APPL ENVIRON MICROB, V44, P640, DOI 10.1128/AEM.44.3.640-646.1982; Weinstein MR, 1997, NEW ENGL J MED, V337, P589, DOI 10.1056/NEJM199708283370902; WRIGHT AC, 1981, INFECT IMMUN, V34, P503, DOI 10.1128/IAI.34.2.503-507.1981	33	228	236	0	14	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	OCT 23	1999	354	9188					1421	1424		10.1016/S0140-6736(99)02471-X	http://dx.doi.org/10.1016/S0140-6736(99)02471-X			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	248LY	10543668				2022-12-01	WOS:000083277400011
J	Law, DA; DeGuzman, FR; Heiser, P; Ministri-Madrid, K; Killeen, N; Phillips, DR				Law, DA; DeGuzman, FR; Heiser, P; Ministri-Madrid, K; Killeen, N; Phillips, DR			Integrin cytoplasmic tyrosine motif is required for outside-in alpha IIb beta 3 signalling and platelet function	NATURE			English	Article							CELL-ADHESION; IIB-IIIA; PHOSPHORYLATION; PROTEIN; TRANSDUCTION; ACTIVATION; DOMAINS	Integrins not only bind adhesive ligands(1), they also act as signalling receptors(2), Both functions allow the integrin alpha IIb beta 3 to mediate platelet aggregation(3), Platelet agonists activate alpha IIb beta 3 (inside-out signalling) to allow the binding of soluble fibrinogen. Subsequent platelet aggregation leads to outside-in alpha IIb beta 3 signalling, which results in calcium mobilization(4), tyrosine phosphorylation of numerous proteins(5,6) including beta 3 itself(7) increased cytoskeletal reorganisations and further activation of alpha IIb beta 3 (ref, 2). Thus, outside-in signals enhance aggregation, although the mechanisms and functional consequences of specific signalling events remain unclear, Here we describe a mouse that expresses an alpha IIb beta 3 in which the tyrosines in the integrin cytoplasmic tyrosine motif have been mutated to phenylalanines. These mice are selectively impaired in outside-in alpha IIb beta 3 signalling, with defective aggregation and clot-retraction responses in vitro, and an in vivo bleeding defect which is characterized by a pronounced tendency to rebleed, These data provide evidence for an important role of outside-in signalling in platelet physiology, Furthermore, they identify the integrin cytoplasmic tyrosine motif as a key mediator of beta-integrin signals and a potential target for new therapeutic agents.	COR Therapeut Inc, S San Francisco, CA 94080 USA; Univ Calif San Francisco, Dept Microbiol & Immunol, San Francisco, CA 94143 USA	University of California System; University of California San Francisco	Phillips, DR (corresponding author), COR Therapeut Inc, 256 E Grand Ave, S San Francisco, CA 94080 USA.			DeGuzman, Francis/0000-0002-4479-1129; Heiser, Patrick/0000-0002-8831-4973				Blystone SD, 1997, J BIOL CHEM, V272, P28757, DOI 10.1074/jbc.272.45.28757; CHEN YP, 1994, BLOOD, V84, P1857; CLARK EA, 1994, J BIOL CHEM, V269, P28859; COLLER BS, 1990, NEW ENGL J MED, V322, P32; Dymecki SM, 1996, P NATL ACAD SCI USA, V93, P6191, DOI 10.1073/pnas.93.12.6191; FILARDO EJ, 1995, J CELL BIOL, V130, P441, DOI 10.1083/jcb.130.2.441; FITZGERALD LA, 1987, J BIOL CHEM, V262, P3936; FOX JEB, 1993, J BIOL CHEM, V268, P25973; Guinto ER, 1999, P NATL ACAD SCI USA, V96, P1852, DOI 10.1073/pnas.96.5.1852; Hodivala-Dilke KM, 1999, J CLIN INVEST, V103, P229, DOI 10.1172/JCI5487; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; Jenkins AL, 1998, J BIOL CHEM, V273, P13878, DOI 10.1074/jbc.273.22.13878; Law DA, 1999, BLOOD, V93, P2645, DOI 10.1182/blood.V93.8.2645.408k13_2645_2652; Law DA, 1996, J BIOL CHEM, V271, P10811, DOI 10.1074/jbc.271.18.10811; LIPFERT L, 1992, J CELL BIOL, V119, P905, DOI 10.1083/jcb.119.4.905; PHILLIPS DR, 1980, J CELL BIOL, V86, P77, DOI 10.1083/jcb.86.1.77; PHILLIPS DR, 1991, CELL, V65, P359, DOI 10.1016/0092-8674(91)90451-4; Romzek NC, 1998, MOL BIOL CELL, V9, P2715, DOI 10.1091/mbc.9.10.2715; Shattil S, 1998, BLOOD, V91, P1; VANDERGEER P, 1995, CURR BIOL, V5, P404, DOI 10.1016/S0960-9822(95)00081-9; Williams Michael J., 1994, Trends in Cell Biology, V4, P109, DOI 10.1016/0962-8924(94)90059-0; YAMAGUCHI K, 1993, AM J HEMATOL, V44, P106, DOI 10.1002/ajh.2830440207; YLANNE J, 1993, J CELL BIOL, V122, P223, DOI 10.1083/jcb.122.1.223	23	256	264	1	5	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	OCT 21	1999	401	6755					808	811		10.1038/44599	http://dx.doi.org/10.1038/44599			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	250BG	10548108				2022-12-01	WOS:000083368700057
J	Reilly, JJ; Dorosty, AR; Emmett, PM				Reilly, JJ; Dorosty, AR; Emmett, PM			Prevalence of overweight and obesity in British children: cohort study	BRITISH MEDICAL JOURNAL			English	Article							INDEX	Estimates of the prevalence of obesity among children are necessary so that the need for preventive measures can be assessed, secular trends monitored, and high risk population groups identified.(1) The aim of this study was therefore to provide current estimates of the prevalence of obesity among British children.	Univ Glasgow, Dept Human Nutr, Yorkhill Hosp, Glasgow G3 8SJ, Lanark, Scotland; Univ Bristol, Inst Child Hlth, Unit Paediat & Perinatal Epidemiol, ALSPAC Study Team, Bristol BS8 1TH, Avon, England	University of Glasgow; University of Bristol	Reilly, JJ (corresponding author), Univ Glasgow, Dept Human Nutr, Yorkhill Hosp, Glasgow G3 8SJ, Lanark, Scotland.		Emmett, Pauline/AAL-6815-2021; Dorosty-Motlagh, Ahmad-Reza/E-1003-2018	Dorosty-Motlagh, Ahmad-Reza/0000-0002-6937-7776; Emmett, Pauline/0000-0003-1076-4779	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		*ALSPAC, 1998, CHILDR 90S; Barlow SE, 1998, PEDIATRICS, V102, DOI 10.1542/peds.102.3.e29; COLE TJ, 1995, ARCH DIS CHILD, V73, P25, DOI 10.1136/adc.73.1.25; Prentice AM, 1998, BRIT MED J, V317, P1401, DOI 10.1136/bmj.317.7170.1401; Reilly JJ, 1999, INT J OBESITY, V23, P217, DOI 10.1038/sj.ijo.0800804	5	127	135	0	5	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	OCT 16	1999	319	7216					1039	1039		10.1136/bmj.319.7216.1039	http://dx.doi.org/10.1136/bmj.319.7216.1039			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	247FH	10521196	Green Submitted, Bronze, Green Published			2022-12-01	WOS:000083210100027
J	Watson, M; Haviland, JS; Greer, S; Davidson, J; Bliss, JM				Watson, M; Haviland, JS; Greer, S; Davidson, J; Bliss, JM			Influence of psychological response on survival in breast cancer: a population-based cohort study	LANCET			English	Article							MAC SCALE; QUESTIONNAIRE MEASURE; MENTAL ADJUSTMENT; EMOTIONAL CONTROL	Background The psychological response to breast cancer, such as a fighting spirit or an attitude of helplessness and hopelessness toward the disease, has been suggested as a prognostic factor with an influence on survival. We have investigated the effect of psychological response on disease outcome in a large cohort of women with early-stage breast cancer. Methods 578 women with early-stage breast cancer were enrolled in a prospective survival study. Psychological response was measured by the mental adjustment to cancer (MAC) scale, the Courtauld emotional control (CEC) scale, and the hospital anxiety and depression (HAD) scale 4-12 weeks and 12 months after diagnosis. The women were followed up for at least 5 years. Cox's proportional-hazards regression was used to obtain the hazard ratios for the measures of psychological response, with adjustment for known clinical factors associated with survival. Findings At 5 years, 395 women were alive and without relapse, 50 were alive with relapse, and 133 had died. There was a significantly increased risk of death from all causes by 5 years in women with a high score on the HAD scale category of depression (hazard ratio 3.59 [95% CI 1.39-9.24]). There was a significantly increased risk of relapse or death at 5 years in women with high scores on the helplessness and hopelessness category of the MAC scale compared with those with a low score in this category (1.55 [1.07-2.25]). There were no significant results found for the category of "fighting spirit". Interpretation For 5-year event-free survival a high helplessness/hopelessness score has a moderate but detrimental effect. A high score for depression is linked to a significantly reduced chance of survival; however, this result is based on a small number of patients and should be interpreted with caution.	Royal Marsden Hosp NHS Trust, Sutton SM2 5PT, Surrey, England; Royal Marsden Hosp NHS Trust, London, England; Inst Canc Res, Sutton, Surrey, England; St Raphaels Hosp, Surrey, England	Royal Marsden NHS Foundation Trust; Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK	Watson, M (corresponding author), Royal Marsden Hosp NHS Trust, Sutton SM2 5PT, Surrey, England.			Bliss, Judith/0000-0001-7957-7424; Haviland, Joanne/0000-0001-5728-3636				BUDDEBERG C, 1991, PSYCHOTHER PSYCHOSOM, V55, P151, DOI 10.1159/000288423; Clarke M, 1998, LANCET, V351, P1451; COPPER CL, 1993, PSYCHOL MED, V23, P653; GOLDSTEIN DA, 1989, PSYCHOL HEALTH, V3, P245, DOI DOI 10.1080/08870448908400384; GREER S, 1979, LANCET, V2, P785, DOI 10.1016/S0140-6736(79)92127-5; GREER S, 1989, J PSYCHOSOM RES, V33, P373, DOI 10.1016/0022-3999(89)90027-5; GREER S, 1992, BRIT MED J, V304, P675, DOI 10.1136/bmj.304.6828.675; HOLLAND J C, 1986, Proceedings American Society of Clinical Oncology Annual Meeting, V5, P237; JAMISON RN, 1987, J CLIN ONCOL, V5, P768, DOI 10.1200/JCO.1987.5.5.768; LEVY SM, 1988, PSYCHOSOM MED, V50, P520, DOI 10.1097/00006842-198809000-00008; MOOREY S, 1991, BRIT J PSYCHIAT, V158, P255, DOI 10.1192/bjp.158.2.255; MORRIS T, 1980, CANCER DETECTION PRE, V3, P102; Nordin K, 1999, PSYCHO-ONCOLOGY, V8, P250, DOI 10.1002/(SICI)1099-1611(199905/06)8:3<250::AID-PON379>3.3.CO;2-A; PETTINGALE KW, 1985, LANCET, V1, P750; Schnoll RA, 1998, PSYCHO-ONCOLOGY, V7, P424, DOI 10.1002/(SICI)1099-1611(1998090)7:5<424::AID-PON322>3.0.CO;2-2; WATSON M, 1991, PSYCHOL MED, V21, P51, DOI 10.1017/S0033291700014641; WATSON M, 1984, J PSYCHOSOM RES, V28, P467, DOI 10.1016/0022-3999(84)90080-1; WATSON M, 1983, J PSYCHOSOM RES, V27, P299, DOI 10.1016/0022-3999(83)90052-1; WATSON M, 1988, PSYCHOL MED, V18, P203, DOI 10.1017/S0033291700002026; Watson M, 1989, MENTAL ADJUSTMENT CA; WEISMAN AD, 1977, COPING VULNERABILITY; ZIGMOND AS, 1983, ACTA PSYCHIAT SCAND, V67, P361, DOI 10.1111/j.1600-0447.1983.tb09716.x	22	474	482	0	24	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	OCT 16	1999	354	9187					1331	1336		10.1016/S0140-6736(98)11392-2	http://dx.doi.org/10.1016/S0140-6736(98)11392-2			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	246DV	10533861	Green Accepted			2022-12-01	WOS:000083149900010
J	Celli, J; Duijf, P; Hamel, BCJ; Bamshad, M; Kramer, B; Smits, APT; Newbury-Ecob, R; Hennekam, RCM; Van Buggenhout, G; van Haeringen, B; Woods, CG; van Essen, AJ; de Waal, R; Vriend, G; Haber, DA; Yang, A; McKeon, F; Brunner, HG; van Bokhoven, H				Celli, J; Duijf, P; Hamel, BCJ; Bamshad, M; Kramer, B; Smits, APT; Newbury-Ecob, R; Hennekam, RCM; Van Buggenhout, G; van Haeringen, B; Woods, CG; van Essen, AJ; de Waal, R; Vriend, G; Haber, DA; Yang, A; McKeon, F; Brunner, HG; van Bokhoven, H			Heterozygous germline mutations in the p53 homolog p63 are the cause of EEC syndrome	CELL			English	Article							SPLIT FOOT LOCUS; LIMB DEVELOPMENT; GENE; PROTEIN; EXPRESSION; SEQUENCE; DATABASE; COMPLEX; DEFECTS; MODEL	EEC syndrome is an autosomal dominant disorder characterized by ectrodactyly, ectodermal dysplasia, and facial clefts. We have mapped the genetic defect in several EEC syndrome families to a region of chromosome 3q27 previously implicated in the EEC-like disorder, limb mammary syndrome (LMS). Analysis of the p63 gene, a homolog of p53 located in the critical LMS/EEC interval, revealed heterozygous mutations in nine unrelated EEC families. Eight mutations result in amino acid substitutions that are predicted to abolish the DNA binding capacity of p63. The ninth is a frameshift mutation that affects the p63 alpha, but not p63 beta and p63 gamma isotypes. Transactivation studies with these mutant p63 isotypes provide a molecular explanation for the dominant character of p63 mutations in EEC syndrome.	Univ Nijmegen Hosp, Dept Human Genet 417, NL-6500 HB Nijmegen, Netherlands; Univ Utah, Hlth Sci Ctr, Dept Pediat, Salt Lake City, UT 84112 USA; Shriners Hosp Children, Intermt Unit, Salt Lake City, UT 84112 USA; Royal Hosp Sick Children, United Bristol Healthcare NHS Trust Clin Genet Se, Bristol BS2 8BJ, Avon, England; Univ Amsterdam, Acad Med Ctr, Inst Human Genet, NL-1105 AZ Amsterdam, Netherlands; Univ Hosp Gasthuisberg, Ctr Human Genet, B-3000 Louvain, Belgium; Leiden Univ, Med Ctr, Dept Clin Genet, NL-2333 SA Leiden, Netherlands; St James Univ Hosp, Dept Clin Genet, Leeds LS9 7TF, W Yorkshire, England; Univ Groningen, Dept Med Genet, NL-9713 AW Groningen, Netherlands; Univ Nijmegen Hosp, Dept Pathol, NL-6500 HB Nijmegen, Netherlands; Univ Nijmegen, CMBI, NL-6500 GL Nijmegen, Netherlands; Massachusetts Gen Hosp, Ctr Canc, Charlestown, MA 02129 USA; Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02115 USA	Radboud University Nijmegen; Utah System of Higher Education; University of Utah; Bristol Royal Hospital For Children; University of Amsterdam; Academic Medical Center Amsterdam; KU Leuven; University Hospital Leuven; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; Saint James's University Hospital; University of Groningen; Radboud University Nijmegen; Radboud University Nijmegen; Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School	van Bokhoven, H (corresponding author), Univ Nijmegen Hosp, Dept Human Genet 417, Box 9101, NL-6500 HB Nijmegen, Netherlands.		Vriend, G./H-8112-2014; Bokhoven, J.H.L.M. van van/H-8015-2014; Waal, R.M.W./L-4739-2015; Vriend, Gert/D-6730-2011; van Bokhoven, Hans/D-8764-2012; woods, christopher g/A-1361-2010; Brunner, Han/C-9928-2013; Duijf, Pascal H.G./E-7110-2012	Bokhoven, J.H.L.M. van van/0000-0002-2153-9254; Duijf, Pascal H.G./0000-0001-8646-9843				AHMAD M, 1987, HUM GENET, V75, P169, DOI 10.1007/BF00591081; CHINEA G, 1995, PROTEINS, V23, P415, DOI 10.1002/prot.340230315; Chitayat D, 1996, AM J MED GENET, V61, P45, DOI 10.1002/(SICI)1096-8628(19960102)61:1<45::AID-AJMG9>3.0.CO;2-W; CHO YJ, 1994, SCIENCE, V265, P346, DOI 10.1126/science.8023157; CHOTHIA C, 1986, EMBO J, V5, P823, DOI 10.1002/j.1460-2075.1986.tb04288.x; Crackower MA, 1996, HUM MOL GENET, V5, P571, DOI 10.1093/hmg/5.5.571; CZEIZEL AE, 1993, J MED GENET, V30, P593, DOI 10.1136/jmg.30.7.593; Dib C, 1996, NATURE, V380, P152, DOI 10.1038/380152a0; EVANS JA, 1994, AM J MED GENET, V49, P52, DOI 10.1002/ajmg.1320490111; Gorlin RJ, 1990, PLAST RECONSTR SURG, V3rd; GREEN ED, 1990, P NATL ACAD SCI USA, V87, P1213, DOI 10.1073/pnas.87.3.1213; Hainaut P, 1998, NUCLEIC ACIDS RES, V26, P205, DOI 10.1093/nar/26.1.205; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; JOHNSON KR, 1995, GENOMICS, V29, P457, DOI 10.1006/geno.1995.9981; Kaghad M, 1997, CELL, V90, P809, DOI 10.1016/S0092-8674(00)80540-1; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; KREMER H, 1994, HUM MOL GENET, V3, P299, DOI 10.1093/hmg/3.2.299; LATHROP GM, 1984, AM J HUM GENET, V36, P460; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; MILLER SA, 1988, NUCLEIC ACIDS RES, V16, P1215, DOI 10.1093/nar/16.3.1215; Mills AA, 1999, NATURE, V398, P708, DOI 10.1038/19531; Niswander L, 1997, CURR OPIN GENET DEV, V7, P530, DOI 10.1016/S0959-437X(97)80082-2; NUNES ME, 1995, HUM MOL GENET, V4, P2165, DOI 10.1093/hmg/4.11.2165; O'Quinn JR, 1998, AM J HUM GENET, V62, P130, DOI 10.1086/301687; Osada M, 1998, NAT MED, V4, P839, DOI 10.1038/nm0798-839; Roelfsema NM, 1996, CLIN DYSMORPHOL, V5, P115, DOI 10.1097/00019605-199604000-00003; ROTHSCHILD AR, 1996, J MED GENET, V33, P996; SANDER C, 1991, PROTEINS, V9, P56, DOI 10.1002/prot.340090107; SCHERER SW, 1994, HUM MOL GENET, V3, P1345; Schmale H, 1997, ONCOGENE, V15, P1363, DOI 10.1038/sj.onc.1201500; Senoo M, 1998, BIOCHEM BIOPH RES CO, V248, P603, DOI 10.1006/bbrc.1998.9013; Seto ML, 1997, TERATOLOGY, V56, P262, DOI 10.1002/(SICI)1096-9926(199710)56:4<262::AID-TERA5>3.0.CO;2-0; Shimada A, 1999, CANCER RES, V59, P2781; SHUBER AP, 1993, HUM MOL GENET, V2, P153, DOI 10.1093/hmg/2.2.153; SIDRANSKY D, 1992, NATURE, V355, P846, DOI 10.1038/355846a0; THESLEFF I, 1995, INT J DEV BIOL, V39, P35; Trink B, 1998, NAT MED, V4, P747, DOI 10.1038/nm0798-747; van Bokhoven H, 1999, AM J HUM GENET, V64, P538, DOI 10.1086/302246; VRIEND G, 1990, J MOL GRAPHICS, V8, P52, DOI 10.1016/0263-7855(90)80070-V; Walker DR, 1999, ONCOGENE, V18, P211, DOI 10.1038/sj.onc.1202298; Yang A, 1999, NATURE, V398, P714, DOI 10.1038/19539; Yang AN, 1998, MOL CELL, V2, P305, DOI 10.1016/S1097-2765(00)80275-0; ZAMBETTI GP, 1993, FASEB J, V7, P855, DOI 10.1096/fasebj.7.10.8344485	43	526	544	0	20	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	OCT 15	1999	99	2					143	153		10.1016/S0092-8674(00)81646-3	http://dx.doi.org/10.1016/S0092-8674(00)81646-3			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	246JB	10535733	Bronze, Green Published			2022-12-01	WOS:000083159700005
J	Golub, TR; Slonim, DK; Tamayo, P; Huard, C; Gaasenbeek, M; Mesirov, JP; Coller, H; Loh, ML; Downing, JR; Caligiuri, MA; Bloomfield, CD; Lander, ES				Golub, TR; Slonim, DK; Tamayo, P; Huard, C; Gaasenbeek, M; Mesirov, JP; Coller, H; Loh, ML; Downing, JR; Caligiuri, MA; Bloomfield, CD; Lander, ES			Molecular classification of cancer: Class discovery and class prediction by gene expression monitoring	SCIENCE			English	Article							ACUTE LYMPHOBLASTIC-LEUKEMIA; ACUTE MYELOID-LEUKEMIA; ALVEOLAR RHABDOMYOSARCOMA; SACCHAROMYCES-CEREVISIAE; BURKITT-LYMPHOMA; SURFACE-ANTIGENS; TRANSLOCATION; CELLS; MICROARRAY; FUSION	Although cancer classification has improved over the past 30 years, there has been no general approach for identifying new cancer classes (class discovery) or for assigning tumors to known classes (class prediction). Here, a generic approach to cancer classification based on gene expression monitoring by DNA microarrays is described and applied to human acute Leukemias as a test case. A class discovery procedure automatically discovered the distinction between acute myeloid Leukemia (AML) and acute Lymphoblastic Leukemia (ALL) without previous knowledge of these classes. An automatically derived class predictor was able to determine the class of new leukemia cases. The results demonstrate the feasibility of cancer classification based solely on gene expression monitoring and suggest a general strategy for discovering and predicting cancer classes for other types of cancer, independent of previous biological knowledge.	MIT, Whitehead Inst, Ctr Genome Res, Cambridge, MA 02139 USA; Dana Farber Canc Inst, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA 02115 USA; St Jude Childrens Res Hosp, Memphis, TN 38105 USA; Ohio State Univ, Ctr Comprehens Canc, Columbus, OH 43210 USA; Ohio State Univ, Canc & Leukemia Grp B, Columbus, OH 43210 USA; MIT, Dept Biol, Cambridge, MA 02142 USA	Massachusetts Institute of Technology (MIT); Whitehead Institute; Harvard University; Dana-Farber Cancer Institute; Harvard University; Harvard Medical School; St Jude Children's Research Hospital; James Cancer Hospital & Solove Research Institute; University System of Ohio; Ohio State University; University System of Ohio; Ohio State University; Massachusetts Institute of Technology (MIT)	Golub, TR (corresponding author), MIT, Whitehead Inst, Ctr Genome Res, 77 Massachusetts Ave, Cambridge, MA 02139 USA.	golub@genome.wi.mit.edu; lander@genome.wi.mit.edu	Peng, Bo/A-6920-2009; Downing, James R./N-8102-2018; Mesirov, Jill/AGF-7626-2022	Peng, Bo/0000-0001-8225-2284; Loh, Mignon/0000-0003-4099-4700; Slonim, Donna/0000-0003-3357-437X				BALABANMALENBAUM G, 1977, SCIENCE, V198, P739, DOI 10.1126/science.71759; BENNETT JM, 1969, BLOOD-J HEMATOL, V33, P341, DOI 10.1182/blood.V33.2.341.341; Bishop JF, 1999, MED J AUSTRALIA, V170, P39, DOI 10.5694/j.1326-5377.1999.tb126866.x; Borrow J, 1996, NAT GENET, V12, P159, DOI 10.1038/ng0296-159; BUCCHERI V, 1993, BLOOD, V82, P853; Cole KA, 1999, NAT GENET, V21, P38, DOI 10.1038/4466; CRAWFORD AW, 1991, J BIOL CHEM, V266, P5847; DALLAFAVERA R, 1982, P NATL ACAD SCI-BIOL, V79, P7824, DOI 10.1073/pnas.79.24.7824; DELATTRE O, 1994, NEW ENGL J MED, V331, P294, DOI 10.1056/NEJM199408043310503; DeRisi J, 1996, NAT GENET, V14, P457; DINNDORF PA, 1992, MED PEDIATR ONCOL, V20, P192, DOI 10.1002/mpo.2950200303; DOUGLASS EC, 1987, CYTOGENET CELL GENET, V45, P148, DOI 10.1159/000132446; FARBER S, 1948, NEW ENGL J MED, V238, P787, DOI 10.1056/NEJM194806032382301; FORKNER CE, 1938, LEUKEMIA ALLIED DISO; FREI E, 1961, BLOOD, V18, P431, DOI 10.1182/blood.V18.4.431.431; GOLUB TR, 1995, P NATL ACAD SCI USA, V92, P4917, DOI 10.1073/pnas.92.11.4917; GOLUB TR, UNPUB; GRAHAM RC, 1965, J HISTOCHEM CYTOCHEM, V13, P150, DOI 10.1177/13.2.150; Huang SY, 1997, BRIT J HAEMATOL, V96, P682, DOI 10.1046/j.1365-2141.1997.d01-2100.x; Iyer VR, 1999, SCIENCE, V283, P83, DOI 10.1126/science.283.5398.83; Khan J, 1999, ELECTROPHORESIS, V20, P223, DOI 10.1002/(SICI)1522-2683(19990201)20:2<223::AID-ELPS223>3.0.CO;2-A; Khan J, 1998, CANCER RES, V58, P5009; Kononen J, 1998, NAT MED, V4, P844, DOI 10.1038/nm0798-844; Konopleva M, 1999, BLOOD, V93, P1668, DOI 10.1182/blood.V93.5.1668.405a15_1668_1676; Kroon E, 1998, EMBO J, V17, P3714, DOI 10.1093/emboj/17.13.3714; Lander ES, 1996, SCIENCE, V274, P536, DOI 10.1126/science.274.5287.536; Lockhart DJ, 1996, NAT BIOTECHNOL, V14, P1675, DOI 10.1038/nbt1296-1675; MASTER PS, 1989, BLUT, V59, P221, DOI 10.1007/BF00320851; McLean TW, 1996, BLOOD, V88, P4252; *MED RES COUNC, 1963, BRIT MED J, V1, P7; Nakamura T, 1996, NAT GENET, V12, P154, DOI 10.1038/ng0296-154; PESANDO JM, 1979, BLOOD, V54, P1240; Pui CH, 1998, NEW ENGL J MED, V339, P605, DOI 10.1056/NEJM199808273390907; QUAGLINO D, 1959, J PATHOL BACTERIOL, V78, P521, DOI 10.1002/path.1700780219; ROMANA SP, 1995, BLOOD, V86, P4263, DOI 10.1182/blood.V86.11.4263.bloodjournal86114263; ROPER M, 1983, BLOOD, V61, P830; ROSS W, 1984, CANCER RES, V44, P5857; ROWLEY JD, 1973, ANN GENET-PARIS, V16, P109; SALLAN SE, 1980, BLOOD, V55, P395; Schena M, 1996, P NATL ACAD SCI USA, V93, P10614, DOI 10.1073/pnas.93.20.10614; SCHLOSSMAN SF, 1976, P NATL ACAD SCI USA, V73, P1288, DOI 10.1073/pnas.73.4.1288; Shurtleff SA, 1995, LEUKEMIA, V9, P1985; Spellman PT, 1998, MOL BIOL CELL, V9, P3273, DOI 10.1091/mbc.9.12.3273; STEPHENSON CF, 1992, HUM PATHOL, V23, P1270, DOI 10.1016/0046-8177(92)90295-E; STONE RM, 1993, HEMATOL ONCOL CLIN N, V7, P47, DOI 10.1016/S0889-8588(18)30257-0; Tamayo P, 1999, P NATL ACAD SCI USA, V96, P2907, DOI 10.1073/pnas.96.6.2907; TAUB R, 1982, P NATL ACAD SCI-BIOL, V79, P7837, DOI 10.1073/pnas.79.24.7837; Triche T J, 1988, Prog Clin Biol Res, V271, P475; TSUKIMOTO I, 1976, NEW ENGL J MED, V294, P245, DOI 10.1056/NEJM197601292940503; TURCCAREL C, 1986, CANCER GENET CYTOGEN, V19, P361, DOI 10.1016/0165-4608(86)90069-5; Wodicka L, 1997, NAT BIOTECHNOL, V15, P1359, DOI 10.1038/nbt1297-1359; Yang GP, 1999, NUCLEIC ACIDS RES, V27, P1517, DOI 10.1093/nar/27.6.1517	52	7951	9674	20	787	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 15	1999	286	5439					531	537		10.1126/science.286.5439.531	http://dx.doi.org/10.1126/science.286.5439.531			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	245RD	10521349				2022-12-01	WOS:000083121200061
J	Rogers, J				Rogers, J			Sequencing - Gels and genomes	SCIENCE			English	Article									Wellcome Trust, Sanger Ctr, Cambridge CB10 1SA, England	Wellcome Trust Sanger Institute	Rogers, J (corresponding author), Wellcome Trust, Sanger Ctr, Genome Campus, Cambridge CB10 1SA, England.								0	1	1	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	OCT 15	1999	286	5439					429	429		10.1126/science.286.5439.429	http://dx.doi.org/10.1126/science.286.5439.429			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	245RD	10577205				2022-12-01	WOS:000083121200033
J	Chowdhury, TR; Basu, GK; Mandal, BK; Biswas, BK; Samanta, G; Chowdhury, UK; Chanda, CR; Lodh, D; Lal Roy, S; Saha, KC; Roy, S; Kabir, S; Quamruzzaman, Q; Chakraborti, D				Chowdhury, TR; Basu, GK; Mandal, BK; Biswas, BK; Samanta, G; Chowdhury, UK; Chanda, CR; Lodh, D; Lal Roy, S; Saha, KC; Roy, S; Kabir, S; Quamruzzaman, Q; Chakraborti, D			Arsenic poisoning in the Ganges delta	NATURE			English	Article							WEST-BENGAL; 6 DISTRICTS; GROUNDWATER; INDIA; BANGLADESH; CALAMITY; DRINKING; WATER		Jadavpur Univ, Sch Environm Studies, Calcutta 700032, W Bengal, India; Dhaka Community Hosp Trust, Dhaka 1217, Bangladesh	Jadavpur University	Chowdhury, TR (corresponding author), Jadavpur Univ, Sch Environm Studies, Calcutta 700032, W Bengal, India.			Roychowdhury, Tarit/0000-0001-6515-5634				AKAI J, 1998, C P 3 FOR ARS CONT G, P51; CHOWDHURY R, 1999, THESIS JADAVPUR U CA; Das D, 1996, ENVIRON GEOCHEM HLTH, V18, P5, DOI 10.1007/BF01757214; DAS D, 1995, ANALYST, V120, P917, DOI 10.1039/an9952000917; DAS D, 1995, THESIS JADAVPUR U CA; Dhar RK, 1997, CURR SCI INDIA, V73, P48; *M MACD LTD, 1999, BRIT GEOL SURV FIN R; Mandal BK, 1998, SCI TOTAL ENVIRON, V218, P185, DOI 10.1016/S0048-9697(98)00220-4; Nickson R, 1998, NATURE, V395, P338, DOI 10.1038/26387; NICKSON R, 1997, THESIS U COLL LONDON; Samanta G, 1999, MICROCHEM J, V62, P174, DOI 10.1006/mchj.1999.1713	11	275	297	4	60	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	OCT 7	1999	401	6753					545	546		10.1038/44056	http://dx.doi.org/10.1038/44056			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	244MG	10524620				2022-12-01	WOS:000083054900035
J	McDonald, LC; Archibald, LK; Rheanpumikankit, S; Tansuphaswadikul, S; Eampokalap, B; Nwanyanawu, O; Kazembe, P; Dobbie, H; Reller, LB; Jarvis, WR				McDonald, LC; Archibald, LK; Rheanpumikankit, S; Tansuphaswadikul, S; Eampokalap, B; Nwanyanawu, O; Kazembe, P; Dobbie, H; Reller, LB; Jarvis, WR			Unrecognised Mycobacterium tuberculosis bacteraemia among hospital inpatients in less developed countries	LANCET			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; BACTEC 12B BOTTLES; INFECTION; BACTEREMIA; DIAGNOSIS; EXTRAPULMONARY; NAIROBI; SYSTEM	Background Nosocomial transmission of Mycobacterium tuberculosis is a global public-health concern. Although early clinical recognition of M tuberculosis in hospital inpatients is critical for effective infection control, such recognition may be difficult in patients with HIV infection. To find out whether M tuberculosis bacteraemia frequently goes unrecognised, we did a prospective blood-culture survey in an infectious-diseases hospital in Thailand and a general hospital in Malawi, Methods Consecutive febrile (greater than or equal to 37.5 degrees C axillary or greater than or equal to 38.0 degrees C orally) hospital inpatients (aged greater than or equal to 18 years) were enrolled; blood was obtained for mycobacterial culture and HIV testing. Simple diagnostic tests, such as chest radiographs and sputum smears, were ordered by clinicians as deemed necessary, and were carried out with existing local resources. Findings Of 344 patients enrolled, 255 (74%) were HIV infected, the median age was 33 years (range 18-87), and 208 (61%) were male. 34 (10%) patients had NI tuberculosis bacteraemia; five of these patients were already on antituberculosis therapy. Only HIV-infected patients had M tuberculosis bacteraemia. Of the 29 patients with M tuberculosis bacteraemia who were not already receiving antituberculosis therapy, 13 (45%) had an abnormal chest radiograph or a positive sputum smear. 16 (55%) patients had no additional diagnostic test results to indicate M tuberculosis infection; 18 (81%) of these had a cough. Interpretation In less developed countries where both M tuberculosis and HIV infections are prevalent, M tuberculosis bacteraemia may frequently go unrecognised among febrile hospital inpatients.	Ctr Dis Control & Prevent, Hosp Infect Program, Atlanta, GA 30333 USA; Bamrasnaradura Hosp, Bangkok, Thailand; Lilongwe Cent Hosp, Lilongwe, Malawi; Duke Univ, Med Ctr, Durham, NC USA	Centers for Disease Control & Prevention - USA; Duke University	Archibald, LK (corresponding author), Ctr Dis Control & Prevent, Hosp Infect Program, Mailstop E-69,1600 Clifton Rd, Atlanta, GA 30333 USA.			McDonald, L. Clifford/0000-0003-3044-5572				[Anonymous], 1994, MMWR Recomm Rep, V43, P1; Archibald LK, 1998, CLIN INFECT DIS, V26, P290, DOI 10.1086/516297; BARBER TW, 1990, MEDICINE, V69, P375, DOI 10.1097/00005792-199011000-00005; BARNES PF, 1988, CHEST, V94, P316, DOI 10.1378/chest.94.2.316; BARNES PF, 1987, J INFECT DIS, V156, P377, DOI 10.1093/infdis/156.2.377; BOUZA E, 1993, ARCH INTERN MED, V153, P496, DOI 10.1001/archinte.153.4.496; DOERN GV, 1994, J CLIN MICROBIOL, V32, P2576, DOI 10.1128/JCM.32.10.2576-2577.1994; ELLIOTT AM, 1993, J TROP MED HYG, V96, P1; Fandinho FCO, 1997, B WORLD HEALTH ORGAN, V75, P361; Fox J, 1998, ASM NEWS, V64, P73; GILKS CF, 1990, AIDS, V4, P981, DOI 10.1097/00002030-199010000-00006; Grinsztejn B, 1997, ARCH INTERN MED, V157, P2359, DOI 10.1001/archinte.157.20.2359; Inderlied Clark B., 1995, P1385; KRAMER F, 1990, AM J MED, V89, P451, DOI 10.1016/0002-9343(90)90375-N; Mattar S, 1992, Enferm Infecc Microbiol Clin, V10, P29; MODILEVSKY T, 1989, ARCH INTERN MED, V149, P2201, DOI 10.1001/archinte.149.10.2201; NUNN P, 1992, TUBERCLE LUNG DIS, V73, P45, DOI 10.1016/0962-8479(92)90079-Y; REIMER LG, 1994, CLIN LAB MED, V14, P99, DOI 10.1016/S0272-2712(18)30397-4; SHAFER RW, 1989, AM REV RESPIR DIS, V140, P1611, DOI 10.1164/ajrccm/140.6.1611; SHAFER RW, 1991, MEDICINE, V70, P384, DOI 10.1097/00005792-199111000-00004; WASILAUSKAS B, 1994, J CLIN MICROBIOL, V32, P654, DOI 10.1128/JCM.32.3.654-657.1994; *WHO, 1998, TUB FACT SHEET	22	75	78	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	OCT 2	1999	354	9185					1159	1163		10.1016/S0140-6736(98)12325-5	http://dx.doi.org/10.1016/S0140-6736(98)12325-5			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	242QX	10513709				2022-12-01	WOS:000082954100011
J	Fisslthaler, B; Popp, R; Kiss, L; Potente, M; Harder, DR; Fleming, I; Busse, R				Fisslthaler, B; Popp, R; Kiss, L; Potente, M; Harder, DR; Fleming, I; Busse, R			Cytochrome P4502C is an EDHF synthase in coronary arteries	NATURE			English	Article							ARACHIDONIC-ACID METABOLITE; HYPERPOLARIZING FACTOR; EPOXYEICOSATRIENOIC ACIDS; K+ CHANNELS; MICROCIRCULATION; ENZYMES	In most arterial beds a significant endothelium-dependent dilation to various stimuli persists even after inhibition of nitric oxide synthase and cyclo-oxygenase. This dilator response is preceded by an endothelium-dependent hyperpolarization of vascular smooth muscle cells, which is sensitive to a combination of the calcium-dependent potassium-channel inhibitors charybdotoxin and apamin, and is assumed to be mediated by an unidentified endothelium-derived hyperpolarizing factor (EDHF)(1,2). Here we show that the induction of cytochrome P450 (CYP) 2C8/34 in native porcine coronary artery endothelial cells by beta-naphthoflavone enhances the formation of 11,12-epoxyeicosatrienoic acid, as well as EDHF-mediated hyperpolarization and relaxation. Transfection of coronary arteries with CYP 2C8/34 antisense oligonucleotides results in decreased levels of CYP 2C and attenuates EDHF-mediated vascular responses. Thus, a CYP-epoxygenase product is an essential component of EDHF-mediated relaxation in the porcine coronary artery, and CYP 2C8/34 fulfils the criteria for the coronary EDHF synthase.	Univ Frankfurt Klinikum, Inst Kardiovask Physiol, D-60590 Frankfurt, Germany; Univ Giessen, Zentrum Inneren Med, D-35392 Giessen, Germany; Med Coll Wisconsin, Cardiovasc Res Ctr, Milwaukee, WI 53226 USA	Goethe University Frankfurt; Goethe University Frankfurt Hospital; Justus Liebig University Giessen; Medical College of Wisconsin	Fleming, I (corresponding author), Univ Frankfurt Klinikum, Inst Kardiovask Physiol, Theodor Stern Kai 7, D-60590 Frankfurt, Germany.		Fleming, Ingrid/L-1225-2014	Fleming, Ingrid/0000-0003-1881-3635; Potente, Michael/0000-0002-5689-0036				ALVAREZ J, 1991, BIOCHEM J, V274, P193, DOI 10.1042/bj2740193; ALVAREZ J, 1992, J BIOL CHEM, V267, P11789; BAUERSACHS J, 1994, BRIT J PHARMACOL, V113, P1548, DOI 10.1111/j.1476-5381.1994.tb17172.x; Bauersachs J, 1996, CIRCULATION, V94, P3341, DOI 10.1161/01.CIR.94.12.3341; Campbell WB, 1996, CIRC RES, V78, P415, DOI 10.1161/01.RES.78.3.415; CHEN G, 1988, BRIT J PHARMACOL, V95, P1165, DOI 10.1111/j.1476-5381.1988.tb11752.x; Edwards G, 1998, NATURE, V396, P269, DOI 10.1038/24388; FULTON D, 1995, BRIT J PHARMACOL, V114, P99, DOI 10.1111/j.1476-5381.1995.tb14911.x; GUENGERICH FP, 1992, FASEB J, V6, P745, DOI 10.1096/fasebj.6.2.1537465; HECKER M, 1994, J PHYSIOL-LONDON, V481, P407, DOI 10.1113/jphysiol.1994.sp020449; Kiss L, 1998, ANAL BIOCHEM, V261, P16, DOI 10.1006/abio.1998.2674; KOMORI K, 1990, BLOOD VESSELS, V27, P238; Mancy A, 1996, BIOCHEMISTRY-US, V35, P16205, DOI 10.1021/bi961950t; Miura H, 1998, CIRC RES, V83, P501, DOI 10.1161/01.RES.83.5.501; Oltman CL, 1998, CIRC RES, V83, P932; PINTO A, 1987, J PHARMACOL EXP THER, V240, P856; Popp R, 1996, J PHYSIOL-LONDON, V497, P699, DOI 10.1113/jphysiol.1996.sp021801; PRITCHARD KA, 1990, AM J PATHOL, V136, P1381; Puntarulo S, 1998, FREE RADICAL BIO MED, V24, P1324, DOI 10.1016/S0891-5849(97)00463-2; Quilley J, 1997, BIOCHEM PHARMACOL, V54, P1059, DOI 10.1016/S0006-2952(97)00039-7; ROSOLOWSKY M, 1993, AM J PHYSIOL, V264, pH327, DOI 10.1152/ajpheart.1993.264.2.H327; RUBANYI GM, 1987, CIRC RES, V61	22	771	798	0	13	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	SEP 30	1999	401	6752					493	497		10.1038/46816	http://dx.doi.org/10.1038/46816			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	243DF	10519554				2022-12-01	WOS:000082981200060
J	Oddy, WH; Holt, PG; Sly, PD; Read, AW; Landau, LI; Stanley, FJ; Kendall, GE; Burton, PR				Oddy, WH; Holt, PG; Sly, PD; Read, AW; Landau, LI; Stanley, FJ; Kendall, GE; Burton, PR			Association between breast feeding and asthma in 6 year old children: findings of a prospective birth cohort study	BMJ-BRITISH MEDICAL JOURNAL			English	Article							PROSPECTIVE FOLLOW-UP; ATOPIC DISEASE; HUMAN-MILK; CHILDHOOD; ALLERGY; INFANTS; PROPHYLAXIS; LIFE; AGE	Objectives To investigate the association between the duration of exclusive breast feeding and the development of asthma related outcomes in children at age 6 years. Design Prospective cohort study, Setting Western Australia. Subjects 2187 children ascertained through antenatal clinics at the major tertiary obstetric hospital in Perth and followed to age 6 years. Main outcome measures Unconditional logistic regression to model the association between duration of exclusive breast feeding and outcomes related ro asthma or atopy at 6 years of age, allowing for several important confounders: sex, gestational age, smoking in the household, and early childcare, Results. After adjustment for confounders, the introduction of milk other than breast milli before ii months of age was a significant risk factor for all asthma and atopy related outcomes in children aged 6) ears: asthma diagnosed by a doctor (odds ratio 1.25, 95% confidence interval 1.02 to 1.52); wheeze three or more rimes since 1 year bf age (1.41, 1.14 to 1.76); wheeze in the past year (1.31, 1.05 to 1.64); sleep disturbance due to wheeze within the past year (1.42, 1.07 to 1.89), age when doctor diagnosed asthma (hazard ratio 1.22, 1.03 to 1.43); age at first wheeze (1.36, 1.17 to 1.59); and positive skin prick test reaction to at least one common aeroallergen (1.30, 1.04 to 1.61). Conclusion A significant reduction in the risk of childhood asthma at age 6 years occurs if exclusive breast feeding is continued for at least the 4 months after birth. These findings are important for our understanding of the cause of childhood asthma and suggest that public health interventions to optimise breast feeding may help to reduce the community burden of childhood asthma and its associated traits.	TVW Telethon, Inst Child Hlth Res, Perth, WA 6872, Australia; Univ Western Australia, Fac Med & Dent, Nedlands, WA 6009, Australia; Univ Western Australia, Princess Margaret Hosp Children, Dept Paediat, Div Biostat & Genet Epidemiol, Subiaco, WA 6008, Australia	Telethon Kids Institute; University of Western Australia; University of Western Australia; University of Western Australia	Oddy, WH (corresponding author), TVW Telethon, Inst Child Hlth Res, POB 855, Perth, WA 6872, Australia.	Wendyo@ichr.uwa.edu.au	Study, Raine/K-4517-2013; Burton, Paul R/H-7527-2016; Sly, Peter D/F-1486-2010; Holt, Patrick G/H-1548-2011	Sly, Peter D/0000-0001-6305-2201; Holt, Patrick G/0000-0003-1193-0935	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Golding J, 1997, EARLY HUM DEV, V49, pS121, DOI 10.1016/S0378-3782(97)00058-3; HALPERN SR, 1973, J ALLERGY CLIN IMMUN, V51, P139, DOI 10.1016/0091-6749(73)90019-5; Hamosh M, 1998, BIOL NEONATE, V74, P163, DOI 10.1159/000014021; Hanson LA, 1998, ANN ALLERG ASTHMA IM, V81, P523, DOI 10.1016/S1081-1206(10)62704-4; Hide D W, 1991, Adv Exp Med Biol, V310, P475; Holt PG, 1997, CURR OPIN IMMUNOL, V9, P782, DOI 10.1016/S0952-7915(97)80178-1; Juvonen P, 1996, ACTA PAEDIATR, V85, P1047, DOI 10.1111/j.1651-2227.1996.tb14215.x; KRAMER MS, 1988, J PEDIATR-US, V112, P181, DOI 10.1016/S0022-3476(88)80054-4; MARTINEZ FD, 1995, NEW ENGL J MED, V332, P133, DOI 10.1056/NEJM199501193320301; MARTINEZ FD, 1994, THORAX, V49, P1189, DOI 10.1136/thx.49.12.1189; McCullagh P, 2019, GEN LINEAR MODELS; NEWNHAM JP, 1993, LANCET, V342, P887, DOI 10.1016/0140-6736(93)91944-H; Pabst HF, 1997, PEDIATR INFECT DIS J, V16, P991, DOI 10.1097/00006454-199710000-00017; Peat JK, 1999, J ALLERGY CLIN IMMUN, V103, P1, DOI 10.1016/S0091-6749(99)70517-8; Robertson CF, 1998, MED J AUSTRALIA, V168, P434, DOI 10.5694/j.1326-5377.1998.tb139022.x; SAARINEN UM, 1995, LANCET, V346, P1065, DOI 10.1016/S0140-6736(95)91742-X; SKASSABROCIEK W, 1987, J ALLERGY CLIN IMMUN, V80, P711, DOI 10.1016/0091-6749(87)90292-2; Strachan DP, 1995, LANCET, V346, P1714, DOI 10.1016/S0140-6736(95)92884-7; STRACHAN DP, 1989, BRIT MED J, V299, P1259, DOI 10.1136/bmj.299.6710.1259; Tariq SM, 1998, J ALLERGY CLIN IMMUN, V101, P587, DOI 10.1016/S0091-6749(98)70164-2; Wilson AC, 1998, BMJ-BRIT MED J, V316, P21, DOI 10.1136/bmj.316.7124.21; Wold AE, 1998, ACTA PAEDIATR, V87, P19, DOI 10.1080/08035259850157804; WRIGHT AL, 1995, ARCH PEDIAT ADOL MED, V149, P758, DOI 10.1001/archpedi.1995.02170200048006; Xanthou M, 1998, BIOL NEONATE, V74, P121, DOI 10.1159/000014018	24	355	365	0	17	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	SEP 25	1999	319	7213					815	819		10.1136/bmj.319.7213.815	http://dx.doi.org/10.1136/bmj.319.7213.815			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	241CR	10496824	Bronze, Green Published			2022-12-01	WOS:000082865200022
J	Skidmore, SJ				Skidmore, SJ			Factors in spread of hepatitis E	LANCET			English	Editorial Material							E VIRUS; INFECTION		Princess Royal Hosp, Publ Hlth Lab Serv, PHLS Midlands, Telford TF6 6TF, Shrops, England		Skidmore, SJ (corresponding author), Princess Royal Hosp, Publ Hlth Lab Serv, PHLS Midlands, Telford TF6 6TF, Shrops, England.							Balayan MS, 1997, J VIRAL HEPATITIS, V4, P155, DOI 10.1046/j.1365-2893.1997.00145.x; BRADLEY DW, 1995, J HEPATOL, V22, P140; Corwin AL, 1999, T ROY SOC TROP MED H, V93, P255, DOI 10.1016/S0035-9203(99)90014-7; Hau CH, 1999, AM J TROP MED HYG, V60, P277, DOI 10.4269/ajtmh.1999.60.277; Hussaini SH, 1997, J VIRAL HEPATITIS, V4, P51, DOI 10.1046/j.1365-2893.1997.00123.x; Lu FM, 1996, CHINESE MED J-PEKING, V109, P919; SCHARSCHMIDT BF, 1995, LANCET, V346, P519, DOI 10.1016/S0140-6736(95)91376-9; SKIDMORE SJ, 1995, BRIT MED J, V310, P414, DOI 10.1136/bmj.310.6977.414; Zhang YF, 1997, CLIN DIAGN LAB IMMUN, V4, P423, DOI 10.1128/CDLI.4.4.423-428.1997	9	22	23	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	SEP 25	1999	354	9184					1049	1050		10.1016/S0140-6736(99)00241-X	http://dx.doi.org/10.1016/S0140-6736(99)00241-X			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	239PA	10509491				2022-12-01	WOS:000082777500005
J	Zhou, YQ; Karplus, M				Zhou, YQ; Karplus, M			Interpreting the folding kinetics of helical proteins	NATURE			English	Article							MOLECULAR-DYNAMICS; SIMULATIONS; SYSTEMS	The detailed mechanism of protein folding is one of the major problems in structural biology(1,2). Its solution is of practical as well as fundamental interest because of its possible role in utilizing the many sequences becoming available from genomic analysis(3). Although the Levinthal paradox(4) (namely, that a polypeptide chain can find its unique native state in spite of the astronomical number of configurations in the denatured state) has been resolved(4-7), the reasons for the differences in the folding behaviour of individual proteins remain to be elucidated. Here a C-alpha-based three-helix-bundle-like protein model with a realistic thermodynamic phase diagram is used to calculate several hundred folding trajectories. By varying a single parameter, the difference between the strength of native and non-native contacts, folding is changed from a diffusion-collision mechanism(8) to one that involves simultaneous collapse and partial secondary-structure formation, followed by reorganization to the native structure. Non-obligatory intermediates are important in the former, whereas there is an obligatory on-pathway intermediate in the latter. Our results provide a basis for understanding the range of folding behaviour that is observed in helical proteins.	Harvard Univ, Dept Chem & Biol Chem, Cambridge, MA 02138 USA; Univ Strasbourg, ISIS, Lab Chim Biophys, F-67000 Strasbourg, France	Harvard University; UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg	Karplus, M (corresponding author), Harvard Univ, Dept Chem & Biol Chem, Cambridge, MA 02138 USA.	marci@tammy.harvard.edu	Zhou, Yaoqi/B-3284-2009	Zhou, Yaoqi/0000-0002-9958-5699				Ballew RM, 1996, P NATL ACAD SCI USA, V93, P5759, DOI 10.1073/pnas.93.12.5759; BOCZKO EM, 1995, SCIENCE, V269, P393, DOI 10.1126/science.7618103; Burton RE, 1998, BIOCHEMISTRY-US, V37, P5337, DOI 10.1021/bi980245c; CAFLISCH A, 1995, J MOL BIOL, V252, P672, DOI 10.1006/jmbi.1995.0528; Cavagnero S, 1999, J MOL BIOL, V285, P269, DOI 10.1006/jmbi.1998.2273; Dill KA, 1997, NAT STRUCT BIOL, V4, P10, DOI 10.1038/nsb0197-10; Dobson CM, 1998, ANGEW CHEM INT EDIT, V37, P868, DOI 10.1002/(SICI)1521-3773(19980420)37:7<868::AID-ANIE868>3.0.CO;2-H; Duan Y, 1998, SCIENCE, V282, P740, DOI 10.1126/science.282.5389.740; Ferguson N, 1999, J MOL BIOL, V286, P1597, DOI 10.1006/jmbi.1998.2548; FERRENBERG AM, 1989, PHYS REV LETT, V63, P1195, DOI 10.1103/PhysRevLett.63.1195; Fersht A., 1998, ENZYME STRUCTURE MEC; Frauenfelder H, 1998, P NATL ACAD SCI USA, V95, P4795, DOI 10.1073/pnas.95.9.4795; GOUDA H, 1992, BIOCHEMISTRY-US, V31, P9665, DOI 10.1021/bi00155a020; Guo ZY, 1997, P NATL ACAD SCI USA, V94, P10161, DOI 10.1073/pnas.94.19.10161; KARPLUS M, 1995, CURR OPIN STRUC BIOL, V5, P58, DOI 10.1016/0959-440X(95)80010-X; KARPLUS M, 1976, NATURE, V260, P404, DOI 10.1038/260404a0; Karplus M, 1997, FOLD DES, V2, pS69, DOI 10.1016/S1359-0278(97)00067-9; Lazaridis T, 1997, SCIENCE, V278, P1928, DOI 10.1126/science.278.5345.1928; LI AJ, 1994, P NATL ACAD SCI USA, V91, P10430, DOI 10.1073/pnas.91.22.10430; Munoz V, 1997, NATURE, V390, P196, DOI 10.1038/36626; Privalov P L, 1979, Adv Protein Chem, V33, P167, DOI 10.1016/S0065-3233(08)60460-X; Ptitsyn OB, 1995, ADV PROTEIN CHEM, V47, P83, DOI 10.1016/S0065-3233(08)60546-X; Roder H, 1997, CURR OPIN STRUC BIOL, V7, P15, DOI 10.1016/S0959-440X(97)80004-8; Sali Andrej, 1998, Nature Structural Biology, V5, P1029, DOI 10.1038/4136; Schlunegger F, 1997, BASIN RES, V9, P1, DOI 10.1046/j.1365-2117.1997.00029.x; Socci ND, 1998, PROTEINS, V32, P136, DOI 10.1002/(SICI)1097-0134(19980801)32:2<136::AID-PROT2>3.3.CO;2-5; TAKETOMI H, 1975, INT J PEPT PROT RES, V7, P445; Zhou YQ, 1999, J MOL BIOL, V285, P1371, DOI 10.1006/jmbi.1998.2374; Zhou YQ, 1997, P NATL ACAD SCI USA, V94, P14429, DOI 10.1073/pnas.94.26.14429; Zhou YQ, 1997, J CHEM PHYS, V107, P10691, DOI 10.1063/1.474186	30	244	246	3	20	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	SEP 23	1999	401	6751					400	403		10.1038/43937	http://dx.doi.org/10.1038/43937			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	240JJ	10517642	Bronze			2022-12-01	WOS:000082822600058
J	Sikorski, R; Peters, R				Sikorski, R; Peters, R			Net tip - Lab search engine	SCIENCE			English	Editorial Material																			0	1	1	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	SEP 17	1999	285	5435					1868	1869						2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	237CT	10515792				2022-12-01	WOS:000082638300037
J	Esteban, CR; Capdevila, J; Economides, AN; Pascual, J; Ortiz, A; Belmonte, JCI				Esteban, CR; Capdevila, J; Economides, AN; Pascual, J; Ortiz, A; Belmonte, JCI			The novel Cer-like protein Caronte mediates the establishment of embryonic left-right asymmetry	NATURE			English	Article							HOMEOBOX GENE; NEURALIZING ACTIVITY; CHICK EMBRYOGENESIS; HEART DEVELOPMENT; NODAL EXPRESSION; SECRETED FACTOR; ORGANIZER; CERBERUS; PATHWAY; CELLS	In the chick embryo, left-right asymmetric patterns of gene expression in the lateral plate mesoderm are initiated by signals located in and around Hensen's node, Here we show that Caronte (Gar), a secreted protein encoded by a member of the Cerberus/Dan gene family, mediates the Sonic hedgehog (Shh)-dependent induction of left-specific genes in the lateral plate mesoderm, Car is induced by Shh and repressed by fibroblast growth factor-8 (FGF-8), Car activates the expression of Nodal by antagonizing a repressive activity of bone morphogenic proteins (BMPs), Our results define a complex network of antagonistic molecular interactions between Activin, FGF-8, Lefty-1, Nodal, BMPs and Car that cooperate to control left-right asymmetry in the chick embryo.	Salk Inst Biol Studies, Gene Express Lab, La Jolla, CA 92037 USA; Regeneron Pharmaceut Inc, Tarrytown, NY 10591 USA; Scripps Res Inst, Dept Mol Biol, La Jolla, CA 92037 USA	Salk Institute; Regeneron; Scripps Research Institute	Belmonte, JCI (corresponding author), Salk Inst Biol Studies, Gene Express Lab, 10010 N Torrey Pines Rd, La Jolla, CA 92037 USA.	belmonte@salk.edu	pascual, jaime/D-4566-2009	pascual, jaime/0000-0001-8992-7475; Economides, Aris/0000-0002-6508-8942				Belo JA, 1997, MECH DEVELOP, V68, P45, DOI 10.1016/S0925-4773(97)00125-1; Biben C, 1998, DEV BIOL, V194, P135, DOI 10.1006/dbio.1997.8812; Boettger T, 1999, CURR BIOL, V9, P277, DOI 10.1016/S0960-9822(99)80119-5; Bouwmeester T, 1996, NATURE, V382, P595, DOI 10.1038/382595a0; Campione M, 1999, DEVELOPMENT, V126, P1225; Capdevila J, 1998, DEV BIOL, V197, P205, DOI 10.1006/dbio.1997.8824; Collignon J, 1996, NATURE, V381, P155, DOI 10.1038/381155a0; Harvey RP, 1996, DEV BIOL, V178, P203, DOI 10.1006/dbio.1996.0212; Harvey RP, 1998, CELL, V94, P273, DOI 10.1016/S0092-8674(00)81468-3; Hsu DR, 1998, MOL CELL, V1, P673, DOI 10.1016/S1097-2765(00)80067-2; Hyatt BA, 1996, NATURE, V384, P62, DOI 10.1038/384062a0; Isaac A, 1997, SCIENCE, V275, P1301, DOI 10.1126/science.275.5304.1301; IZPISUABELMONTE JC, 1993, CELL, V74, P645, DOI 10.1016/0092-8674(93)90512-O; Izraeli S, 1999, NATURE, V399, P691, DOI 10.1038/21429; King T, 1999, CURR BIOL, V9, pR18, DOI 10.1016/S0960-9822(99)80036-0; Levin M, 1996, NATURE, V384, P321, DOI 10.1038/384321a0; LEVIN M, 1995, CELL, V82, P803, DOI 10.1016/0092-8674(95)90477-8; Lohr JL, 1997, DEVELOPMENT, V124, P1465; Lowe LA, 1996, NATURE, V381, P158, DOI 10.1038/381158a0; Meno C, 1997, GENES CELLS, V2, P513, DOI 10.1046/j.1365-2443.1997.1400338.x; Meno C, 1998, CELL, V94, P287, DOI 10.1016/S0092-8674(00)81472-5; Merino R, 1999, DEV BIOL, V206, P33, DOI 10.1006/dbio.1998.9129; Meyers EN, 1999, SCIENCE, V285, P403, DOI 10.1126/science.285.5426.403; Mohammadi M, 1997, SCIENCE, V276, P955, DOI 10.1126/science.276.5314.955; NEW DAT, 1955, J EMBRYOL EXP MORPH, V3, P320; Olson EN, 1996, SCIENCE, V272, P671, DOI 10.1126/science.272.5262.671; Oulad-Abdelghani M, 1998, INT J DEV BIOL, V42, P23; OZAKI T, 1993, P NATL ACAD SCI USA, V90, P2593, DOI 10.1073/pnas.90.7.2593; Pagan-Westphal SM, 1998, CELL, V93, P25, DOI 10.1016/S0092-8674(00)81143-5; Pearce JJH, 1999, DEV BIOL, V209, P98, DOI 10.1006/dbio.1999.9240; Piccolo S, 1999, NATURE, V397, P707, DOI 10.1038/17820; Pizette S, 1999, DEVELOPMENT, V126, P883; Ramsdell AF, 1998, TRENDS GENET, V14, P459, DOI 10.1016/S0168-9525(98)01599-6; Ryan AK, 1998, NATURE, V394, P545, DOI 10.1038/29004; Schneider A, 1999, CURR BIOL, V9, P911, DOI 10.1016/S0960-9822(99)80397-2; Schultheiss TM, 1997, GENE DEV, V11, P451, DOI 10.1101/gad.11.4.451; STANLEY E, MECH DEV, V77, P173; Streit A, 1998, DEVELOPMENT, V125, P507; Supp DM, 1997, NATURE, V389, P963, DOI 10.1038/40140; Thisse C, 1999, DEVELOPMENT, V126, P229; Thomas P, 1997, COLD SPRING HARB SYM, V62, P115; Thompson JD, 1997, NUCLEIC ACIDS RES, V25, P4876, DOI 10.1093/nar/25.24.4876; Topol LZ, 1997, MOL CELL BIOL, V17, P4801, DOI 10.1128/MCB.17.8.4801; Tribioli C, 1997, MECH DEVELOP, V65, P145, DOI 10.1016/S0925-4773(97)00067-1; TSUKUI T, IN PRESS P NATL ACAD; Watanabe Y, 1996, MECH DEVELOP, V57, P69, DOI 10.1016/0925-4773(96)00534-5; YOKOUCHI Y, IN PRESS CELL; Yoshioka H, 1998, CELL, V94, P299, DOI 10.1016/S0092-8674(00)81473-7; Zhu L, 1999, CURR BIOL, V9, P931, DOI 10.1016/S0960-9822(99)80419-9; Zimmerman LB, 1996, CELL, V86, P599, DOI 10.1016/S0092-8674(00)80133-6	50	168	175	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	SEP 16	1999	401	6750					243	251		10.1038/45738	http://dx.doi.org/10.1038/45738			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	237VZ	10499580				2022-12-01	WOS:000082678400044
J	Keefe, R; Dave, V; Allman, D; Wiest, D; Kappes, DJ				Keefe, R; Dave, V; Allman, D; Wiest, D; Kappes, DJ			Regulation of lineage commitment distinct from positive selection	SCIENCE			English	Article							CELL ANTIGEN RECEPTOR; T-CELLS; THYMIC SELECTION; INTERMEDIATE STEPS; CD8 LINEAGE; THYMOCYTES; MICE; MODEL; GENERATION; EXPRESSION	Developing alpha beta T cells diverge into the CD4 and CD8 Lineages as they mature in the thymus. It is unclear whether Lineage commitment is mechanistically distinct from the process that selects for the survival of T cells with useful T cell receptor (TCR) specificities (positive selection). In HD mice, which Lack mature CD4(+) T cells, major histocompatibility complex (MHC) class II-restricted T cells are redirected to the CD8 lineage independent of MHC class I expression. However, neither TCR-mediated signaling nor positive selection is impaired. Thus, the HD mutation provides genetic evidence that lineage commitment may be mechanistically distinct from positive selection.	Fox Chase Canc Ctr, Philadelphia, PA 19111 USA	Fox Chase Cancer Center	Kappes, DJ (corresponding author), Fox Chase Canc Ctr, 7701 Burholme Ave, Philadelphia, PA 19111 USA.			Wiest, David/0000-0002-0792-3188	NATIONAL CANCER INSTITUTE [R01CA074620, P30CA006927] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R29AI034472] Funding Source: NIH RePORTER; NCI NIH HHS [CA06927, CA74620] Funding Source: Medline; NIAID NIH HHS [AI34472] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALLMAN D, UNPUB; ASHTONRICKARDT PG, 1994, IMMUNOL TODAY, V15, P362, DOI 10.1016/0167-5699(94)90174-0; BENDELAC A, 1992, J EXP MED, V175, P731, DOI 10.1084/jem.175.3.731; CHAN SH, 1993, CELL, V73, P225, DOI 10.1016/0092-8674(93)90225-F; COSGROVE D, 1991, CELL, V66, P1051, DOI 10.1016/0092-8674(91)90448-8; Dave VP, 1998, P NATL ACAD SCI USA, V95, P8187, DOI 10.1073/pnas.95.14.8187; DAVE VP, UNPUB; Gabor MJ, 1997, EUR J IMMUNOL, V27, P2010, DOI 10.1002/eji.1830270827; HOGQUIST KA, 1994, CELL, V76, P17, DOI 10.1016/0092-8674(94)90169-4; KAPPES DJ, UNPUB; KAYE J, 1992, J IMMUNOL, V148, P3342; KAYE J, 1989, NATURE, V341, P746, DOI 10.1038/341746a0; KEEFE R, UNPUB; KILLEEN N, 1993, NATURE, V364, P729, DOI 10.1038/364729a0; KIRBERG J, 1994, J EXP MED, V180, P25, DOI 10.1084/jem.180.1.25; KOLLER BH, 1990, SCIENCE, V248, P1227, DOI 10.1126/science.2112266; KYDD R, 1995, J IMMUNOL, V155, P3806; LUCAS B, 1994, J IMMUNOL, V153, P53; Lucas B, 1996, IMMUNITY, V5, P461, DOI 10.1016/S1074-7613(00)80502-6; LUNDBERG K, 1995, J EXP MED, V181, P1643, DOI 10.1084/jem.181.5.1643; Matechak EO, 1996, IMMUNITY, V4, P337, DOI 10.1016/S1074-7613(00)80247-2; Punt JA, 1996, J EXP MED, V184, P2091, DOI 10.1084/jem.184.6.2091; RAVICHANDRAN KS, 1994, J EXP MED, V179, P727, DOI 10.1084/jem.179.2.727; Robey E, 1996, CELL, V87, P483, DOI 10.1016/S0092-8674(00)81368-9; ROBEY EA, 1991, CELL, V64, P99, DOI 10.1016/0092-8674(91)90212-H; SCOLLAY R, 1980, J IMMUNOL, V124, P2845; SCOTT B, 1989, NATURE, V338, P591, DOI 10.1038/338591a0; Sharp LL, 1997, IMMUNITY, V7, P609, DOI 10.1016/S1074-7613(00)80382-9; SUZUKI H, 1995, IMMUNITY, V2, P413, DOI 10.1016/1074-7613(95)90149-3; SWAT W, 1993, EUR J IMMUNOL, V23, P739, DOI 10.1002/eji.1830230326; VEILLETTE A, 1988, CELL, V55, P301, DOI 10.1016/0092-8674(88)90053-0; Wiest DL, 1997, IMMUNITY, V6, P663, DOI 10.1016/S1074-7613(00)80442-2; YAMASHITA I, 1993, INT IMMUNOL, V5, P1139, DOI 10.1093/intimm/5.9.1139	33	86	87	0	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 5	1999	286	5442					1149	1153		10.1126/science.286.5442.1149	http://dx.doi.org/10.1126/science.286.5442.1149			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	253AJ	10550051				2022-12-01	WOS:000083534200041
J	Kroger, N; Deutzmann, R; Sumper, M				Kroger, N; Deutzmann, R; Sumper, M			Polycationic peptides from diatom biosilica that direct silica nanosphere formation	SCIENCE			English	Article							CELL-WALLS; PROTEIN; MORPHOGENESIS; ACID	Diatom cell walls are regarded as a paradigm for controlled production of nanostructured silica, but the mechanisms allowing biosilicification to proceed at ambient temperature at high rates have remained enigmatic. A set of polycationic peptides (called silaffins) isolated from diatom cell walls were shown to generate networks of silica nanospheres within seconds when added to a solution of silicic acid. Silaffins contain covalently modified Lysine-Lysine elements. The first Lysine bears a polyamine consisting of 6 to 11 repeats of the N-methyl-propylamine unit. The second Lysine was identified as epsilon-N,N-dimethyl-lysine. These modifications drastically influence the silica-precipitating activity of silaffins.	Univ Regensburg, Lehrstuhl Biochem 1, D-93053 Regensburg, Germany	University of Regensburg	Kroger, N (corresponding author), Univ Regensburg, Lehrstuhl Biochem 1, D-93053 Regensburg, Germany.	nils.kroeger@vkl.uni-regensburg.de						BOROWITZKA MA, 1978, J PHYCOL, V14, P10; Cha JN, 1999, P NATL ACAD SCI USA, V96, P361, DOI 10.1073/pnas.96.2.361; CHIAPPINO ML, 1977, PROTOPLASMA, V93, P205, DOI 10.1007/BF01275654; GORDON R, 1994, INT REV CYTOL, V150, P243; HECKY RE, 1973, MAR BIOL, V19, P323, DOI 10.1007/BF00348902; Iler R., 1979, CHEM SILICA; Kroger N, 1996, EUR J BIOCHEM, V239, P259, DOI 10.1111/j.1432-1033.1996.0259u.x; Kroger N, 1997, EUR J BIOCHEM, V250, P99, DOI 10.1111/j.1432-1033.1997.00099.x; LINDQUIST GM, 1976, J COLLOID INTERF SCI, V55, P45, DOI 10.1016/0021-9797(76)90007-2; MANN S, 1993, NATURE, V365, P499, DOI 10.1038/365499a0; Mann S, 1996, NATURE, V382, P313, DOI 10.1038/382313a0; Mann S., 1989, BIOMINERALIZATION CH; Mizutani T, 1998, B CHEM SOC JPN, V71, P2017, DOI 10.1246/bcsj.71.2017; NAKAJIMA T, 1969, SCIENCE, V164, P1400, DOI 10.1126/science.164.3886.1400; OLIVER S, 1995, NATURE, V378, P47, DOI 10.1038/378047a0; Pickett-Heaps J., 1990, PROG PHYCOL RES, V7, P1; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SCHMID AMM, 1979, PROTOPLASMA, V100, P267, DOI 10.1007/BF01279316; Shimizu K, 1998, P NATL ACAD SCI USA, V95, P6234, DOI 10.1073/pnas.95.11.6234; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; SWIFT DM, 1992, J PHYCOL, V28, P202, DOI 10.1111/j.0022-3646.1992.00202.x; Volcani B.E., 1981, SILICON SILICEOUS ST, P157; Vrieling EG, 1999, J PHYCOL, V35, P548, DOI 10.1046/j.1529-8817.1999.3530548.x	23	1128	1179	17	329	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 5	1999	286	5442					1129	1132		10.1126/science.286.5442.1129	http://dx.doi.org/10.1126/science.286.5442.1129			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	253AJ	10550045				2022-12-01	WOS:000083534200035
J	Cavalli, G; Paro, R				Cavalli, G; Paro, R			Epigenetic inheritance of active chromatin after removal of the main transactivator	SCIENCE			English	Article							DROSOPHILA BITHORAX COMPLEX; POLYCOMB-PROTEIN; DOMAIN BOUNDARY; MELANOGASTER; TRITHORAX; GENE; EXPRESSION; ELEMENTS; BINDING	The Drosophila Polycomb and trithorax group proteins act through chromosomal elements such as Fab-7 to maintain repressed or active gene expression, respectively. A Fab-7 element is switched from a silenced to a mitotically heritable active state by an embryonic pulse of transcription. Here, histone H4 hyperacetylation was found to be associated with Fab-7 after activation, suggesting that H4 hyperacetylation may be a heritable epigenetic tag of the activated element, Activated Fab-7 enables transcription of a gene even after withdrawal of the primary transcription factor. This feature may allow epigenetic maintenance of active states of developmental genes after decay of their early embryonic regulators.	Univ Heidelberg, Zentrum Mol Biol, D-69120 Heidelberg, Germany; Inst Human Genet, F-34396 Montpellier, France	Ruprecht Karls University Heidelberg; Universite de Montpellier	Paro, R (corresponding author), Univ Heidelberg, Zentrum Mol Biol, Neuenheimer Feld 282, D-69120 Heidelberg, Germany.		Cavalli, Giacomo/A-7958-2008; cavalli, giacomo/Z-2754-2019	Cavalli, Giacomo/0000-0003-3709-3469; cavalli, giacomo/0000-0003-3709-3469				BREILING A, IN PRESS MOL CELL BI; BUSTURIA A, 1993, EMBO J, V12, P1415, DOI 10.1002/j.1460-2075.1993.tb05785.x; Cavalli G, 1998, CELL, V93, P505, DOI 10.1016/S0092-8674(00)81181-2; CHINWALLA V, 1995, EMBO J, V14, P2056, DOI 10.1002/j.1460-2075.1995.tb07197.x; Cosma MP, 1999, CELL, V97, P299, DOI 10.1016/S0092-8674(00)80740-0; Ekwall K, 1997, CELL, V91, P1021, DOI 10.1016/S0092-8674(00)80492-4; FAUVARQUE MO, 1995, MECH DEVELOP, V52, P343, DOI 10.1016/0925-4773(95)00412-T; Gellon G, 1998, BIOESSAYS, V20, P116, DOI 10.1002/(SICI)1521-1878(199802)20:2<116::AID-BIES4>3.3.CO;2-N; Hagstrom K, 1996, GENE DEV, V10, P3202, DOI 10.1101/gad.10.24.3202; Hagstrom K, 1997, GENETICS, V146, P1365; INGHAM PW, 1992, CELL, V68, P221, DOI 10.1016/0092-8674(92)90467-Q; LaJeunesse D, 1996, DEVELOPMENT, V122, P2189; Mihaly J, 1997, DEVELOPMENT, V124, P1809; Orlando V, 1998, EMBO J, V17, P5141, DOI 10.1093/emboj/17.17.5141; Paro R., 1996, EPIGENETIC MECH GENE, P507; Pirrotta V, 1998, CELL, V93, P333, DOI 10.1016/S0092-8674(00)81162-9; Shao ZH, 1999, CELL, V98, P37, DOI 10.1016/S0092-8674(00)80604-2; SIMON J, 1993, DEV BIOL, V158, P131, DOI 10.1006/dbio.1993.1174; Strutt H, 1997, EMBO J, V16, P3621, DOI 10.1093/emboj/16.12.3621; Strutt H, 1997, MOL CELL BIOL, V17, P6773, DOI 10.1128/MCB.17.12.6773; Tillib S, 1999, MOL CELL BIOL, V19, P5189; ZINK B, 1989, NATURE, V337, P468, DOI 10.1038/337468a0; ZINK B, 1991, EMBO J, V10, P153, DOI 10.1002/j.1460-2075.1991.tb07931.x; ZINK D, 1995, EMBO J, V14, P5660, DOI 10.1002/j.1460-2075.1995.tb00253.x	24	198	208	0	11	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	OCT 29	1999	286	5441					955	958		10.1126/science.286.5441.955	http://dx.doi.org/10.1126/science.286.5441.955			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	250BE	10542150				2022-12-01	WOS:000083368500045
J	Mathews, S; Donoghue, MJ				Mathews, S; Donoghue, MJ			The root of angiosperm phylogeny inferred from duplicate phytochrome genes	SCIENCE			English	Article							SEED PLANT PHYLOGENY; DATA SETS; SEQUENCES; EVOLUTION; ORIGIN; DIVERSIFICATION; PARSIMONY; DIVERSITY; FAMILY	An analysis of duplicate phytochrome genes (PHYA and PHYC) is used to root the angiosperms, thereby avoiding the inclusion of highly diverged outgroup sequences. The results unambiguously place the root near Amborella tone species, New Caledonia) and resolve water Lilies (Nymphaeales, similar to 70 species, cosmopolitan), followed by Austrobaileya tone species, Australia), as early branches. These findings bear directly on the interpretation of morphological evolution and diversification within angiosperms.	Harvard Univ Herbaria, Dept Organism & Evolutionary Biol, Cambridge, MA 02138 USA	Harvard University	Mathews, S (corresponding author), Harvard Univ Herbaria, Dept Organism & Evolutionary Biol, 22 Divin Ave, Cambridge, MA 02138 USA.	smathews@oeb.harvard.edu	Mathews, Sarah/A-6513-2015	Mathews, Sarah/0000-0002-5518-7541				BOWE LM, IN PRESS P NATL ACAD; CARLQUIST S, 1992, AM J BOT, V79, P660, DOI 10.2307/2444882; Carlquist S, 1975, ECOLOGICAL STRATEGIE; Chase MW, 1998, AUST SYST BOT, V11, P215, DOI 10.1071/SB97010; CHAW SM, IN PRESS P NATL ACAD; Donoghue MJ, 1998, MOL PHYLOGENET EVOL, V9, P489, DOI 10.1006/mpev.1998.0511; DOYLE JA, 1986, BOT REV, V52, P321, DOI 10.1007/BF02861082; DOYLE JA, 1993, PALEOBIOLOGY, V19, P141, DOI 10.1017/S0094837300015840; Doyle JA, 1996, INT J PLANT SCI, V157, pS3, DOI 10.1086/297401; ENDRESS PK, UNPUB; Farris JS, 1995, SYST BIOL, V44, P570, DOI 10.2307/2413663; FELSENSTEIN J, 1978, SYST ZOOL, V27, P401, DOI 10.2307/2412923; GRAHAM SV, UNPUB; Hansen A, 1999, MOL BIOL EVOL, V16, P1006, DOI 10.1093/oxfordjournals.molbev.a026176; Hecker KH, 1996, BIOTECHNIQUES, V20, P478; Howe GT, 1998, MOL BIOL EVOL, V15, P160, DOI 10.1093/oxfordjournals.molbev.a025912; Igersheim A, 1997, BOT J LINN SOC, V124, P213, DOI 10.1006/bojl.1997.0102; IWABE N, 1989, P NATL ACAD SCI USA, V86, P9355, DOI 10.1073/pnas.86.23.9355; Kim JH, 1996, SYST BIOL, V45, P363, DOI 10.2307/2413570; Larson A., 1994, Experientia Supplementum (Basel), V69, P371; Lavin M, 1998, AM J BOT, V85, P412, DOI 10.2307/2446334; MATHEWS S, 1995, ANN MO BOT GARD, V82, P296, DOI 10.2307/2399882; Mathews S, 1997, PLANT CELL ENVIRON, V20, P666, DOI 10.1046/j.1365-3040.1997.d01-117.x; MATHEWS SM, UNPUB; Nandi OI, 1998, ANN MO BOT GARD, V85, P137, DOI 10.2307/2992003; PARKINSON CJ, UNPUB; QIU YL, IN PRESS NATURE; Renner SS, 1999, AM J BOT, V86, P1301, DOI 10.2307/2656778; SANDERSON MJ, 1994, SCIENCE, V264, P1590, DOI 10.1126/science.264.5165.1590; Sang T, 1997, MOL BIOL EVOL, V14, P994, DOI 10.1093/oxfordjournals.molbev.a025716; Schneider EL, 1996, AM J BOT, V83, P1236, DOI 10.2307/2446207; Schneider-Poetsch HAW, 1998, PHYSIOL PLANTARUM, V102, P612, DOI 10.1034/j.1399-3054.1998.1020417.x; Soltis DE, 1997, ANN MO BOT GARD, V84, P1, DOI 10.2307/2399952; SOLTIS PS, IN PRESS NATURE; SWOFFORD D, 1999, PAUP 4 0; THEIN LB, UNPUB; WELLER SG, 1995, MONOG SYST BOTAN, V53, P355; WHITEHOUSE HLK, 1950, ANN BOT-LONDON, V14, P199, DOI 10.1093/oxfordjournals.aob.a083243; Winter KU, 1999, P NATL ACAD SCI USA, V96, P7342, DOI 10.1073/pnas.96.13.7342; YOUNG DA, 1981, SYST BOT, V6, P313, DOI 10.2307/2418445	40	347	362	1	50	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	OCT 29	1999	286	5441					947	950		10.1126/science.286.5441.947	http://dx.doi.org/10.1126/science.286.5441.947			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	250BE	10542147				2022-12-01	WOS:000083368500042
J	Sestan, N; Artavanis-Tsakonas, S; Rakic, P				Sestan, N; Artavanis-Tsakonas, S; Rakic, P			Contact-dependent inhibition of cortical neurite growth mediated by notch signaling	SCIENCE			English	Article							MAMMALIAN NUMB; IN-VITRO; NEUROGENESIS; DIFFERENTIATION; SYNAPTOGENESIS; TRANSCRIPTION; LOCALIZATION; ACTIVATION; DISEASE; PATHWAY	The exuberant growth of neurites during development becomes markedly reduced as cortical neurons mature. In vitro studies of neurons from mouse cerebral cortex revealed that contact-mediated Notch signaling regulates the capacity of neurons to extend and elaborate neurites, Up-regulation of Notch activity was concomitant with an increase in the number of interneuronal contacts and cessation of neurite growth. In neurons with low Notch activity, which readily extend neurites, up-regulation of Notch activity either inhibited extension or caused retraction of neurites. Conversely, in more mature neurons that had ceased their growth after establishing numerous connections and displayed high Notch activity,inhibition of Notch signaling promoted neurite extension. Thus, the formation of neuronal contacts results in activation of Notch receptors, Leading to restriction of neuronal growth and a subsequent arrest in maturity.	Yale Univ, Sch Med, Neurobiol Sect, New Haven, CT 06510 USA; Harvard Univ, Sch Med, Massachusetts Gen Hosp, Ctr Canc, Charlestown, MA 02129 USA	Yale University; Harvard University; Massachusetts General Hospital	Rakic, P (corresponding author), Yale Univ, Sch Med, Neurobiol Sect, 333 Cedar St, New Haven, CT 06510 USA.	pasko.rakic@yale.edu			NINDS NIH HHS [NS26084, NS14841] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R37NS026084, R01NS014841, R01NS026084] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		AHMAD I, 1995, MECH DEVELOP, V53, P73, DOI 10.1016/0925-4773(95)00425-4; AKAZAWA C, 1992, J BIOL CHEM, V267, P21879; Artavanis-Tsakonas S, 1999, SCIENCE, V284, P770, DOI 10.1126/science.284.5415.770; Aster JC, 1997, J BIOL CHEM, V272, P11336; Beatus P, 1998, J NEUROSCI RES, V54, P125, DOI 10.1002/(SICI)1097-4547(19981015)54:2<125::AID-JNR1>3.0.CO;2-G; Berezovska O, 1999, MOL BRAIN RES, V69, P273, DOI 10.1016/S0169-328X(99)00119-9; Berezovska O, 1999, NEUROSCIENCE, V93, P433, DOI 10.1016/S0306-4522(99)00157-8; Castella P, 1999, J NEUROSCI RES, V56, P229, DOI 10.1002/(SICI)1097-4547(19990501)56:3<229::AID-JNR2>3.0.CO;2-Z; CRAIG AM, 1994, ANNU REV NEUROSCI, V17, P267, DOI 10.1146/annurev.neuro.17.1.267; De Strooper B, 1999, NATURE, V398, P518, DOI 10.1038/19083; DUNN GA, 1971, J COMP NEUROL, V143, P491, DOI 10.1002/cne.901430406; FLETCHER TL, 1994, J NEUROSCI, V14, P6695; Giniger E, 1998, NEURON, V20, P667, DOI 10.1016/S0896-6273(00)81007-7; Gray GE, 1999, AM J PATHOL, V154, P785, DOI 10.1016/S0002-9440(10)65325-4; Greenwald I, 1998, GENE DEV, V12, P1751, DOI 10.1101/gad.12.12.1751; Gridley T, 1997, MOL CELL NEUROSCI, V9, P103, DOI 10.1006/mcne.1997.0610; Horch HW, 1999, NEURON, V23, P353; Hsieh JJD, 1997, J VIROL, V71, P1938, DOI 10.1128/JVI.71.3.1938-1945.1997; Hsieh JJD, 1996, MOL CELL BIOL, V16, P952; Jarriault S, 1998, MOL CELL BIOL, V18, P7423, DOI 10.1128/MCB.18.12.7423; Kimble J, 1997, ANNU REV CELL DEV BI, V13, P333, DOI 10.1146/annurev.cellbio.13.1.333; Lecourtois M, 1998, CURR BIOL, V8, P771, DOI 10.1016/S0960-9822(98)70300-8; Li LH, 1998, IMMUNITY, V8, P43, DOI 10.1016/S1074-7613(00)80457-4; Lu FM, 1996, P NATL ACAD SCI USA, V93, P5663, DOI 10.1073/pnas.93.11.5663; Matsuno K, 1998, NAT GENET, V19, P74, DOI 10.1038/ng0598-74; Nofziger D, 1999, DEVELOPMENT, V126, P1689; Olson EC, 1998, MOL CELL NEUROSCI, V12, P281, DOI 10.1006/mcne.1998.0712; Ordentlich P, 1998, MOL CELL BIOL, V18, P2230, DOI 10.1128/MCB.18.4.2230; PERRY VH, 1982, NATURE, V297, P683, DOI 10.1038/297683a0; Price DL, 1998, ANNU REV NEUROSCI, V21, P479, DOI 10.1146/annurev.neuro.21.1.479; Qi HL, 1999, SCIENCE, V283, P91, DOI 10.1126/science.283.5398.91; RAKIC P, 1982, DEV MODIFIABILITY CE; SASAI Y, 1992, GENE DEV, V6, P2620, DOI 10.1101/gad.6.12b.2620; Schroeter EH, 1998, NATURE, V393, P382, DOI 10.1038/30756; SESTAN N, 1999, THESIS YALE U; Song WH, 1999, P NATL ACAD SCI USA, V96, P6959, DOI 10.1073/pnas.96.12.6959; Struhl G, 1998, CELL, V93, P649, DOI 10.1016/S0092-8674(00)81193-9; Struhl G, 1999, NATURE, V398, P522, DOI 10.1038/19091; Vamum-Finney B, 1998, BLOOD, V91, P4084; Van den Pol AN, 1998, J COMP NEUROL, V399, P541; Verdi J, 1996, CURR BIOL, V6, P1134, DOI 10.1016/S0960-9822(02)70680-5; Wakamatsu Y, 1999, NEURON, V23, P71, DOI 10.1016/S0896-6273(00)80754-0; Wang SL, 1998, NEURON, V21, P63, DOI 10.1016/S0896-6273(00)80515-2; Weinmaster G, 1997, MOL CELL NEUROSCI, V9, P91, DOI 10.1006/mcne.1997.0612; WIESEL TN, 1982, NATURE, V299, P583, DOI 10.1038/299583a0; Yavari R, 1998, HUM MOL GENET, V7, P1161, DOI 10.1093/hmg/7.7.1161; Ye YH, 1999, NATURE, V398, P525, DOI 10.1038/19096; ZAGOURAS P, 1995, P NATL ACAD SCI USA, V92, P6414, DOI 10.1073/pnas.92.14.6414; Zhong WM, 1997, DEVELOPMENT, V124, P1887; Zhong WM, 1996, NEURON, V17, P43, DOI 10.1016/S0896-6273(00)80279-2	50	476	498	0	12	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 22	1999	286	5440					741	746		10.1126/science.286.5440.741	http://dx.doi.org/10.1126/science.286.5440.741			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	248XZ	10531053				2022-12-01	WOS:000083303200045
J	Vassar, R; Bennett, BD; Babu-Khan, S; Kahn, S; Mendiaz, EA; Denis, P; Teplow, DB; Ross, S; Amarante, P; Loeloff, R; Luo, Y; Fisher, S; Fuller, L; Edenson, S; Lile, J; Jarosinski, MA; Biere, AL; Curran, E; Burgess, T; Louis, JC; Collins, F; Treanor, J; Rogers, G; Citron, M				Vassar, R; Bennett, BD; Babu-Khan, S; Kahn, S; Mendiaz, EA; Denis, P; Teplow, DB; Ross, S; Amarante, P; Loeloff, R; Luo, Y; Fisher, S; Fuller, L; Edenson, S; Lile, J; Jarosinski, MA; Biere, AL; Curran, E; Burgess, T; Louis, JC; Collins, F; Treanor, J; Rogers, G; Citron, M			beta-secretase cleavage of Alzheimer's amyloid precursor protein by the transmembrane aspartic protease BACE	SCIENCE			English	Article							TRANSGENIC MICE; DISEASE; PEPTIDE; CELLS; MUTATION; RELEASE; PURIFICATION; GENERATION; INHIBITION; RECEPTOR	Cerebral deposition of amyloid beta peptide (A beta) is an early and critical feature of Alzheimer's disease. A beta generation depends on proteolytic cleavage of the amyloid precursor protein (APP) by two unknown proteases: beta-secretase and gamma-secretase. These proteases are prime therapeutic targets. A transmembrane aspartic protease with all the known characteristics of beta-secretase was cloned and characterized. Overexpression of this protease, termed BACE (for beta-site APP-cleaving enzyme) increased the amount of beta-secretase cleavage products, and these were cleaved exactly and only at known beta-secretase positions. Antisense inhibition of endogenous BACE messenger RNA decreased the amount of beta-secretase cleavage products, and purified BACE protein cleaved APP-derived substrates with the same sequence specificity as beta-secretase. Finally, the expression pattern and subcellular Localization of BACE were consistent with that expected for beta-secretase. Future development of BACE inhibitors may prove beneficial for the treatment of Alzheimer's disease.	Amgen Inc, Thousand Oaks, CA 91320 USA; Brigham & Womens Hosp, Ctr Neurol Dis, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Neurol, Boston, MA 02115 USA	Amgen; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School	Citron, M (corresponding author), Amgen Inc, 1 Amgen Ctr Dr,M-S 29-2-B, Thousand Oaks, CA 91320 USA.							Buxbaum JD, 1998, J BIOL CHEM, V273, P27765, DOI 10.1074/jbc.273.43.27765; CAI XD, 1993, SCIENCE, V259, P514, DOI 10.1126/science.8424174; Capell A, 1996, AMYLOID, V3, P150, DOI 10.3109/13506129609045514; Chyung ASC, 1997, J CELL BIOL, V138, P671, DOI 10.1083/jcb.138.3.671; Citron M, 1996, NEURON, V17, P171, DOI 10.1016/S0896-6273(00)80290-1; CITRON M, 1995, NEURON, V14, P661, DOI 10.1016/0896-6273(95)90323-2; CITRON M, 1992, NATURE, V360, P672, DOI 10.1038/360672a0; CURRAN EJ, 1995, J COMP NEUROL, V361, P57, DOI 10.1002/cne.903610106; De Strooper B, 1999, NATURE, V398, P518, DOI 10.1038/19083; De Strooper B, 1998, NATURE, V391, P387, DOI 10.1038/34910; EVIN G, 1994, AMYLOID, V1, P263, DOI 10.3109/13506129409146118; FIELD J, 1988, MOL CELL BIOL, V8, P2159, DOI 10.1128/MCB.8.5.2159; GAMES D, 1995, NATURE, V373, P523, DOI 10.1038/373523a0; GLENNER GG, 1984, BIOCHEM BIOPH RES CO, V120, P885, DOI 10.1016/S0006-291X(84)80190-4; Gouras GK, 1998, J NEUROCHEM, V71, P1920; HAASS C, 1992, NATURE, V359, P322, DOI 10.1038/359322a0; HAASS C, 1993, J BIOL CHEM, V268, P3021; HAASS C, 1995, NAT MED, V1, P1291, DOI 10.1038/nm1295-1291; KANG J, 1987, NATURE, V325, P733, DOI 10.1038/325733a0; KNOPS J, 1995, J BIOL CHEM, V270, P2419, DOI 10.1074/jbc.270.6.2419; KOO EH, 1994, J BIOL CHEM, V269, P17386; Lammich S, 1999, P NATL ACAD SCI USA, V96, P3922, DOI 10.1073/pnas.96.7.3922; MULLAN M, 1992, NAT GENET, V1, P345, DOI 10.1038/ng0892-345; Murphy MP, 1999, J BIOL CHEM, V274, P11914, DOI 10.1074/jbc.274.17.11914; RAWLINGS ND, 1995, METHOD ENZYMOL, V248, P105; ROHER AE, 1993, J BIOL CHEM, V268, P3072; Ross SL, 1998, J BIOL CHEM, V273, P15309, DOI 10.1074/jbc.273.25.15309; SEUBERT P, 1993, NATURE, V361, P260, DOI 10.1038/361260a0; Wolfe MS, 1999, NATURE, V398, P513, DOI 10.1038/19077; Younkin SG, 1998, J PHYSIOLOGY-PARIS, V92, P289, DOI 10.1016/S0928-4257(98)80035-1; Zhao J, 1996, J BIOL CHEM, V271, P31407, DOI 10.1074/jbc.271.49.31407; ZHONG ZY, 1994, J BIOL CHEM, V269, P627	32	3148	3417	9	463	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	OCT 22	1999	286	5440					735	741		10.1126/science.286.5440.735	http://dx.doi.org/10.1126/science.286.5440.735			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	248XZ	10531052	Green Published			2022-12-01	WOS:000083303200044
J	Howdeshell, KL; Hotchkiss, AK; Thayer, KA; Vandenbergh, JG; vom Saal, FS				Howdeshell, KL; Hotchkiss, AK; Thayer, KA; Vandenbergh, JG; vom Saal, FS			Environmental toxins - Exposure to bisphenol A advances puberty	NATURE			English	Article									Univ Missouri, Div Biol Sci, Columbia, MO 65211 USA; Univ Missouri, Dept Zool, Columbia, MO 65211 USA	University of Missouri System; University of Missouri Columbia; University of Missouri System; University of Missouri Columbia	Howdeshell, KL (corresponding author), Univ Missouri, Div Biol Sci, Columbia, MO 65211 USA.	vomsaalf@missouri.edu						COLBORN T, 1993, ENVIRON HEALTH PERSP, V101, P378, DOI 10.2307/3431890; DODDS E. C, 1936, NATURE [LONDON], V137, P996, DOI 10.1038/137996a0; EVEN MD, 1992, J REPROD FERTIL, V96, P709, DOI 10.1530/jrf.0.0960709; GRAY LE, 1992, ADV MOD ENV, V21, P203; HermanGiddens ME, 1997, PEDIATRICS, V99, P505, DOI 10.1542/peds.99.4.505; HSIEH CC, 1992, AM J EPIDEMIOL, V136, P1321, DOI 10.1093/oxfordjournals.aje.a116444; Nagel SC, 1997, ENVIRON HEALTH PERSP, V105, P70, DOI 10.1289/ehp.9710570; PANAGIOTOPOULOU K, 1990, CANCER CAUSE CONTROL, V1, P119, DOI 10.1007/BF00053162; Paulozzi LJ, 1997, PEDIATRICS, V100, P831, DOI 10.1542/peds.100.5.831; SAAL FSV, 1989, J ANIM SCI, V67, P1824; TAKAO Y, 1999, J HEALTH SCI, V45, P39; VANDENBERGH JG, 1969, ENDOCRINOLOGY, V84, P658, DOI 10.1210/endo-84-3-658; VOMSAAL FS, 1981, J REPROD FERTIL, V62, P633, DOI [10.1530/jrf.0.0620633, 10.1530/jrf.0.0620033]; VOMSAAL FS, 1998, FORUM APPL RES PUBLI, V13, P11	14	657	688	5	131	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	OCT 21	1999	401	6755					763	764		10.1038/44517	http://dx.doi.org/10.1038/44517			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	250BG	10548101				2022-12-01	WOS:000083368700043
J	Yawn, BP; Yawn, RA; Hodge, D; Shaughnessy, WJ; Ilstrup, D; Jacobsen, SJ				Yawn, BP; Yawn, RA; Hodge, D; Shaughnessy, WJ; Ilstrup, D; Jacobsen, SJ			A population-based study of school scoliosis screening	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ADOLESCENT IDIOPATHIC SCOLIOSIS; NATURAL-HISTORY; EPIDEMIOLOGY	Context Although school-based screening programs for adolescent idiopathic scoliosis are mandated in 26 states in the United States, few program outcomes data exist regarding the effectiveness of such programs. Objective To determine the effectiveness of a community-based school scoliosis screening program. Design, Setting, and Participants Retrospective cohort study of children who attended kindergarten or first grade at public or private schools in Rochester, Minn, during 1979-1982. Children were followed up until age 19 years or until they left the school district. Main Outcome Measures Number of children diagnosed and treated for scoliosis, based on results from scoliosis screenings performed annually in grades 5 through 9, linked to community medical records data; performance characteristics of the screening program. Results Of the 2242 children screened, 92 (4.1%) were referred for further evaluation. Of these, 68 (74%) had documented medical or chiropractic evaluation of scoliosis. School screening identified 5 of the 9 children treated for scoliosis but resulted in referrals for another 87 children who were not treated. The cumulative incidence of diagnosed scoliosis in this population was 1.8% (95% confidence interval [CI], 1.2%-2.3 %) for curves of more than 10 degrees, 1.0% (95% CI, 0.6%-1.5%) for curves of at least 20 degrees, and 0.4% (95% CI, 0.1%-0.6%) for curves of 40 degrees or more; 0.4% (0.5% of girls and 0.3% of boys) were treated for scoliosis. The positive predictive value of the school screening program for the identification of treated scoliosis was 0.05 (95% CI, 0.048-0.052), with 448 children needed to screen to identify 1 child who subsequently received treatment. The percent positive agreement across consecutive years of screening varied from 7% to 30%. Conclusion In this population, school scoliosis screening identified some children who went on to receive treatment but referred many more who did not. These data should be considered in making decisions regarding school scoliosis screening.	Olmsted Med Ctr, Dept Res, Rochester, MN 55904 USA; Mayo Clin, Biostat Sect, Rochester, MN USA; Mayo Clin, Clin Epidemiol Sect, Rochester, MN USA; Mayo Clin, Dept Orthoped, Rochester, MN USA	Olmsted Medical Center; Mayo Clinic; Mayo Clinic; Mayo Clinic	Yawn, BP (corresponding author), Olmsted Med Ctr, Dept Res, 210 9th St SE, Rochester, MN 55904 USA.		shaughnessy, william/AAJ-4458-2020	Jacobsen, Steven/0000-0002-8174-8533	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR030582] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR30582] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		AMENDT LE, 1990, PHYS THER, V70, P108, DOI 10.1093/ptj/70.2.108; ASHWORTH MA, 1988, SPINE, V13, P1187, DOI 10.1097/00007632-198810000-00024; BERG O, 1993, J AM BOARD FAM PRACT, V6, P497; BERWICK DM, 1985, PEDIAT REV, V5, P238; BUNNELL WP, 1984, J BONE JOINT SURG AM, V66A, P1381, DOI 10.2106/00004623-198466090-00010; BUNNELL WP, 1986, SPINE, V11, P773, DOI 10.1097/00007632-198610000-00003; BUNNELL WP, 1993, SPINE, V18, P1572, DOI 10.1097/00007632-199309000-00001; BURWELL RG, 1988, SPINE, V13, P1192; DICKSON RA, 1980, BRIT MED J, V281, P265, DOI 10.1136/bmj.281.6235.265; DIGUISEPPI C, 1996, US PREVENTIVE SERVIC; GORE DR, 1981, PEDIATRICS, V67, P196; LEAVER JM, 1982, INT J EPIDEMIOL, V11, P101, DOI 10.1093/ije/11.2.101; LONSTEIN JE, 1982, J BONE JOINT SURG AM, V64, P481, DOI 10.2106/00004623-198264040-00002; LONSTEIN JE, 1988, SPINE, V13, P1198, DOI 10.1097/00007632-198810000-00029; Melton LJ, 1996, MAYO CLIN PROC, V71, P266, DOI 10.4065/71.3.266; MONTGOMERY SA, 1990, INT CLIN PSYCHOPHARM, V5, P67; MORAIS T, 1985, AM J PUBLIC HEALTH, V75, P1377, DOI 10.2105/AJPH.75.12.1377; NACHEMSON AL, 1995, J BONE JOINT SURG AM, V77A, P815, DOI 10.2106/00004623-199506000-00001; OHTSUKA Y, 1988, SPINE, V13, P1251, DOI 10.1097/00007632-198811000-00008; PRUIJS JEH, 1992, SPINE, V17, P431, DOI 10.1097/00007632-199204000-00009; RENSHAW TS, 1988, CLIN ORTHOP RELAT R, P26; ROBITAILLE Y, 1984, INT J EPIDEMIOL, V13, P319, DOI 10.1093/ije/13.3.319; ROGALA EJ, 1978, J BONE JOINT SURG AM, V60, P173, DOI 10.2106/00004623-197860020-00005; SACKETT DL, 1991, CLIN EPIDEMIOLOGY BA, P153; Skaggs DL, 1996, J BONE JOINT SURG AM, V78A, P151, DOI 10.2106/00004623-199601000-00024; SMYRNIS T, 1987, ORTHOPEDICS, V10, P921; Soucacos PN, 1997, J BONE JOINT SURG AM, V79A, P1498, DOI 10.2106/00004623-199710000-00006; WILLNER S, 1982, ACTA ORTHOP SCAND, V53, P233, DOI 10.3109/17453678208992208; WOOLF SH, 1993, JAMA-J AM MED ASSOC, V269, P2664; Yawn BP, 1996, J SCHOOL HEALTH, V66, P171, DOI 10.1111/j.1746-1561.1996.tb06269.x	30	101	106	0	10	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 20	1999	282	15					1427	1432		10.1001/jama.282.15.1427	http://dx.doi.org/10.1001/jama.282.15.1427			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	245LT	10535432	Bronze			2022-12-01	WOS:000083111000027
J	Marcil, M; Brooks-Wilson, A; Clee, SM; Roomp, K; Zhang, LH; Yu, L; Collins, JA; van Dam, M; Molhuizen, HOF; Loubster, O; Ouellette, BFF; Sensen, CW; Fichter, K; Mott, S; Denis, M; Boucher, B; Pimstone, S; Genest, J; Kastelein, JJP; Hayden, MR				Marcil, M; Brooks-Wilson, A; Clee, SM; Roomp, K; Zhang, LH; Yu, L; Collins, JA; van Dam, M; Molhuizen, HOF; Loubster, O; Ouellette, BFF; Sensen, CW; Fichter, K; Mott, S; Denis, M; Boucher, B; Pimstone, S; Genest, J; Kastelein, JJP; Hayden, MR			Mutations in the ABC1 gene in familial HDL deficiency with defective cholesterol efflux	LANCET			English	Article							SUBSTRATE-SPECIFICITY; TANGIER-DISEASE; APOA-I; LIPOPROTEIN; HYPERCATABOLISM; TRANSPORTER; FIBROBLASTS; DYSTROPHY; POSITION; LIPASE	Background A low concentration of HDL cholesterol is the most common lipoprotein abnormality in patients with premature atherosclerosis. We have shown that Tangier disease, a rare and severe form of HDL deficiency characterised by a biochemical defect in cellular cholesterol efflux, is caused by mutations in the ATP-binding-cassette (ABC1) gene. This gene codes for the cholesterol-efflux regulatory protein (CERP). We investigated the presence of mutations in this gene in patients with familiar HDL deficiency. Methods Three French-Canadian families and one Dutch family with familial HDL deficiency were studied. Fibroblasts from the proband of each family were defective in cellular cholesterol efflux. Genomic DNA of each proband was used for mutation detection with primers flanking each exon of the ABC1 gene, and for sequencing of the entire coding region of the gene. PCR and restriction-fragment length polymorphism assays specific to each mutation were used to investigate segregation of the mutation in each family, and to test for absence of the mutation in DNA from normal controls. Findings A different mutation was detected in ABC1 in each family studied. Each mutation either created a stop codon predicted to result in truncation of CERP, or altered a conserved aminoacid residue. Each mutation segregated with low concentrations of HDL-cholesterol in the family, and was not observed in more than 500 control chromosomes tested. Interpretation These data show that mutations in ABC1 are the major cause of familial HDL deficiency associated with defective cholesterol efflux, and that CERP has an essential role in the formation of HDL. Our findings highlight the potential of modulation of ABC1 as a new route for increasing HDL concentrations.	Xenon Biores Inc, NRC Innovat Ctr, Vancouver, BC, Canada; Univ British Columbia, Womens & Childrens Hosp, Ctr Mol Med & Therapeut, Vancouver, BC V5Z 1M9, Canada; Acad Med Ctr, Dept Vasc Med, NL-1005 AZ Amsterdam, Netherlands; Clin Res Inst Montreal, Cardiovasc Genet Lab, Montreal, PQ H2W 1R7, Canada; NRC, Inst Marine Biosci, Halifax, NS, Canada	National Research Council Canada; University of British Columbia; University of Amsterdam; Academic Medical Center Amsterdam; Institut de Recherche Clinique de Montreal (IRCM); Universite de Montreal; National Research Council Canada	Hayden, MR (corresponding author), Ctr Mol Med & Therapeut, 950 W 28th Ave, Vancouver, BC V5Z 4H4, Canada.	mrh@cmmt.ubc.ca	van Dam, Marjel/AFT-3071-2022; Kastelein, John/AAF-7950-2020; Collins, Jennifer/AAE-1895-2020; Brooks-Wilson, Angela/E-9399-2012; Sensen, Christoph W./C-1798-2013; Clee, Susanne/AAC-4278-2020; Hayden, Michael R/D-8581-2011; Clee, Susanne/F-7312-2010	Brooks-Wilson, Angela/0000-0003-1009-6408; Sensen, Christoph W./0000-0001-9604-8962; Hayden, Michael R/0000-0001-5159-1419; Clee, Susanne/0000-0001-7946-688X; Ouellette, B. F. Francis/0000-0003-4676-675X; van Dam, Marjel/0000-0001-9802-7516				Allikmets R, 1997, NAT GENET, V15, P236, DOI 10.1038/ng0397-236; Allikmets R, 1997, SCIENCE, V277, P1805, DOI 10.1126/science.277.5333.1805; Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; ASSMANN G, 1995, METABOLIC MOL BASES, P2053; Batal R, 1998, ARTERIOSCL THROM VAS, V18, P655, DOI 10.1161/01.ATV.18.4.655; Bodzioch M, 1999, NAT GENET, V22, P347, DOI 10.1038/11914; BRECKENRIDGE WC, 1982, ATHEROSCLEROSIS, V45, P161, DOI 10.1016/0021-9150(82)90136-8; Brooks-Wilson A, 1999, NAT GENET, V22, P336, DOI 10.1038/11905; CHEUNG MC, 1993, J CLIN INVEST, V91, P522, DOI 10.1172/JCI116231; Cremers FPM, 1998, HUM MOL GENET, V7, P355, DOI 10.1093/hmg/7.3.355; Eberhart GP, 1998, J CLIN ENDOCR METAB, V83, P836, DOI 10.1210/jc.83.3.836; EISENBERG S, 1984, J LIPID RES, V25, P1017; EMMERICH J, 1993, ARTERIOSCLER THROMB, V13, P1299, DOI 10.1161/01.ATV.13.9.1299; GARTNER J, 1992, NAT GENET, V1, P16, DOI 10.1038/ng0492-16; GENEST J, 1992, J AM COLL CARDIOL, V19, P792, DOI 10.1016/0735-1097(92)90520-W; GENEST JJ, 1992, CIRCULATION, V85, P2025, DOI 10.1161/01.CIR.85.6.2025; Gottesman MM, 1995, ANNU REV GENET, V29, P607, DOI 10.1146/annurev.ge.29.120195.003135; Kuivenhoven JA, 1997, J LIPID RES, V38, P191; Kuivenhoven JA, 1997, ARTERIOSCL THROM VAS, V17, P560, DOI 10.1161/01.ATV.17.3.560; MARCIL M, 1995, ARTERIOSCL THROM VAS, V15, P1015, DOI 10.1161/01.ATV.15.8.1015; Marcil M, 1999, ARTERIOSCL THROM VAS, V19, P159, DOI 10.1161/01.ATV.19.1.159; MOSSER J, 1993, NATURE, V361, P726, DOI 10.1038/361726a0; Murray CJL, 1997, LANCET, V349, P1269, DOI 10.1016/S0140-6736(96)07493-4; REYMER PWA, 1995, NAT GENET, V10, P28, DOI 10.1038/ng0595-28; ROGLER G, 1995, ARTERIOSCL THROM VAS, V15, P683, DOI 10.1161/01.ATV.15.5.683; ROSENTHAL A, 1993, NUCLEIC ACIDS RES, V21, P173, DOI 10.1093/nar/21.1.173; Rust S, 1999, NAT GENET, V22, P352, DOI 10.1038/11921; Schuler GD, 1998, METHOD BIOCHEM ANAL, V39, P145; STAMPFER MJ, 1991, NEW ENGL J MED, V325, P373, DOI 10.1056/NEJM199108083250601; Taguchi Y, 1997, BIOCHEMISTRY-US, V36, P8883, DOI 10.1021/bi970553v; Taguchi Y, 1997, FEBS LETT, V413, P142, DOI 10.1016/S0014-5793(97)00899-5; TALMUD P, 1982, GENET EPIDEMIOL, V45, P161; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Toh S, 1999, AM J HUM GENET, V64, P739, DOI 10.1086/302292; Zielenski J, 1995, ANNU REV GENET, V29, P777, DOI 10.1146/annurev.ge.29.120195.004021	35	299	316	1	4	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	OCT 16	1999	354	9187					1341	1346		10.1016/S0140-6736(99)07026-9	http://dx.doi.org/10.1016/S0140-6736(99)07026-9			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	246DV	10533863				2022-12-01	WOS:000083149900012
J	Posnett, J				Posnett, J			The hospital of the future - Is bigger better? Concentration in the provision of secondary care	BRITISH MEDICAL JOURNAL			English	Editorial Material							VOLUME		Univ York, York Hlth Econ Consortium, York YO1 5DD, N Yorkshire, England	University of York - UK	Posnett, J (corresponding author), Univ York, York Hlth Econ Consortium, York YO1 5DD, N Yorkshire, England.		Sandall, Jane/D-4146-2009	Sandall, Jane/0000-0003-2000-743X				ALETRAS V, 1997, CONCENTRATION CHOICE, P23; Bentham G, 1995, Soc Sci Med, V40, P131, DOI 10.1016/0277-9536(94)E0048-W; Carr-Hill R, 1997, CONCENTRATION CHOICE, P37; *EFF HLTH CAR B, 1996, HOSP VOL HLTH CAR OU; GODDARD M, 1997, HLTH EC SERIES; HOWLAND G, 1997, IHSM HLTH SOCIAL SER; Jones J, 1995, INT J TECHNOL ASSESS, V11, P762, DOI 10.1017/S0266462300009193; SOWDEN A, 1997, CONCENTRATION CHOICE, P9; SOWDEN AJ, 1995, BMJ-BRIT MED J, V311, P151, DOI 10.1136/bmj.311.6998.151	9	55	57	0	6	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	OCT 16	1999	319	7216					1063	1065		10.1136/bmj.319.7216.1063	http://dx.doi.org/10.1136/bmj.319.7216.1063			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	247FH	10521207	Green Published			2022-12-01	WOS:000083210100037
J	Boguski, MS				Boguski, MS			Biosequence exegesis	SCIENCE			English	Editorial Material							SEQUENCE	Annotation of Large-scale gene sequence data will benefit from comprehensive and consistent application of well-documented, standard analysis methods and from progressive and vigilant efforts to ensure quality and utility and to keep the annotation up to date. However, it is imperative to Learn how to apply information derived from functional genomics and proteomics technologies to conceptualize and explain the behaviors of biological systems. Quantitative and dynamical models of systems behaviors will supersede the Limited and static forms of single-gene annotation that are now the norm. Molecular biological epistemology will increasingly encompass both teleological and causal explanations.	NIH, Natl Ctr Biotechnol Informat, Natl Lib Med, Bethesda, MD 20894 USA	National Institutes of Health (NIH) - USA; NIH National Library of Medicine (NLM)	Boguski, MS (corresponding author), NIH, Natl Ctr Biotechnol Informat, Natl Lib Med, 8600 Rockville Pike, Bethesda, MD 20894 USA.							BOGUSKI MS, 1995, TRENDS BIOCHEM SCI, V20, P295, DOI 10.1016/S0968-0004(00)89051-9; COLLINS FS, 1995, NAT GENET, V9, P347, DOI 10.1038/ng0495-347; Doolittle RF, 1997, J MOL MED-JMM, V75, P239; Fambrough D, 1999, CELL, V97, P727, DOI 10.1016/S0092-8674(00)80785-0; Hayles Katherine, 1999, WE BECAME POSTHUMAN; Hieter P, 1997, SCIENCE, V278, P601, DOI 10.1126/science.278.5338.601; INSLOW RL, 1999, CIRC RES, V84, P571; Jeffery CJ, 1999, TRENDS BIOCHEM SCI, V24, P8, DOI 10.1016/S0968-0004(98)01335-8; Judson H. F., 1996, 8 DAY CREATION; SANGER F, 1988, ANNU REV BIOCHEM, V57, P1, DOI 10.1146/annurev.bi.57.070188.000245; SHAW S, 1998, BRIT SOC IMM ANN M H; Sober E, 1993, PHILOS BIOL; Weiner J., 1999, TIME LOVE MEMORY GRE; Wheelan SJ, 1998, GENOME RES, V8, P168, DOI 10.1101/gr.8.3.168	14	44	48	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	OCT 15	1999	286	5439					453	455		10.1126/science.286.5439.453	http://dx.doi.org/10.1126/science.286.5439.453			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	245RD	10521334				2022-12-01	WOS:000083121200045
J	Tabara, H; Sarkissian, M; Kelly, WG; Fleenor, J; Grishok, A; Timmons, L; Fire, A; Mello, CC				Tabara, H; Sarkissian, M; Kelly, WG; Fleenor, J; Grishok, A; Timmons, L; Fire, A; Mello, CC			The rde-1 gene, RNA interference, and transposon silencing in C-elegans	CELL			English	Article							DOUBLE-STRANDED-RNA; CAENORHABDITIS-ELEGANS; MOLECULAR-CLONING; ANTISENSE RNA; MESSENGER-RNA; SEQUENCE; EXPRESSION; ELEMENTS; GERMLINE; EMBRYOS	Double-stranded (ds) RNA can induce sequence-specific inhibition of gene function in several organisms. However, both the mechanism and the physiological role of the interference process remain mysterious. In order to study the interference process, we have selected C. elegans mutants resistant to dsRNA-mediated interference (RNAi). Two loci, rde-1 and rde-4, are defined by mutants strongly resistant to RNAi but with no obvious defects in growth or development. We show that rde-1 is a member of the piwi/sting/argonaute/zwille/elF2C gene family conserved from plants to vertebrates. Interestingly, several, but not all, RNAi-deficient strains exhibit mobilization of the endogenous transposons. We discuss implications for the mechanism of RNAi and the possibility that one natural function of RNAi is transposon silencing.	Univ Massachusetts, Ctr Canc, Program Mol Med, Dept Cell Biol, Worcester, MA 01605 USA; Carnegie Inst Sci, Dept Embryol, Baltimore, MD 21210 USA	University of Massachusetts System; University of Massachusetts Worcester; Carnegie Institution for Science	Mello, CC (corresponding author), Univ Massachusetts, Ctr Canc, Program Mol Med, Dept Cell Biol, Worcester, MA 01605 USA.	craig.mello@ummed.edu	Pillay, Nischalan/F-9536-2012	Fire, Andrew/0000-0001-6217-8312	NICHD NIH HHS [HD08353] Funding Source: Medline; NIGMS NIH HHS [R01 GM037706, GM58800, GM37706] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM058800] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Alvarado AS, 1999, P NATL ACAD SCI USA, V96, P5049, DOI 10.1073/pnas.96.9.5049; Anandalakshmi R, 1998, P NATL ACAD SCI USA, V95, P13079, DOI 10.1073/pnas.95.22.13079; Beclin C, 1998, VIROLOGY, V252, P313, DOI 10.1006/viro.1998.9457; Benfey PN, 1999, CURR BIOL, V9, pR171, DOI 10.1016/S0960-9822(99)80105-5; Birchler JA, 1999, NAT GENET, V21, P148, DOI 10.1038/5926; Bohmert K, 1998, EMBO J, V17, P170, DOI 10.1093/emboj/17.1.170; Boyd L, 1996, DEVELOPMENT, V122, P3075; BRENNER S, 1974, GENETICS, V77, P71; Brigneti G, 1998, EMBO J, V17, P6739, DOI 10.1093/emboj/17.22.6739; Cogoni C, 1997, P NATL ACAD SCI USA, V94, P10233, DOI 10.1073/pnas.94.19.10233; Cogoni C, 1999, NATURE, V399, P166, DOI 10.1038/20215; COLLINS J, 1989, GENETICS, V121, P47; COLLINS J, 1987, NATURE, V328, P726, DOI 10.1038/328726a0; COLLINS JJ, 1994, GENETICS, V137, P771; Cox DN, 1998, GENE DEV, V12, P3715, DOI 10.1101/gad.12.23.3715; DIBB NJ, 1989, J MOL BIOL, V205, P603, DOI 10.1016/0022-2836(89)90229-5; Elmayan T, 1998, PLANT CELL, V10, P1747, DOI 10.1105/tpc.10.10.1747; FIRE A, 1991, DEVELOPMENT, V113, P503; Fire A, 1999, TRENDS GENET, V15, P358, DOI 10.1016/S0168-9525(99)01818-1; Fire A, 1998, NATURE, V391, P806, DOI 10.1038/35888; Henikoff S, 1998, BIOESSAYS, V20, P532, DOI 10.1002/(SICI)1521-1878(199807)20:7<532::AID-BIES3>3.3.CO;2-0; Jensen S, 1999, NAT GENET, V21, P209, DOI 10.1038/5997; Kasschau KD, 1998, CELL, V95, P461, DOI 10.1016/S0092-8674(00)81614-1; Kelly WG, 1998, DEVELOPMENT, V125, P2451; Kelly WG, 1997, GENETICS, V146, P227; KEMPHUES KJ, 1988, CELL, V52, P311, DOI 10.1016/S0092-8674(88)80024-2; Kennerdell JR, 1998, CELL, V95, P1017, DOI 10.1016/S0092-8674(00)81725-0; Ketting RF, 1999, CELL, V99, P133, DOI 10.1016/S0092-8674(00)81645-1; Lynn K, 1999, DEVELOPMENT, V126, P469; Mello C, 1995, METHOD CELL BIOL, V48, P451; MELLO CC, 1991, EMBO J, V10, P3959, DOI 10.1002/j.1460-2075.1991.tb04966.x; MELLO CC, 1994, CELL, V77, P95, DOI 10.1016/0092-8674(94)90238-0; Misquitta L, 1999, P NATL ACAD SCI USA, V96, P1451, DOI 10.1073/pnas.96.4.1451; MOERMAN DG, 1986, P NATL ACAD SCI USA, V83, P2579, DOI 10.1073/pnas.83.8.2579; Montgomery MK, 1998, P NATL ACAD SCI USA, V95, P15502, DOI 10.1073/pnas.95.26.15502; Montgomery MK, 1998, TRENDS GENET, V14, P255, DOI 10.1016/S0168-9525(98)01510-8; MORI I, 1988, GENETICS, V120, P397; Moser MJ, 1997, NUCLEIC ACIDS RES, V25, P5110, DOI 10.1093/nar/25.24.5110; Moussian B, 1998, EMBO J, V17, P1799, DOI 10.1093/emboj/17.6.1799; Nakai K, 1999, TRENDS BIOCHEM SCI, V24, P34, DOI 10.1016/S0968-0004(98)01336-X; Ngo H, 1998, P NATL ACAD SCI USA, V95, P14687, DOI 10.1073/pnas.95.25.14687; PROUD CG, 1995, TRENDS BIOCHEM SCI, V20, P241, DOI 10.1016/S0968-0004(00)89025-8; Rocheleau CE, 1997, CELL, V90, P707, DOI 10.1016/S0092-8674(00)80531-0; ROY AL, 1988, BIOCHEMISTRY-US, V27, P8203, DOI 10.1021/bi00421a033; Schmidt A, 1999, GENETICS, V151, P749; Selker EU, 1999, CELL, V97, P157, DOI 10.1016/S0092-8674(00)80725-4; Sharp PA, 1999, GENE DEV, V13, P139, DOI 10.1101/gad.13.2.139; Tabara H, 1998, SCIENCE, V282, P430, DOI 10.1126/science.282.5388.430; Tabara H, 1999, DEVELOPMENT, V126, P1; Timmons L, 1998, NATURE, V395, P854, DOI 10.1038/27579; VANDERKEYL H, 1994, DEV DYNAM, V201, P86, DOI 10.1002/aja.1002010109; Vaucheret H, 1998, PLANT J, V16, P651, DOI 10.1046/j.1365-313x.1998.00337.x; Wassenegger M, 1998, PLANT MOL BIOL, V37, P349, DOI 10.1023/A:1005946720438; Waterhouse PM, 1998, P NATL ACAD SCI USA, V95, P13959, DOI 10.1073/pnas.95.23.13959; WILLIAMS BD, 1992, GENETICS, V131, P609; YUAN JY, 1991, P NATL ACAD SCI USA, V88, P3334, DOI 10.1073/pnas.88.8.3334; Zou C, 1998, GENE, V211, P187, DOI 10.1016/S0378-1119(98)00107-3	57	951	1088	3	77	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	OCT 15	1999	99	2					123	132		10.1016/S0092-8674(00)81644-X	http://dx.doi.org/10.1016/S0092-8674(00)81644-X			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	246JB	10535731	Bronze			2022-12-01	WOS:000083159700003
J	Lockless, SW; Ranganathan, R				Lockless, SW; Ranganathan, R			Evolutionarily conserved pathways of energetic connectivity in protein families	SCIENCE			English	Article							HORMONE RECEPTOR COMPLEX; K+ CHANNEL; PDZ-DOMAIN; CRYSTAL-STRUCTURE; SIGNALING COMPLEXES; POTASSIUM CHANNEL; MUTANT CYCLES; LONG-RANGE; BINDING; RECOGNITION	For mapping energetic interactions in proteins, a technique was developed that uses evolutionary data for a protein family to measure statistical interactions between amino acid positions, For the PDZ domain family, this analysis predicted a set of energetically coupled positions for a binding site residue that includes unexpected Long-range interactions. Mutational studies confirm these predictions, demonstrating that the statistical energy function is a good indicator of thermodynamic coupling in proteins. Sets of intracting residues form connected pathways through the protein fold that may be the basis for efficient energy conduction within proteins.	Univ Texas, SW Med Ctr, Howard Hughes Med Inst, Dallas, TX 75235 USA; Univ Texas, SW Med Ctr, Dept Pharmacol, Dallas, TX 75235 USA	Howard Hughes Medical Institute; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Ranganathan, R (corresponding author), Univ Texas, SW Med Ctr, Howard Hughes Med Inst, 5323 Harry Hines Blvd, Dallas, TX 75235 USA.	rama@chop.swmed.edu						Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Aravind L, 1999, J MOL BIOL, V285, P1353, DOI 10.1006/jmbi.1998.2394; Atwell S, 1997, SCIENCE, V278, P1125, DOI 10.1126/science.278.5340.1125; BACON D, 1988, J MOL GRAPHICS, V6, P219, DOI 10.1016/S0263-7855(98)80030-1; BARDWELL VJ, 1994, GENE DEV, V8, P1664, DOI 10.1101/gad.8.14.1664; Brenman JE, 1998, J NEUROSCI, V18, P8805; BURLEY SK, 1985, SCIENCE, V229, P23, DOI 10.1126/science.3892686; Cabral JHM, 1996, NATURE, V382, P649, DOI 10.1038/382649a0; CARTER PJ, 1984, CELL, V38, P835, DOI 10.1016/0092-8674(84)90278-2; CLACKSON T, 1995, SCIENCE, V267, P383, DOI 10.1126/science.7529940; Daniels DL, 1998, NAT STRUCT BIOL, V5, P317, DOI 10.1038/nsb0498-317; Doolittle R., 1996, METHOD ENZYMOL, V266, P1; Doyle DA, 1996, CELL, V85, P1067, DOI 10.1016/S0092-8674(00)81307-0; ESSER L, UNPUB; Fanning AS, 1999, J CLIN INVEST, V103, P767, DOI 10.1172/JCI6509; Freire E, 1999, P NATL ACAD SCI USA, V96, P10118, DOI 10.1073/pnas.96.18.10118; GOLDSTEIN SAN, 1994, NEURON, V12, P1377, DOI 10.1016/0896-6273(94)90452-9; Hedstrom L, 1996, BIOL CHEM, V377, P465; HEDSTROM L, 1992, SCIENCE, V255, P1249, DOI 10.1126/science.1546324; Hein R, 1996, CURR BIOL, V6, P178, DOI 10.1016/S0960-9822(02)00450-5; HIDALGO P, 1995, SCIENCE, V268, P307, DOI 10.1126/science.7716527; HOLT JM, 1995, FASEB J, V9, P210, DOI 10.1096/fasebj.9.2.7781923; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Kreusch A, 1998, NATURE, V392, P945, DOI 10.1038/31978; LICATA VJ, 1995, BIOCHEMISTRY-US, V34, P3133, DOI 10.1021/bi00010a001; Lichtarge O, 1996, J MOL BIOL, V257, P342, DOI 10.1006/jmbi.1996.0167; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; MONOD J, 1965, J MOL BIOL, V12, P88, DOI 10.1016/S0022-2836(65)80285-6; NEHER E, 1994, P NATL ACAD SCI USA, V91, P98, DOI 10.1073/pnas.91.1.98; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Patten PA, 1996, SCIENCE, V271, P1086, DOI 10.1126/science.271.5252.1086; PERONA JJ, 1995, BIOCHEMISTRY-US, V34, P1489, DOI 10.1021/bi00005a004; PERRY KM, 1989, BIOCHEMISTRY-US, V28, P7961, DOI 10.1021/bi00445a061; PETTIGREW DW, 1982, P NATL ACAD SCI-BIOL, V79, P1849, DOI 10.1073/pnas.79.6.1849; Ponting CP, 1997, BIOESSAYS, V19, P469, DOI 10.1002/bies.950190606; Ranganathan R, 1997, CURR BIOL, V7, pR770, DOI 10.1016/S0960-9822(06)00401-5; Ranganathan R, 1996, NEURON, V16, P131, DOI 10.1016/S0896-6273(00)80030-6; Schillace RV, 1999, J CLIN INVEST, V103, P761, DOI 10.1172/JCI6491; SCHREIBER G, 1995, J MOL BIOL, V248, P478, DOI 10.1016/S0022-2836(95)80064-6; Sewing S, 1996, NEURON, V16, P455, DOI 10.1016/S0896-6273(00)80063-X; SHEN NV, 1993, NEURON, V11, P67; SOCOLICH M, UNPUB; Songyang Z, 1997, SCIENCE, V275, P73, DOI 10.1126/science.275.5296.73; STAMPE P, 1994, BIOCHEMISTRY-US, V33, P443, DOI 10.1021/bi00168a008; Tolman R. C, 1938, PRINCIPLES STAT MECH; Tsunoda S, 1997, NATURE, V388, P243, DOI 10.1038/40805; TURNER GJ, 1992, PROTEINS, V14, P333, DOI 10.1002/prot.340140303; WELLS JA, 1995, BIO-TECHNOL, V13, P647, DOI 10.1038/nbt0795-647; Wells JA, 1996, P NATL ACAD SCI USA, V93, P1, DOI 10.1073/pnas.93.1.1	49	1011	1027	0	87	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 8	1999	286	5438					295	299		10.1126/science.286.5438.295	http://dx.doi.org/10.1126/science.286.5438.295			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	243YE	10514373				2022-12-01	WOS:000083024400045
J	Salvemini, D; Wang, ZQ; Zweier, JL; Samouilov, A; Macarthur, H; Misko, TP; Currie, MG; Cuzzocrea, S; Sikorski, JA; Riley, DP				Salvemini, D; Wang, ZQ; Zweier, JL; Samouilov, A; Macarthur, H; Misko, TP; Currie, MG; Cuzzocrea, S; Sikorski, JA; Riley, DP			A nonpeptidyl mimic of superoxide dismutase with therapeutic activity in rats	SCIENCE			English	Article							NITRIC-OXIDE; LIPID-PEROXIDATION; IN-VIVO; PEROXYNITRITE; INFLAMMATION; INJURY; COMPLEXES; EDEMA; MICE	Many human diseases are associated with the overproduction of oxygen free radicals that inflict cell damage. A manganese(II) complex with a bis(cyclohexylpyridine)-substituted macrocyclic Ligand (M40403) was designed to be a functional mimic of the superoxide dismutase (SOD) enzymes that normally remove these radicals. M40403 had high catalytic SOD activity and was chemically and biologically stable in vivo. injection of M40403 into rat models of inflammation and ischemia-reperfusion injury protected the animals against tissue damage, Such mimics may result in better clinical therapies for diseases mediated by superoxide radicals.	MetaPhore Pharmaceut, St Louis, MO 63114 USA; Monsanto Co, GD Searle & Co, Discovery Pharmacol, St Louis, MO 63167 USA; Johns Hopkins Univ, Sch Med, Electron Paramagnet Resonance Ctr, Baltimore, MD 21224 USA; St Louis Univ, Sch Med, Dept Pharmacol & Physiol Sci, St Louis, MO 63104 USA; Univ Messina, Sch Med, Inst Pharmacol, I-98123 Messina, Italy; Monsanto Co, GD Searle & Co, Discovery Med Chem, St Louis, MO 63198 USA	Monsanto; Johns Hopkins University; Saint Louis University; University of Messina; Monsanto	Salvemini, D (corresponding author), MetaPhore Pharmaceut, 1910 Innerbelt Business Ctr Dr, St Louis, MO 63114 USA.	dsalvemini@metaphore.com	Samouilov, Alexandre/B-5824-2014; Samouilov, Alexandre/E-4010-2011	Misko, Thomas/0000-0001-7917-422X				BECKMAN JS, 1990, P NATL ACAD SCI USA, V87, P1620, DOI 10.1073/pnas.87.4.1620; BITTERMAN H, 1988, P SOC EXP BIOL MED, V188, P265; CABELLI DE, IN PRESS BIOMIMETIC; Deshmukh DR, 1997, AM J PHYSIOL-CELL PH, V273, pC1130, DOI 10.1152/ajpcell.1997.273.4.C1130; HARDY MM, 1994, J BIOL CHEM, V269, P18535; HIRSCHELMANN R, 1981, EXPERIENTIA, V37, P1313, DOI 10.1007/BF01948381; Horie Y, 1998, CIRC RES, V83, P691, DOI 10.1161/01.RES.83.7.691; IANARO A, 1994, IMMUNOLOGY, V82, P370; JADOT G, 1995, CLIN PHARMACOKINET, V28, P17, DOI 10.2165/00003088-199528010-00003; MCCORD JM, 1969, J BIOL CHEM, V244, P6049; PETKAU A, 1986, CANCER TREAT REV, V13, P17, DOI 10.1016/0305-7372(86)90012-5; Portanova JP, 1996, J EXP MED, V184, P883, DOI 10.1084/jem.184.3.883; RADI R, 1991, ARCH BIOCHEM BIOPHYS, V288, P481, DOI 10.1016/0003-9861(91)90224-7; Riley DP, 1997, J AM CHEM SOC, V119, P6522, DOI 10.1021/ja964271e; Riley DP, 1996, INORG CHEM, V35, P5213, DOI 10.1021/ic960262v; RILEY DP, 1994, J AM CHEM SOC, V116, P387, DOI 10.1021/ja00080a051; Riley DP, 1999, INORG CHEM, V38, P1908, DOI 10.1021/ic981319b; RILEY DP, 1997, CATTECH, V1, P41; ROSA MD, 1971, J PHARM PHARMACOL, V23, P297, DOI 10.1111/j.2042-7158.1971.tb08661.x; RUBBO H, 1994, J BIOL CHEM, V269, P26066; Salvemini D, 1996, BRIT J PHARMACOL, V118, P829, DOI 10.1111/j.1476-5381.1996.tb15475.x; Salvemini D, 1998, P NATL ACAD SCI USA, V95, P2659, DOI 10.1073/pnas.95.5.2659; SALVEMINI D, 1995, J CLIN INVEST, V96, P301, DOI 10.1172/JCI118035; SCHRAUFSTATTER IU, 1987, INT J TISSUE REACT, V9, P317; SEIBERT K, 1994, P NATL ACAD SCI USA, V91, P12013, DOI 10.1073/pnas.91.25.12013; SQUADRITO F, 1995, BRIT J PHARMACOL, V115, P395, DOI 10.1111/j.1476-5381.1995.tb16346.x; WARREN JS, 1990, FREE RADICAL BIO MED, V8, P163, DOI 10.1016/0891-5849(90)90089-2; Weiss RH, 1996, J BIOL CHEM, V271, P26149, DOI 10.1074/jbc.271.42.26149; WEISS RH, 1993, J BIOL CHEM, V268, P23049	29	447	493	1	43	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 8	1999	286	5438					304	306		10.1126/science.286.5438.304	http://dx.doi.org/10.1126/science.286.5438.304			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	243YE	10514375				2022-12-01	WOS:000083024400047
J	Nutt, SL; Heavey, B; Rolink, AG; Busslinger, M				Nutt, SL; Heavey, B; Rolink, AG; Busslinger, M			Commitment to the B-lymphoid lineage depends on the transcription factor Pax5	NATURE			English	Article							MOUSE BONE-MARROW; MURINE FETAL LIVER; COLONY-STIMULATING FACTOR; NATURAL-KILLER-CELLS; STEM-CELLS; DENDRITIC CELLS; FACTOR BSAP; C-FOS; PRO-B; MACROPHAGES	The Pax5 gene encoding the B-cell-specific activator protein (BSAP) is expressed within the haematopoietic system exclusively in the B-lymphoid lineage, where it is required in vivo for progression beyond the pro-B-cell stage. However, Pax5 is not essential for in vitro propagation of pro-B cells in the presence of interleukin-ir and stromal cells. Here we show that pro-B cells lacking Pax5 are also incapable of in vitro B-cell differentiation unless Pax5 expression is restored by retroviral transduction, Pax5(-/-) pro-B cells ape not restricted in their lineage fate, as stimulation with appropriate cytokines induces them to differentiate into functional macrophages, osteoclasts, dendritic cells, granulocytes and natural killer cells. As expected far a clonogenic haematopoietic progenitor with lymphomyeloid developmental potential, the Pax5(-/-) pro-B cell expresses genes of different lineage-affiliated programmes, and restoration of Pax5 activity represses this lineage-promiscuous transcription. Pax5 therefore plays an essential role in B-lineage commitment by suppressing alternative lineage choices.	Res Inst Mol Pathol, A-1030 Vienna, Austria; Basel Inst Immunol, CH-4005 Basel, Switzerland	Vienna Biocenter (VBC); Research Institute of Molecular Pathology (IMP)	Busslinger, M (corresponding author), Res Inst Mol Pathol, Dr Bohr Gasse 7, A-1030 Vienna, Austria.	busslinger@nt.imp.univie.ac.at	Nutt, Stephen L/C-9256-2013; Busslinger, Meinrad J./J-1249-2016	Nutt, Stephen L/0000-0002-0020-6637; Busslinger, Meinrad J./0000-0002-9111-9351				ADAMS B, 1992, GENE DEV, V6, P1589, DOI 10.1101/gad.6.9.1589; Aiba Y, 1997, BLOOD, V90, P3923, DOI 10.1182/blood.V90.10.3923; AKASHI K, 1991, J CELL PHYSIOL, V148, P446, DOI 10.1002/jcp.1041480317; Akerblad P, 1999, MOL CELL BIOL, V19, P392; BAIN G, 1994, CELL, V79, P885, DOI 10.1016/0092-8674(94)90077-9; Banchereau J, 1998, NATURE, V392, P245, DOI 10.1038/32588; Borrello MA, 1996, IMMUNOL TODAY, V17, P471, DOI 10.1016/0167-5699(96)20031-B; BORZILLO GV, 1990, MOL CELL BIOL, V10, P2703, DOI 10.1128/MCB.10.6.2703; Busslinger Meinrad, 1998, P83; CUMANO A, 1992, NATURE, V356, P612, DOI 10.1038/356612a0; DAVIDSON WF, 1988, J EXP MED, V168, P389, DOI 10.1084/jem.168.1.389; Enver T, 1998, CELL, V94, P9, DOI 10.1016/S0092-8674(00)81215-5; Enver T, 1998, BLOOD, V92, P348, DOI 10.1182/blood.V92.2.348.Con3_348_351; GALY A, 1995, IMMUNITY, V3, P459, DOI 10.1016/1074-7613(95)90175-2; GRIGORIADIS AE, 1994, SCIENCE, V266, P443, DOI 10.1126/science.7939685; HARDY RR, 1991, J EXP MED, V173, P1213, DOI 10.1084/jem.173.5.1213; Hu M, 1997, GENE DEV, V11, P774, DOI 10.1101/gad.11.6.774; INABA K, 1992, J EXP MED, V176, P1693, DOI 10.1084/jem.176.6.1693; KARASUYAMA H, 1988, EUR J IMMUNOL, V18, P97, DOI 10.1002/eji.1830180115; Kawamoto H, 1997, INT IMMUNOL, V9, P1011, DOI 10.1093/intimm/9.7.1011; Kee BL, 1998, J EXP MED, V188, P699, DOI 10.1084/jem.188.4.699; KLINKEN SP, 1988, CELL, V53, P857, DOI 10.1016/S0092-8674(88)90309-1; Kondo M, 1997, CELL, V91, P661, DOI 10.1016/S0092-8674(00)80453-5; Kong YY, 1999, NATURE, V397, P315, DOI 10.1038/16852; Lacaud G, 1998, IMMUNITY, V9, P827, DOI 10.1016/S1074-7613(00)80648-2; Li YS, 1996, IMMUNITY, V5, P527, DOI 10.1016/S1074-7613(00)80268-X; LIAO NS, 1991, SCIENCE, V253, P199, DOI 10.1126/science.1853205; LIN HH, 1995, NATURE, V376, P263, DOI 10.1038/376263a0; Liu FL, 1997, BLOOD, V90, P2583, DOI 10.1182/blood.V90.7.2583.2583_2583_2590; Metcalf D, 1998, BLOOD, V92, P345, DOI 10.1182/blood.V92.2.345b.Con2_345_347; Nutt SL, 1997, GENE DEV, V11, P476, DOI 10.1101/gad.11.4.476; Nutt SL, 1998, EMBO J, V17, P2319, DOI 10.1093/emboj/17.8.2319; Nutt SL, 1999, NAT GENET, V21, P390, DOI 10.1038/7720; Ogasawara K, 1998, NATURE, V391, P700, DOI 10.1038/35636; PRINCIPATO M, 1990, MOL CELL BIOL, V10, P3562, DOI 10.1128/MCB.10.7.3562; Raulet DH, 1999, CURR OPIN IMMUNOL, V11, P129, DOI 10.1016/S0952-7915(99)80023-5; Rolink A, 1996, IMMUNITY, V5, P319, DOI 10.1016/S1074-7613(00)80258-7; Rolink A, 1996, J EXP MED, V183, P187, DOI 10.1084/jem.183.1.187; ROLINK A, 1991, EMBO J, V10, P327, DOI 10.1002/j.1460-2075.1991.tb07953.x; ROLINK A, 1994, INT IMMUNOL, V6, P1257, DOI 10.1093/intimm/6.8.1257; Rolink AG, 1999, NATURE, V401, P603, DOI 10.1038/44164; SHINKAI Y, 1992, CELL, V68, P855, DOI 10.1016/0092-8674(92)90029-C; Sigvardsson M, 1997, IMMUNITY, V7, P25, DOI 10.1016/S1074-7613(00)80507-5; Strasser A, 1996, EMBO J, V15, P3823, DOI 10.1002/j.1460-2075.1996.tb00756.x; Thevenin C, 1998, J EXP MED, V188, P735, DOI 10.1084/jem.188.4.735; URBANEK P, 1994, CELL, V79, P901, DOI 10.1016/0092-8674(94)90079-5; VONFREEDENJEFFRY U, 1995, J EXP MED, V181, P1519, DOI 10.1084/jem.181.4.1519; WANG ZQ, 1992, NATURE, V360, P741, DOI 10.1038/360741a0; Yamane T, 1997, BLOOD, V90, P3516, DOI 10.1182/blood.V90.9.3516; ZHUANG Y, 1994, CELL, V79, P875, DOI 10.1016/0092-8674(94)90076-0	50	867	890	0	24	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	OCT 7	1999	401	6753					556	562		10.1038/44076	http://dx.doi.org/10.1038/44076			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	244MG	10524622				2022-12-01	WOS:000083054900041
J	Zangaladze, A; Epstein, CM; Grafton, ST; Sathian, K				Zangaladze, A; Epstein, CM; Grafton, ST; Sathian, K			Involvement of visual cortex in tactile discrimination of orientation	NATURE			English	Article							MAGNETIC BRAIN-STIMULATION; COIL SUPPRESSION; BLIND HUMANS; PERCEPTION; ACTIVATION; TOUCH; SITE; EYE; LIP	The primary sense modalities (vision, touch and so on) are generally thought of as distinct. However, visual imagery is implicated in the normal tactile perception of some object properties, such as orientation(1), shape and size(2). Furthermore, certain tactile tasks, such as discrimination of grating orientation(1) and object recognition: are associated with activity in areas of visual cortex. Here we show that disrupting function of the occipital cortex using focal transcranial magnetic stimulation (TMS) interferes with the tactile discrimination of grating orientation. The specificity of this effect is illustrated by its time course and spatial restriction over the scalp, and by the failure of occipital TMS to affect either detection of an electrical stimulus applied to the fingerpad or tactile discrimination of grating texture. In contrast, TMS over the somatosensory cortex blocked discrimination of grating texture as well as orientation. We also report that, during tactile discrimination of grating orientation, an evoked potential is recorded over posterior scalp regions with a latency corresponding to the peak of the TMS interference effect (about 180 ms). The findings indicate that visual cortex is closely involved in tactile discrimination of orientation. To our knowledge, this is the first demonstration that visual cortical processing is necessary for normal tactile perception.	Emory Univ, Sch Med, Dept Neurol, Atlanta, GA 30322 USA	Emory University	Sathian, K (corresponding author), Emory Univ, Sch Med, Dept Neurol, WMRB-6000,PO Drawer 5,1639 Pierce Dr, Atlanta, GA 30322 USA.			Sathian, Krish/0000-0001-9495-2499				Buchel C, 1998, BRAIN, V121, P409, DOI 10.1093/brain/121.3.409; Cohen LG, 1997, NATURE, V389, P180, DOI 10.1038/38278; Deibert E, 1999, NEUROLOGY, V52, P1413, DOI 10.1212/WNL.52.7.1413; Epstein CM, 1996, J CLIN NEUROPHYSIOL, V13, P247, DOI 10.1097/00004691-199605000-00009; EPSTEIN CM, 1990, NEUROLOGY, V40, P666, DOI 10.1212/WNL.40.4.666; Epstein CM, 1996, NEUROLOGY, V47, P1590, DOI 10.1212/WNL.47.6.1590; Epstein CM, 1996, J CLIN NEUROPHYSIOL, V13, P242, DOI 10.1097/00004691-199605000-00008; GALLETTI C, 1991, EUR J NEUROSCI, V3, P452, DOI 10.1111/j.1460-9568.1991.tb00832.x; Gao JH, 1996, SCIENCE, V272, P545, DOI 10.1126/science.272.5261.545; JOHNSON KO, 1992, ANNU REV NEUROSCI, V15, P227, DOI 10.1146/annurev.neuro.15.1.227; KLATZKY RL, 1987, J EXP PSYCHOL GEN, V116, P356; KUJALA T, 1995, NEUROSCI LETT, V183, P143, DOI 10.1016/0304-3940(94)11135-6; Mellet E, 1996, J NEUROSCI, V16, P6504; PASCUALLEONE A, 1993, ELECTROEN CLIN NEURO, V89, P120, DOI 10.1016/0168-5597(93)90094-6; Roder B, 1996, COGNITIVE BRAIN RES, V4, P77, DOI 10.1016/0926-6410(96)00024-9; Sadato N, 1998, BRAIN, V121, P1213, DOI 10.1093/brain/121.7.1213; Sadato N, 1996, NATURE, V380, P526, DOI 10.1038/380526a0; Sathian K, 1996, NEUROLOGY, V46, P1464, DOI 10.1212/WNL.46.5.1464; Sathian K, 1997, NEUROREPORT, V8, P3877, DOI 10.1097/00001756-199712220-00008; Sathian K, 1997, PERCEPT PSYCHOPHYS, V59, P119, DOI 10.3758/BF03206854; SERGENT J, 1992, BRAIN, V115, P15, DOI 10.1093/brain/115.1.15; VANBOVEN RW, 1994, NEUROLOGY, V44, P2361, DOI 10.1212/WNL.44.12.2361; VEGABERMUDEZ F, 1991, J NEUROPHYSIOL, V65, P531, DOI 10.1152/jn.1991.65.3.531; Ziemann U, 1996, J PHYSIOL-LONDON, V496, P873, DOI 10.1113/jphysiol.1996.sp021734	24	324	329	1	27	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	OCT 7	1999	401	6753					587	590		10.1038/44139	http://dx.doi.org/10.1038/44139			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	244MG	10524625				2022-12-01	WOS:000083054900050
J	Waterlow, J				Waterlow, J			Treatment of children with malnutrition and diarrhoea	LANCET			English	Editorial Material									Univ London London Sch Hyg & Trop Med, Dept Publ Hlth & Policy, London WC1E 7HT, England	University of London; London School of Hygiene & Tropical Medicine	Waterlow, J (corresponding author), Univ London London Sch Hyg & Trop Med, Dept Publ Hlth & Policy, London WC1E 7HT, England.							Ahmed T, 1999, LANCET, V353, P1919, DOI 10.1016/S0140-6736(98)07499-6; Schofield C, 1996, B WORLD HEALTH ORGAN, V74, P223; SMITH R, 1963, LANCET, V1, P771; WATERLOW JC, 1978, NUTRITION CLIN MANAG, P49; Waterlow JC, 1992, PROTEIN ENERGY MALNU; WATERLOW JC, 1992, NUTR CLIN MANAGEMENT; World Health Organization, 1999, MAN SEV MALN MAN PHY	7	12	12	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	OCT 2	1999	354	9185					1142	1142		10.1016/S0140-6736(99)00329-3	http://dx.doi.org/10.1016/S0140-6736(99)00329-3			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	242QX	10513705				2022-12-01	WOS:000082954100007
J	Evans, SK; Lundblad, V				Evans, SK; Lundblad, V			Est1 and Cdc13 as comediators of telomerase access	SCIENCE			English	Article							DNA-BINDING PROTEIN; SACCHAROMYCES-CEREVISIAE; REVERSE-TRANSCRIPTASE; IN-VITRO; YEAST; SENESCENCE; LENGTH; MAINTENANCE; MUTANTS; DEFECT	Cdc13 and Est1 are single-strand telomeric DNA binding proteins that contribute to telomere replication in the yeast Saccharomyces cerevisiae. Here it is shown that fusion of Cdc13 to the telomerase-associated Est1 protein results in greatly elongated telomeres. Fusion proteins consisting of mutant versions of Cdc13 or Est1 confer similar telomere elongation, indicating that close physical proximity can bypass telomerase-defective mutations in either protein. Fusing Cdc13 directly to the catalytic core of telomerase allows stable telomere maintenance in the absence of Est1, consistent with a role for Est1 in mediating telomerase access. Telomere length homeostasis therefore is maintained in part by restricting access of telomerase to chromosome termini, but this limiting situation can be overcome by directly tethering telomerase to the telomere.	Baylor Coll Med, Dept Mol & Human Genet, Houston, TX 77030 USA; Baylor Coll Med, Verna & Marrs McLean Dept Biochem, Houston, TX 77030 USA	Baylor College of Medicine; Baylor College of Medicine	Lundblad, V (corresponding author), Baylor Coll Med, Dept Mol & Human Genet, Houston, TX 77030 USA.				NIGMS NIH HHS [R01GM55867] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM055867] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		CHANDRA A, UNPUB; COHN M, 1995, SCIENCE, V269, P396, DOI 10.1126/science.7618104; EVANS S, UNPUB; GARVIK B, 1995, MOL CELL BIOL, V15, P6128; Grandin N, 1997, GENE DEV, V11, P512, DOI 10.1101/gad.11.4.512; HUGHES TJ, UNPUB; Lendvay TS, 1996, GENETICS, V144, P1399; Lin JJ, 1996, P NATL ACAD SCI USA, V93, P13760, DOI 10.1073/pnas.93.24.13760; Lingner J, 1997, P NATL ACAD SCI USA, V94, P11190, DOI 10.1073/pnas.94.21.11190; Lingner J, 1997, SCIENCE, V276, P561, DOI 10.1126/science.276.5312.561; LUNDBLAD V, 1989, CELL, V57, P633, DOI 10.1016/0092-8674(89)90132-3; LUNDBLAD V, 1993, CELL, V73, P347, DOI 10.1016/0092-8674(93)90234-H; Marcand S, 1997, SCIENCE, V275, P986, DOI 10.1126/science.275.5302.986; Marcand S, 1999, EMBO J, V18, P3509, DOI 10.1093/emboj/18.12.3509; Nugent CI, 1998, GENE DEV, V12, P1073, DOI 10.1101/gad.12.8.1073; Nugent CI, 1996, SCIENCE, V274, P249, DOI 10.1126/science.274.5285.249; NUGENT CI, UNPUB; SHAMPAY J, 1988, P NATL ACAD SCI USA, V85, P534, DOI 10.1073/pnas.85.2.534; SINGER MS, 1994, SCIENCE, V266, P404, DOI 10.1126/science.7545955; vanSteensel B, 1997, NATURE, V385, P740, DOI 10.1038/385740a0; VirtaPearlman V, 1996, GENE DEV, V10, P3094, DOI 10.1101/gad.10.24.3094	21	363	376	0	15	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	OCT 1	1999	286	5437					117	120		10.1126/science.286.5437.117	http://dx.doi.org/10.1126/science.286.5437.117			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	241WT	10506558				2022-12-01	WOS:000082907400048
J	Gil, D; Graves, J; Hazon, N; Wells, A				Gil, D; Graves, J; Hazon, N; Wells, A			Male attractiveness and differential testosterone investment in zebra finch eggs	SCIENCE			English	Article							EXTRA-PAIR PATERNITY; GENETIC QUALITY; MATERNAL TESTOSTERONE; ULTRAVIOLET VISION; BODY-MASS; IMMUNOCOMPETENCE; INDICATOR; ORNAMENTATION; POPULATIONS; VIABILITY	Good-genes hypotheses of sexual selection predict that offspring fathered by preferred males should have increased viability resulting from superior genetic quality. Several studies of birds have reported findings consistent with this prediction, but maternal effects are an important confounding variable. Those studies that have attempted to control for maternal effects have only considered differential maternal investment after egg laying. However, female birds differentially deposit testosterone in the eggs, and this influences the development of the chick. This study shows that female birds deposit higher amounts of testosterone and 5 alpha-dihydrotestosterone in their eggs when mated to more attractive males.	Univ St Andrews, Sch Environm & Evolutionary Biol, St Andrews KY16 9TS, Fife, Scotland	University of St Andrews	Gil, D (corresponding author), Univ Paris 10, Lab Psychophysiol & Ethol, UPRESA CNRS 7025, F-92001 Nanterre, France.	Diego.Gil@u-paris10.fr	Gil, Diego/L-1666-2014	Gil, Diego/0000-0003-3179-1987				Al-Afaleq AI, 1998, IMMUNOPHARM IMMUNOT, V20, P315, DOI 10.3109/08923979809038547; Andersson Malte, 1994; Bennett ATD, 1996, NATURE, V380, P433, DOI 10.1038/380433a0; BURLEY N, 1986, EVOLUTION, V40, P1191, DOI 10.1111/j.1558-5646.1986.tb05744.x; BURLEY N, 1988, AM NAT, V132, P611, DOI 10.1086/284877; Cuthill IC, 1997, P ROY SOC B-BIOL SCI, V264, P1093, DOI 10.1098/rspb.1997.0151; DELOPE F, 1993, EVOLUTION, V47, P1152, DOI 10.1111/j.1558-5646.1993.tb02142.x; FOLSTAD I, 1992, AM NAT, V139, P603, DOI 10.1086/285346; GAUSE WC, 1986, CLIN IMMUNOL IMMUNOP, V39, P464, DOI 10.1016/0090-1229(86)90174-1; Hasselquist D, 1996, NATURE, V381, P229, DOI 10.1038/381229a0; Hasselquist D, 1999, BEHAV ECOL SOCIOBIOL, V45, P167, DOI 10.1007/s002650050550; HEGNER RE, 1986, HORM BEHAV, V20, P313, DOI 10.1016/0018-506X(86)90040-1; Hillgarth Nigella, 1997, P78; Hoikkala A, 1998, P ROY SOC B-BIOL SCI, V265, P503, DOI 10.1098/rspb.1998.0323; Hunt S, 1997, ANIM BEHAV, V54, P1383, DOI 10.1006/anbe.1997.0540; KEMPENAERS B, 1992, NATURE, V357, P494, DOI 10.1038/357494a0; Lipar JL, 1999, AUK, V116, P231, DOI 10.2307/4089471; Mock D.W., 1997, EVOLUTION SIBLING RI; MOLLER AP, 1994, P NATL ACAD SCI USA, V91, P6929, DOI 10.1073/pnas.91.15.6929; NORRIS K, 1993, NATURE, V362, P537, DOI 10.1038/362537a0; PETRIE M, 1994, NATURE, V371, P598, DOI 10.1038/371598a0; Ros AFH, 1997, AM NAT, V150, P201, DOI 10.1086/286063; Saino N, 1995, BEHAV ECOL, V6, P397, DOI 10.1093/beheco/6.4.397; SCHUURS AHWM, 1992, INT ARCH ALLERGY IMM, V97, P337, DOI 10.1159/000236142; Schwabl H, 1997, NATURE, V386, P231, DOI 10.1038/386231a0; Schwabl H, 1996, J EXP ZOOL, V276, P157, DOI 10.1002/(SICI)1097-010X(19961001)276:2<157::AID-JEZ9>3.3.CO;2-Y; SCHWABL H, 1993, P NATL ACAD SCI USA, V90, P11446, DOI 10.1073/pnas.90.24.11446; Schwabl H, 1996, COMP BIOCHEM PHYS A, V114, P271, DOI 10.1016/0300-9629(96)00009-6; SEARCY WA, 1988, ECOLOGY, V69, P85, DOI 10.2307/1943163; Sheldon BC, 1997, P ROY SOC B-BIOL SCI, V264, P297, DOI 10.1098/rspb.1997.0042; Staub NL, 1997, GEN COMP ENDOCR, V108, P1, DOI 10.1006/gcen.1997.6962; Verhulst S, 1999, P NATL ACAD SCI USA, V96, P4478, DOI 10.1073/pnas.96.8.4478; Welch AM, 1998, SCIENCE, V280, P1928, DOI 10.1126/science.280.5371.1928; Wilkinson GS, 1998, NATURE, V391, P276, DOI 10.1038/34640; ZANN RA, 1966, ZEBRA FINCH	35	424	427	0	129	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 1	1999	286	5437					126	128		10.1126/science.286.5437.126	http://dx.doi.org/10.1126/science.286.5437.126			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	241WT	10506561				2022-12-01	WOS:000082907400051
J	Solomon, SC; Bullock, MA; Grinspoon, DH				Solomon, SC; Bullock, MA; Grinspoon, DH			Climate change as a regulator of tectonics on Venus	SCIENCE			English	Article							ATMOSPHERE; HISTORY	Tectonics, volcanism, and climate on Venus may be strongly coupled. Large excursions in surface temperature predicted to follow a global or near-global volcanic event diffuse into the interior and introduce thermal stresses of a magnitude sufficient to influence widespread tectonic deformation. This sequence of events accounts for the timing and many of the characteristics of deformation in the ridged plains of Venus, the most widely preserved volcanic terrain on the planet.	Carnegie Inst Washington, Dept Terr Magnetism, Washington, DC 20015 USA; SW Res Inst, Dept Space Studies, Boulder, CO 80302 USA	Carnegie Institution for Science	Solomon, SC (corresponding author), Carnegie Inst Washington, Dept Terr Magnetism, 5241 Broad Branch Rd NW, Washington, DC 20015 USA.							Basilevsky AT, 1996, GEOPHYS RES LETT, V23, P1497, DOI 10.1029/96GL00975; Basilevsky AT, 1998, J GEOPHYS RES-PLANET, V103, P8531, DOI 10.1029/98JE00487; Bilotti F, 1999, ICARUS, V139, P137, DOI 10.1006/icar.1999.6092; BIRCH F, 1948, AM J SCI, V246, P729; BULLOCK MA, 1994, ICARUS, V107, P142, DOI 10.1006/icar.1994.1012; Bullock MA, 1996, J GEOPHYS RES-PLANET, V101, P7521, DOI 10.1029/95JE03862; BULLOCK MA, 1993, GEOPHYS RES LETT, V20, P2147, DOI 10.1029/93GL02505; BULLOCK MA, UNPUB; COFFIN MF, 1994, REV GEOPHYS, V32, P1, DOI 10.1029/93RG02508; COLLINS GC, 1997, LUNAR PLANET SCI, V28, P243; FEGLEY B, 1989, NATURE, V337, P55, DOI 10.1038/337055a0; GRINSPOON DH, 1993, NATURE, V363, P428, DOI 10.1038/363428a0; Guest JE, 1999, ICARUS, V139, P55, DOI 10.1006/icar.1999.6091; Hansen VL, 1996, ICARUS, V123, P296, DOI 10.1006/icar.1996.0159; HASHIMOTO GL, 1999, LUNAR PLANET SCI, V30, P1867; Head JW, 1998, GEOLOGY, V26, P35, DOI 10.1130/0091-7613(1998)026<0035:SOTDIT>2.3.CO;2; Ivanov MA, 1996, J GEOPHYS RES-PLANET, V101, P14861, DOI 10.1029/96JE01245; IVANOV MA, 1998, LUNAR PLANET SCI, V29, P1653; KRASNOPOLSKY VA, 1994, ICARUS, V109, P58, DOI 10.1006/icar.1994.1077; Kreslavsky MA, 1998, J GEOPHYS RES-PLANET, V103, P11103, DOI 10.1029/98JE00360; KRESLAVSKY MA, 1999, LUNAR PLANET SCI, V30, P1192; MCGILL GE, 1993, GEOPHYS RES LETT, V20, P2047; McKinnon W. B., 1997, VENUS, P969; Phillips RJ, 1998, SCIENCE, V279, P1492, DOI 10.1126/science.279.5356.1492; PHILLIPS RJ, 1992, J GEOPHYS RES, V97, P15921; Sandwell DT, 1997, ICARUS, V129, P232, DOI 10.1006/icar.1997.5721; SCHABER GG, 1992, J GEOPHYS RES-PLANET, V97, P13257, DOI 10.1029/92JE01246; SCHULTZ RA, 1993, J GEOPHYS RES-PLANET, V98, P10883, DOI 10.1029/93JE00691; SOLOMON SC, 1992, J GEOPHYS RES-PLANET, V97, P13199, DOI 10.1029/92JE01418; STROM RG, 1994, J GEOPHYS RES-PLANET, V99, P10899, DOI 10.1029/94JE00388; Timoshenko S., 1970, THEORY ELASTICITY, P433; TURCOTTE DL, 1982, GEODYNAMICS, P158; TURCOTTE DL, 1983, J GEOPHYS RES S, V88, pA585, DOI DOI 10.1029/JB088IS02P0A585	33	61	62	0	12	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	OCT 1	1999	286	5437					87	90		10.1126/science.286.5437.87	http://dx.doi.org/10.1126/science.286.5437.87			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	241WT	10506565				2022-12-01	WOS:000082907400038
J	Wells, AL; Lin, AW; Chen, LQ; Safer, D; Cain, SM; Hasson, T; Carragher, BI; Milligan, RA; Sweeney, HL				Wells, AL; Lin, AW; Chen, LQ; Safer, D; Cain, SM; Hasson, T; Carragher, BI; Milligan, RA; Sweeney, HL			Myosin VI is an actin-based motor that moves backwards	NATURE			English	Article							SMOOTH-MUSCLE MYOSIN; UNCONVENTIONAL MYOSIN; CRYOELECTRON MICROSCOPY; MOLECULAR MOTOR; IMAGE-ANALYSIS; ADP RELEASE; GENE; NCD; DIRECTION; DEAFNESS	Myosins and kinesins are molecular motors that hydrolyse ATP to track along actin filaments and microtubules, respectively. Although the kinesin family includes motors that move towards either the plus or minus ends of microtubules(1), all characterized myosin motors move towards the barbed (+) end of actin filaments(2). Crystal structures of myosin II (refs 3-6) have shown that small movements within the myosin motor core are transmitted through the 'converter domain' to a 'lever arm' consisting of a light-chain-binding helix and associated light chains(5,6), The lever arm further amplifies the motions of the converter domain into large directed movements(3,5-7). Here we report that myosin VI, an unconventional myosin(8-12), moves towards the pointed (-) end of actin. We visualized the myosin VI construct bound to actin using cryo-electron microscopy and image analysis, and found that an ADP-mediated conformational change in the domain distal to the motor, a structure likely to be the effective lever arm, is in the opposite direction to that observed for other myosins, Thus, it appears that myosin VI achieves reverse-direction movement by rotating its lever arm in the opposite direction to conventional myosin lever arm movement.	Univ Penn, Sch Med, Dept Physiol, Philadelphia, PA 19104 USA; Scripps Res Inst, Dept Cell Biol, La Jolla, CA 92037 USA; Univ Calif San Diego, Dept Biol, La Jolla, CA 92093 USA; Univ Illinois, Beckman Inst, Dept Cell & Struct Biol, Urbana, IL 61801 USA	University of Pennsylvania; Scripps Research Institute; University of California System; University of California San Diego; University of Illinois System; University of Illinois Urbana-Champaign	Sweeney, HL (corresponding author), Univ Penn, Sch Med, Dept Physiol, 3700 Hamilton Walk, Philadelphia, PA 19104 USA.	Lsweeney@mail.med.upenn.edu	Sweeney, H Lee/F-1862-2010	HASSON, TAMA/0000-0002-5405-662X; Carragher, Bridget/0000-0002-0624-5020				Avraham KB, 1997, HUM MOL GENET, V6, P1225, DOI 10.1093/hmg/6.8.1225; AVRAHAM KB, 1995, NAT GENET, V11, P369, DOI 10.1038/ng1295-369; BLOOM GS, 1995, PROTEIN PROFILE, V2, P1109; Buss F, 1998, J CELL BIOL, V143, P1535, DOI 10.1083/jcb.143.6.1535; Dominguez R, 1998, CELL, V94, P559, DOI 10.1016/S0092-8674(00)81598-6; ELZINGA M, 1984, P NATL ACAD SCI-BIOL, V81, P6599, DOI 10.1073/pnas.81.21.6599; Endow SA, 1998, SCIENCE, V281, P1200, DOI 10.1126/science.281.5380.1200; ESPREAFICO EM, 1992, J CELL BIOL, V119, P1541, DOI 10.1083/jcb.119.6.1541; FISHER AJ, 1995, BIOCHEMISTRY-US, V34, P8960, DOI 10.1021/bi00028a004; HASSON T, 1994, J CELL BIOL, V127, P425, DOI 10.1083/jcb.127.2.425; Hasson T, 1997, J CELL BIOL, V137, P1287, DOI 10.1083/jcb.137.6.1287; Henningsen U, 1997, NATURE, V389, P93, DOI 10.1038/38022; Hirose K, 1998, J MOL BIOL, V278, P389, DOI 10.1006/jmbi.1998.1709; HOPP TP, 1988, BIO-TECHNOL, V6, P1204, DOI 10.1038/nbt1088-1204; Houdusse A, 1999, CELL, V97, P459, DOI 10.1016/S0092-8674(00)80756-4; JONTES JD, 1995, NATURE, V378, P751, DOI 10.1038/378751a0; Jontes JD, 1997, J CELL BIOL, V139, P683, DOI 10.1083/jcb.139.3.683; KELLERMAN KA, 1992, J CELL BIOL, V119, P823, DOI 10.1083/jcb.119.4.823; KOLODZIEJ PA, 1991, METHOD ENZYMOL, V194, P508; KRON SJ, 1986, P NATL ACAD SCI USA, V83, P6272, DOI 10.1073/pnas.83.17.6272; MERMALL V, 1994, NATURE, V369, P560, DOI 10.1038/369560a0; Mooseker MS, 1995, ANNU REV CELL DEV BI, V11, P633, DOI 10.1146/annurev.cellbio.11.1.633; POLLARD TD, 1982, METHOD ENZYMOL, V85, P123; RAYMENT I, 1993, SCIENCE, V261, P50, DOI 10.1126/science.8316857; Sablin EP, 1998, NATURE, V395, P813, DOI 10.1038/27463; SELLERS JR, 1995, PROTEIN PROFILE, V2, P1323; Sosa H, 1997, CELL, V90, P217, DOI 10.1016/S0092-8674(00)80330-X; Sweeney HL, 1998, J BIOL CHEM, V273, P6262, DOI 10.1074/jbc.273.11.6262; WHITTAKER M, 1995, NATURE, V378, P748, DOI 10.1038/378748a0; WOLENSKI JS, 1995, J CELL SCI, V108, P1489	30	532	543	0	40	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	SEP 30	1999	401	6752					505	508		10.1038/46835	http://dx.doi.org/10.1038/46835			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	243DF	10519557				2022-12-01	WOS:000082981200063
J	Wigle, JT; Oliver, G				Wigle, JT; Oliver, G			Prox1 function is required for the development of the murine lymphatic system	CELL			English	Article							ANGIOGENESIS; GENE; IDENTIFICATION; CAPILLARIES; EXPRESSION; RECEPTOR; PROSPERO	The lack of specific markers has raised problems in documenting the precise manner by which the lymphatic system develops. Here we report that the homeobox gene Prox1 is expressed in a subpopulation of endothelial cells that by budding and sprouting give rise to the lymphatic system. The initial localization of these cells in the veins and their subsequent budding are both polarized, suggesting that unidentified guidance signals regulate this process. In Prox1 null mice, budding and sprouting is arrested, although vasculogenesis and angiogenesis of the vascular system is unaffected. These findings suggest that Prox1 is a specific and required regulator of the development of the lymphatic system and that the vascular and lymphatic systems develop independently.	St Jude Childrens Res Hosp, Dept Genet, Memphis, TN 38105 USA	St Jude Children's Research Hospital	Oliver, G (corresponding author), St Jude Childrens Res Hosp, Dept Genet, 332 N Lauderdale St, Memphis, TN 38105 USA.		Wigle, J.t./G-2005-2014	Wigle, J.t./0000-0002-4985-7684	NATIONAL CANCER INSTITUTE [P30CA021765] Funding Source: NIH RePORTER; NATIONAL EYE INSTITUTE [R01EY012162] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM058462] Funding Source: NIH RePORTER; NCI NIH HHS [CA 21765] Funding Source: Medline; NEI NIH HHS [EY12162] Funding Source: Medline; NIGMS NIH HHS [GM58462] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bach TL, 1998, EXP CELL RES, V238, P324, DOI 10.1006/excr.1997.3844; BOBER E, 1994, DEVELOPMENT, V120, P603; Borges M, 1997, NATURE, V386, P852, DOI 10.1038/386852a0; Cao YH, 1998, P NATL ACAD SCI USA, V95, P14389, DOI 10.1073/pnas.95.24.14389; Dumont DJ, 1998, SCIENCE, V282, P946, DOI 10.1126/science.282.5390.946; EZAKI T, 1990, ARCH HISTOL CYTOL, V53, P77, DOI 10.1679/aohc.53.Suppl_77; FRALEY EE, 1961, AM J ANAT, V109, P85, DOI 10.1002/aja.1001090107; Gale NW, 1999, GENE DEV, V13, P1055, DOI 10.1101/gad.13.9.1055; GRAY H, 1985, ANATOMY HUMAN BODY, P866; Hanahan D, 1997, SCIENCE, V277, P48, DOI 10.1126/science.277.5322.48; Hiraoka N, 1998, CELL, V95, P365, DOI 10.1016/S0092-8674(00)81768-7; Huntington GS, 1910, AM J ANAT, V10, P177, DOI 10.1002/aja.1000100108; Jeltsch M, 1997, SCIENCE, V276, P1423, DOI 10.1126/science.276.5317.1423; KAIPAINEN A, 1995, P NATL ACAD SCI USA, V92, P3566, DOI 10.1073/pnas.92.8.3566; Kukk E, 1996, DEVELOPMENT, V122, P3829; LEAK LV, 1968, J CELL BIOL, V36, P129, DOI 10.1083/jcb.36.1.129; Ma QF, 1998, NEURON, V20, P469, DOI 10.1016/S0896-6273(00)80988-5; NERLICH AG, 1991, HISTOCHEMISTRY, V96, P449, DOI 10.1007/BF00316003; OLIVER G, 1993, MECH DEVELOP, V44, P3, DOI 10.1016/0925-4773(93)90012-M; Risau W, 1997, NATURE, V386, P671, DOI 10.1038/386671a0; Sabin FR, 1902, AM J ANAT, V1, P367, DOI 10.1002/aja.1000010310; Sabin FR, 1904, AM J ANAT, V3, P183, DOI 10.1002/aja.1000030205; Suri C, 1996, CELL, V87, P1171, DOI 10.1016/S0092-8674(00)81813-9; VAESSIN H, 1991, CELL, V67, P941, DOI 10.1016/0092-8674(91)90367-8; Valtola R, 1999, AM J PATHOL, V154, P1381, DOI 10.1016/S0002-9440(10)65392-8; Vittet D, 1997, P NATL ACAD SCI USA, V94, P6273, DOI 10.1073/pnas.94.12.6273; Wigle JT, 1999, NAT GENET, V21, P318, DOI 10.1038/6844	27	1129	1180	0	23	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	SEP 17	1999	98	6					769	778		10.1016/S0092-8674(00)81511-1	http://dx.doi.org/10.1016/S0092-8674(00)81511-1			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	237WH	10499794	Bronze			2022-12-01	WOS:000082679200004
J	Sugita, Y				Sugita, Y			Grouping of image fragments in primary visual cortex	NATURE			English	Article							ILLUSORY CONTOURS; PERCEPTION; MECHANISMS; MONKEY; INHIBITION; RESPONSES	In the visual world, objects are partially occluded by nearer objects, separating them into image fragments. However, the image fragments of the object can easily be grouped and organized together by the visual system(1-4). Psychophysical data(1-4) and theoretical analysis(5) indicate that such perceptual grouping might be mediated in the early stages of visual processing. Here I show that some orientation-selective cells in the primary visual cortex (V1) have response properties that can mediate the grouping of image fragments. These cells stopped responding to a stimulus bar when it was partly occluded by a small patch. The cells also did not respond when the patch had uncrossed disparity so that it appeared to be behind the bar. However, the cells began responding again when the patch had crossed disparity so that it appeared to be in front of the bar. These results indicate that cells as early as V1 have the computational power to make inferences about the nature of partially invisible forms seen behind occluding structures.	Natl Inst Biosci & Human Technol, Lab Neural Informat Proc, Tsukuba, Ibaraki 3058566, Japan; Japan Sci & Technol Corp, Tsukuba, Ibaraki 3058566, Japan	National Institute of Advanced Industrial Science & Technology (AIST); Japan Science & Technology Agency (JST)	Sugita, Y (corresponding author), Natl Inst Biosci & Human Technol, Lab Neural Informat Proc, Higashi 1-1, Tsukuba, Ibaraki 3058566, Japan.							ANDERSON BL, 1995, PSYCHOL REV, V102, P705, DOI 10.1037/0033-295X.102.4.705; BLAKEMORE C, 1972, EXP BRAIN RES, V15, P439; GILBERT CD, 1990, VISION RES, V30, P1689, DOI 10.1016/0042-6989(90)90153-C; GREGORY RL, 1972, NATURE, V238, P51, DOI 10.1038/238051a0; GROSOF DH, 1993, NATURE, V365, P550, DOI 10.1038/365550a0; Grossberg S, 1997, TRENDS NEUROSCI, V20, P106, DOI 10.1016/S0166-2236(96)01002-8; Kanizsa G., 1955, RIV PSICOL, V49, P7; KNIERIM JJ, 1992, J NEUROPHYSIOL, V67, P961, DOI 10.1152/jn.1992.67.4.961; LAMME VAF, 1995, J NEUROSCI, V15, P1605; MAFFEI L, 1976, VISION RES, V16, P1131, DOI 10.1016/0042-6989(76)90253-4; Nakayama K, 1996, P NATL ACAD SCI USA, V93, P634, DOI 10.1073/pnas.93.2.634; NAKAYAMA K, 1992, SCIENCE, V257, P1357, DOI 10.1126/science.1529336; NAKAYAMA K, 1989, PERCEPTION, V18, P55, DOI 10.1068/p180055; NELSON JI, 1978, BRAIN RES, V139, P359, DOI 10.1016/0006-8993(78)90937-X; PETERHANS E, 1989, J NEUROSCI, V9, P1749; ROCK I, 1979, PERCEPTION, V8, P665, DOI 10.1068/p080665; SHIMOJO S, 1990, PERCEPTION, V19, P285, DOI 10.1068/p190285; SILLITO AM, 1995, NATURE, V378, P492, DOI 10.1038/378492a0; VONDERHEYDT R, 1984, SCIENCE, V224, P1260, DOI 10.1126/science.6539501; VONDERHEYDT R, 1989, J NEUROSCI, V9, P1731; Zipser K, 1996, J NEUROSCI, V16, P7376	21	179	181	0	11	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	SEP 16	1999	401	6750					269	272		10.1038/45785	http://dx.doi.org/10.1038/45785			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	237VZ	10499583				2022-12-01	WOS:000082678400051
J	Finkel, TH				Finkel, TH			Potential use of a caspase against HIV - Abstract and commentary	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material									Natl Jewish Med & Res Ctr, Div Basic Sci, Denver, CO USA	National Jewish Health	Finkel, TH (corresponding author), Childrens Hosp Philadelphia, Dept Pediat, Div Rheumatol, Philadelphia, PA 19104 USA.							Casella C R, 1997, Curr Opin Hematol, V4, P24; FINKEL TH, 1995, NAT MED, V1, P129, DOI 10.1038/nm0295-129; FINKEL TH, 1998, CELL DEATH SIGNIFICA, P289; Finzi D, 1997, SCIENCE, V278, P1295, DOI 10.1126/science.278.5341.1295; Hellerstein M, 1999, NAT MED, V5, P83, DOI 10.1038/4772; Perelson AS, 1996, SCIENCE, V271, P1582, DOI 10.1126/science.271.5255.1582; Schulz TF, 1996, LANCET, V348, P587, DOI 10.1016/S0140-6736(95)11033-X; Vocero-Akbani AM, 1999, NAT MED, V5, P29, DOI 10.1038/4710; WEI XP, 1995, NATURE, V373, P117, DOI 10.1038/373117a0	9	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 15	1999	282	11					1021	1022		10.1001/jama.282.11.1021	http://dx.doi.org/10.1001/jama.282.11.1021			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	234YQ	10493188				2022-12-01	WOS:000082512300002
J	Alexander, WS; Starr, R; Fenner, JE; Scott, GL; Handman, E; Sprigg, NS; Corbin, JE; Cornish, AL; Darwiche, R; Owczarek, CM; Kay, TWH; Nicola, NA; Hertzog, PJ; Metcalf, D; Hilton, DJ				Alexander, WS; Starr, R; Fenner, JE; Scott, GL; Handman, E; Sprigg, NS; Corbin, JE; Cornish, AL; Darwiche, R; Owczarek, CM; Kay, TWH; Nicola, NA; Hertzog, PJ; Metcalf, D; Hilton, DJ			SOCS1 is a critical inhibitor of interferon gamma signaling and prevents the potentially fatal neonatal actions of this cytokine	CELL			English	Article							JAK-STAT PATHWAY; MUTANT-CELL LINE; IFN-GAMMA; TARGETED DISRUPTION; TYROSINE PHOSPHORYLATION; SUCKLING MICE; RECEPTOR; PROTEIN; GENE; ACTIVATION	Mice lacking suppressor of cytokine signaling-1 (SOCS1) develop a complex fatal neonatal disease. In this study, SOCS1(-/-) mice were shown to exhibit excessive responses typical of those induced by interferon gamma (IFN gamma), were hyperresponsive to viral infection, and yielded macrophages with an enhanced IFN gamma-dependent capacity to kill L. major parasites. The complex disease in SOCS1(-/-) mice was prevented by administration of anti-IFN gamma antibodies and did not occur in SOCS1(-/-) mice also lacking the IFN gamma gene. Although IFN gamma is essential for resistance to a variety of infections, the potential toxic action of IFN gamma, particularly in neonatal mice, appears to require regulation. Our data indicate that SOCS1 is a key modulator of IFN gamma action, allowing the protective effects of this cytokine to occur without the risk of associated pathological responses.	Walter & Eliza Hall Inst Med Res, Parkville, Vic 3050, Australia; Cooperat Res Ctr Cellular Growth Factors, Parkville, Vic 3050, Australia; Monash Med Ctr, Inst Reprod & Dev, Ctr Funct Gen & Human Dis, Clayton, Vic 3165, Australia	Walter & Eliza Hall Institute; Monash University	Hilton, DJ (corresponding author), Walter & Eliza Hall Inst Med Res, PO Royal Melbourne Hosp, Parkville, Vic 3050, Australia.	hilton@wehi.edu.au	Hertzog, Paul J/I-7053-2013; Hilton, Douglas J/C-7250-2013; Hertzog, Paul J/G-6734-2013; Nicola, Nicos/D-2989-2011	Hertzog, Paul J/0000-0002-1373-8472; Hilton, Douglas J/0000-0002-7698-2392; Hertzog, Paul J/0000-0002-1373-8472; Nicola, Nicos/0000-0003-1054-7889	NCI NIH HHS [CA-22556] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA022556, R37CA022556] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adams TE, 1998, J BIOL CHEM, V273, P1285, DOI 10.1074/jbc.273.3.1285; ALEXANDER WS, 1995, EMBO J, V14, P5569, DOI 10.1002/j.1460-2075.1995.tb00244.x; ANDO K, 1993, J EXP MED, V178, P1541, DOI 10.1084/jem.178.5.1541; Auernhammer CJ, 1998, MOL ENDOCRINOL, V12, P954, DOI 10.1210/me.12.7.954; Bach EA, 1997, ANNU REV IMMUNOL, V15, P563, DOI 10.1146/annurev.immunol.15.1.563; BILLIAU A, 1991, EUR J CLIN INVEST, V21, P559, DOI 10.1111/j.1365-2362.1991.tb01410.x; Billiau A, 1996, ADV IMMUNOL, V62, P61, DOI 10.1016/S0065-2776(08)60428-9; Bjorbaek C, 1998, MOL CELL, V1, P619, DOI 10.1016/S1097-2765(00)80062-3; Boehm U, 1997, ANNU REV IMMUNOL, V15, P749, DOI 10.1146/annurev.immunol.15.1.749; DALTON DK, 1993, SCIENCE, V259, P1739, DOI 10.1126/science.8456300; DAMELL JE, 1994, SCIENCE, V264, P1415; Darnell JE, 1997, SCIENCE, V277, P1630, DOI 10.1126/science.277.5332.1630; De Maeyer Edward, 1998, P491; De Sepulveda P, 1999, EMBO J, V18, P904; Durbin JE, 1996, CELL, V84, P443, DOI 10.1016/S0092-8674(00)81289-1; Endo TA, 1997, NATURE, V387, P921, DOI 10.1038/43213; GREENLUND AC, 1994, EMBO J, V13, P1591, DOI 10.1002/j.1460-2075.1994.tb06422.x; GRESSER I, 1981, AM J PATHOL, V102, P396; Gresser I, 1982, Interferon, V4, P95; GRESSER I, 1987, AM J PATHOL, V128, P13; HANDMAN E, 1983, PARASITE IMMUNOL, V5, P109, DOI 10.1111/j.1365-3024.1983.tb00728.x; HEIM MH, 1995, SCIENCE, V267, P1347, DOI 10.1126/science.7871432; HEMMI S, 1994, CELL, V76, P803, DOI 10.1016/0092-8674(94)90355-7; HERTZOG PJ, 1991, CLIN IMMUNOL IMMUNOP, V58, P18, DOI 10.1016/0090-1229(91)90145-Z; Hilton DJ, 1998, P NATL ACAD SCI USA, V95, P114, DOI 10.1073/pnas.95.1.114; HUANG S, 1993, SCIENCE, V259, P1742, DOI 10.1126/science.8456301; IGARASHI K, 1994, J BIOL CHEM, V269, P14333; IHLE JN, 1994, TRENDS BIOCHEM SCI, V19, P222, DOI 10.1016/0968-0004(94)90026-4; ITO S, 1999, BLOOD, V93, P1; KAMIJO R, 1994, SCIENCE, V263, P1612, DOI 10.1126/science.7510419; Leonard WJ, 1998, ANNU REV IMMUNOL, V16, P293, DOI 10.1146/annurev.immunol.16.1.293; LIU ZQ, 1995, INFECT IMMUN, V63, P2790, DOI 10.1128/IAI.63.7.2790-2792.1995; Lu BF, 1998, P NATL ACAD SCI USA, V95, P8233, DOI 10.1073/pnas.95.14.8233; MACMICKING JD, 1995, CELL, V81, P641, DOI 10.1016/0092-8674(95)90085-3; Massa PT, 1996, J IMMUNOL, V157, P5139; Matsumoto A, 1997, BLOOD, V89, P3148, DOI 10.1182/blood.V89.9.3148; MATSUYAMA T, 1993, CELL, V75, P83, DOI 10.1016/S0092-8674(05)80086-8; MATTHYS P, 1995, INFECT IMMUN, V63, P1158, DOI 10.1128/IAI.63.4.1158-1164.1995; Meraz MA, 1996, CELL, V84, P431, DOI 10.1016/S0092-8674(00)81288-X; Metcalf D, 1999, LEUKEMIA, V13, P926, DOI 10.1038/sj.leu.2401440; MOORE KW, 1993, ANNU REV IMMUNOL, V11, P165, DOI 10.1146/annurev.iy.11.040193.001121; MULLER M, 1993, NATURE, V366, P129, DOI 10.1038/366129a0; MULLER M, 1993, EMBO J, V12, P4221, DOI 10.1002/j.1460-2075.1993.tb06106.x; Naka T, 1997, NATURE, V387, P924, DOI 10.1038/43219; Newport MJ, 1996, NEW ENGL J MED, V335, P1941, DOI 10.1056/NEJM199612263352602; Nicholson SE, 1999, EMBO J, V18, P375, DOI 10.1093/emboj/18.2.375; NOVAK U, 1995, BLOOD, V86, P2948, DOI 10.1182/blood.V86.8.2948.bloodjournal8682948; NOVICK D, 1994, CELL, V77, P391, DOI 10.1016/0092-8674(94)90154-6; OZATO K, 1982, TRANSPLANTATION, V34, P113, DOI 10.1097/00007890-198209000-00001; PAUL WE, 1991, BLOOD, V77, P1859; PROUDFOOT L, 1995, BIOCHEM J, V15, P45; RUFFJAMISON S, 1993, SCIENCE, V261, P1733, DOI 10.1126/science.8378774; Sakamoto H, 1998, BLOOD, V92, P1668, DOI 10.1182/blood.V92.5.1668.417k09_1668_1676; SCHINDLER C, 1995, ANNU REV BIOCHEM, V64, P621, DOI 10.1146/annurev.bi.64.070195.003201; SHUAI K, 1994, CELL, V76, P821, DOI 10.1016/0092-8674(94)90357-3; Song MM, 1998, J BIOL CHEM, V273, P35056, DOI 10.1074/jbc.273.52.35056; Starr R, 1998, P NATL ACAD SCI USA, V95, P14395, DOI 10.1073/pnas.95.24.14395; Starr R, 1997, NATURE, V387, P917, DOI 10.1038/43206; STRASSER A, 1991, CELL, V67, P889, DOI 10.1016/0092-8674(91)90362-3; TATAKE RJ, 1993, P SOC EXP BIOL MED, V203, P405; Thomas HE, 1998, J CLIN INVEST, V102, P1249, DOI 10.1172/JCI2899; TOYONAGA T, 1994, P NATL ACAD SCI USA, V91, P614, DOI 10.1073/pnas.91.2.614; Wang DM, 1996, MOL CELL BIOL, V16, P6141; WATLING D, 1993, NATURE, V366, P166, DOI 10.1038/366166a0; ZURAWSKI G, 1994, IMMUNOL TODAY, V15, P19, DOI 10.1016/0167-5699(94)90021-3	66	623	648	0	27	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	SEP 3	1999	98	5					597	608		10.1016/S0092-8674(00)80047-1	http://dx.doi.org/10.1016/S0092-8674(00)80047-1			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	233NT	10490099	Bronze			2022-12-01	WOS:000082433500007
J	Marine, JC; McKay, C; Wang, DM; Topham, DJ; Parganas, E; Nakajima, H; Pendeville, H; Yasukawa, H; Sasaki, A; Yoshimura, A; Ihle, JN				Marine, JC; McKay, C; Wang, DM; Topham, DJ; Parganas, E; Nakajima, H; Pendeville, H; Yasukawa, H; Sasaki, A; Yoshimura, A; Ihle, JN			SOCS3 is essential in the regulation of fetal liver erythropoiesis	CELL			English	Article							EMBRYONIC STEM-CELLS; TRANSGENIC MICE; DEFICIENT MICE; RECEPTORS; JAK2; HEMATOPOIESIS; EXPRESSION; PROTEIN; BCL-2; DEATH	SOCS3 (CIS3/JAB2) is an SH2-containing protein that binds to the activation loop of Janus kinases, inhibiting kinase activity, and thereby suppressing cytokine signaling. During embryonic development, SOCS3 is highly expressed in erythroid lineage cells and is Epo independent. Transgene-mediated expression blocks fetal erythropoiesis, resulting in embryonic lethality. SOCS3 deletion results in an embryonic lethality at 12-16 days associated with marked erythrocytosis. Moreover, the in vitro proliferative capacity of progenitors is greatly increased. SOCS3-deficient fetal liver stem cells can reconstitute hematopoiesis in lethally irradiated adults, indicating that its absence does not disturb bone marrow erythropoiesis. Reconstitution of lymphoid lineages in JAK3-deficient mice also occurs normally. The results demonstrate that SOCS3 is critical in negatively regulating fetal liver hematopoiesis.	St Jude Childrens Res Hosp, Howard Hughes Med Inst, Memphis, TN 38105 USA; St Jude Childrens Res Hosp, Dept Biochem, Memphis, TN 38105 USA; St Jude Childrens Res Hosp, Dept Immunol, Memphis, TN 38105 USA; Univ Tennessee, Sch Med, Memphis, TN USA; Kurume Univ, Inst Life Sci, Kurume, Fukuoka 8390861, Japan	Howard Hughes Medical Institute; St Jude Children's Research Hospital; St Jude Children's Research Hospital; St Jude Children's Research Hospital; University of Tennessee System; University of Tennessee Health Science Center; Kurume University	Ihle, JN (corresponding author), St Jude Childrens Res Hosp, Howard Hughes Med Inst, 332 N Lauderdale St, Memphis, TN 38105 USA.	jamesihle@stjude.org	Yoshimura, Akihiko/K-5515-2013; Marine, Jean-Christophe/K-3292-2016; Wang, Demin/AAX-4449-2020; Marine, Jean Christophe/J-2237-2015	Marine, Jean-Christophe/0000-0003-2433-9837; Wang, Demin/0000-0001-5549-3795; Sasaki, Atsuo/0000-0003-2963-4501	NATIONAL CANCER INSTITUTE [P30CA021765] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL053749] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK042932] Funding Source: NIH RePORTER; NCI NIH HHS [CA21765] Funding Source: Medline; NHLBI NIH HHS [P01 HL53749] Funding Source: Medline; NIDDK NIH HHS [R01 DK42932] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Adams TE, 1998, J BIOL CHEM, V273, P1285, DOI 10.1074/jbc.273.3.1285; Andrews N C, 1994, Curr Opin Hematol, V1, P119; ANGERER LM, 1991, METHOD CELL BIOL, V35, P37; Auernhammer CJ, 1999, P NATL ACAD SCI USA, V96, P6964, DOI 10.1073/pnas.96.12.6964; Auernhammer CJ, 1998, MOL ENDOCRINOL, V12, P954, DOI 10.1210/me.12.7.954; Auernhammer CJ, 1999, ENDOCRINOLOGY, V140, P1559, DOI 10.1210/en.140.4.1559; Bentley DJ, 1996, NAT GENET, V13, P489, DOI 10.1038/ng0896-489; Bjorbaek C, 1999, ENDOCRINOLOGY, V140, P2035, DOI 10.1210/en.140.5.2035; Bjorbaek C, 1998, MOL CELL, V1, P619, DOI 10.1016/S1097-2765(00)80062-3; Cohney SJ, 1999, MOL CELL BIOL, V19, P4980; Domen J, 1998, BLOOD, V91, P2272, DOI 10.1182/blood.V91.7.2272.2272_2272_2282; GALLI SJ, 1994, ADV IMMUNOL, V55, P1; Hakem R, 1998, CELL, V94, P339, DOI 10.1016/S0092-8674(00)81477-4; IKUTA K, 1990, CELL, V62, P863, DOI 10.1016/0092-8674(90)90262-D; Ito S, 1999, BLOOD, V93, P1456, DOI 10.1182/blood.V93.5.1456; Kamura T, 1998, GENE DEV, V12, P3872, DOI 10.1101/gad.12.24.3872; KLINGMULLER U, 1995, CELL, V80, P729, DOI 10.1016/0092-8674(95)90351-8; Kondo M, 1997, IMMUNITY, V7, P155, DOI 10.1016/S1074-7613(00)80518-X; Marine JC, 1999, CELL, V98, P609, DOI 10.1016/S0092-8674(00)80048-3; Matsumoto A, 1997, BLOOD, V89, P3148, DOI 10.1182/blood.V89.9.3148; MOTOYAMA N, 1995, SCIENCE, V267, P1506, DOI 10.1126/science.7878471; Naka T, 1998, P NATL ACAD SCI USA, V95, P15577, DOI 10.1073/pnas.95.26.15577; Neubauer H, 1998, CELL, V93, P397, DOI 10.1016/S0092-8674(00)81168-X; Orkin SH, 1997, ANNU REV GENET, V31, P33, DOI 10.1146/annurev.genet.31.1.33; Orkin SH, 1998, INT J DEV BIOL, V42, P927; Parganas E, 1998, CELL, V93, P385, DOI 10.1016/S0092-8674(00)81167-8; SASAKI A, 1999, IN PRESS GENES CELLS; Socolovsky M, 1999, CELL, V98, P181, DOI 10.1016/S0092-8674(00)81013-2; Song MM, 1998, J BIOL CHEM, V273, P35056, DOI 10.1074/jbc.273.52.35056; Starr R, 1998, P NATL ACAD SCI USA, V95, P14395, DOI 10.1073/pnas.95.24.14395; Starr R, 1997, NATURE, V387, P917, DOI 10.1038/43206; Teglund S, 1998, CELL, V93, P841, DOI 10.1016/S0092-8674(00)81444-0; VANDEURSEN J, 1993, CELL, V74, P621, DOI 10.1016/0092-8674(93)90510-W; VANDEURSEN J, 1991, NUCLEIC ACIDS RES, V19, P2637, DOI 10.1093/nar/19.10.2637; Varfolomeev EE, 1998, IMMUNITY, V9, P267, DOI 10.1016/S1074-7613(00)80609-3; WU H, 1995, NATURE, V377, P242, DOI 10.1038/377242a0; WU H, 1995, CELL, V83, P59, DOI 10.1016/0092-8674(95)90234-1; Yasukawa H, 1999, EMBO J, V18, P1309, DOI 10.1093/emboj/18.5.1309; Yeh WC, 1998, SCIENCE, V279, P1954, DOI 10.1126/science.279.5358.1954; YOSHIMURA A, 1995, EMBO J, V14, P2816, DOI 10.1002/j.1460-2075.1995.tb07281.x; Zhang JG, 1999, P NATL ACAD SCI USA, V96, P2071, DOI 10.1073/pnas.96.5.2071	41	298	305	0	6	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	SEP 3	1999	98	5					617	627		10.1016/S0092-8674(00)80049-5	http://dx.doi.org/10.1016/S0092-8674(00)80049-5			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	233NT	10490101	Bronze			2022-12-01	WOS:000082433500009
J	Bartsch, P				Bartsch, P			Platelet activation with exercise and risk of cardiac events	LANCET			English	Editorial Material							ACUTE MYOCARDIAL-INFARCTION; STRENUOUS EXERCISE; PHYSICAL EXERTION; FIBRINOLYSIS; COAGULATION; MODERATE; DEATH; MEN		Univ Heidelberg, Div Sports Med, Dept Internal Med, D-69115 Heidelberg, Germany	Ruprecht Karls University Heidelberg	Bartsch, P (corresponding author), Univ Heidelberg, Div Sports Med, Dept Internal Med, Bergheimer Str 58, D-69115 Heidelberg, Germany.							DAVIES MJ, 1984, NEW ENGL J MED, V310, P1137, DOI 10.1056/NEJM198405033101801; KESTIN AS, 1993, CIRCULATION, V88, P1502, DOI 10.1161/01.CIR.88.4.1502; MARON BJ, 1986, J AM COLL CARDIOL, V7, P204, DOI 10.1016/S0735-1097(86)80283-2; MITTLEMAN MA, 1993, NEW ENGL J MED, V329, P1677, DOI 10.1056/NEJM199312023292301; SISCOVICK DS, 1984, NEW ENGL J MED, V311, P874, DOI 10.1056/NEJM198410043111402; STREIFF M, 1994, SEMIN HEMATOL, V31, P155; Wallen NH, 1999, CLIN SCI, V97, P27, DOI 10.1042/CS19990013; WANG JS, 1994, CIRCULATION, V90, P2877, DOI 10.1161/01.CIR.90.6.2877; WANG JS, 1995, ARTERIOSCL THROM VAS, V15, P1668, DOI 10.1161/01.ATV.15.10.1668; Weiss C, 1998, MED SCI SPORT EXER, V30, P246, DOI 10.1097/00005768-199802000-00012; Weiss C, 1998, AM J CARDIOL, V81, P672, DOI 10.1016/S0002-9149(97)01026-6; WILLICH SN, 1993, NEW ENGL J MED, V329, P1684, DOI 10.1056/NEJM199312023292302; WINDER WW, 1978, J APPL PHYSIOL, V45, P370, DOI 10.1152/jappl.1978.45.3.370	13	42	43	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	NOV 20	1999	354	9192					1747	1748		10.1016/S0140-6736(99)90259-3	http://dx.doi.org/10.1016/S0140-6736(99)90259-3			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	258RM	10577632				2022-12-01	WOS:000083853000005
J	Sanchez, Y; Bachant, J; Wang, H; Hu, FH; Liu, D; Tetzlaff, M; Elledge, SJ				Sanchez, Y; Bachant, J; Wang, H; Hu, FH; Liu, D; Tetzlaff, M; Elledge, SJ			Control of the DNA damage checkpoint by Chk1 and Rad53 protein kinases through distinct mechanisms	SCIENCE			English	Article							ANAPHASE-PROMOTING COMPLEX; SACCHAROMYCES-CEREVISIAE; CELL-CYCLE; BUDDING YEAST; TYROSINE PHOSPHORYLATION; PDS1P; INHIBITOR; DESTRUCTION; TRANSITION; METAPHASE	In response to DNA damage, cells activate checkpoint pathways that prevent cell cycle progression. In fission yeast and mammals, mitotic arrest in response to DNA damage requires inhibitory Cdk phosphorylation regulated by Chk1. This study indicates that Chk1 is required for function of the DNA damage checkpoint in Saccharomyces cerevisiae but acts through a distinct mechanism maintaining the abundance of Pds1, an anaphase inhibitor. Unlike other checkpoint mutants, chk1 mutants were only mildly sensitive to DNA damage, indicating that checkpoint functions besides cell cycle arrest influence damage sensitivity. Another kinase, Rad53, was required to both maintain active cyclin-dependent kinase 1, Cdk1(Cdc28), and prevent anaphase entry after checkpoint activation. Evidence suggests that Rad53 exerts its role in checkpoint control through regulation of the Polo kinase Cdc5. These results support a model in which Chk1 and Rad53 function in parallel through Pds1 and Cdc5, respectively, to prevent anaphase entry and mitotic exit after DNA damage. This model provides a possible explanation for the role of Cdc5 in DNA damage checkpoint adaptation.	Baylor Coll Med, Howard Hughes Med Inst, Houston, TX 77030 USA; Baylor Coll Med, Verna & Marrs Mclean Dept Biochem, Houston, TX 77030 USA; Baylor Coll Med, Dept Mol & Human Genet, Houston, TX 77030 USA	Baylor College of Medicine; Howard Hughes Medical Institute; Baylor College of Medicine; Baylor College of Medicine	Elledge, SJ (corresponding author), Baylor Coll Med, Howard Hughes Med Inst, 1 Baylor Plaza, Houston, TX 77030 USA.		Sanchez, Yolanda/L-2847-2014	Sanchez, Yolanda/0000-0002-7650-9319	NIGMS NIH HHS [GM44664] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM044664, R37GM044664] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALLEN JB, 1994, GENE DEV, V8, P2401, DOI 10.1101/gad.8.20.2401; AMON A, 1992, NATURE, V355, P368, DOI 10.1038/355368a0; Charles JF, 1998, CURR BIOL, V8, P497, DOI 10.1016/S0960-9822(98)70201-5; Cheng L, 1998, MOL CELL BIOL, V18, P7360, DOI 10.1128/MCB.18.12.7360; Ciosk R, 1998, CELL, V93, P1067, DOI 10.1016/S0092-8674(00)81211-8; Cohen-Fix O, 1997, P NATL ACAD SCI USA, V94, P14361, DOI 10.1073/pnas.94.26.14361; CohenFix O, 1996, GENE DEV, V10, P3081, DOI 10.1101/gad.10.24.3081; Desany BA, 1998, GENE DEV, V12, P2956, DOI 10.1101/gad.12.18.2956; Elledge SJ, 1996, SCIENCE, V274, P1664, DOI 10.1126/science.274.5293.1664; Gardner R, 1999, EMBO J, V18, P3173, DOI 10.1093/emboj/18.11.3173; GARVIK B, 1995, MOL CELL BIOL, V15, P6128; Kotani S, 1998, MOL CELL, V1, P371, DOI 10.1016/S1097-2765(00)80037-4; Liu QH, 1998, CURR BIOL, V8, P1300, DOI 10.1016/S0960-9822(07)00560-X; Pati D, 1997, MOL CELL BIOL, V17, P3037, DOI 10.1128/MCB.17.6.3037; Sanchez Y, 1996, SCIENCE, V271, P357, DOI 10.1126/science.271.5247.357; SANCHEZ Y, UNPUB; Shirayama M, 1998, EMBO J, V17, P1336, DOI 10.1093/emboj/17.5.1336; SORGER PK, 1992, NATURE, V355, P365, DOI 10.1038/355365a0; Sun ZX, 1998, SCIENCE, V281, P272, DOI 10.1126/science.281.5374.272; SURANA U, 1993, EMBO J, V12, P1969, DOI 10.1002/j.1460-2075.1993.tb05846.x; Toczyski DP, 1997, CELL, V90, P1097, DOI 10.1016/S0092-8674(00)80375-X; Vialard JE, 1998, EMBO J, V17, P5679, DOI 10.1093/emboj/17.19.5679; Visintin R, 1998, MOL CELL, V2, P709, DOI 10.1016/S1097-2765(00)80286-5; Walworth NC, 1996, SCIENCE, V271, P353, DOI 10.1126/science.271.5247.353; Weinert T, 1997, SCIENCE, V277, P1450, DOI 10.1126/science.277.5331.1450; WEINERT TA, 1993, GENETICS, V134, P63; Yamamoto A, 1996, J CELL BIOL, V133, P99, DOI 10.1083/jcb.133.1.99; Yamamoto A, 1996, J CELL BIOL, V133, P85, DOI 10.1083/jcb.133.1.85	28	445	454	2	107	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 5	1999	286	5442					1166	1171		10.1126/science.286.5442.1166	http://dx.doi.org/10.1126/science.286.5442.1166			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	253AJ	10550056				2022-12-01	WOS:000083534200046
J	Molbak, K; Baggesen, DL; Aarestrup, FM; Ebbesen, JM; Engberg, J; Frydendahl, K; Gerner-Smidt, P; Petersen, AM; Wegener, HC				Molbak, K; Baggesen, DL; Aarestrup, FM; Ebbesen, JM; Engberg, J; Frydendahl, K; Gerner-Smidt, P; Petersen, AM; Wegener, HC			An outbreak of multidrug-resistant, quinolone-resistant Salmonella enterica serotype typhimurium DT104	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							GYRA GENE; SEROVAR TYPHIMURIUM; PRODUCTION ANIMALS; PHAGE TYPES; HUMANS; MUTATIONS; DENMARK	Background Food-borne salmonella infections have become a major problem in industrialized countries. The strain of Salmonella enterica serotype typhimurium known as definitive phage type 104 (DT104) is usually resistant to five drugs: ampicillin, chloramphenicol, streptomycin, sulfonamides, and tetracycline. An increasing proportion of DT104 isolates also have reduced susceptibility to fluoroquinolones. Methods The Danish salmonella surveillance program determines the phage types of all typhimurium strains from the food chain, and in the case of suspected outbreaks, five-drug-resistant strains are characterized by molecular methods. All patients infected with five-drug-resistant typhimurium are interviewed to obtain clinical and epidemiologic data. In 1998, an outbreak of salmonella occurred, in which the strain of typhimurium DT104 was new to Denmark. We investigated this outbreak and report our findings here. Results Until 1997, DT104 infections made up less than 1 percent of all human salmonella infections. The strain isolated from patients in the first community outbreak of DT104 in Denmark, in 1998, was resistant to nalidixic acid and had reduced susceptibility to fluoroquinolones. The outbreak included 25 culture-confirmed cases. Eleven patients were hospitalized, and two died. The molecular epidemiology and data from patients indicated that the primary source was a Danish swine herd. Furthermore, the investigation suggested reduced clinical effectiveness of treatment with fluoroquinolones. Conclusions Our investigation of an outbreak of DT104 documented the spread of quinolone-resistant bacteria from food animals to humans; this spread was associated with infections that were difficult to treat. Because of the increase in quinolone resistance in salmonella, the use of fluoroquinolones in food animals should be restricted. (N Engl J Med 1999;341:1420-5.) (C)1999, Massachusetts Medical Society.	Statens Serum Inst, DK-2300 Copenhagen S, Denmark; Danish Vet Lab, Copenhagen, Denmark; Danish Food & Vet Adm, Copenhagen, Denmark; Danish Zoonosis Ctr, Copenhagen, Denmark	Statens Serum Institut	Molbak, K (corresponding author), Statens Serum Inst, Artillerivej 5, DK-2300 Copenhagen S, Denmark.			Engberg, Jorgen/0000-0001-9042-1631; Wegener, Henrik Caspar/0000-0002-6888-2121; Petersen, Andreas Munk/0000-0003-0531-0553; Molbak, Kare/0000-0002-3100-4990; Aarestrup, Frank/0000-0002-7116-2723				ANDERSON ES, 1977, J HYG-CAMBRIDGE, V78, P297, DOI 10.1017/S0022172400056187; Anglim Anne M., 1995, P1525; BAGGESEN DL, 1994, ACTA VET SCAND, V35, P349; CALLOW B R, 1959, J Hyg (Lond), V57, P346; *DIV EM OTH COMM D, 1997, P WHO M BERL GERM 13; Glynn MK, 1998, NEW ENGL J MED, V338, P1333, DOI 10.1056/NEJM199805073381901; Griggs DJ, 1996, ANTIMICROB AGENTS CH, V40, P1009, DOI 10.1128/AAC.40.4.1009; HALD T, 1998, ANN REPORT ZOONOSES; HOLMBERG SD, 1984, NEW ENGL J MED, V311, P617, DOI 10.1056/NEJM198409063111001; National Committee for Clinical Laboratory Standars, 1999, M100S9 NCCLS; OLSEN JE, 1994, J MED MICROBIOL, V40, P15, DOI 10.1099/00222615-40-1-15; Ouabdesselam S, 1996, MICROB DRUG RESIST, V2, P299, DOI 10.1089/mdr.1996.2.299; Piddock LJV, 1998, J ANTIMICROB CHEMOTH, V41, P635, DOI 10.1093/jac/41.6.635; Ridley A, 1998, MICROB DRUG RESIST, V4, P113, DOI 10.1089/mdr.1998.4.113; Ruiz J, 1997, J MED MICROBIOL, V46, P623, DOI 10.1099/00222615-46-7-623; Seyfarth AM, 1997, J ANTIMICROB CHEMOTH, V40, P67, DOI 10.1093/jac/40.1.67; Threlfall EJ, 1996, LANCET, V347, P1053, DOI 10.1016/S0140-6736(96)90199-3; Vasallo FJ, 1998, CLIN INFECT DIS, V26, P535, DOI 10.1086/517087; Wain J, 1997, CLIN INFECT DIS, V25, P1404, DOI 10.1086/516128; WEGENER HC, 1994, APMIS, V102, P521, DOI 10.1111/j.1699-0463.1994.tb05200.x; WISTROM J, 1995, J ANTIMICROB CHEMOTH, V36, P23, DOI 10.1093/jac/36.1.23; YOSHIDA H, 1990, ANTIMICROB AGENTS CH, V34, P1271, DOI 10.1128/AAC.34.6.1271	22	347	360	0	27	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	NOV 4	1999	341	19					1420	1425		10.1056/NEJM199911043411902	http://dx.doi.org/10.1056/NEJM199911043411902			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	251XR	10547404	Bronze			2022-12-01	WOS:000083472100002
J	Page, CC; Moser, CC; Chen, XX; Dutton, PL				Page, CC; Moser, CC; Chen, XX; Dutton, PL			Natural engineering principles of electron tunnelling in biological oxidation-reduction	NATURE			English	Article							PHOTOSYNTHETIC REACTION-CENTER; DELTA-G-DEGREES; RHODOPSEUDOMONAS-VIRIDIS; RHODOBACTER-SPHAEROIDES; DESULFOVIBRIO-GIGAS; PROTEIN-STRUCTURE; CRYSTAL-STRUCTURE; NIFE HYDROGENASE; TEMPERATURE; OXIDASE	We have surveyed proteins with known atomic structure whose function involves electron transfer; in these, electrons can travel up to 14 Angstrom between redox centres through the protein medium. Transfer over longer distances always involves a chain of cofactors. This redox centre proximity alone is sufficient to allow tunnelling of electrons at rates far faster than the substrate redox reactions it supports. Consequently, there has been no necessity for proteins to evolve optimized routes between redox centres. Instead, simple geometry enables rapid tunnelling to high-energy intermediate states. This greatly simplifies any analysis of redox protein mechanisms and challenges the need to postulate mechanisms of superexchange through redox centres or the maintenance of,charge neutrality when investigating electron-transfer reactions. Such tunnelling also allows sequential electron transfer in catalytic sites to surmount radical transition states without involving the movement of hydride ions, as is generally assumed. The 14 Angstrom or less spacing of redox centres provides highly robust engineering for electron transfer, and may reflect selection against designs that have proved more vulnerable to mutations during the course of evolution.	Univ Penn, Dept Biochem & Biophys, Johnson Res Fdn, Philadelphia, PA 19104 USA	University of Pennsylvania	Dutton, PL (corresponding author), Univ Penn, Dept Biochem & Biophys, Johnson Res Fdn, Philadelphia, PA 19104 USA.	dutton@mail.med.upenn.edu	Moser, Christopher C/O-6559-2014	Moser, Christopher C/0000-0003-4814-8568; Chen, Xiaoxi/0000-0002-1049-3537				ALEGRIA G, 1991, BIOCHIM BIOPHYS ACTA, V1057, P239, DOI 10.1016/S0005-2728(05)80107-0; Allen JP, 1998, PHOTOSYNTH RES, V55, P227, DOI 10.1023/A:1005977901937; Bahnson BJ, 1997, P NATL ACAD SCI USA, V94, P12797, DOI 10.1073/pnas.94.24.12797; BERATAN DN, 1992, SCIENCE, V258, P1740, DOI 10.1126/science.1334572; Coelho AV, 1997, J BIOL INORG CHEM, V2, P680, DOI 10.1007/s007750050184; Darwin C., 1872, ORIGIN SPECIES MEANS, V144, P971; DEVAULT D, 1980, Q REV BIOPHYS, V13, P387, DOI 10.1017/S003358350000175X; DOHSE B, 1995, BIOCHEMISTRY-US, V34, P11335, DOI 10.1021/bi00036a006; DUTTON PL, 1998, BIOL ELECT TRANSFER, P3; EBERSON L, 1987, ELECT TRANSFER REACT, P1; EHRENBERG A, 1998, 3 INT S BIOL PHYS, V1, P1; FARRINGTON JA, 1980, BIOCHIM BIOPHYS ACTA, V590, P273, DOI 10.1016/0005-2728(80)90031-6; Gray HB, 1996, ANNU REV BIOCHEM, V65, P537, DOI 10.1146/annurev.bi.65.070196.002541; Gunner M.R., 1982, FUNCTION QUINONES EN, P265; GUNNER MR, 1989, J AM CHEM SOC, V111, P3400, DOI 10.1021/ja00191a043; HOPFIELD JJ, 1974, P NATL ACAD SCI USA, V71, P3640, DOI 10.1073/pnas.71.9.3640; Huber R, 1996, P NATL ACAD SCI USA, V93, P8846, DOI 10.1073/pnas.93.17.8846; HUNT J, 1993, J BIOL CHEM, V268, P18685; Jortner J, 1998, P NATL ACAD SCI USA, V95, P12759, DOI 10.1073/pnas.95.22.12759; JORTNER J, 1976, J CHEM PHYS, V64, P4860, DOI 10.1063/1.432142; Kisker C, 1997, CELL, V91, P973, DOI 10.1016/S0092-8674(00)80488-2; KNAFF DB, 1991, BIOCHEMISTRY-US, V30, P1303, DOI 10.1021/bi00219a021; KUKI A, 1987, SCIENCE, V236, P1647, DOI 10.1126/science.3603005; Li JL, 1998, BIOCHEMISTRY-US, V37, P2818, DOI 10.1021/bi971699x; MARCUS RA, 1985, BIOCHIM BIOPHYS ACTA, V811, P265, DOI 10.1016/0304-4173(85)90014-X; MCLENDON G, 1991, STRUCT BOND, V75, P159; MEYER TE, 1993, BIOCHEMISTRY-US, V32, P4719, DOI 10.1021/bi00069a005; MICHAELIS L, 1951, ENZYMES, P1; MICHEL H, 1986, EMBO J, V5, P2445, DOI 10.1002/j.1460-2075.1986.tb04520.x; MITCHELL P, 1975, FEBS LETT, V59, P137, DOI 10.1016/0014-5793(75)80359-0; MOSER CC, 1992, BIOCHIM BIOPHYS ACTA, V1101, P171, DOI 10.1016/S0005-2728(05)80012-X; MOSER CC, 1992, NATURE, V355, P796, DOI 10.1038/355796a0; Ortega JM, 1999, PHOTOSYNTH RES, V59, P147, DOI 10.1023/A:1006149621029; POWELL MF, 1984, J AM CHEM SOC, V106, P3850, DOI 10.1021/ja00325a024; Proshlyakov DA, 1998, P NATL ACAD SCI USA, V95, P8020, DOI 10.1073/pnas.95.14.8020; PROSS A, 1985, ACCOUNTS CHEM RES, V18, P212, DOI 10.1021/ar00115a004; ROMAO MJ, 1995, SCIENCE, V270, P1170, DOI 10.1126/science.270.5239.1170; Rousset M, 1998, P NATL ACAD SCI USA, V95, P11625, DOI 10.1073/pnas.95.20.11625; SHOPES RJ, 1987, PHOTOSYNTH RES, V12, P165, DOI 10.1007/BF00047946; Siegbahn PEM, 1997, THEOR CHEM ACC, V97, P289, DOI 10.1007/s002140050264; Siegbahn PEM, 1998, J AM CHEM SOC, V120, P8417, DOI 10.1021/ja9736065; SMALLEY JF, 1995, J PHYS CHEM-US, V99, P13141, DOI 10.1021/j100035a016; SOGABE S, 1992, PHOTOSYNTH RES, V34, P154; Spee JH, 1998, FEBS LETT, V432, P55, DOI 10.1016/S0014-5793(98)00827-8; Stubbe J, 1998, CHEM REV, V98, P705, DOI 10.1021/cr9400875; TEIXEIRA M, 1989, J BIOL CHEM, V264, P16435; Venturoli G, 1998, BIOPHYS J, V74, P3226, DOI 10.1016/S0006-3495(98)78029-4; VOLBEDA A, 1995, NATURE, V373, P580, DOI 10.1038/373580a0; WOODBURY NW, 1986, BIOCHIM BIOPHYS ACTA, V851, P6, DOI 10.1016/0005-2728(86)90243-4; Zinth W, 1996, BER BUNSEN PHYS CHEM, V100, P1962, DOI 10.1002/bbpc.19961001206	50	1430	1449	8	287	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	NOV 4	1999	402	6757					47	52		10.1038/46972	http://dx.doi.org/10.1038/46972			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	254XC	10573417				2022-12-01	WOS:000083638600036
J	Ricchetti, M; Fairhead, C; Dujon, B				Ricchetti, M; Fairhead, C; Dujon, B			Mitochondrial DNA repairs double-strand breaks in yeast chromosomes	NATURE			English	Article							SACCHAROMYCES-CEREVISIAE; NONHOMOLOGOUS RECOMBINATION; NUCLEUS; GENOME; ESCAPE; GENES; INTEGRATION; MIGRATION; DELETIONS; SEQUENCE	The endosymbiotic theory for the origin of eukaryotic cells' proposes that genetic information can be transferred from mitochondria to the nucleus of a cell, and genes that are probably of mitochondrial origin have been found in nuclear chromosomes(2). Occasionally, short or rearranged sequences homologous to mitochondrial DNA are seen in the chromosomes of different organisms including yeast, plants and humans(3). Here we report a mechanism by which fragments of mitochondrial DNA, in single or tandem array, are transferred to yeast chromosomes under natural conditions during the repair of double-strand breaks in haploid mitotic cells. These repair insertions originate from noncontiguous regions of the mitochondrial genome. Our analysis of the Saccharomyces cerevisiae mitochondrial genome(4) indicates that the yeast nuclear genome does indeed contain several short sequences of mitochondrial origin which are similar in size and composition to those that repair double-strand breaks. These sequences are located predominantly in non-coding regions of the chromosomes, frequently in the vicinity of retrotransposon long terminal repeats, and appear as recent integration events. Thus, colonization of the yeast genome by mitochondrial DNA is an ongoing process.	Inst Pasteur, CNRS, URA 1773, Unite Physicochim Macromol Biol, F-75724 Paris 15, France; Univ Paris 06, Inst Pasteur, UFR 927, CNRS,URA1300,Unite Genet Mol Levures, F-75724 Paris 15, France	Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; UDICE-French Research Universities; Universite Paris Cite; Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; UDICE-French Research Universities; Sorbonne Universite	Ricchetti, M (corresponding author), Inst Pasteur, CNRS, URA 1773, Unite Physicochim Macromol Biol, 25-28 Rue Docteur Roux, F-75724 Paris 15, France.	mricch@pasteur.fr	Dujon, Bernard A/F-4971-2010; Fairhead, Cecile/D-9011-2014	Fairhead, Cecile/0000-0002-0456-0377				Baudat F, 1997, P NATL ACAD SCI USA, V94, P5213, DOI 10.1073/pnas.94.10.5213; Blanchard JL, 1996, MOL BIOL EVOL, V13, P537, DOI 10.1093/oxfordjournals.molbev.a025614; Byers B, 1981, MOL BIOL YEAST SACCH, P59; Churcher C, 1997, NATURE, V387, P84, DOI 10.1038/387s084; DEZAMAROCZY M, 1986, GENE, V47, P155, DOI 10.1016/0378-1119(86)90060-0; Fairhead C, 1998, GENE, V223, P33, DOI 10.1016/S0378-1119(98)00171-1; Fairhead C, 1996, YEAST, V12, P1439; FAIRHEAD C, 1993, MOL GEN GENET, V240, P170, DOI 10.1007/BF00277054; FARRELLY F, 1983, NATURE, V301, P296, DOI 10.1038/301296a0; Feuermann M, 1997, YEAST, V13, P861, DOI 10.1002/(SICI)1097-0061(199707)13:9<861::AID-YEA125>3.3.CO;2-0; Foury F, 1998, FEBS LETT, V440, P325, DOI 10.1016/S0014-5793(98)01467-7; Goffeau A, 1996, SCIENCE, V274, P546, DOI 10.1126/science.274.5287.546; Gorbunova V, 1997, NUCLEIC ACIDS RES, V25, P4650, DOI 10.1093/nar/25.22.4650; HAUSWIRTH WW, 1987, MITOCHONDRIA, P171; KRAMER KM, 1994, MOL CELL BIOL, V14, P1293, DOI 10.1128/MCB.14.2.1293; LOUIS EJ, 1991, CURR GENET, V20, P411, DOI 10.1007/BF00317070; MARGULIS L, 1970, P349; Moore JK, 1996, NATURE, V383, P644, DOI 10.1038/383644a0; Perna NT, 1996, CURR BIOL, V6, P128, DOI 10.1016/S0960-9822(02)00441-4; RESNICK MA, 1976, MOL GEN GENET, V143, P119, DOI 10.1007/BF00266917; Roth D., 1988, GENETIC RECOMBINATIO, P621; ROTH DB, 1986, MOL CELL BIOL, V6, P4295, DOI 10.1128/MCB.6.12.4295; Sargent RG, 1997, MOL CELL BIOL, V17, P267, DOI 10.1128/MCB.17.1.267; SCHIESTL RH, 1993, MOL CELL BIOL, V13, P2697, DOI 10.1128/MCB.13.5.2697; Teng SC, 1996, NATURE, V383, P641, DOI 10.1038/383641a0; Thorsness PE, 1996, INT REV CYTOL, V165, P207, DOI 10.1016/S0074-7696(08)62223-8; THORSNESS PE, 1993, GENETICS, V134, P21; THORSNESS PE, 1990, NATURE, V346, P376, DOI 10.1038/346376a0; WACH A, 1994, YEAST, V10, P1793, DOI 10.1002/yea.320101310; Wolfe KH, 1997, NATURE, V387, P708, DOI 10.1038/42711	30	185	192	0	17	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	NOV 4	1999	402	6757					96	100		10.1038/47076	http://dx.doi.org/10.1038/47076			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	254XC	10573425				2022-12-01	WOS:000083638600051
J	Krumholz, HM; Radford, MJ; Wang, Y; Chen, J; Marciniak, TA				Krumholz, HM; Radford, MJ; Wang, Y; Chen, J; Marciniak, TA			Early beta-blocker therapy for acute myocardial infarction in elderly patients	ANNALS OF INTERNAL MEDICINE			English	Article						myocardial infarction; age factors; adrenergic beta-antagonists; time factors; outcome assessment (health care)	COOPERATIVE CARDIOVASCULAR PROJECT; MEDICARE PATIENTS; GUIDELINES; MORTALITY; QUALITY; CARE	Background: Despite the evidence supporting the importance of early beta-blocker therapy, this intervention has received little attention as an indicator of quality of care. Objectives: To determine how often beta-blockers are administered as early treatment of acute myocardial infarction in patients 65 years of age or older, to identify predictors of the decision to use beta-blockers, and to evaluate the association between the early use of beta-blockers and in-hospital mortality. Design: Observational study. Setting: Nongovernment, acute care hospitals in the United States. Patients: Medicare beneficiaries who were 65 years of age or older, were hospitalized with an acute myocardial infarction in 1994 and 1995, and did not have a contraindication to beta-blocker therapy. Measurements: Medical chart review to obtain information about the use of beta-blockers, contraindications to these drugs, patient demographics, and clinical factors. Results: Of the 58 165 patients (from a total of 4414 hospitals), 28 256 (49%) received early beta-blocker therapy. Patients with the highest risk for in-hospital death were the least likely to receive therapy. Patients who received beta-blockers had a lower in-hospital mortality rate than patients who did not receive beta-blockers (odds ratio, 0.81 [95% CI, 0.75 to 0.87]), even after adjustment for baseline differences in demographic, clinical, and treatment characteristics between the two groups. Conclusions: Early beta-blocker therapy was not used for 51% of elderly patients who were hospitalized with an acute myocardial infarction and did not have a contraindication to this therapy. Increasing the early use of beta-blockers for these patients would provide an excellent opportunity to improve their care and outcomes.	Yale Univ, Sch Med, New Haven, CT 06520 USA; Yale New Haven Med Ctr, Ctr Outcomes Res & Evaluat, New Haven, CT USA; US Hlth Care Financing Adm, Baltimore, MD 21244 USA	Yale University; Yale University	Krumholz, HM (corresponding author), Yale Univ, Sch Med, 333 Cedar St,Room IE-61 SHM, New Haven, CT 06520 USA.	harlan.krumholz@yale.edu	, Harlan/AAI-2875-2020	Radford, Martha/0000-0001-7503-9557				[Anonymous], 1986, LANCET, V2, P57; Berger AK, 1998, AM HEART J, V135, P349, DOI 10.1016/S0002-8703(98)70104-8; *BUR CENS, 1991, STAT METR AR DAT BOO; Chen J, 1999, NEW ENGL J MED, V340, P286, DOI 10.1056/NEJM199901283400407; DALEY J, 1988, JAMA-J AM MED ASSOC, V260, P3617, DOI 10.1001/jama.260.24.3617; ELLERBECK EF, 1995, JAMA-J AM MED ASSOC, V273, P1509, DOI 10.1001/jama.273.19.1509; FLEMING C, 1992, MED CARE, V30, P377, DOI 10.1097/00005650-199205000-00001; GOLDMAN L, 1988, NEW ENGL J MED, V319, P152, DOI 10.1056/NEJM198807213190306; HANLEY JA, 1982, RADIOLOGY, V143, P29, DOI 10.1148/radiology.143.1.7063747; HJALMARSON A, 1981, LANCET, V2, P823; HJALMARSON A, 1985, EUR HEART J, V6, P199; HJALMARSON A, 1985, AM J CARDIOL, V56, pG15; HOSMER DW, 1988, BIOMETRICAL J, V30, P911, DOI 10.1002/bimj.4710300805; KNAUS WA, 1985, CRIT CARE MED, V13, P818, DOI 10.1097/00003246-198510000-00009; Krumholz HM, 1998, JAMA-J AM MED ASSOC, V280, P623, DOI 10.1001/jama.280.7.623; McLaughlin TJ, 1996, ARCH INTERN MED, V156, P799, DOI 10.1001/archinte.156.7.799; *NAT COMM QUAL ASS, 1997, HLTH PLAN EMPL DAT I; Ryan TJ, 1996, J AM COLL CARDIOL, V28, P1328; SEDERHOLM M, 1984, NEW ENGL J MED, V310, P9; Soumeral SB, 1997, JAMA-J AM MED ASSOC, V277, P115, DOI 10.1001/jama.277.2.115; YUSUF S, 1985, PROG CARDIOVASC DIS, V27, P335, DOI 10.1016/S0033-0620(85)80003-7	21	78	81	1	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	NOV 2	1999	131	9					648	+		10.7326/0003-4819-131-9-199911020-00003	http://dx.doi.org/10.7326/0003-4819-131-9-199911020-00003			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	251LB	10577326				2022-12-01	WOS:000083446200002
J	Sutton, KG; McRory, JE; Guthrie, H; Murphy, TH; Snutch, TP				Sutton, KG; McRory, JE; Guthrie, H; Murphy, TH; Snutch, TP			P/Q-type calcium channels mediate the activity-dependent feedback of syntaxin-1A	NATURE			English	Article							BRAIN CA2+ CHANNELS; GENE-EXPRESSION; TRANSCRIPTION; NEURONS; PROTEIN; CREB; PHOSPHORYLATION; IDENTIFICATION; COMPLEX; FORMS	Spatial and temporal changes in intracellular calcium concentrations are critical for controlling gene expression in neurons(1-5). In many neurons, activity-dependent calcium influx through L-type channels stimulates transcription that depends on the transcription factor CREB by activating a calmodulin-dependent pathway(6-11). Here we show that selective influx of calcium through P/Q-type channels(12-14) is responsible for activating expression of syntaxin-1A, a presynaptic protein that mediates vesicle docking, fusion and neurotransmitter release. The initial P/Q-type calcium signal is amplified by release of calcium from intracellular stores and acts through phosphorylation that is dependent on the calmodulin-dependent kinase CaM K II/IV, protein kinase A and mitogen-activated protein kinase kinase, Initiation of syntaxin-1A expression is rapid and short-lived, with syntaxin-1A ultimately interacting with the P/Q-type calcium channel to decrease channel availability. Our results define an activity-dependent feedback pathway that may regulate synaptic efficacy and function in the nervous system.	Univ British Columbia, Dept Psychiat, Biotechnol Lab, Vancouver, BC V6T 1Z3, Canada; Univ British Columbia, Dept Psychiat, Kinsmen Lab Neurol Res, Vancouver, BC V6T 1Z3, Canada	University of British Columbia; University of British Columbia	Snutch, TP (corresponding author), Univ British Columbia, Dept Psychiat, Biotechnol Lab, Vancouver, BC V6T 1Z3, Canada.	snutch@zoology.ubc.ca	Snutch, Terrance P/L-3464-2019; Murphy, Timothy/AAW-1975-2021; Murphy, Timothy H/I-4982-2014	Snutch, Terrance P/0000-0001-5182-1296; Murphy, Timothy/0000-0002-0093-4490; Murphy, Timothy H/0000-0002-0093-4490				BADING H, 1993, SCIENCE, V260, P181, DOI 10.1126/science.8097060; Betz A, 1997, J BIOL CHEM, V272, P2520; BEZPROZVANNY I, 1995, NATURE, V378, P623, DOI 10.1038/378623a0; Bito H, 1996, CELL, V87, P1203, DOI 10.1016/S0092-8674(00)81816-4; Bito H, 1997, CURR OPIN NEUROBIOL, V7, P419, DOI 10.1016/S0959-4388(97)80072-4; Bourinet E, 1999, NAT NEUROSCI, V2, P407, DOI 10.1038/8070; Carrion AM, 1999, NATURE, V398, P80, DOI 10.1038/18044; Daly C, 1997, J NEUROSCI, V17, P2365; Deisseroth K, 1996, NEURON, V16, P89, DOI 10.1016/S0896-6273(00)80026-4; Deisseroth K, 1998, NATURE, V392, P198, DOI 10.1038/32448; Dolmetsch RE, 1997, NATURE, V386, P855, DOI 10.1038/386855a0; Fujita Y, 1998, NEURON, V20, P905, DOI 10.1016/S0896-6273(00)80472-9; Gafni J, 1997, NEURON, V19, P723, DOI 10.1016/S0896-6273(00)80384-0; GHOSH A, 1995, SCIENCE, V268, P239, DOI 10.1126/science.7716515; GINTY DD, 1994, CELL, V77, P713, DOI 10.1016/0092-8674(94)90055-8; GONZALEZ GA, 1989, CELL, V59, P675, DOI 10.1016/0092-8674(89)90013-5; Hardingham GE, 1997, NATURE, V385, P260, DOI 10.1038/385260a0; HONER WG, 1993, BRAIN RES, V609, P9, DOI 10.1016/0006-8993(93)90848-H; Kim K, 1997, P NATL ACAD SCI USA, V94, P14782, DOI 10.1073/pnas.94.26.14782; Li WH, 1998, NATURE, V392, P936, DOI 10.1038/31965; LLINAS R, 1989, P NATL ACAD SCI USA, V86, P1689, DOI 10.1073/pnas.86.5.1689; MartinMoutot N, 1996, J BIOL CHEM, V271, P6567, DOI 10.1074/jbc.271.12.6567; MINTZ IM, 1992, NEURON, V9, P85, DOI 10.1016/0896-6273(92)90223-Z; PEVSNER J, 1994, NEURON, V13, P353, DOI 10.1016/0896-6273(94)90352-2; Rettig J, 1996, P NATL ACAD SCI USA, V93, P7363, DOI 10.1073/pnas.93.14.7363; SHENG ZH, 1994, NEURON, V13, P1303, DOI 10.1016/0896-6273(94)90417-0; Sheng ZH, 1998, J BIOENERG BIOMEMBR, V30, P335, DOI 10.1023/A:1021985521748; Shieh PB, 1998, NEURON, V20, P727, DOI 10.1016/S0896-6273(00)81011-9; Tao X, 1998, NEURON, V20, P709, DOI 10.1016/S0896-6273(00)81010-7; Williamson LC, 1996, J BIOL CHEM, V271, P7694, DOI 10.1074/jbc.271.13.7694	30	101	106	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	OCT 21	1999	401	6755					800	804		10.1038/44586	http://dx.doi.org/10.1038/44586			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	250BG	10548106				2022-12-01	WOS:000083368700055
J	Yang, D; Chertov, O; Bykovskaia, N; Chen, Q; Buffo, MJ; Shogan, J; Anderson, M; Schroder, JM; Wang, JM; Howard, OMZ; Oppenheim, JJ				Yang, D; Chertov, O; Bykovskaia, N; Chen, Q; Buffo, MJ; Shogan, J; Anderson, M; Schroder, JM; Wang, JM; Howard, OMZ; Oppenheim, JJ			beta-defensins: Linking innate and adaptive immunity through dendritic and T cell CCR6	SCIENCE			English	Article							CHEMOKINE RECEPTOR; CYSTIC-FIBROSIS; PROTEIN; PEPTIDE; HIV-1; IDENTIFICATION; INTERACTS; MIGRATION; RANTES; PLASMA	Defensins contribute to host defense by disrupting the cytoplasmic membrane of microorganisms. This report shows that human beta-defensins are also chemotactic for immature dendritic cells and memory T cells. Human beta-defensin was selectively chemotactic for cells stably transfected to express human CCR6, a chemokine receptor preferentially expressed by immature dendritic cells and memory T cells. The beta-defensin-induced chemotaxis was sensitive to pertussis toxin and inhibited by antibodies to CCR6. The binding of iodinated LARC, the chemokine Ligand for CCR6, to CCR6-transfected cells was competitively displaced by beta-defensin. Thus, beta-defensins may promote adaptive immune responses by recruiting dendritic and T cells to the site of microbial invasion through interaction with CCR6.	NCI, Mol Immunoregulat Lab, Div Basic Sci, SAIC Frederick,Frederick Canc Res & Dev Ctr, Frederick, MD 21702 USA; NCI, Intramural Res Support Program, SAIC Frederick, Frederick Canc Res & Dev Ctr, Frederick, MD 21702 USA; Allegheny Univ Hlth Sci, Pittsburgh, PA 15212 USA; Magainin Res Inst, Plymouth Meeting, PA 19642 USA; Univ Kiel, Dept Dermatol, D-24105 Kiel, Germany	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; University of Kiel	Oppenheim, JJ (corresponding author), NCI, Mol Immunoregulat Lab, Div Basic Sci, SAIC Frederick,Frederick Canc Res & Dev Ctr, Frederick, MD 21702 USA.	oppenhei@mail.ncifcrf.gov	Schroeder, Jens M/B-3994-2009; Howard, O M Zack/B-6117-2012	Howard, O M Zack/0000-0002-0505-7052; Chertov, Oleg/0000-0002-0426-2521	NCI NIH HHS [N01-CO-56000] Funding Source: Medline; NATIONAL CANCER INSTITUTE [Z01BC009369] Funding Source: NIH RePORTER; OFFICE OF THE DIRECTOR, NCI [N01CO056000] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); OFFICE OF THE DIRECTOR, NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Albini A, 1998, P NATL ACAD SCI USA, V95, P13153, DOI 10.1073/pnas.95.22.13153; Banchereau J, 1998, NATURE, V392, P245, DOI 10.1038/32588; BENBARUCH A, 1995, J BIOL CHEM, V270, P22123, DOI 10.1074/jbc.270.38.22123; BENSCH KW, 1995, FEBS LETT, V368, P331, DOI 10.1016/0014-5793(95)00687-5; BROEKAERT WF, 1995, PLANT PHYSIOL, V108, P1353, DOI 10.1016/j.chiabu.2021.105188; Chertov O, 1996, J BIOL CHEM, V271, P2935, DOI 10.1074/jbc.271.6.2935; Diamond G, 1996, P NATL ACAD SCI USA, V93, P5156, DOI 10.1073/pnas.93.10.5156; Dieu MC, 1998, J EXP MED, V188, P373, DOI 10.1084/jem.188.2.373; FALK W, 1980, J IMMUNOL METHODS, V33, P239, DOI 10.1016/S0022-1759(80)80014-7; FEHLBAUM P, 1994, J BIOL CHEM, V269, P33159; GANZ T, 1994, CURR OPIN IMMUNOL, V6, P584, DOI 10.1016/0952-7915(94)90145-7; Goldman MJ, 1997, CELL, V88, P553, DOI 10.1016/S0092-8674(00)81895-4; GranelliPiperno A, 1996, J EXP MED, V184, P2433, DOI 10.1084/jem.184.6.2433; Greaves DR, 1997, J EXP MED, V186, P837, DOI 10.1084/jem.186.6.837; Harder J, 1997, NATURE, V387, P861, DOI 10.1038/43088; Hiratsuka T, 1998, BIOCHEM BIOPH RES CO, V249, P943, DOI 10.1006/bbrc.1998.9239; Lillard JW, 1999, P NATL ACAD SCI USA, V96, P651, DOI 10.1073/pnas.96.2.651; Prohaszka Z, 1997, MOL IMMUNOL, V34, P809, DOI 10.1016/S0161-5890(97)00097-7; Raport CJ, 1996, J BIOL CHEM, V271, P17161, DOI 10.1074/jbc.271.29.17161; Rollins BJ, 1997, BLOOD, V90, P909, DOI 10.1182/blood.V90.3.909.909_909_928; Smith JJ, 1996, CELL, V85, P229, DOI 10.1016/S0092-8674(00)81099-5; Stolzenberg ED, 1997, P NATL ACAD SCI USA, V94, P8686, DOI 10.1073/pnas.94.16.8686; Ueda H, 1997, J BIOL CHEM, V272, P24966, DOI 10.1074/jbc.272.40.24966; Weissman D, 1997, NATURE, V389, P981, DOI 10.1038/40173; Xu LL, 1996, J LEUKOCYTE BIOL, V60, P365, DOI 10.1002/jlb.60.3.365; Yang D., UNPUB	26	1415	1550	0	58	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 15	1999	286	5439					525	528		10.1126/science.286.5439.525	http://dx.doi.org/10.1126/science.286.5439.525			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	245RD	10521347				2022-12-01	WOS:000083121200059
J	Hamburger, ZA; Brown, MS; Isberg, RR; Bjorkman, PJ				Hamburger, ZA; Brown, MS; Isberg, RR; Bjorkman, PJ			Crystal structure of invasin: A bacterial integrin-binding protein	SCIENCE			English	Article							CELL-ADHESION MOLECULE-1; YERSINIA-PSEUDOTUBERCULOSIS; MAMMALIAN-CELLS; LIGAND INTERACTION; RECEPTOR; IDENTIFICATION; DOMAINS; INTERNALIZATION; FIBRONECTIN; LOOP	The Yersinia pseudotuberculosis invasin protein promotes bacterial entry by binding to host cell integrins with higher affinity than natural substrates such as fibronectin, The 2.3 angstrom crystal structure of the invasin extracellular region reveals five domains that form a 180 angstrom rod with structural similarities to tandem fibronectin type III domains. The integrin-binding surfaces of invasin and fibronectin include similarly Located key residues, but in the context of different folds and surface shapes. The structures of invasin and fibronectin provide an example of convergent evolution, in which invasin presents an optimized surface for integrin binding, in comparison with host substrates.	CALTECH, Div Biol 156 29, Pasadena, CA 91125 USA; CALTECH, Howard Hughes Med Inst, Pasadena, CA 91125 USA; Tufts Univ, Sch Med, Howard Hughes Med Inst, Dept Mol Biol & Microbiol, Boston, MA 02111 USA	California Institute of Technology; California Institute of Technology; Howard Hughes Medical Institute; Howard Hughes Medical Institute; Tufts University	Bjorkman, PJ (corresponding author), CALTECH, Div Biol 156 29, Pasadena, CA 91125 USA.	bjorkman@cco.caltech.edu						Abagyan RA, 1997, J MOL BIOL, V273, P355, DOI 10.1006/jmbi.1997.1287; Abrahams JP, 1996, ACTA CRYSTALLOGR D, V52, P30, DOI 10.1107/S0907444995008754; Autenrieth IB, 1996, J MED MICROBIOL, V44, P285, DOI 10.1099/00222615-44-4-285; Bella J, 1998, P NATL ACAD SCI USA, V95, P4140, DOI 10.1073/pnas.95.8.4140; BOWDITCH RD, 1994, J BIOL CHEM, V269, P10856; Boyington JC, 1999, IMMUNITY, V10, P75, DOI 10.1016/S1074-7613(00)80008-4; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Casasnovas JM, 1998, P NATL ACAD SCI USA, V95, P4134, DOI 10.1073/pnas.95.8.4134; CHOTHIA C, 1986, EMBO J, V5, P823, DOI 10.1002/j.1460-2075.1986.tb04288.x; delaFortelle E, 1997, METHOD ENZYMOL, V276, P472, DOI 10.1016/S0076-6879(97)76073-7; Dersch P, 1999, EMBO J, V18, P1199, DOI 10.1093/emboj/18.5.1199; Diederichs K, 1998, PROTEIN SCI, V7, P2413, DOI 10.1002/pro.5560071119; Eble JA, 1998, BIOCHEMISTRY-US, V37, P10945, DOI 10.1021/bi980175+; Ferguson AD, 1998, SCIENCE, V282, P2215, DOI 10.1126/science.282.5397.2215; GRAVES BJ, 1994, NATURE, V367, P532, DOI 10.1038/367532a0; HARPAZ Y, 1994, J MOL BIOL, V238, P528, DOI 10.1006/jmbi.1994.1312; HENDRICKSON WA, 1990, EMBO J, V9, P1665, DOI 10.1002/j.1460-2075.1990.tb08287.x; HODEL A, 1992, ACTA CRYSTALLOGR A, V48, P851, DOI 10.1107/S0108767392006044; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; Isberg Ralph R., 1994, Trends in Microbiology, V2, P10, DOI 10.1016/0966-842X(94)90338-7; ISBERG RR, 1993, J BIOL CHEM, V268, P15840; ISBERG RR, 1987, CELL, V50, P769, DOI 10.1016/0092-8674(87)90335-7; ISBERG RR, 1990, CELL, V60, P861, DOI 10.1016/0092-8674(90)90099-Z; Jap BK, 1996, PHYSIOL REV, V76, P1073, DOI 10.1152/physrev.1996.76.4.1073; JONES EY, 1995, NATURE, V373, P539, DOI 10.1038/373539a0; Jones TA, 1997, METHOD ENZYMOL, V277, P173, DOI 10.1016/S0076-6879(97)77012-5; Kelly G, 1999, NAT STRUCT BIOL, V6, P313; Kenny B, 1997, CELL, V91, P511, DOI 10.1016/S0092-8674(00)80437-7; Kleywegt GJ, 1996, ACTA CRYSTALLOGR D, V52, P826, DOI 10.1107/S0907444995014983; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Krukonis ES, 1998, J BIOL CHEM, V273, P31837, DOI 10.1074/jbc.273.48.31837; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Leahy DJ, 1996, CELL, V84, P155, DOI 10.1016/S0092-8674(00)81002-8; LEONG JM, 1993, J BIOL CHEM, V268, P20524; LEONG JM, 1990, EMBO J, V9, P1979, DOI 10.1002/j.1460-2075.1990.tb08326.x; LEONG JM, 1995, EMBO J, V14, P422, DOI 10.1002/j.1460-2075.1995.tb07018.x; Liu H, 1999, INFECT IMMUN, V67, P2045; Locher KP, 1998, CELL, V95, P771, DOI 10.1016/S0092-8674(00)81700-6; Marra A, 1997, INFECT IMMUN, V65, P3412, DOI 10.1128/IAI.65.8.3412-3421.1997; Matsumoto N, 1998, IMMUNITY, V8, P245, DOI 10.1016/S1074-7613(00)80476-8; McRee D.E., 1999, PRACTICAL PROTEIN CR, V2nd ed., P91; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; NHIEU GTV, 1991, J BIOL CHEM, V266, P24367; NICHOLLS A, 1993, BIOPHYS J, V64, pA166; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; PEPE JC, 1993, INFECT AGENT DIS, V2, P236; READ RJ, 1986, ACTA CRYSTALLOGR A, V42, P140, DOI 10.1107/S0108767386099622; Richardson J S, 1981, Adv Protein Chem, V34, P167, DOI 10.1016/S0065-3233(08)60520-3; Saltman LH, 1996, J BIOL CHEM, V271, P23438, DOI 10.1074/jbc.271.38.23438; Sharma A, 1999, EMBO J, V18, P1468, DOI 10.1093/emboj/18.6.1468; Soltis SM, 1997, J APPL CRYSTALLOGR, V30, P190, DOI 10.1107/S0021889896012939; Su XD, 1998, SCIENCE, V281, P991, DOI 10.1126/science.281.5379.991; TAKADA Y, 1992, J CELL BIOL, V119, P913, DOI 10.1083/jcb.119.4.913; Tao YZ, 1997, STRUCTURE, V5, P789, DOI 10.1016/S0969-2126(97)00233-5; VANNHIEU GT, 1993, EMBO J, V12, P1887, DOI 10.1002/j.1460-2075.1993.tb05837.x; VanNhieu GT, 1996, J BIOL CHEM, V271, P7665, DOI 10.1074/jbc.271.13.7665; WANG JH, 1995, P NATL ACAD SCI USA, V92, P5714, DOI 10.1073/pnas.92.12.5714; WEIS WI, 1994, STRUCTURE, V2, P1227, DOI 10.1016/S0969-2126(94)00124-3; Weis WI, 1998, IMMUNOL REV, V163, P19, DOI 10.1111/j.1600-065X.1998.tb01185.x; Worley MJ, 1998, MOL MICROBIOL, V29, P1471, DOI 10.1046/j.1365-2958.1998.01030.x; YU J, 1992, MOL MICROBIOL, V6, P411, DOI 10.1111/j.1365-2958.1992.tb01484.x	62	224	230	0	12	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 8	1999	286	5438					291	295		10.1126/science.286.5438.291	http://dx.doi.org/10.1126/science.286.5438.291			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	243YE	10514372				2022-12-01	WOS:000083024400044
J	Steinmann, T; Geldner, N; Grebe, M; Mangold, S; Jackson, CL; Paris, S; Galweiler, L; Palme, K; Jurgens, G				Steinmann, T; Geldner, N; Grebe, M; Mangold, S; Jackson, CL; Paris, S; Galweiler, L; Palme, K; Jurgens, G			Coordinated polar localization of auxin efflux carrier PIN1 by GNOM ARF GEF	SCIENCE			English	Article							ARABIDOPSIS GENE MONOPTEROS; PATTERN-FORMATION; BREFELDIN-A; TRANSCRIPTION FACTOR; VASCULAR DEVELOPMENT; NUCLEOTIDE EXCHANGE; PROTEIN; EMBRYO; CELLS; REDISTRIBUTION	The plant hormone auxin is transported in a polar manner along the shoot-root axis, which requires efflux carriers such as PIN1. Asymmetric localization-of PIN1 develops from a random distribution in Arabidopsis early embryogenesis. Coordinated polar localization of PIN1 is defective in gnom embryos. GNOM is a membrane-associated guanine-nucleotide exchange factor on ADP-ribosylation factor G protein (ARF GEF). Thus, GNOM-dependent vesicle trafficking may establish cell polarity, resulting in polar auxin transport.	Univ Tubingen, Zentrum Mol Biol Pflanzen, D-72076 Tubingen, Germany; CEA Saclay, Serv Biochim & Genet Mol, F-91191 Gif Sur Yvette, France; CNRS, Inst Pharmacol Mol & Cellulaire, F-06560 Valbonne, France; Max Planck Gesell, Max Delbruck Lab, D-50829 Cologne, Germany	Eberhard Karls University of Tubingen; CEA; UDICE-French Research Universities; Universite Paris Saclay; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Cote d'Azur; Max Planck Society	Jurgens, G (corresponding author), Univ Tubingen, Zentrum Mol Biol Pflanzen, Morgenstelle 1, D-72076 Tubingen, Germany.		Palme, Klaus/A-9524-2013; Geldner, Niko/Y-2481-2019; Jackson, Catherine/T-5688-2019; Jackson, Catherine/A-3421-2013	Palme, Klaus/0000-0002-2728-3835; Jackson, Catherine/0000-0002-0843-145X; Geldner, Niko/0000-0002-2300-9644; Grebe, Markus/0000-0001-7571-0670				BERLETH T, 1993, DEVELOPMENT, V118, P575; Busch M, 1996, MOL GEN GENET, V250, P681, DOI 10.1007/s004380050121; Delbarre A, 1998, PLANT PHYSIOL, V116, P833, DOI 10.1104/pp.116.2.833; FRANCO M, 1995, J BIOL CHEM, V270, P1337, DOI 10.1074/jbc.270.3.1337; Galweiler L, 1998, SCIENCE, V282, P2226, DOI 10.1126/science.282.5397.2226; Hadfi K, 1998, DEVELOPMENT, V125, P879; Hamann T, 1999, DEVELOPMENT, V126, P1387; Hardtke CS, 1998, EMBO J, V17, P1405, DOI 10.1093/emboj/17.5.1405; Jurgens G, 1994, COLOUR ATLAS DEV EMB EMBRYOS COLOR ATLAS, P7; Lauber MH, 1997, J CELL BIOL, V139, P1485, DOI 10.1083/jcb.139.6.1485; LIPPINCOTTSCHWARTZ J, 1989, CELL, V56, P801, DOI 10.1016/0092-8674(89)90685-5; MAYER U, 1993, DEVELOPMENT, V117, P149; Morris DA, 1998, PLANTA, V205, P606, DOI 10.1007/s004250050363; Park JM, 1997, PLANT PHYSIOL, V115, P763, DOI 10.1104/pp.115.2.763; Peyroche A, 1999, MOL CELL, V3, P275, DOI 10.1016/S1097-2765(00)80455-4; Peyroche A, 1996, NATURE, V384, P479, DOI 10.1038/384479a0; Przemeck GKH, 1996, PLANTA, V200, P229, DOI 10.1007/BF00208313; SACHS T, 1991, DEVELOPMENT S, V1, P83; SATIATJEUNEMAITRE B, 1992, J CELL SCI, V103, P1153; Ulmasov T, 1997, SCIENCE, V276, P1865, DOI 10.1126/science.276.5320.1865; Vroemen CW, 1996, PLANT CELL, V8, P783, DOI 10.1105/tpc.8.5.783; WENT FW, 1929, REC TRAV BOT NEERL, V25, P1	22	564	597	5	88	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	OCT 8	1999	286	5438					316	318		10.1126/science.286.5438.316	http://dx.doi.org/10.1126/science.286.5438.316			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	243YE	10514379				2022-12-01	WOS:000083024400051
J	Heron, E; Lozinguez, O; Emmerich, J; Laurian, C; Fiessinger, JN				Heron, E; Lozinguez, O; Emmerich, J; Laurian, C; Fiessinger, JN			Long-term sequelae of spontaneous axillary-subclavian venous thrombosis	ANNALS OF INTERNAL MEDICINE			English	Article							DEEP-VEIN THROMBOSIS; UPPER-EXTREMITY; PAIN	Background: The frequency and severity of post-thrombotic sequelae after spontaneous axillary-subclavian venous thrombosis remain poorly known. Objective: To determine the late sequelae of conventionally treated spontaneous axillary-subclavian venous thrombosis. Design: Cross-sectional study. Setting: University department of vascular medicine. Patients: 54 patients seen during an 18-year period (mean follow-up, 5 years). Measurements: Scores for the severity of post-thrombotic symptoms were graded on a numerical rating scale ranging from 0 to 10 and on a 6-point verbal rating scale. Ultrasonographic sequelae were classified as grade 0, normal flow; grade 1, moderate obstruction; or grade 2, severe obstruction or occlusion. Results: Verbal scores were "nil/negligible" in 47% of patients and "severe/intolerable" in 13%; numerical scores were 0 to 3 in 78% of patients and 7 to 10 in 9%. Grade 2 ultrasonographic sequelae were found in 22% of cases. No relation was seen between ultrasonographic sequelae and symptom severity scores. Conclusion: The overall clinical outcome of spontaneous axillary-subclavian venous thrombosis is good, and there is no relation between the severity of late symptoms and ultrasonographic sequelae.	Hop Broussais, Serv Med Vasc, F-75674 Paris 14, France; Hop Broussais, Ctr Blaude Bernard Rech Malad Vasc Peripher, F-75674 Paris 14, France; Hop St Joseph, Serv Chirurg Vasc, F-75674 Paris 14, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Europeen Georges-Pompidou - APHP; UDICE-French Research Universities; Universite Paris Cite; Hopital Paris Saint-Joseph; UDICE-French Research Universities; Universite Paris Cite	Fiessinger, JN (corresponding author), Hop Broussais, Serv Med Vasc, 96 Rue Didot, F-75674 Paris 14, France.							ADAMS JT, 1965, ARCH SURG-CHICAGO, V91, P29; AMELI FM, 1987, CAN J SURG, V30, P167; BECKER DM, 1991, ARCH INTERN MED, V151, P1934, DOI 10.1001/archinte.151.10.1934; DOWNIE WW, 1978, ANN RHEUM DIS, V37, P378, DOI 10.1136/ard.37.4.378; Elliott G, 1997, LANCET, V349, P1188, DOI 10.1016/S0140-6736(05)62408-7; GLOVICZKI P, 1986, J VASC SURG, V4, P333, DOI 10.1067/mva.1986.avs0040333; GRASSI CJ, 1990, RADIOLOGY, V175, P651, DOI 10.1148/radiology.175.3.2188295; HAIRE WD, 1995, CLIN CHEST MED, V16, P341; HOUDE RW, 1982, ACTA ANAESTH SCAND, V26, P25, DOI 10.1111/j.1399-6576.1982.tb01840.x; HUSKISSON EC, 1974, LANCET, V2, P1127, DOI 10.1016/S0140-6736(74)90884-8; JENSEN MP, 1994, PAIN, V58, P387, DOI 10.1016/0304-3959(94)90133-3; Lindblad B, 1988, Eur J Vasc Surg, V2, P161, DOI 10.1016/S0950-821X(88)80069-0; MACHLEDER HI, 1993, J VASC SURG, V17, P305, DOI 10.1016/0741-5214(93)90416-J; Meier GH, 1996, J VASC SURG, V24, P974, DOI 10.1016/S0741-5214(96)70043-5; MOLINA JE, 1995, J AM COLL SURGEONS, V181, P414; Prandoni P, 1997, ARCH INTERN MED, V157, P57, DOI 10.1001/archinte.157.1.57; RICHARD HM, 1992, RADIOGRAPHICS, V12, P527, DOI 10.1148/radiographics.12.3.1609143; TILNEY NL, 1970, ARCH SURG-CHICAGO, V101, P792	18	49	49	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	OCT 5	1999	131	7					510	513		10.7326/0003-4819-131-7-199910050-00006	http://dx.doi.org/10.7326/0003-4819-131-7-199910050-00006			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	243VU	10507960				2022-12-01	WOS:000083018800005
J	Montagne, J; Stewart, MJ; Stocker, H; Hafen, E; Kozma, SC; Thomas, G				Montagne, J; Stewart, MJ; Stocker, H; Hafen, E; Kozma, SC; Thomas, G			Drosophila S6 kinase: A regulator of cell size	SCIENCE			English	Article							RECEPTOR TYROSINE KINASE; WING DEVELOPMENT; GROWTH; MELANOGASTER; COORDINATION; ACTIVATION; DIVISION; PROTEIN; CYCLE; DISKS	Cell proliferation requires cell growth; that is. cells only divide after they reach a critical size. However, the mechanisms by which cells grow and maintain their appropriate size have remained elusive. Drosophila deficient in the S6 kinase gene (dS6K) exhibited an extreme delay in development and a severe reduction in body size. These flies had smaller cells rather than fewer cells. The effect was cell-autonomous, displayed throughout Larval development, and distinct from that of ribosomal protein mutants (Minutes). Thus, the dS6K gene product regulates cell size in a cell-autonomous manner without impinging on cell number.	Friedrich Miescher Inst, CH-4056 Basel, Switzerland; Univ Zurich, Inst Zool, CH-8057 Zurich, Switzerland	Friedrich Miescher Institute for Biomedical Research; University of Zurich	Thomas, G (corresponding author), Friedrich Miescher Inst, Maulbeerstr 66, CH-4056 Basel, Switzerland.		Thomas, George/K-9235-2014; Stoecker, Horst/F-8382-2012	Thomas, George/0000-0003-3518-8149; Stoecker, Horst/0000-0002-3282-3664	NIGMS NIH HHS [F32 GM15926] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [F32GM015926] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ashburner M., 2004, DROSOPHILA LAB MANUA, V2nd; BASLER K, 1991, CELL, V64, P1069, DOI 10.1016/0092-8674(91)90262-W; BRAND AH, 1993, DEVELOPMENT, V118, P401; Conlon I, 1999, CELL, V96, P235, DOI 10.1016/S0092-8674(00)80563-2; CONSORTIUM TF, 1994, NUCLEIC ACIDS RES, V22, P3456; Dennis PB, 1999, CURR OPIN GENET DEV, V9, P49, DOI 10.1016/S0959-437X(99)80007-0; DIAZBENJUMEA FJ, 1993, CELL, V75, P741, DOI 10.1016/0092-8674(93)90494-B; FAIN MJ, 1982, DEV BIOL, V92, P247, DOI 10.1016/0012-1606(82)90169-5; FRISTROM D, 1993, DEVELOPMENT, V117, P509; GARCIABELLIDO A, 1994, P NATL ACAD SCI USA, V91, P10222, DOI 10.1073/pnas.91.21.10222; GARCIABELLIDO A, 1971, DEV BIOL, V24, P61, DOI 10.1016/0012-1606(71)90047-9; GARCIABELLIDO A, 1973, NATURE-NEW BIOL, V245, P251, DOI 10.1038/newbio245251a0; GAUL U, 1992, CELL, V68, P1007, DOI 10.1016/0092-8674(92)90073-L; GLOOR GB, 1993, GENETICS, V135, P81; Gorfinkiel N, 1997, GENE DEV, V11, P2259, DOI 10.1101/gad.11.17.2259; GRAVES BJ, 1982, DEV BIOL, V93, P104, DOI 10.1016/0012-1606(82)90243-3; Jefferies HBJ, 1997, EMBO J, V16, P3693, DOI 10.1093/emboj/16.12.3693; JOHNSTON GC, 1977, EXP CELL RES, V105, P79, DOI 10.1016/0014-4827(77)90154-9; KARPEN GH, 1992, GENETICS, V132, P737; Lambert A, 1998, REPROD NUTR DEV, V38, P69, DOI 10.1051/rnd:19980106; Laser M, 1998, J BIOL CHEM, V273, P24610, DOI 10.1074/jbc.273.38.24610; Leevers SJ, 1996, EMBO J, V15, P6584, DOI 10.1002/j.1460-2075.1996.tb01049.x; Leibiger IB, 1998, MOL CELL, V1, P933, DOI 10.1016/S1097-2765(00)80093-3; Lindsley D.L., 1992, GENOME DROSOPHILA ME; MADHAVAN MM, 1977, ROUX ARCH DEV BIOL, V183, P269, DOI 10.1007/BF00848459; MITCHISON JM, 1971, BIOL CELL CYCLE; Nasmyth K, 1996, NATURE, V382, P28, DOI 10.1038/382028a0; Nasmyth K, 1993, CURR OPIN CELL BIOL, V5, P166, DOI 10.1016/0955-0674(93)90099-C; Neufeld TP, 1998, CELL, V93, P1183, DOI 10.1016/S0092-8674(00)81462-2; NIELSEN FC, 1995, NATURE, V377, P358, DOI 10.1038/377358a0; Nurse P., 1985, P185; PIRROTTA V, 1986, DROSOPHILA PRACTICAL, P82; RUBIN GM, 1982, SCIENCE, V218, P348, DOI 10.1126/science.6289436; SCHUBIGER M, 1987, DEV BIOL, V123, P145, DOI 10.1016/0012-1606(87)90436-2; Shima H, 1998, EMBO J, V17, P6649, DOI 10.1093/emboj/17.22.6649; Stewart MJ, 1996, P NATL ACAD SCI USA, V93, P10791, DOI 10.1073/pnas.93.20.10791; STEWART MJ, 1993, MOL CELL BIOL, V13, P2524, DOI 10.1128/MCB.13.4.2524; Su TT, 1998, CURR BIOL, V8, pR687, DOI 10.1016/S0960-9822(98)70436-1; THEURKAUF WE, 1986, P NATL ACAD SCI USA, V83, P8477, DOI 10.1073/pnas.83.22.8477; TUCKER JB, 1986, EUR J CELL BIOL, V41, P279; XU T, 1993, DEVELOPMENT, V117, P1223	41	598	616	0	24	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	SEP 24	1999	285	5436					2126	2129		10.1126/science.285.5436.2126	http://dx.doi.org/10.1126/science.285.5436.2126			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	238VF	10497130				2022-12-01	WOS:000082734300042
J	Lindsay, EA; Botta, A; Jurecic, V; Carattini-Rivera, S; Cheah, YC; Rosenblatt, HM; Bradley, A; Baldini, A				Lindsay, EA; Botta, A; Jurecic, V; Carattini-Rivera, S; Cheah, YC; Rosenblatt, HM; Bradley, A; Baldini, A			Congenital heart disease in mice deficient for the DiGeorge syndrome region	NATURE			English	Article							22Q11 DELETIONS; MOUSE; GENE; PAX3	The heterozygous chromosome deletion within the band 22q11 (del22q11) is an important cause of congenital cardiovascular defects(1), It is the genetic basis of DiGeorge syndrome and causes the most common deletion syndrome in humans(2). Because the deleted region is largely conserved in the mouse, we were able to engineer a chromosome deletion (Df1) spanning a segment of the murine region homologous to the human deleted region. Here we describe heterozygously deleted (Df1/+) mice with cardiovascular abnormalities of the same type as those associated with del22q11; we have traced the embryological origin of these abnormalities to defective development of the fourth pharyngeal arch arteries. Genetic complementation of the deletion using a chromosome duplicated for the Df1 DNA segment corrects the heart defects, indicating that they are caused by reduced dosage of genes located within Df1. The Df1/+ mouse model reveals the pathogenic basis of the most clinically severe aspect of DiGeorge syndrome and uncovers a new mechanism leading to aortic arch abnormalities. These mutants represent a mouse model of a human deletion syndrome generated by chromosome engineering.	Baylor Coll Med, Dept Mol & Human Genet, Houston, TX 77030 USA; Baylor Coll Med, Howard Hughes Med Inst, Houston, TX 77030 USA; Baylor Coll Med, Dept Pediat Allergy & Immunol, Houston, TX 77030 USA	Baylor College of Medicine; Baylor College of Medicine; Howard Hughes Medical Institute; Baylor College of Medicine	Baldini, A (corresponding author), Baylor Coll Med, Dept Mol & Human Genet, 1 Baylor Plaza, Houston, TX 77030 USA.		genes, anthony/F-2541-2012; BOTTA, ANNALISA/AAD-1581-2022; botta, annalisa/AAB-8680-2019; Baldini, Antonio/M-2355-2015	BOTTA, ANNALISA/0000-0003-4031-5624; Bradley, Allan/0000-0002-2349-8839; Baldini, Antonio/0000-0002-5330-0256				BALDINI A, 1994, IN SITU HYBRIDIZATIO, P75; Botta A, 1997, MAMM GENOME, V8, P890, DOI 10.1007/s003359900606; Conway SJ, 1997, DEVELOPMENT, V124, P505; Farrell MJ, 1999, CIRC RES, V84, P127, DOI 10.1161/01.RES.84.2.127; Galili N, 1997, GENOME RES, V7, P17, DOI 10.1101/gr.7.1.17; Iida K, 1997, DEVELOPMENT, V124, P4627; Kaufman M.H., 1992, ATLAS MOUSE DEV; Kidd PG, 1997, MANUAL CLIN LAB IMMU, V5th, P229; KIRBY ML, 1999, HEART DEV, P179; KRUISBECK AM, 1991, CURRENT PROTOCOLS IM; KRUISBECK AM, 1993, CURRENT PROTOCOLS IM; KURIHARA Y, 1995, J CLIN INVEST, V96, P293, DOI 10.1172/JCI118033; Lindsay EA, 1998, HUM MOL GENET, V7, P629, DOI 10.1093/hmg/7.4.629; Lindsay EA, 1998, MOL MED TODAY, V4, P350, DOI 10.1016/S1357-4310(98)01302-1; Liu PT, 1998, GENETICS, V150, P1155; Magnaghi P, 1998, NAT GENET, V20, P74, DOI 10.1038/1739; MATZUK MM, 1992, NATURE, V360, P313, DOI 10.1038/360313a0; MCLEOD MJ, 1980, TERATOLOGY, V22, P299, DOI 10.1002/tera.1420220306; Pizzuti A, 1997, HUM MOL GENET, V6, P259, DOI 10.1093/hmg/6.2.259; Puech A, 1997, P NATL ACAD SCI USA, V94, P14608, DOI 10.1073/pnas.94.26.14608; RAMIREZSOLIS R, 1995, NATURE, V378, P720, DOI 10.1038/378720a0; Ryan AK, 1997, J MED GENET, V34, P798, DOI 10.1136/jmg.34.10.798; Sutherland HF, 1998, GENOMICS, V52, P37, DOI 10.1006/geno.1998.5414; WILSON DI, 1994, AM J HUM GENET S, V55, pA975; Yamagishi H, 1999, SCIENCE, V283, P1158, DOI 10.1126/science.283.5405.1158; Yanagisawa H, 1998, J CLIN INVEST, V102, P22, DOI 10.1172/JCI2698	26	309	313	0	10	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	SEP 23	1999	401	6751					379	383		10.1038/43903	http://dx.doi.org/10.1038/43903			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	240JJ	10517636				2022-12-01	WOS:000082822600052
J	Gray, PA; Rekling, JC; Bocchiaro, CM; Feldman, JL				Gray, PA; Rekling, JC; Bocchiaro, CM; Feldman, JL			Modulation of respiratory frequency by peptidergic input to rhythmogenic neurons in the PreBotzinger complex	SCIENCE			English	Article							PRE-BOTZINGER COMPLEX; LATERAL TEGMENTAL FIELD; INFANT-DEATH-SYNDROME; STEM IN-VITRO; BRAIN-STEM; SUBNUCLEAR ORGANIZATION; CEREBROSPINAL-FLUID; INSPIRATORY NEURONS; GENERATION; MAMMALS	Neurokinin-1 receptor (NK1R) and mu-opioid receptor (mu OR) agonists affected respiratory rhythm when injected directly into the preBotzinger Complex (preBotC), the hypothesized site for respiratory rhythmogenesis in mammals. These effects were mediated by actions on preBotC rhythmogenic neurons. The distribution of NK1R(+) neurons anatomically defined the preBotC. Type 1 neurons in the preBotC, which have rhythmogenic properties, expressed both NK1Rs and mu ORs, whereas type 2 neurons expressed only NK1Rs. These findings suggest that the preBotC is a definable anatomic structure with unique physiological function and that a subpopulation of neurons expressing both NK1Rs and mu ORs generate respiratory rhythm and modulate respiratory frequency.	Univ Calif Los Angeles, Dept Neurobiol, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Dept Physiol Sci, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Interdept Program Neurosci PHD, Los Angeles, CA 90095 USA	University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles	Gray, PA (corresponding author), Univ Calif Los Angeles, Dept Neurobiol, Box 951763, Los Angeles, CA 90095 USA.		feldman, jack/AAO-7505-2021	feldman, jack/0000-0003-3692-9412; Rekling, Jens C./0000-0002-8568-2332	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL040959, R37HL037941, R01HL037941] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL40959, R01 HL040959-12, HL37941, R01 HL040959] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BIANCHI AL, 1995, PHYSIOL REV, V75, P1, DOI 10.1152/physrev.1995.75.1.1; BONHAM AC, 1995, RESP PHYSIOL, V101, P219, DOI 10.1016/0034-5687(95)00045-F; Brockhaus J, 1998, EUR J NEUROSCI, V10, P3823, DOI 10.1046/j.1460-9568.1998.00396.x; Butera RJ, 1999, J NEUROPHYSIOL, V82, P398, DOI 10.1152/jn.1999.82.1.398; Butera RJ, 1999, J NEUROPHYSIOL, V82, P382, DOI 10.1152/jn.1999.82.1.382; Carpentier V, 1998, NEUROSCIENCE, V86, P159, DOI 10.1016/S0306-4522(98)00002-5; COQUEREL A, 1992, NEUROCHEM INT, V20, P97, DOI 10.1016/0197-0186(92)90131-A; DOBBINS EG, 1994, J COMP NEUROL, V347, P64, DOI 10.1002/cne.903470106; ELLENBERGER HH, 1990, J COMP NEUROL, V294, P212, DOI 10.1002/cne.902940206; ELLENBERGER HH, 1990, J COMP NEUROL, V294, P202, DOI 10.1002/cne.902940205; FELDMAN JL, 1988, ANNU REV PHYSIOL, V50, P593; FELDMAN JL, 1989, ANN NY ACAD SCI, V563, P114, DOI 10.1111/j.1749-6632.1989.tb42194.x; FIELDS HL, 1985, PHILOS T ROY SOC B, V308, P361, DOI 10.1098/rstb.1985.0037; FLEDMAN JL, 1986, HDB PHYSL NERVOUS SY, P463; Fletcher E C, 1997, Cardiologia, V42, P469; FLETCHER EC, 1986, ABNORMALITIES RESPIR, P203; FUNK GD, 1993, J NEUROPHYSIOL, V70, P1497, DOI 10.1152/jn.1993.70.4.1497; GRAY P, UNPUB; Hsieh JH, 1998, J AUTONOM NERV SYST, V73, P7, DOI 10.1016/S0165-1838(98)00117-9; Johnson SM, 1996, J APPL PHYSIOL, V80, P2120, DOI 10.1152/jappl.1996.80.6.2120; Koshiya N, 1996, J PHYSIOL-LONDON, V491, P859, DOI 10.1113/jphysiol.1996.sp021263; Koshiya N, 1999, NATURE, V400, P360, DOI 10.1038/22540; MCCRIMMON DR, 1995, REGULATION BREATHING, V79, P151; MONNIER A, 1998, SOC NEUR ABSTR, V346, P5; Onimaru H, 1997, JPN J PHYSIOL, V47, P385, DOI 10.2170/jjphysiol.47.385; ORLOWSKI JP, 1986, PEDIATRICS, V78, P233; Ramirez JM, 1998, J PHYSIOL-LONDON, V507, P895, DOI 10.1111/j.1469-7793.1998.895bs.x; Rekling JC, 1998, ANNU REV PHYSIOL, V60, P385, DOI 10.1146/annurev.physiol.60.1.385; Rekling JC, 1996, J NEUROPHYSIOL, V75, P811, DOI 10.1152/jn.1996.75.2.811; Rekling JC, 1996, J NEUROPHYSIOL, V75, P795, DOI 10.1152/jn.1996.75.2.795; REKLING JC, UNPUB; Shao XM, 1997, J NEUROPHYSIOL, V77, P1853, DOI 10.1152/jn.1997.77.4.1853; SMITH JC, 1991, SCIENCE, V254, P726, DOI 10.1126/science.1683005; Thalhofer S, 1997, RESPIRATION, V64, P2	34	469	477	0	15	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 19	1999	286	5444					1566	1568		10.1126/science.286.5444.1566	http://dx.doi.org/10.1126/science.286.5444.1566			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	257DZ	10567264	Green Accepted			2022-12-01	WOS:000083768300060
J	Dundas, S; Murphy, J; Soutar, RL; Jones, GA; Hutchinson, SJ; Todd, WTA				Dundas, S; Murphy, J; Soutar, RL; Jones, GA; Hutchinson, SJ; Todd, WTA			Effectiveness of therapeutic plasma exchange in the 1996 Lanarkshire Escherichia coli O157 : H7 outbreak	LANCET			English	Article							HEMOLYTIC-UREMIC SYNDROME; THROMBOTIC THROMBOCYTOPENIC PURPURA; HEMORRHAGIC COLITIS	Background The haemolytic uraemic syndrome (HUS)/thrombotic thrombocytopenic purpura (TTP) during an Escherichia coli O157 outbreak occurred in 1996 in central Scotland. Adults who develop HUS/TTP induced by E coli O157 tend to be elderly and have a historical mortality rate of almost 90% when treated conservatively, Therefore the decision was made to treat adults who developed HUS/TTP during this outbreak with therapeutic plasma exchange (TPE). We report our outcome with this controversial treatment. largest number of adult cases of uraemic syndrome (HUS)/thrombotic Methods A case definition for HUS/TTP was developed at the beginning of the outbreak. All cases meeting this definition were considered for TPE. Information on demographics, clinical features, treatment and outcome of patients was obtained by retrospective case note review. Findings 22 adults developed HUS/TTP. They had a mean age of 71 years. 16 cases received TPE. Six cases had contraindications to TPE or died before the procedure could be done. Ten of the 22 (45%) adults with HUS/TTP died. Five of the 16 (31%) TPE treated cases died, four of eight aged over 70 years compared with one of eight aged less than 70 years. Premorbid illness, neurological features, treatment with ciprofloxacin or prostacyclin, and the laboratory severity of HUS/TTP were not associated with death; the number of cases, however, was too small to allow statistical conclusion. Interpretation The mortality rate is high in adults who develop HUS/TTP induced by E coli O157. TPE appears to be a promising treatment that was well tolerated in our elderly patients. A national register of adult cases of HUS/TTP induced by E coli O157 should be established.	Monklands Hosp, Dept Infect Dis, Airdrie ML6 0JS, Lanark, Scotland; Monklands Hosp, Dept Haematol, Airdrie ML6 0JS, Lanark, Scotland; Dumfries & Galloway Royal Infirm, Dept Med, Dumfries, Scotland; Scottish Ctr Infect & Environm Hlth, Glasgow, Lanark, Scotland	Monklands Hospital; Monklands Hospital	Todd, WTA (corresponding author), Monklands Hosp, Dept Infect Dis, Airdrie ML6 0JS, Lanark, Scotland.	andrew@todds.demon.co.uk						Armstrong GL, 1996, EPIDEMIOL REV, V18, P29, DOI 10.1093/oxfordjournals.epirev.a017914; Begue RE, 1998, SOUTHERN MED J, V91, P798, DOI 10.1097/00007611-199809000-00001; CARTER AO, 1987, NEW ENGL J MED, V317, P1496, DOI 10.1056/NEJM198712103172403; CIMOLAI N, 1990, J PEDIATR-US, V116, P589, DOI 10.1016/S0022-3476(05)81609-9; DELAHUNT MN, 1991, BRIT J SURG, V78, P1469, DOI 10.1002/bjs.1800781220; DRUMMOND KN, 1985, NEW ENGL J MED, V312, P116, DOI 10.1056/NEJM198501103120211; Duncan L., 1986, ONTARIO DIS SURVEILL, V7, P604; DUNDAS S, 1996, IN PRESS CENTRAL SCO; GRIFFIN PM, 1990, GASTROENTEROLOGY, V99, P142, DOI 10.1016/0016-5085(90)91241-W; HUGHES DA, 1991, SCOT MED J, V36, P9, DOI 10.1177/003693309103600105; Karch H, 1996, J CLIN MICROBIOL, V34, P516, DOI 10.1128/JCM.34.3.516-519.1996; KARMALI MA, 1985, J INFECT DIS, V151, P775, DOI 10.1093/infdis/151.5.775; LOUSI CB, 1991, INFECT IMMUN, V59, P4173; MCBRIEN AD, 1983, LANCET, V1, P702; Mead PS, 1998, LANCET, V352, P1207, DOI 10.1016/S0140-6736(98)01267-7; MOAKE JL, 1989, AM J MED, V87, P3; PETITT RM, 1980, SEMIN THROMB HEMOST, V6, P350, DOI 10.1055/s-2007-1005108; REILLY WJ, 1997, SCIEH WKLY REP, V97, P4; RILEY LW, 1983, NEW ENGL J MED, V308, P681, DOI 10.1056/NEJM198303243081203; Rock G, 1996, BRIT J HAEMATOL, V94, P383, DOI 10.1046/j.1365-2141.1996.d01-1800.x; ROCK GA, 1991, NEW ENGL J MED, V325, P393, DOI 10.1056/NEJM199108083250604; RUGGENENTI P, 1997, KIDNEY INT S, V58, pS97; TESH VL, 1991, MOL MICROBIOL, V5, P1817, DOI 10.1111/j.1365-2958.1991.tb00805.x; WALTERS MDS, 1989, PEDIATR NEPHROL, V3, P130, DOI 10.1007/BF00852893; 1986, MMWR MORB MORTAL WKL, V35, P549	25	116	122	0	3	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	OCT 16	1999	354	9187					1327	1330		10.1016/S0140-6736(99)01251-9	http://dx.doi.org/10.1016/S0140-6736(99)01251-9			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	246DV	10533860				2022-12-01	WOS:000083149900009
J	Neri, P; Parker, AJ; Blakemore, C				Neri, P; Parker, AJ; Blakemore, C			Probing the human stereoscopic system with reverse correlation	NATURE			English	Article							BINOCULAR DISPARITY; DEPTH-PERCEPTION; NEURONS; CORTEX	Our two eyes obtain slightly different views of the world. The resulting differences in the two retinal images, called binocular disparities, provide us with a stereoscopic sense of depth(1). The primary visual cortex (V1) contains neurons that are selective for the disparity(2-4) of individual elements in an image, but this information must be further analysed to complete the stereoscopic process(5,6). Here we apply the psychophysical technique of reverse correlation(7) to investigate disparity processing in human vision. Observers viewed binocular random-dot patterns, with 'signal' dots in a specific depth plane plus 'noise' dots with randomly assigned disparities. By examining the correlation between the observers' ability to detect the plane and the particular sample of 'noise' disparities presented on each trial, we revealed detection 'filters: whose disparity selectivity was remarkably similar to that of individual neurons in monkey V1. Moreover, if the noise dots were of opposite contrast in the two eyes, the tuning inverted, just like the response patterns of V1 neurons(5,6). Reverse correlation appears to probe disparity processing at the earliest stages of binocular combination, prior to the generation of a full stereoscopic depth percept.	Univ Oxford, Physiol Lab, Oxford OX1 3PT, England	University of Oxford	Neri, P (corresponding author), Univ Oxford, Physiol Lab, Parks Rd, Oxford OX1 3PT, England.		Parker, Andrew J/I-7867-2013; Neri, Peter/G-1066-2012	Parker, Andrew J/0000-0001-5800-0407; Neri, Peter/0000-0003-1981-5309; Blakemore, Colin/0000-0003-2659-7899	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BARLOW HB, 1967, J PHYSIOL-LONDON, V193, P327, DOI 10.1113/jphysiol.1967.sp008360; Beard BL, 1998, P SOC PHOTO-OPT INS, V3299, P79, DOI 10.1117/12.320099; COGAN AI, 1995, PERCEPTION, V24, P33, DOI 10.1068/p240033; COGAN AI, 1993, VISION RES, V33, P1959, DOI 10.1016/0042-6989(93)90021-N; CORMACK LK, 1993, VISUAL NEUROSCI, V10, P585, DOI 10.1017/S0952523800005290; Cumming BG, 1997, NATURE, V389, P280, DOI 10.1038/38487; Cumming BG, 1998, PERCEPTION, V27, P1367, DOI 10.1068/p271367; Efron B., 1993, MONOGRAPHS STAT APPL, DOI 10.1007/978-1-4899-4541-9; Fleet DJ, 1996, VISION RES, V36, P1839, DOI 10.1016/0042-6989(95)00313-4; GREEN DM, 1966, SIGNAL DETECTION THE; Julesz B., 1971, FDN CYCLOPEAN PERCEP; MARR D, 1979, PROC R SOC SER B-BIO, V204, P301, DOI 10.1098/rspb.1979.0029; Masson GS, 1997, NATURE, V389, P283, DOI 10.1038/38496; NIKARA T, 1968, EXP BRAIN RES, V6, P353; OHZAWA I, 1990, SCIENCE, V249, P1037, DOI 10.1126/science.2396096; POGGIO GF, 1977, J NEUROPHYSIOL, V40, P1392, DOI 10.1152/jn.1977.40.6.1392; SCHOR C, 1984, VISION RES, V24, P661, DOI 10.1016/0042-6989(84)90207-4; STEVENSON SB, 1992, VISION RES, V32, P1685, DOI 10.1016/0042-6989(92)90161-B; WATSON AB, 1983, PERCEPT PSYCHOPHYS, V33, P113, DOI 10.3758/BF03202828; Wheatstone C, 1838, PHILOS T R SOC LOND, V128, P371	20	94	95	1	11	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	OCT 14	1999	401	6754					695	698		10.1038/44409	http://dx.doi.org/10.1038/44409			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	247EJ	10537107				2022-12-01	WOS:000083207400056
J	Macklin, R				Macklin, R			The ethical problems with sham surgery in clinical research	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							DEVELOPING-COUNTRIES; PLACEBO ORTHODOXY; TRIALS; MYTHS		Yeshiva Univ Albert Einstein Coll Med, Bronx, NY 10461 USA	Yeshiva University; Albert Einstein College of Medicine	Macklin, R (corresponding author), Yeshiva Univ Albert Einstein Coll Med, 1300 Morris Pk Ave, Bronx, NY 10461 USA.							Advisory Committee on Human Radiation Experiments, 1996, FIN REP ADV COMM HUM; Angell M, 1997, NEW ENGL J MED, V337, P847, DOI 10.1056/NEJM199709183371209; APPELBAUM PS, 1982, INT J LAW PSYCHIAT, V5, P319, DOI 10.1016/0160-2527(82)90026-7; CLARK PI, 1994, ANNU REV PUBL HEALTH, V15, P19; COBB LA, 1959, NEW ENGL J MED, V260, P1115, DOI 10.1056/NEJM195905282602204; Cohen Peter J, 1998, IRB, V20, P6, DOI 10.2307/3563555; Freedman B, 1996, J LAW MED ETHICS, V24, P243, DOI 10.1111/j.1748-720X.1996.tb01859.x; Freedman B, 1996, J LAW MED ETHICS, V24, P252, DOI 10.1111/j.1748-720X.1996.tb01860.x; Freedman Benjamin, 1990, IRB, V12, P1, DOI 10.2307/3564541; JOHANNES L, 1998, WALL STREET J   1211, pA8; Johannes Laura, 1998, Wall St J (East Ed), pA1; JOHNSON AG, 1994, LANCET, V344, P1140, DOI 10.1016/S0140-6736(94)90637-8; KING NMP, 1995, HASTINGS CENT REP, V25, P6, DOI 10.2307/3562155; Levit K R, 1985, Health Care Financ Rev, V7, P1; Lurie P, 1997, NEW ENGL J MED, V337, P853, DOI 10.1056/NEJM199709183371212; Martin Douglas K, 1995, IRB, V17, P8, DOI 10.2307/3563530; Meslin Eric M, 1990, IRB, V12, P7, DOI 10.2307/3563683; *NAT BIOETH ADV CO, 1998, RES INV PERS MENT DI; National Commission for the Protection of Human Subjects of Biomedical and Behavioral Research, 1978, BELM REP ETH PRINC G; Orr RD, 1996, PSYCHIATR SERV, V47, P1262; ROTHMAN KJ, 1994, NEW ENGL J MED, V331, P394, DOI 10.1056/NEJM199408113310611; Stolberg Sheryl Gay, 1999, N Y Times Web, pF2; Stolberg Sheryl Gay, 1999, N Y Times Web, P3; Varmus H, 1997, NEW ENGL J MED, V337, P1003, DOI 10.1056/NEJM199710023371411; Williams Peter C, 1984, IRB, V6, P1, DOI 10.2307/3563870	25	197	200	0	8	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	SEP 23	1999	341	13					992	996		10.1056/NEJM199909233411312	http://dx.doi.org/10.1056/NEJM199909233411312			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	237LP	10498498				2022-12-01	WOS:000082658100012
J	Harbour, JW; Luo, RX; Santi, AD; Postigo, AA; Dean, DC				Harbour, JW; Luo, RX; Santi, AD; Postigo, AA; Dean, DC			Cdk phosphorylation triggers sequential intramolecular interactions that progressively block Rb functions as cells move through G1	CELL			English	Article							TRANSCRIPTIONAL REPRESSOR MOTIF; CYCLIN-DEPENDENT KINASES; RETINOBLASTOMA PROTEIN; HISTONE DEACETYLASE; PRB PHOSPHORYLATION; PHASE-TRANSITION; E2F; FAMILY; BINDING; POCKET	We present evidence that phosphorylation of the C-terminal region of Rb by Cdk4/6 initiates successive intramolecular interactions between the C-terminal region and the central pocket. The initial interaction displaces histone deacetylase from the pocket, blocking active transcriptional repression by Rb. This facilitates a second interaction that leads to phosphorylation of the pocket by Cdk2 and disruption of pocket structure. These intramolecular interactions provide a molecular basis for sequential phosphorylation of Rb by Cdk4/6 and Cdk2. Cdk4/6 is activated early in G1, blocking active repression by Rb. However, it is not until near the end of G1, when cyclin E is expressed and Cdk2 is activated, that Rb is prevented from binding and inactivating E2F.	Washington Univ, Sch Med, Dept Med, Div Mol Oncol, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Ophthalmol & Visual Sci, St Louis, MO 63110 USA	Washington University (WUSTL); Washington University (WUSTL)	Dean, DC (corresponding author), Washington Univ, Sch Med, Dept Med, Div Mol Oncol, St Louis, MO 63110 USA.	ddean@im.wustl.edu	Harbour, J. William/B-1448-2015	Harbour, J. William/0000-0002-1104-9809; Postigo, Antonio/0000-0003-4605-2634				Adams PD, 1996, CURR TOP MICROBIOL, V208, P79; Adams PD, 1999, MOL CELL BIOL, V19, P1068; Brehm A, 1998, NATURE, V391, P597, DOI 10.1038/35404; CHELLAPPAN SP, 1991, CELL, V65, P1053, DOI 10.1016/0092-8674(91)90557-F; Chew YP, 1998, ONCOGENE, V17, P2177, DOI 10.1038/sj.onc.1202443; Chow KNB, 1996, MOL CELL BIOL, V16, P4862; Chow KNB, 1996, MOL CELL BIOL, V16, P7173; DOWDY SF, 1993, CELL, V73, P499, DOI 10.1016/0092-8674(93)90137-F; Dyson N, 1998, GENE DEV, V12, P2245, DOI 10.1101/gad.12.15.2245; EWEN ME, 1993, CELL, V73, P487, DOI 10.1016/0092-8674(93)90136-E; EWEN ME, 1994, CANCER METAST REV, V13, P45, DOI 10.1007/BF00690418; Ezhevsky SA, 1997, P NATL ACAD SCI USA, V94, P10699, DOI 10.1073/pnas.94.20.10699; Geng Y, 1999, CELL, V97, P767, DOI 10.1016/S0092-8674(00)80788-6; Geng Y, 1996, ONCOGENE, V12, P1173; Hassig CA, 1997, CELL, V89, P341, DOI 10.1016/S0092-8674(00)80214-7; HATAKEYAMA M, 1994, GENE DEV, V8, P1759, DOI 10.1101/gad.8.15.1759; HINDS PW, 1992, CELL, V70, P993, DOI 10.1016/0092-8674(92)90249-C; Holmes JK, 1996, J BIOL CHEM, V271, P25240, DOI 10.1074/jbc.271.41.25240; Hua XQH, 1998, J CELL BIOL, V140, P271, DOI 10.1083/jcb.140.2.271; KATO J, 1993, GENE DEV, V7, P331; Knudsen ES, 1996, J BIOL CHEM, V271, P8313, DOI 10.1074/jbc.271.14.8313; Knudsen ES, 1998, GENE DEV, V12, P2278, DOI 10.1101/gad.12.15.2278; Knudsen ES, 1997, MOL CELL BIOL, V17, P5771, DOI 10.1128/MCB.17.10.5771; LAM EWF, 1994, CURR OPIN CELL BIOL, V6, P859; LATHANGUE NB, 1994, TRENDS BIOCHEM SCI, V19, P108, DOI 10.1016/0968-0004(94)90202-X; Lee JO, 1998, NATURE, V391, P859, DOI 10.1038/36038; Lundberg AS, 1998, MOL CELL BIOL, V18, P753, DOI 10.1128/MCB.18.2.753; Luo RX, 1998, CELL, V92, P463, DOI 10.1016/S0092-8674(00)80940-X; Magnaghi-Jaulin L, 1998, NATURE, V391, P601, DOI 10.1038/35410; MITTNACHT S, 1994, EMBO J, V13, P118, DOI 10.1002/j.1460-2075.1994.tb06241.x; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; Nasmyth K, 1993, CURR OPIN CELL BIOL, V5, P166, DOI 10.1016/0955-0674(93)90099-C; NEVINS JR, 1992, SCIENCE, V258, P424; NORBURY C, 1992, ANNU REV BIOCHEM, V61, P441, DOI 10.1146/annurev.bi.61.070192.002301; OHTSUBO M, 1995, MOL CELL BIOL, V15, P2612; REED SI, 1992, ANNU REV CELL BIOL, V8, P529, DOI 10.1146/annurev.cb.08.110192.002525; ROBERTS JM, 1994, COLD SPRING HARB SYM, V59, P31, DOI 10.1101/SQB.1994.059.01.006; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; Slansky JE, 1996, CURR TOP MICROBIOL, V208, P1; TEMPLETON DJ, 1991, P NATL ACAD SCI USA, V88, P3033, DOI 10.1073/pnas.88.8.3033; VANDENHEUVEL S, 1993, SCIENCE, V262, P2050, DOI 10.1126/science.8266103; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; WEINTRAUB SJ, 1992, NATURE, V358, P259, DOI 10.1038/358259a0; WEINTRAUB SJ, 1995, NATURE, V375, P812, DOI 10.1038/375812a0; Whitaker LL, 1998, MOL CELL BIOL, V18, P4032, DOI 10.1128/MCB.18.7.4032; XU M, 1994, MOL CELL BIOL, V14, P8420, DOI 10.1128/MCB.14.12.8420; Zarkowska T, 1997, J BIOL CHEM, V272, P12738, DOI 10.1074/jbc.272.19.12738; Zhang HS, 1999, CELL, V97, P53, DOI 10.1016/S0092-8674(00)80714-X; ZHOU SY, 1994, CURR BIOL, V4, P973, DOI 10.1016/S0960-9822(00)00221-9	49	789	818	0	37	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	SEP 17	1999	98	6					859	869		10.1016/S0092-8674(00)81519-6	http://dx.doi.org/10.1016/S0092-8674(00)81519-6			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	237WH	10499802	Bronze			2022-12-01	WOS:000082679200012
J	Ames, RS; Sarau, HM; Chambers, JK; Willette, RN; Alyar, NV; Romanic, AM; Louden, CS; Foley, JJ; Sauermelch, CF; Coatney, RW; Ao, ZH; Disa, J; Holmes, SD; Stadel, JM; Martin, JD; Liu, WS; Glover, GI; Wilson, S; McNulty, DE; Ellis, CE; Elshourbagy, NA; Shabon, U; Trill, JJ; Hay, DWP; Ohlstein, EH; Bergsma, DJ; Douglas, SA				Ames, RS; Sarau, HM; Chambers, JK; Willette, RN; Alyar, NV; Romanic, AM; Louden, CS; Foley, JJ; Sauermelch, CF; Coatney, RW; Ao, ZH; Disa, J; Holmes, SD; Stadel, JM; Martin, JD; Liu, WS; Glover, GI; Wilson, S; McNulty, DE; Ellis, CE; Elshourbagy, NA; Shabon, U; Trill, JJ; Hay, DWP; Ohlstein, EH; Bergsma, DJ; Douglas, SA			Human urotensin-II is a potent vasoconstrictor and agonist for the orphan receptor GPR14	NATURE			English	Article							CLONING; PEPTIDE; GENES; RATS	Urotensin-II (U-II) is a vasoactive 'somatostatin-like' cyclic peptide which was originally isolated from fish spinal cords(1,2), and which has recently been cloned from man(3). Here we describe the identification of an orphan human G-protein-coupled receptor homologous to rat GPR14 (refs 4, 5) and expressed predominantly in cardiovascular tissue, which functions as a U-II receptor. Goby and human U-II bind to recombinant human GPR14 with high affinity, and the binding is functionally coupled to calcium mobilization. Human U-II is found within both vascular and cardiac tissue (including coronary atheroma) and effectively constricts isolated arteries from non-human primates. The potency of vasoconstriction of U-II is an order of magnitude greater than that of endothelin-1, making human U-II the most potent mammalian vasoconstrictor identified so far. In vivo, human U-II markedly increases total peripheral resistance in anaesthetized non-human primates, a response associated with profound cardiac contractile dysfunction. Furthermore, as U-II immunoreactivity is also found within central nervous system and endocrine tissues, it may have additional activities.	SmithKline Beecham Pharmaceut, Dept Mol Biol, King Of Prussia, PA 19406 USA; SmithKline Beecham Pharmaceut, Dept Pulm & Cardiovasc Pharmacol, King Of Prussia, PA 19406 USA; SmithKline Beecham Pharmaceut, Dept Funct Gene Anal, King Of Prussia, PA 19406 USA; SmithKline Beecham Pharmaceut, Dept Pathol, King Of Prussia, PA 19406 USA; SmithKline Beecham Pharmaceut, Dept Lab Anim Sci, King Of Prussia, PA 19406 USA; SmithKline Beecham Pharmaceut, Dept Immunol, King Of Prussia, PA 19406 USA; SmithKline Beecham Pharmaceut, Dept Prot Biochem, King Of Prussia, PA 19406 USA; SmithKline Beecham Pharmaceut, Dept Gene Express Sci, King Of Prussia, PA 19406 USA; USA & So Way, Harlow CM19 5AW, Essex, England	GlaxoSmithKline; GlaxoSmithKline; GlaxoSmithKline; GlaxoSmithKline; GlaxoSmithKline; GlaxoSmithKline; GlaxoSmithKline; GlaxoSmithKline; GlaxoSmithKline	Ames, RS (corresponding author), SmithKline Beecham Pharmaceut, Dept Mol Biol, 709 Swedeland Rd, King Of Prussia, PA 19406 USA.							AIYAR N, 1994, MOL CELL BIOCHEM, V131, P75, DOI 10.1007/BF01075727; Bern H.A., 1985, Recent Progress in Hormone Research, V41, P533; Chambers J, 1999, NATURE, V400, P261, DOI 10.1038/22313; Conlon JM, 1996, J EXP ZOOL, V275, P226, DOI 10.1002/(SICI)1097-010X(19960601/15)275:2/3<226::AID-JEZ14>3.3.CO;2-Y; Coulouarn Y, 1998, P NATL ACAD SCI USA, V95, P15803, DOI 10.1073/pnas.95.26.15803; DOUGLAS SA, 1991, BRIT J PHARMACOL, V104, P311, DOI 10.1111/j.1476-5381.1991.tb12428.x; Elshourbagy NA, 1998, ENDOCRINOLOGY, V139, P1678, DOI 10.1210/en.139.4.1678; GIBSON A, 1986, GEN COMP ENDOCR, V64, P435, DOI 10.1016/0016-6480(86)90080-8; HASEGAWA K, 1992, NEUROENDOCRINOL LETT, V14, P357; ITOH H, 1988, EUR J PHARMACOL, V149, P61, DOI 10.1016/0014-2999(88)90042-8; KING DS, 1990, INT J PEPT PROT RES, V36, P255; Libert F, 1991, CURR OPIN CELL BIOL, V3, P218, DOI 10.1016/0955-0674(91)90142-L; MARCHESE A, 1995, GENOMICS, V29, P335, DOI 10.1006/geno.1995.9996; ODOWD BF, 1995, GENOMICS, V28, P84, DOI 10.1006/geno.1995.1109; OHSAKO S, 1986, J NEUROSCI, V6, P2730; PEARSON D, 1980, P NATL ACAD SCI-BIOL, V77, P5021, DOI 10.1073/pnas.77.8.5021; Stadel JM, 1997, TRENDS PHARMACOL SCI, V18, P430, DOI 10.1016/S0165-6147(97)01117-6; TAL M, 1995, BIOCHEM BIOPH RES CO, V209, P752, DOI 10.1006/bbrc.1995.1563; YANAGISAWA M, 1988, NATURE, V332, P411, DOI 10.1038/332411a0	19	713	865	3	19	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	SEP 16	1999	401	6750					282	286		10.1038/45809	http://dx.doi.org/10.1038/45809			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	237VZ	10499587				2022-12-01	WOS:000082678400055
J	Jog, MS; Kubota, Y; Connolly, CI; Hillegaart, V; Graybiel, AM				Jog, MS; Kubota, Y; Connolly, CI; Hillegaart, V; Graybiel, AM			Building neural representations of habits	SCIENCE			English	Article							OBSESSIVE-COMPULSIVE DISORDER; BASAL GANGLIA; CAUDATE-NUCLEUS; DORSOLATERAL STRIATUM; TRIPLE DISSOCIATION; FUNCTIONAL-ANATOMY; SYSTEMATIC CHANGES; ACTION REPERTOIRES; NEURONAL-ACTIVITY; CORTEX	Memories for habits and skills ("implicit or procedural memory") and memories for facts ("explicit or episodic memory") are built up in different brain systems and are vulnerable to different neurodegenerative disorders in humans. So that the striatum-based mechanisms underlying habit formation could be studied, chronic recordings from ensembles of striatal neurons were made with multiple tetrodes as rats learned a T-maze procedural task. Large and widely distributed changes in the neuronal activity patterns occurred in the sensorimotor striatum during behavioral acquisition, culminating in task-related activity emphasizing the beginning and end of the automatized procedure. The new ensemble patterns remained stable during weeks of subsequent performance of the same task. These results suggest that the encoding of action in the sensorimotor striatum undergoes dynamic reorganization as habit learning proceeds.	MIT, Dept Brain & Cognit Sci, Cambridge, MA 02139 USA; London Hlth Sci Ctr, London, ON N6A 5A5, Canada; SRI Int, Menlo Park, CA 94025 USA; Karolinska Inst, Dept Physiol & Pharmacol, S-17177 Stockholm, Sweden	Massachusetts Institute of Technology (MIT); London Health Sciences Centre; SRI International; Karolinska Institutet	Graybiel, AM (corresponding author), MIT, Dept Brain & Cognit Sci, E25-618, Cambridge, MA 02139 USA.			Graybiel, Ann/0000-0002-4326-7720	NATIONAL INSTITUTE OF MENTAL HEALTH [R03MH057878] Funding Source: NIH RePORTER; NIMH NIH HHS [R03 MH57878] Funding Source: Medline	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		ALBIN RL, 1989, TRENDS NEUROSCI, V12, P366, DOI 10.1016/0166-2236(89)90074-X; AOSAKI T, 1994, J NEUROSCI, V14, P3969; Apicella P, 1998, J NEUROPHYSIOL, V80, P3341, DOI 10.1152/jn.1998.80.6.3341; BENECKE R, 1987, BRAIN, V110, P361, DOI 10.1093/brain/110.2.361; Buonomano DV, 1998, ANNU REV NEUROSCI, V21, P149, DOI 10.1146/annurev.neuro.21.1.149; Carelli RM, 1997, J NEUROSCI, V17, P1804; CARELLI RM, 1991, J COMP NEUROL, V309, P231, DOI 10.1002/cne.903090205; Deadwyler SA, 1997, ANNU REV NEUROSCI, V20, P217, DOI 10.1146/annurev.neuro.20.1.217; DELONG MR, 1990, TRENDS NEUROSCI, V13, P281, DOI 10.1016/0166-2236(90)90110-V; Denny-Brown D, 1976, Res Publ Assoc Res Nerv Ment Dis, V55, P115; Donoghue JP, 1995, CURR OPIN NEUROBIOL, V5, P749, DOI 10.1016/0959-4388(95)80102-2; EICHENBAUM H, 1998, NEURONAL ENSEMBLES S; Gerloff C, 1998, BRAIN, V121, P1513, DOI 10.1093/brain/121.8.1513; Gray CM, 1995, J NEUROSCI METH, V63, P43, DOI 10.1016/0165-0270(95)00085-2; GRAYBIEL AM, 1994, SCIENCE, V265, P1826, DOI 10.1126/science.8091209; Graybiel AM, 1998, NEUROBIOL LEARN MEM, V70, P119, DOI 10.1006/nlme.1998.3843; Graybiel AM, 1995, CURR OPIN NEUROBIOL, V5, P733, DOI 10.1016/0959-4388(95)80100-6; Hanes DP, 1996, SCIENCE, V274, P427, DOI 10.1126/science.274.5286.427; HIKOSAKA O, 1989, J NEUROPHYSIOL, V61, P814, DOI 10.1152/jn.1989.61.4.814; HIRSH R, 1974, BEHAV BIOL, V12, P421, DOI 10.1016/S0091-6773(74)92231-7; James W., 1890, PRINCIPLES PSYCHOL; Karni A, 1998, P NATL ACAD SCI USA, V95, P861, DOI 10.1073/pnas.95.3.861; Kawagoe R, 1998, NAT NEUROSCI, V1, P411, DOI 10.1038/1625; KESNER RP, 1993, EXP BRAIN RES, V93, P462; Knowlton BJ, 1996, SCIENCE, V273, P1399, DOI 10.1126/science.273.5280.1399; Koob GF, 1998, NEURON, V21, P467, DOI 10.1016/S0896-6273(00)80557-7; Kubota Y., 1999, Society for Neuroscience Abstracts, V25, P1384; Kubota Y., UNPUB; MCDONALD RJ, 1993, BEHAV NEUROSCI, V107, P3, DOI 10.1037/0735-7044.107.1.3; MCGEORGE AJ, 1989, NEUROSCIENCE, V29, P503, DOI 10.1016/0306-4522(89)90128-0; Mishkin M., 1984, NEUROBIOLOGY LEARNIN, P65, DOI DOI 10.1523/JNEUROSCI.0840-16.2016; Miyachi S, 1997, EXP BRAIN RES, V115, P1, DOI 10.1007/PL00005669; Nakamura K, 1998, J NEUROPHYSIOL, V80, P2671, DOI 10.1152/jn.1998.80.5.2671; Packard MG, 1996, NEUROBIOL LEARN MEM, V65, P65, DOI 10.1006/nlme.1996.0007; Petersen SE, 1998, P NATL ACAD SCI USA, V95, P853, DOI 10.1073/pnas.95.3.853; Picard N, 1997, J NEUROPHYSIOL, V77, P2197, DOI 10.1152/jn.1997.77.4.2197; RIDLEY RM, 1994, PROG NEUROBIOL, V44, P221, DOI 10.1016/0301-0082(94)90039-6; ROBBINS TW, 1992, SEMIN NEUROSCI, V4, P119; ROLLS ET, 1983, BEHAV BRAIN RES, V7, P179, DOI 10.1016/0166-4328(83)90191-2; Sakai K, 1998, J NEUROSCI, V18, P1827; SALMON DP, 1995, CURR OPIN NEUROBIOL, V5, P184, DOI 10.1016/0959-4388(95)80025-5; Schultz W, 1997, SCIENCE, V275, P1593, DOI 10.1126/science.275.5306.1593; SCHWAB RS, 1954, AMA ARCH NEUROL PSY, V72, P591, DOI 10.1001/archneurpsyc.1954.02330050061010; Schwartz JM, 1996, ARCH GEN PSYCHIAT, V53, P109; Shadmehr R, 1997, SCIENCE, V277, P821, DOI 10.1126/science.277.5327.821; SWEDO SE, 1992, ARCH GEN PSYCHIAT, V49, P690; Toni I, 1998, NEUROIMAGE, V8, P50, DOI 10.1006/nimg.1998.0349; Tremblay L, 1998, J NEUROPHYSIOL, V80, P964, DOI 10.1152/jn.1998.80.2.964; WEST MO, 1990, J NEUROPHYSIOL, V64, P1233, DOI 10.1152/jn.1990.64.4.1233; White NM, 1997, CURR OPIN NEUROBIOL, V7, P164, DOI 10.1016/S0959-4388(97)80004-9; Wilson C.J., 1998, SYNAPTIC ORG BRAIN, P329; WILSON MA, 1993, SCIENCE, V261, P10552; Wise SP, 1998, EXP BRAIN RES, V121, P285, DOI 10.1007/s002210050462; [No title captured]	54	599	610	3	55	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 26	1999	286	5445					1745	1749		10.1126/science.286.5445.1745	http://dx.doi.org/10.1126/science.286.5445.1745			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	259UK	10576743				2022-12-01	WOS:000083912200041
J	Stock, D; Leslie, AGW; Walker, JE				Stock, D; Leslie, AGW; Walker, JE			Molecular architecture of the rotary motor in ATP synthase	SCIENCE			English	Article							ESCHERICHIA-COLI F1-ATPASE; BOVINE HEART-MITOCHONDRIA; C-SUBUNIT OLIGOMER; EPSILON-SUBUNIT; GAMMA-SUBUNIT; ENERGY TRANSDUCTION; CRYSTAL-STRUCTURE; MEMBRANE DOMAIN; CROSS-LINKING; F1F0 ATPASE	Adenosine triphosphate (ATP) synthase contains a rotary motor involved in biological energy conversion. Its membrane-embedded F-0 sector has a rotation generator fueled by the proton-motive force, which provides the energy required for the synthesis of ATP by the F-1 domain. An electron density map obtained from crystals of a subcomplex of yeast mitochondrial ATP synthase shows a ring of 10 c subunits. Each c subunit forms an alpha-helical hairpin. The interhelical loops of six to seven of the c subunits are in close contact with the gamma and delta subunits of the central stalk. The extensive contact between the c ring and the stalk suggests that they may rotate as an ensemble during catalysis.	MRC, Dunn Nutr Unit, Cambridge CB2 2XY, England; MRC, Mol Biol Lab, Cambridge CB2 2QH, England	MRC Laboratory Molecular Biology	Walker, JE (corresponding author), MRC, Dunn Nutr Unit, Hills Rd, Cambridge CB2 2XY, England.	walker@mrc-dunn.cam.ac.uk		Walker, John/0000-0001-7929-2162				ABRAHAMS JP, 1994, NATURE, V370, P621, DOI 10.1038/370621a0; Abrahams JP, 1996, ACTA CRYSTALLOGR D, V52, P30, DOI 10.1107/S0907444995008754; Abrahams JP, 1996, P NATL ACAD SCI USA, V93, P9420, DOI 10.1073/pnas.93.18.9420; AGGELER R, 1995, J BIOL CHEM, V270, P9185, DOI 10.1074/jbc.270.16.9185; Arnold I, 1998, EMBO J, V17, P7170, DOI 10.1093/emboj/17.24.7170; Arselin G, 1996, J BIOL CHEM, V271, P20284, DOI 10.1074/jbc.271.34.20284; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Bateson M, 1999, J BIOL CHEM, V274, P7462, DOI 10.1074/jbc.274.11.7462; Bateson M, 1996, ANAL BIOCHEM, V238, P14, DOI 10.1006/abio.1996.0242; Berry S, 1996, BBA-BIOENERGETICS, V1276, P51, DOI 10.1016/0005-2728(96)00031-X; Beuron F, 1998, J STRUCT BIOL, V123, P248, DOI 10.1006/jsbi.1998.4039; Bianchet MA, 1998, P NATL ACAD SCI USA, V95, P11065, DOI 10.1073/pnas.95.19.11065; Bottcher B, 1998, J MOL BIOL, V281, P757, DOI 10.1006/jmbi.1998.1957; Boyer PD, 1997, ANNU REV BIOCHEM, V66, P717, DOI 10.1146/annurev.biochem.66.1.717; BOYER PD, 1993, BIOCHIM BIOPHYS ACTA, V1140, P215, DOI 10.1016/0005-2728(93)90063-L; CHAYEN NE, 1992, J CRYST GROWTH, V122, P176, DOI 10.1016/0022-0248(92)90241-A; Cherepanov DA, 1999, FEBS LETT, V449, P1, DOI 10.1016/S0014-5793(99)00386-5; COLLINSON IR, 1994, J MOL BIOL, V242, P408; COX GB, 1993, J MOL BIOL, V229, P1159, DOI 10.1006/jmbi.1993.1113; DEVENISH RJ, 1992, ANN NY ACAD SCI, V671, P403, DOI 10.1111/j.1749-6632.1992.tb43814.x; Dmitriev OY, 1999, P NATL ACAD SCI USA, V96, P7785, DOI 10.1073/pnas.96.14.7785; Elston T, 1998, NATURE, V391, P510, DOI 10.1038/35185; Engelbrecht S, 1997, FEBS LETT, V414, P485, DOI 10.1016/S0014-5793(97)00997-6; FILLINGAME RH, 1992, BIOCHIM BIOPHYS ACTA, V1101, P240, DOI 10.1016/0005-2728(92)90235-T; Fillingame RH, 1998, BBA-BIOENERGETICS, V1365, P135, DOI 10.1016/S0005-2728(98)00053-X; FILLINGAME RH, 1990, BACTERIA TREATISE ST, V12, P345; FOSTER DL, 1982, J BIOL CHEM, V257, P2009; Girvin ME, 1998, BIOCHEMISTRY-US, V37, P8817, DOI 10.1021/bi980511m; Groth G, 1997, FEBS LETT, V410, P117, DOI 10.1016/S0014-5793(97)00529-2; Groth G, 1998, J MOL BIOL, V281, P49, DOI 10.1006/jmbi.1998.1936; HENDRIX RW, 1978, P NATL ACAD SCI USA, V75, P4779, DOI 10.1073/pnas.75.10.4779; Hendrix RW, 1998, CELL, V94, P147, DOI 10.1016/S0092-8674(00)81413-0; Hermolin J, 1999, J BIOL CHEM, V274, P17011, DOI 10.1074/jbc.274.24.17011; Jiang WP, 1998, P NATL ACAD SCI USA, V95, P6607, DOI 10.1073/pnas.95.12.6607; Jones PC, 1998, J BIOL CHEM, V273, P29701, DOI 10.1074/jbc.273.45.29701; Jones PC, 1998, J BIOL CHEM, V273, P17178, DOI 10.1074/jbc.273.27.17178; Junge W, 1997, TRENDS BIOCHEM SCI, V22, P420, DOI 10.1016/S0968-0004(97)01129-8; Kaim G, 1998, EMBO J, V17, P688, DOI 10.1093/emboj/17.3.688; Karrasch S, 1999, J MOL BIOL, V290, P379, DOI 10.1006/jmbi.1999.2897; Kato-Yamada Y, 1998, J BIOL CHEM, V273, P19375, DOI 10.1074/jbc.273.31.19375; Law RHP, 1995, METHOD ENZYMOL, V260, P133, DOI 10.1016/0076-6879(95)60135-X; Leslie AGW, 1992, JOINT CCP4 ESF EACMB; Matthey U, 1999, EUR J BIOCHEM, V261, P459, DOI 10.1046/j.1432-1327.1999.00288.x; MICHEL H, 1983, TRENDS BIOCHEM SCI, V8, P56, DOI 10.1016/0968-0004(83)90390-0; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; Nicholls D.G., 1992, BIOENERGETICS, V2, P22; Noji H, 1997, NATURE, V386, P299, DOI 10.1038/386299a0; Orriss GL, 1998, STRUCT FOLD DES, V6, P831, DOI 10.1016/S0969-2126(98)00085-9; Orriss GL, 1996, BIOCHEM J, V314, P695, DOI 10.1042/bj3140695; Panke O, 1999, BBA-BIOENERGETICS, V1412, P118, DOI 10.1016/S0005-2728(99)00059-6; Prescott M, 1997, FEBS LETT, V411, P97, DOI 10.1016/S0014-5793(97)00670-4; Ruppert C, 1999, J BIOL CHEM, V274, P25281, DOI 10.1074/jbc.274.36.25281; Sawada K, 1997, ARCH BIOCHEM BIOPHYS, V348, P183, DOI 10.1006/abbi.1997.0397; Schemidt RA, 1998, J BACTERIOL, V180, P3205, DOI 10.1128/JB.180.12.3205-3208.1998; SCHEMIDT RA, 1995, ARCH BIOCHEM BIOPHYS, V323, P423, DOI 10.1006/abbi.1995.0063; SENIOR AE, 1990, ANNU REV BIOPHYS BIO, V19, P7; Shirakihara Y, 1997, STRUCTURE, V5, P825, DOI 10.1016/S0969-2126(97)00236-0; Singh S, 1996, FEBS LETT, V397, P30, DOI 10.1016/S0014-5793(96)01127-1; Spannagel C, 1997, EUR J BIOCHEM, V247, P1111, DOI 10.1111/j.1432-1033.1997.01111.x; Takeyasu K, 1996, FEBS LETT, V392, P110, DOI 10.1016/0014-5793(96)00796-X; Thomas DR, 1999, P NATL ACAD SCI USA, V96, P10134, DOI 10.1073/pnas.96.18.10134; TURK D, 1992, THESIS TU MUNCHEN MU; Uhlin U, 1997, STRUCTURE, V5, P1219, DOI 10.1016/S0969-2126(97)00272-4; Valiyaveetil FI, 1997, J BIOL CHEM, V272, P32635, DOI 10.1074/jbc.272.51.32635; Valpuesta JM, 1999, STRUCTURE, V7, P289, DOI 10.1016/S0969-2126(99)80039-2; vanRaaij MJ, 1996, P NATL ACAD SCI USA, V93, P6913, DOI 10.1073/pnas.93.14.6913; Vik SB, 1998, J BIOL CHEM, V273, P16229, DOI 10.1074/jbc.273.26.16229; Walker JE, 1998, ANGEW CHEM INT EDIT, V37, P2309, DOI 10.1002/(SICI)1521-3773(19980918)37:17<2308::AID-ANIE2308>3.0.CO;2-W; WATTS SD, 1995, FEBS LETT, V368, P235, DOI 10.1016/0014-5793(95)00658-V; Watts SD, 1996, J BIOL CHEM, V271, P28341, DOI 10.1074/jbc.271.45.28341; WETZEL CM, 1993, PLANT PHYSIOL, V102, P241, DOI 10.1104/pp.102.1.241; Wilkens S, 1998, NATURE, V393, P29, DOI 10.1038/29908	72	1042	1075	8	149	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 26	1999	286	5445					1700	1705		10.1126/science.286.5445.1700	http://dx.doi.org/10.1126/science.286.5445.1700			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	259UK	10576729				2022-12-01	WOS:000083912200027
J	Bonni, A; Brunet, A; West, AE; Datta, SR; Takasu, MA; Greenberg, ME				Bonni, A; Brunet, A; West, AE; Datta, SR; Takasu, MA; Greenberg, ME			Cell survival promoted by the Ras-MAPK signaling pathway by transcription-dependent and -independent mechanisms	SCIENCE			English	Article							CEREBELLAR GRANULE NEURONS; PROTEIN-KINASE AKT; GENE-EXPRESSION; BINDING PROTEIN; BCL-2 FAMILY; PHOSPHORYLATION; APOPTOSIS; DEATH; CREB; CAMP	A mechanism by which the Ras-mitogen-activated protein kinase (MAPK) signaling pathway mediates growth factor-dependent cell survival was characterized. The MAPK-activated kinases, the Rsks, catalyzed the phosphorylation of the pro-apoptotic protein BAD at serine 112 both in vitro and in vivo. The Rsk-induced phosphorylation of BAD at serine 112 suppressed BAD-mediated apoptosis in neurons. Rsks also are known to phosphorylate the transcription factor CREB (cAMP response element-binding protein) at serine 133. Activated CREB promoted cell survival, and inhibition of CREB phosphorylation at serine 133 triggered apoptosis. These findings suggest that the MAPK signaling pathway promotes cell survival by a dual mechanism comprising the posttranslational modification and inactivation of a component of the cell death machinery and the increased transcription of pro-survival genes.	Childrens Hosp, Div Neurosci, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Neurobiol, Boston, MA 02115 USA	Harvard University; Boston Children's Hospital; Harvard University; Harvard Medical School	Greenberg, ME (corresponding author), Childrens Hosp, Div Neurosci, 300 Longwood Ave, Boston, MA 02115 USA.			Datta, Sandeep/0000-0002-8068-3862	NICHD NIH HHS [P01 HD 24926, NIHP30-HD18655] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [P30HD018655] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [P01HD024926] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Adams JM, 1998, SCIENCE, V281, P1322, DOI 10.1126/science.281.5381.1322; Alessi DR, 1996, FEBS LETT, V399, P333, DOI 10.1016/S0014-5793(96)01370-1; Alessi DR, 1996, EMBO J, V15, P6541, DOI 10.1002/j.1460-2075.1996.tb01045.x; BLENIS J, 1993, P NATL ACAD SCI USA, V90, P5889, DOI 10.1073/pnas.90.13.5889; Blume-Jensen P, 1998, CURR BIOL, V8, P779, DOI 10.1016/S0960-9822(98)70302-1; BONNI A, 1995, MOL CELL NEUROSCI, V6, P168, DOI 10.1006/mcne.1995.1015; Bonni A, 1997, CAN J NEUROL SCI, V24, P272, DOI 10.1017/S0317167100032935; BONNI A, UNPUB; BORASIO GD, 1989, NEURON, V2, P1087; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Chao DT, 1998, ANNU REV IMMUNOL, V16, P395, DOI 10.1146/annurev.immunol.16.1.395; D'MELLO SR, 1993, P NATL ACAD SCI USA, V90, P10989, DOI 10.1073/pnas.90.23.10989; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; Datta SR, 1998, HORM SIGNALING, V1, P257; De Cesare D, 1998, P NATL ACAD SCI USA, V95, P12202, DOI 10.1073/pnas.95.21.12202; delPeso L, 1997, SCIENCE, V278, P687; Downward J, 1998, CURR OPIN GENET DEV, V8, P49, DOI 10.1016/S0959-437X(98)80061-0; Dudek H, 1997, SCIENCE, V275, P661, DOI 10.1126/science.275.5300.661; FRANK DA, 1994, CELL, V79, P5, DOI 10.1016/0092-8674(94)90394-8; GINTY DD, 1994, CELL, V77, P713, DOI 10.1016/0092-8674(94)90055-8; Harada H, 1999, MOL CELL, V3, P413, DOI 10.1016/S1097-2765(00)80469-4; HENGARTNER MO, 1994, CURR OPIN GENE DEV, V4, P481; HILL CS, 1995, CELL, V80, P199, DOI 10.1016/0092-8674(95)90403-4; Jacobson MD, 1997, CELL, V88, P347, DOI 10.1016/S0092-8674(00)81873-5; KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33; KOHN AD, 1995, EMBO J, V14, P4288, DOI 10.1002/j.1460-2075.1995.tb00103.x; Kurada P, 1998, CELL, V95, P319, DOI 10.1016/S0092-8674(00)81764-X; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; Meier P, 1998, CELL, V95, P295, DOI 10.1016/S0092-8674(00)81760-2; Minichiello L, 1996, GENE DEV, V10, P2849, DOI 10.1101/gad.10.22.2849; NOBES CD, 1995, EUR J NEUROSCI, V7, P344, DOI 10.1111/j.1460-9568.1995.tb01069.x; Reed J C, 1997, Adv Pharmacol, V41, P501, DOI 10.1016/S1054-3589(08)61070-4; RICCIO A, 1996, MOL CELL BIOL, V16, P5546; Rudolph D, 1998, P NATL ACAD SCI USA, V95, P4481, DOI 10.1073/pnas.95.8.4481; Schwartz PM, 1997, NEURON, V19, P269, DOI 10.1016/S0896-6273(00)80938-1; Segal RA, 1996, ANNU REV NEUROSCI, V19, P463, DOI 10.1146/annurev.ne.19.030196.002335; SEGAL RA, 1992, NEURON, V9, P1041, DOI 10.1016/0896-6273(92)90064-K; Shaywitz AJ, 1999, ANNU REV BIOCHEM, V68, P821, DOI 10.1146/annurev.biochem.68.1.821; SHIMAMURA A, UNPUB; Somers JP, 1999, MOL ENDOCRINOL, V13, P1364, DOI 10.1210/me.13.8.1364; STELLER H, 1995, SCIENCE, V267, P1445, DOI 10.1126/science.7878463; Su B, 1996, CURR OPIN IMMUNOL, V8, P402, DOI 10.1016/S0952-7915(96)80131-2; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; Treisman R, 1996, CURR OPIN CELL BIOL, V8, P205, DOI 10.1016/S0955-0674(96)80067-6; Vaux DL, 1999, CELL, V96, P245, DOI 10.1016/S0092-8674(00)80564-4; VOGEL KS, 1995, CELL, V82, P733, DOI 10.1016/0092-8674(95)90470-0; WALTON KM, 1992, MOL ENDOCRINOL, V6, P647, DOI 10.1210/me.6.4.647; Wasylyk B, 1998, TRENDS BIOCHEM SCI, V23, P213, DOI 10.1016/S0968-0004(98)01211-0; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; Xia ZG, 1996, J NEUROSCI, V16, P5425; Xing J, 1998, MOL CELL BIOL, V18, P1946, DOI 10.1128/MCB.18.4.1946; Xing J, 1996, SCIENCE, V273, P959, DOI 10.1126/science.273.5277.959; XING J, UNPUB; Zha JP, 1996, CELL, V87, P619, DOI 10.1016/S0092-8674(00)81382-3	54	1590	1672	6	113	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 12	1999	286	5443					1358	1362		10.1126/science.286.5443.1358	http://dx.doi.org/10.1126/science.286.5443.1358			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	255NF	10558990				2022-12-01	WOS:000083675500042
J	Pages, G; Guerin, S; Grall, D; Bonino, FD; Smith, A; Anjuere, F; Auberger, P; Pouyssegur, J				Pages, G; Guerin, S; Grall, D; Bonino, FD; Smith, A; Anjuere, F; Auberger, P; Pouyssegur, J			Defective thymocyte maturation in p44 MAP kinase (Erk 1) knockout mice	SCIENCE			English	Article							PROTEIN-KINASE; NEGATIVE SELECTION; PATHWAYS; TYROSINE; INSULIN; DIFFERENTIATION; ACTIVATION; CASCADE	The p42 and p44 mitogen-activated protein kinases (MAPKs), also called Erk2 and Erk1, respectively, have been implicated in proliferation as well as in differentiation programs. The specific role of the p44 MAPK isoform in the whole animal was evaluated by generation of p44 MAPK-deficient mice by homologous recombination in embryonic stem cells. The p44 MAPK(-/-) mice were viable, fertile, and of normal size. Thus, p44 MAPK is apparently dispensable and p42 MAPK (Erk2) may compensate for its Loss. However, in p44 MAPK(-/-) mice, thymocyte maturation beyond the CD4(+)CD8(+) stage was reduced by half, with a similar diminution in the thymocyte subpopulation expressing high Levels of T cell receptor (CD3(high)). In p44 MAPK(-/-) thymocytes, proliferation in response to activation with a monoclonal antibody to the T cell receptor in the presence of phorbol myristate acetate was severely reduced even though activation of p42 MAPK was more sustained in these cells. The p44 MAPK apparently has a specific role in thymocyte development.	Ctr Antoine Lacassagne, Inst Signal Dev Biol & Canc Res, CNRS, UMR 6543, F-06189 Nice, France; Fac Med, INSERM, U364, F-06107 Nice, France; Fac Med, CJF 96 05, F-06107 Nice, France; Ctr Genome Res, Edinburgh, Midlothian, Scotland	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Cote d'Azur; UNICANCER; Centre Antoine Lacassagne; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Cote d'Azur; Universite de Franche-Comte; Universite de Franche-Comte	Pages, G (corresponding author), Ctr Antoine Lacassagne, Inst Signal Dev Biol & Canc Res, CNRS, UMR 6543, 33 Ave Valornbrose, F-06189 Nice, France.		AUBERGER, Patrick/G-1491-2013; Pages, Gilles/N-7135-2017; Anjuere-Casile, Fabienne/O-5779-2016; Bonino, Ferruccio/B-7522-2013	AUBERGER, Patrick/0000-0002-2481-8275; Anjuere-Casile, Fabienne/0000-0003-3144-8652; Smith, Austin/0000-0002-3029-4682				Ahn Natalie G., 1992, Current Opinion in Cell Biology, V4, P992, DOI 10.1016/0955-0674(92)90131-U; AlberolaIla J, 1996, J EXP MED, V184, P9, DOI 10.1084/jem.184.1.9; ALBEROLAILA J, 1995, NATURE, V373, P620, DOI 10.1038/373620a0; ALESSI DR, 1994, EMBO J, V13, P1610, DOI 10.1002/j.1460-2075.1994.tb06424.x; BOULTON TG, 1990, SCIENCE, V249, P64, DOI 10.1126/science.2164259; BOULTON TG, 1991, CELL, V65, P663, DOI 10.1016/0092-8674(91)90098-J; Brunet A, 1997, ESSAYS BIOCHEM, V32, P1; Brunet A, 1999, EMBO J, V18, P664, DOI 10.1093/emboj/18.3.664; CAPECCHI MR, 1989, SCIENCE, V244, P1288, DOI 10.1126/science.2660260; Crompton T, 1996, CELL, V86, P243, DOI 10.1016/S0092-8674(00)80096-3; Guerin S, 1997, FASEB J, V11, P376, DOI 10.1096/fasebj.11.5.9141505; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MCKENZIE F, IN PRESS BIOCH BIOPH; McKenzie FR, 1996, J BIOL CHEM, V271, P13476, DOI 10.1074/jbc.271.23.13476; NISHIDA E, 1993, TRENDS BIOCHEM SCI, V18, P128, DOI 10.1016/0968-0004(93)90019-J; OShea CC, 1996, EUR J IMMUNOL, V26, P2350, DOI 10.1002/eji.1830261012; PAGES G, 1995, J BIOL CHEM, V270, P26986, DOI 10.1074/jbc.270.45.26986; PAGES G, 1993, P NATL ACAD SCI USA, V90, P8319, DOI 10.1073/pnas.90.18.8319; PAGES G, 1994, EMBO J, V13, P3003, DOI 10.1002/j.1460-2075.1994.tb06599.x; PAGES G, UNPUB; RAY LB, 1988, P NATL ACAD SCI USA, V85, P3753, DOI 10.1073/pnas.85.11.3753; SEGER R, 1995, FASEB J, V9, P726, DOI 10.1096/fasebj.9.9.7601337; Sharp LL, 1997, IMMUNITY, V7, P609, DOI 10.1016/S1074-7613(00)80382-9; Sugawara T, 1998, IMMUNITY, V9, P565, DOI 10.1016/S1074-7613(00)80639-1; SWAN KA, 1995, EMBO J, V14, P276, DOI 10.1002/j.1460-2075.1995.tb07001.x	25	455	467	1	13	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 12	1999	286	5443					1374	1377		10.1126/science.286.5443.1374	http://dx.doi.org/10.1126/science.286.5443.1374			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	255NF	10558995				2022-12-01	WOS:000083675500047
J	Golan, L; Birkmeyer, JD; Welch, HG				Golan, L; Birkmeyer, JD; Welch, HG			The cost-effectiveness of treating all patients with type 2 diabetes with angiotensin-converting enzyme inhibitors	ANNALS OF INTERNAL MEDICINE			English	Article						cost-benefit analysis; diabetes mellitus, non-insulin-dependent; angiotensin-converting enzyme inhibitors; outcome and process assessment (health care); diabetic nephropathies	NEPHROPATHY; QUALITY; RECOMMENDATIONS; MELLITUS; OUTCOMES	Background: Although guidelines recommend angiotensin-converting enzyme inhibitors for diabetic patients with microalbuminuria, this strategy requires that providers adhere to screening recommendations. In addition, the benefit of angiotensin-converting enzyme inhibitors in normoalbuminuric patients was recently demonstrated. Objective: To evaluate the cost-effectiveness of treating all patients with type 2 diabetes. Design: Markov model simulating the progression of diabetic nephropathy. Data Sources: Randomized trials estimating the progression of diabetic nephropathy with and without angiotensin-converting enzyme inhibitors. Target Population: Patients 50 years of age with newly diagnosed type 2 diabetes (fasting plasma glucose level greater than or equal to 7.8 mmol/L [140 mg/dL]). Time Horizon: Lifetime. Perspective: Societal. Interventions: Patients received angiotensin-converting enzyme inhibitors, screening for microalbuminuria, or screening for gross proteinuria. Outcome Measures: Lifetime cost, quality-adjusted life expectancy, and marginal cost-effectiveness. Results of Base-Case Analysis: Screening for gross proteinuria had the highest cost and the lowest benefit. Compared with screening for microalbuminuria, treating all patients was more expensive ($15 240 and $14 940 per patient) but was associated with increased quality-adjusted life expectancy (11.82 and 11.78 quality-adjusted life-years). The marginal cost-effectiveness ratio was $7500 per quality-adjusted life-year gained. Results of Sensitivity Analysis: Results were sensitive to the cost, effectiveness, and quality of life associated with angiotensin-converting enzyme inhibitor therapy, as well as age at diagnosis. The model was relatively insensitive to adherence with screening and costs of treating end-stage renal disease. Conclusions: Treating all middle-aged diabetic patients with angiotensin-converting enzyme inhibitors is a simple strategy that provides additional benefit at modest additional cost. The strategy assumes that patients meet the older diagnostic criteria for diabetes and makes sense only for those who are not bothered by treatment.	Dept Vet Affairs Med Ctr, Vet Affairs Outcomes Grp, White River Jct, VT 05009 USA		Welch, HG (corresponding author), Dept Vet Affairs Med Ctr, Vet Affairs Outcomes Grp, White River Jct, VT 05009 USA.		Golan, Lubor/O-2359-2017	Golan, Lubor/0000-0003-1705-1157				BENNETT PH, 1995, AM J KIDNEY DIS, V25, P107; CHURCHILL DN, 1987, CLIN INVEST MED, V10, P14; DONOHOE JF, 1988, AM J MED, V85, P31, DOI 10.1016/0002-9343(88)90347-6; Frank E, 1997, J CLIN PSYCHIAT, V58, P11; FRYBACK DG, 1993, MED DECIS MAKING, V13, P89, DOI 10.1177/0272989X9301300202; Gaster B, 1998, ARCH INTERN MED, V158, P134, DOI 10.1001/archinte.158.2.134; ISRAILI ZH, 1992, ANN INTERN MED, V117, P234, DOI 10.7326/0003-4819-117-3-234; Kraft SK, 1999, J GEN INTERN MED, V14, P88, DOI 10.1046/j.1525-1497.1999.00292.x; LEWIS EJ, 1993, NEW ENGL J MED, V329, P1456, DOI 10.1056/NEJM199311113292004; LOVELL HG, 1998, COCHRANE DATABASE SY, V3; Miller N H, 1997, Am J Med, V102, P43; Miller NH, 1997, CIRCULATION, V95, P1085; Niskanen LK, 1996, DIABETES CARE, V19, P486, DOI 10.2337/diacare.19.5.486; PARVING HH, 1995, AM J KIDNEY DIS, V26, P99, DOI 10.1016/0272-6386(95)90162-0; PARVING HH, 1994, KIDNEY INT, V45, pS165; Ravid M, 1998, ANN INTERN MED, V128, P982, DOI 10.7326/0003-4819-128-12_Part_1-199806150-00004; RAVID M, 1993, ANN INTERN MED, V118, P577, DOI 10.7326/0003-4819-118-8-199304150-00001; *REP EXP COMM DIAG, 1997, DAIB CAR, V20, P183; Ritz E, 1996, AM J KIDNEY DIS, V27, P167, DOI 10.1016/S0272-6386(96)90538-7; RUDD P, 1995, AM HEART J, V130, P572, DOI 10.1016/0002-8703(95)90368-2; Schwartz L M, 1999, Eff Clin Pract, V2, P76; WALTERS DP, 1994, DIABETIC MED, V11, P968, DOI 10.1111/j.1464-5491.1994.tb00255.x; WEINER JP, 1995, JAMA-J AM MED ASSOC, V273, P1503, DOI 10.1001/jama.273.19.1503; 1998, AM J KIDNEY, V32, pS69; 1996, NAT CTR HLTH STAT; 1996, LIFE EXPECTANCY	26	127	131	0	7	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	NOV 2	1999	131	9					660	+		10.7326/0003-4819-131-9-199911020-00005	http://dx.doi.org/10.7326/0003-4819-131-9-199911020-00005			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	251LB	10577328				2022-12-01	WOS:000083446200004
J	Danesh, J; Youngman, L; Clark, S; Parish, S; Peto, R; Collins, R				Danesh, J; Youngman, L; Clark, S; Parish, S; Peto, R; Collins, R		Int Studies Infarct Survival ISIS	Helicobacter pylori infection and early onset myocardial infarction: case-control and sibling pairs study	BRITISH MEDICAL JOURNAL			English	Article							CORONARY HEART-DISEASE; RISK; AGE	Objectives To examine the association between coronary heart disease and chronic Helicobacter pylori infection. Design Case-control study of myocardial infarction at young ages and study of sibling pairs with one member affected and the other not. Setting United Kingdom. Participants 1122 survivors of suspected acute myocardial infarction at ages 30-49 (mean age 44 years) and 1122 age and sex matched controls with no history of coronary heart disease; 510 age and sex matched pairs of siblings (mean age 59 years) in which one sibling had survived myocardial infarction and one had no history of coronary heart disease. Main outcome measures Serological evidence of chronic infection with H pylori. Results 472 (42%) of the 1122 cases with early onset myocardial infarction were seropositive for H pylori antibodies compared with 272 (24%) of the 1122 age and sex matched controls, giving an odds ratio of 2.28 (99% confidence interval 1.80 to 2.90). This odds ratio fell to 1.87 (1.42 to 2.47; P < 0.0001) after smoking and indicators of socioeconomic status were adjusted for and to 1.75 (1.29 to 2.36) after additional adjustment for blood lipid concentrations and obesity. Only 158 of the 510 pairs of siblings were discordant for H pylori status; among these, 91 cases and 6'7 controls were seropositive (odds ratio 1.33 (0.86 to 2.05)). No strong correlations were observed between H pylori seropositivity and measurements of other risk factors for coronary heart disease (plasma lipids, fibrinogen, C reactive protein, albumin, etc). Conclusion In the context of results from other relevant studies, these two studies suggest a moderate association between coronary hear: disease and H pylori seropositivity that cannot be fully accounted for by other risk factors. But even if this association is causal and largely reversible by eradication of chronic infection, very large randomised trials would be needed to show this.	Univ Oxford, Radcliffe Infirm, Nuffield Dept Clin Med, Clin Trial Serv Unit, Oxford OX2 6HE, England; Univ Oxford, Radcliffe Infirm, Nuffield Dept Clin Med, Epidemiol Studies Unit, Oxford OX2 6HE, England	Radcliffe Infirmary; University of Oxford; Radcliffe Infirmary; University of Oxford	Danesh, J (corresponding author), Univ Oxford, Radcliffe Infirm, Nuffield Dept Clin Med, Clin Trial Serv Unit, Oxford OX2 6HE, England.							BLASER MJ, 1995, CANCER RES, V55, P562; Collins R, 1996, OXFORD TXB MED, V1, P21; CRABTREE JE, 1991, LANCET, V338, P332, DOI 10.1016/0140-6736(91)90477-7; Danesh J, 1997, LANCET, V350, P430, DOI 10.1016/S0140-6736(97)03079-1; Danesh J, 1998, Expert Opin Investig Drugs, V7, P691, DOI 10.1517/13543784.7.5.691; Danesh J, 1998, BRIT MED J, V316, P1130, DOI 10.1136/bmj.316.7138.1130; Danesh J, 1999, BRIT MED J, V318, P843, DOI 10.1136/bmj.318.7187.843; FELDMAN RA, 1995, ALIMENT PHARM THER, V9, P21; GOODMAN KJ, 1995, INT J EPIDEMIOL, V24, P875, DOI 10.1093/ije/24.5.875; HUNT D, 1992, LANCET, V339, P753; MACMAHON S, 1990, LANCET, V335, P765, DOI 10.1016/0140-6736(90)90878-9; MALATY HM, 1994, ANN INTERN MED, V120, P982, DOI 10.7326/0003-4819-120-12-199406150-00002; MENDALL MA, 1992, LANCET, V339, P896, DOI 10.1016/0140-6736(92)90931-R; PARISH S, 1995, BMJ-BRIT MED J, V311, P471, DOI 10.1136/bmj.311.7003.471; Pasceri V, 1998, CIRCULATION, V97, P1675, DOI 10.1161/01.CIR.97.17.1675; Qizilbash N, 1995, LANCET, V346, P1647; SITAS F, 1991, GUT, V32, P25, DOI 10.1136/gut.32.1.25; Sonke GS, 1996, BRIT MED J, V313, P853; YARNELL JWG, 1992, EUR HEART J, V13, P1602, DOI 10.1093/oxfordjournals.eurheartj.a060111	19	122	127	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	OCT 30	1999	319	7218					1157	1162		10.1136/bmj.319.7218.1157	http://dx.doi.org/10.1136/bmj.319.7218.1157			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	253BF	10541503	Bronze, Green Published			2022-12-01	WOS:000083536200019
J	Wilton, LV; Stephens, MDB; Mann, RD				Wilton, LV; Stephens, MDB; Mann, RD			Visual field defect associated with vigabatrin: observational cohort study	BRITISH MEDICAL JOURNAL			English	Article							CONSTRICTION		Drug Safety Res Unit, Southampton SO31 1AA, Hants, England		Wilton, LV (corresponding author), Drug Safety Res Unit, Southampton SO31 1AA, Hants, England.							*COMM ADV TROP MED, 1998, CAN COMMUN DIS REP, V24, P1; Eke T, 1997, BRIT MED J, V314, P180, DOI 10.1136/bmj.314.7075.180; Mackenzie R, 1998, BRIT MED J, V316, P233; Mann RD, 1998, BRIT J CLIN PHARMACO, V46, P195, DOI 10.1046/j.1365-2125.1998.00774.x	4	29	29	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	OCT 30	1999	319	7218					1165	1166		10.1136/bmj.319.7218.1165	http://dx.doi.org/10.1136/bmj.319.7218.1165			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	253BF	10541505	Bronze, Green Published			2022-12-01	WOS:000083536200021
J	Chun, TW; Davey, RT; Engel, D; Lane, HC; Fauci, AS				Chun, TW; Davey, RT; Engel, D; Lane, HC; Fauci, AS			AIDS - Re-emergence of HIV after stopping therapy	NATURE			English	Article							IMMUNODEFICIENCY-VIRUS INFECTION; ANTIRETROVIRAL THERAPY; INDINAVIR		NIAID, Immunoregulat Lab, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)	Chun, TW (corresponding author), NIAID, Immunoregulat Lab, NIH, 9000 Rockville Pike, Bethesda, MD 20892 USA.		Chun, Tae-Wook/W-9187-2019; Chun, Tae-Wook/AAC-3101-2020	Chun, Tae-Wook/0000-0001-5153-7340; 				Chun TW, 1997, NATURE, V387, P183, DOI 10.1038/387183a0; Chun TW, 1997, P NATL ACAD SCI USA, V94, P13193, DOI 10.1073/pnas.94.24.13193; Chun TW, 1998, P NATL ACAD SCI USA, V95, P8869, DOI 10.1073/pnas.95.15.8869; CHUN TW, 1999, NAT MED, V5, P615; Cohen OJ, 1998, JAMA-J AM MED ASSOC, V280, P87, DOI 10.1001/jama.280.1.87; DAVEY RT, IN PRESS P NATL ACAD; Finzi D, 1999, NAT MED, V5, P512, DOI 10.1038/8394; Gulick RM, 1997, NEW ENGL J MED, V337, P734, DOI 10.1056/NEJM199709113371102; Hammer SM, 1997, NEW ENGL J MED, V337, P725, DOI 10.1056/NEJM199709113371101; Zhang LQ, 1999, NEW ENGL J MED, V340, P1605, DOI 10.1056/NEJM199905273402101	10	329	333	0	13	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	OCT 28	1999	401	6756					874	875		10.1038/44755	http://dx.doi.org/10.1038/44755			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	251UL	10553903				2022-12-01	WOS:000083464700044
J	Parker, L; Pearce, MS; Dickinson, HO; Aitkin, M; Craft, AW				Parker, L; Pearce, MS; Dickinson, HO; Aitkin, M; Craft, AW			Stillbirths among offspring of male radiation workers at Sellafield nuclear reprocessing plant	LANCET			English	Article							CONGENITAL-MALFORMATIONS; IONIZING-RADIATION; TUMOR-INDUCTION; WEST CUMBRIA; MALE-MICE; INSTALLATION; IRRADIATION; LEUKEMIA; EXPOSURE; ENGLAND	Background Ionising radiation is a known mutagen, but few studies have examined transgenerational effects of paternal exposure in human beings. The workforce at the Sellafield nuclear reprocessing plant in the county of Cumbria, UK, is the most highly exposed workforce in western Europe and North America. This study, which is part of a larger programme of work investigating the health of the children of the Sellafield workforce, set out to find whether there was evidence of an association between stillbirth risk and paternal exposure to ionising radiation. Methods We collected details from birth registration documents for all singleton 248 097 livebirths and 3715 stillbirths in the county of Cumbria 1950-89. Within this cohort the 130 stillbirths and 9078 livebirths to partners of male radiation workers employed at Sellafield were identified. Logistic regression was' used to analyse the relation between stillbirth risk and father's preconceptional radiation exposure, with adjustment for social class, year of birth, father's age, and birth order. Findings A significant positive association was found between the risk of a baby being stillborn and the father's total exposure to external ionising radiation before conception (adjusted odds ratio per 100 mSv 1.24 [95% CI 1.04-1.45], p=0.009); The risk was higher for stillbirths with congenital anomaly and was highest for the nine stillbirths with neural-tube defects. The statistical models predicted that, were the association to be interpreted as causal, between 0 and 31.9 of the 130 stillbirths to the workforce may be attributable to father's radiation exposure. Interpretation The findings of an increased risk of stillbirth with increasing paternal occupational exposure to external radiation are qualitatively consistent with those from animal models, though the risk estimate is higher. Although we cannot exclude the possibility of an unmeasured risk factor for stillbirth, confounded with paternal preconceptional irradiation, extensive checks confirmed that the statistical models were a good fit to the data and there was not statistical evidence of unmeasured factors.	Newcastle Univ, Dept Child Hlth, Newcastle Upon Tyne NE1 7RU, Tyne & Wear, England; Newcastle Univ, Dept Stat, Newcastle Upon Tyne NE1 7RU, Tyne & Wear, England	Newcastle University - UK; Newcastle University - UK	Parker, L (corresponding author), Royal Victoria Infirm, Sir James Spence Inst, Newcastle Upon Tyne NE1 4LP, Tyne & Wear, England.	Louise.Parker@ncl.ac.uk		Pearce, Mark/0000-0002-0583-3779; PARKER, LOUISE/0000-0002-5188-8113				Aitkin M, 1999, BIOMETRICS, V55, P117, DOI 10.1111/j.0006-341X.1999.00117.x; Aitkin M, 1996, STAT COMPUT, V6, P251, DOI 10.1007/BF00140869; ALBERMAN E, 1994, ARCH DIS CHILD, V70, P403, DOI 10.1136/adc.70.5.403; BOBROW M, 1988, 2 COMARE; BRENDER JD, 1990, AM J EPIDEMIOL, V131, P517, DOI 10.1093/oxfordjournals.aje.a115526; Breslow NE, 1987, STAT METHODS CANC RE, VII; BRIDGES BA, 1996, 4 COMARE; CARDIS E, 1994, LANCET, V344, P1039; CATTANACH BM, 1995, INT J RADIAT BIOL, V67, P607, DOI 10.1080/09553009514550721; Copp AJ, 1998, CURR OPIN NEUROL, V11, P97, DOI 10.1097/00019052-199804000-00003; Daher A, 1998, CARCINOGENESIS, V19, P1553, DOI 10.1093/carcin/19.9.1553; Denniston C, 1998, MUTAT RES-FUND MOL M, V405, P57, DOI 10.1016/S0027-5107(98)00146-8; Dickinson HO, 1996, J EPIDEMIOL COMMUN H, V50, P645, DOI 10.1136/jech.50.6.645; DOLL R, 1994, NATURE, V367, P678, DOI 10.1038/367678a0; Draper GJ, 1997, BRIT MED J, V315, P1181, DOI 10.1136/bmj.315.7117.1181; Dummer TJB, 1998, INT J EPIDEMIOL, V27, P74, DOI 10.1093/ije/27.1.74; Dummer TJB, 1999, PAEDIATR PERINAT EP, V13, P131; GARDNER MJ, 1990, BRIT MED J, V300, P423, DOI 10.1136/bmj.300.6722.423; GREENLAND S, 1993, BIOMETRICS, V49, P865, DOI 10.2307/2532206; *INT COMM RAD PROT, 1988, ICRP PUB, V54; KIRK KM, 1984, MUTAT RES, V125, P75, DOI 10.1016/0027-5107(84)90034-4; Kite AV, 1996, RADIAT PROT DOSIM, V67, P23, DOI 10.1093/oxfordjournals.rpd.a031792; Lord BI, 1998, BRIT J CANCER, V78, P301, DOI 10.1038/bjc.1998.491; MACFARLANE A, 1984, BIRTH COUNTS STAT PR; McCullagh P, 2019, GEN LINEAR MODELS; National Council on Radiation Protection and Measurements, 1997, 126 NCRP; Neel J V, 1991, CHILDREN ATOMIC BOMB; *OFF POP CENS SURV, 1974, BIRT STAT FM1; *OFF POP CENS SURV, 1974, MORT SER; Office of Population Censuses and Surveys, 1990, STAND OCC CLASS, V3; Office of Population Censuses and Surveys, 1990, STAND OCC CLASS, V1; Office of Population Censuses and Surveys, 1990, STAND OCC CLASS, V2; PARKER L, 1993, BRIT MED J, V307, P966, DOI 10.1136/bmj.307.6910.966; ROYSTON P, 1994, J R STAT SOC C-APPL, V43, P429, DOI 10.2307/2986270; Russell WL, 1998, GENETICS, V148, P1567; SEVER LE, 1988, AM J EPIDEMIOL, V127, P226, DOI 10.1093/oxfordjournals.aje.a114799; *UN, 1994, SCI COMM EFF AT RAD; *UN, 1993, SCI COMM EFF AT RAD; Wakeford R., 1994, Journal of Radiological Protection, V14, P3, DOI 10.1088/0952-4746/14/1/001; [No title captured]	40	81	88	0	5	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	OCT 23	1999	354	9188					1407	1414		10.1016/S0140-6736(99)04138-0	http://dx.doi.org/10.1016/S0140-6736(99)04138-0			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	248LY	10543666				2022-12-01	WOS:000083277400009
J	Freeland, SJ; Knight, RD; Landweber, LF				Freeland, SJ; Knight, RD; Landweber, LF			Molecular evolution - Do proteins predate DNA?	SCIENCE			English	Editorial Material							GENETIC-CODE; RNA WORLD; RIBONUCLEOTIDE REDUCTASES; ERROR MINIMIZATION; ORIGIN		Princeton Univ, Dept Ecol & Evolutionary Biol, Princeton, NJ 08544 USA	Princeton University	Freeland, SJ (corresponding author), Princeton Univ, Dept Ecol & Evolutionary Biol, Princeton, NJ 08544 USA.	freeland@rnaworld.prince-ton.edu; rdknight@princeton.edu; lfl@princeton.edu		Knight, Rob/0000-0002-0975-9019				ALBERTS B, 1994, MOL BIOL CELL, pCH9; Ardell DH, 1998, J MOL EVOL, V47, P1, DOI 10.1007/PL00006356; BENNER SA, 1989, P NATL ACAD SCI USA, V86, P7054, DOI 10.1073/pnas.86.18.7054; Cate JH, 1999, SCIENCE, V285, P2095, DOI 10.1126/science.285.5436.2095; CRICK FHC, 1968, J MOL BIOL, V38, P367, DOI 10.1016/0022-2836(68)90392-6; Freeland SJ, 1998, P ROY SOC B-BIOL SCI, V265, P2111, DOI 10.1098/rspb.1998.0547; Freeland SJ, 1998, J MOL EVOL, V47, P238, DOI 10.1007/PL00006381; Gesteland R. F., 1999, RNA WORLD; HAIG D, 1991, J MOL EVOL, V33, P412, DOI 10.1007/BF02103132; HIRAO I, 1995, CURR BIOL, V5, P1017, DOI 10.1016/S0960-9822(95)00205-3; Jordan A, 1998, ANNU REV BIOCHEM, V67, P71, DOI 10.1146/annurev.biochem.67.1.71; Lazcano A, 1996, CELL, V85, P793, DOI 10.1016/S0092-8674(00)81263-5; LAZCANO A, 1988, J MOL EVOL, V27, P283, DOI 10.1007/BF02101189; Leon PE, 1998, J MOL EVOL, V47, P122, DOI 10.1007/PL00006368; Logan DT, 1999, SCIENCE, V283, P1499, DOI 10.1126/science.283.5407.1499; Maynard Smith J., 1995, MAJOR TRANSITIONS EV; Olsen GJ, 1996, TRENDS GENET, V12, P377, DOI 10.1016/0168-9525(96)30092-9; ORGEL LE, 1968, J MOL BIOL, V38, P381, DOI 10.1016/0022-2836(68)90393-8; REICHARD P, 1993, SCIENCE, V260, P1773, DOI 10.1126/science.8511586; Sawers G, 1998, MOL MICROBIOL, V29, P945, DOI 10.1046/j.1365-2958.1998.00941.x; Szathmary E, 1999, TRENDS GENET, V15, P223, DOI 10.1016/S0168-9525(99)01730-8; WHITE HB, 1976, J MOL EVOL, V7, P101, DOI 10.1007/BF01732468; WOESE CR, 1967, GENETIC CODE; WONG JTF, 1979, J MOL EVOL, V13, P115, DOI 10.1007/BF01732867	24	67	68	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 22	1999	286	5440					690	692		10.1126/science.286.5440.690	http://dx.doi.org/10.1126/science.286.5440.690			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	248XZ	10577226				2022-12-01	WOS:000083303200033
J	Wang, H; Tessier-Lavigne, M				Wang, H; Tessier-Lavigne, M			En passant neurotrophic action of an intermediate axonal target in the developing mammalian CNS	NATURE			English	Article							SENSORY NEURONS; COMMISSURAL AXONS; NERVOUS-SYSTEM; SPINAL-CORD; SURVIVAL; PROMOTE; DEATH; GUIDANCE; NETRINS	During development, neurons extend axons to their targets, then become dependent for their survival on trophic substances secreted by their target cells. Competition for limiting amounts of these substances is thought to account for much of the extensive naturally-occurring cell death that is seen throughout the nervous system. Here we show that spinal commissural neurons, a group of long projection neurons in the central nervous system (CNS), are also dependent for their survival on trophic support from one of their intermediate targets, the floor plate of the spinal cord. This dependence occurs during a several-day-long period when their axons extend along the floor plate, following which they develop additional trophic requirements. A dependence of neurons on trophic support derived en passant from their intermediate axonal targets provides a mechanism for rapidly eliminating misprojecting neurons, which may help to prevent the formation of aberrant neuronal circuits during the development of the nervous system.	Univ Calif San Francisco, Howard Hughes Med Inst, Dept Anat, San Francisco, CA 94143 USA; Univ Calif San Francisco, Howard Hughes Med Inst, Dept Biochem & Biophys, San Francisco, CA 94143 USA	Howard Hughes Medical Institute; University of California System; University of California San Francisco; Howard Hughes Medical Institute; University of California System; University of California San Francisco	Tessier-Lavigne, M (corresponding author), Univ Calif San Francisco, Howard Hughes Med Inst, Dept Anat, San Francisco, CA 94143 USA.							ALTMAN J, 1984, ADV ANAT EMBRYOL CEL, V85, P1; BUCHMAN VL, 1993, DEVELOPMENT, V118, P989; COMPENOT RB, 1982, DEV BIOL, V93, P1; COWAN W, 1984, S CEL HARV MED SCH B, P643; Davies AM, 1997, CURR OPIN NEUROBIOL, V7, P110, DOI 10.1016/S0959-4388(97)80128-6; Farinas I, 1996, NEURON, V17, P1065, DOI 10.1016/S0896-6273(00)80240-8; Huang EJ, 1999, DEVELOPMENT, V126, P2191; KeinoMasu K, 1996, CELL, V87, P175, DOI 10.1016/S0092-8674(00)81336-7; KENNEDY TE, 1994, CELL, V78, P425, DOI 10.1016/0092-8674(94)90421-9; Liebl DJ, 1997, J NEUROSCI, V17, P9113; MEYERFRANKE A, 1995, NEURON, V15, P805, DOI 10.1016/0896-6273(95)90172-8; Oppenheim RW, 1996, NEURON, V17, P195, DOI 10.1016/S0896-6273(00)80151-8; Pettmann B, 1998, NEURON, V20, P633, DOI 10.1016/S0896-6273(00)81004-1; Pinon LGP, 1996, DEVELOPMENT, V122, P3255; PLACZEK M, 1990, DEVELOPMENT, V110, P19; PURVES D, 1985, PRINCIPLES NEURAL DE; Serafini T, 1996, CELL, V87, P1001, DOI 10.1016/S0092-8674(00)81795-X; SERAFINI T, 1994, CELL, V78, P409, DOI 10.1016/0092-8674(94)90420-0; TESSIERLAVIGNE M, 1988, NATURE, V336, P775, DOI 10.1038/336775a0; Wilkinson GA, 1996, J NEUROSCI, V16, P7661; WRIGHT EM, 1992, NEURON, V9, P139, DOI 10.1016/0896-6273(92)90229-7	21	53	55	0	0	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	OCT 21	1999	401	6755					765	769		10.1038/44521	http://dx.doi.org/10.1038/44521			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	250BG	10548102				2022-12-01	WOS:000083368700045
J	Akaaboune, M; Culican, SM; Turney, SG; Lichtman, JW				Akaaboune, M; Culican, SM; Turney, SG; Lichtman, JW			Rapid and reversible effects of activity on acetylcholine receptor density at the neuromuscular junction in vivo	SCIENCE			English	Article							LONG-TERM POTENTIATION; RAT DIAPHRAGM; POSTSYNAPTIC CHANGES; PROLONGED PARALYSIS; ALPHA-BUNGAROTOXIN; VERTEBRATE MUSCLE; TURNOVER RATE; DEGRADATION; SYNAPSE; STABILIZATION	Quantitative fluorescence imaging was used to study the regulation of acetylcholine receptor (AChR) number and density at neuromuscular junctions in Living adult mice. At fully functional synapses, AChRs have a half-life of about 14 days. However, 2 hours after neurotransmission was blocked, the half-life of the AChRs was now Less than a day; the rate was 25 times faster than before. Most of the Lost receptors were not quickly replaced. Direct muscle stimulation or restoration of synaptic transmission inhibited this process. AChRs that were removed from nonfunctional synapses resided for hours in the perijunctional membrane before being Locally internalized. Dispersed AChRs could also reaggregate at the junction once neurotransmission was restored. The rapid and reversible alterations in AChR density at the neuromuscular junction in vivo parallel changes thought to occur in the central nervous system at synapses undergoing potentiation and depression.	Washington Univ, Sch Med, Dept Anat & Neurobiol, St Louis, MO 63110 USA	Washington University (WUSTL)	Akaaboune, M (corresponding author), Washington Univ, Sch Med, Dept Anat & Neurobiol, St Louis, MO 63110 USA.		Culican, Susan/F-4279-2019	Culican, Susan/0000-0002-0273-4310				ANDREOSE JS, 1993, J NEUROSCI, V13, P3433; BALICEGORDON RJ, 1994, NATURE, V372, P519, DOI 10.1038/372519a0; BALICEGORDON RJ, 1993, J NEUROSCI, V13, P834; BRETT RS, 1982, BRAIN RES, V233, P133, DOI 10.1016/0006-8993(82)90935-0; Carroll RC, 1999, NAT NEUROSCI, V2, P454, DOI 10.1038/8123; CULICAN SM, UNPUB; Cummings JA, 1996, NEURON, V16, P825, DOI 10.1016/S0896-6273(00)80102-6; DENNIS MJ, 1974, J PHYSIOL-LONDON, V237, P431, DOI 10.1113/jphysiol.1974.sp010490; FAMBROUGH DM, 1972, SCIENCE, V176, P189, DOI 10.1126/science.176.4031.189; FERTUCK H C, 1974, Proceedings of the National Academy of Sciences of the United States of America, V71, P1376, DOI 10.1073/pnas.71.4.1376; FERTUCK HC, 1976, J CELL BIOL, V69, P144, DOI 10.1083/jcb.69.1.144; FU DX, 1994, J BIOL CHEM, V269, P26152; GOOCH JL, 1991, CRIT CARE MED, V19, P1125, DOI 10.1097/00003246-199109000-00006; HARTZELL HC, 1972, J GEN PHYSIOL, V60, P248, DOI 10.1085/jgp.60.3.248; Kurt TL, 1996, J TOXICOL-CLIN TOXIC, V34, P253, DOI 10.3109/15563659609013783; LEVITT TA, 1980, SCIENCE, V210, P550, DOI 10.1126/science.7423205; LINGLE CJ, 1988, INT ANESTHESIOL CLIN, V26, P288, DOI 10.1097/00004311-198802640-00007; Lissin DV, 1999, J NEUROSCI, V19, P1263; MANABE T, 1992, NATURE, V355, P50, DOI 10.1038/355050a0; McKinney RA, 1999, NAT NEUROSCI, V2, P44, DOI 10.1038/4548; MCMANAMAN JL, 1981, J NEUROSCI, V1, P771, DOI 10.1523/JNEUROSCI.01-07-00771.1981; PERKEL DJ, 1993, NEURON, V11, P817, DOI 10.1016/0896-6273(93)90111-4; RAMSAY DA, 1992, BRAIN RES, V581, P198, DOI 10.1016/0006-8993(92)90709-I; RAVDIN P, 1977, ANAL BIOCHEM, V80, P585, DOI 10.1016/0003-2697(77)90682-0; RICH MM, 1989, J NEUROSCI, V9, P1781, DOI 10.1523/jneurosci.09-05-01781.1989; ROTZLER S, 1991, NATURE, V349, P337, DOI 10.1038/349337a0; SALPETER MM, 1983, J CELL BIOL, V96, P1781, DOI 10.1083/jcb.96.6.1781; SALPETER MM, 1988, J CELL BIOL, V106, P2087, DOI 10.1083/jcb.106.6.2087; SALPETER MM, 1985, PROG NEUROBIOL, V25, P297, DOI 10.1016/0301-0082(85)90018-8; Sanes JR, 1999, ANNU REV NEUROSCI, V22, P389, DOI 10.1146/annurev.neuro.22.1.389; SEGREDO V, 1992, NEW ENGL J MED, V327, P524, DOI 10.1056/NEJM199208203270804; SHYNG SL, 1989, J CELL BIOL, V108, P647, DOI 10.1083/jcb.108.2.647; STANLEY EF, 1983, SCIENCE, V222, P67, DOI 10.1126/science.6623057; STYA M, 1984, J NEUROSCI, V4, P70; Turney SG, 1996, J NEUROSCI METH, V64, P199, DOI 10.1016/0165-0270(95)00135-2	35	189	189	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	OCT 15	1999	286	5439					503	507		10.1126/science.286.5439.503	http://dx.doi.org/10.1126/science.286.5439.503			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	245RD	10521340				2022-12-01	WOS:000083121200052
J	Casadio, A; Martin, KC; Giustetto, M; Zhu, HX; Chen, M; Bartsch, D; Bailey, CH; Kandel, ER				Casadio, A; Martin, KC; Giustetto, M; Zhu, HX; Chen, M; Bartsch, D; Bailey, CH; Kandel, ER			A transient, neuron-wide form of CREB-mediated long-term facilitation can be stabilized at specific synapses by local protein synthesis	CELL			English	Article							APLYSIA SENSORY NEURONS; CAMP-RESPONSIVE ELEMENT; SYNAPTIC FACILITATION; STRUCTURAL-CHANGES; TRANSLATION INITIATION; MEMORY STORAGE; SEROTONIN; SENSITIZATION; VARICOSITIES; POTENTIATION	In a culture system where a bifurcated Aplysia sensory neuron makes synapses with two motor neurons, repeated application of serotonin (5-HT) to one synapse produces a CREB-mediated, synapse-specific, longterm facilitation, which can be captured at the opposite synapse by a single pulse of 5-HT. Repeated pulses of 5-HT applied to the cell body of the sensory neuron produce a CREB-dependent, cell-wide facilitation, which, unlike synapse-specific facilitation, is not associated with growth and does not persist beyond 48 hr. Persistent facilitation and synapse-specific growth can be induced by a single pulse of 5-HT applied to a peripheral synapse. Thus, the short-term process initiated by a single pulse of 5-HT serves not only to produce transient facilitation, but also to mark and stabilize any synapse of the neuron for long-term facilitation by means of a covalent mark and rapamycin-sensitive local protein synthesis.	Columbia Univ Coll Phys & Surg, Howard Hughes Med Inst, New York, NY 10032 USA; Columbia Univ Coll Phys & Surg, Ctr Neurobiol & Behav, New York, NY 10032 USA	Columbia University; Howard Hughes Medical Institute; Columbia University	Kandel, ER (corresponding author), Columbia Univ Coll Phys & Surg, Howard Hughes Med Inst, New York, NY 10032 USA.	erk5@columbia.edu	giustetto, maurizio/D-6606-2011	giustetto, maurizio/0000-0003-1323-4060	NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH037134] Funding Source: NIH RePORTER; NIMH NIH HHS [MH 37134] Funding Source: Medline	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		ALBERINI CM, 1994, CELL, V76, P1099, DOI 10.1016/0092-8674(94)90386-7; BACSKAI BJ, 1993, SCIENCE, V260, P222, DOI 10.1126/science.7682336; BAILEY CH, 1983, SCIENCE, V220, P91, DOI 10.1126/science.6828885; BAILEY CH, 1989, J NEUROSCI, V9, P1774; Bailey CH, 1996, P NATL ACAD SCI USA, V93, P13445, DOI 10.1073/pnas.93.24.13445; BAILEY CH, 1988, P NATL ACAD SCI USA, V85, P2373, DOI 10.1073/pnas.85.7.2373; BAILEY CH, 1993, ANNU REV PHYSIOL, V55, P397, DOI 10.1146/annurev.ph.55.030193.002145; BARTSCH D, 1995, CELL, V83, P979, DOI 10.1016/0092-8674(95)90213-9; Bartsch D, 1998, CELL, V95, P211, DOI 10.1016/S0092-8674(00)81752-3; Berset C, 1998, P NATL ACAD SCI USA, V95, P4264, DOI 10.1073/pnas.95.8.4264; BLISS TVP, 1993, NATURE, V361, P31, DOI 10.1038/361031a0; BOURTCHULADZE R, 1994, CELL, V79, P59, DOI 10.1016/0092-8674(94)90400-6; Brown EJ, 1996, CELL, V86, P517, DOI 10.1016/S0092-8674(00)80125-7; CLARK GA, 1993, P NATL ACAD SCI USA, V90, P11411, DOI 10.1073/pnas.90.23.11411; DASH PK, 1990, NATURE, V345, P718, DOI 10.1038/345718a0; EMPTAGE NJ, 1993, SCIENCE, V262, P253, DOI 10.1126/science.8211146; Frey U, 1998, NEUROPHARMACOLOGY, V37, P545, DOI 10.1016/S0028-3908(98)00040-9; Frey U, 1997, NATURE, V385, P533, DOI 10.1038/385533a0; FROST WN, 1985, P NATL ACAD SCI USA, V82, P8266, DOI 10.1073/pnas.82.23.8266; GLANZMAN DL, 1990, SCIENCE, V249, P799, DOI 10.1126/science.2389145; GOELET P, 1986, NATURE, V322, P419, DOI 10.1038/322419a0; GOLDBERG DJ, 1980, J PHYSIOL-LONDON, V307, P259, DOI 10.1113/jphysiol.1980.sp013434; HAWKINS RD, 1983, SCIENCE, V219, P400, DOI 10.1126/science.6294833; Hegde AN, 1997, CELL, V89, P115, DOI 10.1016/S0092-8674(00)80188-9; ISAAC JTR, 1995, NEURON, V15, P427, DOI 10.1016/0896-6273(95)90046-2; JEFFERIES HBJ, 1996, TRANSLATIONAL CONTRO, P389; KISTLER HB, 1985, J NEUROSCI, V5, P72; Martin KC, 1997, NEURON, V18, P899, DOI 10.1016/S0896-6273(00)80330-X; Martin KC, 1997, CELL, V91, P927, DOI 10.1016/S0092-8674(00)80484-5; MONTAROLO PG, 1986, SCIENCE, V234, P1249, DOI 10.1126/science.3775383; Rousseau D, 1996, P NATL ACAD SCI USA, V93, P1065, DOI 10.1073/pnas.93.3.1065; Sun ZY, 1998, J NEUROSCI, V18, P3991; Yanow SK, 1998, J NEUROCHEM, V70, P572; YIN JCP, 1995, CELL, V81, P107, DOI 10.1016/0092-8674(95)90375-5; YIN JCP, 1994, CELL, V79, P49, DOI 10.1016/0092-8674(94)90399-9; ZHANG ZS, 1991, J COMP NEUROL, V311, P259, DOI 10.1002/cne.903110207	36	399	409	0	22	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	OCT 15	1999	99	2					221	237		10.1016/S0092-8674(00)81653-0	http://dx.doi.org/10.1016/S0092-8674(00)81653-0			17	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	246JB	10535740	Bronze			2022-12-01	WOS:000083159700012
J	Jaeger, JJ; Thein, T; Benammi, M; Chaimanee, Y; Soe, AN; Lwin, T; Tun, T; Wai, S; Ducrocq, S				Jaeger, JJ; Thein, T; Benammi, M; Chaimanee, Y; Soe, AN; Lwin, T; Tun, T; Wai, S; Ducrocq, S			A new primate from the Middle Eocene of Myanmar and the Asian early origin of anthropoids	SCIENCE			English	Article							THAILAND; CHINA	A new genus and species of anthropoid primate, Bahinia pondaungensis gen. et sp. nov., is described from the Yashe Kyitchaung Locality in the Late Middle Eocene Pondaung Formation (Myanmar). it is related to Eosimias, but it is represented by more complete remains. including upper dentition with associated lower jaw fragment. it is interpreted as a new representative of the family Eosimiidae, which corresponds to the sister group of the Amphipithecidae and of all other anthropoids. Eosimiidae are now recorded from three distinct Middle Eocene Localities in Asia, giving support to the hypothesis of an Asian origin of anthropoids.	Univ Montpellier 2, Inst Sci Evolut, F-34095 Montpellier 5, France; Univ Pathein, Dept Geol, Pathein, Myanmar; Dept Mineral Resources, Geol Survey Div, Paleontol Sect, Bangkok 10400, Thailand; Univ Yangon, Dept Geol, Yangon, Myanmar; Minist Def, Off Strateg Studies, Yangon, Myanmar	Centre National de la Recherche Scientifique (CNRS); Institut de Recherche pour le Developpement (IRD); Universite de Montpellier; Department of Mineral Resources - Thailand; University of Yangon	Ducrocq, S (corresponding author), Univ Montpellier 2, Inst Sci Evolut, Case 064, F-34095 Montpellier 5, France.			chaimanee, yaowalak/0000-0002-8432-3880				Beard K. Christopher, 1998, Bulletin of Carnegie Museum of Natural History, V34, P260; Beard KC, 1996, SCIENCE, V272, P82, DOI 10.1126/science.272.5258.82; BEARD KC, 1994, NATURE, V368, P604, DOI 10.1038/368604a0; Chaimanee Y, 1997, NATURE, V385, P429, DOI 10.1038/385429a0; CHOW M, 1961, VERTEBRAT PALASIATIC, V1, P1; DUCROCQ S, 1995, J HUM EVOL, V28, P477, DOI 10.1006/jhev.1995.1035; GINGERICH PD, 1980, AM J PHYS ANTHROPOL, V52, P231; Gingerich Philip D., 1994, P163; GODINOT M, 1992, NATURE, V357, P324, DOI 10.1038/357324a0; Godinot Marc, 1994, P235; JAEGER JA, UNPUB; Jaeger JJ, 1998, CR ACAD SCI III-VIE, V321, P953, DOI 10.1016/S0764-4469(99)80010-9; Kay Richard F., 1994, P361; Legendre S., 1989, Muenchner Geowissenschaftliche Abhandlungen Reihe A Geologie und Palaeontologie, V16, P1; MARTIN RD, 1993, NATURE, V363, P223, DOI 10.1038/363223a0; Rose Kenneth D., 1994, P1; Rossow KD, 1998, VET PATHOL, V35, P1, DOI 10.1177/030098589803500101; RUSSELL DE, 1980, CR ACAD SCI D NAT, V291, P621; RUSSELL DE, 1987, CR ACAD SCI II, V304, P209; SIGE B, 1990, Palaeontographica Abteilung A Palaeozoologie-Stratigraphie, V214, P31; SIMONS EL, 1985, NATURE, V313, P475, DOI 10.1038/313475a0; SIMONS EL, 1995, SCIENCE, V268, P1885, DOI 10.1126/science.7604261; Simons Elwyn L., 1994, P179; Szalay F.S., 1979, EVOLUTIONARY HIST PR; TONG YS, 1997, PALEONTOLOGICA SIN C, V26, P189	25	104	111	0	7	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	OCT 15	1999	286	5439					528	530		10.1126/science.286.5439.528	http://dx.doi.org/10.1126/science.286.5439.528			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	245RD	10521348				2022-12-01	WOS:000083121200060
J	O'Hanlan, KA				O'Hanlan, KA			Domestic partnership benefits at medical universities	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material									Stanford Med Ctr, Palo Alto, CA 94305 USA	Stanford University	O'Hanlan, KA (corresponding author), Stanford Med Ctr, Palo Alto, CA 94305 USA.		O'Hanlan, Katherine/A-4073-2017	O'Hanlan, Katherine/0000-0002-7577-4188				*AM MED WOM ASS, 1993, J AM MED WOMEN ASSOC, V49, P86; *AM PSYCH ASS, 1994, DIAGN STAT MAN MENT, P538; BERSOFF DN, 1991, AM PSYCHOL, V46, P950, DOI 10.1037/0003-066X.46.9.950; BUSH CN, 1991, STANFORD U CAMPUS RE, P1; Davis RM, 1996, JAMA-J AM MED ASSOC, V275, P1354, DOI 10.1001/jama.1996.03530410068036; FRIED B, 1992, REPORT SUBCOMMITTEE, P37; KOHN S, 1999, DOMESTIC PARTNER ORG, P120; OHANLAN KA, 1991, FAC SEN STANF U OCT; 1992, TOT COMP NEWS    DEC, P1	9	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 6	1999	282	13					1289	+		10.1001/jama.282.13.1289	http://dx.doi.org/10.1001/jama.282.13.1289			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	241UM	10517436	hybrid			2022-12-01	WOS:000082901100041
J	Borg, LE; Connelly, JN; Nyquist, LE; Shih, CY; Wiesmann, H; Reese, Y				Borg, LE; Connelly, JN; Nyquist, LE; Shih, CY; Wiesmann, H; Reese, Y			The age of the carbonates in martian meteorite ALH84001	SCIENCE			English	Article							PETROLOGIC EVIDENCE; SM-ND; MARS; ORIGIN; DIFFERENTIATION; TEMPERATURE; CHRONOLOGY; RB; SR	The age of secondary carbonate mineralization in the martian meteorite ALH84001 was determined to be 3.90 +/- 0.04 billion years by rubidium-strontium (Rb-Sr) dating and 4.04 +/- 0.10 billion years by Lead-Lead (Pb-Pb) dating. The Rb-Sr and Pb-Pb isochrons are defined by Leachates of a mixture of high-graded carbonate (visually estimated as similar to 5 percent). whitlockite (trace), and orthopyroxene (similar to 95 percent). The carbonate formation age is contemporaneous with a period in martian history when the surface is thought to have had flowing water, but also was undergoing heavy bombardment by meteorites. Therefore, this age does not distinguish between aqueous and impact origins for the carbonates.	NASA, Lyndon B Johnson Space Ctr, Houston, TX 77058 USA; Univ Texas, Dept Geol Sci, Austin, TX 78713 USA; Lockheed Engn & Sci Co, Houston, TX 77258 USA	National Aeronautics & Space Administration (NASA); NASA JOHNSON SPACE CENTER; University of Texas System; University of Texas Austin; Lockheed Martin	Borg, LE (corresponding author), Univ New Mexico, Inst Meteorit, Albuquerque, NM 87131 USA.		Connelly, James/O-7996-2015					BENOTHMAN D, 1989, EARTH PLANET SC LETT, V94, P1, DOI 10.1016/0012-821X(89)90079-4; Bogard DD, 1999, METEORIT PLANET SCI, V34, P451, DOI 10.1111/j.1945-5100.1999.tb01353.x; Borg LE, 1997, GEOCHIM COSMOCHIM AC, V61, P4915, DOI 10.1016/S0016-7037(97)00276-7; CARR MH, 1983, ICARUS, V56, P476, DOI 10.1016/0019-1035(83)90168-9; CARR MH, 1996, WATER MARS, V20, P229; FANNALE FP, 1992, MARS, P1135; Gilmour JD, 1997, METEORIT PLANET SCI, V32, pA48; Gleason JD, 1997, GEOCHIM COSMOCHIM AC, V61, P3503, DOI 10.1016/S0016-7037(97)00173-7; HARPER CL, 1995, SCIENCE, V267, P213, DOI 10.1126/science.7809625; Hartmann W.K., 1981, BASALTIC VOLCANISM T, P1049; Harvey RP, 1996, NATURE, V382, P49, DOI 10.1038/382049a0; JAGOUTZ E, 1994, METEORITICS, V29, P478; LUGMAIR GW, 1992, GEOCHIM COSMOCHIM AC, V56, P1673, DOI 10.1016/0016-7037(92)90234-A; McKay DS, 1996, SCIENCE, V273, P924, DOI 10.1126/science.273.5277.924; McSween HY, 1998, INT GEOL REV, V40, P774, DOI 10.1080/00206819809465238; MITTLEFEHLDT DW, 1994, METEORITICS, V29, P214, DOI 10.1111/j.1945-5100.1994.tb00673.x; NAKAMURA N, 1982, GEOCHIM COSMOCHIM AC, V46, P1555, DOI 10.1016/0016-7037(82)90314-3; NEUKUM G, 1976, SCIENCE, V194, P1381, DOI 10.1126/science.194.4272.1381; NYQUIST LE, 1995, LUNAR PLANET SCI, V26, P1065; ROMANEK CS, 1994, NATURE, V372, P655, DOI 10.1038/372655a0; Scott ERD, 1998, METEORIT PLANET SCI, V33, P709, DOI 10.1111/j.1945-5100.1998.tb01677.x; Scott ERD, 1997, NATURE, V387, P377, DOI 10.1038/387377a0; SHIH CY, 1982, GEOCHIM COSMOCHIM AC, V46, P2323, DOI 10.1016/0016-7037(82)90205-8; TATSUMOTO M, 1973, SCIENCE, V180, P1279, DOI 10.1126/science.180.4092.1279; TRIEMAN AH, 1995, METEORITICS, V30, P294; Turner G, 1997, GEOCHIM COSMOCHIM AC, V61, P3835, DOI 10.1016/S0016-7037(97)00285-8; Wadhwa M, 1998, METEORIT PLANET SCI, V33, P685, DOI 10.1111/j.1945-5100.1998.tb01674.x; Wadhwa M., 1996, METEORIT PLANET SCI, V31, pA145; Warren PH, 1998, J GEOPHYS RES-PLANET, V103, P16759, DOI 10.1029/98JE01544; YORK D, 1966, CAN J PHYS, V44, P1079, DOI 10.1139/p66-090; [No title captured]; [No title captured]	32	130	134	0	29	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	OCT 1	1999	286	5437					90	94		10.1126/science.286.5437.90	http://dx.doi.org/10.1126/science.286.5437.90			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	241WT	10506566	Green Submitted			2022-12-01	WOS:000082907400039
J	Andreu, AL; Hanna, MG; Reichmann, H; Bruno, C; Penn, AS; Tanji, K; Pallotti, F; Iwata, S; Bonilla, E; Lach, B; Morgan-Hughes, J; DiMauro, S				Andreu, AL; Hanna, MG; Reichmann, H; Bruno, C; Penn, AS; Tanji, K; Pallotti, F; Iwata, S; Bonilla, E; Lach, B; Morgan-Hughes, J; DiMauro, S			Exercise intolerance due to mutations in the cytochrome b gene of mitochondrial DNA	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							COMPLEX-III DEFICIENCY; C-OXIDASE DEFICIENCY; SKELETAL-MUSCLE; POINT MUTATION; MYOPATHY; MTDNA; PATIENT; DISEASE; GENOME	Background The mitochondrial myopathies typically affect many organ systems and are associated with mutations in mitochondrial DNA (mtDNA) that are maternally inherited. However, there is also a sporadic form of mitochondrial myopathy in which exercise intolerance is the predominant symptom. We studied the biochemical and molecular characteristics of this sporadic myopathy. Methods We sequenced the mtDNA cytochrome b gene in blood and muscle specimens from five patients with severe exercise intolerance, lactic acidosis in the resting state (in four patients), and biochemical evidence of complex III deficiency. We compared the clinical and molecular features of these patients with those previously described in four other patients with mutations in the cytochrome b gene. Results We found a total of three different nonsense mutations (G15084A, G15168A, and G15723A), one missense mutation (G14846A), and a 24-bp deletion (nucleotides 15498 to 15521) in the cytochrome b gene in the five patients. Each of these mutations impairs the enzymatic function of the cytochrome b protein. In these patients and those previously described, the clinical manifestations included progressive exercise intolerance, proximal limb weakness, and in some cases, attacks of myoglobinuria. There was no maternal inheritance and there were no mutations in tissues other than muscle. The absence of these findings suggests that the disorder is due to somatic mutations in myogenic stem cells after germ-layer differentiation. All the point mutations involved the substitution of adenine for guanine, but all were in different locations. Conclusions The sporadic form of mitochondrial myopathy is associated with somatic mutations in the cytochrome b gene of mtDNA. This myopathy is one cause of the common and often elusive syndrome of exercise intolerance. (N Engl J Med 1999; 341:1037-44.) (C)1999, Massachusetts Medical Society.	Columbia Univ Coll Phys & Surg, H Houston Merritt Clin Res Ctr Muscular Dystrophy, Dept Neurol, New York, NY 10032 USA; Hosp Valle De Hebron, Ctr Invest Bioquim & Biol Mol, Barcelona, Spain; UCL, Inst Neurol, London, England; Tech Univ Dresden, Klinikum Carl Gustav Carus, Neurol Klin, D-8027 Dresden, Germany; Univ Genoa, Ist Giannina Gaslini, Dept Pediat, Genoa, Italy; NINDS, NIH, Bethesda, MD 20892 USA; Uppsala Univ, Dept Biochem, Uppsala, Sweden; Ottawa Hosp, Dept Lab Med, Ottawa, ON, Canada	Columbia University; Hospital Universitari Vall d'Hebron; University of London; University College London; Technische Universitat Dresden; University of Genoa; IRCCS Istituto Giannina Gaslini; National Institutes of Health (NIH) - USA; NIH National Institute of Neurological Disorders & Stroke (NINDS); Uppsala University; University of Ottawa; Ottawa Hospital Research Institute	DiMauro, S (corresponding author), 4 420 Coll Phys & Surg, 630 W 168th St, New York, NY 10032 USA.	sd12@columbia.edu	Bruno, Claudio/A-3148-2015; Hanna, Michael G/B-1995-2009	Bruno, Claudio/0000-0002-3426-2901; ANDREU, antonio luis/0000-0002-3936-3234; Hanna, Michael/0000-0003-0825-4075; Pallotti, Francesco/0000-0001-9946-8516	NICHD NIH HHS [P01HD32062] Funding Source: Medline; NINDS NIH HHS [NS11766] Funding Source: Medline; Wellcome Trust Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [P01HD032062] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P01NS011766, P50NS011766] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); Wellcome Trust(Wellcome TrustEuropean Commission); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ANDERSON S, 1981, NATURE, V290, P457, DOI 10.1038/290457a0; Andreu AL, 1999, MOL GENET METAB, V67, P49, DOI 10.1006/mgme.1999.2843; Andreu AL, 1998, NEUROLOGY, V51, P1444, DOI 10.1212/WNL.51.5.1444; Andreu AL, 1999, ANN NEUROL, V45, P127, DOI 10.1002/1531-8249(199901)45:1<127::AID-ART20>3.0.CO;2-Y; Beckman KB, 1997, J BIOL CHEM, V272, P19633, DOI 10.1074/jbc.272.32.19633; BOUZIDI MF, 1993, NEUROMUSCULAR DISORD, V3, P599; Cadet J, 1997, Rev Physiol Biochem Pharmacol, V131, P1; DIMAURO S, 1987, ANN NEUROL, V22, P498, DOI 10.1002/ana.410220409; DiMauro S, 1997, MOL GENETIC BASIS NE, P201; Dumoulin R, 1996, MOL CELL PROBE, V10, P389, DOI 10.1006/mcpr.1996.0053; ELEFF S, 1984, P NATL ACAD SCI-BIOL, V81, P3529, DOI 10.1073/pnas.81.11.3529; ENGEL WK, 1963, NEUROLOGY, V13, P919, DOI 10.1212/WNL.13.11.919; Fu K, 1996, HUM MOL GENET, V5, P1835, DOI 10.1093/hmg/5.11.1835; Hanna MG, 1998, AM J HUM GENET, V63, P29, DOI 10.1086/301910; Iwata S, 1998, SCIENCE, V281, P64, DOI 10.1126/science.281.5373.64; JOHNS DR, 1995, NEW ENGL J MED, V333, P638, DOI 10.1056/NEJM199509073331007; Kennaway N. G., 1998, MOL GENET METAB, V63, P49; Kogelnik AM, 1998, NUCLEIC ACIDS RES, V26, P112, DOI 10.1093/nar/26.1.112; MARTIN GM, 1973, TISSUE CULTURE METHO, P39; MIRANDA AF, 1986, METHOD ENZYMOL, V119, P619; Moraes C T, 1996, Methods Enzymol, V264, P522, DOI 10.1016/S0076-6879(96)64046-4; MORAES CT, 1993, NAT GENET, V4, P284, DOI 10.1038/ng0793-284; MORGANHUGHES JA, 1977, BRAIN, V100, P617, DOI 10.1093/brain/100.4.617; REICHMANN H, 1986, ARCH NEUROL-CHICAGO, V43, P957, DOI 10.1001/archneur.1986.00520090081024; Sciacco M, 1996, Methods Enzymol, V264, P509, DOI 10.1016/S0076-6879(96)64045-2; SCIACCO M, 1994, HUM MOL GENET, V3, P687; SCIACCO M, 1994, HUM MOL GENET, V3, P13, DOI 10.1093/hmg/3.1.13; Weber K, 1997, AM J HUM GENET, V60, P373	28	312	320	0	11	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	SEP 30	1999	341	14					1037	1044		10.1056/NEJM199909303411404	http://dx.doi.org/10.1056/NEJM199909303411404			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	241JX	10502593				2022-12-01	WOS:000082880500004
J	Fauci, AS				Fauci, AS			The AIDS epidemic - Considerations for the 21st century	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; ACTIVE ANTIRETROVIRAL THERAPY; HIV-INFECTION; UNITED-STATES; TRANSMISSION; RESERVOIR; MORTALITY		NIAID, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)	Fauci, AS (corresponding author), NIAID, NIH, 9000 Rockville Pike, Bethesda, MD 20892 USA.	afauci@niaid.nih.gov						[Anonymous], 1998, MMWR Recomm Rep, V47, P1; *CDCP, 1998, HIV AIDS SURVEILLANC, V10, P1; Chun TW, 1997, P NATL ACAD SCI USA, V94, P13193, DOI 10.1073/pnas.94.24.13193; Chun TW, 1999, NAT MED, V5, P651, DOI 10.1038/9498; Chun TW, 1998, P NATL ACAD SCI USA, V95, P8869, DOI 10.1073/pnas.95.15.8869; Coates TJ, 1998, SCI AM, V279, P96, DOI 10.1038/scientificamerican0798-96; CONNOR EM, 1994, NEW ENGL J MED, V331, P1173, DOI 10.1056/NEJM199411033311801; Cooper DA, 1999, NAT MED, V5, P611, DOI 10.1038/9454; Detels R, 1998, JAMA-J AM MED ASSOC, V280, P1497, DOI 10.1001/jama.280.17.1497; Dore GJ, 1998, AIDS, V12, P2354; Durant J, 1999, LANCET, V353, P2195, DOI 10.1016/S0140-6736(98)12291-2; Elias CJ, 1996, AIDS, V10, pS43; Evans TG, 1999, J INFECT DIS, V180, P290, DOI 10.1086/314895; FAUCI AS, 1988, SCIENCE, V239, P617, DOI 10.1126/science.3277274; Finzi D, 1999, NAT MED, V5, P512, DOI 10.1038/8394; Finzi D, 1997, SCIENCE, V278, P1295, DOI 10.1126/science.278.5341.1295; Folkers GK, 1998, NAT MED, V4, P491, DOI 10.1038/nm0598supp-491; Francis DP, 1998, AIDS RES HUM RETROV, V14, pS325; Furtado MR, 1999, NEW ENGL J MED, V340, P1614, DOI 10.1056/NEJM199905273402102; Gao F, 1999, NATURE, V397, P436, DOI 10.1038/17130; Guay LA, 1999, LANCET, V354, P795, DOI 10.1016/S0140-6736(99)80008-7; Harrigan PR, 1999, AIDS, V13, pF59, DOI 10.1097/00002030-199905280-00001; HIRSCH VM, 1989, NATURE, V339, P389, DOI 10.1038/339389a0; Hoyert D L, 1999, Natl Vital Stat Rep, V47, P1; Karon JM, 1996, JAMA-J AM MED ASSOC, V276, P126, DOI 10.1001/jama.276.2.126; Kilbourne E.D., 1987, INFLUENZA, P3; Kramer Larry, 1994, REPORTS HOLOCAUST ST; Krause RM, 1998, BIOMED RES REP, P1; Mann JM, 1997, HASTINGS CENT REP, V27, P6, DOI 10.2307/3528660; Mocroft A, 1998, LANCET, V352, P1725, DOI 10.1016/S0140-6736(98)03201-2; Mofenson LM, 1999, LANCET, V353, P766, DOI 10.1016/S0140-6736(99)90028-4; Palella FJ, 1998, NEW ENGL J MED, V338, P853, DOI 10.1056/NEJM199803263381301; *PHS TASK FORC, 1998, MMWR-MORBID MORTAL W, V47, P1; Pomerantz RJ, 1999, NEW ENGL J MED, V340, P1672, DOI 10.1056/NEJM199905273402110; Quinn TC, 1998, BIOMED RES REP, P327; ROSENBERG PS, 1994, NEW ENGL J MED, V330, P789, DOI 10.1056/NEJM199403173301114; ROSENBERG PS, 1995, SCIENCE, V270, P1372, DOI 10.1126/science.270.5240.1372; SABA J, 1999, RESULTS PETRA INTERV; SWEENEY PA, 1997, INT C ANT AG CHEM TO; *UN, 1999, DEM IMP HIV AIDS; Vittinghoff E, 1999, J INFECT DIS, V179, P717, DOI 10.1086/314623; Weiss RA, 1999, NATURE, V397, P385, DOI 10.1038/17008; *WHO, 1998, AIDS EP UPD DEC 1998; Wong JK, 1997, SCIENCE, V278, P1291, DOI 10.1126/science.278.5341.1291; World Health Organization, 1999, WORLD HLTH REP 1999; World Health Organization, 1999, REM OBST HLTH DEV; Zhang LQ, 1999, NEW ENGL J MED, V340, P1605, DOI 10.1056/NEJM199905273402101; 1998, MMWR MORB MORTAL WKL, P47	48	188	195	0	4	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	SEP 30	1999	341	14					1046	1050		10.1056/NEJM199909303411406	http://dx.doi.org/10.1056/NEJM199909303411406			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	241JX	10502595				2022-12-01	WOS:000082880500006
J	Rauskolb, C; Correla, T; Irvine, KD				Rauskolb, C; Correla, T; Irvine, KD			Fringe-dependent separation of dorsal and ventral cells in the Drosophila wing	NATURE			English	Article							IMAGINAL DISC; NOTCH; LIMB; COMPARTMENTALIZATION; EXPRESSION; ACTIVATION; BOUNDARY; RECEPTOR; PROTEIN; SERRATE	The separation of cells into populations that do not intermix, termed compartments, is a fundamental organizing principle during development(1-5). Dorsal-ventral compartmentalization of the Drosophila wing is regulated downstream of the apterous (np) gene, which encodes a transcription factor that specifies dorsal wing fate(6-8). fringe (fng) is normally expressed by dorsal cells downstream of ap(9); here we show that fng plays a key role in dorsal-ventral compartmentalization. Loss of fng function causes dorsal cells to violate the compartment boundary, and ectopic expression of the Fng protein causes ventral cells to violate the compartment boundary. Fng modulates signalling through the Notch receptor(10,11). Notch and its ligands are essential for formation of the dorsal-ventral compartment border, and repositioning the stripe of Notch activation that is normally established there appears to reposition the compartment border. However, activation of Notch does not itself confer either dorsal or ventral cell location, and fng can influence compartmentalization even within regions of ubiquitous Notch activation. Our results indicate that the primary mechanism by which fng establishes a compartment border is by positioning a stripe of Notch activation, but also that fng may exert additional influences on compartmentalization.	Rutgers State Univ, Waksman Inst, Piscataway, NJ 08854 USA; Rutgers State Univ, Dept Mol Biol & Biochem, Piscataway, NJ 08854 USA	Rutgers State University New Brunswick; Rutgers State University New Brunswick	Irvine, KD (corresponding author), Rutgers State Univ, Waksman Inst, POB 759, Piscataway, NJ 08854 USA.	irvine@waksman.rutgers.edu						Altabef M, 1997, DEVELOPMENT, V124, P4547; BLAIR SS, 1993, DEVELOPMENT, V119, P339; BLAIR SS, 1994, DEVELOPMENT, V120, P1805; Blair SS, 1997, DEVELOPMENT, V124, P4053; COHEN B, 1992, GENE DEV, V6, P715, DOI 10.1101/gad.6.5.715; DIAZBENJUMEA FJ, 1993, CELL, V75, P741, DOI 10.1016/0092-8674(93)90494-B; FEHON RG, 1990, CELL, V61, P523, DOI 10.1016/0092-8674(90)90534-L; Fleming RJ, 1997, DEVELOPMENT, V124, P2973; FRASER S, 1990, NATURE, V344, P431, DOI 10.1038/344431a0; GARCIABELLIDO A, 1973, NATURE-NEW BIOL, V245, P251, DOI 10.1038/newbio245251a0; Greenwald I, 1998, GENE DEV, V12, P1751, DOI 10.1101/gad.12.12.1751; Irvine KD, 1999, CURR OPIN GENET DEV, V9, P434, DOI 10.1016/S0959-437X(99)80066-5; IRVINE KD, 1994, CELL, V79, P595, DOI 10.1016/0092-8674(94)90545-2; Irvine KD, 1997, CURR OPIN CELL BIOL, V9, P867, DOI 10.1016/S0955-0674(97)80090-7; Ito K, 1997, DEVELOPMENT, V124, P761; KIM J, 1995, CELL, V82, P795, DOI 10.1016/0092-8674(95)90476-X; Lawrence PA, 1996, CELL, V85, P951, DOI 10.1016/S0092-8674(00)81297-0; Lawrence PA, 1999, DEVELOPMENT, V126, P2441; LYMAN D, 1993, P NATL ACAD SCI USA, V90, P10395, DOI 10.1073/pnas.90.21.10395; Micchelli CA, 1997, DEVELOPMENT, V124, P1485; Michaud JL, 1997, DEVELOPMENT, V124, P1453; Panin VM, 1998, SEMIN CELL DEV BIOL, V9, P609, DOI 10.1006/scdb.1998.0263; Panin VM, 1997, NATURE, V387, P908, DOI 10.1038/43191; Rauskolb C, 1999, DEV BIOL, V210, P339, DOI 10.1006/dbio.1999.9273; REBAY I, 1991, CELL, V67, P687, DOI 10.1016/0092-8674(91)90064-6; Rodriguez I, 1997, NATURE, V389, P614, DOI 10.1038/39343; RULIFSON EJ, 1995, DEVELOPMENT, V121, P2813; STRUHL G, 1993, CELL, V74, P331, DOI 10.1016/0092-8674(93)90424-O; XU T, 1993, DEVELOPMENT, V117, P1223	29	90	91	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	SEP 30	1999	401	6752					476	480		10.1038/46786	http://dx.doi.org/10.1038/46786			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	243DF	10519550				2022-12-01	WOS:000082981200056
J	Gussoni, E; Soneoka, Y; Strickland, CD; Buzney, EA; Khan, MK; Flint, AF; Kunkel, LM; Mulligan, RC				Gussoni, E; Soneoka, Y; Strickland, CD; Buzney, EA; Khan, MK; Flint, AF; Kunkel, LM; Mulligan, RC			Dystrophin expression in the mdx mouse restored by stem cell transplantation	NATURE			English	Article							GENE-THERAPY; ENDOTHELIAL-CELLS; NUCLEAR DOMAINS; SKELETAL-MUSCLE; FULL-LENGTH; MICE; MARROW; BONE; INJECTION; MYOBLASTS	The development of cell or gene therapies for diseases involving cells that are widely distributed throughout the body has been severely hampered by the inability to achieve the disseminated delivery of cells or genes to the affected tissues or organ(1). Here we report the results of bone marrow transplantation studies in the mdx mouse, an animal model of Duchenne's muscular dystrophy(2), which indicate that the intravenous injection of either normal haematopoietic stem cells or a novel population of muscle-derived stem cells into irradiated animals results in the reconstitution of the haematopoietic compartment of the transplanted recipients, the incorporation of donor-derived nuclei into muscle, and the partial restoration of dystrophin expression in the affected muscle. These results suggest that the transplantation of different stem cell populations, using the procedures of bone marrow transplantation, might provide an unanticipated avenue for treating muscular dystrophy as well as other diseases where the systemic delivery of therapeutic cells to sites throughout the body is critical. Our studies also suggest that the inherent developmental potential of stem cells isolated from diverse tissues or organs may be more similar than previously anticipated.	Childrens Hosp, Howard Hughes Med Inst, Boston, MA 02115 USA; Childrens Hosp, Div Genet, Boston, MA 02115 USA; Childrens Hosp, Dept Surg Res, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Genet, Boston, MA 02115 USA	Harvard University; Boston Children's Hospital; Howard Hughes Medical Institute; Harvard University; Boston Children's Hospital; Harvard University; Boston Children's Hospital; Harvard University; Harvard Medical School	Mulligan, RC (corresponding author), Childrens Hosp, Howard Hughes Med Inst, Boston, MA 02115 USA.	kunkel@rascal.med.harvard.edu; mulligan@rascal.med.harvard.edu	Gussoni, Emanuela/AAL-6150-2021; Ahmad Khan, Mohammad Kalim/AAA-2751-2022	Gussoni, Emanuela/0000-0002-9915-3677; Ahmad Khan, Mohammad Kalim/0000-0002-8004-1448				ACSADI G, 1991, NATURE, V352, P815, DOI 10.1038/352815a0; Asahara T, 1997, SCIENCE, V275, P964, DOI 10.1126/science.275.5302.964; Baroffio A, 1995, DIFFERENTIATION, V59, P259, DOI 10.1046/j.1432-0436.1995.5940259.x; Bittner RE, 1999, ANAT EMBRYOL, V199, P391, DOI 10.1007/s004290050237; Bjornson CRR, 1999, SCIENCE, V283, P534, DOI 10.1126/science.283.5401.534; Ferrari G, 1998, SCIENCE, V279, P1528, DOI 10.1126/science.279.5356.1528; Goodell MA, 1997, NAT MED, V3, P1337, DOI 10.1038/nm1297-1337; Goodell MA, 1996, J EXP MED, V183, P1797, DOI 10.1084/jem.183.4.1797; Gussoni E, 1996, NAT BIOTECHNOL, V14, P1012, DOI 10.1038/nbt0896-1012; Gussoni E, 1997, NAT MED, V3, P970, DOI 10.1038/nm0997-970; HALL ZW, 1989, CELL, V59, P771, DOI 10.1016/0092-8674(89)90597-7; HOFFMAN EP, 1990, J NEUROL SCI, V99, P9, DOI 10.1016/0022-510X(90)90195-S; KARPATI G, 1989, AM J PATHOL, V135, P27; Kochanek S, 1996, P NATL ACAD SCI USA, V93, P5731, DOI 10.1073/pnas.93.12.5731; LICHTER P, 1988, P NATL ACAD SCI USA, V85, P9664, DOI 10.1073/pnas.85.24.9664; MAURO A, 1961, J BIOPHYS BIOCHEM CY, V9, P493, DOI 10.1083/jcb.9.2.493; MULLIGAN RC, 1993, SCIENCE, V260, P926, DOI 10.1126/science.8493530; PARTRIDGE TA, 1991, MUSCLE NERVE, V14, P197, DOI 10.1002/mus.880140302; PARTRIDGE TA, 1989, NATURE, V337, P176, DOI 10.1038/337176a0; PAVLATH GK, 1989, NATURE, V337, P570, DOI 10.1038/337570a0; PEREIRA RF, 1995, P NATL ACAD SCI USA, V92, P4857, DOI 10.1073/pnas.92.11.4857; PHELPS SF, 1995, HUM MOL GENET, V4, P1251, DOI 10.1093/hmg/4.8.1251; Prockop DJ, 1997, SCIENCE, V276, P71, DOI 10.1126/science.276.5309.71; RAFAEL JA, 1994, HUM MOL GENET, V3, P1725, DOI 10.1093/hmg/3.10.1725; RAGOT T, 1993, NATURE, V361, P647, DOI 10.1038/361647a0; RANDO TA, 1994, J CELL BIOL, V125, P1275, DOI 10.1083/jcb.125.6.1275; Saito T, 1995, Tissue Eng, V1, P327, DOI 10.1089/ten.1995.1.327; Shi Q, 1998, BLOOD, V92, P362, DOI 10.1182/blood.V92.2.362.414k38_362_367; SICINSKI P, 1989, SCIENCE, V244, P1578, DOI 10.1126/science.2662404	29	1440	1637	1	91	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	SEP 23	1999	401	6751					390	394		10.1038/43919	http://dx.doi.org/10.1038/43919			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	240JJ	10517639	Bronze			2022-12-01	WOS:000082822600055
J	Quinn, C				Quinn, C			The pirates	ANNALS OF INTERNAL MEDICINE			English	Article											Quinn, C (corresponding author), 49 Thomas Rd, Rockville Ctr, NY 11570 USA.								0	2	2	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	SEP 21	1999	131	6					472	473		10.7326/0003-4819-131-6-199909210-00015	http://dx.doi.org/10.7326/0003-4819-131-6-199909210-00015			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	237DY	10498567				2022-12-01	WOS:000082641100013
J	Cardosa, MJ; Krishnan, S; Tio, PH; Perera, D; Wong, SC				Cardosa, MJ; Krishnan, S; Tio, PH; Perera, D; Wong, SC			Isolation of subgenus B adenovirus during a fatal outbreak of enterovirus 71-associated hand, foot, and mouth disease in Sibu, Sarawak	LANCET			English	Article							NEUROGENIC PULMONARY-EDEMA; POLYMERASE CHAIN-REACTION; JAPANESE ENCEPHALITIS; ENZYME-IMMUNOASSAY; RAPID DIAGNOSIS; MYOCARDITIS; VIRUS; ENCEPHALOMYELITIS; IDENTIFICATION; SAMPLES	Background In mid-1997, several children died in Sarawak, Malaysia,during an epidemic of enterovirus-71 (EV71) hand, foot, and mouth disease. The children who died had a febrile illness that rapidly progressed to cardiopulmonary failure and the cause was not satisfactorily resolved. We describe the isolation and identification of a subgenus B adenovirus from the children who died. Methods We studied two groups of children presenting to Sibu Hospital from April 14 to Sept 30, 1997. For children who died, the inclusion criterion was death after febrile illness, and for those who did not die it was acute flaccid paralysis (AFP). Serum and cerebrospinal fluid samples were tested for IgM antibodies to Japanese encephalitis and dengue viruses. Viruses isolated were identified by immunofluorescence, reverse-transcriptase PCR, or PCR and DNA sequencing. Findings Enterovirus was isolated in three (19%) of 16 children who died and in none of the eight surviving children with AFP. However, an agent that was initially difficult to identify was found in ten (63%) children who died and five (63%) surviving children who had AFP. The agents isolated from ten (66.7%) of these 15 children were eventually identified as adenoviruses and were isolated mainly from clinically important sterile sites or tissues. All the enterovirus positive children who died had this second agent. Interpretation Our data raises doubts that EV71 was the only aetiological agent in these deaths.	Univ Malaysia Sarawak, Inst Hlth & Community Med, Kota Samarahan 94300, Sarawak, Malaysia; Sibu Hosp, Sibu, Sarawak, Malaysia	University of Malaysia Sarawak	Cardosa, MJ (corresponding author), Univ Malaysia Sarawak, Inst Hlth & Community Med, Kota Samarahan 94300, Sarawak, Malaysia.	jcardosa@mailhost.unimas.my	Cardosa, Mary Jane/A-3611-2009					ALLARD A, 1990, J CLIN MICROBIOL, V28, P2659, DOI 10.1128/JCM.28.12.2659-2667.1990; [Anonymous], 1997, Wkly Epidemiol Rec, V72, P211; BOWLES NE, 1986, LANCET, V1, P1120; BRANDON F. B., 1962, ADVANCES VIRUS RES, V9, P157; CARDOSA MJ, 1995, CLIN DIAGN VIROL, V3, P343, DOI 10.1016/0928-0197(94)00049-Z; Centers for Disease Control and Prevention (CDC), 1998, MMWR Morb Mortal Wkly Rep, V47, P629; Chang LY, 1998, LANCET, V352, P367, DOI 10.1016/S0140-6736(98)24031-1; Kidd AH, 1996, J CLIN MICROBIOL, V34, P622, DOI 10.1128/JCM.34.3.622-627.1996; Libby P, 1997, CIRCULATION, V95, P551, DOI 10.1161/01.CIR.95.3.551; Lum LCS, 1998, LANCET, V352, P1391, DOI 10.1016/S0140-6736(05)60789-1; Lum LCS, 1998, J PEDIATR-US, V133, P795, DOI 10.1016/S0022-3476(98)70155-6; MARTIN AB, 1994, CIRCULATION, V90, P330, DOI 10.1161/01.CIR.90.1.330; Romero Jose R., 1993, P401; Solomon T, 1998, J CLIN MICROBIOL, V36, P2030, DOI 10.1128/JCM.36.7.2030-2034.1998; Solomon T, 1998, LANCET, V351, P1094, DOI 10.1016/S0140-6736(97)07509-0; TANAKA M, 1993, J VIROL METHODS, V41, P311, DOI 10.1016/0166-0934(93)90020-R; *WHO, 1997, WKLY EPIDEMIOL REC, V72, P184; YOKOYAMA T, 1993, J CLIN INVEST, V92, P2303, DOI 10.1172/JCI116834	18	106	116	0	13	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	SEP 18	1999	354	9183					987	991		10.1016/S0140-6736(98)11032-2	http://dx.doi.org/10.1016/S0140-6736(98)11032-2			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	236JG	10501361	Green Accepted			2022-12-01	WOS:000082596000012
J	Lee, SB; Huang, K; Palmer, R; Truong, VB; Herzlinger, D; Kolquist, KA; Wong, J; Paulding, C; Yoon, SK; Gerald, W; Oliner, JD; Haber, DA				Lee, SB; Huang, K; Palmer, R; Truong, VB; Herzlinger, D; Kolquist, KA; Wong, J; Paulding, C; Yoon, SK; Gerald, W; Oliner, JD; Haber, DA			The Wilms tumor suppressor WT1 encodes a transcriptional activator of amphiregulin	CELL			English	Article							EPIDERMAL GROWTH-FACTOR; MICE LACKING GDNF; GENE-PRODUCT; KIDNEY DEVELOPMENT; DNA-BINDING; EXPRESSION; PROTEIN; PROLIFERATION; RECEPTOR; SEQUENCE	WT1 encodes a zinc finger transcription factor implicated in kidney differentiation and tumorigenesis. In reporter assays, WT1 represses transcription from GC- and To-rich promoters, but its physiological targets remain uncertain. We used hybridization to high-density oligonucleotide arrays to search for native genes whose expression is altered following inducible expression of WT1. The major target of WT1 was amphiregulin, a member of the epidermal growth factor family. The WT1(-KTS) isoform binds directly to the amphiregulin promoter, resulting in potent transcriptional activation. The in vivo expression profile of amphiregulin during fetal kidney development mirrors the highly specific pattern of WT1 itself, and recombinant Amphiregulin stimulates epithelial branching in organ cultures of embryonic mouse kidney. These observations suggest a model for WT1 as a transcriptional regulator during kidney differentiation.	Massachusetts Gen Hosp, Ctr Canc, Genet Mol Lab, Charlestown, MA 02129 USA; Harvard Med Sch, Charlestown, MA 02129 USA; Affymetrix, Santa Clara, CA 95051 USA; Cornell Univ, Dept Physiol & Biophys, New York, NY 10021 USA; Mem Sloan Kettering Canc Ctr, Dept Pathol, New York, NY 10021 USA	Harvard University; Massachusetts General Hospital; Affymetrix; Cornell University; Memorial Sloan Kettering Cancer Center	Haber, DA (corresponding author), Massachusetts Gen Hosp, Ctr Canc, Genet Mol Lab, Charlestown, MA 02129 USA.			Lee, Sean/0000-0001-6211-3498; Wong, Jenise C./0000-0003-0573-6650	NATIONAL CANCER INSTITUTE [F32CA071167, R37CA058596, R01CA058596] Funding Source: NIH RePORTER; NCI NIH HHS [CA58596, CA71167] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Cho RJ, 1998, MOL CELL, V2, P65, DOI 10.1016/S1097-2765(00)80114-8; COLES HSR, 1993, DEVELOPMENT, V118, P777; Davies JA, 1996, ACTA ANAT, V156, P187; Donovan MJ, 1999, DEV GENET, V24, P252, DOI 10.1002/(SICI)1520-6408(1999)24:3/4<252::AID-DVG8>3.0.CO;2-K; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Englert C, 1997, CANCER RES, V57, P1429; ENGLERT C, 1995, EMBO J, V14, P4662, DOI 10.1002/j.1460-2075.1995.tb00148.x; English MA, 1999, J BIOL CHEM, V274, P13258, DOI 10.1074/jbc.274.19.13258; FISHER DA, 1989, ANNU REV PHYSIOL, V51, P67, DOI 10.1146/annurev.physiol.51.1.67; HABER DA, 1993, SCIENCE, V262, P2057, DOI 10.1126/science.8266105; HABER DA, 1991, P NATL ACAD SCI USA, V88, P9618, DOI 10.1073/pnas.88.21.9618; Harkin DP, 1999, CELL, V97, P575, DOI 10.1016/S0092-8674(00)80769-2; HASTIE ND, 1994, ANNU REV GENET, V28, P523; HSU SM, 1981, J HISTOCHEM CYTOCHEM, V29, P577, DOI 10.1177/29.4.6166661; Iyer VR, 1999, SCIENCE, V283, P83, DOI 10.1126/science.283.5398.83; Kadonaga JT, 1998, CELL, V92, P307, DOI 10.1016/S0092-8674(00)80924-1; Kim J, 1999, MOL CELL BIOL, V19, P2289; KREIDBERG JA, 1993, CELL, V74, P679, DOI 10.1016/0092-8674(93)90515-R; LARSSON SH, 1995, CELL, V81, P391, DOI 10.1016/0092-8674(95)90392-5; Lockhart DJ, 1996, NAT BIOTECHNOL, V14, P1675, DOI 10.1038/nbt1296-1675; Luetteke NC, 1999, DEVELOPMENT, V126, P2739; Maheswaran S, 1998, GENE DEV, V12, P1108, DOI 10.1101/gad.12.8.1108; Montminy M, 1997, ANNU REV BIOCHEM, V66, P807, DOI 10.1146/annurev.biochem.66.1.807; Moore MW, 1996, NATURE, V382, P76, DOI 10.1038/382076a0; Nachtigal MW, 1998, CELL, V93, P445, DOI 10.1016/S0092-8674(00)81172-1; NAKAGAMA H, 1995, MOL CELL BIOL, V15, P1489; Pepicelli CV, 1997, DEV BIOL, V192, P193, DOI 10.1006/dbio.1997.8745; Pichel JG, 1996, NATURE, V382, P73, DOI 10.1038/382073a0; PLOWMAN GD, 1990, MOL CELL BIOL, V10, P1969, DOI 10.1128/MCB.10.5.1969; PRITCHARDJONES K, 1990, NATURE, V346, P194, DOI 10.1038/346194a0; Qiao JZ, 1999, DEVELOPMENT, V126, P547; RAUSCHER FJ, 1990, SCIENCE, V250, P1259, DOI 10.1126/science.2244209; RAUSCHER FJ, 1993, FASEB J, V7, P896, DOI 10.1096/fasebj.7.10.8393820; Reddy JC, 1996, BBA-REV CANCER, V1287, P1, DOI 10.1016/0304-419X(95)00014-7; Sanchez MP, 1996, NATURE, V382, P70, DOI 10.1038/382070a0; Saxen L., 1987, ORGANOGENESIS KIDNEY; SETO E, 1992, P NATL ACAD SCI USA, V89, P12028, DOI 10.1073/pnas.89.24.12028; SHOYAB M, 1988, P NATL ACAD SCI USA, V85, P6528, DOI 10.1073/pnas.85.17.6528; Vainio S, 1997, CELL, V90, P975, DOI 10.1016/S0092-8674(00)80363-3; VELCULESCU VE, 1995, SCIENCE, V270, P484, DOI 10.1126/science.270.5235.484; WANG ZY, 1993, P NATL ACAD SCI USA, V90, P8896, DOI 10.1073/pnas.90.19.8896; Wodicka L, 1997, NAT BIOTECHNOL, V15, P1359, DOI 10.1038/nbt1297-1359	42	238	242	0	5	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	SEP 3	1999	98	5					663	673		10.1016/S0092-8674(00)80053-7	http://dx.doi.org/10.1016/S0092-8674(00)80053-7			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	233NT	10490105	Bronze			2022-12-01	WOS:000082433500013
J	Oya, T; Enoki, T; Grosberg, AY; Masamune, S; Sakiyama, T; Takeoka, Y; Tanaka, K; Wang, GQ; Yilmaz, Y; Feld, MS; Dasari, R; Tanaka, T				Oya, T; Enoki, T; Grosberg, AY; Masamune, S; Sakiyama, T; Takeoka, Y; Tanaka, K; Wang, GQ; Yilmaz, Y; Feld, MS; Dasari, R; Tanaka, T			Reversible molecular adsorption based on multiple-point interaction by shrinkable gels	SCIENCE			English	Article							N-ISOPROPYLACRYLAMIDE	A general approach is presented for creating polymer-gels that can recognize and capture a target molecule by multiple-point interaction and that can reversibly change their affinity to the target by more than one order of magnitude. The polymers consist of majority monomers that make the gel reversibly swell and shrink and minority monomers that constitute multiple-point adsorption centers for the target molecule, Multiple-point interaction is experimentally proven by power Laws found between the affinity and the concentration of the adsorbing monomers within the gels.	MIT, Dept Phys, Cambridge, MA 02139 USA; MIT, Ctr Mat Sci & Engn, Cambridge, MA 02139 USA; MIT, Dept Chem, Cambridge, MA 02139 USA; MIT, George R Harrison Spect Lab, Cambridge, MA 02139 USA	Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT)	Oya, T (corresponding author), MIT, Dept Phys, Cambridge, MA 02139 USA.		Takeoka, Yukikazu/I-6785-2014; Grosberg, Alexander Y/O-2122-2015; Grosberg, Alexander/AAD-9614-2019; yilmaz, yasar/D-6190-2014; Takeoka, Yukikazu/W-9627-2019	Takeoka, Yukikazu/0000-0002-1406-0704; Grosberg, Alexander Y/0000-0002-4230-8690; Grosberg, Alexander/0000-0002-4230-8690; yilmaz, yasar/0000-0003-2352-4723; Takeoka, Yukikazu/0000-0002-1406-0704				HIROTSU S, 1987, J CHEM PHYS, V87, P1392, DOI 10.1063/1.453267; RICKA J, 1985, MACROMOLECULES, V18, P83, DOI 10.1021/ma00143a013; SCHILD HG, 1992, PROG POLYM SCI, V17, P163, DOI 10.1016/0079-6700(92)90023-R; Tanaka T, 1995, FARADAY DISCUSS, V101, P201, DOI 10.1039/fd9950100201; YAMATO M, 1999, CONNECT TISSUE, V31, P13	5	179	186	1	55	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 19	1999	286	5444					1543	1545		10.1126/science.286.5444.1543	http://dx.doi.org/10.1126/science.286.5444.1543			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	257DZ	10567256				2022-12-01	WOS:000083768300052
J	Swain, SL; Hu, H; Huston, G				Swain, SL; Hu, H; Huston, G			Class II-independent generation of CD4 memory T cells from effecters	SCIENCE			English	Article							ANTIGEN; SURVIVAL; RECEPTOR; NAIVE; MOLECULES; REQUIREMENTS; LYMPHOCYTES; MICE; TH1	The factors required for the generation of memory CD4 T cells remain unclear, and whether there is a continuing requirement for antigen stimulation is critical to design of vaccine strategies. CD4 effecters generated in vitro from naive CD4 T cells of mice efficiently gave rise to small resting memory cells after transfer to class II-deficient hosts, indicating no requirement for further antigen or class ii recognition.	Trudeau Inst Inc, Biomed Res Labs, Saranac Lake, NY 12983 USA	Trudeau Institute	Swain, SL (corresponding author), Trudeau Inst Inc, Biomed Res Labs, 100 Algonquin Ave, Saranac Lake, NY 12983 USA.							Brocker T, 1997, J EXP MED, V186, P1223, DOI 10.1084/jem.186.8.1223; DECKER G, UNPUB; Dubey C, 1996, J IMMUNOL, V157, P3280; GRAY D, 1991, J EXP MED, V174, P969, DOI 10.1084/jem.174.5.969; HOGQUIST KA, 1994, CELL, V76, P17, DOI 10.1016/0092-8674(94)90169-4; KAYE J, 1989, NATURE, V341, P746, DOI 10.1038/341746a0; Kirberg J, 1997, J EXP MED, V186, P1269, DOI 10.1084/jem.186.8.1269; LAU LL, 1994, NATURE, V369, P648, DOI 10.1038/369648a0; Linton PJ, 1996, J EXP MED, V184, P1891, DOI 10.1084/jem.184.5.1891; Markiewicz MA, 1998, P NATL ACAD SCI USA, V95, P3065, DOI 10.1073/pnas.95.6.3065; Murali-Krishna K, 1999, SCIENCE, V286, P1377, DOI 10.1126/science.286.5443.1377; Nesic D, 1998, J IMMUNOL, V160, P3705; ROCHA B, 1989, EUR J IMMUNOL, V19, P905, DOI 10.1002/eji.1830190518; Rogers PR, 1998, J IMMUNOL, V161, P3844; Rooke R, 1997, IMMUNITY, V7, P123, DOI 10.1016/S1074-7613(00)80515-4; SHINKAI Y, 1993, SCIENCE, V259, P822, DOI 10.1126/science.8430336; SWAIN SL, 1994, IMMUNITY, V1, P543, DOI 10.1016/1074-7613(94)90044-2; SWAIN SL, UNPUB; Takeda S, 1996, IMMUNITY, V5, P217, DOI 10.1016/S1074-7613(00)80317-9; Tanchot C, 1997, SCIENCE, V276, P2057, DOI 10.1126/science.276.5321.2057; TOUGH DF, 1994, J EXP MED, V179, P1127, DOI 10.1084/jem.179.4.1127; Zhang XH, 1997, J EXP MED, V185, P1837, DOI 10.1084/jem.185.10.1837	22	345	354	0	8	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 12	1999	286	5443					1381	1383		10.1126/science.286.5443.1381	http://dx.doi.org/10.1126/science.286.5443.1381			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	255NF	10558997				2022-12-01	WOS:000083675500049
J	Marcotte, EM; Pellegrini, M; Thompson, MJ; Yeates, TO; Eisenberg, D				Marcotte, EM; Pellegrini, M; Thompson, MJ; Yeates, TO; Eisenberg, D			A combined algorithm for genome-wide prediction of protein function	NATURE			English	Article							SACCHAROMYCES-CEREVISIAE; COLON-CANCER; GENES; YEAST; DATABASE; INTERACT; MUTATION; HOMOLOG; MSH6	The availability of over 20 fully sequenced genomes has driven the development of new methods to find protein function and interactions. Here we group proteins by correlated evolution(1), correlated messenger RNA expression patterns(2) and patterns of domain fusion(3) to determine functional relationships among the 6,217 proteins of the yeast Saccharomyces cervisiae. Using these methods, we discover over 93,000 pairwise links between functionally related yeast proteins. Links between characterized and uncharacterized proteins allow a general function to be assigned to more than half of the 2,557 previously uncharacterized yeast proteins. Examples of functional links are given for a protein family of previously unknown function, a protein whose human homologues are implicated in colon cancer and the yeast prion Sup35.	Univ Calif Los Angeles, Inst Mol Biol, US DOE, Lab Struct Biol & Mol Med, Los Angeles, CA 90095 USA	United States Department of Energy (DOE); University of California System; University of California Los Angeles	Eisenberg, D (corresponding author), Univ Calif Los Angeles, Inst Mol Biol, US DOE, Lab Struct Biol & Mol Med, POB 951570, Los Angeles, CA 90095 USA.			Yeates, Todd/0000-0001-5709-9839; Marcotte, Edward/0000-0001-8808-180X; Thompson, Michael/0000-0002-2914-1080; Pellegrini, Matteo/0000-0001-9355-9564				Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Bairoch A, 1999, NUCLEIC ACIDS RES, V27, P49, DOI 10.1093/nar/27.1.49; BARDOSI A, 1990, ACTA NEUROPATHOL, V79, P387, DOI 10.1007/BF00308714; CHEN XY, 1994, P NATL ACAD SCI USA, V91, P9111, DOI 10.1073/pnas.91.19.9111; Chu S, 1998, SCIENCE, V282, P699, DOI 10.1126/science.282.5389.699; Dandekar T, 1998, TRENDS BIOCHEM SCI, V23, P324, DOI 10.1016/S0968-0004(98)01274-2; DeRisi JL, 1997, SCIENCE, V278, P680, DOI 10.1126/science.278.5338.680; Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863; FISHEL R, 1993, CELL, V75, P1027, DOI 10.1016/0092-8674(93)90546-3; Horton Paul, 1997, INTELLIGENT SYSTEMS, V5, P147; Johnson RE, 1996, J BIOL CHEM, V271, P7285, DOI 10.1074/jbc.271.13.7285; Karp PD, 1998, NUCLEIC ACIDS RES, V26, P50, DOI 10.1093/nar/26.1.50; KUSHNIROV VV, 1988, GENE, V66, P45, DOI 10.1016/0378-1119(88)90223-5; Lynch HT, 1997, ANN NY ACAD SCI, V833, P1, DOI 10.1111/j.1749-6632.1997.tb48588.x; Marcotte EM, 1999, SCIENCE, V285, P751, DOI 10.1126/science.285.5428.751; Mewes HW, 1998, NUCLEIC ACIDS RES, V26, P33, DOI 10.1093/nar/26.1.33; Miyaki M, 1997, NAT GENET, V17, P271, DOI 10.1038/ng1197-271; Myers LC, 1999, P NATL ACAD SCI USA, V96, P67, DOI 10.1073/pnas.96.1.67; Overbeek R, 1999, P NATL ACAD SCI USA, V96, P2896, DOI 10.1073/pnas.96.6.2896; PAPADOPOULOS N, 1994, SCIENCE, V263, P1625, DOI 10.1126/science.8128251; Pellegrini M, 1999, P NATL ACAD SCI USA, V96, P4285, DOI 10.1073/pnas.96.8.4285; Spellman PT, 1998, MOL BIOL CELL, V9, P3273, DOI 10.1091/mbc.9.12.3273; STANSFIELD I, 1995, EMBO J, V14, P4365, DOI 10.1002/j.1460-2075.1995.tb00111.x; West MG, 1996, BIOCHEMISTRY-US, V35, P3122, DOI 10.1021/bi952713d; WICKNER RB, 1994, SCIENCE, V264, P566, DOI 10.1126/science.7909170; 1997, NATURE S, V387, P1	26	681	723	2	25	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	NOV 4	1999	402	6757					83	86		10.1038/47048	http://dx.doi.org/10.1038/47048			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	254XC	10573421				2022-12-01	WOS:000083638600047
J	Reynolds, AJ; Lawrence, C; Cserhalmi-Friedman, PB; Christiano, AM; Jahoda, CAB				Reynolds, AJ; Lawrence, C; Cserhalmi-Friedman, PB; Christiano, AM; Jahoda, CAB			Trans-gender induction of hair follicles	NATURE			English	Article							DERMAL PAPILLA CELLS; GROWTH		Univ Durham, Dept Biol Sci, Durham DH1 3LE, England; Royal Victoria Infirm, Dept Dermatol, Newcastle Upon Tyne NE1 4LP, Tyne & Wear, England; Columbia Univ, Dept Dermatol, New York, NY 10032 USA; Columbia Univ, Dept Genet & Dev, New York, NY 10032 USA	Durham University; Newcastle University - UK; Columbia University; Columbia University	Reynolds, AJ (corresponding author), Univ Durham, Dept Biol Sci, South Rd, Durham DH1 3LE, England.	c.a.b.jahoda@durham.ac.uk		Jahoda, Colin/0000-0002-1762-1220				CHONG SS, 1993, HUM MOL GENET, V2, P1187, DOI 10.1093/hmg/2.8.1187; FABRE JW, 1987, TRANSPLANT P, V19, P45; GIBSON WT, 1991, ANN NY ACAD SCI, V642, P291; Halloran P F, 1993, Transpl Immunol, V1, P3, DOI 10.1016/0966-3274(93)90055-D; HARDY MH, 1992, TRENDS GENET, V8, P55, DOI 10.1016/0168-9525(92)90350-D; IBRAHIM MAA, 1995, IMMUNOL TODAY, V16, P181, DOI 10.1016/0167-5699(95)80118-9; JAHODA CAB, 1993, J INVEST DERMATOL, V101, P584, DOI 10.1111/1523-1747.ep12366039; REYNOLDS AJ, 1992, DEVELOPMENT, V115, P587; Simone NL, 1998, TRENDS GENET, V14, P272, DOI 10.1016/S0168-9525(98)01489-9; STREILEIN JW, 1995, SCIENCE, V270, P1158, DOI 10.1126/science.270.5239.1158	10	172	197	0	5	NATURE RESEARCH	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	NOV 4	1999	402	6757					33	34		10.1038/46938	http://dx.doi.org/10.1038/46938			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	254XC	10573414				2022-12-01	WOS:000083638600030
J	Ananth, CV; Berkowitz, GS; Savitz, DA; Lapinski, RH				Ananth, CV; Berkowitz, GS; Savitz, DA; Lapinski, RH			Placental abruption and adverse perinatal outcomes	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							PREGNANCY; RISK; ASPIRIN; COCAINE; MODELS; RATIO; RACE	Context Pregnancies complicated by abruption result in increased frequency of perinatal death and decreased fetal size and gestational duration, yet the extent of placental separation and its effect on these adverse outcomes is unknown. Objective To assess the contribution of placental abruption and extent of placental separation to stillbirth, preterm delivery, and fetal growth restriction. Design Hospital-based, retrospective cohort study. Setting Mount Sinai Hospital, New York City, NY. Participants A total of 53 371 pregnancies occurring in 40 789 women who were delivered of singleton births between 1986 and 1996. Main Outcome Measures Risks and relative risks for stillbirth (>20 weeks), preterm delivery (<37 weeks), and fetal growth restriction (birth weight below 10th percentile for gestational age) in relation to abruption. Results The incidence of abruption was 1% (n = 530), Abruption was associated with an 8.9-fold (95% confidence interval [CI], 6.0-13.0) adjusted relative risk (aRR) of stillbirth. Preterm birth proportions among women with and without abruption were 39.6% and 9.1%, respectively, yielding an aRR of 3.9 (95% CI, 3.5-4.4). In the abruption group, 14.3% of neonates were growth restricted, compared with 8.1% among all other births (aRR, 2.0; 95% CI, 1.5-2.4). Extent of placental separation had a profound effect on stillbirth (aRR for 75% separation, 31.5; 95% CI, 17.0-58.4), although evident only among those with at least 50% separation. However, the risk of preterm delivery was substantially increased even for mild abruptions (aRR for 25% separation, 5.5; 95% CI, 4.2-7.3). Conclusions In this cohort, placental abruption had a profound impact on stillbirth, preterm delivery, and fetal growth restriction. The risk of stillbirth was dramatically increased for severe placental separation, but preterm delivery was common even among women with lesser degrees of placental separation.	Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Obstet Gynecol & Reprod Sci, Div Epidemiol & Biostat, New Brunswick, NJ 08901 USA; Mt Sinai Sch Med, Dept Community & Prevent Med, New York, NY USA; Mt Sinai Sch Med, Dept Obstet Gynecol & Reprod Sci, New York, NY USA; Univ N Carolina, Sch Publ Hlth, Dept Epidemiol, Chapel Hill, NC USA	Rutgers State University New Brunswick; Rutgers State University Medical Center; Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; University of North Carolina; University of North Carolina Chapel Hill	Ananth, CV (corresponding author), Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Obstet Gynecol & Reprod Sci, Div Epidemiol & Biostat, 125 Paterson St, New Brunswick, NJ 08901 USA.		Savitz, David A/I-2211-2014	Ananth, Cande/0000-0002-0410-2595				Ananth CV, 1999, OBSTET GYNECOL, V93, P622, DOI 10.1016/S0029-7844(98)00408-6; BALLARD JL, 1979, J PEDIATR-US, V95, P769, DOI 10.1016/S0022-3476(79)80734-9; BELIZAN JM, 1991, NEW ENGL J MED, V325, P1399, DOI 10.1056/NEJM199111143252002; BERKOWITZ GS, 1992, AM J EPIDEMIOL, V135, P965, DOI 10.1093/oxfordjournals.aje.a116408; CREASY RK, 1993, AM J OBSTET GYNECOL, V168, P1223, DOI 10.1016/0002-9378(93)90373-Q; DURRLEMAN S, 1989, STAT MED, V8, P551, DOI 10.1002/sim.4780080504; FLEMING AD, 1991, CRIT CARE CLIN, V7, P865, DOI 10.1016/S0749-0704(18)30285-9; FUCHS F, 1993, PRETERM BIRTH, P217; HARRIS BA, 1985, OBSTET GYNECOL, V66, P774; HAUTH JC, 1993, AM J OBSTET GYNECOL, V168, P1083, DOI 10.1016/0002-9378(93)90351-I; HIBBARD BM, 1966, OBSTET GYNECOL, V27, P155; HURD WW, 1983, OBSTET GYNECOL, V61, P467; Kistin N, 1996, PAEDIATR PERINAT EP, V10, P269, DOI 10.1111/j.1365-3016.1996.tb00050.x; Kline J, 1997, AM J PUBLIC HEALTH, V87, P352, DOI 10.2105/AJPH.87.3.352; KNAB DR, 1978, OBSTET GYNECOL, V52, P625; LIANG KY, 1986, BIOMETRIKA, V73, P13, DOI 10.2307/2336267; NAEYE RL, 1980, OBSTET GYNECOL, V55, P701; NISWANDER KR, 1966, AM J OBSTET GYNECOL, V95, P838, DOI 10.1016/0002-9378(66)90088-3; SAFTLAS AF, 1991, OBSTET GYNECOL, V78, P1081; SCHIFF E, 1989, NEW ENGL J MED, V321, P351, DOI 10.1056/NEJM198908103210603; WOLF EJ, 1992, J MATERN FETAL MED, V14, P206; Zhang J, 1998, JAMA-J AM MED ASSOC, V280, P1690, DOI 10.1001/jama.280.19.1690; ZHANG J, 1995, OBSTET GYNECOL, V86, P200, DOI 10.1016/0029-7844(95)00142-E	23	224	230	0	9	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 3	1999	282	17					1646	1651		10.1001/jama.282.17.1646	http://dx.doi.org/10.1001/jama.282.17.1646			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	250BD	10553791	Bronze			2022-12-01	WOS:000083368400030
J	Wiemels, JL; Cazzaniga, G; Daniotti, M; Eden, OB; Addison, GM; Masera, G; Saha, V; Biondi, A; Greaves, MF				Wiemels, JL; Cazzaniga, G; Daniotti, M; Eden, OB; Addison, GM; Masera, G; Saha, V; Biondi, A; Greaves, MF			Prenatal origin of acute lymphoblastic leukaemia in children	LANCET			English	Article							CHILDHOOD LEUKEMIA; INFANT LEUKEMIAS; IDENTICAL-TWINS; BLOOD SPOTS; FUSION; CANCER; GENE; DETERMINANTS; MALIGNANCY; ETIOLOGY	Background There is little current insight into the natural history of childhood leukaemia or the timing of relevant mutational events. TEL-AML1 gene fusion due to chromosomal translocation is frequently-seen in the common form of childhood acute lymphoblastic leukaemia. We investigated whether this abnormality arises prenatally. Methods We identified, by reverse-transcriptase PCR screening of blood or bone marrow, TEL-AML1 fusion in 12 children, plus a pair of identical twins, aged 2-5 years from Italy and the UK, who had newly diagnosed acute lymphoblastic leukaemia. We amplified and sequenced the genomic TEL-AMLI fusion gene with a long-distance inverse PCR method. Primers were designed that could be used in short-range PCR to screen for patient-specific, leukaemia clone-specific TEL-AMLI genomic fusion sequences in neonatal blood spots from each child. Findings We initially identified TEL-AMLI fusion sequences in blood spots from the identical twins, diagnosed with concordant acute lymphoblastic leukaemia at age 4 years, who shared a single or clonotypic TEL-AMLI sequence that suggested prenatal origin in one twin. Three children were excluded because control genes could not be amplified. Of the other nine patients, six had positive blood spots. Blood spots that were classified as negative were uninformative. Interpretation Our findings showed that childhood acute lymphoblastic leukaemia is frequently initiated by a chromosome translocation event in utero. Studies in identical twins show however that such an event is insufficient for clinical leukaemia and that a postnatal promotional event is also required.	Inst Canc Res, Chester Beatty Labs, Leukaemia Res Fund Ctr, London SW3 6JB, England; Univ Milan, Osped San Gerardo, Ctr Ric Tettamanti, Pediat Clin, Milan, Italy; Christie Hosp NHS Trust, Acad Unit Paediat Oncol, Manchester M20 4BX, Lancs, England; Royal Manchester Childrens Hosp, Dept Clin Biochem, Manchester M27 1HA, Lancs, England; Royal London Hosp, Dept Paediat Haematol & Oncol, London E1 1BB, England	Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK; San Gerardo Hospital; University of Milan; Christie NHS Foundation Trust; Christie Hospital; Royal Manchester Children's Hospital; Barts Health NHS Trust; Royal London Hospital	Greaves, MF (corresponding author), Inst Canc Res, Chester Beatty Labs, Leukaemia Res Fund Ctr, London SW3 6JB, England.		Biondi, Andrea/AAX-1865-2020; Biondi, Andrea/K-9997-2016; Cazzaniga, Giovanni/K-6338-2016	Biondi, Andrea/0000-0002-6757-6173; Cazzaniga, Giovanni/0000-0003-2955-4528; Saha, Vaskar/0000-0002-2916-9649				Alexander FE, 1998, BRIT J CANCER, V77, P818, DOI 10.1038/bjc.1998.133; BHATIA S, 1999, CHILDHOOD LEUKEMIAS, P38; BITHELL JF, 1975, BRIT J CANCER, V31, P271, DOI 10.1038/bjc.1975.62; Borkhardt A, 1997, BLOOD, V90, P571, DOI 10.1182/blood.V90.2.571.571_571_577; Buckley JD, 1996, MED PEDIATR ONCOL, V26, P223, DOI 10.1002/(SICI)1096-911X(199604)26:4<223::AID-MPO1>3.0.CO;2-L; CHESSELLS JM, 1977, LANCET, V2, P1307; COMEAU AM, 1993, J PEDIATR-US, V123, P252, DOI 10.1016/S0022-3476(05)81697-X; *COMM MED ASP RAD, 1996, INC CANC LEUK YOUNG; DRAPER GJ, 1974, 11 INT CANC C, P150; FORD AM, 1993, NATURE, V363, P358, DOI 10.1038/363358a0; Ford AM, 1998, P NATL ACAD SCI USA, V95, P4584, DOI 10.1073/pnas.95.8.4584; Ford AM, 1997, BLOOD, V89, P281, DOI 10.1182/blood.V89.1.281.281_281_285; Gale KB, 1997, P NATL ACAD SCI USA, V94, P13950, DOI 10.1073/pnas.94.25.13950; GOLUB TR, 1995, P NATL ACAD SCI USA, V92, P4917, DOI 10.1073/pnas.92.11.4917; Greaves M, 1999, EUR J CANCER, V35, P173, DOI 10.1016/S0959-8049(98)00433-X; GREAVES M, 1993, BLOOD, V82, P1043; Greaves MF, 1997, LANCET, V349, P344, DOI 10.1016/S0140-6736(96)09412-3; GREAVES MF, 1985, LEUKEMIA RES, V9, P715, DOI 10.1016/0145-2126(85)90281-4; GREAVES MF, 1988, LEUKEMIA, V2, P120; GREAVES MF, 1993, LEUKEMIA, V7, P349; JINKS DC, 1989, HUM GENET, V81, P363, DOI 10.1007/BF00283692; Kersey JH, 1997, BLOOD, V90, P4243, DOI 10.1182/blood.V90.11.4243.4243_4243_4251; KINLEN LJ, 1995, BRIT J CANCER, V71, P1, DOI 10.1038/bjc.1995.1; MAKOWSKI GS, 1995, NUCLEIC ACIDS RES, V23, P3788, DOI 10.1093/nar/23.18.3788; OCHS J, 1996, LEUKEMIA, P419; Parkin DM, 1998, IARC SCI PUBLICATION, V144; PUI CH, 1995, LEUKEMIA, V9, P762; RAIMONDI SC, 1993, BLOOD, V81, P2237; Raskin S, 1992, PCR Methods Appl, V2, P154; Raynaud S, 1996, BLOOD, V87, P2891, DOI 10.1182/blood.V87.7.2891.bloodjournal8772891; RODVALL Y, 1990, INT J CANCER, V46, P362, DOI 10.1002/ijc.2910460304; Roman E, 1997, BRIT J CANCER, V76, P406, DOI 10.1038/bjc.1997.399; ROMANA SP, 1995, BLOOD, V86, P4263, DOI 10.1182/blood.V86.11.4263.bloodjournal86114263; SAHA V, 1993, ARCH DIS CHILD, V68, P771, DOI 10.1136/adc.68.6.771; Smith MA, 1997, J NATL CANCER I, V89, P1542, DOI 10.1093/jnci/89.20.1542; Taylor GM, 1996, LEUKEMIA, P210; Wiemels JL, 1999, BLOOD, V94, P1057, DOI 10.1182/blood.V94.3.1057.415k10_1057_1062; Wiemels JL, 1999, CANCER RES, V59, P4075	39	450	458	1	23	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	OCT 30	1999	354	9189					1499	1503		10.1016/S0140-6736(99)09403-9	http://dx.doi.org/10.1016/S0140-6736(99)09403-9			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	250WB	10551495				2022-12-01	WOS:000083411300009
J	Lee, JO; Yang, HJ; Georgescu, MM; Di Cristofano, A; Maehama, T; Shi, YG; Dixon, JE; Pandolfi, P; Pavletich, NP				Lee, JO; Yang, HJ; Georgescu, MM; Di Cristofano, A; Maehama, T; Shi, YG; Dixon, JE; Pandolfi, P; Pavletich, NP			Crystal structure of the PTEN tumor suppressor: Implications for its phosphoinositide phosphatase activity and membrane association	CELL			English	Article							PROTEIN-TYROSINE-PHOSPHATASE; C2 DOMAIN; PHOSPHOLIPID-BINDING; CYTOSOLIC PHOSPHOLIPASE-A2; GLIOMA-CELLS; SYNAPTOTAGMIN; GENE; RECOGNITION; CANCER; DELTA	The PTEN tumor suppressor is mutated in diverse human cancers and in hereditary cancer predisposition syndromes. PTEN is a phosphatase that can act on both polypeptide and phosphoinositide substrates in vitro. The PTEN structure reveals a phosphatase domain that is similar to protein phosphatases but has an enlarged active site important for the accommodation of the phosphoinositide substrate. The structure also reveals that PTEN has a C2 domain. The PTEN C2 domain binds phospholipid membranes in vitro, and mutation of basic residues that could mediate this reduces PTEN's membrane affinity and its ability to suppress the growth of glioblastoma tumor cells. The phosphatase and C2 domains associate across an extensive interface, suggesting that the C2 domain may serve to productively position the catalytic domain on the membrane.	Mem Sloan Kettering Canc Ctr, Cellular Biochem & Biophys Program, New York, NY 10021 USA; Mem Sloan Kettering Canc Ctr, Howard Hughes Med Inst, New York, NY 10021 USA; Mem Sloan Kettering Canc Ctr, Dept Human Genet, New York, NY 10021 USA; Mem Sloan Kettering Canc Ctr, Program Mol Biol, New York, NY 10021 USA; Cornell Univ, Joan & Sanford I Weill Grad Sch Med Sci, Sloan Kettering Div, Dept Pharmacol, New York, NY 10021 USA; Rockefeller Univ, Mol Oncol Lab, New York, NY 10021 USA; Univ Michigan, Dept Biol Chem, Ann Arbor, MI 48109 USA; Princeton Univ, Dept Mol Biol, Princeton, NJ 08544 USA	Memorial Sloan Kettering Cancer Center; Howard Hughes Medical Institute; Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; Cornell University; Memorial Sloan Kettering Cancer Center; Rockefeller University; University of Michigan System; University of Michigan; Princeton University	Pavletich, NP (corresponding author), Mem Sloan Kettering Canc Ctr, Cellular Biochem & Biophys Program, 1275 York Ave, New York, NY 10021 USA.	nikola@xray2.mskcc.org	Di Cristofano, Antonio/B-4148-2016; Georgescu, Maria-Magdalena/AAJ-6359-2020; Lee, Jie-Oh/AAG-4302-2020; di cristofano, antonio/AAJ-3796-2020; Lee, Jie-Oh/C-1581-2011; Maehama, Tomohiko/AAX-8926-2020	di cristofano, antonio/0000-0003-2537-3228; Lee, Jie-Oh/0000-0001-6519-6049; Maehama, Tomohiko/0000-0002-9685-2317; Shi, Yigong/0000-0003-2030-168X	NCI NIH HHS [CA09673] Funding Source: Medline	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Baraldi E, 1999, STRUCTURE, V7, P449, DOI 10.1016/S0969-2126(99)80057-4; BARFORD D, 1994, SCIENCE, V263, P1397, DOI 10.1126/science.8128219; Bittova L, 1999, J BIOL CHEM, V274, P9665, DOI 10.1074/jbc.274.14.9665; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; CHAPMAN ER, 1994, J BIOL CHEM, V269, P5735; Chapman ER, 1998, J BIOL CHEM, V273, P13995, DOI 10.1074/jbc.273.22.13995; DAVIETOV BA, 1993, J BIOL CHEM, V268, P26386; Davletov B, 1998, J BIOL CHEM, V273, P19093, DOI 10.1074/jbc.273.30.19093; Di Cristofano A, 1998, NAT GENET, V19, P348, DOI 10.1038/1235; Essen LO, 1997, BIOCHEMISTRY-US, V36, P2753, DOI 10.1021/bi962466t; Essen LO, 1996, NATURE, V380, P595, DOI 10.1038/380595a0; Fukuda M, 1996, J BIOL CHEM, V271, P8430, DOI 10.1074/jbc.271.14.8430; Furnari FB, 1997, P NATL ACAD SCI USA, V94, P12479, DOI 10.1073/pnas.94.23.12479; Furnari FB, 1998, CANCER RES, V58, P5002; Georgescu MM, 1999, P NATL ACAD SCI USA, V96, P10182, DOI 10.1073/pnas.96.18.10182; JIA ZC, 1995, SCIENCE, V268, P1754, DOI 10.1126/science.7540771; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Li DM, 1998, P NATL ACAD SCI USA, V95, P15406, DOI 10.1073/pnas.95.26.15406; Li J, 1997, SCIENCE, V275, P1943, DOI 10.1126/science.275.5308.1943; Maehama T, 1998, J BIOL CHEM, V273, P13375, DOI 10.1074/jbc.273.22.13375; Maehama T, 1999, TRENDS CELL BIOL, V9, P125, DOI 10.1016/S0962-8924(99)01519-6; Miller RT, 1996, FASEB J, V10, P171, DOI 10.1096/fasebj.10.1.8566539; Myers MP, 1997, P NATL ACAD SCI USA, V94, P9052, DOI 10.1073/pnas.94.17.9052; Myers MP, 1998, P NATL ACAD SCI USA, V95, P13513, DOI 10.1073/pnas.95.23.13513; Ogg S, 1998, MOL CELL, V2, P887, DOI 10.1016/S1097-2765(00)80303-2; Pappa H, 1998, STRUCT FOLD DES, V6, P885, DOI 10.1016/S0969-2126(98)00090-2; Perisic O, 1998, J BIOL CHEM, V273, P1596, DOI 10.1074/jbc.273.3.1596; Podsypanina K, 1999, P NATL ACAD SCI USA, V96, P1563, DOI 10.1073/pnas.96.4.1563; Rizo J, 1998, J BIOL CHEM, V273, P15879, DOI 10.1074/jbc.273.26.15879; Singer WD, 1997, ANNU REV BIOCHEM, V66, P475, DOI 10.1146/annurev.biochem.66.1.475; Stambolic V, 1998, CELL, V95, P29, DOI 10.1016/S0092-8674(00)81780-8; Steck PA, 1997, NAT GENET, V15, P356, DOI 10.1038/ng0497-356; STUCKEY JA, 1994, NATURE, V370, P571, DOI 10.1038/370571a0; Sun H, 1999, P NATL ACAD SCI USA, V96, P6199, DOI 10.1073/pnas.96.11.6199; Sutton RB, 1998, STRUCTURE, V6, P1395, DOI 10.1016/S0969-2126(98)00139-7; Suzuki A, 1998, CURR BIOL, V8, P1169, DOI 10.1016/S0960-9822(07)00488-5; Tamura M, 1998, SCIENCE, V280, P1614, DOI 10.1126/science.280.5369.1614; Teng DHF, 1997, CANCER RES, V57, P5221; Wang J, 1999, CELL, V98, P47, DOI 10.1016/S0092-8674(00)80605-4; Yuvaniyama J, 1996, SCIENCE, V272, P1328, DOI 10.1126/science.272.5266.1328	42	819	857	7	107	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	OCT 29	1999	99	3					323	334		10.1016/S0092-8674(00)81663-3	http://dx.doi.org/10.1016/S0092-8674(00)81663-3			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	251HX	10555148	Bronze			2022-12-01	WOS:000083440600010
J	Rohani, P; Earn, DJD; Grenfell, BT				Rohani, P; Earn, DJD; Grenfell, BT			Opposite patterns of synchrony in sympatric disease metapopulations	SCIENCE			English	Article							INSECT POPULATION; MEASLES DYNAMICS; TIME-SERIES; CHAOS; VACCINATION; PERTUSSIS; TRANSMISSION; PERSISTENCE; ENGLAND; WALES	Measles epidemics in UK cities, which were regular and highly synchronous before vaccination, are known to have become irregular and spatially uncorrelated in the vaccine era. Whooping cough shows the reverse pattern, namely a shift from spatial incoherence and irregularity before vaccination to regular, synchronous epidemics afterward. Models show that these patterns can arise from disease-specific responses to dynamical noise. This analysis has implications for vaccination strategies and illustrates the power of comparative dynamical studies of sympatric metapopulations.	Univ Cambridge, Dept Zool, Cambridge CB2 3EJ, England	University of Cambridge	Rohani, P (corresponding author), Univ Cambridge, Dept Zool, Downing St, Cambridge CB2 3EJ, England.	pej@zoo.cam.ac.uk		rohani, pejman/0000-0002-7221-3801; Earn, David/0000-0002-7562-1341				AGUR Z, 1993, P NATL ACAD SCI USA, V90, P11698, DOI 10.1073/pnas.90.24.11698; ANDERSON R M, 1991; ARON JL, 1990, THEOR POPUL BIOL, V38, P58, DOI 10.1016/0040-5809(90)90003-E; BARTLETT MS, 1957, J R STAT SOC SER A-G, V120, P48, DOI 10.2307/2342553; Bjornstad ON, 1999, ECOLOGY, V80, P622, DOI 10.2307/176640; Bjornstad ON, 1998, J ANIM ECOL, V67, P110, DOI 10.1046/j.1365-2656.1998.00168.x; Bolker BM, 1996, P NATL ACAD SCI USA, V93, P12648, DOI 10.1073/pnas.93.22.12648; CLARKSON JA, 1985, INT J EPIDEMIOL, V14, P153, DOI 10.1093/ije/14.1.153; Costantino RF, 1997, SCIENCE, V275, P389, DOI 10.1126/science.275.5298.389; Earn DJD, 1998, P ROY SOC B-BIOL SCI, V265, P7, DOI 10.1098/rspb.1998.0256; EARN DJD, UNPUB; ELLNER S, 1995, AM NAT, V145, P343, DOI 10.1086/285744; FINE PEM, 1982, LANCET, V1, P666; Grenfell B, 1997, TRENDS ECOL EVOL, V12, P395, DOI 10.1016/S0169-5347(97)01174-9; Grenfell BT, 1998, NATURE, V394, P674, DOI 10.1038/29291; GRENFELL BT, 1995, P ROY SOC B-BIOL SCI, V259, P97, DOI 10.1098/rspb.1995.0015; GRENFELL BT, 1992, J ROY STAT SOC B MET, V54, P383; GRENFELL BT, 1989, PROC R SOC SER B-BIO, V236, P213, DOI 10.1098/rspb.1989.0022; Grenfell BT, 1998, ECOL LETT, V1, P63; GRENFELL BT, 1999, CHAOS REAL DATA ANAL; HASSELL MP, 1991, NATURE, V353, P255, DOI 10.1038/353255a0; HASSELL MP, 1977, J ANIM ECOL, V46, P249, DOI 10.2307/3959; Hethcote HW, 1997, MATH BIOSCI, V145, P89, DOI 10.1016/S0025-5564(97)00014-X; Higgins K, 1997, SCIENCE, V276, P1431, DOI 10.1126/science.276.5317.1431; LEVINS R, 1969, Bulletin of the Entomological Society of America, V15, P237; MAY RM, 1974, SCIENCE, V186, P645, DOI 10.1126/science.186.4164.645; Miller E, 1997, DEV BIOLOGICALS, V89, P15; Miller E, 1992, Commun Dis Rep CDR Rev, V2, pR152; NOKES DJ, 1997, J MATH APPL MED BIOL, V12, P29; Rohani P, 1998, P ROY SOC B-BIOL SCI, V265, P2033, DOI 10.1098/rspb.1998.0537; ROHANI P, UNPUB; SCHENZLE D, 1984, J MATH APPL MED BIOL, V1, P169; Scott PT, 1997, AM FAM PHYSICIAN, V56, P1121; Shulgin B, 1998, B MATH BIOL, V60, P1123, DOI 10.1016/S0092-8240(98)90005-2; SUGIHARA G, 1990, NATURE, V344, P734, DOI 10.1038/344734a0	35	228	233	0	21	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 29	1999	286	5441					968	971		10.1126/science.286.5441.968	http://dx.doi.org/10.1126/science.286.5441.968			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	250BE	10542154				2022-12-01	WOS:000083368500049
J	Rudolph, U; Crestani, F; Benke, D; Brunig, I; Benson, JA; Fritschy, JM; Martin, JR; Bluethmann, H; Mohler, H				Rudolph, U; Crestani, F; Benke, D; Brunig, I; Benson, JA; Fritschy, JM; Martin, JR; Bluethmann, H; Mohler, H			Benzodiazepine actions mediated by specific gamma-aminobutyric acid(A) receptor subtypes	NATURE			English	Article							ANTI-ANXIETY AGENTS; SINGLE HISTIDINE; DIAZEPAM; PHARMACOLOGY; SUBUNITS; ETHANOL; MOUSE	GABA(A) (gamma-aminobutyric acid(A)) receptors are molecular substrates for the regulation of vigilance, anxiety, muscle tension, epileptogenic activity and memory functions, which is evident from the spectrum of actions elicited by clinically effective drugs acting at their modulatory benzodiazepine-binding site. Here we show, by introducing a histidine-to-arginine point mutation at position 101 of the murine alpha 1-subunit gene, that alpha 1-type GABA(A) receptors, which are mainly expressed in cortical areas and thalamus(1), are rendered insensitive to allosteric modulation by benzodiazepine-site ligands, whilst regulation by the physiological neurotransmitter gamma-aminobutyric acid is preserved. alpha 1(H101R) mice failed to show the sedative, amnesic and partly the anticonvulsant action of diazepam. In contrast, the anxiolytic-like, myorelaxant, motor-impairing and ethanol-potentiating effects were fully retained, and are attributed to the nonmutated GABA(A) receptors found in the limbic system (alpha 2, alpha 5), in monoaminergic neurons (alpha 3) and in motoneurons (alpha 2, alpha 5)(1). Thus, benzodiazepine-induced behavioural responses are mediated by specific GABA(A) receptor subtypes in distinct neuronal circuits, which is of interest for drug design.	Univ Zurich, Inst Pharmacol, CH-8057 Zurich, Switzerland; ETH Zurich, CH-8057 Zurich, Switzerland; Ciba Geigy AG, Div Pharma, Preclin Res, CH-4002 Basel, Switzerland	University of Zurich; Swiss Federal Institutes of Technology Domain; ETH Zurich; Novartis	Rudolph, U (corresponding author), Univ Zurich, Inst Pharmacol, Winterthurestr 190, CH-8057 Zurich, Switzerland.			Fritschy, Jean-Marc/0000-0002-8552-3702				Barnard EA, 1998, PHARMACOL REV, V50, P291; Benson JA, 1998, FEBS LETT, V431, P400, DOI 10.1016/S0014-5793(98)00803-5; BERNARD F, 1996, ZOLPIDEM UPDATE ITS, P21; BEUZEN A, 1995, PHYSIOL BEHAV, V58, P111, DOI 10.1016/0031-9384(95)00013-9; BONETTI EP, 1988, PHARMACOL BIOCHEM BE, V31, P733, DOI 10.1016/0091-3057(88)90259-6; BONETTI EP, 1982, PSYCHOPHARMACOLOGY, V78, P8, DOI 10.1007/BF00470579; BRAESTRUP C, 1977, NATURE, V269, P702, DOI 10.1038/269702a0; FRITSCHY JM, 1995, J COMP NEUROL, V359, P154, DOI 10.1002/cne.903590111; FRITSCHY JM, 1992, P NATL ACAD SCI USA, V89, P6726, DOI 10.1073/pnas.89.15.6726; HUNKELER W, 1981, NATURE, V290, P514, DOI 10.1038/290514a0; KLEINGOOR C, 1993, NEUROREPORT, V4, P187, DOI 10.1097/00001756-199302000-00018; Knoflach F, 1996, MOL PHARMACOL, V50, P1253; Lakso M, 1996, P NATL ACAD SCI USA, V93, P5860, DOI 10.1073/pnas.93.12.5860; LISTER RG, 1987, PSYCHOPHARMACOLOGY, V92, P180; MELCHIOR CL, 1992, PHARMACOL BIOCHEM BE, V42, P605, DOI 10.1016/0091-3057(92)90005-Z; MISSLIN R, 1989, BEHAV PROCESS, V18, P119, DOI 10.1016/S0376-6357(89)80010-5; MOHLER H, 1977, SCIENCE, V198, P849, DOI 10.1126/science.918669; VOGEL JR, 1971, PSYCHOPHARMACOLOGIA, V21, P1, DOI 10.1007/BF00403989; WIELAND HA, 1992, J BIOL CHEM, V267, P1426	19	944	972	1	103	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	OCT 21	1999	401	6755					796	800		10.1038/44579	http://dx.doi.org/10.1038/44579			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	250BG	10548105				2022-12-01	WOS:000083368700054
J	Shamoo, Y; Steitz, TA				Shamoo, Y; Steitz, TA			Building a replisome from interacting pieces: Sliding clamp complexed to a peptide from DNA polymerase and a polymerase editing complex	CELL			English	Article							3'-5' EXONUCLEASE ACTIVITY; I KLENOW FRAGMENT; CRYSTAL-STRUCTURE; REPLICATION COMPLEX; CONSERVED REGION; BINDING-PROTEIN; III HOLOENZYME; BACTERIOPHAGE-T4; SUBUNIT; SITES	We have solved the crystal structures of the bacteriophage RB69 sliding clamp, its complex with a peptide essential for DNA polymerase interactions, and the DNA polymerase complexed with primer-template DNA. The editing complex structure shows a partially melted duplex DNA exiting from the exonuclease domain at an unexpected angle and significant changes in the protein structure. The clamp complex shows the C-terminal 11 residues of polymerase bound in a hydrophobic pocket, and it allows docking of the editing and clamp structures together. The peptide binds to the sliding clamp at a position identical to that of a replication inhibitor peptide bound to PCNA, suggesting that the replication inhibitor protein p21(CIP1) functions by competing with eukaryotic polymerases for the same binding pocket on the clamp.	Yale Univ, Dept Mol Biophys & Biochem, New Haven, CT 06520 USA; Yale Univ, Dept Chem, New Haven, CT 06520 USA; Yale Univ, Howard Hughes Med Inst, New Haven, CT 06520 USA	Yale University; Yale University; Howard Hughes Medical Institute; Yale University	Steitz, TA (corresponding author), Yale Univ, Dept Mol Biophys & Biochem, POB 6666, New Haven, CT 06520 USA.		Steitz, Thomas A./C-6559-2009	Shamoo, Yousif/0000-0001-9241-8962	NIGMS NIH HHS [GM-22778] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		[Anonymous], 1994, ACTA CRYSTALLOGR D, V50, P760; Baker RP, 1998, P NATL ACAD SCI USA, V95, P3507, DOI 10.1073/pnas.95.7.3507; Baker TA, 1998, CELL, V92, P295, DOI 10.1016/S0092-8674(00)80923-X; BEESE LS, 1991, EMBO J, V10, P25, DOI 10.1002/j.1460-2075.1991.tb07917.x; BEESE LS, 1993, SCIENCE, V260, P352, DOI 10.1126/science.8469987; Berdis AJ, 1996, P NATL ACAD SCI USA, V93, P12822, DOI 10.1073/pnas.93.23.12822; BERNAD A, 1990, GENE, V94, P45, DOI 10.1016/0378-1119(90)90466-5; Brautigam CA, 1998, CURR OPIN STRUC BIOL, V8, P54, DOI 10.1016/S0959-440X(98)80010-9; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; CARSON M, 1991, J APPL CRYSTALLOGR, V24, P958, DOI 10.1107/S0021889891007240; COPELAND WC, 1993, J BIOL CHEM, V268, P11041; COWART M, 1989, BIOCHEMISTRY-US, V28, P1975, DOI 10.1021/bi00431a004; DONLIN MJ, 1991, BIOCHEMISTRY-US, V30, P538, DOI 10.1021/bi00216a031; Doublie S, 1998, NATURE, V391, P251, DOI 10.1038/34593; Eom SH, 1996, NATURE, V382, P278, DOI 10.1038/382278a0; FORMOSA T, 1983, P NATL ACAD SCI-BIOL, V80, P2442, DOI 10.1073/pnas.80.9.2442; FREEMONT PS, 1988, P NATL ACAD SCI USA, V85, P8924, DOI 10.1073/pnas.85.23.8924; Gibbs E, 1997, J BIOL CHEM, V272, P2373; Goodrich LD, 1997, BIOCHEMISTRY-US, V36, P10474, DOI 10.1021/bi9708949; GOPALAKRISHNAN V, 1994, J BIOL CHEM, V269, P21123; Gulbis JM, 1996, CELL, V87, P297, DOI 10.1016/S0092-8674(00)81347-1; HERENDEEN DR, 1990, SCIENCE, V248, P573, DOI 10.1126/science.2185541; JARVIS TC, 1989, J BIOL CHEM, V264, P12709; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; JOUNG I, 1991, VIROLOGY, V184, P235, DOI 10.1016/0042-6822(91)90840-8; JOYCE CM, 1987, TRENDS BIOCHEM SCI, V12, P288, DOI 10.1016/0968-0004(87)90143-5; JOYCE CM, 1989, J BIOL CHEM, V264, P10858; JOYCE CM, 1994, ANNU REV BIOCHEM, V63, P777, DOI 10.1146/annurev.biochem.63.1.777; KABOORD BF, 1993, P NATL ACAD SCI USA, V90, P10881, DOI 10.1073/pnas.90.22.10881; KELMAN Z, 1995, NUCLEIC ACIDS RES, V23, P3613, DOI 10.1093/nar/23.18.3613; Kiefer JR, 1998, NATURE, V391, P304, DOI 10.1038/34693; KONG XP, 1992, CELL, V69, P425, DOI 10.1016/0092-8674(92)90445-I; KRISHNA TSR, 1994, CELL, V79, P1233, DOI 10.1016/0092-8674(94)90014-0; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LIN TC, 1994, J BIOL CHEM, V269, P19286; MORRIS CF, 1979, J BIOL CHEM, V254, P6787; NICHOLLS KA, 1993, BIOPHYS J, V64, pA166; NOSSAL NG, 1992, FASEB J, V6, P871, DOI 10.1096/fasebj.6.3.1310946; OLLIS DL, 1985, NATURE, V313, P762, DOI 10.1038/313762a0; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; REDDY MK, 1993, P NATL ACAD SCI USA, V90, P3211, DOI 10.1073/pnas.90.8.3211; Reha-Krantz LJ, 1998, J BIOL CHEM, V273, P22969, DOI 10.1074/jbc.273.36.22969; Rice LM, 1998, J APPL CRYSTALLOGR, V31, P798, DOI 10.1107/S0021889898006645; SHAMOO Y, 1995, NATURE, V376, P362, DOI 10.1038/376362a0; Soumillion P, 1998, BIOCHEMISTRY-US, V37, P1819, DOI 10.1021/bi972526a; SPACCIAPOLI P, 1994, J BIOL CHEM, V269, P438; SPICER EK, 1982, J BIOL CHEM, V257, P8972; STOCKI SA, 1995, J MOL BIOL, V254, P15, DOI 10.1006/jmbi.1995.0595; STUKENBERG PT, 1991, J BIOL CHEM, V266, P11328; TINKER RL, 1995, J BIOL CHEM, V270, P15899, DOI 10.1074/jbc.270.26.15899; WANG CC, 1995, J BIOL CHEM, V270, P26558, DOI 10.1074/jbc.270.44.26558; Wang J, 1997, CELL, V89, P1087, DOI 10.1016/S0092-8674(00)80296-2; Wu P, 1998, BIOCHEMISTRY-US, V37, P14748, DOI 10.1021/bi980835a; Yeh LS, 1998, J BACTERIOL, V180, P2005, DOI 10.1128/JB.180.8.2005-2013.1998	54	304	321	0	14	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	OCT 15	1999	99	2					155	166		10.1016/S0092-8674(00)81647-5	http://dx.doi.org/10.1016/S0092-8674(00)81647-5			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	246JB	10535734	Bronze			2022-12-01	WOS:000083159700006
J	Venkataraman, G; Shriver, Z; Raman, R; Sasisekharan, R				Venkataraman, G; Shriver, Z; Raman, R; Sasisekharan, R			Sequencing complex polysaccharides	SCIENCE			English	Article							HEPARAN-SULFATE PROTEOGLYCANS; ENZYMATIC DEGRADATION; GLYCOSAMINOGLYCANS; OLIGOSACCHARIDES; BINDING	Although rapid sequencing of polynucleotides and polypeptides has become commonplace, it has not been possible to rapidly sequence femto- to picomole amounts of tissue-derived complex polysaccharides. Heparin-like glycosaminoglycans (HLGAGs) were readily sequenced by a combination of matrix-assisted Laser desorption ionization mass spectrometry and a notation system for representation of polysaccharide sequences. This will enable identification of sequences that are critical to HLGAG biological activities in anticoagulation, cell growth, and differentiation.	Harvard Univ, MIT, Div Hlth Sci & Technol, Cambridge, MA 02139 USA; MIT, Div Bioengn & Environm Hlth, Cambridge, MA 02139 USA	Harvard University; Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT)	Sasisekharan, R (corresponding author), Harvard Univ, MIT, Div Hlth Sci & Technol, Cambridge, MA 02139 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM057073] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 57073] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BERNFIELD M, 1992, ANNU REV CELL BIOL, V8, P365, DOI 10.1146/annurev.cb.08.110192.002053; Chen YP, 1997, NAT MED, V3, P866, DOI 10.1038/nm0897-866; Conrad H. E., 1998, HEPARIN BINDING PROT; Cumberledge S, 1997, TRENDS GENET, V13, P421, DOI 10.1016/S0168-9525(97)01275-4; ERNST S, 1995, CRIT REV BIOCHEM MOL, V30, P387, DOI 10.3109/10409239509083490; Ernst S, 1998, P NATL ACAD SCI USA, V95, P4182, DOI 10.1073/pnas.95.8.4182; Hung SL, 1999, VIROLOGY, V257, P156, DOI 10.1006/viro.1999.9633; JACKSON RL, 1991, PHYSIOL REV, V71, P481, DOI 10.1152/physrev.1991.71.2.481; Jacquet A, 1998, VIRUS RES, V53, P197, DOI 10.1016/S0168-1702(97)00149-4; Joyce JG, 1999, J BIOL CHEM, V274, P5810, DOI 10.1074/jbc.274.9.5810; JUHASZ P, 1994, P NATL ACAD SCI USA, V91, P4333, DOI 10.1073/pnas.91.10.4333; JUHASZ P, 1995, CARBOHYD RES, V270, P131, DOI 10.1016/0008-6215(94)00012-5; KJELLEN L, 1991, ANNU REV BIOCHEM, V60, P443, DOI 10.1146/annurev.bi.60.070191.002303; LANE DL, 1989, HEPARIN CHEM BIOL PR; Lindahl U, 1998, J BIOL CHEM, V273, P24979, DOI 10.1074/jbc.273.39.24979; LINDAHL U, 1995, THROMB RES, V75, P1; McCormick C, 1998, NAT GENET, V19, P158, DOI 10.1038/514; Rapraeger AC, 1993, CURR OPIN CELL BIOL, V5, P844, DOI 10.1016/0955-0674(93)90034-N; Rhomberg AJ, 1998, P NATL ACAD SCI USA, V95, P4176, DOI 10.1073/pnas.95.8.4176; Rosenberg RD, 1997, J CLIN INVEST, V99, P2062, DOI 10.1172/JCI119377; Salmivirta M, 1996, FASEB J, V10, P1270, DOI 10.1096/fasebj.10.11.8836040; Sporn M. B., 1990, PEPTIDE GROWTH FACTO; Toida T, 1996, J BIOL CHEM, V271, P32040, DOI 10.1074/jbc.271.50.32040; TURNBULL JH, 1999, P NATL ACAD SCI USA, V96, P2703; VARKI A, 1993, GLYCOBIOLOGY, V3, P97, DOI 10.1093/glycob/3.2.97; Venkataraman G, 1999, P NATL ACAD SCI USA, V96, P1892, DOI 10.1073/pnas.96.5.1892; Vives RR, 1999, BIOCHEM J, V339, P767, DOI 10.1042/0264-6021:3390767; Waksman G, 1998, NAT STRUCT BIOL, V5, P527, DOI 10.1038/778; Wodarz A, 1998, ANNU REV CELL DEV BI, V14, P59, DOI 10.1146/annurev.cellbio.14.1.59	29	209	248	0	34	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	OCT 15	1999	286	5439					537	542		10.1126/science.286.5439.537	http://dx.doi.org/10.1126/science.286.5439.537			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	245RD	10521350				2022-12-01	WOS:000083121200062
J	Shih, NY; Li, J; Karpitskii, V; Nguyen, A; Dustin, ML; Kanagawa, O; Miner, JH; Shaw, AS				Shih, NY; Li, J; Karpitskii, V; Nguyen, A; Dustin, ML; Kanagawa, O; Miner, JH; Shaw, AS			Congenital nephrotic syndrome in mice lacking CD2-associated protein	SCIENCE			English	Article							PODOCYTES; CONTACTS; GENES	CD2-associated protein (CD2AP) is an 80-kilodalton protein that is critical for stabilizing contacts between T cells and antigen-presenting cells. In CD2AP-deficient mice, immune function was compromised, but the mice died at 6 to 7 weeks of age from renal failure. In the kidney, CD2AP was expressed primarily in glomerular epithelial cells. Knockout mice exhibited defects in epithelial tell foot processes, accompanied by mesangial cell hyperplasia and extracellular matrix deposition. Supporting a role for CD2AP in the specialized cell junction known as the slit diaphragm, CD2AP associated with nephrin, the primary component of the slit diaphragm.	Washington Univ, Ctr Immunol, St Louis, MO 63110 USA; Washington Univ, Dept Pathol, St Louis, MO 63110 USA; Washington Univ, Dept Med, Div Renal, St Louis, MO 63110 USA	Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL)	Shih, NY (corresponding author), Washington Univ, Ctr Immunol, St Louis, MO 63110 USA.		Dustin, Michael/AAM-4611-2020; Shih, Neng-Yao/D-2086-2010	Dustin, Michael/0000-0003-4983-6389				Cheng YS, 1997, J BIOL CHEM, V272, P31525, DOI 10.1074/jbc.272.50.31525; DIPERSIO CM, 1995, J CELL SCI, V108, P2321; Dustin ML, 1998, CELL, V94, P667, DOI 10.1016/S0092-8674(00)81608-6; GAUEN LT, 1992, MOL CELL BIOL, V38, P5438; KATO M, 1988, J CELL BIOL, V106, P2203, DOI 10.1083/jcb.106.6.2203; Kestila M, 1998, MOL CELL, V1, P575, DOI 10.1016/S1097-2765(00)80057-X; Kirsch KH, 1999, P NATL ACAD SCI USA, V96, P6211, DOI 10.1073/pnas.96.11.6211; MANSOUR SL, 1988, NATURE, V336, P348, DOI 10.1038/336348a0; MINER JH, 1994, J CELL BIOL, V127, P879, DOI 10.1083/jcb.127.3.879; MUNDEL P, 1991, J HISTOCHEM CYTOCHEM, V39, P1047, DOI 10.1177/39.8.1856454; Mundel P, 1997, J CELL BIOL, V139, P193, DOI 10.1083/jcb.139.1.193; REIS LFL, 1994, EMBO J, V13, P4798, DOI 10.1002/j.1460-2075.1994.tb06805.x; Ruotsalainen V, 1999, P NATL ACAD SCI USA, V96, P7962, DOI 10.1073/pnas.96.14.7962; SHIH N, UNPUB	14	628	683	0	14	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	OCT 8	1999	286	5438					312	315		10.1126/science.286.5438.312	http://dx.doi.org/10.1126/science.286.5438.312			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	243YE	10514378				2022-12-01	WOS:000083024400050
J	Loisel, TP; Boujemaa, R; Pantaloni, D; Carlier, MF				Loisel, TP; Boujemaa, R; Pantaloni, D; Carlier, MF			Reconstitution of actin-based motility of Listeria and Shigella using pure proteins	NATURE			English	Article							FILAMENT TURNOVER; CELL MOTILITY; MONOCYTOGENES; SURFACE; DYNAMICS; FLEXNERI; POLYMERIZATION; SUFFICIENT; NUCLEATION; COMPLEX	Actin polymerization is essential for cell locomotion and is thought to generate the force responsible for cellular protrusions. The Arp2/3 complex is required to stimulate actin assembly at the leading edge in response to signalling(1-6). The bacteria Listeria and Shigella bypass the signalling pathway and harness the Arp2/3 complex to induce actin assembly and to propel themselves in living cells(7-10). However, the Arp2/3 complex alone is insufficient to promote movement. Here we have used pure components of the actin cytoskeleton to reconstitute sustained movement in Listeria and Shigella in vitro. Actin-based propulsion is driven by the free energy released by ATP hydrolysis linked to actin polymerization, and does not require myosin. In addition to actin and activated Arp2/3 complex, actin depolymerizing factor (ADF, or cofilin) and capping protein are also required for motility as they maintain a high steady-state level of G-actin, which controls the rate of unidirectional growth of actin filaments at the surface of the bacterium. The movement is more effective when profilin, alpha-actinin and VASP (for Listeria) are also included. These results have implications for our understanding of the mechanism of actin-based motility in cells.	CNRS, LEBS, Gif Sur Yvette, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay	Carlier, MF (corresponding author), CNRS, LEBS, Gif Sur Yvette, France.	carlier@lebs.caps-gif.fr		Boujemaa-Paterski, Rajaa/0000-0001-9645-387X				Carlier MF, 1998, CURR OPIN CELL BIOL, V10, P45, DOI 10.1016/S0955-0674(98)80085-9; Carlier MF, 1997, J MOL BIOL, V269, P459, DOI 10.1006/jmbi.1997.1062; Carlier MF, 1997, J CELL BIOL, V136, P1307, DOI 10.1083/jcb.136.6.1307; CUNNINGHAM CC, 1991, SCIENCE, V251, P1233, DOI 10.1126/science.1848726; Didry D, 1998, J BIOL CHEM, V273, P25602, DOI 10.1074/jbc.273.40.25602; Egile C, 1999, J CELL BIOL, V146, P1319, DOI 10.1083/jcb.146.6.1319; GOLDBERG MB, 1995, P NATL ACAD SCI USA, V92, P6572, DOI 10.1073/pnas.92.14.6572; Goldberg MB, 1997, CELL MOTIL CYTOSKEL, V37, P44, DOI 10.1002/(SICI)1097-0169(1997)37:1<44::AID-CM5>3.3.CO;2-S; HUG C, 1995, CELL, V81, P591, DOI 10.1016/0092-8674(95)90080-2; KOCKS C, 1995, MOL MICROBIOL, V18, P413, DOI 10.1111/j.1365-2958.1995.mmi_18030413.x; Kuhlman PA, 1997, BIOCHEMISTRY-US, V36, P13461, DOI 10.1021/bi970601b; Lasa I, 1997, EMBO J, V16, P1531, DOI 10.1093/emboj/16.7.1531; Laurent V, 1999, J CELL BIOL, V144, P1245, DOI 10.1083/jcb.144.6.1245; Machesky LM, 1999, P NATL ACAD SCI USA, V96, P3739, DOI 10.1073/pnas.96.7.3739; Machesky LM, 1998, CURR BIOL, V8, P1347, DOI 10.1016/S0960-9822(98)00015-3; MARCHAND JB, 1995, J CELL BIOL, V130, P331, DOI 10.1083/jcb.130.2.331; Miki H, 1998, NATURE, V391, P93, DOI 10.1038/34208; NANAVATI D, 1994, CELL MOTIL CYTOSKEL, V28, P346, DOI 10.1002/cm.970280408; Ressad F, 1999, J BIOL CHEM, V274, P20970, DOI 10.1074/jbc.274.30.20970; Rohatgi R, 1999, CELL, V97, P221, DOI 10.1016/S0092-8674(00)80732-1; Rottner K, 1999, NAT CELL BIOL, V1, P321, DOI 10.1038/13040; SMALL JV, 1995, TRENDS CELL BIOL, V5, P52, DOI 10.1016/S0962-8924(00)88939-4; Smith GA, 1996, J CELL BIOL, V135, P647, DOI 10.1083/jcb.135.3.647; Sun J P, 1995, J Am Soc Echocardiogr, V8, P29, DOI 10.1016/S0894-7317(05)80355-4; Suzuki T, 1998, EMBO J, V17, P2767, DOI 10.1093/emboj/17.10.2767; Svitkina TM, 1999, J CELL BIOL, V145, P1009, DOI 10.1083/jcb.145.5.1009; THERIOT JA, 1992, NATURE, V357, P257, DOI 10.1038/357257a0; Welch MD, 1997, NATURE, V385, P265, DOI 10.1038/385265a0; Welch MD, 1998, SCIENCE, V281, P105, DOI 10.1126/science.281.5373.105; Winter D, 1999, CURR BIOL, V9, P501, DOI 10.1016/S0960-9822(99)80218-8; Yarar D, 1999, CURR BIOL, V9, P555, DOI 10.1016/S0960-9822(99)80243-7	31	786	799	0	64	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	OCT 7	1999	401	6753					613	616		10.1038/44183	http://dx.doi.org/10.1038/44183			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	244MG	10524632				2022-12-01	WOS:000083054900057
J	Millstone, E; Brunner, E; Mayer, S				Millstone, E; Brunner, E; Mayer, S			Beyond 'substantial equivalence'	NATURE			English	Editorial Material									Univ Sussex, Sci Policy Res Unit, Brighton BN1 9RF, E Sussex, England; UCL, Dept Epidemiol & Publ Hlth, London WC1E 6BT, England; GeneWatch UK, Buxton SK17 8NY, Derby, England	University of Sussex; University of London; University College London	Millstone, E (corresponding author), Univ Sussex, Sci Policy Res Unit, Mantell Bldg, Brighton BN1 9RF, E Sussex, England.	e.p.millstone@sussex.ac.uk	Kesim, Haydar K/B-4662-2010; Brunner, Eric/H-2114-2011	Brunner, Eric/0000-0002-0595-4474				Bowers J, 1999, SCIENCE, V285, P1562, DOI 10.1126/science.285.5433.1562; *EUR COMM, 1980, FOOD ADD CONS, P41; KUIPER H, 1998, FOOD SAFETY EVALUATI; LYDON J, 1989, PESTIC SCI, V25, P361, DOI 10.1002/ps.2780250406; Masood E, 1999, NATURE, V398, P98, DOI 10.1038/18086; *OECD, 1993, SAF EV FOODS DER MOD; Padgette SR, 1996, J NUTR, V126, P702, DOI 10.1093/jn/126.3.702; WHO, 1991, STRAT ASS SAF FOODS	8	200	226	1	32	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	OCT 7	1999	401	6753					525	526		10.1038/44006	http://dx.doi.org/10.1038/44006			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	244MG	10524614				2022-12-01	WOS:000083054900020
J	Jalan, R; Damink, SWMO; Deutz, NEP; Lee, A; Hayes, PC				Jalan, R; Damink, SWMO; Deutz, NEP; Lee, A; Hayes, PC			Moderate hypothermia for uncontrolled intracranial hypertension in acute liver failure	LANCET			English	Article							FULMINANT HEPATIC-FAILURE; CEREBRAL BLOOD-FLOW; TOTAL HEPATECTOMY; BODY-TEMPERATURE; CONTROLLED TRIAL; BRAIN EDEMA; GLUTAMINE; RAT; METABOLISM; AMMONIA	Background Increased intracranial pressure as a complication of acute liver failure has a mortality of about 90% in patients who do not respond to treatment with mannitol and ultrafiltration. We investigated the safety and efficacy of moderate hypothermia for uncontrolled increase in intracranial pressure in patients with acute liver failure. Methods We studied seven consecutive patients aged 16-46 years (five women, four candidates for orthotopic liver transplantation [OLT]) with acute liver failure who fulfilled criteria for poor-prognosis liver failure and had increased intracranial pressure that was unresponsive to two treatments with mannitol and ultrafiltration. We used cooling blankets to lower the patients' core temperature to 32-33 degrees C. Patients who were not suitable candidates for OLT (patients 1-3) were cooled for 8 h and then gradually rewarmed over 1 h to 8 baseline temperature of 37 degrees C. Patients who were suitable candidates for OLT (patients 4-7) were cooled before and during the OLT procedure; We measured cerebral blood flow and metabolic indices before and after cooling. Findings The four patients who were candidates for OLT were successfully maintained until transplantation with 13 (range 10-14) h of hypothermia. The three patients who were unsuitable candidates for OLT died after rewarming. Intracranial pressure before cooling was 45 (25-49) mm Hg and was reduced in all patients to 16 (13-17) mm Hg (p<0.05). Cerebral blood flow decreased from 103 (25-134) mt 100 g(-1) min(-1) before cooling to 44 (24-75) mt 100 g(-1) min(-1) after cooling (p<005). The corresponding changes for cerebral perfusion pressure was an increase from 45 (37-56) mm Hg to 70 (60-78) mm Hg (p<0.05) and for cardiac index a decrease from 9.8 (7-13) to 5.1 (4.3-6.1) L per min per m(2) of body surface area. During hypothermia there was no significant relapse of increased intracranial pressure. Arterial ammonia and cerebral uptake of ammonia were significantly reduced with cooling. No adverse effects of hypothermia were observed. Interpretation Moderate hypothermia is useful in the treatment of uncontrolled increase in intracranial pressure in patients with acute liver failure and may serve as a bridge to OLT.	Royal Infirm Edinburgh, Liver Unit, Edinburgh EH3 9YW, Midlothian, Scotland; Royal Infirm Edinburgh, Scottish Liver Transplantat Unit, Edinburgh EH3 9YW, Midlothian, Scotland; Royal Infirm Edinburgh, Dept Anaesthet, Edinburgh EH3 9YW, Midlothian, Scotland; Royal Infirm Edinburgh, Intens Care Unit, Edinburgh EH3 9YW, Midlothian, Scotland; Maastricht Univ, Dept Surg, Maastricht, Netherlands	Royal Infirmary of Edinburgh; Royal Infirmary of Edinburgh; Royal Infirmary of Edinburgh; Royal Infirmary of Edinburgh; Maastricht University	Jalan, R (corresponding author), Royal Infirm Edinburgh, Liver Unit, Edinburgh EH3 9YW, Midlothian, Scotland.		Deutz, Nicolaas E/J-5200-2012; Damink, Steven WM Olde/U-7919-2019	Damink, Steven WM Olde/0000-0002-5202-9345; Deutz, Nicolaas/0000-0001-5845-6447	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		AGGARWAL S, 1994, HEPATOLOGY, V19, P80, DOI 10.1002/hep.1840190114; ASCHER NL, 1993, ARCH SURG-CHICAGO, V128, P677; CANALESE J, 1982, GUT, V23, P625, DOI 10.1136/gut.23.7.625; Clemmesen JO, 1997, HEPATOLOGY, V26, P1423; COOPER AJL, 1987, PHYSIOL REV, V67, P440, DOI 10.1152/physrev.1987.67.2.440; DEJONG CHC, 1993, J CLIN INVEST, V92, P2834, DOI 10.1172/JCI116903; EDE RJ, 1986, J HEPATOL, V2, P43, DOI 10.1016/S0168-8278(86)80007-1; Eguchi S, 1996, HEPATOLOGY, V24, P1452; EJLERSEN E, 1994, TRANSPLANT P, V26, P1794; FORBES A, 1989, HEPATOLOGY, V10, P306, DOI 10.1002/hep.1840100309; Hirata T, 1996, STROKE, V27, P729, DOI 10.1161/01.STR.27.4.729; HOOFNAGLE JH, 1995, HEPATOLOGY, V21, P240, DOI 10.1002/hep.1840210137; JACOBSEN M, 1989, J CEREB BLOOD FLOW M, V9, P717; KEAYS R, 1991, BRIT MED J, V303, P1026, DOI 10.1136/bmj.303.6809.1026; KETY SS, 1948, J CLIN INVEST, V27, P476, DOI 10.1172/JCI101994; Larsen FS, 1996, SEMIN LIVER DIS, V16, P281, DOI 10.1055/s-2007-1007241; MAKIN AJ, 1995, GASTROENTEROLOGY, V109, P1907, DOI 10.1016/0016-5085(95)90758-0; Marion DW, 1997, NEW ENGL J MED, V336, P540, DOI 10.1056/NEJM199702203360803; MCCONNELL JR, 1995, HEPATOLOGY, V22, P69, DOI 10.1016/0270-9139(95)90354-2; OGRADY JG, 1989, GASTROENTEROLOGY, V97, P439, DOI 10.1016/0016-5085(89)90081-4; OLAFSSON S, 1995, GASTROENTEROLOGY, V108, P1097, DOI 10.1016/0016-5085(95)90208-2; PEIGNOUX M, 1982, CLIN SCI, V62, P273, DOI 10.1042/cs0620273; Philips BJ, 1998, HEPATOLOGY, V27, P369, DOI 10.1002/hep.510270209; POWERS WJ, 1985, J CEREBR BLOOD F MET, V5, P600, DOI 10.1038/jcbfm.1985.89; Rao VLR, 1998, METAB BRAIN DIS, V13, P175, DOI 10.1023/A:1023281307660; TAKAHASHI H, 1991, AM J PHYSIOL, V261, P825; TRABER P, 1989, GASTROENTEROLOGY, V96, P885; Trey C, 1970, Prog Liver Dis, V3, P282; WENDON JA, 1994, HEPATOLOGY, V19, P1407, DOI 10.1016/0270-9139(94)90235-6; WillardMack CL, 1996, NEUROSCIENCE, V71, P589, DOI 10.1016/0306-4522(95)00462-9	30	255	265	0	6	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	OCT 2	1999	354	9185					1164	1168		10.1016/S0140-6736(98)12440-6	http://dx.doi.org/10.1016/S0140-6736(98)12440-6			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	242QX	10513710				2022-12-01	WOS:000082954100012
J	Micchelli, CA; Blair, SS				Micchelli, CA; Blair, SS			Dorsoventral lineage restriction in wing imaginal discs requires Notch	NATURE			English	Article							DORSAL-VENTRAL BOUNDARY; GENE-EXPRESSION; VESTIGIAL GENE; DROSOPHILA; SERRATE; FRINGE; ACTIVATION; CELLS; COMPARTMENT; SIGNAL	The formation of boundaries that prevent the intermixing of cells is an important developmental patterning mechanism. The compartmental lineage restrictions that appear in the developing imaginal discs of Drosophila are striking examples of such boundaries(1). However, little is known about the cellular mechanism underlying compartmental lineage restrictions. The dorsoventral (D/V) lineage restriction that arises late in the developing wing imaginal disc requires the dorsal expression of the transcription factor Apterous and it has been hypothesized that apterous (ap) maintains compartmentalization by directly regulating the expression of molecules that modify cell adhesion or affinity(2). However, ap expression also regulates signalling between dorsal and ventral compartments, resulting in high levels of Notch signalling at the D/V boundary(3-17). Here we show that the formation of Notch-dependent boundary cells ig required for the D/V lineage restriction.	Univ Wisconsin, Dept Zool, Madison, WI 53706 USA; Univ Wisconsin, Neurosci Training Program, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison	Blair, SS (corresponding author), Univ Wisconsin, Dept Zool, 250 N Mills St, Madison, WI 53706 USA.							Artavanis-Tsakonas S, 1999, SCIENCE, V284, P770, DOI 10.1126/science.284.5415.770; BLAIR SS, 1993, DEVELOPMENT, V119, P339; BLAIR SS, 1994, DEVELOPMENT, V120, P1805; Blair SS, 1997, DEVELOPMENT, V124, P4053; Blair SS, 1997, CURR BIOL, V7, pR686, DOI 10.1016/S0960-9822(06)00356-3; BLAIR SS, 1999, DEV GENETICS EPIGENE, P347; Brennan K, 1997, GENETICS, V147, P177; BROWER DL, 1985, DEV BIOL, V108, P120, DOI 10.1016/0012-1606(85)90014-4; Couso JP, 1995, CURR BIOL, V5, P1437, DOI 10.1016/S0960-9822(95)00281-8; DECELIS JF, 1994, MECH DEVELOP, V46, P109, DOI 10.1016/0925-4773(94)90080-9; deCelis JF, 1996, DEVELOPMENT, V122, P359; deCelis JF, 1997, DEVELOPMENT, V124, P3241; DiazBenjumea FJ, 1995, DEVELOPMENT, V121, P4215; DIAZBENJUMEA FJ, 1993, CELL, V75, P741, DOI 10.1016/0092-8674(93)90494-B; Doherty D, 1996, GENE DEV, V10, P421, DOI 10.1101/gad.10.4.421; FEHON RG, 1990, CELL, V61, P523, DOI 10.1016/0092-8674(90)90534-L; Fleming RJ, 1997, DEVELOPMENT, V124, P2973; Gho M, 1996, DEVELOPMENT, V122, P1673; IRVINE KD, 1994, CELL, V79, P595, DOI 10.1016/0092-8674(94)90545-2; KIDD S, 1986, MOL CELL BIOL, V6, P3094, DOI 10.1128/MCB.6.9.3094; Kim J, 1996, NATURE, V382, P133, DOI 10.1038/382133a0; KIM J, 1995, CELL, V82, P795, DOI 10.1016/0092-8674(95)90476-X; Klein T, 1998, DEVELOPMENT, V125, P2951; Micchelli CA, 1997, DEVELOPMENT, V124, P1485; Neumann CJ, 1996, DEVELOPMENT, V122, P3477; Panin VM, 1997, NATURE, V387, P908, DOI 10.1038/43191; REBAY I, 1993, CELL, V74, P319, DOI 10.1016/0092-8674(93)90423-N; Rodriguez I, 1997, NATURE, V389, P614, DOI 10.1038/39343; RULIFSON EJ, 1995, DEVELOPMENT, V121, P2813; SHELLENBARGER DL, 1978, DEV BIOL, V62, P432, DOI 10.1016/0012-1606(78)90226-9	30	87	89	0	3	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	SEP 30	1999	401	6752					473	476		10.1038/46779	http://dx.doi.org/10.1038/46779			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	243DF	10519549				2022-12-01	WOS:000082981200055
J	Boden, D; Hurley, A; Zhang, LQ; Cao, YZ; Guo, Y; Jones, E; Tsay, J; Ip, J; Farthing, C; Limoli, K; Parkin, N; Markowitz, M				Boden, D; Hurley, A; Zhang, LQ; Cao, YZ; Guo, Y; Jones, E; Tsay, J; Ip, J; Farthing, C; Limoli, K; Parkin, N; Markowitz, M			HIV-1 drug resistance in newly infected individuals	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; REVERSE-TRANSCRIPTASE; ANTIRETROVIRAL THERAPY; ZIDOVUDINE-RESISTANCE; PROTEASE INHIBITORS; TYPE-1; TRANSMISSION; MUTATIONS; CELL; INDINAVIR	Context There is concern that the widespread use of antiretroviral drugs to treat human immunodeficiency virus 1 (HIV-1) infection may result in the increased transmission of drug-resistant virus. Objective To determine the prevalence of drug resistance-conferring mutations and phenotypic resistance to antiretroviral agents in a cohort of individuals newly infected with HIV-1. Design Case series with genetic analyses of the HIV-1 plasma-derived pol gene using reverse transcriptase polymerase chain reaction followed by direct sequencing of polymerase chain reaction products. Phenotypic analysis was performed with a recombinant virus assay. Setting and Patients Eighty individuals referred, on average, 1.7 months after infection with HIV-1 to the Aaron Diamond AIDS Research Center between July 1995 and April 1999, Subjects were from large urban areas (65 from New York, NY; 11 from Los Angeles, Calif); 60 (75%) were white, and 75 (93.8%) were homosexual men. Main Outcome Measures Prevalence of known resistance-conferring genotypes and reduced susceptibility to individual antiviral agents by phenotype. Results Thirteen individuals (16.3%) had genotypes associated with drug resistance to any antiretroviral agent. Virus with known resistance-conferring mutations to any nucleoside reverse transcriptase inhibitors was found in 10 individuals, to any nonnucleoside reverse transcriptase inhibitors in 6 subjects, and to any protease inhibitors in 2 cases. Multidrug-resistant Virus was identified in 3 individuals (3.8%), Extensive polymorphism in the protease gene was identified. Interpretation of genotypes and phenotypes was concordant in 57 (85%) of the 67 cases in which both studies were performed. Conclusion The prevalence of HIV-1 variants with known resistance-conferring genotypes to any antiretroviral agent in this cohort of 80 newly infected individuals is 16.3%., These data support expanded use of resistance testing in the setting of primary HIV-1 infection. Clinical trials should be initiated to establish whether therapy guided by resistance testing, compared with the use of empirical tri pie combination antiretroviral therapy, provides additional virological and immunological benefit when treating primary HIV-1 infection. Further efforts to expand the study of transmission of drug-resistant HIV-1 variants, particularly in cohorts with different epidemiological profiles, are indicated.	Rockefeller Univ, Aaron Diamond AIDS Res Ctr, New York, NY 10016 USA; AIDS Healthcare Fdn, Los Angeles, CA USA; ViroLog Inc, San Francisco, CA USA	Rockefeller University	Markowitz, M (corresponding author), Rockefeller Univ, Aaron Diamond AIDS Res Ctr, 455 1st Ave,7th Floor, New York, NY 10016 USA.	mmarkowitz@adarc.org	Guo, Yong/ABF-9338-2020; Ip, James E./I-1235-2019; Parkin, Neil/P-2724-2019	Ip, James E./0000-0002-3461-505X; 	NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000102] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P30AI042848, U01AI041534] Funding Source: NIH RePORTER; NCRR NIH HHS [M01-RR00102] Funding Source: Medline; NIAID NIH HHS [AI-41534, P30AI42848] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ANGARANO G, 1994, AIDS, V8, P1013, DOI 10.1097/00002030-199407000-00023; BALFE P, 1990, J VIROL, V64, P6221, DOI 10.1128/JVI.64.12.6221-6233.1990; Carpenter CCJ, 1998, JAMA-J AM MED ASSOC, V280, P78, DOI 10.1001/jama.280.1.78; Cohen OJ, 1998, NEW ENGL J MED, V339, P341, DOI 10.1056/NEJM199807303390511; Condra JH, 1996, J VIROL, V70, P8270, DOI 10.1128/JVI.70.12.8270-8276.1996; CONDRA JH, 1995, NATURE, V374, P569, DOI 10.1038/374569a0; CONLON CP, 1994, J INFECT DIS, V169, P411, DOI 10.1093/infdis/169.2.411; Deeks SG, 1999, AIDS, V13, pF35, DOI 10.1097/00002030-199904160-00001; DUNCOMBE C, 1998, 5 C RETR OPP INF FEB; Eastman PS, 1998, J VIROL, V72, P5154, DOI 10.1128/JVI.72.6.5154-5164.1998; ERICE A, 1993, NEW ENGL J MED, V328, P1163, DOI 10.1056/NEJM199304223281605; Fatkenheuer G, 1997, AIDS, V11, pF113, DOI 10.1097/00002030-199714000-00001; FELSENSTEIN J, 1988, ANNU REV GENET, V22, P521, DOI 10.1146/annurev.ge.22.120188.002513; FITZGIBBON JE, 1993, NEW ENGL J MED, V329, P1835, DOI 10.1056/NEJM199312163292502; Gervaix A, 1997, P NATL ACAD SCI USA, V94, P4653, DOI 10.1073/pnas.94.9.4653; Gulick RM, 1997, NEW ENGL J MED, V337, P734, DOI 10.1056/NEJM199709113371102; Hammer SM, 1997, NEW ENGL J MED, V337, P725, DOI 10.1056/NEJM199709113371101; Havlir DV, 1996, J VIROL, V70, P7894, DOI 10.1128/JVI.70.11.7894-7899.1996; Hecht FM, 1998, NEW ENGL J MED, V339, P307, DOI 10.1056/NEJM199807303390504; Hertogs K, 1998, ANTIMICROB AGENTS CH, V42, P269, DOI 10.1093/jac/42.2.269; Imrie A, 1997, J INFECT DIS, V175, P1502, DOI 10.1086/516487; Jena PK, 1996, J IMMUNOL METHODS, V190, P199, DOI 10.1016/0022-1759(95)00277-4; Kleim JP, 1996, P NATL ACAD SCI USA, V93, P34, DOI 10.1073/pnas.93.1.34; Kozal MJ, 1996, NAT MED, V2, P753, DOI 10.1038/nm0796-753; Molla A, 1996, NAT MED, V2, P760, DOI 10.1038/nm0796-760; Palella FJ, 1998, NEW ENGL J MED, V338, P853, DOI 10.1056/NEJM199803263381301; PARKIN N, 1997, 37 INT C ANT AG CHEM; Patick AK, 1998, ANTIMICROB AGENTS CH, V42, P2637, DOI 10.1128/AAC.42.10.2637; Perelson AS, 1997, NATURE, V387, P188, DOI 10.1038/387188a0; Quigg M, 1997, AIDS, V11, P835; Rosenberg ES, 1997, SCIENCE, V278, P1447, DOI 10.1126/science.278.5342.1447; Shafer RW, 1998, ANN INTERN MED, V128, P906, DOI 10.7326/0003-4819-128-11-199806010-00008; Shi CF, 1997, ANTIMICROB AGENTS CH, V41, P2781, DOI 10.1128/AAC.41.12.2781; SIMMONDS P, 1990, J VIROL, V64, P864, DOI 10.1128/JVI.64.2.864-872.1990; SONNERBORG A, 1993, AIDS, V7, P1684, DOI 10.1097/00002030-199312000-00027; TISDALE M, 1995, ANTIMICROB AGENTS CH, V39, P1704, DOI 10.1128/AAC.39.8.1704; Wainberg MA, 1998, JAMA-J AM MED ASSOC, V279, P1977, DOI 10.1001/jama.279.24.1977	37	368	381	0	4	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 22	1999	282	12					1135	1141		10.1001/jama.282.12.1135	http://dx.doi.org/10.1001/jama.282.12.1135			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	236JJ	10501116	Bronze			2022-12-01	WOS:000082596200028
J	Marine, JC; Topham, DJ; McKay, C; Wang, DM; Parganas, E; Stravopodis, D; Yoshimura, A; Ihle, JN				Marine, JC; Topham, DJ; McKay, C; Wang, DM; Parganas, E; Stravopodis, D; Yoshimura, A; Ihle, JN			SOCS1 deficiency causes a lymphocyte-dependent perinatal lethality	CELL			English	Article							CHRONIC ACTIVE HEPATITIS; MICE LACKING JAK3; INTERFERON-GAMMA; INDUCIBLE GENE; CELL-DEATH; EXPRESSION; LIVER; THYMOCYTES; INHIBITOR; RECEPTORS	SOCS1. is an SH2-containing protein that is primarily expressed in thymocytes in a cytokine- and T cell receptor-independent manner. SOCS1 deletion causes perinatal lethality with death by 2-3 weeks. During this period thymic changes include a loss of cellularity and a switch from predominantly CD4(+)CD8(+) to single positive cells. Peripheral T cells express activation antigens and proliferate to IL-2 in the absence of anti-CD3. In addition, IFN gamma is present in the serum. Reconstitution of the lymphoid lineage of JAK3-deficient mice with SOCS1-deficient stem cells recapitulates the lethality and T cell alterations. Introducing a RAG2 or IFN gamma deficiency eliminates lethality. The results demonstrate that lymphocytes are critical to SOCS1-associated perinatal lethality and implicate SOCS1 in lymphocyte differentiation or regulation.	St Jude Childrens Res Hosp, Howard Hughes Med Inst, Memphis, TN 38105 USA; St Jude Childrens Res Hosp, Dept Biochem, Memphis, TN 38105 USA; St Jude Childrens Res Hosp, Dept Immunol, Memphis, TN 38105 USA; Univ Tennessee, Sch Med, Dept Biochem, Memphis, TN USA; Kurume Univ, Inst Life Sci, Kurume, Fukuoka 8390861, Japan	Howard Hughes Medical Institute; St Jude Children's Research Hospital; St Jude Children's Research Hospital; St Jude Children's Research Hospital; University of Tennessee System; University of Tennessee Health Science Center; Kurume University	Ihle, JN (corresponding author), St Jude Childrens Res Hosp, Howard Hughes Med Inst, 332 N Lauderdale St, Memphis, TN 38105 USA.		Marine, Jean-Christophe/K-3292-2016; Marine, Jean Christophe/J-2237-2015; Yoshimura, Akihiko/K-5515-2013; Wang, Demin/AAX-4449-2020	Marine, Jean-Christophe/0000-0003-2433-9837; Wang, Demin/0000-0001-5549-3795; Stravopodis, Dimitrios/0000-0002-9535-2134	NATIONAL CANCER INSTITUTE [P30CA021765] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL053749] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK042932] Funding Source: NIH RePORTER; NCI NIH HHS [CA21765] Funding Source: Medline; NHLBI NIH HHS [P01 HL53749] Funding Source: Medline; NIDDK NIH HHS [R01 DK42932] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Adams TE, 1998, J BIOL CHEM, V273, P1285, DOI 10.1074/jbc.273.3.1285; Boehm U, 1997, ANNU REV IMMUNOL, V15, P749, DOI 10.1146/annurev.immunol.15.1.749; Bunting KD, 1998, NAT MED, V4, P58, DOI 10.1038/nm0198-058; Endo TA, 1997, NATURE, V387, P921, DOI 10.1038/43213; GRESSER I, 1981, AM J PATHOL, V102, P396; Hettmann T, 1999, J EXP MED, V189, P145, DOI 10.1084/jem.189.1.145; Hilton DJ, 1998, P NATL ACAD SCI USA, V95, P114, DOI 10.1073/pnas.95.1.114; Lerner A, 1996, EMBO J, V15, P5876, DOI 10.1002/j.1460-2075.1996.tb00974.x; MATTSSON R, 1992, BIOL REPROD, V46, P1176, DOI 10.1095/biolreprod46.6.1176; Naka T, 1997, NATURE, V387, P924, DOI 10.1038/43219; Naka T, 1998, P NATL ACAD SCI USA, V95, P15577, DOI 10.1073/pnas.95.26.15577; NOSAKA T, 1995, SCIENCE, V270, P800, DOI 10.1126/science.270.5237.800; Okamoto T, 1996, BIOCHEM BIOPH RES CO, V226, P762, DOI 10.1006/bbrc.1996.1426; Parganas E, 1998, CELL, V93, P385, DOI 10.1016/S0092-8674(00)81167-8; Rodig SJ, 1998, CELL, V93, P373, DOI 10.1016/S0092-8674(00)81166-6; Sakamoto H, 1998, BLOOD, V92, P1668, DOI 10.1182/blood.V92.5.1668.417k09_1668_1676; SHI YF, 1991, J IMMUNOL, V146, P3340; Starr R, 1998, P NATL ACAD SCI USA, V95, P14395, DOI 10.1073/pnas.95.24.14395; Starr R, 1997, NATURE, V387, P917, DOI 10.1038/43206; SUDA T, 1990, J IMMUNOL, V144, P3039; THOMIS DC, 1995, SCIENCE, V270, P794, DOI 10.1126/science.270.5237.794; TIVOL EA, 1995, IMMUNITY, V3, P541, DOI 10.1016/1074-7613(95)90125-6; TOYONAGA T, 1994, P NATL ACAD SCI USA, V91, P614, DOI 10.1073/pnas.91.2.614; Yasukawa H, 1999, EMBO J, V18, P1309, DOI 10.1093/emboj/18.5.1309; YOSHIMURA A, 1995, EMBO J, V14, P2816, DOI 10.1002/j.1460-2075.1995.tb07281.x; Young HA, 1997, BLOOD, V89, P583, DOI 10.1182/blood.V89.2.583	26	430	444	0	5	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	SEP 3	1999	98	5					609	616		10.1016/S0092-8674(00)80048-3	http://dx.doi.org/10.1016/S0092-8674(00)80048-3			8	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	233NT	10490100	Bronze			2022-12-01	WOS:000082433500008
J	Trewavas, A				Trewavas, A			Much food, many problems	NATURE			English	Editorial Material									Univ Edinburgh, Inst Cell & Mol Biol, Edinburgh EH9 3JH, Midlothian, Scotland	University of Edinburgh	Trewavas, A (corresponding author), Univ Edinburgh, Inst Cell & Mol Biol, Edinburgh EH9 3JH, Midlothian, Scotland.							Ames B. N., 1990, P NATL ACAD SCI USA, V87, P777; AVERY D, 1999, FEARING FOOD RISK HL, P3; BAUM M, 1992, ANNU REV PLANT PHYS, V43, P117, DOI 10.1146/annurev.pp.43.060192.001001; *BR MED ASS, 1999, IMP GEN MOD AGR FOOD; Chrispeels MJ, 1994, PLANTS GENES AGR; *CHRIST AID, 1999, SELL SUIC FARM FALS; Daniell H, 1998, NAT BIOTECHNOL, V16, P345, DOI 10.1038/nbt0498-345; de Maagd RA, 1999, TRENDS PLANT SCI, V4, P9, DOI 10.1016/S1360-1385(98)01356-9; Evans L.T, 1998, FEEDING 10 BILLION P; FITT GP, 1994, BIOCONTROL SCI TECHN, V4, P535, DOI 10.1080/09583159409355367; HOLLIDAY RJ, 1980, J APPL ECOL, V17, P779, DOI 10.2307/2402655; Kota M, 1999, P NATL ACAD SCI USA, V96, P1840, DOI 10.1073/pnas.96.5.1840; Losey JE, 1999, NATURE, V399, P214, DOI 10.1038/20338; MacKenzie D, 1999, NEW SCI, V162, P4; Mann CC, 1999, SCIENCE, V283, P310, DOI 10.1126/science.283.5400.310; RAYBOUD RF, 1999, TRENDS PLANT SCI, V4, P247; Richards A.J, 1997, PLANT BREEDING SYSTE; Schuler TH, 1999, NATURE, V400, P825, DOI 10.1038/23605; Tilman D, 1998, NATURE, V396, P211, DOI 10.1038/24254; *US FAO, 1992, WORLD FOOD SUPPL PRE	20	25	25	1	23	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	NOV 18	1999	402	6759					231	232		10.1038/46157	http://dx.doi.org/10.1038/46157			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	257ZP	10580487				2022-12-01	WOS:000083813700021
J	Luo, D; Carpenter, R; Copsey, L; Vincent, C; Clark, J; Coen, E				Luo, D; Carpenter, R; Copsey, L; Vincent, C; Clark, J; Coen, E			Control of organ asymmetry in flowers of Antirrhinum	CELL			English	Article							BITHORAX COMPLEX; IDENTITY GENES; ABDOMINAL-B; MAJUS; DROSOPHILA; EXPRESSION; MERISTEM; BOUNDARY; ELEMENT; DOMAIN	Organ asymmetry is thought to have evolved many times independently in plants. In Antirrhinum, asymmetry of the flower and its component organs requires eye and dich gene activity. We show that, like eye, the dich gene encodes a product belonging to the TCP family of DNA-binding proteins that is first expressed in the dorsal domain of early floral meristems. However, whereas eye continues to be expressed throughout dorsal regions, expression of dich eventually becomes restricted to the most dorsal half of each dorsal petal. This correlates with the effects of dich mutations and ectopic eye expression on petal shape, providing an indication that plant organ asymmetry can reflect subdomains of gene activity. Taken together, the results indicate that plant organ asymmetry can arise through a series of steps during which early asymmetry in the developing meristem is progressively built upon.	John Innes Ctr Plant Sci Res, Dept Genet, Norwich NR4 7UH, Norfolk, England	UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); John Innes Center	Coen, E (corresponding author), John Innes Ctr Plant Sci Res, Dept Genet, Colney Lane, Norwich NR4 7UH, Norfolk, England.							Almeida J, 1997, DEVELOPMENT, V124, P1387; Carpenter R, 1995, PLANT CELL, V7, P2001, DOI 10.1105/tpc.7.12.2001; CARPENTER R, 1990, GENE DEV, V4, P1483, DOI 10.1101/gad.4.9.1483; CARPENTER R, 1987, MOL GEN GENET, V207, P82, DOI 10.1007/BF00331494; CELNIKER SE, 1990, EMBO J, V9, P4277, DOI 10.1002/j.1460-2075.1990.tb07876.x; Charlton W.A., 1998, SYMMETRY PLANTS, P61; COEN ES, 1990, CELL, V63, P1311, DOI 10.1016/0092-8674(90)90426-F; Coen ES, 1996, EMBO J, V15, P6777, DOI 10.1002/j.1460-2075.1996.tb01069.x; Cubas P, 1999, PLANT J, V18, P215, DOI 10.1046/j.1365-313X.1999.00444.x; DINGWALL C, 1991, TRENDS BIOCHEM SCI, V16, P478, DOI 10.1016/0968-0004(91)90184-W; Doebley J, 1997, NATURE, V386, P485, DOI 10.1038/386485a0; Goodrich J, 1997, NATURE, V386, P44, DOI 10.1038/386044a0; GYURKOVICS H, 1990, EMBO J, V9, P2579, DOI 10.1002/j.1460-2075.1990.tb07439.x; Ingram GC, 1997, EMBO J, V16, P6521, DOI 10.1093/emboj/16.21.6521; Kosugi S, 1997, PLANT CELL, V9, P1607, DOI 10.1105/tpc.9.9.1607; KUCKUCK H, 1930, Z IND ABST VER, V56, P51; Luo D, 1996, NATURE, V383, P794, DOI 10.1038/383794a0; LUO D, 1991, PLANT J, V1, P59, DOI 10.1111/j.1365-313X.1991.00059.x; Mihaly J, 1997, DEVELOPMENT, V124, P1809; SANCHEZHERRERO E, 1991, DEVELOPMENT, V111, P437; SIMON J, 1992, DEVELOPMENT, V114, P493; SIMON R, 1994, CELL, V78, P99, DOI 10.1016/0092-8674(94)90576-2; SOMMER H, 1990, EMBO J, V9, P605, DOI 10.1002/j.1460-2075.1990.tb08152.x; STUBBE H, 1966, GENETIK ZYTOLOGIE AN; Wolpert L., 1998, PRINCIPLES DEV; ZINK D, 1995, EMBO J, V14, P5660, DOI 10.1002/j.1460-2075.1995.tb00253.x	26	301	352	3	64	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	NOV 12	1999	99	4					367	376						10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	256CX	10571179	Bronze			2022-12-01	WOS:000083709300004
J	Murali-Krishna, K; Lau, LL; Sambhara, S; Lemonnier, F; Altman, J; Ahmed, R				Murali-Krishna, K; Lau, LL; Sambhara, S; Lemonnier, F; Altman, J; Ahmed, R			Persistence of memory CD8 T cells in MHC class I-deficient mice	SCIENCE			English	Article							SURVIVAL; MATURE; MOLECULES; ANTIGEN; LYMPHOCYTES; SELECTION; NAIVE; VIVO; IMMUNOGLOBULIN; PROLIFERATION	An understanding of how T cell memory is maintained is crucial for the rational design of vaccines. Memory T tells were shown to persist indefinitely in major histocompatibility complex (MHC) class I-deficient mice and retained the ability to make rapid cytokine responses upon reencounter with antigen. In addition, memory CD8 T cells, unlike naive cells, divided without MHC-T cell receptor interactions. This "homeostatic" proliferation is Likely to be important in maintaining memory T cell numbers in the periphery. Thus, after naive CD8 T cells differentiate into memory cells, they evolve an MHC class I-independent "life-style" and do not require further stimulation with specific or cross-reactive antigen for their maintenance.	Emory Univ, Emory Vaccine Ctr, Atlanta, GA 30322 USA; Emory Univ, Dept Microbiol & Immunol, Atlanta, GA 30322 USA; Pasteur Merieux Connaught Canada, N York, ON M2R 3TA, Canada; Inst Pasteur, Dept SIDA & Retrovirus, F-75724 Paris, France	Emory University; Emory University; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris	Ahmed, R (corresponding author), Emory Univ, Emory Vaccine Ctr, Atlanta, GA 30322 USA.		Sambhara, Suryaprakash/AAC-4428-2021		NIAID NIH HHS [AI30048] Funding Source: Medline; NINDS NIH HHS [NS21496] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI030048, R01AI030048] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS021496] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Agarwal S, 1998, IMMUNITY, V9, P765, DOI 10.1016/S1074-7613(00)80642-1; AHMED R, 1996, SCIENCE, V272, P55; Bachmann MF, 1999, J EXP MED, V189, P1521, DOI 10.1084/jem.189.10.1521; Bachmann MF, 1999, EUR J IMMUNOL, V29, P291, DOI 10.1002/(SICI)1521-4141(199901)29:01<291::AID-IMMU291>3.0.CO;2-K; Barthlott T, 1998, J IMMUNOL, V161, P3992; Bender J, 1999, J EXP MED, V190, P367, DOI 10.1084/jem.190.3.367; BEVERLEY PCL, 1990, IMMUNOL TODAY, V11, P203, DOI 10.1016/0167-5699(90)90083-L; Bird JJ, 1998, IMMUNITY, V9, P229, DOI 10.1016/S1074-7613(00)80605-6; BIX M, 1992, NATURE, V359, P330, DOI 10.1038/359330a0; Boursalian TE, 1999, J IMMUNOL, V162, P3795; Brocker T, 1997, J EXP MED, V186, P1223, DOI 10.1084/jem.186.8.1223; Bruno L, 1996, EUR J IMMUNOL, V26, P3179, DOI 10.1002/eji.1830261251; BRUNO L, 1995, IMMUNITY, V2, P37, DOI 10.1016/1074-7613(95)90077-2; Cho BK, 1999, P NATL ACAD SCI USA, V96, P2976, DOI 10.1073/pnas.96.6.2976; Dutton RW, 1998, ANNU REV IMMUNOL, V16, P201, DOI 10.1146/annurev.immunol.16.1.201; Ernst B, 1999, IMMUNITY, V11, P173, DOI 10.1016/S1074-7613(00)80092-8; Fitzpatrick DR, 1998, J EXP MED, V188, P103, DOI 10.1084/jem.188.1.103; Goldrath AW, 1999, IMMUNITY, V11, P183, DOI 10.1016/S1074-7613(00)80093-X; Hamann D, 1997, J EXP MED, V186, P1407, DOI 10.1084/jem.186.9.1407; HOU S, 1994, NATURE, V369, P652, DOI 10.1038/369652a0; Irving BA, 1998, SCIENCE, V280, P905, DOI 10.1126/science.280.5365.905; Kedl RM, 1998, J IMMUNOL, V161, P674; Kirberg J, 1997, J EXP MED, V186, P1269, DOI 10.1084/jem.186.8.1269; Lalvani A, 1997, J EXP MED, V186, P859, DOI 10.1084/jem.186.6.859; Lam KP, 1997, CELL, V90, P1073, DOI 10.1016/S0092-8674(00)80373-6; LAU LL, 1994, NATURE, V369, P648, DOI 10.1038/369648a0; LYONS AB, 1994, J IMMUNOL METHODS, V171, P131, DOI 10.1016/0022-1759(94)90236-4; Markiewicz MA, 1998, P NATL ACAD SCI USA, V95, P3065, DOI 10.1073/pnas.95.6.3065; MCDONAGH M, 1995, IMMUNOLOGY, V84, P514; MCHEYZERWILLIAMS MG, 1995, SCIENCE, V268, P106, DOI 10.1126/science.7535476; Moran M, 1998, IMMUNITY, V9, P787, DOI 10.1016/S1074-7613(00)80644-5; MULLBACHER A, 1994, J EXP MED, V179, P317, DOI 10.1084/jem.179.1.317; Murali-Krishna K, 1998, IMMUNITY, V8, P177, DOI 10.1016/S1074-7613(00)80470-7; Nesic D, 1998, J IMMUNOL, V160, P3705; PEREIRA P, 1991, INT IMMUNOL, V3, P1077, DOI 10.1093/intimm/3.11.1077; Pestano GA, 1999, SCIENCE, V284, P1187, DOI 10.1126/science.284.5417.1187; Pihlgren M, 1996, J EXP MED, V184, P2141, DOI 10.1084/jem.184.6.2141; PIRCHER H, 1990, NATURE, V346, P629, DOI 10.1038/346629a0; Simpson EM, 1997, NAT GENET, V16, P19, DOI 10.1038/ng0597-19; SPRENT J, 1991, J EXP MED, V174, P717, DOI 10.1084/jem.174.3.717; SPRENT J, 1997, CURR OPIN IMMUNOL, V9, P37; Swain SL, 1999, SCIENCE, V286, P1381, DOI 10.1126/science.286.5443.1381; Takeda S, 1996, IMMUNITY, V5, P217, DOI 10.1016/S1074-7613(00)80317-9; Tanchot C, 1997, SCIENCE, V276, P2057, DOI 10.1126/science.276.5321.2057; Tough DF, 1996, SCIENCE, V272, P1947, DOI 10.1126/science.272.5270.1947; Viret C, 1999, IMMUNITY, V10, P559, DOI 10.1016/S1074-7613(00)80055-2; Vugmeyster Y, 1998, P NATL ACAD SCI USA, V95, P12492, DOI 10.1073/pnas.95.21.12492; Zimmermann C, 1996, J EXP MED, V183, P1367, DOI 10.1084/jem.183.4.1367; Zimmermann C, 1999, EUR J IMMUNOL, V29, P284, DOI 10.1002/(SICI)1521-4141(199901)29:01<284::AID-IMMU284>3.0.CO;2-C; Zinkernagel RM, 1997, IMMUNOL TODAY, V18, P258, DOI 10.1016/S0167-5699(97)80017-5	50	613	636	0	13	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 12	1999	286	5443					1377	1381		10.1126/science.286.5443.1377	http://dx.doi.org/10.1126/science.286.5443.1377			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	255NF	10558996				2022-12-01	WOS:000083675500048
J	Antman, KH; Heitjan, DF; Hortobagyi, GN				Antman, KH; Heitjan, DF; Hortobagyi, GN			High-dose chemotherapy for breast cancer	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							RANDOMIZED TRIAL; CELL SUPPORT; FOLLOW-UP		Columbia Univ, Herbert Irving Comprehens Canc Ctr, New York, NY USA; Univ Texas, MD Anderson Canc Ctr, Austin, TX USA	Columbia University; University of Texas System; University of Texas Austin; UTMD Anderson Cancer Center	Antman, KH (corresponding author), MHB 6N 435,177 Ft Washington Ave, New York, NY 10032 USA.		Heitjan, Daniel F./D-1116-2009	/0000-0002-1093-8356				Antman KH, 1997, J CLIN ONCOL, V15, P1870, DOI 10.1200/JCO.1997.15.5.1870; BERGH J, 1999, P AN M AM SOC CLIN, V18, pA2; BEZWODA WR, 1995, J CLIN ONCOL, V13, P2483, DOI 10.1200/JCO.1995.13.10.2483; BEZWODA WR, 1999, P AN M AM SOC CLIN, V18, pA2; BEZWODA WR, 1998, P AN M AM SOC CLIN, V17, pA115; BONADONNA G, 1995, NEW ENGL J MED, V332, P901, DOI 10.1056/NEJM199504063321401; CLARK GM, 1987, J CLIN ONCOL, V5, P55, DOI 10.1200/JCO.1987.5.1.55; DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2; FREI E, 1980, AM J MED, V69, P585, DOI 10.1016/0002-9343(80)90472-6; Greenberg PAC, 1996, J CLIN ONCOL, V14, P2197, DOI 10.1200/JCO.1996.14.8.2197; HORTOBAGYI GN, 1998, P AN M AM SOC CLIN, V17, P12; Landis SH, 1999, CA-CANCER J CLIN, V49, P8, DOI 10.3322/canjclin.49.1.8; LOTZ JP, 1999, P AN M AM SOC CLIN, V18, pA43; MICK R, 1989, BREAST CANCER RES TR, V13, P33, DOI 10.1007/BF01806548; PETERS W, 1999, P AN M AM SOC CLIN, V18, pA1; PETERS WP, 1996, P AN M AM SOC CLIN, V15, P121; Rodenhuis S, 1998, LANCET, V352, P515, DOI 10.1016/S0140-6736(98)01350-6; STADTMAUER EA, 1999, P AN M AM SOC CLIN, V18, pA1; Wingo PA, 1998, CANCER-AM CANCER SOC, V82, P1197, DOI 10.1002/(SICI)1097-0142(19980315)82:6<1197::AID-CNCR26>3.0.CO;2-0	19	16	17	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 10	1999	282	18					1701	1703		10.1001/jama.282.18.1701	http://dx.doi.org/10.1001/jama.282.18.1701			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	251XJ	10568629				2022-12-01	WOS:000083471400001
J	Johansen, HK; Gotzsche, PC				Johansen, HK; Gotzsche, PC			Problems in the design and reporting of trials of antifungal agents encountered during meta-analysis	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ORAL AMPHOTERICIN-B; PREVENTING FUNGAL INFECTION; NEUTROPENIC PATIENTS; ACUTE-LEUKEMIA; HEMATOLOGICAL MALIGNANCIES; OROPHARYNGEAL CANDIDIASIS; GRANULOCYTOPENIC PATIENTS; REMISSION INDUCTION; FLUCONAZOLE; NYSTATIN	Meta-analyses may become biased if the reported data in the individual trials are biased and if overlap among trials cannot be identified. We describe the unanticipated problems we encountered in collecting data for a metaanalysis comparing a new antifungal agent, fluconazole, with amphotericin B in patients with cancer complicated by neutropenia. In 3 large trials that comprised 43% of the patients identified for the meta-analysis, results for amphotericin B were combined with results for nystatin in a "polyene" group. Because nystatin is recognized as an ineffective drug in these circumstances, this approach creates a bias in favor of fluconazole. Furthermore, 79% of the patients were randomized to receive oral amphotericin B, which is poorly absorbed and not an established treatment, in contrast to intravenous amphotericin B, which was administered in 4 of 5 placebo-controlled trials, or 86% of patients. It was unclear whether there was overlap among the "polyene" trials, and it is possible that results from single-center trials were included in multicenter trial reports. We were unable to obtain information to clarify these issues from the trial authors or the manufacturer of fluconazole. Two of 11 responding authors replied that the data were with the drug manufacturer and two indicated that they did not have access to their data because of change of affiliation. In the meta-analyses, fluconazole and amphotericin B (mostly given orally) had similar effects (13 trials), whereas nystatin was no better than placebo (3 trials). Since individual trials are rarely conclusive, investigators, institutions, and pharmaceutical companies should provide essential details about their work to ensure that meta-analyses can accurately reflect: the studies conducted and that patients will realize maximum benefits from treatments. We recommend that: investigators keep copies of their trial data to help facilitate accurate and unbiased meta-analyses.	Rigshosp, Nord Cochrane Ctr, Dept 7112, DK-2100 Copenhagen O, Denmark	Rigshospitalet	Gotzsche, PC (corresponding author), Rigshosp, Nord Cochrane Ctr, Dept 7112, DK-2100 Copenhagen O, Denmark.							AKIYAMA H, 1993, MYCOSES, V36, P373, DOI 10.1111/j.1439-0507.1993.tb00725.x; Anaissie EJ, 1996, CLIN INFECT DIS, V23, P964, DOI 10.1093/clinids/23.5.964; BODEY GP, 1994, CANCER-AM CANCER SOC, V73, P2099, DOI 10.1002/1097-0142(19940415)73:8&lt;2099::AID-CNCR2820730814&gt;3.0.CO;2-N; BODEY GP, 1974, MEDICINE, V53, P209, DOI 10.1097/00005792-197405000-00004; BOW EJ, 1997, 37 INT C ANT AG CHEM; Brammer K W, 1990, Haematol Blood Transfus, V33, P546; BUCHANAN AG, 1985, CLIN INVEST MED, V8, P139; *COCHR COLL, 1998, REV MAN REVM COMP PR; DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2; EGGER T, 1995, SUPPORT CARE CANCER, V3, P139, DOI 10.1007/BF00365855; ELLIS ME, 1994, J ANTIMICROB CHEMOTH, V33, P1223, DOI 10.1093/jac/33.6.1223; ELLIS ME, 1994, EUR J CLIN MICROBIOL, V13, P3, DOI 10.1007/BF02026116; ELLIS ME, 1995, J INFECTION, V30, P141, DOI 10.1016/S0163-4453(95)80009-3; EPSTEIN JB, 1992, ORAL SURG ORAL MED O, V73, P682, DOI 10.1016/0030-4220(92)90009-F; Finke R, 1990, Mycoses, V33 Suppl 1, P42; FLYNN PM, 1995, J PEDIATR-US, V127, P322, DOI 10.1016/S0022-3476(95)70321-7; GOTZSCHE PC, 1989, EUR J CLIN PHARMACOL, V36, P429, DOI 10.1007/BF00558064; Gotzsche PC, 1997, BMJ-BRIT MED J, V314, P1238, DOI 10.1136/bmj.314.7089.1238; GOTZSCHE PC, 1998, COCHRANE REV CD ROM; Groll AH, 1997, J ANTIMICROB CHEMOTH, V40, P855, DOI 10.1093/jac/40.6.855; HEMMINKI E, 1980, BRIT MED J, V280, P833, DOI 10.1136/bmj.280.6217.833; HOPPE JE, 1995, MYCOSES, V38, P41, DOI 10.1111/j.1439-0507.1995.tb00007.x; Huston P, 1996, LANCET, V347, P1024, DOI 10.1016/S0140-6736(96)90153-1; JOHANSEN HK, 1998, COCHRANE REV; Lake DE, 1996, CHEMOTHERAPY, V42, P308, DOI 10.1159/000239459; Lapierre V, 1992, 32 INT C ANT AG CHEM, P214; Lumbreras C, 1996, J INFECT DIS, V174, P583, DOI 10.1093/infdis/174.3.583; MARIE JP, 1993, CAH ONCOL, V2, P171; MENICHETTI F, 1994, ANN INTERN MED, V120, P913, DOI 10.7326/0003-4819-120-11-199406010-00003; MEUNIER F, 1991, DRUG INVEST, V3, P258, DOI 10.1007/BF03259575; NAKIELNY J, 1993, BRIT MED J, V306, P1125, DOI 10.1136/bmj.306.6885.1125-b; NINANE J, 1994, EUR J CLIN MICROBIOL, V13, P330, DOI 10.1007/BF01974614; PHILPOTTHOWARD JN, 1993, J ANTIMICROB CHEMOTH, V31, P973, DOI 10.1093/jac/31.6.973; Pons V, 1997, CLIN INFECT DIS, V24, P1204, DOI 10.1086/513664; Rogers TRF, 1995, J ANTIMICROB CHEMOTH, V36, P899, DOI 10.1093/jac/36.6.899; ROZENBERGARSKA M, 1991, J ANTIMICROB CHEMOTH, V27, P369, DOI 10.1093/jac/27.3.369; SAVINO JA, 1994, J TRAUMA, V36, P20, DOI 10.1097/00005373-199401000-00004; Silling-Engelhardt G, 1994, BLOOD S, V10, p306a; Smith GD, 1998, BMJ-BRIT MED J, V316, P221; SONG FJ, 1993, BMJ-BRIT MED J, V306, P683, DOI 10.1136/bmj.306.6879.683; Stern JM, 1997, BMJ-BRIT MED J, V315, P640, DOI 10.1136/bmj.315.7109.640; Teshima H, 1994, DRUG EVALUATION, V7, P535; Tian D, 1997, 20 INT C CHEM JUN 29, P87; Tramer MR, 1997, BMJ-BRIT MED J, V315, P635, DOI 10.1136/bmj.315.7109.635; Viscoli C, 1996, EUR J CANCER, V32A, P814, DOI 10.1016/0959-8049(95)00619-2; VISCOLI C, 1995, 7 EUR C CLIN MICR IN; WILLIAMS C, 1977, MED PEDIATR ONCOL, V3, P275, DOI 10.1002/mpo.2950030309; WINSTON DJ, 1997, 20 INT C CHEM JUN 29	48	101	104	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 10	1999	282	18					1752	1759		10.1001/jama.282.18.1752	http://dx.doi.org/10.1001/jama.282.18.1752			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	251XJ	10568648				2022-12-01	WOS:000083471400030
J	Shann, F				Shann, F			Haemophilus influenzae pneumonia: type b or non-type b?	LANCET			English	Editorial Material							PAPUA-NEW-GUINEA; CHILDREN; ETIOLOGY; PAKISTAN		Royal Childrens Hosp, Intens Care Unit, Parkville, Vic 3052, Australia	Royal Children's Hospital Melbourne	Shann, F (corresponding author), Royal Childrens Hosp, Intens Care Unit, Flemington Rd, Parkville, Vic 3052, Australia.		Shann, Frank/C-9510-2011					ADEGBOLA RA, 1994, PEDIATR INFECT DIS J, V13, P975, DOI 10.1097/00006454-199411000-00008; GRATTEN M, 1991, PAPUA NEW GUINEA MED, V34, P185; MOXON ER, 1991, REV INFECT DIS, V13, pS518; MUSHER DM, 1982, ARCH INTERN MED, V142, P448, DOI 10.1001/archinte.142.3.632; SHANN F, 1984, LANCET, V2, P537; STGEME JW, 1993, INFECT AGENT DIS, V2, P1; Straus WL, 1998, LANCET, V352, P270, DOI 10.1016/S0140-6736(97)10294-X; Utsunomiya Y, 1998, J TROP PEDIATRICS, V44, P338, DOI 10.1093/tropej/44.6.338; WALL RA, 1986, B WORLD HEALTH ORGAN, V64, P553; WEINBERG GA, 1990, REV INFECT DIS, V12, pS1017; WEINBERG GA, 1989, J INFECT DIS, V160, P634, DOI 10.1093/infdis/160.4.634; WONG SN, 1991, J PAEDIATR CHILD H, V27, P113, DOI 10.1111/j.1440-1754.1991.tb00364.x	12	20	21	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	OCT 30	1999	354	9189					1488	1490		10.1016/S0140-6736(99)00232-9	http://dx.doi.org/10.1016/S0140-6736(99)00232-9			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	250WB	10551490				2022-12-01	WOS:000083411300004
J	Ahmed, A; Sesti, F; Ilan, N; Shih, TM; Sturley, SL; Goldstein, SAN				Ahmed, A; Sesti, F; Ilan, N; Shih, TM; Sturley, SL; Goldstein, SAN			A molecular target for viral killer toxin: TOK1 potassium channels	CELL			English	Article							DOUBLE-STRANDED-RNA; RECTIFYING K+ CHANNEL; 2 PORE DOMAINS; SACCHAROMYCES-CEREVISIAE; FUNCTIONAL DOMAINS; HANSENULA-ANOMALA; YEAST; PREPROTOXIN; EXPRESSION; GENE	Killer strains of S. cerevisiae harbor double-stranded RNA viruses and secrete protein toxins that kill virus-free cells. The K1 killer toxin acts on sensitive yeast cells to perturb potassium homeostasis and cause cell death. Here, the toxin is shown to activate the plasma membrane potassium channel of S. cerevisiae, TOK1. Genetic deletion of TOK1 confers toxin resistance; overexpression increases susceptibility. Cells expressing TOK1 exhibit toxin-induced potassium flux; those without the gene do not. K1 toxin acts in the absence of other viral or yeast products: toxin synthesized from a cDNA increases open probability of single TOK1 channels (via reversible destabilization of closed states) whether channels are studied in yeast cells or X. laevis oocytes.	Yale Univ, Sch Med, Boyer Ctr Mol Med, Dept Pediat, New Haven, CT 06536 USA; Yale Univ, Sch Med, Boyer Ctr Mol Med, Dept Cellular & Mol Physiol, New Haven, CT 06536 USA; Columbia Univ Coll Phys & Surg, Inst Human Nutr, Dept Physiol, New York, NY 10032 USA; Columbia Univ Coll Phys & Surg, Inst Human Nutr, Dept Pediat, New York, NY 10032 USA	Yale University; Yale University; Columbia University; Columbia University	Goldstein, SAN (corresponding author), Yale Univ, Sch Med, Boyer Ctr Mol Med, Dept Pediat, 333 Cedar St, New Haven, CT 06536 USA.	steve.goldstein@yale.edu	; Goldstein, Steven A./E-9817-2015	Ahmed, Aamir/0000-0001-7405-5336; Goldstein, Steven A./0000-0001-5207-5061				Abbott GW, 1999, CELL, V97, P175, DOI 10.1016/S0092-8674(00)80728-X; ALAIDROOS K, 1978, CAN J MICROBIOL, V24, P228, DOI 10.1139/m78-041; ANDERSON JA, 1992, P NATL ACAD SCI USA, V89, P3736, DOI 10.1073/pnas.89.9.3736; Bertl A, 1998, J MEMBRANE BIOL, V162, P67, DOI 10.1007/s002329900343; BOONE C, 1990, J CELL BIOL, V110, P1833, DOI 10.1083/jcb.110.5.1833; BOONE C, 1986, CELL, V46, P105, DOI 10.1016/0092-8674(86)90864-0; BOSTIAN KA, 1984, CELL, V36, P741, DOI 10.1016/0092-8674(84)90354-4; Brachmann CB, 1998, YEAST, V14, P115; BUSSEY H, 1979, J BACTERIOL, V140, P888, DOI 10.1128/JB.140.3.888-892.1979; BUSSEY H, 1981, ADV MICROB PHYSIOL, V22, P93, DOI 10.1016/S0065-2911(08)60326-4; BUSSEY H, 1976, ANTIMICROB AGENTS CH, V9, P352, DOI 10.1128/AAC.9.2.352; BUSSEY H, 1990, EXPERIENTIA, V46, P193, DOI 10.1007/BF02027313; BUSSEY H, 1973, J BACTERIOL, V113, P1193, DOI 10.1128/JB.113.3.1193-1197.1973; CHENG RH, 1994, J MOL BIOL, V244, P255, DOI 10.1006/jmbi.1994.1726; Colquhoun David, 1995, P483; DELAPENA P, 1980, BIOCHEM BIOPH RES CO, V96, P544, DOI 10.1016/0006-291X(80)91390-X; DELAPENA P, 1981, J BIOL CHEM, V256, P420; Fairman C, 1999, J MEMBRANE BIOL, V168, P149, DOI 10.1007/s002329900505; Goldstein SAN, 1998, J MOL MED-JMM, V76, P13, DOI 10.1007/s109-1998-8100-0; Goldstein SAN, 1996, P NATL ACAD SCI USA, V93, P13256, DOI 10.1073/pnas.93.23.13256; ICHO T, 1989, J BIOL CHEM, V264, P6716; Ilan N, 1999, BIOPHYS J, V76, pA411; KETCHUM KA, 1995, NATURE, V376, P690, DOI 10.1038/376690a0; KO CH, 1991, MOL CELL BIOL, V11, P4266, DOI 10.1128/MCB.11.8.4266; KURZWEILOVA H, 1993, FOLIA MICROBIOL, V38, P524, DOI 10.1007/BF02814408; Loukin SH, 1997, EMBO J, V16, P4817, DOI 10.1093/emboj/16.16.4817; MacKinnon R, 1998, SCIENCE, V280, P106, DOI 10.1126/science.280.5360.106; Magliani W, 1997, CLIN MICROBIOL REV, V10, P369, DOI 10.1128/CMR.10.3.369; Bevan E. A., 1963, Genetics today. Proceedings of the XI International Congress of Genetics, The Hague, The Netherlands, September 1963., V1, P202; MARTINAC B, 1990, P NATL ACAD SCI USA, V87, P6228, DOI 10.1073/pnas.87.16.6228; McIntosh J M, 1999, Methods Enzymol, V294, P605; MILLER C, 1995, NEURON, V15, P5, DOI 10.1016/0896-6273(95)90057-8; Minor DL, 1999, CELL, V96, P879, DOI 10.1016/S0092-8674(00)80597-8; MURPHY N, 1986, LANCET, V1, P291; PALFREE RGE, 1979, EUR J BIOCHEM, V93, P487, DOI 10.1111/j.1432-1033.1979.tb12847.x; Perozo E, 1998, NAT STRUCT BIOL, V5, P459, DOI 10.1038/nsb0698-459; PETTOELLOMANTOVANI M, 1995, GASTROENTEROLOGY, V109, P1900, DOI 10.1016/0016-5085(95)90757-2; POLONELLI L, 1986, MYCOPATHOLOGIA, V96, P103, DOI 10.1007/BF00436668; Roberts SK, 1999, J BACTERIOL, V181, P291, DOI 10.1128/JB.181.1.291-297.1999; SCHACHTMAN DP, 1994, NATURE, V370, P655, DOI 10.1038/370655a0; Schmitt MJ, 1995, ARCH MICROBIOL, V164, P435; SENTENAC H, 1992, SCIENCE, V256, P663, DOI 10.1126/science.1585180; SIKORSKI RS, 1989, GENETICS, V122, P19; SKIPPER N, 1984, EMBO J, V3, P107, DOI 10.1002/j.1460-2075.1984.tb01769.x; SKIPPER N, 1977, J BACTERIOL, V129, P668, DOI 10.1128/JB.129.2.668-677.1977; STARMER WT, 1987, CAN J MICROBIOL, V33, P783, DOI 10.1139/m87-134; STURLEY SL, 1986, EMBO J, V5, P3381, DOI 10.1002/j.1460-2075.1986.tb04654.x; TerBush DR, 1996, EMBO J, V15, P6483, DOI 10.1002/j.1460-2075.1996.tb01039.x; THIELE DJ, 1982, NUCLEIC ACIDS RES, V10, P6903, DOI 10.1093/nar/10.21.6903; VANVUUREN HJJ, 1992, AM J ENOL VITICULT, V43, P119; Vergani P, 1997, FEBS LETT, V405, P337, DOI 10.1016/S0014-5793(97)00211-1; WICKNER RB, 1974, J BACTERIOL, V117, P1356, DOI 10.1128/JB.117.3.1356-1357.1974; Wickner RB, 1996, ANNU REV GENET, V30, P109, DOI 10.1146/annurev.genet.30.1.109; WICKNER RB, 1992, ANNU REV MICROBIOL, V46, P347, DOI 10.1146/annurev.micro.46.1.347; Yellen G, 1998, Q REV BIOPHYS, V31, P239, DOI 10.1017/S0033583598003448; ZHU H, 1991, MOL CELL BIOL, V11, P175, DOI 10.1128/MCB.11.1.175	56	70	72	0	2	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	OCT 29	1999	99	3					283	291		10.1016/S0092-8674(00)81659-1	http://dx.doi.org/10.1016/S0092-8674(00)81659-1			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	251HX	10555144	Bronze			2022-12-01	WOS:000083440600006
J	He, TC; Chan, TA; Vogelstein, B; Kinzler, KW				He, TC; Chan, TA; Vogelstein, B; Kinzler, KW			PPAR delta is an APC-regulated target of nonsteroidal anti-inflammatory drugs	CELL			English	Article							PROLIFERATOR-ACTIVATED RECEPTOR; TUMOR-SUPPRESSOR PROTEIN; HUMAN COLORECTAL-CANCER; RETINOID-X-RECEPTOR; PEROXISOME-PROLIFERATOR; BETA-CATENIN; FATTY-ACIDS; COLON-CANCER; ANTIINFLAMMATORY DRUGS; ADENOMATOUS POLYPOSIS	PPAR delta was identified as a target of APC through the analysis of global gene expression profiles in human colorectal cancer (CRC) cells. PPAR delta expression was elevated in CRCs and repressed by APC in CRC cells. This repression was mediated by beta-catenin/Tcf-4-responsive elements in the PPAR delta promotor. The ability of PPARs to bind eicosanoids suggested that PPAR delta might be a target of chemopreventive nonsteroidal anti-inflammatory drugs (NSAIDs). Reporters containing PPAR delta-responsive elements were repressed by the NSAID sulindac. Furthermore, sulindac was able to disrupt the ability of PPAR delta to bind its recognition sequences. These findings suggest that NSAIDs inhibit tumorigenesis through inhibition of PPAR delta, the gene for which is normally regulated by APC.	Johns Hopkins Oncol Ctr, Baltimore, MD 21231 USA; Johns Hopkins Univ, Howard Hughes Med Inst, Baltimore, MD 21231 USA	Johns Hopkins University; Johns Hopkins Medicine; Howard Hughes Medical Institute; Johns Hopkins University	Kinzler, KW (corresponding author), Johns Hopkins Oncol Ctr, Baltimore, MD 21231 USA.	kinzlke@welchlink.welch.jhu.edu	Chan, Timothy A/ABD-5850-2021		NCI NIH HHS [R37 CA057345, P50 CA062924, R01 CA057345, CA62924, CA57345] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R37CA057345, R01CA057345, P50CA062924] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ahnen DJ, 1998, EUR J SURG, V164, P111, DOI 10.1080/11024159850191544; AMRI EZ, 1995, J BIOL CHEM, V270, P2367, DOI 10.1074/jbc.270.5.2367; Behrens J, 1996, NATURE, V382, P638, DOI 10.1038/382638a0; Brockman JA, 1998, GASTROENTEROLOGY, V115, P1049, DOI 10.1016/S0016-5085(98)70072-1; Chan TA, 1998, P NATL ACAD SCI USA, V95, P681, DOI 10.1073/pnas.95.2.681; Charalambous D, 1998, J GASTROEN HEPATOL, V13, P1195; DIETRICH WF, 1993, CELL, V75, P631, DOI 10.1016/0092-8674(93)90484-8; EBERHART CE, 1994, GASTROENTEROLOGY, V107, P1183, DOI 10.1016/0016-5085(94)90246-1; Elder DJE, 1997, CLIN CANCER RES, V3, P1679; Forman BM, 1997, P NATL ACAD SCI USA, V94, P4312, DOI 10.1073/pnas.94.9.4312; GEARING KL, 1993, P NATL ACAD SCI USA, V90, P1440, DOI 10.1073/pnas.90.4.1440; Hanif R, 1996, BIOCHEM PHARMACOL, V52, P237, DOI 10.1016/0006-2952(96)00181-5; He TC, 1998, P NATL ACAD SCI USA, V95, P2509, DOI 10.1073/pnas.95.5.2509; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; JOW L, 1995, J BIOL CHEM, V270, P3836, DOI 10.1074/jbc.270.8.3836; JugeAubry C, 1997, J BIOL CHEM, V272, P25252, DOI 10.1074/jbc.272.40.25252; KASTNER P, 1995, CELL, V83, P859, DOI 10.1016/0092-8674(95)90202-3; KELLER H, 1993, P NATL ACAD SCI USA, V90, P2160, DOI 10.1073/pnas.90.6.2160; Kinzler KW, 1996, CELL, V87, P159, DOI 10.1016/S0092-8674(00)81333-1; Kliewer SA, 1997, P NATL ACAD SCI USA, V94, P4318, DOI 10.1073/pnas.94.9.4318; Korinek V, 1997, SCIENCE, V275, P1784, DOI 10.1126/science.275.5307.1784; Lefebvre AM, 1998, NAT MED, V4, P1053, DOI 10.1038/2036; Lehmann JM, 1997, J BIOL CHEM, V272, P3406, DOI 10.1074/jbc.272.6.3406; Lemberger T, 1996, ANNU REV CELL DEV BI, V12, P335, DOI 10.1146/annurev.cellbio.12.1.335; Lim H, 1999, GENE DEV, V13, P1561, DOI 10.1101/gad.13.12.1561; MACPHEE M, 1995, CELL, V81, P957, DOI 10.1016/0092-8674(95)90015-2; Mahmoud NN, 1998, CARCINOGENESIS, V19, P87, DOI 10.1093/carcin/19.1.87; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; Mann B, 1999, P NATL ACAD SCI USA, V96, P1603, DOI 10.1073/pnas.96.4.1603; Molenaar M, 1996, CELL, V86, P391, DOI 10.1016/S0092-8674(00)80112-9; Morin PJ, 1996, P NATL ACAD SCI USA, V93, P7950, DOI 10.1073/pnas.93.15.7950; Morin PJ, 1997, SCIENCE, V275, P1787, DOI 10.1126/science.275.5307.1787; MUNEMITSU S, 1995, P NATL ACAD SCI USA, V92, P3046, DOI 10.1073/pnas.92.7.3046; NARISAWA T, 1984, J CANCER RES CLIN, V108, P239, DOI 10.1007/BF00402475; Oshima M, 1996, CELL, V87, P803, DOI 10.1016/S0092-8674(00)81988-1; Pennica D, 1998, P NATL ACAD SCI USA, V95, P14717, DOI 10.1073/pnas.95.25.14717; PIAZZA GA, 1995, CANCER RES, V55, P3110; Piazza GA, 1997, CANCER RES, V57, P2909; Prescott SM, 1996, CELL, V87, P783, DOI 10.1016/S0092-8674(00)81983-2; Reddy BS, 1999, CANCER RES, V59, P3387; Rubinfeld B, 1997, SCIENCE, V275, P1790, DOI 10.1126/science.275.5307.1790; RUBINFELD B, 1993, SCIENCE, V262, P1731, DOI 10.1126/science.8259518; Saez E, 1998, NAT MED, V4, P1058, DOI 10.1038/2042; SANO H, 1995, CANCER RES, V55, P3785; Sarraf P, 1998, NAT MED, V4, P1046, DOI 10.1038/2030; Sarraf P, 1999, MOL CELL, V3, P799, DOI 10.1016/S1097-2765(01)80012-5; SCHMIDT A, 1992, MOL ENDOCRINOL, V6, P1634, DOI 10.1210/me.6.10.1634; Shattuck-Brandt RL, 1999, MOL CARCINOGEN, V24, P177, DOI 10.1002/(SICI)1098-2744(199903)24:3<177::AID-MC4>3.0.CO;2-6; SHIFF SJ, 1995, J CLIN INVEST, V96, P491, DOI 10.1172/JCI118060; Simmons DL, 1999, P NATL ACAD SCI USA, V96, P3275, DOI 10.1073/pnas.96.6.3275; Smalley W E, 1997, Adv Pharmacol, V39, P1, DOI 10.1016/S1054-3589(08)60067-8; SU LK, 1993, SCIENCE, V262, P1734, DOI 10.1126/science.8259519; Tetsu O, 1999, NATURE, V398, P422, DOI 10.1038/18884; Thun MJ, 1997, ADV EXP MED BIOL, V400, P395; TSUJII M, 1995, CELL, V83, P493, DOI 10.1016/0092-8674(95)90127-2; TUGWOOD JD, 1992, EMBO J, V11, P433, DOI 10.1002/j.1460-2075.1992.tb05072.x; VANDENHEUVEL JP, 1999, J NUTR, V129, P575; WILLETT WC, 1990, NEW ENGL J MED, V323, P1664, DOI 10.1056/NEJM199012133232404; YU K, 1995, J BIOL CHEM, V270, P23975, DOI 10.1074/jbc.270.41.23975; Zawel L, 1998, MOL CELL, V1, P611, DOI 10.1016/S1097-2765(00)80061-1; Zhang XP, 1999, J EXP MED, V190, P451, DOI 10.1084/jem.190.4.451	61	977	1026	0	30	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	OCT 29	1999	99	3					335	345		10.1016/S0092-8674(00)81664-5	http://dx.doi.org/10.1016/S0092-8674(00)81664-5			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	251HX	10555149	Green Accepted, Bronze			2022-12-01	WOS:000083440600011
J	Lahn, BT; Page, DC				Lahn, BT; Page, DC			Four evolutionary strata on the human X chromosome	SCIENCE			English	Article							HUMAN Y-CHROMOSOME; MAMMALIAN SEX-CHROMOSOMES; KALLMANN SYNDROME GENE; PROTEIN-KINASE GENE; RNA-BINDING PROTEIN; PSEUDOAUTOSOMAL REGION; HUMAN GENOME; MARSUPIAL-X; INACTIVATION; HOMOLOG	Human sex chromosomes evolved from autosomes. Nineteen ancestral autosomal genes persist as differentiated homologs on the X and Y chromosomes. The ages of individual X-Y gene pairs (measured by nucleotide divergence) and the Locations of their X members on the X chromosome were found to be highly correlated. Age decreased in stepwise fashion from the distal long arm to the distal short arm in at least four "evolutionary strata." Human sex chromosome evolution was probably punctuated by at Least four events, each suppressing X-Y recombination in one stratum, without disturbing gene order on the X chromosome. The first event, which marked the beginnings of X-Y differentiation, occurred about 240 to 320 million years ago, shortly after divergence of the mammalian and avian lineages.	MIT, Howard Hughes Med Inst, Whitehead Inst, Cambridge, MA 02142 USA; MIT, Dept Biol, Cambridge, MA 02142 USA	Howard Hughes Medical Institute; Massachusetts Institute of Technology (MIT); Whitehead Institute; Massachusetts Institute of Technology (MIT)	Lahn, BT (corresponding author), MIT, Howard Hughes Med Inst, Whitehead Inst, 9 Cambridge Ctr, Cambridge, MA 02142 USA.	dcpage@wi.mit.edu			NATIONAL HUMAN GENOME RESEARCH INSTITUTE [R01HG000257] Funding Source: NIH RePORTER; NHGRI NIH HHS [HG00257] Funding Source: Medline	NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NHGRI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI))		AGULNIK AI, 1994, HUM MOL GENET, V3, P879, DOI 10.1093/hmg/3.6.879; BENGTSSON BO, 1987, ANN HUM GENET, V51, P57, DOI 10.1111/j.1469-1809.1987.tb00865.x; BLAIR HJ, 1994, GENOMICS, V19, P215, DOI 10.1006/geno.1994.1050; Brown CJ, 1997, AM J HUM GENET, V60, P1333, DOI 10.1086/515488; Bull J.J., 1983, EVOLUTION SEX DETERM; CHANDRA HS, 1985, P NATL ACAD SCI USA, V82, P6947, DOI 10.1073/pnas.82.20.6947; Charlesworth B, 1996, CURR BIOL, V6, P149, DOI 10.1016/S0960-9822(02)00448-7; Cohen AR, 1998, J CELL BIOL, V142, P129, DOI 10.1083/jcb.142.1.129; Delbridge ML, 1999, NAT GENET, V22, P223, DOI 10.1038/10279; DELCASTILLO I, 1992, NAT GENET, V2, P305, DOI 10.1038/ng1292-305; DEVER TE, 1994, J BIOL CHEM, V269, P3212; FISHER EMC, 1990, CELL, V63, P1205, DOI 10.1016/0092-8674(90)90416-C; FOSTER JW, 1992, NATURE, V359, P531, DOI 10.1038/359531a0; FOSTER JW, 1994, P NATL ACAD SCI USA, V91, P1927, DOI 10.1073/pnas.91.5.1927; FRANCO B, 1991, NATURE, V353, P529, DOI 10.1038/353529a0; Fridolfsson AK, 1998, P NATL ACAD SCI USA, V95, P8147, DOI 10.1073/pnas.95.14.8147; GONDO H, 1987, J IMMUNOL, V139, P3840; Graves JAM, 1995, PHILOS T R SOC B, V350, P305, DOI 10.1098/rstb.1995.0166; Graves JAM, 1996, ANNU REV GENET, V30, P233, DOI 10.1146/annurev.genet.30.1.233; Gyapay G, 1996, HUM MOL GENET, V5, P339, DOI 10.1093/hmg/5.3.339; HANDLEY PM, 1991, P NATL ACAD SCI USA, V88, P258, DOI 10.1073/pnas.88.1.258; HUDSON TJ, 1995, SCIENCE, V270, P1945, DOI 10.1126/science.270.5244.1945; INCERTI B, 1992, NAT GENET, V2, P311, DOI 10.1038/ng1292-311; Jegalian K, 1998, NATURE, V394, P776, DOI 10.1038/29522; Jones MH, 1996, HUM MOL GENET, V5, P1695, DOI 10.1093/hmg/5.11.1695; KLINK A, 1995, HUM MOL GENET, V4, P869, DOI 10.1093/hmg/4.5.869; Kumar S, 1998, NATURE, V392, P917, DOI 10.1038/31927; Lahn BT, 1997, SCIENCE, V278, P675, DOI 10.1126/science.278.5338.675; LEGOUIS R, 1991, CELL, V67, P423, DOI 10.1016/0092-8674(91)90193-3; Li W.H., 1997, MOL EVOLUTION; LI WH, 1993, J MOL EVOL, V36, P96, DOI 10.1007/BF02407308; MA K, 1993, CELL, V75, P1287, DOI 10.1016/0092-8674(93)90616-X; Mazeyrat S, 1999, NAT GENET, V22, P224, DOI 10.1038/10282; Meroni G, 1996, HUM MOL GENET, V5, P423, DOI 10.1093/hmg/5.4.423; Mitchell MJ, 1998, HUM MOL GENET, V7, P429, DOI 10.1093/hmg/7.3.429; MITCHELL MJ, 1992, NATURE, V359, P528, DOI 10.1038/359528a0; Mu J, 1997, J BIOL CHEM, V272, P27589, DOI 10.1074/jbc.272.44.27589; NAKAHORI Y, 1991, GENOMICS, V9, P264, DOI 10.1016/0888-7543(91)90251-9; PAGE DC, 1987, CELL, V51, P1091, DOI 10.1016/0092-8674(87)90595-2; PILBEAM D, 1984, SCI AM, V250, P84, DOI 10.1038/scientificamerican0384-84; Rice WR, 1996, BIOSCIENCE, V46, P331, DOI 10.2307/1312947; Schiebel K, 1997, HUM MOL GENET, V6, P1985, DOI 10.1093/hmg/6.11.1985; SCHNEIDERGADICKE A, 1989, CELL, V57, P1247, DOI 10.1016/0092-8674(89)90061-5; SILVER LM, 1993, TRENDS GENET, V9, P250, DOI 10.1016/0168-9525(93)90090-5; SINCLAIR AH, 1990, NATURE, V346, P240, DOI 10.1038/346240a0; SOULARD M, 1993, NUCLEIC ACIDS RES, V21, P4210, DOI 10.1093/nar/21.18.4210; SPENCER JA, 1991, GENOMICS, V9, P598, DOI 10.1016/0888-7543(91)90352-F; SPENCER JA, 1991, GENOMICS, V11, P339, DOI 10.1016/0888-7543(91)90141-Z; STEVANOVIC M, 1993, HUM MOL GENET, V2, P2013, DOI 10.1093/hmg/2.12.2013; SUN C, IN PRESS NATURE GENE; TODER R, 1995, HUM GENET, V95, P22; Toder R, 1998, MAMM GENOME, V9, P373, DOI 10.1007/s003359900772; VOLLRATH D, 1992, SCIENCE, V258, P52, DOI 10.1126/science.1439769; WATSON JM, 1992, GENOMICS, V14, P785, DOI 10.1016/S0888-7543(05)80187-9; WELLER PA, 1995, HUM MOL GENET, V4, P859, DOI 10.1093/hmg/4.5.859; Willard HF, 1996, CELL, V86, P5, DOI 10.1016/S0092-8674(00)80071-9; WU JS, 1994, HUM MOL GENET, V3, P153, DOI 10.1093/hmg/3.1.153; YEN PH, 1988, CELL, V55, P1123, DOI 10.1016/0092-8674(88)90257-7	58	652	675	1	74	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 29	1999	286	5441					964	967		10.1126/science.286.5441.964	http://dx.doi.org/10.1126/science.286.5441.964			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	250BE	10542153				2022-12-01	WOS:000083368500048
J	Ridker, PM; Hennekens, CH; Buring, JE; Kundsin, R; Shih, J				Ridker, PM; Hennekens, CH; Buring, JE; Kundsin, R; Shih, J			Baseline IgG antibody titers to Chlamydia pneumoniae, Helicobacter pylori, herpes simplex virus, and cytomegalovirus and the risk for cardiovascular disease in women	ANNALS OF INTERNAL MEDICINE			English	Article						cardiovascular diseases; Chlamydia pneumoniae; Helicobacter pylori; simplexvirus; cytomegalovirus; antibodies, anti-adiotypic	CORONARY HEART-DISEASE; INFECTION; ATHEROSCLEROSIS; SEROPOSITIVITY; MORTALITY; EVENTS	Background: Results of cross-sectional and retrospective studies have suggested that chronic infection may be a risk factor for cardiovascular disease. However, prospective data evaluating the relation between baseline antibody titers against various plausible agents and risk for cardiovascular disease are sparse, particularly among women. Objective: To determine whether previous exposure to Chlamydia pneumoniae, Helicobacter pylori, herpes simplex virus, or cytomegalovirus is associated with increased risk for cardiovascular events. Design: Prospective, nested, case-control study. Setting: Women's Health Study. Participants: Apparently healthy postmenopausal women. Measurements: IgG antibody titers against C. pneumoniae, H. pylori, herpes simplex virus, and cytomegalovirus were measured in baseline blood samples obtained from 122 study participants who subsequently reported a first cardiovascular event (case-patients) and 244 participants matched for age and smoking status who did not report a cardiovascular event (controls) during 3 years of follow-up. Results: Little evidence was found of an association between risk for cardiovascular events and baseline IgG sero-positivity for antibodies against C. pneumoniae (rate ratio, 1.1 [95% CI, 0.7 to 1.8]), H. pylori (rate ratio, 0.90 ICI, 0.6 to 1.4]), herpes simplex virus (rate ratio, 1.2 [CI, 0.6 to 2.1]), and cytomegalovirus (rate ratio, 0.9 [CI, 0.6 to 1.5]). In addition, there was little evidence of an association between a participant's total number of infections and subsequent cardiovascular risk (P > 0.2). Conclusion: In apparently healthy postmenopausal women, little evidence was found that previous infection, as measured by IgG antibody titers to C. pneumoniae, H. pylori, herpes simplex virus, and cytomegalovirus, is associated with subsequent risk for cardiovascular disease.	Brigham & Womens Hosp, Div Cardiovasc, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA USA; Brigham & Womens Hosp, Dept Med, Boston, MA 02115 USA; Abbott Labs, Abbott Pk, IL 60064 USA	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Abbott Laboratories	Ridker, PM (corresponding author), Brigham & Womens Hosp, Div Cardiovasc, 75 Francis St, Boston, MA 02115 USA.	bhudson@mail.acponline.org			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL058755] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL58755] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Buring JE, 1992, J MYOCARDIAL ISCHEMI, V4, P27; Danesh J, 1997, LANCET, V350, P430, DOI 10.1016/S0140-6736(97)03079-1; Davidson M, 1998, CIRCULATION, V98, P628, DOI 10.1161/01.CIR.98.7.628; Folsom AR, 1998, CIRCULATION, V98, P845, DOI 10.1161/01.CIR.98.9.845; Libby P, 1997, CIRCULATION, V96, P4095; Miettinen H, 1996, EUR HEART J, V17, P682; Ridker PM, 1999, JAMA-J AM MED ASSOC, V281, P1817, DOI 10.1001/jama.281.19.1817; Ridker PM, 1998, CIRCULATION, V97, P1671, DOI 10.1161/01.CIR.97.17.1671; Ridker PM, 1998, CIRCULATION, V98, P731, DOI 10.1161/01.CIR.98.8.731; Ridker PM, 1998, CIRCULATION, V98, P2796, DOI 10.1161/01.CIR.98.25.2796; Ridker PM, 1999, CIRCULATION, V99, P1161, DOI 10.1161/01.CIR.99.9.1161; ROTHMAN KJ, 1986, MODERN EPIDEMIOLOGY, P346; SAIKKU P, 1992, ANN INTERN MED, V116, P273, DOI 10.7326/0003-4819-116-4-273; Strachan DP, 1999, BMJ-BRIT MED J, V318, P1035, DOI 10.1136/bmj.318.7190.1035; Strachan DP, 1998, CIRCULATION, V98, P1286, DOI 10.1161/01.CIR.98.13.1286; Strandberg TE, 1997, BRIT MED J, V314, P1317, DOI 10.1136/bmj.314.7090.1317; Wald NJ, 1997, BMJ-BRIT MED J, V315, P1199, DOI 10.1136/bmj.315.7117.1199; WANG SP, 1984, 1983 INT S MED VIR, P87; Whincup PH, 1996, HEART, V75, P568, DOI 10.1136/hrt.75.6.568; ZHU J, 1998, CIRCULATION, V98, P1	20	102	103	0	6	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	OCT 19	1999	131	8					573	+		10.7326/0003-4819-131-8-199910190-00004	http://dx.doi.org/10.7326/0003-4819-131-8-199910190-00004			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	246ZR	10523217				2022-12-01	WOS:000083196600003
J	Dietz, PH; Spitz, AM; Anda, RF; Williamson, DF; McMahon, PM; Santelli, JS; Nordenberg, DF; Felitti, VJ; Kendrick, JS				Dietz, PH; Spitz, AM; Anda, RF; Williamson, DF; McMahon, PM; Santelli, JS; Nordenberg, DF; Felitti, VJ; Kendrick, JS			Unintended pregnancy among adult women exposed to abuse or household dysfunction during their childhood	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							UNITED-STATES; SEXUAL ABUSE; ADOLESCENT PREGNANCY; PREVALENCE; ABORTION; RISK	Context Studies have identified childhood sexual and physical abuse as a risk factor for adolescent pregnancy but the relationship between exposure to childhood abuse and unintended pregnancy in adulthood has, to our knowledge, not been studied. Objective To assess whether unintended pregnancy during adulthood is associated with exposure to psychological, physical, or sexual abuse or household dysfunction during childhood. Design and Setting Analysis of data from the Adverse Childhood Experiences Study, a survey mailed to members of a large health maintenance organization who visited a clinic in San Diego, Calif, between August and November 1995 and January and March 1996, The survey had a 63.4% response rate among the target population for this study. Participants A total of 1193 women aged 20 to 50 years whose first pregnancy occurred at or after age 20 years. Main Outcome Measure Risk of unintended first pregnancy by type of abuse (psychological, physical, or sexual abuse; peer sexual assault) and type of household dysfunction (physical abuse of mother by her partner, substance abuse by a household member, mental illness of a household member). Results More than 45% of the women reported that their first pregnancy was unintended, and 65.8% reported exposure to 2 or more types of childhood abuse or household dysfunction. After adjustment for confounders (marital status at first pregnancy and age at first pregnancy), the strongest associations between childhood experiences and unintended first pregnancy included frequent psychological abuse (risk ratio [RR], 1.4; 95% confidence interval [CI], 1.2-1.6), frequent physical abuse of the mother by her partner (RR, 1.4, 95% CI, 1.1-1.7), and frequent physical abuse (RR, 1.5; 95% CI, 1.2-1.8). Women who experienced 4 or more types of abuse during their childhood were 1.5 times (95% CI, 1.2-1.8) more likely to have an unintended first pregnancy during adulthood than women who did not experience any abuse. Conclusions This study indicates that there may be a dose-response association between exposure to childhood abuse or household dysfunction and unintended first pregnancy in adulthood. Additional research is needed to fully understand the causal pathway of this association.	Ctr Dis Control & Prevent, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30341 USA; Ctr Dis Control & Prevent, Natl Ctr Injury Prevent & Control, Atlanta, GA 30341 USA; Emory Univ, Sch Med, Dept Pediat, Atlanta, GA USA; So Calif Permanente Med Grp, Dept Prevent Med, San Diego, CA 92120 USA	Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA; Emory University; Kaiser Permanente; Southern California Permanente Medical Group (SCPMG); Permanente Medical Groups	Spitz, AM (corresponding author), Ctr Dis Control & Prevent, Natl Ctr Chron Dis Prevent & Hlth Promot, MS K-35,4770 Buford Hwy NE, Atlanta, GA 30341 USA.	AMS2@cdc.gov	Santelli, John/AAG-3046-2021		ATSDR CDC HHS [TS-44-10/12] Funding Source: Medline	ATSDR CDC HHS		BOYER D, 1992, FAM PLANN PERSPECT, V24, P4, DOI 10.2307/2135718; Evins G, 1996, WOMEN HEALTH ISS, V6, P204, DOI 10.1016/1049-3867(95)00012-7; Felitti VJ, 1998, AM J PREV MED, V14, P245, DOI 10.1016/S0749-3797(98)00017-8; FINKELHOR D, 1990, CHILD ABUSE NEGLECT, V14, P19, DOI 10.1016/0145-2134(90)90077-7; Glander SS, 1998, OBSTET GYNECOL, V91, P1002, DOI 10.1016/S0029-7844(98)00089-1; Glei DA, 1999, FAM PLANN PERSPECT, V31, P73, DOI 10.2307/2991642; Henshaw SK, 1998, FAM PLANN PERSPECT, V30, P24, DOI 10.2307/2991522; JONES EF, 1992, DEMOGRAPHY, V29, P113, DOI 10.2307/2061366; KOST K, 1995, FAM PLANN PERSPECT, V27, P11, DOI 10.2307/2135971; MALDONADO G, 1993, AM J EPIDEMIOL, V138, P923, DOI 10.1093/oxfordjournals.aje.a116813; MARSIGLIO W, 1988, J MARRIAGE FAM, V50, P1023, DOI 10.2307/352112; NAGY S, 1995, PEDIATRICS, V96, P944; *NAT CTR HLTH STAT, 1991, EXP ALC FAM US 1988, P205; PARKER B, 1994, OBSTET GYNECOL, V84, P323; Rothman KJ, 1998, MODERN EPIDEMIOLOGY, P53; STEVENSSIMON C, 1994, CHILD ABUSE NEGLECT, V18, P569, DOI 10.1016/0145-2134(94)90083-3; Strauss M.A., 1990, PHYS VIOLENCE AM FAM, P29; WYATT GE, 1985, CHILD ABUSE NEGLECT, V9, P507, DOI 10.1016/0145-2134(85)90060-2; Zhang J, 1998, JAMA-J AM MED ASSOC, V280, P1690, DOI 10.1001/jama.280.19.1690	19	199	201	1	16	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 13	1999	282	14					1359	1364		10.1001/jama.282.14.1359	http://dx.doi.org/10.1001/jama.282.14.1359			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	243MB	10527183	Bronze			2022-12-01	WOS:000083000800031
J	Prasad, BVV; Hardy, ME; Dokland, T; Bella, J; Rossmann, MG; Estes, MK				Prasad, BVV; Hardy, ME; Dokland, T; Bella, J; Rossmann, MG; Estes, MK			X-ray crystallographic structure of the Norwalk virus capsid	SCIENCE			English	Article							TURNIP CRINKLE VIRUS; 3-DIMENSIONAL STRUCTURE; RESOLUTION; CALICIVIRUS; ORGANIZATION; PROTEINS; SEQUENCE; TU	Norwalk virus, a noncultivatable human calicivirus, is the major cause of epidemic gastroenteritis in humans. The first x-ray structure of a calicivirus capsid, which consists of 180 copies of a single protein, has been determined by phase extension from a Low-resolution electron microscopy structure. The capsid protein has a protruding (P) domain connected by a flexible hinge to a shell (S) domain that has a classical eight-stranded P-sandwich motif. The structure of the P domain is unlike that of any other viral protein with a subdomain exhibiting a fold similar to that of the second domain in the eukaryotic translation elongation factor-Tu. This subdomain, Located at the exterior of the capsid, has the Largest sequence variation among Norwalk-Like human calici-viruses and is Likely to contain the determinants of strain specificity and cell binding.	Baylor Coll Med, Verna & Marrs Mclean Dept Biochem, Houston, TX 77030 USA; Baylor Coll Med, Div Mol Virol, Houston, TX 77030 USA; Purdue Univ, Dept Life Sci, W Lafayette, IN 47907 USA	Baylor College of Medicine; Baylor College of Medicine; Purdue University System; Purdue University; Purdue University West Lafayette Campus	Prasad, BVV (corresponding author), Baylor Coll Med, Verna & Marrs Mclean Dept Biochem, Houston, TX 77030 USA.	vprasad@bcm.tmc.edu	Bella, Jordi/F-3794-2018	Bella, Jordi/0000-0003-0443-4562; Prasad, B.V.Venkataram/0000-0002-1172-2071				ABADZAPATERO C, 1980, NATURE, V286, P33, DOI 10.1038/286033a0; Estes Mary K., 1995, P1009; Fankhauser RL, 1998, J INFECT DIS, V178, P1571, DOI 10.1086/314525; FISHER AJ, 1993, NATURE, V361, P176, DOI 10.1038/361176a0; GLASS P, UNPUB; GREENBERG HB, 1981, J VIROL, V37, P994, DOI 10.1128/JVI.37.3.994-999.1981; HARRISON SC, 1978, NATURE, V276, P368, DOI 10.1038/276368a0; HARRISON SC, 1996, VIROLOGY, V1, P59; HOGLE JM, 1986, J MOL BIOL, V191, P625, DOI 10.1016/0022-2836(86)90450-X; HOLM L, 1993, J MOL BIOL, V233, P123, DOI 10.1006/jmbi.1993.1489; Hornung V, 1998, BIOCHEMISTRY-US, V37, P7260, DOI 10.1021/bi972969e; JIANG X, 1990, Science (Washington D C), V250, P1580; JIANG X, 1993, VIROLOGY, V195, P51, DOI 10.1006/viro.1993.1345; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KAPIKIAN AZ, 1996, FIELDS VIROLOGY, V1, P783; KJELDGAARD M, 1993, STRUCTURE, V1, P35, DOI 10.1016/0969-2126(93)90007-4; LAMBDEN PR, 1993, SCIENCE, V259, P516, DOI 10.1126/science.8380940; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LUO M, 1987, SCIENCE, V235, P182, DOI 10.1126/science.3026048; MATSUI SM, 1991, J CLIN INVEST, V87, P1456, DOI 10.1172/JCI115152; NICHOLLS A, 1993, BIOPHYS J, V64, pA166; PALMENBERG AC, 1989, MOL ASPECTS PICORNAV, P211; PRASAD BVV, 1994, J VIROL, V68, P5117, DOI 10.1128/JVI.68.8.5117-5125.1994; PRASAD BVV, 1994, J MOL BIOL, V240, P256, DOI 10.1006/jmbi.1994.1439; RAO ST, 1973, J MOL BIOL, V76, P241, DOI 10.1016/0022-2836(73)90388-4; RICHARDSON JS, 1985, METHOD ENZYMOL, V115, P341; ROSSMANN MG, 1979, J APPL CRYSTALLOGR, V12, P225, DOI 10.1107/S0021889879012218; ROSSMANN MG, 1992, J APPL CRYSTALLOGR, V25, P166, DOI 10.1107/S002188989101141X; ROSSMANN MG, 1979, J APPL CRYSTALLOGR, V12, P570, DOI 10.1107/S0021889879013273; ROSSMANN MG, 1989, ANNU REV BIOCHEM, V58, P533, DOI 10.1146/annurev.bi.58.070189.002533; ROSSMANN MG, 1962, ACTA CRYSTALLOGR, V15, P24, DOI 10.1107/S0365110X62000067; ROSSMMANN M G, 1983, Journal of Molecular Biology, V166, P37, DOI 10.1016/S0022-2836(83)80049-7; SORGER PK, 1986, J MOL BIOL, V191, P639, DOI 10.1016/0022-2836(86)90451-1; Thouvenin E, 1997, J MOL BIOL, V270, P238, DOI 10.1006/jmbi.1997.1095; TONG L, 1990, ACTA CRYSTALLOGR A, V46, P783, DOI 10.1107/S0108767390005530; WERY JP, 1994, J MOL BIOL, V235, P565, DOI 10.1006/jmbi.1994.1014; WHITE L, 1997, THESIS BAYLOR COLLEG; White LJ, 1996, J VIROL, V70, P6589, DOI 10.1128/JVI.70.10.6589-6597.1996; Wirblich C, 1996, J VIROL, V70, P7974, DOI 10.1128/JVI.70.11.7974-7983.1996; XI JA, 1992, J VIROL, V66, P6527, DOI 10.1128/JVI.66.11.6527-6532.1992	40	666	716	1	68	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 8	1999	286	5438					287	290		10.1126/science.286.5438.287	http://dx.doi.org/10.1126/science.286.5438.287			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	243YE	10514371				2022-12-01	WOS:000083024400043
J	Choi, G; Yi, H; Lee, J; Kwon, YK; Soh, MS; Shin, BC; Luka, Z; Hahn, TR; Song, PS				Choi, G; Yi, H; Lee, J; Kwon, YK; Soh, MS; Shin, BC; Luka, Z; Hahn, TR; Song, PS			Phytochrome signalling is mediated through nucleoside diphosphate kinase 2	NATURE			English	Article							LIGHT CONTROL; TRANSDUCTION; ARABIDOPSIS; GENE; PURIFICATION; MUTANTS; PROTEIN	Because plants are sessile, they have developed intricate strategies to adapt to changing environmental variables, including light, Their growth and development, from germination to flowering, is critically influenced by Light, particularly at red (660 nm) and far-red (730 mn) wavelengths(1,2). Higher plants perceive red and far-red Light by means of specific light sensors called phytochromes(A-E)(3), However, very little is known about how light signals are transduced to elicit responses in plants. Here we report that nucleoside diphosphate kinase 2 (NDPK2) is an upstream component in the phytochrome signalling pathway in the plant Arabidopsis thaliana. In animal and human cells, NDPK acts as a tumour suppressor(4). We show that recombinant NDPK2 in Arabidopsis preferentially binds to the red-light-activated form of phytochrome in vitro and that this interaction increases the activity of recombinant NDPK2. Furthermore, a mutant lacking NDPK2 showed a partial defect in responses to both red and far-red light, including cotyledon opening and greening. These results indicate that NDPK2 is a positive signalling component of the phytochrome-mediated light-signal-transduction pathway in Arabidopsis.	Kumho Life & Environm Sci Lab, Kwangju 500712, South Korea; Kyung Hee Univ, Dept Genet Engn, Suwon 449701, South Korea; Univ Nebraska, Dept Chem, Lincoln, NE 68588 USA; Kwangju Inst & Technol, Dept Life Sci, Kwangju 500712, South Korea	Kyung Hee University; University of Nebraska System; University of Nebraska Lincoln; Gwangju Institute of Science & Technology (GIST)	Choi, G (corresponding author), Kumho Life & Environm Sci Lab, Kwangju 500712, South Korea.		Choi, Giltsu/C-1601-2011	SOH, MOON-SOO/0000-0002-4430-516X				Ahmad M, 1996, PLANT J, V10, P1103, DOI 10.1046/j.1365-313X.1996.10061103.x; Barnes SA, 1996, PLANT J, V10, P1155, DOI 10.1046/j.1365-313X.1996.10061155.x; BIGGS J, 1990, CELL, V63, P933, DOI 10.1016/0092-8674(90)90496-2; BOMINAAR AA, 1993, EMBO J, V12, P2275, DOI 10.1002/j.1460-2075.1993.tb05881.x; BOWLER C, 1994, CELL, V77, P73, DOI 10.1016/0092-8674(94)90236-4; BOWLER C, 1994, CELL, V79, P743; DEAROLF CR, 1988, DEV BIOL, V13, P203; DELAROSA A, 1995, BIOESSAYS, V17, P53, DOI 10.1002/bies.950170111; Elich TD, 1997, CELL, V91, P713, DOI 10.1016/S0092-8674(00)80458-4; ENGEL M, 1995, EUR J BIOCHEM, V234, P200, DOI 10.1111/j.1432-1033.1995.200_c.x; Fankhauser C, 1997, ANNU REV CELL DEV BI, V13, P203, DOI 10.1146/annurev.cellbio.13.1.203; Fankhauser C, 1999, SCIENCE, V284, P1539, DOI 10.1126/science.284.5419.1539; FELDMANN KA, 1991, PLANT J, V1, P71, DOI 10.1111/j.1365-313X.1991.00071.x; Hoecker U, 1998, PLANT CELL, V10, P19, DOI 10.1105/tpc.10.1.19; KOSOWER EM, 1995, METHOD ENZYMOL, V251, P133, DOI 10.1016/0076-6879(95)51117-2; Kwok SF, 1996, PLANT PHYSIOL, V110, P731, DOI 10.1104/pp.110.3.731; LAPKO VN, 1995, PHOTOCHEM PHOTOBIOL, V62, P194, DOI 10.1111/j.1751-1097.1995.tb05258.x; Lu Q, 1996, J BIOL CHEM, V271, P32886, DOI 10.1074/jbc.271.51.32886; Ni M, 1998, CELL, V95, P657, DOI 10.1016/S0092-8674(00)81636-0; Ogura T, 1999, PHOTOCHEM PHOTOBIOL, V69, P397, DOI 10.1562/0031-8655(1999)069<0397:COPCCN>2.3.CO;2; Soh MS, 1998, PLANT J, V16, P411, DOI 10.1046/j.1365-313x.1998.00307.x; SOMMER D, 1994, BBA-MOL CELL RES, V1222, P464, DOI 10.1016/0167-4889(94)90055-8; vonArnim A, 1996, ANNU REV PLANT PHYS, V47, P215, DOI 10.1146/annurev.arplant.47.1.215; Wagner D, 1996, P NATL ACAD SCI USA, V93, P4011, DOI 10.1073/pnas.93.9.4011; Wagner D, 1997, PLANT CELL, V9, P731, DOI 10.1105/tpc.9.5.731; Wagner PD, 1997, P NATL ACAD SCI USA, V94, P9000, DOI 10.1073/pnas.94.17.9000; WHITELAM GC, 1993, PLANT CELL, V5, P757, DOI 10.1105/tpc.5.7.757; Yeh KC, 1997, SCIENCE, V277, P1505, DOI 10.1126/science.277.5331.1505; Zimmermann S, 1999, J BIOL CHEM, V274, P17017, DOI 10.1074/jbc.274.24.17017	29	242	261	0	20	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	OCT 7	1999	401	6753					610	613		10.1038/44176	http://dx.doi.org/10.1038/44176			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	244MG	10524631				2022-12-01	WOS:000083054900056
J	Aaby, P; Gomes, J; Fernandes, M; Djana, Q; Lisse, I; Jensen, H				Aaby, P; Gomes, J; Fernandes, M; Djana, Q; Lisse, I; Jensen, H			Nutritional status and mortality of refugee and resident children in a non-camp setting during conflict: follow up study in Guinea-Bissau	BRITISH MEDICAL JOURNAL			English	Article							MEASLES	Objective To study the effects on children of humanitarian aid agencies restricting help to refugee families (internally displaced people). Design Follow up study of 3 months. Setting Prabis peninsular outside Bissau, the capital of Guinea-Bissau, which has functioned as a refugee area for internally displaced people in the ongoing war, and the study area of the Bandim health project in Bissau. Participants 422 children aged 9-23 months in 30 clusters. Main outcome measures Mid upper arm circumference and survival in relation to residence status. Results During the refugee situation all children deteriorated nutritionally, and mortality was high (3.0% in a 6 week period). Rice consumption was higher in families resident in Prabis than in refugees from Bissau but there was no difference in food expenditure. Nutritional status, measured by mid-upper arm circumference, was not associated with rice consumption levels in the family and the decline in circumference was significantly worse for resident than for refugee children, the mid-upper arm circumference of refugee children increased faster than that of resident children, For resident children, mortality was 4.5 times higher (95% confidence interval 1.1 to 30.0) than for refugee children. Mortality for both resident and refugee children was 7.2 times higher (1.3 to 133.9) during the refugee's stay in Prabis compared with the period after the departure of the refugees. Conclusion In a non-camp setting, residents may be more malnourished and have higher mortality than refugees. Major improvements in nutritional status and a reduction in mortality occurred in resident and refugee children as soon as refugees returned home despite the fact that there was no improvement in food availability.	Statens Serum Inst, Danish Epidemiol Sci Ctr, Dept Epidemiol Res, DK-2300 Copenhagen S, Denmark; Bandim Hlth Project, Bissau, Guinea Bissau	Aarhus University; Statens Serum Institut	Aaby, P (corresponding author), Statens Serum Inst, Danish Epidemiol Sci Ctr, Dept Epidemiol Res, DK-2300 Copenhagen S, Denmark.			Aaby, Peter/0000-0001-8331-1389				Aaby P, 1998, LANCET, V352, P1229, DOI 10.1016/S0140-6736(05)60575-2; AABY P, 1984, AM J EPIDEMIOL, V120, P49, DOI 10.1093/oxfordjournals.aje.a113874; AABY P, 1997, PROSPECTIVE COMMUNIT, P276; TOOLE MJ, 1990, JAMA-J AM MED ASSOC, V263, P3296, DOI 10.1001/jama.263.24.3296; Van Damme W, 1998, LANCET, V351, P1609, DOI 10.1016/S0140-6736(97)10348-8; VANDAMME W, 1995, LANCET, V346, P360	6	40	41	0	6	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	OCT 2	1999	319	7214					878	881		10.1136/bmj.319.7214.878	http://dx.doi.org/10.1136/bmj.319.7214.878			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	243AU	10506040	Bronze, Green Published			2022-12-01	WOS:000082975600020
J	Rudenko, G; Nguyen, T; Chelliah, Y; Sudhof, TC; Deisenhofer, J				Rudenko, G; Nguyen, T; Chelliah, Y; Sudhof, TC; Deisenhofer, J			The structure of the ligand-binding domain of neurexin I beta: Regulation of LNS domain function by alternative splicing	CELL			English	Article							PROTEIN SECONDARY STRUCTURE; CELL-SURFACE PROTEINS; CRYSTAL-STRUCTURE; ALPHA-LATROTOXIN; A-CHAIN; AGRIN; RECEPTOR; LECTIN; DYSTROGLYCAN; LAMININ	Neurexins are expressed in hundreds of isoforms on the neuronal cell surface, where they may function as cell recognition molecules. Neurexins contain LNS domains, folding units found in many proteins like the G domain of laminin A, agrin, and slit. The crystal structure of neurexin I beta, a single LNS domain, reveals two seven-stranded beta sheets forming a jelly roll fold with unexpected structural similarity Po lectins. The LNS domains of neurexin and agrin undergo alternative splicing that modulates their affinity for protein ligands in a neuron-specific manner. These splice sites are localized within loops at one edge of the jelly roll, suggesting a distinct protein interaction surface in LNS domains that is regulated by alternative splicing.	Univ Texas, SW Med Ctr, Howard Hughes Med Inst, Dallas, TX 75235 USA; Univ Texas, SW Med Ctr, Dept Biochem, Dallas, TX 75235 USA; Univ Texas, SW Med Ctr, Ctr Basic Neurosci, Dallas, TX 75235 USA; Univ Texas, SW Med Ctr, Dept Mol Genet, Dallas, TX 75235 USA	Howard Hughes Medical Institute; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Deisenhofer, J (corresponding author), Univ Texas, SW Med Ctr, Howard Hughes Med Inst, 5323 Harry Hines Blvd, Dallas, TX 75235 USA.	johann.deisenhofer@email.swmed.edu	Rudenko, Gabrielle (Gabby)/O-7938-2018	Rudenko, Gabrielle (Gabby)/0000-0002-7372-0530				Ay J, 1998, P NATL ACAD SCI USA, V95, P6613, DOI 10.1073/pnas.95.12.6613; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Butz S, 1998, CELL, V94, P773, DOI 10.1016/S0092-8674(00)81736-5; Campanelli JT, 1996, DEVELOPMENT, V122, P1663; Cowtan K., 1994, JT CCP4 ESF EACBM NE, V31, P34; CRENNELL S, 1994, STRUCTURE, V2, P535, DOI 10.1016/S0969-2126(00)00053-8; DELBAERE LTJ, 1993, J MOL BIOL, V230, P950, DOI 10.1006/jmbi.1993.1212; DEUTZMANN R, 1988, EUR J BIOCHEM, V177, P35, DOI 10.1111/j.1432-1033.1988.tb14342.x; DIVNE C, 1994, SCIENCE, V265, P524, DOI 10.1126/science.8036495; EMSLEY J, 1994, NATURE, V367, P338, DOI 10.1038/367338a0; Esnouf RM, 1999, ACTA CRYSTALLOGR D, V55, P938, DOI 10.1107/S0907444998017363; FERNS MJ, 1993, NEURON, V11, P491, DOI 10.1016/0896-6273(93)90153-I; Gesemann M, 1998, J BIOL CHEM, V273, P600, DOI 10.1074/jbc.273.1.600; Gesemann M, 1996, NEURON, V16, P755, DOI 10.1016/S0896-6273(00)80096-3; HAAPARANTA T, 1991, MATRIX, V11, P151, DOI 10.1016/S0934-8832(11)80153-8; Hata Y, 1996, J NEUROSCI, V16, P2488; Higgins DG, 1996, METHOD ENZYMOL, V266, P383; HOCH W, 1993, NEURON, V11, P479, DOI 10.1016/0896-6273(93)90152-H; HOLM L, 1993, J MOL BIOL, V233, P123, DOI 10.1006/jmbi.1993.1489; Ichtchenko K, 1996, J BIOL CHEM, V271, P2676, DOI 10.1074/jbc.271.5.2676; ICHTCHENKO K, 1995, CELL, V81, P435, DOI 10.1016/0092-8674(95)90396-8; Irie M, 1997, SCIENCE, V277, P1511, DOI 10.1126/science.277.5331.1511; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; JOSEPH DR, 1992, FASEB J, V6, P2477, DOI 10.1096/fasebj.6.7.1532944; KABSCH W, 1983, BIOPOLYMERS, V22, P2577, DOI 10.1002/bip.360221211; KEITEL T, 1993, P NATL ACAD SCI USA, V90, P5287, DOI 10.1073/pnas.90.11.5287; KIM E, 1995, NATURE, V378, P85, DOI 10.1038/378085a0; Kleiman RJ, 1996, CELL, V85, P461, DOI 10.1016/S0092-8674(00)81245-3; KNELLER DG, 1990, J MOL BIOL, V214, P171, DOI 10.1016/0022-2836(90)90154-E; KORNAU HC, 1995, SCIENCE, V269, P1737, DOI 10.1126/science.7569905; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LESLIE AGW, 1992, JOINT CCP4 ESFEACBM; LIAO DI, 1994, P NATL ACAD SCI USA, V91, P1428, DOI 10.1073/pnas.91.4.1428; Lu GG, 1999, J APPL CRYSTALLOGR, V32, P365, DOI 10.1107/S0021889898015052; MATTHEWS BW, 1968, J MOL BIOL, V33, P491, DOI 10.1016/0022-2836(68)90205-2; McMahan Uel J., 1992, Current Opinion in Cell Biology, V4, P869, DOI 10.1016/0955-0674(92)90113-Q; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; Missler M, 1998, J NEUROSCI, V18, P3630; Missler M, 1998, TRENDS GENET, V14, P20, DOI 10.1016/S0168-9525(97)01324-3; Nguyen T, 1997, J BIOL CHEM, V272, P26032, DOI 10.1074/jbc.272.41.26032; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Otwinowski Z., 1991, ISOMORPHOUS REPLACEM, P80; Petrenko AG, 1996, J NEUROSCI, V16, P4360; ROSENTHAL L, 1989, PHARMACOL THERAPEUT, V42, P115, DOI 10.1016/0163-7258(89)90024-7; ROST B, 1994, PROTEINS, V19, P55, DOI 10.1002/prot.340190108; Ruegg MA, 1998, TRENDS NEUROSCI, V21, P22, DOI 10.1016/S0166-2236(97)01154-5; Sanes JR, 1998, J PHYSIOLOGY-PARIS, V92, P167, DOI 10.1016/S0928-4257(98)80004-1; Smith GD, 1998, ACTA CRYSTALLOGR D, V54, P799, DOI 10.1107/S0907444997018805; Song JY, 1999, P NATL ACAD SCI USA, V96, P1100, DOI 10.1073/pnas.96.3.1100; Sugita S, 1999, NEURON, V22, P489, DOI 10.1016/S0896-6273(00)80704-7; Talts JF, 1999, EMBO J, V18, P863, DOI 10.1093/emboj/18.4.863; TIMPL R, 1994, MATRIX BIOL, V14, P275, DOI 10.1016/0945-053X(94)90192-9; ULLRICH B, 1995, NEURON, V14, P497, DOI 10.1016/0896-6273(95)90306-2; Umland TC, 1997, NAT STRUCT BIOL, V4, P788, DOI 10.1038/nsb1097-788; USHKARYOV YA, 1992, SCIENCE, V257, P50, DOI 10.1126/science.1621094; USHKARYOV YA, 1994, J BIOL CHEM, V269, P11987; USHKARYOV YA, 1993, P NATL ACAD SCI USA, V90, P6410, DOI 10.1073/pnas.90.14.6410; Weis WI, 1996, ANNU REV BIOCHEM, V65, P441, DOI 10.1146/annurev.bi.65.070196.002301	60	113	116	0	6	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	OCT 1	1999	99	1					93	101		10.1016/S0092-8674(00)80065-3	http://dx.doi.org/10.1016/S0092-8674(00)80065-3			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	243DK	10520997	Bronze			2022-12-01	WOS:000082981600011
J	Haase, SB; Reed, SI				Haase, SB; Reed, SI			Evidence that a free-running oscillator drives G1 events in the budding yeast cell cycle	NATURE			English	Article							SACCHAROMYCES-CEREVISIAE; S-PHASE; POSITIVE FEEDBACK; KINASE; PHOSPHORYLATION; IDENTIFICATION; TRANSITION; GENES; G(1); DEGRADATION	In yeast and somatic cells, mechanisms ensure cell-cycle events are initiated only when preceding events have been completed(1). In contrast, interruption of specific cell-cycle processes in early embryonic cells of many organisms does not affect the timing of subsequent events(2), indicating that cell-cycle events are triggered by a free-running cell-cycle oscillator. Here we present evidence for an independent cell-cycle oscillator in the budding yeast Saccharomyces cerevisiae. We observed periodic activation of events normally restricted to the G1 phase of the cell cycle, in cells lacking mitotic cyclin-dependent kinase activities that are essential far cell-cycle progression, As in embryonic cells, G1 events cycled on schedule, in the absence of S phase or mitosis, with a period similar to the cell-cycle time of wild-type cells. Oscillations of similar periodicity were observed in cells responding to mating pheromone in the absence of G1 cyclin (Cln)- and mitotic cyclin (Clb)-associated kinase activity, indicating that the oscillator may function independently of cyclin-dependent kinase dynamics. We also show that Clb-associated kinase activity is essential for ensuring dependencies by preventing the initiation of new G1 events when cell-cycle progression is delayed.	Scripps Res Inst, Dept Mol Biol, La Jolla, CA 94303 USA	Scripps Research Institute	Reed, SI (corresponding author), Scripps Res Inst, Dept Mol Biol, 10550 N Torrey Pines Rd, La Jolla, CA 94303 USA.	sreed@scripps.edu		Haase, Steve/0000-0001-8127-8992				ADAMS AEM, 1991, METHOD ENZYMOL, V194, P729; AMON A, 1993, CELL, V74, P993, DOI 10.1016/0092-8674(93)90722-3; BASCO RD, 1995, MOL CELL BIOL, V15, P5030; BUCKINGTHROM E, 1973, EXP CELL RES, V76, P99, DOI 10.1016/0014-4827(73)90424-2; CHENEVERT J, 1994, GENETICS, V136, P1287; COLLART MA, 1993, CURRENT PROTOCOLS MO, V2; CROSS FR, 1991, CELL, V65, P875, DOI 10.1016/0092-8674(91)90394-E; DAHMANN C, 1995, CURR BIOL, V5, P1257, DOI 10.1016/S0960-9822(95)00252-1; DIRICK L, 1991, NATURE, V351, P754, DOI 10.1038/351754a0; GEHRUNG S, 1990, J CELL BIOL, V111, P1451, DOI 10.1083/jcb.111.4.1451; HARTWELL LH, 1971, EXP CELL RES, V69, P265, DOI 10.1016/0014-4827(71)90223-0; HARTWELL LH, 1989, SCIENCE, V246, P629, DOI 10.1126/science.2683079; Lanker S, 1996, SCIENCE, V271, P1597, DOI 10.1126/science.271.5255.1597; Mathias N, 1996, MOL CELL BIOL, V16, P6634; Measday V, 1997, MOL CELL BIOL, V17, P1212, DOI 10.1128/MCB.17.3.1212; MURRAY AW, 1989, SCIENCE, V246, P614, DOI 10.1126/science.2683077; Ngo LG, 1997, EUR J BIOCHEM, V245, P182, DOI 10.1111/j.1432-1033.1997.00182.x; NOVAK B, 1986, J CELL SCI, V86, P191; REED S, 1992, COLD SPRING HARB SYM, V56, P61; Schwab M, 1997, CELL, V90, P683, DOI 10.1016/S0092-8674(00)80529-2; SCHWOB E, 1994, CELL, V79, P233, DOI 10.1016/0092-8674(94)90193-7; SCLAFANI RA, 1984, P NATL ACAD SCI-BIOL, V81, P5821, DOI 10.1073/pnas.81.18.5821; SORGER PK, 1992, NATURE, V355, P365, DOI 10.1038/355365a0; Spellman PT, 1998, MOL BIOL CELL, V9, P3273, DOI 10.1091/mbc.9.12.3273; STUELAND CS, 1993, MOL CELL BIOL, V13, P3744, DOI 10.1128/MCB.13.6.3744; SURANA U, 1991, CELL, V65, P145, DOI 10.1016/0092-8674(91)90416-V; TYERS M, 1992, EMBO J, V11, P1773, DOI 10.1002/j.1460-2075.1992.tb05229.x; Verma R, 1997, SCIENCE, V278, P455, DOI 10.1126/science.278.5337.455; WHITAKER M, 1990, DEVELOPMENT, V108, P525; XU HX, 1992, MOL CELL BIOL, V12, P5249, DOI 10.1128/MCB.12.11.5249	30	91	91	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	SEP 23	1999	401	6751					394	397		10.1038/43930	http://dx.doi.org/10.1038/43930			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	240JJ	10517640				2022-12-01	WOS:000082822600056
J	Cappuccio, FP; Meilahn, E; Zmuda, JM; Cauley, JA				Cappuccio, FP; Meilahn, E; Zmuda, JM; Cauley, JA		Study Osteoporotic Fractures Res Grp	High blood pressure and bone-mineral loss In elderly white women: a prospective study	LANCET			English	Article							ESSENTIAL-HYPERTENSION; CALCIUM-METABOLISM; URINARY CALCIUM; HIP FRACTURE; OSTEOPOROTIC FRACTURES; YOUNG-PEOPLE; THIAZIDE; DENSITY; POPULATION; PREVENTION	Background High blood pressure is associated with abnormalities in calcium metabolism. Sustained calcium loss may lead to increased bone-mineral loss in people with high blood pressure. We investigated the prospective association between blood pressure and bone-mineral loss over time in elderly white women. Methods We studied 3676 women who were initially assessed in 1988-90 (mean age 73 years [SD 4, range 66-91 years]; mean bodyweight 65.3 kg [11.5]; blood pressure 137/75 mm Hg [17/9]) who were not on thiazide diuretics. Mean follow-up was 3.5 years. Anthropometry, blood pressure, and bone-mineral density at the femoral neck were measured at baseline and bone densitometry was repeated after 3.5 years by dual-energy X-ray absorptiometry. Findings After adjustment for age, initial hone-mineral density, weight and weight change, smoking, and regular use of hormone-replacement therapy, the rate of bone loss at the femoral neck increased with blood pressure at baseline. In the quartiles of systolic blood pressure, yearly bone losses increased from 2.26 mg/cm(2) (95% CI 1.48-3.04) in the first quartile to 3.79 mg/cm(2) in the fourth quartile (3.13-4.45; test for heterogeneity, p=0.03; test for linear trend, p=0.01), equivalent to yearly changes of 0.34% (0.20-0.46) and 0.59% (0.49-0.69; test for heterogeneity, p=0.02; test for linear trend, p=0.005). There was no significant interaction with age. The exclusion of women on antihypertensive drugs did not alter the results, For diastolic blood pressure, there was an association with bone loss in women younger than 75 years. Interpretation Higher blood pressure in elderly white women is associated with increased bone loss at the femoral neck. This association may reflect greater calcium losses associated with high blood pressure, which may contribute to the risk of hip fractures.	St George Hosp, Sch Med, Dept Med, Blood Pressure Unit, London SW17 0RE, England; London Sch Hyg & Trop Med, Dept Epidemiol & Populat Hlth, Epidemiol Unit, London, England; Univ Pittsburgh, Dept Epidemiol, Pittsburgh, PA 15261 USA	St Georges University London; University of London; London School of Hygiene & Tropical Medicine; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Cappuccio, FP (corresponding author), St George Hosp, Sch Med, Dept Med, Blood Pressure Unit, London SW17 0RE, England.	f.cappuccio@sghms.ac.uk	Cappuccio, Francesco Paolo/ABF-1094-2020; Cauley, Jane A/N-4836-2015; Cappuccio, Francesco/D-3028-2009	Cappuccio, Francesco Paolo/0000-0002-7842-5493; Cauley, Jane A/0000-0003-0752-4408; 				BRICKMAN AS, 1990, HYPERTENSION, V16, P515, DOI 10.1161/01.HYP.16.5.515; BROWNER WS, 1993, STROKE, V24, P940, DOI 10.1161/01.STR.24.7.940; BROWNER WS, 1991, LANCET, V338, P355, DOI 10.1016/0140-6736(91)90489-C; Cappuccio FP, 1997, LANCET, V350, P850, DOI 10.1016/S0140-6736(97)02264-2; CAULEY JA, 1993, ANN INTERN MED, V118, P666, DOI 10.7326/0003-4819-118-9-199305010-00002; CIRILLO M, 1989, AM J HYPERTENS, V2, P741, DOI 10.1093/ajh/2.10.741; CUMMINGS SR, 1995, NEW ENGL J MED, V332, P767, DOI 10.1056/NEJM199503233321202; *DEP DRUGS DIV DRU, 1991, DRUG EV ANN 1991, P683; DEVINE A, 1995, AM J CLIN NUTR, V62, P740, DOI 10.1093/ajcn/62.4.740; DONALDSON LJ, 1990, J EPIDEMIOL COMMUN H, V44, P241, DOI 10.1136/jech.44.3.241; Ensrud KE, 1997, ARCH INTERN MED, V157, P857, DOI 10.1001/archinte.157.8.857; ENSRUD KE, 1995, J BONE MINER RES, V10, P1778; GADALLAH M, 1991, AM J HYPERTENS, V4, P404, DOI 10.1093/ajh/4.5.404; Geleijnse JM, 1996, J HYPERTENS, V14, P1491, DOI 10.1097/00004872-199612000-00018; GROBBEE DE, 1988, BRIT MED J, V296, P814, DOI 10.1136/bmj.296.6625.814; HVARFNER A, 1987, J HYPERTENS, V5, P451; IZAWA Y, 1985, CALCIFIED TISSUE INT, V37, P605, DOI 10.1007/BF02554916; LACROIX AZ, 1990, NEW ENGL J MED, V322, P286, DOI 10.1056/NEJM199002013220502; LAW MR, 1991, BMJ-BRIT MED J, V303, P453, DOI 10.1136/bmj.303.6800.453; MACGREGOR GA, 1993, J HYPERTENS, V11, P781, DOI 10.1097/00004872-199308000-00003; MATKOVIC V, 1995, AM J CLIN NUTR, V62, P417, DOI 10.1093/ajcn/62.2.417; MCCARRON DA, 1980, HYPERTENSION, V2, P162, DOI 10.1161/01.HYP.2.2.162; RIGGS BL, 1992, NEW ENGL J MED, V327, P620; STEIGER P, 1992, J BONE MINER RES, V7, P625; STRAZZULLO P, 1983, CLIN SCI, V65, P137, DOI 10.1042/cs0650137; STRAZZULLO P, 1987, J HUM HYPERTENS, V1, P155; Strazzullo P., 1991, NUTR METABOLISM CARD, V1, P98; Tsuda K, 1998, J HYPERTENS, V16, pS209; UMEMURA S, 1986, J HYPERTENS, V4, P19, DOI 10.1097/00004872-198602000-00004; VANHOOFT IMS, 1993, HYPERTENSION, V21, P267, DOI 10.1161/01.HYP.21.3.267; WASNICH R, 1990, BRIT MED J, V301, P1303, DOI 10.1136/bmj.301.6764.1303; WASNICH RD, 1983, NEW ENGL J MED, V309, P344, DOI 10.1056/NEJM198308113090605; WONDERRECKE P, 1999, AM J MED, V106, P273; YAMAKAWA H, 1992, HYPERTENSION, V19, P528, DOI 10.1161/01.HYP.19.6.528; YOUNG EW, 1992, J LAB CLIN MED, V120, P624	35	266	286	0	9	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	SEP 18	1999	354	9183					971	975		10.1016/S0140-6736(99)01437-3	http://dx.doi.org/10.1016/S0140-6736(99)01437-3			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	236JG	10501357				2022-12-01	WOS:000082596000008
J	Chen, HW; Lin, RJ; Xie, W; Wilpitz, D; Evans, RM				Chen, HW; Lin, RJ; Xie, W; Wilpitz, D; Evans, RM			Regulation of hormone-induced histone hyperacetylation and gene activation via acetylation of an acetylase	CELL			English	Article							BREAST-CANCER-CELLS; RECEPTOR COACTIVATOR COMPLEX; NUCLEAR-RECEPTOR; ESTROGEN-RECEPTOR; RETINOIC ACID; IN-VIVO; TRANSCRIPTIONAL ACTIVATION; ACETYLTRANSFERASE ACTIVITY; CHROMATIN STRUCTURE; LEUKEMIA-CELLS	Nuclear receptors have been postulated to regulate gene expression via their association with histone acetylase (HAT) or deacetylase complexes. We report that hormone induces dramatic hyperacetylation at endogenous target genes through the HAT activity of p300/CBP. Unexpectedly, this hyperacetylation is transient and coincides with attenuation of hormone-induced gene activation. In exploring the underlying mechanism, we found that the acetylase ACTR can be acetylated by p300/CBP. The acetylation neutralizes the positive charges of two lysine residues adjacent to the core LXXLL motif and disrupts the association of HAT coactivator complexes with promoter-bound estrogen receptors. These results provide strong in vivo evidence that histone acetylation plays a key role in hormone-induced gene activation and define cofactor acetylation as a novel regulatory mechanism in hormonal signaling.	Salk Inst Biol Studies, Howard Hughes Med Inst, La Jolla, CA 92037 USA; Univ Calif San Diego, Grad Program Mol Pathol, La Jolla, CA 92037 USA	Howard Hughes Medical Institute; Salk Institute; University of California System; University of California San Diego	Evans, RM (corresponding author), Salk Inst Biol Studies, Howard Hughes Med Inst, La Jolla, CA 92037 USA.		Evans, Ronald/AAF-4001-2019; Xie, Wen/M-1768-2016	Evans, Ronald/0000-0002-9986-5965; Lin, Richard/0000-0002-0834-7880	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM026444, R37GM026444] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM26444] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bannister AJ, 1996, NATURE, V384, P641, DOI 10.1038/384641a0; BRAUNSTEIN M, 1993, GENE DEV, V7, P592, DOI 10.1101/gad.7.4.592; BROWN AMC, 1984, P NATL ACAD SCI-BIOL, V81, P6344, DOI 10.1073/pnas.81.20.6344; Brownell JE, 1996, CELL, V84, P843, DOI 10.1016/S0092-8674(00)81063-6; Brzozowski AM, 1997, NATURE, V389, P753, DOI 10.1038/39645; CAVAILLES V, 1988, NUCLEIC ACIDS RES, V16, P1903, DOI 10.1093/nar/16.5.1903; Chakravarti D, 1996, NATURE, V383, P99, DOI 10.1038/383099a0; Chen HW, 1997, CELL, V90, P569, DOI 10.1016/S0092-8674(00)80516-4; CHEN KS, 1995, BBA-GENE STRUCT EXPR, V1263, P1, DOI 10.1016/0167-4781(95)00060-T; Darimont BD, 1998, GENE DEV, V12, P3343, DOI 10.1101/gad.12.21.3343; DRACH J, 1993, BIOCHEM BIOPH RES CO, V195, P545, DOI 10.1006/bbrc.1993.2080; DUBIK D, 1988, J BIOL CHEM, V263, P12705; Fondell JD, 1996, P NATL ACAD SCI USA, V93, P8329, DOI 10.1073/pnas.93.16.8329; Grunstein M, 1997, NATURE, V389, P349, DOI 10.1038/38664; Gu W, 1997, CELL, V90, P595, DOI 10.1016/S0092-8674(00)80521-8; Hanstein B, 1996, P NATL ACAD SCI USA, V93, P11540, DOI 10.1073/pnas.93.21.11540; He TC, 1998, P NATL ACAD SCI USA, V95, P2509, DOI 10.1073/pnas.95.5.2509; Heery DM, 1997, NATURE, V387, P733, DOI 10.1038/42750; Hong H, 1999, J BIOL CHEM, V274, P3496, DOI 10.1074/jbc.274.6.3496; Hyder SM, 1997, CANCER RES, V57, P2547; Imhof A, 1997, CURR BIOL, V7, P689, DOI 10.1016/S0960-9822(06)00296-X; Ito M, 1999, MOL CELL, V3, P361, DOI 10.1016/S1097-2765(00)80463-3; JIANG HP, 1994, ONCOGENE, V9, P3397; Kadonaga JT, 1998, CELL, V92, P307, DOI 10.1016/S0092-8674(00)80924-1; Kamei Y, 1996, CELL, V85, P403, DOI 10.1016/S0092-8674(00)81118-6; KONTANI K, 1993, J BIOL CHEM, V268, P16895; Kraus WL, 1998, GENE DEV, V12, P331, DOI 10.1101/gad.12.3.331; Kuo MH, 1998, GENE DEV, V12, P627, DOI 10.1101/gad.12.5.627; Kuo MH, 1996, NATURE, V383, P269, DOI 10.1038/383269a0; Lanz RB, 1999, CELL, V97, P17, DOI 10.1016/S0092-8674(00)80711-4; Lin RJ, 1998, NATURE, V391, P811, DOI 10.1038/35895; Liu M, 1996, GENE DEV, V10, P142, DOI 10.1101/gad.10.2.142; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; McInerney EM, 1998, GENE DEV, V12, P3357, DOI 10.1101/gad.12.21.3357; Mizzen CA, 1996, CELL, V87, P1261, DOI 10.1016/S0092-8674(00)81821-8; Munshi N, 1998, MOL CELL, V2, P457, DOI 10.1016/S1097-2765(00)80145-8; Nagy L, 1997, CELL, V89, P373, DOI 10.1016/S0092-8674(00)80218-4; Nolte RT, 1998, NATURE, V395, P137, DOI 10.1038/25931; Ogryzko VV, 1998, CELL, V94, P35, DOI 10.1016/S0092-8674(00)81219-2; Ogryzko VV, 1996, CELL, V87, P953, DOI 10.1016/S0092-8674(00)82001-2; Orlando V, 1997, METHODS, V11, P205, DOI 10.1006/meth.1996.0407; Perlmann T, 1997, CELL, V90, P391, DOI 10.1016/S0092-8674(00)80498-5; Pratt MAC, 1996, J BIOL CHEM, V271, P20346, DOI 10.1074/jbc.271.34.20346; Rachez C, 1998, GENE DEV, V12, P1787, DOI 10.1101/gad.12.12.1787; ROBERTSON KA, 1992, BLOOD, V80, P1885; Rundlett SE, 1998, NATURE, V392, P831, DOI 10.1038/33952; Ryu SJ, 1999, NATURE, V397, P446, DOI 10.1038/17141; SASAKI K, 1984, J BIOL CHEM, V259, P5242; Schiltz RL, 1999, J BIOL CHEM, V274, P1189, DOI 10.1074/jbc.274.3.1189; Shiau AK, 1998, CELL, V95, P927, DOI 10.1016/S0092-8674(00)81717-1; Spencer TE, 1997, NATURE, V389, P194, DOI 10.1038/38304; Struhl K, 1998, GENE DEV, V12, P599, DOI 10.1101/gad.12.5.599; Torchia J, 1997, NATURE, V387, P677, DOI 10.1038/42652; Torchia J, 1998, CURR OPIN CELL BIOL, V10, P373, DOI 10.1016/S0955-0674(98)80014-8; Voegel JJ, 1998, EMBO J, V17, P507, DOI 10.1093/emboj/17.2.507; WADE PA, 1997, CURR BIOL, V7, P82; Wang L, 1998, GENE DEV, V12, P640, DOI 10.1101/gad.12.5.640; Watanabe T, 1998, MOL CELL BIOL, V18, P442, DOI 10.1128/MCB.18.1.442; Workman JL, 1998, ANNU REV BIOCHEM, V67, P545, DOI 10.1146/annurev.biochem.67.1.545; Yang XJ, 1996, NATURE, V382, P319, DOI 10.1038/382319a0; Yao TP, 1996, P NATL ACAD SCI USA, V93, P10626, DOI 10.1073/pnas.93.20.10626; Yuan CX, 1998, P NATL ACAD SCI USA, V95, P7939, DOI 10.1073/pnas.95.14.7939; Zou AH, 1997, J BIOL CHEM, V272, P19027, DOI 10.1074/jbc.272.30.19027	63	534	548	0	13	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	SEP 3	1999	98	5					675	686		10.1016/S0092-8674(00)80054-9	http://dx.doi.org/10.1016/S0092-8674(00)80054-9			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	233NT	10490106	Bronze			2022-12-01	WOS:000082433500014
J	Roelvink, PW; Lee, GM; Einfeld, DA; Kovesdi, I; Wickham, TJ				Roelvink, PW; Lee, GM; Einfeld, DA; Kovesdi, I; Wickham, TJ			Identification of a conserved receptor-binding site on the fiber proteins of CAR-recognizing adenoviridae	SCIENCE			English	Article							INFLUENZA-VIRUS HEMAGGLUTININ; GP120 ENVELOPE GLYCOPROTEIN; CELLULAR RECEPTORS; SIALIC-ACID; SUBGROUP-C; DOMAIN; ATTACHMENT; SEROTYPES; TYPE-2	The human adenovirus serotype 5 (Ad5) is used widely for applications in human gene therapy. Cellular attachment of Ad5 is mediated by binding of the carboxyl-terminal knob of its fiber coat protein to the Coxsackie adenovirus receptor (CAR) protein. However, Ad5 binding to CAR hampers the development of adenovirus vectors capable of specifically targeting (diseased) tissues or organs, Through sequence analysis and mutagenesis, a conserved receptor-binding region was identified on the side of three divergent CAR-binding knobs. The feasibility of simultaneous CAR ablation and redirection of an adenovirus to a new receptor is demonstrated.	GenVec Inc, Gaithersburg, MD 20879 USA		Roelvink, PW (corresponding author), GenVec Inc, 65 W Watkins Mill Rd, Gaithersburg, MD 20879 USA.			Kovesdi, Imre/0000-0002-0322-3969				BAI M, 1994, J VIROL, V68, P5925, DOI 10.1128/JVI.68.9.5925-5932.1994; Bergelson JM, 1997, SCIENCE, V275, P1320, DOI 10.1126/science.275.5304.1320; Bewley MC, 1999, SCIENCE, V286, P1579, DOI 10.1126/science.286.5444.1579; Brough DE, 1996, J VIROL, V70, P6497, DOI 10.1128/JVI.70.9.6497-6501.1996; Einfeld DA, 1999, J VIROL, V73, P9130, DOI 10.1128/JVI.73.11.9130-9136.1999; Freimuth P, 1999, J VIROL, V73, P1392, DOI 10.1128/JVI.73.2.1392-1398.1999; HENRY LJ, 1994, J VIROL, V68, P5239, DOI 10.1128/JVI.68.8.5239-5246.1994; HORWITZ MS, 1990, VIROLOGY, V2, P1679; Kwong PD, 1998, NATURE, V393, P648, DOI 10.1038/31405; LOUIS N, 1994, J VIROL, V68, P4104, DOI 10.1128/JVI.68.6.4104-4106.1994; Rizzuto CD, 1998, SCIENCE, V280, P1949, DOI 10.1126/science.280.5371.1949; Roelvink PW, 1996, J VIROL, V70, P7614, DOI 10.1128/JVI.70.11.7614-7621.1996; Roelvink PW, 1998, J VIROL, V72, P7909, DOI 10.1128/JVI.72.10.7909-7915.1998; ROELVINK PW, UNPUB; SAUTER NK, 1992, BIOCHEMISTRY-US, V31, P9609, DOI 10.1021/bi00155a013; SCHNURR D, 1993, INTERVIROLOGY, V36, P79, DOI 10.1159/000150325; Shenk T., 1996, FIELDS VIROLOGY, V2, P2111; STEVENSON SC, 1995, J VIROL, V69, P2850, DOI 10.1128/JVI.69.5.2850-2857.1995; Tomko RP, 1997, P NATL ACAD SCI USA, V94, P3352, DOI 10.1073/pnas.94.7.3352; WEIS W, 1988, NATURE, V333, P426, DOI 10.1038/333426a0; WILSON IA, 1984, CELL, V37, P767, DOI 10.1016/0092-8674(84)90412-4; Wyatt R, 1998, NATURE, V393, P705, DOI 10.1038/31514; Xia D, 1995, Curr Top Microbiol Immunol, V199 ( Pt 1), P39; XIA D, 1994, STRUCTURE, V2, P1259, DOI 10.1016/S0969-2126(94)00126-X; YEH HY, 1994, VIRUS RES, V33, P179	25	320	337	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 19	1999	286	5444					1568	1571		10.1126/science.286.5444.1568	http://dx.doi.org/10.1126/science.286.5444.1568			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	257DZ	10567265				2022-12-01	WOS:000083768300061
J	Berger, K; Ajani, UA; Kase, CS; Gaziano, JM; Buring, JE; Glynn, RJ; Hennekens, CH				Berger, K; Ajani, UA; Kase, CS; Gaziano, JM; Buring, JE; Glynn, RJ; Hennekens, CH			Light-to-moderate alcohol consumption and the risk of stroke among US male physicians.	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CORONARY HEART-DISEASE; TISSUE PLASMINOGEN-ACTIVATOR; CARDIOVASCULAR MORTALITY; CAROTID ATHEROSCLEROSIS; JAPANESE POPULATION; CIGARETTE-SMOKING; SHAPED CURVE; BRITISH MEN; LIPOPROTEINS; HYPERTENSION	Background: Several studies have shown U- or J-shaped relations between alcohol consumption and the risk of stroke. We evaluated the effect of light-to-moderate alcohol intake on the risk of stroke, with separate analyses of ischemic stroke and hemorrhagic stroke. Methods: Our analyses were based on a prospective cohort study of 22,071 male physicians, 40 to 84 years old, who were participating in the Physicians' Health Study. At base line, the participants reported that they had no history of stroke, transient ischemic attack, or myocardial infarction and were free of cancer. Alcohol intake, reported by 21,870 participants at base line, ranged from none or almost none to two or more drinks per day. Results: During an average of 12.2 years of follow-up, 679 strokes were reported. As compared with participants who had less than one drink per week, those who drank more had a reduced overall risk of stroke (relative risk, 0.79; 95 percent confidence interval, 0.66 to 0.94) and a reduced risk of ischemic stroke (relative risk, 0.77; 95 percent confidence interval, 0.63 to 0.94). There was no statistically significant association between alcohol consumption and hemorrhagic stroke. The overall relative risks of stroke for the men who had one drink per week, two to four drinks per week, five or six drinks per week, or one or more drinks per day were 0.78 (95 percent confidence interval, 0.59 to 1.04), 0.75 (95 percent confidence interval, 0.58 to 0.96), 0.83 (95 percent confidence interval, 0.62 to 1.11), and 0.80 (95 percent confidence interval, 0.64 to 0.99), respectively, in an analysis in which we controlled for major risk factors for stroke. Conclusions: Light-to-moderate alcohol consumption reduces the overall risk of stroke and the risk of ischemic stroke in men. The benefit is apparent with as little as one drink per week. Greater consumption, up to one drink per day, does not increase the observed benefit. (N Engl J Med 1999;341:1557-64.) (C) 1999, Massachusetts Medical Society.	Brigham & Womens Hosp, Div Prevent Med, Dept Med, Boston, MA 02215 USA; Dept Vet Affairs Boston Healthcare Syst, Massachusetts Vet Epidemiol Res & Informat Ctr, Boston, MA USA; Harvard Univ, Sch Med, Dept Ambulatory Care & Prevent, Boston, MA USA; Harvard Univ, Sch Publ Hlth, Dept Biostat, Boston, MA 02115 USA; Boston Univ, Sch Med, Dept Neurol, Boston, MA 02118 USA; Univ Munster, Inst Epidemiol & Social Med, Munster, Germany; Univ Munster, Dept Neurol, Munster, Germany; Univ Miami, Sch Med, Dept Epidemiol & Publ Hlth, Miami, FL USA	Harvard University; Brigham & Women's Hospital; US Department of Veterans Affairs; Veterans Health Administration (VHA); Harvard University; VA Boston Healthcare System; Harvard University; Harvard Medical School; Harvard University; Harvard T.H. Chan School of Public Health; Boston University; University of Munster; University of Munster; University of Miami	Ajani, UA (corresponding author), Brigham & Womens Hosp, Div Prevent Med, Dept Med, 900 Commonwealth Ave E, Boston, MA 02215 USA.	uajani@rics.bwh.harvard.edu		Kase, Carlos/0000-0002-3047-5010	NATIONAL CANCER INSTITUTE [R01CA040360] Funding Source: NIH RePORTER; NCI NIH HHS [CA 34944, CA 40360] Funding Source: Medline; NHLBI NIH HHS [HL 26490] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ADAMS RJ, 1989, STROKE, V20, P448, DOI 10.1161/01.STR.20.4.448; ALTURA BM, 1994, ALCOHOL CLIN EXP RES, V18, P1057, DOI 10.1111/j.1530-0277.1994.tb00082.x; ASCHERIO A, 1992, CIRCULATION, V86, P1475, DOI 10.1161/01.CIR.86.5.1475; Berger K, 1996, STROKE, V27, P238, DOI 10.1161/01.STR.27.2.238; BIHARIVARGA M, 1981, ATHEROSCLEROSIS, V40, P337, DOI 10.1016/0021-9150(81)90144-1; Boffetta P, 1990, Epidemiology, V1, P342, DOI 10.1097/00001648-199009000-00003; CAMARGO CA, 1989, STROKE, V20, P1611, DOI 10.1161/01.STR.20.12.1611; Camargo CA, 1997, ARCH INTERN MED, V157, P79, DOI 10.1001/archinte.157.1.79; Camargo CA, 1996, CLIN CHIM ACTA, V246, P107, DOI 10.1016/0009-8981(96)06231-6; COX DR, 1972, J R STAT SOC B, V34, P187; CRIQUI MH, 1990, BRIT J ADDICT, V85, P854; CRIQUI MH, 1987, AM J EPIDEMIOL, V126, P629, DOI 10.1093/oxfordjournals.aje.a114702; DONAHUE RP, 1986, JAMA-J AM MED ASSOC, V255, P2311, DOI 10.1001/jama.255.17.2311; DUARTE APT, 1995, THROMB RES, V78, P107, DOI 10.1016/0049-3848(95)00039-9; DURANTE W, 1995, BIOCHEM J, V308, P231, DOI 10.1042/bj3080231; ERNST E, 1993, ANN INTERN MED, V118, P956, DOI 10.7326/0003-4819-118-12-199306150-00008; Fields C E, 1998, Semin Vasc Surg, V11, P181; Flegal K M, 1985, Recent Dev Alcohol, V3, P165; GILL JS, 1991, AM J MED, V90, P489, DOI 10.1016/0002-9343(91)80090-9; GILL JS, 1988, INT J EPIDEMIOL, V17, P542, DOI 10.1093/ije/17.3.542; GILL JS, 1986, NEW ENGL J MED, V315, P1041, DOI 10.1056/NEJM198610233151701; GIOVANNUCCI E, 1991, AM J EPIDEMIOL, V133, P810; GLUECK CJ, 1995, J LAB CLIN MED, V125, P319; GORDON T, 1981, ARCH INTERN MED, V141, P1128, DOI 10.1001/archinte.141.9.1128; Hennekens C., 1987, EPIDEMIOLOGY MED; HENNEKENS CH, 1989, NEW ENGL J MED, V321, P129, DOI 10.1056/nejm198907203210301; HILLBOM M, 1982, NEUROLOGY, V32, P706, DOI 10.1212/WNL.32.7.706; JURGENS G, 1987, NEUROLOGY, V37, P513, DOI 10.1212/WNL.37.3.513; JUVELA S, 1993, STROKE, V24, P639, DOI 10.1161/01.STR.24.5.639; JUVELA S, 1995, STROKE, V26, P1558, DOI 10.1161/01.STR.26.9.1558; KASTURI R, 1992, STROKE, V23, P1257, DOI 10.1161/01.STR.23.9.1257; Kauhanen J, 1997, BMJ-BRIT MED J, V315, P846, DOI 10.1136/bmj.315.7112.846; Kiechl S, 1998, STROKE, V29, P900, DOI 10.1161/01.STR.29.5.900; KIECHL S, 1994, STROKE, V25, P1593, DOI 10.1161/01.STR.25.8.1593; KIYOHARA Y, 1995, STROKE, V26, P368, DOI 10.1161/01.STR.26.3.368; Klag M J, 1993, Ann Epidemiol, V3, P442; KONO S, 1986, INT J EPIDEMIOL, V15, P527, DOI 10.1093/ije/15.4.527; LANDOLFI R, 1984, BLOOD, V64, P679; LANGER RD, 1992, CIRCULATION, V85, P910, DOI 10.1161/01.CIR.85.3.910; MANSON JE, 1991, AM J PREV MED, V7, P150, DOI 10.1016/S0749-3797(18)30931-0; MARMOT M, 1991, BMJ-BRIT MED J, V303, P565, DOI 10.1136/bmj.303.6802.565; Murray CJL, 1997, LANCET, V349, P1436, DOI 10.1016/S0140-6736(96)07495-8; NAGO N, 1995, AM J EPIDEMIOL, V141, P815, DOI 10.1093/oxfordjournals.aje.a117516; PALMER AJ, 1995, J HYPERTENS, V13, P957, DOI 10.1097/00004872-199509000-00004; PALOMAKI H, 1993, STROKE, V24, P1828, DOI 10.1161/01.STR.24.12.1828; Quyyumi Arshed A., 1998, American Journal of Medicine, V105, p32S, DOI 10.1016/S0002-9343(98)00209-5; RATH M, 1989, ARTERIOSCLEROSIS, V9, P579, DOI 10.1161/01.ATV.9.5.579; REED DM, 1988, STROKE, V19, P820, DOI 10.1161/01.STR.19.7.820; RENAUD S, 1992, LANCET, V339, P1523, DOI 10.1016/0140-6736(92)91277-F; RENAUD S, 1993, HLTH ISSUES RELATED, P81; RIDKER PM, 1994, JAMA-J AM MED ASSOC, V272, P929, DOI 10.1001/jama.272.12.929; RIDKER PM, 1993, ARTERIOSCLER THROMB, V13, P1587, DOI 10.1161/01.ATV.13.11.1587; RIDKER PM, 1994, LANCET, V343, P940, DOI 10.1016/S0140-6736(94)90064-7; RODGERS H, 1993, STROKE, V24, P1473, DOI 10.1161/01.STR.24.10.1473; ROSE G, 1990, BRIT MED J, V301, P1031, DOI 10.1136/bmj.301.6759.1031; RUF JC, 1995, ARTERIOSCL THROM VAS, V15, P140, DOI 10.1161/01.ATV.15.1.140; Sacco RL, 1999, JAMA-J AM MED ASSOC, V281, P53, DOI 10.1001/jama.281.1.53; SCHERR PA, 1992, J AM GERIATR SOC, V40, P651, DOI 10.1111/j.1532-5415.1992.tb01954.x; SHAPER AG, 1990, BRIT J ADDICT, V85, P837; SHAPER AG, 1988, LANCET, V2, P1267; STAMPFER MJ, 1988, NEW ENGL J MED, V319, P267, DOI 10.1056/NEJM198808043190503; Thun MJ, 1997, NEW ENGL J MED, V337, P1705, DOI 10.1056/NEJM199712113372401; Wannamethee SG, 1996, STROKE, V27, P1033, DOI 10.1161/01.STR.27.6.1033; WATTS GF, 1995, QJM-MON J ASSOC PHYS, V88, P321; WILLIAMS GD, 1985, J STUD ALCOHOL, V46, P223, DOI 10.15288/jsa.1985.46.223; WOLF PA, 1988, ANN NEUROL, V24, P177	66	219	225	0	9	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	NOV 18	1999	341	21					1557	1564		10.1056/NEJM199911183412101	http://dx.doi.org/10.1056/NEJM199911183412101			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	256GF	10564684				2022-12-01	WOS:000083717000001
J	Sutton, LN; Adzick, NS; Bilaniuk, LT; Johnson, MP; Crombleholme, TM; Flake, AW				Sutton, LN; Adzick, NS; Bilaniuk, LT; Johnson, MP; Crombleholme, TM; Flake, AW			Improvement in hindbrain herniation demonstrated by serial fetal magnetic resonance imaging following fetal surgery for myelomeningocele	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CHIARI-II MALFORMATION; SPINAL-CORD INJURY; IN-UTERO; DEFORMITY; CHILDREN; BIFIDA; LEVEL	Context Hindbrain herniation occurs in a large percentage of children with myelomeningocele and is the leading cause of death in this population. The effect of early fetal closure of myelomeningocele on hindbrain herniation is unknown. Objective To determine whether early fetal closure of myelomeningocele affects hindbrain herniation, Design Case series of patients undergoing fetal myelomeningocele closure with serial measurements of hindbrain herniation and a mean follow-up of 182 days, Setting Tertiary care medical center. Participants Ten patients undergoing fetal myelomeningocele closure at 22 to 25 weeks' gestation between March 1998 and February 1999. Main Outcome Measures Need for shunt placement; degree of hindbrain herniation (grades 0-3) found on magnetic resonance imaging (MRI) performed prior to surgery and 3 and 6 weeks after fetal surgery, as well as shortly after birth; gestational age at delivery. Results All initial fetal MRI scans performed at 19 to 24 weeks' gestation showed significant (grade 3) cerebellar herniation and absence of spinal fluid spaces around the cerebellum Six fetuses were delivered electively at 36 weeks' gestation after lung maturity was established. The other 4 were delivered prematurely, at 25, 30, 30, and 31 weeks of gestation, and the 25-week gestation neonate died. All 9 surviving neonates showed improvement in the hindbrain hernia at the 3-week postoperative fetal scan (grade 2, n = 4; grade 1, n = 5). On the postnatal scan, all patients showed grade 1 hindbrain herniation. Only 1 patient required placement of a ventriculoperitoneal shunt. Conclusion In this series of patients, fetal myelomeningocele closure resulted in improvement in hindbrain herniation as demonstrated by serial MRI scans.	Childrens Hosp Philadelphia, Div Neurosurg, Philadelphia, PA 19104 USA; Childrens Hosp Philadelphia, Div Pediat Gen & Thorac Surg, Philadelphia, PA 19104 USA; Childrens Hosp Philadelphia, Ctr Fetal Diag & Treatment, Philadelphia, PA 19104 USA; Childrens Hosp Philadelphia, Neuroradiol Sect, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Dept Neurosurg, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Dept Surg, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Dept Radiol, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Dept Obstet & Gynecol, Philadelphia, PA 19104 USA	University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; University of Pennsylvania; University of Pennsylvania; University of Pennsylvania; University of Pennsylvania	Sutton, LN (corresponding author), Childrens Hosp Philadelphia, Div Neurosurg, 34th St & Civic Ctr Blvd, Philadelphia, PA 19104 USA.		Crombleholme, Timothy/Y-1477-2019					Adzick NS, 1998, LANCET, V352, P1675, DOI 10.1016/S0140-6736(98)00070-1; ADZICK NS, 1994, LANCET, V343, P897, DOI 10.1016/S0140-6736(94)90012-4; BABCOOK CJ, 1994, RADIOLOGY, V190, P703, DOI 10.1148/radiology.190.3.8115615; Bannister CM, 1998, EUR J PEDIATR SURG, V8, P15, DOI 10.1055/s-2008-1071245; BELL WO, 1987, J NEUROSURG, V66, P812, DOI 10.3171/jns.1987.66.6.0812; BONO R, 1993, ITAL J NEUROL SCI, V14, P553, DOI 10.1007/BF02339214; Bruner JP, 1999, AM J OBSTET GYNECOL, V180, P153, DOI 10.1016/S0002-9378(99)70167-5; Coniglio SJ, 1996, DEV MED CHILD NEUROL, V38, P675; Dias M S, 1993, Neurosurg Clin N Am, V4, P715; Dias MS, 1999, PEDIATR NEUROSURG, V30, P108, DOI 10.1159/000028773; ELGAMMAL T, 1988, AM J ROENTGENOL, V150, P163, DOI 10.2214/ajr.150.1.163; HEFFEZ DS, 1990, NEUROSURGERY, V26, P987, DOI 10.1227/00006123-199006000-00011; HOFFMAN HJ, 1987, NEUROSURGERY, V21, P347, DOI 10.1227/00006123-198709000-00012; Hutchins GM, 1996, PEDIATR PATHOL LAB M, V16, P701, DOI 10.1080/107710496175327; KOLLIAS SS, 1992, RADIOLOGY, V185, P109, DOI 10.1148/radiology.185.1.1523291; Lary J M, 1996, MMWR CDC Surveill Summ, V45, P15; McLone DG, 1998, NEUROSURG CLIN N AM, V9, P111; MCLONE DG, 1992, AM J NEURORADIOL, V13, P463; MEULI M, 1995, NAT MED, V1, P342, DOI 10.1038/nm0495-342; OHARA IB, 1999, ATLAS ANESTHESIA; OSAKA K, 1978, J NEUROSURG, V49, P711, DOI 10.3171/jns.1978.49.5.0711; PATTEN BM, 1953, AM J ANAT, V93, P365, DOI 10.1002/aja.1000930304; Quinn TM, 1997, OBSTET GYN CLIN N AM, V24, P143, DOI 10.1016/S0889-8545(05)70294-1; Tulipan N, 1998, PEDIATR NEUROSURG, V29, P274, DOI 10.1159/000028735; Tulipan N, 1998, PEDIATR NEUROSURG, V28, P177, DOI 10.1159/000028645; WOLPERT SM, 1988, AM J NEURORADIOL, V9, P1075; XU XM, 1991, J COMP NEUROL, V313, P103, DOI 10.1002/cne.903130108	27	298	305	0	12	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 17	1999	282	19					1826	1831		10.1001/jama.282.19.1826	http://dx.doi.org/10.1001/jama.282.19.1826			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	254MD	10573273	Bronze			2022-12-01	WOS:000083615700025
J	Novack, DH				Novack, DH			Roxanne	ANNALS OF INTERNAL MEDICINE			English	Editorial Material									Med Coll Penn & Hahnemann Univ, Div Med Educ, Philadelphia, PA 19129 USA	Drexel University	Novack, DH (corresponding author), Med Coll Penn & Hahnemann Univ, Div Med Educ, 2900 Queen Lane, Philadelphia, PA 19129 USA.	Dennis.Novack@drexel.edu							0	0	0	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	NOV 16	1999	131	10					784	785		10.7326/0003-4819-131-10-199911160-00012	http://dx.doi.org/10.7326/0003-4819-131-10-199911160-00012			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	255QC	10577304				2022-12-01	WOS:000083680100011
J	Cole, CR; Blackstone, EH; Pashkow, FJ; Snader, CE; Lauer, MS				Cole, CR; Blackstone, EH; Pashkow, FJ; Snader, CE; Lauer, MS			Heart-rate recovery immediately after exercise as a predictor of mortality	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							EMISSION COMPUTED-TOMOGRAPHY; FOLLOW-UP; INFARCTION; STRESS; DEATH	Background The increase in heart rate that accompanies exercise is due in part to a reduction in vagal tone. Recovery of the heart rate immediately after exercise is a function of vagal reactivation. Because a generalized decrease in vagal activity is known to be a risk factor for death, we hypothesized that a delayed fall in the heart rate after exercise might be an important prognostic marker. Methods For six years we followed 2428 consecutive adults (mean [+/-SD] age, 57+/-12 years; 63 percent men) without a history of heart failure or coronary revascularization and without pacemakers. The patients were undergoing symptom-limited exercise testing and single-photon-emission computed tomography with thallium scintigraphy for diagnostic purposes. The value for the recovery of heart rate was defined as the decrease in the heart rate from peak exercise to one minute after the cessation of exercise. An abnormal value for the recovery of heart rate was defined as a reduction of 12 beats per minute or less from the heart rate at peak exercise. Results There were 213 deaths from all causes. A total of 639 patients (26 percent) had abnormal values for heart-rate recovery. In univariate analyses, a low value for the recovery of heart rate was strongly predictive of death (relative risk, 4.0; 95 percent confidence interval, 3.0 to 5.2; P<0.001). After adjustments were made for age, sex, the use or nonuse of medications, the presence or absence of myocardial perfusion defects on thallium scintigraphy, standard cardiac risk factors, the resting heart rate, the change in heart rate during exercise, and workload achieved, a low value for heart-rate recovery remained predictive of death (adjusted relative risk, 2.0; 95 percent confidence interval, 1.5 to 2.7; P<0.001). Conclusions A delayed decrease in the heart rate during the first minute after graded exercise, which may be a reflection of decreased vagal activity, is a powerful predictor of overall mortality, independent of workload, the presence or absence of myocardial perfusion defects, and changes in heart rate during exercise. (N Engl J Med 1999;341:1351-7.) (C) 1999, Massachusetts Medical Society.	Cleveland Clin Fdn, Dept Cardiol, Sect Heart Failure & Cardiac Transplantat Med, Cleveland, OH 44195 USA; Cleveland Clin Fdn, Dept Cardiothorac Surg, Cleveland, OH 44195 USA; Cleveland Clin Fdn, Dept Epidemiol & Biostat, Cleveland, OH 44195 USA; Cleveland Clin Fdn, George M & Linda H Kaufman Ctr Heart Failure, Cleveland, OH 44195 USA	Cleveland Clinic Foundation; Cleveland Clinic Foundation; Cleveland Clinic Foundation; Cleveland Clinic Foundation	Lauer, MS (corresponding author), Cleveland Clin Fdn, Dept Cardiol, Sect Heart Failure & Cardiac Transplantat Med, Desk F25,9500 Euclid Ave, Cleveland, OH 44195 USA.		Lauer, Michael S/L-9656-2013	Lauer, Michael S/0000-0002-9217-8177				ARAI Y, 1989, AM J PHYSIOL, V256, pH132, DOI 10.1152/ajpheart.1989.256.1.H132; COX DR, 1972, J R STAT SOC B, V34, P187; CURB JD, 1985, AM J EPIDEMIOL, V121, P754, DOI 10.1093/aje/121.5.754; ELLESTAD MH, 1975, CIRCULATION, V51, P363, DOI 10.1161/01.CIR.51.2.363; FLETCHER GF, 1995, CIRCULATION, V91, P580, DOI 10.1161/01.CIR.91.2.580; GIFFORD RW, 1993, ARCH INTERN MED, V153, P154; GO RT, 1990, J NUCL MED, V31, P1899; Goldstein RE, 1999, JAMA-J AM MED ASSOC, V281, P565, DOI 10.1001/jama.281.6.565; Gottlieb SS, 1997, LANCET, V349, P662, DOI 10.1016/S0140-6736(97)22010-6; Hosmer DW, 2000, APPL LOGISTIC REGRES, V2nd; IMAI K, 1994, J AM COLL CARDIOL, V24, P1529, DOI 10.1016/0735-1097(94)90150-3; La Rovere MT, 1998, LANCET, V351, P478; Lauer MS, 1999, JAMA-J AM MED ASSOC, V281, P524, DOI 10.1001/jama.281.6.524; Lauer MS, 1996, AM J CARDIOL, V78, P278, DOI 10.1016/S0002-9149(96)00277-9; LAUER MS, 1996, CIRCULATION, V93, P150; LEBLANC M, 1992, BIOMETRICS, V48, P411, DOI 10.2307/2532300; MANTEL N, 1963, J AM STAT ASSOC, V58, P690; NALLAMOTHU N, 1995, J AM COLL CARDIOL, V25, P830, DOI 10.1016/0735-1097(94)00471-2; SANDVIK L, 1995, CORONARY ARTERY DIS, V6, P667, DOI 10.1097/00019501-199508000-00012; SCHWARTZ PJ, 1992, CIRCULATION, V85, P77; Snader CE, 1997, J AM COLL CARDIOL, V30, P641, DOI 10.1016/S0735-1097(97)00217-9; Wilkoff Bruce L., 1992, Cardiology Clinics, V10, P705	22	1251	1319	0	92	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 28	1999	341	18					1351	1357		10.1056/NEJM199910283411804	http://dx.doi.org/10.1056/NEJM199910283411804			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	249XE	10536127	Bronze			2022-12-01	WOS:000083357800004
J	Wee, CC; McCarthy, EP; Davis, RB; Phillips, RS				Wee, CC; McCarthy, EP; Davis, RB; Phillips, RS			Physician counseling about exercise	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							POSTMENOPAUSAL WOMEN; LIFE-STYLE; US ADULTS; HEALTH; MORTALITY; DISEASE; SMOKING; RECOMMENDATIONS; INTERVENTION; ASSOCIATION	Context The increase in sedentary lifestyle may contribute to the rise in obesity nationally. Although guidelines suggest that physicians counsel all patients about exercise, physicians counsel only a minority of their patients. Whether patient factors influence physician counseling is not well established. Objectives To examine and to identify factors associated with exercise counseling by US physicians. Design and Setting National population-based supplemental (Year 2000) survey to the 1995 National Health Interview Survey. Participants Of the 17 317 respondents to the Year 2000 supplemental survey, 9711 adults had seen a physician in the previous year, and 9299 responded when asked about physician counseling on exercise. Main Outcome Measure Physician counseling to begin or to continue to exercise. Results Of 9299 respondents, 34% reported being counseled about exercise at their last visit. After adjustment for other sociodemographic and clinical factors, women were slightly more likely to be counseled, with an adjusted odds ratio (AOR) of 1.15 (95% confidence interval [CI], 1.02-1.29). Physicians counseled older patients (>30 years) more often than younger patients; those aged 40 to 49 years were counseled most often (AOR, 1.71 [95% CI, 1.34-2.20]). Patients with incomes above $50 000, those with higher levels of physical activity, college graduates, and patients who were overweight to obese (body mass index: 25 to greater than or equal to 30 kg/m(2)) were more likely to be counseled, as were patients with cardiac disease (AOR, 1.81 [95% CI, 1.52-2.14]) and diabetes (AOR, 1.87 [95% CI, 1.46-2.38]), Counseling did not vary by physician specialty or patient race. Conclusion The rate of physician counseling about exercise is low nationally. Physicians appear to counsel as secondary prevention and are less likely to counsel patients at risk for obesity. The failure to counsel younger, disease-free adults and those from lower socioeconomic groups may represent important missed opportunities for primary prevention.	Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Div Gen Med & Primary Care, Boston, MA 02215 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School	Wee, CC (corresponding author), Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Div Gen Med & Primary Care, 330 Brookline Ave,Libby 330, Boston, MA 02215 USA.				BHP HRSA HHS [5T32PE11001] Funding Source: Medline	BHP HRSA HHS		BERLIN JA, 1990, AM J EPIDEMIOL, V132, P612, DOI 10.1093/oxfordjournals.aje.a115704; BLAIR SN, 1989, JAMA-J AM MED ASSOC, V262, P2395, DOI 10.1001/jama.262.17.2395; Bull FC, 1998, AM J PREV MED, V15, P85, DOI 10.1016/S0749-3797(98)00040-3; BURTON LC, 1995, PREV MED, V24, P492, DOI 10.1006/pmed.1995.1078; COULTER A, 1995, BRIT MED J, V310, P1099; DALSKY GP, 1988, ANN INTERN MED, V108, P824, DOI 10.7326/0003-4819-108-6-824; Donato KA, 1998, ARCH INTERN MED, V158, P1855, DOI 10.1001/archinte.158.17.1855; Eaton CB, 1998, BRIT J SPORT MED, V32, P11, DOI 10.1136/bjsm.32.1.11; FLETCHER GF, 1992, CIRCULATION, V86, P340, DOI 10.1161/01.CIR.86.1.340; HARRIS SS, 1989, JAMA-J AM MED ASSOC, V261, P3588, DOI 10.1001/jama.261.24.3588; HELMRICH SP, 1991, NEW ENGL J MED, V325, P147, DOI 10.1056/NEJM199107183250302; KOCH GG, 1975, INT STAT REV, V43, P59, DOI 10.2307/1402660; Kreuter MW, 1997, PREV MED, V26, P825, DOI 10.1006/pmed.1997.0216; KUCZMARSKI R J, 1992, American Journal of Clinical Nutrition, V55, p495S, DOI 10.1093/ajcn/55.2.495s; KUCZMARSKI RJ, 1994, JAMA-J AM MED ASSOC, V272, P205, DOI 10.1001/jama.272.3.205; Kushi LH, 1997, JAMA-J AM MED ASSOC, V277, P1287, DOI 10.1001/jama.277.16.1287; LEWIS CE, 1991, ANN INTERN MED, V114, P54, DOI 10.7326/0003-4819-114-1-54; *NAT CTR HLTH STAT, 1997, CD ROM SER, V10; OCKENE JK, 1994, J GEN INTERN MED, V9, P379, DOI 10.1007/BF02629517; PAFFENBARGER RS, 1993, NEW ENGL J MED, V328, P538, DOI 10.1056/NEJM199302253280804; PATE RR, 1995, JAMA-J AM MED ASSOC, V273, P402, DOI 10.1001/jama.273.5.402; REED BD, 1991, AM J PREV MED, V7, P410, DOI 10.1016/S0749-3797(18)30880-8; *RES TRIANGL I, 1992, SUDAAN US MAN REL 5; Rosenberg IH, 1998, ANN INTERN MED, V129, P133, DOI 10.7326/0003-4819-129-2-199807150-00015; Swinburn BA, 1998, AM J PUBLIC HEALTH, V88, P288, DOI 10.2105/AJPH.88.2.288; Taira DA, 1997, JAMA-J AM MED ASSOC, V278, P1412, DOI 10.1001/jama.278.17.1412; U.S. Preventive Services Task Force, 1996, GUID CLIN PREV SERV; WELLS KB, 1986, AM J PUBLIC HEALTH, V76, P1009, DOI 10.2105/AJPH.76.8.1009; WILLIAMSON DF, 1990, ARCH INTERN MED, V150, P665, DOI 10.1001/archinte.150.3.665; WILLIAMSON DF, 1993, INT J OBESITY, V17, P279; WINKLEBY MA, 1990, PREV MED, V19, P1, DOI 10.1016/0091-7435(90)90001-Z; 1998, MMWR MORB MORTAL WKL, V47, P91	32	239	239	0	3	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 27	1999	282	16					1583	1588		10.1001/jama.282.16.1583	http://dx.doi.org/10.1001/jama.282.16.1583			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	248MB	10546701	Bronze			2022-12-01	WOS:000083277800029
J	Coulehan, J				Coulehan, J			An alternative view: listening to patients	LANCET			English	Article									SUNY Stony Brook, Hlth Sci Ctr, Dept Prevent Med, Stony Brook, NY 11794 USA	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook	Coulehan, J (corresponding author), SUNY Stony Brook, Hlth Sci Ctr, Dept Prevent Med, L3-086, Stony Brook, NY 11794 USA.								0	7	7	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	OCT 23	1999	354	9188					1467	1468		10.1016/S0140-6736(05)77604-2	http://dx.doi.org/10.1016/S0140-6736(05)77604-2			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	248LY	10543688				2022-12-01	WOS:000083277400042
J	Harris, AJ				Harris, AJ			Cortical origin of pathological pain	LANCET			English	Article							PRIMARY SOMATOSENSORY CORTEX; FOCAL HAND DYSTONIA; BRAILLE READERS; PHANTOM LIMBS; PLASTICITY; REPRESENTATION; REORGANIZATION; STIMULATION; AMPUTATION; MONKEYS	Pain without accompanying tissue pathology poses a classic puzzle, presented in extreme form by phantom pain in a non-existent amputated limb. A clue to the origin of such pain is given by the recent discovery of a region of cortex active in response to incongruence between motor intention, awareness of movement, and visual feedback. Phantom-limb sensation, and repetitive strain injuries or focal hand dystonias in writers, musicians, or keyboard operators, are accompanied by plastic changes in sensorimotor cortex and by pathological pain. Disorganised or inappropriate cortical representation of proprioception may falsely signal incongruence between motor intention and movement, which results in pathological pain in the same way that incongruence between vestibular and visual sensation results in motion sickness.	Univ Otago, Sch Med, Dev Biol Unit, Dunedin, New Zealand; Univ Otago, Sch Med, Dept Physiol, Dunedin, New Zealand	University of Otago; University of Otago	Harris, AJ (corresponding author), Univ Otago, Sch Med, Dev Biol Unit, POB 913, Dunedin, New Zealand.							Bara-Jimenez W, 1998, ANN NEUROL, V44, P828, DOI 10.1002/ana.410440520; BISIACH E, 1991, NEUROPSYCHOLOGIA, V29, P1029, DOI 10.1016/0028-3932(91)90066-H; Borsook D, 1998, NEUROREPORT, V9, P1013, DOI 10.1097/00001756-199804200-00011; Byl N, 1996, J ORTHOP SPORT PHYS, V23, P234, DOI 10.2519/jospt.1996.23.4.234; Byl N N, 1997, J Hand Ther, V10, P160; Byl NN, 1996, NEUROLOGY, V47, P508, DOI 10.1212/WNL.47.2.508; Elbert T, 1998, NEUROREPORT, V9, P3571, DOI 10.1097/00001756-199811160-00006; Fink GR, 1999, BRAIN, V122, P497, DOI 10.1093/brain/122.3.497; Flor H, 1998, EXP BRAIN RES, V119, P205, DOI 10.1007/s002210050334; Goodale MA, 1998, NOVART FDN SYMP, V218, P21; Hallett M, 1998, Adv Neurol, V78, P11; JENKINS WM, 1990, J NEUROPHYSIOL, V63, P82, DOI 10.1152/jn.1990.63.1.82; KAAS JH, 1979, SCIENCE, V204, P521, DOI 10.1126/science.107591; Knecht S, 1998, BRAIN, V121, P717, DOI 10.1093/brain/121.4.717; Kopp B, 1999, NEUROREPORT, V10, P807, DOI 10.1097/00001756-199903170-00026; Miltner WHR, 1999, STROKE, V30, P586, DOI 10.1161/01.STR.30.3.586; PASCUALLEONE A, 1993, BRAIN, V116, P39, DOI 10.1093/brain/116.1.39; Ramachandran VS, 1996, P ROY SOC B-BIOL SCI, V263, P377, DOI 10.1098/rspb.1996.0058; RAMACHANDRAN VS, 1995, CONSCIOUS COGN, V4, P22, DOI 10.1006/ccog.1995.1002; Ramachandran VS, 1998, BRAIN, V121, P1603, DOI 10.1093/brain/121.9.1603; SLLARD T, 1991, J COMP NEUROL, V311, P563; Sterr A, 1998, J NEUROSCI, V18, P4417; Topp KS, 1999, MOVEMENT DISORD, V14, P295, DOI 10.1002/1531-8257(199903)14:2<295::AID-MDS1015>3.0.CO;2-J; YANG TT, 1994, NEUROREPORT, V5, P701, DOI 10.1097/00001756-199402000-00010	24	229	236	0	31	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	OCT 23	1999	354	9188					1464	1466		10.1016/S0140-6736(99)05003-5	http://dx.doi.org/10.1016/S0140-6736(99)05003-5			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	248LY	10543687				2022-12-01	WOS:000083277400041
J	Acharyya, SK; Chakraborty, P; Lahiri, S; Raymahashay, BC; Guha, S; Bhowmik, A				Acharyya, SK; Chakraborty, P; Lahiri, S; Raymahashay, BC; Guha, S; Bhowmik, A			Arsenic poisoning in the Ganges delta	NATURE			English	Article							GROUNDWATER		Geol Survey India, Kolkata 700016, W Bengal, India; Indian Inst Technol, Dept Civil Engn, Kanpur 208016, Uttar Pradesh, India	Geological Survey India; Indian Institute of Technology System (IIT System); Indian Institute of Technology (IIT) - Kanpur	Acharyya, SK (corresponding author), Geol Survey India, Kolkata 700016, W Bengal, India.							Bagla P, 1996, SCIENCE, V274, P174, DOI 10.1126/science.274.5285.174; Bhattacharya P., 1997, INT J WATER RESOUR D, V13, P79, DOI DOI 10.1080/07900629749944; Hiller K., 1988, GEOL JB D, V90, P3; Joshi A, 1996, J ENVIRON ENG-ASCE, V122, P769, DOI 10.1061/(ASCE)0733-9372(1996)122:8(769); Mallick S, 1996, CURR SCI INDIA, V70, P956; MUKHERJEE A, 1997, INDIAN J GEOL, V69, P41; Nickson R, 1998, NATURE, V395, P338, DOI 10.1038/26387; WONG PLN, 1995, CHIN I ENV ENG, V5, P241	8	315	341	6	98	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	OCT 7	1999	401	6753					545	545		10.1038/44052	http://dx.doi.org/10.1038/44052			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	244MG	10524619	Bronze			2022-12-01	WOS:000083054900036
J	Simon, HU; Plotz, SG; Dummer, R; Blaser, K				Simon, HU; Plotz, SG; Dummer, R; Blaser, K			Abnormal clones of T cells producing interleukin-5 in idiopathic eosinophilia	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							LYMPHOMA STUDY-GROUP; HYPEREOSINOPHILIC SYNDROME; INTERFERON-ALPHA; SEZARY-SYNDROME; APOPTOSIS; FAS; IDENTIFICATION; CLASSIFICATION; NEOPLASMS; EXPANSION	Background The cause of persistent eosinophilia and the hypereosinophilic syndrome is unknown. Recent work suggests that in some patients with the hypereosinophilic syndrome, a clone of abnormal T cells produces large amounts of interleukin-5, a cytokine required for the growth and differentiation of eosinophils. We examined T-cell surface markers, rearranged T-cell-receptor genes, and in vitro production of cytokines by T cells from patients with idiopathic eosinophilia. Methods The expression of surface molecules on T cells was measured by flow cytometry. Cytokine expression was measured by enzyme-linked immunosorbent assay, flow cytometry, and immunohistochemical analysis. To identify dominant (clonal) rearrangements of the T-cell receptor within the lymphocyte population, Southern blot analysis (beta chain) and the polymerase chain reaction (gamma chain) were performed according to standard protocols. Results Among 60 patients with idiopathic eosinophilia, 16 had circulating T cells with an aberrant immunophenotype. In each of these patients, the abnormal immunophenotype was unique. Evidence of clonal rearrangements of the T-cell receptor was obtained in 8 of the 16 patients. In most instances, the abnormal T cells expressed large amounts of surface proteins associated with T-cell activation (the a chain of the interleukin-2 receptor and the HLA-DR antigen). Moreover, the aberrant T cells produced large amounts of interleukin-5 in vitro. Conclusions Clonal populations of abnormal T cells producing interleukin-5 occur in some patients with idiopathic eosinophilia. (N Engl J Med 1999;341:1112-20.) (C)1999, Massachusetts Medical Society.	Univ Zurich, Swiss Inst Allergy & Asthma Res, CH-7270 Davos, Switzerland; Tech Univ Munich, Res Ctr Environm & Hlth, D-8000 Munich, Germany; Univ Zurich, Dept Dermatol, Zurich, Switzerland	Swiss Institute of Allergy & Asthma Research; University of Zurich; Technical University of Munich; University of Zurich	Simon, HU (corresponding author), Univ Zurich, Swiss Inst Allergy & Asthma Res, Obere Str 22, CH-7270 Davos, Switzerland.	hus@siaf.unizh.ch	Simon, Hans-Uwe/AAU-7410-2020	Simon, Hans-Uwe/0000-0002-9404-7736				Akdis CA, 1998, J CLIN INVEST, V102, P98, DOI 10.1172/JCI2250; AZZAWI M, 1990, AM REV RESPIR DIS, V142, P1407, DOI 10.1164/ajrccm/142.6_Pt_1.1407; Bogen SA, 1996, AM J CLIN PATHOL, V106, P739; BOURGUIN A, 1990, P NATL ACAD SCI USA, V87, P8536, DOI 10.1073/pnas.87.21.8536; Brugnoni D, 1996, BLOOD, V87, P1416, DOI 10.1182/blood.V87.4.1416.bloodjournal8741416; Buechner SA, 1997, J CLIN INVEST, V100, P2691, DOI 10.1172/JCI119814; COGAN E, 1994, NEW ENGL J MED, V330, P535, DOI 10.1056/NEJM199402243300804; Dibbert B, 1998, BLOOD, V92, P778, DOI 10.1182/blood.V92.3.778.415k38_778_783; Dummer R, 1996, BLOOD, V88, P1383, DOI 10.1182/blood.V88.4.1383.bloodjournal8841383; Egle A, 1996, EUR J IMMUNOL, V26, P3119, DOI 10.1002/eji.1830261244; HARRIS NL, 1994, BLOOD, V84, P1361; Kamarashev J, 1998, J CUTAN PATHOL, V25, P407, DOI 10.1111/j.1600-0560.1998.tb01766.x; Meyer JC, 1997, EXP DERMATOL, V6, P122, DOI 10.1111/j.1600-0625.1997.tb00158.x; NAGATA S, 1995, IMMUNOL TODAY, V16, P39, DOI 10.1016/0167-5699(95)80069-7; SANDERSON CJ, 1992, BLOOD, V79, P3101, DOI 10.1182/blood.V79.12.3101.3101; Selleri C, 1997, BLOOD, V89, P957, DOI 10.1182/blood.V89.3.957; Simon HU, 1996, J EXP MED, V183, P1071, DOI 10.1084/jem.183.3.1071; SIMON HU, 1995, IMMUNOL TODAY, V16, P53, DOI 10.1016/0167-5699(95)80086-7; Simon HU, 1997, J IMMUNOL, V158, P3902; WELLER PF, 1994, BLOOD, V83, P2759, DOI 10.1182/blood.V83.10.2759.2759; Willemze R, 1997, BLOOD, V90, P354; WOOD GS, 1991, AM J PATHOL, V138, P1503	22	378	394	0	1	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	OCT 7	1999	341	15					1112	1120		10.1056/NEJM199910073411503	http://dx.doi.org/10.1056/NEJM199910073411503			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	245BW	10511609	Bronze			2022-12-01	WOS:000083087200003
J	Blanche, S; Tardieu, M; Rustin, P; Slama, A; Barret, B; Firtion, G; Ciraru-Vigneron, N; Lacroix, C; Rouzioux, C; Mandelbrot, L; Desguerre, I; Rotig, A; Mayaux, MJ; Delfraissy, JF				Blanche, S; Tardieu, M; Rustin, P; Slama, A; Barret, B; Firtion, G; Ciraru-Vigneron, N; Lacroix, C; Rouzioux, C; Mandelbrot, L; Desguerre, I; Rotig, A; Mayaux, MJ; Delfraissy, JF			Persistent mitochondrial dysfunction and perinatal exposure to antiretroviral nucleoside analogues	LANCET			English	Article; Proceedings Paper	6th Conference on Retroviruses and Opportunistic Infections	JAN 31-FEB 04, 1999	CHICAGO, IL				IMMUNODEFICIENCY-VIRUS TYPE-1; ZIDOVUDINE TREATMENT; RESPIRATORY-CHAIN; HIV TRANSMISSION; PREVENTION; TOXICITY; DNA; AZT	Background Zidovudine is commonly administered during pregnancy to prevent mother-to-child HIV-transmission. We investigated mitochondrial toxic effects in children exposed to zidovudine in utero and after birth. Methods We analysed observations of a trial of tolerance of combined zidovudine and lamivudine and preliminary results of a continuing retrospective analysis of clinical and biological symptoms of mitochondrial dysfunction in children born to HIV-1-infected women in France. Mitochondrial dysfunction was studied by spectrophotometry and polarography of respiratory-chain complexes in various tissues. Findings Fight children had mitochondrial dysfunction. Five, of whom two died, presented with delayed neurological symptoms and three were symptom-free but had severe biological or neurological abnormalities. Four of these children had been exposed to combined zidovudine and lamivudine, and four to zidovudine alone. No child was infected with HIV-1. All children had abnormally low absolute or relative activities of respiratory-chain complexes I, IV, or both months or years after the end of antiretroviral treatment. No mutation currently associated with constitutional disease was detected in any patient. Interpretation Our findings support the hypothesis of a link between mitochondrial dysfunction and the perinatal administration of prophylactic nucleoside analogues. Current recommendations for zidovudine monotherapy should however be maintained. Further assessment of the toxic effects of these drugs is required.	Hop Necker Enfants Malad, Unite Immunol Hematol Pediat, Serv Immunol Hematol Pediat, F-75743 Paris, France; Hop Necker Enfants Malad, INSERM, U429 Lab, F-75743 Paris, France; Hop Necker Enfants Malad, INSERM, U393 Lab, F-75743 Paris, France; Hop Necker Enfants Malad, Virol Lab, F-75743 Paris, France; Hop Bicetre, Serv Neurol Pediat, Le Kremlin Bicetre, France; Hop Bicetre, INSERM, U292 Lab, Le Kremlin Bicetre, France; Hop Bicetre, INSERM, CRI 9612 Lab, Le Kremlin Bicetre, France; Hop Bicetre, Biochim Lab, Le Kremlin Bicetre, France; Hop Bicetre, Serv Neuropathol, Le Kremlin Bicetre, France; Hop Bicetre, Serv Med Interne, Le Kremlin Bicetre, France; Hop Cochin Port Royal, Paris, France; Hop Lariboisiere, F-75475 Paris, France; Hop St Vincent de Paul, Serv Neurol, F-75674 Paris, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Bicetre - APHP; UDICE-French Research Universities; Universite Paris Saclay; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Bicetre - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Saclay; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Bicetre - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Saclay; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Bicetre - APHP; UDICE-French Research Universities; Universite Paris Saclay; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Bicetre - APHP; UDICE-French Research Universities; Universite Paris Saclay; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Bicetre - APHP; UDICE-French Research Universities; Universite Paris Saclay; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Lariboisiere-Fernand-Widal - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; UDICE-French Research Universities; Universite Paris Cite	Blanche, S (corresponding author), Hop Necker Enfants Malad, Unite Immunol Hematol Pediat, Serv Immunol Hematol Pediat, F-75743 Paris, France.	stephane.blanche@nck.ap-hop-paris.fr	Mandelbrot, Laurent/AAD-3554-2019; Rötig, Agnès/G-9592-2017	Mandelbrot, Laurent/0000-0002-5883-7597; Rötig, Agnès/0000-0003-0589-0703				Centers for Disease Control and Prevention (CDC), 1994, MMWR Morb Mortal Wkly Rep, V43, P1; [Anonymous], 1994, LANCET, V344, P207; BLANCHE S, 1989, NEW ENGL J MED, V320, P1643, DOI 10.1056/NEJM198906223202502; BOURGERON T, 1993, J BIOL CHEM, V268, P19369; Brinkman K, 1998, AIDS, V12, P1735, DOI 10.1097/00002030-199814000-00004; CHRETIEN D, BIOCH J, V329, P249; CONNOR EM, 1994, NEW ENGL J MED, V331, P1173, DOI 10.1056/NEJM199411033311801; Culnane M, 1999, JAMA-J AM MED ASSOC, V281, P151, DOI 10.1001/jama.281.2.151; DALAKAS MC, 1990, NEW ENGL J MED, V322, P1098, DOI 10.1056/NEJM199004193221602; DIMAURO S, 1993, ARCH NEUROL-CHICAGO, V50, P1197, DOI 10.1001/archneur.1993.00540110075008; Fischel-Ghodsian N, 1998, AM J HUM GENET, V62, P15, DOI 10.1086/301695; GERSCHENSON M, 1998, AM J HUM GENET, V63, pA164; Hall SM, 1998, CHILD CARE HLTH DEV, V24, P129; JOHNS DR, 1995, NEW ENGL J MED, V333, P638, DOI 10.1056/NEJM199509073331007; Kreuzer KA, 1997, ANN HEMATOL, V75, P179, DOI 10.1007/s002770050340; LEWIS W, 1995, NAT MED, V1, P417, DOI 10.1038/nm0595-417; Mayaux MJ, 1997, J PEDIATR-US, V131, P857, DOI 10.1016/S0022-3476(97)70033-7; Morris K, 1998, LANCET, V351, P651, DOI 10.1016/S0140-6736(05)78436-1; NEWELL ML, 1995, DRUG SAFETY, V12, P274, DOI 10.2165/00002018-199512040-00007; Olivero OA, 1997, J NATL CANCER I, V89, P1602, DOI 10.1093/jnci/89.21.1602; PONCHAUT S, 1995, EUR J PEDIATR, V154, P79, DOI 10.1007/BF01972980; Poulton J, 1998, Eur J Paediatr Neurol, V2, P99, DOI 10.1016/S1090-3798(98)80049-4; *PUBL HLTH SERV, 1998, MMWR-MORBID MORTAL W, V47, P688; ROUSE DJ, 1995, J ACQ IMMUN DEF SYND, V9, P401; RUSTIN P, 1994, CLIN CHIM ACTA, V228, P35, DOI 10.1016/0009-8981(94)90055-8; RUSTIN P, 1991, LANCET, V338, P60, DOI 10.1016/0140-6736(91)90057-V; Scalfaro P, 1998, INTENS CARE MED, V24, P247, DOI 10.1007/s001340050558; Sperling RS, 1998, AIDS, V12, P1805, DOI 10.1097/00002030-199814000-00012	28	479	495	0	6	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	SEP 25	1999	354	9184					1084	1089		10.1016/S0140-6736(99)07219-0	http://dx.doi.org/10.1016/S0140-6736(99)07219-0			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	General & Internal Medicine	239PA	10509500				2022-12-01	WOS:000082777500014
J	Sikorski, R; Peters, R				Sikorski, R; Peters, R			Protein interaction - Complex grabbing	SCIENCE			English	Editorial Material																		RIGAUT G, IN PRESS NATURE BIOT	1	1	1	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	SEP 17	1999	285	5435					1868	1868						1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	237CT	10515792				2022-12-01	WOS:000082638300036
J	Zeisel, SH				Zeisel, SH			Health - Regulation of "nutraceuticals"	SCIENCE			English	Editorial Material									Univ N Carolina, Sch Publ Hlth, Chapel Hill, NC 27599 USA; Univ N Carolina, Sch Med, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine	Zeisel, SH (corresponding author), Univ N Carolina, Sch Publ Hlth, Chapel Hill, NC 27599 USA.							AARTS T, 1998, NUTR BUS J, V3, P1; Clydesdale FM, 1997, NUTR REV, V55, P413, DOI 10.1111/j.1753-4887.1997.tb01588.x; Klepser TB, 1999, AM J HEALTH-SYST PH, V56, P125, DOI 10.1093/ajhp/56.2.125; VOGEL MR, 1998, PHARM TODAY, V4, P14; Williamson BL, 1998, TOXICOL LETT, V99, P139, DOI 10.1016/S0378-4274(98)00223-9; 1997, FED REG         0604, V62, P30677; 1999, MORB MORTAL WKLY REP, V481, P37; 1997, FED REG         0206, V62, P5699	8	200	207	0	12	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	SEP 17	1999	285	5435					1853	+		10.1126/science.285.5435.1853	http://dx.doi.org/10.1126/science.285.5435.1853			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	237CT	10515789				2022-12-01	WOS:000082638300027
J	Kwok, JMF; Miller, TD; Christian, TF; Hodge, DO; Gibbons, RJ				Kwok, JMF; Miller, TD; Christian, TF; Hodge, DO; Gibbons, RJ			Prognostic value of a treadmill exercise score in symptomatic patients with nonspecific ST-T abnormalities on resting ECG	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CORONARY-HEART-DISEASE; LEFT-VENTRICULAR FUNCTION; ASSOCIATION TASK-FORCE; SEGMENT DEPRESSION; ELECTROCARDIOGRAPHIC FINDINGS; ARTERY-DISEASE; DIAGNOSIS; PREVALENCE; GUIDELINES; MORTALITY	Context Exercise testing of patients with ST-T abnormalities on the resting electrocardiogram (ECG) is problematic because in the presence of pre-existing ST-T abnormalities, the exercise test is less specific for the diagnosis of coronary artery disease. The prognostic capability of the Duke treadmill score in patients with ST-T abnormalities vs those with normal findings on resting ECG has, to our knowledge, not been evaluated. Objective To compare the prognostic accuracy of the Duke treadmill score in patients with nonspecific ST-T abnormalities vs those with normal results on resting ECG. Design Inception cohort study with 7 years of follow-up. Setting Nuclear cardiology laboratory of a US referral center. Patients All symptomatic patients who underwent exercise thallium testing between 1989 and 1991, 939 of whom had nonspecific ST-T abnormalities and 1466 of whom had normal findings on resting ECG. Exclusion criteria included congenital, valvular, or cardiomyopathic heart disease; prior coronary artery revascularization; resting ECC with secondary ST-T abnormalities; or missing data. Main Outcome Measures Rates of overall mortality and cardiac death for subjects classified by Duke treadmill store risk group. Results For the end point cardiac death, 7-year survival in the study population in the low-, intermediate-, and high-risk groups was 97%, 92%, and 76%, respectively (P<.001), Compared with the control group, the study group had lower 7-year survival (94% vs 98%; P<.001), fewer low-risk patients (426 [45%] vs 811 [55%]; P<.001) with worse 7-year survival (97% vs 99%; P=.008), and more high-risk patients (49 [5%] vs 34 [2%];P<.001) with a nonsignificant trend toward worse 7-year survival (76% vs 93%; P =.36). Conclusions The Duke treadmill score can effectively risk-stratify patients with ST-T abnormalities on the resting EGG. In classified risk categories, patients with ST-T abnormalities have a worse prognosis than those with normal results on resting ECG.	Mayo Clin & Mayo Fdn, Div Cardiovasc Dis, Rochester, MN 55905 USA; Mayo Clin & Mayo Fdn, Dept Internal Med, Rochester, MN 55905 USA; Mayo Clin & Mayo Fdn, Dept Biostat, Rochester, MN 55905 USA; Princess Margaret Hosp, Dept Med, Kowloon, Peoples R China	Mayo Clinic; Mayo Clinic; Mayo Clinic	Miller, TD (corresponding author), Mayo Clin & Mayo Fdn, Div Cardiovasc Dis, Rochester, MN 55905 USA.	miller.todd@mayo.edu						ARAVINDAKSHAN V, 1977, AM HEART J, V93, P706, DOI 10.1016/S0002-8703(77)80065-3; ARONOW WS, 1989, AM J CARDIOL, V64, P232, DOI 10.1016/0002-9149(89)90465-7; BERMAN JL, 1978, CIRCULATION, V58, P505, DOI 10.1161/01.CIR.58.3.505; Braunwald E, 1994, AHCPR PUBLICATION, V94-0602, P1; Christian TF, 1997, AM J CARDIOL, V79, P1295, DOI 10.1016/S0002-9149(97)00108-2; CHRISTIAN TF, 1994, ANN INTERN MED, V121, P825, DOI 10.7326/0003-4819-121-11-199412010-00001; COHN K, 1979, CIRCULATION, V59, P286, DOI 10.1161/01.CIR.59.2.286; COHN PF, 1971, CIRCULATION, V43, P648, DOI 10.1161/01.CIR.43.5.648; CONNOLLY DC, 1984, MAYO CLIN PROC, V59, P247, DOI 10.1016/S0025-6196(12)61257-9; CULLEN K, 1982, BRIT HEART J, V47, P209; DETRANO R, 1989, J AM COLL CARDIOL, V14, P1501, DOI 10.1016/0735-1097(89)90388-4; DIAMOND GA, 1983, J AM COLL CARDIOL, V1, P474; ELLESTAD MH, 1975, CIRCULATION, V51, P363, DOI 10.1161/01.CIR.51.2.363; Gibbons RJ, 1997, J AM COLL CARDIOL, V30, P260; Gibbons RJ, 1999, J AM COLL CARDIOL, V33, P2092, DOI 10.1016/S0735-1097(99)00150-3; GOLDSCHLAGER N, 1976, ANN INTERN MED, V85, P277, DOI 10.7326/0003-4819-85-3-277; HARRIS FJ, 1977, ADV CARDIOL, V22, P11; HOLLENBERG M, 1980, CIRCULATION, V61, P276, DOI 10.1161/01.CIR.61.2.276; KANNEL WB, 1987, AM HEART J, V113, P370, DOI 10.1016/0002-8703(87)90280-8; KANSAL S, 1976, CIRCULATION, V54, P636, DOI 10.1161/01.CIR.54.4.636; KREGER BE, 1987, AM HEART J, V113, P377, DOI 10.1016/0002-8703(87)90281-X; LADENHEIM ML, 1987, AM J CARDIOL, V59, P270, DOI 10.1016/0002-9149(87)90798-3; LINHART JW, 1974, CIRCULATION, V49, P667; MARK DB, 1987, ANN INTERN MED, V106, P793, DOI 10.7326/0003-4819-106-6-793; MARK DB, 1991, NEW ENGL J MED, V325, P849, DOI 10.1056/NEJM199109193251204; MCNEER JF, 1978, CIRCULATION, V57, P64, DOI 10.1161/01.CIR.57.1.64; MEYERS DG, 1990, AM HEART J, V119, P272, DOI 10.1016/S0002-8703(05)80016-X; MIRANDA CP, 1991, AM HEART J, V122, P1617, DOI 10.1016/0002-8703(91)90279-Q; MIRVIS DM, 1990, AM J CARDIOL, V66, P699, DOI 10.1016/0002-9149(90)91133-Q; OKEEFE JH, 1989, AM J MED, V86, P658, DOI 10.1016/0002-9343(89)90439-7; OSTOR E, 1981, EUR HEART J, V2, P317; Pollock ML, 1990, EXERCISE HLTH DIS EV; REUNANEN A, 1977, ADV CARDIOL, V21, P310; ROMHILT DW, 1968, CIRCULATION, V37, P15, DOI 10.1161/01.CIR.37.1.15; ROSE G, 1978, BRIT HEART J, V40, P636; Sigurdsson E, 1996, J AM COLL CARDIOL, V27, P1140, DOI 10.1016/0735-1097(95)00614-1; WEINER DA, 1983, AM HEART J, V105, P749, DOI 10.1016/0002-8703(83)90236-3	37	65	66	0	2	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 15	1999	282	11					1047	1053		10.1001/jama.282.11.1047	http://dx.doi.org/10.1001/jama.282.11.1047			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	234YQ	10493203	Bronze			2022-12-01	WOS:000082512300028
J	Lin, RCY; Wang, WYS; Morris, BJ				Lin, RCY; Wang, WYS; Morris, BJ			High penetrance, overweight and glucocorticoid receptor variant: case-control study	BMJ-BRITISH MEDICAL JOURNAL			English	Article							GENE		Univ Sydney, Dept Physiol, Gene Lab, Sydney, NSW 2006, Australia; Univ Sydney, Inst Biomed Res, Sydney, NSW 2006, Australia	University of Sydney; University of Sydney	Morris, BJ (corresponding author), Univ Sydney, Dept Physiol, Gene Lab, Bldg F13, Sydney, NSW 2006, Australia.	brianm@physiol.usyd.edu.au	Wang, William/E-7862-2013; Lin, Ruby CY/A-1636-2009	Wang, William/0000-0002-5369-5446; Lin, Ruby CY/0000-0003-4163-511X				Clement K, 1996, INT J OBESITY, V20, P507; Huizenga NATM, 1998, J CLIN ENDOCR METAB, V83, P144, DOI 10.1210/jc.83.1.144; Koper JW, 1997, HUM GENET, V99, P663, DOI 10.1007/s004390050425; Meirhaeghe A, 1999, LANCET, V353, P896, DOI 10.1016/S0140-6736(99)00251-2; Takami S, 1999, AM J PHYSIOL-HEART C, V276, pH1379, DOI 10.1152/ajpheart.1999.276.4.H1379	5	84	87	0	2	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	NOV 20	1999	319	7221					1337	1338		10.1136/bmj.319.7221.1337	http://dx.doi.org/10.1136/bmj.319.7221.1337			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	260CF	10567137	Bronze, Green Published			2022-12-01	WOS:000083930200024
J	Gross, R				Gross, R			Leg lengthening	LANCET			English	Editorial Material							LIMB		Med Univ S Carolina, Dept Orthopaed, Charleston, SC 29424 USA	Medical University of South Carolina	Gross, R (corresponding author), Med Univ S Carolina, Dept Orthopaed, Charleston, SC 29424 USA.							Aldegheri R, 1999, J BONE JOINT SURG AM, V81A, P624, DOI 10.2106/00004623-199905000-00004; ANDERSON WV, 1967, MODERN TRENDS ORTHOP, P1; Cheng JCY, 1998, J BONE JOINT SURG BR, V80B, P772, DOI 10.1302/0301-620X.80B5.8475; Codivilla A, 1905, J BONE JOINT SURG, V2, P353; DEBASTIANI G, 1987, J PEDIATR ORTHOPED, V7, P129; GROSS RH, 1971, J BONE JOINT SURG AM, VA 53, P693, DOI 10.2106/00004623-197153040-00008; ILIZAROV GA, 1990, CLIN ORTHOP RELAT R, P8; Mahomed NN, 1998, AM J MED GENET, V78, P30, DOI 10.1002/(SICI)1096-8628(19980616)78:1<30::AID-AJMG7>3.0.CO;2-P; MOSCA V, 1986, ORTHOP T, V10, P462; Sharma M, 1996, J PEDIATR ORTHOPED, V16, P438, DOI 10.1097/01241398-199607000-00004; SOFIELD HA, 1958, J BONE JOINT SURG AM, V40, P311, DOI 10.2106/00004623-195840020-00006; WAGNER H, 1978, CLIN ORTHOP RELAT R, P125; 1988, LANCET, V1, P1032	13	3	3	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	NOV 6	1999	354	9190					1574	1575		10.1016/S0140-6736(99)00221-4	http://dx.doi.org/10.1016/S0140-6736(99)00221-4			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	253HM	10560667				2022-12-01	WOS:000083551000004
J	Cox, JS; Chen, B; McNeil, M; Jacobs, WR				Cox, JS; Chen, B; McNeil, M; Jacobs, WR			Complex lipid determine tissue specific replication of Mycobacterium tuberculosis in mice	NATURE			English	Article							MYCOCEROSIC ACID SYNTHASE; BOVIS BCG; TRANSPOSON MUTAGENESIS; VIRULENCE GENES; COENZYME-A; IDENTIFICATION; ADJACENT	Tuberculosis is the leading cause of death in the world resulting from a single bacterial infection(1). Despite its enormous burden on world health, little is known about the molecular mechanisms of pathogenesis of Mycobacterium tuberculosis. Bacterial multiplication and concomitant tissue damage within an infected host, including experimentally infected mice, occurs primarily in the lungs-the favoured niche of M. tuberculosis(2). Although it has been proposed that the distinctive cell wall of M. tuberculosis is important for virulence, rigorous genetic proof has been lacking. Here, using signature-tagged mutagenesis, we isolated three attenuated M. tuberculosis mutants that cannot synthesize or transport a complex, cell wall-associated lipid called phthiocerol dimycocerosate (PDIM) which is found only in pathogenic mycobacteria(3,4), Two mutants have transposon insertions affecting genes implicated in PDIM synthesis; the third has a disruption in a gene encoding a large transmembrane protein required for proper subcellular localization of PDIM. Synthesis and transport of this complex lipid is only required for growth in the lung; all three mutants are unaffected for growth in the liver and spleen. This clearly shows that a lipid is required for M. tuberculosis virulence.	Yeshiva Univ Albert Einstein Coll Med, Dept Microbiol & Immunol, Howard Hughes Med Inst, Bronx, NY 10461 USA; Colorado State Univ, Dept Microbiol, Ft Collins, CO 80523 USA	Howard Hughes Medical Institute; Yeshiva University; Albert Einstein College of Medicine; Colorado State University	Jacobs, WR (corresponding author), Yeshiva Univ Albert Einstein Coll Med, Dept Microbiol & Immunol, Howard Hughes Med Inst, 1300 Morris Pk Ave, Bronx, NY 10461 USA.		McNeil, Michael/G-3325-2019	Jacobs, William/0000-0003-3321-3080				Azad AK, 1997, J BIOL CHEM, V272, P16741, DOI 10.1074/jbc.272.27.16741; Azad AK, 1996, P NATL ACAD SCI USA, V93, P4787, DOI 10.1073/pnas.93.10.4787; Bardarov S, 1997, P NATL ACAD SCI USA, V94, P10961, DOI 10.1073/pnas.94.20.10961; Besra Gurdyal S., 1994, P285; BRENNAN PJ, 1995, ANNU REV BIOCHEM, V64, P29, DOI 10.1146/annurev.bi.64.070195.000333; Bystrykh LV, 1996, J BACTERIOL, V178, P2238, DOI 10.1128/jb.178.8.2238-2244.1996; Chiang SL, 1998, MOL MICROBIOL, V27, P797, DOI 10.1046/j.1365-2958.1998.00726.x; Cole ST, 1998, NATURE, V393, P537, DOI 10.1038/31159; Fitzmaurice AM, 1997, J BACTERIOL, V179, P2608, DOI 10.1128/jb.179.8.2608-2615.1997; Fitzmaurice AM, 1998, J BIOL CHEM, V273, P8033, DOI 10.1074/jbc.273.14.8033; FOLCH J, 1957, J BIOL CHEM, V226, P497; Garay S, 1996, TUBERCULOSIS, P373; HENSEL M, 1995, SCIENCE, V269, P400, DOI 10.1126/science.7618105; HUNTER SW, 1983, J BIOL CHEM, V258, P7556; Kolattukudy PE, 1997, MOL MICROBIOL, V24, P263, DOI 10.1046/j.1365-2958.1997.3361705.x; MATHUR M, 1992, J BIOL CHEM, V267, P19388; MCADAM RA, 1995, INFECT IMMUN, V63, P1004, DOI 10.1128/IAI.63.3.1004-1012.1995; Mei JM, 1997, MOL MICROBIOL, V26, P399, DOI 10.1046/j.1365-2958.1997.5911966.x; MIDDLEBROOK G, 1947, J EXP MED, V86, P175, DOI 10.1084/jem.86.2.175; OCHMAN H, 1988, GENETICS, V120, P621; PIERCE CH, 1956, AM REV TUBERC PULM, V74, P667; RAINWATER DL, 1983, J BIOL CHEM, V258, P2979; World Health Organization, 1999, WORLD HLTH REP 1999	23	587	614	1	35	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	NOV 4	1999	402	6757					79	83		10.1038/47042	http://dx.doi.org/10.1038/47042			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	254XC	10573420				2022-12-01	WOS:000083638600046
J	Henney, JE				Henney, JE			Infections from endoscopes	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	News Item											Henney, JE (corresponding author), HF-1,Room 14-71,5600 Fishers Ln, Rockville, MD 20857 USA.							1999, MMWR, V48, P557	1	5	5	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 3	1999	282	17					1613	1613		10.1001/jama.282.17.1613	http://dx.doi.org/10.1001/jama.282.17.1613			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	250BD	10553774				2022-12-01	WOS:000083368400008
J	Minamisawa, S; Hoshijima, M; Chu, GX; Ward, CA; Frank, K; Gu, YS; Martone, ME; Wang, YB; Ross, J; Kranias, EG; Giles, WR; Chien, KR				Minamisawa, S; Hoshijima, M; Chu, GX; Ward, CA; Frank, K; Gu, YS; Martone, ME; Wang, YB; Ross, J; Kranias, EG; Giles, WR; Chien, KR			Chronic phospholamban-sarcoplasmic reticulum calcium ATPase interaction is the critical calcium cycling defect in dilated cardiomyopathy	CELL			English	Article							HEART-FAILURE; CARDIAC-HYPERTROPHY; MYOCARDIAL-CONTRACTILITY; VENTRICULAR MYOCYTES; TRANSGENIC MICE; GENE-EXPRESSION; PROTEIN; KINASE; MOUSE; PHOSPHORYLATION	Dilated cardiomyopathy and end-stage heart failure result in multiple defects in cardiac excitation-contraction coupling. Via complementation of a genetically based mouse model of dilated cardiomyopathy, we now provide evidence that progressive chamber dilation and heart failure are dependent on a Ca2+ cycling defect in the cardiac sarcoplasmic reticulum. The ablation of a muscle-specific sarcoplasmic reticulum Ca2+ ATPase (SERCA2a) inhibitor, phospholamban, rescued the spectrum of phenotypes that resemble human heart failure. Inhibition of phospholamban-SERCA2a interaction via in vivo expression of a phospholamban point mutant dominantly activated the contractility of ventricular muscle cells. Thus, interfering with phospholamban-SERCA2a interaction may provide a novel therapeutic approach for preventing the progression of dilated cardiomyopathy.	Univ Calif San Diego, UCSD Salk Program Mol Med, La Jolla, CA 92093 USA; Univ Calif San Diego, Dept Med, La Jolla, CA 92093 USA; Univ Calif San Diego, Ctr Mol Genet, La Jolla, CA 92093 USA; Univ Calif San Diego, Dept Neurosci, La Jolla, CA 92093 USA; Univ Cincinnati, Coll Med, Dept Pharmacol & Cell Biophys, Cincinnati, OH 45267 USA; Univ Calgary, Sch Med, Dept Physiol & Biophys, Calgary, AB T2N 4N1, Canada	University of California System; University of California San Diego; University of California System; University of California San Diego; University of California System; University of California San Diego; University of California System; University of California San Diego; University System of Ohio; University of Cincinnati; University of Calgary	Chien, KR (corresponding author), Univ Calif San Diego, UCSD Salk Program Mol Med, La Jolla, CA 92093 USA.			Minamisawa, Susumu/0000-0003-4728-2116; Wang, Yibin/0000-0003-0852-0767	NCRR NIH HHS [P40RR12358] Funding Source: Medline; NHLBI NIH HHS [HL26057, HL52318] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [P40RR012358] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL026057, P50HL052318, R01HL026057] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Arber S, 1997, CELL, V88, P393, DOI 10.1016/S0092-8674(00)81878-4; Badorff C, 1999, NAT MED, V5, P320, DOI 10.1038/6543; Balke CW, 1998, CARDIOVASC RES, V37, P290, DOI 10.1016/S0008-6363(97)00272-1; BRISTOW MR, 1982, NEW ENGL J MED, V307, P205, DOI 10.1056/NEJM198207223070401; Chen J, 1999, J CLIN INVEST, V103, P1483, DOI 10.1172/JCI7297; CHIEN KR, 1993, ANNU REV PHYSIOL, V55, P77, DOI 10.1146/annurev.ph.55.030193.000453; Chien KR, 1999, CELL, V98, P555, DOI 10.1016/S0092-8674(00)80043-4; CHIEN KR, 1999, MOL BASIS CARDIOVASC, P211; CHRISTENSEN G, 1999, IN PRESS CIRCULATION; Chu GX, 1996, CIRC RES, V79, P1064, DOI 10.1161/01.RES.79.6.1064; Coral-Vazquez R, 1999, CELL, V98, P465, DOI 10.1016/S0092-8674(00)81975-3; FELDMAN AM, 1988, J CLIN INVEST, V82, P189, DOI 10.1172/JCI113569; Gomez AM, 1997, SCIENCE, V276, P800, DOI 10.1126/science.276.5313.800; GRUVER CL, 1993, ENDOCRINOLOGY, V133, P376, DOI 10.1210/en.133.1.376; Hasenfuss G, 1998, CARDIOVASC RES, V37, P279, DOI 10.1016/S0008-6363(97)00277-0; Hirota H, 1999, CELL, V97, P189, DOI 10.1016/S0092-8674(00)80729-1; Hunter JJ, 1999, NEW ENGL J MED, V341, P1276, DOI 10.1056/NEJM199910213411706; Jones WK, 1996, J CLIN INVEST, V98, P1906, DOI 10.1172/JCI118992; Kimura Y, 1997, J BIOL CHEM, V272, P15061, DOI 10.1074/jbc.272.24.15061; Kimura Y, 1998, J BIOL CHEM, V273, P14238, DOI 10.1074/jbc.273.23.14238; KOCH WJ, 1995, SCIENCE, V268, P1350, DOI 10.1126/science.7761854; Koss KL, 1997, BASIC RES CARDIOL, V92, P17, DOI 10.1007/BF00794064; Koss KL, 1996, CIRC RES, V79, P1059, DOI 10.1161/01.RES.79.6.1059; Lindner M, 1998, J MOL CELL CARDIOL, V30, P743, DOI 10.1006/jmcc.1997.0626; Luo WS, 1998, J BIOL CHEM, V273, P4734, DOI 10.1074/jbc.273.8.4734; LUO WS, 1994, CIRC RES, V75, P401, DOI 10.1161/01.RES.75.3.401; Martone ME, 1999, J NEUROSCI, V19, P1988; McDonough PM, 1997, J BIOL CHEM, V272, P24046, DOI 10.1074/jbc.272.38.24046; MERRITT JE, 1990, BIOCHEM J, V269, P513, DOI 10.1042/bj2690513; MEYER M, 1995, CIRCULATION, V92, P778, DOI 10.1161/01.CIR.92.4.778; Minamisawa S, 1999, J BIOL CHEM, V274, P10066, DOI 10.1074/jbc.274.15.10066; Molkentin JD, 1998, CELL, V93, P215, DOI 10.1016/S0092-8674(00)81573-1; MORGAN JP, 1991, NEW ENGL J MED, V325, P625; Olson TM, 1998, SCIENCE, V280, P750, DOI 10.1126/science.280.5364.750; Palakodeti V, 1997, AM J PHYSIOL-HEART C, V273, pH1283, DOI 10.1152/ajpheart.1997.273.3.H1283; PIESKE B, 1995, CIRCULATION, V92, P1169, DOI 10.1161/01.CIR.92.5.1169; Qi M, 1997, AM J PHYSIOL-HEART C, V272, pH2416, DOI 10.1152/ajpheart.1997.272.5.H2416; Ramirez MT, 1997, J BIOL CHEM, V272, P31203, DOI 10.1074/jbc.272.49.31203; Rockman HA, 1998, P NATL ACAD SCI USA, V95, P7000, DOI 10.1073/pnas.95.12.7000; Santana LF, 1998, J GEN PHYSIOL, V112, p11A; Sato Y, 1998, J BIOL CHEM, V273, P28470, DOI 10.1074/jbc.273.43.28470; Schmidt U, 1999, AM J PHYSIOL-HEART C, V277, pH474, DOI 10.1152/ajpheart.1999.277.2.H474; Schwinger RHG, 1999, J MOL CELL CARDIOL, V31, P479, DOI 10.1006/jmcc.1998.0897; Simmerman HKB, 1998, PHYSIOL REV, V78, P921, DOI 10.1152/physrev.1998.78.4.921; SORDAHL LA, 1973, AM J PHYSIOL, V224, P497, DOI 10.1152/ajplegacy.1973.224.3.497; Tada M, 1998, TRENDS CARDIOVAS MED, V8, P330, DOI 10.1016/S1050-1738(98)00032-2; TADA M, 1982, MOL CELL BIOCHEM, V46, P73; Tanaka N, 1996, CIRCULATION, V94, P1109, DOI 10.1161/01.CIR.94.5.1109; TOYOFUKU T, 1994, J BIOL CHEM, V269, P3088; Wang YB, 1998, J BIOL CHEM, V273, P2161, DOI 10.1074/jbc.273.4.2161; Ward CA, 1997, J PHYSIOL-LONDON, V500, P631, DOI 10.1113/jphysiol.1997.sp022048; WHITMER JT, 1988, CIRC RES, V62, P81, DOI 10.1161/01.RES.62.1.81	52	397	406	0	15	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	OCT 29	1999	99	3					313	322		10.1016/S0092-8674(00)81662-1	http://dx.doi.org/10.1016/S0092-8674(00)81662-1			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	251HX	10555147	Bronze			2022-12-01	WOS:000083440600009
J	Raaymakers, TWM; Rinkel, GJE; van Gijn, J; Greebe, P; Algra, A; Buskens, E; Buys, PC; Ramos, LMP; Witkamp, TD; Mali, WPTM; Tulleken, CAF; Limburg, M; Gorissen, A; Vonk, CM; Bossuyt, PMM; Bonsel, GJ; Verbeeten, B; Hulsmans, FJ; Albrecht, KW				Raaymakers, TWM; Rinkel, GJE; van Gijn, J; Greebe, P; Algra, A; Buskens, E; Buys, PC; Ramos, LMP; Witkamp, TD; Mali, WPTM; Tulleken, CAF; Limburg, M; Gorissen, A; Vonk, CM; Bossuyt, PMM; Bonsel, GJ; Verbeeten, B; Hulsmans, FJ; Albrecht, KW		Magnetic Resonance Angiography Rel	Risks and benefits of screening for intracranial aneurysms in first-degree relatives of patients with sporadic subarachnoid hemorrhage	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							UNRUPTURED CEREBRAL ANEURYSMS; SACCULAR ANEURYSMS; NATURAL-HISTORY; MR-ANGIOGRAPHY; RUPTURE; SURGERY	Background The first-degree relatives of patients who have subarachnoid hemorrhage from ruptured intracranial aneurysms are themselves at risk for subarachnoid hemorrhage. We studied the benefits and risks of screening for aneurysms in the first-degree relatives of patients with sporadic subarachnoid hemorrhage. Methods We screened 626 first-degree relatives (parents, siblings, or children) of 160 patients with sporadic subarachnoid hemorrhage, from a prospective series of 193 consecutive index patients. Magnetic resonance angiography was the screening tool, and conventional angiography was used as the reference test in subjects thought to have aneurysms. Six months after elective operation, outcome was assessed by means of the modified Rankin scale of neurologic function. This observational study design was combined with a decision-analysis model to estimate the effectiveness of screening. The efficiency of screening was defined by the number of relatives who needed to be screened in order to prevent one subarachnoid hemorrhage. Results Aneurysms were found in 25 of 626 first-degree relatives (4.0 percent; 95 percent confidence interval, 2.6 to 5.8 percent). Eighteen underwent surgery, which resulted in a decrease in function in 11 (disabling in 1). Five had medium-sized aneurysms that were 5 to 11 mm in diameter, 11 had small aneurysms that were less than 5 mm, and 2 had both small and medium-sized aneurysms. On average, surgery increased estimated life expectancy by 2.5 years for these 18 subjects (or by 0.9 month per person screened), at the expense of 19 years of decreased function per person. The number of relatives who would need to be screened in order to prevent 1 subarachnoid hemorrhage on a lifetime basis was 149, and 298 would have to be screened in order to prevent 1 fatal subarachnoid hemorrhage. Conclusions Implementation of a screening program for the first-degree relatives of patients with sporadic subarachnoid hemorrhage does not seem warranted at this time, since the resulting slight increase in life expectancy does not offset the risk of postoperative sequelae. (N Engl J Med 1999;341:1344-50.) (C) 1999, Massachusetts Medical Society.	Univ Utrecht Hosp, Dept Neurol, NL-3584 CX Utrecht, Netherlands; Julius Ctr Patient Oriented Res, Utrecht, Netherlands; Acad Med Ctr, Dept Neurosurg, Amsterdam, Netherlands; Acad Med Ctr, Dept Radiol, Amsterdam, Netherlands; Acad Med Ctr, Dept Neurol, Amsterdam, Netherlands; Acad Med Ctr, Dept Clin Epidemiol & Biostat, Amsterdam, Netherlands	Utrecht University; Utrecht University Medical Center; University of Amsterdam; Academic Medical Center Amsterdam; University of Amsterdam; Academic Medical Center Amsterdam; University of Amsterdam; Academic Medical Center Amsterdam; University of Amsterdam; Academic Medical Center Amsterdam	Raaymakers, TWM (corresponding author), Univ Utrecht Hosp, Dept Neurol, H2-128,Heidelberglaan 100, NL-3584 CX Utrecht, Netherlands.		van Gijn, Jan/A-9444-2008; Bossuyt, Patrick M./B-4557-2016; Mali, Willem PThM/I-1123-2014; Bossuyt, Patrick M/AAR-1183-2021	Bossuyt, Patrick M./0000-0003-4427-0128; Mali, Willem PThM/0000-0003-4391-0904; Bossuyt, Patrick M/0000-0003-4427-0128				ASARI S, 1993, CLIN NEUROL NEUROSUR, V95, P205, DOI 10.1016/0303-8467(93)90125-Z; Atlas SW, 1997, RADIOLOGY, V203, P807, DOI 10.1148/radiology.203.3.9169709; Auger R G, 1991, J Stroke Cerebrovasc Dis, V1, P174, DOI 10.1016/S1052-3057(10)80014-X; BAMFORD JM, 1989, STROKE, V20, P828, DOI 10.1161/01.STR.20.6.828; BROMBERG JEC, 1995, BRIT MED J, V311, P288, DOI 10.1136/bmj.311.7000.288; Caplan LR, 1998, NEW ENGL J MED, V339, P1774, DOI 10.1056/NEJM199812103392409; CHANG HS, 1995, J NEUROSURG, V83, P413, DOI 10.3171/jns.1995.83.3.0413; Crawley F, 1999, STROKE, V30, P312, DOI 10.1161/01.STR.30.2.312; Eskesen V, 1987, Br J Neurosurg, V1, P47, DOI 10.3109/02688698709034340; Eskesen V, 1988, Br J Neurosurg, V2, P379, DOI 10.3109/02688698809001009; HABBEMA JDF, 1990, STAT MED, V9, P1229, DOI 10.1002/sim.4780091104; HEISERMAN JE, 1994, AM J NEURORADIOL, V15, P1401; Hop JW, 1997, STROKE, V28, P660, DOI 10.1161/01.STR.28.3.660; INAGAWA T, 1992, SURG NEUROL, V38, P364, DOI 10.1016/0090-3019(92)90023-G; Inomiya K, 1995, Medinfo, V8 Pt 2, P889; JUVELA S, 1993, J NEUROSURG, V79, P174, DOI 10.3171/jns.1993.79.2.0174; Kojima M, 1998, NEUROSURGERY, V43, P776, DOI 10.1097/00006123-199810000-00026; KOROGI Y, 1994, RADIOLOGY, V193, P181, DOI 10.1148/radiology.193.1.8090889; LEBLANC R, 1994, NEUROSURGERY, V35, P9, DOI 10.1227/00006123-199407000-00002; LOCKSLEY HB, 1966, J NEUROSURG, V25, P321, DOI 10.3171/jns.1966.25.3.0321; MCCORMICK WF, 1970, J NEUROSURG, V33, P422, DOI 10.3171/jns.1970.33.4.0422; Mizoi K, 1995, SURG NEUROL, V44, P114, DOI 10.1016/0090-3019(95)00035-6; OBUCHOWSKI NA, 1995, J NEUROSURG, V83, P42, DOI 10.3171/jns.1995.83.1.0042; PRZELOMSKI MM, 1986, NEUROLOGY, V36, P584, DOI 10.1212/WNL.36.4.584; Raaymakers TWM, 1998, NEUROLOGY, V51, P1125, DOI 10.1212/WNL.51.4.1125; Raaymakers TWM, 1998, STROKE, V29, P1531, DOI 10.1161/01.STR.29.8.1531; RANKIN J, 1957, Scott Med J, V2, P200; Rembold CM, 1998, BMJ-BRIT MED J, V317, P307, DOI 10.1136/bmj.317.7154.307; Rinkel GJE, 1998, STROKE, V29, P251, DOI 10.1161/01.STR.29.1.251; RONKAINEN A, 1995, RADIOLOGY, V195, P35, DOI 10.1148/radiology.195.1.7892491; Ronkainen A, 1998, STROKE, V29, P359, DOI 10.1161/01.STR.29.2.359; Ronkainen A, 1997, LANCET, V349, P380, DOI 10.1016/S0140-6736(97)80009-8; SCHIEVINK WI, 1995, J NEUROSURG, V83, P426, DOI 10.3171/jns.1995.83.3.0426; SONNENBERG FA, 1993, MED DECIS MAKING, V13, P322, DOI 10.1177/0272989X9301300409; Tas R F, 1998, Maandstat Bevolking, V46, P8; Wiebers D, 1999, NEW ENGL J MED, V340, P744; Wiebers D, 1998, NEW ENGL J MED, V339, P1725, DOI 10.1056/nejm199812103392401; WIEBERS DO, 1987, J NEUROSURG, V66, P23, DOI 10.3171/jns.1987.66.1.0023; WILMS G, 1996, NEURORADIOLOGY, V38, P20; Wright JC, 1998, NEW ENGL J MED, V339, P380, DOI 10.1056/NEJM199808063390606; ZACKS DJ, 1980, ARCH NEUROL-CHICAGO, V37, P39, DOI 10.1001/archneur.1980.00500500069010	41	92	95	0	2	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 28	1999	341	18					1344	1350						7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	249XE	10536126				2022-12-01	WOS:000083357800003
J	Mulligan, J; Voss, LD				Mulligan, J; Voss, LD			Identifying very fat and very thin children: test of criterion standards for screening test	BRITISH MEDICAL JOURNAL			English	Article							BODY-MASS INDEX		Univ Southampton, Southampton Gen Hosp, Southampton SO16 6YD, Hants, England	University of Southampton	Mulligan, J (corresponding author), Univ Southampton, Southampton Gen Hosp, Southampton SO16 6YD, Hants, England.							FREEMAN JV, 1995, INT J EPIDEMIOL, V24, P970, DOI 10.1093/ije/24.5.970; Hulse J A, 1995, J Med Screen, V2, P168; Power C, 1997, AM J CLIN NUTR, V66, P1094, DOI 10.1093/ajcn/66.5.1094; Prentice AM, 1998, BRIT MED J, V317, P1401, DOI 10.1136/bmj.317.7170.1401; Ruderman N, 1998, DIABETES, V47, P699, DOI 10.2337/diabetes.47.5.699	5	9	9	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	OCT 23	1999	319	7217					1103	1104		10.1136/bmj.319.7217.1103	http://dx.doi.org/10.1136/bmj.319.7217.1103			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	250ZE	10531099	Bronze, Green Published			2022-12-01	WOS:000083419500022
J	Underhill, DM; Ozinsky, A; Hajjar, AM; Stevens, A; Wilson, CB; Bassetti, M; Aderem, A				Underhill, DM; Ozinsky, A; Hajjar, AM; Stevens, A; Wilson, CB; Bassetti, M; Aderem, A			The Toll-like receptor 2 is recruited to macrophage phagosomes and discriminates between pathogens	NATURE			English	Article							DROSOPHILA HOST-DEFENSE; GENE; FAMILY; MYD88; LIPOPOLYSACCHARIDE; 18-WHEELER; EXPRESSION; ADAPTER; COMPLEX; MICE	Macrophages orchestrate innate immunity by phagocytosing pathogens and coordinating inflammatory responses(1). Effective defence requires the host to discriminate between different pathogens. The specificity of innate immune recognition in Drosophila is mediated by the Toll family of receptors(2,3); Toll mediates anti-fungal responses, whereas 18-wheeler mediates anti-bacterial defence(4-6). A large number of Toll homologues have been identified in mammals, and Toll-like receptor 4 is critical in responses to Gram-negative bacteria(7-11). Here we show that Toll-like receptor 2 is recruited specifically to macrophage phagosomes containing yeast, and that a point mutation in the receptor abrogates inflammatory responses to yeast and Gram-positive bacteria, but not to Gram-negative bacteria. Thus, during the phagocytosis of pathogens, two classes of innate immune receptors cooperate to mediate host defence: phagocytic receptors, such as the mannose receptor, signal particle internalization, and the Toll-like receptors sample the contents of the vacuole and trigger an inflammatory response appropriate to defence against the specific organism.	Univ Washington, Dept Immunol, Seattle, WA 98195 USA	University of Washington; University of Washington Seattle	Aderem, A (corresponding author), Univ Washington, Dept Immunol, Box 357650, Seattle, WA 98195 USA.	aaderem@u.washington.edu	UNDERHILL, DAVID/ABE-2185-2021; Bassetti, Matteo/L-3081-2019	Underhill, David/0000-0002-2989-658X; Hajjar, Adeline/0000-0002-4838-8070				Adachi O, 1998, IMMUNITY, V9, P143, DOI 10.1016/S1074-7613(00)80596-8; Aderem A, 1999, ANNU REV IMMUNOL, V17, P593, DOI 10.1146/annurev.immunol.17.1.593; Chaudhary PM, 1998, BLOOD, V91, P4020, DOI 10.1182/blood.V91.11.4020.411a44_4020_4027; ELDON E, 1994, DEVELOPMENT, V120, P885; FREUDENBERG MA, 1991, INFECT IMMUN, V59, P2110, DOI 10.1128/IAI.59.6.2110-2115.1991; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; Heine H, 1999, J IMMUNOL, V162, P6971; Hoffmann JA, 1999, SCIENCE, V284, P1313, DOI 10.1126/science.284.5418.1313; Hoshino K, 1999, J IMMUNOL, V162, P3749; Kirschning CJ, 1998, J EXP MED, V188, P2091, DOI 10.1084/jem.188.11.2091; Lemaitre B, 1997, P NATL ACAD SCI USA, V94, P14614, DOI 10.1073/pnas.94.26.14614; Medzhitov R, 1998, P NATL ACAD SCI USA, V95, P429, DOI 10.1073/pnas.95.2.429; Medzhitov R, 1998, MOL CELL, V2, P253, DOI 10.1016/S1097-2765(00)80136-7; Muzio M, 1997, SCIENCE, V278, P1612, DOI 10.1126/science.278.5343.1612; Poltorak A, 1998, SCIENCE, V282, P2085, DOI 10.1126/science.282.5396.2085; Qureshi ST, 1999, J EXP MED, V189, P615, DOI 10.1084/jem.189.4.615; Rock FL, 1998, P NATL ACAD SCI USA, V95, P588, DOI 10.1073/pnas.95.2.588; SCHINDLER U, 1994, MOL CELL BIOL, V14, P5820, DOI 10.1128/MCB.14.9.5820; Schwandner R, 1999, J BIOL CHEM, V274, P17406, DOI 10.1074/jbc.274.25.17406; Stahl PD, 1998, CURR OPIN IMMUNOL, V10, P50, DOI 10.1016/S0952-7915(98)80031-9; Sweetser MT, 1998, J BIOL CHEM, V273, P34775, DOI 10.1074/jbc.273.52.34775; Takeuchi O, 1999, GENE, V231, P59, DOI 10.1016/S0378-1119(99)00098-0; Underhill DM, 1998, J BIOL CHEM, V273, P33619, DOI 10.1074/jbc.273.50.33619; Wesche H, 1997, IMMUNITY, V7, P837, DOI 10.1016/S1074-7613(00)80402-1; Williams MJ, 1997, EMBO J, V16, P6120, DOI 10.1093/emboj/16.20.6120; Yang RB, 1998, NATURE, V395, P284, DOI 10.1038/26239; Yoshimura A, 1999, J IMMUNOL, V163, P1	27	1148	1209	1	59	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	OCT 21	1999	401	6755					811	815		10.1038/44605	http://dx.doi.org/10.1038/44605			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	250BG	10548109				2022-12-01	WOS:000083368700058
J	Naren, AP; Cormet-Boyaka, E; Fu, J; Villain, M; Blalock, JE; Quick, MW; Kirk, KL				Naren, AP; Cormet-Boyaka, E; Fu, J; Villain, M; Blalock, JE; Quick, MW; Kirk, KL			CFPR chloride channel regulation by an interdomain interaction	SCIENCE			English	Article							CYSTIC-FIBROSIS; CFTR; SYNTAXIN; DOMAIN	The cystic fibrosis gene encodes a chloride channel, CFTR (cystic fibrosis transmembrane conductance regulator), that regulates salt and water transport across epithelial tissues. Phosphorylation of the cytoplasmic regulatory (R) domain by protein kinase A activates CFTR by an unknown mechanism. The amino-terminal cytoplasmic tail of CFTR was found to control protein kinase A-dependent channel gating through a physical interaction with the R domain. This regulatory activity mapped to a cluster of acidic residues in the NH2-terminal tail; mutating these residues proportionately inhibited R domain binding and CFTR channel function. CFTR activity appears to be governed by an interdomain interaction involving the amino-terminal tail, which is a potential target for physiologic and pharmacologic modulators of this ion channel.	Univ Alabama Birmingham, Gregory Fleming James Cyst Fibrosis Res Ctr, Dept Physiol & Biophys, Birmingham, AL 35294 USA; Univ Alabama Birmingham, Gregory Fleming James Cyst Fibrosis Res Ctr, Dept Neurobiol, Birmingham, AL 35294 USA	University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham	Naren, AP (corresponding author), Univ Alabama Birmingham, Gregory Fleming James Cyst Fibrosis Res Ctr, Dept Physiol & Biophys, Birmingham, AL 35294 USA.	kirk@phybio.bhs.uab.edu	Cormet-Boyaka, Estelle/H-5624-2011	Blalock, J. Edwin/0000-0001-5303-8123	NIDA NIH HHS [DA10509] Funding Source: Medline; NIDDK NIH HHS [DK51868, DK50830] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK050830] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [R29DA010509, R01DA010509] Funding Source: NIH RePORTER	NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)		BAUKROWITZ T, 1994, NEURON, V12, P473, DOI 10.1016/0896-6273(94)90206-2; BEAR CE, 1992, CELL, V68, P809, DOI 10.1016/0092-8674(92)90155-6; CARSON MR, 1995, J BIOL CHEM, V270, P1711, DOI 10.1074/jbc.270.4.1711; CHENG SH, 1990, CELL, V63, P827, DOI 10.1016/0092-8674(90)90148-8; CHENG SH, 1989, CELL, V66, P1066; FU J, UNPUB; GABRIEL SE, 1994, SCIENCE, V266, P107, DOI 10.1126/science.7524148; Ma JJ, 1997, J BIOL CHEM, V272, P28133, DOI 10.1074/jbc.272.44.28133; Mathews CJ, 1998, J PHYSIOL-LONDON, V508, P365, DOI 10.1111/j.1469-7793.1998.365bq.x; Naren AP, 1998, P NATL ACAD SCI USA, V95, P10972, DOI 10.1073/pnas.95.18.10972; Naren AP, 1997, NATURE, V390, P302, DOI 10.1038/36882; NAREN AP, UNPUB; Prince LS, 1999, J BIOL CHEM, V274, P3602, DOI 10.1074/jbc.274.6.3602; QUICK MW, UNPUB; WELSH MJ, 1993, CELL, V73, P1251, DOI 10.1016/0092-8674(93)90353-R; Wilkinson DJ, 1996, J GEN PHYSIOL, V107, P103, DOI 10.1085/jgp.107.1.103; Winter MC, 1997, NATURE, V389, P294, DOI 10.1038/38514	17	108	108	0	8	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 15	1999	286	5439					544	548		10.1126/science.286.5439.544	http://dx.doi.org/10.1126/science.286.5439.544			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	245RD	10521352				2022-12-01	WOS:000083121200064
J	Burzlaff, NI; Rutledge, PJ; Clifton, IJ; Hensgens, CMH; Pickford, M; Adlington, RM; Roach, PL; Baldwin, JE				Burzlaff, NI; Rutledge, PJ; Clifton, IJ; Hensgens, CMH; Pickford, M; Adlington, RM; Roach, PL; Baldwin, JE			The reaction cycle of isopenicillin N synthase observed by X-ray diffraction	NATURE			English	Article							PENICILLIN BIOSYNTHESIS; LACTAM FORMATION; CRYSTALLOGRAPHY; PROGRAM; SULFUR	Isopenicillin N synthase (IPNS), a non-haem iron-dependent oxidase, catalyses the biosynthesis of isopenicillin N (IPN), the precursor of all penicillins and cephalosporins'. The key steps in this reaction are the two iron-dioxygen-mediated ring closures of the tripeptide delta-(L-alpha-aminoadipoyl)-L-cysteinyl-D-valin (ACV). It has been proposed that the four-membered beta-lactam ring forms initially, associated with a highly oxidized iron(rv)-oxo (ferryl) moiety, which subsequently mediates closure of the five-membered thiazolidine ring(2). Here we describe observation of the IPNS reaction in crystals by X-ray crystallography. IPNS.Fe2+.substrate crystals were grown anaerobically(3,4), exposed to high pressures of oxygen to promote reaction and frozen, and their structures were elucidated by X-ray diffraction. Using the natural substrate ACV, this resulted in the IPNS.Fe2+.IPN product complex. With the substrate analogue, delta-(L-alpha-aminoadipoyl)-L-cysteinyl-L-S-methyl-cysteine (ACmC) in the crystal, the reaction cycle was interrupted at the monocyclic stage. These mono- and bicyclic structures support our hypothesis of a two-stage reaction sequence leading to penicillin. Furthermore, the formation of a monocyclic sulphoxide product from ACmC is most simply explained by the interception of a high-valency iron-ore species.	Univ Oxford, Dyson Perrins Lab, Oxford OX1 3QY, England; Univ Oxford, Oxford Ctr Mol Sci, Oxford OX1 3QY, England; Univ Oxford, Lab Mol Biophys, Oxford OX1 3QY, England	University of Oxford; University of Oxford; University of Oxford	Baldwin, JE (corresponding author), Univ Oxford, Dyson Perrins Lab, S Parks Rd, Oxford OX1 3QY, England.	jack.baldwin@chem.oz.ac.uk	Roach, Peter/AAW-7071-2021; Roach, Peter/C-6248-2013; Rutledge, Peter J/D-6253-2012	Rutledge, Peter/0000-0002-0767-5196				BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BALDWIN JE, 1984, J CHEM SOC CHEM COMM, P984, DOI 10.1039/c39840000984; BALDWIN JE, 1988, NAT PROD REP, V5, P129, DOI 10.1039/np9880500129; BALDWIN JE, 1988, J CHEM SOC CHEM COMM, P1128, DOI 10.1039/c39880001128; BALDWIN JE, 1990, CHEM REV, V90, P1079, DOI 10.1021/cr00105a001; BALDWIN JE, 1988, J CHEM SOC CHEM COMM, P1125, DOI 10.1039/c39880001125; BALDWIN JE, 1986, J CHEM SOC CHEM COMM, P110, DOI 10.1039/c39860000110; Berendzen J, 1998, BIOPHYS J, V74, pA250; HADFIELD A, 1993, J APPL CRYSTALLOGR, V26, P839, DOI 10.1107/S0021889893005552; HAJDU J, 1993, ANNU REV BIOPH BIOM, V22, P467, DOI 10.1146/annurev.bb.22.060193.002343; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; KRIAUCIUNAS A, 1991, J BIOL CHEM, V266, P11779; LEE SK, 1993, J BIOL CHEM, V268, P21569; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; RIGAU JJ, 1970, J ORG CHEM, V35, P3655, DOI 10.1021/jo00836a013; Roach PL, 1996, EUR J BIOCHEM, V242, P736, DOI 10.1111/j.1432-1033.1996.0736r.x; Roach PL, 1997, NATURE, V387, P827, DOI 10.1038/42990; SCHLICHTING I, 1997, FASEB J, V1, pP2; Sheldrick GM, 1997, METHOD ENZYMOL, V277, P319, DOI 10.1016/S0076-6879(97)77018-6	21	162	163	0	31	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	OCT 14	1999	401	6754					721	724		10.1038/44400	http://dx.doi.org/10.1038/44400			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	247EJ	10537113				2022-12-01	WOS:000083207400062
J	Uchida, J; Yasui, T; Takaoka-Shichijo, Y; Muraoka, M; Kulwichit, W; Raab-Traub, N; Kikutani, H				Uchida, J; Yasui, T; Takaoka-Shichijo, Y; Muraoka, M; Kulwichit, W; Raab-Traub, N; Kikutani, H			Mimicry of CD40 signals by Epstein-Barr virus LMP1 in B lymphocyte responses	SCIENCE			English	Article							NF-KAPPA-B; GERMINAL CENTER FORMATION; NECROSIS-FACTOR RECEPTOR; ACUTE INFECTIOUS-MONONUCLEOSIS; CELLS IN-VIVO; AFFINITY MATURATION; DEFICIENT MICE; CD40-DEFICIENT MICE; CYTOPLASMIC DOMAIN; IMMUNE-RESPONSES	The effect of the Epstein-Barr virus (EBV) latent membrane protein 1 (LMP1) on the activation and differentiation of normal B cells was investigated. B cells of transgenic mice expressing LMP1 under the control of immunoglobulin promoter/enhancer displayed enhanced expression of activation antigens and spontaneously proliferated and produced antibody. Humoral immune responses of LMP1 transgenic mice in CD40-deficient or normal backgrounds revealed that LMP1 mimics CD40 signals to induce extrafollicular 13 cell differentiation but, unlike CD40, blocks germinal center formation. Thus, these specific properties of LMP1 may determine the site of primary B cell infection and the state of infection in the natural course of EBV infection, whereas subsequent loss of LMP1 expression may affect the site of persistent latent infection.	Osaka Univ, Microbial Dis Res Inst, Dept Mol Immunol, Osaka 5650871, Japan; Univ N Carolina, Dept Microbiol & Immunol, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA	Osaka University; University of North Carolina; University of North Carolina Chapel Hill	Uchida, J (corresponding author), Osaka Univ, Microbial Dis Res Inst, Dept Mol Immunol, 3-1 Yamada Oka, Osaka 5650871, Japan.	kikutani@ragtime.biken.osaka-u.ac.jp	Kikutani, Hitoshi/C-9525-2009	Muraoka, Masaaki/0000-0002-2926-5374	NCI NIH HHS [CA19014] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA019014] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AMAN P, 1986, CURR TOP MICROBIOL, V132, P266; ANAGNOSTOPOULOS I, 1995, BLOOD, V85, P744, DOI 10.1182/blood.V85.3.744.bloodjournal853744; Babcock GJ, 1998, IMMUNITY, V9, P395, DOI 10.1016/S1074-7613(00)80622-6; BANCHEREAU J, 1991, SCIENCE, V251, P70, DOI 10.1126/science.1702555; CASTIGLI E, 1994, P NATL ACAD SCI USA, V91, P12135, DOI 10.1073/pnas.91.25.12135; CATTORETTI G, 1997, BLOOD, V90, P175; CHENG GH, 1995, SCIENCE, V267, P1494, DOI 10.1126/science.7533327; COHEN JI, 1991, J VIROL, V65, P2545, DOI 10.1128/JVI.65.5.2545-2554.1991; CUMANO A, 1985, EUR J IMMUNOL, V15, P512, DOI 10.1002/eji.1830150517; Dent AL, 1997, SCIENCE, V276, P589, DOI 10.1126/science.276.5312.589; Devergne O, 1996, MOL CELL BIOL, V16, P7098; Eliopoulos AG, 1999, J VIROL, V73, P1023, DOI 10.1128/JVI.73.2.1023-1035.1999; FUJITA T, 1992, GENE DEV, V6, P775, DOI 10.1101/gad.6.5.775; Futterer A, 1998, IMMUNITY, V9, P59, DOI 10.1016/S1074-7613(00)80588-9; GAUCHAT JF, 1992, J IMMUNOL, V148, P2291; GRAY D, 1988, IMMUNOLOGY, V65, P73; HAMMARSKJOLD ML, 1992, J VIROL, V66, P6496; Hanissian SH, 1997, IMMUNITY, V6, P379, DOI 10.1016/S1074-7613(00)80281-2; HSU HL, 1995, CELL, V81, P495, DOI 10.1016/0092-8674(95)90070-5; HU HM, 1994, J BIOL CHEM, V269, P30069; HURLEY EA, 1988, J EXP MED, V168, P2059, DOI 10.1084/jem.168.6.2059; Ishida T, 1996, J BIOL CHEM, V271, P28745, DOI 10.1074/jbc.271.46.28745; Ishida T, 1996, P NATL ACAD SCI USA, V93, P9437, DOI 10.1073/pnas.93.18.9437; IZURNI KM, 1997, P NATL ACAD SCI USA, V94, P12592; JABARA HH, 1990, J IMMUNOL, V145, P3468; JACOB J, 1991, J EXP MED, V173, P1165, DOI 10.1084/jem.173.5.1165; Kato J, 1998, J IMMUNOL, V160, P4788; KAWABE T, 1994, IMMUNITY, V1, P167, DOI 10.1016/1074-7613(94)90095-7; KAYE KM, 1993, P NATL ACAD SCI USA, V90, P9150, DOI 10.1073/pnas.90.19.9150; Kulwichit W, 1998, P NATL ACAD SCI USA, V95, P11963, DOI 10.1073/pnas.95.20.11963; LAHERTY CD, 1992, J BIOL CHEM, V267, P24157; LIEBOWITZ D, 1986, J VIROL, V58, P233, DOI 10.1128/JVI.58.1.233-237.1986; LIEBOWITZ D, 1987, MOL CELL BIOL, V7, P2299, DOI 10.1128/MCB.7.7.2299; LIEBOWITZ D, 1992, J VIROL, V66, P4612, DOI 10.1128/JVI.66.7.4612-4616.1992; MACLENNAN ICM, 1988, CURR TOP MICROBIOL, V141, P138; MARTIN J, 1991, CELL GROWTH DIFFER, V2, P653; Matsumoto M, 1996, NATURE, V382, P462, DOI 10.1038/382462a0; METLAY JP, 1990, J EXP MED, V171, P1753, DOI 10.1084/jem.171.5.1753; MIYASHITA EM, 1995, CELL, V80, P593, DOI 10.1016/0092-8674(95)90513-8; MOSIALOS G, 1995, CELL, V80, P389, DOI 10.1016/0092-8674(95)90489-1; NIEDOBITEK G, 1992, BLOOD, V79, P2520; RENSHAW BR, 1994, J EXP MED, V180, P1889, DOI 10.1084/jem.180.5.1889; RICKINSON AB, 1996, FIELDS VIROLOGY, P2397; ROBINSON JE, 1981, J EXP MED, V153, P235, DOI 10.1084/jem.153.2.235; ROTHE M, 1994, CELL, V78, P681, DOI 10.1016/0092-8674(94)90532-0; ROWE M, 1994, J VIROL, V68, P5602, DOI 10.1128/JVI.68.9.5602-5612.1994; Sandberg M, 1997, J VIROL, V71, P4649, DOI 10.1128/JVI.71.6.4649-4656.1997; SATO T, 1995, FEBS LETT, V358, P113, DOI 10.1016/0014-5793(94)01406-Q; SCHREIBER E, 1988, EMBO J, V7, P4221, DOI 10.1002/j.1460-2075.1988.tb03319.x; UCHIDA J, UNPUB; WANG D, 1985, CELL, V43, P831, DOI 10.1016/0092-8674(85)90256-9; XU JC, 1994, IMMUNITY, V1, P423, DOI 10.1016/1074-7613(94)90073-6	52	299	312	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 8	1999	286	5438					300	303		10.1126/science.286.5438.300	http://dx.doi.org/10.1126/science.286.5438.300			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	243YE	10514374				2022-12-01	WOS:000083024400046
J	Buchwitz, BJ; Ahmad, K; Moore, LL; Roth, MB; Henikoff, S				Buchwitz, BJ; Ahmad, K; Moore, LL; Roth, MB; Henikoff, S			Cell division - A histone-H3-like protein in C-elegans	NATURE			English	Article							CENP-A; CAENORHABDITIS-ELEGANS; CENTROMERE; HISTONE		Fred Hutchinson Canc Res Ctr, Div Basic Sci, Seattle, WA 98109 USA; Fred Hutchinson Canc Res Ctr, Mol & Cellular Biol Program, Seattle, WA 98109 USA; Fred Hutchinson Canc Res Ctr, Howard Hughes Med Inst, Seattle, WA 98109 USA	Fred Hutchinson Cancer Center; Fred Hutchinson Cancer Center; Fred Hutchinson Cancer Center; Howard Hughes Medical Institute	Buchwitz, BJ (corresponding author), Fred Hutchinson Canc Res Ctr, Div Basic Sci, 1100 Fairview Ave N, Seattle, WA 98109 USA.			Henikoff, Steven/0000-0002-7621-8685				ALBERTSON DG, 1982, CHROMOSOMA, V86, P409, DOI 10.1007/BF00292267; EARNSHAW WC, 1985, CHROMOSOMA, V91, P313, DOI 10.1007/BF00328227; Fire A, 1998, NATURE, V391, P806, DOI 10.1038/35888; Meluh PB, 1998, CELL, V94, P607, DOI 10.1016/S0092-8674(00)81602-5; PALMER DK, 1987, J CELL BIOL, V104, P805, DOI 10.1083/jcb.104.4.805; PALMER DK, 1991, P NATL ACAD SCI USA, V88, P3734, DOI 10.1073/pnas.88.9.3734; Riddle D. L, 1997, C ELEGANS, P47; STOLER S, 1995, GENE DEV, V9, P573, DOI 10.1101/gad.9.5.573; SULLIVAN KF, 1994, J CELL BIOL, V127, P581, DOI 10.1083/jcb.127.3.581; WILSON R, 1994, NATURE, V368, P32, DOI 10.1038/368032a0; ZINKOWSKI RP, 1991, J CELL BIOL, V113, P1091, DOI 10.1083/jcb.113.5.1091	11	202	208	0	8	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	OCT 7	1999	401	6753					547	548		10.1038/44062	http://dx.doi.org/10.1038/44062			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	244MG	10524621				2022-12-01	WOS:000083054900038
J	Zuniga, A; Haramis, APG; McMahon, AP; Zeller, R				Zuniga, A; Haramis, APG; McMahon, AP; Zeller, R			Signal relay by BMP antagonism controls the SHH/FGF4 feedback loop in vertebrate limb buds	NATURE			English	Article							APICAL ECTODERMAL RIDGE; DEVELOPING CHICK LIMB; SONIC HEDGEHOG; DEFORMITY GENE; PATTERN-FORMATION; PROTEINS; GROWTH; FGF-4; EXPRESSION; INDUCTION	Outgrowth and patterning of the vertebrate limb are controlled by reciprocal interactions between the posterior mesenchyme (polarizing region) and a specialized ectodermal structure, the apical ectodermal ridge (AER)(1). Sonic hedgehog (SHH) signalling by the polarizing region modulates fibroblast growth factor (FGF)4 signalling by the posterior AER, which in turn maintains the polarizing region (SHH/FGF4 feedback loop)(2,3). Here we report that the secreted bone-morphogenetic-protein (BMP) antagonist Gremlin(4) relays the SHH signal from the polarizing region to the AER. Mesenchymal Gremlin expression is lost in limb buds of mouse embryos homozygous for the limb deformity (Id) mutation, which disrupts establishment of the SHH/FGF4 feedback loop(5-7). Grafting Gremlin-expressing cells into Id mutant limb buds rescues Fgf4 expression and restores the SHH/FGF4 feedback loop. Analysis of Shh-null mutant embryos(8,9) reveals that SHH signalling is required for maintenance of Gremlin and Formin (the gene disrupted by the ld mutations)(10,11). In contrast, Formin, Gremlin and Fgf4 activation are independent of SHH signalling. This study uncovers the cascade by which the SHH signal is relayed from the posterior mesenchyme to the AER and establishes that Formin-dependent activation of the BMP antagonist Gremlin is sufficient to induce Fgf4 and establish the SHH/FGF4 feedback loop.	Univ Utrecht, Fac Biol, Dept Dev Biol, NL-3584 CH Utrecht, Netherlands; European Mol Biol Lab, D-69117 Heidelberg, Germany; Harvard Univ, Cambridge, MA 02138 USA	Utrecht University; European Molecular Biology Laboratory (EMBL); Harvard University	Zeller, R (corresponding author), Univ Utrecht, Fac Biol, Dept Dev Biol, Padualaan 8, NL-3584 CH Utrecht, Netherlands.	R.Zeller@bio.uu.nl	Zuniga, Aimée/AAG-7335-2020; McMahon, Andrew P/ABE-7520-2020; Zuniga, Aimée/Q-2692-2018; Zeller, Rolf/C-2610-2013	Zuniga, Aimée/0000-0002-9953-3637; Zuniga, Aimée/0000-0002-9953-3637; Zeller, Rolf/0000-0002-3186-7403				Brunet LJ, 1998, SCIENCE, V280, P1455, DOI 10.1126/science.280.5368.1455; CHAN DC, 1995, DEVELOPMENT, V121, P3151; Chiang C, 1996, NATURE, V383, P407, DOI 10.1038/383407a0; Cho KWY, 1998, CURR OPIN GENET DEV, V8, P443, DOI 10.1016/S0959-437X(98)80116-0; Duprez D, 1998, DEVELOPMENT, V125, P495; Duprez DM, 1996, DEVELOPMENT, V122, P1821; Fraidenraich D, 1998, DEV BIOL, V204, P197, DOI 10.1006/dbio.1998.9053; FRANCIS PH, 1994, DEVELOPMENT, V120, P209; Haramis AG, 1995, DEVELOPMENT, V121, P4237; Hofmann C, 1996, DEV GENET, V19, P43, DOI 10.1002/(SICI)1520-6408(1996)19:1&lt;43::AID-DVG5&gt;3.0.CO;2-0; Hsu DR, 1998, MOL CELL, V1, P673, DOI 10.1016/S1097-2765(00)80067-2; Ingham PW, 1998, EMBO J, V17, P3505, DOI 10.1093/emboj/17.13.3505; Johnson RL, 1997, CELL, V90, P979, DOI 10.1016/S0092-8674(00)80364-5; Kuhlman J, 1997, DEVELOPMENT, V124, P133; LAMB TM, 1993, SCIENCE, V262, P713, DOI 10.1126/science.8235591; LAUFER E, 1994, CELL, V79, P993, DOI 10.1016/0092-8674(94)90030-2; LUSSIER M, 1993, INT J DEV BIOL, V37, P555; MAAS RL, 1990, NATURE, V346, P853, DOI 10.1038/346853a0; Marigo V, 1996, DEV BIOL, V180, P273, DOI 10.1006/dbio.1996.0300; Marigo V, 1996, DEVELOPMENT, V122, P1225; McMahon JA, 1998, GENE DEV, V12, P1438, DOI 10.1101/gad.12.10.1438; Nellen D, 1996, CELL, V85, P357, DOI 10.1016/S0092-8674(00)81114-9; NISWANDER L, 1994, NATURE, V371, P609, DOI 10.1038/371609a0; NISWANDER L, 1993, NATURE, V361, P68, DOI 10.1038/361068a0; Pizette S, 1999, DEVELOPMENT, V126, P883; St-Jacques B, 1998, CURR BIOL, V8, P1058, DOI 10.1016/S0960-9822(98)70443-9; TRUMPP A, 1992, GENE DEV, V6, P14, DOI 10.1101/gad.6.1.14; WOYCHIK RP, 1990, NATURE, V346, P850, DOI 10.1038/346850a0; ZELLER R, 1989, GENE DEV, V3, P1481, DOI 10.1101/gad.3.10.1481; Zuniga A, 1999, DEVELOPMENT, V126, P13	30	364	368	1	20	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	OCT 7	1999	401	6753					598	602		10.1038/44157	http://dx.doi.org/10.1038/44157			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	244MG	10524628				2022-12-01	WOS:000083054900053
J	Young, LS				Young, LS			Epstein-Barr-virus infection and persistence: a B-cell marriage in sickness and in health	LANCET			English	Editorial Material							EBV PERSISTENCE; TUMORS		Univ Birmingham, Sch Med, CRC, Inst Canc Studies, Birmingham B15 2TA, W Midlands, England	University of Birmingham	Young, LS (corresponding author), Univ Birmingham, Sch Med, CRC, Inst Canc Studies, Birmingham B15 2TA, W Midlands, England.		Young, Lawrence S/B-7213-2009	Young, Lawrence S/0000-0003-3919-4298				ALLDAY MJ, 1988, LANCET, V1, P855; Babcock GJ, 1998, IMMUNITY, V9, P395, DOI 10.1016/S1074-7613(00)80622-6; Bonnet M, 1999, J NATL CANCER I, V91, P1376, DOI 10.1093/jnci/91.16.1376; Faulkner GC, 1999, J VIROL, V73, P1555, DOI 10.1128/JVI.73.2.1555-1564.1999; GREENSPAN JS, 1985, NEW ENGL J MED, V313, P1564, DOI 10.1056/NEJM198512193132502; NIEDOBITEK G, 1994, LANCET, V343, P333, DOI 10.1016/S0140-6736(94)91167-3; RICKINSON AB, 1996, FIELDS VIROLOGY, P2397; Rooney CM, 1998, BLOOD, V92, P1549, DOI 10.1182/blood.V92.5.1549.417k32_1549_1555; Sugawara Y, 1999, VIROLOGY, V256, P196, DOI 10.1006/viro.1999.9619	9	8	10	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	OCT 2	1999	354	9185					1141	1142		10.1016/S0140-6736(99)00237-8	http://dx.doi.org/10.1016/S0140-6736(99)00237-8			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	242QX	10513704				2022-12-01	WOS:000082954100006
J	Forster, R; Schubel, A; Breitfeld, D; Kremmer, E; Renner-Muller, I; Wolf, E; Lipp, M				Forster, R; Schubel, A; Breitfeld, D; Kremmer, E; Renner-Muller, I; Wolf, E; Lipp, M			CCR7 coordinates the primary immune response by establishing functional microenvironments in secondary lymphoid organs	CELL			English	Article							DENDRITIC CELL MATURATION; CHEMOKINE RECEPTOR; T-CELLS; MOLECULAR-CLONING; TISSUE CHEMOKINE; B-CELLS; LYMPHOCYTES; EXPRESSION; MEMORY; LIGAND	The proper function of immune surveillance requires well-coordinated mechanisms in order to guide the patrolling immune cells through peripheral tissues and into secondary lymphoid organs. Analyzing gene-targeted mice, we identified the chemokine receptor CCR7 as an important organizer of the primary immune response. CCR7-deficient mice show severely delayed kinetics regarding the antibody response and lack contact sensitivity and delayed type hypersensitivity reactions. Due to the impaired migration of lymphocytes, these animals reveal profound morphological alterations in all secondary lymphoid organs. Upon activation, mature skin dendritic cells fail to migrate into the draining lymph nodes. Thus, in order to bring together lymphocytes and dendritic cells to form the characteristic microarchitecture of secondary lymphoid organs, CCR7 is required to rapidly initiate an adoptive immune response.	Max Delbruck Ctr Mol Med, D-13092 Berlin, Germany; GSF, Res Ctr Environm & Hlth, Inst Mol Immunol, D-81377 Munich, Germany; Univ Munich, Inst Mol Anim Breeding, Gene Ctr, D-81377 Munich, Germany	Helmholtz Association; Max Delbruck Center for Molecular Medicine; Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health; University of Munich	Forster, R (corresponding author), Max Delbruck Ctr Mol Med, D-13092 Berlin, Germany.		Förster, Reinhold/D-6770-2011; Lipp, Martin/G-2235-2010	Forster, Reinhold/0000-0001-6190-7923; Wolf, Eckhard/0000-0002-0430-9510; Lipp, Martin/0000-0002-0087-2672				Baggiolini M, 1998, NATURE, V392, P565, DOI 10.1038/33340; BURGSTAHLER R, 1995, BIOCHEM BIOPH RES CO, V215, P737, DOI 10.1006/bbrc.1995.2525; Butcher EC, 1996, SCIENCE, V272, P60, DOI 10.1126/science.272.5258.60; Campbell JJ, 1998, J CELL BIOL, V141, P1053, DOI 10.1083/jcb.141.4.1053; Campbell JJ, 1998, SCIENCE, V279, P381, DOI 10.1126/science.279.5349.381; CAPECCHI MR, 1989, SCIENCE, V244, P1288, DOI 10.1126/science.2660260; Chaplin DD, 1998, CURR OPIN IMMUNOL, V10, P289, DOI 10.1016/S0952-7915(98)80167-2; Dieu MC, 1998, J EXP MED, V188, P373, DOI 10.1084/jem.188.2.373; Dutton RW, 1998, ANNU REV IMMUNOL, V16, P201, DOI 10.1146/annurev.immunol.16.1.201; FORSTER R, 1994, BLOOD, V84, P830; Forster R, 1996, CELL, V87, P1037, DOI 10.1016/S0092-8674(00)81798-5; Gunn MD, 1999, J EXP MED, V189, P451, DOI 10.1084/jem.189.3.451; Gunn MD, 1998, NATURE, V391, P799, DOI 10.1038/35876; Gunn MD, 1998, P NATL ACAD SCI USA, V95, P258, DOI 10.1073/pnas.95.1.258; HILL S, 1990, IMMUNOLOGY, V71, P277; Legler DF, 1998, J EXP MED, V187, P655, DOI 10.1084/jem.187.4.655; Liu YJ, 1997, J EXP MED, V186, P625, DOI 10.1084/jem.186.5.625; MACKAY CR, 1990, J EXP MED, V171, P801, DOI 10.1084/jem.171.3.801; Nagira M, 1997, J BIOL CHEM, V272, P19518, DOI 10.1074/jbc.272.31.19518; Nakano H, 1998, BLOOD, V91, P2886, DOI 10.1182/blood.V91.8.2886.2886_2886_2895; Ngo VN, 1999, J EXP MED, V189, P403, DOI 10.1084/jem.189.2.403; Ngo VN, 1998, J EXP MED, V188, P181, DOI 10.1084/jem.188.1.181; PICKER LJ, 1992, ANNU REV IMMUNOL, V10, P561, DOI 10.1146/annurev.immunol.10.1.561; Rollins BJ, 1997, BLOOD, V90, P909, DOI 10.1182/blood.V90.3.909.909_909_928; Sallusto F, 1998, EUR J IMMUNOL, V28, P2760, DOI 10.1002/(SICI)1521-4141(199809)28:09<2760::AID-IMMU2760>3.0.CO;2-N; SCHWEICKART VL, 1994, GENOMICS, V23, P643, DOI 10.1006/geno.1994.1553; Sozzani S, 1998, J IMMUNOL, V161, P1083; SPRINGER TA, 1994, CELL, V76, P301, DOI 10.1016/0092-8674(94)90337-9; Steinman RM, 1997, IMMUNOL REV, V156, P25, DOI 10.1111/j.1600-065X.1997.tb00956.x; Tanabe S, 1997, J IMMUNOL, V159, P5671; Willimann K, 1998, EUR J IMMUNOL, V28, P2025, DOI 10.1002/(SICI)1521-4141(199806)28:06<2025::AID-IMMU2025>3.0.CO;2-C; Yanagihara S, 1998, J IMMUNOL, V161, P3096; Yoshida R, 1998, J BIOL CHEM, V273, P7118, DOI 10.1074/jbc.273.12.7118; Yoshida R, 1997, J BIOL CHEM, V272, P13803, DOI 10.1074/jbc.272.21.13803	34	1801	1873	2	54	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	OCT 1	1999	99	1					23	33		10.1016/S0092-8674(00)80059-8	http://dx.doi.org/10.1016/S0092-8674(00)80059-8			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	243DK	10520991	Bronze			2022-12-01	WOS:000082981600005
J	Takahashi, JS				Takahashi, JS			Perspectives: Neurobiology - Narcolepsy genes wake up the sleep field	SCIENCE			English	Editorial Material							DEPRIVATION; NEURONS		Northwestern Univ, Dept Neurobiol & Physiol, Howard Hughes Med Inst, Evanston, IL 60208 USA	Howard Hughes Medical Institute; Northwestern University	Takahashi, JS (corresponding author), Northwestern Univ, Dept Neurobiol & Physiol, Howard Hughes Med Inst, 2153 N Campus Dr, Evanston, IL 60208 USA.	J-takahashi@nwu.edu	Takahashi, Joseph S./Y-2781-2019; Takahashi, Joseph S/E-8482-2012	Takahashi, Joseph S./0000-0003-0384-8878; Takahashi, Joseph S/0000-0003-0384-8878				Aldrich MS, 1998, NEUROLOGY, V50, pS2, DOI 10.1212/WNL.50.2_Suppl_1.S2; ASERINSKY E, 1953, SCIENCE, V118, P273, DOI 10.1126/science.118.3062.273; Chemelli RM, 1999, CELL, V98, P437, DOI 10.1016/S0092-8674(00)81973-X; Date Y, 1999, P NATL ACAD SCI USA, V96, P748, DOI 10.1073/pnas.96.2.748; De Lecea L, 1998, P NATL ACAD SCI USA, V95, P322, DOI 10.1073/pnas.95.1.322; Dement VV, 1994, PRINCIPLES PRACTICE, P3; DEMENT W, 1957, ELECTROEN CLIN NEURO, V9, P673, DOI 10.1016/0013-4694(57)90088-3; DEMENT WC, 1994, PRINCIPLES PRACTICES, P309; KUSHIDA CA, 1989, SLEEP, V12, P22, DOI 10.1093/sleep/12.1.22; Lin L, 1999, CELL, V98, P365, DOI 10.1016/S0092-8674(00)81965-0; Mignot E, 1998, NEUROLOGY, V50, pS16, DOI 10.1212/WNL.50.2_Suppl_1.S16; Nishino S, 1997, PROG NEUROBIOL, V52, P27, DOI 10.1016/S0301-0082(96)00070-6; Peyron C, 1998, J NEUROSCI, V18, P9996; RECHTSCHAFFEN A, 1983, SCIENCE, V221, P182, DOI 10.1126/science.6857280; Sakurai T, 1998, CELL, V92, P573, DOI 10.1016/S0092-8674(00)80949-6; Siegel JM, 1999, CELL, V98, P409, DOI 10.1016/S0092-8674(00)81969-8; van den Pol AN, 1998, J NEUROSCI, V18, P7962; van den Pol AN, 1999, J NEUROSCI, V19, P3171	18	11	11	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 24	1999	285	5436					2076	2077		10.1126/science.285.5436.2076	http://dx.doi.org/10.1126/science.285.5436.2076			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	238VF	10523205				2022-12-01	WOS:000082734300028
J	Huang, CC; Liu, CC; Chang, YC; Chen, CY; Wang, ST; Yeh, TF				Huang, CC; Liu, CC; Chang, YC; Chen, CY; Wang, ST; Yeh, TF			Neurologic complications in children with enterovirus 71 infection	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							BRAIN-STEM ENCEPHALITIS; CENTRAL NERVOUS-SYSTEM; MOUTH-DISEASE; POLIOMYELITIS; MRI; PARALYSIS; OUTBREAK; HAND; FOOT	Background Enterovirus 71 infection causes hand-foot-and-mouth disease in young children, which is characterized by several days of fever and vomiting, ulcerative lesions in the oral mucosa, and vesicles on the backs of the hands and feet. The initial illness resolves bur is sometimes followed by aseptic meningitis, encephalomyelitis, or even acute flaccid paralysis similar to paralytic poliomyelitis. Methods We describe the neurologic complications associated with the enterovirus 71 epidemic that occurred in Taiwan in 1998. At three major hospitals we identified 41 children with culture-confirmed entero; virus 71 infection and acute neurologic manifestations. Magnetic resonance imaging (MRI) was performed in 4 patients with acute flaccid paralysis and 24 with rhombencephalitis. Results The mean age of the patients was 2.5 years (range, 3 months to 8.2 years). Twenty-eight patients had hand-foot-and-mouth disease (68 percent), and six had herpangina (15 percent). The other seven patients had no skin or mucosal lesions. Three neurologic syndromes were identified: aseptic meningitis tin 3 patients); brain-stem encephalitis, or rhombencephalitis (in 37); and acute flaccid paralysis (in 4), which followed rhombencephalitis in 3 patients. In 20 patients with rhombencephalitis, the syndrome was characterized by myoclonic jerks and tremor, ataxia, or both (grade I disease). Ten patients had myoclonus and cranial-nerve involvement (grade II disease). In seven patients the brain-stem infection produced transient myoclonus followed by the rapid onset of respiratory distress, cyanosis, poor peripheral perfusion, shock, coma, loss of the doll's eye reflex, and apnea (grade III disease); five of these patients died within 12 hours after admission. In 17 of the 24 patients with rhombencephalitis who underwent MRI, T-2-weighted scans showed high-intensity lesions in the brain stem, most commonly in the pontine tegmentum. At follow-up, two of the patients with acute flaccid paralysis had residual limb weakness, and five of the patients with rhombencephalitis had persistent neurologic deficits, including myoclonus tin one child), cranial-nerve deficits (in two), and ventilator-dependent apnea (in two). Conclusions In the 1998 enterovirus 71 epidemic in Taiwan, the chief neurologic complication was rhombencephalitis, which had a fatality rare of 14 percent. The most common initial symptoms were myoclonic jerks, and MRI usually showed evidence of brainstem involvement. (N Engl J Med 1999;341:936-42.) (C) 1999, Massachusetts Medical Society.	Natl Cheng Kung Univ, Coll Med, Dept Pediat, Tainan 704, Taiwan; Natl Cheng Kung Univ, Coll Med, Dept Publ Hlth, Tainan 704, Taiwan; Chang Gung Childrens Hosp, Dept Pediat, Kaohsiung, Taiwan; Triserv Gen Hosp & Natl Def Med Ctr, Dept Radiol, Taipei, Taiwan	National Cheng Kung University; National Cheng Kung University; Chang Gung Memorial Hospital; National Defense Medical Center	Huang, CC (corresponding author), Natl Cheng Kung Univ, Coll Med, Dept Pediat, 138 Sheng Li Rd, Tainan 704, Taiwan.			Chen, Cheng-Yu/0000-0003-0428-4373; Huang, Chao-Ching/0000-0003-2799-7181				ALEXANDER JP, 1994, J INFECT DIS, V169, P905, DOI 10.1093/infdis/169.4.905; [Anonymous], 1998, MMWR MORB MORTAL WKL, V47, P629; ARMSTRONG RW, 1993, CLIN INFECT DIS, V16, P689, DOI 10.1093/clind/16.5.689; BICKERSTAFF ER, 1951, BMJ-BRIT MED J, V2, P77, DOI 10.1136/bmj.2.4723.77; BLOMBERG J, 1974, LANCET, V2, P112; Chang LY, 1998, LANCET, V352, P367, DOI 10.1016/S0140-6736(98)24031-1; CHONMAITREE T, 1981, PEDIATRICS, V67, P489; GELLER TJ, 1987, ANN NEUROL, V21, P602, DOI 10.1002/ana.410210614; GILBERT GL, 1988, PEDIATR INFECT DIS J, V7, P484, DOI 10.1097/00006454-198807000-00007; Hall W A, 1993, Neurosurg Clin N Am, V4, P543; HATTORI T, 1988, J NEUROL NEUROSUR PS, V51, P1572, DOI 10.1136/jnnp.51.12.1572; Hauw J J, 1986, Adv Neurol, V43, P201; HAYWARD JC, 1989, PEDIATR INFECT DIS J, V8, P611, DOI 10.1097/00006454-198909000-00009; HSIUNG GD, 1994, HSIUNGS DIAGNOSTIC V, P119; HURST DL, 1988, PEDIATR NEUROL, V4, P122, DOI 10.1016/0887-8994(88)90054-9; ISHIMARU Y, 1980, ARCH DIS CHILD, V55, P583, DOI 10.1136/adc.55.8.583; James D., 1998, TXB PEDIAT INFECT DI, P1787; Kornreich L, 1996, NEURORADIOLOGY, V38, P371; Lai YY, 1997, BRAIN RES, V745, P257, DOI 10.1016/S0006-8993(96)01177-8; Lam SK, 1998, EMERG INFECT DIS, V4, P145, DOI 10.3201/eid0402.980201; Landry ML, 1995, PEDIATR INFECT DIS J, V14, P1095, DOI 10.1097/00006454-199512000-00013; Lum LCS, 1998, J PEDIATR-US, V133, P795, DOI 10.1016/S0022-3476(98)70155-6; MALZBERG MS, 1993, AM J ROENTGENOL, V161, P863, DOI 10.2214/ajr.161.4.8372775; MELNICK JL, 1984, REV INFECT DIS, V6, pS387; PROTHEROE SM, 1991, ARCH DIS CHILD, V66, P702, DOI 10.1136/adc.66.6.702; Sakakibara R, 1998, J NEUROL NEUROSUR PS, V64, P269, DOI 10.1136/jnnp.64.2.269; SCHMIDT NJ, 1974, J INFECT DIS, V129, P304, DOI 10.1093/infdis/129.3.304; SHIAN WJ, 1994, PEDIATR RADIOL, V24, P596, DOI 10.1007/BF02012744; SHINDAROV LM, 1979, J HYG EPID MICROB IM, V23, P284; SVED AF, 1999, FUNDAMENTAL NEUROSCI, P1051; Takimoto S, 1998, T ROY SOC TROP MED H, V92, P25, DOI 10.1016/S0035-9203(98)90939-7; Tartaglino LM, 1996, RADIOLOGY, V201, P661, DOI 10.1148/radiology.201.3.8939212; WAKAMOTO H, 1992, PEDIATR RADIOL, V22, P533, DOI 10.1007/BF02013004; 1998, MMWR MORB MORTAL WKL, V47, P718	34	512	609	0	50	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	SEP 23	1999	341	13					936	942		10.1056/NEJM199909233411302	http://dx.doi.org/10.1056/NEJM199909233411302			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	237LP	10498488	Bronze			2022-12-01	WOS:000082658100002
J	Johnston, LA; Prober, DA; Edgar, BA; Eisenman, RN; Gallant, P				Johnston, LA; Prober, DA; Edgar, BA; Eisenman, RN; Gallant, P			Drosophila myc regulates cellular growth during development	CELL			English	Article							C-MYC; N-MYC; CYCLE PROGRESSION; DISC DEVELOPMENT; IN-VIVO; GENE; PROTEIN; TRANSCRIPTION; TARGET; CELLS	Transcription factors of the Myc proto-oncogene family promote cell division, but how they do this is poorly understood. Here we address the functions of Drosophila Myc (dMyc) during development. Using mosaic analysis in the fly wing, we show that loss of dMyc retards cellular growth (accumulation of cell mass) and reduces cell size, whereas dMyc overproduction increases growth rates and cell size, dMyc-induced growth promotes G1/S progression but fails to accelerate cell division because G2/M progression is independently controlled by Cdc25/String. We also show that the secreted signal Wingless patterns growth in the wing primordium by modulating dMyc expression. Our results indicate that dMyc links patterning signals to cell division by regulating primary targets involved in cellular growth and metabolism.	Fred Hutchinson Canc Res Ctr, Div Basic Sci, Seattle, WA 98109 USA	Fred Hutchinson Cancer Center	Eisenman, RN (corresponding author), Fred Hutchinson Canc Res Ctr, Div Basic Sci, Seattle, WA 98109 USA.		Johnston, Laura A/ABC-1945-2021	JOHNSTON, LAURA A/0000-0001-9477-7897	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM051186, F32GM017373] Funding Source: NIH RePORTER; NIGMS NIH HHS [F32 GM017373, R01 GM051186, F32 GM017373-03, F32 GM017373-04] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AMATI B, 1994, CURR OPIN GENET DEV, V4, P102, DOI 10.1016/0959-437X(94)90098-1; ARMELIN HA, 1984, NATURE, V310, P655, DOI 10.1038/310655a0; Ashburner M., 1989, DROSOPHILA LAB HDB; Blackwood EM, 1992, CURR OPIN GENET DEV, V2, P227, DOI 10.1016/S0959-437X(05)80278-3; Bohni R, 1999, CELL, V97, P865, DOI 10.1016/S0092-8674(00)80799-0; CHARRON J, 1992, GENE DEV, V6, P2248, DOI 10.1101/gad.6.12a.2248; Conlon I, 1999, CELL, V96, P235, DOI 10.1016/S0092-8674(00)80563-2; CRAIG RW, 1993, CELL GROWTH DIFFER, V4, P349; Dang CV, 1999, MOL CELL BIOL, V19, P1; DAVIS AC, 1993, GENE DEV, V7, P671, DOI 10.1101/gad.7.4.671; DOWNS KM, 1989, GENE DEV, V3, P860, DOI 10.1101/gad.3.6.860; EILERS M, 1991, EMBO J, V10, P133, DOI 10.1002/j.1460-2075.1991.tb07929.x; Galaktionov K, 1996, NATURE, V382, P511, DOI 10.1038/382511a0; Gallant P, 1996, SCIENCE, V274, P1523, DOI 10.1126/science.274.5292.1523; GARCIABELLIDO A, 1971, DEV BIOL, V24, P61, DOI 10.1016/0012-1606(71)90047-9; Grandori C, 1996, EMBO J, V15, P4344, DOI 10.1002/j.1460-2075.1996.tb00808.x; Grandori C, 1997, TRENDS BIOCHEM SCI, V22, P177, DOI 10.1016/S0968-0004(97)01025-6; HANN SR, 1985, NATURE, V314, P366, DOI 10.1038/314366a0; HAY BA, 1994, DEVELOPMENT, V120, P2121; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; HEIKKILA R, 1987, NATURE, V328, P445, DOI 10.1038/328445a0; Henriksson M, 1996, ADV CANCER RES, V68, P109, DOI 10.1016/S0065-230X(08)60353-X; Johnston LA, 1998, NATURE, V394, P82, DOI 10.1038/27925; KARN J, 1989, ONCOGENE, V4, P773; KELLY K, 1983, CELL, V35, P603, DOI 10.1016/0092-8674(83)90092-2; KESSLER DJ, 1992, J EXP MED, V176, P787, DOI 10.1084/jem.176.3.787; Lambert A, 1998, REPROD NUTR DEV, V38, P69, DOI 10.1051/rnd:19980106; Lehman DA, 1999, DEVELOPMENT, V126, P1793; Leone G, 1997, NATURE, V387, P422, DOI 10.1038/387422a0; LI LH, 1994, EMBO J, V13, P4070, DOI 10.1002/j.1460-2075.1994.tb06724.x; Mateyak MK, 1997, CELL GROWTH DIFFER, V8, P1039; McCabe J, 1997, GENET RES, V69, P61, DOI 10.1017/S0016672397002620; Milan M, 1996, P NATL ACAD SCI USA, V93, P640, DOI 10.1073/pnas.93.2.640; Milan M, 1996, P NATL ACAD SCI USA, V93, P11687, DOI 10.1073/pnas.93.21.11687; MOENS CB, 1992, GENE DEV, V6, P691, DOI 10.1101/gad.6.5.691; MORATA G, 1975, DEV BIOL, V42, P211, DOI 10.1016/0012-1606(75)90330-9; Neufeld TP, 1998, CELL, V93, P1183, DOI 10.1016/S0092-8674(00)81462-2; OBROCHTA DA, 1985, NATURE, V313, P138, DOI 10.1038/313138a0; PHILLIPS RG, 1993, DEVELOPMENT, V118, P427; Pignoni F, 1997, DEVELOPMENT, V124, P271; Polymenis M, 1999, CURR OPIN GENET DEV, V9, P76, DOI 10.1016/S0959-437X(99)80011-2; Raff MC, 1996, CELL, V86, P173, DOI 10.1016/S0092-8674(00)80087-2; ROUSSEL MF, 1991, NATURE, V353, P361, DOI 10.1038/353361a0; SAWAI S, 1993, DEVELOPMENT, V117, P1445; SchreiberAgus N, 1997, P NATL ACAD SCI USA, V94, P1235, DOI 10.1073/pnas.94.4.1235; SIMPSON P, 1981, DEV BIOL, V85, P299, DOI 10.1016/0012-1606(81)90261-X; SORRENTINO V, 1986, P NATL ACAD SCI USA, V83, P8167, DOI 10.1073/pnas.83.21.8167; STANTON BR, 1992, GENE DEV, V6, P2235, DOI 10.1101/gad.6.12a.2235; STERN DF, 1986, MOL CELL BIOL, V6, P870, DOI 10.1128/MCB.6.3.870; Stern DL, 1999, DEVELOPMENT, V126, P1091; STRUHL G, 1993, CELL, V72, P527, DOI 10.1016/0092-8674(93)90072-X; THOMAS BJ, 1994, CELL, V77, P1003, DOI 10.1016/0092-8674(94)90440-5; vandeWetering M, 1997, CELL, V88, P789, DOI 10.1016/S0092-8674(00)81925-X; WAKAMATSU Y, 1993, NEURON, V10, P1, DOI 10.1016/0896-6273(93)90236-K; XU T, 1993, DEVELOPMENT, V117, P1223; Zaffran S, 1998, DEVELOPMENT, V125, P3571; Zornig M, 1996, CURR BIOL, V6, P1553, DOI 10.1016/S0960-9822(02)70769-0	57	508	517	0	20	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	SEP 17	1999	98	6					779	790		10.1016/S0092-8674(00)81512-3	http://dx.doi.org/10.1016/S0092-8674(00)81512-3			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	237WH	10499795	Bronze, Green Accepted			2022-12-01	WOS:000082679200005
J	Stephenson, J				Stephenson, J			Shingles vaccine trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	News Item																			0	1	1	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 18	1999	282	7					625	625		10.1001/jama.282.7.625	http://dx.doi.org/10.1001/jama.282.7.625			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	226QY	10532854				2022-12-01	WOS:000082033700008
J	GOLOUBINOFF, P; CHRISTELLER, JT; GATENBY, AA; LORIMER, GH				GOLOUBINOFF, P; CHRISTELLER, JT; GATENBY, AA; LORIMER, GH			RECONSTITUTION OF ACTIVE DIMERIC RIBULOSE BISPHOSPHATE CARBOXYLASE FROM AN UNFOLDED STATE DEPENDS ON 2 CHAPERONIN PROTEINS AND MG-ATP	NATURE			English	Article									DUPONT CO,DEPT CENT RES & DEV,DIV MOLEC BIOL,EXPTL STN,WILMINGTON,DE 19880	DuPont			Christeller, John T/E-6904-2010	Goloubinoff, Pierre/0000-0002-4802-0807				ANDERSSON I, 1989, NATURE, V337, P229, DOI 10.1038/337229a0; BARRACLOUGH R, 1980, BIOCHIM BIOPHYS ACTA, V608, P19, DOI 10.1016/0005-2787(80)90129-X; BAUM J, 1989, BIOCHEMISTRY-US, V28, P7, DOI 10.1021/bi00427a002; BOCHKAREVA ES, 1988, NATURE, V336, P254, DOI 10.1038/336254a0; CHANDRASEKHAR GN, 1986, J BIOL CHEM, V261; CHAPMAN MS, 1987, NATURE, V329, P354, DOI 10.1038/329354a0; CHENG MY, 1989, NATURE, V337, P620, DOI 10.1038/337620a0; CHORY J, 1985, J BACTERIOL, V161, P307, DOI 10.1128/JB.161.1.307-313.1985; DOLGIKH DA, 1981, FEBS LETT, V136, P311, DOI 10.1016/0014-5793(81)80642-4; ELLIS RJ, 1988, PHOTOSYNTH RES, V16, P101, DOI 10.1007/BF00039488; ELLIS RJ, 1989, TRENDS BIOCHEM SCI, V14, P339, DOI 10.1016/0968-0004(89)90168-0; ELLIS RJ, 1989, BIOCHEM SOC SYMP, V55, P145; FISCHER G, 1984, BIOMED BIOCHIM ACTA, V43, P1101; FREEDMAN RB, 1989, CELL, V57, P1069, DOI 10.1016/0092-8674(89)90043-3; GATENBY AA, 1988, EMBO J, V7, P1307, DOI 10.1002/j.1460-2075.1988.tb02945.x; GEORGOPOULOS CP, 1973, J MOL BIOL, V76, P45, DOI 10.1016/0022-2836(73)90080-6; GOLOUBINOFF P, 1989, NATURE, V337, P44, DOI 10.1038/337044a0; HEMMINGSEN SM, 1988, NATURE, V333, P330, DOI 10.1038/333330a0; HENDRIX RW, 1979, J MOL BIOL, V129, P375, DOI 10.1016/0022-2836(79)90502-3; LANDRY SJ, 1989, J BIOL CHEM, V264, P9090; LANG K, 1987, NATURE, V329, P268, DOI 10.1038/329268a0; LARIMER FW, 1987, J BIOL CHEM, V262, P15327; LUBBEN TH, 1989, PLANT CELL, V1, P1223, DOI 10.1105/tpc.1.12.1223; MCMULLIN TW, 1988, MOL CELL BIOL, V8, P371, DOI 10.1128/MCB.8.1.371; MEHRA V, 1986, P NATL ACAD SCI USA, V83, P7013, DOI 10.1073/pnas.83.18.7013; MUSGROVE JE, 1986, PHILOS T ROY SOC B, V313, P419, DOI 10.1098/rstb.1986.0048; OHGUSHI M, 1983, FEBS LETT, V164, P21, DOI 10.1016/0014-5793(83)80010-6; OSTERMANN J, 1989, NATURE, V341, P125, DOI 10.1038/341125a0; PELHAM HRB, 1986, CELL, V46, P959, DOI 10.1016/0092-8674(86)90693-8; PICKETTS DJ, 1989, J BIOL CHEM, V264, P12001; PIERCE J, 1985, APPL ENVIRON MICROB, V49, P1094, DOI 10.1128/AEM.49.5.1094-1100.1985; PIERCE J, 1986, ARCH BIOCHEM BIOPHYS, V245, P483, DOI 10.1016/0003-9861(86)90241-9; PUSHKIN AV, 1982, BIOCHIM BIOPHYS ACTA, V704, P379, DOI 10.1016/0167-4838(82)90169-8; READING DS, 1989, NATURE, V337, P655, DOI 10.1038/337655a0; ROY H, 1982, J CELL BIOL, V94, P20, DOI 10.1083/jcb.94.1.20; ROY H, 1988, BIOCHIM BIOPHYS ACTA, V957, P323, DOI 10.1016/0167-4838(88)90221-X; SCHNEIDER G, 1986, EMBO J, V5, P3409, DOI 10.1002/j.1460-2075.1986.tb04662.x; STERNBERG N, 1973, J MOL BIOL, V76, P25, DOI 10.1016/0022-2836(73)90079-X; TABITA FR, 1974, J BIOL CHEM, V249, P3459; TILLY K, 1981, P NATL ACAD SCI-BIOL, V78, P1629, DOI 10.1073/pnas.78.3.1629; TORRESRUIZ JA, 1988, ARCH BIOCHEM BIOPHYS, V261, P196, DOI 10.1016/0003-9861(88)90118-X; VODKIN MH, 1988, J BACTERIOL, V170, P1227, DOI 10.1128/jb.170.3.1227-1234.1988	42	646	660	0	22	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	DEC 21	1989	342	6252					884	889		10.1038/342884a0	http://dx.doi.org/10.1038/342884a0			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CF637	10532860				2022-12-01	WOS:A1989CF63700049
J	Matsumoto, I; Staub, A; Benoist, C; Mathis, D				Matsumoto, I; Staub, A; Benoist, C; Mathis, D			Arthritis provoked by linked T and B cell recognition of a glycolytic enzyme	SCIENCE			English	Article							RHEUMATOID-ARTHRITIS; AUTOIMMUNITY; COLLAGEN; MODEL	The hallmark of rheumatoid arthritis (RA) is specific destruction of the synovial joints. In a mouse line that spontaneously develops a disorder with many of the features of human RA, disease is initiated by T cell recognition of a ubiquitously expressed self-antigen; once initiated, pathology is driven almost entirely by immunoglobulins. In this study, the target of both the initiating T cells and pathogenic immunoglobulins was identified as glucose-6-phosphate isomerase, a glycolytic enzyme, Thus, some forms of RA or related arthritides may develop by a mechanism fundamentally different from the currently popular paradigm of a joint-specific T cell response.	ULP, INSERM, CNRS, Inst Genet & Biol Mol & Cellulaire, F-67404 Illkirch, CU Strasbourg, France	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg	Benoist, C (corresponding author), Harvard Univ, Sch Med, Joslin Diabet Ctr, 1 Joslin Pl, Boston, MA 02215 USA.							Amigorena S, 1998, CURR OPIN IMMUNOL, V10, P88, DOI 10.1016/S0952-7915(98)80037-X; Burmester GR, 1997, ARTHRITIS RHEUM, V40, P5, DOI 10.1002/art.1780400104; Feldmann M, 1996, CELL, V85, P307, DOI 10.1016/S0092-8674(00)81109-5; Fox DA, 1997, ARTHRITIS RHEUM, V40, P598, DOI 10.1002/art.1780400403; HALLBOOK F, 1989, J NEUROSCI RES, V23, P142, DOI 10.1002/jnr.490230204; Kalden JR, 1998, ARTHRITIS RHEUM, V41, P191, DOI 10.1002/1529-0131(199802)41:2<191::AID-ART2>3.3.CO;2-3; KEFFER J, 1991, EMBO J, V10, P4025, DOI 10.1002/j.1460-2075.1991.tb04978.x; Korganow AS, 1999, IMMUNITY, V10, P451, DOI 10.1016/S1074-7613(00)80045-X; Kouskoff V, 1996, CELL, V87, P811, DOI 10.1016/S0092-8674(00)81989-3; MANGIALAIO S, IN PRESS ARTHRITIS R; MATSUMOTO I, UNPUB; NAPORSTECK Y, 1993, ANNU REV IMMUNOL, V11, P79; NERI B, 1983, ONCOLOGY, V40, P332, DOI 10.1159/000225756; OHNO O, 1978, ARTHRITIS RHEUM, V21, P516, DOI 10.1002/art.1780210505; PECCOUD J, 1990, EMBO J, V9, P4215, DOI 10.1002/j.1460-2075.1990.tb07869.x; Thomas R, 1996, ARTHRITIS RHEUM, V39, P183, DOI 10.1002/art.1780390202; TRENTHAM DE, 1977, J EXP MED, V146, P857, DOI 10.1084/jem.146.3.857; WARNER CM, 1985, GERONTOLOGY, V31, P315, DOI 10.1159/000212715; WEST JD, 1990, GENET RES, V56, P223, DOI 10.1017/S0016672300035321; Zvaifler N J, 1973, Adv Immunol, V16, P265, DOI 10.1016/S0065-2776(08)60299-0	20	461	487	0	19	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 26	1999	286	5445					1732	1735		10.1126/science.286.5445.1732	http://dx.doi.org/10.1126/science.286.5445.1732			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	259UK	10576739				2022-12-01	WOS:000083912200037
J	Knight, SJL; Regan, R; Nicod, A; Horsley, SW; Kearney, L; Homfray, T; Winter, RM; Bolton, P; Flint, J				Knight, SJL; Regan, R; Nicod, A; Horsley, SW; Kearney, L; Homfray, T; Winter, RM; Bolton, P; Flint, J			Subtle chromosomal rearrangements in children with unexplained mental retardation	LANCET			English	Article							WOLF-HIRSCHHORN-SYNDROME; FRAGILE-X-SYNDROME; MOLECULAR CHARACTERIZATION; TRANSLOCATION; HYBRIDIZATION; RECURRENCE; TELOMERES; DELETIONS; ETIOLOGY; BORN	Background No explanation for moderate to severe mental retardation is apparent in about 40% of cases. Although small chromosomal rearrangements may account for some undiagnosed cases, a lack of genome-wide screening methods has made it impossible to ascertain the frequency of such abnormalities. Methods A fluorescence in-situ hybridisation (FISH) test was used to examine the integrity of chromosome ends in 284 children with unexplained moderate to severe retardation, and in 182 children with unexplained mild retardation. 75 normal men were also tested. When a chromosomal rearrangement was found, its size was estimated, and members of the child's family were investigated. Findings Subtle chromosomal abnormalities occurred with a frequency of 7.4% in the children with moderate to severe mental retardation, and of 0.5% in the children with mild retardation. The abnormalities had an estimated population prevalence of 2.1 per 10000, and were familial in almost half of cases. Interpretation Once recognisable syndromes have been excluded, abnormalities that include the ends of chromosomes are the commonest cause of mental retardation in children with undiagnosed moderate to severe mental retardation. Owing to the high prevalence of familial cases, screening for subtle chromosomal rearrangements is warranted in children with unexplained moderate to severe mental retardation.	John Radcliffe Hosp, Inst Mol Med, Mol Hematol Unit, Oxford OX3 9DS, England; Univ London, Inst Child Hlth, Mothercare Unit Paediat Genet & Fetal Med, London WC1N 1EH, England; Univ Cambridge, Dept Psychiat, Dev Psychiat Sect, Cambridge, England; Univ London St Georges Hosp, Dept Genet, London, England	University of Oxford; University of London; University College London; University of Cambridge; St Georges University London	Flint, J (corresponding author), John Radcliffe Hosp, Inst Mol Med, Mol Hematol Unit, Oxford OX3 9DS, England.			Flint, Jonathan/0000-0002-9427-4429; Knight, Samantha/0000-0002-6047-3462	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ALTHERR MR, 1991, AM J HUM GENET, V49, P1235; Altherr MR, 1997, AM J MED GENET, V71, P47, DOI 10.1002/(SICI)1096-8628(19970711)71:1<47::AID-AJMG9>3.0.CO;2-N; Birch HG, 1970, MENTAL SUBNORMALITY; Broman S., 1987, RETARDATION YOUNG CH; Buckle VJ, 1993, HUMAN GENETIC DISEAS, P59; BUNDEY S, 1989, J MED GENET, V26, P260, DOI 10.1136/jmg.26.4.260; CASSIMAN JJ, 1975, HUMANGENETIK, V28, P43, DOI 10.1007/BF00272481; CURTIS A, 1991, AM J HUM GENET, V49, P299; Dib C, 1996, NATURE, V380, P152, DOI 10.1038/380152a0; EINFELD SL, 1984, J MENT DEFIC RES, V28, P129; ELWOOD JH, 1981, J MENT DEFIC RES, V25, P147; FLINT J, 1995, NAT GENET, V9, P132, DOI 10.1038/ng0295-132; Giraudeau F, 1997, J MED GENET, V34, P314, DOI 10.1136/jmg.34.4.314; GOODSHIP J, 1992, J MED GENET, V29, P451; GRAHAM SM, 1993, J PAEDIATR CHILD H, V29, P360, DOI 10.1111/j.1440-1754.1993.tb00535.x; GRIPENBERG U, 1980, HEREDITAS, V92, P223; GUSTAVSON KH, 1977, NEUROPADIATRIE, V8, P293, DOI 10.1055/s-0028-1091525; JACOBS PA, 1993, J MED GENET, V30, P454, DOI 10.1136/jmg.30.6.454; JACOBS PA, 1978, CLIN GENET, V13, P37; Knight SJL, 1997, EUR J HUM GENET, V5, P1; LAMB J, 1989, LANCET, V2, P819; LAMONT MA, 1988, ARCH DIS CHILD, V63, P1032, DOI 10.1136/adc.63.9.1032; Law CJ, 1998, J MED GENET, V35, P685, DOI 10.1136/jmg.35.8.685; LAXOVA R, 1977, AM J MED GENET, V1, P75, DOI 10.1002/ajmg.1320010109; MCDONALD AD, 1973, AM J MENT DEF, V78, P205; Morton JE, 1997, J MED GENET, V34, P1, DOI 10.1136/jmg.34.1.1; Moser HW, 1971, NERVOUS SYSTEM, P117; NESSLINGER NJ, 1994, AM J HUM GENET, V54, P464; Ning Y, 1996, NAT GENET, V14, P86, DOI 10.1038/ng0996-86; Opitz J M, 1978, Birth Defects Orig Artic Ser, V14, P1; Rosenberg M, 1997, GENOME RES, V7, P917, DOI 10.1101/gr.7.9.917; Rutter Michael, 1970, ED HLTH BEHAV; Sambrook J., 1989, MOL CLONING LAB MANU; SLANEY SF, 1995, ARCH DIS CHILD, V72, P33, DOI 10.1136/adc.72.1.33; Strathdee G, 1997, AM J HUM GENET, V60, P860; SUTHERLAND GR, 1976, HUM GENET, V36, P231	36	354	417	0	5	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	NOV 13	1999	354	9191					1676	1681		10.1016/S0140-6736(99)03070-6	http://dx.doi.org/10.1016/S0140-6736(99)03070-6			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	255CW	10568569				2022-12-01	WOS:000083652800010
J	Chiba, Y; Ishikawa, M; Kijima, F; Tyson, RH; Kim, J; Yamamoto, A; Nambara, E; Leustek, T; Wallsgrove, RM; Naito, S				Chiba, Y; Ishikawa, M; Kijima, F; Tyson, RH; Kim, J; Yamamoto, A; Nambara, E; Leustek, T; Wallsgrove, RM; Naito, S			Evidence for autoregulation of cystathionine gamma-synthase mRNA stability in Arabidopsis	SCIENCE			English	Article							STORAGE PROTEIN GENE; METHIONINE BIOSYNTHESIS; THALIANA MUTANT; MOSAIC-VIRUS; GUS FUSIONS; EXPRESSION; PLANTS; MULTIPLICATION; PROTOPLASTS; PROMOTER	Control of messenger RNA (mRNA) stability serves as an important mechanism, for regulating gene expression. Analysis of Arabidopsis mutants that overaccumulate soluble methionine (Met) revealed that the gene for cystathionine gamma-synthase (CCS), the key enzyme in Met biosynthesis, is regulated at the Level of mRNA stability, Transfection experiments with wild-type and mutant forms of the CCS gene suggest that an amino acid sequence encoded by the first exon of CCS acts in cis to destabilize its own mRNA in a process that is activated by Met or one of its metabolites.	Hokkaido Univ, Grad Sch Agr, Div Appl Biosci, Sapporo, Hokkaido 0608589, Japan; AFRC, Inst Arable Crops Res, Dept Biochem & Physiol, Harpenden AL5 2JQ, Herts, England; Rutgers State Univ, Biotechnol Ctr Agr & Environm, New Brunswick, NJ 08901 USA	Hokkaido University; UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); Rothamsted Research; Rutgers State University New Brunswick	Naito, S (corresponding author), Hokkaido Univ, Grad Sch Agr, Div Appl Biosci, Sapporo, Hokkaido 0608589, Japan.	naito@abs.agr.hokudai.ac.jp	Nambara, Eiji/E-5533-2012; Chiba, Yukako/AAA-9238-2019; Chiba, Yukako/B-7057-2009	Chiba, Yukako/0000-0002-7329-2775				ARNDT KT, 1987, SCIENCE, V237, P874, DOI 10.1126/science.3303332; BELL CJ, 1994, GENOMICS, V19, P137, DOI 10.1006/geno.1994.1023; CHIBA Y, UNPUB; DATKO AH, 1978, PLANT PHYSIOL, V62, P629, DOI 10.1104/pp.62.4.629; FUJIWARA T, 1991, PLANT CELL REP, V9, P602, DOI 10.1007/BF00231797; GIOVANELLI J, 1990, SULFUR NUTRITION AND SULFUR ASSIMILATION IN HIGHER PLANTS, P33; GUZMAN P, 1988, NUCLEIC ACIDS RES, V16, P11091, DOI 10.1093/nar/16.23.11091; HIRAI MY, 1994, PLANT CELL PHYSIOL, V35, P927; INABA K, 1994, PLANT PHYSIOL, V104, P881, DOI 10.1104/pp.104.3.881; ISHIKAWA M, 1993, J VIROL, V67, P5328, DOI 10.1128/JVI.67.9.5328-5338.1993; JEFFERSON RA, 1987, EMBO J, V6, P3901; Kim J., 1999, Plant Physiology, V120, P635; Kim JS, 1996, PLANT MOL BIOL, V32, P1117, DOI 10.1007/BF00041395; LAST RL, 1988, SCIENCE, V240, P305, DOI 10.1126/science.240.4850.305; LEGUEN L, 1994, MOL GEN GENET, V245, P390, DOI 10.1007/BF00290120; Matthews BF, 1999, BOOK SOIL P, P205; NAITO S, 1994, PLANT PHYSIOL, V104, P497, DOI 10.1104/pp.104.2.497; NEWMAN TC, 1993, PLANT CELL, V5, P701, DOI 10.1105/tpc.5.6.701; Ravanel S, 1998, BIOCHEM J, V331, P639, DOI 10.1042/bj3310639; Ravanel S, 1998, P NATL ACAD SCI USA, V95, P7805, DOI 10.1073/pnas.95.13.7805; Rogers EE, 1997, PLANT CELL, V9, P305, DOI 10.1105/tpc.9.3.305; ROGNES SE, 1986, PLANT SCI, V43, P45, DOI 10.1016/0168-9452(86)90106-8; Rose AB, 1997, PLANT J, V11, P455, DOI 10.1046/j.1365-313X.1997.11030455.x; SAKATA Y, 1994, BIOSCI BIOTECH BIOCH, V58, P2104, DOI 10.1271/bbb.58.2104; Sambrook J., 1989, MOL CLONING LAB MANU, V3; THOMPSON GA, 1982, PLANT PHYSIOL, V69, P1077, DOI 10.1104/pp.69.5.1077; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; WALLSGROVE RM, 1983, PLANT PHYSIOL, V71, P780, DOI 10.1104/pp.71.4.780; YANOFSKY C, 1981, NATURE, V289, P751, DOI 10.1038/289751a0; YEN TJ, 1988, NATURE, V334, P580, DOI 10.1038/334580a0; Yoshii M, 1998, J VIROL, V72, P8731, DOI 10.1128/JVI.72.11.8731-8737.1998	31	145	156	1	13	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 12	1999	286	5443					1371	1374		10.1126/science.286.5443.1371	http://dx.doi.org/10.1126/science.286.5443.1371			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	255NF	10558994				2022-12-01	WOS:000083675500046
J	Deshpande, G; Calhoun, G; Yanowitz, JL; Schedl, PD				Deshpande, G; Calhoun, G; Yanowitz, JL; Schedl, PD			Novel functions of nanos in downregulating mitosis and transcription during the development of the Drosophila germline	CELL			English	Article							POSTERIOR MORPHOGEN NANOS; SYNCYTIAL EMBRYOS; SEX DETERMINATION; CELL-DEVELOPMENT; GENE-EXPRESSION; BODY PATTERN; OSKAR; POLE; MIGRATION; RNA	It has previously been shown that germ cells in embryos derived from nos mutant mothers do not migrate to the primitive gonad and prematurely express several germline-specific markers. In the studies reported here, we have traced these defects back to the syncytial blastoderm stage. We show that pole cells in nos(-) embryos fail to establish/maintain transcriptional quiescence; the sex determination gene Sex-lethal (Sxl) and the segmentation genes fushi tarazu and even-skipped are ectopically activated in nos- germ cells. We show that nos- germ cells are unable to attenuate the cell cycle and instead continue dividing. Unexpectedly, removal of the Sxl gene in the zygote mitigates both the migration and mitotic defects of nos(-) germ cells. Supporting the conclusion that Sri is an important target for nos repression, ectopic, premature expression of Sxl protein in germ cells disrupts migration and stimulates mitotic activity.	Princeton Univ, Dept Mol Biol, Princeton, NJ 08544 USA	Princeton University	Deshpande, G (corresponding author), Princeton Univ, Dept Mol Biol, Princeton, NJ 08544 USA.		Yanowitz, Judith L/AGJ-8504-2022	Yanowitz, Judith L/0000-0001-6886-8787				Asaoka M, 1998, MECH DEVELOP, V78, P153, DOI 10.1016/S0925-4773(98)00164-6; Batchelder C, 1999, GENE DEV, V13, P202, DOI 10.1101/gad.13.2.202; BOPP D, 1991, GENE DEV, V5, P403, DOI 10.1101/gad.5.3.403; CHOU TB, 1992, GENETICS, V131, P643; Cline TW, 1996, ANNU REV GENET, V30, P637, DOI 10.1146/annurev.genet.30.1.637; DAHMUS ME, 1996, J BIOL CHEM, V265, P19185; DALBY B, 1992, DEVELOPMENT, V115, P989; DESHPANDE G, 1995, MOL CELL BIOL, V15, P4430; Edgar BA, 1996, SCIENCE, V274, P1646, DOI 10.1126/science.274.5293.1646; EPHRUSSI A, 1991, CELL, V66, P37, DOI 10.1016/0092-8674(91)90137-N; EPHRUSSI A, 1992, NATURE, V358, P387, DOI 10.1038/358387a0; FOE VE, 1983, J CELL SCI, V61, P31; Forbes A, 1998, DEVELOPMENT, V125, P679; HAY B, 1988, DEVELOPMENT, V103, P625; HAY B, 1990, CELL, V18, P577; HULSKAMP M, 1989, NATURE, V338, P629, DOI 10.1038/338629a0; ILMENSEE K, 1976, DEV BIOL, V49, P40; IRISH V, 1989, NATURE, V338, P646, DOI 10.1038/338646a0; JAGLARZ MK, 1995, DEVELOPMENT, V121, P3495; KEYES LN, 1992, CELL, V68, P933, DOI 10.1016/0092-8674(92)90036-C; KIMHA J, 1991, CELL, V66, P23, DOI 10.1016/0092-8674(91)90136-M; Kobayashi S, 1996, NATURE, V380, P708, DOI 10.1038/380708a0; LASKO PF, 1990, GENE DEV, V4, P905, DOI 10.1101/gad.4.6.905; Lehmann Ruth, 1995, Seminars in Developmental Biology, V6, P25, DOI 10.1016/S1044-5781(06)80082-4; Lindsley D.L., 1992, GENOME DROSOPHILA ME; Seydoux G, 1997, DEVELOPMENT, V124, P2191; Seydoux G, 1996, NATURE, V382, P713, DOI 10.1038/382713a0; SMITH JL, 1992, CELL, V70, P849, DOI 10.1016/0092-8674(92)90318-7; STRUHL G, 1989, NATURE, V338, P741, DOI 10.1038/338741a0; Su TT, 1998, DEV BIOL, V196, P160, DOI 10.1006/dbio.1998.8855; Su TT, 1998, GENE DEV, V12, P1495, DOI 10.1101/gad.12.10.1495; Van Doren M, 1998, CURR BIOL, V8, P243; WARRIOR R, 1994, DEV BIOL, V166, P180, DOI 10.1006/dbio.1994.1306; Wei Y, 1998, TRENDS CELL BIOL, V8, P266; WHARTON RP, 1991, CELL, V67, P955, DOI 10.1016/0092-8674(91)90368-9; Williamson A, 1996, ANNU REV CELL DEV BI, V12, P365, DOI 10.1146/annurev.cellbio.12.1.365; ZALOKAR M, 1976, J MICROSC BIOL CELL, V25, P97	37	123	130	0	5	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	OCT 29	1999	99	3					271	281		10.1016/S0092-8674(00)81658-X	http://dx.doi.org/10.1016/S0092-8674(00)81658-X			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	251HX	10555143	Bronze			2022-12-01	WOS:000083440600005
J	Mayer, TU; Kapoor, TM; Haggarty, SJ; King, RW; Schreiber, SL; Mitchison, TJ				Mayer, TU; Kapoor, TM; Haggarty, SJ; King, RW; Schreiber, SL; Mitchison, TJ			Small molecule inhibitor of mitotic spindle bipolarity identified in a phenotype-based screen	SCIENCE			English	Article							MICROTUBULE MOTOR; KINESIN MOTORS; PROTEINS; CELLS	Small molecules that perturb specific protein functions are valuable tools for dissecting complex processes in mammalian cells. A combination of two phenotype-based screens, one based on a specific posttranslational modification, the other visualizing microtubules and chromatin, was used to identify compounds that affect mitosis. One compound, here named monastrol, arrested mammalian cells in mitosis with monopolar spindles. In vitro, monastrol specifically inhibited the motility of the mitotic kinesin Eg5, a motor protein required for spindle bipolarity. All previously known small molecules that specifically affect the mitotic machinery target tubulin. Monastrol will therefore be a particularly useful tool for studying mitotic mechanisms.	Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Inst Chem & Cell Biol, Boston, MA 02115 USA; Harvard Univ, Howard Hughes Med Inst, Dept Chem & Biol Chem, Cambridge, MA 02138 USA; Harvard Univ, Dept Mol & Cellular Biol, Cambridge, MA 02138 USA	Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Howard Hughes Medical Institute; Harvard University	Mayer, TU (corresponding author), Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02115 USA.		Haggarty, Stephen J/M-9495-2016	Haggarty, Stephen J/0000-0002-7872-168X; Mayer, Thomas/0000-0001-6954-2287	NCI NIH HHS [CA78048] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA078048] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Anderson HJ, 1998, EXP CELL RES, V238, P498, DOI 10.1006/excr.1997.3862; Blangy A, 1995, CELL, V83, P1159, DOI 10.1016/0092-8674(95)90142-6; CRAMER LP, 1994, CURR OPIN CELL BIOL, V6, P82, DOI 10.1016/0955-0674(94)90120-1; Desai A, 1999, CELL, V96, P69, DOI 10.1016/S0092-8674(00)80960-5; ENOS AP, 1990, CELL, V60, P1019, DOI 10.1016/0092-8674(90)90350-N; HAGGARTY SJ, UNPUB; Hamel E, 1996, MED RES REV, V16, P207, DOI 10.1002/(SICI)1098-1128(199603)16:2<207::AID-MED4>3.3.CO;2-I; Hirokawa N, 1998, SCIENCE, V279, P519, DOI 10.1126/science.279.5350.519; Jordan MA, 1998, METHOD ENZYMOL, V298, P252, DOI 10.1016/S0076-6879(98)98024-7; Kapoor TM, 1999, P NATL ACAD SCI USA, V96, P9106, DOI 10.1073/pnas.96.16.9106; Lewandowski K, 1999, J COMB CHEM, V1, P105, DOI 10.1021/cc980014p; Mitchison TJ, 1994, CHEM BIOL, V1, P3, DOI 10.1016/1074-5521(94)90034-5; RIEDER CL, 1986, J CELL BIOL, V103, P581, DOI 10.1083/jcb.103.2.581; Sakowicz R, 1998, SCIENCE, V280, P292, DOI 10.1126/science.280.5361.292; SAWIN KE, 1992, NATURE, V359, P540, DOI 10.1038/359540a0; SAXTON WM, 1994, METHOD CELL BIOL, V44, P279, DOI 10.1016/S0091-679X(08)60919-X; Schreiber SL, 1998, BIOORGAN MED CHEM, V6, P1127, DOI 10.1016/S0968-0896(98)00126-6; Stockwell BR, 1999, CHEM BIOL, V6, P71, DOI 10.1016/S1074-5521(99)80004-0; Vale RD, 1997, ANNU REV CELL DEV BI, V13, P745, DOI 10.1146/annurev.cellbio.13.1.745; Walczak CE, 1998, CURR BIOL, V8, P903, DOI 10.1016/S0960-9822(07)00370-3	20	1531	1653	2	128	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	OCT 29	1999	286	5441					971	974		10.1126/science.286.5441.971	http://dx.doi.org/10.1126/science.286.5441.971			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	250BE	10542155	Green Submitted			2022-12-01	WOS:000083368500050
J	Must, A; Spadano, J; Coakley, EH; Field, AE; Colditz, G; Dietz, WH				Must, A; Spadano, J; Coakley, EH; Field, AE; Colditz, G; Dietz, WH			The disease burden associated with overweight and obesity	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article; Proceedings Paper	North-American-Association-for-the-Study-of-Obesity Meeting	NOV 10, 1997	CANCUN, MEXICO	N Amer Assoc Study Obesity			BODY-MASS INDEX; CORONARY HEART-DISEASE; FAT DISTRIBUTION; WOMEN; MORTALITY; RISK; PREVALENCE; WEIGHT; POPULATION; PREDICTORS	Context Overweight and obesity are increasing dramatically in the United States and most likely contribute substantially to the burden of chronic health conditions. Objective To describe the relationship between weight status and prevalence of health conditions by severity of overweight and obesity in the US population. Design and Setting Nationally representative cross-sectional survey using data from the Third National Health and Nutrition Examination Survey (NHANES III), which was conducted in 2 phases from 1988 to 1994. Participants A total of 16 884 adults, 25 years and older, classified as overweight and obese (body mass index [BMI] greater than or equal to 25 kg/m(2)) based on National Institutes of Health recommended guidelines. Main Outcome Measures Prevalence of type 2 diabetes mellitus, gallbladder disease, coronary heart disease, high blood cholesterol level, high blood pressure, or osteoarthritis, Results Sixty-three percent of men and 55% of women had a body mass index of 25 kg/m(2) or greater. A graded increase in the prevalence ratio (PR) was observed with increasing severity of overweight and obesity for all of the health outcomes except for coronary heart disease in men and high blood cholesterol level in both men and women. With normal-weight individuals as the reference, for individuals with BMIs of at least 40 kg/m(2) and who were younger than 55 years, PRs were highest for type 2 diabetes for men (PR, 18.1; 95% confidence interval [CI], 6.7-46.8) and women (PR, 12.9; 95% CI, 5.7-28.1) and gallbladder disease for men (PR, 21.1; 95% CI, 4.1-84.2) and women (PR, 5.2; 95% CI, 2.9-8.9). Prevalence ratios generally were greater in younger than in older adults. The prevalence of having 2 or more health conditions increased with weight status category across all racial and ethnic subgroups. Conclusions Based on these results, more than half of all US adults are considered overweight or obese. The prevalence of obesity-related comorbidities emphasizes the need for concerted efforts to prevent and treat obesity rather than just its associated comorbidities.	Tufts Univ, Sch Med, Dept Family Med & Community Hlth, Boston, MA 02111 USA; Tufts Univ, USDA, Human Nutr Res Ctr, Medford, MA 02155 USA; Harvard Univ, Sch Publ Hlth, Dept Nutr, Cambridge, MA 02138 USA; Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Cambridge, MA 02138 USA; Brigham & Womens Hosp, Channing Lab, Boston, MA 02115 USA; Harvard Univ, Sch Med, Cambridge, MA 02138 USA; Tufts Univ New England Med Ctr, Dept Pediat Gastroenterol & Nutr, Boston, MA USA; Ctr Dis Control & Prevent, Ctr Dis Prevent & Hlth Promot, Div Nutr & Phys Activ, Atlanta, GA USA	Tufts University; Tufts University; United States Department of Agriculture (USDA); Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Brigham & Women's Hospital; Harvard University; Tufts Medical Center; Centers for Disease Control & Prevention - USA	Must, A (corresponding author), Tufts Univ, Sch Med, Dept Family Med & Community Hlth, 136 Harrison Ave, Boston, MA 02111 USA.	amust@hnrc.tufts.edu	Colditz, Graham/A-3963-2009; Kohn, Geoffrey P/A-9056-2009; Field, Alison/AAA-4508-2021	Colditz, Graham/0000-0002-7307-0291; 				ANDRES R, 1993, ANN INTERN MED, V119, P737, DOI 10.7326/0003-4819-119-7_Part_2-199310011-00022; [Anonymous], 1994, VITAL HLTH STAT, V1, P1; BURT VL, 1995, HYPERTENSION, V26, P60, DOI 10.1161/01.HYP.26.1.60; BURTON BT, 1985, INT J OBESITY, V9, P155; COLDITZ GA, 1995, ANN INTERN MED, V122, P481, DOI 10.7326/0003-4819-122-7-199504010-00001; Drewnowski A, 1997, NUTR REV, V55, P31, DOI 10.1111/j.1753-4887.1997.tb01593.x; Ernst ND, 1997, J AM DIET ASSOC, V97, pS47, DOI 10.1016/S0002-8223(97)00729-3; Flegal KM, 1998, INT J OBESITY, V22, P39, DOI 10.1038/sj.ijo.0800541; FOLSOM AR, 1993, JAMA-J AM MED ASSOC, V269, P483, DOI 10.1001/jama.269.4.483; FORBES GB, 1970, METABOLIS, V19, P653, DOI 10.1016/0026-0495(70)90062-4; HANSEN RG, 1995, J IND ECON, V43, P261, DOI 10.2307/2950579; Harris MI, 1998, DIABETES CARE, V21, P518, DOI 10.2337/diacare.21.4.518; Huang ZP, 1998, ANN INTERN MED, V128, P81, DOI 10.7326/0003-4819-128-2-199801150-00001; HYPERTENSION DETECTION FOLLOW-UP, 1977, AM J EPIDEMIOL, V106, P351; Kassirer JP, 1998, NEW ENGL J MED, V338, P52, DOI 10.1056/NEJM199801013380109; KUMANYIKA S, 1987, EPIDEMIOL REV, V9, P31, DOI 10.1093/oxfordjournals.epirev.a036307; LAPIDUS L, 1984, BMJ-BRIT MED J, V289, P1257, DOI 10.1136/bmj.289.6454.1257; LEE J, 1984, AM J PUBLIC HEALTH, V74, P376, DOI 10.2105/AJPH.74.4.376; National Center for Health Statistics, 1996, 3 NAT HLTH NUTR EX S; Pi-Sunyer FX, 1998, OBES RES, V6, p51S; RIMM EB, 1995, AM J EPIDEMIOL, V141, P1117, DOI 10.1093/oxfordjournals.aje.a117385; Rose G.A., 1982, CARDIOVASCULAR SURVE; SAVAGE P J, 1991, Ethnicity and Disease, V1, P200; Schwartz LM, 1997, ANN INTERN MED, V127, P966, DOI 10.7326/0003-4819-127-11-199712010-00003; Shah BV, 1997, SOFTWARE STAT ANAL C; Stevens J, 1998, NEW ENGL J MED, V338, P1, DOI 10.1056/NEJM199801013380101; Stevens J, 1998, OBES RES, V6, P268, DOI 10.1002/j.1550-8528.1998.tb00349.x; STEVENS J, 1992, ARCH INTERN MED, V152, P1257, DOI 10.1001/archinte.152.6.1257; Sundquist J, 1999, AM J PUBLIC HEALTH, V89, P723, DOI 10.2105/AJPH.89.5.723; *US DEP HHS, 1996, LAB PROD US NHANES, V3; *USDA, 1995, HOM GARD B, V232; WHO, 1997, OBESITY PREVENTING M; *WHO MONICA PROJ, 1989, INT J EPIDEMIOL S1, V18, pS46; WIENPAHL J, 1990, J CLIN EPIDEMIOL, V43, P949, DOI 10.1016/0895-4356(90)90078-4; WILLETT WC, 1995, JAMA-J AM MED ASSOC, V273, P461, DOI 10.1001/jama.273.6.461; Winkleby MA, 1999, JAMA-J AM MED ASSOC, V281, P1006, DOI 10.1001/jama.281.11.1006; Zhang J, 1998, JAMA-J AM MED ASSOC, V280, P1690, DOI 10.1001/jama.280.19.1690; ZILLIKENS MC, 1990, AM J CLIN NUTR, V52, P45, DOI 10.1093/ajcn/52.1.45; [No title captured]	39	3206	3304	11	379	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 27	1999	282	16					1523	1529		10.1001/jama.282.16.1523	http://dx.doi.org/10.1001/jama.282.16.1523			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	General & Internal Medicine	248MB	10546691				2022-12-01	WOS:000083277800019
J	Johnston, K; Brown, J				Johnston, K; Brown, J			Two view mammography at incident screens: cost effectiveness analysis of policy options	BRITISH MEDICAL JOURNAL			English	Article								Objective To determine the cost effectiveness of two view mammography at incident screens. Design Incremental cost effectiveness analyses recognising differences in current reading policy, based on effectiveness data from an observational study. Setting Breast screening programmes in England and Wales. Main outcome measures Health service costs, cancers detected, incremental cost effectiveness ratios per cancer detected, whole time equivalent staff. Results For programmes currently using one view with some form of double reading, the incremental cost effectiveness ratio of two view mammography art incident screens ranged between pound 6589 and pound 6716, depending on the reading policy. For programmes currently using one view with single reading, two policy options were found to be more efficient than two view single reading: one view with double reading (arbitration; incremental cost effectiveness ratio of pound 210) and two view double reading (arbitration). Tf programmes using one view with single reading changed to double reading (arbitration) and then subsequently to two views double reading (arbitration), additional cancers could be detected with an incremental cost effectiveness ratio of pound 7983. The implementation cost of two view mammography at incident screens in programmes in England and Wales would be pound 2.9 million and would require 13.4 whole time equivalent radiologists. Conclusions The cost effectiveness of two view mammography at incident screens depends on the film reading policy. A policy of two view mammography at incident screens in England and Wales would be efficient only if programmes using single reading moved to double reading. Given limited resources, priority should be given to introducing double reading in the subset of programmes currently using single reading as this requires fewer additional radiologists and is more cost effective.	Univ Oxford, Inst Hlth Sci, Hlth Econ Res Ctr, Oxford OX3 7LF, England; Brunel Univ, Hlth Econ Res Grp, Uxbridge UB8 3PH, Middx, England	University of Oxford; Brunel University	Johnston, K (corresponding author), Univ Oxford, Inst Hlth Sci, Hlth Econ Res Ctr, Oxford OX3 7LF, England.							Blanks R G, 1996, J Med Screen, V3, P79; Blanks RG, 1998, J MED SCREEN, V5, P195, DOI 10.1136/jms.5.4.195; BRIGGS A, 1994, HEALTH ECON, V3, P95, DOI 10.1002/hec.4730030206; Brown J, 1996, BRIT MED J, V312, P809; BRYAN S, 1995, J EPIDEMIOL COMMUN H, V49, P70, DOI 10.1136/jech.49.1.70; Forrest APM, 1986, BREAST CANC SCREENIN; JOHNSTON K, 1996, NHS COSTS BREAST SCR; Karlsson G, 1996, PHARMACOECONOMICS, V9, P113, DOI 10.2165/00019053-199609020-00003; LAUPACIS A, 1992, CAN MED ASSOC J, V146, P473; *NHS, 1995, QUAL NAT HLTH SERV B; WALD NJ, 1995, BRIT MED J, V311, P1189, DOI 10.1136/bmj.311.7014.1189; WARREN RML, 1995, BRIT J RADIOL, V68, P958, DOI 10.1259/0007-1285-68-813-958	12	10	10	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	OCT 23	1999	319	7217					1097	1102		10.1136/bmj.319.7217.1097	http://dx.doi.org/10.1136/bmj.319.7217.1097			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	250ZE	10531098	Green Published, Bronze			2022-12-01	WOS:000083419500021
J	Watts, DM; Porter, KR; Putvatana, P; Vasquez, B; Calampa, C; Hayes, CG; Halstead, SB				Watts, DM; Porter, KR; Putvatana, P; Vasquez, B; Calampa, C; Hayes, CG; Halstead, SB			Failure of secondary infection with American genotype dengue 2 to cause dengue haemorrhagic fever	LANCET			English	Article							HEMORRHAGIC-FEVER; SHOCK SYNDROME; MOLECULAR EVOLUTION; TYPE-2 VIRUS; RISK-FACTORS; IDENTIFICATION; NUCLEOTIDE; ANTIBODIES; EPIDEMIC; THAILAND	Background Population-based epidemiological studies have shown that infection with dengue type 2 (DEN-2) virus in individuals previously infected with a different serotype of the virus is a major risk factor for dengue haemorrhagic fever and dengue shock syndrome. However, the western hemisphere was spared epidemics of these two syndromes, until the introduction of a southeast Asian DEN-2 genotype. Possibly American DEN-2 genotype strains lacked properties necessary to cause severe disease. We report on a major epidemic of DEN-2 in Peru in 1995, about 5 years after an epidemic of DEN-1 in the same population. Methods In Iquitos, a city of 344 686 inhabitants in Peru, cases of dengue fever were studied prospectively from 1990. Acute phase of illness serum samples from patients were tested for virus in C6/36 cells, and virus isolates were identified by immunofluorescence. Isolates of dengue 2 virus obtained from patients during an outbreak of mild febrile illness in 1995 were sequenced to determine the genotype. Serological analysis of paired samples from the patients was done with an IgM capture ELISA and an indirect IgG ELISA. In addition, serum samples collected annually between 1993 and 1996 from a large cohort of students were tested for dengue IgG antibody by an ELISA. Serum samples from a random sample of 129 students from this cohort were tested for dengue neutralising antibodies to quantify the serotype specific infection rates. Findings Among the 129 students (aged 7-20 years in 1993) who had serum samples available before and after the epidemic, 78 (60.5%) had a secondary DEN-2 virus infection. By extrapolation, 49 266 of the 81 479 children (aged 5-14 years) in Iquitos would have experienced such infections. From previous studies, between 887 and 10 247 cases of dengue haemorrhagic fever and dengue shock syndrome would have been expected. No cases were found. DEN-2 isolates were of the American genotype. Interpretation This prospective study shows that secondary infection by the American DEN-2 genotype did not cause dengue haemorrhagic fever and dengue shock syndrome.	USN, Med Res Ctr Detachment, AMEMB NAMRID, Unit 3800, Bethesda, MD USA; Peruvian Navy, Ctr Med Naval, Bellavista, Callao, Peru; Loreto Reg Minist Hlth, Iquitos, Loreto, Peru; Off Naval Res, Arlington, VA 22217 USA	United States Department of Defense; United States Navy; United States Department of Defense; United States Navy	Watts, DM (corresponding author), USN, Med Res Ctr, Detachment AMEMB NAMRID, Unit 3800, APO, AA 34031 USA.	Watts@namrid.sld.pe	Porter, Kevin/A-8027-2011					BURKE DS, 1988, AM J TROP MED HYG, V38, P172, DOI 10.4269/ajtmh.1988.38.172; CHUNGUE E, 1993, J GEN VIROL, V74, P2765, DOI 10.1099/0022-1317-74-12-2765; DEUBEL V, 1988, VIROLOGY, V165, P234, DOI 10.1016/0042-6822(88)90677-0; Duangchanda Sumlee, 1994, Southeast Asian Journal of Tropical Medicine and Public Health, V25, P243; Graham RR, 1999, AM J TROP MED HYG, V61, P412, DOI 10.4269/ajtmh.1999.61.412; GUZMAN MG, 1995, AM J TROP MED HYG, V52, P241, DOI 10.4269/ajtmh.1995.52.241; GUZMAN MG, 1990, AM J TROP MED HYG, V42, P179, DOI 10.4269/ajtmh.1990.42.179; Halstead S.B., 1980, TOGAVIRUSES BIOL STR, p107e173; HALSTEAD SB, 1967, JPN J MED SCI BIOL, VS 20, P96; Halstead Scott B., 1997, P23; Hayes CG, 1996, AM J TROP MED HYG, V55, P459, DOI 10.4269/ajtmh.1996.55.459; HENCHAL EA, 1983, AM J TROP MED HYG, V32, P164, DOI 10.4269/ajtmh.1983.32.164; KLIKS SC, 1988, AM J TROP MED HYG, V38, P411, DOI 10.4269/ajtmh.1988.38.411; KLIKS SC, 1989, AM J TROP MED HYG, V40, P444, DOI 10.4269/ajtmh.1989.40.444; KOURI G, 1988, B PAN AM HLTH ORG, V20, P24; Kyaw-Zin-Thant, 1995, Southeast Asian J Trop Med Public Health, V26, P664; Leitmeyer KC, 1999, J VIROL, V73, P4738, DOI 10.1128/JVI.73.6.4738-4747.1999; Mangada MNM, 1998, VIROLOGY, V244, P458, DOI 10.1006/viro.1998.9093; MORENS DM, 1985, J CLIN MICROBIOL, V22, P250, DOI 10.1128/JCM.22.2.250-254.1985; NEFF JM, 1967, AM J EPIDEMIOL, V86, P162, DOI 10.1093/oxfordjournals.aje.a120722; Phillips I, 1992, Bull Pan Am Health Organ, V26, P201; Pinheiro Fransisco P., 1997, World Health Statistics Quarterly, V50, P161; Rico-Hesse R, 1998, AM J TROP MED HYG, V58, P96, DOI 10.4269/ajtmh.1998.58.96; RICOHESSE R, 1990, VIROLOGY, V174, P479, DOI 10.1016/0042-6822(90)90102-W; RicoHesse R, 1997, VIROLOGY, V230, P244, DOI 10.1006/viro.1997.8504; ROSEN L, 1977, AM J TROP MED HYG, V26, P337, DOI 10.4269/ajtmh.1977.26.337; RUSSELL PK, 1968, AM J TROP MED HYG, V17, P600, DOI 10.4269/ajtmh.1968.17.600; SANGKAWIBHA N, 1984, AM J EPIDEMIOL, V120, P653, DOI 10.1093/oxfordjournals.aje.a113932; SRIVASTAVA VK, 1990, ANN TROP PAEDIATR, V10, P329, DOI 10.1080/02724936.1990.11747453; TESH RB, 1979, AM J TROP MED HYG, V28, P1053, DOI 10.4269/ajtmh.1979.28.1053; Thein S, 1997, AM J TROP MED HYG, V56, P566, DOI 10.4269/ajtmh.1997.56.566; Watts DM, 1998, AM J TROP MED HYG, V58, P35, DOI 10.4269/ajtmh.1998.58.35; 1994, PAHO SCI PUB, V548, P98; 1993, EPIDEMIOL B PAN AM H, V14, P1	34	217	230	0	11	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	OCT 23	1999	354	9188					1431	1434		10.1016/S0140-6736(99)04015-5	http://dx.doi.org/10.1016/S0140-6736(99)04015-5			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	248LY	10543670				2022-12-01	WOS:000083277400013
J	Calle, EE; Thun, MJ; Petrelli, JM; Rodriguez, C; Heath, CW				Calle, EE; Thun, MJ; Petrelli, JM; Rodriguez, C; Heath, CW			Body-mass index and mortality in a prospective cohort of US adults	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							NUTRITION EXAMINATION SURVEY; ISCHEMIC-HEART-DISEASE; RISK-FACTORS; FOLLOW-UP; NATIONAL-HEALTH; RELATIVE WEIGHT; OLDER PERSONS; EVANS COUNTY; 26-YEAR RISK; WHITE WOMEN	Background Body-mass index (the weight in kilograms divided by the square of the height in meters) is known to be associated with overall mortality. We investigated the effects of age, race, sex, smoking status, and history of disease on the relation between body-mass index and mortality. Methods In a prospective study of more than 1 million adults in the United States (457,785 men and 588,369 women), 201,622 deaths occurred during 14 years of follow-up. We examined the relation between body-mass index and the risk of death from all causes in four subgroups categorized according to smoking status and history of disease. In healthy people who had never smoked, we further examined whether the relation varied according to race, cause of death, or age. The relative risk was used to assess the relation between mortality and body-mass index. Results The association between body-mass index and the risk of death was substantially modified by smoking status and the presence of disease. In healthy people who had never smoked, the nadir of the curve for body-mass index and mortality was found at a body-mass index of 23.5 to 24.9 in men and 22.0 to 23.4 in women. Among subjects with the highest body-mass indexes, white men and women had a relative risk of death of 2.58 and 2.00, respectively, as compared with those with a body-mass index of 23.5 to 24.9. Black men and women with the highest body-mass indexes had much lower risks of death (1.35 and 1.21), which did not differ significantly from 1.00. A high body-mass index was most predictive of death from cardiovascular disease, especially in men (relative risk, 2.90; 95 percent confidence interval, 2.37 to 3.56). Heavier men and women in all age groups had an increased risk of death. Conclusions The risk of death from all causes, cardiovascular disease, cancer, or other diseases increases throughout the range of moderate and severe overweight for both men and women in all age groups. The risk associated with a high body-mass index is greater for whites than for blacks. (N Engl J Med 1999;341:1097-105.) (C)1999, Massachusetts Medical Society.	Amer Canc Soc, Dept Epidemiol & Surveillance Res, Atlanta, GA 30329 USA	American Cancer Society	Calle, EE (corresponding author), Amer Canc Soc, Dept Epidemiol & Surveillance Res, 1599 Clifton Rd NE, Atlanta, GA 30329 USA.							Allison DB, 1997, INT J OBESITY, V21, P424, DOI 10.1038/sj.ijo.0800423; [Anonymous], 1995, WHO TECHN REP SER, V854, P1, DOI DOI 10.1002/(sici)1520-6300(1996)8:6<786::aid-ajhb11>3.0.co;2-i; BORKAN GA, 1983, J GERONTOL, V38, P673, DOI 10.1093/geronj/38.6.673; CALLE EE, 1993, AM J EPIDEMIOL, V137, P235, DOI 10.1093/oxfordjournals.aje.a116664; CORNONIHUNTLEY JC, 1991, J CLIN EPIDEMIOL, V44, P743, DOI 10.1016/0895-4356(91)90126-T; COX DR, 1972, J R STAT SOC B, V34, P187; *DEP AGR, 1995, HOM GARD B, V232; *DEP AGR, 1990, HOM GARD B, V232; Diehr P, 1998, AM J PUBLIC HEALTH, V88, P623, DOI 10.2105/AJPH.88.4.623; Dunn SE, 1997, CANCER RES, V57, P4667; DurazoArvizu R, 1997, ANN EPIDEMIOL, V7, P383, DOI 10.1016/S1047-2797(97)00044-6; FOLSOM AR, 1993, JAMA-J AM MED ASSOC, V269, P1254; FREEDMAN DS, 1995, AM J EPIDEMIOL, V142, P53, DOI 10.1093/oxfordjournals.aje.a117545; GARFINKEL L, 1986, CANCER-AM CANCER SOC, V58, P1826, DOI 10.1002/1097-0142(19861015)58:8+<1826::AID-CNCR2820581407>3.0.CO;2-6; Garfinkel L, 1985, Natl Cancer Inst Monogr, V67, P49; HARRIS T, 1988, JAMA-J AM MED ASSOC, V259, P1520; JOHNSON JL, 1986, AM J EPIDEMIOL, V123, P209, DOI 10.1093/oxfordjournals.aje.a114230; KEYS A, 1972, J CHRON DIS, V25, P329, DOI 10.1016/0021-9681(72)90027-6; Kuczmarski RJ, 1997, OBES RES, V5, P542, DOI 10.1002/j.1550-8528.1997.tb00575.x; LEE IM, 1993, JAMA-J AM MED ASSOC, V270, P2823, DOI 10.1001/jama.270.23.2823; LEW EA, 1979, J CHRON DIS, V32, P563, DOI 10.1016/0021-9681(79)90119-X; LINDSTED K, 1991, INT J OBESITY, V15, P397; Lindsted KD, 1997, AM J EPIDEMIOL, V146, P1, DOI 10.1093/oxfordjournals.aje.a009185; LOSONCZY KG, 1995, AM J EPIDEMIOL, V141, P312, DOI 10.1093/aje/141.4.312; MANSON JE, 1987, JAMA-J AM MED ASSOC, V257, P353, DOI 10.1001/jama.257.3.353; MANSON JE, 1995, NEW ENGL J MED, V333, P677, DOI 10.1056/NEJM199509143331101; Rexrode KM, 1997, JAMA-J AM MED ASSOC, V277, P1539, DOI 10.1001/jama.277.19.1539; Rothman KJ, 1986, MODERN EPIDEMIOLOGY; Singh PN, 1998, EPIDEMIOLOGY, V9, P246, DOI 10.1097/00001648-199805000-00007; STEVENS J, 1993, J GERONTOL, V48, pM249, DOI 10.1093/geronj/48.6.M249; Stevens J, 1998, NEW ENGL J MED, V338, P1, DOI 10.1056/NEJM199801013380101; STEVENS J, 1990, AM J EPIDEMIOL, V132, P1156, DOI 10.1093/oxfordjournals.aje.a115758; Stevens J, 1998, OBES RES, V6, P268, DOI 10.1002/j.1550-8528.1998.tb00349.x; STEVENS J, 1992, ARCH INTERN MED, V152, P1257, DOI 10.1001/archinte.152.6.1257; THUN MJ, 1992, JNCI-J NATL CANCER I, V84, P1491, DOI 10.1093/jnci/84.19.1491; Troiano RP, 1996, INT J OBESITY, V20, P63; TYROLER HA, 1984, AM HEART J, V108, P738, DOI 10.1016/0002-8703(84)90667-7; WHO, 1977, MAN INT STAT CLASS D, V1; WIENPAHL J, 1990, J CLIN EPIDEMIOL, V43, P949, DOI 10.1016/0895-4356(90)90078-4; WILLETT WC, 1991, AM J CLIN NUTR, V53, P1102, DOI 10.1093/ajcn/53.5.1102	40	2677	2767	3	79	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	OCT 7	1999	341	15					1097	1105		10.1056/NEJM199910073411501	http://dx.doi.org/10.1056/NEJM199910073411501			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	245BW	10511607				2022-12-01	WOS:000083087200001
J	Dodt, HU; Eder, M; Frick, A; Zieglgansberger, W				Dodt, HU; Eder, M; Frick, A; Zieglgansberger, W			Precisely localized LTD in the neocortex revealed by infrared-guided laser stimulation	SCIENCE			English	Article							LONG-TERM POTENTIATION; POSTSYNAPTIC ACTIVATION; DENDRITIC SPINES; RAT HIPPOCAMPUS; AMPA RECEPTORS; VISUAL-CORTEX; DEPRESSION; NMDA; PHOTOSTIMULATION; ENHANCEMENT	In a direct approach to elucidate the origin of long-term depression (LTD), glutamate was applied onto dendrites of neurons in rat neocortical slices. An infrared-guided laser stimulation was used to release glutamate from caged glutamate in the focal spot df an ultraviolet laser. A burst of light flashes caused an LTD-like depression of glutamate receptor responses, which was highly confined to the region of "tetanic" stimulation (<10 micrometers). A similar depression of glutamate receptor responses was observed during LTD of synaptic transmission. A spatially highly specific postsynaptic mechanism tan account for the LTD induced by glutamate release.	Max Planck Inst Psychiat, D-80804 Munich, Germany	Max Planck Society	Dodt, HU (corresponding author), Max Planck Inst Psychiat, Kraepelinstr 2, D-80804 Munich, Germany.			Eder, Matthias/0000-0002-2579-2628				ANDREASEN M, 1994, J NEUROPHYSIOL, V72, P326, DOI 10.1152/jn.1994.72.1.326; BAUDE A, 1995, NEUROSCIENCE, V69, P1031, DOI 10.1016/0306-4522(95)00350-R; Benke TA, 1998, NATURE, V393, P793, DOI 10.1038/31709; BLISS TVP, 1996, CORTICAL PLASTICITY, P61; BONHOEFFER T, 1989, P NATL ACAD SCI USA, V86, P8113, DOI 10.1073/pnas.86.20.8113; BROCHER S, 1992, P NATL ACAD SCI USA, V89, P123, DOI 10.1073/pnas.89.1.123; Carroll RC, 1999, NAT NEUROSCI, V2, P454, DOI 10.1038/8123; CORMIER RJ, 1993, NEURON, V10, P907, DOI 10.1016/0896-6273(93)90206-7; DALVA MB, 1994, SCIENCE, V265, P255, DOI 10.1126/science.7912852; DAVIES SN, 1989, NATURE, V338, P500, DOI 10.1038/338500a0; Dodt HU, 1998, EUR J NEUROSCI, V10, P3351, DOI 10.1046/j.1460-9568.1998.00338.x; Kandler K, 1998, NAT NEUROSCI, V1, P119, DOI 10.1038/368; KATZ LC, 1994, J NEUROSCI METH, V54, P205, DOI 10.1016/0165-0270(94)90194-5; KUNG G, 1972, Z MIKROSK ANAT FORSC, V3, P396; Lee HK, 1998, NEURON, V21, P1151, DOI 10.1016/S0896-6273(00)80632-7; LYNCH GS, 1976, NATURE, V263, P151, DOI 10.1038/263151a0; MANABE T, 1992, NATURE, V355, P50, DOI 10.1038/355050a0; MULKEY RM, 1992, NEURON, V9, P967, DOI 10.1016/0896-6273(92)90248-C; PETIT DL, 1997, NEURON, V19, P465; Schiller J, 1998, NAT NEUROSCI, V1, P114, DOI 10.1038/363; STAUBLI U, 1990, BRAIN RES, V513, P113, DOI 10.1016/0006-8993(90)91096-Y; SWARTZWELDER HS, 1989, NEUROPHARMACOLOGY, V28, P441, DOI 10.1016/0028-3908(89)90076-2; TSIEN RW, 1990, COLD SH Q B, V55, P147; WANG SSH, 1995, NEURON, V15, P755, DOI 10.1016/0896-6273(95)90167-1; YUSTE R, 1995, NATURE, V375, P682, DOI 10.1038/375682a0	25	68	90	0	9	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	OCT 1	1999	286	5437					110	113		10.1126/science.286.5437.110	http://dx.doi.org/10.1126/science.286.5437.110			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	241WT	10506556				2022-12-01	WOS:000082907400046
J	Onichtchouk, D; Chen, YG; Dosch, R; Gawantka, V; Dellus, H; Massague, J; Niehrs, C				Onichtchouk, D; Chen, YG; Dosch, R; Gawantka, V; Dellus, H; Massague, J; Niehrs, C			Silencing of TGF-beta signalling by the pseudoreceptor BAMBI	NATURE			English	Article							BONE MORPHOGENETIC PROTEIN-4; VENTRALIZING FACTOR; XENOPUS-EMBRYOS; RECEPTOR; GENE; ORGANIZER; IDENTIFICATION; TRANSDUCTION; EXPRESSION; ACTIVATION	Members of the transforming growth factor-beta (TGF-beta) superfamily, including TGF-beta, bone morphogenetic proteins (BMPs), activins and nodals, are vital for regulating growth and differentiation(1). These growth factors transduce their signals through pairs of transmembrane type I and type II receptor kinases(2-4). Here, we have cloned a transmembrane protein, BAMBI, which is related to TGP-beta-family type I receptors but lacks an intracellular kinase domain. We show that BAMBI is co-expressed with the ventralizing morphogen BMP4 (refs 5, 6) during Xenopus embryogenesis and that it requires BMP signalling for its expression. The protein stably associates with TGF-beta-family receptors and inhibits BMP and activin as well as TGF-beta signalling. Finally, we provide evidence that BAMBI's inhibitory effects are mediated by its intracellular domain, which resembles the homodimerization interface of a type I receptor and prevents the formation of receptor complexes. The results indicate that BAMBI negatively regulates TGF-beta-family signalling by a regulatory mechanism involving the interaction of signalling receptors with a pseudoreceptor.	Deutsch Krebsforschungszentrum, Div Mol Embryol, D-69120 Heidelberg, Germany; Deutsch Krebsforschungszentrum, Div Appl Tumor Virol, D-69120 Heidelberg, Germany; Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA; Howard Hughes Med Inst, New York, NY 10021 USA	Helmholtz Association; German Cancer Research Center (DKFZ); Helmholtz Association; German Cancer Research Center (DKFZ); Memorial Sloan Kettering Cancer Center; Howard Hughes Medical Institute	Niehrs, C (corresponding author), Deutsch Krebsforschungszentrum, Div Mol Embryol, Neuenheimer Feld 280, D-69120 Heidelberg, Germany.		Onichtchouk, Daria/E-1741-2012; Dosch, Roland/H-9633-2019	Onichtchouk, Daria/0000-0001-6497-1445; Dosch, Roland/0000-0001-9247-8586; Massague, Joan/0000-0001-9324-8408				CANDIA AF, 1992, DEVELOPMENT, V116, P1123; Candia AF, 1997, DEVELOPMENT, V124, P4467; Chen X, 1996, NATURE, V383, P691, DOI 10.1038/383691a0; Chen YG, 1999, J BIOL CHEM, V274, P3672, DOI 10.1074/jbc.274.6.3672; Chen YG, 1997, EMBO J, V16, P3866, DOI 10.1093/emboj/16.13.3866; Chen YG, 1998, GENE DEV, V12, P2144, DOI 10.1101/gad.12.14.2144; DALE L, 1992, DEVELOPMENT, V115, P573; Degen WGJ, 1996, INT J CANCER, V65, P460, DOI 10.1002/(SICI)1097-0215(19960208)65:4<460::AID-IJC12>3.3.CO;2-B; Derynck R, 1997, BBA-REV CANCER, V1333, pF105, DOI 10.1016/S0304-419X(97)00017-6; Gawantka V, 1998, MECH DEVELOP, V77, P95, DOI 10.1016/S0925-4773(98)00115-4; Gawantka V, 1995, EMBO J, V14, P6268, DOI 10.1002/j.1460-2075.1995.tb00317.x; Glinka A, 1996, MECH DEVELOP, V60, P221, DOI 10.1016/S0925-4773(96)00624-7; GRAFF JM, 1994, CELL, V79, P169, DOI 10.1016/0092-8674(94)90409-X; Harland R, 1997, ANNU REV CELL DEV BI, V13, P611, DOI 10.1146/annurev.cellbio.13.1.611; Heldin CH, 1997, NATURE, V390, P465, DOI 10.1038/37284; Hoodless PA, 1998, CURR TOP MICROBIOL, V228, P235; Howell M, 1997, EMBO J, V16, P7411, DOI 10.1093/emboj/16.24.7411; HUANG HC, 1995, EMBO J, V14, P5965, DOI 10.1002/j.1460-2075.1995.tb00285.x; Huse M, 1999, CELL, V96, P425, DOI 10.1016/S0092-8674(00)80555-3; JONES CM, 1992, DEVELOPMENT, V115, P639; KAUFMANN E, 1996, EMBO J, V15, P6379; Luo KX, 1996, EMBO J, V15, P4485, DOI 10.1002/j.1460-2075.1996.tb00826.x; Massague J, 1998, ANNU REV BIOCHEM, V67, P753, DOI 10.1146/annurev.biochem.67.1.753; MASSAGUE J, 1987, METHOD ENZYMOL, V146, P174; RUPP RAW, 1994, GENE DEV, V8, P1311, DOI 10.1101/gad.8.11.1311; Sasai Y, 1997, DEV BIOL, V182, P5, DOI 10.1006/dbio.1996.8445; Stockwell BR, 1998, CURR BIOL, V8, P761, DOI 10.1016/S0960-9822(98)70299-4; SUZUKI A, 1994, P NATL ACAD SCI USA, V91, P10255, DOI 10.1073/pnas.91.22.10255; WeisGarcia F, 1996, EMBO J, V15, P276, DOI 10.1002/j.1460-2075.1996.tb00358.x; WRANA JL, 1994, NATURE, V370, P341, DOI 10.1038/370341a0	30	548	585	0	19	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	SEP 30	1999	401	6752					480	485		10.1038/46794	http://dx.doi.org/10.1038/46794			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	243DF	10519551				2022-12-01	WOS:000082981200057
J	van Wilpe, S; Ryan, MT; Hill, K; Maarse, AC; Meisinger, C; Brix, J; Dekker, PJT; Moczko, M; Wagner, R; Meijer, M; Guiard, B; Honlinger, A; Pfanner, N				van Wilpe, S; Ryan, MT; Hill, K; Maarse, AC; Meisinger, C; Brix, J; Dekker, PJT; Moczko, M; Wagner, R; Meijer, M; Guiard, B; Honlinger, A; Pfanner, N			Tom22 is a multifunctional organizer of the mitochondrial preprotein translocase	NATURE			English	Article							OUTER-MEMBRANE PROTEIN; GENERAL IMPORT PORE; RECEPTOR COMPLEX; YEAST MITOCHONDRIA; NEUROSPORA-CRASSA; CELL VIABILITY; CHANNEL; COMPONENT; DOMAINS; MOM22	Mitochondrial preproteins are imported by a multisubunit translocase of the outer membrane (TOM), including receptor proteins and a general import pore(1-5). The central receptor Tom22 binds preproteins through both its cytosolic domain and its intermembrane space domain(6-10) and is stably associated with the channel protein Tom40 (refs 11-13). Here we report the unexpected observation that a yeast strain can survive without Tom22, although it is strongly reduced in growth and the import of mitochondrial proteins. Tom22 is a multifunctional protein that is required for the higher-level organization of the TOM machinery. In the absence of Tom22, the translocase dissociates into core complexes, representing the basic import units, but lacks a tight control of channel gating. The single membrane anchor of Tom22 is required for a stable interaction between the core complexes, whereas its cytosolic domain, serves as docking point for the peripheral receptors Tom20 and Tom70. Thus a preprotein translocase can combine receptor functions with distinct organizing roles in a multidomain protein.	Univ Freiburg, Inst Biochem & Mol Biol, D-79104 Freiburg, Germany; Biocentrum Amsterdam, Inst Mol Cell Biol, NL-1098 SM Amsterdam, Netherlands; Univ Osnabruck, Fachbereich Biol Chem, D-49034 Osnabruck, Germany; Univ Paris 06, Ctr Genet Mol, CNRS, F-91190 Gif Sur Yvette, France	University of Freiburg; University of Amsterdam; University Osnabruck; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Sorbonne Universite; Universite Paris Saclay	Pfanner, N (corresponding author), Univ Freiburg, Inst Biochem & Mol Biol, Hermann Herder Str 7, D-79104 Freiburg, Germany.		Ryan, Michael T/C-6673-2011; Ryan, Michael/X-2152-2019; Pfanner, Nikolaus/AAV-7878-2021; Meisinger, Chris/J-1110-2014	Ryan, Michael T/0000-0003-2586-8829; Ryan, Michael/0000-0003-2586-8829; Meisinger, Chris/0000-0002-8326-3548; Dekker, Peter/0000-0002-8197-8822				ALCONADA A, 1995, MOL CELL BIOL, V15, P6196; Alconada A, 1995, METHOD ENZYMOL, V260, P263, DOI 10.1016/0076-6879(95)60144-9; BAKER KP, 1990, NATURE, V348, P605, DOI 10.1038/348605a0; Bolliger L, 1995, EMBO J, V14, P6318, DOI 10.1002/j.1460-2075.1995.tb00322.x; Brix J, 1997, J BIOL CHEM, V272, P20730, DOI 10.1074/jbc.272.33.20730; Dekker PJT, 1998, MOL CELL BIOL, V18, P6515, DOI 10.1128/MCB.18.11.6515; Dietmeier K, 1997, NATURE, V388, P195, DOI 10.1038/40663; Guthrie C, 1991, METHOD ENZYMOL, P194; Haucke V, 1996, EMBO J, V15, P1231, DOI 10.1002/j.1460-2075.1996.tb00464.x; Hill K, 1998, NATURE, V395, P516, DOI 10.1038/26780; Hinnah SC, 1997, EMBO J, V16, P7351, DOI 10.1093/emboj/16.24.7351; HONLINGER A, 1995, MOL CELL BIOL, V15, P3382; Honlinger A, 1996, EMBO J, V15, P2125, DOI 10.1002/j.1460-2075.1996.tb00566.x; KASSENBROCK CK, 1993, EMBO J, V12, P3023, DOI 10.1002/j.1460-2075.1993.tb05971.x; Kunkele KP, 1998, CELL, V93, P1009, DOI 10.1016/S0092-8674(00)81206-4; LITHGOW T, 1994, P NATL ACAD SCI USA, V91, P11973, DOI 10.1073/pnas.91.25.11973; MAYER A, 1995, EMBO J, V14, P4205; Moczko M, 1997, MOL CELL BIOL, V17, P6574, DOI 10.1128/MCB.17.11.6574; NARGANG FE, 1995, EMBO J, V14, P1099, DOI 10.1002/j.1460-2075.1995.tb07093.x; Neupert W, 1997, ANNU REV BIOCHEM, V66, P863, DOI 10.1146/annurev.biochem.66.1.863; Pfanner N, 1997, ANNU REV CELL DEV BI, V13, P25, DOI 10.1146/annurev.cellbio.13.1.25; RYAN KR, 1995, CELL, V83, P517, DOI 10.1016/0092-8674(95)90089-6; Schatz G, 1998, NATURE, V395, P439, DOI 10.1038/26620; Schatz G, 1996, SCIENCE, V271, P1519, DOI 10.1126/science.271.5255.1519; SOLLNER T, 1991, METHOD CELL BIOL, V34, P345; VESTWEBER D, 1989, NATURE, V341, P205, DOI 10.1038/341205a0	26	231	236	0	13	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	SEP 30	1999	401	6752					485	489		10.1038/46802	http://dx.doi.org/10.1038/46802			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	243DF	10519552				2022-12-01	WOS:000082981200058
J	Balen, A				Balen, A			Pathogenesis of polycystic ovary syndrome - the enigma unravels?	LANCET			English	Editorial Material							INSULIN-RESISTANCE; PREGNANCY; MECHANISM		Gen Infirm, Dept Reprod Med, Leeds LS2 9NS, W Yorkshire, England	Leeds General Infirmary	Balen, A (corresponding author), Gen Infirm, Dept Reprod Med, Leeds LS2 9NS, W Yorkshire, England.							BALEN AH, 1993, BRIT J OBSTET GYNAEC, V100, P1082, DOI 10.1111/j.1471-0528.1993.tb15170.x; Balen AH, 1995, HUM REPROD, V10, P2705; CLARK AM, 1995, HUM REPROD, V10, P2705, DOI 10.1093/oxfordjournals.humrep.a135772; Dunaif A, 1997, ENDOCR REV, V18, P774, DOI 10.1210/er.18.6.774; Franks S, 1997, HUM REPROD, V12, P2641, DOI 10.1093/humrep/12.12.2641; Homburg R, 1996, HUM REPROD, V11, P29; Jacobs HS, 1999, HUM REPROD UPDATE, V5, P166, DOI 10.1093/humupd/5.2.166; Lockwood GM, 1998, J CLIN ENDOCR METAB, V83, P1730, DOI 10.1210/jc.83.5.1730; MICHELMORE KF, IN PRESS CLIN ENDOCR; Nestler JE, 1999, NEW ENGL J MED, V340, P1314, DOI 10.1056/NEJM199904293401703; Ong KKL, 1999, NAT GENET, V21, P262, DOI 10.1038/6775; POLSON DW, 1988, LANCET, V1, P870; Tapanainen JS, 1999, J CLIN ENDOCR METAB, V84, P1711, DOI 10.1210/jc.84.5.1711; VELAZQUEZ EM, 1994, METABOLISM, V43, P647, DOI 10.1016/0026-0495(94)90209-7; Waterworth DM, 1997, LANCET, V349, P986, DOI 10.1016/S0140-6736(96)08368-7	15	77	78	0	2	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	SEP 18	1999	354	9183					966	967		10.1016/S0140-6736(99)00218-4	http://dx.doi.org/10.1016/S0140-6736(99)00218-4			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	236JG	10501353				2022-12-01	WOS:000082596000004
J	Calin, A; Brophy, S; Blake, D				Calin, A; Brophy, S; Blake, D			Impact of sex on inheritance of ankylosing spondylitis: a cohort study	LANCET			English	Article							HLA; SUSCEPTIBILITY; ARTHRITIS; HLA-B27	Background Ankylosing spondylitis is a genetically determined and commonly familial disorder. Men and women differ in their susceptibility to ankylosing spondylitis, with about 2.5 men affected for every woman with the disease. We investigated the influence of the sex of the index case on disease penetrance within families. Methods The ages at which 50% and 75% of patients were diagnosed with ankylosing spondylitis were ascertained from a database of 4400 cases. Index patients with children or siblings who were old enough to have obtained a diagnosis (50% and 75% rates) were assessed for prevalence of disease among relatives. Confirmation of diagnosis for affected relatives was sought for all offspring and a random 25% selection of siblings. Findings Ankylosing spondylitis was more prevalent among children (odds ratio 1.9 [95% CI 1.2-3.0], p < 0.005) and siblings (1.5 [1.2-1.9], p < 0.0001) of female index cases than among those of male cases. Analyses restricted to index cases with a young age at onset (less than or equal to 21 years) indicated that children of women had an even higher incidence of ankylosing spondylitis (7.2 [1.5-34], p = 0.013) than did children of men at similar age at onset. 38% of children of female cases had disease compared with 8% of male cases. There was no difference in sex distribution among affected children or siblings of female patients with ankylosing spondylitis. By contrast, the sons and brothers of male patients had a higher prevalence of the disease (odds ratio 2.6 [1.4-5.2], p = 0.003) than did daughters and sisters (1.7 [1.3-2.2], p < 0.0001). Interpretation The influence of female sex is greater than that of male sex in determining increased susceptibility to ankylosing spondylitis in children. The striking maternal effect is greatest for women with young age at onset, which is not seen in men. The sex ratio of affected children depends on the sex of the affected parent.	Royal Natl Hosp Rheumat Dis, Bath BA1 1RL, Avon, England	Royal National Hospital for Rheumatic Diseases (RNHRD)	Calin, A (corresponding author), Royal Natl Hosp Rheumat Dis, Upper Borough Walls, Bath BA1 1RL, Avon, England.			Brophy, Sinead/0000-0001-7417-2858				ARMSTRONG BD, 1985, BR J RHEUMATOL, V24, P277; Bennett PH, 1968, POPULATION STUDIES R; Brown MA, 1997, ARTHRITIS RHEUM, V40, P1823, DOI 10.1002/art.1780401015; BROWN MA, 1995, BR J RHEUMATOL S1, V34, P76; CALIN A, 1983, ARTHRITIS RHEUM, V26, P1460, DOI 10.1002/art.1780261207; CALIN A, 1985, CLIN RHEUM DIS, V11, P41; CALIN A, 1993, OXFORD TXB RHEUMATOL, V2; CALIN A, 1998, SPONDYLARTHRITIDES; CHO Y, 1997, GASTROENTEROLOGY, V112, pA948; LYNN AH, 1995, AM J HUM GENET, V57, P150; MACKAY K, 1997, ARTHRITIS RHEUM, V40, P561; MILLIGAN RA, 1984, ULTRAMICROSCOPY, V13, P1, DOI 10.1016/0304-3991(84)90051-2; Nair RP, 1997, HUM MOL GENET, V6, P1349, DOI 10.1093/hmg/6.8.1349; Simmons WA, 1997, J IMMUNOL, V159, P2750; THOMSON G, 1995, CRIT REV CL LAB SCI, V32, P183, DOI 10.3109/10408369509084684; Tromp G, 1996, AM J HUM GENET, V59, P1097; VANDERLINDEN SM, 1984, ARTHRITIS RHEUM, V27, P241	17	68	69	0	3	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	NOV 13	1999	354	9191					1687	1690		10.1016/S0140-6736(99)03219-5	http://dx.doi.org/10.1016/S0140-6736(99)03219-5			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	255CW	10568571				2022-12-01	WOS:000083652800012
J	Muller-Trutwin, M; Barre-Sinoussi, F				Muller-Trutwin, M; Barre-Sinoussi, F			Towards improvements in molecular tools for diagnosis and management of HIV infections	LANCET			English	Editorial Material							POLYMERASE CHAIN-REACTION; GROUP-O; QUANTIFICATION		Inst Pasteur, Dept Virol, F-75724 Paris 15, France	Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris	Muller-Trutwin, M (corresponding author), Inst Pasteur, Dept Virol, F-75724 Paris 15, France.		Barre-Sinoussi, Françoise/G-8355-2011	Muller-Trutwin, Michaela/0000-0002-3854-2396				Alaeus A, 1999, AIDS RES HUM RETROV, V15, P889, DOI 10.1089/088922299310593; Alaeus A, 1997, AIDS, V11, P859, DOI 10.1097/00002030-199707000-00004; [Anonymous], 1998, MMWR Recomm Rep, V47, P1; FRANSEN K, 1994, MOL CELL PROBE, V8, P317, DOI 10.1006/mcpr.1994.1043; Gao F, 1999, NATURE, V397, P436, DOI 10.1038/17130; HU D, 1998, AIDS OTHER MANIFESTA, P27; Le Corfec E, 1999, TRANSFUSION, V39, P1141, DOI 10.1046/j.1537-2995.1999.39101141.x; LEPONT F, 1995, TRANSFUSION, V35, P542; LOUSSERTAJAKA I, 1995, LANCET, V346, P912, DOI 10.1016/S0140-6736(95)92762-X; Parekh B, 1999, AIDS RES HUM RETROV, V15, P133, DOI 10.1089/088922299311556; Respess RA, 1997, J CLIN MICROBIOL, V35, P1284, DOI 10.1128/JCM.35.5.1284-1286.1997; Simon F, 1998, NAT MED, V4, P1032, DOI 10.1038/2017; Triques K, 1999, J CLIN MICROBIOL, V37, P110, DOI 10.1128/JCM.37.1.110-116.1999; Wilber JC, 1997, IMMUNOL INVEST, V26, P9, DOI 10.3109/08820139709048911; Yang CF, 1999, J CLIN MICROBIOL, V37, P2581, DOI 10.1128/JCM.37.8.2581-2586.1999	15	5	7	0	2	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	NOV 13	1999	354	9191					1660	1662		10.1016/S0140-6736(99)00211-1	http://dx.doi.org/10.1016/S0140-6736(99)00211-1			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	255CW	10568563				2022-12-01	WOS:000083652800004
J	Shirasu, K; Lahaye, T; Tan, MW; Zhou, FS; Azevedo, C; Schulze-Lefert, P				Shirasu, K; Lahaye, T; Tan, MW; Zhou, FS; Azevedo, C; Schulze-Lefert, P			A novel class of eukaryotic zinc-binding proteins is required for disease resistance signaling in barley and development in C-elegans	CELL			English	Article							POWDERY MILDEW INTERACTION; PROGRAMMED CELL-DEATH; OXIDATIVE BURST; GENE ML-A12; PLANTS; ARABIDOPSIS; PATHOGEN; FINGER; LOCUS; RESPONSES	Barley Rar1 is a convergence point in the signaling of resistance to powdery mildew, triggered by multiple race-specific resistance (R) genes. Rar1 is shown to function upstream of H2O2 accumulation in attacked host cells, which precedes localized host cell death. We isolated Rar1 by map-based cloning. The sequence of the deduced 25.5 kDa protein reveals two copies of a 60-amino acid domain, CHORD, conserved in tandem organization in protozoa, plants, and metazoa. CHORD defines a novel eukaryotic Zn2+-binding domain. Silencing of the C. elegans CHORD-containing gene, chp, results in semisterility and embryo lethality, suggesting an essential function of the wild-type gene in nematode development. Our findings indicate that plant R genes have recruited a fundamental cellular control element for signaling of disease resistance and cell death.	John Innes Ctr Plant Sci Res, Sainsbury Lab, Norwich NR4 7UH, Norfolk, England; Massachusetts Gen Hosp, Dept Mol Biol, Boston, MA 02114 USA; Harvard Univ, Sch Med, Dept Genet, Boston, MA 02115 USA	UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); John Innes Center; Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School	Schulze-Lefert, P (corresponding author), John Innes Ctr Plant Sci Res, Sainsbury Lab, Colney Lane, Norwich NR4 7UH, Norfolk, England.	schlet@bbsrc.ac.uk	Azevedo, Cristina/Y-4296-2019; Shirasu, Ken/A-4455-2010; Schulze-Lefert, Paul/B-6707-2011; Shirasu, Ken/ABF-5306-2020; Schulze-Lefert, Paul/A-7746-2008	Azevedo, Cristina/0000-0002-6997-1265; Shirasu, Ken/0000-0002-0349-3870; Shirasu, Ken/0000-0002-0349-3870; 				Aarts N, 1998, P NATL ACAD SCI USA, V95, P10306, DOI 10.1073/pnas.95.17.10306; Baker B, 1997, SCIENCE, V276, P726, DOI 10.1126/science.276.5313.726; BENDAHMANE A, 1999, IN PRESS BIOTECHNIQU; Borden KLB, 1996, CURR OPIN STRUC BIOL, V6, P395, DOI 10.1016/S0959-440X(96)80060-1; CENTURY KS, 1995, P NATL ACAD SCI USA, V92, P6597, DOI 10.1073/pnas.92.14.6597; DIETRICH RA, 1994, CELL, V77, P565, DOI 10.1016/0092-8674(94)90218-6; EDWARDS A, 1999, IN PRESS EUR J BIOCH; FALK A, 1999, P NATL ACAD SCI USA, V95, P10306; Fire A, 1998, NATURE, V391, P806, DOI 10.1038/35888; FREIALDENHOVEN A, 1994, PLANT CELL, V6, P983; GIEDROC DP, 1986, P NATL ACAD SCI USA, V83, P8452, DOI 10.1073/pnas.83.22.8452; Gill GN, 1995, STRUCTURE, V3, P1285, DOI 10.1016/S0969-2126(01)00265-9; GOODALL GJ, 1991, EMBO J, V10, P2635, DOI 10.1002/j.1460-2075.1991.tb07806.x; GREENBERG JT, 1994, CELL, V77, P551, DOI 10.1016/0092-8674(94)90217-8; Groom QJ, 1996, PLANT J, V10, P515, DOI 10.1046/j.1365-313X.1996.10030515.x; Gumienny TL, 1999, DEVELOPMENT, V126, P1011; HORTON RM, 1989, GENE, V77, P61, DOI 10.1016/0378-1119(89)90359-4; Huckelhoven R, 1999, PLANT PHYSIOL, V119, P1251, DOI 10.1104/pp.119.4.1251; Jones DA, 1997, ADV BOT RES, V24, P89; JORGENSEN JH, 1988, GENOME, V30, P129, DOI 10.1139/g88-022; Jorgensen JH, 1996, GENOME, V39, P492, DOI 10.1139/g96-063; KIM JS, 1994, ANAL BIOCHEM, V219, P165, DOI 10.1006/abio.1994.1251; Kitagawa K, 1999, MOL CELL, V4, P21, DOI 10.1016/S1097-2765(00)80184-7; Lahaye T, 1998, MOL GEN GENET, V260, P92, DOI 10.1007/s004380050874; Lamb C, 1997, ANNU REV PLANT PHYS, V48, P251, DOI 10.1146/annurev.arplant.48.1.251; LEVINE A, 1994, CELL, V79, P583, DOI 10.1016/0092-8674(94)90544-4; Marcotte EM, 1999, SCIENCE, V285, P751, DOI 10.1126/science.285.5428.751; MARTIN W, 1989, NATURE, V339, P46, DOI 10.1038/339046a0; Parniske M, 1997, CELL, V91, P821, DOI 10.1016/S0092-8674(00)80470-5; Pennell RI, 1997, PLANT CELL, V9, P1157, DOI 10.1105/tpc.9.7.1157; Peterhansel C, 1997, PLANT CELL, V9, P1397, DOI 10.1105/tpc.9.8.1397; SANCHEZGARCIA I, 1994, TRENDS GENET, V10, P315, DOI 10.1016/0168-9525(94)90034-5; Schiffer R, 1997, MOL PLANT MICROBE IN, V10, P830, DOI 10.1094/MPMI.1997.10.7.830; SCHWABE JWR, 1994, NAT STRUCT BIOL, V1, P345, DOI 10.1038/nsb0694-345; Shirasu K, 1997, PLANT CELL, V9, P261, DOI 10.1105/tpc.9.2.261; ThordalChristensen H, 1997, PLANT J, V11, P1187, DOI 10.1046/j.1365-313X.1997.11061187.x; TORP J, 1986, CAN J GENET CYTOL, V28, P725, DOI 10.1139/g86-102; van der Biezen EA, 1998, CURR BIOL, V8, pR226, DOI 10.1016/S0960-9822(98)70145-9; Vaux DL, 1999, CELL, V96, P245, DOI 10.1016/S0092-8674(00)80564-4; von Ropenack E, 1998, J BIOL CHEM, V273, P9013, DOI 10.1074/jbc.273.15.9013; WEBSTER LC, 1991, P NATL ACAD SCI USA, V88, P9989, DOI 10.1073/pnas.88.22.9989; WEI F, 1999, IN PRESS GENETICS	42	280	311	2	20	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	NOV 12	1999	99	4					355	366		10.1016/S0092-8674(00)81522-6	http://dx.doi.org/10.1016/S0092-8674(00)81522-6			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	256CX	10571178	Bronze			2022-12-01	WOS:000083709300003
J	Troemel, ER; Sagasti, A; Bargmann, CI				Troemel, ER; Sagasti, A; Bargmann, CI			Lateral signaling mediated by axon contact and calcium entry regulates asymmetric odorant receptor expression in C-elegans	CELL			English	Article							NUCLEOTIDE-GATED CHANNEL; CAENORHABDITIS-ELEGANS; SENSORY NEURONS; CHEMOSENSORY RECEPTORS; SYNAPTIC PLASTICITY; GENE; PROTEIN; ENCODES; GUIDANCE; SYSTEM	C. elegans detects several odorants with the bilaterally symmetric pair of AWC olfactory neurons. A stochastic, coordinated decision ensures that the candidate odorant receptor gene str-2 is expressed in only one AWC neuron in each animal-either the left or the right neuron, but never both. An interaction between the two AWC neurons generates asymmetric str-2 expression in a process that requires normal axon guidance and probably AWC axon contact. This interaction induces str-a expression by reducing calcium signaling through a voltage-dependent Ca2+ channel and the CaM kinase II UNC-43. CaMKII activity acts as a switch in the initial decision to express str-2; thus, calcium signals can define distinct cell types during neuronal development. A cGMP signaling pathway that is used in olfaction maintains str-2 expression after the initial decision has been made.	Univ Calif San Francisco, Howard Hughes Med Inst, San Francisco, CA 94143 USA; Univ Calif San Francisco, Program Dev Biol, San Francisco, CA 94143 USA; Univ Calif San Francisco, Program Neurosci, San Francisco, CA 94143 USA; Univ Calif San Francisco, Genet Program, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Anat, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Biochem & Biophys, San Francisco, CA 94143 USA	Howard Hughes Medical Institute; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco	Bargmann, CI (corresponding author), Univ Calif San Francisco, Howard Hughes Med Inst, San Francisco, CA 94143 USA.	cori@itsa.ucsf.edu		Bargmann, Cornelia/0000-0002-8484-0618				Anderson P, 1995, METHOD CELL BIOL, V48, P31; BAIER H, 1994, P NATL ACAD SCI USA, V91, P11646, DOI 10.1073/pnas.91.24.11646; BARGMANN CI, 1991, NEURON, V7, P729, DOI 10.1016/0896-6273(91)90276-6; Bargmann CI, 1998, SCIENCE, V282, P2028, DOI 10.1126/science.282.5396.2028; BARGMANN CI, 1993, CELL, V74, P515, DOI 10.1016/0092-8674(93)80053-H; BLAIR SS, 1990, J NEUROSCI, V10, P3183; BRAUN AP, 1995, ANNU REV PHYSIOL, V57, P417, DOI 10.1146/annurev.ph.57.030195.002221; BUCK L, 1991, CELL, V65, P175, DOI 10.1016/0092-8674(91)90418-X; CHESS A, 1994, CELL, V78, P823, DOI 10.1016/S0092-8674(94)90562-2; Chou WH, 1999, DEVELOPMENT, V126, P607; Clyne PJ, 1999, NEURON, V22, P327, DOI 10.1016/S0896-6273(00)81093-4; Coburn CM, 1996, NEURON, V17, P695, DOI 10.1016/S0896-6273(00)80201-9; DeVries SH, 1997, J NEUROPHYSIOL, V78, P2048, DOI 10.1152/jn.1997.78.4.2048; Dwyer ND, 1998, CELL, V93, P455, DOI 10.1016/S0092-8674(00)81173-3; GOVIND CK, 1992, J NEUROBIOL, V23, P1423, DOI 10.1002/neu.480231006; Greenwald I, 1998, GENE DEV, V12, P1751, DOI 10.1101/gad.12.12.1751; GRUNERT U, 1994, J COMP NEUROL, V348, P607, DOI 10.1002/cne.903480410; HALL DH, 1991, CELL, V65, P837, DOI 10.1016/0092-8674(91)90391-B; HEDGECOCK EM, 1985, DEV BIOL, V111, P158, DOI 10.1016/0012-1606(85)90443-9; HUANG LS, 1994, MOL BIOL CELL, V5, P395, DOI 10.1091/mbc.5.4.395; Jansen G, 1999, NAT GENET, V21, P414, DOI 10.1038/7753; Komatsu H, 1996, NEURON, V17, P707, DOI 10.1016/S0896-6273(00)80202-0; Lee RYN, 1997, EMBO J, V16, P6066, DOI 10.1093/emboj/16.20.6066; MacNeil MA, 1998, NEURON, V20, P971, DOI 10.1016/S0896-6273(00)80478-X; Malnic B, 1999, CELL, V96, P713, DOI 10.1016/S0092-8674(00)80581-4; MARUYAMA IN, 1991, P NATL ACAD SCI USA, V88, P5729, DOI 10.1073/pnas.88.13.5729; MAYFORD M, 1992, SCIENCE, V256, P638, DOI 10.1126/science.1585176; MELLO CC, 1991, EMBO J, V10, P3959, DOI 10.1002/j.1460-2075.1991.tb04966.x; Mombaerts P, 1996, CELL, V87, P675, DOI 10.1016/S0092-8674(00)81387-2; NONET ML, 1993, CELL, V73, P1291, DOI 10.1016/0092-8674(93)90357-V; OTSUKA AJ, 1995, J CELL BIOL, V129, P1081, DOI 10.1083/jcb.129.4.1081; Papatsenko D, 1997, DEVELOPMENT, V124, P1665; REINER DJ, 1999, IN PRESS NATURE; Roayaie K, 1998, NEURON, V20, P55, DOI 10.1016/S0896-6273(00)80434-1; Robey E, 1997, CURR OPIN GENET DEV, V7, P551, DOI 10.1016/S0959-437X(97)80085-8; Sagasti A, 1999, GENE DEV, V13, P1794, DOI 10.1101/gad.13.14.1794; SCHAFER WR, 1995, NATURE, V375, P73, DOI 10.1038/375073a0; Schuster CM, 1996, NEURON, V17, P655, DOI 10.1016/S0896-6273(00)80198-1; SENGUPTA P, 1994, CELL, V79, P971, DOI 10.1016/0092-8674(94)90028-0; Sengupta P, 1996, CELL, V84, P899, DOI 10.1016/S0092-8674(00)81068-5; STARICH TA, 1993, GENETICS, V133, P527; Troemel ER, 1997, CELL, V91, P161, DOI 10.1016/S0092-8674(00)80399-2; TROEMEL ER, 1995, CELL, V83, P207, DOI 10.1016/0092-8674(95)90162-0; Vosshall LB, 1999, CELL, V96, P725, DOI 10.1016/S0092-8674(00)80582-6; WASSLE H, 1991, PHYSIOL REV, V71, P447, DOI 10.1152/physrev.1991.71.2.447; WEINSHENKER DZ, 1999, IN PRESS J NEUROSCI; WHITE JG, 1986, PHILOS T R SOC B, V314, P1, DOI 10.1098/rstb.1986.0056; WILLIAMS BD, 1992, GENETICS, V131, P609; YOCHEM J, 1989, CELL, V58, P553, DOI 10.1016/0092-8674(89)90436-4; YOCHEM J, 1988, NATURE, V335, P547, DOI 10.1038/335547a0; Yu S, 1997, P NATL ACAD SCI USA, V94, P3384, DOI 10.1073/pnas.94.7.3384; Zallen JA, 1999, DEVELOPMENT, V126, P3679; Zallen JA, 1998, CELL, V92, P217, DOI 10.1016/S0092-8674(00)80916-2; ZORAN MJ, 1993, DEV BIOL, V158, P163, DOI 10.1006/dbio.1993.1176	54	206	240	1	8	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	NOV 12	1999	99	4					387	398		10.1016/S0092-8674(00)81525-1	http://dx.doi.org/10.1016/S0092-8674(00)81525-1			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	256CX	10571181	Bronze			2022-12-01	WOS:000083709300006
J	Gerber, AP; Keller, W				Gerber, AP; Keller, W			An adenosine deaminase that generates inosine at the wobble position of tRNAs	SCIENCE			English	Article							TRANSITION-STATE ANALOG; CYTIDINE DEAMINASE; TRANSFER-RNA; SACCHAROMYCES-CEREVISIAE; MUTATIONS; ENZYME; MECHANISM	Several transfer RNAs (tRNAs) contain inosine (I) at the first. position of their anticodon (position 34): this modification is thought. to enlarge the codon recognition capacity during protein synthesis. The tRNA-specific adenosine deaminase of Saccharomyces cerevisiae that forms I-34 in tRNAs is described. The heteroclimeric enzyme consists of two sequence-related subunits (Tad2p/ADAT2 and Tad3p/ADAT3), both of which contain cytidine deaminase (CDA) motifs. Each subunit is encoded by an essential gene (TAD2 and TAD3), indicating that I-34 is an indispensable base modification in elongating tRNAs. These results provide an evolutionary Link between the CDA superfamily and RNA-dependent adenosine deaminases (ADARs/ADATs).	Univ Basel, Bioctr, Dept Cell Biol, CH-4056 Basel, Switzerland	University of Basel	Keller, W (corresponding author), Univ Basel, Bioctr, Dept Cell Biol, CH-4056 Basel, Switzerland.	walter.keller@unibas.ch		Gerber, Andre/0000-0002-2398-6592				Amrani N, 1996, MOL GEN GENET, V252, P552, DOI 10.1007/BF02172401; Auxilien S, 1996, J MOL BIOL, V262, P437, DOI 10.1006/jmbi.1996.0527; Bass BL, 1997, TRENDS BIOCHEM SCI, V22, P157, DOI 10.1016/S0968-0004(97)01035-9; Bass BL, 1997, RNA, V3, P947; BETTS L, 1994, J MOL BIOL, V235, P635, DOI 10.1006/jmbi.1994.1018; BONNEAUD N, 1991, YEAST, V7, P609, DOI 10.1002/yea.320070609; Carlow D, 1998, BIOCHEMISTRY-US, V37, P11873, DOI 10.1021/bi980959n; Carter Jr C. W., 1998, MODIFICATION EDITING, P363; CRICK FHC, 1966, J MOL BIOL, V19, P548, DOI 10.1016/S0022-2836(66)80022-0; Gerber A, 1998, EMBO J, V17, P4780, DOI 10.1093/emboj/17.16.4780; Grosjean H, 1996, BIOCHIMIE, V78, P488, DOI 10.1016/0300-9084(96)84755-9; Hofmann K, 1999, NUCLEIC ACIDS RES, V27, P215, DOI 10.1093/nar/27.1.215; HOLLEY RW, 1965, J BIOL CHEM, V240, P2122; Keller W, 1999, FEBS LETT, V452, P71, DOI 10.1016/S0014-5793(99)00590-6; LAI F, 1995, J BIOL CHEM, V270, P17098, DOI 10.1074/jbc.270.29.17098; Maas S, 1999, P NATL ACAD SCI USA, V96, P8895, DOI 10.1073/pnas.96.16.8895; Maas S, 1997, CURR OPIN CELL BIOL, V9, P343, DOI 10.1016/S0955-0674(97)80006-3; MIKAELIAN I, 1992, NUCLEIC ACIDS RES, V20, P376, DOI 10.1093/nar/20.2.376; Navaratnam N, 1998, J MOL BIOL, V275, P695, DOI 10.1006/jmbi.1997.1506; OConnell MA, 1997, CURR BIOL, V7, pR437, DOI 10.1016/S0960-9822(06)00212-0; SCOTT J, 1995, CELL, V81, P833, DOI 10.1016/0092-8674(95)90002-0; Spingola M, 1999, RNA, V5, P221, DOI 10.1017/S1355838299981682; Sprinzl M, 1998, NUCLEIC ACIDS RES, V26, P148, DOI 10.1093/nar/26.1.148; TENG BB, 1993, SCIENCE, V260, P1816, DOI 10.1126/science.8511591; WILSON DK, 1991, SCIENCE, V252, P1278, DOI 10.1126/science.1925539	25	221	235	0	11	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 5	1999	286	5442					1146	1149		10.1126/science.286.5442.1146	http://dx.doi.org/10.1126/science.286.5442.1146			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	253AJ	10550050				2022-12-01	WOS:000083534200040
J	Ives, AR; Gross, K; Klug, JL				Ives, AR; Gross, K; Klug, JL			Stability and variability in competitive communities	SCIENCE			English	Article							STATISTICAL INEVITABILITY; DIVERSITY; ECOLOGY; BIODIVERSITY; ECOSYSTEM	Long-term variability in the abundance of populations depends on the sensitivity of species to environmental fluctuations and the amplification of environmental fluctuations by interactions among species. Although competitive interactions and species number may have diverse effects on variability measured at the individual species level, a combination of theoretical analyses shows that these factors have no effect on variability measured at the community level. Therefore, biodiversity may increase community stability by promoting diversity among species in their responses to environmental fluctuations, but increasing the number and strength of competitive interactions has little effect.	Univ Wisconsin, Dept Zool, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison	Ives, AR (corresponding author), Univ Wisconsin, Dept Zool, Madison, WI 53706 USA.	arives@facstaff.wisc.edu	Ives, Anthony/A-5698-2008	Ives, Anthony/0000-0001-9375-9523				Doak DF, 1998, AM NAT, V151, P264, DOI 10.1086/286117; ELTON CS, 1958, ECOLOGY INVASIONS PL; FROST TM, 1994, LINKING SPECIES ECOS, P224; Ives AR, 1998, ECOLOGY, V79, P1039, DOI 10.1890/0012-9658(1998)079[1039:CDISTM]2.0.CO;2; IVES AR, 1995, ECOL MONOGR, V65, P217, DOI 10.2307/2937138; LAWTON JH, 1993, BIODIVERSITY ECOSYST, V80, P255; MACARTHUR R, 1955, ECOLOGY, V36, P533, DOI 10.2307/1929601; MARGALEF R, 1969, BROOKHAVEN SYM BIOL, P25; MAY RM, 1972, NATURE, V238, P413, DOI 10.1038/238413a0; May RM, 1974, SYST MAN CYBERN, DOI 10.2307/j.ctvs32rq4; MCNAUGHTON SJ, 1985, ECOL MONOGR, V55, P259, DOI 10.2307/1942578; MCNAUGHTON SJ, 1977, AM NAT, V111, P515, DOI 10.1086/283181; Pimm S.L., 1991, BALANCE NATURE; PIMM SL, 1984, NATURE, V307, P321, DOI 10.1038/307321a0; Tilman D, 1998, AM NAT, V151, P277, DOI 10.1086/286118; Tilman D, 1999, ECOLOGY, V80, P1455, DOI 10.1890/0012-9658(1999)080[1455:TECOCI]2.0.CO;2; Tilman D, 1996, ECOLOGY, V77, P350, DOI 10.2307/2265614; TILMAN D, 1994, NATURE, V367, P363, DOI 10.1038/367363a0	18	225	242	3	107	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 15	1999	286	5439					542	544		10.1126/science.286.5439.542	http://dx.doi.org/10.1126/science.286.5439.542			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	245RD	10521351				2022-12-01	WOS:000083121200063
J	Jenney, FE; Verhagen, MFJM; Cui, XY; Adams, MWW				Jenney, FE; Verhagen, MFJM; Cui, XY; Adams, MWW			Anaerobic microbes: Oxygen detoxification without superoxide dismutase	SCIENCE			English	Article							COMPLETE GENOME SEQUENCE; ALKYL HYDROPEROXIDE REDUCTASE; AMINO-ACID-SEQUENCE; RBO GENE-PRODUCT; PYROCOCCUS-FURIOSUS; ESCHERICHIA-COLI; SALMONELLA-TYPHIMURIUM; DESULFOVIBRIO-GIGAS; REDOX PROTEINS; RESOLUTION	Superoxide reductase from the hyperthermophilic anaerobe Pyrococcus furiosus uses electrons from reduced nicotinamide adenine dinucleotide phosphate, by way of rubredoxin and an oxidoreductase, to reduce superoxide to hydrogen peroxide, which is then reduced to water by peroxidases. Unlike superoxide dismutase, the enzyme that protects aerobes from the toxic effects of oxygen, SOR does not catalyze the production of oxygen from superoxide and therefore confers a selective advantage on anaerobes. Superoxide reductase and associated proteins are catalytically active 80 degrees C below the optimum growth temperature (100 degrees C) of P. furiosus, conditions under which the organism is likely to be exposed to oxygen.	Univ Georgia, Ctr Metalloenzyme Studies, Dept Biochem & Mol Biol, Athens, GA 30602 USA	University System of Georgia; University of Georgia	Adams, MWW (corresponding author), Univ Georgia, Ctr Metalloenzyme Studies, Dept Biochem & Mol Biol, Athens, GA 30602 USA.	adams@bmb.uga.edu						Adams MWW, 1996, ADV PROTEIN CHEM, V48, P101; ADAMS MWW, 1992, ADV INORG CHEM, V38, P341, DOI 10.1016/S0898-8838(08)60068-9; AEBI H, 1984, METHOD ENZYMOL, V105, P121; Alban PS, 1998, J APPL MICROBIOL, V85, P875, DOI 10.1046/j.1365-2672.1998.00602.x; AZZI A, 1975, BIOCHEM BIOPH RES CO, V65, P597, DOI 10.1016/S0006-291X(75)80188-4; Bau R, 1998, J BIOL INORG CHEM, V3, P484, DOI 10.1007/s007750050258; BEAUCHAMP C, 1970, J BIOL CHEM, V245, P4641; Beauchamp C, 1971, ANAL BIOCHEM, V44, P276, DOI [10.1016/0003-2697(71)90370-8, DOI 10.1016/0003-2697(71)90370-8]; BLAKE PR, 1991, BIOCHEMISTRY-US, V30, P10885, DOI 10.1021/bi00109a012; Blattner FR, 1997, SCIENCE, V277, P1453, DOI 10.1126/science.277.5331.1453; Bonomi F, 1996, J BIOL INORG CHEM, V1, P67, DOI 10.1007/s007750050024; Bult CJ, 1996, SCIENCE, V273, P1058, DOI 10.1126/science.273.5278.1058; CHANCE B, 1979, PHYSIOL REV, V59, P527, DOI 10.1152/physrev.1979.59.3.527; CHEN L, 1993, EUR J BIOCHEM, V216, P443, DOI 10.1111/j.1432-1033.1993.tb18162.x; CHEN LA, 1994, EUR J BIOCHEM, V226, P613, DOI 10.1111/j.1432-1033.1994.tb20087.x; Choudhury SB, 1999, BIOCHEMISTRY-US, V38, P3744, DOI 10.1021/bi982537j; Coelho AV, 1997, J BIOL INORG CHEM, V2, P680, DOI 10.1007/s007750050184; CYPIONKA H, 1985, FEMS MICROBIOL ECOL, V31, P39, DOI 10.1016/0378-1097(85)90045-X; DEMONTELLANO PRO, 1992, ANNU REV PHARMACOL, V32, P89, DOI 10.1146/annurev.pharmtox.32.1.89; FIALA G, 1986, ARCH MICROBIOL, V145, P56, DOI 10.1007/BF00413027; Flohe L, 1988, CRC HDB FREE RADICAL, V3, P287; FOUQUET Y, 1993, ECON GEOL BULL SOC, V88, P2018, DOI 10.2113/gsecongeo.88.8.2018; Fraser CM, 1998, SCIENCE, V281, P375, DOI 10.1126/science.281.5375.375; Fridovich I, 1998, J EXP BIOL, V201, P1203; HUBER R, 1990, NATURE, V345, P179, DOI 10.1038/345179a0; JENNEY FE, UNPUB; Johnson MS, 1997, J BACTERIOL, V179, P5598, DOI 10.1128/jb.179.17.5598-5601.1997; Kaneko T, 1996, DNA Res, V3, P185, DOI 10.1093/dnares/3.3.185; Kang SW, 1998, J BIOL CHEM, V273, P6303, DOI 10.1074/jbc.273.11.6303; Kawarabayasi Y, 1998, DNA Res, V5, P55, DOI 10.1093/dnares/5.2.55; KITAMURA M, 1998, AB020341 GENBANK; Klenk HP, 1997, NATURE, V390, P364, DOI 10.1038/37052; Kurtz DM, 1997, J BIOL INORG CHEM, V2, P159, DOI 10.1007/s007750050120; LAI KN, 1992, M96560 GENBANK; LEE TH, 1998, AAD03716 GANBANK; Lehmann Y, 1996, J BACTERIOL, V178, P7152, DOI 10.1128/jb.178.24.7152-7158.1996; Liochev SI, 1997, J BIOL CHEM, V272, P25573, DOI 10.1074/jbc.272.41.25573; LUDWIG ML, 1991, J MOL BIOL, V219, P335, DOI 10.1016/0022-2836(91)90569-R; Ma K, 1999, J BACTERIOL, V181, P5530, DOI 10.1128/JB.181.17.5530-5533.1999; Mallett TC, 1998, BIOCHEMISTRY-US, V37, P8790, DOI 10.1021/bi9803630; Marklund, 1985, HDB METHODS OXYGEN R, V243, P247; MARVINSIKKEMA FD, 1993, ARCH MICROBIOL, V160, P388; MCCORD JM, 1969, J BIOL CHEM, V244, P6049; MOORE GR, 1990, CYTOCHROMES C EVOLUT, P328; NAKAYAMA K, 1994, J BACTERIOL, V176, P1939, DOI 10.1128/jb.176.7.1939-1943.1994; Nelson KE, 1999, NATURE, V399, P323, DOI 10.1038/20601; Pianzzola MJ, 1996, J BACTERIOL, V178, P6736, DOI 10.1128/jb.178.23.6736-6742.1996; Poole LB, 1996, BIOCHEMISTRY-US, V35, P56, DOI 10.1021/bi951887s; PRIEUR D, 1999, GENOSCOPE; ROBERTON AM, 1970, J BACTERIOL, V102, P43, DOI 10.1128/JB.102.1.43-51.1970; Rocha ER, 1996, J BACTERIOL, V178, P6895, DOI 10.1128/jb.178.23.6895-6903.1996; Romao CV, 1999, EUR J BIOCHEM, V261, P438, DOI 10.1046/j.1432-1327.1999.00278.x; ROSS RP, 1992, J MOL BIOL, V227, P658, DOI 10.1016/0022-2836(92)90215-6; SAWYER DT, 1981, ACCOUNTS CHEM RES, V14, P393, DOI 10.1021/ar00072a005; SEARCY DG, 1995, ARCH BIOCHEM BIOPHYS, V318, P251, DOI 10.1006/abbi.1995.1228; SHENVI NV, 1997, AF034841 GENBANK; SHENVI NV, 1997, AF034965 GENBANK; Silva G, 1999, EUR J BIOCHEM, V259, P235, DOI 10.1046/j.1432-1327.1999.00025.x; Smith DR, 1997, J BACTERIOL, V179, P7135, DOI 10.1128/jb.179.22.7135-7155.1997; STEHLE T, 1991, J MOL BIOL, V221, P1325, DOI 10.1016/0022-2836(91)90936-Z; STODDARD BL, 1990, BIOCHEMISTRY-US, V29, P8885, DOI 10.1021/bi00490a002; Summit M, 1998, DEEP-SEA RES PT II, V45, P2751, DOI 10.1016/S0967-0645(98)00092-7; TAINER JA, 1983, NATURE, V306, P284, DOI 10.1038/306284a0; TARTAGLIA LA, 1990, J BIOL CHEM, V265, P10535; TIVEY MK, 1995, SEAFLOOR HYDROTHERMA, P158; Valentine JS, 1998, CURR OPIN CHEM BIOL, V2, P253, DOI 10.1016/S1367-5931(98)80067-7; van Niel EWJ, 1998, APPL ENVIRON MICROB, V64, P1034	67	317	324	2	44	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 8	1999	286	5438					306	309		10.1126/science.286.5438.306	http://dx.doi.org/10.1126/science.286.5438.306			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	243YE	10514376				2022-12-01	WOS:000083024400048
J	Joazeiro, CAP; Wing, SS; Huang, HK; Leverson, JD; Hunter, T; Liu, YC				Joazeiro, CAP; Wing, SS; Huang, HK; Leverson, JD; Hunter, T; Liu, YC			The tyrosine kinase negative regulator c-Cbl as a RING-type, E2-dependent ubiquitin-protein ligase	SCIENCE			English	Article							GROWTH-FACTOR RECEPTOR; IDENTIFICATION; PRODUCT; CONJUGATION; DEGRADATION; ONCOGENE; COMPLEX; SYSTEM; YEAST	Ubiquitination of receptor protein-tyrosine kinases (RPTKs) terminates signaling by marking active receptors for degradation. c-Cbl, an adapter protein for RPTKs, positively regulates RPTK ubiquitination in a manner dependent on its variant SRC homology 2 (SH2) and RING finger domains. Ubiquitin-protein Ligases (or E3s) are the components of ubiquitination pathways that recognize target substrates and promote their Ligation to ubiquitin. The c-Cbl protein acted as an E3 that can recognize tyrosine-phosphorylated substrates, such as the activated platelet-derived growth factor receptor, through its SH2 domain and that recruits and allosterically activates an E2 ubiquitin-conjugating enzyme through its RING domain. These results reveal an SH2-containing protein that functions as a ubiquitin-protein Ligase and thus provide a distinct mechanism for substrate targeting in the ubiquitin system.	Salk Inst Biol Studies, Mol Biol & Virol Lab, La Jolla, CA 92037 USA; McGill Univ, Dept Med, Montreal, PQ H3A 2B2, Canada; La Jolla Inst Allergy & Immunol, San Diego, CA 92121 USA	Salk Institute; McGill University; La Jolla Institute for Immunology	Hunter, T (corresponding author), Salk Inst Biol Studies, Mol Biol & Virol Lab, La Jolla, CA 92037 USA.	hunter@salk.edu		LIU, YUN-CAI/0000-0002-0996-7109	NATIONAL CANCER INSTITUTE [R35CA039780, T32CA009523] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK056558] Funding Source: NIH RePORTER; NCI NIH HHS [CA39780, T32CA09523] Funding Source: Medline; NIDDK NIH HHS [R01 DK56558] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANDONIOU CE, 1994, EMBO J, V13, P4515, DOI 10.1002/j.1460-2075.1994.tb06773.x; BANERJEE A, 1993, J BIOL CHEM, V268, P5668; CLAESSONWELSH L, 1988, MOL CELL BIOL, V8, P3476, DOI 10.1128/MCB.8.8.3476; FREEMONT PS, 1993, ANN NY ACAD SCI, V684, P174, DOI 10.1111/j.1749-6632.1993.tb32280.x; Grossberger R, 1999, J BIOL CHEM, V274, P14500, DOI 10.1074/jbc.274.20.14500; Haas AL, 1997, FASEB J, V11, P1257; Hampton RY, 1996, MOL BIOL CELL, V7, P2029, DOI 10.1091/mbc.7.12.2029; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; Hicke L, 1997, FASEB J, V11, P1215, DOI 10.1096/fasebj.11.14.9409540; JOAZEIRO CAP, UNPUB; Kamura T, 1999, SCIENCE, V284, P657, DOI 10.1126/science.284.5414.657; Koegl M, 1999, CELL, V96, P635, DOI 10.1016/S0092-8674(00)80574-7; Lee PSW, 1999, EMBO J, V18, P3616, DOI 10.1093/emboj/18.13.3616; Levkowitz G, 1998, GENE DEV, V12, P3663, DOI 10.1101/gad.12.23.3663; Liu YC, 1998, CELL SIGNAL, V10, P377, DOI 10.1016/S0898-6568(97)00179-4; Miyake S, 1999, J BIOL CHEM, V274, P16619, DOI 10.1074/jbc.274.23.16619; Miyake S, 1997, CRIT REV ONCOGENESIS, V8, P189, DOI 10.1615/CritRevOncog.v8.i2-3.30; Miyake S, 1998, P NATL ACAD SCI USA, V95, P7927, DOI 10.1073/pnas.95.14.7927; Mori S, 1997, EUR J BIOCHEM, V247, P1190, DOI 10.1111/j.1432-1033.1997.01190.x; Ohta T, 1999, MOL CELL, V3, P535, DOI 10.1016/S1097-2765(00)80482-7; OU F, COMMUNICATION; Oughtred R, 1998, J BIOL CHEM, V273, P18435, DOI 10.1074/jbc.273.29.18435; Parkinson J, 1999, J VIROL, V73, P650, DOI 10.1128/JVI.73.1.650-657.1999; Rajapurohitam V, 1999, DEV BIOL, V212, P217, DOI 10.1006/dbio.1999.9342; Seol JH, 1999, GENE DEV, V13, P1614, DOI 10.1101/gad.13.12.1614; Shimizu A, 1998, GENES CELLS, V3, P125, DOI 10.1046/j.1365-2443.1998.00174.x; Skowyra D, 1999, SCIENCE, V284, P662, DOI 10.1126/science.284.5414.662; Tan PL, 1999, MOL CELL, V3, P527, DOI 10.1016/S1097-2765(00)80481-5; THILEN CB, 1998, IMMUNOL CELL BIOL, V76, P473; Waterman H, 1999, J BIOL CHEM, V274, P22151, DOI 10.1074/jbc.274.32.22151; YOON CH, 1995, SCIENCE, V269, P1102, DOI 10.1126/science.7652556; Zachariae W, 1998, SCIENCE, V279, P1216, DOI 10.1126/science.279.5354.1216	32	876	903	5	55	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 8	1999	286	5438					309	312		10.1126/science.286.5438.309	http://dx.doi.org/10.1126/science.286.5438.309			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	243YE	10514377				2022-12-01	WOS:000083024400049
J	Rolink, AG; Nutt, SL; Melchers, F; Busslinger, M				Rolink, AG; Nutt, SL; Melchers, F; Busslinger, M			Long-term in vivo reconstitution of T-cell development by Pax5-deficient B-cell progenitors	NATURE			English	Article							RECEPTOR-ALPHA-GENE; BONE-MARROW; REARRANGEMENT; MICE; IDENTIFICATION; EXPRESSION; CHAIN; DIFFERENTIATION; THYMOCYTES; THYMUS	The mechanisms controlling the commitment of haematopoietic progenitors to the B-lymphoid lineage are poorly understood. The observations that mice deficient in E2A(1,2) and EBF3 lack B-lineage cells have implicated these two transcription factors in the commitment process. Moreover, the expression of genes encoding components of the rearrangement machinery (RAG1, RAG2, TdT) or pre-B-cell receptor (lambda 5, VpreB, Ig alpha, Ig beta) has been considered to indicate B-lineage commitment(4). All these genes including E2A and EBF are expressed in pro-B cells lacking the transcription factor Pax5 (refs 5-7). Here we show that cloned Pax5-deficient pro-B cells transferred into RAG2-deficient mice provide longterm reconstitution of the thymus and give rise to mature T cells expressing alpha/beta-T-cell receptors. The bone marrow of these mice contains a population of cells of Pax5(-/-) origin with the same phenotype as the donor pro-B cells. When transferred into secondary recipients, these pro-B cells again home to the bone marrow and reconstitute the thymus. Hence, B-Lineage commitment is determined neither by immunoglobulin DJ rearrangement nor by the expression of E2A, EBF, lambda 5, VpreB, Ig alpha and Ig beta. Instead, our data implicate Pax5 in the control of B-lineage commitment.	Basel Inst Immunol, CH-4005 Basel, Switzerland; Res Inst Mol Pathol, A-1030 Vienna, Austria	Vienna Biocenter (VBC); Research Institute of Molecular Pathology (IMP)	Rolink, AG (corresponding author), Basel Inst Immunol, Grenzacherstr 487, CH-4005 Basel, Switzerland.		Nutt, Stephen L/C-9256-2013; Busslinger, Meinrad J./J-1249-2016	Nutt, Stephen L/0000-0002-0020-6637; Busslinger, Meinrad J./0000-0002-9111-9351				Backstrom BT, 1996, IMMUNITY, V5, P437, DOI 10.1016/S1074-7613(00)80500-2; BAIN G, 1994, CELL, V79, P885, DOI 10.1016/0092-8674(94)90077-9; BORN W, 1988, J IMMUNOL, V140, P3228; BRUNO L, 1995, EUR J IMMUNOL, V25, P1877, DOI 10.1002/eji.1830250713; CEREDIG R, 1984, THYMUS, V6, P15; FEHLING HJ, 1995, NATURE, V375, P795, DOI 10.1038/375795a0; GRAWUNDER U, 1993, INT IMMUNOL, V5, P1609, DOI 10.1093/intimm/5.12.1609; GRIGORIADIS AE, 1994, SCIENCE, V266, P443, DOI 10.1126/science.7939685; GU H, 1991, CELL, V65, P47, DOI 10.1016/0092-8674(91)90406-O; Kondo M, 1997, CELL, V91, P661, DOI 10.1016/S0092-8674(00)80453-5; LIN HH, 1995, NATURE, V376, P263, DOI 10.1038/376263a0; MARKOWITZ D, 1988, J VIROL, V62, P1120, DOI 10.1128/JVI.62.4.1120-1124.1988; Melchers F, 1999, FUNDAMENTAL IMMUNOLO, V4th, P183; Nutt SL, 1997, GENE DEV, V11, P476, DOI 10.1101/gad.11.4.476; Nutt SL, 1998, EMBO J, V17, P2319, DOI 10.1093/emboj/17.8.2319; Nutt SL, 1999, NATURE, V401, P556, DOI 10.1038/44076; Reininger L, 1996, J EXP MED, V184, P853, DOI 10.1084/jem.184.3.853; REININGER L, 1992, J EXP MED, V176, P1343, DOI 10.1084/jem.176.5.1343; RODEWALD HR, 1994, EMBO J, V13, P4229, DOI 10.1002/j.1460-2075.1994.tb06743.x; ROLINK A, 1993, J EXP MED, V178, P1263, DOI 10.1084/jem.178.4.1263; ROLLINK A, 1991, EMBO J, V10, P327; ROLLINK A, 1994, INT IMMUNOL, V6, P1257; SHINKAI Y, 1992, CELL, V68, P855, DOI 10.1016/0092-8674(92)90029-C; URBANEK P, 1994, CELL, V79, P901, DOI 10.1016/0092-8674(94)90079-5; Wang H, 1998, P NATL ACAD SCI USA, V95, P6831, DOI 10.1073/pnas.95.12.6831; ZHUANG Y, 1994, CELL, V79, P875, DOI 10.1016/0092-8674(94)90076-0	26	293	300	0	8	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	OCT 7	1999	401	6753					603	606		10.1038/44164	http://dx.doi.org/10.1038/44164			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	244MG	10524629				2022-12-01	WOS:000083054900054
J	Sheehan, KM; Sheahan, K; O'Donoghue, DP; MacSweeney, F; Conroy, RM; Fitzgerald, DJ; Murray, FE				Sheehan, KM; Sheahan, K; O'Donoghue, DP; MacSweeney, F; Conroy, RM; Fitzgerald, DJ; Murray, FE			The relationship between cyclooxygenase-2 expression and colorectal cancer	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							FAMILIAL ADENOMATOUS POLYPOSIS; HUMAN COLON-CANCER; NONSTEROIDAL ANTIINFLAMMATORY DRUG; SPONTANEOUS INTESTINAL ADENOMAS; MIN MOUSE MODEL; PLASMINOGEN-ACTIVATOR; DEPENDENT INCREASE; REDUCED RISK; ASPIRIN USE; SULINDAC	Context Epidemiological studies have implicated the inducible form of cyclooxygenase (COX-2) in the pathogenesis of colorectal cancer; however, its role is not fully understood. Objective To examine the relationship between the expression of COX-2 in human colorectal cancer and patient survival. Design Patients diagnosed as having colorectal cancer were evaluated and followed up for up to 9.4 years (median follow-up, 2.7 years). Tumor sections were stained for COX-2 using a rabbit polyclonal antibody raised against human COX-2, The extent of COX-2 staining was graded by 2 observers blinded to outcome, Preabsorption of the anti-COX-2 antibody with a COX-2 peptide abolished the staining, demonstrating the specificity of the assay. Setting Gastrointestinal unit of a large general teaching hospital in Dublin, Ireland. Participants Seventy-six patients (median age, 66.5 years) with colorectal cancer (Dukes tumor stage A, n = 9; Dukes B, n = 30; Dukes C, n = 25; Dukes D, n = 12) whose diagnosis was made between 1988 and 1991, Fourteen normal colon biopsies were stained for COX-2 as controls. Main Outcome Measures Survival in years following diagnosis compared by extent of COX-2 epithelial staining (grade 1, <1%; grade 2, 1%-19%; grade 3, 20%-49%; grade 4, greater than or equal to 50%), Dukes stage, tumor size, and lymph mode metastasis. Results COX-2 was found in tumor epithelial cells, inflammatory cells, vascular endothelium, and/or fibroblasts. The extent of epithelial staining was heterogeneous, varying markedly among different tumors. Normal tissue adjacent to the tumors also stained weakly for COX-2, No COX-2 was detected in control tissue samples, The Kaplan-Meier survival estimate was 68% in patients who had grade 1 tumor epithelial staining compared with 35% in those with higher grades combined (log-rank chi(2) = 5.7; P =.02). Greater expression of COX-2 correlated with more advanced Dukes stage (Kendall tau-b, 0.22; P=.03) and larger tumor size (Kendall tau-b, 0.21; P=.02) and was particularly evident in tumors with lymph node involvement (Kendall tau-b, 0.26; P=.02). Conclusions Our data indicate that COX-2 expression in colorectal cancer may be related to survival. These data add to the growing epidemiological and experimental evidence that COX-2 may play a role in colorectal tumorigenesis.	Royal Coll Surgeons Ireland, Dept Clin Pharmacol, Dublin 2, Ireland; Royal Coll Surgeons Ireland, Dept Epidemiol, Dublin 2, Ireland; St Vincents Hosp, Dept Pathol, Dublin 4, Ireland; St Vincents Hosp, Dept Gastroenterol, Dublin 4, Ireland; Beaumont Hosp, Dept Gastroenterol, Dublin 9, Ireland	Royal College of Surgeons - Ireland; Royal College of Surgeons - Ireland; University College Dublin; University College Dublin	Sheehan, KM (corresponding author), Royal Coll Surgeons Ireland, Dept Clin Pharmacol, 123 St Stephens Green, Dublin 2, Ireland.	ksheehan@rcsi.ie	Conroy, Ronan/C-6416-2008	Conroy, Ronan/0000-0001-5983-8682; Sheehan, Katherine/0000-0002-8969-3610				Barnes CJ, 1998, GASTROENTEROLOGY, V114, P873, DOI 10.1016/S0016-5085(98)70305-1; CHAPUIS PH, 1985, BRIT J SURG, V72, P698, DOI 10.1002/bjs.1800720909; DUBOIS RN, 1994, AM J PHYSIOL, V266, pG822; Dukes CE, 1932, J PATHOL BACTERIOL, V35, P323, DOI 10.1002/path.1700350303; Elder DJE, 1997, CLIN CANCER RES, V3, P1679; Fujita T, 1998, CANCER RES, V58, P4823; GIARDIELLO FM, 1993, NEW ENGL J MED, V328, P1313, DOI 10.1056/NEJM199305063281805; GRAHAM DM, 1990, MODERN PATHOL, V3, P332; GREENBERG ER, 1993, JNCI-J NATL CANCER I, V85, P912, DOI 10.1093/jnci/85.11.912; HLA T, 1992, P NATL ACAD SCI USA, V89, P7384, DOI 10.1073/pnas.89.16.7384; Jacoby RF, 1996, CANCER RES, V56, P710; JASS JR, 1987, J CLIN PATHOL, V40, P1016, DOI 10.1136/jcp.40.9.1016; JONES DA, 1993, J BIOL CHEM, V268, P9049; KARGMAN SL, 1995, CANCER RES, V55, P2556; Kune GA, 2007, INT J EPIDEMIOL, V36, P951, DOI 10.1093/ije/dym193; METZGER U, 1984, DIS COLON RECTUM, V27, P366, DOI 10.1007/BF02553001; MOORGHEN M, 1988, J PATHOL, V156, P341, DOI 10.1002/path.1711560411; MULCAHY HE, 1994, LANCET, V344, P583, DOI 10.1016/S0140-6736(94)91968-2; Mulcahy HE, 1997, DIS COLON RECTUM, V40, P326, DOI 10.1007/BF02050424; Oshima M, 1996, CELL, V87, P803, DOI 10.1016/S0092-8674(00)81988-1; PASRICHA PJ, 1995, GASTROENTEROLOGY, V109, P994, DOI 10.1016/0016-5085(95)90411-5; RIGAS B, 1993, J LAB CLIN MED, V122, P518; Sandler RS, 1998, GASTROENTEROLOGY, V114, P441, DOI 10.1016/S0016-5085(98)70526-8; SANO H, 1995, CANCER RES, V55, P3785; SHEPHERD NA, 1989, HISTOPATHOLOGY, V14, P613, DOI 10.1111/j.1365-2559.1989.tb02202.x; SHIFF SJ, 1995, J CLIN INVEST, V96, P491, DOI 10.1172/JCI118060; Skelly MM, 1997, CLIN CANCER RES, V3, P1837; THUN MJ, 1991, NEW ENGL J MED, V325, P1593, DOI 10.1056/NEJM199112053252301; Troisi RJ, 1999, CANCER, V85, P1670, DOI 10.1002/(SICI)1097-0142(19990415)85:8<1670::AID-CNCR5>3.0.CO;2-M; Tsujii M, 1997, P NATL ACAD SCI USA, V94, P3336, DOI 10.1073/pnas.94.7.3336; Tsujii M, 1998, CELL, V93, P705, DOI 10.1016/S0092-8674(00)81433-6; Williams CS, 1997, J CLIN INVEST, V100, P1325, DOI 10.1172/JCI119651; Yang VW, 1998, CANCER RES, V58, P1750	33	355	381	0	8	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 6	1999	282	13					1254	1257		10.1001/jama.282.13.1254	http://dx.doi.org/10.1001/jama.282.13.1254			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	241UM	10517428	Bronze			2022-12-01	WOS:000082901100033
J	Carvalho, AB; Clark, AG				Carvalho, AB; Clark, AG			Genetic recombination - Intron size and natural selection	NATURE			English	Article							SMALL DROSOPHILA INTRON; MELANOGASTER; SEQUENCES		Univ Fed Rio de Janeiro, Dept Genet, Rio De Janeiro, Brazil; Penn State Univ, Inst Mol Evolutionary Genet, Mueller Lab 208, University Pk, PA 16802 USA	Universidade Federal do Rio de Janeiro; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park	Carvalho, AB (corresponding author), Univ Fed Rio de Janeiro, Dept Genet, Rio De Janeiro, Brazil.		Carvalho, Antonio/D-5402-2013	Carvalho, Antonio/0000-0001-8959-6469; Clark, Andrew/0000-0001-7159-8511				Comeron JM, 1999, GENETICS, V151, P239; GUO M, 1995, J MOL BIOL, V253, P426, DOI 10.1006/jmbi.1995.0564; HILL WG, 1966, GENET RES, V8, P269, DOI 10.1017/S0016672300010156; HUGHES AL, 1995, NATURE, V377, P391, DOI 10.1038/377391a0; Kennedy CF, 1997, MOL CELL BIOL, V17, P2774, DOI 10.1128/MCB.17.5.2774; KLIMAN RM, 1993, MOL BIOL EVOL, V10, P1239; Moriyama EN, 1998, MOL BIOL EVOL, V15, P770, DOI 10.1093/oxfordjournals.molbev.a025980; MORONI G, 1993, ATLAS DROSOPHILA GEN, P319; MOUNT SM, 1992, NUCLEIC ACIDS RES, V20, P4255, DOI 10.1093/nar/20.16.4255; Ogata H, 1996, FEBS LETT, V390, P99, DOI 10.1016/0014-5793(96)00636-9; Petrov DA, 1996, NATURE, V384, P346, DOI 10.1038/384346a0; SNIEGOWSKI PD, 1994, GENETICS, V137, P815; STEPHAN W, 1994, GENETICS, V138, P135, DOI 10.1093/genetics/138.1.135	13	105	107	0	8	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	SEP 23	1999	401	6751					344	344		10.1038/43827	http://dx.doi.org/10.1038/43827			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	240JJ	10517631				2022-12-01	WOS:000082822600041
J	Peters, JM; McKay, RM; McKay, JP; Graff, JM				Peters, JM; McKay, RM; McKay, JP; Graff, JM			Casein kinase I transduces Wnt signals	NATURE			English	Article							GLYCOGEN-SYNTHASE KINASE-3; EARLY XENOPUS-EMBRYOS; C-ELEGANS EMBRYOS; BETA-CATENIN; CAENORHABDITIS-ELEGANS; SPEMANN ORGANIZER; AXIS FORMATION; BUDDING YEAST; PROTEIN; TRANSCRIPTION	The Wnt signalling cascade is essential for the development of both invertebrates and vertebrates, and is altered during tumorigenesis. Although a general framework for Wnt signalling has been elucidated, not all of the components have been identified. Here we describe a serine kinase, casein kinase I (CKI), which was isolated by expression cloning in Xenopus embryos. CKI reproduces several properties of Wnt signals, including generation of complete dorsal axes, stabilization of beta-catenin and induction of genes that are direct targets of Wnt signals. Dominant-negative forms of CKI and a pharmacological blocker of CKI inhibited Wnt signals in Xenopus, Inhibiting CKI in Caenorhabditis elegans generated worms with a mom phenotype, indicative of a loss of Wnt signals. In addition, CKI bound to and increased the phosphorylation of dishevelled, a known component of the Wnt pathway. These data indicate that CKI may be a conserved component of the Wnt pathway.	Univ Texas, SW Med Ctr, Ctr Dev Biol, Dept Mol Biol, Dallas, TX 75235 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Graff, JM (corresponding author), Univ Texas, SW Med Ctr, Ctr Dev Biol, Dept Mol Biol, 5323 Harry Hines Blvd,NB 5-208, Dallas, TX 75235 USA.	graff02@utsw.swmed.edu						Behrens J, 1996, NATURE, V382, P638, DOI 10.1038/382638a0; Bhanot P, 1996, NATURE, V382, P225, DOI 10.1038/382225a0; BOWERMAN B, 1993, CELL, V74, P443, DOI 10.1016/0092-8674(93)80046-H; BOWERMAN B, 1992, DEVELOPMENT, V116, P1113; Brannon M, 1997, GENE DEV, V11, P2359, DOI 10.1101/gad.11.18.2359; Cadigan KM, 1997, GENE DEV, V11, P3286, DOI 10.1101/gad.11.24.3286; Camac G., 1996, DEVELOPMENT, V122, P3055; CHIEN CT, 1991, P NATL ACAD SCI USA, V88, P9578, DOI 10.1073/pnas.88.21.9578; CHIJIWA T, 1989, J BIOL CHEM, V264, P4924; Deardorff' MA, 1998, DEVELOPMENT, V125, P2687; DEMAGGIO AJ, 1992, P NATL ACAD SCI USA, V89, P7008, DOI 10.1073/pnas.89.15.7008; EPSTEIN HF, 1995, METHODS CELL BIOL; Fire A, 1998, NATURE, V391, P806, DOI 10.1038/35888; FISH KJ, 1995, J BIOL CHEM, V270, P14875, DOI 10.1074/jbc.270.25.14875; Graff JM, 1996, CELL, V85, P479, DOI 10.1016/S0092-8674(00)81249-0; GRAFF JM, 1994, CELL, V79, P169, DOI 10.1016/0092-8674(94)90409-X; HE X, 1995, NATURE, V374, P617, DOI 10.1038/374617a0; HEASMAN J, 1994, CELL, V79, P791, DOI 10.1016/0092-8674(94)90069-8; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; HOEKSTRA MF, 1991, SCIENCE, V253, P1031, DOI 10.1126/science.1887218; Hoppler S, 1996, GENE DEV, V10, P2805, DOI 10.1101/gad.10.21.2805; Kloss B, 1998, CELL, V94, P97, DOI 10.1016/S0092-8674(00)81225-8; KRIEG PA, 1989, DEV BIOL, V133, P93, DOI 10.1016/0012-1606(89)90300-X; LeSuer JA, 1999, DEVELOPMENT, V126, P137; McKendry R, 1997, DEV BIOL, V192, P420, DOI 10.1006/dbio.1997.8797; MCMAHON AP, 1989, CELL, V58, P1075, DOI 10.1016/0092-8674(89)90506-0; Molenaar M, 1996, CELL, V86, P391, DOI 10.1016/S0092-8674(00)80112-9; Moon RT, 1997, TRENDS GENET, V13, P157, DOI 10.1016/S0168-9525(97)01093-7; NEWPORT J, 1982, CELL, V30, P687, DOI 10.1016/0092-8674(82)90273-2; NUSSE R, 1982, CELL, V31, P99, DOI 10.1016/0092-8674(82)90409-3; PIERCE SB, 1995, DEVELOPMENT, V121, P755; Rocheleau CE, 1997, CELL, V90, P707, DOI 10.1016/S0092-8674(00)80531-0; Rubinfeld B, 1997, SCIENCE, V275, P1790, DOI 10.1126/science.275.5307.1790; SASAI Y, 1994, CELL, V79, P779, DOI 10.1016/0092-8674(94)90068-X; SCHARF SR, 1983, DEV BIOL, V99, P75, DOI 10.1016/0012-1606(83)90255-5; Sharp PA, 1999, GENE DEV, V13, P139, DOI 10.1101/gad.13.2.139; SMITH WC, 1991, CELL, V67, P753, DOI 10.1016/0092-8674(91)90070-F; Sokol SY, 1996, CURR BIOL, V6, P1456, DOI 10.1016/S0960-9822(96)00750-6; Songyang Z, 1996, MOL CELL BIOL, V16, P6486; Tabara H, 1998, SCIENCE, V282, P430, DOI 10.1126/science.282.5388.430; THOMSEN G, 1990, CELL, V63, P485, DOI 10.1016/0092-8674(90)90445-K; Thorpe CJ, 1997, CELL, V90, P695, DOI 10.1016/S0092-8674(00)80530-9; Tuazon P. T., 1991, ADV 2 MESSENGER PHOS, V23, P123; Willert K, 1997, EMBO J, V16, P3089, DOI 10.1093/emboj/16.11.3089; Xu QH, 1998, DEVELOPMENT, V125, P4767; YANAGAWA SI, 1995, GENE DEV, V9, P1087, DOI 10.1101/gad.9.9.1087; Yost C, 1996, GENE DEV, V10, P1443, DOI 10.1101/gad.10.12.1443; Yost C, 1998, CELL, V93, P1031, DOI 10.1016/S0092-8674(00)81208-8; Zeng L, 1997, CELL, V90, P181, DOI 10.1016/S0092-8674(00)80324-4; Zhu JY, 1998, CELL, V93, P851, DOI 10.1016/S0092-8674(00)81445-2	50	374	390	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	SEP 23	1999	401	6751					345	350		10.1038/43830	http://dx.doi.org/10.1038/43830			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	240JJ	10517632				2022-12-01	WOS:000082822600042
J	Tanaka, TU; Cosma, MP; Wirth, K; Nasmyth, K				Tanaka, TU; Cosma, MP; Wirth, K; Nasmyth, K			Identification of cohesin association sites at centromeres and along chromosome arms	CELL			English	Article							SISTER-CHROMATID COHESION; SACCHAROMYCES-CEREVISIAE; REPLICATION ORIGINS; DNA-REPLICATION; BUDDING YEAST; MCM PROTEIN; MEIOSIS; COMPLEX; NONDISJUNCTION; RECOMBINATION	A multisubunit cohesin complex holds sister chromatids together after DNA replication. Using chromatin immunoprecipitation, we detected cohesin association with centromeres and with discrete sites along chromosome arms from S phase until metaphase in S. cerevisiae, Short DNA sequences (130-280 bp) are sufficient to confer cohesin association. Cohesin association with a centromere depends on Mif2p, the centromere binding factor CBF3, and a centromere-specific histone variant, Cse4p. Because only active centromeres confer cohesin association with centromeric DNA, we suggest that cohesin is recruited by the same chromatin structure that confers the attachment of microtubules. Propagation of this structure might be partly epigenetic. Finally, cohesion associated with "minimal" centromeres is insufficient to resist the splitting force exerted by microtubules and appears to be reinforced by cohesion provided by their flanking DNA sequences.	Res Inst Mol Pathol, A-1030 Vienna, Austria	Vienna Biocenter (VBC); Research Institute of Molecular Pathology (IMP)	Nasmyth, K (corresponding author), Res Inst Mol Pathol, Dr Bohr Gasse 7, A-1030 Vienna, Austria.	nasmyth@nt.imp.univie.ac.at	Cosma, Maria Pia/E-8731-2015; Tanaka, Tomoyuki U/A-4775-2008	Cosma, Maria Pia/0000-0003-4207-5097; Tanaka, Tomoyuki/0000-0002-9886-5947; Nasmyth, Kim/0000-0001-7030-4403				Bickel SE, 1996, BIOESSAYS, V18, P293, DOI 10.1002/bies.950180407; BISHOP DK, 1992, CELL, V69, P439, DOI 10.1016/0092-8674(92)90446-J; BROWN MT, 1993, J CELL BIOL, V123, P387, DOI 10.1083/jcb.123.2.387; Choo KHA., 1997, CENTROMERE; Ciosk R, 1998, CELL, V93, P1067, DOI 10.1016/S0092-8674(00)81211-8; CohenFix O, 1996, GENE DEV, V10, P3081, DOI 10.1101/gad.10.24.3081; DERSHOWITZ A, 1993, MOL CELL BIOL, V13, P391, DOI 10.1128/MCB.13.1.391; GOH PY, 1993, J CELL BIOL, V121, P503, DOI 10.1083/jcb.121.3.503; Guacci V, 1997, CELL, V91, P47, DOI 10.1016/S0092-8674(01)80008-8; Hartwell L.H., 1982, REC ADV YEAST MOL BI, V1, P28; HIETER P, 1985, CELL, V40, P381, DOI 10.1016/0092-8674(85)90152-7; HILL A, 1989, MOL CELL BIOL, V9, P1368, DOI 10.1128/MCB.9.3.1368; HOGAN E, 1992, P NATL ACAD SCI USA, V89, P3098, DOI 10.1073/pnas.89.7.3098; Hyman AA, 1995, ANNU REV CELL DEV BI, V11, P471, DOI 10.1146/annurev.cellbio.11.1.471; JEHN B, 1991, MOL CELL BIOL, V11, P5212, DOI 10.1128/MCB.11.10.5212; Karpen GH, 1997, TRENDS GENET, V13, P489, DOI 10.1016/S0168-9525(97)01298-5; KRANZ JE, 1990, P NATL ACAD SCI USA, V87, P6629, DOI 10.1073/pnas.87.17.6629; Losada A, 1998, GENE DEV, V12, P1986, DOI 10.1101/gad.12.13.1986; Megee PC, 1999, SCIENCE, V285, P254, DOI 10.1126/science.285.5425.254; Meluh PB, 1997, GENE DEV, V11, P3401, DOI 10.1101/gad.11.24.3401; Meluh PB, 1998, CELL, V94, P607, DOI 10.1016/S0092-8674(00)81602-5; Michaelis C, 1997, CELL, V91, P35, DOI 10.1016/S0092-8674(01)80007-6; MIYAZAKI WY, 1994, ANNU REV GENET, V28, P167, DOI 10.1146/annurev.ge.28.120194.001123; Nasmyth K, 1999, TRENDS BIOCHEM SCI, V24, P98, DOI 10.1016/S0968-0004(99)01358-4; Ortiz J, 1999, GENE DEV, V13, P1140, DOI 10.1101/gad.13.9.1140; SEARS DD, 1995, GENETICS, V139, P1159; Shirayama M, 1998, EMBO J, V17, P1336, DOI 10.1093/emboj/17.5.1336; Skibbens RV, 1999, GENE DEV, V13, P307, DOI 10.1101/gad.13.3.307; SORGER PK, 1994, J CELL BIOL, V127, P995, DOI 10.1083/jcb.127.4.995; STOLER S, 1995, GENE DEV, V9, P573, DOI 10.1101/gad.9.5.573; Tanaka TU, 1998, EMBO J, V17, P5182, DOI 10.1093/emboj/17.17.5182; Tanaka TU, 1997, CELL, V90, P649, DOI 10.1016/S0092-8674(00)80526-7; Toth A, 1999, GENE DEV, V13, P320, DOI 10.1101/gad.13.3.320; Uhlmann F, 1999, NATURE, V400, P37, DOI 10.1038/21831; Uhlmann F, 1998, CURR BIOL, V8, P1095, DOI 10.1016/S0960-9822(98)70463-4; Visintin R, 1997, SCIENCE, V278, P460, DOI 10.1126/science.278.5337.460	36	248	252	1	7	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	SEP 17	1999	98	6					847	858		10.1016/S0092-8674(00)81518-4	http://dx.doi.org/10.1016/S0092-8674(00)81518-4			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	237WH	10499801	Bronze			2022-12-01	WOS:000082679200011
J	Kelz, MB; Chen, JS; Carlezon, WA; Whisler, K; Gilden, L; Beckmann, AM; Steffen, C; Zhang, YJ; Marotti, L; Self, DW; Tkatch, T; Baranauskas, G; Surmeier, DJ; Neve, RL; Duman, RS; Picciotto, MR; Nestler, EJ				Kelz, MB; Chen, JS; Carlezon, WA; Whisler, K; Gilden, L; Beckmann, AM; Steffen, C; Zhang, YJ; Marotti, L; Self, DW; Tkatch, T; Baranauskas, G; Surmeier, DJ; Neve, RL; Duman, RS; Picciotto, MR; Nestler, EJ			Expression of the transcription factor Delta FosB in the brain controls sensitivity to cocaine	NATURE			English	Article							NUCLEUS-ACCUMBENS NEURONS; DOPAMINE-RECEPTORS; GENE-EXPRESSION; SENSITIZATION; INDUCTION; ADDICTION; PROTEINS; MICE; RAT; PSYCHOMOTOR	Acute exposure to cocaine transiently induces several Fos family transcription factors in the nucleus accumbens(1), a region of the brain that is important for addiction(2,3). In contrast, chronic exposure to cocaine does not induce these proteins, but instead causes the persistent expression of highly stable isoforms of Delta FosB(4-6). Delta FoSB is also induced in the nucleus accumbens by repeated exposure to other drugs of abuse, including amphetamine, morphine, nicotine and phencyclidine(7-10). The sustained accumulation of Delta FosB in the nucleus accumbens indicates that this transcription factor may mediate some of the persistent neural and behavioural plasticity that accompanies chronic drug exposure(1). Using transgenic mice in which Delta FosB can be induced in adults in the subset of nucleus accumbens neurons in which cocaine induces the protein,we show that Delta FosB expression increases the responsiveness of an animal to the rewarding and locomotor-activating effects of cocaine. These effects of Delta FosB appear to be mediated partly by induction of the AMPA (alpha-amino-3-hydroxy-5-methyl-4-isoxazole) glutamate receptor subunit GluR2 in the nucleus accumbens. These results support a model in which Delta FosB, by altering gene expression, enhances sensitivity to cocaine and may thereby contribute to cocaine addiction.	Yale Univ, Sch Med, Lab Mol Psychiat, New Haven, CT 06508 USA; Yale Univ, Sch Med, Yale Ctr Genes & Behav, New Haven, CT 06508 USA; Connecticut Mental Hlth Ctr, New Haven, CT 06508 USA; Harvard Univ, McLean Hosp, Sch Med, Dept Psychiat, Belmont, MA 02178 USA; Harvard Univ, McLean Hosp, Sch Med, Dept Genet, Belmont, MA 02178 USA; Northwestern Univ, Inst Neurosci, Chicago, IL 60611 USA	Yale University; Yale University; Harvard University; McLean Hospital; Harvard University; McLean Hospital; Northwestern University	Nestler, EJ (corresponding author), Yale Univ, Sch Med, Lab Mol Psychiat, New Haven, CT 06508 USA.		Kelz, Max/E-4054-2010; Picciotto, Marina R./F-8747-2012	Kelz, Max/0000-0002-2803-6078; Picciotto, Marina R./0000-0002-4404-1280; Tkatch, Tatiana/0000-0001-6626-7435; /0000-0002-4162-3947				Atkins JB, 1999, SYNAPSE, V33, P118, DOI 10.1002/(SICI)1098-2396(199908)33:2<118::AID-SYN2>3.3.CO;2-C; BAI G, 1993, BIOCHIM BIOPHYS ACTA, V1152, P197, DOI 10.1016/0005-2736(93)90249-Y; Brene S., 1997, Society for Neuroscience Abstracts, V23, P923; Carlezon WA, 1998, SCIENCE, V282, P2272, DOI 10.1126/science.282.5397.2272; Carlezon WA, 1997, SCIENCE, V277, P812, DOI 10.1126/science.277.5327.812; Chen JS, 1998, MOL PHARMACOL, V54, P495, DOI 10.1124/mol.54.3.495; Chen JS, 1997, J NEUROSCI, V17, P4933; FURTH PA, 1994, P NATL ACAD SCI USA, V91, P9302, DOI 10.1073/pnas.91.20.9302; GERFEN CR, 1991, J NEUROSCI, V11, P1016; Hiroi N, 1998, J NEUROSCI, V18, P6952; Hiroi N, 1997, P NATL ACAD SCI USA, V94, P10397, DOI 10.1073/pnas.94.19.10397; HOLLMANN M, 1994, ANNU REV NEUROSCI, V17, P31, DOI 10.1146/annurev.ne.17.030194.000335; HOPE BT, 1994, NEURON, V13, P1235, DOI 10.1016/0896-6273(94)90061-2; Kalivas PW, 1998, J PSYCHOPHARMACOL, V12, P49, DOI 10.1177/026988119801200107; Koob GF, 1997, SCIENCE, V278, P52, DOI 10.1126/science.278.5335.52; Moratalla R, 1996, NEUROREPORT, V8, P1, DOI 10.1097/00001756-199612200-00001; Myers SJ, 1999, ANNU REV PHARMACOL, V39, P221, DOI 10.1146/annurev.pharmtox.39.1.221; Nestler EJ, 1997, SCIENCE, V278, P58, DOI 10.1126/science.278.5335.58; Nye HE, 1995, J PHARMACOL EXP THER, V275, P1671; Nye HE, 1996, MOL PHARMACOL, V49, P636; PENNARTZ CMA, 1994, PROG NEUROBIOL, V42, P719, DOI 10.1016/0301-0082(94)90025-6; Peoples LL, 1998, NEUROSCIENCE, V86, P13, DOI 10.1016/S0306-4522(98)00116-X; Pich EM, 1997, SCIENCE, V275, P83; ROBINSON TE, 1993, BRAIN RES REV, V18, P247, DOI 10.1016/0165-0173(93)90013-P; Rocha BA, 1998, NATURE, V393, P175, DOI 10.1038/30259; Seeburg PH, 1998, BRAIN RES REV, V26, P217, DOI 10.1016/S0165-0173(97)00062-3; Surmeier DJ, 1996, J NEUROSCI, V16, P6579, DOI 10.1523/jneurosci.16-20-06579.1996; White F J, 1998, Adv Pharmacol, V42, P1006; Wise RA, 1998, DRUG ALCOHOL DEPEN, V51, P13, DOI 10.1016/S0376-8716(98)00063-5; Wolf ME, 1998, PROG NEUROBIOL, V54, P679, DOI 10.1016/S0301-0082(97)00090-7	30	490	508	0	31	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	SEP 16	1999	401	6750					272	276		10.1038/45790	http://dx.doi.org/10.1038/45790			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	237VZ	10499584				2022-12-01	WOS:000082678400052
J	Evans, D				Evans, D			Ethical viewpoint	BRITISH MEDICAL JOURNAL			English	Article									Univ Otago, Dunedin Sch Med, Ctr Bioeth, Dunedin, New Zealand	University of Otago	Evans, D (corresponding author), Univ Otago, Dunedin Sch Med, Ctr Bioeth, POB 913, Dunedin, New Zealand.								0	0	0	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	AUG 7	1999	319	7206					374	375						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	226CA	10490324				2022-12-01	WOS:000082001700030
J	Halperin, DT; Bailey, RC				Halperin, DT; Bailey, RC			Male circumcision and HIV infection: 10 years and counting	LANCET			English	Editorial Material							SEXUALLY-TRANSMITTED DISEASES; RISK; MEN; TRANSMISSION; PREVENTION		Univ Illinois, Sch Publ Hlth, Div Epidemiol & Biostat, Chicago, IL 60612 USA; Univ Illinois, Dept Anthropol, Chicago, IL 60612 USA; Univ Calif San Francisco, Dept Community Hlth Syst, San Francisco, CA USA; Univ Calif San Francisco, Med Anthropol Program, San Francisco, CA USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of California System; University of California San Francisco; University of California System; University of California San Francisco	Bailey, RC (corresponding author), Univ Illinois, Sch Publ Hlth, Div Epidemiol & Biostat, Chicago, IL 60612 USA.							BAILEY RC, 1999, PHASE 1 2 TRIAL INTE; Caldwell JC, 1996, SCI AM, V274, P62, DOI 10.1038/scientificamerican0396-62; CAMERON DW, 1989, LANCET, V2, P403; DEVINCENZI I, 1994, AIDS, V8, P153, DOI 10.1097/00002030-199402000-00002; Fleiss PM, 1998, SEX TRANSM INFECT, V74, P364, DOI 10.1136/sti.74.5.364; GREEN EC, 1993, TROP DOCT, V23, P182, DOI 10.1177/004947559302300423; HUSSAIN LA, 1995, IMMUNOLOGY, V85, P475; Kelly R, 1999, AIDS, V13, P399, DOI 10.1097/00002030-199902250-00013; Kleinbaum D.G., 1982, EPIDEMIOLOGIC RES PR, P1; MOSES S, 1994, SEX TRANSM DIS, V21, P201, DOI 10.1097/00007435-199407000-00004; Moses S, 1998, SEX TRANSM INFECT, V74, P368, DOI 10.1136/sti.74.5.368; MOSES S, 1995, HLTH TRANSITION REV, V5, P100; Padian NS, 1997, AM J EPIDEMIOL, V146, P350, DOI 10.1093/oxfordjournals.aje.a009276; SEED J, 1995, J ACQ IMMUN DEF SYND, V8, P83; SIMONSEN JN, 1988, NEW ENGL J MED, V319, P274, DOI 10.1056/NEJM198808043190504; Urassa M, 1997, AIDS, V11, P73, DOI 10.1097/00002030-199701000-00011	16	147	157	0	7	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	NOV 20	1999	354	9192					1813	1815		10.1016/S0140-6736(99)03421-2	http://dx.doi.org/10.1016/S0140-6736(99)03421-2			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	258RM	10577659				2022-12-01	WOS:000083853000045
J	Pascual, E; Batlle-Gualda, E; Martinez, A; Rosas, J; Vela, P				Pascual, E; Batlle-Gualda, E; Martinez, A; Rosas, J; Vela, P			Synovial fluid analysis for diagnosis of intercritical gout	ANNALS OF INTERNAL MEDICINE			English	Article							MONOSODIUM URATE CRYSTALS; KNEE JOINTS; CLASSIFICATION; CRITERIA	Background: The diagnosis of gout in the intercritical phase can be difficult. Objective: To determine whether synovial fluid analysis allows the diagnosis of intercritical gout. Design: Cross-sectional study. Setting: Outpatient rheumatology clinics. Patients: 101 patients with gout. Intervention: Arthrocentesis of 80 knees and 21 first metatarsophalangeal joints teach joint from a different patient) that had been inflamed but were currently asymptomatic. Measurements: Frequency with which arthrocentesis yielded synovial fluid; presence of monosodium urate crystals in the synovial fluid sample; and, for synovial fluid with crystals, the number of microscope fields that had to be scanned before crystals were found. Results: Synovial fluid was obtained from 91 of 101 joints. The fluid from all 43 patients not receiving hypouricemic agents contained monosodium urate crystals. These crystals were found in the synovial fluid of only 34 of 48 patients receiving hypouricemic agents. In 90% of the synovial fluid samples that contained crystals, crystals were seen in the first five microscope fields examined. Conclusions: Arthrocentesis of asymptomatic knees and first metatarsophalangeal joints and synovial fluid analysis are simple procedures that facilitate the diagnosis of gout during intercritical periods.	Gen Hosp Univ Alicante, Alicante 03010, Spain; Hosp Marina Baja, Alicante 03570, Spain; Hosp Gen Elche, Alicante, Spain	General University Hospital of Alicante	Pascual, E (corresponding author), Gen Hosp Univ Alicante, Maestro Alonso 109, Alicante 03010, Spain.	e.pascual@san.gva.es	Vela Casasempere, Paloma/HCH-3831-2022	Vela Casasempere, Paloma/0000-0001-8566-5172; Pascual, Eliseo/0000-0002-3056-4478				AGUDELO CA, 1979, ARTHRITIS RHEUM, V22, P559, DOI 10.1002/art.1780220521; BLOCH DA, 1990, ARTHRITIS RHEUM, V33, P1137; BOMALASKI JS, 1986, ARTHRITIS RHEUM, V29, P1480, DOI 10.1002/art.1780291209; GORDON TP, 1982, J RHEUMATOL, V9, P967; Hunder GG, 1998, ANN INTERN MED, V129, P417, DOI 10.7326/0003-4819-129-5-199809010-00013; KENNEDY TD, 1984, J ROY SOC MED, V77, P747, DOI 10.1177/014107688407700907; PASCUAL E, 1991, ARTHRITIS RHEUM, V34, P141, DOI 10.1002/art.1780340203; Pascual E, 1996, BRIT J RHEUMATOL, V35, P306; PHELPS P, 1968, J AMER MED ASSOC, V203, P508, DOI 10.1001/jama.203.7.508; ROUAULT T, 1982, ARTHRITIS RHEUM, V25, P209, DOI 10.1002/art.1780250215; WALLACE SL, 1977, ARTHRITIS RHEUM, V20, P895, DOI 10.1002/art.1780200320; WEINBERGER A, 1979, ANN INTERN MED, V91, P56, DOI 10.7326/0003-4819-91-1-56; WOLFE F, 1991, J RHEUMATOL, V18, P1232; WYNGAARDEN JB, 1976, GOUT HYPERURICEMIA	14	148	152	0	15	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	NOV 16	1999	131	10					756	759		10.7326/0003-4819-131-10-199911160-00007	http://dx.doi.org/10.7326/0003-4819-131-10-199911160-00007			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	255QC	10577299				2022-12-01	WOS:000083680100006
J	McAlister, FA; Straus, SE; Sackett, DL				McAlister, FA; Straus, SE; Sackett, DL		CARE-COAD1 Grp	Why we need large, simple studies of the clinical examination: the problem and a proposed solution	LANCET			English	Editorial Material							OBSTRUCTIVE AIRWAYS DISEASE; FORCED EXPIRATORY TIME; DEEP-VEIN THROMBOSIS; PHYSICAL-EXAMINATION; RESEARCH NETWORKS; PATIENT; DIAGNOSIS; HISTORY; PROBABILITY		Univ Alberta Hosp, Edmonton, AB T6G ZB7, Canada; John Radcliffe Hosp, Nuffield Dept Clin Med, Ctr Evidence Based Med, Oxford OX3 9DU, England	University of Alberta; University of Oxford	McAlister, FA (corresponding author), Univ Alberta Hosp, 2E324 WMC,8440-112 St, Edmonton, AB T6G ZB7, Canada.		McAlister, Finlay/C-4151-2013	McAlister, Finlay/0000-0001-7435-3341				Anand SS, 1998, JAMA-J AM MED ASSOC, V279, P1094, DOI 10.1001/jama.279.14.1094; BADGETT RG, 1993, AM J MED, V94, P188, DOI 10.1016/0002-9343(93)90182-O; Badgett RG, 1997, JAMA-J AM MED ASSOC, V277, P1712, DOI 10.1001/jama.277.21.1712; Cook DJ, 1996, JAMA-J AM MED ASSOC, V275, P630, DOI 10.1001/jama.275.8.630; CROMBIE D L, 1963, J Coll Gen Pract, V6, P579; DETSKY A, 1994, JAMA-J AM MED ASSOC, V271, P1114; DIAMOND GA, 1979, NEW ENGL J MED, V300, P1350, DOI 10.1056/NEJM197906143002402; Etchells E, 1997, JAMA-J AM MED ASSOC, V277, P564, DOI 10.1001/jama.277.7.564; FLEMING KA, 1997, EVIDENCE BASED MED, V2, P132; FLETCHER CM, 1952, P ROY SOC MED, V45, P577; FROOM J, 1990, BRIT MED J, V300, P582, DOI 10.1136/bmj.300.6724.582; GODFREY S, 1969, THORAX, V24, P4, DOI 10.1136/thx.24.1.4; GOLDSTEIN LB, 1994, JAMA-J AM MED ASSOC, V271, P1114, DOI 10.1001/jama.271.14.1114; GREEN LA, 1994, J FAM PRACTICE, V38, P400; GROVER SA, 1993, JAMA-J AM MED ASSOC, V270, P2218, DOI 10.1001/jama.270.18.2218; HEPPER NG, 1969, ARCH ENVIRON HEALTH, V19, P806, DOI 10.1080/00039896.1969.10666934; HOLLEMAN DR, 1993, J GEN INTERN MED, V8, P63, DOI 10.1007/BF02599985; KERN DG, 1991, CHEST, V100, P636, DOI 10.1378/chest.100.3.636; KING DK, 1989, ANN INTERN MED, V110, P451, DOI 10.7326/0003-4819-110-6-451; LAL S, 1964, BRIT MED J, V1, P814, DOI 10.1136/bmj.1.5386.814; Lederle FA, 1999, JAMA-J AM MED ASSOC, V281, P77, DOI 10.1001/jama.281.1.77; MANNINO DM, 1993, ARCH INTERN MED, V153, P1892, DOI 10.1001/archinte.153.16.1892; MARINI JJ, 1979, AM REV RESPIR DIS, V120, P1069; MULROW CD, 1986, J GEN INTERN MED, V1, P364, DOI 10.1007/BF02596418; NAIRN J R, 1969, British Journal of Diseases of the Chest, V63, P29, DOI 10.1016/S0007-0971(69)80041-0; NAYLOR CD, 1994, JAMA-J AM MED ASSOC, V271, P1859, DOI 10.1001/jama.271.23.1859; NIEBAUER L, 1994, J FAM PRACTICE, V38, P425; Nutting PA, 1996, J FAM PRACTICE, V42, P199; Panju AA, 1998, JAMA-J AM MED ASSOC, V280, P1256, DOI 10.1001/jama.280.14.1256; PARDEE NE, 1980, CHEST, V77, P354, DOI 10.1378/chest.77.3.354; PATEL A, 1992, CLIN RES, V40, pA370; PETERSDORF RG, 1983, NEW ENGL J MED, V309, P1053, DOI 10.1056/NEJM198310273091711; Sackett D.L., 1997, EVIDENCE BASED MED P; SACKETT DL, 1992, JAMA-J AM MED ASSOC, V267, P2638, DOI 10.1001/jama.267.19.2638; SACKETT DL, 1992, JAMA-J AM MED ASSOC, V267, P2650, DOI 10.1001/jama.267.19.2650; SANDLER G, 1980, AM HEART J, V100, P928, DOI 10.1016/0002-8703(80)90076-9; SCHAPIRA RM, 1993, JAMA-J AM MED ASSOC, V270, P731, DOI 10.1001/jama.270.6.731; SCHEINHORN DJ, 1982, SOUTHERN MED J, V75, P434, DOI 10.1097/00007611-198204000-00014; Simel DL, 1997, JAMA-J AM MED ASSOC, V277, P572, DOI 10.1001/jama.277.7.572; SURPRENANT EL, 1967, DIS CHEST, V52, P760, DOI 10.1378/chest.52.6.760; TURNBULL JM, 1995, JAMA-J AM MED ASSOC, V274, P1299, DOI 10.1001/jama.274.16.1299; van Schayck C P, 1991, Scand J Prim Health Care, V9, P232, DOI 10.3109/02813439109018525; Wells PS, 1997, LANCET, V350, P1795, DOI 10.1016/S0140-6736(97)08140-3; Whited JD, 1998, JAMA-J AM MED ASSOC, V279, P696, DOI 10.1001/jama.279.9.696; WILLIAMS JW, 1993, JAMA-J AM MED ASSOC, V270, P1242, DOI 10.1001/jama.270.10.1242; WILLIAMS JW, 1992, JAMA-J AM MED ASSOC, V267, P2645, DOI 10.1001/jama.267.19.2645; YUSUF S, 1990, STAT MED, V9, P73, DOI 10.1002/sim.4780090114	47	79	80	0	5	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	NOV 13	1999	354	9191					1721	1724		10.1016/S0140-6736(99)01174-5	http://dx.doi.org/10.1016/S0140-6736(99)01174-5			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	255CW	10568588				2022-12-01	WOS:000083652800042
J	Francastel, C; Walters, MC; Groudine, M; Martin, DIK				Francastel, C; Walters, MC; Groudine, M; Martin, DIK			A functional enhancer suppresses silencing of a transgene and prevents its localization close to centromeric heterochromatin	CELL			English	Article							BETA-GLOBIN LOCUS; POSITION-EFFECT VARIEGATION; PROTEIN DNA INTERACTIONS; TRANSCRIPTION FACTORS; NUCLEAR-ORGANIZATION; GENE-EXPRESSION; CONTROL REGION; CHROMATIN; DROSOPHILA; YEAST	To explore the mechanism by which enhancers maintain gene expression, we have assessed the ability of an enhancer and derivative mutants to influence silencing and nuclear location of a transgene. Using site-specific recombination to place different constructs at the same integration sites, we find that disruption of Gore enhancer motifs impairs the enhancer's ability to suppress silencing. FISH analysis reveals that active transgenes linked to a functional enhancer localize away from centromeres. However, enhancer mutations that result in increased rates of transgene silencing fail to localize the transgene away from centromeric heterochromatin, even when the transgene is in an active state. These mutations thus dissociate transcriptional activity and subnuclear location. Together, our results suggest that the functional enhancer antagonizes gene silencing by preventing localization of a gene near centromeric heterochromatin.	Fred Hutchinson Canc Res Ctr, Seattle, WA 98109 USA; Univ Washington, Sch Med, Dept Radiat Oncol, Seattle, WA 98195 USA	Fred Hutchinson Cancer Center; University of Washington; University of Washington Seattle	Groudine, M (corresponding author), Fred Hutchinson Canc Res Ctr, 1100 Fairview Ave N, Seattle, WA 98109 USA.		Francastel, Claire/AAI-4798-2021	Francastel, Claire/0000-0002-6353-4320				Aagaard L, 1999, EMBO J, V18, P1923, DOI 10.1093/emboj/18.7.1923; ANDREWS NC, 1993, NATURE, V362, P722, DOI 10.1038/362722a0; Andrulis ED, 1998, NATURE, V394, P592, DOI 10.1038/29100; APARICIO OM, 1994, GENE DEV, V8, P1133, DOI 10.1101/gad.8.10.1133; APARICIO OM, 1991, CELL, V66, P1279, DOI 10.1016/0092-8674(91)90049-5; Ashe HL, 1997, GENE DEV, V11, P2494, DOI 10.1101/gad.11.19.2494; Bouhassira EE, 1997, BLOOD, V90, P3332, DOI 10.1182/blood.V90.9.3332; Brown KE, 1999, MOL CELL, V3, P207, DOI 10.1016/S1097-2765(00)80311-1; Brown KE, 1997, CELL, V91, P845, DOI 10.1016/S0092-8674(00)80472-9; CATERINA JJ, 1994, NUCLEIC ACIDS RES, V22, P1006, DOI 10.1093/nar/22.6.1006; CATERINA JJ, 1991, P NATL ACAD SCI USA, V88, P1626, DOI 10.1073/pnas.88.5.1626; CHIEN CT, 1993, CELL, V75, P531, DOI 10.1016/0092-8674(93)90387-6; Cockell M, 1999, CURR OPIN GENET DEV, V9, P199, DOI 10.1016/S0959-437X(99)80030-6; Csink AK, 1996, NATURE, V381, P529, DOI 10.1038/381529a0; Dernburg AF, 1996, CELL, V85, P745, DOI 10.1016/S0092-8674(00)81240-4; FARKAS G, 1994, NATURE, V371, P806, DOI 10.1038/371806a0; FIERING SN, 1991, CYTOMETRY, V12, P291, DOI 10.1002/cyto.990120402; FORRESTER WC, 1990, GENE DEV, V4, P1637, DOI 10.1101/gad.4.10.1637; GLANVILLE N, 1981, NATURE, V292, P267, DOI 10.1038/292267a0; Gotta M, 1996, EXPERIENTIA, V52, P1136, DOI 10.1007/BF01952113; Gregory PD, 1998, EUR J BIOCHEM, V251, P9, DOI 10.1046/j.1432-1327.1998.2510009.x; Hardison R, 1997, GENE, V205, P73, DOI 10.1016/S0378-1119(97)00474-5; Henikoff S, 1992, CURR OPIN GENET DEV, V2, P907, DOI 10.1016/S0959-437X(05)80114-5; IKUTA T, 1991, P NATL ACAD SCI USA, V88, P10188, DOI 10.1073/pnas.88.22.10188; Kadonaga JT, 1998, CELL, V92, P307, DOI 10.1016/S0092-8674(00)80924-1; Kim J, 1999, IMMUNITY, V10, P345, DOI 10.1016/S1074-7613(00)80034-5; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; Laroche T, 1998, CURR BIOL, V8, P653, DOI 10.1016/S0960-9822(98)70252-0; LIU DP, 1992, P NATL ACAD SCI USA, V89, P3899, DOI 10.1073/pnas.89.9.3899; Maillet L, 1996, GENE DEV, V10, P1796, DOI 10.1101/gad.10.14.1796; ORKIN SH, 1995, J BIOL CHEM, V270, P4955, DOI 10.1074/jbc.270.10.4955; REDDY PMS, 1991, P NATL ACAD SCI USA, V88, P8676, DOI 10.1073/pnas.88.19.8676; ROMEO PH, 1990, NATURE, V344, P447, DOI 10.1038/344447a0; Saurin AJ, 1998, J CELL BIOL, V142, P887, DOI 10.1083/jcb.142.4.887; Sutherland HGE, 1997, MOL CELL BIOL, V17, P1607, DOI 10.1128/MCB.17.3.1607; Wakimoto BT, 1998, CELL, V93, P321, DOI 10.1016/S0092-8674(00)81159-9; Walters MC, 1999, MOL CELL BIOL, V19, P3714; WALTERS MC, 1995, P NATL ACAD SCI USA, V92, P7125, DOI 10.1073/pnas.92.15.7125; Walters MC, 1996, GENE DEV, V10, P185, DOI 10.1101/gad.10.2.185; Wolffe AP, 1996, CELL, V84, P817, DOI 10.1016/S0092-8674(00)81059-4; WREGGETT KA, 1994, CYTOGENET CELL GENET, V66, P99, DOI 10.1159/000133676	41	209	211	0	2	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	OCT 29	1999	99	3					259	269		10.1016/S0092-8674(00)81657-8	http://dx.doi.org/10.1016/S0092-8674(00)81657-8			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	251HX	10555142	Bronze			2022-12-01	WOS:000083440600004
J	de Abajo, FJ; Rodriguez, LAG; Montero, D				de Abajo, FJ; Rodriguez, LAG; Montero, D			Association between selective serotonin reuptake inhibitors and upper gastrointestinal bleeding: population based case-control study	BRITISH MEDICAL JOURNAL			English	Article							NONSTEROIDAL ANTIINFLAMMATORY DRUGS; FLUOXETINE; PERFORATION; DISORDER; THERAPY; RISK	Objective To examine the association between selective serotonin reuptake inhibitors and risk of upper gastrointestinal bleeding. Design Population based case-control study. Setting General practices included in the UK general practice research database. Subjects 1651 incident cases of upper gastrointestinal bleeding and 248 cases of ulcer perforation among patients aged 40 to 79 years between April 1993 and September 1997, and 10 000 controls matched for age, sex, and year that the case was identified. Interventions Review of computer profiles for all potential cases, and an internal validation study to confirm the accuracy of the diagnosis on the basis of the computerised information. Main outcome measures Current use of selective serotonin reuptake inhibitors or other antidepressants within 30 days before the index date. Results Current exposure to selective serotonin reuptake inhibitors was identified in 3.1% (52 of 1651) of patients with upper gastrointestinal bleeding but only 1.0% (95 of 10 000) of controls, giving an adjusted rate ratio of 3.0 (95% confidence interval 2.1 to 4.4). This effect measure was not modified by sex, age, dose, or treatment duration. A crude incidence of 1 case per 8000 prescriptions was estimated. A small association was found with non-selective serotonin reuptake inhibitors (relative risk 1.4, 1.1 to 1.9) but not with antidepressants lacking this inhibitory effect None of the groups of antidepressants was associated with ulcer perforation. The concurrent use of select-ive serotonin reuptake inhibitors with non-steroidal anti-inflammatory drugs increased the risk of upper gastrointestinal bleeding beyond the sum of their independent effects (15.6, 6.6 to 36.6). A smaller interaction was also found between selective serotonin reuptake inhibitors and low dose-aspirin (7.2, 3.1 to 17.1). Conclusions Selective serotonin reuptake inhibitors increase the risk of upper gastrointestinal bleeding The absolute effect is, however, moderate and about equivalent to low dose ibuprofen. The concurrent use of non-steroidal anti-inflammatory drugs or aspirin with selective serotonin reuptake inhibitors greatly increases the risk of upper gastrointestinal bleeding.	Agencia Espanola Medicamento, Div Farmacoepidemiol, Madrid 28220, Spain; Agencia Espanola Medicamento, Div Parmacoepidemiol & Farmacovigilancia, Safety Evaluat Unit, Madrid 28220, Spain; Ctr Espanol Invest Farmacoepidemiol, Madrid, Spain		de Abajo, FJ (corresponding author), Agencia Espanola Medicamento, Div Farmacoepidemiol, Madrid 28220, Spain.		de Abajo, Fancisco/Z-1711-2019; rodriguez, luis a garcia/B-1980-2010	de Abajo, Fancisco/0000-0001-9119-8646; 				ALDERMAN CP, 1992, ANN PHARMACOTHER, V26, P1517, DOI 10.1177/106002809202601205; [Anonymous], [No title captured]; Baldessarini RJ, 1996, GOODMAN GILMANS PHAR, P431; EVANS TG, 1991, NEW ENGL J MED, V324, P1671; Gutthann SP, 1997, EPIDEMIOLOGY, V8, P18, DOI 10.1097/00001648-199701000-00003; ISHIKAWA K, 1986, EUR J PHARMACOL, V120, P63, DOI 10.1016/0014-2999(86)90640-0; JICK H, 1991, BRIT MED J, V302, P766, DOI 10.1136/bmj.302.6779.766; Jick H., 1992, PHARMACOEPIDEM DR S, V1, P347, DOI DOI 10.1002/PDS.2630010607; LANCASTER SG, 1989, DRUGS, V38, P123, DOI 10.2165/00003495-198938010-00005; LESCH KP, 1993, J NEUROCHEM, V60, P2319, DOI 10.1111/j.1471-4159.1993.tb03522.x; Li N, 1997, BLOOD COAGUL FIBRIN, V8, P517, DOI 10.1097/00001721-199711000-00006; MAREK GJ, 1992, PSYCHOPHARMACOLOGY, V109, P2, DOI 10.1007/BF02245475; MONTERO DR, 1996, 4 ANN M EUR SOC PHAR; OTTERVANGER JD, 1994, AM J PSYCHIAT, V151, P781; POTTER WZ, 1991, NEW ENGL J MED, V325, P633; Rodriguez LAG, 1998, BRIT J CLIN PHARMACO, V45, P419; RODRIGUEZ LAG, 1994, LANCET, V343, P769, DOI 10.1016/S0140-6736(94)91843-0; ROSS SB, 1980, PSYCHOPHARMACOLOGY, V67, P1, DOI 10.1007/BF00427588; ROTHMAN KJ, 1986, MODER EPIDEMIOLOGY; Skop BP, 1996, PSYCHOSOMATICS, V37, P12, DOI 10.1016/S0033-3182(96)71592-X; TIELENS JAE, 1997, AM J PSYCHIAT, V153, P883; WAGNER A, 1990, J AFFECT DISORDERS, V20, P101, DOI 10.1016/0165-0327(90)90123-P; YARYURATOBIAS JA, 1991, AM J PSYCHIAT, V148, P949; 1998, WHO ADR NEWSLETTER, V3, P1	24	285	288	0	10	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	OCT 23	1999	319	7217					1106	1109		10.1136/bmj.319.7217.1106	http://dx.doi.org/10.1136/bmj.319.7217.1106			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	250ZE	10531103	Bronze, Green Published			2022-12-01	WOS:000083419500025
J	Shay, DK; Holman, RC; Newman, RD; Liu, LL; Stout, JW; Anderson, LJ				Shay, DK; Holman, RC; Newman, RD; Liu, LL; Stout, JW; Anderson, LJ			Bronchiolitis-associated hospitalizations among US children, 1980-1996	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							RESPIRATORY-SYNCYTIAL-VIRUS; GROUP-A; GROUP-B; UNITED-STATES; INFECTION; EPIDEMIOLOGY; CARE; WASHINGTON; EMERGENCY; ILLNESS	Context Respiratory syncytial virus (RSV) causes more lower respiratory tract infections, often manifested as bronchiolitis, among young children than any other pathogen. Few national estimates exist of the hospitalizations attributable to RSV, and recent advances in prophylaxis warrant an update of these estimates. Objectives To describe rates of bronchiolitis-associated hospitalizations and to estimate current hospitalizations associated with RSV infection. Design and Setting Descriptive analysis of US National Hospital Discharge Survey data from 1980 through 1996. Participants Children younger than 5 years who were hospitalized in short-stay, nonfederal hospitals for bronchiolitis. Main Outcome Measure Bronchiolitis-associated hospitalization rates by age and year. Results During the 17-year study period, an estimated 1.65 million hospitalizations for bronchiolitis occurred among children younger than 5 years, accounting for 7.0 million inpatient days. Fifty-seven percent of these hospitalizations occurred among children younger than 6 months and 81 % among those younger than 1 year. Among children younger than 1 year, annual bronchiolitis hospitalization rates increased 2.4-fold, from 12.9 per 1000 in 1980 to 31.2 per 1000 in 1996. During 1988-1995, infant hospitalization rates for bronchiolitis increased significantly (P for trend <.001), while hospitalization rates for lower respiratory tract diseases excluding bronchiolitis did not vary significantly (P for trend = .20). The proportion of hospitalizations for lower respiratory tract illnesses among children younger than 1 year associated with bronchiolitis increased from 2.2% in 1980 to 47.4% in 1996; among total hospitalizations, this proportion increased from 5.4% to 16.4%, Averaging bronchiolitis hospitalizations during 1994-1996 and assuming that RSV was the etiologic agent in 50% to 80% of November through April hospitalizations, an estimated 51 240 to 81 985 annual bronchiolitis hospitalizations among children younger than 1 year were related to RSV infection. Conclusions During 1980-1996, rates of hospitalization of infants with bronchiolitis increased substantially, as did the proportion of total and lower respiratory tract hospitalizations associated with bronchiolitis. Annual bronchiolitis hospitalizations associated with RSV infection among infants may be greater than previous estimates for RSV bronchiolitis and pneumonia hospitalizations combined.	Ctr Dis Control & Prevent, Resp & Enter Viruses Branch, Atlanta, GA 30333 USA; Ctr Dis Control & Prevent, Natl Ctr Infect Dis, Div Viral & Rickettsial Dis, Off Director, Atlanta, GA USA; Univ Washington, Sch Med, Dept Pediat, Div Gen Pediat, Seattle, WA 98195 USA; Univ Washington, Sch Publ Hlth & Community Med, Dept Hlth Serv, Seattle, WA USA	Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle	Shay, DK (corresponding author), Ctr Dis Control & Prevent, Resp & Enter Viruses Branch, 1600 Clifton Rd NE,MS A-34, Atlanta, GA 30333 USA.	dks4@cdc.gov		Shay, David/0000-0001-9619-4820				ANDERSON LJ, 1988, PEDIATRICS, V82, P300; ANDERSON LJ, 1985, J INFECT DIS, V151, P626, DOI 10.1093/infdis/151.4.626; ANDERSON LJ, 1991, J INFECT DIS, V163, P687, DOI 10.1093/infdis/163.4.687; [Anonymous], 1998, Pediatrics, V102, P1211; BRANDT CD, 1973, AM J EPIDEMIOL, V98, P355, DOI 10.1093/oxfordjournals.aje.a121565; BREESE C, 1975, NEW ENGL J MED, V293, P1343, DOI 10.1056/NEJM197512252932604; CAUL EO, 1976, J HYG-CAMBRIDGE, V77, P383, DOI 10.1017/S0022172400055765; *CDCP, 1997, MMWR-MORBID MORTAL W, V46, P1163; CRAIN EF, 1995, ARCH PEDIAT ADOL MED, V149, P893, DOI 10.1001/archpedi.1995.02170210067012; DAGAN R, 1993, PEDIATR INFECT DIS J, V12, P381, DOI 10.1097/00006454-199305000-00006; FOY HM, 1973, AM J EPIDEMIOL, V97, P80, DOI 10.1093/oxfordjournals.aje.a121492; GARDNER PS, 1973, BMJ-BRIT MED J, V2, P571, DOI 10.1136/bmj.2.5866.571; GILCHRIST S, 1994, J INFECT DIS, V170, P986, DOI 10.1093/infdis/170.4.986; Gillum B S, 1996, Vital Health Stat 13, P1; GLEZEN WP, 1986, AM J DIS CHILD, V140, P543, DOI 10.1001/archpedi.1986.02140200053026; GLEZEN WP, 1981, J PEDIATR-US, V98, P708, DOI 10.1016/S0022-3476(81)80829-3; GLEZEN WP, 1977, PEDIATR RES, V11, P239; GLEZEN WP, 1987, PEDIAT VIROL, V2, P1; GRAVES EJ, 1999, VITAL HLTH STAT, V13, P1; HALL CB, 1975, J INFECT DIS, V131, P1, DOI 10.1093/infdis/131.1.1; HALL CB, 1994, SCIENCE, V265, P1393, DOI 10.1126/science.7915433; HALL CB, 1990, J INFECT DIS, V162, P1283, DOI 10.1093/infdis/162.6.1283; HALL CB, 1998, TXB PEDIAT INFECT DI, P2087; HAUPT BJ, 1992, VITAL HLTH STAT, V13, P1; HENDERSON FW, 1979, NEW ENGL J MED, V300, P530, DOI 10.1056/NEJM197903083001004; Hofferth SL, 1996, FUTURE CHILD, V6, P41, DOI 10.2307/1602418; *I MED, 1986, NEW VACC DEV EST PRI, V2, P299; Institute of Medicine, 1986, NEW VACC DEV EST PRI, V1, P397; Karron RA, 1997, J INFECT DIS, V176, P1428, DOI 10.1086/514138; KIM HW, 1973, AM J EPIDEMIOL, V98, P216, DOI 10.1093/oxfordjournals.aje.a121550; Kozak L J, 1995, Adv Data, P1; LAW BJ, 1993, PEDIATR INFECT DIS J, V12, P659, DOI 10.1097/00006454-199308000-00007; MANEKER AJ, 1995, ANN EMERG MED, V25, P36, DOI 10.1016/S0196-0644(95)70352-7; MCCONNOCHLE KM, 1990, J PEDIAT, V162, P1283; MCINTOSH EDG, 1993, PEDIATR INFECT DIS J, V12, P815, DOI 10.1097/00006454-199310000-00004; MONTO AS, 1971, AM J EPIDEMIOL, V94, P290, DOI 10.1093/oxfordjournals.aje.a121322; Murphy BR, 1997, B WORLD HEALTH ORGAN, V75, P307; *NAT CTR HLTH STAT, 1998, NAT HOSP DISCH SURV; Null D, 1998, PEDIATRICS, V102, P531, DOI 10.1542/peds.102.3.531; PARROTT RH, 1973, AM J EPIDEMIOL, V98, P289, DOI 10.1093/oxfordjournals.aje.a121558; Peret TCT, 1998, J GEN VIROL, V79, P2221, DOI 10.1099/0022-1317-79-9-2221; *RES COUNC SUBC RE, 1978, BRIT MED J, V2, P796; Saijo Masayuki, 1993, Acta Paediatrica Japonica, V35, P233; Shah BV, 1996, SUDAAN USERS MANUAL; SIMS DG, 1976, BRIT MED J, V2, P1095, DOI 10.1136/bmj.2.6044.1095; SINGLETON RJ, 1995, PEDIATR INFECT DIS J, V14, P26, DOI 10.1097/00006454-199501000-00005; SIRKEN MG, 1992, MANUAL STANDARDS PRO; *US BUR CENS, 1998, INT EST POP AG SEX R; *US DHHS, 1998, DET DAT 1979 96 PUBL; *US PHS HLTH CAR F, 1998, INT CLASS DIS; Walsh EE, 1997, J INFECT DIS, V175, P814, DOI 10.1086/513976; YAMAMOTO LG, 1993, AM J EMERG MED, V11, P109, DOI 10.1016/0735-6757(93)90101-G; Yun BY, 1995, PEDIATR INFECT DIS J, V14, P1054, DOI 10.1097/00006454-199512000-00005	53	1028	1105	0	14	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 20	1999	282	15					1440	1446		10.1001/jama.282.15.1440	http://dx.doi.org/10.1001/jama.282.15.1440			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	245LT	10535434	Bronze			2022-12-01	WOS:000083111000029
J	Van Rie, A; Warren, R; Richardson, M; Victor, TC; Gie, RP; Enarson, DA; Beyers, N; van Helden, PD				Van Rie, A; Warren, R; Richardson, M; Victor, TC; Gie, RP; Enarson, DA; Beyers, N; van Helden, PD			Exogenous reinfection as a cause of recurrent tuberculosis after curative treatment	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							MYCOBACTERIUM-TUBERCULOSIS	Background For decades it has been assumed that postprimary tuberculosis is usually caused by reactivation of endogenous infection rather than by a new, exogenous infection. Methods We performed DNA fingerprinting with restriction-fragment-length polymorphism analysis on pairs of isolates of Mycobacterium tuberculosis from 16 compliant patients who had a relapse of pulmonary tuberculosis after curative treatment of post-primary tuberculosis. The patients lived in areas of South Africa where tuberculosis is endemic. Medical records were reviewed for clinical data. Results For 12 of the 16 patients, the restriction-fragment-length polymorphism banding patterns for the isolates obtained after the relapse were different from those for the isolates from the initial tuberculous disease. This finding indicates that reinfection was the cause of the recurrence of tuberculosis after curative treatment. Two patients had reinfections with a multidrug-resistant strain. All 15 patients who were tested for the human immunodeficiency virus were seronegative. Conclusions Exogenous reinfection appears to be a major cause of postprimary tuberculosis after a previous cure in an area with a high incidence of this disease. This finding emphasizes the importance of achieving cures and of preventing anyone with infectious tuberculosis from exposing others to the disease. (N Engl J Med 1999;341:1174-9.) (C)1999, Massachusetts Medical Society.	Univ Stellenbosch, Dept Pediat & Child Hlth, ZA-7505 Tygerberg, South Africa; Univ Stellenbosch, MRC, Ctr Cellular & Mol Biol, ZA-7505 Tygerberg, South Africa; Univ Stellenbosch, Dept Biochem Med, ZA-7505 Tygerberg, South Africa; Katholieke Univ Leuven, Dept Pediat, Louvain, Belgium	Stellenbosch University; Stellenbosch University; Stellenbosch University; KU Leuven	van Helden, PD (corresponding author), Univ Stellenbosch, Dept Biochem Med, POB 19063, ZA-7505 Tygerberg, South Africa.		Van Rie, Annelies/C-2082-2017	Van Rie, Annelies/0000-0001-7666-3263; Warren, Robin/0000-0001-5741-7358				ALLAN WGL, 1982, TUBERCLE, V63, P89; ALLAN WGL, 1977, AM REV RESPIR DIS, V115, P727; Beyers N, 1996, S AFR MED J, V86, P40; BRITISH THORACIC ASSOCIATION, 1982, American Review of Respiratory Disease, V126, P460; CANETTI G, 1972, Bulletin of the International Union Against Tuberculosis, V47, P116; DAS S, 1993, TUBERCLE LUNG DIS, V74, P48; KATZ HL, 1958, VETERANS ADM ARMED F, P214; MCKINNEY JD, 1997, PERSISTING PROBLEMS, P69; MITCHISON DA, 1980, TUBERCLE, V61, P135, DOI 10.1016/0041-3879(80)90002-1; SAHADEVAN R, 1995, J CLIN MICROBIOL, V33, P3037, DOI 10.1128/JCM.33.11.3037-3039.1995; SMALL PM, 1993, NEW ENGL J MED, V328, P1137, DOI 10.1056/NEJM199304223281601; STYBLO K, 1991, P TUBERC RES COUNC, V24, P62; VANEMBDEN JDA, 1993, J CLIN MICROBIOL, V31, P406, DOI 10.1128/JCM.31.2.406-409.1993; Vynnycky E, 1997, EPIDEMIOL INFECT, V119, P183, DOI 10.1017/S0950268897007917; Warren R, 1996, J CLIN MICROBIOL, V34, P2219, DOI 10.1128/JCM.34.9.2219-2224.1996	15	471	483	0	10	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 14	1999	341	16					1174	1179		10.1056/NEJM199910143411602	http://dx.doi.org/10.1056/NEJM199910143411602			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	245BY	10519895				2022-12-01	WOS:000083087400002
J	Brogan, DJ; Frank, E; Elon, L; Sivanesan, SP; O'Hanlan, KA				Brogan, DJ; Frank, E; Elon, L; Sivanesan, SP; O'Hanlan, KA			Harassment of lesbians as medical students and physicians	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							WOMEN PHYSICIANS		Emory Univ, Atlanta, GA 30322 USA; Stanford Med Ctr, Stanford, CA USA	Emory University; Stanford University	Frank, E (corresponding author), Emory Univ, Atlanta, GA 30322 USA.		O'Hanlan, Katherine/A-4073-2017	O'Hanlan, Katherine/0000-0002-7577-4188; Frank, Erica/0000-0001-7159-5417				Frank E, 1995, J Am Med Womens Assoc (1972), V50, P64; Frank E, 1998, ARCH INTERN MED, V158, P342, DOI 10.1001/archinte.158.4.342; Frank E, 1998, ARCH INTERN MED, V158, P352, DOI 10.1001/archinte.158.4.352; MATHEWS WC, 1986, WESTERN J MED, V144, P106; ORIEL KA, 1996, FAM MED, V28, P7205; Schatz B., 1994, ANTIGAY DISCRIMINATI; STEVENS PE, 1991, INT J HEALTH SERV, V21, P291, DOI 10.2190/R2AW-MTCR-U0Q7-XMMY	7	31	31	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 6	1999	282	13					1290	+		10.1001/jama.282.13.1290	http://dx.doi.org/10.1001/jama.282.13.1290			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	241UM	10532853	hybrid			2022-12-01	WOS:000082901100042
J	Wabnitz, PA; Bowie, JH; Tyler, MJ; Wallace, JC; Smith, BP				Wabnitz, PA; Bowie, JH; Tyler, MJ; Wallace, JC; Smith, BP			Animal behaviour - Aquatic sex pheromone from a male tree frog	NATURE			English	Article							SKIN; PEPTIDE; LITORIA		Univ Adelaide, Dept Chem, Adelaide, SA 5005, Australia; Univ Adelaide, Dept Environm Biol, Adelaide, SA 5005, Australia; Univ Adelaide, Dept Biochem, Adelaide, SA 5005, Australia	University of Adelaide; University of Adelaide; University of Adelaide	Wabnitz, PA (corresponding author), Univ Adelaide, Dept Chem, Adelaide, SA 5005, Australia.		Smith, Ben PC/GXZ-8778-2022; , John/AAP-5150-2020	Wabnitz, Paul/0000-0002-0820-9509; Smith, Benjamin/0000-0003-0651-9420				AGOSTA WC, 1994, J CHEM EDUC, V71, P242, DOI 10.1021/ed071p242; BIRCH MC, 1974, PHEROMONES, V32, P1; BUTENANDT A, 1984, TECHNIQUES PHEROMONE, P4; Erspamer V., 1993, AMPHIBIAN BIOL, P178; Houck LD, 1998, AM ZOOL, V38, P108; JOHNSTONE RE, 1983, PHEROMONES REPROD MA, P8; KIKUYAMA S, 1995, SCIENCE, V267, P1643, DOI 10.1126/science.7886452; LAZARUS LH, 1993, PROG NEUROBIOL, V41, P473, DOI 10.1016/0301-0082(93)90027-P; Steinborner ST, 1998, J PEPT RES, V51, P121; TYLER MJ, 1992, J PHARMACOL TOXICOL, V28, P199, DOI 10.1016/1056-8719(92)90004-K; Wabnitz PA, 1998, J PEPT RES, V52, P477; Wong H, 1997, EUR J BIOCHEM, V247, P545, DOI 10.1111/j.1432-1033.1997.00545.x	12	106	111	1	25	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	SEP 30	1999	401	6752					444	445		10.1038/46724	http://dx.doi.org/10.1038/46724			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	243DF	10519546				2022-12-01	WOS:000082981200043
J	Mellemkjaer, L; Sorensen, HT; Dreyer, L; Olsen, J; Olsen, JH				Mellemkjaer, L; Sorensen, HT; Dreyer, L; Olsen, J; Olsen, JH			Admission for and mortality from primary venous thromboembolism in women of fertile age in Denmark, 1977-95	BRITISH MEDICAL JOURNAL			English	Article							MYOCARDIAL-INFARCTION; ORAL-CONTRACEPTIVES; RISK		Danish Canc Soc, Inst Canc Epidemiol, DK-2100 Copenhagen O, Denmark; Aarhus Univ Hosp, Dept Med 5, DK-8000 Aarhus, Denmark; Aarhus Univ, Dept Epidemiol & Social Med, Danish Epidemiol Sci Ctr, DK-8000 Aarhus C, Denmark	Danish Cancer Society; Aarhus University; Aarhus University	Mellemkjaer, L (corresponding author), Danish Canc Soc, Inst Canc Epidemiol, DK-2100 Copenhagen O, Denmark.		Sorensen, Henrik Toft/Z-6181-2019	Sorensen, Henrik Toft/0000-0003-4299-7040; Olsen, Jorgen Helge/0000-0001-9633-5662				JICK H, 1995, LANCET, V346, P1589, DOI 10.1016/S0140-6736(95)91928-7; POULTER NR, 1995, LANCET, V346, P1575; Spitzer WO, 1996, BRIT MED J, V312, P83; Thomas SHL, 1996, LANCET, V348, P402, DOI 10.1016/S0140-6736(05)65016-7; Vandenbroucke JP, 1996, LANCET, V348, P401, DOI 10.1016/S0140-6736(96)24032-2	5	26	26	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	SEP 25	1999	319	7213					820	821		10.1136/bmj.319.7213.820	http://dx.doi.org/10.1136/bmj.319.7213.820			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	241CR	10496825	Bronze, Green Published			2022-12-01	WOS:000082865200023
J	Fynes, M; Donnelly, V; Behan, M; O'Connell, PR; O'Herlihy, C				Fynes, M; Donnelly, V; Behan, M; O'Connell, PR; O'Herlihy, C			Effect of second vaginal delivery on anorectal physiology and faecal continence: a prospective study	LANCET			English	Article							ANAL-SPHINCTER INJURY; FECAL INCONTINENCE; PELVIC FLOOR; CHILDBIRTH; DAMAGE; WOMEN	Background Because obstetric injury to the anal sphincters may be occult, and because the mechanism of injury differs between first and subsequent deliveries, we prospectively assessed the effects of first and second vaginal deliveries on anal physiology and continence. Methods We undertook a prospective observational study of 59 previously nulliparous women through two successive vaginal deliveries by means of a bower-function questionnaire, and an anorectal-physiology assessment, both antepartum and 6-12 weeks post parium. Findings 13 (22%) women reported altered faecal continence after their first vaginal delivery: eight had persistent symptoms during their second pregnancy, of whom seven deteriorated after the second delivery; five regained continence before their second pregnancy, but two became incontinent again after the second delivery. Five women developed incontinence for the first time after their second vaginal delivery, of whom three had occult primiparous sphincter injury. 20 (34%) women, seven of whom had no symptoms, had anal-sphincter injury as a result of their first delivery, but only two new injuries occurred after the second vaginal delivery (p=0.013). Although pudendal neuropathy was no more common after the second than after the first vaginal delivery (15 vs 19%, p=0.8), pudendal-nerve latency was longer after the second delivery (p=0.02). Interpretation Primiparous women with persistent symptoms of altered faecal continence experience deterioration after a second vaginal delivery. Women with transient faecal incontinence or occult anal-sphincter injury after their first vaginal delivery are at high risk of faecal incontinence after a second vaginal delivery. The risk of mechanical anal sphincter injury is greatest after the first delivery.	Univ Coll Dublin, Natl Matern Hosp, Dept Obstet & Gynaecol, Dublin 2, Ireland; Mater Misericordiae Hosp, Dept Radiol, Dublin, Ireland; Mater Misericordiae Hosp, Dept Surg, Dublin, Ireland	National Maternity Hospital, Dublin; University College Dublin; Mater Misericordiae University Hospital; University College Dublin; Mater Misericordiae University Hospital; University College Dublin	O'Herlihy, C (corresponding author), Univ Coll Dublin, Natl Matern Hosp, Dept Obstet & Gynaecol, Holles St, Dublin 2, Ireland.		O'Connell, Patrick Ronan/H-6583-2019	O'Connell, Patrick Ronan/0000-0002-1846-5629				ALLEN RE, 1990, BRIT J OBSTET GYNAEC, V97, P770, DOI 10.1111/j.1471-0528.1990.tb02570.x; AlMufti R, 1996, LANCET, V347, P544, DOI 10.1016/S0140-6736(96)91176-9; BEK KM, 1992, BRIT J OBSTET GYNAEC, V99, P724, DOI 10.1111/j.1471-0528.1992.tb13870.x; BOYLAN P, ANN CLIN REPORTS 199; Campbell DM, 1996, CLIN RADIOL, V51, P559, DOI 10.1016/S0009-9260(96)80135-8; CHERRY DA, 1988, SURG CLIN N AM, V68, P1217; Donnelly V, 1998, OBSTET GYNECOL, V92, P955, DOI 10.1016/S0029-7844(98)00255-5; Donnelly V, 1997, BRIT J OBSTET GYNAEC, V104, P311, DOI 10.1111/j.1471-0528.1997.tb11459.x; Donnelly VS, 1998, DIS COLON RECTUM, V41, P586, DOI 10.1007/BF02235263; Fynes M, 1998, OBSTET GYNECOL, V92, P496, DOI 10.1016/S0029-7844(98)00256-7; Fynes MM, 1999, DIS COLON RECTUM, V42, P753, DOI 10.1007/BF02236930; LAW PJ, 1991, BRIT J SURG, V78, P312, DOI 10.1002/bjs.1800780315; LEIGH RJ, 1982, LANCET, V1, P1349; MacArthur C, 1997, BRIT J OBSTET GYNAEC, V104, P46, DOI 10.1111/j.1471-0528.1997.tb10648.x; ODRISCOLL MD, 1986, ACTIVE MANAGEMENT LA; PERRY RE, 1990, AM J SURG, V159, P112, DOI 10.1016/S0002-9610(05)80615-4; PESCATORI M, 1992, DIS COLON RECTUM, V35, P482, DOI 10.1007/BF02049407; SNOOKS JJ, 1985, COLOPROCTOLOGY PELVI, P112; SNOOKS SJ, 1990, BRIT J SURG, V77, P1358, DOI 10.1002/bjs.1800771213; SNOOKS SJ, 1984, LANCET, V2, P546; Sultan AH, 1996, BRIT J OBSTET GYNAEC, V103, P731, DOI 10.1111/j.1471-0528.1996.tb09864.x; SULTAN AH, 1993, NEW ENGL J MED, V329, P1905, DOI 10.1056/NEJM199312233292601; SWASH M, 1993, BRIT MED J, V307, P636, DOI 10.1136/bmj.307.6905.636	23	149	151	0	2	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	SEP 18	1999	354	9183					983	986		10.1016/S0140-6736(98)11205-9	http://dx.doi.org/10.1016/S0140-6736(98)11205-9			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	236JG	10501360				2022-12-01	WOS:000082596000011
J	Carrell, RW				Carrell, RW			Biochemistry - How serpins are shaping up	SCIENCE			English	Editorial Material							PLASMINOGEN-ACTIVATOR INHIBITOR-1; ANTITHROMBIN; ADHESION		Univ Cambridge, Cambridge Inst Med Res, Dept Haematol, Cambridge CB2 2XY, England	University of Cambridge	Carrell, RW (corresponding author), Univ Cambridge, Cambridge Inst Med Res, Dept Haematol, Hills Rd, Cambridge CB2 2XY, England.							Bajou K, 1998, NAT MED, V4, P923, DOI 10.1038/nm0898-923; BANDA M, 1998, J BIOL CHEM, V263, P4481; CARRELL RW, 1991, NATURE, V353, P576, DOI 10.1038/353576a0; Chang WSW, 1997, THROMB HAEMOSTASIS, V77, P323; Deng G, 1996, J CELL BIOL, V134, P1563, DOI 10.1083/jcb.134.6.1563; Engh RA, 1995, TRENDS BIOTECHNOL, V13, P503, DOI 10.1016/S0167-7799(00)89013-7; Jin L, 1997, P NATL ACAD SCI USA, V94, P14683, DOI 10.1073/pnas.94.26.14683; Preissner KT, 1997, THROMB HAEMOSTASIS, V78, P88; Stefansson S, 1998, TRENDS CARDIOVAS MED, V8, P175, DOI 10.1016/S1050-1738(98)00003-6; Torriglia A, 1998, MOL CELL BIOL, V18, P3612, DOI 10.1128/MCB.18.6.3612; ZHOU A, IN PRESS BLOOD; 1999, P 2 INT S STRUCT BIO	12	23	25	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	SEP 17	1999	285	5435					1861	+		10.1126/science.285.5435.1861	http://dx.doi.org/10.1126/science.285.5435.1861			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	237CT	10515791				2022-12-01	WOS:000082638300033
J	Lin, CR; Kioussi, C; O'Connell, S; Briata, P; Szeto, D; Liu, F; Izpisua-Belmonte, JC; Rosenfeld, MG				Lin, CR; Kioussi, C; O'Connell, S; Briata, P; Szeto, D; Liu, F; Izpisua-Belmonte, JC; Rosenfeld, MG			Pitx2 regulates lung asymmetry, cardiac positioning and pituitary and tooth morphogenesis	NATURE			English	Article							SIGNALING PATHWAY; NODAL EXPRESSION; HOMEOBOX GENE; ORGANOGENESIS; FAMILY; EHAND; MOUSE	Pitx1 (refs 1-3) and Pitx2 (refs 4, 5) are highly homologous, bicoid-related transcription factors. Pitx2 was initially identified as the gene responsible for the human Rieger syndrome(4), an autosomal dominant condition that causes developmental abnormalities. Pitx2 is asymmetrically expressed in the left lateral-plate mesoderm(5-11), and mutant mice with laterality defects show altered patterns of Pitx2 expression that correlate with changes in the visceral symmetry (situs). Ectopic expression of Pitx2 in the right lateral-plate mesoderm alters looping of the heart and gut and reverses body rotation in chick and Xenopus embryose(6-11). Here we describe the phenotype of Pitx2 gene-deleted mice, characterized by defective body-wall closure, right pulmonary isomerism, altered cardiac position, arrest in turning and, subsequently a block in the determination and proliferation events of anterior pituitary gland and tooth organogenesis. Thus, Pitx2 is a transcription factor that encodes 'leftness' of the lung.	Univ Calif San Diego, Howard Hughes Med Inst, Dept Med, La Jolla, CA 92093 USA; Univ Calif San Diego, Howard Hughes Med Inst, Sch Med, La Jolla, CA 92093 USA; Salk Inst Biol Studies, La Jolla, CA 92037 USA	Howard Hughes Medical Institute; University of California System; University of California San Diego; Howard Hughes Medical Institute; University of California System; University of California San Diego; Salk Institute	Rosenfeld, MG (corresponding author), Univ Calif San Diego, Howard Hughes Med Inst, Dept Med, 9500 Gilman Dr, La Jolla, CA 92093 USA.	mrosenfeld@ucsd.edu	Briata, Paola/AAC-6039-2020	Briata, Paola/0000-0003-3470-0454				Biben C, 1997, GENE DEV, V11, P1357, DOI 10.1101/gad.11.11.1357; Boettger T, 1999, CURR BIOL, V9, P277, DOI 10.1016/S0960-9822(99)80119-5; Campione M, 1999, DEVELOPMENT, V126, P1225; Collignon J, 1996, NATURE, V381, P155, DOI 10.1038/381155a0; Dasen JS, 1999, CELL, V97, P587, DOI 10.1016/S0092-8674(00)80770-9; Ericson J, 1998, DEVELOPMENT, V125, P1005; Gage PJ, 1997, HUM MOL GENET, V6, P457, DOI 10.1093/hmg/6.3.457; Hogan BLM, 1999, CELL, V96, P225, DOI 10.1016/S0092-8674(00)80562-0; Lanctot C, 1997, DEVELOPMENT, V124, P2807; Logan M, 1999, SCIENCE, V283, P1736, DOI 10.1126/science.283.5408.1736; Logan M, 1998, CELL, V94, P307, DOI 10.1016/S0092-8674(00)81474-9; Lowe LA, 1996, NATURE, V381, P158, DOI 10.1038/381158a0; Martinez S, 1999, DEVELOPMENT, V126, P1189; Meno C, 1998, CELL, V94, P287, DOI 10.1016/S0092-8674(00)81472-5; Mucchielli ML, 1997, DEV BIOL, V189, P275, DOI 10.1006/dbio.1997.8672; Oh SP, 1997, GENE DEV, V11, P1812, DOI 10.1101/gad.11.14.1812; Peters H, 1999, TRENDS GENET, V15, P59, DOI 10.1016/S0168-9525(98)01662-X; Piedra ME, 1998, CELL, V94, P319, DOI 10.1016/S0092-8674(00)81475-0; Ryan AK, 1998, NATURE, V394, P545, DOI 10.1038/29004; Semina EV, 1997, HUM MOL GENET, V6, P2109, DOI 10.1093/hmg/6.12.2109; Semina EV, 1996, NAT GENET, V14, P392, DOI 10.1038/ng1296-392; Sheng HZ, 1997, SCIENCE, V278, P1809, DOI 10.1126/science.278.5344.1809; Szeto DP, 1999, GENE DEV, V13, P484, DOI 10.1101/gad.13.4.484; Thomas T, 1998, DEV BIOL, V196, P228, DOI 10.1006/dbio.1998.8849; Treier M, 1998, GENE DEV, V12, P1691, DOI 10.1101/gad.12.11.1691; Yoshioka H, 1998, CELL, V94, P299, DOI 10.1016/S0092-8674(00)81473-7	26	452	464	1	22	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	SEP 16	1999	401	6750					279	282		10.1038/45803	http://dx.doi.org/10.1038/45803			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	237VZ	10499586				2022-12-01	WOS:000082678400054
J	Bailey, JE; Van Brunt, DL; Mirvis, DM; McDaniel, S; Spears, CR; Chang, CF; Schaberg, DR				Bailey, JE; Van Brunt, DL; Mirvis, DM; McDaniel, S; Spears, CR; Chang, CF; Schaberg, DR			Academic managed care organizations and adverse selection under Medicaid managed care in Tennessee	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							RISK-ADJUSTMENT; RAPID CHANGES; CENTERS; TENNCARE; SYSTEM; PAYMENTS	Context Health plans competing in a managed care system may face serious financial consequences if they are disproportionately selected by enrollees with expensive health conditions. Academic medical centers (AMCs) have traditionally provided medical care for the sickest patients and may be at particularly high risk for adverse selection, but whether this occurs is not known. Objective To determine whether managed care organizations (MCOs) representing AMCs are adversely selected by Medicaid managed care (MMC) enrollees with expensive chronic health conditions. Design and Setting Observational study using state Medicaid claims data from all of 1994 and January to August 1995 for Tennessee's statewide MMC program (TennCare). Participants All 12 capitated MCOs in Tennessee, which collectively provided services for 1.2 million Medicaid enrollees from January 1994 through August 1995 following the initiation of TennCare. Main Outcome Measures Prevalence of 6 state-specified high-cost chronic conditions-acquired immunodeficiency syndrome (AIDS), coagulation defects, cystic fibrosis, pregnancy, prematurity, and organ transplantation-and 27 additional high-cost conditions compared by academic, statewide, and regional MCOs, Results The prevalence of state-specified high-cost chronic conditions was generally higher for academic MCOs compared with other MCOs, Specifically, prevalence of AIDS was 14.1 times higher in academic MCOs than in statewide MCOs; coagulation defects, 6.4 times higher; transplantations, 4.4; pregnancy, 3.3; cystic fibrosis, 2.4; and prevalence of prematurity was equivalent. Prevalence was higher for academic than for statewide MCOs for 22 of the additional 27 high-cost conditions considered and similar for the remaining 5 conditions, Conclusions Our results suggest that academic MCOs in an MMC system are selected by a large percentage of the sickest patients. Adverse selection may present serious financial risks for AMCs participating in managed care.	Univ Tennessee, Dept Med, Div Gen Internal Med, Memphis, TN 38103 USA; Univ Tennessee, Dept Prevent Med, Memphis, TN 38103 USA; Univ Memphis, Memphis Managed Care Corp, Memphis, TN 38103 USA; Univ Memphis, Dept Econ, Memphis, TN 38103 USA	University of Tennessee System; University of Tennessee Health Science Center; University of Tennessee System; University of Tennessee Health Science Center; University of Memphis; University of Memphis	Bailey, JE (corresponding author), Univ Tennessee, Dept Med, Div Gen Internal Med, 842 Jefferson Ave,Room A607, Memphis, TN 38103 USA.	jebailey@utmem.edu						CLARK DO, 1995, MED CARE, V33, P783, DOI 10.1097/00005650-199508000-00004; Culbertson RA, 1997, J HEALTH POLIT POLIC, V22, P1359; DIEHR P, 1993, MED CARE, V31, P1093, DOI 10.1097/00005650-199312000-00003; Eggers P, 1980, Health Care Financ Rev, V1, P91; Ellis RP, 1996, HEALTH CARE FINANC R, V17, P101; EPSTEIN AM, 1995, JAMA-J AM MED ASSOC, V273, P1203, DOI 10.1001/jama.273.15.1203; Fowles JB, 1996, JAMA-J AM MED ASSOC, V276, P1316, DOI 10.1001/jama.276.16.1316; FOX PD, 1993, HEALTH AFFAIR, V12, P85, DOI 10.1377/hlthaff.12.1.85; GOLDMAN L, 1995, JAMA-J AM MED ASSOC, V273, P1549, DOI 10.1001/jama.273.19.1549; Hellinger F J, 1987, Health Care Financ Rev, V9, P55; HILLMAN AL, 1991, ACAD MED, V66, P134, DOI 10.1097/00001888-199103000-00003; Holahan J, 1999, HEALTH AFFAIR, V18, P217, DOI 10.1377/hlthaff.18.3.217; HUGHES R, 1995, PUBLICATION GAO HEHS; HUNT S, 1999, ACTUARIAL REV CAPITA; IGLEHART JK, 1994, NEW ENGL J MED, V331, P1391, DOI 10.1056/NEJM199411173312025; IGLEHART JK, 1995, NEW ENGL J MED, V332, P407, DOI 10.1056/NEJM199502093320624; IGLEHART JK, 1995, NEW ENGL J MED, V332, P1727, DOI 10.1056/NEJM199506223322525; Kilbreth EH, 1998, INQUIRY-J HEALTH CAR, V35, P250; KRONICK R, 1997, CHALLENGE RISK ADJUS, P1; Ku LT, 1998, INQUIRY-J HEALTH CAR, V35, P332; Meyer GS, 1996, JAMA-J AM MED ASSOC, V276, P672, DOI 10.1001/jama.276.9.672; MIRVIS DM, 1995, JAMA-J AM MED ASSOC, V274, P1235, DOI 10.1001/jama.274.15.1235; NEWHOUSE JP, 1997, HLTH AFF MILLWOOD, V15, P27; REUTER JA, 1999, PATTERNS SPECIALITY; ROBINSON JC, 1995, MED CARE, V33, P1161, DOI 10.1097/00005650-199512000-00001; Rogal DL, 1998, INQUIRY-J HEALTH CAR, V35, P115; Smith N S, 1994, Manag Care Q, V2, P21; Summitt RL, 1998, JAMA-J AM MED ASSOC, V279, P767, DOI 10.1001/jama.279.10.767; Wilensky G R, 1986, Health Aff (Millwood), V5, P66, DOI 10.1377/hlthaff.5.1.66	29	24	24	0	2	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 15	1999	282	11					1067	1072		10.1001/jama.282.11.1067	http://dx.doi.org/10.1001/jama.282.11.1067			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	234YQ	10493206				2022-12-01	WOS:000082512300031
J	Druss, BG; Rosenheck, RA				Druss, BG; Rosenheck, RA			Association between use of unconventional therapies and conventional medical services	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HEALTH MAINTENANCE ORGANIZATION; ALTERNATIVE MEDICINE; UNITED-STATES; COSTS; DEPRESSION; CARE; PATTERNS	Context The terms alternative and complementary medicine suggest 2 contradictory possibilities. Whether individuals use unconventional therapies as a substitute for or as an "add on" to conventional medical treatments is uncertain. Objective To determine the association between use of unconventional therapies and conventional medical care in a national sample. Design, Setting, and Participants The 1996 Medical Expenditure Panel Survey was distributed to a probability sample of the noninstitutionalized civilian US population. Of 24 676 individuals responding (77.7% response rate), 16 068 adults 18 years or older were included in the analysis. Main Outcome Measures Visits to practitioners for unconventional therapies and conventional medical services, including number of inpatient, outpatient, and emergency department visits and use of 8 types of preventive medical services (blood pressure, cholesterol level, physical examination, influenza vaccination, prostate examination, breast examination, mammography, and Papanicolaou test). Results During 1996, an estimated 6.5% of the US population had visits for both unconventional therapies and conventional medical care; 1.8% used only unconventional services; 59.5% used only conventional care; and 32.2% used neither. Compared with those with only conventional visits, those who used both types of care had significantly more outpatient physician visits (7.9 vs 5.4; P<.001), and used more of all types of preventive services except mammography. These groups did not differ significantly in inpatient care, prescription drug use, or number of emergency department visits. Individuals in the top quartile of number of physician visits were more than twice as likely as those in the bottom quartile to have used unconventional therapies in the past year (14.5% vs 6.4%; P<.001). The association between unconventional treatments and physician visits remained after adjusting for potential confounders and across different types of unconventional treatment. Conclusions In this sample, use of unconventional therapies was substantially lower than has been reported in previous national surveys, but was associated with increased use of physician services. From a health services perspective, practitioner-based unconventional therapies appear to serve more as a complement than an alternative to conventional medicine.	Yale Univ, Dept Psychiat, West Haven, CT USA; Yale Univ, Dept Publ Hlth, West Haven, CT USA	Yale University; Yale University	Druss, BG (corresponding author), 950 Campbell Ave,116A, West Haven, CT 06516 USA.	benjamin.druss@yale.edu	Young, Alexander/A-1523-2009	Young, Alexander/0000-0002-9367-9213	NIMH NIH HHS [K08 MH01556] Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTH [K08MH001556] Funding Source: NIH RePORTER	NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		Angell M, 1998, NEW ENGL J MED, V339, P839, DOI 10.1056/NEJM199809173391210; Astin JA, 1998, JAMA-J AM MED ASSOC, V279, P1548, DOI 10.1001/jama.279.19.1548; CAIRNS J, 1995, BRIT MED J, V311, P1520, DOI 10.1136/bmj.311.7019.1520; COHEN J, 1997, AHCPR PUBL; COHEN S, 1997, AHCPR PUBL; CONOVER WJ, 1980, PRACTICAL NONPARAMET, P263; DADY PJ, 1987, NEW ZEAL MED J, V100, P110; EISENBERG DM, 1993, NEW ENGL J MED, V328, P246, DOI 10.1056/NEJM199301283280406; Eisenberg DM, 1998, JAMA-J AM MED ASSOC, V280, P1569, DOI 10.1001/jama.280.18.1569; Eskinazi DP, 1998, JAMA-J AM MED ASSOC, V280, P1621, DOI 10.1001/jama.280.18.1621; Fontanarosa PB, 1998, JAMA-J AM MED ASSOC, V280, P1618, DOI 10.1001/jama.280.18.1618; Gundling KE, 1998, ARCH INTERN MED, V158, P2185, DOI 10.1001/archinte.158.20.2185; HASKELL W, 1998, STANF CTR RES DIS PR; Henk HJ, 1996, ARCH GEN PSYCHIAT, V53, P899; Jonas W, 1998, JAMA, V279, P708; Jonas WB, 1998, JAMA-J AM MED ASSOC, V280, P1616, DOI 10.1001/jama.280.18.1616; KOLATA G, 1998, N Y TIMES       0604, P4; Marwick C, 1998, JAMA-J AM MED ASSOC, V280, P1553, DOI 10.1001/jama.280.18.1553; MCFARLAND BH, 1985, MED CARE, V23, P1221, DOI 10.1097/00005650-198511000-00001; *MED EXP PAN SURV, 1997, AHCPR PUBL; Paramore LC, 1997, J PAIN SYMPTOM MANAG, V13, P83, DOI 10.1016/S0885-3924(96)00299-0; SPIGELBLATT L, 1994, PEDIATRICS, V94, P811; Von Korff M, 1998, PSYCHOSOM MED, V60, P143, DOI 10.1097/00006842-199803000-00005; VONKORFF M, 1992, ARCH GEN PSYCHIAT, V49, P91; ZOOK CJ, 1980, NEW ENGL J MED, V302, P996, DOI 10.1056/NEJM198005013021804	25	292	292	1	12	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 18	1999	282	7					651	656		10.1001/jama.282.7.651	http://dx.doi.org/10.1001/jama.282.7.651			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	226QY	10517718	Bronze			2022-12-01	WOS:000082033700024
J	Chaix, C; Durand-Zaleski, I; Alberti, C; Brun-Buisson, C				Chaix, C; Durand-Zaleski, I; Alberti, C; Brun-Buisson, C			Control of endemic methicillin-resistant Staphylococcus aureus - A cost-benefit analysis in an intensive care unit	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							NOSOCOMIAL INFECTIONS; BACTEREMIA; IMPACT; MRSA; EPIDEMIOLOGY; ERADICATION; PREVALENCE; PREVENTION; MORTALITY; OUTBREAK	Context Despite the success of some countries in controlling endemic methicillin-resistant Staphylococcus aureus (MRSA), such programs have not been implemented for some hospitals with endemic infection because of concerns that these programs would be costly and of limited benefit. Objective To compare the costs and benefits of an MRSA control program in an endemic setting. Design and Setting Case-control study conducted at a medical intensive care unit (ICU) of a French university hospital with a 4% prevalence of MRSA carriage at ICU admission. Patients Twenty-seven randomly selected patients who had ICU-acquired MRSA infection between January 1993 and June 1997, matched to 27 controls hospitalized during the same period without MRSA infection. Main Outcome Measures Intensive care unit costs attributable to MRSA infection, computed from excess therapeutic intensity in cases using estimates from a cost model derived in the same ICU, were compared with costs of the control program, derived from time-motion study of nurses and physicians. The threshold for MRSA carriage that would make the control strategy dominant was determined; sensitivity analyses varied rates of MRSA transmission and ratio of infection to transmission, length of ICU stay, and costs of isolation precautions. Results The mean cost attributable to MRSA infection was US $9275 (median, $5885; interquartile range, $1400-$16720). Total costs of the control program ranged from $340 to $1480 per patient. A 14% reduction in MRSA infection rate resulted in the control program being beneficial. In sensitivity analyses, the control strategy was dominant for a prevalence of MRSA carriage on ICU admission ranging from 1% to 7%, depending on costs of control measures and MRSA transmission, for infection rates greater than 50% following transmission. Conclusions In this example of a hospital with endemic MRSA infection, selective screening and isolation of carriers on ICU admission are beneficial compared with no isolation.	Hop Henri Mondor, Infect Control Unit, F-94010 Creteil, France; Hop Henri Mondor, Med Intens Care Unit, F-94010 Creteil, France	Assistance Publique Hopitaux Paris (APHP); Universite Paris-Est-Creteil-Val-de-Marne (UPEC); Hopital Universitaire Henri-Mondor - APHP; Assistance Publique Hopitaux Paris (APHP); Universite Paris-Est-Creteil-Val-de-Marne (UPEC); Hopital Universitaire Henri-Mondor - APHP	Brun-Buisson, C (corresponding author), Hop Henri Mondor, Assistance Publ Hop Paris, Unite Hyg & Prevent Infect, 51 Ave Marechal de Lattre de Tassigny, F-94010 Creteil, France.	christian.brun-buisson@hmn.ap-hop.paris.fr						AubryDamon H, 1997, CLIN INFECT DIS, V25, P647, DOI 10.1086/513749; Ayliffe GAJ, 1997, CLIN INFECT DIS, V24, pS74, DOI 10.1093/clinids/24.Supplement_1.S74; Barrett SP, 1998, J HOSP INFECT, V39, P85, DOI 10.1016/S0195-6701(98)90322-X; BOYCE JM, 1991, INFECT CONT HOSP EP, V12, P46, DOI 10.2307/30147088; BOYCE JM, 1990, INFECT CONT HOSP EP, V11, P639; BOYCE JM, 1983, J INFECT DIS, V148, P763, DOI 10.1093/infdis/148.4.763; Chaix C, 1999, PHARMACOECONOMICS, V15, P573, DOI 10.2165/00019053-199915060-00005; COHEN SH, 1991, AM J MED, V91, pS233, DOI 10.1016/0002-9343(91)90374-7; DRUMMOND M, 1989, METHODS EC EVALUATIO, P18; EMMERSON M, 1994, SCAND J INFECT DIS, P47; Girou E, 1998, CLIN INFECT DIS, V27, P543, DOI 10.1086/514695; HALEY RW, 1995, J INFECT DIS, V171, P614, DOI 10.1093/infdis/171.3.614; Harbarth S, 1998, ARCH INTERN MED, V158, P182, DOI 10.1001/archinte.158.2.182; Humphreys H, 1997, J HOSP INFECT, V36, P167, DOI 10.1016/S0195-6701(97)90191-2; Jarvis WR, 1996, INFECT CONT HOSP EP, V17, P552; Jernigan JA, 1995, INFECT CONT HOSP EP, V16, P686; Jernigan JA, 1996, AM J EPIDEMIOL, V143, P496, DOI 10.1093/oxfordjournals.aje.a008770; KREGER BE, 1980, AM J MED, V68, P344, DOI 10.1016/0002-9343(80)90102-3; LEGALL JR, 1993, JAMA-J AM MED ASSOC, V270, P2957, DOI 10.1001/jama.270.24.2957; Miranda DR, 1997, INTENS CARE MED, V23, P760, DOI 10.1007/s001340050406; MULLIGAN ME, 1993, AM J MED, V94, P313, DOI 10.1016/0002-9343(93)90063-U; RAO N, 1988, INFECT CONT HOSP EP, V9, P255, DOI 10.1086/645848; ROBINSON R, 1993, BMJ-BRIT MED J, V307, P670, DOI 10.1136/bmj.307.6905.670; RomeroVivas J, 1995, CLIN INFECT DIS, V21, P1417, DOI 10.1093/clinids/21.6.1417; STAMM AM, 1993, AM J INFECT CONTROL, V21, P70, DOI 10.1016/0196-6553(93)90227-U; Sznajder M, 1998, INTENS CARE MED, V24, P582, DOI 10.1007/s001340050619; TABLAN OC, 1995, INFECT CONT HOSP EP, V16, P105; THOMPSON RL, 1982, ANN INTERN MED, V97, P309, DOI 10.7326/0003-4819-97-3-309; VandenbrouckeGrauls CMJE, 1996, INFECT CONT HOSP EP, V17, P512; VINCENT JL, 1995, JAMA-J AM MED ASSOC, V274, P639, DOI 10.1001/jama.274.8.639; VOSS A, 1994, EUR J CLIN MICROBIOL, V13, P50, DOI 10.1007/BF02026127; WAKEFIELD DS, 1988, AM J INFECT CONTROL, V16, P185, DOI 10.1016/0196-6553(88)90058-2; WENZEL RP, 1991, AM J MED, V91, pS221, DOI 10.1016/0002-9343(91)90372-5; WESTH H, 1992, CLIN INFECT DIS, V14, P1186, DOI 10.1093/clinids/14.6.1186	34	249	257	0	9	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 10	1999	282	18					1745	1751		10.1001/jama.282.18.1745	http://dx.doi.org/10.1001/jama.282.18.1745			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	251XJ	10568647	Bronze			2022-12-01	WOS:000083471400029
J	Magee, JT; Pritchard, EL; Fitzgerald, KA; Dunstan, FDJ; Howard, AJ				Magee, JT; Pritchard, EL; Fitzgerald, KA; Dunstan, FDJ; Howard, AJ		Welsh Antibiotic Study Grp	Antibiotic prescribing and antibiotic resistance in community practice: retrospective study, 1996-8	BMJ-BRITISH MEDICAL JOURNAL			English	Article									Univ Wales Hosp, Dept Med Microbiol, Cardiff CF14 4XW, S Glam, Wales; Univ Wales Hosp, Publ Hlth Lab, Cardiff CF14 4XW, S Glam, Wales; Univ Wales Coll Cardiff, Coll Med, Cardiff CF14 4XW, S Glam, Wales; Bro Taf Hlth Author, Cardiff CF1 4TW, S Glam, Wales; Univ Wales Coll Cardiff, Coll Med, Dept Med Comp & Stat, Cardiff CF1 3NS, S Glam, Wales	Cardiff University; Cardiff University; Cardiff University; Cardiff University	Howard, AJ (corresponding author), Univ Wales Hosp, Dept Med Microbiol, Cardiff CF14 4XW, S Glam, Wales.	tony.howard@phls.wales.nhs.uk						AMYES SGB, 1989, J MED MICROBIOL, V28, P73, DOI 10.1099/00222615-28-2-73; LONDON N, 1994, J ANTIMICROB CHEMOTH, V34, P239, DOI 10.1093/jac/34.2.239; Standing Medical Advisory Committee: Sub-group on Antimicrobial Resistance, 1998, PATH LEAST RES	3	152	155	0	6	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	NOV 6	1999	319	7219					1239	1240		10.1136/bmj.319.7219.1239	http://dx.doi.org/10.1136/bmj.319.7219.1239			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	254RH	10550088	Bronze, Green Published			2022-12-01	WOS:000083625600025
J	Kaufman, J; Milne, S; Gobel, TWF; Walker, BA; Jacob, JP; Auffray, C; Zoorob, R; Beck, S				Kaufman, J; Milne, S; Gobel, TWF; Walker, BA; Jacob, JP; Auffray, C; Zoorob, R; Beck, S			The chicken B locus is a minimal essential major histocompatibility complex	NATURE			English	Article							MHC CLASS-I; CELL-INTERACTION; POLYMORPHISM; TRANSPORTERS; MOLECULES; GENE; RAT	Here we report the sequence of the region that determines rapid allograft rejection in chickens, the chicken major histocompatibility complex (MHC). This 92-kilobase region of the B locus(1-4) contains only 19 genes, making the chicken MHC roughly 20-fold smaller than the human MHC5. Virtually all the genes have counterparts in the human MHC, defining a minimal essential set of MHC genes conserved over 200 million years of divergence between birds and mammals. They are organized differently, with the class III region genes located outside the class II and class I region genes. The absence of proteasome genes(5,6) is unexpected and might explain unusual peptide-binding specificities of chicken class I molecules. The presence of putative natural killer receptor gene(s)(5,7) is unprecedented and might explain the importance of the B locus in the response to the herpes virus responsible for Marek's diseases(8-10). The small size and simplicity of the chicken MHC allows co-evolution of genes as haplotypes over considerable periods of time, and makes it possible to study the striking MHC-determined pathogen-specific disease resistances(8-10) at the molecular level.	Inst Anim Hlth, Compton RG20 7NN, England; Sanger Ctr, Hinxton CB10 1SA, England; Inst Anim Physiol, D-80539 Munich, Germany; CNRS, UPR420, Villejuif, France	UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); Pirbright Institute; Wellcome Trust Sanger Institute; University of Munich; Centre National de la Recherche Scientifique (CNRS)	Kaufman, J (corresponding author), Inst Anim Hlth, Compton RG20 7NN, England.	jim.kaufman@bbsrc.ac.uk	Gobel, Thomas/A-9919-2009; Walker, Brian/A-4984-2013	Kaufman, Jim/0000-0002-7216-8422; Walker, Brian/0000-0002-8615-6254	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Bacon L D, 1987, Prog Clin Biol Res, V238, P219; Beck S, 1999, NATURE, V401, P921, DOI 10.1038/44853; BRILES WE, 1950, GENETICS, V35, P633; BRILES WE, 1983, SCIENCE, V219, P977, DOI 10.1126/science.6823560; Bumstead N, 1998, AVIAN PATHOL, V27, pS78, DOI 10.1080/03079459808419296; Frangoulis B, 1999, IMMUNOGENETICS, V49, P328, DOI 10.1007/s002510050500; GERMAIN RN, 1985, CELL, V43, P233, DOI 10.1016/0092-8674(85)90028-5; GUILLEMOT F, 1988, EMBO J, V7, P2775, DOI 10.1002/j.1460-2075.1988.tb03132.x; Henry J, 1999, IMMUNOL TODAY, V20, P285, DOI 10.1016/S0167-5699(98)01418-2; Joly E, 1998, CURR BIOL, V8, P169, DOI 10.1016/S0960-9822(98)70065-X; Kandil E, 1996, J IMMUNOL, V156, P4245; KAUFMAN J, 1995, IMMUNOL REV, V143, P63, DOI 10.1111/j.1600-065X.1995.tb00670.x; KAUFMAN J, 1991, CRIT REV IMMUNOL, V11, P113; KAUFMAN J, 1996, MAJOR HISTOCOMPATIBI; Kaufman J., 1995, ADV AVIAN IMMUNOLOGY, P119; Lanier LL, 1998, ANNU REV IMMUNOL, V16, P359, DOI 10.1146/annurev.immunol.16.1.359; Miller MM, 1996, P NATL ACAD SCI USA, V93, P3958, DOI 10.1073/pnas.93.9.3958; MOMBURG F, 1994, NATURE, V367, P648, DOI 10.1038/367648a0; Nonaka M, 1997, P NATL ACAD SCI USA, V94, P5789, DOI 10.1073/pnas.94.11.5789; Pamer E, 1998, ANNU REV IMMUNOL, V16, P323, DOI 10.1146/annurev.immunol.16.1.323; PAZDERKA F, 1975, IMMUNOGENETICS, V2, P101, DOI 10.1007/BF01572280; Pharr GT, 1998, IMMUNOGENETICS, V47, P350, DOI 10.1007/s002510050369; PINK JRL, 1977, IMMUNOGENETICS, V5, P203, DOI 10.1007/BF01570477; PLACHY J, 1992, CRIT REV IMMUNOL, V12, P47; RAMMENSEE HG, 1995, IMMUNOGENETICS, V41, P178, DOI 10.1007/BF00172063; SKJODT K, 1985, TISSUE ANTIGENS, V25, P278, DOI 10.1111/j.1399-0039.1985.tb00450.x; Thorpe KL, 1996, IMMUNOGENETICS, V44, P391, DOI 10.1007/s002510050142; VAINIO O, 1984, IMMUNOGENETICS, V19, P131, DOI 10.1007/BF00387856; VAINIO O, 1988, J IMMUNOL, V140, P2864	29	485	513	2	57	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	OCT 28	1999	401	6756					923	925		10.1038/44856	http://dx.doi.org/10.1038/44856			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	251UL	10553909				2022-12-01	WOS:000083464700061
J	Stratakis, CA; Sarlis, N; Kirschner, LS; Carney, JA; Doppman, JL; Nieman, LK; Chrousos, GP; Papanicolaou, DA				Stratakis, CA; Sarlis, N; Kirschner, LS; Carney, JA; Doppman, JL; Nieman, LK; Chrousos, GP; Papanicolaou, DA			Paradoxical response to dexamethasone in the diagnosis of primary pigmented nodular adrenocortical disease	ANNALS OF INTERNAL MEDICINE			English	Article						dexamethasone; adrenocortical disorder, primary, pigmented; adrenocortical disorder, macronodular; Carney complex; Cushing syndrome	GASTRIC-INHIBITORY POLYPEPTIDE; FAMILIAL CUSHINGS-SYNDROME; CARNEY COMPLEX; ADRENAL-CELLS; FREE CORTISOL; RARE CAUSE; DYSPLASIA; MYXOMAS; SUBTYPE; CT	Background: Primary pigmented nodular adrenocortical disease causes the Cushing syndrome in children and young adults and is most frequently associated with the Carney complex. Objective: To evaluate diagnostic tests for primary pigmented nodular adrenocortical disease. Design: Retrospective cohort study. Setting: Tertiary care center. Patients: 21 patients with primary pigmented nodular adrenocortical disease. The control groups consisted of 9 patients with macronodular adrenocortical disease and 15 patients with primary unilateral adrenocortical disease (single adenomas). Measurements: Clinical characteristics, radiologic imaging, and a 6-day Liddle test with determination of urinary free cortisol and 17-hydroxycorticosteroid excretion. Results: Adrenal imaging and other tests were of limited value for the diagnosis of primary pigmented nodular adrenocortical disease. The Liddle test, however, distinguished patients with this disorder from those with other primary adrenocortical lesions. An increase of 50% or more in urinary free cortisol levels on day 6 of the Liddle test identified 9 of 13 patients (69.2% [95% Cl, 46.6% to 91.8%]) with primary pigmented nodular adrenocortical disease, excluded all patients with macronodular adrenocortical disease, and was present in only 3 of the 15 patients with single adrenocortical adenomas (20% [Cl, 0% to 40.2%]). An increase in urinary free cortisol excretion of 100% or more on day 6 of the Liddle test identified only patients with primary pigmented nodular adrenocortical disease. Conclusions: Patients with primary pigmented nodular adrenocortical disease responded to dexamethasone with a paradoxical increase in glucocorticoid excretion during the Liddle test. This feature distinguishes such patients from those who have the Cushing syndrome caused by other primary adrenal disorders and may lead to timely detection of the Carney complex (a potentially fatal disorder) in asymptomatic patients.	NIH, Bethesda, MD 20892 USA; Mayo Clin & Mayo Fdn, Rochester, MN 55905 USA	National Institutes of Health (NIH) - USA; Mayo Clinic	Stratakis, CA (corresponding author), NIH, Bldg 10,Room 10N262,10 Ctr Dr,MSC 1862, Bethesda, MD 20892 USA.	stratakc@cc1.nichd.nih.gov	Stratakis, Constantine A./AAP-4745-2020; Sarlis, Nicholas/AAN-9444-2020		EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [ZIAHD000638, ZIAHD000615] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [ZIAHD000642, Z01HD000615, Z01HD000638, Z01HD000642] Funding Source: NIH RePORTER	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ARCHAMBEAUDMOUV.F, 1996, 10 INT C END SAN FRA, P899; Basson CT, 1997, AM J CARDIOL, V79, P994, DOI 10.1016/S0002-9149(97)00033-7; BOHM N, 1983, ACTA ENDOCRINOL-COP, V102, P428, DOI 10.1530/acta.0.1020428; Bornstein SR, 1999, ANN INTERN MED, V130, P759, DOI 10.7326/0003-4819-130-9-199905040-00017; BROOKS RV, 1966, J ENDOCRINOL, V36, P53, DOI 10.1677/joe.0.0360053; Carney JA., 1992, ENDOCRINOLOGIST, V2, P6, DOI DOI 10.1097/00019616-199201000-00003; Casey M, 1998, CIRCULATION, V98, P2560, DOI 10.1161/01.CIR.98.23.2560; CATICHA O, 1993, J CLIN ENDOCR METAB, V77, P494, DOI 10.1210/jc.77.2.494; CLOUSTON WM, 1989, CLIN ENDOCRINOL, V31, P467, DOI 10.1111/j.1365-2265.1989.tb01270.x; DEMOOR P, 1965, J CLIN ENDOCR METAB, V25, P612, DOI 10.1210/jcem-25-5-612; DOPPMAN JL, 1989, RADIOLOGY, V172, P415, DOI 10.1148/radiology.172.2.2748822; Doppman JL, 1997, ENDOCRIN METAB CLIN, V26, P973, DOI 10.1016/S0889-8529(05)70290-5; DOPPMAN JL, 1991, J COMPUT ASSIST TOMO, V15, P773, DOI 10.1097/00004728-199109000-00009; ELIAS LL, 1999, ENDOCINE SOC, P582; FLACK MR, 1992, ANN INTERN MED, V116, P211, DOI 10.7326/0003-4819-116-3-211; GarciaMayor RV, 1997, J CLIN ENDOCR METAB, V82, P3517; GOMEZ MT, 1991, J PEDIATR-US, V118, P256, DOI 10.1016/S0022-3476(05)80496-2; KIRSCHNER MA, 1964, J CLIN ENDOCR METAB, V24, P947, DOI 10.1210/jcem-24-10-947; LACROIX A, 1992, NEW ENGL J MED, V327, P974, DOI 10.1056/NEJM199210013271402; LAMBERTS SWJ, 1990, J CLIN ENDOCR METAB, V70, P192, DOI 10.1210/jcem-70-1-192; LARSEN JL, 1986, AM J MED, V80, P976, DOI 10.1016/0002-9343(86)90648-0; LEVIN ME, 1966, AM J MED, V40, P318, DOI 10.1016/0002-9343(66)90112-4; LIDDLE GW, 1960, J CLIN ENDOCR METAB, V20, P1539, DOI 10.1210/jcem-20-12-1539; LIEBERMAN SA, 1994, EUR J ENDOCRINOL, V131, P67, DOI 10.1530/eje.0.1310067; MUGURUZA MTG, 1989, J PEDIATR-US, V115, P270, DOI 10.1016/S0022-3476(89)80081-2; MURPHY BEP, 1968, J CLIN ENDOCR METAB, V28, P343, DOI 10.1210/jcem-28-3-343; OELKERS W, 1986, ACTA ENDOCRINOL-COP, V113, P370, DOI 10.1530/acta.0.1130370; Papanicolaou DA, 1998, J CLIN ENDOCR METAB, V83, P1163, DOI 10.1210/jc.83.4.1163; REZNIK Y, 1992, NEW ENGL J MED, V327, P981, DOI 10.1056/NEJM199210013271403; RUDER HJ, 1974, J CLIN ENDOCR METAB, V39, P1138, DOI 10.1210/jcem-39-6-1138; Sarlis NJ, 1997, J CLIN ENDOCR METAB, V82, P1274, DOI 10.1210/jc.82.4.1274; SHENOY BV, 1984, AM J SURG PATHOL, V8, P335, DOI 10.1097/00000478-198405000-00002; SILVERMAN SR, 1963, J CLIN ENDOCR METAB, V23, P167, DOI 10.1210/jcem-23-2-167; Stratakis CA, 1996, J CLIN INVEST, V97, P699, DOI 10.1172/JCI118467; Stratakis CA, 1999, J CLIN ENDOCR METAB, V84, P1122, DOI 10.1210/jc.84.3.1122; Stratakis CA, 1998, HORM METAB RES, V30, P456, DOI 10.1055/s-2007-978914; Stratakis CA, 1996, J CLIN ENDOCR METAB, V81, P3607, DOI 10.1210/jc.81.10.3607; WULFFRAAT NM, 1988, J CLIN ENDOCR METAB, V66, P301, DOI 10.1210/jcem-66-2-301; YOTSUMOTO S, 1979, J CLIN ENDOCR METAB, V48, P660, DOI 10.1210/jcem-48-4-660; YOUNG WF, 1989, NEW ENGL J MED, V321, P1659, DOI 10.1056/NEJM198912143212407; ZEIGER MA, 1991, SURGERY, V110, P1106	41	155	166	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	OCT 19	1999	131	8					585	+		10.7326/0003-4819-131-8-199910190-00006	http://dx.doi.org/10.7326/0003-4819-131-8-199910190-00006			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	246ZR	10523219				2022-12-01	WOS:000083196600005
J	Helweg-Larsen, J; Benfield, TL; Eugen-Olsen, J; Lundgren, JD; Lundgren, B				Helweg-Larsen, J; Benfield, TL; Eugen-Olsen, J; Lundgren, JD; Lundgren, B			Effects of mutations in Pneumocystis carinii dihydropteroate synthase gene on outcome of AIDS-associated P carinii pneumonia	LANCET			English	Article							ACQUIRED-IMMUNODEFICIENCY-SYNDROME; SULFONAMIDE RESISTANCE; PROGNOSTIC FACTORS; ESCHERICHIA-COLI; INFECTION; CORTICOSTEROIDS; PROPHYLAXIS; THERAPY; PCR	Background Sulpha drugs are widely used for the treatment and long-term prophylaxis of Pneumocystis carinii pneumonia (PCP) in HIV-1-infected individuals. Sulpha resistance in many microorganisms Is caused by point mutations in dihydropteroate synthase (DHPS), an enzyme that Is essential for folate biosynthesis. We assessed whether mutations in the DHPS gene of P carinii were associated with exposure to sulpha drugs and influenced outcome from PCP. Methods We studied bronchoalveolar samples collected in 1989-99 from prospective cohort of HIV-1-infected patients who had PCP. In 144 patients with 152 episodes of PCP, we analysed portions of DHPS using PCR and direct sequencing. The relation between survival, P carinii DHPS mutations, and other predictors of treatment failure was assessed by Kaplan-Meier and multivariate Cox regression analysis. Findings P carinii DHPS mutations were found in 31 (20.4%) of 152 PCP episodes. 3-month survival was significantly lower in patients infected with mutant P carinii DHPS strains than in those with wild-type strains (p=0.002). After adjustment for other prognostic variables, presence of DHPS mutations remained the most important predictor of mortality (hazard ratio 3.1 [95% CI 1.2-8.1]). DHPS mutations were significantly more common in patients who had previous exposure to sulpha drugs (18 of 29 [62%]) than in those who had no exposure (13 of 123 [10.5%]; p<0.0001). A significant increase with time in the rate of DHPS mutations (p=0.01 for trend) was closely correlated with the rate of previous or current use of sulpha drugs as chemoprophylaxis. Interpretation Mutations in DHPS are associated with impaired prognosis in PCP, and may develop as a result of exposure to sulpha drugs.	Univ Copenhagen, Hvidovre Hosp, Dept Infect Dis, Copenhagen, Denmark; Univ Copenhagen, Hvidovre Hosp, Climat Res Unit, Copenhagen, Denmark; State Serum Inst, Dept Mycobacteriol, Copenhagen, Denmark	University of Copenhagen; University of Copenhagen; Statens Serum Institut	Helweg-Larsen, J (corresponding author), Hvidovre Hosp, Dept Infect Dis, DK-2650 Hvidovre, Denmark.		Lundgren, Jens/AAE-6876-2019	Eugen-Olsen, Jesper/0000-0002-4630-4275; Benfield, Thomas/0000-0003-0698-9385; Lundgren, Jens/0000-0001-8901-7850				Balslev U, 1997, SCAND J INFECT DIS, V29, P337, DOI 10.3109/00365549709011827; BENFIELD TL, 1995, AM J RESP CRIT CARE, V151, P1058; BOZZETTE SA, 1990, J INFECT DIS, V162, P1365, DOI 10.1093/infdis/162.6.1365; BRENNER M, 1987, AM REV RESPIR DIS, V136, P1199, DOI 10.1164/ajrccm/136.5.1199; DALLAS WS, 1992, J BACTERIOL, V174, P5961, DOI 10.1128/jb.174.18.5961-5970.1992; FERNANDEZ P, 1995, THORAX, V50, P668, DOI 10.1136/thx.50.6.668; Fishman JA, 1998, ANTIMICROB AGENTS CH, V42, P1309, DOI 10.1128/AAC.42.6.1309; Fishman JA, 1998, ANTIMICROB AGENTS CH, V42, P995, DOI 10.1128/AAC.42.5.995; HARDY WD, 1992, NEW ENGL J MED, V327, P1842, DOI 10.1056/NEJM199212243272604; Helweg-Larsen J, 1998, J CLIN MICROBIOL, V36, P2068, DOI 10.1128/JCM.36.7.2068-2072.1998; Helweg-Larsen J, 1998, QJM-INT J MED, V91, P813, DOI 10.1093/qjmed/91.12.813; HelwegLarsen J, 1997, LANCET, V350, P1363, DOI 10.1016/S0140-6736(97)24045-6; Kazanjian P, 1998, AIDS, V12, P873, DOI 10.1097/00002030-199808000-00009; Kirk O, 1998, AIDS, V12, P2031, DOI 10.1097/00002030-199815000-00015; Kumar SD, 1998, CHEST, V113, P430, DOI 10.1378/chest.113.2.430; Lane BR, 1997, J INFECT DIS, V175, P482, DOI 10.1093/infdis/175.2.482; LUNDGREN JD, 1996, CLIN PULM MED, V3, P304; MASON GR, 1989, AM REV RESPIR DIS, V139, P1336, DOI 10.1164/ajrccm/139.6.1336; Mei Q, 1998, LANCET, V351, P1631, DOI 10.1016/S0140-6736(05)77687-X; MONTANER JSG, 1990, ANN INTERN MED, V113, P14, DOI 10.7326/0003-4819-113-1-14; NIELSEN TL, 1992, J ACQ IMMUN DEF SYND, V5, P726; Stringer JR, 1996, AIDS, V10, P561, DOI 10.1097/00002030-199606000-00001; Swedberg G, 1998, ANTIMICROB AGENTS CH, V42, P1062, DOI 10.1128/AAC.42.5.1062; Triglia T, 1997, P NATL ACAD SCI USA, V94, P13944, DOI 10.1073/pnas.94.25.13944; Vedantam G, 1998, ANTIMICROB AGENTS CH, V42, P88, DOI 10.1128/AAC.42.1.88; VOLPE F, 1993, EUR J BIOCHEM, V216, P449, DOI 10.1111/j.1432-1033.1993.tb18163.x; Wakefield AE, 1998, FEMS IMMUNOL MED MIC, V22, P59, DOI 10.1111/j.1574-695X.1998.tb01187.x; WALZER PD, 1992, ANTIMICROB AGENTS CH, V36, P1935, DOI 10.1128/AAC.36.9.1935; Weverling GJ, 1999, LANCET, V353, P1293, DOI 10.1016/S0140-6736(99)03287-0	29	198	202	0	4	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	OCT 16	1999	354	9187					1347	1351		10.1016/S0140-6736(99)03320-6	http://dx.doi.org/10.1016/S0140-6736(99)03320-6			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	246DV	10533864				2022-12-01	WOS:000083149900013
J	Sallusto, F; Lenig, D; Forster, R; Lipp, M; Lanzavecchia, A				Sallusto, F; Lenig, D; Forster, R; Lipp, M; Lanzavecchia, A			Two subsets of memory T lymphocytes with distinct homing potentials and effector functions	NATURE			English	Article							IMMUNOLOGICAL MEMORY; T-HELPER-2 CELLS; B-CELL; EXPRESSION; IMMUNITY; NAIVE; CHEMOKINES; ADHESION	Naive T lymphocytes travel to T-cell areas of secondary lymphoid organs in search of antigen presented by dendritic cells(1,2). Once activated, they proliferate vigorously, generating effector cells that can migrate to B-cell areas or to inflamed tissues(3-6). A fraction of primed T lymphocytes persists as circulating memory cells that can confer protection and give, upon secondary challenge, a qualitatively different and quantitatively enhanced response(7-9) The nature of the cells that mediate the different facets of immunological memory remains unresolved. Here we show that expression of CCR7, a chemokine receptor that controls homing to secondary lymphoid organs, divides human memory T cells into two functionally distinct subsets, CCR7(-) memory cells express receptors for migration to inflamed tissues and display immediate effector function. In contrast, CCR7(+) memory cells express lymph-node homing receptors and lack immediate effector function, but efficiently stimulate dendritic cells and differentiate into CCR7(-) effector cells upon secondary stimulation. The CCR7(+) and CCR7(-) T cells, which we have named central memory (T-CM) and effector memory (T-EM), differentiate in a step-wise fashion from naive T cells, persist for years after immunization and allow a division of labour in the memory response.	Basel Inst Immunol, CH-4005 Basel, Switzerland; Max Delbruck Ctr Mol Med, D-13122 Berlin, Germany	Helmholtz Association; Max Delbruck Center for Molecular Medicine	Sallusto, F (corresponding author), Basel Inst Immunol, Grenzacherstr 487, CH-4005 Basel, Switzerland.		Lipp, Martin/G-2235-2010; Förster, Reinhold/D-6770-2011	Forster, Reinhold/0000-0001-6190-7923; Lipp, Martin/0000-0002-0087-2672				Abbas AK, 1996, NATURE, V383, P787, DOI 10.1038/383787a0; Ahmed R, 1996, SCIENCE, V272, P54, DOI 10.1126/science.272.5258.54; Austrup F, 1997, NATURE, V385, P81, DOI 10.1038/385081a0; Baggiolini M, 1998, NATURE, V392, P565, DOI 10.1038/33340; Banchereau J, 1998, NATURE, V392, P245, DOI 10.1038/32588; BARON JL, 1993, J EXP MED, V177, P57, DOI 10.1084/jem.177.1.57; Butcher EC, 1996, SCIENCE, V272, P60, DOI 10.1126/science.272.5258.60; Campbell JJ, 1998, J CELL BIOL, V141, P1053, DOI 10.1083/jcb.141.4.1053; Campbell JJ, 1998, SCIENCE, V279, P381, DOI 10.1126/science.279.5349.381; CASAMAYORPALLEJA M, 1995, J EXP MED, V181, P1293, DOI 10.1084/jem.181.4.1293; Dutton RW, 1998, ANNU REV IMMUNOL, V16, P201, DOI 10.1146/annurev.immunol.16.1.201; Garside P, 1998, SCIENCE, V281, P96, DOI 10.1126/science.281.5373.96; Grewal IS, 1998, ANNU REV IMMUNOL, V16, P111, DOI 10.1146/annurev.immunol.16.1.111; Gunn MD, 1999, J EXP MED, V189, P451, DOI 10.1084/jem.189.3.451; Gunn MD, 1998, P NATL ACAD SCI USA, V95, P258, DOI 10.1073/pnas.95.1.258; Hamann D, 1997, J EXP MED, V186, P1407, DOI 10.1084/jem.186.9.1407; Kagi D, 1996, ANNU REV IMMUNOL, V14, P207, DOI 10.1146/annurev.immunol.14.1.207; MACKAY CR, 1990, J EXP MED, V171, P801, DOI 10.1084/jem.171.3.801; MACKAY CR, 1993, CURR OPIN IMMUNOL, V5, P423, DOI 10.1016/0952-7915(93)90063-X; MacLennan ICM, 1997, IMMUNOL REV, V156, P53, DOI 10.1111/j.1600-065X.1997.tb00958.x; MICHIE CA, 1992, NATURE, V360, P264, DOI 10.1038/360264a0; Sallusto F, 1998, J EXP MED, V187, P875, DOI 10.1084/jem.187.6.875; Sallusto F, 1997, SCIENCE, V277, P2005, DOI 10.1126/science.277.5334.2005; Sprent J, 1997, IMMUNOL REV, V156, P79, DOI 10.1111/j.1600-065X.1997.tb00960.x; Tanchot C, 1998, IMMUNOL TODAY, V19, P575, DOI 10.1016/S0167-5699(98)01344-9; Tang HL, 1999, SCIENCE, V284, P819, DOI 10.1126/science.284.5415.819; Weng NP, 1998, IMMUNITY, V9, P151, DOI 10.1016/S1074-7613(00)80597-X; Wu LJ, 1997, J EXP MED, V185, P1681, DOI 10.1084/jem.185.9.1681; Zinkernagel RM, 1996, ANNU REV IMMUNOL, V14, P333, DOI 10.1146/annurev.immunol.14.1.333	29	4441	4571	5	228	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	OCT 14	1999	401	6754					708	712		10.1038/44385	http://dx.doi.org/10.1038/44385			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	247EJ	10537110				2022-12-01	WOS:000083207400059
J	Rodstrom, K; Bengtsson, C; Lissner, L; Bjorkelund, C				Rodstrom, K; Bengtsson, C; Lissner, L; Bjorkelund, C			Pre-existing risk factor profiles in users and non-users of hormone replacement therapy: prospective cohort study in Gothenburg, Sweden	BMJ-BRITISH MEDICAL JOURNAL			English	Article							CORONARY HEART-DISEASE; CARDIOVASCULAR-DISEASE; FOLLOW-UP; PROSPECTIVE POPULATION; POSTMENOPAUSAL WOMEN; ESTROGEN REPLACEMENT; LIPOPROTEINS; MENOPAUSE; MORTALITY; HEALTH	Objective To assess whether risk factor profiles for cardiovascular disease differed, before starting treatment, between women who would subsequently use hormone replacement therapy and those who would remain untreated. Design Prospective population study, initiated in 1968-9, with follow ups in 1974, 1980, and 1992. Setting Gothenburg, Sweden. Participants 1201 women born in 1918, 1922, and 1930, representative of women of the same age in the general population. Main outcome measures Hormone replacement therapy as a function of initial systolic and diastolic blood pressure, waist and hip circumference, waist to hip ratio, body mass index, serum concentrations of cholesterol and triglycerides, smoking status, education, leisure time activity, and socioeconomic group. Results 179 of the 1201 women (14.9%) used hormone replacement therapy sometime during the 24 year follow up period. Multivariate models indicated that these women had significantly lower blood pressure, had less obesity, and belonged to a higher social group before the start of treatment than women who would remain untreated. Conclusion Women who would subsequently use hormone replacement therapy were already at lower cardiovascular risk before the start of treatment than women who would remain untreated. Some of the claimed beneficial effects of treatment may thus be explained by women who would use hormone replacement therapy representing a healthier cohort than women who would remain untreated.	Univ Gothenburg, Vasa Hosp, Dept Primary Hlth, SE-41133 Gothenburg, Sweden; Univ Gothenburg, Sahlgrens Univ Hosp, Dept Internal Med, SE-41345 Gothenburg, Sweden	University of Gothenburg; Sahlgrenska University Hospital; University of Gothenburg	Rodstrom, K (corresponding author), Univ Gothenburg, Vasa Hosp, Dept Primary Hlth, SE-41133 Gothenburg, Sweden.	Kerstin.Rodstrom@allmed.gu.se						BarrettConnor E, 1996, MATURITAS, V23, P227, DOI 10.1016/0378-5122(95)00975-2; BARRETTCONNOR E, 1991, JAMA-J AM MED ASSOC, V265, P1861, DOI 10.1001/jama.265.14.1861; BENGTSSON C, 1989, SCAND J SOC MED, V17, P141, DOI 10.1177/140349488901700203; BENGTSSON C, 1978, SCAND J SOC MED, V6, P49, DOI 10.1177/140349487800600201; Bengtsson C, 1997, SCAND J PRIM HEALTH, V15, P214, DOI 10.3109/02813439709035031; BENGTSSON C, 1993, BMJ-BRIT MED J, V307, P1385, DOI 10.1136/bmj.307.6916.1385; BENGTSSON C, 1973, ACTA MED SCAND, P311; BENGTSSON C, 1973, ACTA MED SCAND S, V549; Carlsson G., 1958, SOCIAL MOBILITY CLAS; CHRISTIANSEN C, 1991, AM J MED, V90, P107; FALKEBORN M, 1992, BRIT J OBSTET GYNAEC, V99, P821, DOI 10.1111/j.1471-0528.1992.tb14414.x; GORDON T, 1978, ANN INTERN MED, V89, P157, DOI 10.7326/0003-4819-89-2-157; HALLING A, 1984, SWED DENT J, V8, P183; Hulley S, 1998, JAMA-J AM MED ASSOC, V280, P605, DOI 10.1001/jama.280.7.605; Lissner L, 1996, AM J EPIDEMIOL, V143, P54; LOBO RA, 1991, J CLIN ENDOCR METAB, V73, P925, DOI 10.1210/jcem-73-5-925; MANTEL N, 1963, J AM STAT ASSOC, V58, P690; Matthews KA, 1996, AM J EPIDEMIOL, V143, P971; STAMPFER MJ, 1991, NEW ENGL J MED, V325, P756, DOI 10.1056/NEJM199109123251102; VANDERMAAREL SM, 1995, EUR J HUM GENET, V3, P207; WALSH BW, 1991, NEW ENGL J MED, V325, P1196, DOI 10.1056/NEJM199110243251702; WINKLEBY MA, 1992, AM J PUBLIC HEALTH, V82, P816, DOI 10.2105/AJPH.82.6.816	22	51	52	0	2	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	OCT 2	1999	319	7214					890	893		10.1136/bmj.319.7214.890	http://dx.doi.org/10.1136/bmj.319.7214.890			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	243AU	10506047	Green Published, Bronze			2022-12-01	WOS:000082975600026
J	Lee, AYY; Julian, JA; Levine, MN; Weitz, JI; Kearon, C; Wells, PS; Ginsberg, JS				Lee, AYY; Julian, JA; Levine, MN; Weitz, JI; Kearon, C; Wells, PS; Ginsberg, JS			Clinical utility of a rapid whole-blood D-dimer assay in patients with cancer who present with suspected acute deep venous thrombosis	ANNALS OF INTERNAL MEDICINE			English	Article							FIBRIN DEGRADATION PRODUCTS; VEIN THROMBOSIS; PULMONARY-EMBOLISM; DIAGNOSIS; THROMBOEMBOLISM; ULTRASONOGRAPHY; OUTPATIENTS; IMMUNOASSAY; HOME	Background: Although D-dimer assays have high negative predictive values for the diagnosis of deep venous thrombosis, their accuracy in patients with cancer is uncertain. Objective: To compare the clinical utility of a whole-blood D-dimer assay for the diagnosis of deep venous thrombosis in patients with and those without cancer. Design: Retrospective analysis of three prospective studies. Setting: Two tertiary care hospitals. Patients: 1068 consecutive outpatients with suspected deep venous thrombosis. Measurements: All patients underwent D-dimer testing and assessment with a priori diagnostic strategies that incorporated impedance plethysmography, compression ultrasonography, or contrast venography. Patients in whom deep venous thrombosis was not diagnosed initially were followed for 3 months for the development of thrombosis. Results of D-dimer testing were assessed according to the final diagnosis based on objective testing and clinical follow-up. Cancer status was identified at presentation. Results: The prevalence of deep venous thrombosis was 48.8% in 121 patients with cancer and 14.6% in 947 pa patients without cancer. Although the sensitivity of the D-dimer assay was similar in patients with and those without cancer (86.4% [95% CI, 75.0% to 94.0%] and 82.6% [CI, 75.2% to 88.5%], respectively), the specificity was significantly lower in patients with cancer (48.4% [CI, 35.5% to 61.4%] and 82.2% [CI, 79.4% to 84.8%]), as was the negative predictive value (78.9% [CI, 62.7% to 90.4%] and 96.5% [CI, 94.9% to 97.8%]). In contrast, the likelihood ratios of a negative test result (0.28 [CI, 0.14 to 0.56] and 0.21 [CI, 0.15 to 0.31]) did not differ significantly. Conclusions: A negative D-dimer test result in patients with cancer does not reliably exclude deep venous thrombosis because the negative predictive value of the test is significantly lower in these patients than in patients without cancer.	McMaster Univ, Hamilton, ON, Canada; Univ Ottawa, Ottawa, ON K1N 6N5, Canada	McMaster University; University of Ottawa	Lee, AYY (corresponding author), Hamilton Civ Hosp, Res Ctr, 711 Concess St, Hamilton, ON L8V 1C3, Canada.	alee@thrombosis.hhscr.org	Weitz, Jeffrey/AAD-1929-2019; ginsberg, jeffrey s/ABC-1065-2020	Weitz, Jeffrey/0000-0002-1092-7550; 				AMBRUS JL, 1975, J MED, V6, P61; Becker DM, 1996, ARCH INTERN MED, V156, P939, DOI 10.1001/archinte.156.9.939; Birdwell BG, 1998, ANN INTERN MED, V128, P1, DOI 10.7326/0003-4819-128-1-199801010-00001; BOUNAMEAUX H, 1994, THROMB HAEMOSTASIS, V71, P1; BRENNER B, 1995, BLOOD COAGUL FIBRIN, V6, P219, DOI 10.1097/00001721-199505000-00004; CHAPMAN CS, 1990, CLIN LAB HAEMATOL, V12, P37; Dvorak HF, 1994, HEMOSTASIS THROMBOSI, P1238; Falanga A, 1999, SEMIN THROMB HEMOST, V25, P173, DOI 10.1055/s-2007-994919; FALANGA A, 1993, THROMB HAEMOSTASIS, V70, P540; Fleiss J L, 1993, Stat Methods Med Res, V2, P121, DOI 10.1177/096228029300200202; GABAZZA EC, 1991, EUR J CANCER, V30, P1271; Ginsberg JS, 1997, ARCH INTERN MED, V157, P1077, DOI 10.1001/archinte.157.10.1077; Ginsberg JS, 1998, ANN INTERN MED, V129, P1006, DOI 10.7326/0003-4819-129-12-199812150-00003; JAESCHKE R, 1994, JAMA-J AM MED ASSOC, V271, P703, DOI 10.1001/jama.271.9.703; JOHN MA, 1990, THROMB RES, V58, P273, DOI 10.1016/0049-3848(90)90097-V; KATZ D, 1978, BIOMETRICS, V34, P469, DOI 10.2307/2530610; Kearon C, 1997, THROMB HAEMOSTASIS, V78, P553; KEEFE DL, 1994, ANGIOLOGY, V45, P771, DOI 10.1177/000331979404500904; Koopman MMW, 1996, NEW ENGL J MED, V334, P682, DOI 10.1056/NEJM199603143341102; Levine M, 1996, NEW ENGL J MED, V334, P677, DOI 10.1056/NEJM199603143341101; LEVINE M, 1990, SEMIN ONCOL, V17, P160; LUZZATTO G, 1990, SEMIN ONCOL, V17, P147; Mayer W, 1997, VASA-J VASCULAR DIS, V26, P97; NANNINGA PB, 1990, THROMB HAEMOSTASIS, V64, P361; Perrier A, 1996, ARCH INTERN MED, V156, P531, DOI 10.1001/archinte.156.5.531; PINI M, 1993, FIBRINOLYSIS, V7, P391, DOI 10.1016/0268-9499(93)90064-3; RAIMONDI P, 1993, THROMB RES, V69, P125, DOI 10.1016/0049-3848(93)90009-D; Sackett D, 1991, CLIN EPIDEMIOLOGY BA; SCATES SM, 1992, SEMIN THROMB HEMOST, V18, P373, DOI 10.1055/s-2007-1002576; tenCate JW, 1997, NEW ENGL J MED, V337, P657; Turkstra F, 1996, THROMB HAEMOSTASIS, V76, P9; WELLS PS, 1995, CIRCULATION, V91, P2184, DOI 10.1161/01.CIR.91.8.2184; WHEELER HB, 1994, ARCH INTERN MED, V154, P1921, DOI 10.1001/archinte.154.17.1921; WILDE JT, 1989, BRIT J HAEMATOL, V71, P65, DOI 10.1111/j.1365-2141.1989.tb06276.x; ZUFFA M, 1982, NEOPLASMA, V29, P241	35	98	103	0	8	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	SEP 21	1999	131	6					417	423		10.7326/0003-4819-131-6-199909210-00004	http://dx.doi.org/10.7326/0003-4819-131-6-199909210-00004			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	237DY	10498557				2022-12-01	WOS:000082641100003
J	Chin, J; Lee, SS; Lee, KJ; Park, S; Kim, DH				Chin, J; Lee, SS; Lee, KJ; Park, S; Kim, DH			A metal complex that binds alpha-amino acids with high and predictable stereospecificity	NATURE			English	Article							COBALT(III) COMPLEXES; RECOGNITION; RECEPTORS; LIGANDS; ESTERS; RNA	Molecular recognition is the key step in a wide range of controlled separation and chemical transformation processes, with enzymes performing this task with an unsurpassed degree of selectivity. Enzymes contain only 20 simple amino acids, yet it remains difficult to rationalize or even predict these stereospecific recognition events. Nonetheless, the rational design of receptors able to recognize amino acids stereospecifically is attracting considerable interest because therapeutic drugs, that may be developed from chiral amino acid intermediates, are increasingly required in enantiomerically pure form(1). Early work(2-4) has stimulated the development of efficient receptors based on small molecules(5-8), but binding of amino acids with high and predictable stereospecificity remains difficult to achieve. Directed molecular evolution(9), on the other hand, does select for RNA sequences or antibodies that bind amino acids with high specificity(10-12), but typically without providing insights into the molecular recognition mechanisms involved. Here we show that a rationally designed metal complex formed from a trivalent cobalt ion and a tetradentate ligand binds natural amino acids, including the simple yet challenging amino acid alanine, with high and predictable regio- and stereospecificity. We expect that our approach will allow the binding as well as separation and stereospecific catalytic formation of its target amino acids.	McGill Univ, Dept Chem, Montreal, PQ H3A 2K6, Canada; Pohang Univ Sci & Technol, Ctr Biofunct Mol, Pohang 790784, South Korea	McGill University; Pohang University of Science & Technology (POSTECH)	Chin, J (corresponding author), McGill Univ, Dept Chem, 801 Sherbrooke St W, Montreal, PQ H3A 2K6, Canada.							BUCKINGHAM DA, 1967, J AM CHEM SOC, V89, P5133, DOI 10.1021/ja00996a009; CHIN J, 1991, ACCOUNTS CHEM RES, V24, P145, DOI 10.1021/ar00005a004; Collins A.N., 1997, CHIRALITY IND, VII; COLLINS AN, 1992, CHIRALITY IND, V1; CRAM DJ, 1988, SCIENCE, V240, P760, DOI 10.1126/science.3283937; DABROWIAK JC, 1975, INORG CHEM, V14, P1305, DOI 10.1021/ic50148a020; ELLINGTON AD, 1990, NATURE, V346, P818, DOI 10.1038/346818a0; Evans DA, 1997, J AM CHEM SOC, V119, P7893, DOI 10.1021/ja971521y; FAMULOK M, 1992, J AM CHEM SOC, V114, P3990, DOI 10.1021/ja00036a065; FENTON RR, 1995, INORG CHIM ACTA, V236, P109, DOI 10.1016/0020-1693(95)04625-J; FUJII Y, 1981, B CHEM SOC JPN, V54, P2029, DOI 10.1246/bcsj.54.2029; GREENSTEIN JP, 1996, CHEM AMINO ACIDS, V1, P594; Hofstetter O, 1998, J AM CHEM SOC, V120, P3251, DOI 10.1021/ja973680n; JOB RC, 1974, J AM CHEM SOC, V96, P809, DOI 10.1021/ja00810a028; JOYCE GE, 1992, SCI AM, V12, P92; KURODA Y, 1995, J AM CHEM SOC, V117, P10950, DOI 10.1021/ja00149a018; LEHN JM, 1978, J CHEM SOC CHEM COMM, P949, DOI 10.1039/c39780000949; Li GG, 1996, ANGEW CHEM INT EDIT, V35, P451, DOI 10.1002/anie.199604511; SCRIMIN P, 1994, J ORG CHEM, V59, P4194, DOI 10.1021/jo00094a034; Sessler JL, 1998, CHEM-EUR J, V4, P159, DOI 10.1002/(SICI)1521-3765(199801)4:1<159::AID-CHEM159>3.0.CO;2-N; Still WC, 1996, ACCOUNTS CHEM RES, V29, P155, DOI 10.1021/ar950166i; Tokunaga M, 1997, SCIENCE, V277, P936, DOI 10.1126/science.277.5328.936; YAMAGUCHI M, 1980, INORG CHEM, V19, P2010, DOI 10.1021/ic50209a035; Zelewsky A.V., 1996, STEREOCHEMISTRY COOR; Zhang XX, 1997, CHEM REV, V97, P3313, DOI 10.1021/cr960144p	25	155	158	1	28	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	SEP 16	1999	401	6750					254	257		10.1038/45751	http://dx.doi.org/10.1038/45751			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	237VZ	10499581				2022-12-01	WOS:000082678400046
J	Gilliver, MA; Bennett, M; Begon, M; Hazel, SM; Hart, CA				Gilliver, MA; Bennett, M; Begon, M; Hazel, SM; Hart, CA			Enterobacteria - Antibiotic resistance found in wild rodents	NATURE			English	Article							BACTERIA; FITNESS		Univ Liverpool, Ctr Comp Infect Dis, Liverpool L69 3BX, Merseyside, England	University of Liverpool	Gilliver, MA (corresponding author), Univ Liverpool, Ctr Comp Infect Dis, POB 147, Liverpool L69 3BX, Merseyside, England.		; Bennett, Malcolm/G-4004-2010	Begon, Mike/0000-0003-1715-5327; Bennett, Malcolm/0000-0003-0475-390X				Bjorkman J, 1998, P NATL ACAD SCI USA, V95, P3949, DOI 10.1073/pnas.95.7.3949; *BSAC, GUID SENS TEST METH, V35; Davies JE, 1997, CIBA F SYMP, V207, P15; HUGHES VM, 1983, NATURE, V302, P725, DOI 10.1038/302725a0; LENSKI RE, 1994, J BACTERIOL, V176, P3140, DOI 10.1128/jb.176.11.3140-3147.1994; LEVIN BR, 1997, CLIN INFECT DIS   S1, V24, P9; MEDEIROS AA, 1997, CLIN INFECT DIS   S1, V24, P19; Piddock LJV, 1996, J ANTIMICROB CHEMOTH, V38, P1, DOI 10.1093/jac/38.1.1; ROLLAND RM, 1985, APPL ENVIRON MICROB, V49, P791, DOI 10.1128/AEM.49.4.791-794.1985; Schrag SJ, 1996, NATURE, V381, P120, DOI 10.1038/381120b0; Schrag SJ, 1997, P ROY SOC B-BIOL SCI, V264, P1287, DOI 10.1098/rspb.1997.0178; Waters B, 1997, ANTIMICROB AGENTS CH, V41, P2766, DOI 10.1128/AAC.41.12.2766; Wiener P, 1998, MOL ECOL, V7, P1205, DOI 10.1046/j.1365-294x.1998.00450.x	13	192	198	4	29	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	SEP 16	1999	401	6750					233	234		10.1038/45724	http://dx.doi.org/10.1038/45724			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	237VZ	10499578				2022-12-01	WOS:000082678400041
J	Scita, G; Nordstrom, J; Carbone, R; Tenca, P; Giardina, G; Gutkind, S; Bjarnegard, M; Betsholtz, C; Di Fiore, PP				Scita, G; Nordstrom, J; Carbone, R; Tenca, P; Giardina, G; Gutkind, S; Bjarnegard, M; Betsholtz, C; Di Fiore, PP			EPS8 and E3B1 transduce signals from Ras to Rac	NATURE			English	Article							SH3 DOMAIN; BINDING-PROTEIN; RHO-GTPASES; GROWTH; KINASE; CDC42; AFFINITY; PATHWAYS	The small guanine nucleotide (GTP)-binding protein Rac regulates mitogen-induced cytoskeletal changes and c-Jun aminoterminal kinase (JNK), and its activity is required for Ras-mediated cell transformation(1). Epistatic analysis placed Rac as a key downstream target in pas signalling(2); however, the biochemical mechanism regulating the cross-talk among these small GTP-binding proteins remains to be elucidated. Eps8 (relative molecular mass 97,000) is a substrate of receptors with tyrosine kinase activity(3) which binds, through its SH3 domain, to a protein designated E3b1/Abi-1 (refs 4, 5). Here we show that Eps8 and E3b1/Abi-1 participate in the transduction of signals from pas to Rac, by regulating Rac-specific guanine nucleotide exchange factor (GEF) activities. We also show that Eps8, E3b1 and Sos-1 form a tri-complex in vivo that exhibits Rac-specific GEF activity in vitro. We propose a model in which Eps8 mediates the transfer of signals between Ras and pac, by forming a complex with E3b1 and Sos-1.	European Inst Oncol, Dept Expt Oncol, I-20141 Milan, Italy; Univ Gothenburg, Dept Med Biochem, SE-40530 Gothenburg, Sweden; Univ Bari, Ist Microbiol, I-70124 Bari, Italy; NIH, Mol Signaling Unit, Cellular Dev & Oncol Lab, Bethesda, MD 20892 USA	IRCCS European Institute of Oncology (IEO); University of Gothenburg; Universita degli Studi di Bari Aldo Moro; National Institutes of Health (NIH) - USA	Di Fiore, PP (corresponding author), European Inst Oncol, Dept Expt Oncol, Via Ripamonti 435, I-20141 Milan, Italy.	pdifiore@ieo.cilea.it	Di Fiore, Pier Paolo/K-2130-2012; Gutkind, J. Silvio/A-1053-2009; Scita, Giorgio/J-9670-2012; Gutkind, J. Silvio/J-1201-2016	Di Fiore, Pier Paolo/0000-0002-2252-0950; Gutkind, J. Silvio/0000-0002-5150-4482; Scita, Giorgio/0000-0001-7984-1889				Biesova Z, 1997, ONCOGENE, V14, P233, DOI 10.1038/sj.onc.1200822; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; FAZIOLI F, 1993, EMBO J, V12, P3799, DOI 10.1002/j.1460-2075.1993.tb06058.x; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; Han JW, 1998, SCIENCE, V279, P558, DOI 10.1126/science.279.5350.558; Joneson T, 1997, SCIENCE, V276, P185; Kishan KVR, 1997, NAT STRUCT BIOL, V4, P739; Lamarche N, 1996, CELL, V87, P519, DOI 10.1016/S0092-8674(00)81371-9; LANFRANCONE L, 1995, ONCOGENE, V10, P907; LANFRANCONE L, 1995, ONCOGENE, V11, P607; LEVEEN P, 1994, GENE DEV, V8, P1875, DOI 10.1101/gad.8.16.1875; Manser E, 1998, MOL CELL, V1, P183, DOI 10.1016/S1097-2765(00)80019-2; MANSER E, 1994, NATURE, V367, P40, DOI 10.1038/367040a0; Matoskova B, 1996, ONCOGENE, V12, P2679; Nimnual AS, 1998, SCIENCE, V279, P560, DOI 10.1126/science.279.5350.560; Reif K, 1996, CURR BIOL, V6, P1445, DOI 10.1016/S0960-9822(96)00749-X; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; RodriguezViciana P, 1996, PHILOS T ROY SOC B, V351, P225, DOI 10.1098/rstb.1996.0020; SASTRY L, 1995, ONCOGENE, V11, P1107; SHI YG, 1995, GENE DEV, V9, P2583, DOI 10.1101/gad.9.21.2583; VanAelst L, 1997, GENE DEV, V11, P2295, DOI 10.1101/gad.11.18.2295; Westwick JK, 1997, MOL CELL BIOL, V17, P1324, DOI 10.1128/MCB.17.3.1324; ZHENG Y, 1995, METHOD ENZYMOL, V256, P77	23	278	289	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	SEP 16	1999	401	6750					290	293		10.1038/45822	http://dx.doi.org/10.1038/45822			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	237VZ	10499589				2022-12-01	WOS:000082678400057
J	Schopfer, CR; Nasrallah, ME; Nasrallah, JB				Schopfer, CR; Nasrallah, ME; Nasrallah, JB			The male determinant of self-incompatibility in Brassica	SCIENCE			English	Article							POLLEN COAT PROTEIN; S-LOCUS GENE; ANTIMICROBIAL PEPTIDES; OLERACEA; CAMPESTRIS; EVOLUTION; SEQUENCES; PLANTS	In the S locus-controlled self-incompatibility system of Brassica, recognition of self-related pollen at the surface of stigma epidermal cells leads to inhibition of pollen tube development. The female (stigmatic) determinant of this recognition reaction is a polymorphic transmembrane receptor protein kinase encoded at the 5 Locus. Another highly polymorphic, anther-expressed gene, SCR, also encoded at the 5 locus, fulfills the requirements for the hypothesized pollen determinant. Loss-of-function and gain-of-function studies prove that the SCR gene product is necessary and sufficient for determining pollen self-incompatibility specificity, possibly by acting as a Ligand for the stigmatic receptor.	Cornell Univ, Dept Plant Biol, Ithaca, NY 14853 USA	Cornell University	Nasrallah, JB (corresponding author), Cornell Univ, Dept Plant Biol, Ithaca, NY 14853 USA.		Swaibu, Ramadhani A/H-3164-2011		NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM057527] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM57527] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Boyes DC, 1997, PLANT CELL, V9, P237, DOI 10.1105/tpc.9.2.237; BOYES DC, 1995, PLANT CELL, V7, P1283, DOI 10.1105/tpc.7.8.1283; BOYES DC, 1991, GENETICS, V127, P221; BROEKAERT WF, 1995, PLANT PHYSIOL, V108, P1353, DOI 10.1016/j.chiabu.2021.105188; Broekaert WF, 1997, CRIT REV PLANT SCI, V16, P297, DOI 10.1080/713608148; CASSELMAN AL, UNPUB; Conner JA, 1998, PLANT CELL, V10, P801, DOI 10.1105/tpc.10.5.801; DIXIT R, UNPUB; Doughty J, 1998, PLANT CELL, V10, P1333, DOI 10.1105/tpc.10.8.1333; DWYER KG, 1991, PLANT MOL BIOL, V16, P481, DOI 10.1007/BF00024000; KHO YO, 1968, EUPHYTICA, V17, P298; Kusaba M, 1997, P NATL ACAD SCI USA, V94, P7673, DOI 10.1073/pnas.94.14.7673; Nasrallah JB, 1997, P NATL ACAD SCI USA, V94, P9516, DOI 10.1073/pnas.94.18.9516; NASRALLAH JB, 1994, SCIENCE, V266, P1505, DOI 10.1126/science.266.5190.1505; NASRALLAH JB, IN PRESS ANN BOT; Stanchev BS, 1996, PLANT J, V10, P303, DOI 10.1046/j.1365-313X.1996.10020303.x; Stein JC, 1996, PLANT CELL, V8, P429, DOI 10.1105/tpc.8.3.429; Stephenson AG, 1997, PLANT J, V12, P1351, DOI 10.1046/j.1365-313x.1997.12061351.x; Suzuki G, 1999, GENETICS, V153, P391; TERRAS FRG, 1992, J BIOL CHEM, V267, P15301; TORIYAMA K, 1991, THEOR APPL GENET, V81, P769, DOI 10.1007/BF00224988; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; Yu KF, 1996, PLANT CELL, V8, P2369, DOI 10.1105/tpc.8.12.2369	23	561	639	2	89	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 26	1999	286	5445					1697	1700		10.1126/science.286.5445.1697	http://dx.doi.org/10.1126/science.286.5445.1697			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	259UK	10576728				2022-12-01	WOS:000083912200026
J	Ayanian, JZ; Cleary, PD; Weissman, JS; Epstein, AM				Ayanian, JZ; Cleary, PD; Weissman, JS; Epstein, AM			The effect of patients' preferences on racial differences in access to renal transplantation	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							REVASCULARIZATION PROCEDURES; SURGICAL-PROCEDURES; HEART-DISEASE; RACE; WOMEN; ENDARTERECTOMY; ANGIOGRAPHY; DIALYSIS; QUALITY; SURGERY	Background: In the United States, black patients undergo renal transplantation less often than white patients, but few studies have directly assessed the association between race and patients' preferences with respect to transplantation. Methods: To assess preferences with respect to transplantation and experiences with medical care, we interviewed 1392 (82.9 percent) of 1679 eligible patients with end-stage renal disease (age range, 18 to 54 years) approximately 10 months after they had begun maintenance treatment with dialysis. Participants were selected from a stratified random sample of patients undergoing dialysis in four regions of the United States (Alabama, southern California, Michigan, and the mid-Atlantic region of Maryland, Virginia, and the District of Columbia) in 1996 and 1997. Patients were followed until March 1999. Results: The interviews were conducted with 384 black women, 354 white women, 337 black men, and 317 white men. Black patients were less likely than white patients to want a transplant (76.3 percent of black women reported such a preference, vs. 79.3 percent of white women, and 80.7 percent of black men vs. 85.5 percent of white men), and they were less likely to be very certain about this preference (58.3 percent vs. 65.3 percent and 64.1 percent vs. 75.7 percent, respectively; P<0.01 for each comparison with both sexes combined). However, much larger differences were evident in rates of referral for evaluation at a transplantation center (50.4 percent for black women vs. 70.5 percent for white women, and 53.9 percent for black men vs. 76.2 percent for white men; P<0.001 for each comparison) and placement on a waiting list or transplantation within 18 months after the start of dialysis therapy (31.3 percent for black women vs. 56.5 percent for white women, and 35.3 percent for black men vs. 60.6 percent for white men; P<0.001). These racial differences remained significant after adjustment for patients' preferences and expectations about transplantation, sociodemographic characteristics, the type of dialysis facility, perceptions of care, health status, the cause of renal failure, and the presence or absence of coexisting illnesses. Conclusions: In the United States, the preferences and expectations with respect to renal transplantation among patients with end-stage renal disease differ according to race. These differences, however, explain only a small fraction of the substantial racial differences in access to transplantation. Physicians should ensure that black patients who desire renal transplantation are fully informed about it and are referred for evaluation. (N Engl J Med 1999;341:1661-9.) (C) 1999, Massachusetts Medical Society.	Harvard Univ, Sch Med, Dept Hlth Care Policy, Boston, MA 02115 USA; Brigham & Womens Hosp, Dept Med, Div Gen Med & Primary Care, Sect Hlth Serv & Policy Res, Boston, MA 02115 USA; Massachusetts Gen Hosp, Inst Hlth Policy, Boston, MA 02114 USA; Harvard Univ, Sch Publ Hlth, Dept Hlth Policy & Management, Boston, MA 02115 USA	Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Harvard T.H. Chan School of Public Health	Ayanian, JZ (corresponding author), Harvard Univ, Sch Med, Dept Hlth Care Policy, 180 Longwood Ave, Boston, MA 02115 USA.	ayanian@hcp.med.harvard.edu	Cleary, Paul/AAF-7048-2019					Alexander GC, 1998, JAMA-J AM MED ASSOC, V280, P1148, DOI 10.1001/jama.280.13.1148; AYANIAN JZ, 1993, JAMA-J AM MED ASSOC, V269, P2642, DOI 10.1001/jama.269.20.2642; AYANIAN JZ, 1993, NEW ENGL J MED, V329, P656, DOI 10.1056/NEJM199308263290912; Burns RB, 1996, ANN INTERN MED, V125, P173, DOI 10.7326/0003-4819-125-3-199608010-00002; EGGERS P, 1992, SEMIN NEPHROL, V12, P284; Eggers P W, 1995, Health Care Financ Rev, V17, P89; EGGERS PW, 1988, NEW ENGL J MED, V318, P223, DOI 10.1056/NEJM198801283180406; ELIXHAUSER A, 1994, AHCPR PUBLICATION; ESCARCE JJ, 1993, AM J PUBLIC HEALTH, V83, P948, DOI 10.2105/AJPH.83.7.948; EVANS RW, 1985, NEW ENGL J MED, V312, P553, DOI 10.1056/NEJM198502283120905; Garg PP, 1999, NEW ENGL J MED, V341, P1653, DOI 10.1056/NEJM199911253412205; GAYLIN DS, 1993, JAMA-J AM MED ASSOC, V269, P603, DOI 10.1001/jama.269.5.603; Giacomini MK, 1996, ARCH INTERN MED, V156, P1217, DOI 10.1001/archinte.156.11.1217; Gornick ME, 1996, NEW ENGL J MED, V335, P791, DOI 10.1056/NEJM199609123351106; GUADAGNOLI E, 1995, ARCH SURG-CHICAGO, V130, P381; HAYS RD, 1994, QUAL LIFE RES, V3, P329, DOI 10.1007/BF00451725; HELD PJ, 1988, ARCH INTERN MED, V148, P2594, DOI 10.1001/archinte.148.12.2594; HORNER RD, 1995, MILBANK Q, V73, P443, DOI 10.2307/3350374; Kao AC, 1998, JAMA-J AM MED ASSOC, V280, P1708, DOI 10.1001/jama.280.19.1708; KASISKE BL, 1991, NEW ENGL J MED, V324, P302, DOI 10.1056/NEJM199101313240505; KJELLSTRAND CM, 1988, ARCH INTERN MED, V148, P1305; LEVY DR, 1985, PEDIATRICS, V75, P639; MAYNARD C, 1986, AM J PUBLIC HEALTH, V76, P1446, DOI 10.2105/AJPH.76.12.1446; McCauley J, 1997, AM J KIDNEY DIS, V30, P739, DOI 10.1016/S0272-6386(97)90077-9; MORT EA, 1994, ARCH INTERN MED, V154, P761, DOI 10.1001/archinte.154.7.761; ODDONE EZ, 1993, ARCH INTERN MED, V153, P2781, DOI 10.1001/archinte.153.24.2781; Oddone EZ, 1998, J NATL MED ASSOC, V90, P25; Ozminkowski RJ, 1997, AM J KIDNEY DIS, V30, P749, DOI 10.1016/S0272-6386(97)90078-0; Peterson ED, 1997, NEW ENGL J MED, V336, P480, DOI 10.1056/NEJM199702133360706; *REN DAT SYST, 1998, USRDS 1998 ANN DAT R; Saha S., 1999, JGIM, V14, P67; Satcher D, 1973, JAMA, V223, P1498; Schecter AD, 1996, AM J CARDIOL, V78, P996, DOI 10.1016/S0002-9149(96)00523-1; Schulman KA, 1999, NEW ENGL J MED, V340, P618, DOI 10.1056/NEJM199902253400806; Schulman KA, 1999, NEW ENGL J MED, V340, P1130; SOUCIE JM, 1992, AM J KIDNEY DIS, V19, P414, DOI 10.1016/S0272-6386(12)80947-4; WENNEKER MB, 1989, JAMA-J AM MED ASSOC, V261, P253, DOI 10.1001/jama.261.2.253; Whittle J, 1997, J GEN INTERN MED, V12, P267, DOI 10.1007/s11606-006-5062-0; WHITTLE J, 1993, NEW ENGL J MED, V329, P621, DOI 10.1056/NEJM199308263290907; Wilson Marcus Garvey, 1994, Ethnicity and Disease, V4, P57; Zhang J, 1998, JAMA-J AM MED ASSOC, V280, P1690, DOI 10.1001/jama.280.19.1690	41	493	493	0	11	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	NOV 25	1999	341	22					1661	1669		10.1056/NEJM199911253412206	http://dx.doi.org/10.1056/NEJM199911253412206			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	258PL	10572155				2022-12-01	WOS:000083847500006
J	Johnson, S; Samore, MH; Farrow, KA; Killgore, GE; Tenover, FC; Lyras, D; Rood, JI; DeGirolami, P; Baltch, AL; Rafferty, ME; Pear, SM; Gerding, DN				Johnson, S; Samore, MH; Farrow, KA; Killgore, GE; Tenover, FC; Lyras, D; Rood, JI; DeGirolami, P; Baltch, AL; Rafferty, ME; Pear, SM; Gerding, DN			Epidemics of diarrhea caused by a clindamycin-resistant strain of Clostridium difficile in four hospitals.	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							PERFRINGENS; LINCOSAMIDE; MACROLIDE; OUTBREAK; TETRACYCLINE; RESTRICTION; PLASMIDS; SEQUENCE; COLITIS; GENES	Background: Large outbreaks of diarrhea caused by a newly recognized strain of Clostridium difficile occurred in four hospitals located in different parts of the United States between 1989 and 1992. Since frequent use of clindamycin was associated with the outbreak in one of the hospitals, we examined the resistance genes of the epidemic-strain isolates and studied the role of clindamycin use in these outbreaks. Methods: Case-control studies were performed at three of the four hospitals to assess the relation of the use of clindamycin to C. difficile-associated diarrhea. All isolates of the epidemic strain and representative isolates of other strains identified during each outbreak were tested for susceptibility to clindamycin. Chromosomal DNA from these representative isolates was also analyzed by dot blot hybridization and amplification with the polymerase chain reaction (PCR) with the use of probes and primers from a previously described determinant of erythromycin resistance -- the erythromycin ribosomal methylase B (ermB) gene -- found in C. perfringens and C. difficile. Results: In a stratified analysis of the case-control studies with pooling of the results according to the Mantel-Haenszel method, we found that the use of clindamycin was significantly increased among patients with diarrhea due to the epidemic strain of C. difficile, as compared with patients whose diarrhea was due to nonepidemic strains (pooled odds ratio, 4.35; 95 percent confidence interval, 2.02 to 9.38; P<0.001). Exposure to other types of antibiotics or hospitalization in a surgical ward was not significantly associated with the risk of C. difficile-associated diarrhea due to the epidemic strain. All epidemic-strain isolates were highly resistant to clindamycin (minimal inhibitory concentration, >256 microg per milliliter). DNA hybridization and PCR analysis showed that all these isolates had an ermB gene, which encodes a 23S ribosomal RNA methylase that mediates resistance to macrolide, lincosamide, and streptogramin antibiotics. Only 15 percent of the nonepidemic strains were resistant to clindamycin. Conclusions: A strain of C. difficile that is highly resistant to clindamycin was responsible for large outbreaks of diarrhea in four hospitals in different states. The use of clindamycin is a specific risk factor for diarrhea due to this strain. Resistance to clindamycin further increases the risk of C. difficile-associated diarrhea, an established complication of antimicrobial use. (N Engl J Med 1999;341:1645-51.) (C) 1999, Massachusetts Medical Society.	Vet Affairs Chicago Hlth Care Syst, Lakeside Div, Med Serv, Dept Med,Infect Dis Sect, Chicago, IL 60611 USA; Northwestern Univ, Sch Med, Chicago, IL USA; Beth Israel Deaconess Med Ctr, Dept Med, Infect Dis Sect, Boston, MA USA; Harvard Univ, Sch Med, Boston, MA USA; Monash Univ, Dept Microbiol, Clayton, Vic 3168, Australia; Ctr Dis Control & Prevent, Atlanta, GA USA; Stratton Vet Affairs Med Ctr, Albany, NY USA; Albany Med Coll, Albany, NY 12208 USA; Vet Affairs Med Ctr, Tucson, AZ USA	Northwestern University; Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School; Monash University; Centers for Disease Control & Prevention - USA; Albany Medical College; US Department of Veterans Affairs; Veterans Health Administration (VHA); Southern Arizona Veterans Affairs Health Care System	Johnson, S (corresponding author), Vet Affairs Chicago Hlth Care Syst, Lakeside Div, Med Serv, Dept Med,Infect Dis Sect, 333 E Huron, Chicago, IL 60611 USA.	stu-johnson@nwu.edu	Rood, Julian I/A-4858-2008	Rood, Julian I/0000-0003-2126-7209; Johnson, Stuart/0000-0001-9548-229X; Lyras, Dena/0000-0003-2345-9271				ABRAHAM LJ, 1985, J BACTERIOL, V161, P636, DOI 10.1128/JB.161.2.636-640.1985; ARTHUR M, 1987, J ANTIMICROB CHEMOTH, V20, P783, DOI 10.1093/jac/20.6.783; BARTLETT JG, 1978, NEW ENGL J MED, V298, P531, DOI 10.1056/NEJM197803092981003; BERRYMAN DI, 1995, ANTIMICROB AGENTS CH, V39, P1830, DOI 10.1128/AAC.39.8.1830; BERRYMAN DI, 1994, ANTIMICROB AGENTS CH, V38, P1041, DOI 10.1128/AAC.38.5.1041; Brazier JS, 1998, J ANTIMICROB CHEMOTH, V41, P47, DOI 10.1093/jac/41.suppl_3.47; BREFORT G, 1977, PLASMID, V1, P52, DOI 10.1016/0147-619X(77)90008-7; CARTMILL TDI, 1994, J HOSP INFECT, V27, P1, DOI 10.1016/0195-6701(94)90063-9; CLABOTS CR, 1992, J INFECT DIS, V166, P561, DOI 10.1093/infdis/166.3.561; CLABOTS CR, 1991, 31 INT C ANT AG CHEM, P352; Climo MW, 1998, ANN INTERN MED, V128, P989, DOI 10.7326/0003-4819-128-12_Part_1-199806150-00005; GERDING DN, 1995, INFECT CONT HOSP EP, V16, P459; JOHNSON S, 1990, LANCET, V336, P97, DOI 10.1016/0140-6736(90)91605-A; KILLGORE GE, 1994, J CLIN MICROBIOL, V32, P1591, DOI 10.1128/JCM.32.6.1591-1593.1994; LYRAS D, 1997, CLOSTRIDIA MOL BIOL, P73; MEKONEN E, 1996, INFECT CONTROL HOS S, V17, pP32; MULLANY P, 1995, J ANTIMICROB CHEMOTH, V35, P305, DOI 10.1093/jac/35.2.305; *NAT COMM CLIN LAB, 1997, M11A4 NCCLS; NELSON DE, 1994, INFECT CONT HOSP EP, V15, P88; NELSON DE, 1994, INFECT CONT HOSP EP, V15, P366; PEAR SM, 1994, ANN INTERN MED, V120, P272, DOI 10.7326/0003-4819-120-4-199402150-00003; Rafferty ME, 1998, J CLIN MICROBIOL, V36, P2957, DOI 10.1128/JCM.36.10.2957-2963.1998; ROTHMAN KJ, 1998, MODERN EPIDEMIOLOGY, P270; Samore M, 1997, J INFECT DIS, V176, P1233, DOI 10.1086/514117; SAMORE MH, 1994, J INFECT DIS, V170, P615, DOI 10.1093/infdis/170.3.615; Samore MH, 1996, AM J MED, V100, P32, DOI 10.1016/S0002-9343(96)90008-X; SMITH CJ, 1981, ANTIMICROB AGENTS CH, V19, P997, DOI 10.1128/AAC.19.6.997; Tenover FC, 1997, INFECT CONT HOSP EP, V18, P426; WUST J, 1983, ANTIMICROB AGENTS CH, V23, P784, DOI 10.1128/AAC.23.5.784	29	252	260	1	2	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	NOV 25	1999	341	22					1645	1651		10.1056/NEJM199911253412203	http://dx.doi.org/10.1056/NEJM199911253412203			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	258PL	10572152				2022-12-01	WOS:000083847500003
J	Surks, HK; Mochizuki, N; Kasai, Y; Georgescu, SP; Tang, KM; Ito, M; Lincoln, TM; Mendelsohn, ME				Surks, HK; Mochizuki, N; Kasai, Y; Georgescu, SP; Tang, KM; Ito, M; Lincoln, TM; Mendelsohn, ME			Regulation of myosin phosphatase by a specific interaction with cGMP-dependent protein kinase I alpha	SCIENCE			English	Article							LIGHT-CHAIN PHOSPHATASE; VASCULAR SMOOTH-MUSCLE; DNA-BINDING DOMAIN; LEUCINE-ZIPPER; SIGNAL-TRANSDUCTION; TARGETING SUBUNITS; GMP; CALCIUM; PHOSPHORYLATION; IDENTIFICATION	Contraction and relaxation of smooth muscle are regulated by myosin light-chain kinase and myosin phosphatase through phosphorylation and dephosphorylation of myosin light chains. Cyclic guanosine monophosphate (cGMP)-dependent protein kinase I alpha (cGKI alpha) mediates physiologic relaxation of vascular smooth muscle in response to nitric oxide and cGMP. It is shown here that cGKI alpha is targeted to the smooth muscle cell contractile apparatus py a Leucine zipper interaction with the myosin-binding subunit (MBS) of myosin phosphatase. Uncoupling of the cGKI alpha-MBS interaction prevents cGMP-dependent dephosphorylation of myosin light chain, demonstrating that this interaction is essential to the regulation of vascular smooth muscle cell tone.	Tufts Univ, Sch Med, Mol Cardiol Res Inst, Boston, MA 02111 USA; Tufts Univ, Sch Med, Dept Med, Div Cardiol, Boston, MA 02111 USA; Tufts Univ New England Med Ctr, Boston, MA 02111 USA; Int Med Ctr Japan, Res Inst, Dept Pathol, Tokyo 1628655, Japan; Mie Univ, Sch Med, Dept Internal Med 1, Tsu, Mie 514, Japan; Univ Alabama Birmingham, Dept Pathol, Div Mol & Cellular Pathol, Birmingham, AL 35294 USA	Tufts University; Tufts University; Tufts Medical Center; National Center for Global Health & Medicine - Japan; Mie University; University of Alabama System; University of Alabama Birmingham	Mendelsohn, ME (corresponding author), Tufts Univ, Sch Med, Mol Cardiol Res Inst, Boston, MA 02111 USA.	mmendelsohn@lfespan.org			NHLBI NIH HHS [HL09330, HL55309] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [F32HL009330] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALESSI D, 1992, EUR J BIOCHEM, V210, P1023, DOI 10.1111/j.1432-1033.1992.tb17508.x; ATKINSON RA, 1991, BIOCHEMISTRY-US, V30, P9387, DOI 10.1021/bi00103a001; BRADLEY AB, 1987, J PHYSIOL-LONDON, V385, P437, DOI 10.1113/jphysiol.1987.sp016500; BRAUTIGAN DL, 1988, METHOD ENZYMOL, V159, P339; CHEVRAY PM, 1992, P NATL ACAD SCI USA, V89, P5789, DOI 10.1073/pnas.89.13.5789; CHOI KY, 1994, CELL, V78, P499; COHEN P, 1991, METHOD ENZYMOL, V201, P389; CORNWELL TL, 1989, J BIOL CHEM, V264, P1146; DellAcqua ML, 1997, J BIOL CHEM, V272, P12881, DOI 10.1074/jbc.272.20.12881; FILO RS, 1965, SCIENCE, V147, P1581, DOI 10.1126/science.147.3665.1581; GLATZ RHD, 1992, NUCLEIC ACIDS RES, V20, P1425; GONG MC, 1992, J BIOL CHEM, V267, P21492; GUTFREUND H, 1971, ENZYMES PHYSICAL PRI, P67; HARBURY PB, 1993, SCIENCE, V262, P1401, DOI 10.1126/science.8248779; HARTSHORNE DJ, 1987, PHYSL GASTROINTESTIN, V1, P423; HEIL WG, 1987, EUR J BIOCHEM, V168, P117, DOI 10.1111/j.1432-1033.1987.tb13395.x; Hirano K, 1997, J BIOL CHEM, V272, P3683, DOI 10.1074/jbc.272.6.3683; HUBBARD MJ, 1993, TRENDS BIOCHEM SCI, V18, P172, DOI 10.1016/0968-0004(93)90109-Z; ISHIHARA H, 1989, BIOCHEM BIOPH RES CO, V159, P871, DOI 10.1016/0006-291X(89)92189-X; Johnson DF, 1996, EUR J BIOCHEM, V239, P317, DOI 10.1111/j.1432-1033.1996.0317u.x; KAMM KE, 1985, ANNU REV PHARMACOL, V25, P593, DOI 10.1146/annurev.pharmtox.25.1.593; Kimura K, 1996, SCIENCE, V273, P245, DOI 10.1126/science.273.5272.245; KITAZAWA T, 1991, J BIOL CHEM, V266, P1708; Klauck TM, 1996, SCIENCE, V271, P1589, DOI 10.1126/science.271.5255.1589; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LANDSCHULZ WH, 1989, SCIENCE, V243, P1681, DOI 10.1126/science.2494700; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; Lee MR, 1997, J BIOL CHEM, V272, P5063, DOI 10.1074/jbc.272.8.5063; Lincoln T.M., 1994, CYCLIC GMP BIOCH PHY, P97; LINCOLN TM, 1977, J BIOL CHEM, V252, P4269; LINCOLN TM, 1993, FASEB J, V7, P328, DOI 10.1096/fasebj.7.2.7680013; Lohmann SM, 1997, TRENDS BIOCHEM SCI, V22, P307, DOI 10.1016/S0968-0004(97)01086-4; MACMILLANCROW LA, 1994, BIOCHEMISTRY-US, V33, P8035, DOI 10.1021/bi00192a007; MASUO M, 1994, J GEN PHYSIOL, V104, P265, DOI 10.1085/jgp.104.2.265; MOCHLYROSEN D, 1995, SCIENCE, V268, P247, DOI 10.1126/science.7716516; MONKEN CE, 1980, J BIOL CHEM, V255, P7067; MORGAN JP, 1984, J PHYSIOL-LONDON, V357, P539, DOI 10.1113/jphysiol.1984.sp015516; Nakamura M, 1999, CELL SIGNAL, V11, P671, DOI 10.1016/S0898-6568(99)00036-4; Pawson T, 1997, SCIENCE, V278, P2075, DOI 10.1126/science.278.5346.2075; Pfeifer A, 1998, EMBO J, V17, P3045, DOI 10.1093/emboj/17.11.3045; RUBIN CS, 1994, BBA-MOL CELL RES, V1224, P467; SCOTTJD, 1996, TRENDS BIOCHEM SCI, V21, P312; SHIMIZU H, 1994, J BIOL CHEM, V269, P30407; SOMLYO AP, 1989, FASEB J, V3, P2266, DOI 10.1096/fasebj.3.11.2506092; SOMLYO AP, 1994, NATURE, V372, P231, DOI 10.1038/372231a0; SURKS HK, UNPUB; Takahashi N, 1997, GENOMICS, V44, P150, DOI 10.1006/geno.1997.4859; Tamura N, 1996, HYPERTENSION, V27, P552, DOI 10.1161/01.HYP.27.3.552; TAYLOR DA, 1988, J BIOL CHEM, V263, P14456; TURNER R, 1989, SCIENCE, V243, P1689, DOI 10.1126/science.2494701; Vidal M, 1996, P NATL ACAD SCI USA, V93, P10315, DOI 10.1073/pnas.93.19.10315; Wang GR, 1998, P NATL ACAD SCI USA, V95, P4888, DOI 10.1073/pnas.95.9.4888; Wu XQ, 1996, BIOCHEM BIOPH RES CO, V220, P658, DOI 10.1006/bbrc.1996.0460	53	400	418	0	7	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 19	1999	286	5444					1583	1587		10.1126/science.286.5444.1583	http://dx.doi.org/10.1126/science.286.5444.1583			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	257DZ	10567269				2022-12-01	WOS:000083768300065
J	Zhang, ZQ; Schuler, T; Zupancic, M; Wietgrefe, S; Staskus, KA; Reimann, KA; Reinhart, TA; Rogan, M; Cavert, W; Miller, CJ; Veazey, RS; Notermans, D; Little, S; Danner, SA; Richman, DD; Havlir, D; Wong, J; Jordan, HL; Schacker, TW; Racz, P; Tenner-Racz, K; Letvin, NL; Wolinsky, S; Haase, AT				Zhang, ZQ; Schuler, T; Zupancic, M; Wietgrefe, S; Staskus, KA; Reimann, KA; Reinhart, TA; Rogan, M; Cavert, W; Miller, CJ; Veazey, RS; Notermans, D; Little, S; Danner, SA; Richman, DD; Havlir, D; Wong, J; Jordan, HL; Schacker, TW; Racz, P; Tenner-Racz, K; Letvin, NL; Wolinsky, S; Haase, AT			Sexual transmission and propagation of SIV and HIV in resting and activated CD4(+) T cells	SCIENCE			English	Article							SIMIAN IMMUNODEFICIENCY VIRUS; ANTIRETROVIRAL THERAPY; DENDRITIC CELLS; RHESUS MACAQUES; VAGINAL TRANSMISSION; VIRAL REPLICATION; TYPE-1 INFECTION; IN-VITRO; CYCLE; LYMPHOCYTES	In sexual transmission of simian immunodeficiency virus, and early and later stages of human immunodeficiency virus-type 1 (HIV-1) infection, both viruses were found to replicate predominantly in CD4(+) T cells at the portal of entry and in Lymphoid tissues, infection was propagated not only in activated and proliferating T cells but also, surprisingly, in resting T cells. The infected proliferating cells correspond to the short-lived population that produces the bulk of HIV-1. Most of the HIV-1-infected resting T cells persisted after antiretroviral therapy. Latently and chronically infected cells that may be derived from this population pose challenges to eradicating infection and developing an effective vaccine.	Univ Minnesota, Sch Med, Dept Microbiol, Minneapolis, MN 55455 USA; Harvard Univ, Beth Israel Hosp, Div Viral Pathogenesis, Boston, MA 02215 USA; Univ Pittsburgh, Dept Infect Dis & Microbiol, Pittsburgh, PA 15261 USA; Calif Reg Primate Res Ctr, Davis, CA 95616 USA; Univ Amsterdam, Acad Med Ctr, Acad Hosp, Div Infect Dis Trop Med & AIDS, NL-1105 AZ Amsterdam, Netherlands; Univ Calif San Diego, Dept Pathol, La Jolla, CA 92093 USA; Univ Calif San Diego, Dept Med, La Jolla, CA 92093 USA; Univ Minnesota, Sch Med, Dept Med, Minneapolis, MN 55455 USA; Bernhard Nocht Inst Trop Med, D-20359 Hamburg, Germany; Northwestern Univ, Sch Med, Div Infect Dis, Chicago, IL 60611 USA; San Diego VA Hlth Care Syst, La Jolla, CA 92093 USA	University of Minnesota System; University of Minnesota Twin Cities; Harvard University; Beth Israel Deaconess Medical Center; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; University of Amsterdam; Academic Medical Center Amsterdam; University of California System; University of California San Diego; University of California System; University of California San Diego; University of Minnesota System; University of Minnesota Twin Cities; Bernhard Nocht Institut fur Tropenmedizin; Northwestern University	Haase, AT (corresponding author), Univ Minnesota, Sch Med, Dept Microbiol, Minneapolis, MN 55455 USA.		Little, Susan/AAA-6116-2019; Wolinsky, Steven/B-2893-2012	Wolinsky, Steven/0000-0002-9625-6697	NATIONAL CENTER FOR RESEARCH RESOURCES [P51RR000168] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI038565, R37AI028246, R01AI138565] Funding Source: NIH RePORTER; NCRR NIH HHS [RR 00168] Funding Source: Medline; NIAID NIH HHS [AI 28246, AI 38565] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Autran B, 1997, SCIENCE, V277, P112, DOI 10.1126/science.277.5322.112; Benoist C, 1997, SCIENCE, V276, P2000, DOI 10.1126/science.276.5321.2000; BRAHIC M, 1989, CURR TOP MICROBIOL, V143, P9; BRAVO R, 1987, J CELL BIOL, V105, P1549, DOI 10.1083/jcb.105.4.1549; BURKRINSKY MI, 1991, SCIENCE, V254, P423; CAMERON PU, 1992, SCIENCE, V257, P383, DOI 10.1126/science.1352913; Cavert W, 1997, SCIENCE, V276, P960, DOI 10.1126/science.276.5314.960; Chou CS, 1997, P NATL ACAD SCI USA, V94, P1361, DOI 10.1073/pnas.94.4.1361; Chun TW, 1997, P NATL ACAD SCI USA, V94, P13193, DOI 10.1073/pnas.94.24.13193; Finzi D, 1997, SCIENCE, V278, P1295, DOI 10.1126/science.278.5341.1295; Freitas AA, 1997, SCIENCE, V277, P1950, DOI 10.1126/science.277.5334.1950; Haase AT, 1996, SCIENCE, V274, P985, DOI 10.1126/science.274.5289.985; HAASE AT, 1986, NATURE, V322, P130, DOI 10.1038/322130a0; Hirsch VM, 1998, NAT MED, V4, P1401, DOI 10.1038/3992; Kahn JO, 1998, NEW ENGL J MED, V339, P33, DOI 10.1056/NEJM199807023390107; Korin YD, 1998, J VIROL, V72, P3161, DOI 10.1128/JVI.72.4.3161-3168.1998; Markiewicz MA, 1998, P NATL ACAD SCI USA, V95, P3065, DOI 10.1073/pnas.95.6.3065; Marx PA, 1996, NAT MED, V2, P1084, DOI 10.1038/nm1096-1084; Miller C. J., 1992, Laboratory Investigation, V68, P129; Miller CJ, 1998, J VIROL, V72, P3248, DOI 10.1128/JVI.72.4.3248-3258.1998; MILLER CJ, 1992, J MED PRIMATOL, V21, P64; *NAT RES COUNC, 1996, GUID CAR US LAB; Orendi JM, 1998, J INFECT DIS, V178, P1279, DOI 10.1086/314451; Ostrowski MA, 1999, J VIROL, V73, P6430, DOI 10.1128/JVI.73.8.6430-6435.1999; POPE M, 1995, J EXP MED, V182, P2045, DOI 10.1084/jem.182.6.2045; POPE M, 1994, CELL, V78, P389, DOI 10.1016/0092-8674(94)90418-9; Royce RA, 1997, NEW ENGL J MED, V336, P1072, DOI 10.1056/NEJM199704103361507; Schacker TW, 1998, ANN INTERN MED, V128, P613, DOI 10.7326/0003-4819-128-8-199804150-00001; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; SPINA CA, 1995, J VIROL, V69, P2977, DOI 10.1128/JVI.69.5.2977-2988.1995; Spira AI, 1996, J EXP MED, V183, P215, DOI 10.1084/jem.183.1.215; Stahl-Hennig C, 1999, SCIENCE, V285, P1261, DOI 10.1126/science.285.5431.1261; Sutton RE, 1998, J VIROL, V72, P5781, DOI 10.1128/JVI.72.7.5781-5788.1998; Tanchot C, 1997, SCIENCE, V276, P2057, DOI 10.1126/science.276.5321.2057; TANG SB, 1995, J VIROL, V69, P5659, DOI 10.1128/JVI.69.9.5659-5665.1995; VANTWOUT AB, 1994, J CLIN INVEST, V94, P2060, DOI 10.1172/JCI117560; Veazey RS, 1998, SCIENCE, V280, P427, DOI 10.1126/science.280.5362.427; Wong JK, 1997, P NATL ACAD SCI USA, V94, P12574, DOI 10.1073/pnas.94.23.12574; Wong JK, 1997, SCIENCE, V278, P1291, DOI 10.1126/science.278.5341.1291; ZACK JA, 1992, J VIROL, V66, P1717, DOI 10.1128/JVI.66.3.1717-1725.1992; ZACK JA, 1990, CELL, V61, P213, DOI 10.1016/0092-8674(90)90802-L	41	699	710	0	21	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 12	1999	286	5443					1353	1357		10.1126/science.286.5443.1353	http://dx.doi.org/10.1126/science.286.5443.1353			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	255NF	10558989				2022-12-01	WOS:000083675500041
J	Enright, AJ; Iliopoulos, I; Kyrpides, NC; Ouzounis, CA				Enright, AJ; Iliopoulos, I; Kyrpides, NC; Ouzounis, CA			Protein interaction maps for complete genomes based on gene fusion events	NATURE			English	Article							SACCHAROMYCES-CEREVISIAE; ENZYMES	A large-scale effort to measure, detect and analyse protein-protein interactions using experimental methods is under way(1,2). These include biochemistry such as co-immunoprecipitation or crosslinking, molecular biology such as the two-hybrid system or phage display, and genetics such as unlinked noncomplementing mutant detection). Using the two-hybrid system(4), an international effort to analyse the complete yeast genome is in progress'. Evidently, all these approaches are tedious, labour intensive and inaccurate(6). From a computational perspective, the question is how can we predict that two proteins interact from structure or sequence alone. Here we present a method that identifies gene-fusion events in complete genomes, solely based on sequence comparison. Because there must be selective pressure for certain genes to be fused over the course of evolution, we are able to predict functional associations of proteins. We show that 215 genes or proteins in the complete genomes of Escherichia coli, Haemophilus influenzae and Methanococcus jannaschii are involved in 64 unique fusion events. The approach is general, and can be applied even to genes of unknown function.	EMBL Cambridge Outstn, European Bioinformat Inst, Computat Genom Grp, Cambridge CB10 1SD, England; Integrated Genom Inc, Chicago, IL 60612 USA	European Molecular Biology Laboratory (EMBL)	Ouzounis, CA (corresponding author), EMBL Cambridge Outstn, European Bioinformat Inst, Computat Genom Grp, Cambridge CB10 1SD, England.	ouzounis@ebi.ac.uk	Enright, Anton/F-3094-2011; Kyrpides, Nikos C./A-6305-2014; Ouzounis, Christos A/G-2302-2010	Enright, Anton/0000-0002-6090-3100; Kyrpides, Nikos C./0000-0002-6131-0462; Ouzounis, Christos A/0000-0002-0086-8657				ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; Andrade MA, 1999, BIOINFORMATICS, V15, P391, DOI 10.1093/bioinformatics/15.5.391; Blackstock WP, 1999, TRENDS BIOTECHNOL, V17, P121, DOI 10.1016/S0167-7799(98)01245-1; Bulow L, 1990, Biochem Soc Symp, V57, P123; BURNS DM, 1990, J BIOL CHEM, V265, P2060; Dandekar T, 1998, TRENDS BIOCHEM SCI, V23, P324, DOI 10.1016/S0968-0004(98)01274-2; DENISDUPHIL M, 1989, BIOCHEM CELL BIOL, V67, P612, DOI 10.1139/o89-094; DUNCAN K, 1988, FEBS LETT, V241, P83, DOI 10.1016/0014-5793(88)81036-6; Janin J, 1995, PROTEINS, V23, P580, DOI 10.1002/prot.340230413; Jones S, 1996, P NATL ACAD SCI USA, V93, P13, DOI 10.1073/pnas.93.1.13; Lakey JH, 1998, CURR OPIN STRUC BIOL, V8, P119, DOI 10.1016/S0959-440X(98)80019-5; Larsen TA, 1998, STRUCT FOLD DES, V6, P421, DOI 10.1016/S0969-2126(98)00044-6; Lecrenier N, 1998, BIOESSAYS, V20, P1; Luban Jeremy, 1995, Current Opinion in Biotechnology, V6, P59, DOI 10.1016/0958-1669(95)80010-7; Marcotte EM, 1999, SCIENCE, V285, P751, DOI 10.1126/science.285.5428.751; Mendelsohn AR, 1999, SCIENCE, V284, P1948, DOI 10.1126/science.284.5422.1948; Ouzounis CA, 1997, J MOL EVOL, V45, P708, DOI 10.1007/PL00013145; Overbeek R, 1999, P NATL ACAD SCI USA, V96, P2896, DOI 10.1073/pnas.96.6.2896; Pearson WR, 1996, METHOD ENZYMOL, V266, P227; Pellegrini M, 1999, P NATL ACAD SCI USA, V96, P4285, DOI 10.1073/pnas.96.8.4285; PHIZICKY EM, 1995, MICROBIOL REV, V59, P94, DOI 10.1128/MMBR.59.1.94-123.1995; Rivera MC, 1998, P NATL ACAD SCI USA, V95, P6239, DOI 10.1073/pnas.95.11.6239; SMITH S, 1994, FASEB J, V8, P1248, DOI 10.1096/fasebj.8.15.8001737; SMITH TF, 1981, J MOL BIOL, V147, P195, DOI 10.1016/0022-2836(81)90087-5; Tamames J, 1997, J MOL EVOL, V44, P66, DOI 10.1007/PL00006122; WALES ME, 1991, METHOD ENZYMOL, V202, P687; WELCH GR, 1994, TRENDS BIOCHEM SCI, V19, P193	27	788	841	5	61	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	NOV 4	1999	402	6757					86	90		10.1038/47056	http://dx.doi.org/10.1038/47056			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	254XC	10573422				2022-12-01	WOS:000083638600048
J	Molinari, M; Helenius, A				Molinari, M; Helenius, A			Glycoproteins form mixed disulphides with oxidoreductases during folding in living cells	NATURE			English	Article							PROTEIN DISULFIDE-ISOMERASE; ENDOPLASMIC-RETICULUM	The formation of intra- and interchain disulphide bonds constitutes an integral part of the maturation of most secretory and membrane-bound proteins in the endoplasmic reticulum(1,2). Evidence indicates that members of the protein disulphide isomerase (PDI) superfamily are part of the machinery needed for proper oxidation and isomerization of disulphide bonds(3-6). Models based on in vitro studies predict that the formation of mixed disulphide bonds between oxidoreductase and substrate is intermediate in the generation of the native intrachain disulphide bond in the substrate polypeptide(7). Whether this is how thiol oxidoreductases work inside the endoplasmic reticulum is not clear. Nor has it been established which of the many members of the PDI superfamily interacts directly with newly synthesized substrate proteins, because transient mixed disulphides have never been observed in the mammalian endoplasmic reticulum during oxidative protein folding(7,8). Here we describe the mechanisms involved in co- and post-translational protein oxidation in vivo. We show that the endoplasmic-reticulum-resident oxidoreductases PDI and ERp57 are directly involved in disulphide oxidation and isomerization, and, together with the lectins calnexin and calreticulin, are central in glycoprotein folding in the endoplasmic reticulum of mammalian cells.	Swiss Fed Inst Technol, Inst Biochem, CH-8092 Zurich, Switzerland	Swiss Federal Institutes of Technology Domain; ETH Zurich	Helenius, A (corresponding author), Swiss Fed Inst Technol, Inst Biochem, Univ Str 16, CH-8092 Zurich, Switzerland.	ari.helenius@bc.biol.ethz.ch	Molinari, Maurizio/N-2587-2019	Molinari, Maurizio/0000-0002-7636-5829				BRAAKMAN I, 1992, NATURE, V356, P260, DOI 10.1038/356260a0; CHEN W, 1995, P NATL ACAD SCI USA, V92, P6229, DOI 10.1073/pnas.92.14.6229; FREEDMAN RB, 1994, TRENDS BIOCHEM SCI, V19, P331, DOI 10.1016/0968-0004(94)90072-8; GAROFF H, 1978, J MOL BIOL, V124, P587, DOI 10.1016/0022-2836(78)90173-0; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; Gilbert HF, 1998, METHOD ENZYMOL, V290, P26, DOI 10.1016/S0076-6879(98)90005-2; GOLDBERGER RF, 1963, J BIOL CHEM, V238, P628; Helenius Ari, 1992, Trends in Cell Biology, V2, P227, DOI 10.1016/0962-8924(92)90309-B; Huppa JB, 1998, CELL, V92, P145, DOI 10.1016/S0092-8674(00)80907-1; KRIJNSELOCKER J, 1999, J CELL BIOL, V144, P267; MARQUARDT T, 1992, J CELL BIOL, V117, P505, DOI 10.1083/jcb.117.3.505; Oliver JD, 1999, MOL BIOL CELL, V10, P2573, DOI 10.1091/mbc.10.8.2573; Oliver JD, 1997, SCIENCE, V275, P86, DOI 10.1126/science.275.5296.86; Ruddon RW, 1997, J BIOL CHEM, V272, P3125, DOI 10.1074/jbc.272.6.3125; SOMMER A, 1974, P NATL ACAD SCI USA, V71, P3946, DOI 10.1073/pnas.71.10.3946; STRAUSS JH, 1994, MICROBIOL REV, V58, P491, DOI 10.1128/MMBR.58.3.491-562.1994; VanLeeuwen JEM, 1996, P NATL ACAD SCI USA, V93, P13997, DOI 10.1073/pnas.93.24.13997; WEISSMAN JS, 1993, NATURE, V365, P185, DOI 10.1038/365185a0; WEISSMAN JS, 1991, SCIENCE, V253, P1386, DOI 10.1126/science.1716783	19	263	268	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	NOV 4	1999	402	6757					90	93		10.1038/47062	http://dx.doi.org/10.1038/47062			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	254XC	10573423				2022-12-01	WOS:000083638600049
J	Grammatopoulos, DK; Hillhouse, EW				Grammatopoulos, DK; Hillhouse, EW			Role of corticotropin-releasing hormone in onset of labour	LANCET			English	Article							HUMAN-FETAL MEMBRANES; HUMAN MYOMETRIUM; BINDING PROTEIN; LOCAL STIMULATION; HUMAN PARTURITION; HUMAN-PREGNANCY; FACTOR CRF; RECEPTOR; PROGESTERONE; EXPRESSION	Corticotropin-releasing hormone (CRH) derived from the placenta is secreted into the maternal circulation in Targe amounts during the third trimester of human pregnancy and may have an important role in the onset of labour. Although the biological role of CRH remains enigmatic, the presence of functional CRH receptors in the myometrium suggests that CRH may modulate myometrial contractility and hence parturition. CRH action is mediated via multiple receptor subtypes and pregnancy results in differential receptor expression. These receptors are primarily linked to the adenylate cyclase second messenger system, which would help the Intracellular microenvironment to maintain the required myometrial quiescence. CRH can exert further actions such as inhibition of prostaglandin production to prevent contractions. At term under the influence of oxytocin there is a modification in the coupling mechanisms that leads to a decrease in the biological activity of the CRH receptor and in the generation of cyclic adenosine monophosphate which favours myometrial contractions. CRH, via distinct receptor subtypes, is then able to enhance the contractile response of the myometrium. This hypothesis places CRH in a central role in coordinating the smooth transition from a state of relaxation to one of contraction.	Univ Warwick, Dept Biol Sci, Sir Quinton Hazell Mol Med Res Ctr, Coventry CV4 7AL, W Midlands, England	University of Warwick	Grammatopoulos, DK (corresponding author), Univ Warwick, Dept Biol Sci, Sir Quinton Hazell Mol Med Res Ctr, Coventry CV4 7AL, W Midlands, England.			grammatopoulos, dimitris/0000-0002-6296-8290	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BEHAN DP, 1989, J ENDOCRINOL, V122, P23, DOI 10.1677/joe.0.1220023; BENEDETTO C, 1994, AM J OBSTET GYNECOL, V171, P126, DOI 10.1016/0002-9378(94)90457-X; CAMBELL EA, 1987, J CLIN ENDOCR METAB, V64, P1054; Clifton VL, 1998, J CLIN ENDOCR METAB, V83, P3716, DOI 10.1210/jc.83.10.3716; CLIFTON VL, 1994, J CLIN ENDOCR METAB, V79, P666, DOI 10.1210/jc.79.2.666; EUROPEFINNER GN, 1994, J CLIN ENDOCR METAB, V79, P1835, DOI 10.1210/jc.79.6.1835; FUCHS AR, 1982, SCIENCE, V215, P1396, DOI 10.1126/science.6278592; GOLAND RS, 1993, J CLIN ENDOCR METAB, V77, P1174, DOI 10.1210/jc.77.5.1174; GOLAND RS, 1995, PLACENTA, V16, P375, DOI 10.1016/0143-4004(95)90095-0; GRAMMATOPOULOS D, 1995, J CLIN ENDOCR METAB, V80, P2388, DOI 10.1210/jc.80.8.2388; Grammatopoulos D, 1998, J CLIN ENDOCR METAB, V83, P2539, DOI 10.1210/jc.83.7.2539; Grammatopoulos D, 1996, J CLIN ENDOCR METAB, V81, P745, DOI 10.1210/jc.81.2.745; GRAMMATOPOULOS D, 1994, MOL CELL ENDOCRINOL, V99, P245, DOI 10.1016/0303-7207(94)90014-0; Grammatopoulos DK, 1999, J CLIN ENDOCR METAB, V84, P2204, DOI 10.1210/jc.84.6.2204; Grammatopoulos DK, 1999, ENDOCRINOLOGY, V140, P585, DOI 10.1210/en.140.2.585; HILLHOUSE EW, 1993, J CLIN ENDOCR METAB, V76, P736, DOI 10.1210/jc.76.3.736; JONES SA, 1989, BIOCHEM BIOPH RES CO, V159, P192, DOI 10.1016/0006-291X(89)92422-4; Karalis K, 1996, NAT MED, V2, P556, DOI 10.1038/nm0596-556; LINTON EA, 1990, J CLIN ENDOCR METAB, V70, P1574, DOI 10.1210/jcem-70-6-1574; LINTON EA, 1993, J CLIN ENDOCR METAB, V76, P260, DOI 10.1210/jc.76.1.260; MCLEAN M, 1995, NAT MED, V1, P460, DOI 10.1038/nm0595-460; MITCHELL BF, 1993, AM J OBSTET GYNECOL, V168, P1377, DOI 10.1016/S0002-9378(11)90768-6; PETRAGLIA F, 1987, NATURE, V328, P717, DOI 10.1038/328717a0; Petraglia F, 1996, J CLIN ENDOCR METAB, V81, P852, DOI 10.1210/jc.81.2.852; PETROCELLI T, 1993, ENDOCRINOLOGY, V133, P284, DOI 10.1210/en.133.1.284; QUARTERO HWP, 1989, PLACENTA, V10, P439, DOI 10.1016/0143-4004(89)90054-4; Rezapour M, 1996, STEROIDS, V61, P338, DOI 10.1016/0039-128X(96)00035-9; Rodriguez-Linares B, 1998, J ENDOCRINOL, V156, P15, DOI 10.1677/joe.0.1560015; Stevens MY, 1998, J CLIN ENDOCR METAB, V83, P4107, DOI 10.1210/jc.83.11.4107; Wallace EM, 1999, LANCET, V353, P1404, DOI 10.1016/S0140-6736(98)08229-4; WOLFE CDA, 1988, BRIT J OBSTET GYNAEC, V95, P1003, DOI 10.1111/j.1471-0528.1988.tb06504.x; ZUO J, 1994, J CLIN ENDOCR METAB, V79, P894, DOI 10.1210/jc.79.3.894	32	127	131	0	7	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	OCT 30	1999	354	9189					1546	1549		10.1016/S0140-6736(99)03418-2	http://dx.doi.org/10.1016/S0140-6736(99)03418-2			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	250WB	10551516				2022-12-01	WOS:000083411300042
J	Bengtsson, BA				Bengtsson, BA			Rethink about growth-hormone therapy for critically ill patients	LANCET			English	Editorial Material							PROLONGED CRITICAL ILLNESS; ADULTS; GH		Sahlgrenska Univ Hosp, Res Ctr Endocrinol & Metab, SE-41345 Gothenburg, Sweden	Sahlgrenska University Hospital	Bengtsson, BA (corresponding author), Sahlgrenska Univ Hosp, Res Ctr Endocrinol & Metab, SE-41345 Gothenburg, Sweden.							BENGTSSON BA, 1993, J CLIN ENDOCR METAB, V76, P309, DOI 10.1210/jc.76.2.309; Johannsson G, 1997, CLIN ENDOCRINOL, V47, P571, DOI 10.1046/j.1365-2265.1997.3271123.x; ROSS R, 1991, CLIN ENDOCRINOL, V35, P47, DOI 10.1111/j.1365-2265.1991.tb03495.x; Takala J, 1999, NEW ENGL J MED, V341, P785, DOI 10.1056/NEJM199909093411102; Van den Berghe G, 1998, J CLIN ENDOCR METAB, V83, P1827, DOI 10.1210/jc.83.6.1827; Van den Berghe G, 1999, J CLIN ENDOCR METAB, V84, P1311, DOI 10.1210/jc.84.4.1311; Van den Berghe G, 1998, J CLIN ENDOCR METAB, V83, P309, DOI 10.1210/jc.83.2.309	7	10	10	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	OCT 23	1999	354	9188					1403	1404		10.1016/S0140-6736(99)00330-X	http://dx.doi.org/10.1016/S0140-6736(99)00330-X			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	248LY	10543662				2022-12-01	WOS:000083277400005
J	Edman, K; Nollert, P; Royant, A; Belrhali, H; Pebay-Peyroula, E; Hajdu, J; Neutze, R; Landau, EM				Edman, K; Nollert, P; Royant, A; Belrhali, H; Pebay-Peyroula, E; Hajdu, J; Neutze, R; Landau, EM			High-resolution X-ray structure of an early intermediate in the bacteriorhodopsin photocycle	NATURE			English	Article							LIPIDIC CUBIC PHASES; ANGSTROM RESOLUTION; MEMBRANE-PROTEINS; PURPLE MEMBRANE; DIFFRACTION; CRYSTALLOGRAPHY; CRYSTALLIZATION; MODEL	Bacteriorhodopsin is the simplest known photon-driven proton pump(1) and as such provides a model for the study of a basic function in bioenergetics. Its seven transmembrane helices' encompass a proton translocation pathway containing the chromophore, a retinal molecule covalently bound to lysine 216 through a protonated Schiff base, and a series of proton donors and accepters. Photoisomerization of the all-trans retinal to the) 13-cis configuration initiates the vectorial translocation of a proton from the Schiff base, the primary proton donor, to the extracellular side, followed by reprotonation of the Schiff base from the cytoplasm. Here we describe the high-resolution X-ray structure of an early intermediate in the photocycle of bacteriorhodopsin, which is formed directly after photoexcitation. A key water molecule is dislocated, allowing the primary proton acceptor, Asp 85, to move. Movement of the main-chain Lys 216 locally disrupts the hydrogen-bonding network of helix G, facilitating structural changes later in the photocycle.	Univ Basel, Biozentrum, Dept Mol Microbiol, CH-4056 Basel, Switzerland; Uppsala Univ, Ctr Biomed, Dept Biochem, S-75123 Uppsala, Sweden; European Synchrotron Radiat Facil, F-38043 Grenoble, France; Univ Grenoble 1, CNRS, CEA, Inst Biol Struct, F-38027 Grenoble 2, France	University of Basel; Uppsala University; European Synchrotron Radiation Facility (ESRF); UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); CEA; Centre National de la Recherche Scientifique (CNRS)	Landau, EM (corresponding author), Univ Basel, Biozentrum, Dept Mol Microbiol, Klingelbergstr 70, CH-4056 Basel, Switzerland.	neutze@xray.bmc.uu.se; landau@ubaclu.unibas.ch	Neutze, Richard/A-7573-2010; Royant, Antoine/G-3684-2012	Neutze, Richard/0000-0003-0986-6153; Royant, Antoine/0000-0002-1919-8649				BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Belrhali H, 1999, STRUCTURE, V7, P909, DOI 10.1016/S0969-2126(99)80118-X; BRAIMAN M, 1982, P NATL ACAD SCI-BIOL, V79, P403, DOI 10.1073/pnas.79.2.403; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Bulllough PA, 1999, J MOL BIOL, V286, P1663, DOI 10.1006/jmbi.1999.2570; DENCHER NA, 1989, P NATL ACAD SCI USA, V86, P7876, DOI 10.1073/pnas.86.20.7876; DOIG SJ, 1991, J PHYS CHEM-US, V95, P6372, DOI 10.1021/j100169a054; Esnouf RM, 1997, J MOL GRAPH MODEL, V15, P132, DOI 10.1016/S1093-3263(97)00021-1; GAT Y, 1993, J AM CHEM SOC, V115, P3772, DOI 10.1021/ja00062a052; Genick UK, 1998, NATURE, V392, P206, DOI 10.1038/32462; Genick UK, 1997, SCIENCE, V275, P1471, DOI 10.1126/science.275.5305.1471; HADFIELD A, 1993, J APPL CRYSTALLOGR, V26, P839, DOI 10.1107/S0021889893005552; HENDERSON R, 1975, NATURE, V257, P28, DOI 10.1038/257028a0; JONES TA, 1990, CRYSTALLOGRAPHIC MOD, P189; KOCH MHJ, 1991, EMBO J, V10, P521, DOI 10.1002/j.1460-2075.1991.tb07978.x; Landau EM, 1996, P NATL ACAD SCI USA, V93, P14532, DOI 10.1073/pnas.93.25.14532; Luecke H, 1998, SCIENCE, V280, P1934, DOI 10.1126/science.280.5371.1934; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; NAKASATO K, 1991, FEBS LETT, V292, P75; Nollert P, 1998, BIOCHEM SOC T, V26, P709, DOI 10.1042/bst0260709; OESTERHELT D, 1971, NATURE-NEW BIOL, V233, P149, DOI 10.1038/newbio233149a0; OTWINOWSKI Z, 1993, DATA COLLECTION PROC, P55; Rummel G, 1998, J STRUCT BIOL, V121, P82, DOI 10.1006/jsbi.1997.3952; SCHLICHTING I, 1994, NATURE, V371, P808, DOI 10.1038/371808a0; SONG IK, 1991, KOREAN J CHEM ENG, V8, P33, DOI 10.1007/BF02697695; SUBRAMANIAM S, 1993, EMBO J, V12, P1; TAKEI H, 1994, J BIOL CHEM, V269, P7387; Ursby T, 1997, ACTA CRYSTALLOGR A, V53, P564, DOI 10.1107/S0108767397004522; Valegard K, 1998, NATURE, V394, P805, DOI 10.1038/29575; Vonck J, 1996, BIOCHEMISTRY-US, V35, P5870, DOI 10.1021/bi952663c; XIE A, 1990, BIOPHYS J, V58, P1127, DOI 10.1016/S0006-3495(90)82455-3; Yeates TO, 1997, METHOD ENZYMOL, V276, P344, DOI 10.1016/S0076-6879(97)76068-3	32	292	301	1	41	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	OCT 21	1999	401	6755					822	826		10.1038/44623	http://dx.doi.org/10.1038/44623			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	250BG	10548112				2022-12-01	WOS:000083368700061
J	Hawker, JI; Bakhshi, SS; Ali, S; Farrington, CP				Hawker, JI; Bakhshi, SS; Ali, S; Farrington, CP			Ecological analysis of ethnic differences in relation between tuberculosis and poverty	BRITISH MEDICAL JOURNAL			English	Article							SOCIOECONOMIC DEPRIVATION; IMMIGRATION; ENGLAND	Objective To examine the effect of ethnicity on the relation between tuberculosis and deprivation. Design Retrospective ecological study comparing incidence of tuberculosis in white and south Asian residents of the 39 electoral wards in Birmingham with ethnic specific indices of deprivation. Setting Birmingham, 1989-93. Subjects 1516 notified cases of tuberculosis. Main outcome measures Rates of tuberculosis and measures of deprivation. Results Univariate analysis showed significant associations of tuberculosis rates for the whole population with several indices of deprivation (P < 0.01) and with the proportion of the population of south Asian origin (P < 0.01). All deprivation covariates were positively associated with each other but on multiple regression, higher level of overcrowding was independently associated with tuberculosis rates. For the white population, overcrowding was associated with tuberculosis rates independently of ether variables (P = 0.0036). No relation with deprivation was found for the south Asian population in either single or multivariable analyses. Conclusions Poverty is significantly associated with tuberculosis in the white population, but no such relation exists far those of Asian ethnicity. These findings suggest that causal factors, and therefore potential interventions, will also differ by ethnic group.	Birmingham Heartlands Hosp, Publ Hlth Lab Serv, Communicable Dis Surveillance Ctr W Midlands, Birmingham B9 5SS, W Midlands, England; Birmingham Hlth Author, Birmingham B16 9RG, W Midlands, England; Open Univ, Dept Stat, Milton Keynes MK7 6AA, Bucks, England	Heart of England NHS Foundation Trust; University of Birmingham; Open University - UK	Hawker, JI (corresponding author), Birmingham Heartlands Hosp, Publ Hlth Lab Serv, Communicable Dis Surveillance Ctr W Midlands, Bordesley Green E, Birmingham B9 5SS, W Midlands, England.			Farrington, Conor Patrick/0000-0002-7148-2612				Bakhshi S S, 1997, Ethn Health, V2, P147; BAKHSHI SS, 1995, J PUBLIC HEALTH MED, V17, P343; BHATTI N, 1995, BRIT MED J, V310, P967, DOI 10.1136/bmj.310.6985.967; Borgdorff MW, 1998, AM J EPIDEMIOL, V147, P187; BOX GEP, 1964, J ROY STAT SOC B, V26, P211, DOI 10.1111/j.2517-6161.1964.tb00553.x; *BRIT TUB ASS, 1966, TUBERCLE, V47, P145; DARBYSHIRE JH, 1995, BRIT MED J, V310, P954, DOI 10.1136/bmj.310.6985.954; DOHERTY MJ, 1995, BRIT MED J, V311, P187, DOI 10.1136/bmj.311.6998.187b; GREENLAND S, 1989, INT J EPIDEMIOL, V18, P269, DOI 10.1093/ije/18.1.269; KEARNEY MT, 1993, BRIT MED J, V307, P1143, DOI 10.1136/bmj.307.6912.1143; MANGTANI P, 1995, BRIT MED J, V310, P963, DOI 10.1136/bmj.310.6985.963; MCCARTHY OR, 1984, BRIT J DIS CHEST, V78, P248, DOI 10.1016/S0007-0971(84)80118-7; MEREDITH SK, 1992, THORAX, V47, P770; Ormerod P, 1996, BRIT J HOSP MED, V56, P209; PACKE GE, 1988, ARCH DIS CHILD, V63, P277, DOI 10.1136/adc.63.3.277; SPENCE DPS, 1993, BRIT MED J, V307, P759, DOI 10.1136/bmj.307.6907.759; Springett V H, 1991, CDR (Lond Engl Rev), V1, pR149; *STAT SCI, 1997, S PLUS WIND US MAN V; Tocque K, 1998, INT J TUBERC LUNG D, V2, P213; Townsend P, 1988, HLTH DEPRIVATION INE; Vynnycky E, 1997, EPIDEMIOL INFECT, V119, P183, DOI 10.1017/S0950268897007917; WEBER HW, 1899, TUBERCULOSIS, V1, P101; *WHO, 1995, STOP TB SOURC REP TU	23	52	56	1	4	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	OCT 16	1999	319	7216					1031	1034		10.1136/bmj.319.7216.1031	http://dx.doi.org/10.1136/bmj.319.7216.1031			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	247FH	10521193	Green Accepted, Green Published, Bronze			2022-12-01	WOS:000083210100024
J	Pop, VJ; van Baar, AL; Vulsma, T				Pop, VJ; van Baar, AL; Vulsma, T			Should all pregnant women be screened for hypothyroidism?	LANCET			English	Editorial Material									Tilburg Univ, Dept Clin Hlth Psychol, NL-5000 LE Tilburg, Netherlands; Emmas Children Hosp, Dept Neonatal, Amsterdam, Netherlands; Emmas Children Hosp, Dept Paediat Endocrinol, Amsterdam, Netherlands	Tilburg University; Emma Children's Hospital; Emma Children's Hospital	Pop, VJ (corresponding author), Tilburg Univ, Dept Clin Hlth Psychol, NL-5000 LE Tilburg, Netherlands.		van Baar, Anneloes/L-8236-2013	van Baar, Anneloes/0000-0002-3498-9019				BURROW GN, 1994, NEW ENGL J MED, V331, P1072; Cohen J., 2013, STAT POWER ANAL BEHA, DOI 10.4324/9780203771587; De Santiago J., 1999, J ENDOCRINOL INVES S, V22, P68; Haddow JE, 1999, NEW ENGL J MED, V341, P549, DOI 10.1056/NEJM199908193410801; Kester MHA, 1999, J CLIN ENDOCR METAB, V84, P2577, DOI 10.1210/jc.84.7.2577; Lazarus JH, 1999, THYROID, V9, P659, DOI 10.1089/thy.1999.9.659; Pop VJ, 1999, CLIN ENDOCRINOL, V50, P149, DOI 10.1046/j.1365-2265.1999.00639.x; Rovet J, 1996, J CHILD PSYCHOL PSYC, V37, P579, DOI 10.1111/j.1469-7610.1996.tb01444.x; Utiger RD, 1999, NEW ENGL J MED, V341, P601, DOI 10.1056/NEJM199908193410809	9	16	16	1	1	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	OCT 9	1999	354	9186					1224	1225						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	243RE	10520627				2022-12-01	WOS:000083010400004
J	Rozov, A; Burnashev, N				Rozov, A; Burnashev, N			Polyamine-dependent facilitation of postsynaptic AMPA receptors counteracts paired-pulse depression	NATURE			English	Article							TERM SYNAPTIC PLASTICITY; RAT HIPPOCAMPAL SLICES; CALCIUM-PERMEABLE AMPA; GLUTAMATE RECEPTORS; KAINATE RECEPTORS; RECTIFICATION; INTERNEURONS; NEURONS; BLOCK; BRAIN	At many glutamatergic synapses in the brain, calcium-permeable alpha - amino - 3 - hydro - 5 - methyl - 4 - isoxazolepropionate receptor (AMPAR) channels mediate fast excitatory transmission(1-6). These channels are blocked by endogenous intracellular polyamines(7-9), which are found in virtually every type of cell(10,11). In excised patches, use-dependent relief of polyamine block enhances glutamate-evoked currents through recombinant and native calcium-permeable, polyamine-sensitive AMPAR channels(12). The contribution of polyamine unblock to synaptic currents during high-frequency stimulation may be to facilitate currents and maintain current amplitudes in the face of a slow recovery from desensitization or presynaptic depression(12,13). Here we show, on pairs and triples of synaptically connected neurons in slices, that this mechanism contributes to short-term plasticity in local circuits formed by presynaptic pyramidal neurons and postsynaptic multipolar interneurons in layer 2/3 of rat neocortex, Activity-dependent relief from polyamine block of postsynaptic calcium-permeable AMPARs in the interneurons either reduces the rate of paired-pulse depression in a frequency-dependent manner or, at a given stimulation frequency, induces facilitation of a synaptic response that would otherwise depress. This mechanism for the enhancement of synaptic gain appears to be entirely postsynaptic.	Max Planck Inst Med Forsch, Abt Zellphysiol Mol Neurobiol, D-69120 Heidelberg, Germany	Max Planck Society	Burnashev, N (corresponding author), Max Planck Inst Med Forsch, Abt Zellphysiol Mol Neurobiol, Jahnstr 29, D-69120 Heidelberg, Germany.		Rozov, Andrei/C-1997-2015; Burnashev, Nail/G-4056-2013					BarnesDavies M, 1996, J PHYSIOL-LONDON, V495P, pP44; BOWIE D, 1995, NEURON, V15, P453, DOI 10.1016/0896-6273(95)90049-7; COLQUHOUN D, 1992, J PHYSIOL-LONDON, V458, P261, DOI 10.1113/jphysiol.1992.sp019417; Fisher SA, 1997, TRENDS NEUROSCI, V20, P170, DOI 10.1016/S0166-2236(96)01001-6; Gu JG, 1996, NATURE, V381, P793, DOI 10.1038/381793a0; Isa T, 1996, J PHYSIOL-LONDON, V491, P719, DOI 10.1113/jphysiol.1996.sp021252; JONES HC, 1988, J PHYSIOL-LONDON, V402, P579, DOI 10.1113/jphysiol.1988.sp017223; KAMBOJ SK, 1995, J PHYSIOL-LONDON, V486, P297, DOI 10.1113/jphysiol.1995.sp020812; KOH DS, 1995, J PHYSIOL-LONDON, V486, P305, DOI 10.1113/jphysiol.1995.sp020813; Mahanty NK, 1998, NATURE, V394, P683, DOI 10.1038/29312; MCBAIN CJ, 1993, J PHYSIOL-LONDON, V462, P373, DOI 10.1113/jphysiol.1993.sp019560; McBain CJ, 1998, J PHYSIOL-LONDON, V511, P331, DOI 10.1111/j.1469-7793.1998.331bh.x; OTIS TS, 1995, J PHYSIOL-LONDON, V482, P309, DOI 10.1113/jphysiol.1995.sp020519; PEGG AE, 1986, BIOCHEM J, V234, P249, DOI 10.1042/bj2340249; Reyes A, 1998, NAT NEUROSCI, V1, P279, DOI 10.1038/1092; Rozov A, 1998, J PHYSIOL-LONDON, V511, P361, DOI 10.1111/j.1469-7793.1998.361bh.x; SHAW GG, 1979, BIOCHEM PHARMACOL, V28, P1, DOI 10.1016/0006-2952(79)90261-2; STEVENS CF, 1995, NEURON, V14, P795, DOI 10.1016/0896-6273(95)90223-6; STUART GJ, 1993, PFLUG ARCH EUR J PHY, V423, P511, DOI 10.1007/BF00374949; Thomson AM, 1997, J PHYSIOL-LONDON, V502, P131, DOI 10.1111/j.1469-7793.1997.131bl.x; WATANABE S, 1991, J BIOL CHEM, V266, P20803; ZUCKER RS, 1989, ANNU REV NEUROSCI, V12, P13, DOI 10.1146/annurev.neuro.12.1.13; ZUCKER RS, 1994, NETH J ZOOL, V44, P495	23	151	153	0	4	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	OCT 7	1999	401	6753					594	598		10.1038/44151	http://dx.doi.org/10.1038/44151			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	244MG	10524627				2022-12-01	WOS:000083054900052
J	Epstein, N				Epstein, N			To dream	ANNALS OF INTERNAL MEDICINE			English	Article											Epstein, N (corresponding author), 2820 E 4th St, Tucson, AZ 85716 USA.	Nempe@aol.com							0	1	1	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	OCT 5	1999	131	7					540	541		10.7326/0003-4819-131-7-199910050-00013	http://dx.doi.org/10.7326/0003-4819-131-7-199910050-00013			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	243VU	10507966				2022-12-01	WOS:000083018800010
J	Chelala, C; Beyrer, C				Chelala, C; Beyrer, C			Drug use and HIV/AIDS in Burma	LANCET			English	Editorial Material									Johns Hopkins Univ, Sch Hyg & Publ Hlth, Baltimore, MD 21205 USA	Johns Hopkins University	Chelala, C (corresponding author), 390 W Broadway, New York, NY 10012 USA.							United Nations Children's Fund World Health Organization World Bank Group, 2021, LEVELS TRENDS CHILD	1	3	3	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	SEP 25	1999	354	9184					1119	1119		10.1016/S0140-6736(05)76908-7	http://dx.doi.org/10.1016/S0140-6736(05)76908-7			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	239PA	10509520				2022-12-01	WOS:000082777500047
J	Perucchini, D; Fischer, U; Spinas, GA; Huch, R; Huch, A; Lehmann, R				Perucchini, D; Fischer, U; Spinas, GA; Huch, R; Huch, A; Lehmann, R			Using fasting plasma glucose concentrations to screen for gestational diabetes mellitus: prospective population based study	BMJ-BRITISH MEDICAL JOURNAL			English	Article							PREGNANCY; TOLERANCE; TESTS; CRITERIA; INSULIN; DISEASE; BIRTH; WOMEN	Objective To evaluate whether measuring fasting Plasma glucose concentration is an easier screening procedure for gestational diabetes mellitus than the 1 hour 50 g glucose challenge test. Design Prospective population based study. Setting Outpatient clinic in a university hospital. Participants 520 pregnant women (328 (63%) white, 99 (19%) Asian, 31 (6%) African, 62 (12%) others) with mean age 28.4 (SD 0.2; range 17-45) years. All underwent a glucose challenge test between the 24th and 28th gestational week, followed by a diagnostic 3 hour 100 g or al glucose tolerance test within one week. This was done irrespective of the result of the challenge lest. Main outcome measure Receiver operating curves were used to determine the best cut off values for screening with fasting plasma glucose concentrations, Results Fasting plasma glucose concentration at a threshold value of 4.5 mmol/l and the glucose challenge test with a threshold value of 7.8 mmol/l. yielded sensitivities of 81%, and 59% respectively and specificities of 76%, and 91% respectively Measuring fasting plasma glucose concentration as a screening procedure required a diagnostic test in 30%, compared with 14% when the challenge test was used. Conclusions Measuring fasting plasma glucose concentrations using a cut off value of greater than or equal to 4.8 mmol/l is an easier screening procedure for gestational diabetes than the 50 g glucose challenge test and allows 70% of women to avoid the challenge test.	Univ Zurich Hosp, Dept Internal Med, Div Endocrinol & Diabet, Zurich, Switzerland; Univ Zurich Hosp, Dept Obstet, CH-8091 Zurich, Switzerland; Univ Zurich Hosp, Dept Gynaecol, CH-8091 Zurich, Switzerland	University of Zurich; University Zurich Hospital; University of Zurich; University Zurich Hospital; University of Zurich; University Zurich Hospital	Lehmann, R (corresponding author), Univ Zurich Hosp, Dept Internal Med, Div Endocrinol & Diabet, Zurich, Switzerland.	Roger.Lehmann@dim.usz.ch	Lehmann, Roger/B-9120-2015	Lehmann, Roger/0000-0002-3681-4431				Alberti KGMM, 1998, DIABETIC MED, V15, P539, DOI 10.1002/(SICI)1096-9136(199807)15:7<539::AID-DIA668>3.0.CO;2-S; BECK JR, 1986, ARCH PATHOL LAB MED, V110, P958; BECK JR, 1986, ARCH PATHOL LAB MED, V110, P13; BORTHEIRY AL, 1994, DIABETES CARE, V17, P1269, DOI 10.2337/diacare.17.11.1269; CARPENTER MW, 1982, AM J OBSTET GYNECOL, V144, P768, DOI 10.1016/0002-9378(82)90349-0; COUSTAN DR, 1984, AM J OBSTET GYNECOL, V150, P836, DOI 10.1016/0002-9378(84)90459-9; COUSTAN DR, 1993, DIABETES CARE, V16, P8, DOI 10.2337/diacare.16.3.8; DOOLEY SL, 1991, DIABETES, V40, P25, DOI 10.2337/diab.40.2.S25; ENGELGAU MM, 1995, DIABETES CARE, V18, P1606, DOI 10.2337/diacare.18.12.1606; Eriksson UJ, 1996, DIABETOLOGIA, V39, P1123; Gavin JR, 1997, DIABETES CARE, V20, P1183; LANGER O, 1987, AM J OBSTET GYNECOL, V157, P758, DOI 10.1016/S0002-9378(87)80045-5; LEWIS GF, 1993, DIABETES CARE, V16, P1551, DOI 10.2337/diacare.16.12.1551; MAGEE MS, 1993, JAMA-J AM MED ASSOC, V269, P609, DOI 10.1001/jama.269.5.609; MESTMAN JH, 1972, OBSTET GYNECOL, V39, P421; Metzger BE, 1998, DIABETES CARE, V21, pB161; Mooy JM, 1996, DIABETOLOGIA, V39, P298, DOI 10.1007/BF00418345; MORTENSEN HB, 1985, DIABETES METAB, V11, P249; Purdy LP, 1996, DIABETOLOGIA, V39, P1126; Reichelt AJ, 1998, DIABETES CARE, V21, P1246, DOI 10.2337/diacare.21.8.1246; SACKS DA, 1992, J REPROD MED, V37, P907; SERMER M, 1995, AM J OBSTET GYNECOL, V173, P146, DOI 10.1016/0002-9378(95)90183-3; SILVERMAN BL, 1995, DIABETES CARE, V18, P611, DOI 10.2337/diacare.18.5.611; TALLARIGO L, 1986, NEW ENGL J MED, V315, P989, DOI 10.1056/NEJM198610163151603; Weiss PAM, 1998, GYNAKOLOGE, V31, P12, DOI 10.1007/s001290050219; *WHO EXP COMM DIAB, 1985, DIAB MELL REP WHO ST	26	75	78	1	2	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	SEP 25	1999	319	7213					812	815		10.1136/bmj.319.7213.812	http://dx.doi.org/10.1136/bmj.319.7213.812			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	241CR	10496823	Bronze, Green Published			2022-12-01	WOS:000082865200021
J	Davis, RL; Shrimpton, AE; Holohan, PD; Bradshaw, C; Feiglin, D; Collins, GH; Sonderegger, P; Kinter, J; Becker, LM; Lacbawan, F; Krasnewich, D; Muenke, M; Lawrence, DA; Yerby, MS; Shaw, CM; Gooptu, B; Elliott, PR; Finch, JT; Carrell, RW; Lomas, DA				Davis, RL; Shrimpton, AE; Holohan, PD; Bradshaw, C; Feiglin, D; Collins, GH; Sonderegger, P; Kinter, J; Becker, LM; Lacbawan, F; Krasnewich, D; Muenke, M; Lawrence, DA; Yerby, MS; Shaw, CM; Gooptu, B; Elliott, PR; Finch, JT; Carrell, RW; Lomas, DA			Familial dementia caused by polymlerization of mutant neurosergin	NATURE			English	Article							ALPHA-1-ANTITRYPSIN; INHIBITOR; MUTATION; DISEASE; LOOP; POLYMERIZATION; SERPINS; LIVER	Aberrant protein processing with tissue deposition is associated with many common neurodegenerative disorders(1,2); however, the complex interplay of genetic and environmental factors has made it difficult to decipher the sequence of events linking protein aggregation with clinical disease(3). Substantial progress has been made toward understanding the pathophysiology of prototypical conformational diseases and protein polymerization in the super-family of serine proteinase inhibitors (serpins)(4,5). Here we describe a new disease, familial encephalopathy with neuroserpin inclusion bodies, characterized clinically as an autosomal dominantly inherited dementia, histologically by unique neuronal inclusion bodies and biochemically by polymers of the neuron-specific serpin, neuroserpin(6,7). We report the cosegregation of point mutations in the neuroserpin gene (PI12) with the disease in two families. The significance of one mutation, S49P, is evident from its homology to a previously described serpin mutation(8), whereas that of the other, S52R, is predicted by modelling of the serpin template. Our findings provide a molecular mechanism for a familial dementia and imply that inhibitors of protein polymerization may be effective therapies for this disorder and perhaps for other more common neurodegenerative diseases.	SUNY Hlth Sci Ctr, Dept Clin Pathol, Syracuse, NY 13210 USA; SUNY Hlth Sci Ctr, Dept Pharmacol, Syracuse, NY 13210 USA; SUNY Hlth Sci Ctr, Dept Neurol, Syracuse, NY 13210 USA; SUNY Hlth Sci Ctr, Dept Radiol, Syracuse, NY 13210 USA; Univ Zurich, Dept Biochem, CH-8057 Zurich, Switzerland; Natl Human Genome Res Inst, NIH, Bethesda, MD 20892 USA; Amer Red Cross, Holland Labs, Rockville, MD 20855 USA; Oregon Hlth Sci Univ, Dept Neurol, Portland, OR 97210 USA; Oregon Hlth Sci Univ, Dept Publ Hlth, Portland, OR 97210 USA; Oregon Hlth Sci Univ, Dept Obstet Gynecol, Portland, OR 97210 USA; Univ Washington, Sch Med, Dept Pathol, Seattle, WA 98104 USA; Univ Cambridge, Cambridge Inst Med Res, Dept Haematol, Cambridge CB2 2XY, England; Univ Cambridge, Cambridge Inst Med Res, Dept Med, Cambridge CB2 2XY, England; MRC Ctr, Mol Biol Lab, Cambridge CB2 2XY, England	State University of New York (SUNY) System; State University of New York (SUNY) Upstate Medical Center; State University of New York (SUNY) System; State University of New York (SUNY) Upstate Medical Center; State University of New York (SUNY) System; State University of New York (SUNY) Upstate Medical Center; State University of New York (SUNY) System; State University of New York (SUNY) Upstate Medical Center; University of Zurich; National Institutes of Health (NIH) - USA; NIH National Human Genome Research Institute (NHGRI); American Red Cross; Oregon Health & Science University; Oregon Health & Science University; Oregon Health & Science University; University of Washington; University of Washington Seattle; University of Cambridge; University of Cambridge; MRC Laboratory Molecular Biology	Shrimpton, AE (corresponding author), SUNY Hlth Sci Ctr, Dept Clin Pathol, 750 E Adams St, Syracuse, NY 13210 USA.		Kinter, Jochen/C-4515-2008	Gooptu, Bibek/0000-0002-5223-1121; Muenke, Maximilian/0000-0002-7719-6545; Lawrence, Daniel/0000-0003-3126-1935	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		AULAK KS, 1993, J BIOL CHEM, V268, P18088; Beauchamp NJ, 1998, BLOOD, V92, P2696, DOI 10.1182/blood.V92.8.2696.420a43_2696_2706; Carrell RW, 1997, LANCET, V350, P134, DOI 10.1016/S0140-6736(97)02073-4; Carrell RW, 1998, CURR OPIN STRUC BIOL, V8, P799, DOI 10.1016/S0959-440X(98)80101-2; CERVOSNAVARRO, 1995, METABOLIC DEGENERATI; ELDERING E, 1995, J BIOL CHEM, V270, P2579, DOI 10.1074/jbc.270.6.2579; Elliott PR, 1996, NAT STRUCT BIOL, V3, P676, DOI 10.1038/nsb0896-676; ERIKSSON S, 1986, NEW ENGL J MED, V314, P736, DOI 10.1056/NEJM198603203141202; Hastings GA, 1997, J BIOL CHEM, V272, P33062, DOI 10.1074/jbc.272.52.33062; HUBER R, 1989, BIOCHEMISTRY-US, V28, P8951, DOI 10.1021/bi00449a001; Kakizuka A, 1998, TRENDS GENET, V14, P396, DOI 10.1016/S0168-9525(98)01559-5; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Lansbury PT, 1997, NEURON, V19, P1151, DOI 10.1016/S0896-6273(00)80406-7; LOMAS DA, 1992, NATURE, V357, P605, DOI 10.1038/357605a0; LOMAS DA, 1993, J BIOL CHEM, V268, P15333; Mahadeva R, 1998, THORAX, V53, P1022, DOI 10.1136/thx.53.12.1022; Osterwalder T, 1996, EMBO J, V15, P2944, DOI 10.1002/j.1460-2075.1996.tb00657.x; PRUSINER SB, 1994, J R COLL PHYSICIAN S, V28, P1; Schrimpf SP, 1997, GENOMICS, V40, P55, DOI 10.1006/geno.1996.4514; SEYAMA K, 1991, J BIOL CHEM, V266, P12627; Shrimpton AE, 1997, HUM MUTAT, V10, P436, DOI 10.1002/(SICI)1098-1004(1997)10:6<436::AID-HUMU4>3.0.CO;2-B; STEIN PE, 1995, NAT STRUCT BIOL, V2, P96, DOI 10.1038/nsb0295-96; Tran PB, 1999, TRENDS NEUROSCI, V22, P194, DOI 10.1016/S0166-2236(99)01409-5; WALLACE AJ, 1993, J MED GENET, V30, P346; Yankner BA, 1996, NAT MED, V2, P850, DOI 10.1038/nm0896-850; YERBY MS, 1986, NEUROLOGY, V36, P68, DOI 10.1212/WNL.36.1.68	26	285	298	0	12	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	SEP 23	1999	401	6751					376	379		10.1038/43897	http://dx.doi.org/10.1038/43897			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	240JJ	10517635	Bronze			2022-12-01	WOS:000082822600051
J	Herrington, DM				Herrington, DM			The HERS trial results: Paradigms lost?	ANNALS OF INTERNAL MEDICINE			English	Editorial Material							HORMONE REPLACEMENT THERAPY; POSTMENOPAUSAL WOMEN; VENOUS THROMBOEMBOLISM; MYOCARDIAL-INFARCTION; RISK; ESTROGEN; DISEASE; USERS; PREVENTION; PROGESTIN	The Heart and Estrogen/progestin Replacement Study (HERS) found no overall effect of 4.1 years of therapy with estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. However, within the overall null effect, a 50% increase in cardiovascular events was seen in the first year, followed by fewer events after 2 years of treatment in the hormone therapy group than in the placebo group. Understanding the cause of th is pattern of early increase and late reduction in risk is key to interpreting the HERS results and reconciling them with the large number of observational and other studies of the cardiovascular effects of estrogen. There are two possibilities. One is that the HERS regimen of estrogen plus progestin has no effect on risk for heart disease, and the pattern of changing risk over time is simply the result of chance or confounding. The other is that the pattern of early increase and late reduction in risk is due to real but opposing effects of this regimen. Several lines of evidence support each possibility. Attrition of a susceptible cohort of women uniquely at risk for a cardiovascular complication from hormone therapy coupled with a gradually progressive beneficial effect due to lipid lowering and other factors is a promising potential explanation. The HERS results remind us of the need for clinical trials to evaluate both the benefits and risks of new therapies. They also illustrate how much more we need to know about the cardiovascular effects of hormone replacement therapy.	Wake Forest Univ, Sch Med, Dept Internal Med Cardiol, Winston Salem, NC 27157 USA	Wake Forest University	Herrington, DM (corresponding author), Wake Forest Univ, Sch Med, Dept Internal Med Cardiol, Med Ctr Blvd, Winston Salem, NC 27157 USA.	dherring@wfubmc.edu						Adams MR, 1997, ARTERIOSCL THROM VAS, V17, P217, DOI 10.1161/01.ATV.17.1.217; Daly E, 1996, LANCET, V348, P977, DOI 10.1016/S0140-6736(96)07113-9; Grodstein F, 1996, NEW ENGL J MED, V335, P453, DOI 10.1056/NEJM199608153350701; Grodstein F, 1996, LANCET, V348, P983, DOI 10.1016/S0140-6736(96)07308-4; Grundy SM, 1997, CIRCULATION, V95, P2329, DOI 10.1161/01.CIR.95.9.2329; Hulley S, 1999, JAMA-J AM MED ASSOC, V281, P796; Hulley S, 1998, JAMA-J AM MED ASSOC, V280, P605, DOI 10.1001/jama.280.7.605; Jick H, 1996, LANCET, V348, P981, DOI 10.1016/S0140-6736(96)07114-0; MILLER VT, 1995, JAMA-J AM MED ASSOC, V273, P199, DOI 10.1001/jama.1995.03520270033028; *NAT CHOL ED PROGR, 1994, CIRCULATION, V89, P1329; PSATY BM, 1994, ARCH INTERN MED, V154, P1333, DOI 10.1001/archinte.154.12.1333; SHAMOON H, 1993, NEW ENGL J MED, V329, P977, DOI 10.1056/nejm199309303291401; Sidney S, 1997, ANN INTERN MED, V127, P501, DOI 10.7326/0003-4819-127-7-199710010-00001; SMITH SC, 1995, CIRCULATION, V92, P2; VANDENBROUCKE JP, 1994, LANCET, V344, P1453, DOI 10.1016/S0140-6736(94)90286-0; WILLIAMS JK, 1994, J AM COLL CARDIOL, V24, P1757, DOI 10.1016/0735-1097(94)90184-8	16	84	88	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	SEP 21	1999	131	6					463	466		10.7326/0003-4819-131-6-199909210-00012	http://dx.doi.org/10.7326/0003-4819-131-6-199909210-00012			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	237DY	10498564				2022-12-01	WOS:000082641100010
J	Calverley, PMA				Calverley, PMA			Blood pressure, breathing, and the carotid body	LANCET			English	Editorial Material							OBSTRUCTIVE SLEEP-APNEA; SYMPATHETIC ACTIVITY; HYPERTENSION		Univ Hosp Aintree, Dept Med Pulm & Rehabil, Liverpool L9 7AL, Merseyside, England		Calverley, PMA (corresponding author), Univ Hosp Aintree, Dept Med Pulm & Rehabil, Liverpool L9 7AL, Merseyside, England.							Brooks D, 1997, J CLIN INVEST, V99, P106, DOI 10.1172/JCI119120; DOUGLAS NJ, 1994, LANCET, V344, P653, DOI 10.1016/S0140-6736(94)92088-5; Engleman HM, 1996, SLEEP, V19, P378, DOI 10.1093/sleep/19.5.378; HEDNER J, 1995, EUR RESPIR J, V8, P222, DOI 10.1183/09031936.95.08020222; Narkiewicz K, 1998, CIRCULATION, V98, P772, DOI 10.1161/01.CIR.98.8.772; Narkiewicz K, 1997, J HYPERTENS, V15, P1613, DOI 10.1097/00004872-199715120-00062; Narkiewicz K, 1998, CIRCULATION, V98, P1071, DOI 10.1161/01.CIR.98.11.1071; Osanai S, 1999, EUR RESPIR J, V13, P418, DOI 10.1183/09031936.99.13241899; REES K, 1995, AM J RESP CRIT CARE, V152, P1016, DOI 10.1164/ajrccm.152.3.7663777; SOMERS VK, 1995, J CLIN INVEST, V96, P1897, DOI 10.1172/JCI118235; Wright J, 1997, BRIT MED J, V314, P851; Young T, 1997, ARCH INTERN MED, V157, P1746, DOI 10.1001/archinte.157.15.1746; YOUNG T, 1993, NEW ENGL J MED, V328, P1230, DOI 10.1056/NEJM199304293281704	16	5	5	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	SEP 18	1999	354	9183					969	970		10.1016/S0140-6736(99)90135-6	http://dx.doi.org/10.1016/S0140-6736(99)90135-6			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	236JG	10501355				2022-12-01	WOS:000082596000006
J	Heppenstall, B; Tan, V				Heppenstall, B; Tan, V			Well-leg compartment syndrome	LANCET			English	Editorial Material							LITHOTOMY POSITION		Hosp Univ Penn, Dept Orthopaed Surg, Philadelphia, PA 19104 USA	University of Pennsylvania	Tan, V (corresponding author), Hosp Univ Penn, Dept Orthopaed Surg, 3400 Spruce St, Philadelphia, PA 19104 USA.							Adler LM., 1997, TECH ORTHOP, V12, P133, DOI [10.1097/00013611-199706010-00007, DOI 10.1097/00013611-199706010-00007]; Halliwill JR, 1998, ANESTHESIOLOGY, V89, P1373, DOI 10.1097/00000542-199812000-00014; MATSEN FA, 1983, PRACTICAL APPROACH C, P88; MOSES TA, 1994, UROLOGY, V43, P746, DOI 10.1016/0090-4295(94)90204-6; Mulhall J P, 1993, Conn Med, V57, P129; SLATER RR, 1994, ORTHOPEDICS, V17, P954; TAN V, 1998, ORTH TRAUM ASS 14 AN; TAN V, IN PRESS J ORTHOPAED; Wiger P, 1998, J ORTHOP TRAUMA, V12, P343, DOI 10.1097/00005131-199806000-00008	9	37	37	0	2	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	SEP 18	1999	354	9183					970	970		10.1016/S0140-6736(98)00409-7	http://dx.doi.org/10.1016/S0140-6736(98)00409-7			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	236JG	10501356				2022-12-01	WOS:000082596000007
J	Antson, AA; Dodson, EJ; Dodson, G; Greaves, RB; Chen, XP; Gollnick, P				Antson, AA; Dodson, EJ; Dodson, G; Greaves, RB; Chen, XP; Gollnick, P			Structure of the trp RNA-binding attenuation protein, TRAP, bound to RNA	NATURE			English	Article							BACILLUS-SUBTILIS BINDS; CRYSTAL-STRUCTURE; LEADER RNA; TRANSCRIPTION ATTENUATION; OPERON; COMPLEX; SYNTHETASE; EXPRESSION; REPEATS; DOMAIN	The frp RNA-binding attenuation protein (TRAP) regulates expression of the tryptophan biosynthetic genes of several bacilli by binding single-stranded RNA. The binding sequence is composed of eleven triplet repeats, predominantly GAG, separated by two or three non-conserved nucleotides, Here we present the crystal structure of a complex of TRAP and a 53-base single-stranded RNA containing eleven GAG triplets, revealing that each triplet is accommodated in a binding pocket formed by beta-strands. In the complex, the RNA has an extended structure without any base-pairing and binds to the protein mostly by specific protein-base interactions. Eleven binding pockets on the circular TRAP Il-mer form a belt with a diameter of about 80 Angstrom. This simple but elegant mechanism of arresting the RNA segment by encircling it around a protein disk is applicable to both transcription, when TRAP binds the nascent RNA, and to translation, when TRAP binds the same sequence within a non-coding leader region of the messenger RNA.	Univ York, Dept Chem, York Struct Biol Lab, York Y010 5DD, N Yorkshire, England; SUNY Buffalo, Dept Biol Sci, Buffalo, NY 14260 USA	University of York - UK; State University of New York (SUNY) System; State University of New York (SUNY) Buffalo	Antson, AA (corresponding author), Univ York, Dept Chem, York Struct Biol Lab, York Y010 5DD, N Yorkshire, England.	fred@yorvic.york.ac.uk	Antson, Alfred/N-2551-2016	Antson, Alfred/0000-0002-4533-3816				Allemand JF, 1998, P NATL ACAD SCI USA, V95, P14152, DOI 10.1073/pnas.95.24.14152; ANTSON AA, 1994, J MOL BIOL, V244, P1, DOI 10.1006/jmbi.1994.1698; ANTSON AA, 1995, NATURE, V374, P693, DOI 10.1038/374693a0; Avis JM, 1996, J MOL BIOL, V257, P398, DOI 10.1006/jmbi.1996.0171; Babitzke P, 1996, J BACTERIOL, V178, P5159, DOI 10.1128/jb.178.17.5159-5163.1996; BABITZKE P, 1995, P NATL ACAD SCI USA, V92, P7916, DOI 10.1073/pnas.92.17.7916; BABITZKE P, 1993, P NATL ACAD SCI USA, V90, P133, DOI 10.1073/pnas.90.1.133; BABITZKE P, 1994, J BIOL CHEM, V269, P16597; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Baumann C, 1996, J BIOL CHEM, V271, P12269, DOI 10.1074/jbc.271.21.12269; Baumann C, 1997, J BIOL CHEM, V272, P19863, DOI 10.1074/jbc.272.32.19863; BERNSTEIN FC, 1977, J MOL BIOL, V112, P535, DOI 10.1016/S0022-2836(77)80200-3; BIOU V, 1994, SCIENCE, V263, P1404, DOI 10.1126/science.8128220; Bochkarev A, 1997, NATURE, V385, P176, DOI 10.1038/385176a0; BROOKS BR, 1983, J COMPUT CHEM, V4, P187, DOI 10.1002/jcc.540040211; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; BRZOZOWSKI AM, 1993, ACTA CRYSTALLOGR D, V49, P352, DOI 10.1107/S0907444993000952; CAVARELLI J, 1993, NATURE, V362, P181, DOI 10.1038/362181a0; Chen XP, 1999, J MOL BIOL, V289, P1003, DOI 10.1006/jmbi.1999.2834; Conn GL, 1999, SCIENCE, V284, P1171, DOI 10.1126/science.284.5417.1171; DOCKBREGEON AC, 1988, NATURE, V335, P375, DOI 10.1038/335375a0; Du HS, 1998, J BIOL CHEM, V273, P20494, DOI 10.1074/jbc.273.32.20494; ELLIOTT MB, IN PRESS RNA; Esnouf RM, 1997, J MOL GRAPH MODEL, V15, P132, DOI 10.1016/S1093-3263(97)00021-1; GOLLNICK P, 1994, MOL MICROBIOL, V11, P991, DOI 10.1111/j.1365-2958.1994.tb00377.x; GOLLNICK P, 1990, P NATL ACAD SCI USA, V87, P8726, DOI 10.1073/pnas.87.22.8726; Handa N, 1999, NATURE, V398, P579, DOI 10.1038/19242; HOUMAN F, 1990, CELL, V62, P1153, DOI 10.1016/0092-8674(90)90392-R; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; KURODA MI, 1988, J BACTERIOL, V170, P3080, DOI 10.1128/jb.170.7.3080-3088.1988; MERINO E, 1995, J BACTERIOL, V177, P6362, DOI 10.1128/jb.177.22.6362-6370.1995; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; OLDFIELD TJ, 1994, P CCP4 STUD WEEK; OTRIDGE J, 1993, P NATL ACAD SCI USA, V90, P128, DOI 10.1073/pnas.90.1.128; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; OUBRIDGE C, 1994, NATURE, V372, P432, DOI 10.1038/372432a0; PAULING L, 1953, P NATL ACAD SCI USA, V39, P84, DOI 10.1073/pnas.39.2.84; Price SR, 1998, NATURE, V394, P645, DOI 10.1038/29234; PUGLISI JD, 1995, SCIENCE, V270, P1200, DOI 10.1126/science.270.5239.1200; ROULD MA, 1991, NATURE, V352, P213, DOI 10.1038/352213a0; Schneider B, 1997, BIOPOLYMERS, V42, P113, DOI 10.1002/(SICI)1097-0282(199707)42:1<113::AID-BIP10>3.3.CO;2-F; SHIMOTSU H, 1986, J BACTERIOL, V166, P461, DOI 10.1128/jb.166.2.461-471.1986; SLOCK J, 1990, J BACTERIOL, V172, P7211, DOI 10.1128/jb.172.12.7211-7226.1990; Tomchick DR, 1998, STRUCTURE, V6, P337, DOI 10.1016/S0969-2126(98)00036-7; VALEGARD K, 1994, NATURE, V371, P623, DOI 10.1038/371623a0; Wimberly BT, 1999, CELL, V97, P491, DOI 10.1016/S0092-8674(00)80759-X; YANG M, 1995, J BACTERIOL, V177, P4272, DOI 10.1128/jb.177.15.4272-4278.1995; Yang M, 1997, J MOL BIOL, V270, P696, DOI 10.1006/jmbi.1997.1149; YANOFSKY C, 1981, NATURE, V289, P751, DOI 10.1038/289751a0; Ziehler WA, 1996, BIOTECHNIQUES, V20, P622	50	203	209	0	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	SEP 16	1999	401	6750					235	242		10.1038/45730	http://dx.doi.org/10.1038/45730			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	237VZ	10499579				2022-12-01	WOS:000082678400043
J	Lu, MF; Pressman, C; Dyer, R; Johnson, RL; Martin, JF				Lu, MF; Pressman, C; Dyer, R; Johnson, RL; Martin, JF			Function of Rieger syndrome gene in left-right asymmetry and craniofacial development	NATURE			English	Article							SIGNALING PATHWAY; PITX2; REGULATOR; SEQUENCE; TISSUES; FAMILY	Rieger syndrome, an autosomal dominant disorder, includes ocular, craniofacial and umbilical abnormalities, The pitx2 homeobox gene, which is mutated in Rieger syndrome(1,2), has been proposed to be the effector molecule interpreting left-right axial information from the early embryonic trunk to each organ(3-7). Here we have used gene targeting in mice to generate a loss-of-function allele that would be predicted to result in organ randomization or isomerization. Although pitx2(-/-) embryos had abnormal cardiac morphogenesis, mutant hearts looped in the normal direction. Pitx2(-/-) embryos had correctly oriented, but arrested, embryonic rotation and right pulmonary isomerism. They also had defective development of the mandibular and maxillary facial prominences, regression of the stomodeum and arrested tooth development. Fgf8 expression was absent, and Bmp4 expression was expanded in the branchial-arch ectoderm. These data reveal a critical role for pitx2 in left-right asymmetry but indicate that pitx2 may function at an intermediate step in cardiac morphogenesis and embryonic rotation.	Texas A&M Univ Syst Hlth Sci Ctr, Ctr Canc Biol & Nutr, Alkek Inst Biosci & Technol, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Biochem & Mol Biol, Houston, TX 77030 USA	Texas A&M University System; Texas A&M University College Station; Texas A&M Health Science Center; University of Texas System; UTMD Anderson Cancer Center	Martin, JF (corresponding author), Texas A&M Univ Syst Hlth Sci Ctr, Ctr Canc Biol & Nutr, Alkek Inst Biosci & Technol, 2121 Holcombe Blvd, Houston, TX 77030 USA.							Biben C, 1997, GENE DEV, V11, P1357, DOI 10.1101/gad.11.11.1357; Campione M, 1999, DEVELOPMENT, V126, P1225; Flomen RH, 1998, GENOMICS, V47, P409, DOI 10.1006/geno.1997.5127; Gage PJ, 1997, HUM MOL GENET, V6, P457, DOI 10.1093/hmg/6.3.457; Gebbia M, 1997, NAT GENET, V17, P305, DOI 10.1038/ng1197-305; Harvey RP, 1998, CELL, V94, P273, DOI 10.1016/S0092-8674(00)81468-3; JOHNSTON MC, 1979, EXP EYE RES, V29, P27, DOI 10.1016/0014-4835(79)90164-7; Kaufman M.H., 1992, ATLAS MOUSE DEV; Logan M, 1998, CELL, V94, P307, DOI 10.1016/S0092-8674(00)81474-9; Lu MF, 1999, DEVELOPMENT, V126, P495; Meno C, 1998, CELL, V94, P287, DOI 10.1016/S0092-8674(00)81472-5; MIKKILA SP, 1994, AM J MED GENET, V49, P435, DOI 10.1002/ajmg.1320490417; Neubuser A, 1997, CELL, V90, P247, DOI 10.1016/S0092-8674(00)80333-5; Oh SP, 1997, GENE DEV, V11, P1812, DOI 10.1101/gad.11.14.1812; Piedra ME, 1998, CELL, V94, P319, DOI 10.1016/S0092-8674(00)81475-0; Ryan AK, 1998, NATURE, V394, P545, DOI 10.1038/29004; Semina EV, 1996, NAT GENET, V14, P392, DOI 10.1038/ng1296-392; VAINIO S, 1993, CELL, V75, P45, DOI 10.1016/0092-8674(93)90678-J; Yoshioka H, 1998, CELL, V94, P299, DOI 10.1016/S0092-8674(00)81473-7; YOST HJ, 1995, CELL, V82, P689, DOI 10.1016/0092-8674(95)90464-6	20	403	405	0	11	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	SEP 16	1999	401	6750					276	278		10.1038/45797	http://dx.doi.org/10.1038/45797			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	237VZ	10499585				2022-12-01	WOS:000082678400053
J	Kumana, CR; Cheung, BMY; Lauder, IJ				Kumana, CR; Cheung, BMY; Lauder, IJ			Gauging the impact of statins using number needed to treat	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							CORONARY HEART-DISEASE; PREVENTION; HYPERCHOLESTEROLEMIA; PRAVASTATIN		Univ Hong Kong, Dept Med, Hong Kong, Peoples R China; Univ Hong Kong, Dept Stat, Hong Kong, Peoples R China	University of Hong Kong; University of Hong Kong	Kumana, CR (corresponding author), Univ Hong Kong, Queen Mary Hosp, Dept Med, Pokfulam Rd, Hong Kong, Peoples R China.		/E-9829-2010	/0000-0001-9106-7363				ABRAMOWICZ M, 1994, MED LETT DRUGS THER, V36, P45; ABRAMOWICZ M, 1996, MED LETT, V38, P67; *AD TREATM PAN 2, 1994, CIRCULATION, V89, P1329; Hulley S, 1998, JAMA-J AM MED ASSOC, V280, P605, DOI 10.1001/jama.280.7.605; ILLINGWORTH DR, 1994, CLIN THER, V16, P366; *JOINT FORM COMM L, 1995, BR NATL FORMULARY, V29, P107; Kumana C. R., 1998, Hong Kong Medical Journal, V4, P158; OSE L, 1995, CLIN DRUG INVEST, V10, P127, DOI 10.2165/00044011-199510030-00001; OWNS JR, 1998, JAMA-J AM MED ASSOC, V279, P1615; PEDERSEN TR, 1994, LANCET, V344, P1383; Petitti DB, 1998, JAMA-J AM MED ASSOC, V280, P650, DOI 10.1001/jama.280.7.650; Plehn JF, 1999, CIRCULATION, V99, P216, DOI 10.1161/01.CIR.99.2.216; Rosenson RS, 1998, JAMA-J AM MED ASSOC, V279, P1643, DOI 10.1001/jama.279.20.1643; Sacks FM, 1996, NEW ENGL J MED, V335, P1001, DOI 10.1056/NEJM199610033351401; SHEPHERD J, 1995, NEW ENGL J MED, V333, P1301, DOI 10.1056/NEJM199511163332001; SIMONS LA, 1994, INSERT AUSTR SCHEDUL; Sourander L, 1998, LANCET, V352, P1965, DOI 10.1016/S0140-6736(98)05066-1; Tonkin A, 1998, NEW ENGL J MED, V339, P1349	18	41	41	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 24	1999	282	20					1899	1901		10.1001/jama.282.20.1899	http://dx.doi.org/10.1001/jama.282.20.1899			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	257BZ	10580441				2022-12-01	WOS:000083763400002
J	Mayberry, JC				Mayberry, JC			Prevention of the abdominal compartment syndrome	LANCET			English	Editorial Material							PRESSURE; TRAUMA		Oregon Hlth Sci Univ, Dept Surg, Portland, OR 97201 USA	Oregon Health & Science University	Mayberry, JC (corresponding author), Oregon Hlth Sci Univ, Dept Surg, Portland, OR 97201 USA.			Mayberry, John/0000-0001-6978-9079				Behrman SW, 1998, J TRAUMA, V45, P227, DOI 10.1097/00005373-199808000-00005; BRADLEY SE, 1947, J CLIN INVEST, V26, P1010, DOI 10.1172/JCI101867; CALDWELL CB, 1987, J SURG RES, V43, P14, DOI 10.1016/0022-4804(87)90041-2; Ciresi DL, 1999, AM SURGEON, V65, P720; GROSS RE, 1948, SURGERY, V24, P277; Ivatury RR, 1998, J TRAUMA, V44, P1016, DOI 10.1097/00005373-199806000-00014; KRON IL, 1984, ANN SURG, V199, P28, DOI 10.1097/00000658-198401000-00005; Meldrum DR, 1997, AM J SURG, V174, P667, DOI 10.1016/S0002-9610(97)00201-8; Ogilvie WH, 1940, LANCET, V2, P253; OLERUD S, 1953, ACTA PHYSL SCAN S109, V30, P4; RICHARDSON JD, 1976, J SURG RES, V20, P401, DOI 10.1016/0022-4804(76)90112-8	11	27	31	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	NOV 20	1999	354	9192					1749	1750		10.1016/S0140-6736(99)00407-9	http://dx.doi.org/10.1016/S0140-6736(99)00407-9			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	258RM	10577634				2022-12-01	WOS:000083853000007
J	Lauderdale, DS; Oram, RJ; Goldstein, KP; Daum, RS				Lauderdale, DS; Oram, RJ; Goldstein, KP; Daum, RS			Hepatitis B vaccination among children in inner-city public housing, 1991-1997	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							IMMUNIZATION COVERAGE; INFANTS	Context In 1991, the Advisory Committee on Immunization Practices recommended universal vaccination of infants against hepatitis B virus (HBV), with series initiation within days of birth. Objective To determine HBV vaccine coverage in a low-income urban population and to examine whether HBV immunization within the first month of life affects subsequent vaccine receipt. Design Cohort study based on immunization records collected in the Pediatric Immunization Program. Setting Large public housing development in Chicago, ill. Participants All 1143 children who were born between 1991 and 1997 and enrolled between 1993 and mid-1998, with follow-up to age 35 months. Main Outcome Measures On-time vaccine receipt of HBV vaccine doses, diphtheria-tetanus-pertussis vaccine (DTP) dose 1, and the 4:3:1 series (4 doses of DTP vaccine, 3 doses of poliomyelitis vaccine, and 1 dose of measles-containing vaccine), analyzed by year. Results On-time HBV vaccination increased quickly following new guidelines and reached a plateau of about 50% coverage for those born in or after 1995, Since 1994, more children (64%) received the first HBV vaccine dose on time than any other vaccine. Children who received a dose of HBV vaccine during their first month of life were more likely to receive the first DTP vaccine dose on time (60.1%) than those who did not get an HBV vaccine dose during the first month (36.4%; chi(2) = 53.7; P<.001). Children who received the first HBV vaccine dose during their first month were more likely than those receiving it at age 1 to 2 months to complete 3 HBV doses by 19 months (70.6% vs 51.1%; chi(2) = 11.6; P =.001) and to complete the 4:3:1 series by age 19 months (49.8% vs 37.9%; chi(2) = 4.0; P = .05). Conclusions In this inner-city population, HBV vaccine has been received at rates similar to those of other vaccines within 3 years of issuance of new recommendations. Of note, immunization with HBV vaccine at birth was associated with timely receipt of other vaccines and, therefore, may have the potential to increase vaccination among groups less likely to be up-to-date on early childhood vaccines.	Univ Chicago, Dept Hlth Studies, Chicago, IL 60637 USA; Univ Chicago, Dept Pediat, Chicago, IL 60637 USA	University of Chicago; University of Chicago	Lauderdale, DS (corresponding author), Univ Chicago, Dept Hlth Studies, 5841 S Maryland Ave,MC 2007, Chicago, IL 60637 USA.							Bolton P, 1998, PUBLIC HEALTH REP, V113, P527; *CDC, 1989, MMWR-MORBID MORTAL W, V38, P818; *CDC, 1991, MMWR-MORBID MORTAL W, V4, P1; *CDCP, 1998, MMWR-MORBID MORTAL W, V47, P108; *CDCP, 1999, MMWR-MORBID MORTAL W, V48, P563; Centers for Disease Control and Prevention (CDC), 1999, MMWR Morb Mortal Wkly Rep, V48, P780; *CHIC DEP PUBL HLT, 1995, R TAYL IN; FREED GL, 1994, PEDIATRICS, V93, P747; Goldstein KP, 1996, JAMA-J AM MED ASSOC, V276, P56, DOI 10.1001/jama.276.1.56; GOLDSTEIN KP, IN PRESS PEDIATRICS; Hoekstra EJ, 1998, JAMA-J AM MED ASSOC, V280, P1143, DOI 10.1001/jama.280.13.1143; Kenyon TA, 1998, PEDIATRICS, V101, P612, DOI 10.1542/peds.101.4.612; Ross A, 1998, PEDIATRICS, V101, P970, DOI 10.1542/peds.101.6.970; WILLIAMS IT, 1995, PEDIATRICS, V96, P439	14	36	37	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 10	1999	282	18					1725	1730		10.1001/jama.282.18.1725	http://dx.doi.org/10.1001/jama.282.18.1725			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	251XJ	10568644	Bronze			2022-12-01	WOS:000083471400026
J	Smilenov, LB; Mikhailov, A; Pelham, RJ; Marcantonio, EE; Gundersen, GG				Smilenov, LB; Mikhailov, A; Pelham, RJ; Marcantonio, EE; Gundersen, GG			Focal adhesion motility revealed in stationary fibroblasts	SCIENCE			English	Article							CONTRACTILITY; INHIBITORS; INTEGRINS; MIGRATION; CONTACTS; DYNAMICS; MATRIX	Focal adhesions (FAs) are clustered integrins and associated proteins that mediate cell adhesion and signaling. A green fluorescent protein-pi integrin chimera was used to label FAs in Living cells. in stationary cells, FAs were highly motile, moving linearly for several plaque lengths toward the cell center. FA motility was independent of cell density and resulted from contraction of associated actin fibers. In migrating cells, FAs were stationary and only moved in the tail. FA motility in stationary cells suggests that cell movement may be regulated by a clutch-like mechanism by which the affinity of integrins to substrate may be altered in response to migratory cues.	Columbia Univ, Dept Pathol, New York, NY 10032 USA; Columbia Univ, Dept Anat & Cell Biol, New York, NY 10032 USA	Columbia University; Columbia University	Gundersen, GG (corresponding author), Columbia Univ, Dept Pathol, New York, NY 10032 USA.				NIGMS NIH HHS [GM44585, GM42026] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM042026, R01GM044585] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BURRIDGE K, 1988, ANNU REV CELL BIOL, V4, P487, DOI 10.1146/annurev.cb.04.110188.002415; Burridge K, 1996, ANNU REV CELL DEV BI, V12, P463, DOI 10.1146/annurev.cellbio.12.1.463; CRAMER LP, 1995, J CELL BIOL, V131, P179, DOI 10.1083/jcb.131.1.179; CUNNINGHAM CC, 1991, SCIENCE, V251, P1233, DOI 10.1126/science.1848726; DANOWSKI BA, 1989, J CELL SCI, V93, P255; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; IZZARD CS, 1976, J CELL SCI, V21, P129; LAFLAMME SE, 1994, J CELL BIOL, V126, P1287, DOI 10.1083/jcb.126.5.1287; Mikhailov A, 1998, CELL MOTIL CYTOSKEL, V41, P325, DOI 10.1002/(SICI)1097-0169(1998)41:4<325::AID-CM5>3.0.CO;2-D; Palecek SP, 1997, NATURE, V385, P537, DOI 10.1038/385537a0; REGEN CM, 1992, J CELL BIOL, V119, P1347, DOI 10.1083/jcb.119.5.1347; SCHMIDT CE, 1993, J CELL BIOL, V123, P977, DOI 10.1083/jcb.123.4.977; SMILENOV L, 1994, MOL BIOL CELL, V5, P1215, DOI 10.1091/mbc.5.11.1215	13	283	286	1	18	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 5	1999	286	5442					1172	1174		10.1126/science.286.5442.1172	http://dx.doi.org/10.1126/science.286.5442.1172			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	253AJ	10550057				2022-12-01	WOS:000083534200047
J	Galarreta, M; Hestrin, S				Galarreta, M; Hestrin, S			A network of fast-spiking cells in the neocortex connected by electrical synapses	NATURE			English	Article							RAT FRONTAL-CORTEX; NONPYRAMIDAL CELLS; INHIBITORY INTERNEURONS; GABAERGIC INTERNEURONS; GAMMA-OSCILLATION; NEURONAL NETWORKS; CORTICAL-NEURONS; IN-VITRO; HIPPOCAMPUS; SYNCHRONIZATION	Encoding of information in the cortex is thought to depend on synchronous firing of cortical neurons(1,2). Inhibitory neurons are known to be critical in the coordination of cortical activity(3-5), but how interaction among inhibitory cells promotes synchrony is not well understood(4,6-12). To address this issue directly, we have recorded simultaneously from pairs of fast-spiking (FS) cells, a type of gamma-aminobutyric acid (GABA)-containing neocortical interneuron(13). Here we report a high occurrence of electrical coupling among FS cells. Electrical synapses were not found among pyramidal neurons or between FS cells and other cortical cells. Some FS cells were interconnected by both electrical and GABAergic synapses. We show that communication through electrical synapses allows excitatory signalling among inhibitory cells and promotes their synchronous spiking. These results indicate that electrical synapses establish a network of fast-spiking cells in the neocortex which may play a key role in coordinating cortical activity.	Univ Tennessee, Dept Anat & Neurobiol, Memphis, TN 38163 USA	University of Tennessee System; University of Tennessee Health Science Center	Hestrin, S (corresponding author), Univ Tennessee, Dept Anat & Neurobiol, 855 Monroe Ave, Memphis, TN 38163 USA.	shaul@nb.utmem.edu	Hestrin, Shaul/F-4410-2010	Vargas-Caballero, Mariana/0000-0003-2326-4001				Angulo MC, 1999, J NEUROSCI, V19, P1566; Benardo LS, 1997, J NEUROPHYSIOL, V77, P3134, DOI 10.1152/jn.1997.77.6.3134; BRAGIN A, 1995, J NEUROSCI, V15, P47; Buhl EH, 1998, J PHYSIOL-LONDON, V513, P117, DOI 10.1111/j.1469-7793.1998.117by.x; Bush P, 1996, J COMPUT NEUROSCI, V3, P91, DOI 10.1007/BF00160806; Cauli B, 1997, J NEUROSCI, V17, P3894; COBB SR, 1995, NATURE, V378, P75, DOI 10.1038/378075a0; CONNORS BW, 1983, J NEUROSCI, V3, P773; Galarreta M, 1998, NAT NEUROSCI, V1, P587, DOI 10.1038/2822; HUBEL DH, 1959, J PHYSIOL-LONDON, V147, P226, DOI 10.1113/jphysiol.1959.sp006238; Jefferys JGR, 1996, TRENDS NEUROSCI, V19, P202, DOI 10.1016/S0166-2236(96)10023-0; KATSUMARU H, 1988, EXP BRAIN RES, V72, P363; Kawaguchi Y, 1997, CEREB CORTEX, V7, P476, DOI 10.1093/cercor/7.6.476; KAWAGUCHI Y, 1993, J NEUROPHYSIOL, V70, P387, DOI 10.1152/jn.1993.70.1.387; KAWAGUCHI Y, 1995, J NEUROSCI, V15, P2638; LYTTON WW, 1991, J NEUROPHYSIOL, V66, P1059, DOI 10.1152/jn.1991.66.3.1059; MICHELSON HB, 1994, J PHYSIOL-LONDON, V477, P35, DOI 10.1113/jphysiol.1994.sp020169; NEYTON J, 1985, NATURE, V317, P331, DOI 10.1038/317331a0; PEINADO A, 1993, NEURON, V10, P103, DOI 10.1016/0896-6273(93)90246-N; Rinzel J, 1998, SCIENCE, V279, P1351, DOI 10.1126/science.279.5355.1351; Ritz R, 1997, CURR OPIN NEUROBIOL, V7, P536, DOI 10.1016/S0959-4388(97)80034-7; SINGER W, 1995, ANNU REV NEUROSCI, V18, P555, DOI 10.1146/annurev.neuro.18.1.555; SLOPER JJ, 1972, BRAIN RES, V44, P640, DOI 10.1016/0006-8993(72)90327-7; Stevens CF, 1998, NAT NEUROSCI, V1, P210, DOI 10.1038/659; Strata F, 1997, J NEUROSCI, V17, P1435; Tamas G, 1998, J NEUROSCI, V18, P4255; Traub RD, 1996, NATURE, V383, P621, DOI 10.1038/383621a0; Wang XJ, 1996, J NEUROSCI, V16, P6402; WHITTINGTON MA, 1995, NATURE, V373, P612, DOI 10.1038/373612a0; Zhang Y, 1998, J NEUROSCI, V18, P9256	30	733	742	1	35	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	NOV 4	1999	402	6757					72	75		10.1038/47029	http://dx.doi.org/10.1038/47029			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	254XC	10573418				2022-12-01	WOS:000083638600044
J	Chan, A; Cundy, PJ; Foster, BK; Keane, RJ; Byron-Scott, R				Chan, A; Cundy, PJ; Foster, BK; Keane, RJ; Byron-Scott, R			Late diagnosis of congenital dislocation of the hip and presence of a screening programme: South Australian population-based study	LANCET			English	Article							DEVELOPMENTAL DYSPLASIA; RISK-FACTORS; MANAGEMENT	Background The Medical Research Council Working Party on Congenital Dislocation of the Hip have reported an ascertainment-adjusted incidence of a first operative procedure for congenital dislocation of the hip (CDH) of 0.78 per 1000 livebirths, which is similar to the incidence of CDH before the start of the UK screening programme. The report showed that CDH had not been detected by routine screening before age 3 months in 70% of children reported to the national orthopaedic surveillance scheme. This report raised concerns about the merit of screening at birth for CDH. We aimed to find out the incidence of an operative procedure for CDH in the first 5 years of life among children born in South Australia between 1988 and 1993, and the proportion of these patients that were detected at age 3 months or older. Methods The state's database for inpatient separations between January, 1988, and April, 1998 was searched. Case records were examined for the age and circumstances of diagnosis, and type of operative procedures. Prevalence rates of CDH were obtained from the South Australian Birth Defects Register, which receives notifications from a statutory perinatal data collection of birth defects detected at birth and subsequent voluntary notifications for children up to age 5 years. Findings Of the 55 children born in South Australia between 1988 and 1993 identified as having non-teratological CDH and operative procedures, only 22 (40%) had been diagnosed at age 3 months or order. 18 had an open reduction of the hip joint or osteotomy, or both, and the remainder had arthrograms, closed reductions, and/or tenotomy. The prevalence of non-teratological CDH in children was 7.74 per 1000 livebirths. The incidence of surgery for CDH in the first 5 years of life was 0.46 per 1000 livebirths (95% CI 0.34-0.59) and only 0.19 per 1000 livebirths (0.11-0.26) for those diagnosed late (age 3 months or older). These children diagnosed late represented 2.4% of ail known cases of CDH. Interpretation Only 2.4% of known cases of CDH in children born in South Australia had been detected late and required surgery. These results shaw that a screening programme for CDH can be successful, contrary to the findings of the UK Medical Research Council Working Party.	Dept Human Serv, Pregnancy Outcome Unit, Adelaide, SA 5000, Australia; Womens & Childrens Hosp, Dept Orthopaed Surg, N Adelaide, SA 5006, Australia; Womens & Childrens Hosp, S Australian Birth Defects Register, N Adelaide, SA 5006, Australia		Chan, A (corresponding author), Dept Human Serv, Pregnancy Outcome Unit, POB 6 Rundle Mall, Adelaide, SA 5000, Australia.							BERMAN L, 1986, BRIT MED J, V293, P719, DOI 10.1136/bmj.293.6549.719; BURGER BJ, 1990, LANCET, V336, P1549, DOI 10.1016/0140-6736(90)93317-I; Chan A, 1997, ARCH DIS CHILD-FETAL, V76, pF94, DOI 10.1136/fn.76.2.F94; CUNNINGHAM KT, 1984, LANCET, V1, P668; Dezateux C, 1996, ARCH DIS CHILD, V74, P445, DOI 10.1136/adc.74.5.445; Dunn P, 1998, LANCET, V352, P317, DOI 10.1016/S0140-6736(98)26030-2; DUNN PM, 1985, ARCH DIS CHILD, V60, P407, DOI 10.1136/adc.60.5.407; FREDENSBORG N, 1976, ACTA PAEDIATR SCAND, V65, P323, DOI 10.1111/j.1651-2227.1976.tb04893.x; Godward S, 1998, LANCET, V351, P1149, DOI 10.1016/S0140-6736(97)10466-4; Hiertonn T, 1968, J Bone Joint Surg Br, V50, P542; JONES D, 1977, J BONE JOINT SURG BR, V59, P318, DOI 10.1302/0301-620X.59B3.893510; MACKENZIE IG, 1981, J BONE JOINT SURG BR, V63, P38, DOI 10.1302/0301-620X.63B1.7204472; McKee L, 1998, BRIT MED J, V316, P1265; MCKINNON B, 1984, J PEDIATR ORTHOPED, V4, P422, DOI 10.1097/01241398-198408000-00006; MITCHELL G P, 1972, Journal of Bone and Joint Surgery British Volume, V54, P4; PALMEN K, 1984, ACTA ORTHOP SCAND, V55, P1; PATERSON DC, 1976, CLIN ORTHOP RELAT R, P28; Raffle AE, 1998, LANCET, V352, P317, DOI 10.1016/S0140-6736(05)60288-7; *US DEP HHS, 1980, INT CLASS DIS, V1; *US DEP HHS, 1980, INT CLASS DIS, V3; WALKER G, 1971, BRIT MED J, V3, P147, DOI 10.1136/bmj.3.5767.147; Wilson JMG, 1968, 34 WHO PUBL HLTH, V34; Wynne-Davies R, 1970, J Bone Joint Surg Br, V52, P704; Yiv BC, 1997, J PAEDIATR CHILD H, V33, P151, DOI 10.1111/j.1440-1754.1997.tb01019.x; 1991, LANCET, V337, P947	25	48	49	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	OCT 30	1999	354	9189					1514	1517		10.1016/S0140-6736(98)12469-8	http://dx.doi.org/10.1016/S0140-6736(98)12469-8			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	250WB	10551498				2022-12-01	WOS:000083411300012
J	Annas, GJ				Annas, GJ			The last resort - The use of physical restraints in medical emergencies	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Boston Univ, Sch Publ Hlth, Hlth Law Dept, Boston, MA 02118 USA	Boston University	Annas, GJ (corresponding author), Boston Univ, Sch Publ Hlth, Hlth Law Dept, Boston, MA 02118 USA.			Annas, George/0000-0001-5836-7831				ANNAS GJ, 1984, TOLEDO LAW REV, V15, P561; BOWMAN C, 1999, BNAS HLTH LAW R 0826, P1405; Donat DC, 1998, J BEHAV THER EXP PSY, V29, P13, DOI 10.1016/S0005-7916(97)00039-6; EVANS LK, 1989, J AM GERIATR SOC, V37, P65, DOI 10.1111/j.1532-5415.1989.tb01571.x; Greenlaw J, 1982, Law Med Health Care, V10, P125; Janelli L M, 1995, J Nurs Care Qual, V9, P86; MILES SH, 1992, GERONTOLOGIST, V32, P762, DOI 10.1093/geront/32.6.762; Parker KP, 1997, J AM GERIATR SOC, V45, P797, DOI 10.1111/j.1532-5415.1997.tb01504.x; PROSSER WL, 1984, TORTS, P117; WEISS EM, 1999, HARTFORD COURAN 0731, pA14; WEISS EM, 1998, HARTFORD COURAN 1011, pA1; 1998, HARTFORD COURAN 1022, pA18; 1998, FED REG, V64, P36070; 1998, HARTFORD COURAN 1011, pA12	14	34	35	0	3	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 28	1999	341	18					1408	1412		10.1056/NEJM199910283411820	http://dx.doi.org/10.1056/NEJM199910283411820			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	249XE	10536135	Green Published			2022-12-01	WOS:000083357800028
J	Hensher, M; Fulop, N; Coast, J; Jefferys, E				Hensher, M; Fulop, N; Coast, J; Jefferys, E			The hospital of the future - Better out than in? Alternatives to acute hospital care	BRITISH MEDICAL JOURNAL			English	Article							COST MINIMIZATION ANALYSIS; HOME CARE; AT-HOME; ADMISSIONS; APPROPRIATENESS		Univ London London Sch Hyg & Trop Med, London Hlth Econ Consortium, London WC1E 7HT, England; Univ London London Sch Hyg & Trop Med, Hlth Serv Res Unit, London WC1E 7HT, England; Univ Bristol, Dept Social Med, Bristol BS8 2PR, Avon, England	University of London; London School of Hygiene & Tropical Medicine; University of London; London School of Hygiene & Tropical Medicine; University of Bristol	Hensher, M (corresponding author), Univ London London Sch Hyg & Trop Med, London Hlth Econ Consortium, Keppel St, London WC1E 7HT, England.		Hensher, Martin C/N-4635-2017	Hensher, Martin C/0000-0001-6444-6827; Fulop, Naomi/0000-0001-5306-6140; Coast, Joanna/0000-0002-3537-5166				ABELSMITH B, 1994, HEALTH POLICY, V28, P89, DOI 10.1016/0168-8510(94)90030-2; Apolone G, 1997, EUR J PUBLIC HEALTH, V7, P34, DOI 10.1093/eurpub/7.1.34; BAKER JE, 1986, J EPIDEMIOL COMMUN H, V40, P117, DOI 10.1136/jech.40.2.117; Coast J, 1998, BRIT MED J, V316, P1802, DOI 10.1136/bmj.316.7147.1802; COAST J, 1995, J EPIDEMIOL COMMUN H, V49, P194, DOI 10.1136/jech.49.2.194; Coast J, 1996, BRIT MED J, V312, P162; HAYES CB, 1995, IRISH MED J, V88, P124; Hensher M, 1996, J ROY SOC MED, V89, P548, DOI 10.1177/014107689608901003; Iliffe S, 1997, J ROY SOC MED, V90, P181, DOI 10.1177/014107689709000401; KNOWELDEN J, 1991, J PUBLIC HEALTH MED, V13, P182, DOI 10.1093/oxfordjournals.pubmed.a042616; Raftery J, 1998, J Health Serv Res Policy, V3, P149; READ S, 1994, PATIENTS MINOR INJUR; Richards SH, 1998, BRIT MED J, V316, P1796, DOI 10.1136/bmj.316.7147.1796; Shepperd S, 1998, BRIT MED J, V316, P1786, DOI 10.1136/bmj.316.7147.1786; Shepperd S, 1998, BRIT MED J, V316, P1791, DOI 10.1136/bmj.316.7147.1791; SHEPPERD S, 1998, COCHRANE LIB; Smith HE, 1997, J ROY COLL PHYS LOND, V31, P527; Steiner A, 1997, INTERMEDIATE CARE CO; Victor C, 1993, Health Trends, V25, P94; VICTOR CR, 1994, J PUBLIC HEALTH MED, V16, P286; Wilson A., 1997, J EPIDEMIOL COMMUNIT, V51, P593	21	37	37	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	OCT 23	1999	319	7217					1127	1130		10.1136/bmj.319.7217.1127	http://dx.doi.org/10.1136/bmj.319.7217.1127			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	250ZE	10531112	Green Published			2022-12-01	WOS:000083419500035
J	Lee, DD; Seung, HS				Lee, DD; Seung, HS			Learning the parts of objects by non-negative matrix factorization	NATURE			English	Article							BLIND SEPARATION; RECOGNITION; ALGORITHM; REPRESENTATION	Is perception of the whole based on perception of its parts? There is psychological(1) and physiological(2,3) evidence for parts-based representations in the brain, and certain computational theories of object recognition rely on such representations(4,5). But little is known about how brains or computers might learn the parts of objects. Here we demonstrate an algorithm for non-negative matrix factorization that is able to learn parts of faces and semantic features of text. This is in contrast to other methods, such as principal components analysis and vector quantization, that learn holistic, not parts-based, representations. Non-negative matrix factorization is distinguished from the other methods by its use of non-negativity constraints. These constraints lead to a parts-based representation because they allow only additive, not subtractive, combinations. When non-negative matrix factorization is implemented as a neural network, parts-based representations emerge by virtue of two properties: the firing rates of neurons are never negative and synaptic strengths do not change sign.	AT&T Bell Labs, Lucent Technol, Murray Hill, NJ 07974 USA; MIT, Dept Brain & Cognit Sci, Cambridge, MA 02139 USA	Alcatel-Lucent; Lucent Technologies; AT&T; Nokia Corporation; Nokia Bell Labs; Massachusetts Institute of Technology (MIT)	Seung, HS (corresponding author), AT&T Bell Labs, Lucent Technol, 600 Mt Ave, Murray Hill, NJ 07974 USA.		Lee, Daniel D./B-5753-2013					Bartlett MS, 1998, P SOC PHOTO-OPT INS, V3299, P528, DOI 10.1117/12.320144; BELL AJ, 1995, NEURAL COMPUT, V7, P1129, DOI 10.1162/neco.1995.7.6.1129; BIEDERMAN I, 1987, PSYCHOL REV, V94, P115, DOI 10.1037/0033-295X.94.2.115; DEMPSTER AP, 1977, J ROY STAT SOC B MET, V39, P1, DOI 10.1111/j.2517-6161.1977.tb01600.x; FIELD DJ, 1994, NEURAL COMPUT, V6, P559, DOI 10.1162/neco.1994.6.4.559; FOLDIAK P, 1995, HDB BRAIN THEORY NEU, P895; HINTON GE, 1995, SCIENCE, V268, P1158, DOI 10.1126/science.7761831; JUTTEN C, 1991, SIGNAL PROCESS, V24, P1, DOI 10.1016/0165-1684(91)90079-X; Landauer TK, 1997, PSYCHOL REV, V104, P211, DOI 10.1037/0033-295X.104.2.211; Lee DD, 1997, ADV NEUR IN, V9, P515; Logothetis NK, 1996, ANNU REV NEUROSCI, V19, P577, DOI 10.1146/annurev.ne.19.030196.003045; LUCY LB, 1974, ASTRON J, V79, P745, DOI 10.1086/111605; NAKAYAMA K, 1992, SCIENCE, V257, P1357, DOI 10.1126/science.1529336; Olshausen BA, 1996, NATURE, V381, P607, DOI 10.1038/381607a0; Paatero P, 1997, CHEMOMETR INTELL LAB, V37, P23, DOI 10.1016/S0169-7439(96)00044-5; PALMER SE, 1977, COGNITIVE PSYCHOL, V9, P441, DOI 10.1016/0010-0285(77)90016-0; RICHARDSON WH, 1972, J OPT SOC AM, V62, P55, DOI 10.1364/JOSA.62.000055; SALTON G, 1983, INTRO MODERN INFORMA; SAUL L, 1997, P 2 C EMP METH NAT L, P81; Shepp L A, 1982, IEEE Trans Med Imaging, V1, P113, DOI 10.1109/TMI.1982.4307558; TURK M, 1991, J COGNITIVE NEUROSCI, V3, P71, DOI 10.1162/jocn.1991.3.1.71; Ullman S., 1996, HIGH LEVEL VISION OB	22	7696	8329	42	767	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	OCT 21	1999	401	6755					788	791		10.1038/44565	http://dx.doi.org/10.1038/44565			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	250BG	10548103				2022-12-01	WOS:000083368700052
J	Vazquez-Torres, A; Jones-Carson, J; Baumler, AJ; Falkow, S; Valdivia, R; Brown, W; Le, M; Berggren, R; Parks, WT; Fang, FC				Vazquez-Torres, A; Jones-Carson, J; Baumler, AJ; Falkow, S; Valdivia, R; Brown, W; Le, M; Berggren, R; Parks, WT; Fang, FC			Extraintestinal dissemination of Salmonella by CD18-expressing phagocytes	NATURE			English	Article							PEYERS-PATCHES; M-CELLS; TYPHIMURIUM; IDENTIFICATION; MUTANTS; IMMUNIZATION; CONSTRUCTION; EXPRESSION; MUTATIONS; INFECTION	Specialized epithelia known as M cells overlying the lymphoid follicles of Peyer's patches are important in the mucosal immune system, but also provide a portal of entry for pathogens such as Salmonella typhimurium, Mycobacterium bovis, Shigella flexneri, Yersinia enterocolitica and reoviruses(1-4). Penetration of intestinal M cells and epithelial cells by Salmonella typhimurium requires the invasion genes of Salmonella Pathogenicity Island 1 (SPI1)(3,5-9) SPI1-deficient S, typhimurium strains gain access to the spleen following oral administration and cause lethal infection in mice(5) without invading M cells(3,9) or localizing in Payer's patches(10), which indicates that Salmonella uses an alternative strategy to disseminate from the gastrointestinal tract, Here we report that Salmonella is transported from the gastrointestinal tract to the bloodstream by CD18-expressing phagocytes, and that CD18-deficient mice are resistant to dissemination of Salmonella to the liver and spleen after oral administration. This CD18-dependent pathway of extraintestinal dissemination may be important for the development of systemic immunity to gastrointestinal pathogens, because oral challenge with SPI1-deficient S. typhimurium elicits a specific systemic Ige humoral immune response, despite an inability to stimulate production of specific mucosal IgA.	Univ Colorado, Hlth Sci Ctr, Dept Med, Denver, CO 80262 USA; Univ Colorado, Hlth Sci Ctr, Dept Pathol, Denver, CO 80262 USA; Univ Colorado, Hlth Sci Ctr, Dept Microbiol, Denver, CO 80262 USA; Natl Jewish Ctr Immunol & Resp Med, Dept Immunol, Denver, CO 80262 USA; Texas A&M Univ, Dept Med Microbiol & Immunol, College Stn, TX 77843 USA; Stanford Univ, Sch Med, Dept Microbiol & Immunol, Stanford, CA 94305 USA; Vet Affairs Med Ctr, Dept Med, Denver, CO 80262 USA; NCI, Cel Regulat & Carcinogenesis Lab, NIH, Bethesda, MD 20892 USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; National Jewish Health; Texas A&M University System; Texas A&M University College Station; Stanford University; US Department of Veterans Affairs; Veterans Health Administration (VHA); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Fang, FC (corresponding author), Univ Colorado, Hlth Sci Ctr, Dept Med, Denver, CO 80262 USA.	ferric.fang@uchsc.edu	Baumler, Andreas J/H-2301-2011; Valdivia, Raphael/R-5377-2019	Baumler, Andreas J/0000-0001-9152-7809; Valdivia, Raphael/0000-0003-0961-073X; Fang, Ferric/0000-0002-3243-110X; Parks, W. Tony/0000-0001-7341-3277	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI044486] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Autenrieth IB, 1996, INFECT IMMUN, V64, P1357, DOI 10.1128/IAI.64.4.1357-1368.1996; Baumler AJ, 1997, INFECT IMMUN, V65, P2254; Baumler AJ, 1996, P NATL ACAD SCI USA, V93, P279, DOI 10.1073/pnas.93.1.279; BERGGREN RE, 1995, J ACQ IMMUN DEF SYND, V10, P489; Bernstein CN, 1996, CLIN EXP IMMUNOL, V106, P160; Collazo CM, 1997, GENE, V192, P51, DOI 10.1016/S0378-1119(96)00825-6; CONLAN JW, 1994, INFECT IMMUN, V62, P2702, DOI 10.1128/IAI.62.7.2702-2706.1994; FIELDS PI, 1986, P NATL ACAD SCI USA, V83, P5189, DOI 10.1073/pnas.83.14.5189; FRANCIS CL, 1993, NATURE, V364, P639, DOI 10.1038/364639a0; GALAN JE, 1989, P NATL ACAD SCI USA, V86, P6383, DOI 10.1073/pnas.86.16.6383; GERICHTER C. B., 1960, JOUR HYG, V58, P307; JONES BD, 1994, J EXP MED, V180, P15, DOI 10.1084/jem.180.1.15; KINDER SA, 1993, GENE, V136, P271, DOI 10.1016/0378-1119(93)90478-L; KISHIMOTO TK, 1992, INFLAMMATION BASIC P, P353; LEE CA, 1992, P NATL ACAD SCI USA, V89, P1847, DOI 10.1073/pnas.89.5.1847; MILLER VL, 1988, J BACTERIOL, V170, P2575, DOI 10.1128/JB.170.6.2575-2583.1988; Neutra MR, 1996, CELL, V86, P345, DOI 10.1016/S0092-8674(00)80106-3; Neutra MR, 1998, AM J PHYSIOL-GASTR L, V274, pG785, DOI 10.1152/ajpgi.1998.274.5.G785; OSKOUI R, 1993, ARCH INTERN MED, V153, P517, DOI 10.1001/archinte.153.4.517; PEHHEITER KL, 1997, MOL MICROBIOL, V24, P697; RAHN K, 1992, MOL CELL PROBE, V6, P271, DOI 10.1016/0890-8508(92)90002-F; Shang XZ, 1998, EUR J IMMUNOL, V28, P1970, DOI 10.1002/(SICI)1521-4141(199806)28:06<1970::AID-IMMU1970>3.0.CO;2-H; STOJILJKOVIC I, 1995, J BACTERIOL, V177, P1357, DOI 10.1128/jb.177.5.1357-1366.1995; TSOLIS RM, 1995, J BACTERIOL, V177, P4628, DOI 10.1128/jb.177.16.4628-4637.1995; Valdivia RH, 1996, MOL MICROBIOL, V22, P367, DOI 10.1046/j.1365-2958.1996.00120.x; Valentine PJ, 1998, INFECT IMMUN, V66, P3378, DOI 10.1128/IAI.66.7.3378-3383.1998; WASSEF JS, 1989, INFECT IMMUN, V57, P858, DOI 10.1128/IAI.57.3.858-863.1989; WILSON RW, 1993, J IMMUNOL, V151, P1571; WOLF JL, 1981, SCIENCE, V212, P471, DOI 10.1126/science.6259737	29	508	515	0	30	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	OCT 21	1999	401	6755					804	808		10.1038/44593	http://dx.doi.org/10.1038/44593			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	250BG	10548107				2022-12-01	WOS:000083368700056
J	Lyden, D; Young, AZ; Zagzag, D; Yan, W; Gerald, W; O'Reilly, R; Bader, BL; Hynes, RO; Zhuang, Y; Manova, K; Benezra, R				Lyden, D; Young, AZ; Zagzag, D; Yan, W; Gerald, W; O'Reilly, R; Bader, BL; Hynes, RO; Zhuang, Y; Manova, K; Benezra, R			Id1 and Id3 are required for neurogenesis, angiogenesis and vascularization of tumour xenografts	NATURE			English	Article							LOOP-HELIX PROTEIN; MUSCLE DIFFERENTIATION; TRANSCRIPTION FACTORS; EXPRESSION PATTERNS; CELL DEVELOPMENT; E2A PROTEINS; MOUSE EMBRYO; NEURAL-TUBE; GENE FAMILY; T-CELL	Id proteins may control cell differentiation by interfering with DNA binding of transcription factors. Here we show that targeted disruption of the dominant negative helix-loop-helix proteins Id1 and ld3 in mice results in premature withdrawal of neuroblasts from the cell cycle and expression of neural-specific differentiation markers. The ld1-ld3 double knockout mice also display vascular malformations in the forebrain and an absence of branching and sprouting of blood vessels into the neuroectoderm. As angiogenesis both in the brain and in tumours requires invasion of avascular tissue by endothelial cells, we examined the Id knockout mice for their ability to support the growth of tumour xenografts, Three different tumours failed to grow and/or metastasize in ld1(+/-)ld3(-/-) mice, and any tumour growth present showed poor vascularization and extensive necrosis, Thus, the Id genes are required to maintain the timing of neuronal differentiation in the embryo and invasiveness of the vasculature, Because the Id genes are expressed at very low levels in adults, they make attractive new targets for anti-angiogenic drug design.	Mem Sloan Kettering Canc Ctr, Dept Cell Biol, New York, NY 10021 USA; Mem Sloan Kettering Canc Ctr, Mol Cytol Core Facil, New York, NY 10021 USA; Mem Sloan Kettering Canc Ctr, Dept Pathol, New York, NY 10021 USA; Mem Sloan Kettering Canc Ctr, Dept Pediat, New York, NY 10021 USA; NYU, Kaplan Canc Ctr, Dept Pathol, Div Neuropathol, New York, NY 10016 USA; MIT, Howard Hughes Med Inst Canc Res, Cambridge, MA 02139 USA; MIT, Dept Biol, Cambridge, MA 02139 USA; Max Planck Inst Biochem, Dept Prot Chem, D-82152 Martinsried, Germany; Duke Univ, Med Ctr, Dept Immunol, Durham, NC 27710 USA	Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; New York University; Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT); Max Planck Society; Duke University	Benezra, R (corresponding author), Mem Sloan Kettering Canc Ctr, Dept Cell Biol, 1275 York Ave, New York, NY 10021 USA.			zhuang, yuan/0000-0002-2964-3654				AKAZAWA C, 1995, J BIOL CHEM, V270, P8730, DOI 10.1074/jbc.270.15.8730; Bader BL, 1998, CELL, V95, P507, DOI 10.1016/S0092-8674(00)81618-9; BAIN G, 1994, CELL, V79, P885, DOI 10.1016/0092-8674(94)90077-9; Boehm T, 1997, NATURE, V390, P404, DOI 10.1038/37126; BROOKS PC, 1994, CELL, V79, P1157, DOI 10.1016/0092-8674(94)90007-8; Brooks PC, 1996, CELL, V85, P683, DOI 10.1016/S0092-8674(00)81235-0; Deed RW, 1998, J BIOL CHEM, V273, P8278, DOI 10.1074/jbc.273.14.8278; Desprez PY, 1998, MOL CELL BIOL, V18, P4577, DOI 10.1128/MCB.18.8.4577; DUNCAN M, 1992, DEV BIOL, V154, P1, DOI 10.1016/0012-1606(92)90042-F; ECHELARD Y, 1993, CELL, V75, P1417, DOI 10.1016/0092-8674(93)90627-3; ELLMEIER W, 1995, DEV DYNAM, V203, P163, DOI 10.1002/aja.1002030205; ERICKSON JW, 1991, SCIENCE, V251, P1071, DOI 10.1126/science.1900130; Heemskerk MHM, 1997, J EXP MED, V186, P1597, DOI 10.1084/jem.186.9.1597; HOGAN BLM, 1986, J EMBRYOL EXP MORPH, V97, P95; Ishibashi M, 1995, GENE DEV, V9, P3136, DOI 10.1101/gad.9.24.3136; Jen Y, 1996, DEV DYNAM, V207, P235; JEN Y, 1992, GENE DEV, V6, P1466, DOI 10.1101/gad.6.8.1466; Jen Y, 1997, DEV DYNAM, V208, P92, DOI 10.1002/(SICI)1097-0177(199701)208:1<92::AID-AJA9>3.0.CO;2-X; KATAGIRI T, 1994, J CELL BIOL, V127, P1755, DOI 10.1083/jcb.127.6.1755; KATAGIRI T, 1995, J CELL BIOL, V128, P713; LASSAR AB, 1994, CURR OPIN CELL BIOL, V6, P788, DOI 10.1016/0955-0674(94)90046-9; Lee JE, 1997, CURR OPIN NEUROBIOL, V7, P13, DOI 10.1016/S0959-4388(97)80115-8; LEE JE, 1995, SCIENCE, V268, P836, DOI 10.1126/science.7754368; Lindahl P, 1997, SCIENCE, V277, P242, DOI 10.1126/science.277.5323.242; Manova K, 1998, DEV DYNAM, V213, P293, DOI 10.1002/(SICI)1097-0177(199811)213:3<293::AID-AJA6>3.0.CO;2-D; Martinsen BJ, 1998, SCIENCE, V281, P988, DOI 10.1126/science.281.5379.988; McCormick MB, 1996, MOL CELL BIOL, V16, P5792; Melnikova IN, 1996, CELL GROWTH DIFFER, V7, P1067; NEUMAN T, 1993, DEV BIOL, V160, P186, DOI 10.1006/dbio.1993.1297; Norton JD, 1998, TRENDS CELL BIOL, V8, P58, DOI 10.1016/S0962-8924(97)01183-5; OGATA T, 1993, P NATL ACAD SCI USA, V90, P9219, DOI 10.1073/pnas.90.19.9219; OReilly MS, 1997, CELL, V88, P277, DOI 10.1016/S0092-8674(00)81848-6; Pan LH, 1999, MOL CELL BIOL, V19, P5969; PERLMAN JM, 1986, AM J DIS CHILD, V140, P1122, DOI 10.1001/archpedi.1986.02140250048034; PRICE M, 1991, NATURE, V351, P748, DOI 10.1038/351748a0; QUERTERMOUS EE, 1994, P NATL ACAD SCI USA, V91, P7066, DOI 10.1073/pnas.91.15.7066; Risau W, 1997, NATURE, V386, P671, DOI 10.1038/386671a0; RON D, 1992, GENE DEV, V6, P439, DOI 10.1101/gad.6.3.439; SHERWOOD A, 1978, NEUROPATH APPL NEURO, V4, P245, DOI 10.1111/j.1365-2990.1978.tb00543.x; Shimamura K, 1995, DEVELOPMENT, V121, P3923; SIMEONE A, 1993, EMBO J, V12, P2735, DOI 10.1002/j.1460-2075.1993.tb05935.x; SIMONSON MS, 1993, NUCLEIC ACIDS RES, V21, P5767, DOI 10.1093/nar/21.24.5767; TREACY MN, 1991, NATURE, V350, P577, DOI 10.1038/350577a0; VORONOVA AF, 1994, P NATL ACAD SCI USA, V91, P5952, DOI 10.1073/pnas.91.13.5952; WALTHER C, 1991, DEVELOPMENT, V113, P1435; Winnier GE, 1997, GENE DEV, V11, P926, DOI 10.1101/gad.11.7.926; XUAN SH, 1995, NEURON, V14, P1141, DOI 10.1016/0896-6273(95)90262-7; Yan W, 1997, MOL CELL BIOL, V17, P7317, DOI 10.1128/MCB.17.12.7317; Yokota Y, 1999, NATURE, V397, P702, DOI 10.1038/17812; Zetter BR, 1998, ANNU REV MED, V49, P407, DOI 10.1146/annurev.med.49.1.407; ZHUANG Y, 1994, CELL, V79, P875, DOI 10.1016/0092-8674(94)90076-0	51	738	775	1	36	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	OCT 14	1999	401	6754					670	677		10.1038/44334	http://dx.doi.org/10.1038/44334			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	247EJ	10537105				2022-12-01	WOS:000083207400048
J	Snijder, HJ; Ubarretxena-Belandia, I; Blaauw, M; Kalk, KH; Verheij, HM; Egmond, MR; Dekker, N; Dijkstra, BW				Snijder, HJ; Ubarretxena-Belandia, I; Blaauw, M; Kalk, KH; Verheij, HM; Egmond, MR; Dekker, N; Dijkstra, BW			Structural evidence for dimerization-regulated activation of an integral membrane phospholipase	NATURE			English	Article							ESCHERICHIA-COLI; ENZYMATIC-ACTIVITY; CRYSTAL-STRUCTURES; DIFFRACTION DATA; MOLSCRIPT	Dimerization is a biological regulatory mechanism employed by both soluble and membrane proteins'. However, there are few structural data on the factors that govern dimerization of membrane proteins. Outer membrane phospholipase A (OMPLA) is an integral membrane enzyme which participates in secretion of colicins in Escherichia coli. In Campilobacter(2) and Helicobacter pylori strains(3), OMPLA is implied in virulence. Its activity is regulated by reversible dimerization(4,5) Here we report X-ray structures of monomeric and dimeric OMPLA from E. coli. Dimer interactions occur almost exclusively in the apolar membrane-embedded parts, with two hydrogen bonds within the hydrophobic membrane area being key interactions. Dimerization results in functional oxyanion holes and substrate-binding pockets, which are absent in monomeric OMPLA. These results provide a detailed view of activation by dimerization of a membrane protein.	Univ Groningen, BIOSON Res Inst, Biophys Chem Lab, NL-9747 AG Groningen, Netherlands; Univ Utrecht, Ctr Biomembranes & Lipid Enzymol, Inst Biomembranes, Dept Enzymol & Prot Engn, NL-3584 CH Utrecht, Netherlands	University of Groningen; Utrecht University	Dijkstra, BW (corresponding author), Univ Groningen, BIOSON Res Inst, Biophys Chem Lab, Nijenborgh 4, NL-9747 AG Groningen, Netherlands.		Ubarretxena-Belandia, Iban/AAA-8939-2019; Dijkstra, Bauke W./H-4308-2019; Ubarretxena-Belandia, Iban/A-8389-2009	Dijkstra, Bauke W./0000-0001-9731-6586; 				BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BLAAUW M, 1995, FEBS LETT, V373, P10, DOI 10.1016/0014-5793(95)01002-V; Brok RGPM, 1996, BIOCHEMISTRY-US, V35, P7787, DOI 10.1021/bi952970i; Brok RGPM, 1995, EUR J BIOCHEM, V234, P934, DOI 10.1111/j.1432-1033.1995.934_a.x; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; Buchanan SK, 1999, NAT STRUCT BIOL, V6, P56; Bukholm G, 1997, SCAND J GASTROENTERO, V32, P445, DOI 10.3109/00365529709025079; Dekker N, 1999, J BACTERIOL, V181, P3281, DOI 10.1128/JB.181.10.3281-3283.1999; Dekker N, 1997, J BIOL CHEM, V272, P3179, DOI 10.1074/jbc.272.6.3179; Dodson G, 1998, TRENDS BIOCHEM SCI, V23, P347, DOI 10.1016/S0968-0004(98)01254-7; Esnouf RM, 1997, J MOL GRAPH MODEL, V15, P132, DOI 10.1016/S1093-3263(97)00021-1; Grant KA, 1997, INFECT IMMUN, V65, P1172, DOI 10.1128/IAI.65.4.1172-1180.1997; HORREVOETS AJG, 1989, BIOCHEMISTRY-US, V28, P1139, DOI 10.1021/bi00429a031; HORREVOETS AJG, 1991, EUR J BIOCHEM, V198, P247, DOI 10.1111/j.1432-1033.1991.tb16008.x; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KABSCH W, 1993, J APPL CRYSTALLOGR, V26, P795, DOI 10.1107/S0021889893005588; Klemm JD, 1998, ANNU REV IMMUNOL, V16, P569, DOI 10.1146/annurev.immunol.16.1.569; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Locher KP, 1998, CELL, V95, P771, DOI 10.1016/S0092-8674(00)81700-6; Merck KB, 1997, J BACTERIOL, V179, P3443, DOI 10.1128/jb.179.11.3443-3450.1997; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Pautsch A, 1998, NAT STRUCT BIOL, V5, P1013, DOI 10.1038/2983; SCHIRMER T, 1995, SCIENCE, V267, P512, DOI 10.1126/science.7824948; Ubarretxena-Belandia I, 1999, BIOCHEMISTRY-US, V38, P7398, DOI 10.1021/bi983077x; Ubarretxena-Belandia I, 1998, BIOCHEMISTRY-US, V37, P16011, DOI 10.1021/bi9814181; WEI YY, 1995, NAT STRUCT BIOL, V2, P218, DOI 10.1038/nsb0395-218; WEISS MS, 1991, SCIENCE, V254, P1627, DOI 10.1126/science.1721242	29	202	210	0	24	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	OCT 14	1999	401	6754					717	721		10.1038/44890	http://dx.doi.org/10.1038/44890			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	247EJ	10537112	Green Published			2022-12-01	WOS:000083207400061
J	Cate, JH; Yusupov, MM; Yusupova, GZ; Earnest, TN; Noller, HF				Cate, JH; Yusupov, MM; Yusupova, GZ; Earnest, TN; Noller, HF			X-ray crystal structures of 70S ribosome functional complexes	SCIENCE			English	Review							ESCHERICHIA-COLI RIBOSOME; TRANSFER-RNA BINDING; NUCLEAR MAGNETIC-RESONANCE; P-SITE; THERMUS-THERMOPHILUS; A-SITE; BACILLUS-STEAROTHERMOPHILUS; CRYOELECTRON MICROSCOPY; 3-DIMENSIONAL STRUCTURE; PROMOTES TRANSLOCATION	Structures of 70S ribosome complexes containing messenger RNA and transfer RNA (tRNA), or tRNA analogs, have been solved by x-ray crystallography at up to 7.8 angstrom resolution. Many details of the interactions between tRNA and the ribosome, and of the packing arrangements of ribosomal RNA (rRNA) helices in and between the ribosomal subunits, can be seen. Numerous contacts are made between the 30S subunit and the P-tRNA anticodon stem-loop; in contrast, the anticodon region of A-tRNA is much more exposed. A complex network of molecular interactions suggestive of a functional relay is centered around the Long penultimate stem of 16S rRNA at the subunit interface, including interactions involving the "switch" helix and decoding site of 16S rRNA, and RNA bridges from the 50S subunit.	Univ Calif Santa Cruz, Sinsheimer Labs, Ctr Mol Biol RNA, Santa Cruz, CA 95064 USA; Lawrence Berkeley Lab, Phys Biosci Div, Macromol Crystallog Facil, Berkeley, CA 94720 USA	University of California System; University of California Santa Cruz; United States Department of Energy (DOE); Lawrence Berkeley National Laboratory	Cate, JH (corresponding author), MIT, Whitehead Inst Biomed Res, Cambridge, MA 02142 USA.	cate@wi.mit.edu; marat@darwin.ucsc.edu; harry@nuvolari.ucsc.edu	Yusupova, Gulnara/E-1877-2014; Yusupov, Marat/I-6126-2013	Yusupov, Marat/0000-0001-5544-0597	NIGMS NIH HHS [GM-59140, GM-17129] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM017129, R01GM017129, R01GM059140] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abrahams JP, 1996, ACTA CRYSTALLOGR D, V52, P30, DOI 10.1107/S0907444995008754; Agrawal RK, 1996, SCIENCE, V271, P1000, DOI 10.1126/science.271.5251.1000; Agrawal RK, 1999, NAT STRUCT BIOL, V6, P643, DOI 10.1038/10695; Agrawal RK, 1999, CURR OPIN STRUC BIOL, V9, P215, DOI 10.1016/S0959-440X(99)80031-1; ALLEN PN, 1989, J MOL BIOL, V208, P457, DOI 10.1016/0022-2836(89)90509-3; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Ban N, 1998, CELL, V93, P1105, DOI 10.1016/S0092-8674(00)81455-5; Ban N, 1999, NATURE, V400, P841, DOI 10.1038/23641; Borowski C, 1996, P NATL ACAD SCI USA, V93, P4202, DOI 10.1073/pnas.93.9.4202; BOUSSERT AS, 1977, J MOL BIOL, V116, P577; BOWMAN CM, 1971, P NATL ACAD SCI USA, V68, P964, DOI 10.1073/pnas.68.5.964; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Carson M, 1997, METHOD ENZYMOL, V277, P493, DOI 10.1016/S0076-6879(97)77027-7; Cate JH, 1996, STRUCTURE, V4, P1221, DOI 10.1016/S0969-2126(96)00129-3; Cate JH, 1996, SCIENCE, V273, P1678, DOI 10.1126/science.273.5282.1678; CHAPMAN NM, 1977, J MOL BIOL, V109, P131, DOI 10.1016/S0022-2836(77)80049-1; Clemons WM, 1999, NATURE, V400, P833, DOI 10.1038/23631; Conn GL, 1999, SCIENCE, V284, P1171, DOI 10.1126/science.284.5417.1171; Correll CC, 1997, CELL, V91, P705, DOI 10.1016/S0092-8674(00)80457-2; Correll CC, 1998, P NATL ACAD SCI USA, V95, P13436, DOI 10.1073/pnas.95.23.13436; COWGILL CA, 1984, J BIOL CHEM, V259, P5257; Culver GM, 1999, SCIENCE, V285, P2133, DOI 10.1126/science.285.5436.2133; CULVER GM, UNPUB; Dallas A, 1997, STRUCTURE, V5, P1639, DOI 10.1016/S0969-2126(97)00311-0; Easterwood TR, 1995, BIOCHEM CELL BIOL, V73, P751, DOI 10.1139/o95-083; Fink DL, 1996, RNA, V2, P851; Fourmy D, 1998, J MOL BIOL, V277, P333, DOI 10.1006/jmbi.1997.1551; Fourmy D, 1996, SCIENCE, V274, P1367, DOI 10.1126/science.274.5291.1367; Frank J, 1995, BIOCHEM CELL BIOL, V73, P757, DOI 10.1139/o95-084; FRANK J, 1995, NATURE, V376, P441, DOI 10.1038/376441a0; Gabashvili IS, 1999, J MOL BIOL, V286, P1285, DOI 10.1006/jmbi.1999.2538; GATE L, UNPUB; GAUTHERET D, 1994, J MOL BIOL, V242, P1, DOI 10.1006/jmbi.1994.1552; GAVRILOVA L P, 1972, Molecular Biology (English Translation of Molekulyarnaya Biologiya (Moscow)), V6, P248; GERSTEIN M, 1992, ACTA CRYSTALLOGR A, V48, P271, DOI 10.1107/S0108767391012680; GOGIYA Z B, 1986, Molekulyarnaya Biologiya (Moscow), V20, P519; Green R, 1997, ANNU REV BIOCHEM, V66, P679, DOI 10.1146/annurev.biochem.66.1.679; GROSJEAN H, 1976, J MOL BIOL, V103, P499, DOI 10.1016/0022-2836(76)90214-X; Gudkov AT, 1997, FEBS LETT, V407, P253, DOI 10.1016/S0014-5793(97)00361-X; GUDKOV AT, 1982, FEBS LETT, V138, P229, DOI 10.1016/0014-5793(82)80448-1; GULVER GM, 1999, J MOL BIOL, V286, P355; HANSEN HAS, 1990, BIOCHIM BIOPHYS ACTA, V1050, P1, DOI 10.1016/0167-4781(90)90132-L; HARAUZ G, 1988, METHOD ENZYMOL, V164, P35; HARDESTY B, 1986, STRUCTURE FUNCTION G, P495; HERR W, 1979, J MOL BIOL, V130, P421, DOI 10.1016/0022-2836(79)90432-7; HEUS HA, 1991, SCIENCE, V253, P191, DOI 10.1126/science.1712983; Hill WE., 1990, RIBOSOME STRUCTURE F; HINGERTY B, 1978, J MOL BIOL, V124, P523, DOI 10.1016/0022-2836(78)90185-7; HOPFIELD JJ, 1974, P NATL ACAD SCI USA, V71, P4135, DOI 10.1073/pnas.71.10.4135; HUTTENHOFER A, 1992, P NATL ACAD SCI USA, V89, P7851, DOI 10.1073/pnas.89.17.7851; JONES TA, 1986, EMBO J, V5, P819, DOI 10.1002/j.1460-2075.1986.tb04287.x; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; JONES TA, 1992, MOL REPLACEMENT, P91; Joseph S, 1997, SCIENCE, V278, P1093, DOI 10.1126/science.278.5340.1093; KASTNER B, 1981, P NATL ACAD SCI-BIOL, V78, P6652, DOI 10.1073/pnas.78.11.6652; KIRILLOV SV, 1983, FEBS LETT, V157, P91, DOI 10.1016/0014-5793(83)81122-3; KUHLBRANDT W, 1982, J MOL BIOL, V156, P431, DOI 10.1016/0022-2836(82)90259-5; KURLAND CG, 1980, RIBOSOMES STRUCTURE, P597; LAKE JA, 1976, J MOL BIOL, V105, P131, DOI 10.1016/0022-2836(76)90200-X; Lata KR, 1996, J MOL BIOL, V262, P43, DOI 10.1006/jmbi.1996.0497; Leontis NB, 1998, J MOL BIOL, V283, P571, DOI 10.1006/jmbi.1998.2106; LILL R, 1989, EMBO J, V8, P3933, DOI 10.1002/j.1460-2075.1989.tb08574.x; Lodmell JS, 1997, SCIENCE, V277, P1262, DOI 10.1126/science.277.5330.1262; Malhotra A, 1998, J MOL BIOL, V280, P103, DOI 10.1006/jmbi.1998.1859; Mangroo D, 1995, BIOCHEM CELL BIOL, V73, P1023, DOI 10.1139/o95-109; Merryman C, 1999, J MOL BIOL, V285, P97, DOI 10.1006/jmbi.1998.2242; Merryman C, 1999, J MOL BIOL, V285, P107, DOI 10.1006/jmbi.1998.2243; MICHEL F, 1990, J MOL BIOL, V216, P585, DOI 10.1016/0022-2836(90)90386-Z; MITCHELL P, 1992, BIOCHEMISTRY-US, V31, P3004, DOI 10.1021/bi00126a023; MOAZED D, 1989, NATURE, V342, P142, DOI 10.1038/342142a0; MOAZED D, 1990, J MOL BIOL, V211, P135, DOI 10.1016/0022-2836(90)90016-F; MOAZED D, 1986, CELL, V47, P985, DOI 10.1016/0092-8674(86)90813-5; MOAZED D, 1987, NATURE, V327, P389, DOI 10.1038/327389a0; MONRO RE, 1967, J MOL BIOL, V26, P147, DOI 10.1016/0022-2836(67)90271-9; Moore PB, 1998, ANNU REV BIOPH BIOM, V27, P35, DOI 10.1146/annurev.biophys.27.1.35; Mueller F, 1997, J MOL BIOL, V271, P524, DOI 10.1006/jmbi.1997.1210; Newcomb LF, 1999, BIOCHEMISTRY-US, V38, P945, DOI 10.1021/bi981644a; Nikonov SV, 1998, BIOL CHEM, V379, P795, DOI 10.1515/bchm.1998.379.7.795; NIRENBERG MW, 1964, SCIENCE, V145, P1399, DOI 10.1126/science.145.3639.1399; NISSEN P, 1995, SCIENCE, V270, P1464, DOI 10.1126/science.270.5241.1464; NOLLER HF, 1990, RIBOSOME, P73; Noller HF, 1995, BIOCHEM CELL BIOL, V73, P997, DOI 10.1139/o95-107; NOLLER HF, 1986, STRUCTURE FUNCTION G, P143; ODOM OW, 1990, BIOCHEMISTRY-US, V29, P10734, DOI 10.1021/bi00500a004; OFENGAND J, 1979, BIOCHEMISTRY-US, V18, P4322, DOI 10.1021/bi00587a010; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Otwinowski Z., 1991, ISOMORPHOUS REPLACEM, P80; PESTKA S, 1969, J BIOL CHEM, V244, P1533; POWERS T, 1995, RNA, V1, P194; PRINCE JB, 1982, P NATL ACAD SCI-BIOL, V79, P5450, DOI 10.1073/pnas.79.18.5450; Puglisi EV, 1997, NAT STRUCT BIOL, V4, P775; PYLE AM, 1992, NATURE, V358, P123, DOI 10.1038/358123a0; RADERMACHER M, 1987, EMBO J, V6, P1107, DOI 10.1002/j.1460-2075.1987.tb04865.x; Ramakrishnan V, 1998, TRENDS BIOCHEM SCI, V23, P208, DOI 10.1016/S0968-0004(98)01214-6; RHEINBERGER HJ, 1981, P NATL ACAD SCI-BIOL, V78, P5310, DOI 10.1073/pnas.78.9.5310; ROSE SJ, 1983, J MOL BIOL, V167, P103, DOI 10.1016/S0022-2836(83)80036-9; ROULD MA, 1989, SCIENCE, V246, P1135, DOI 10.1126/science.2479982; RUFF M, 1991, SCIENCE, V252, P1682, DOI 10.1126/science.2047877; SAMAHA RR, 1995, NATURE, V377, P309, DOI 10.1038/377309a0; Sankaranarayanan R, 1999, CELL, V97, P371, DOI 10.1016/S0092-8674(00)80746-1; SANTER M, 1977, J BACTERIOL, V130, P900, DOI 10.1128/JB.130.2.900-910.1977; SCHNEIDER G, 1994, ACTA CRYSTALLOGR D, V50, P186, DOI 10.1107/S0907444993009679; SCHWEDLER G, 1993, EUR J BIOCHEM, V217, P361, DOI 10.1111/j.1432-1033.1993.tb18254.x; SPIRIN AS, 1974, FEBS LETT, V40, P38; Stark H, 1997, CELL, V88, P19, DOI 10.1016/S0092-8674(00)81854-1; Stark H, 1997, NATURE, V389, P403, DOI 10.1038/38770; STARK H, 1995, STRUCTURE, V3, P815, DOI 10.1016/S0969-2126(01)00216-7; Strobel SA, 1998, NAT STRUCT BIOL, V5, P60, DOI 10.1038/nsb0198-60; SZEWCZAK AA, 1995, J MOL BIOL, V247, P81, DOI 10.1006/jmbi.1994.0124; TRAKHANOV S, 1989, J MOL BIOL, V209, P327, DOI 10.1016/0022-2836(89)90282-9; TRAKHANOV SD, 1987, FEBS LETT, V220, P319, DOI 10.1016/0014-5793(87)80838-4; TRAUT RR, 1986, STRUCTURE FUNCTION G; VASILIEV VD, 1983, J MOL BIOL, V171, P561, DOI 10.1016/0022-2836(83)90043-8; VASSILENKO SK, 1981, J MOL BIOL, V152, P699, DOI 10.1016/0022-2836(81)90123-6; VONAHSEN U, 1995, SCIENCE, V267, P234, DOI 10.1126/science.7528943; WATSON JD, 1964, B SOC CHIM BIOL, V46, P1399; WIMBERLY B, 1993, BIOCHEMISTRY-US, V32, P1078, DOI 10.1021/bi00055a013; Wimberly BT, 1999, CELL, V97, P491, DOI 10.1016/S0092-8674(00)80759-X; WOESE CR, 1983, MICROBIOL REV, V47, P621, DOI 10.1128/MMBR.47.4.621-669.1983; WOWER J, 1990, BIOCHIM BIOPHYS ACTA, V1050, P38, DOI 10.1016/0167-4781(90)90138-R; YONATH AE, 1980, BIOCHEM INT, V1, P428; YUSUPOV M M, 1987, Doklady Akademii Nauk SSSR, V292, P1271; YUSUPOV MM, 1986, FEBS LETT, V197, P229, DOI 10.1016/0014-5793(86)80332-5; YUSUPOV MM, 1991, BIOCHIMIE, V73, P887, DOI 10.1016/0300-9084(91)90130-S; YUSUPOVA G, 1991, FEBS LETT, V290, P69, DOI 10.1016/0014-5793(91)81228-Z	125	500	525	1	36	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 24	1999	285	5436					2095	2104		10.1126/science.285.5436.2095	http://dx.doi.org/10.1126/science.285.5436.2095			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	238VF	10497122				2022-12-01	WOS:000082734300034
J	Plotnikov, AN; Schlessinger, J; Hubbard, SR; Mohammadi, M				Plotnikov, AN; Schlessinger, J; Hubbard, SR; Mohammadi, M			Structural basis for FGF receptor dimerization and activation	CELL			English	Article							FIBROBLAST-GROWTH-FACTOR; LIGAND-BINDING SPECIFICITY; 3-DIMENSIONAL STRUCTURE; SIGNAL-TRANSDUCTION; POINT MUTATION; CELL-ADHESION; FACTOR FAMILY; HEPARIN; AFFINITY; PROTEIN	The crystal structure of FGF2 bound to a naturally occurring variant of FGF receptor 1 (FGFR1) consisting of immunoglobulin-like domains 2 (D2) and 3 (D3) has been determined at 2.8 Angstrom resolution. Two FGF2:FGFR1 complexes form a 2-fold symmetric dimer. Within each complex, FGF2 interacts extensively with D2 and D3 as well as with the linker between the two domains. The dimer is stabilized by interactions between FGF2 and D2 of the adjoining complex and by a direct interaction between D2 of each receptor. A positively charged canyon formed by a cluster of exposed basic residues likely represents the heparin-binding site. A general model for FGF- and heparin-induced FGFR dimerization is inferred from the crystal structure, unifying a wealth of biochemical data.	NYU, Sch Med, Dept Pharmacol, New York, NY 10016 USA; NYU, Sch Med, Skirball Inst Biomol Med, New York, NY 10016 USA	New York University; New York University	Mohammadi, M (corresponding author), NYU, Sch Med, Dept Pharmacol, New York, NY 10016 USA.		kasaei, fahime/T-7197-2018; Mohammadi, Moosa/ABA-6745-2020	Mohammadi, Moosa/0000-0003-2434-9437; Hubbard, Stevan/0000-0002-2707-9383				AVIVI A, 1993, FEBS LETT, V330, P249, DOI 10.1016/0014-5793(93)80882-U; BATEMAN A, 1995, NAT STRUCT BIOL, V2, P1068, DOI 10.1038/nsb1295-1068; BELLOT F, 1991, EMBO J, V10, P2849, DOI 10.1002/j.1460-2075.1991.tb07834.x; BLASCHUK OW, 1990, DEV BIOL, V139, P227, DOI 10.1016/0012-1606(90)90290-Y; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; BURGESS WH, 1989, ANNU REV BIOCHEM, V58, P575, DOI 10.1146/annurev.bi.58.070189.003043; CHEON HG, 1994, P NATL ACAD SCI USA, V91, P989, DOI 10.1073/pnas.91.3.989; DELL KR, 1992, J BIOL CHEM, V267, P21225; Doherty P, 1996, MOL CELL NEUROSCI, V8, P99, DOI 10.1006/mcne.1996.0049; DOHERTY P, 1995, NEURON, V14, P57, DOI 10.1016/0896-6273(95)90240-6; ERIKSSON AE, 1991, P NATL ACAD SCI USA, V88, P3441, DOI 10.1073/pnas.88.8.3441; Faham S, 1996, SCIENCE, V271, P1116, DOI 10.1126/science.271.5252.1116; Galzie Z, 1997, BIOCHEM CELL BIOL, V75, P669, DOI 10.1139/bcb-75-6-669; GAO GX, 1995, EMBO J, V14, P2183, DOI 10.1002/j.1460-2075.1995.tb07212.x; HOLDEN HM, 1992, J MOL BIOL, V227, P840, DOI 10.1016/0022-2836(92)90226-A; JAYE M, 1992, BIOCHIM BIOPHYS ACTA, V1135, P185, DOI 10.1016/0167-4889(92)90136-Y; JOHNSON DE, 1993, ADV CANCER RES, V60, P1; JOHNSON DE, 1990, MOL CELL BIOL, V10, P4728, DOI 10.1128/MCB.10.9.4728; JOHNSON DE, 1991, MOL CELL BIOL, V11, P4327; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KAN MK, 1993, SCIENCE, V259, P1918, DOI 10.1126/science.8456318; KOBRIN MS, 1993, CANCER RES, V53, P4741; Kouhara H, 1997, CELL, V89, P693, DOI 10.1016/S0092-8674(00)80252-4; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LEMMON MA, 1994, TRENDS BIOCHEM SCI, V19, P459, DOI 10.1016/0968-0004(94)90130-9; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; MIKI T, 1992, P NATL ACAD SCI USA, V89, P246, DOI 10.1073/pnas.89.1.246; MIKI T, 1991, SCIENCE, V251, P72, DOI 10.1126/science.1846048; MOHAMMADI M, 1992, NATURE, V358, P681, DOI 10.1038/358681a0; Naski M C, 1998, Front Biosci, V3, pd781; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Noe V, 1999, J CELL SCI, V112, P127; Ornitz DM, 1996, J BIOL CHEM, V271, P15292, DOI 10.1074/jbc.271.25.15292; ORNITZ DM, 1992, MOL CELL BIOL, V12, P240, DOI 10.1128/MCB.12.1.240; OTWINOWSKI Z, 1993, P CCP4 STUD WEEK DAR; PANTOLIANO MW, 1994, BIOCHEMISTRY-US, V33, P10229, DOI 10.1021/bi00200a003; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; PETERS KG, 1992, NATURE, V358, P678, DOI 10.1038/358678a0; ROGHANI M, 1994, J BIOL CHEM, V269, P3976; SCHLESSINGER J, 1995, CELL, V83, P357, DOI 10.1016/0092-8674(95)90112-4; SHAPIRO L, 1995, NATURE, V374, P327, DOI 10.1038/374327a0; SPIVAKKROIZMAN T, 1994, CELL, V79, P1015, DOI 10.1016/0092-8674(94)90032-9; SPRINGER BA, 1994, J BIOL CHEM, V269, P26879; WANG F, 1995, J BIOL CHEM, V270, P10231, DOI 10.1074/jbc.270.17.10231; Wang F, 1997, J BIOL CHEM, V272, P23887, DOI 10.1074/jbc.272.38.23887; Wang F, 1999, BIOCHEMISTRY-US, V38, P160, DOI 10.1021/bi981758m; WILLIAMS AF, 1988, ANNU REV IMMUNOL, V6, P381, DOI 10.1146/annurev.iy.06.040188.002121; YAMAGUCHI F, 1994, P NATL ACAD SCI USA, V91, P484, DOI 10.1073/pnas.91.2.484; YAYON A, 1993, P NATL ACAD SCI USA, V90, P10643, DOI 10.1073/pnas.90.22.10643; YAYON A, 1992, EMBO J, V11, P1885, DOI 10.1002/j.1460-2075.1992.tb05240.x; ZHANG JD, 1991, P NATL ACAD SCI USA, V88, P3446, DOI 10.1073/pnas.88.8.3446; Zhu HY, 1997, PROTEIN ENG, V10, P417, DOI 10.1093/protein/10.4.417; ZHU HY, 1995, J BIOL CHEM, V270, P21869, DOI 10.1074/jbc.270.37.21869; Zhu HY, 1998, PROTEIN ENG, V11, P937, DOI 10.1093/protein/11.10.937; ZHU X, 1991, SCIENCE, V251, P90, DOI 10.1126/science.1702556	57	481	527	2	51	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	SEP 3	1999	98	5					641	650		10.1016/S0092-8674(00)80051-3	http://dx.doi.org/10.1016/S0092-8674(00)80051-3			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	233NT	10490103	Bronze			2022-12-01	WOS:000082433500011
J	Frischknecht, F; Moreau, V; Rottger, S; Gonfloni, S; Reckmann, I; Superti-Furga, G; Way, M				Frischknecht, F; Moreau, V; Rottger, S; Gonfloni, S; Reckmann, I; Superti-Furga, G; Way, M			Actin-based motility of vaccinia virus mimics receptor tyrosine kinase signalling	NATURE			English	Article							LISTERIA-MONOCYTOGENES; ARP2/3 COMPLEX; PROTEIN; SRC; NUCLEATION; CORTACTIN; PATHOGENS; DOMAINS; NCK	Studies of the actin-based motility of the intracellular pathogens Listeria monocytogenes and Shigella flexneri have provided important insight into the events occurring at the leading edges of motile cells(1-5). Like the bacteria Listeria and Shigella, vaccinia virus, a relative of the causative agent of smallpox, uses actin-based motility to spread between cells(6). In contrast to Listeria or Shigella, the actin-based motility of vaccinia is dependent on an unknown phosphotyrosine protein, but the underlying mechanism remains obscure(7). Here we show that phosphorylation of tyrosine 112 in the viral protein A36R by Src-family kinases is essential for the actin-based motility of vaccinia. Tyrosine phosphorylation of A36R results in a direct interaction with the adaptor protein Nck(8) and the recruitment of the Ena/VASP family member N-WASP(9) to the site of actin assembly. We also show that Nck and N-WASP are essential for the actin-based motility of vaccinia virus. We suggest that vaccinia virus spreads by mimicking the signalling pathways that are normally involved in actin polymerization at the plasma membrane.	European Mol Biol Lab, Cell Programme, D-69117 Heidelberg, Germany; European Mol Biol Lab, Dev Biol Programme, D-69117 Heidelberg, Germany	European Molecular Biology Laboratory (EMBL); European Molecular Biology Laboratory (EMBL)	Way, M (corresponding author), European Mol Biol Lab, Cell Programme, Meyerhofstr 1, D-69117 Heidelberg, Germany.		Superti-Furga, Giulio/F-4755-2015; Superti-Furga, Giulio/AAE-5681-2019	Superti-Furga, Giulio/0000-0002-0570-1768; GONFLONI, STEFANIA/0000-0002-9392-4258; Moreau, Violaine/0000-0002-4513-7022; Way, Michael/0000-0001-7207-2722; Frischknecht, Friedrich/0000-0002-8332-6668				Chakrabarti S, 1997, BIOTECHNIQUES, V23, P1094, DOI 10.2144/97236st07; CUDMORE S, 1995, NATURE, V378, P636, DOI 10.1038/378636a0; DEHIO C, 1995, EMBO J, V14, P2471, DOI 10.1002/j.1460-2075.1995.tb07244.x; Dramsi S, 1998, ANNU REV CELL DEV BI, V14, P137, DOI 10.1146/annurev.cellbio.14.1.137; Finlay BB, 1997, SCIENCE, V276, P718, DOI 10.1126/science.276.5313.718; Frischknecht F, 1999, CURR BIOL, V9, P89, DOI 10.1016/S0960-9822(99)80020-7; Gonfloni S, 1997, EMBO J, V16, P7261, DOI 10.1093/emboj/16.24.7261; Hanke JH, 1996, J BIOL CHEM, V271, P695, DOI 10.1074/jbc.271.2.695; HEMSLEY A, 1989, NUCLEIC ACIDS RES, V17, P6545, DOI 10.1093/nar/17.16.6545; Machesky LM, 1999, P NATL ACAD SCI USA, V96, P3739, DOI 10.1073/pnas.96.7.3739; Machesky LM, 1998, CURR BIOL, V8, P1347, DOI 10.1016/S0960-9822(98)00015-3; McCarty JH, 1998, BIOESSAYS, V20, P913, DOI 10.1002/(SICI)1521-1878(199811)20:11<913::AID-BIES6>3.0.CO;2-T; Miki H, 1996, EMBO J, V15, P5326, DOI 10.1002/j.1460-2075.1996.tb00917.x; Mullins RD, 1998, P NATL ACAD SCI USA, V95, P6181, DOI 10.1073/pnas.95.11.6181; RIVEROLEZCANO OM, 1995, MOL CELL BIOL, V15, P5725; Rohatgi R, 1999, CELL, V97, P221, DOI 10.1016/S0092-8674(00)80732-1; Rottger S, 1999, J VIROL, V73, P2863; Sanderson CM, 1998, J VIROL, V72, P1235, DOI 10.1128/JVI.72.2.1235-1243.1998; Sanderson CM, 1998, J GEN VIROL, V79, P1415, DOI 10.1099/0022-1317-79-6-1415; Sanderson CM, 1998, J VIROL, V72, P9924, DOI 10.1128/JVI.72.12.9924-9933.1998; Snapper SB, 1999, ANNU REV IMMUNOL, V17, P905, DOI 10.1146/annurev.immunol.17.1.905; SONG MY, 1995, SUPERCOND SCI TECH, V8, P20, DOI 10.1088/0953-2048/8/1/004; WAY M, 1992, J CELL BIOL, V119, P835, DOI 10.1083/jcb.119.4.835; Welch MD, 1997, NATURE, V385, P265, DOI 10.1038/385265a0; Welch MD, 1998, SCIENCE, V281, P105, DOI 10.1126/science.281.5373.105; Wolffe EJ, 1998, VIROLOGY, V244, P20, DOI 10.1006/viro.1998.9103; WU H, 1993, J CELL BIOL, V120, P1417, DOI 10.1083/jcb.120.6.1417	27	333	342	2	19	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	OCT 28	1999	401	6756					926	929		10.1038/44860	http://dx.doi.org/10.1038/44860			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	251UL	10553910				2022-12-01	WOS:000083464700062
J	Stroschein, SL; Wang, W; Zhou, SL; Zhou, Q; Luo, KX				Stroschein, SL; Wang, W; Zhou, SL; Zhou, Q; Luo, KX			Negative feedback regulation of TGF-beta signaling by the SnoN oncoprotein	SCIENCE			English	Article							GROWTH-FACTOR-BETA; TUMOR-SUPPRESSOR SMAD4; DNA-BINDING PROTEIN; MAD-RELATED PROTEIN; TRANSCRIPTIONAL REPRESSION; HISTONE DEACETYLASE; CDNA CLONES; N-COR; PROMOTER; SKI	Smad proteins mediate transforming growth factor-beta (TGF-beta) signaling to regulate cell growth and differentiation. The SnoN oncoprotein was found to interact with Smad2 and Smad4 and to repress their abilities to activate transcription through recruitment of the transcriptional corepressor N-CoR, Immediately after TGF-beta stimulation, SnoN is rapidly degraded by the nuclear accumulation of Smad3, allowing the activation of TGF-beta target genes. By 2 hours, TGF-beta induces a marked increase in SnoN expression, resulting in termination of Smad-mediated transactivation. Thus, SnoN maintains the repressed state of TGF-beta-responsive genes in the absence of ligand and participates in negative feedback regulation of TGF-beta signaling.	Univ Calif Berkeley, Lawrence Berkeley Lab, Div Life Sci, Berkeley, CA 94720 USA; Univ Calif Berkeley, Dept Mol & Cell Biol, Berkeley, CA 94720 USA	United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; University of California System; University of California Berkeley; University of California System; University of California Berkeley	Luo, KX (corresponding author), Univ Calif Berkeley, Lawrence Berkeley Lab, Div Life Sci, 229 Stanley Hall,Mail Code 3206, Berkeley, CA 94720 USA.							Abdollah S, 1997, J BIOL CHEM, V272, P27678, DOI 10.1074/jbc.272.44.27678; Alland L, 1997, NATURE, V387, P49, DOI 10.1038/387049a0; Baker JC, 1996, GENE DEV, V10, P1880, DOI 10.1101/gad.10.15.1880; BOYER PL, 1993, ONCOGENE, V8, P457; Chen X, 1997, NATURE, V389, P85, DOI 10.1038/38008; Chen X, 1996, NATURE, V383, P691, DOI 10.1038/383691a0; Cohen SB, 1998, ONCOGENE, V17, P2505, DOI 10.1038/sj.onc.1202177; Dahl R, 1998, P NATL ACAD SCI USA, V95, P11187, DOI 10.1073/pnas.95.19.11187; deCaestecker MP, 1997, J BIOL CHEM, V272, P13690, DOI 10.1074/jbc.272.21.13690; Dennler S, 1998, EMBO J, V17, P3091, DOI 10.1093/emboj/17.11.3091; Dennler S, 1999, ONCOGENE, V18, P1643, DOI 10.1038/sj.onc.1202729; Feng XH, 1998, GENE DEV, V12, P2153, DOI 10.1101/gad.12.14.2153; Heinzel T, 1997, NATURE, V387, P43, DOI 10.1038/387043a0; Heldin CH, 1997, NATURE, V390, P465, DOI 10.1038/37284; Hoodless PA, 1996, CELL, V85, P489, DOI 10.1016/S0092-8674(00)81250-7; Janknecht R, 1998, GENE DEV, V12, P2114, DOI 10.1101/gad.12.14.2114; Jonk LJC, 1998, J BIOL CHEM, V273, P21145, DOI 10.1074/jbc.273.33.21145; Labbe E, 1998, MOL CELL, V2, P109, DOI 10.1016/S1097-2765(00)80119-7; Lagna G, 1996, NATURE, V383, P832, DOI 10.1038/383832a0; LEE KAW, 1988, GENE ANAL TECH, V5, P22, DOI 10.1016/0735-0651(88)90023-4; LI Y, 1986, J VIROL, V57, P1065, DOI 10.1128/JVI.57.3.1065-1072.1986; Liu F, 1996, NATURE, V381, P620, DOI 10.1038/381620a0; Liu XD, 1997, P NATL ACAD SCI USA, V94, P10669, DOI 10.1073/pnas.94.20.10669; Luo KX, 1999, GENE DEV, V13, P2196, DOI 10.1101/gad.13.17.2196; MaciasSilva M, 1996, CELL, V87, P1215, DOI 10.1016/S0092-8674(00)81817-6; Massague J, 1998, ANNU REV BIOCHEM, V67, P753, DOI 10.1146/annurev.biochem.67.1.753; Moustakas A, 1998, P NATL ACAD SCI USA, V95, P6733, DOI 10.1073/pnas.95.12.6733; Nakao A, 1997, J BIOL CHEM, V272, P2896, DOI 10.1074/jbc.272.5.2896; NOMURA N, 1989, NUCLEIC ACIDS RES, V17, P5489, DOI 10.1093/nar/17.14.5489; Nomura T, 1999, GENE DEV, V13, P412, DOI 10.1101/gad.13.4.412; PEARSONWHITE S, 1993, NUCLEIC ACIDS RES, V21, P4632, DOI 10.1093/nar/21.19.4632; PearsonWhite S, 1997, NUCLEIC ACIDS RES, V25, P2930, DOI 10.1093/nar/25.14.2930; Pouponnot C, 1998, J BIOL CHEM, V273, P22865, DOI 10.1074/jbc.273.36.22865; Shen X, 1998, MOL BIOL CELL, V9, P3309, DOI 10.1091/mbc.9.12.3309; Shi YG, 1998, CELL, V94, P585, DOI 10.1016/S0092-8674(00)81600-1; Shi YG, 1997, NATURE, V388, P87, DOI 10.1038/40431; Song CZ, 1998, J BIOL CHEM, V273, P29287, DOI 10.1074/jbc.273.45.29287; STAVNEZER E, 1986, J VIROL, V57, P1073, DOI 10.1128/JVI.57.3.1073-1083.1986; Stroschein SL, 1999, J BIOL CHEM, V274, P9431, DOI 10.1074/jbc.274.14.9431; Topper JN, 1998, P NATL ACAD SCI USA, V95, P9506, DOI 10.1073/pnas.95.16.9506; Vindevoghel L, 1998, J BIOL CHEM, V273, P13053, DOI 10.1074/jbc.273.21.13053; Wong C, 1999, MOL CELL BIOL, V19, P1821; Wu RY, 1997, MOL CELL BIOL, V17, P2521, DOI 10.1128/MCB.17.5.2521; Yingling JM, 1997, MOL CELL BIOL, V17, P7019, DOI 10.1128/MCB.17.12.7019; Zawel L, 1998, MOL CELL, V1, P611, DOI 10.1016/S1097-2765(00)80061-1; Zhang Y, 1997, CURR BIOL, V7, P270, DOI 10.1016/S0960-9822(06)00123-0; Zhang Y, 1998, NATURE, V394, P909, DOI 10.1038/29814; Zhang Y, 1996, NATURE, V383, P168, DOI 10.1038/383168a0; Zhou Q, 1998, EMBO J, V17, P3681, DOI 10.1093/emboj/17.13.3681	49	423	454	0	10	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	OCT 22	1999	286	5440					771	774		10.1126/science.286.5440.771	http://dx.doi.org/10.1126/science.286.5440.771			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	248XZ	10531062	Green Submitted			2022-12-01	WOS:000083303200054
J	Strausberg, RL; Feingold, EA; Klausner, RD; Collins, FS				Strausberg, RL; Feingold, EA; Klausner, RD; Collins, FS			The mammalian gene collection	SCIENCE			English	Editorial Material							HUMAN-GENOME-PROJECT; EXPRESSION; SEQUENCE; CDNA	The Mammalian Cone Collection (MGC) project is a new effort by the NIH to generate full-length complementary DNA (cDNA) resources. This project will provide publicly accessible resources to the full research community. The MGC project entails the production of libraries, sequencing, and database and repository development, as well as the support of Library construction, sequencing, and analytic technologies dedicated to the goal of obtaining a full set of human and other mammalian full-length (open reading frame) sequences and clones of expressed genes.	NCI, NIH, Bethesda, MD 20892 USA; Natl Human Genome Res Inst, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Human Genome Research Institute (NHGRI)	Collins, FS (corresponding author), NCI, NIH, Bethesda, MD 20892 USA.							ADAMS MD, 1995, NATURE, V377, P3; ADAMS MD, 1991, SCIENCE, V252, P1651, DOI 10.1126/science.2047873; [Anonymous], COMMUNICATION; Bonaldo MDF, 1996, GENOME RES, V6, P791, DOI 10.1101/gr.6.9.791; Carninci P, 1997, DNA Res, V4, P61, DOI 10.1093/dnares/4.1.61; Collins FS, 1998, SCIENCE, V282, P682, DOI 10.1126/science.282.5389.682; *COMM MAPP SEQ HUM, 1988, REP COMM MAPP SEQ HU; Deloukas P, 1998, SCIENCE, V282, P744, DOI 10.1126/science.282.5389.744; EDERY I, 1995, MOL CELL BIOL, V15, P3363; Lennon G, 1996, GENOMICS, V33, P151, DOI 10.1006/geno.1996.0177; Marra M, 1999, NAT GENET, V21, P191, DOI 10.1038/5976; Rubin GM, 1998, TRENDS GENET, V14, P340, DOI 10.1016/S0168-9525(98)01568-6; Seki M, 1998, PLANT J, V15, P707, DOI 10.1046/j.1365-313x.1998.00237.x; SOARES MA, UNPUB; Strausberg RL, 1997, NAT GENET, V15, P415, DOI 10.1038/ng0497supp-415; Williamson AR, 1999, DRUG DISCOV TODAY, V4, P115, DOI 10.1016/S1359-6446(99)01303-3	16	210	229	2	8	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	OCT 15	1999	286	5439					455	457		10.1126/science.286.5439.455	http://dx.doi.org/10.1126/science.286.5439.455			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	245RD	10521335				2022-12-01	WOS:000083121200046
J	Tomita, H; Ohbayashi, M; Nakahara, K; Hasegawa, I; Miyashita, Y				Tomita, H; Ohbayashi, M; Nakahara, K; Hasegawa, I; Miyashita, Y			Top-down signal from prefrontal cortex in executive control of memory retrieval	NATURE			English	Article							INFERIOR TEMPORAL NEURONS; LONG-TERM-MEMORY; FRONTAL DISCONNECTION; COGNITIVE INTERACTION; WORKING-MEMORY; MONKEYS; TASK; ORGANIZATION; ACTIVATION	Knowledge or experience is voluntarily recalled from memory by reactivation of the neural representations in the cerebral association cortex(1-4). In inferior temporal cortex, which serves as the storehouse of visual long-term memory(5-8), activation of mnemonic engrams through electric stimulation results in imagery recall in humans(9), and neurons can be dynamically activated by the necessity for memory recall in monkeys(10,11). Neuropsychological studies(12) and previous split-brain experiments(13) predicted that prefrontal cortex exerts executive control upon inferior temporal cortex in memory retrieval; however, no neuronal correlate of this process has ever been detected. Here we show evidence of the top-down signal from prefrontal cortex. In the absence of bottom-up visual inputs, single inferior temporal neurons were activated by the top-down signal, which conveyed information on semantic categorization imposed by visual stimulus-stimulus association. Behavioural performance was severely impaired with loss of the top-down signal. Control experiments confirmed that the signal was transmitted not through a subcortical but through a frontotemporal cortical pathway. Thus, feedback projections from prefrontal cortex to the posterior association cortex(2,3,14) appear to serve the executive control of voluntary recall.	Univ Tokyo, Sch Med, Dept Physiol, Bunkyo Ku, Tokyo 1130033, Japan; Japan Sci & Technol Corp, ICORP, Mind Articulat Project, Bunkyo Ku, Tokyo 1130034, Japan; Natl Inst Physiol Sci, Okazaki, Aichi 4448585, Japan	University of Tokyo; Japan Science & Technology Agency (JST); National Institutes of Natural Sciences (NINS) - Japan; National Institute for Physiological Sciences (NIPS)	Tomita, H (corresponding author), Univ Tokyo, Sch Med, Dept Physiol, Bunkyo Ku, 7-3-1 Hongo, Tokyo 1130033, Japan.	hyoe@m.u-tokyo.ac.jp; yasushi_miyashita@m.u-tokyo.ac.jp	Miyashita, Yasushi/B-7171-2019; Ohbayashi, Machiko/A-6910-2018; Hasegawa, Isao/AAW-5682-2021	Miyashita, Yasushi/0000-0003-3496-8637; Ohbayashi, Machiko/0000-0003-2563-9049; Hasegawa, Isao/0000-0002-8633-2502; Nakahara, Kiyoshi/0000-0001-6701-6216				Buckner RL, 1996, J NEUROSCI, V16, P6219; Chafee MV, 1998, J NEUROPHYSIOL, V79, P2919, DOI 10.1152/jn.1998.79.6.2919; DESIMONE R, 1995, ANNU REV NEUROSCI, V18, P193, DOI 10.1146/annurev.ne.18.030195.001205; DOTY RW, 1988, BEHAV BRAIN RES, V29, P267, DOI 10.1016/0166-4328(88)90031-9; EACOTT MJ, 1992, EUR J NEUROSCI, V4, P1320, DOI 10.1111/j.1460-9568.1992.tb00157.x; EACOTT MJ, 1989, EXP BRAIN RES, V74, P348; Felleman DJ, 1991, CEREB CORTEX, V1, P1, DOI 10.1093/cercor/1.1.1; Fletcher PC, 1998, BRAIN, V121, P1249, DOI 10.1093/brain/121.7.1249; Fuster J., 2015, PREFRONTAL CORTEX; FUSTER JM, 1985, BRAIN RES, V330, P299, DOI 10.1016/0006-8993(85)90689-4; GAZZANIGA MS, 1995, NEURON, V14, P217, DOI 10.1016/0896-6273(95)90280-5; Goldman-Rakic P. S., 1987, HDB PHYSL, V5, P373, DOI DOI 10.1002/CPHY.CP010509; GoldmanRakic PS, 1996, P NATL ACAD SCI USA, V93, P13473, DOI 10.1073/pnas.93.24.13473; GROSS CG, 1977, BRAIN RES, V131, P227, DOI 10.1016/0006-8993(77)90517-0; Gutnikov SA, 1997, EUR J NEUROSCI, V9, P1524, DOI 10.1111/j.1460-9568.1997.tb01507.x; Hasegawa I, 1998, SCIENCE, V281, P814, DOI 10.1126/science.281.5378.814; MACPHERSON JM, 1979, BRAIN RES, V175, P183, DOI 10.1016/0006-8993(79)90530-4; MISHKIN M, 1982, PHILOS T R SOC B, V298, P85, DOI 10.1098/rstb.1982.0074; MIYASHITA Y, 1993, ANNU REV NEUROSCI, V16, P245, DOI 10.1146/annurev.ne.16.030193.001333; MIYASHITA Y, IN PRESS COGNITIVE N; Naya Y, 1996, P NATL ACAD SCI USA, V93, P2664, DOI 10.1073/pnas.93.7.2664; PENFIELD W, 1963, BRAIN, V86, P595, DOI 10.1093/brain/86.4.595; Petrides M, 1994, HDB NEUROPSYCHOLOGY, V9, P59; Rainer G, 1999, J NEUROSCI, V19, P5493; RINGO JL, 1993, J NEUROPHYSIOL, V70, P2215, DOI 10.1152/jn.1993.70.6.2215; Rolls E T, 1991, Curr Opin Neurobiol, V1, P274, DOI 10.1016/0959-4388(91)90090-T; SAKAI K, 1991, NATURE, V354, P152, DOI 10.1038/354152a0; SARY G, 1993, SCIENCE, V260, P995, DOI 10.1126/science.8493538; SIDTIS JJ, 1981, SCIENCE, V212, P344, DOI 10.1126/science.6782673	29	448	458	0	42	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	OCT 14	1999	401	6754					699	703		10.1038/44372	http://dx.doi.org/10.1038/44372			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	247EJ	10537108				2022-12-01	WOS:000083207400057
J	Brodine, SK; Shaffer, RA; Starkey, MJ; Tasker, SA; Gilcrest, JL; Louder, MK; Barile, A; VanCott, TC; Vahey, MT; McCutchan, FE; Birx, DL; Richman, DD; Mascola, JR				Brodine, SK; Shaffer, RA; Starkey, MJ; Tasker, SA; Gilcrest, JL; Louder, MK; Barile, A; VanCott, TC; Vahey, MT; McCutchan, FE; Birx, DL; Richman, DD; Mascola, JR			Drug resistance patterns, genetic subtypes, clinical features, and risk factors in military personnel with HIV-1 seroconversion	ANNALS OF INTERNAL MEDICINE			English	Article						epidemiology, molecular; drug resistance, microbial; human immunodeficiency virus; human immunodeficiency virus infections; anti-HIV agents	TYPE-1 SUBTYPE; UNITED-STATES; VIRUS; SENSITIVITY; PREVALENCE; INFECTION; DIVERSITY; COMMUNITY; THERAPY; PLASMA	Background: Regular testing of military personnel identifies early HIV infection; this identification provides a sentinel cohort in which to describe the evolving molecular epidemiology of HIV-1 transmission. Objective: To describe the prevalence and epidemiologic correlates associated with the acquisition of non-subtype B and drug-resistant HIV infections. Design: Cross-sectional study. Setting: Military referral hospital. Patients: 95 military personnel with HIV-1 seroconversion. Measurements: Self-reported questionnaire, CD4 cell counts, plasma HIV-1 RNA levels, and nucleic acid sequence analysis for drug-resistant mutations and HIV-1 genetic subtype. Results: 95 patients were enrolled between February 1997 and February 1998. The likely geographic location of HIV-1 acquisition was overseas in 8% of patients, the United States in 68%, and either overseas or the United States in 24%. Seven patients (7.4%) had subtype E infection; the remainder had subtype B infection. Eight of 31 (26%) treatment-naive patients had mutations in the reverse transcriptase or protease gene associated with drug resistance. Conclusions: The percentage of HIV-1 non-subtype B infection and antiretroviral drug-resistant mutations was relatively high in U.S. military personnel with recently acquired HIV-1 infection.	San Diego State Univ, Coll Hlth & Human Serv, Grad Sch Publ Hlth, San Diego, CA 92182 USA; Naval Hlth Res Ctr, Div Clin Epidemiol, San Diego, CA 92186 USA; Naval Hlth Res Ctr, San Diego, CA 92152 USA; Naval Med Ctr, San Diego, CA 92134 USA; Henry M Jackson Fdn Advancement Mil Med, Rockville, MD USA; Walter Reed Army Inst Res, Div Retrovirol, Rockville, MD 20850 USA; Univ Calif San Diego, La Jolla, CA 92093 USA	California State University System; San Diego State University; United States Department of Defense; United States Navy; Naval Medical Research Center (NMRC); Naval Health Research Center (NHRC); United States Department of Defense; United States Navy; Naval Medical Research Center (NMRC); Naval Health Research Center (NHRC); United States Department of Defense; United States Navy; Naval Medical Center San Diego; Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc; United States Department of Defense; United States Army; Walter Reed Army Institute of Research (WRAIR); University of California System; University of California San Diego	Brodine, SK (corresponding author), San Diego State Univ, Coll Hlth & Human Serv, Grad Sch Publ Hlth, 5500 Campanile Dr, San Diego, CA 92182 USA.		Mascola, John/AAI-7193-2021		NIAID NIH HHS [AI 38858, AI 27670, AI 36214] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P30AI036214, U01AI038858, U01AI027670] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AUERBACH JD, 1998, CURRENT OPINION INFE, P3; Brodine SK, 1997, INFECT MED, V14, P739; BRODINE SK, 1995, LANCET, V346, P1198, DOI 10.1016/S0140-6736(95)92901-0; Debyser Z, 1998, AIDS RES HUM RETROV, V14, P453, DOI 10.1089/aid.1998.14.453; Gaywee J, 1996, J ACQ IMMUN DEF SYND, V13, P392, DOI 10.1097/00042560-199612010-00014; Gomez-Cano M, 1998, AIDS, V12, P1015, DOI 10.1097/00002030-199809000-00007; Havlir DV, 1998, NEW ENGL J MED, V339, P1261, DOI 10.1056/NEJM199810293391801; Hawkes S, 1998, INFECT DIS CLIN N AM, V12, P413, DOI 10.1016/S0891-5520(05)70011-8; Hecht FM, 1998, NEW ENGL J MED, V339, P307, DOI 10.1056/NEJM199807303390504; Hirsch MS, 1998, JAMA-J AM MED ASSOC, V279, P1984, DOI 10.1001/jama.279.24.1984; Hu DJ, 1996, JAMA-J AM MED ASSOC, V275, P210, DOI 10.1001/jama.275.3.210; Irwin KL, 1997, J INFECT DIS, V176, P1629, DOI 10.1086/517343; LEVIN LI, 1995, AM J PUBLIC HEALTH, V85, P1500, DOI 10.2105/AJPH.85.11.1500; Mayers DL, 1998, JAMA-J AM MED ASSOC, V279, P2000, DOI 10.1001/jama.279.24.2000; Nolte FS, 1998, J CLIN MICROBIOL, V36, P716, DOI 10.1128/JCM.36.3.716-720.1998; Palmer S, 1998, AIDS RES HUM RETROV, V14, P157, DOI 10.1089/aid.1998.14.157; Pinkerton SD, 1998, AM J PUBLIC HEALTH, V88, P1239, DOI 10.2105/AJPH.88.8.1239; Rayfield MA, 1996, EMERG INFECT DIS, V2, P209, DOI 10.3201/eid0203.960307; SCHABLE C, 1994, LANCET, V344, P1333, DOI 10.1016/S0140-6736(94)90695-5; Wainberg MA, 1998, JAMA-J AM MED ASSOC, V279, P1977, DOI 10.1001/jama.279.24.1977	20	95	96	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	OCT 5	1999	131	7					502	+		10.7326/0003-4819-131-7-199910050-00004	http://dx.doi.org/10.7326/0003-4819-131-7-199910050-00004			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	243VU	10507958				2022-12-01	WOS:000083018800003
J	Berger, A				Berger, A			What is allodynia?	BRITISH MEDICAL JOURNAL			English	Editorial Material																		BERDE C, 1995, PAIN, V62, P1, DOI 10.1016/0304-3959(95)00035-Q; Faura CC, 1998, PAIN, V74, P43, DOI 10.1016/S0304-3959(97)00142-5; Gardmark M, 1998, J PHARM SCI, V87, P813, DOI 10.1021/js980056f; 1998, CURRENT OPINION ANAE, V11, P436	4	1	1	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	SEP 4	1999	319	7210					629	629						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	234AJ	10523091				2022-12-01	WOS:000082460300030
J	Xu, QA; Buckley, D; Guan, CD; Guo, HC				Xu, QA; Buckley, D; Guan, CD; Guo, HC			Structural insights into the mechanism of intramolecular proteolysis	CELL			English	Article							N-TERMINAL NUCLEOPHILE; CRYSTAL-STRUCTURE; 20S PROTEASOME; LYSOSOMAL ASPARTYLGLUCOSAMINIDASE; FLAVOBACTERIUM-MENINGOSEPTICUM; HISTIDINE-DECARBOXYLASE; BETA-SUBUNITS; GLYCOSYLASPARAGINASE; RESOLUTION; HEDGEHOG	A variety of proteins, including glycosylasparaginase, have recently been found to activate functions by self-catalyzed peptide bond rearrangements from single-chain precursors. Here we present the 1.9 Angstrom crystal structures of glycosylasparaginase precursors that are able to autoproteolyze via an N --> O acyl shift. Several conserved residues are aligned around the scissile peptide bond that is in a highly strained trans peptide bond configuration. The structure illustrates how a nucleophilic side chain may attack the scissile peptide bond at the immediate upstream backbone carbonyl and provides an understanding of the structural basis for peptide bond cleavage via an N --> O or N --> S acyl shift that is used by various groups of intramolecular autoprocessing proteins.	Boston Univ, Sch Med, Dept Biophys, Boston, MA 02118 USA; New England Biolabs Inc, Beverly, MA 01915 USA	Boston University	Guo, HC (corresponding author), Boston Univ, Sch Med, Dept Biophys, Boston, MA 02118 USA.	hcguo@bu.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK053893] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK53893] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Albert A, 1998, NAT STRUCT BIOL, V5, P289, DOI 10.1038/nsb0498-289; Aronson NN, 1996, GLYCOBIOLOGY, V6, P669, DOI 10.1093/glycob/6.7.669; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BALASUBR.R, 1972, INT J PEPT PROT RES, V4, P91; Baumeister W, 1998, CELL, V92, P367, DOI 10.1016/S0092-8674(00)80929-0; BRANNIGAN JA, 1995, NATURE, V378, P416, DOI 10.1038/378416a0; Brunger A. T., 1992, XPLOR VERSION 3 1 SY; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; Chan YM, 1998, CELL, V94, P423, DOI 10.1016/S0092-8674(00)81583-4; Chong SR, 1998, J BIOL CHEM, V273, P10567, DOI 10.1074/jbc.273.17.10567; Cocks TM, 1999, NATURE, V398, P156, DOI 10.1038/18223; CUI T, 1999, IN PRESS ACTA CRYS D; DAVIE EW, 1995, THROMB HAEMOSTASIS, V74, P1; Ditzel L, 1998, J MOL BIOL, V279, P1187, DOI 10.1006/jmbi.1998.1818; Duan XQ, 1997, CELL, V89, P555, DOI 10.1016/S0092-8674(00)80237-8; DUGGLEBY HJ, 1995, NATURE, V373, P264, DOI 10.1038/373264a0; Fisher AJ, 1996, J BIOL CHEM, V271, P21956, DOI 10.1074/jbc.271.36.21956; GALLAGHER T, 1993, J MOL BIOL, V230, P516, DOI 10.1006/jmbi.1993.1168; Groll M, 1997, NATURE, V386, P463, DOI 10.1038/386463a0; Guan C, 1998, J BIOL CHEM, V273, P9695, DOI 10.1074/jbc.273.16.9695; Guan CD, 1996, J BIOL CHEM, V271, P1732, DOI 10.1074/jbc.271.3.1732; Guo HC, 1998, J BIOL CHEM, V273, P20205, DOI 10.1074/jbc.273.32.20205; Hall TMT, 1997, CELL, V91, P85, DOI 10.1016/S0092-8674(01)80011-8; IKONEN E, 1993, EMBO J, V12, P295, DOI 10.1002/j.1460-2075.1993.tb05656.x; Isupov MN, 1996, STRUCTURE, V4, P801, DOI 10.1016/S0969-2126(96)00087-1; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KAARTINEN V, 1991, J BIOL CHEM, V266, P5860; Khan AR, 1998, PROTEIN SCI, V7, P815; King RW, 1996, SCIENCE, V274, P1652, DOI 10.1126/science.274.5293.1652; Klabunde T, 1998, NAT STRUCT BIOL, V5, P31, DOI 10.1038/nsb0198-31; Klenk Hans-Dieter, 1994, Trends in Microbiology, V2, P39, DOI 10.1016/0966-842X(94)90123-6; Kleywegt GJ, 1999, J MOL BIOL, V285, P1887, DOI 10.1006/jmbi.1998.2393; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LANG K, 1987, NATURE, V329, P268, DOI 10.1038/329268a0; LEE JJ, 1994, SCIENCE, V266, P1528, DOI 10.1126/science.7985023; Liu Y, 1998, J BIOL CHEM, V273, P9688, DOI 10.1074/jbc.273.16.9688; LOWE J, 1995, SCIENCE, V268, P533, DOI 10.1126/science.7725097; McRee DE, 1992, J MOL GRAPHICS, V10, P44, DOI DOI 10.1016/0263-7855(92)80022-6; Mesecar AD, 1997, SCIENCE, V277, P202, DOI 10.1126/science.277.5323.202; MONONEN I, 1993, FASEB J, V7, P1247, DOI 10.1096/fasebj.7.13.8405810; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; OINONEN C, 1995, NAT STRUCT BIOL, V2, P1102, DOI 10.1038/nsb1295-1102; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Paulus H, 1998, CHEM SOC REV, V27, P375, DOI 10.1039/a827375z; Perler FB, 1998, NAT STRUCT BIOL, V5, P249, DOI 10.1038/nsb0498-249; Perler FB, 1997, NUCLEIC ACIDS RES, V25, P1087, DOI 10.1093/nar/25.6.1087; Perler FB, 1998, CELL, V92, P1, DOI 10.1016/S0092-8674(00)80892-2; PONDER JW, 1987, J MOL BIOL, V193, P775, DOI 10.1016/0022-2836(87)90358-5; Porter JA, 1996, SCIENCE, V274, P255, DOI 10.1126/science.274.5285.255; RECSEI PA, 1983, P NATL ACAD SCI-BIOL, V80, P973, DOI 10.1073/pnas.80.4.973; Saarela J, 1998, J BIOL CHEM, V273, P25320, DOI 10.1074/jbc.273.39.25320; Sakon J, 1996, BIOCHEMISTRY-US, V35, P10648, DOI 10.1021/bi9604439; Salvesen GS, 1997, CELL, V91, P443, DOI 10.1016/S0092-8674(00)80430-4; Schmidtke G, 1996, EMBO J, V15, P6887, DOI 10.1002/j.1460-2075.1996.tb01081.x; SEEMULLER E, 1995, SCIENCE, V268, P579, DOI 10.1126/science.7725107; SMITH JL, 1994, SCIENCE, V264, P1427, DOI 10.1126/science.8197456; TARENTINO AL, 1995, ARCH BIOCHEM BIOPHYS, V316, P399, DOI 10.1006/abbi.1995.1053; TOLLERSRUD OK, 1992, BIOCHEM J, V282, P891, DOI 10.1042/bj2820891; Vallet V, 1997, NATURE, V389, P607, DOI 10.1038/39329; XU MQ, 1994, EMBO J, V13, P5517, DOI 10.1002/j.1460-2075.1994.tb06888.x; Xuan JC, 1998, PROTEIN SCI, V7, P774, DOI 10.1002/pro.5560070327; ZWICKL P, 1994, NAT STRUCT BIOL, V1, P765, DOI 10.1038/nsb1194-765	62	115	116	0	13	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	SEP 3	1999	98	5					651	661		10.1016/S0092-8674(00)80052-5	http://dx.doi.org/10.1016/S0092-8674(00)80052-5			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	233NT	10490104	Bronze			2022-12-01	WOS:000082433500012
J	Fetscher, S				Fetscher, S			An entirely benign disorder	ANNALS OF INTERNAL MEDICINE			English	Editorial Material									Univ Freiburg, Med Ctr, Dept Hematol & Oncol, D-79106 Freiburg, Germany	University of Freiburg	Fetscher, S (corresponding author), Univ Freiburg, Med Ctr, Dept Hematol & Oncol, Hugstetter Str 55, D-79106 Freiburg, Germany.	fetscher@mml1.ukl.uni-freiburg.de							0	1	1	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	NOV 16	1999	131	10					786	788		10.7326/0003-4819-131-10-199911160-00014	http://dx.doi.org/10.7326/0003-4819-131-10-199911160-00014			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	255QC	10577305				2022-12-01	WOS:000083680100012
J	Kim, L; Liu, JC; Kimmel, AR				Kim, L; Liu, JC; Kimmel, AR			The novel tyrosine kinase ZAK1 activates GSK3 to direct cell fate specification	CELL			English	Article							GLYCOGEN-SYNTHASE KINASE-3; PROTEIN-KINASES; DICTYOSTELIUM-DISCOIDEUM; AXIS SPECIFICATION; RECEPTOR; XENOPUS; PHOSPHORYLATION; IDENTIFICATION; DIFFERENTIATION; CLASSIFICATION	Inhibition of GSK3 by 7-TM Wnt/wg receptor signaling is critical for specifying embryonic cell fate patterns. In Dictyostelium, the 7-TM cAMP receptors regulate GSK3 by parallel, antagonistic pathways to establish a developmental body plan. We describe here a novel tyrosine kinase, ZAK1, downstream of 7-TM cAMP receptor signaling that is required for GSK3 activation during development, zak1-nulls have reduced GSK3 activity and are defective in GSK3-regulated developmental pathways. Moreover, recombinant ZAK1 phosphorylates and activates GSK3 in vitro. We propose that ZAK1 is a positive regulator of GSK3 activity required for cell pattern formation in Dictyostelium and speculate that similar mechanisms exist to antagonize Wnt/wg signaling for metazoan cell fate specification.	NIDDKD, Cellular & Dev Biol Lab, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)	Kimmel, AR (corresponding author), NIDDKD, Cellular & Dev Biol Lab, NIH, Bethesda, MD 20892 USA.	ark1@helix.nih.gov			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [Z01DK015503] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Adams Douglas, 1979, HITCHHIKERS GUIDE GA; Adler K, 1996, FEBS LETT, V395, P286, DOI 10.1016/0014-5793(96)01053-8; Ali MS, 1997, J BIOL CHEM, V272, P23382, DOI 10.1074/jbc.272.37.23382; Baldauf SL, 1997, P NATL ACAD SCI USA, V94, P12007, DOI 10.1073/pnas.94.22.12007; Brannon M, 1997, GENE DEV, V11, P2359, DOI 10.1101/gad.11.18.2359; Clevers H, 1997, TRENDS GENET, V13, P485, DOI 10.1016/S0168-9525(97)01305-X; COOPER JA, 1981, MOL CELL BIOL, V1, P394, DOI 10.1128/MCB.1.5.394; Darnell JE, 1997, P NATL ACAD SCI USA, V94, P11767, DOI 10.1073/pnas.94.22.11767; Ginsburg GT, 1997, GENE DEV, V11, P2112, DOI 10.1101/gad.11.16.2112; Girault JA, 1999, TRENDS BIOCHEM SCI, V24, P54, DOI 10.1016/S0968-0004(98)01331-0; GuilletDeniau I, 1997, J BIOL CHEM, V272, P14825, DOI 10.1074/jbc.272.23.14825; HANKS SK, 1995, FASEB J, V9, P576, DOI 10.1096/fasebj.9.8.7768349; HARWOOD AJ, 1995, CELL, V80, P139, DOI 10.1016/0092-8674(95)90458-1; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; HE X, 1995, NATURE, V374, P617, DOI 10.1038/374617a0; HUGHES K, 1993, EMBO J, V12, P803, DOI 10.1002/j.1460-2075.1993.tb05715.x; Hunter T, 1997, TRENDS BIOCHEM SCI, V22, P18, DOI 10.1016/S0968-0004(96)10068-2; Jin T, 1998, EMBO J, V17, P5076, DOI 10.1093/emboj/17.17.5076; Johnson LN, 1996, CELL, V85, P149, DOI 10.1016/S0092-8674(00)81092-2; JOHNSON RL, 1993, GENE DEV, V7, P273, DOI 10.1101/gad.7.2.273; KAY RR, 1987, METHOD CELL BIOL, V28, P433; KIM L, 1995, MOL CELL BIOL, V15, P4553; Leonard WJ, 1998, ANNU REV IMMUNOL, V16, P293, DOI 10.1146/annurev.immunol.16.1.293; LOUIS JM, 1994, GENE DEV, V8, P2086, DOI 10.1101/gad.8.17.2086; Luo H, 1997, MOL CELL BIOL, V17, P1562, DOI 10.1128/MCB.17.3.1562; Moon RT, 1998, BIOESSAYS, V20, P536, DOI 10.1002/(SICI)1521-1878(199807)20:7<536::AID-BIES4>3.0.CO;2-I; Nusse R, 1999, TRENDS GENET, V15, P1, DOI 10.1016/S0168-9525(98)01634-5; Plyte SE, 1999, DEVELOPMENT, V126, P325; RESH MD, 1994, CELL, V76, P411, DOI 10.1016/0092-8674(94)90104-X; RICHARDSON DL, 1994, DEVELOPMENT, V120, P2891; ROGERS KC, 1997, DICTYOSTELIUM MODEL, P163; Roose J, 1998, NATURE, V395, P608, DOI 10.1038/26989; SAXE CL, 1993, GENE DEV, V7, P262, DOI 10.1101/gad.7.2.262; Shulman JM, 1998, TRENDS GENET, V14, P452, DOI 10.1016/S0168-9525(98)01584-4; TAYLOR SS, 1995, FASEB J, V9, P1255, DOI 10.1096/fasebj.9.13.7557015; Torres MA, 1996, J CELL BIOL, V133, P1123, DOI 10.1083/jcb.133.5.1123; Verkerke-Van Wijk I, 1998, MOL CELL BIOL, V18, P5744, DOI 10.1128/MCB.18.10.5744; WANG QM, 1994, J BIOL CHEM, V269, P14566	38	136	141	0	3	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	NOV 12	1999	99	4					399	408		10.1016/S0092-8674(00)81526-3	http://dx.doi.org/10.1016/S0092-8674(00)81526-3			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	256CX	10571182	Bronze			2022-12-01	WOS:000083709300007
J	Wang, YX; Neamati, N; Jacob, J; Palmer, I; Stahl, SJ; Kaufman, JD; Huang, PL; Huang, PL; Winslow, HE; Pommier, Y; Wingfield, PT; Lee-Huang, S; Bax, A; Torchia, DA				Wang, YX; Neamati, N; Jacob, J; Palmer, I; Stahl, SJ; Kaufman, JD; Huang, PL; Huang, PL; Winslow, HE; Pommier, Y; Wingfield, PT; Lee-Huang, S; Bax, A; Torchia, DA			Solution structure of anti-HIV-1 and anti-tumor protein MAP30: Structural insights into its multiple functions	CELL			English	Article							RIBOSOME-INACTIVATING PROTEINS; POKEWEED ANTIVIRAL PROTEIN; ADENOSINE GLYCOSIDASE ACTIVITY; RICIN A-CHAIN; CRYSTAL-STRUCTURE; STAPHYLOCOCCAL NUCLEASE; BACKBONE DYNAMICS; STRANDED-DNA; J-COUPLINGS; NMR	We present the solution structure of MAP30, a plant protein with anti-HIV and anti-tumor activities. Structural analysis and subsequent biochemical assays lead to several novel discoveries. First, MAP30 acts like a DNA glycosylase/apurinic (ap) lyase, an additional activity distinct from its known RNA N-glycosidase activity toward the 28S rRNA. Glycosylase/ap lyase activity explains MAP30's apparent inhibition of the HIV-1 integrase, MAP30's ability to irreversibly relax supercoiled DNA, and may be an alternative cytotoxic pathway that contributes to MAP30's anti-HIV/anti-tumor activities. Second, two distinct, but contiguous, subsites are responsible for MAP30's glycosylase/ap lyase activity. Third, Mn2+ and Zn2+ interact with negatively charged surfaces next to the catalytic sites, facilitating DNA substrate binding instead of directly participating in catalysis.	NCI, Mol Pharmacol Lab, NIH, Bethesda, MD 20892 USA; Natl Inst Dent & Craniofacial Res, Mol Struct Biol Lab, NIH, Bethesda, MD 20892 USA; NIAMSD, Prot Express Lab, NIH, Bethesda, MD 20892 USA; Amer BioSci, New York, NY 10021 USA; Massachusetts Gen Hosp, Dept Med, Boston, MA 02114 USA; Harvard Univ, Sch Med, Boston, MA 02114 USA; NYU, Sch Med, Dept Biochem, New York, NY 10016 USA; NIDDKD, Chem Phys Lab, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR); National Institutes of Health (NIH) - USA; NIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS); Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; New York University; National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)	Lee-Huang, S (corresponding author), NCI, Mol Pharmacol Lab, NIH, Bethesda, MD 20892 USA.			Huang, Paul/0000-0002-5436-8658; Lee-Huang, Sylvia/0000-0003-3302-241X; Wingfield, Paul/0000-0002-9515-4752	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI031343] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [ZIAAR041115, Z01AR041115] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [Z01DE000687] Funding Source: NIH RePORTER; NIAID NIH HHS [R01 AI-31343] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ARCHER SJ, 1991, J MAGN RESON, V95, P636, DOI 10.1016/0022-2364(91)90182-S; Barbieri L, 1997, NUCLEIC ACIDS RES, V25, P518, DOI 10.1093/nar/25.3.518; Barbieri L, 1996, BIOCHEM J, V319, P507, DOI 10.1042/bj3190507; BARBIERI L, 1993, BIOCHIM BIOPHYS ACTA, V1154, P237, DOI 10.1016/0304-4157(93)90002-6; BEHMOARAS T, 1981, NATURE, V292, P858, DOI 10.1038/292858a0; Clore GM, 1998, J MAGN RESON, V133, P216, DOI 10.1006/jmre.1998.1419; Cornilescu G, 1999, J BIOMOL NMR, V13, P289, DOI 10.1023/A:1008392405740; Day PJ, 1998, EUR J BIOCHEM, V258, P540, DOI 10.1046/j.1432-1327.1998.2580540.x; Garrett DS, 1997, BIOCHEMISTRY-US, V36, P2517, DOI 10.1021/bi962924y; GRZESIEK S, 1993, J BIOMOL NMR, V3, P627; GRZESIEK S, 1995, J AM CHEM SOC, V117, P5312, DOI 10.1021/ja00124a014; GRZESIEK S, 1995, J AM CHEM SOC, V117, P9594, DOI 10.1021/ja00142a040; HUANG PL, 1992, BIOFACTORS, V4, P37; HUSAIN J, 1994, FEBS LETT, V342, P154, DOI 10.1016/0014-5793(94)80491-5; IRVIN JD, 1992, PHARMACOL THERAPEUT, V55, P279, DOI 10.1016/0163-7258(92)90053-3; Jones S, 1999, J MOL BIOL, V287, P877, DOI 10.1006/jmbi.1999.2659; KAY LE, 1989, BIOCHEMISTRY-US, V28, P8972, DOI 10.1021/bi00449a003; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Kuszewski J, 1997, J MAGN RESON, V125, P171, DOI 10.1006/jmre.1997.1116; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LEEHUANG S, 1991, FEBS LETT, V291, P139, DOI 10.1016/0014-5793(91)81122-O; LEEHUANG S, 1995, GENE, V161, P151, DOI 10.1016/0378-1119(95)00186-A; LEEHUANG S, 1990, FEBS LETT, V272, P12, DOI 10.1016/0014-5793(90)80438-O; LEEHUANG S, 1995, P NATL ACAD SCI USA, V92, P8818, DOI 10.1073/pnas.92.19.8818; LI MX, 1991, NUCLEIC ACIDS RES, V19, P6309, DOI 10.1093/nar/19.22.6309; LING J, 1994, FEBS LETT, V345, P143, DOI 10.1016/0014-5793(94)00421-8; Mazumder A, 1996, J BIOL CHEM, V271, P27330, DOI 10.1074/jbc.271.44.27330; MAZUMDER A, 1995, NUCLEIC ACIDS RES, V23, P3865; MCGRATH MS, 1989, P NATL ACAD SCI USA, V86, P2844, DOI 10.1073/pnas.86.8.2844; MLSNA D, 1993, PROTEIN SCI, V2, P429; MONTFORT W, 1987, J BIOL CHEM, V262, P5398; MONZINGO AF, 1993, J MOL BIOL, V233, P705, DOI 10.1006/jmbi.1993.1547; MONZINGO AF, 1992, J MOL BIOL, V227, P1136, DOI 10.1016/0022-2836(92)90526-P; Neamati N, 1998, J MED CHEM, V41, P3202, DOI 10.1021/jm9801760; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Nicolas E, 1998, J BIOL CHEM, V273, P17216, DOI 10.1074/jbc.273.27.17216; Nicolas E, 1997, BIOCHEM J, V327, P413, DOI 10.1042/bj3270413; NILGES M, 1988, FEBS LETT, V239, P129, DOI 10.1016/0014-5793(88)80559-3; Ottiger M, 1999, J BIOMOL NMR, V13, P187, DOI 10.1023/A:1008395916985; Roncuzzi L, 1996, FEBS LETT, V392, P16, DOI 10.1016/0014-5793(96)00776-4; Sawa R., 1995, NATURE, V373, P487; Slupphaug G, 1996, NATURE, V384, P87, DOI 10.1038/384087a0; Stein EG, 1997, J MAGN RESON, V124, P154, DOI 10.1006/jmre.1996.1027; SUN B, 1995, J BIOL CHEM, V270, P19501, DOI 10.1074/jbc.270.33.19501; SZEWCZAK AA, 1993, P NATL ACAD SCI USA, V90, P9581, DOI 10.1073/pnas.90.20.9581; THAYER MM, 1995, EMBO J, V14, P4108, DOI 10.1002/j.1460-2075.1995.tb00083.x; Tjandra N, 1997, SCIENCE, V278, P1111, DOI 10.1126/science.278.5340.1111; Tjandra N, 1997, NAT STRUCT BIOL, V4, P443, DOI 10.1038/nsb0697-443; Tjandra N, 1996, J AM CHEM SOC, V118, P6986, DOI 10.1021/ja960510m; Tumer NE, 1997, P NATL ACAD SCI USA, V94, P3866, DOI 10.1073/pnas.94.8.3866; Tumer NE, 1998, J VIROL, V72, P1036, DOI 10.1128/JVI.72.2.1036-1042.1998; VASSYLYEV DG, 1995, CELL, V83, P773, DOI 10.1016/0092-8674(95)90190-6; VUISTER GW, 1993, J MAGN RESON SER B, V101, P210, DOI 10.1006/jmrb.1993.1035; VUISTER GW, 1994, J BIOMOL NMR, V4, P193; Wang P, 1999, NUCLEIC ACIDS RES, V27, P1900, DOI 10.1093/nar/27.8.1900; Wang YX, 1998, J AM CHEM SOC, V120, P7385, DOI 10.1021/ja980862o; Wang YX, 1999, J BIOMOL NMR, V14, P181, DOI 10.1023/A:1008346517302; WANG YX, 1999, IN PRESS PROTEIN SCI; WISHART DS, 1994, METHOD ENZYMOL, V239, P363; Wuthrich K., 1986, NMR PROTEINS NUCL AC; Xiong JP, 1997, CHINESE J CHEM, V15, P265; Yamazaki T, 1996, PROTEIN SCI, V5, P495; ZARLING JM, 1990, NATURE, V347, P92, DOI 10.1038/347092a0	63	66	79	2	12	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	NOV 12	1999	99	4					433	442		10.1016/S0092-8674(00)81529-9	http://dx.doi.org/10.1016/S0092-8674(00)81529-9			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	256CX	10571185	Bronze			2022-12-01	WOS:000083709300010
J	Bendszus, M; Koltzenburg, M; Burger, R; Warmuth-Metz, M; Hofmann, E; Solymosi, L				Bendszus, M; Koltzenburg, M; Burger, R; Warmuth-Metz, M; Hofmann, E; Solymosi, L			Silent embolism in diagnostic cerebral angiography and neurointerventional procedures: a prospective study	LANCET			English	Article							COMPLICATIONS; MICROEMBOLI; RISK; DSA	Background Cerebral angiography is associated with a small but definite risk of neurological complications with an unknown incidence of clinically silent embolism. We assessed the neurological complication rate compared with the frequency of silent embolism after angiography Methods We used diffusion-weighted magnetic resonance imaging (MRI) before and after angiography to assess embolic events. 100 consecutive angiographies (66 diagnostic and 34 interventional procedures) were done on 91 patients. Patients underwent neurological assessment before, immediately after, and 1 day after angiography. Findings Before angiography, no abnormalities were seen on diffusion-weighted MRI. Diffusion-weighted MRI showed 42 bright lesions in 23 patients after 23 procedures (17 diagnostic, six interventional) in a pattern consistent with embolic events. There was no new neurological deficit after any angiographic procedure. After diagnostic angiography in patients with a history of vasculopathy, the frequency of lesions was significantly higher than in patients without vascular risk factors (12 [44%] of 27 vs five [13%] of 39 patients, p=0.03), in diagnostic angiography, the appearance of lesions was significantly correlated with whether Vessels were difficult to probe (p=0.01), amount of contrast medium needed (p<0.01), fluoroscopy time (p<0.01), and use of additional catheters (p=0.02). Interpretation After diagnostic and interventional cerebral angiography, embolic events are more frequent than the apparent neurological complication rate. In diagnostic procedures, the incidence of embolism is closely related to a vascular risk profile.	Univ Wurzburg, Dept Neuroradiol, D-97080 Wurzburg, Germany; Univ Wurzburg, Dept Neurol, D-97080 Wurzburg, Germany; Univ Wurzburg, Dept Neurosurg, D-97080 Wurzburg, Germany	University of Wurzburg; University of Wurzburg; University of Wurzburg	Bendszus, M (corresponding author), Univ Wurzburg, Dept Neuroradiol, Josef Schneider Str 11, D-97080 Wurzburg, Germany.		Solymosi, László/E-6449-2018; Koltzenburg, Martin/C-1349-2008	Solymosi, László/0000-0001-9647-8647; Koltzenburg, Martin/0000-0001-9181-5966				DAGIRMANJIAN A, 1993, AM J ROENTGENOL, V161, P1037, DOI 10.2214/ajr.161.5.7903842; DAVIES KN, 1993, J NEUROL NEUROSUR PS, V56, P967, DOI 10.1136/jnnp.56.9.967; DION JE, 1987, STROKE, V18, P997, DOI 10.1161/01.STR.18.6.997; EARNEST F, 1984, AM J ROENTGENOL, V142, P247, DOI 10.2214/ajr.142.2.247; GRZYSKA U, 1990, NEURORADIOLOGY, V32, P296, DOI 10.1007/BF00593048; HEISERMAN JE, 1994, AM J NEURORADIOL, V15, P1401; Horowitz MB, 1998, INTERV NEURORADIOL, V4, P27, DOI 10.1177/159101999800400103; MARKUS H, 1993, LANCET, V341, P784, DOI 10.1016/0140-6736(93)90561-T; MOODY DM, 1990, ANN NEUROL, V28, P477, DOI 10.1002/ana.410280403; MOSELEY ME, 1990, AM J NEURORADIOL, V11, P432; WARACH S, 1995, ANN NEUROL, V37, P231, DOI 10.1002/ana.410370214; WAUGH JR, 1992, RADIOLOGY, V182, P243, DOI 10.1148/radiology.182.1.1727290; Woolfenden AR, 1997, STROKE, V28, P2311, DOI 10.1161/01.STR.28.11.2311	13	370	385	0	5	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	NOV 6	1999	354	9190					1594	1597		10.1016/S0140-6736(99)07083-X	http://dx.doi.org/10.1016/S0140-6736(99)07083-X			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	253HM	10560674				2022-12-01	WOS:000083551000011
J	Jones, R; Pearson, J; McGregor, S; Gilmour, WH; Atkinson, JM; Barrett, A; Cawsey, AJ; McEwen, J				Jones, R; Pearson, J; McGregor, S; Gilmour, WH; Atkinson, JM; Barrett, A; Cawsey, AJ; McEwen, J			Cross sectional survey of patients' satisfaction with information about cancer	BRITISH MEDICAL JOURNAL			English	Article									Univ Glasgow, Dept Publ Hlth, Glasgow G12 8RZ, Lanark, Scotland; Western Infirm & Associated Hosp, Beatson Oncol Ctr, Glasgow G11 6NT, Lanark, Scotland; Heriot Watt Univ, Dept Comp Sci, Edinburgh EH14 4AS, Midlothian, Scotland	University of Glasgow; Beatson Oncology Centre; Heriot Watt University	Jones, R (corresponding author), Univ Glasgow, Dept Publ Hlth, Glasgow G12 8RZ, Lanark, Scotland.							Carstairs V., 1991, DEPRIVATION HLTH SCO; Jones R, 1999, BRIT MED J, V319, P1241, DOI 10.1136/bmj.319.7219.1241; Meredith C, 1996, BMJ-BRIT MED J, V313, P724; National Cancer Alliance, 1996, PAT CTR CANC SERV WH; ZIGMOND AS, 1983, ACTA PSYCHIAT SCAND, V67, P361, DOI 10.1111/j.1600-0447.1983.tb09716.x	5	75	76	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	NOV 6	1999	319	7219					1247	1248		10.1136/bmj.319.7219.1247	http://dx.doi.org/10.1136/bmj.319.7219.1247			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	254RH	10550091	Green Published, Bronze			2022-12-01	WOS:000083625600027
J	Youn, HD; Sun, L; Prywes, R; Liu, JO				Youn, HD; Sun, L; Prywes, R; Liu, JO			Apoptosis of T cells mediated by Ca2+-induced release of the transcription factor MEF2	SCIENCE			English	Article							ORPHAN STEROID-RECEPTOR; NUR77; GENE; CALCINEURIN; LYMPHOCYTES; PROTEINS; DEATH	T cell receptor (TCR)-induced apoptosis of thymocytes is media ted by calcium-dependent expression of the steroid receptors Nur77 and Nor1, Nur77 expression is controlled by the transcription factor myocyte enhancer factor 2 (MEF2), but how MEF2 is activated by calcium signaling is still obscure. Cabin1, a calcineurin inhibitor, was found to regulate MEF2. MEF2 was normally sequestered by Cabin1 in a transcriptionally inactive state. TCR engagement led to an increase in intracellular calcium concentration and the dissociation of MEF2 from Cabin1, as a result of competitive binding of activated calmodulin to Cabin1. The interplay between Cabin1, MEF2, and calmodulin defines a distinct signaling pathway from the TCR to the Nur77 promoter during T cell apoptosis.	MIT, Ctr Canc Res, Cambridge, MA 02139 USA; MIT, Dept Biol, Cambridge, MA 02139 USA; MIT, Dept Chem, Cambridge, MA 02139 USA; Columbia Univ, Dept Biol Sci, New York, NY 10027 USA	Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT); Columbia University	Liu, JO (corresponding author), MIT, Ctr Canc Res, Cambridge, MA 02139 USA.		Youn, Hong-Duk/J-2774-2012		NIGMS NIH HHS [GM55783] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM055783] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Black BL, 1998, ANNU REV CELL DEV BI, V14, P167, DOI 10.1146/annurev.cellbio.14.1.167; Cheng LEC, 1997, EMBO J, V16, P1865, DOI 10.1093/emboj/16.8.1865; CORNELIUSSEN B, 1994, NATURE, V368, P760, DOI 10.1038/368760a0; GOSSETT LA, 1989, MOL CELL BIOL, V9, P5022, DOI 10.1128/MCB.9.11.5022; HSU HL, 1994, P NATL ACAD SCI USA, V91, P3181, DOI 10.1073/pnas.91.8.3181; IKURA M, 1992, SCIENCE, V256, P632, DOI 10.1126/science.1585175; Lai MM, 1998, J BIOL CHEM, V273, P18325, DOI 10.1074/jbc.273.29.18325; LEIFER D, 1993, P NATL ACAD SCI USA, V90, P1546, DOI 10.1073/pnas.90.4.1546; LIU ZG, 1994, NATURE, V367, P281, DOI 10.1038/367281a0; MARTIN JF, 1994, MOL CELL BIOL, V14, P1647, DOI 10.1128/MCB.14.3.1647; MARTIN JF, 1993, P NATL ACAD SCI USA, V90, P5282, DOI 10.1073/pnas.90.11.5282; POLLOCK R, 1991, GENE DEV, V5, P2327, DOI 10.1101/gad.5.12a.2327; SELLINS KS, 1987, J IMMUNOL, V139, P3199; Sun L, 1998, IMMUNITY, V8, P703, DOI 10.1016/S1074-7613(00)80575-0; Winoto A, 1997, CURR OPIN IMMUNOL, V9, P365, DOI 10.1016/S0952-7915(97)80083-0; Wong B, 1997, CURR OPIN IMMUNOL, V9, P358, DOI 10.1016/S0952-7915(97)80082-9; WORONICZ JD, 1995, MOL CELL BIOL, V15, P6364; WORONICZ JD, 1994, NATURE, V367, P277, DOI 10.1038/367277a0; YOUN HD, UNPUB DATA; YOUN HW, UNPUB; YU YT, 1992, GENE DEV, V6, P1783, DOI 10.1101/gad.6.9.1783	21	225	234	1	15	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	OCT 22	1999	286	5440					790	793		10.1126/science.286.5440.790	http://dx.doi.org/10.1126/science.286.5440.790			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	248XZ	10531067				2022-12-01	WOS:000083303200059
J	Dye, C; Scheele, S; Dolin, P; Pathania, V; Raviglione, RC				Dye, C; Scheele, S; Dolin, P; Pathania, V; Raviglione, RC		WHO Global Surveillance Monitoring Project	Global burden of tuberculosis - Estimated incidence, prevalence, and mortality by country	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; RESISTANT MYCOBACTERIUM-TUBERCULOSIS; PULMONARY TUBERCULOSIS; INFECTION; TRANSMISSION; SURVIVAL; ISSUES	Objective To estimate the risk and prevalence of Mycobacterium tuberculosis (MTB) infection and tuberculosis (TB) incidence, prevalence, and mortality, including disease attributable to human immunodeficiency virus (HIV), for 212 countries in 1997. Participants A panel of 86 TB experts and epidemiologists from more than 40 countries was chosen by the World Health Organization (WHO), with final agreement being reached between country experts and WHO staff. Evidence Incidence of TB and mortality in each country was determined by (1) case notification to the WHO, (2) annual risk of infection data from tuberculin surveys, and (3) data on prevalence of smear-positive pulmonary disease from prevalence surveys, Estimates derived from relatively poor data were strongly influenced by panel member opinion. Objective estimates were derived from high-quality data collected recently by approved procedures, Consensus Process Agreement was reached by (1) participants reviewing methods and data and making provisional estimates in dosed workshops held at WHO's 6 regional offices, (2) principal authors refining estimates using standard methods and all available data, and (3) country experts reviewing and adjusting these estimates and reaching final agreement with WHO staff. Conclusions In 1997, new cases of TB totaled an estimated 7.96 million (range, 6.3 million-11.1 million), including 3.52 million (2.8 million-4.9 million) cases (44%) of infectious pulmonary disease (smear-positive), and there were 16.2 million (12.1 million-22.5 million) existing cases of disease. An estimated 1.87 million (1.4 million-2.8 million) people died of TB and the global case fatality rate was 23% but exceeded 50% in some African countries with high HIV rates, Global prevalence of MTB infection was 32% (1.86 billion people). Eighty percent of all incident TB cases were found in 22 countries, with more than half the cases occurring in 5 Southeast Asian countries, Nine of 10 countries with the highest incidence rates per capita were in Africa. Prevalence of MTB/HIV coinfection worldwide was 0.18% and 640 000 incident TB cases (8%) had HIV infection. The global burden of tuberculosis remains enormous, mainly because of poor control in Southeast Asia, sub-Saharan Africa, and eastern Europe, and because of high rates of M tuberculosis and HIV coinfection in some African countries.	WHO, Communicable Dis Prevent & Control, CH-1211 Geneva 27, Switzerland	World Health Organization	Dye, C (corresponding author), WHO, Communicable Dis Prevent & Control, CH-1211 Geneva 27, Switzerland.		Dye, Christopher/AIC-4659-2022	Dye, Christopher/0000-0002-2957-1793; RAVIGLIONE, Mario/0000-0002-9331-2067				BARNETT G D, 1977, Bulletin of the International Union Against Tuberculosis, V52, P5; BUSILLO CP, 1992, CHEST, V102, P797, DOI 10.1378/chest.102.3.797; CAUTHEN G, 1988, WHO PUBL; Cauthen GM, 1996, AM J EPIDEMIOL, V144, P69, DOI 10.1093/oxfordjournals.aje.a008856; *CDC, 1991, MMWR-MORBID MORTAL W, V40, P585; CORONADO VG, 1993, J INFECT DIS, V168, P1052, DOI 10.1093/infdis/168.4.1052; DATTA M, 1993, TUBERCLE LUNG DIS, V74, P180, DOI 10.1016/0962-8479(93)90008-L; DeCock KM, 1996, JAMA-J AM MED ASSOC, V276, P1502, DOI 10.1001/jama.276.18.1502; *DEP HLTH TUB CONT, 1997, NAT TUB PREV SURV 19; DOLIN PJ, 1994, B WORLD HEALTH ORGAN, V72, P213; Dye C, 1998, LANCET, V352, P1886, DOI 10.1016/S0140-6736(98)03199-7; EDLIN BR, 1992, NEW ENGL J MED, V326, P1514, DOI 10.1056/NEJM199206043262302; Espinal MA, 1996, J ACQ IMMUN DEF SYND, V13, P155, DOI 10.1097/00042560-199610010-00006; GITHUI W, 1992, TUBERCLE LUNG DIS, V73, P203, DOI 10.1016/0962-8479(92)90087-Z; Hilleboe HE, 1941, PUBLIC HEALTH REP, V56, P895, DOI 10.2307/4583713; KREBS W, 1930, AARGAULSCHEN HEILSTA, P345; MURRAY C, 1993, DIS CONTROL PRIORITI; MURRAY CJL, 1996, GLOBAL HLTH STAT, V2; OHMORI M, 1995, STAGNATION DECLINE T; Raviglione M C, 1997, AIDS, V11 Suppl B, pS115; RIEDER HL, 1995, TUBERCLE LUNG DIS, V76, P114, DOI 10.1016/0962-8479(95)90552-9; Shafer RW, 1996, CLIN INFECT DIS, V22, P683, DOI 10.1093/clinids/22.4.683; STYBLO K, 1978, Bulletin of the International Union Against Tuberculosis, V53, P141; Styblo K, 1985, B INT UNION TUBERC L, V60, P117; STYBLO K, 1997, EXPECTED DECREASE TU; Styblo K, 1991, EPIDEMIOLOGY TUBERCU; SUDRE P, 1992, B WORLD HEALTH ORGAN, V70, P149; *UNAIDS WHO, 1998, REP GLOB HIV AIDS EP; *US BUR BENS, 1997, HIV AIDS SURV DAT JA; van den Broek J, 1998, INT J TUBERC LUNG D, V2, P547; Whalen C, 1996, AM J RESP CRIT CARE, V153, P1977, DOI 10.1164/ajrccm.153.6.8665064; *WHO, 1999, GLOB TUB CONR WHO RE; *WHO, 1998, 1996 WHO STAT ANN; *WHO, 1994, WHO PUBL; *WHO, 1996, DEM DAT HLTH SIT ASS; *WORLD BANK, 1993, WORLD DEV REP; World Health Organization, 1998, GLOB TUB CONTR WHO R	37	2361	2523	7	193	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 18	1999	282	7					677	686		10.1001/jama.282.7.677	http://dx.doi.org/10.1001/jama.282.7.677			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	226QY	10517722				2022-12-01	WOS:000082033700028
